<SEC-DOCUMENT>0001193125-26-132085.txt : 20260330
<SEC-HEADER>0001193125-26-132085.hdr.sgml : 20260330
<ACCEPTANCE-DATETIME>20260330173927
ACCESSION NUMBER:		0001193125-26-132085
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260330
DATE AS OF CHANGE:		20260330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexeo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001907108
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				854012572
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41855
		FILM NUMBER:		26813842

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		FLOOR 6
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		(212) 547-9879

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		FLOOR 6
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lxeo-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-30T15:16:35.8983+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:lxeo="http://www.lexeotx.com/20251231" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e7a01de1-bf3e-40e8-9e7e-4cd9492acbf1" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d">FY</ix:nonNumeric><ix:nonNumeric id="F_6085f8d5-1d88-4b06-8022-add485b42a8d" name="ecd:TrdArrDuration" contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5" format="ixt-sec:durday">605</ix:nonNumeric><ix:nonNumeric id="F_2541e626-1367-458b-bbab-46a459670ae0" name="dei:AmendmentFlag" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_38234b1c-5edd-4426-bbe6-7a9362d9b0dd" name="dei:EntityCentralIndexKey" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"> 0001907108</ix:nonNumeric><ix:nonFraction id="F_ceacd56d-047e-42df-8382-2f180e72f798" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_368454f4-1de5-47d4-a463-ff48edb9c65d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_4283524d-7551-4b90-bb15-d2729ab6b502" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member</ix:nonNumeric><ix:nonNumeric id="F_33986856-2fc0-46e5-a0a8-20e6e13001c1" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_a037ea15-adec-409e-8c43-b3ef64e5bcf7" name="us-gaap:NumberOfReportableSegments" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">One</ix:nonFraction><ix:nonFraction id="F_b1bf8275-7776-4ea4-af70-17f51659f92f" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">One</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lxeo-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80886119-480b-48c9-8ffb-65158995fa72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80a79c85-4eb7-478c-9356-9eedeabc3701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lxeo:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80d471cc-64f2-4ab5-9d83-c7f5596929ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-28</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8453d8e7-a1f5-4915-bf2c-6ebc643f48ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84571f91-58c3-4594-8881-2ecd5286cf9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84e826fb-ff2b-461e-a57d-ab9f5b605b0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8525b582-4e2a-4627-be2a-eadd8568fd9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_890b7df4-85e3-41e4-b1fd-4859a5a3807e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-24</xbrli:startDate><xbrli:endDate>2025-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8be8bafc-0873-440f-bfc2-64f112f3e6ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d5bfde0-a484-4470-9cd3-618c66bc014d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eaec952-271e-49b4-9770-a01b8320fedf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f865621-f365-4210-8b47-da03eb5738c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_929d55a0-9e11-462d-ad46-1599e64792f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lxeo:InvestmentInEquitySecuritiesOfInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9610981c-dbfa-4244-b967-0edb48cea85b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96240578-4334-4f1a-be14-256259efbda3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9779ca0e-2456-4a3d-a96f-ccee925f0ee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97bf9bb9-fd01-4c00-b07e-186f54c06f37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98d0b57c-8a4e-4d95-ac5f-068c0243f116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:Thirty-DayUnderwriterOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99561f6d-e4ca-4b39-a707-cdaeb6211e33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lxeo:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ad9569e-82f6-46d0-91e6-51f179cc5dad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-28</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9af02223-ca95-445a-b4e5-6659c2e7fccc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b72a311-fda5-4b44-874c-7a79d1c0981d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:ThirdPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c4cb1e5-c1a2-4e02-af65-dbb6700815f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a00433da-f67f-4690-982b-b7fff11be3f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a240413b-0d7d-487c-bc56-518232b357e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-28</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a31771a9-2900-4c49-8cb5-d8544ddd403d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyFiveInducementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a404e138-86a1-415f-86fa-bd92d7670e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5a4ebfd-7511-4fbc-860a-5324a475f3a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a707e4a6-c6ec-4da3-a440-f202623bc25e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a71aae44-530b-4c44-887c-3235e51cb928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a77def4a-c9cb-4e98-960a-031f93bc0880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a87f627d-9dbd-40af-86cb-7af479bf48e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa8f2f22-e100-44a6-a895-7f6b95043573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-21</xbrli:startDate><xbrli:endDate>2024-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab655c89-08d2-4df1-80c6-4cd7801eced4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-28</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac474d05-a4df-41bb-8c49-c9dddccf1523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae431a33-037b-46c8-a9af-9018491b4fb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af7f7cbb-e358-4e01-9e01-445a10e44bc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b108cd4a-1106-42e3-838b-ca809495548e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lxeo:InvestmentInEquitySecuritiesOfInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5e6a80b-0a90-4061-b5e3-d557692232e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7328e55-a04d-45a3-8322-e2fb9ba87bc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7718c79-bbe6-4525-98cb-4ccd075faa86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b783d3da-cc32-4fce-b2ea-93ee7627889c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b80b39e4-ee70-4ac9-8254-8612c66068cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b91348ae-b86b-4d6f-a90a-d0705420ee0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b95a7326-401b-4311-bbad-80ce85f07dc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2029-08-01</xbrli:startDate><xbrli:endDate>2034-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba4e7baf-9823-4208-bf61-fb7520c113df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba541477-4977-4a4d-8ea6-08f08a69b3a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc2c08ed-32fb-4bb9-9165-ff7bf6d493e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:Thirty-DayUnderwriterOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc5f8bd3-0209-4df6-a1d0-ca324664dc73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be3196c0-6c7d-48a3-80e1-3571e67be6c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-21</xbrli:startDate><xbrli:endDate>2024-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_beac3254-3c89-4564-8632-f79760e1f8b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf8a2e00-8278-456e-a9f7-bbc406b2f028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfb6f0b8-2842-4607-80c2-158502e95022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c04bdcf3-b841-4689-9b64-38b332249fe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:PerformanceRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0f2a034-41be-457c-99b1-4288da908b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c104adc9-73de-4e0a-aec0-20142b5b14fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c43d4a9b-6f01-447c-8344-401a3e883847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6383d22-c520-4a85-89c6-6b07e625c012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6ce4425-ba2c-49ff-99d6-85aeeb9dd72e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8a465c9-e39f-4d34-ac7a-5fe710f82f82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8d1b98f-fda8-4237-9715-247e14f34e52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c98b542f-c785-4f70-99a0-bd604bf1c422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cddcf69a-38e1-41ca-92b2-1dc2813f0ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondAmendmentToTheThirdCornellLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce351259-df29-4736-b0f7-5bd85eaae4a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondAmendmentToTheThirdCornellLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ceb6a661-0f1c-4d6c-bf35-6817f0cf2a23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lxeo:InvestmentInEquitySecuritiesOfInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf7275ec-9001-4e72-987c-f42dac6949d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf9feab1-814e-43f8-90af-29fdc96653e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1c75657-09b5-459b-b8d8-8d04ceccb855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2859d77-9d6d-417d-b711-d050b24f282f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-17</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3d8d14a-d897-4e92-bd97-3e0646e0e634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5204099-2478-4b5e-b1d3-d4947afd3ec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6948e0b-b33e-4c10-b2f9-1d23d6fdb1f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d98675e8-bd97-4502-824d-9b7f8f9d89bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d98866d0-7481-4b7b-bca4-1dd7071333f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da57ec1f-8f38-4bd6-9e52-115625f9b6b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db28a574-1df7-4c2a-a2c9-fa8fa1f5bb06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2029-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcf1d763-8592-412d-b293-cc3b5ba5d13f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddd009c3-4182-4517-ab43-5a05f6879a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de179b0b-31a8-495a-bf4e-3b6ec6689dce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e04e0666-d468-4c9d-9610-e8fa883f856b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e09c5ca9-c296-43da-b854-8d0d1dd047e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0c81d42-7bd1-4198-a287-73123a961a0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e272bdc5-b039-4362-8f99-fa87bcc9aa26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxeo:RNolanTownsendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4a107b2-cde8-4301-ac61-de3823035653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedUCSDSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e52cbdd7-cdf3-4600-944f-875c024f274c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5d2a857-7730-4e56-882a-9078bd9748d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8b9a53b-cf8f-4ca6-984a-ef4b65858fd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9b9062b-8c12-49f1-a351-c5a94c169bed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9dc71b0-9639-4d01-9da6-f620a88b25a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eca6767a-469e-41ac-95c7-b2ab4461a834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee384e21-7454-414e-9150-7230bc2c8387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0efe85b-fed2-44b8-8e9c-9573fb1386d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f15ba613-2ee7-4a4a-a5f6-e7630c6a7078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f35a4807-02c2-465e-a506-734387ea3d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3a8649e-4f53-4947-a5b7-6b4f853ce45b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f42c0641-10f4-40b1-862a-8bb73b4c2821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f55932cf-ba63-4d0b-b12f-3a6366360e35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5b4784b-582b-414e-b258-a9581e148ae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5cfe846-47a5-4562-b31a-858c10c03a88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6ffc1a5-c795-4565-95e3-4d24febe677f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f806ed52-1a8c-4157-881e-dbcb5b86b7fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f97419ff-d263-47c9-8d19-9400a45c4996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedUCSDSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb7cdb9c-5e73-4b92-9e27-ac79a42a2be1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc0d444a-c280-451e-a6ac-f592154451d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc4e6f8b-c480-46e3-af2f-471fb85da201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff8f1290-9480-4529-b296-ace3425207d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffbe2738-6916-44a3-9ab9-b7d08af02d03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00ff945d-1722-46c0-8cb8-739f6c508cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_016a9c4e-9503-4416-a9e9-6e06fb5aba55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_028187ae-2bdd-401c-9d01-a0eff189025b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02c649ee-2689-4467-af86-e845ba2c5b89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04fb7643-33b5-4b2c-b8e1-4cf6f989f885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0869a89c-0354-44a1-82dc-7940298b2ae8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08eca4a4-adfe-4cb1-ad4d-04bbfa80f9d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09b1664a-a411-44c8-8629-2f95a673f0c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bf10b12-a23b-4f45-9d50-7e648eecff42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c86e317-598b-4fc3-9ec5-6c3828cd4653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d4934d2-685d-4142-9a39-88dfc50f3990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0eb85a0b-e29d-45c6-a281-a90d66d244dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f7ea42a-4e43-4f1e-a004-b523e0aeb298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10c07d1a-63f8-4282-9c3d-df142d9339e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedFirstUcsdAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_112bc5bb-417e-47b7-868a-20b951733299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15d4c068-ac5b-4885-91c7-6d538b1e1b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1735de27-a8af-415d-8fe1-67386826cc66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18edec8b-db33-4c8f-b074-18226230e3bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f09b079-161e-4135-8af4-e2998386a171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f1718fb-6b55-4400-93d6-9f15b60b4646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f3e3006-1af0-48a7-9634-48ce1dc96196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f5a81d6-9a7a-4e3d-81e3-123c0c43d34b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fd1bb70-d88e-4bd3-9f2b-0ae04cc83ef6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_213bc6a0-4d38-4376-bd17-5ea5dbcd6e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxeo:RNolanTownsendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22f53fb5-b715-4275-818b-b00d6389e9cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23f2cf9c-eb2c-4874-9bb5-0b7e43ac44cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_248d415b-1dda-43fc-94db-d4c94d4bcf0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_250aa9ae-d108-452e-bc1b-21c4551179b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25fca7a5-ade5-42ee-82c0-94f05ff45965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26366915-140b-4c96-93b7-e237b4213687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_276b6562-55aa-419f-88ec-75b79f842098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2917ec7c-ddbb-4d8a-a527-3f8895a2283c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_292ca90b-72fb-49a6-a3ab-69036c90f439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29a85535-be63-45f2-b8b1-970ed18a0e41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c5a6104-de8c-4a89-b38f-5b76f25de136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d45877d-8c3e-4498-98ab-785fe7b33f59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d6d8b8b-f338-4359-9fa9-714c220f91b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f5d2c9e-b849-4bde-ac52-df6ce3e72476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_304ec79b-72af-4cbd-af93-f335e40345bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_306cf451-d0e8-4733-9390-77a092116c12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30c2f2ac-b0af-4f98-a1b6-41ccc4e13693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-14</xbrli:startDate><xbrli:endDate>2025-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_324cf665-a528-4a30-91f6-882210006248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-13</xbrli:startDate><xbrli:endDate>2024-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33a1d373-61e1-4dbc-8ca5-46559d2ba9d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34b52306-94cc-4920-be25-ed2fc77dc45f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_357e96c3-27bb-4127-968c-48df3cab0274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3740bd83-e4cd-4204-8ee9-2432a933e74a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38fa9b64-95c3-4a46-9bf4-5fef14d31d49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39a48e76-d9cd-4ef5-a9db-a32bb4c223a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-31</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b196e9a-f7ba-488f-8a3f-bdc43e626635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-24</xbrli:startDate><xbrli:endDate>2025-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bd21372-e009-4064-a11c-8bf9c564cecf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellFirstLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bd640a5-6ed0-4cd8-a0d7-639661192341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cd08b17-0362-4b62-b0f6-efc4c3963b9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d145bd9-a80d-4e38-8f51-01b475e8e55b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:TwoPortfoliosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e5cdc3c-a4d4-462c-af4f-ff0564c0387a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3efbfffb-0778-4c28-91b0-3428da47503f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_407ffdfb-fc65-4627-a3b0-cb0f4c4c5eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40e7b7c8-b1b6-4586-9359-a5aa9b41336e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_418db8cc-20a6-4c63-bc80-22f00e85ab78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_425a9b2c-585d-47dc-ace4-2331628255c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4295b1e1-3df8-42bb-8a20-af116ecee6bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44925c32-c071-4fdb-951d-3cec6e8d40c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:PerformanceRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_464f0f91-9b5b-4c2d-9f37-9b998e5a31ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46c792b5-6c67-472c-9304-76b2d83ce68a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_487136e8-5828-4a30-8230-e11cfaee5e4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4883c806-04d5-4bad-8a04-6447a094163d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bb6390f-6ce6-4793-8fc3-7a90375636cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bc16bb1-ead2-4dbd-aca6-b88278c3172f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c89430b-37d5-4909-a62c-9a1965b0a9b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cb98960-d47c-4c98-b396-48e50d6696e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AbiomedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cdd6443-84d6-48d5-acd5-108c91102bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e91b53a-c865-4846-b046-8b4dbf9ae7f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51b02334-8c26-4f78-ac6e-af4cbca2320e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54cd63d0-b34f-4997-8bdf-7b733713a458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58b9ae1c-e54e-4971-8058-707bb52b2a1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59ff464b-49f8-40f8-92d9-92d1e9a17142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b4016c9-50ff-46d1-a19f-672dd8c141a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c2eaa43-838e-4de5-ab2b-12e3438f3233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-21</xbrli:startDate><xbrli:endDate>2024-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f0fb589-18d5-4129-b711-24379e2c8f87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f20fea3-e69b-4604-90bc-497426fe388f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_601b6cb4-c759-4fde-8d48-72ad686bc4c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62dae8ef-bcab-47b7-8b50-1e70e0f56090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63514d7b-26f0-4ca4-a6a2-01e151213a0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63a872cf-6e8e-4d40-9cbb-3023e8fdb46c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:PerformanceRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_650a7937-a18f-466c-853a-cd74ae06db6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondAmendmentToTheThirdCornellLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b7cf2f5-7ba2-40f3-98b8-0a47a4bcab82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bba1c1b-df97-48f4-bb20-fa63b15d96c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2029-07-01</xbrli:startDate><xbrli:endDate>2029-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bf5181b-cf84-46b5-b3bd-e929f2acc332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6efb2e92-a65f-43f5-9c07-dfb2973f3821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_725ecbd1-08d1-4d48-b06f-22dc4a077218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72e10212-d78b-4f0e-a46a-69781278fac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_736d03a4-f8aa-492d-b0a2-7f25fcc32295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73d54a48-f66f-434c-bf6c-25a6a7ff448b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74917b61-bde0-47fb-a510-eeb410d819a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75180180-4d90-42c6-8270-15e1f3cc0ebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75647768-9be4-4729-b3de-fab3b1e0526d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76a788a3-f953-4f3e-ab5a-d2f1c0ac015b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_773cd297-399a-44b4-b688-630eaee896cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-14</xbrli:startDate><xbrli:endDate>2025-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79952fb3-c2a3-4723-8ef3-9b6960397749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b1bb5e1-9fac-4bb1-8736-1cc221d0c743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c175820-3a63-46e1-a5a5-b8abc4c71645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e067386-c3d6-4f06-8490-86af6f1f1e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e56c74e-cfef-48b5-b83f-54670366ec44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Installment"><xbrli:measure>lxeo:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>lxeo:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_IntegerItem"><xbrli:measure>lxeo:IntegerItem</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employees"><xbrli:measure>lxeo:Employees</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:40%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0a776b4-cd38-4a5b-a550-b174de5f9791" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4c373ade-17c9-42a4-8fca-94f68ac71857" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b046694-f296-4bda-81c8-a1694365c5bb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b91d79a0-c67e-443d-a0f1-de72a46d783a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef6143c7-40ca-47ed-bba3-3e02960ea5ea" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_54184ca8-2817-4c72-a416-25c1444dfd33" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a26e98e3-8309-4c29-bc73-0c2fc2b1f8e4" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-41855</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80f3740b-8306-412b-a0a8-017c5b78fde8" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0280aeed-0d23-4730-9854-12115c0638f2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a16615ff-d376-44b7-b6f7-d3936bfe6eb6" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">85-4012572</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ad6bb34f-8403-4d29-b855-bccb6ae1ba53" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">345 Park Avenue South</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_cfaf305d-eddb-479b-868a-60c8295ca6e2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Floor 6</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_973c998a-a639-4e54-8d76-820d21acdc5b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_85dd90ad-6ea7-40d3-bbad-a5ac9738c8f5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_be0308c6-cb64-4089-b1cc-b5e66ebb9e88" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10010</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a294f0d-2543-400b-8cb4-020328ece41b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">212</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b81d9c79-cecf-40dc-98f6-45b3801cecd5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">547-9879</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:39%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_767d0f28-eee6-4994-831a-77d2efc545cb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value $0.0001</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_2c6fff88-97bd-46d3-bf06-f481c8035d6e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LXEO</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_991a37e5-e1b1-4103-bfec-b75a8d04b261" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a29c0ca0-98a8-4996-a7fd-3f3de7b9ea1b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fcaa6e2-ff60-4b99-a275-1b11379dd84d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4210625f-858d-4816-9e52-eccb3888eda1" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbe00754-361e-4855-ac39-f22cd40b79ac" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:58.34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:19%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.66%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_3773621d-e60d-4505-a141-b361e2f7b1fd" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_cf83e2fe-79cf-4541-8359-f3133dcf2271" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_67c6dfd6-e4c0-4151-acf3-3d7b451c23ec" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8b3e257f-508e-4c72-83c7-9c50022e8826" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_92bf24e8-b018-4172-be48-40d9adf3deef" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_34f30981-b50b-4387-90c6-72eb5ff6ed77" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0aaae845-30a0-4f82-9bd0-c75a4f26b0a9" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the last day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f6d003c-d867-42b9-89ac-493f659b5790" contextRef="C_ffbe2738-6916-44a3-9ab9-b7d08af02d03" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">216.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Registrant&#8217;s common stock outstanding as of March 27, 2026 was </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05de7b49-e43d-4d9e-be95-4208d3f41f61" contextRef="C_f5cfe846-47a5-4562-b31a-858c10c03a88" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">74,087,063</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><div><ix:nonNumeric id="F_c288761d-28b1-42b5-ae2b-b6e8d33ac086" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2026 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2025.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NTENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.1%;box-sizing:content-box;"/>
     <td style="width:82.82%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5__market_for_registrants_common_eq"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and_supplem"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements_with"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#certain_relationships_and_related_transa"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#principal_accounting_fees_and_service"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits_and_financial_statement_schedul"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions intended to identify statements about the future. Forward-looking statements contained in this Annual Report include, without limitation, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of our planned investigational new drug, or IND, submissions, initiation of planned clinical trials and timing of expected clinical results for LX2006 and LX2020, if applicable, and our other future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing for receipt and announcement of data from our preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of any submission of filings for regulatory approval of and our ability to obtain and maintain regulatory approvals for LX2006, LX2020 and any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of public health crises and other adverse global economic conditions on our operations and the potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers, and collaborators with whom we conduct business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify patients with the diseases treated by our product candidates, and to enroll patients in trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of our product candidates, if approved for commercial use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on third party manufacturing partners to comply with significant regulations with respect to manufacturing our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the scope of any approved indication for LX2006, LX2020 or any other product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to leverage our platform to identify and develop future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain additional funding before we can expect to generate any revenue from product sales;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish or maintain collaborations or strategic relationships and any expected benefits related thereto;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify, recruit and retain key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on commercially reasonable terms or at all;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to protect and enforce our intellectual property position for our product candidates, and the scope of such protection;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive position and the development of and projections relating to our competitors or our industry;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding future revenue, expenses and needs for additional financing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our anticipated use of our cash, cash equivalents, and investments balances and any proceeds from the ATM Program (as defined below);</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of current and future laws and regulations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We caution you that the foregoing list does not contain all of the forward-looking statements made in this Annual Report. We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">usiness.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial. In October 2025, we reported positive interim clinical data demonstrating an encouraging safety profile and evidence of meaningful cardiac and functional benefit. Further, interim clinical data presented in a late-breaker presentation at the American College of Cardiology (ACC) Annual Meeting in March 2026 continue to show sustained or deepening improvements across both cardiac and neurologic measures of FA. In February 2026, we submitted the final registrational trial design and statistical analysis plan for the SUNRISE-FA 2 study to the U.S. Food and Drug Administration (FDA) following a Type B meeting. We expect to receive final feedback from the FDA in the second quarter of 2026 and plan to initiate a registrational study in the first half of 2026.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, or ACM, caused by mutations in the PKP2 gene, referred to as PKP2-ACM, is currently being evaluated in HEROIC-PKP2, an ongoing Phase 1/2 clinical trial. In January 2026, we announced positive interim data from the HEROIC Phase 1/2 clinical trial. Across dose cohorts, LX2020 was generally well tolerated and led to robust transduction, increased PKP2 protein expression, and clinically meaningful improvement or stabilization in measures of arrhythmia burden in the majority of participants. We plan to share additional safety and clinical efficacy data for LX2020 in the fourth quarter of 2026, once all participants in the high dose cohorts reach at least twelve months of follow up.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our gene therapy candidates utilizes the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease. Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, potential for lower toxicity given the opportunity to utilize lower doses compared to other well-established AAV serotypes, and low pre-existing immunity.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilizing a stepwise, capital-efficient development approach, we are leveraging early proof-of-concept functional and biomarker data to advance a deep and diverse pipeline of cardiovascular programs for larger-rare and prevalent indications. We retain exclusive worldwide development and commercialization rights to all of our product candidates and programs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_0.jpg" alt="img147150826_0.jpg" style="width:615px;height:279px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have high unmet need and no approved treatments that address the underlying genetic cause of the disease. These programs include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2006</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional frataxin, or FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the treatment of FA cardiomyopathy, which is the most common cause of mortality in patients with FA and affects approximately 5,000 patients in the United States. LX2006 is designed to promote the expression of the protein frataxin to restore normal mitochondrial function and energy production in myocardial cells. LX2006 has received Rare Pediatric Disease, Orphan Drug, Fast Track, Regenerative Medicine Advanced Therapy (RMAT), and Breakthrough Therapy designations from the FDA, and Orphan Medicinal Product designation from the European Commission. LX2006 has also been selected by the FDA to participate in its Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, which is intended to facilitate expedited CMC development of investigational therapies with expedited clinical development timeframes via an increased level of communication with the FDA on CMC development.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to cardiac muscle for the treatment of PKP2-ACM. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mutations are associated with approximately 75% of all genetic cases of ACM, and we estimate they affect approximately 60,000 patients in the United States. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mutations can cause replacement of heart muscle with fibrotic tissue and fatty deposits and severe abnormal heart rhythms, or arrhythmias, that cause cardiac dysfunction and can result in sudden cardiac death. LX2020 is designed to increase desmosomal PKP2 protein levels, reassemble desmosomes and restore myocardial cell function. LX2020 has received Fast Track and Orphan Drug designations from the FDA and Orphan Medicinal Product designation from the European Commission. </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a gene therapy candidate we are developing to intravenously deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including ACM and certain forms of dilated cardiomyopathy. We believe restoring the Cx43 protein can potentially treat multiple genetic causes of ACM because the cardiac loss of Cx43 is a molecular deficit generally observed in all ACM patient populations. Our LX2021 program is initially targeting Desmoplakin, or DSP, cardiomyopathy, a distinct form of ACM as well as a certain form of dilated cardiomyopathy, with a prevalence that may be as high as 4% of all inherited dilated cardiomyopathies and 4% of all ACMs, impacting approximately 30,000 to 35,000 patients in the United States.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a gene therapy candidate we are developing to intravenously deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy, or HCM, due to mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene. Mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene often result in left ventricular hypertrophy and restrictive cardiomyopathy, leading to arrhythmias and heart failure. With an estimated prevalence of 1 in 500 people in the United States, HCM is one of the most common forms of genetic cardiomyopathy and is caused by mutations that affect the cardiac sarcomere in approximately 75% of cases. It is estimated that as many as 25,000 patients in the United States and 34,000 patients in the European Union are affected by HCM caused by mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we are seeking business development opportunities for our portfolio of candidates targeting APOE4-associated Alzheimer's disease, including LX1001 which has completed a Phase 1/2 clinical trial.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Approach</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our technology approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, higher ratio of cardiac to liver biodistribution, potentially lower toxicity given the ability to utilize lower doses, compared to other well-established AAV serotypes, and lower pre-existing immunity. The AAVrh10 vector has been shown to be capable of transducing myocardial cells based on preclinical research and ongoing clinical studies. We believe these results demonstrate that among currently available, commonly used serotypes, AAVrh10 is an efficient vector for delivery and expression of transgenes for the treatment of the cardiovascular diseases that we are currently targeting. We have observed organ-specific biodistribution advantages for our AAVrh10 vector compared to AAV9, a well-known serotype that has been evaluated in several clinical trials, including one cardiovascular clinical trial. For example, we have observed vector distribution of AAVrh10 in cardiac tissue of non-human primates, or NHPs, that is two times greater than for AAV9. Additionally, our preliminary studies in Yucatan minipigs have shown that AAVrh10 has approximately 1.5 times greater biodistribution in the heart than AAV9. In addition, preclinical studies conducted by Weill Cornell Medical College, or Weill Cornell Medicine, have demonstrated that systemic administration of AAVrh10 promotes a ratio of cardiac-to-liver biodistribution that is more favorable than what is known of other commonly used vector serotypes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disease area strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cardiovascular gene therapy programs are designed to have the following characteristics:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indications that may be effectively treated by gene therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We select targets that correspond to populations with a specific genetic profile and clearly defined disease phenotype.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indications with the potential to demonstrate early evidence of meaningful clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We pursue clearly defined biomarkers and functional endpoints that can provide early proof-of-mechanism and inform clinical development decisions, including the potential to seek accelerated approval pathways.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Present opportunity to address high unmet medical need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are focused on genetically defined cardiovascular diseases where there are no currently approved treatments or where we believe our therapeutic candidates will have a meaningful improvement relative to existing standards of care.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant market opportunity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We pursue indications with significant commercial opportunities beyond those typically associated with gene therapy companies targeting rare monogenic diseases. </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Targets that have established proof-of-concept</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have leveraged our relationships with academic institutions to in-license product candidates with established proof-of-concept in relevant preclinical models that closely resemble the clinical phenotype we are pursuing.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our manufacturing approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing gene therapy candidates for larger-rare and prevalent disease patient populations that require a high-quality process that can produce vectors in relatively large quantities while utilizing traditional biologics manufacturing infrastructure. We utilize a baculovirus/Sf9 expression system to manufacture our gene therapy candidates. Our manufacturing platform is designed to infect Sf9 cells at high densities in suspension cell culture with both an AAVrh10 and baculovirus containing the transgene. The output is coupled with a chromatography- based purification process which allows for efficient AAV purification, resulting in higher yields and fewer empty AAV capsids than traditional plasmid HEK adherent cell culture approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our manufacturing process enables us to efficiently pursue our goal of targeting larger-rare and prevalent patient populations. Historically, manufacturing challenges, largely driven by the quantity of vector required to pursue large commercial opportunities have limited the utility of gene therapy for large patient populations. We believe our proprietary Sf9 baculovirus process will allow us to produce vectors at the necessary scale to support the patient populations we are targeting at a cost-of-goods profile similar to what the pharmaceutical marketplace has seen with biologics. To date, we have developed a highly reproducible and scalable 200L GMP AAV production process using the Sf9-baculovirus system, which does not require costly plasmids. Purification is also a straightforward 2-column process. The overall process delivers over 1E15 vg/L of purified AAVrh.10 product that contains less than 25% empty capsids.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, we presented new data at the 28th American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting on AAV manufacturing optimization via our Sf9-baculovirus process. Data presentations reviewed the high purity and potency of our yields with improved scalability of production and reduced cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we shared CMC data for LX2006, which were submitted to the FDA to support analytical comparability between the HEK293 manufacturing process and the Sf9-baculovirus manufacturing platform. These data demonstrate similar frataxin expression </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">between the two processes as measured by a quantitative relative potency assay in cardiomyocytes. In November 2025, the FDA approved this analytical comparability report establishing comparability between LX2006 HEK293 and Sf9 manufacturing processes, endorsing use of the optimized, Sf9 final commercial manufacturing process for LX2006 in the planned pivotal study and clearing comparability requirements to begin dosing patients.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2026, we conducted an initial CMC Development and Readiness Program meeting with the FDA for LX2006, during which the agency reiterated its support for a flexible validation approach including potential for reduced process performance qualification runs and concurrent process validation. We are proceeding with validation and commercial manufacturing readiness activities to support the Biologic License Application (BLA) submission for LX2006.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our approach, we expect that our existing partnerships can supply material for all of our currently ongoing and planned clinical trials as well as potential commercial production of some of our programs. We will own the intellectual property created by our manufacturing process development activities or have the ability to license it and will maintain the option to transfer the process to other CDMOs in the future and/or to our own potential facility to ensure ongoing redundancy and reliability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cardiovascular gene therapy programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2006 for the treatment of FA cardiomyopathy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of FA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FA is a genetic, progressive, and degenerative multi-system disorder with a prevalence of 1:50,000 or approximately 5,000 people in the United States. It is estimated that approximately 80% of these patients will develop FA cardiomyopathy. FA is caused by a mutation in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene that disrupts the normal production of the protein frataxin, which is critical to the function of mitochondria in a cell and to the maintenance of cardiac function. The most common FA phenotype presents with significantly reduced frataxin levels compared to healthy individuals, however levels of frataxin in the cardiac tissue of FA patients is unknown. The frataxin deficiency in the mitochondria of myocardial cells in FA patients causes disruption of normal iron-sulfur cluster biosynthesis leading to mitochondrial dysfunction and deficient energy production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The neurologic disease and cardiac disease are two distinct manifestations of FA. The disease is inherited in an autosomal recessive manner, where both inherited genes are abnormal, and symptoms usually begin in childhood. Absence of fully functional frataxin leads to damage to peripheral nerves and the parts of the brain that control movement and balance, leading to neurological symptoms that include impaired muscle coordination, or ataxia, that worsen over time. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements. Affected individuals often develop slurred speech, hearing loss, scoliosis, diabetes, characteristic foot deformities, and an irregular curvature of the spine. The typical age of onset of neurological symptoms is five to 15 years old. As the disease progresses, patients typically experience various heart conditions, including thickening of the heart muscle, or hypertrophic cardiomyopathy, and arrhythmias. Hypertrophic cardiomyopathy, fibrosis, heart failure and arrhythmias are the cause of death in approximately two-thirds of FA patients. Typical onset of the cardiac disease is at 15 to 30 years old.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By the time the cardiac disease of FA emerges, the neurologic disease is generally significantly advanced and may not be amenable to gene therapy. There are currently no approved treatments for the cardiac manifestations of FA. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Skyclarys</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the only approved treatment for FA, is an Nrf2 activator which targets only the CNS component of the disease. As a result, patients with FA have significant unmet need for a therapy to treat cardiovascular complications associated with the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach: LX2006</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing LX2006 as an AAVrh10-based gene therapy delivered intravenously for the treatment of FA cardiomyopathy. LX2006 is designed to deliver the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene under the transcriptional control of the CAG promoter, a strong synthetic promoter frequently used in viral vectors. LX2006 utilizes AAVrh10 based on its favorable cardiac affinity and vector distribution profile observed in preclinical studies, as compared to AAV9. LX2006 is designed to transfer the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to myocardial cells and increase frataxin levels in the mitochondria. The increase in frataxin levels in the mitochondria is intended to restore mitochondrial function and energy production in cardiac myocytes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lexeo-sponsored LX2006 clinical development and trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2006 is currently being evaluated in an ongoing, multi-site Phase 1/2 clinical trial, or SUNRISE-FA, in patients with FA cardiomyopathy. SUNRISE-FA is a first-in-human, 52-week, dose-ascending, open-label trial of LX2006 in patients who have FA cardiomyopathy. LX2006 is administered as a one-time intravenous infusion with prednisone utilized for immune suppression. The trial consists of three dose cohorts. The cohort 1 dose level is 1.8&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, the cohort 2 dose level is 5.6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, and the cohort 3 dose level is 1.2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg. There is a long-term follow-up for patients who receive LX2006 to monitor ongoing safety for a total of five years, per FDA requirement.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cardiac biopsy results from SUNRISE-FA trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, we provided an interim clinical update, which included frataxin protein expression from eight participants in SUNRISE-FA that had undergone cardiac biopsies. These data demonstrated increase in frataxin protein expression versus baseline at three months in all participants as measured by liquid chromatography-mass spectrometry, or LCMS. Dose-dependent increases were observed across cohorts on average, with 115% mean increase in the high-dose cohort 3 (n=4). To our knowledge, SUNRISE-FA is the first clinical trial to evaluate frataxin levels in the target organ of FA cardiomyopathy patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increased frataxin expression across all participants evaluated at 3-months post treatment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img147150826_1.jpg" alt="img147150826_1.jpg" style="width:503px;height:244px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional ongoing clinical trial of AAVrh10.hFXN (LX2006 at Lexeo)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AAVrh10.hFXN, which we refer to as LX2006, is currently being evaluated in an additional ongoing investigator-initiated, single-site clinical trial conducted by Weill Cornell Medicine (NCT05302271). Both the Weill Cornell investigator-initiated clinical study and our SUNRISE-FA clinical study use drug product manufactured at Weill Cornell Medicine utilizing the same process with identical doses in each study&#8217;s cohort 1 and cohort 2. In April 2024 we announced a license agreement with Cornell University for intellectual property rights including current and future clinical data from the ongoing Weill Cornell Medicine investigator-initiated trial of LX2006.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cardiac biomarker data from ongoing clinical trials of LX2006</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we provided an interim clinical update, which included baseline characteristics and safety data from the 17 treated participants across the two studies, and clinical efficacy data from the 16 participants who had reached at least six months follow-up as of that time. These data showed sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of FA.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in LVMI among participants with abnormal baseline LVMI (n=6). Five of six participants achieved &gt;10% by 12-month visit or sooner and six of six participants achieved LVMI measurements within the normal range as of latest visit. A 18% mean improvement in LVMI was observed at 6-month visit and a 23% mean improvement in LVMI was observed at 12-month visit, exceeding 10% FDA-aligned threshold for pivotal study. In the mid- and high-dose cohorts (n=3), a 28% mean improvement in LVMI was observed at 6-month visit and a 33% mean improvement in LVMI was observed at 12-month visit, suggesting dose-dependent improvement. Among participants with normal baseline LVMI (n=10), the majority demonstrated LVMI improvement or stabilization over time.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participants with abnormal LVMI at baseline, LVMI % change</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_2.jpg" alt="img147150826_2.jpg" style="width:419px;height:277px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in secondary cardiac biomarkers. Fourteen of sixteen participants achieved &gt;25% reduction in high-sensitivity troponin I from baseline at latest visit. Fourteen of sixteen participants achieved reduction or stabilization in LWT from baseline at latest visit.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All participants, improvements in LWT and high-sensitivity troponin I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_3.jpg" alt="img147150826_3.jpg" style="width:575px;height:271px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in mFARS as demonstrated by a 2.0-point mean improvement from baseline at latest visit across all participants. Eleven of sixteen participants achieved reduction or stabilization in mFARS from baseline at latest visit.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All participants, functional improvement over time using mFARS</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_4.jpg" alt="img147150826_4.jpg" style="width:440px;height:287px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2026, we shared updated interim clinical data for LX2006 at the ACC Annual Meeting. Phase 1/2 interim clinical data presented at the ACC Annual Meeting continue to show sustained or deepening improvements across both cardiac and neurologic measures of FA, including statistically significant improvement in mean mFARS scores for LX2006-treated participants compared to a propensity-matched control cohort from the UNIFAI natural history study.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safety profile of LX2006 from ongoing clinical trials of LX2006</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LX2006 has been generally well tolerated with no Grade 3 treatment-related SAEs to date, no clinically significant complement activation, minimal, transient liver function test (LFT) elevations, and no signs of frataxin over-expression observed in cardiac tissue. One previously disclosed, possibly treatment-related Grade 2 event of asymptomatic myocarditis observed one year after dosing. No participants discontinued from either study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Updates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, we announced Breakthrough Therapy designation based on interim clinical data from Phase 1/2 trials showing clinically meaningful improvements in cardiac biomarkers and functional measures. We also announced that LX2006 was selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, in response to our questions regarding the possibility of a faster path to a Biologics License Application, or BLA, the FDA indicated openness to a BLA submission for accelerated approval that includes clinical data from the ongoing Phase 1/2 studies of LX2006 pooled with new clinical data to be generated in the planned pivotal study. The FDA also previously agreed to evaluate the co-primary endpoint of LVMI at a time point earlier than 12 months. Collectively, we believe this regulatory feedback has the potential to reduce the size and length of the planned pivotal study, possibly accelerating the overall timeline to BLA submission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2026, we submitted the final registrational trial design and statistical analysis plan for the SUNRISE&#8209;FA 2 study to the FDA following a Type B meeting. The proposed open-label study is generally consistent with previously communicated guidance on key design elements, such as study size, duration, patient population, and the LVMI primary endpoint, and incorporates FDA feedback on minimizing bias, including physician selection bias of study participants. We expect to receive final feedback from the FDA in the second quarter of 2026 and plan to provide a more detailed update at that time. Initiation of the SUNRISE-FA 2 study is expected in the first half of 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020 for the treatment of ACM caused by </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PKP2 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of ACM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACM is a genetic heart disease primarily characterized by myocardial cell loss and the replacement of heart muscle with fibrotic tissue and fatty deposits. ACM can result from mutations in several desmosomal genes. These genetic mutations impair the structure and function of cardiac desmosomes, which are membrane protein complexes engaged in cell-to-cell adhesion and the structural integrity of the ventricular myocardium. Lack of functioning cardiac desmosomes can lead to myocardial cell death and fibrosis, heart dysfunction, rhythm abnormalities, and sudden death. Standard of care may include antiarrhythmics, implantable cardioverter-defibrillators, and ablation procedures; however, none of these therapies address the underlying cause of myocardial dysfunction and ACM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate that ACM has a prevalence of approximately 130,000 patients in the United States and estimate that over half of all ACM patients have a genetic form of the disease with five desmosomal genes accounting for nearly all of the identified genetic causes of ACM. We have initially targeted the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene because mutations in this gene are the most commonly known genetic cause of ACM. We believe that mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene are associated with approximately 75% of all genetic cases of ACM, resulting in approximately 60,000 patients affected by the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mutation in the United States. Most familial cases of the disease have an autosomal dominant pattern of inheritance, meaning one copy of an altered gene in each cell is sufficient to cause the disorder. Since having only one functioning copy of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene is insufficient to produce the wild-type phenotype, this results in a phenomenon in genetics known as haploinsufficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Symptoms of the disease can include palpitations, dizziness, heart failure and sudden death. Abnormal function of the right ventricle, fatty or fibrotic infiltrates in the myocardium, abnormal electrocardiogram, or ECG, arrhythmias, or a family history of ACM can all lead physicians to diagnose the disease. No effective treatments for PKP2-ACM exist.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach: LX2020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing LX2020 as an AAVrh10-based gene therapy candidate for the treatment of PKP2-ACM. LX2020 is designed to intravenously deliver a functional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to cardiac muscle to increase desmosomal PKP2 protein levels and restore myocardial cell function. We believe that by delivering a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene, LX2020 has the potential to address the underlying cause of PKP2-ACM for many patients and have a significant effect on lifespan by reassembling the cardiac desmosomes, preventing cardiac arrhythmias and preventing or treating cardiac dysfunction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020 clinical development and trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2020 is currently being evaluated in HEROIC-PKP2, a first-in-human, 52-week, open-label, dose-ascending multicenter trial to determine the safety and tolerability of LX2020 in patients with PKP2-ACM. Preliminary efficacy measures include myocardial protein expression, biomarkers measuring cardiac structure and function, and arrhythmia burden. Key inclusion criteria include: patients aged 18-65 years with a confirmed diagnosis of ACM with either 2010 Task Force Criteria or 2020 International Criteria for ACM; documented PKP2 mutation; existing implantable cardioverter defibrillator (ICD) that is MRI compatible; and a minimum threshold of PVCs over a 24-hour period. LX2020 is administered as a one-time intravenous infusion to patients in at least two ascending-dose cohorts of three patients each, with the potential for cohort expansion. Prednisone and rapamycin are utilized for immune suppression. We have completed enrollment and dosing in this trial, with ten participants dosed: three in the low dose cohort 1 (2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg), three in the high dose cohort 2 (6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg), and four in the dose-expansion high dose cohort 3 (6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg). There is a long-term follow-up for patients who receive LX2020 to monitor ongoing safety for a total of five years, per FDA requirement.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cardiac biopsy results from HEROIC-PKP2 trial</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, we provided an interim clinical update, which included PKP2 protein expression from participants in HEROIC-PKP2 with post-treatment cardiac biopsies (n=7). The data demonstrated dose-dependent transduction and protein expression, with mean increase in PKP2 protein of 93% in low-dose (n=2) and 162% in high dose (n=5) by western blot, assessed at 3 months post dosing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increases in PKP2 protein expression</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_5.jpg" alt="img147150826_5.jpg" style="width:366px;height:239px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, dose-dependent increases were observed in mean vector copy number and exogenous mRNA in all participants.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2020 transduction and transcription observed in all participants</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_6.jpg" alt="img147150826_6.jpg" style="width:522px;height:218px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in two participants at the high dose, immunofluorescence demonstrates appropriate co-localization of PKP2 in desmosome. Following LX2020 administration, PKP2 protein colocalizes with Cx43, a gap junction protein, and Ncad, a desmosomal adhesion protein, within cardiac intercalated discs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immunofluorescence demonstrates appropriate co-localization of PKP2 in desmosome</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_7.jpg" alt="img147150826_7.jpg" style="width:420px;height:251px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cardiac biomarker data from HEROIC-PKP2</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, we provided an interim clinical data update, which included baseline characteristics and safety data from the ten participants dosed, including three participants in cohort 1 at the low dose and seven participants in cohorts 2 and 3 at the high dose. Clinical efficacy data were inclusive of those participants with at least 6 months of follow-up (n=8).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in NSVT and PVCs. NSVT reduced or stabilized in the majority of participants, with a 22% mean improvement in high-dose cohorts at latest visit (n=5). PVCs reduced or stabilized in the majority of participants, with a 14% mean improvement in high-dose cohorts at latest visit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reductions in arrhythmia burden over time</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_8.jpg" alt="img147150826_8.jpg" style="width:652px;height:219px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, four of five participants in high-dose cohorts report improvement relative to baseline on the Patient Global Impression of Change, or PGIC, scale, a patient-reported outcome measure. Participants stable across other clinical measures including QRS duration, T-wave inversion, RVEF and New York Heart Association, or NYHA, Class.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safety profile of LX2020 from HEROIC-PKP2</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Across all participants dosed, LX2020 has been generally well-tolerated to date with no clinically significant complement activation. Elevations in liver function tests (LFT) observed in seven participants at the high dose, treated successfully with re-introduction of low-dose prednisone in five participants and increased prednisone and sirolimus in two participants per the trial protocol. All elevations resolved without complication, hospitalization or other treatment. One Grade 3 serious adverse event of sustained ventricular tachycardia (VT) was observed three months after dosing in a single participant at the high dose and assessed as possibly treatment related. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required. No participants discontinued from the HEROIC-PKP2 Phase 1/2 study.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have initiated SNAPSHOT-PKP2, a natural history study designed to evaluate PKP2-ACM disease progression up to two years retrospectively and over twelve months prospectively. The study will enroll up to 20 patients in the United States.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate sharing additional safety and clinical efficacy data for LX2020 in the fourth quarter of 2026, once all participants in the high dose cohorts reach at least twelve months of follow up.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2021 for the treatment of DSP cardiomyopathy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2021 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a gene therapy candidate we are developing to intravenously deliver the coding sequence for the functional Cx43 protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including ACM and certain forms of dilated cardiomyopathy, which are typically due to abnormalities or deficits in cardiac desmosomes. Cx43 is an integral protein component of gap junctions and functionally allows small molecules and ions to flow directly between cells to allow for electrical synchronization of muscle contraction. In patients with heart disease, including heart failure, Cx43 is often relocalized in the lateral walls of myocardial cells. As a result, it is significantly reduced at cardiac muscle cell junctions, especially in ACM populations. Restoring Cx43 protein to cardiac muscle cell-cell junctions can potentially treat multiple genetic causes of ACM because the cardiac loss of Cx43 is a molecular deficit generally observed in all ACM patient populations. DSP is a structural protein critical for force transmission in heart muscle. Mutations in DSP cause a distinct form of ACM and a certain form of dilated cardiomyopathy, known as DSP cardiomyopathy. Unlike many forms of ACM that predominantly affect the right side of the heart, DSP cardiomyopathy frequently affects the left side of the heart. The prevalence of DSP cardiomyopathy is unknown but may be as high as 4% of all inherited dilated cardiomyopathies and 4% of ACM, impacting up to 35,000 individuals in the U.S. Given the role of Cx43 in other forms of heart failure, we are also evaluating LX2021 for the treatment of additional indications beyond DSP cardiomyopathy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted a preclinical study in a cardiac-specific DSP loss-of-function mouse model, or DSP-cKO mice, which is a genetic model of ACM. DSP-cKO mice develop molecular, histological and physiological features of ACM and ultimately die prematurely from heart failure. In this study, we observed that severely diseased mice treated with AAV-based gene therapy expressing Cx43 display fewer arrhythmias, have improved cardiac mechanical function, and experience an almost two-fold increase in lifespan when compared to untreated DSP-cKO adult mice. A single dose of an AAV-based gene therapy candidate representing Cx43 was administered intravenously to the cardiac-specific DSP-cKO mice, at four to six weeks of age. DSP-cKO mice are a genetic model of ACM harboring severe structural disease and loss of Cx43. RNA analysis of the treated mice revealed that cardiac-specific Cx43 gene delivery increased Cx43 RNA levels. Additionally, the Cx43-treated DSP-cKO mice showed a re-expression of mechanical junction proteins in their hearts compared to controls. Essential basement membrane proteins, including N-cadherin, as well as desmosomal proteins, PKP2 and junction plakoglobin, were also restored to cell-cell junctions in Cx43-treated DSP-cKO hearts compared to end-stage untreated DSP-cKO hearts, which had limited localization of junctional proteins at cell-cell junctions. These findings further validate the ability of Cx43 to resurrect the cardiac mechanical muscle junction complex in diseased hearts.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2022 for the treatment of HCM caused by TNNI3 mutations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2022 is a gene therapy candidate we are developing to intravenously deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to myocardial cells to treat a distinct form of HCM due to mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene. With an estimated prevalence of 1 in 500 people in the United States, HCM is one of the most common forms of genetic cardiomyopathy caused by mutations that affect the cardiac sarcomere in approximately 75% of cases. It is estimated that as many as 25,000 patients in the United States are affected by HCM caused by mutations in the gene </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene encodes troponin I, an essential protein in the thin filament of the sarcomere, which is involved in cardiac contraction and relaxation. Mutations in the gene often result in left ventricular hypertrophy and restrictive cardiomyopathy, leading to arrhythmias and heart failure.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical data from an A157V </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> murine model, a model which results in cardiac dysfunction, was generated to validate the delivery of an AAV-based therapy candidate expressing human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regulated by a cardiac-specific promoter. At four weeks post injection, the level and specificity of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene expression were evaluated in the liver, skeletal muscle, and heart tissue. As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was regulated by a cardiac-specific promoter, expression of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was only detected in the heart tissue. Additionally, retro-orbital injection of AAV9-hTNNI3 expressing A157V mutation was performed on three- month-old mice euthanized four weeks later. The hearts were dissected and immunostained. Immunostaining revealed robust expression of human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the cardiomyocyte after treatment with AAV-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Moreover, high magnification imaging demonstrated the incorporation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within the cardiac sarcomere. Based on these preclinical findings, we believe that AAV-based therapy expressing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> can be administered to achieve transgene expression in heart tissue.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of Core Focus Area: APOE4-associated Alzheimer&#8217;s disease programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our cardiac gene therapy programs, we have a portfolio of approaches aimed at treating the genetics underlying Alzheimer&#8217;s disease. We believe precision therapies, particularly those focused on the underlying genetics of Alzheimer&#8217;s disease, may have a substantial impact on this treatment landscape. Importantly, we believe gene therapy allows for a unique approach to treating the genetics of Alzheimer&#8217;s disease by delivering a therapeutic which acts upstream of both the amyloid-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and tau-driven pathology of Alzheimer&#8217;s disease. This treatment strategy is designed to impact multiple pathways, as opposed to most other treatments in development which target a single mechanism of Alzheimer&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our lead Alzheimer&#8217;s disease program, LX1001, we are initially targeting homozygous APOE4-associated Alzheimer&#8217;s disease patients by administering AAVrh10 containing the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene. Our approach to treating Alzheimer&#8217;s disease is predicated on the belief that expressing the protective APOE2 in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients will halt or slow the progression of Alzheimer&#8217;s disease. We believe these patients represent an ideal target for gene therapy because the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">homozygous profile is the most common genetic driver of Alzheimer&#8217;s disease.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current gene therapy programs for the treatment of Alzheimer&#8217;s disease are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX1001: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a clinical-stage AAVrh10-based gene therapy candidate that is designed to express the protective APOE2 protein in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX1021: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an early-stage AAVrh10-based gene therapy candidate that is designed to express the Christchurch-modified APOE2 protein in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients. The Christchurch mutation has been observed to protect patients against Alzheimer&#8217;s disease even in the presence of significant amyloid pathology.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX1020: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an early-stage AAVrh10-based gene therapy candidate that is designed to express the protective APOE2 protein in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients, while concurrently delivering miRNA to suppress the expression of the APOE4 protein.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX1001 has been evaluated in an open-label, dose-ranging Phase 1/2 clinical trial in patients who are </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients with clinical diagnoses ranging from mild cognitive impairment to mild or moderate dementia due to Alzheimer&#8217;s disease. All participants had evidence of amyloid plaque by PET scan and/or CSF biomarkers consistent with Alzheimer&#8217;s disease at baseline. The trial evaluated four ascending dose cohorts (1.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vg/ml, 4.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vg/ml, 1.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vg/ml and 1.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> total genomes), with the dose for each patient in the first three cohorts determined based on CSF volume measured by MRI and patients in the fourth cohort receiving a fixed dose. Fifteen patients were enrolled in the study across the four dose cohorts. The primary objective of the trial was to evaluate the safety of LX1001 administered to the CNS via injection between cervical vertebrae 1 and 2, or intracisternal injection, and to establish the maximum tolerated dose. The trial was also designed to evaluate the conversion of the CSF from the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous profile to an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4/E2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> profile. Additional secondary endpoints included CSF biomarkers, including A&#223;42, total tau, and phosphorylated tau, amyloid PET scan, structural MRI imaging and cognitive tests. Corticosteroids were utilized for immune suppression. Participants will continue to be evaluated for ongoing safety in a long-term follow-up study, per FDA requirement.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed the Phase 1/2 trial of LX1001 and shared preliminary results across all four dose cohorts in a late-breaking oral presentation at the Clinical Trials on Alzheimer&#8217;s Disease Conference in October 2024. In January 2025 we announced that we are seeking partnering opportunities to continue development.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. This is also true for the development and commercialization of treatments for cardiovascular and neurodegenerative diseases such as FA and PKP2-ACM and broadly across gene therapies. While we believe that our management and scientific team&#8217;s deep expertise in gene therapy provides us with competitive advantages, we face competition from several sources, including large and small biopharmaceutical companies, government agencies and academic and private research institutions. Not only must we compete with other companies that are focused on gene therapy technology, but any product candidates that we successfully develop and commercialize will compete with existing therapies, to the extent applicable, and new therapies that may become available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development, particularly in the gene therapy field, is highly competitive and subject to rapid and significant technological advancements. A significant unmet medical need exists in each of the indications that we are targeting, and it is likely that additional drugs will become available in the future for the treatment of these diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evaluating next steps for vatiquinone following a Complete Response Letter on their new drug application to the FDA. Reata Pharmaceuticals, Inc.&#8217;s omaveloxolone (Skyclarys) was approved by the FDA in 2023, and Biogen Inc. acquired Reata Pharmaceuticals, Inc. for approximately $7.3 billion in the same year and is currently commercializing Skyclarys.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to LX2020, both Rocket Pharmaceuticals Inc., or Rocket, and Tenaya Therapeutics Inc. are developing an AAV-based gene therapy candidate designed to deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene to patients with PKP2-ACM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will face competition from other drugs or from other non-drug products and treatments currently approved or that will be approved in the future in the cardiovascular and neurology field, including for the treatment of diseases and diseases in the therapeutic categories we intend to target. Therefore, our ability to compete successfully will depend largely on our ability to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop, manufacture and commercialize drugs that are superior to other products in the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate through our clinical trials that our product candidates are differentiated from existing and future therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract qualified scientific, product development and commercial personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain patent or other proprietary protection for our medicines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain required regulatory approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidate we develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects. In addition, the reimbursement structure of currently approved or future gene therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if approved, and our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving regulatory and marketing approval for, or commercializing, drugs before we do, which would have an adverse impact on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively seek to protect our proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, such as seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also may rely on trade secrets and know-how relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop, strengthen and maintain the strength of our position in the field of gene therapy that may be important for the development of our business. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets, and that may be used to manufacture and develop novel gene therapy products. We are a party to license agreements that give us rights to use specific technologies in our gene therapy candidates and in manufacturing our products. Additional regulatory protection may also be afforded through data exclusivity, market exclusivity and patent term extensions where available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we in-licensed four U.S. patents, 16 pending U.S. non-provisional patent applications, one pending PCT application, eight foreign patents and 106 pending foreign applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2006 product candidate, we in-license from Cornell University and Adverum Biotechnologies, Inc., or Adverum, two U.S. patents, five pending U.S. non-provisional patent applications, five foreign patents granted in India, Mexico, South Africa, and New Zealand and nine pending foreign applications pending in such jurisdictions as Australia, Brazil, Canada, Eurasia, Europe, Hong Kong, Israel and Mexico. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, these patents, if granted, will expire in 2033. These patents and pending patent applications disclose and/or contain composition-of-matter claims to an AAV vector encoding </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or a fragment thereof, and disclose and/or contain claims to methods of producing and methods of treatment using the AAV </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vector. Cornell University co-owns these patents and patent applications with Institut National de la Sant&#233; et de la Recherche M&#233;dicale, Centre National de la Recherche Scientifique, Universit&#233; de Strasbourg, Universit&#233; Paris-Saclay and Assistance Publique-H&#244;pitaux de Paris.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have rights to additional patent applications that we co-own with Cornell University, and which also relate to our LX2006 cardiac FA program. We in-license Cornell University's interest in one pending U.S. non-provisional patent application and 14 pending foreign applications in such jurisdictions as Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico, New Zealand, and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patents issuing from these applications will expire in 2043. These pending applications disclose and/or contain composition-of-matter claims to a pharmaceutical dosage form of viral vectors encoding </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and disclose and/or contain claims to methods of producing and methods of treatment using the pharmaceutical dosage form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2020 product candidate, we in-license from The Regents of the University of California one pending U.S. non-provisional patent application and 17 pending foreign applications in such jurisdictions as Australia, Brazil, Canada, China, Colombia, Eurasia, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patents issuing from these applications will expire in 2042. These pending applications disclose and/or contain composition-of-matter claims to a vector encoding human PKP2, and disclose and/or contain claims to methods of producing and methods of treatment using the PKP2 vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2021 product candidate, we in-license from The Regents of the University of California two U.S. patents, three pending U.S. non-provisional patent applications, two foreign patents granted in Australia and Europe, respectively, and nine pending foreign applications pending in Australia, Canada, China, Europe, Israel, and Japan. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, these patents and patent applications will expire in 2038. These pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding a human Cx43 polypeptide, and disclose and/or contain claims to methods of producing and methods of treatment using the Cx43 vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2022 product candidate, we in-license from The Regents of the University of California one pending U.S. non-provisional patent application. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patent applications claiming the priority to this patent application, will expire in 2040. This pending U.S. non-provisional patent application discloses and/or contains composition-of-matter claims to a vector encoding a human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene, and discloses and/or contains claims to methods of producing and methods of treatment using the TNNI3 vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX1020 product candidate, we in-license from Cornell University one pending U.S. non-provisional application and 16 pending foreign applications pending in Australia, Brazil, Canada, China, Colombia, Europe, Hong Kong, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, these patent applications will expire in 2040. We also in-license from Cornell an additional pending PCT application related to our LX1020 product candidate. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patents claiming priority to the pending PCT application will expire in 2045. The pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding human APOE2 protein and encoding one or more RNAi nucleic acid sequences for inhibition of APOE4 mRNA, and disclose and/or contain claims to methods of producing and methods of treatment using the APOE2+/APOE4- vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX1021 product candidate, we in-license from Cornell University two pending U.S. non-provisional application, one foreign patent granted in Australia, and 13 pending foreign applications pending in Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, these patent applications will expire in 2040. The patent and pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding a mutated human apolipoprotein E protein, and disclose and/or contain claims to methods of producing and methods of treatment using the mutated human apolipoprotein E vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also in-license from Cornell additional patent applications, which relate to our LX1021 product candidate. We in-license from Cornell University one pending U.S. non-provisional application and 12 pending foreign applications pending in such jurisdictions as Australia, Brazil, Canada, China, Europe, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, the pending patent applications will expire in 2044. The pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding a mutated human apolipoprotein E protein, and disclose and/or contain claims to methods of producing and methods of treatment using the mutated human apolipoprotein E vector.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX1001 product candidate, we co-own pending patent applications with Cornell University. We in-license Cornell University's interest in one pending U.S. non-provisional patent application and 13 pending foreign applications pending in such jurisdictions as Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, the pending patent applications will expire in 2043. The pending patent applications disclose and/or contain composition-of-matter claims to a pharmaceutical dosage form of viral vectors encoding human APOE2, and discloses and/or contains claims to methods of producing and methods of treatment using the pharmaceutical dosage form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License, research collaboration and sponsored research agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First license agreement with Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2020, we entered into a license agreement with Cornell University, or the Cornell First License Agreement, pursuant to which we obtained a sublicensable, worldwide license under certain patents to make, use, and sell products that are covered by a valid claim of a licensed patent, are based on the transferred IND from Cornell University, use any licensed materials, or are produced using a licensed method, and to practice certain licensed technology, in all cases, for all human and non-human prophylactic and therapeutic uses. In July 2022, we entered into Amendment No. 1 to the Cornell First License Agreement that updated fees and royalties payable by us under the Cornell First License Agreement. In September 2022, we entered into Amendment No. 2 to the Cornell First License Agreement that clarified patent prosecution and maintenance obligations and added certain inventions and patents to the list of inventions and patent rights covered under the Cornell First License Agreement. The technology under the license includes portfolios for APOE, Alzheimer&#8217;s disease, and Anti-Tau, although our license is not restricted by such indications. The license is exclusive with respect to certain patents and non-exclusive with respect to other patents. Additionally, under the Cornell First License Agreement, Cornell University assigned to us an IND for the use of AAVrh10.hAPOE2 vector to treat </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients who are at risk of having or have Alzheimer&#8217;s disease. Cornell University reserved the rights to publish and disseminate information about inventions included in the licensed technology and licensed patents, and to use, and allow other nonprofit institutions to use, the patents and technology for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within specified time frames, to achieve certain development milestones within specified time frames, to meet agreed minimum-spend requirements, and to meet other diligence obligations. If we fail to perform these obligations, Cornell University could terminate the Cornell First License Agreement in full or in part in specified circumstances, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell First License Agreement, we paid Cornell University an upfront payment of approximately $0.15 million and entered into a purchase agreement for approximately $0.6 million of convertible preferred securities. We are obligated to pay Cornell University an annual license maintenance fee ranging from the low four digits to the mid five digits, increasing annually until such time that we are commercially selling a licensed product. Under the Cornell First License Agreement, we are obligated to pay Cornell University up to $8.4 million for each portfolio upon the achievement of specific clinical and regulatory milestones. We are obligated to pay Cornell University a flat royalty in the mid-single-digits based on net sales of a licensed product in a country, which royalty rate increases by one percent if the licensed product is an orphan drug, subject to a reduction upon the expiration of valid claims in licensed patents and certain reductions for third-party licenses. In addition, in certain specific instances where sales are made by a sublicensee, the royalty rate increases by an amount in the low to mid-single digits. If the royalties are below certain agreed amounts, we are required to pay Cornell University minimum annual royalties ranging from low-six digits to low-seven digits. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) expiration or invalidation of the last valid claim in the licensed patent, (b) the expiration of regulatory exclusivity, and (c) the month of the first commercial launch of a generic equivalent in such country. We are also obligated to pay Cornell University a percentage of sublicensing fees in the low-double digits to mid-double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate the Cornell First License Agreement or any portfolio thereunder at any time upon ninety (90)-days&#8217; advance written notice to Cornell University. Cornell University may terminate the Cornell First License Agreement if we commit a material breach and fail to cure such breach within a specified cure period after written notice or if we challenge the validity of a licensed patent. Upon expiration of the royalty term of a given licensed product in a country, the license becomes non-exclusive and royalty-free. Upon termination of the Cornell First License Agreement, all licenses and rights granted by either party will terminate, although we will have a period of time to sell off any remaining licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Second license agreement with Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2020, we entered into a second license agreement with Cornell University, or the Cornell Second License Agreement, pursuant to which we obtained a sublicensable, worldwide license under certain patents to make, use, and sell products that are covered by a valid claim of a licensed patent, are based on the transferred IND from Cornell University, use any licensed materials, or are produced using a licensed method, and to practice certain licensed technology, in all cases, for all human and non-human prophylactic and therapeutic uses. In January 2022, we entered into Amendment No. 1 to the Cornell Second License Agreement, whereby we paid Cornell a material transfer fee and a license fee totaling $30,000, and Cornell added certain materials to the list of original materials subject to the Cornell Second License Agreement. In July 2022, we entered into Amendment No. 2 to the Cornell Second License Agreement that updated fees and royalties payable by us under the Cornell Second License Agreement. The technology under the license includes a portfolio for FA, although our license is not restricted by such indications. The license is exclusive with respect to certain patents and non-exclusive with respect to other patents. Cornell University reserved the rights to publish and disseminate information about inventions included in the licensed technology and licensed patents, and to use, and allow other nonprofit institutions to use, the patents and technology for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within specified time frames, to achieve certain development milestones within specified time frames, to meet agreed minimum-spend requirements, and to meet other diligence obligations. If we fail to perform these obligations, Cornell University could terminate the Cornell Second License Agreement in full or in part in specified circumstances, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell Second License Agreement, we paid Cornell University an upfront payment of approximately $0.15 million and entered into a purchase agreement for approximately $0.6 million of convertible preferred securities. We are obligated to pay Cornell University an annual license maintenance fee ranging from the low four digits to the mid five digits, increasing annually until such time that we are commercially selling a licensed product. Under the Cornell Second License Agreement, we are obligated to pay Cornell University up to $4.3 million for two portfolios and up to $0.6 million for a third portfolio upon the achievement of specific clinical and regulatory milestones. Upon submitting our IND application for LX2006 to the FDA in the first quarter of 2022, we achieved the first clinical milestone under the Cornell Second License Agreement, and we paid $0.1 million to Cornell University in the second quarter of 2022 in connection with this milestone. We are obligated to pay Cornell University a flat royalty in the mid-single-digits based on net sales of a licensed product in a country, which royalty rate increases by one percent if the licensed product is an orphan drug, subject to a reduction upon the expiration of valid claims in licensed patents and certain reductions for third-party licenses. In addition, in certain specific instances where sales are made by a sublicensee, the royalty rate increases by an amount in the low to mid-single digits. If the royalties are below certain agreed amounts, we are required to pay Cornell University minimum annual royalties ranging from low six digits to low seven digits. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) expiration or invalidation of the last valid claim in the licensed patent, (b) the expiration of regulatory exclusivity, and (c) the month of the first commercial launch of a generic equivalent in such country. We are also obligated to pay Cornell University a percentage of sublicensing fees ranging in the low double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate the Cornell Second License Agreement or any portfolio thereunder at any time upon ninety (90)-days&#8217; advance written notice to Cornell University. Cornell University may terminate the Cornell Second License Agreement if we commit a material breach and fail to cure such breach within a specified cure period after written notice or if we challenge the validity of a licensed patent. Upon expiration of the royalty term of a given licensed product in a country, the license becomes non-exclusive and royalty-free. Upon termination of the Cornell Second License Agreement, all licenses and rights granted by either party will terminate, although we will have a period of time to sell off any remaining licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third license agreement with Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we entered into a third license agreement with Cornell University, or the Cornell Third License Agreement, pursuant to which we obtained certain rights for FA cardiomyopathy, including an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell University on our behalf and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo, to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell University has also granted us a right of reference to its IND application for a gene therapy for FA cardiomyopathy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within specified time frames, to achieve certain development milestones within specified time frames, to meet agreed minimum-spend requirements, and to meet other diligence obligations. If we fail to perform these obligations, Cornell University could terminate the Cornell Third License Agreement in full or in part in specified circumstances, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell Third License Agreement, we paid a license issue fee and an initial data transfer fee to Cornell University totaling $0.6 million. Additionally, we will be paying an annual data transfer fee of $50,000 until data is no longer being gathered. We have agreed to pay annual license maintenance fees ranging from $2,500 to $25,000 until such time we commercialize a licensed product. In addition, we will pay Cornell University up to an aggregate of $2.1 million in regulatory milestones and up to an aggregate of $100 million in commercial milestones, plus low single digit royalties on net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we entered into a Research Collaboration Agreement with Cornell University on behalf of Weill Cornell Medicine, or the 2025 Cornell Collaboration Agreement, in connection with the Cornell Third License Agreement entered into in April 2024. Under the 2025 Cornell Collaboration Agreement, we committed to fund scientific research at Weill Cornell Medicine related to intellectual property and know-how licensed to us pursuant to the Cornell Third License Agreement. Cornell University reserved the rights to publish and disseminate information about the results generated from Cornell University's investigator's conduct of the research.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell Third License Agreement, we committed to provide funding for research projects at Weill Cornell Medicine of $500,000 per year over a two-year period. The total budget for the research under the 2025 Cornell Collaboration Agreement is approximately $1.1 million, which will be credited against our research funding commitment under the Cornell Third License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to each Weill Cornell Medicine invention and joint invention and related joint results that is either an improvement to, or is dominated by, the patent rights under the Cornell Third License Agreement or is specifically designed for a licensed product under the Cornell Third License Agreement, or an Improvement, and for which we have made an election to obtain such inventions, the Cornell Third License Agreement will be amended to include license grants to such Improvements following payment of the relevant amendment fee in the low five digits. With respect to each Weill Cornell Medicine invention and joint invention and related joint results that are not Improvements, we have the first option to negotiate for a royalty-bearing, worldwide license under such intellectual property to develop, make, have made, use, offer for sale, sell, have sold and import products on commercially reasonable terms.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2025 Cornell Collaboration Agreement has a two-year term and may be terminated earlier by either party upon a material breach that remains uncured for 60 days following written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Adverum</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, we entered into a license agreement with Adverum, which we amended in February 2022 pursuant to the First Amendment to the Adverum Agreement, such agreement as amended, the Amended Adverum Agreement. Pursuant to the Amended Adverum Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents, know-how, and other intellectual property relating to viral vector technology for gene therapy applications for the treatment of FA cardiomyopathy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are responsible for the development, manufacture, and commercialization of gene therapy products that consist of a specific nucleic acid sequence that is delivered by a specific gene therapy, or the Products. We are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize the Products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Amended Adverum Agreement, we paid Adverum a $7.5 million upfront payment. We are obligated to pay Adverum up to $17.5 million upon the achievement of specified development and regulatory milestones, including a $3.5 million development milestone that was achieved in the first quarter of 2023, and up to $49 million in commercialization and sales milestones for the Products. We are obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products, subject to reductions upon the expiration of valid claims in licensed patents and third-party licenses. The royalty term continues for each Product on a country-by-country basis beginning on the first commercial sale of such Product and ending on the latest of (a) expiration of the last valid claim in the licensed patent that covers the manufacture, use, or sale of the Product in such country, (b) the expiration of all regulatory and data exclusivity in such country, and (c) ten years after the first commercial sale of such Product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Adverum Agreement will expire, unless earlier terminated, on the expiration of the last royalty term for a Product in a particular country. We have the right to terminate the Amended Adverum Agreement at any time upon one-hundred twenty days&#8217; advance written notice to Adverum. In addition, subject to certain conditions, either we or Adverum may terminate the Amended Adverum Agreement upon the insolvency of the other or if the other party commits a material breach of the agreement and fails to cure such breach within a specified cure period after written notice is provided. Additionally, Adverum may terminate the Amended Adverum Agreement if we challenge the validity of any licensed patents. Upon expiration of the Amended Adverum Agreement, the license becomes royalty-free, irrevocable and perpetual. Upon termination of the Amended Adverum Agreement, all licenses, sublicenses, and rights granted by either party will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 9, 2025, Eli Lilly and Company, or Lilly, announced the acquisition of Adverum pursuant to a tender offer by Lilly's wholly owned subsidiary to purchase all outstanding shares of Adverum common stock. Accordingly, Lilly assumed all of Adverum's obligations and responsibilities under the Amended Adverum Agreement after the acquisition.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First license agreement with The Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios Therapeutics, Inc., or Stelios, which we acquired in August 2021, is successor-in-interest to ARVC Therapeutics, Inc., or ARVC Therapeutics, under a worldwide license agreement entered into by ARVC Therapeutics and The Regents of the University of California, on April 23, 2020, or the UCSD First License Agreement, pursuant to which they obtained a license to certain intellectual property related to gene therapies for ARVC. The UCSD First License Agreement relates to our development efforts for our LX2021 program. Pursuant to the UCSD First License Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents to make, use, sell, offer for sale and import services, methods, composition and products that incorporate or are developed using any licensed invention or licensed methods, or is covered by a valid claim of a licensed patent, or a Product, in all cases for all diagnostic and therapeutic uses. The Regents of University of California, San Diego, or UCSD, reserved the right to practice the relevant invention and licensed patents for educational and research purposes, to publish and disseminate information about the relevant invention and licensed patents, and to allow other nonprofit institutions to use, publish, or disseminate information about the relevant inventions and licensed patents for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the UCSD First License Agreement, we are obligated to achieve certain development milestones within specified time frames, to use commercially reasonable efforts to diligently develop, manufacture, and sell Products, and to meet agreed minimum-spend requirements. If we fail to perform any of these obligations, UCSD could either terminate the UCSD First License Agreement or convert the exclusive license to a nonexclusive license, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD First License Agreement required Stelios to pay one-time up-front non-refundable cash fees of $20,000. We are obligated to pay annual license maintenance fees in the mid-four digits to low-five digits, increasing until such time that we are commercially selling a Product. We are also obligated to pay up to $4.75 million upon the achievement of specific development and commercialization milestones for the first Product and low- to mid-single digit royalties based on aggregate net sales, subject to certain reductions for third-party licenses. The royalty term continues until the expiration of the UCSD First License Agreement. Under the UCSD First License Agreement, if the royalties are below certain agreed amounts, we are required to pay UCSD minimum annual royalties ranging from low- to mid-five digits. We are also obligated to pay UCSD a percentage of sublicensing fees ranging in the low double digits. In the event that we assign the UCSD First License Agreement, we will be obligated to pay an assignment fee that will be determined based on certain aspects of the assignment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD First License Agreement will expire, unless earlier terminated, on the expiration of the last claim of any licensed patent or patent applications in a particular country. We have the right to terminate the UCSD First License Agreement at any time upon sixty (60)-days&#8217; written notice to UCSD. UCSD may terminate the UCSD First License Agreement if we commit a material breach, if we fail to meet certain specified milestones within the prescribed time periods, if we are delinquent on any report or payment or provide an intentionally misleading report, if we fail to diligently develop and commercialize the licensed products, or if we challenge the validity of a licensed patent, in each case only if we fail to cure such problem within a specified cure period after written notice. Upon termination of the UCSD First License Agreement, all licenses and rights granted by UCSD to us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Second license agreement with The Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios, which we acquired in August 2021, entered into a worldwide license agreement in August 2020 with The Regents of the University of California, or the UCSD Second License Agreement, pursuant to which they obtained a license to certain intellectual property and materials related to gene therapies for HCM. The UCSD Second License Agreement relates to our development efforts for our LX2022 programs. Pursuant to the UCSD Second License Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents to make, use, sell, offer for sale and import services, methods, composition and products that incorporate or are developed using any licensed invention or licensed methods or is covered by a valid claim of a licensed patent, or a Product, and a non-exclusive license to use nonpublic technical information, or Technology, in all cases for all diagnostic and therapeutic uses. UCSD reserved the rights to practice the relevant invention, Technology and licensed patents for educational and research purposes, to publish and disseminate information about the relevant invention, Technology and licensed patents, and to allow other nonprofit institutions to use, publish, or disseminate information about the relevant invention, Technology and licensed patents for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the UCSD Second License Agreement, we are obligated to achieve certain development milestones within specified time frames and to use commercially reasonable efforts to diligently develop, manufacture, and sell Products. If we fail to perform any of these obligations, UCSD could either terminate the UCSD Second License Agreement or convert the exclusive license to a nonexclusive license subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Second License Agreement required Stelios to pay one-time up-front non-refundable cash fees of $20,000. We are obligated to pay annual license maintenance fees in the mid-four digits to low-five digits, increasing until such time that we are commercially selling a Product. We are also obligated to pay up to $2.4 million upon the achievement of certain development and commercialization milestones for the first Product and low-single digit royalties based on aggregate net sales, subject to certain reductions for third-party licenses. The royalty term continues until the expiration of the UCSD Second License Agreement. We are also obligated to pay UCSD a percentage of sublicensing fees ranging in the low double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 14, 2025, the Company entered into an amended and restated license agreement with UCSD, which amended, restated, and superseded the UCSD Second License Agreement in its entirety (the "Amended and Restated UCSD Second License Agreement"). The Amended and Restated UCSD Second License Agreement maintained the Company's prior exclusive worldwide license to materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy, replaced Stelios with the Company as licensee, and exclusively in-licensed additional materials and intellectual property related to the LX2022 program. The economic terms in the Amended and Restated UCSD Second License Agreement are substantially similar to the terms of the UCSD Second License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended and Restated UCSD Second License Agreement will expire, unless earlier terminated, on the expiration of the last claim of any licensed patent or patent applications in a particular country. We have the right to terminate the Amended and Restated UCSD Second License Agreement at any time upon sixty (60)-days&#8217; written notice to UCSD. UCSD may terminate the Amended and Restated UCSD Second License Agreement if we commit a breach, if we fail to meet certain specified milestones within the prescribed time periods, if we are delinquent on any report or payment, if we are not diligently developing or commercializing Products in accordance with our diligence obligations, if we provide any intentionally false report, or if we challenge the validity of a licensed patent, in each case only if we fail to cure such problem within a specified cure period after written notice. In the event that we assign the Amended and Restated UCSD Second License Agreement, we will be obligated to pay an assignment fee that will be determined based on the acquisition price. Upon termination of the Amended and Restated UCSD Second License Agreement, all licenses and rights granted by UCSD to us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third license agreement with The Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, we entered into a worldwide license agreement with UCSD, or the UCSD Third License Agreement, and collectively with the UCSD First License Agreement and the UCSD Second License Agreement, The UCSD License Agreements, pursuant to which we obtained a license to materials and intellectual property related to a gene therapy for ARVC. The UCSD Third License Agreement relates to our development efforts for our LX2020 program. Pursuant to the UCSD Third License Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents to make, use, and sell, offer for sale and import services, methods, composition and products that incorporate or are developed using any licensed invention or licensed methods, or is covered by a valid claim of a licensed patent, or a Product, and an exclusive license to use nonpublic technical information, or Technology, in all cases for all diagnostic and therapeutic uses. UCSD reserved the rights to practice the relevant invention, Technology and licensed patents for educational and research purposes, to publish and disseminate information about the relevant invention, Technology and licensed patents, and to allow other nonprofit institutions to use, publish, or disseminate information about the relevant invention, Technology and licensed patents for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the UCSD Third License Agreement, we are obligated to achieve certain development milestones within specified time frames, to use commercially reasonable efforts to diligently develop, manufacture, and sell licensed products, and to meet agreed minimum-spend requirements. If we fail to perform any of these obligations, UCSD could either terminate the UCSD Third License Agreement or convert the exclusive license to a nonexclusive license subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Third License Agreement required us to pay a one-time up-front non-refundable cash fee of $20,000. We are obligated to pay annual license maintenance fees in the mid-four digits to low-five digits, increasing until such time that we are commercially selling a Product. We are also obligated to pay up to $4.0 million upon the achievement of specified development and commercialization milestones for the first Product and low- to mid-single digit royalties based on aggregate net sales, subject to certain reductions for third-party licenses. The royalty term continues until the expiration of the UCSD Third License Agreement. If the royalties are below certain agreed amounts, we are required to pay UCSD minimum annual royalties ranging from low- to mid-five digits. We are also obligated to pay UCSD a percentage of sublicensing fees ranging in the low double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Third License Agreement will expire, unless earlier terminated, on the expiration of the last claim of any licensed patent or patent applications in a particular country. We have the right to terminate the UCSD Third License Agreement at any time upon sixty (60)-days&#8217; written notice to the UCSD. UCSD may terminate the UCSD Third License Agreement if we commit a material breach, if we fail to meet certain specified milestones within the prescribed time periods, if we are delinquent on any report or payment, if we are not diligently developing or commercializing Products in accordance with our diligence obligations, if we provide any intentionally false report, or if we challenge the validity of a licensed patent, in each case only if we fail to cure such problem within a specified cure period after written notice. In the event that we assign the UCSD Third License Agreement or we undergo a change of control, we will be obligated to pay a flat low-six digit fee or a fee that will be determined based on the acquisition price. Upon termination of the UCSD Third License Agreement, all licenses and rights granted by The Regents of UCSD to us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sponsored research agreements with The Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the UCSD License Agreements, on December 3, 2021, we entered into a sponsored research agreement with UCSD for our LX2020 and LX2021 programs, or First UCSD SRA, which was subsequently amended on April 5, 2023 and August 31, 2023, and another sponsored research agreement with UCSD for our LX2022 program, or Second UCSD SRA, which was subsequently amended on April 19, 2023. We refer to these agreements, as amended, as the Amended UCSD SRAs. UCSD reserved the rights to publish and disseminate information about the results generated from UCSD&#8217;s investigator&#8217;s conduct of the research. The total costs to be invoiced to us under the terms of the Amended UCSD SRAs are approximately $5.6 million. Under the terms of the Amended UCSD SRAs, we have the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses to any inventions generated by UCSD or UCSD&#8217;s interest in any inventions generated jointly by The Regents of UCSD and us, and we retain the rights to any inventions generated solely by us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, we entered into a third sponsored research agreement with UCSD, or the Third UCSD SRA, for our LX2022 program in connection with the UCSD Second License Agreement. Under the terms of the Third UCSD SRA, we have the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by UCSD or resulting inventions jointly owned between us and UCSD, and we retain the rights to any resulting inventions owned by us. The Third UCSD SRA has a two-year term and may be terminated early by us at any time upon the giving of thirty (30)-days&#8217; written notice to UCSD. The costs to be invoiced to us over the term of the Third UCSD SRA are $0.7 million, and we may incur additional costs of $0.6 million under the Third UCSD SRA if certain study objectives are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, we entered into another amendment to the Second UCSD SRA for our LX2022 program that extended the term of the Second UCSD SRA to December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 19, 2024 and September 27, 2024, we entered into amendments, respectively, to the First UCSD SRA for our LX2021 program in connection with the UCSD First License Agreement. We refer to the First UCSD SRA, as amended, as the Amended First UCSD SRA. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to us under the Amended First UCSD SRA are $0.7 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government regulation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics, including gene therapies, such as those we are developing. Generally, before a new biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. biologics regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, biological products are subject to regulation under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations and other federal, state, local and foreign statutes and regulations. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative actions or judicial sanctions. These actions and sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal fines or penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates must be approved by the FDA through the BLA the process which is required by the FDA before biological product candidates may be marketed in the United States and generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s good laboratory practices, or GLPs, regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, the FDA&#8217;s current Good Clinical Practices, or cGCPs, and other clinical trial-related regulations to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of a BLA that contains sufficient data to demonstrate substantial evidence of effectiveness;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of user fees for FDA review of the BLA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-license inspection of the manufacturing facility or facilities at which the proposed product will be produced to assess compliance with current good manufacturing practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to ensure and preserve the biological product&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with the cGCPs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval, or licensure, of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and clinical development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND application to the FDA. An IND application is a request for authorization from the FDA to administer an IND product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND application also includes results of animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND application must become effective before human clinical trials may begin. The IND application automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises concerns or questions about the proposed clinical trial. In such a case, the IND application may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND application therefore may or may not result in FDA authorization to begin a clinical trial. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs and could generate requests for information or clinical holds on other product candidates or programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators, generally physicians not employed by or under the sponsor&#8217;s control, in accordance with cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND application must be made for each successive clinical protocol conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed to ensure that the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND application. If a foreign clinical trial is not conducted under an IND application, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND application if the foreign data are applicable to the United States population and medical practice, the trial was performed by clinical investigators of recognized competence, the trial was conducted in accordance with cGCP requirements, and the data may be considered valid without the need for an on-site inspection by the FDA or the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of BLA approval of a product candidate, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For gene therapies in general, the investigational product is initially introduced into patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The investigational product is administered to a limited patient population to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When these phases overlap or are combined, the trials may be referred to as Phase 1/2 or Phase 2/3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, potency, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical study investigators. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious, unexpected and suspected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious, and unexpected suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor may suspend a clinical study at any time on various grounds, including a finding that the research patients or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated checkpoints based on access to certain data from the study and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicaltrials.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA submission and review</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. No user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The FDA reviews all submitted BLAs before it accepts them for filing, and may request additional information rather than accepting the BLA for filing. The FDA has 60 days from the applicant&#8217;s submission of a BLA to either issue a refusal to file letter or accept the BLA for filing, indicating that it is sufficiently complete to permit substantive review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process can be significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent for its intended use, and whether the facility in which it is manufactured, processed, packed or held meets standards designed to ensure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee, typically a panel that includes clinicians and other experts, to provide clinical insight on applications for novel products or products which present difficult questions of safety or efficacy. The advisory committee will provide a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter will usually describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification, which may include the potential requirement for additional preclinical studies or clinical trials or additional manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor the safety or efficacy of a product. Further, FDA&#8217;s &#8220;real time&#8221; release of newly issued Complete Response Letters associated with withdrawn or abandoned applications, if applicable to any of our product candidates, can materially impact our business and competitive advantage.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited development and review programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA offers a number of expedited development and reviews programs for qualifying product candidates. The Fast Track program is intended to expedite or facilitate the process for developing new products that meet certain criteria. Specifically, product candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track designated product candidate has opportunities for frequent interactions with the FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A Fast Track designated product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The sponsor can request the FDA to designate the product candidate for Fast Track status any time before receiving BLA approval, but ideally no later than the pre-BLA meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate may receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the 21st Century Cures Act, Congress amended the FDCA to facilitate an efficient development program for, and expedite review of regenerative medicine therapies, which include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a &#8220;regenerative medicine therapy.&#8221; A product candidate may be eligible for RMAT designation if it meets the following criteria: (1) it is a regenerative medicine therapy; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that it has the potential to address unmet medical needs for such a disease or condition. A sponsor may request that the FDA designate a product candidate as an RMAT concurrently with or at any time after the submission of an IND. A BLA for a product candidate that has received RMAT designation may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A product candidate with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review. A product is eligible for priority review if it is designed to treat a serious or life threatening disease or condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a product candidate may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies with due diligence to verify and describe the anticipated effect on IMM or other clinical benefit. The FDA may withdraw approval of a product or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, pre-approval of all advertising and promotional materials intended for dissemination or publication, which could adversely impact the timing of the commercial launch of the product. The Food and Drug Omnibus Reform Act also made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, RMAT designation, and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant Orphan Drug designation to a product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that product candidate. Orphan Drug designation must be requested before submitting a BLA. After the FDA grants Orphan Drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has Orphan Drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or if the holder of the orphan drug exclusivity cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the product was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research and a waiver of the BLA application fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received Orphan Drug designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In view of the court decision in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharms., Inc. v. Becerra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 14 F.4th 1299 (11th Cir. 2021), in January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#8217;s order in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. The Consolidated Appropriations Act of 2026, signed into law in February 2026, codified this longstanding FDA interpretation of the Orphan Drug Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the U.S. Supreme Court overruled the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine, which gives deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies, which could lead to uncertainties in the industry. Further, changes in the leadership of the FDA and other federal agencies under the Trump administration may lead to new policies, changes in the regulations, or disruptions to the operations of federal agencies, any of which may impact our clinical development plans.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rare Pediatric Disease designation and priority review vouchers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, as amended, the FDA incentivizes the development of product candidates that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received from sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biologic application after the date of approval of the rare pediatric disease drug product. A sponsor may request Rare Pediatric Disease designation from the FDA prior to the submission of its BLA. A Rare Pediatric Disease designation does not guarantee that a sponsor will receive a priority review voucher, or PRV, upon approval of its BLA. Moreover, a sponsor who chooses not to submit a Rare Pediatric Disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. The Consolidated Appropriations Act of 2026 extended the rare pediatric disease PRV program to September 30, 2029, which means the FDA may not award any PRVs under this program after September 30, 2029, unless Congress takes further action to extend the program.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric information and pediatric exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act, or PREA, certain BLAs and certain supplements to a BLA must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for the submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning or untitled letters or holds on post-approval clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and reference product exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act, or BPCIA, which created an abbreviated approval pathway for biologics that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics, as well as the processes by which such products are manufactured, pose significant hurdles to the implementation of the abbreviated approval pathway that are still being worked out by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact and implementation of the BPCIA are subject to significant uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of companion diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an in vitro diagnostic, which is regulated by the FDA as a medical device, is essential to the safe and effective use of a therapeutic and is not available on the market, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics. According to the guidance, an unapproved or uncleared companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational medical device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. The sponsor of the diagnostic device will be required to comply with the IDE regulations for clinical studies involving the investigational diagnostic device. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same clinical trial, if the trial meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the clinical trial protocol, the investigational product(s), and subjects involved, a sponsor may seek to submit an IDE alone (e.g., if the drug has already been approved by FDA and is used consistent with its approved labeling), or both an IND and an IDE.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuing FDA approval/clearance of an in vitro companion diagnostic would require either a pre-market notification, also called 510(k) clearance, or a pre-market approval, or PMA, or a de novo classification for that diagnostic. The review of companion diagnostics involves coordination of review with the FDA&#8217;s Center for Devices and Radiological Health. Once cleared or approved, the companion diagnostic must adhere to post-marketing requirements including the requirements of FDA&#8217;s quality system regulation, medical device reporting, recalls and corrections along with product marketing requirements and limitations. Companion diagnostic manufacturers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#8217;s facilities for compliance with its authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">510(k) clearance process</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain 510(k) clearance, a pre-market notification is submitted to the FDA demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet required the submission of a PMA application. The FDA&#8217;s 510(k) clearance process may take three to 12 months from the date the application is submitted and filed with the FDA, but may take longer if FDA requests additional information, among other reasons. In some cases, the FDA may require clinical data to support substantial equivalence. In reviewing a pre-market notification submission, the FDA may request additional information, which may significantly prolong the review process. Notwithstanding compliance with all these requirements, clearance is never assured. After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new 510(k) clearance or require a PMA. In addition, the FDA may make substantial changes to industry requirements, including which devices are eligible for 510(k) clearance, which may significantly affect the process.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">De novo classification process</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a new medical device does not qualify for the 510(k) pre-market notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act of 1997 established a different route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be inadequate to control the risks and special controls cannot be developed. Obtaining FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several years, and generally requires significant scientific and clinical data.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PMA process</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years or longer. The applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, including information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application fee. In addition, PMAs for medical devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality Management System Regulation, which imposes extensive testing, control, documentation, and other quality assurance and GMP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other healthcare laws and compliance requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business, particularly once they have a commercialized product that is reimbursable by third-party payor programs. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, the civil False Claims Act, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar foreign, federal and state fraud and abuse, transparency and privacy laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, including stock options. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly, and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Civil and criminal false claims laws, and civil monetary penalty laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For example, the civil False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA created additional federal civil and criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the U.S. federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose certain requirements on HIPAA covered entities, which include certain healthcare providers, healthcare clearing houses and health plans, and individuals and entities that provide services on their behalf that involve individually identifiable health information, known as business associates, relating to the privacy, security and transmission of individually identifiable health information, as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor, state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state and local laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws which require the reporting of information related to product pricing, state and local laws requiring the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval in the future. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, it is possible that one or more of our product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biologics, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third party not to cover a product could reduce physician usage and patient demand for the product. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, ensuring adequate coverage and payment for any biological candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA, which was enacted in 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. In addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2032. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. The Inflation Reduction Act of 2022, or the IRA, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the U.S. Department of Health and Human Services, or the HHS, rebate rule that would have limited the fees that pharmacy benefit managers can charge. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for single-source biologics) can qualify for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D drugs in 2023, negotiations began in 2024, and the negotiated maximum fair price for each drug has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, up to an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, up to 20 additional Part B or Part D drugs will be selected. HHS has and will continue to issue and update guidance as these programs are implemented. Various industry stakeholders have initiated lawsuits against the federal government asserting that the price negotiation provisions of IRA are unconstitutional. Additionally, the One Big Beautiful Bill Act (OBBBA), which was signed into law in July 2025, includes provisions that are expected to impact the U.S. healthcare system in various ways, including cuts to Medicaid and introducing new requirements for Medicaid coverage. The current administration also issued executive orders focused on decreasing prescription drug prices, including directing the Secretary of Health and Human Services to establish a mechanism through which American patients can buy drugs directly from manufacturers who sell at a most-favored-nation price and directing the U.S. Trade Representative and Secretary of Commerce to take action to ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. In November 2025, CMS announced a voluntary initiative called the GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid Model) to introduce the option of most-favored-nation pricing to the Medicaid program, whereby a drug manufacturer may voluntarily offer supplemental rebates to participating state Medicaid programs for a manufacturer&#8217;s covered outpatient drugs. Government agreements with pharmaceutical companies and other government measures that use most-favored-nation pricing targets for prescription drugs, including the use of international pricing reference to set drug prices in the United States, or that increase generic drug and biosimilar entry sooner than expected, could materially harm the Company&#8217;s business, including with respect to its ability to set adequate pricing for new drugs to recover its research and development costs. It is currently unclear how the ongoing judicial challenges as well as other legislative, executive, and administrative actions, including how the IRA will be implemented, will impact the pharmaceutical industry. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and human capital resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 59 full-time employees. Of our 59 full-time employees, 41 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our employees. We believe our success depends on our ability to attract, retain, develop and motivate highly skilled personnel. In particular, we depend upon the personal efforts and abilities of the principal members of our senior management to partner effectively as a team, and to provide strategic direction, develop our business, manage our operations and maintain a cohesive and stable work environment. We also rely on qualified managers and skilled employees, such as scientists, medical professionals, engineers and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering skills and quality management experience in order to operate our business successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees. Accordingly, we use a mix of competitive base salary, performance-based equity compensation awards and other employee benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2017, we were formed as a Delaware limited liability company under the name LEXEO Therapeutics, LLC. In November 2020, we converted into a Delaware corporation and were renamed Lexeo Therapeutics, Inc. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York 10010, and our telephone number is (212) 547-9879.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our website address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.lexeotx.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The information contained on, or accessible through, our website is not incorporated by reference into this Annual Report. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are filed with the SEC. Such reports and other information filed by us with the SEC are available free of charge on our website at ir.lexeotx.com when such reports are available on the SEC&#8217;s website. The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The information contained on the websites referenced in this Annual Report is not incorporated by reference into this filing. Further, our references to website URLs are intended to be inactive textual references only.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Channels of Distribution</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We announce material information to the public through filings with the SEC, the investor relations page on our website, press releases, public conference calls, our LinkedIn account and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and for complying with our disclosure obligations under Regulation FD. We encourage investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on our website.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sk Factors</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this Annual Report, before deciding whether to invest in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. We cannot provide assurance that any of the events discussed below will not occur.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors Summary</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock risky include, among others:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have incurred significant losses since our inception, and we expect to incur significant net losses for the foreseeable future and may not be able to achieve or sustain revenue or profitability in the future;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have a limited operating history and have no products approved for commercial sale;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval or the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interim &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce, publish or present from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates. We may also identify safety and efficacy concerns after the approval of a product candidate which can result in negative consequences to our business and results of operations; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">some of the diseases we initially seek to treat have low prevalence and it may be difficult to identify and enroll patients with these diseases. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may seek Orphan Drug designation or Rare Pediatric Disease designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with Orphan Drug designation, including the potential for market exclusivity, for product candidates for which we obtain Orphan Drug designation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy designation that we may receive from the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and we may seek such designation for future product candidates if Congress extends the rare pediatric disease priority review program. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we rely on our collaborations with several leading academic institutions to conduct research and development for many of our pipeline programs, including conducting preclinical and IND-enabling studies for portions of our near-term future pipeline. Failure or delay of our academic partners to fulfill all or part of their respective obligations to us under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of either of these relationships could materially harm our business;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the FDA and other government agencies, regulatory actions and other actions under the current administration could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may become subject to claims that we and our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or trade secrets of third parties.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our financial position and capital needs</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. For the years ended December 31, 2025 and December 31, 2024, we incurred net losses of $100.0 million and $98.3 million, respectively, and we had an accumulated deficit of $380.1 million as of December 31, 2025. We have primarily financed our operations with net proceeds from the October 2025 Financing Transactions (as defined below), May 2025 Private Placement (as defined below), the March 2024 Private Placement (as defined below), net proceeds raised in our IPO and the subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares of common stock, as well as sales of our convertible equity securities. We have no products approved for commercialization and have never generated any revenue from product sales.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are still in the early clinical stages of development of our lead product candidates. We expect to continue to incur significant expenses and operating losses over the next several years. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to advance the preclinical and clinical development of our product candidates and discovery programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate and complete additional clinical trials of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approval for any product candidates that successfully complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to develop our gene therapy product candidate pipeline; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scale up our clinical and regulatory capabilities; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">work with our third party manufacturing partners to produce material in accordance with cGMP for clinical trials or potential commercial sales; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish, either alone or with a third party, a commercialization infrastructure and scale up manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio and patent claims; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional clinical, quality control, regulatory, manufacturing, scientific and administrative personnel; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting and other expenses while operating as a public company.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from the commercialization of our product candidates. To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities and all of our product candidates are in early clinical trials or preclinical development. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage genetic medicine company with a limited operating history. We commenced substantive business operations in 2020, and our operations to date have been largely focused on organizing and staffing our company, business planning, raising capital, entering into collaboration and license agreements for conducting preclinical and clinical research and development activities for our product candidates and gene therapy pipeline, and conducting clinical trials for our product candidates through CROs and other third parties. To date, we have not yet demonstrated our ability to successfully complete pivotal clinical trials, manufacture a product on a commercial scale or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates, preclinical development for our other product candidates, and potential commercialization of these product candidates, if any are approved. We expect our spending levels to significantly increase in connection with our planned clinical trials of our lead product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our clinical trials, our research and development programs or other operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had cash, cash equivalents, and investments in U.S. Treasury securities of $246.6 million. We believe that our cash, cash equivalents, and investments in U.S. Treasury securities balances will be sufficient to fund our operating expenses and capital requirements into 2028. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional product candidates, and changes in regulation. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of and investment in ongoing and future development of our gene therapy product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, costs and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we develop, in-license or acquire other product candidates and technologies in our product candidate pipeline;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of, and development requirements for, product candidates that we may pursue;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial infrastructure;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing and maintaining commercial-scale cGMP manufacturing capabilities, either internally or with third parties;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of any collaborations that we may establish and our license agreements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome of any legal proceedings involving us;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under our collaboration agreements or any additional collaboration agreements we may enter into; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional capital to achieve our business objectives. While the long-term economic impact of the ongoing geopolitical conflicts in Ukraine and the Middle East is difficult to assess or predict, each of these events has caused significant disruptions to the global financial markets and contributed to a general global economic slowdown. Furthermore, inflation rates, particularly in the United States, have increased recently to levels not seen in decades. Increased inflation may result in increased operating costs and may affect our operating budgets, specifically with respect to increased labor costs and associated difficulties in recruiting qualified personnel. In addition, the U.S. Federal Reserve has raised, and may further raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our financial condition and we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, government or private party grants, debt financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates, grant licenses on terms that may not be favorable to us or commit to future payment streams. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the development of our product candidates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our product candidates and technology platforms. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize LX2006, LX2020 and any other product candidates in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our product candidates and programs will require additional preclinical and/or clinical development, regulatory approval and significant marketing efforts, and we will be required to obtain manufacturing supply and expertise and to build a commercial organization or successfully outsource commercialization before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from our product candidates, which may not occur for several years, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our lead product candidates, or any other product candidates that we develop or otherwise may acquire will depend on various factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable, under the FDA's GLPs;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability or development of suitable animal disease models for nonclinical studies to enable us to proceed into clinical development or support the submission of a marketing application; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective IND applications from the FDA or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful enrollment and completion of clinical trials, including under the FDA's current cGCPs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of our own manufacturing capabilities and/or arrangements with third-party manufacturers for our commercial manufacturing processes for any of our product candidates that receive regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of timely marketing approvals from applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launch of commercial sales of products, if approved, whether alone or in collaboration with others;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of the benefits and use of our products, including method of administration, if and when approved, by patients, the medical community and third-party payors, for their approved indications;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of adverse events experienced with any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any diseases for which we are developing our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to produce our product candidates on a commercial scale;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attainment and maintenance of patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of compliance with regulatory requirements such as cGMPs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attainment and maintenance of third-party coverage and adequate reimbursement for our product candidates and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of a continued acceptable safety, tolerability and efficacy profile of our products following approval. </span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on the successful development of a novel therapeutic approach. To date, very few products that utilize gene transfer have been approved in the United States or Europe. There have been a limited number of clinical trials using AAVrh10. Although gene therapies have been studied in human clinical trials for over 30 years, only a limited number of AAV-based gene therapy products have been approved by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that our AAVrh10-based gene therapy product candidates will successfully complete clinical trials or that any future product candidates utilizing this or other vector constructs will successfully complete preclinical studies or clinical trials. We may not be successful in developing product candidates that avoid triggering toxicities or other side effects in preclinical studies or clinical trials. Our intravenous and intrathecal routes of administration may cause unforeseen side effects or present other challenges. Any such results could impact our ability to develop a product candidate, including our ability to enroll patients in our clinical trials. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our approach to gene therapy, or any similar or competitive programs, will result in the identification, development, and regulatory approval of any product candidate, or that other gene therapy programs will not be considered better or more favorable. There can be no assurance that any development problems we experience in the future related to our current gene therapy product candidates or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays and challenges in achieving sustainable, reproducible, and scalable production. Any of these factors may prevent us from completing our preclinical studies or clinical trials or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval nor the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory requirements that will govern any novel gene therapy product candidates we develop are not entirely clear and are subject to change. The novel nature of our capsids makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the European Union or other jurisdictions. Within the broader genetic medicine field, very few gene therapy products have received marketing authorization from the FDA or the European Medicines Agency, or EMA. Even with respect to gene therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products have changed frequently and will likely continue to change in the future, including with respect to those responsible for regulation of existing gene therapy products. For example, in 2016, the FDA established the Office of Tissues and Advanced Therapies, or OTAT, within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and to advise the CBER on its review. In March 2023, the FDA retitled the OTAT to the Office of Therapeutic Products, or OTP, and elevated OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates will need to meet safety and efficacy standards applicable to any new biologic being pursued for a given disease under the regulatory framework administered by the FDA. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies, including IRBs, can impede or delay the initiation of a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same applies in the European Union. The EMA&#8217;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. Advanced-therapy medicinal products include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. This could mean that any gene therapy product candidate we may develop in the future could be required to comply with additional and/or more stringent gene therapy guidelines in the European Union.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we are developing novel potential treatments for diseases in which, in some cases, there is little clinical experience with potential new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. In addition, we may not be able to identify or develop appropriate animal disease models to enable or support planned clinical development. Any natural history studies that we may rely upon in our clinical development may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory review committees and advisory groups described above and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment product candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates are in preclinical or clinical development, and the risk of failure is high. The preclinical studies, clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we may test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target disease. In particular, because our product candidates are subject to regulation as biologics, we will need to demonstrate that they are sufficiently safe and of sufficient purity and potency for use in their target diseases. Each product candidate must demonstrate an adequate risk-versus-benefit profile in its intended patient population and for its intended use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing is expensive, can take many years to complete and is subject to uncertainty. We cannot guarantee that any clinical trials will be initiated on schedule, conducted as planned or completed on schedule, if at all. To date, we are sponsoring clinical trials of LX2006 and LX2020, but we have not successfully completed any clinical trial that we have internally sponsored. Failure can occur at any time during the clinical trial process. Even if our ongoing and future clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted diseases or support continued clinical development of such product candidates. Our future clinical trial results may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. This is particularly true for clinical trials in rare diseases, where the small patient populations make it difficult or impossible to conduct two traditional, adequate and well-controlled trials, and therefore the FDA or comparable foreign regulatory authorities are often required to exercise flexibility in approving therapies for such diseases. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays in initiating and conducting clinical trials of our lead product candidates and we do not know whether our clinical trials will begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data to support the initiation of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in sourcing or qualifying ancillaries required for administration of our clinical drug product (such as vials, stoppers, or tubing);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement with the FDA, EMA or other regulatory authorities as to the design or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain regulatory approval to commence a clinical trial;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to reach an agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to obtain IRB approval for each clinical trial site;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to recruit suitable patients to participate in a clinical trial in a timely manner;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to have patients complete a clinical trial or return for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deviations by clinical trial sites, CROs or other third parties from trial protocol;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to perform our planned clinical trials in accordance with the FDA&#8217;s cGCP requirements, or applicable regulatory guidelines in other countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to address patient-safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to initiate a sufficient number of clinical trial sites; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing sufficient quantities of a product candidate for use in clinical trials.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience changes in regulatory requirements or guidance, or receive feedback from regulatory authorities, that require us to modify the design of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or halt development programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, our investigators or regulators may suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may not have funds to cover the costs;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any future collaborators that conduct clinical trials may face any of the above issues and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully initiate or complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur unplanned costs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval in some countries and not in others;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval for diseases or patient populations that are not as broad as intended or desired;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings REMS;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA, EMA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates will require extensive clinical testing before we are prepared to submit a BLA, or marketing authorization application, or MAA, for regulatory approval. We cannot predict with any certainty if or when we might complete the clinical development for our product candidates and submit a BLA or MAA for regulatory approval of any of our product candidates or whether any such BLA or MAA will be approved. We may also seek feedback from the FDA, EMA or other regulatory authorities on our clinical development program, and the FDA, EMA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict with any certainty whether or when we might complete a given clinical trial. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues from our product candidates may be delayed or lost. In addition, any delays in our clinical trials could increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval or other marketing authorizations by the FDA, EMA and comparable foreign authorities is unpredictable, and it typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to develop in the future. Neither we nor any collaborator is permitted to market any of our biologic product candidates in the United States until we receive regulatory approval of a BLA from the FDA, and we cannot market any of our product candidates in the European Union until we receive approval for an MAA from the EMA, or other required regulatory approval in other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe, effective and of sufficient purity for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates meet regulatory standards, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs, or require changes to our manufacturing approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our product candidates and technology platforms. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize LX2006, LX2020, and our other product candidates in a timely manner.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a BLA or foreign marketing application for any of our product candidates, the FDA, EMA or the applicable foreign regulatory agency may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-marketing clinical trials. The FDA, EMA or the applicable foreign regulatory agency also may approve or authorize for marketing a product candidate for a more limited disease or patient population than we originally request, and the FDA, EMA or applicable foreign regulatory agency may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In June 2024, the Supreme Court overruled the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Chevron</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> doctrine, which had given deference to regulatory agencies&#8217; statutory interpretations of ambiguous regulations in litigation against federal government agencies, such as the FDA. The overruling of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine may significantly increase the number of challenges brought by companies and other stakeholders against federal agencies such as the FDA and its longstanding decisions and policies, including the FDA&#8217;s statutory interpretations of market exclusivities and the &#8220;substantial evidence&#8221; requirements for drug approvals, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, under the current administration, agency reorganization, government shutdown, lapse in government appropriation, voluntary departures at the FDA, and layoffs due to the reduction in force initiative and other measures implemented by the Department of Government Efficiency may impact the normal operations of the FDA as well as other federal agencies. FDA may lack adequate staff and resources to meet current review, approval, and inspection schedules, which could delay our anticipated timelines. In January 2025, an executive order entitled &#8220;Unleashing Prosperity Through Deregulation&#8221;, was issued which calls for at least 10 existing regulations to be repealed whenever an executive department or agency publicly proposes for notice and comment or otherwise promulgates a new regulation. Recent developments at the FDA include announcement of a plan to phase out animal testing for monoclonal antibodies and certain other drugs and the announcement of a new Commissioner&#8217;s National Priority Voucher program for companies supporting certain U.S. national health priorities and interests. To the extent our competitors are selected for this new voucher pilot program and obtain faster approval than us, our competitive position may be harmed. FDA has also increased its scrutiny of foreign drug manufacturing facilities and other contractors based in China, especially with respect to the transfer of biological materials, genetic data, and other sensitive data of American patients to parties located in China. FDA&#8217;s &#8220;real-time&#8221; release of newly issued Complete Response Letters associated with withdrawn or abandoned applications, if received for any of our product candidates, can materially impact our competitive advantage and intellectual property. It is unclear how our industry and our clinical programs will be impacted by the current government shutdown, policies and regulations implemented under the current administration and FDA leadership, or other executive orders. There is significant uncertainty in the industry about how federal agencies like the FDA will change in the coming years under the current administration. To the extent the agency reorganization and other agency changes lead to disruptions in FDA&#8217;s operations, our correspondence and regulatory review processes with the FDA may be materially delayed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials does not ensure that later larger-scale efficacy and safety trials will be successful, nor does it predict final results. For example, we may be unable to identify suitable animal disease models for our product candidates, which could delay or frustrate our ability to proceed into clinical trials or obtain marketing approval. In addition, the preclinical studies conducted by Stelios (an entity that we acquired in 2021) and The Regents of UCSD for our product candidates LX2021 and LX2022 employed an AAV9-based formulation and studies using this vector may not be predictive of future testing we intend to conduct using an AAVrh10-based formulation or other potential capsid serotypes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials. Furthermore, our currently ongoing and most future clinical trials involve or will involve a small patient population. Because of the small sample sizes studied in our trials thus far, the results of these trials may not be indicative of results of future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some of our ongoing and planned clinical trials utilize, or may utilize, an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results when studied in a controlled environment with a placebo or active control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce, publish or present from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we have and may continue to publish or present interim top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates. We may also identify safety and efficacy concerns after the approval of a product candidate which can result in negative consequences to our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, effective and of sufficient purity for use in each target disease, and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target disease. While we have developed our AAVrh10-mediated gene therapy product candidates to leverage the low seropositivity of AAVrh10, any gene therapy product based on viral vectors carries the risks of immunogenicity, elevated liver enzymes and insertional oncogenesis, which is the process whereby the insertion of a functional gene near a gene that is important in cell growth or division results in uncontrolled cell division, which could potentially enhance the risk of malignant transformation. In one of our preclinical studies of LX2006, we observed four cases of hepatocellular carcinoma, or HCC, in wild-type mice at 10 months post-treatment. Although data reported by the FDA Cellular, Tissue, and Gene Therapies Advisory Committee in September 2021 suggests that HCC observed in mice after AAV treatment is unlikely to translate to risks for humans, any future instances of HCC in our clinical trials could result in delays or the abandonment of our trials. Health authorities also ask that sponsors closely monitor the risk of elevated liver enzymes and abnormal liver ultrasound on a routine basis in patients participating in gene therapy clinical trials.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration, which, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. For example, in previous third-party clinical trials involving AAV capsids for gene therapy, some subjects experienced the development of a T-cell antibody response, whereby after the vector is within the target cell types, the cellular immune response system triggers the removal of transduced cell types by activated T-cells. If any of our product candidates demonstrate a similar effect, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. Our APOE-associated Alzheimer&#8217;s disease product candidates are designed to be delivered via intracisternal administration. While the intracisternal method of administration has been available for some years, its use for gene therapies is new and no gene therapy is currently approved for this method of administration. Intracisternal administration may have greater risk and/or be perceived as having greater risk than more common methods of administration, such as intravenous injection. Other gene therapy product candidates in clinical development utilizing intracisternal delivery could also generate data that could adversely affect the clinical, regulatory or commercial perception of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If adverse events occur, either as a result of the product candidate or administration process, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted diseases. Even if we are able to demonstrate that serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly. Furthermore, negative results in our development of LX2006 or LX2020 could be interpreted as a failure to achieve proof of concept for our technology and result in the abandonment of other development programs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products or the administration procedure, a number of potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw approvals of such product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the labels;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or other requirements subject to a REMS;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to obtain or maintain third-party payor coverage and adequate reimbursement; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation and physician or patient acceptance of our products may suffer.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory agency in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some of the diseases we initially seek to treat have low prevalence and it may be difficult to identify and enroll patients with these diseases. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population and competition for patients with other trials. The rare genetic diseases which some of our product candidates are designed to target have low incidence and prevalence and may be difficult to diagnose. In particular, because we are focused on patients with specific genetic mutations, our ability to enroll eligible patients may be limited or enrollment may be slower than we anticipate. For example, we estimate that approximately 6,600 people in the United States have FA and that approximately 80% of these patients will develop the cardiac manifestation of FA, or FA cardiomyopathy, and accordingly it may be difficult for us to identify and timely recruit a sufficient number of eligible patients to conduct our clinical trials. While the patient population for LX2020, our program targeting PKP2-ACM, is significantly larger than FA, we may face challenges in identifying and recruiting eligible patients to conduct our clinical trial given competing clinical trials. Even for more prevalent conditions such as Alzheimer&#8217;s disease, it may be difficult to recruit patients to clinical trials due to the number of approved products, difficulty identifying patients with the specific genotype we are studying, and the number of clinical trials being conducted in this indication.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA or other foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility criteria for the trial in question;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population and process for identifying patients;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the diseases we are investigating;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of competing commercially available therapies and other competing therapeutic product candidates&#8217; clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion of their treatment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we rely on CROs and clinical trial sites to help ensure the proper and timely conduct of our clinical trials and we may have limited influence over their performance. For additional information, see the risk factor in this section under the heading &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek Orphan Drug designation or Rare Pediatric Disease designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with Orphan Drug designation, including the potential for market exclusivity, for product candidates for which we obtain Orphan Drug designation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs or biologics intended to treat relatively small patient populations as orphan drug products. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, Orphan Drug designation entitles a party to potential financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs or biologics for rare diseases, regardless of whether the drugs or biologics are designated for the orphan use. In addition, if a drug or biologic with an Orphan Drug designation subsequently receives the first marketing approval for the disease for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and disease for that time period, except in limited circumstances. If our competitors are able to obtain orphan drug exclusivity prior to us, for products that constitute the &#8220;same drug&#8221; and treat the same diseases as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, in the European Union, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants Orphan Drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either the prevalence of the condition is not more than 5 in 10,000 persons in the European Union, or, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug. In each case, there must be no satisfactory method of diagnosis, prevention or treatment of the condition that has been authorized, or, if such a method exists, the product in question must be of significant benefit to those affected by such condition. In the European Union, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained from the FDA Orphan Drug designation for LX2006 for the treatment of FA and for LX2020 for the treatment of PKP2-ACM. LX2006 and LX2020 have also received Orphan Medicinal Product designation from the European Commission. We may seek orphan designation for some or all of our product candidates in orphan indications in which there is a medically plausible basis for the use of these product candidates. However, we may be unsuccessful in obtaining Orphan Drug designation and may be unable to maintain the benefits associated with such designations. Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect those product candidates from competition because different drugs can be approved for the same condition, and orphan drug exclusivity does not prevent the FDA from approving the same or a different drug in another indication. Even after an orphan drug is granted orphan exclusivity and approved, the FDA can subsequently approve a later application for the same drug for the same condition before the expiration of the seven-year exclusivity period if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s preexisting regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The statute supplants prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. Moreover, in the Consolidated Appropriations Act of 2021, Congress clarified that the interpretation of orphan drug exclusivity codified in FDARA would apply in cases where the FDA issued an orphan designation before the enactment of FDARA but where product approval came after the enactment of FDARA. In addition, a designated Orphan Drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease for which it received orphan designation. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharms., Inc. v. Becerra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 14 F.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that orphan drug exclusivity only applies to the approved use or indication within an eligible disease. However, in January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#8217;s order in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. The Consolidated Appropriations Act of 2026, signed into law in February 2026, codified this longstanding FDA interpretation of the Orphan Drug Act. However, the overturn of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies, including regulatory exclusivities, which could lead to uncertainties in the industry. Further, changes in the leadership of the FDA and other federal agencies under the current administration may lead to new policies and changes in the regulations and operations of the FDA, which may impact our clinical development plans. We do not know if, when, or how the FDA, Congress, or future judicial challenges may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. Moreover, orphan drug-exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan Drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy designation that we may receive from the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Fast Track, Breakthrough Therapy or Regenerative Medicine Advanced Therapy, or RMAT, designation from the FDA for some or all of our product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with such designations. The FDA&#8217;s Fast Track, Breakthrough Therapy, and RMAT designation programs are intended to expedite the development of certain qualifying product candidates intended for the treatment of serious diseases and conditions. If a product candidate is intended for the treatment of a serious or life- threatening condition and preclinical or clinical data demonstrate the product&#8217;s potential to address an unmet medical need for this condition, the sponsor may apply for FDA Fast Track designation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate may be designated as a breakthrough therapy if it is intended, alone or in combination with one or more other drugs or biologics to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs and biologics designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate may receive RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate has the potential to address an unmet medical need for such condition. RMAT designation allows companies developing regenerative medicine therapies to work more closely and frequently with the FDA, and RMAT-designated product candidates may be eligible for priority review and accelerated approval. FDA has confirmed that gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. For product candidates that have received an RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received Fast Track designation for LX2006 for the treatment of FA cardiomyopathy, and for LX2020 for the treatment of PKP2-ACM. We have also received Breakthrough Therapy designation for LX2006 for the treatment of FA cardiomyopathy as well as RMAT designation for LX2006 for the treatment of FA cardiomyopathy. LX2006 has also been selected by the FDA to participate in its CDRP program, which is intended to facilitate expedited CMC development of investigational therapies with expedited clinical development timeframes via an increased level of communication with the FDA on CMC development. While we may seek Fast Track, Breakthrough Therapy and/or RMAT designation, or participation in the CDRP program, for some or all of our product candidates, there is no guarantee that we will be successful in obtaining any such designation. Even if we do obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A Fast Track, Breakthrough Therapy, or RMAT designation, or participation in the CDRP program, does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular time frame. In addition, the FDA may withdraw Fast Track, Breakthrough Therapy, or RMAT designation, or remove a product candidate from the CDRP program, if it believes that the designation is no longer supported by data from our clinical development program. Fast Track, Breakthrough Therapy and/or RMAT designation, or participation in the CDRP program, alone, does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and we may seek such designation for future product candidates. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and LX1004 for the treatment of CLN2 disease and we may seek Rare Pediatric Disease designation for future product candidates. The FDA defines &#8220;rare pediatric disease&#8221; as a (i) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (ii) a rare disease or condition within the meaning of the Orphan Drug Act. Designation of a product candidate as a product for a rare pediatric disease does not guarantee that a marketing application for such product candidate will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the FDCA, we will need to request a rare pediatric disease priority review voucher in our original marketing application for our product candidates for which we have received Rare Pediatric Disease designation. The FDA may determine that a marketing application for any such product candidates, if approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rare pediatric disease that received such designation no longer meets the definition of a &#8220;rare pediatric disease&#8221;;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in a marketing application;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application is not deemed eligible for priority review;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application does not rely on clinical data derived from studies examining a pediatric population and dosages of the product intended for that population (that is, if the marketing application does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application is approved for a different adult indication than the rare pediatric disease for which our product candidates are designated.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Consolidated Appropriations Act of 2026 extended the rare pediatric disease PRV program to September 30, 2029, which means the FDA may not award any PRVs under this program after September 30, 2029, unless Congress takes further action to extend the rare pediatric disease priority review program. As such, if we do not obtain approval of a marketing application for LX2006 in patients with FA on or before September 30, 2029, and if the PRV program is not extended by Congressional action, we may not receive a PRV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Where appropriate, we may seek approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where possible, we may pursue accelerated development strategies in areas of high medical need. We may seek an accelerated approval pathway for one or more of our therapeutic product candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the FDCA and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate that is designed to treat a serious or life-threatening condition, generally provides a meaningful therapeutic benefit over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than IMM that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on IMM that is reasonably likely to predict an effect on IMM or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new product over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. If such post-approval studies fail to confirm the product&#8217;s clinical benefit, the FDA may withdraw its approval of the product. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA or comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. However, there can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval for LX2006 or any other product candidate. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA determines that a product candidate is intended to treat a serious disease or condition and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of such disease or condition, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review a marketing application is six months from filing of the application, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may disagree and decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific diseases. As such, currently we are primarily focused on the development of our current pipeline of product candidates. As a result, we may forego or delay pursuit of opportunities with other product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific diseases may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to build a pipeline of additional product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business model is centered on developing product candidates targeting patient populations that place significant burden on society and are most amenable to our genetic medicine approach. We are targeting diseases that have seen limited penetration of precision medicine and where we believe there is significant opportunity for gene therapy to play a role as a key therapeutic option. We aim to select, develop and advance product candidates that we believe will have a high probability of technical and regulatory success through development into commercialization. We may not be able to continue to identify and develop new product candidates. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to have side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the clinical development of our product candidates for certain indications, we intend to work with collaborators to develop or obtain access to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. The FDA generally will require approval or clearance of the diagnostic at the same time that the FDA approves the therapeutic product if the FDA determines that safe and effective use of a therapeutic product depends on an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostic. The clearance or approval of a companion diagnostic as part of the product label will also limit the use of the product candidate to patients who have met the screening criteria tested for by the companion diagnostic.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these product candidates, or experience delays in doing so, the development of these product candidates may be adversely affected, these product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the manufacturing of our product candidates</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have relationships with a limited number of suppliers for the manufacturing of all components of our product candidates. However, if we experience slowdowns or problems with our manufacturing partners and are unable to establish or scale our internal manufacturing capabilities, we will need to continue to contract with manufacturers that can produce the preclinical, clinical and commercial supply of our products. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain and we may be unable to license such intellectual property rights on reasonable commercial terms or to transfer or sublicense the intellectual property rights we may have with respect to such activities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for components of our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials in the United States and European Union must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including recordkeeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA or an MAA on a timely basis. Our potential manufacturing facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted, and they could put a hold on one or more of our clinical trials if the facilities of our contract manufacturing organizations, or CMOs, do not pass such audit or inspections. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory authorities also may, at any time following approval of a product for sale, inspect or audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be harmed. Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA and/or an MAA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully, if approved. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers to manufacture our product candidates for preclinical studies and clinical trials. The manufacturers of pharmaceutical products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure by us or our CMOs to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability of our product candidate materials for clinical trials or enforcement action from the FDA, EMA or foreign regulatory authorities. If we or our manufacturers fail to comply with the requirements of the FDA, EMA or other regulatory authority, sanctions could be imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurances that our third-party manufacturers will be able to meet our timetable and requirements. If any third party with whom we contract fails to perform its obligations, we may be forced to either manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials and future commercial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original third-party manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize our products, if approved, in a timely manner or within budget.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, we may be delayed in the development of our product candidates. Our dependence upon others for the manufacture of our product candidates may also adversely affect our future profit margins and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our modified virus generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Although we believe that the manufacture of our product candidates may be simplified due to their shared raw materials and other similarities, we cannot be certain that this will be the case and we may be required to develop manufacturing methods that ultimately differ significantly between product candidates, which would require that we invest substantial time and capital to develop suitable manufacturing methods. Our program materials are manufactured using technically complex processes requiring specialized equipment and facilities, highly specific raw materials, cell types and reagents, and other production constraints. Our production process also requires a number of highly specific raw materials, cell types and reagents with limited suppliers. Even though we aim to have backup supplies of raw materials, cell types and reagents whenever possible, we cannot be certain they will be sufficient if our primary sources are unavailable. A shortage of a critical raw material, cell line, or reagent, or a technical issue during manufacturing may lead to delays in clinical development or commercialization plans. We are particularly susceptible to any shortages, delays or our inability to obtain suitable raw materials for our lead product candidates. Any changes in the manufacturing of components of the raw materials we use could result in unanticipated or unfavorable effects in our manufacturing processes, resulting in delays.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our product candidates obtain approval, the FDA, EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party suppliers for the materials and components required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to manufacture gene therapy products. As a small company, our negotiation leverage is limited, and we may get lower priority than our competitors that are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials within the timelines that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole-sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers of viruses to deliver necessary components could result in delays in our clinical development or marketing schedules.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the nature of gene therapy manufacturing, there is a risk of contamination occurring during the manufacturing process. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics. Such changes carry the risk that they will not achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay the initiation and completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes to our upstream and downstream processes across our pipeline, which could delay the development of our future product candidates. Regulatory agencies, and in particular the FDA and EMA, have demonstrated increased caution in their regulation of gene therapies, including increased scrutiny related to CMC issues. This increased regulatory scrutiny around gene therapy CMC may result in us being required to conduct additional preclinical studies or clinical trials with respect to any of our product candidates, which may result in delays and increased costs in the development or commercialization of our product candidates and ultimately could lead to the failure to obtain approval for any gene therapy product.</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the commercialization of our product candidates</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their efficacy, safety and potential advantages compared to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to offer our products for sale at competitive prices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their convenience and ease of administration compared to alternative treatments;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA or foreign regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling, including any boxed warning or REMS;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new treatments, such as gene therapy as a novel modality for treatment of our target indications and of physicians to prescribe these treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to hire and retain a sales force in the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement for our product candidates, once approved, from third-party payors and government authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our products together with other medications.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or commercial success of our current and future product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates involve introducing genetic material into a patient&#8217;s cells via intrathecal and intravenous administration. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy and gene regulation are unsafe, unethical or immoral, and consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. In recent years, sponsors of other clinical trials involving gene therapies have announced imposition of clinical holds by the FDA to evaluate safety issues arising during the trials. Among the risks in any gene therapy product based on viral vectors are the risks of immunogenicity, elevated liver enzymes and insertional oncogenesis. If any of our vectors demonstrate a similar effect, we may decide or be required to halt or delay further clinical development of any product candidates that utilize that vector. Adverse events in our or others&#8217; clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene therapy, and we cannot assure that it will not occur in any of our planned or future clinical trials or in any clinical trials conducted by other companies. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. In addition, for our regulated gene replacement therapy product candidates which require that the expression of a therapeutic transgene be tightly regulated, we may inadvertently cause overexpression, which could lead to numerous issues, including safety and toxicity concerns. Furthermore, one of our regulatory gene replacement therapy candidates, LX1020, requires the insertion of miRNA targets into the viral genome, which is a technology that to our knowledge is not present in any approved gene therapy products. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The affected populations for our other product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently focus our research and product development on several indications that are larger-rare diseases. However, our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are estimates based on our knowledge and understanding of these diseases. These estimates may prove to be incorrect and new studies may further reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product candidate or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors, including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be accurate, and the methodology is forward-looking and potentially speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included in this Annual Report should be viewed in that context. Further, the data and statistical information used in this Annual Report, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development, particularly in the gene therapy field, is highly competitive and subject to rapid and significant technological advancements. As a significant unmet medical need exists in the cardiovascular disease area, there are several large and small pharmaceutical companies focused on delivering therapeutics for the treatment of these diseases, including those that we are initially targeting. It is likely that additional drugs will become available in the future for the treatment of our target diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evaluating next steps for vatiquinone following a Complete Response Letter on their new drug application to the FDA. Reata Pharmaceuticals, Inc.&#8217;s omaveloxolone (Skyclarys) was approved by the FDA in 2023, and Biogen Inc. acquired Reata Pharmaceuticals, Inc. for approximately $7.3 billion in the same year and is currently commercializing Skyclarys.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to LX2020, both Rocket Pharmaceuticals Inc., or Rocket, and Tenaya Therapeutics Inc. are developing an AAV-based gene therapy candidate designed to deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene to patients with PKP2-ACM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Our current and potential future competitors may also have significantly more experience commercializing drugs, particularly gene therapy and other biologics, that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will face competition from other drugs or from other non-drug products currently approved or that will be approved in the future in the cardiac and neurology fields, including for the treatment of diseases and diseases in the therapeutic categories we intend to target. Therefore, our ability to compete successfully will depend largely on our ability to:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop and commercialize drugs that are advantageous as compared to other products in the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate through our clinical trials that our product candidates are differentiated from existing and future therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract qualified scientific, product development and commercial personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain patent or other proprietary protection for our product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain required regulatory approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully collaborate with other pharmaceutical companies in the discovery, development and commercialization of new medicines.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidate we develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects. In addition, the reimbursement structure of approved gene therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if approved, and our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving regulatory and marketing approval for, or commercializing, drugs before we do, which would have an adverse impact on our business and results of operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologics that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our biologics.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologics is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients, commercial and government payors to pay for these procedures.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our success depends on obtaining and maintaining coverage and adequate reimbursement for our product candidates, including LX2006 and LX2020, and the extent to which patients will be willing to pay out-of-pocket for such products, in the absence of reimbursement for all or part of the cost. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage, and adequate reimbursement.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Most significantly, in August 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026); imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. HHS has issued and will continue to issue and update guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. Only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for single-source biologics) can qualify for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D drugs in 2023, negotiations began in 2024, and the negotiated maximum fair price for each drug has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, up to an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, up to 20 additional Part B or Part D drugs will be selected. Further, the current administration has issued executive orders focused on decreasing prescription drug prices, including directing the Secretary of HHS to establish a mechanism through which American patients can buy drugs directly from manufacturers who sell at a most-favored-nation price and directing the U.S. Trade Representative and Secretary of Commerce to take action to ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. Government agreements with pharmaceutical companies and other government measures that use most-favored-nation pricing targets for prescription drugs, including the use of international pricing reference to set drug prices in the United States, or that increase generic and biosimilar drug entry sooner than expected, can have a material adverse effect on our industry, ability to set adequate pricing for new drugs to recover research and development costs, ability to attract potential investors and potential buyers in the future. We cannot predict the full impact of the executive orders focused on reducing prescription drug prices or increasing domestic drug manufacturing capacity, or other measures that may be implemented by the current administration related to drug pricing, drug supply chain and manufacturing in the United States. Such cost containment policies and executive orders could substantially and negatively impact the prices we may charge for any approved products, which could harm our valuation, ability to generate revenue and achieve and sustain profitability. In addition, the One Big Beautiful Bill Act, or OBBBA, which was signed into law in July 2025, includes provisions that will impact the United States healthcare system in various ways, including by cuts to Medicaid and introducing new participant work and eligibility requirements for Medicaid coverage, which are expected to significantly change the administration and applicability of Medicaid coverage. Although the full impact of the OBBBA on the healthcare system and our business is uncertain, the resulting changes may increase the cost and complexity of completing clinical development of and launching any product candidates for which we may receive regulatory approval, which could adversely affect our business and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors determine which products and procedures they will cover and establish reimbursement levels. Even if a third-party payor covers a particular product or procedure, the resulting reimbursement payment rates may not be adequate. Patients who are treated in-office for a medical condition generally rely on third-party payors to reimburse all or part of the costs associated with the procedure, including costs associated with products used during the procedure, and may be unwilling to undergo such procedures in the absence of such coverage and adequate reimbursement. Physicians may be unlikely to offer procedures for such treatment if they are not covered by insurance and may be unlikely to purchase and use our product candidates, if approved, for our stated diseases unless coverage is provided and reimbursement is adequate. In addition, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Further, coverage policies and third-party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a procedure is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign governments also have their own healthcare reimbursement systems, which vary significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that LX2006, LX2020 or any other product candidates, if approved for sale in the United States or in other countries, will be considered medically reasonable and necessary, that it will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that reimbursement policies and practices in the United States and in foreign countries where our products are sold will not adversely affect our ability to sell our product candidates profitably, if they are approved for sale.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any product candidates or drugs that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant costs to defend the related litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards paid to trial participants or patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced resources of our management to pursue our business strategy; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any products that we may develop.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our dependence on third parties</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currently, we rely on our collaborations with Cornell University and The Regents of UCSD to conduct research and development for many of our pipeline programs, including conducting preclinical and IND-enabling studies for portions of our near-term future pipeline. Failure or delay of Cornell University or The Regents of UCSD to fulfill all or part of their respective obligations to us under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of either of these relationships could materially harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration with Cornell University is critical to our business and in May 2020, we entered into two separate license agreements with Cornell University pursuant to which we obtained rights under certain patents, know-how and data to exploit products and technologies covered by such intellectual property. As part of our first license agreement, as amended, we assumed oversight for the conduct of the Phase 1/2 clinical trial of LX1001 that was initiated by Cornell University at the end of 2019. As part of our second license agreement with Cornell University, as amended, we obtained certain rights to portfolios for infantile neuronal ceroid lipofuscinosis type 2 (also called CLN2 Batten disease) and FA cardiomyopathy, as well as an assignment of Cornell University&#8217;s IND to support the development of our LX1004 program. We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo. Pursuant to our license agreements with Cornell University, we are obligated to diligently proceed with the development, manufacture, and sale of licensed products. If Cornell University delays or fails to perform its obligations under the license agreements, terminates any of the license agreements in accordance with its terms, or a dispute otherwise arises between the parties concerning the terms of the agreements or our respective rights to licensed technology, our pipeline of product candidates would be significantly adversely affected and our prospects may be materially harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration with UCSD is also highly important to our business, as we have licensed from UCSD intellectual property rights related to our LX2020, LX2021 and LX2022 programs under three separate license agreements, and we have entered into sponsored research agreements with UCSD for preclinical research and development for these programs. If The Regents of UCSD delays or fails to perform its obligations under either of the sponsored research agreements or any of the license agreements, disagrees with our interpretation of the terms of the sponsored research agreements, license agreements or our discovery plans, or terminates any of our existing license agreements, our pipeline of product candidates would be significantly adversely affected and our prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage CROs to help conduct our ongoing clinical trials. We expect to continue to rely on third parties, including clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials and any future clinical trials. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding a CRO involves substantial cost and requires management's time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on these parties for execution of our preclinical studies and clinical trials, and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCP regulations, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicaltrials.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, within specified time frames. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable cGCPs, or experience material protocol deviations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. If the FDA or any regulatory authority determines that our clinical data are not reliable for any reason, or if we encounter any data integrity issues, the FDA or other regulatory authorities may require us to exclude such data, which may cause the trial to be underpowered and fail to meet the trial endpoints. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of LX2006, LX2020 or any other product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential revenue.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek collaborations with non-academic third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek third-party collaborators for the development and commercialization of our product candidates, including for the commercialization of any of our product candidates that are approved for marketing outside the United States. Our likely collaborators for any such arrangements include regional and national pharmaceutical companies and biotechnology companies. If we enter into any additional such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates pose the following risks to us:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not perform their obligations as expected;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar diseases that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to intellectual property</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates, including LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, and other programs, their respective components, formulations, therapies, methods used to manufacture them and methods of treatment.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot offer any assurances about which of our patent applications will issue, the breadth of any resulting patent or whether any of the issued patents will be found invalid and unenforceable or will be threatened by third parties. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing and commercializing a product, including a biosimilar product that would be competitive with one or more of our product candidates. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any of our product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive and time-consuming. We may not be able to prepare, file and prosecute all necessary or desirable patent applications at a commercially reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and patents being in the public domain. In some cases, the work of certain academic researchers in the gene therapy field has entered the public domain, which may preclude our ability to obtain patent protection for certain inventions relating to such work. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not be able to prevent any third party from using any technology that is in the public domain to compete with our product candidates. In addition, as the licensee of patents from Cornell University and UCSD, we have less control over the prosecution and enforcement of those patents than we would if we owned the patents. While we do have typical rights with respect to those patents under university license agreements, our ability to enforce those patents to maintain exclusivity in our markets may be limited by the terms of our agreements with Cornell University and UCSD. In addition, to the extent the federal government provided research funding to the licensor university for any technology licensed under the license agreements, then if the federal government elects to exercise any of its overriding rights which may apply as a result of provision of such funding, we may be subject to changes in market exclusivity or other material business requirements or constraints. Moreover, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patent rights are highly uncertain. Our owned and licensed pending and future patent applications may not result in issued patents which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product candidates or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our technologies and product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing technologies and products, and the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Any failure to obtain, maintain or defend our patents and other intellectual property could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority or entitlement disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Since patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we were in the past or will be in the future the first to file any patent application related to our product candidates. For example, some patent applications in the United States may be maintained in secrecy until the patents are issued. Further, publications in the scientific literature often lag behind actual discoveries. Consequently, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor, were the first to invent or first to file an application for the technology.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example, with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection provided by our patent estate, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not amenable to patent protection. Although we generally require all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed. In addition, while we have undertaken reasonable efforts to ensure such agreements are enforceable and that employees and third parties comply with their obligations thereunder, these agreements may be found insufficient by a court of law or may be breached, or we may not enter into sufficient agreements with such individuals in the first instance, in either case potentially resulting in the unauthorized use or disclosure of our trade secrets and other intellectual property, including to our competitors, which could cause us to lose any competitive advantage resulting from this intellectual property. Individuals not subject to invention assignment agreements may make adverse ownership claims to our current and future intellectual property. Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products, if approved, and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable, and we may not be able to obtain adequate remedies for such breaches.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by working to maintain the physical security of our premises and physical and electronic security of our information technology systems. Our confidentiality agreements may, however, be breached, and we may not have adequate remedies for any breach. Our and other applicable security measures may also not be able to prevent security breaches and other compromises of the security of our trade secrets or other data. Also, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA is considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar non-United States legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We in-license key intellectual property necessary for the development of each of our current product candidates. If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, resulting in the termination of such licenses, we could lose rights that are important to our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are heavily reliant upon licenses to certain patent rights and proprietary technology for the development of each of our current product candidates. In particular, we in-license key patents and patent applications from Adverum related to LX2006, we in-license patent applications and know-how from Cornell University related to our LX2006, LX1001, LX1020 and LX1021 product candidates, and we in-license patent applications and know-how from UCSD related to our LX2020, LX2021 and LX2022 product candidates. Our license agreements impose diligence and milestone and royalty payment obligations on us, and also contain certain development requirements. If we fail to comply with our obligations, our licensors may have the right to terminate our licenses, in which event we will not be able to develop, manufacture or market any product using the intellectual property under any such terminated agreement and may face other penalties. Such an occurrence would materially adversely affect our business prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. In addition, the intellectual property rights licensed to us by our licensors, including certain intellectual property licensed by Cornell University UCSD, and Adverum, at least in some respects, may be used by such licensors or licensed to third parties, and such third parties may have certain enforcement rights with respect to such intellectual property. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses to additional third-party technology and materials that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. In such events, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates. Even if we are able to obtain such additional licenses, they may be non-exclusive thereby giving our competitors and other third parties access to the same technology licensed to us.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our licensors fail to adequately protect our licensed intellectual property, our ability to commercialize our product candidates and technology could suffer. Although we have oversight rights, Cornell University and UCSD generally control the prosecution, maintenance and enforcement of our in-licensed patents and patent applications. Therefore, we cannot be certain that the prosecution, maintenance and enforcement of these patent rights will be in a manner consistent with the best interests of our business, or in compliance with applicable laws and regulations, or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests. If we or our licensors fail to maintain such patents or patent applications, or if we or our licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we fail to comply with our development obligations under our license agreements, we may lose our patent rights with respect to such agreement on a territory-by-territory basis, which would affect our patent rights worldwide. In spite of our efforts, our current and future licensors might conclude that we have materially breached our obligations under our license agreements and might therefore terminate such license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial and other obligations under the license agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates. In addition, if any such disputes result in the termination of our intellectual property licenses, this could result in the loss of our ability to develop and commercialize our lead product candidates, or we could lose other significant rights, experience significant delays in the development and commercialization of our other product candidates, or incur liability for damages, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our future agreements with certain of our third-party research partners may provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner. If we determine that rights to such improvements owned solely by a third-party research partner or other third party with whom we collaborate are necessary to commercialize our therapeutic product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of our current or any future license agreements would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, intellectual property rights that we in-license in the future may be sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a third party may in the future bring claims that our performance under our license agreements, including our sponsoring of clinical trials, interferes with such third party&#8217;s rights under its agreement with one of our licensors. If any such claim were successful, it may adversely affect our rights and ability to advance our product candidates as clinical candidates or subject us to liability for monetary damages, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described above and below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Presently, we have obtained rights to certain intellectual property rights through licenses from third parties to develop, manufacture and commercialize our lead product candidates and other potential product candidates in our pipeline. Because the commercialization of our product candidates may require the use of additional intellectual property rights held by third parties, the growth of our business likely will depend, in part, on our ability to acquire or license these intellectual property rights. Our product candidates also require specific formulations and manufacturing processes to work effectively and efficiently, and some of these rights are held by others.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, important or more expedient to further our business operations. In addition, even if we are able to obtain such licenses, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Were that to happen, we may need to cease use of the product candidates and technologies covered by those third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe, misappropriate or violate those intellectual property rights, which may entail additional costs and development delays if we are able to develop such alternatives, or which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully obtain rights to required third-party intellectual property or maintain the existing intellectual property rights we have licensed, we may be required to expend significant time and resources to redesign our product candidates, or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis, and we may have to abandon development of our product candidates, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently depend, and will continue to depend, on our license agreements, including the license agreements with Cornell University and Adverum related to LX2006, with Cornell University related to our LX1001, LX1020 and LX1021 product candidates, and with UCSD related to LX2020, LX2021 and LX2022 product candidates. The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our licenses or material relationships or any in-licenses upon which our licenses are based are terminated or breached, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose our rights to develop and market our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose patent protection for our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience significant delays in the development or commercialization of our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be able to obtain any other licenses on acceptable terms, if at all; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur liability for damages.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These risks apply to any agreements that we may enter into in the future for our products or for any future product candidates. If we experience any of the foregoing, it could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that any of our or licensed pending patent applications or our future owned or licensed patent applications will result in issued patent claims covering such aspects of our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Composition-of-matter patents on the active pharmaceutical ingredient, or API, in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because those types of patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. Although we intend to file patent applications in the future that cover these product candidates, we cannot be certain that our future owned or licensed patent applications will cover our current or future product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Method-of-use patents protect the use of a product for the specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common, and this type of infringement is difficult to prevent or prosecute. In addition, there are numerous publications and other prior art that may be relevant to our owned or in-licensed method-of-use patents and patent applications and may be used to challenge the validity of these owned or in-licensed patents and patent applications in litigation or other intellectual property-related proceedings. If these types of challenges are successful, our owned or in-licensed patents and patent applications may be narrowed or found to be invalid, and we may lose valuable intellectual property rights. Any of the foregoing could have a material adverse effect on our business, financial condition, prospects and results of operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other countries. Even if patents do successfully issue, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and third parties may challenge the validity, enforceability or scope of our owned and licensed patents in courts or patent offices in the United States and abroad, which may result in those patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. If the breadth or strength of protection provided by the patents and patent applications we own or license with respect to our product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe the patents for which we have applied. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. In an infringement proceeding, a court may decide that the patent claims we are asserting are invalid and/or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover the technology in question. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could have a material adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patent applications. An unfavorable outcome could require us to cease using the related technology or force us to take a license under the patent rights of the prevailing party, if available. Furthermore, our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay us a &#8220;reasonable royalty&#8221; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a material adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For certain of our in-licensed patent rights, such as patent rights in-licensed from Cornell University and Adverum, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business, and our commercialization efforts may suffer as a result.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we or our licensors, as the case may be, may not be able to detect infringement against our owned or in-licensed patents, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect infringement by a third party of our owned or in-licensed patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third party. If we or our licensors later sue such third party for patent infringement, the third party may have certain legal defenses available to it that otherwise would not be available but for the delay between when the infringement was first detected and when the suit was brought. These legal defenses may make it impossible for us or our licensors to enforce our owned or in-licensed patents, as the case may be, against that third party.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As our current and future product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. We cannot provide any assurance that our current and future product candidates do not infringe other parties&#8217; patents or other proprietary rights, and competitors or other parties may assert that we infringe their proprietary rights in any event. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and future product candidates, including interference or derivation proceedings before the USPTO, or oppositions and other proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates, manufacturing methods, formulations, administration methods and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, the claim scope that may issue from pending patent applications owned by third parties or which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties, including our competitors, may allege they have patent rights encompassing our product candidates, technologies or methods and that we are employing their proprietary technology without authorization.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we were sued for patent infringement, we would need to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is high and requires us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would agree with us and invalidate the claims of any such United States patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes that one of our product candidates infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any third-party patents are held by a court of competent jurisdiction to be valid and enforceable and to cover any of our technology or product candidates, including the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product. If we were required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively, or additionally, it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to claims that we and our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information or trade secrets of third parties.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or biopharmaceutical companies. Although we require, evidenced by written agreements, that all of our employees, consultants and advisors not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents. Litigation may be necessary to defend against these claims, and there is no guarantee of success in defending these claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in defending against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. Some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information regarding our legal proceedings, see Note 11 to the financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patent applications, our future patents, or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates and platform discovery. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we rely on third parties to manufacture or commercialize our product candidates, or if we collaborate with additional third parties for the development of such product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make or use capsids, nucleic acids and vectors that are similar to the biological compositions of our products that are the same as or similar to our product candidates but that are not covered by the claims of owned or in-licensed patents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that others may circumvent our owned or in-licensed patents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others, including inventors or developers of our owned or in-licensed patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) who should be listed as inventor(s) or include individual(s) who should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or our other collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or our other collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license to, or will own or will have obtained a license;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors may fail to meet obligations to the U.S. government with respect to in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no patent protection may be available with regard to formulation or method of use;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or exclusively license may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not exclusively license our patents and, therefore, may not have a competitive advantage if such patents are licensed to others;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the laws of other countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">countries other than the United States may, under certain circumstances, force us or our licensors to grant a license under our patents to a competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not successfully commercialize the product candidates, if approved, before our relevant patents expire;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that product candidates or technologies we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ownership, validity or enforceability of our or our licensors&#8217; patents or patent applications may be challenged by third parties; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing and prosecuting patent applications and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States or Europe. These products may compete with our product candidates, and our future patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and Europe and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, which could make it difficult for us to stop the infringement of our future patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and/or applications and any patent rights we may obtain in the future. Furthermore, the USPTO and various non-United States government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse of a patent or patent application can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patents or patent applications, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market, which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and genetic medicine industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and genetic medicine patents is costly, time-consuming and inherently uncertain. In addition, the Leahy-Smith America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the U.S. patent system.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or in-licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Some of our licensed patents are subject to the provisions of the Bayh-Dole Act. If our licensors fail to comply with the regulations of the Bayh-Dole Act, they could lose title to any patents subject to such regulations, which could affect our license rights under the patents and our ability to stop others from using or commercializing similar or identical technology and products, or limit patent protection for our technology and products.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to legal and regulatory compliance matters</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future relationships with customers, healthcare providers, including physicians, and third- party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently or will in the future be subject to healthcare regulation and enforcement by the U.S. federal government and the states in which we will conduct our business once our product candidates are approved by the FDA and commercialized in the United States. In addition to the FDA&#8217;s restrictions on marketing of pharmaceutical products, the U.S. healthcare laws and regulations that may affect our ability to operate include: the federal fraud and abuse laws, including the federal anti-kickback and false claims laws; federal data privacy and security laws; and federal transparency laws related to payments and/or other transfers of value made to physicians and other healthcare professionals and teaching hospitals. Many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous federal laws and may apply regardless of payor. In addition, state laws regarding the privacy and security of health information may differ from each other and may not be preempted by federal law. Moreover, several states have enacted legislation requiring pharmaceutical manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, report information related to drug pricing, require the registration of sales representatives, and prohibit certain other sales and marketing practices. These laws may adversely affect our sales, marketing and other activities with respect to any product candidate for which we receive approval to market in the United States by imposing administrative and compliance burdens on us. It is possible that governmental authorities will conclude that our current or future business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain FDA or EMA approval for any of our product candidates in the United States or European Union, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval by the FDA in the United States or the EMA in the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to ongoing regulatory requirements for, among other things, manufacturing processes, submission of post-approval clinical data and safety information, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, promotional activities and product tracking and tracing. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, applicable tracking and tracing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and cGCP requirements for any clinical trials that we conduct post-approval.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates or any future product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or requirements that we conduct potentially costly post-marketing testing, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the product. An unsuccessful post- marketing study or failure to complete such a study could result in the withdrawal of marketing approval. We will further be required to immediately report any serious and unexpected adverse events and certain quality or production problems with our products to regulatory authorities along with other periodic reports.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and EMA closely regulate the post-approval marketing and promotion of genetic therapy medicines to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products for uses beyond their approved diseases, we may be subject to enforcement action for off-label marketing. Violations of the FDCA, relating to the promotion of prescription drugs for unapproved uses may lead to enforcement actions and investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. The holder of an approved BLA must submit new or supplemental applications and obtain prior approval for certain changes to the approved product, product labeling, or manufacturing process. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on manufacturing such products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to allow entry into supply contracts, including government contracts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters, or holds on clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of administrative, civil or criminal penalties or monetary fines.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s policies, and the policies of foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, executive orders or other actions could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. If such executive actions were to impose restrictions on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business could be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current product candidates or any future product candidates and harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may adversely affect:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to set a price that we believe is fair for any of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenues and achieve or maintain profitability;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical and biologic products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. In April 2025, the President issued an executive order and an accompanying fact sheet focused on lowering drug prices, but it is unclear what actions will be implemented by the Department of Health and Human Services, CMS, and FDA under the new leadership, and how those actions will impact our industry and our business. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures and could negatively affect our customers and accordingly, our financial operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in federal funding, layoffs, government shutdown, staff departures, lapse in government appropriations, and other policies and executive order impacting the normal operations of the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, any of which could negatively impact our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the current government shutdown, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Changes in the leadership of the FDA and other federal agencies under the current administration, including return-to-office policy, hiring freeze, layoffs, and other policies implemented by the Department of Government Efficiency, may lead to changes in the operations of the FDA, which may have a material impact on the industry and our clinical development plans.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Additionally, changes in the FDA leadership, regulatory actions and other actions under the current administration, may result in delays in regulatory approval. Our business depends upon the ability of the FDA to accept and review our potential regulatory filings. If a prolonged government shutdown occurs or if a significant number of federal employees are laid off or leave federal agencies, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our ability to advance clinical development of our product candidates, delay our clinical development timelines, and increase the costs of clinical development process.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates or realizing the synergies in the target diseases of our programs, even if they are approved.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. We expect to build a focused sales, distribution and marketing infrastructure to market our product candidates in the United States and European Union, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of our product candidates. Additionally, if the commercial launch of our product candidates for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have the resources in the foreseeable future to allocate to the sales and marketing of our product candidates in certain international markets. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in the product and such collaborator&#8217;s ability to successfully market and sell the product. We may pursue collaborative arrangements regarding the sale and marketing of LX2006 or LX2020, if approved, for certain markets overseas; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of LX2006, LX2020 or LX1001, or any of our other product candidates, if approved, we may be forced to delay the potential commercialization of LX2006, or LX2020 or any of our other product candidates or reduce the scope of our sales or marketing activities for LX2006 or LX2020 or any of our other product candidates. If we elect to increase our expenditures to fund commercialization activities internationally, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LX2006 or LX2020 or any of our other product candidates or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing LX2006, or LX2020 or any of our other product candidates, if approved, and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we obtain approval to commercialize any products outside of the United States or the European Union, a variety of risks associated with international operations could adversely affect our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LX2006, LX2020 or any of our other product candidates are approved for commercialization, we may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States and the European Union. We expect that we would be subject to additional risks related to international pharmaceutical operations, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for drug and biologic approvals and rules governing drug and biologic commercialization in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater difficulty with enforcing our contracts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, or the FCPA, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are complex regulatory, tax, labor and other legal requirements imposed by individual countries in Europe with which we will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to a variety of privacy, data protection, and cybersecurity laws, rules, regulations, policies, industry standards and contractual obligations, and our failure to comply with them could harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain and otherwise process a large quantity of sensitive information, including confidential business and personal information in connection with the conduct of our clinical trials and related to our employees and others, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, numerous federal and state privacy and cybersecurity laws and regulations govern the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state consumer protection laws. The legislative and regulatory landscape for privacy, data protection and cybersecurity continues to evolve, and there has been an increasing focus on privacy, data protection and cybersecurity issues, which may affect our business and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state and federal data breach notification laws, federal regulations prohibiting or restricting certain transfers of sensitive personal information, and state health information privacy and cybersecurity laws and federal and state consumer protection laws and regulations that govern the collection, use, disclosure and protection of health-related and other personal information. Among these regulations are: Section 5 of the Federal Trade Commission Act, which prohibits unfair or deceptive commercial practices; rules adopted by the SEC in July 2023, which require public companies to disclose material cybersecurity incidents they experience and to disclose on an annual basis material information regarding their cybersecurity risk management, strategy, and governance; and the HIPAA, as amended by HITECH, and the regulations promulgated thereunder.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may obtain health and other data from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, and depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Economic Area, or the EEA, and the United Kingdom, or the UK, the collection, use, disclosure, transfer or other processing of personal data, including clinical trial data, of individuals is governed by the General Data Protection Regulation, or European Union GDPR (with regard to the EEA), and UK GDPR (with regard to the UK), as well as applicable national data protection legislation and requirements. In this document, &#8220;GDPR&#8221; refers to both the European Union GDPR and the UK GDPR, unless specified otherwise. The GDPR is wide ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million (&#163;17.5 million for the UK) or 4% of our consolidated annual worldwide gross revenue), and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR also includes restrictions on cross-border data transfers of personal data to countries outside the EEA and the UK that are not considered by the European Commission or UK government as providing &#8220;adequate&#8221; protection to personal data, or third countries, including the United States, unless a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses, or SCCs, and the UK International Data Transfer Agreement/Addendum, or UK IDTA) has been put in place. Where relying on the SCCs or UK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. The international transfer obligations under the EEA and UK data protection regimes require significant effort and cost, and may result in us needing to make strategic considerations around where EEA and UK personal data is transferred and which service providers we can utilize for processing EEA and UK personal data.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK government made targeted amendments to its data protection regime in the Data (Use and Access) Act 2025, which entered into force in August 2025. The European Commission renewed its adequacy determination for the UK in 2025, extending to December 2031, but the UK&#8217;s adequacy determination remains subject to modification or revocation. The UK&#8217;s proposal to modify its data protection regime may impact this adequacy determination. Any loss by the UK of its adequacy determination by the European Commission may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the European Union GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with these and any other applicable privacy, data protection and cybersecurity laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with new and evolving laws and regulations. Further, many privacy, data protection, and cybersecurity regimes are evolving and are inconsistent across jurisdictions. If we fail, or are alleged to fail, to comply with any such laws or regulations, we may face regulatory inquiries, investigations, and other proceedings, private claims and litigation, and significant fines and penalties that could adversely affect our business, financial condition and results of operations. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020, became enforceable on July 1, 2020 and has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act, or CPRA, which became effective as of January 1, 2023, amended the CCPA and imposes additional privacy obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and opt outs for certain uses of sensitive data. The amendments introduced by the CPRA also created a new California Privacy Protection Agency to implement and enforce this legislation, and it is anticipated that this development could result in increased privacy and information security enforcement. Although the CCPA, as amended by the CPRA, currently exempts certain health-related information, including clinical trial data, the CCPA may increase our compliance costs and potential liability if we expand our operations into California. Similar broad consumer privacy laws have been enacted in Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Kentucky, Maryland, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah and Virginia and have been proposed in numerous other states and at the federal level. If passed, these bills may provide for various requirements that would make compliance challenging, particularly in light of certain conflicting and otherwise various requirements in the state privacy laws that have been enacted.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to these consumer privacy laws, certain states have enacted health-focused privacy legislation. For example, Washington has enacted the My Health, My Data Act, which became effective in March 2024. This law imposes strict requirements on the collection, use and processing of certain health-related information that is not subject to HIPAA. This law also provides for a private right of action. Other states are considering, and in certain cases have enacted, bills with similar requirements. The Washington law and other state bills that have been, or may be, enacted, have added and, if enacted, would add additional complexity to our compliance obligations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the GDPR, CCPA, and other laws, regulations and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations, and with substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses in an effort to do so. We do not currently have formal data privacy policies and procedures in place and have not completed formal assessments of whether we are in compliance with all applicable data privacy laws and regulations. It is possible that both existing and new laws, regulations, and other actual or asserted obligations to which we are or may be subject may be interpreted and applied in manners inconsistent with our existing or future privacy, data protection and cybersecurity practices. Any failure or perceived failure by us to comply with our current or future obligations relating to privacy, data protection or cybersecurity, or any actual or perceived failure by any third party with which we work, such as third-party CMOs, CROs, manufacturers, contractors, consultants, collaborators, vendors, or service providers, to comply with our applicable policies or other applicable obligations, may result in governmental investigations, enforcement actions, or other proceedings, litigation, claims, or public statements against us and could result in significant liability, cause harm to our brand and reputation, and otherwise materially and adversely affect our reputation and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to various governmental export control and trade sanctions laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate these controls.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may be subject to export control and import laws and regulations, including the U.S. Export Administration Regulations administered by the U.S. Department of Commerce and U.S. Customs laws and regulations and our product candidates and activities may be subject to various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, or collectively, Trade Controls. As such, a license may be required to export or re-export our product candidate, or provide related services, to certain countries and end-users, and for certain end-uses. The process for obtaining necessary licenses may be time-consuming or unsuccessful, potentially causing delays in sales or losses of sales opportunities and these licenses may not be issued. Compliance with applicable regulatory requirements regarding the export or import of our product candidates may create delays in the introduction of our product candidates in international markets or, in some cases, prevent the export of our product candidates to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain product candidates and services to countries, territories, governments and persons targeted by U.S. sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Controls are complex and dynamic regimes and monitoring and ensuring compliance can be challenging. Although we have procedures in place designed to ensure our compliance with Trade Controls, any failure to comply could subject us to both civil and criminal penalties, including substantial fines, possible incarceration of responsible individuals for willful violations, possible loss of our export or import privileges, and reputational harm. Although we have no knowledge that our activities have resulted in violations of Trade Controls, there is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, or those of our affiliates, will comply with all applicable export and import control and sanctions laws and regulations, particularly given the high level of complexity of these laws. Any failure by us or our partners to comply with applicable laws and regulations could have negative consequences for us, including reputational harm, government investigations, penalties, fines, settlements, investigations, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of additional compliance programs, and prohibitions on the conduct of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign anti-corruption laws and regulations. We could face liability and other serious consequences for violations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to anti-corruption laws and regulations, including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and will be subject to local and national anti-bribery laws in the countries in which we may conduct activities in the future. Anti-corruption laws are interpreted broadly and generally prohibit companies and their employees, agents, representatives, contractors and other third-party intermediaries from offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly through third parties, to any person in the public or private sector to obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-United States governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and therefore will be considered foreign officials for purposes of the FCPA. We also expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals on our behalf outside of the United States. We can be held liable for the corrupt or other illegal activities of our employees, agents, representatives, CROs, contractors and other third-party intermediaries, even if we do not explicitly authorize or have actual knowledge of such activities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no certainty that all of our employees, agents, representatives, contractors or third-party intermediaries will comply with all applicable anti-corruption laws. Allegations concerning or violations of these laws and regulations could result in whistleblower complaints, fines, settlements, investigations, criminal or civil sanctions, adverse media coverage or suspension or debarment from government contracts, all of which could damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. Responding to any investigation or action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees.</span></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to employee matters and managing our growth</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to attract and retain key executives and advisors and to attract, retain and motivate qualified personnel.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on the management, development, clinical, financial and business development expertise of our executive officers, particularly R. Nolan Townsend, our Chief Executive Officer and a member of our board of directors, Narinder Bhalla, M.D., our Chief Medical Officer, Jose Manuel Otero, our Chief Operating Officer, Louis Tamayo, our Chief Financial Officer, as well as on the scientific expertise of our founder, Ronald G. Crystal, M.D., Professor and Chairman of Weill Cornell Medicine&#8217;s Department of Genetic Medicine. Each of our executive officers may currently terminate their employment with us at any time and we do not have an employment contract with Dr. Crystal. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining qualified executives, scientists and clinical personnel and, if we progress the development of our product pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees, or our inability to recruit certain executives, could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, recruiting executive officers, or replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize gene therapy products.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition to hire from this limited pool is intense, and we have experienced and may continue to experience challenges filling certain executive roles. We may be unable to hire, train, retain or motivate key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our clinical development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 59 full-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our choice to focus on multiple therapeutic areas may negatively affect our ability to develop adequately the specialized capability and expertise necessary for operations. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may be improperly classified and may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We endeavor to properly classify our employees as exempt or non-exempt with respect to wage and hour laws (including, but not limited to, for purposes of minimum wage, overtime and applicable meal and rest periods), and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any employees have been incorrectly classified as exempt, the possibility nevertheless exists that certain job roles could be deemed to have been incorrectly classified as exempt. In addition, we endeavor to classify our workforce properly, and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any independent contractors have been incorrectly classified, the possibility nevertheless exists that certain contractors could be deemed to be employees.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Although we have adopted a code of business conduct and ethics, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The administrator of the 2023 Plan is authorized to exercise its discretion to reprice stock options and stock appreciation rights, and if a repricing occurs, there may be adverse consequences to our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The administrator of the 2023 Plan, which is our compensation committee, is authorized, subject to the consent of any award holder whose award is materially impaired by such action, to reduce the exercise price of a stock option or stock appreciation right; to cancel a stock option or stock appreciation right in exchange for a different award, cash or other consideration; or to take any other action that is treated as a repricing under generally accepted accounting principles, or each such action, a repricing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no current expectation that a repricing will occur. However, if the administrator were to implement a repricing without seeking prior stockholder approval, certain proxy advisory firms and/or institutional investors may express a lack of support for the repricing, and proxy advisory firms may recommend an &#8220;against&#8221; or &#8220;withhold&#8221; vote for members of our compensation committee or our board of directors. In addition, if we are required to hold an advisory vote on named executive officer compensation (known as a &#8220;say on pay&#8221; vote) at the time of, or subsequent to, any such repricing, it is likely, based on their current policies, that proxy advisory firms would issue an &#8220;against&#8221; recommendation on our say on pay proposal. Defending against negative recommendations with respect to our directors and/or say on pay proposal would require management attention, and could be costly and time-consuming.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our stockholders agree with proxy advisory firms&#8217; recommendations, we may need to make changes to our compensation and corporate governance practices, and perhaps the composition of our board of directors and its committees, potentially leading to business disruptions and a negative impact on our stock price. Even absent negative reactions from proxy advisory firms and institutional investors, we may be required to recognize a compensation expense and the repricing will require management&#8217;s time and attention and the payment of administrative costs and attorney and accounting firm fees. As such, a repricing could cause a negative impact on our stock price, and adverse consequences to our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to ownership of our common stock and our status as a public company</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The trading price for our common stock may be influenced by many factors, including those discussed in this &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; section and elsewhere in this Annual Report on Form 10-K and:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reporting of unfavorable preclinical and clinical results;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of our clinical trials of LX2006, LX2020 or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for LX2006, LX2020 or any other product candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results from, delays in or termination of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of LX2006, LX2020 or any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates by us or by any equity research analysts who might cover our stock;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions or trends in our industry;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock trading price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our relationships with our collaborators;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investors&#8217; general perception of our company and our business;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation or employee or independent contractor litigation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable geopolitical and economic conditions; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets and the banking sector, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, supply chain shortages, increases in inflation rates, bank failures, higher interest rates, changing foreign trade policies and uncertainty about economic stability. For example, the ongoing wars in Ukraine and the Middle East have created volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. In addition, investor concerns regarding the U.S. or international financial systems and governmental stability, including as a result of recent tariffs announcements and increased volatility in the credit and equity markets, may impair our ability to raise additional capital or enter into opportunistic strategic partnerships or acquisitions in a timely manner or on favorable terms, or at all. The deterioration of the equity and credit markets may also make any necessary debt or equity financings more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, higher inflation and macro turmoil and uncertainty could also adversely affect our buyers and sellers, which could reduce demand for our products. These factors may negatively affect the trading price of our common stock, regardless of our actual operating performance.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the trading prices of these companies&#8217; stock. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the trading price of our common stock. While we currently have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the last day of the fiscal year ending after the fifth anniversary of our IPO, or, if earlier, (i) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (ii) the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this Annual Report may be different than the information investors may receive from other public companies in which they hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in our trading price.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any derivative action or proceeding brought on our behalf;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a breach of fiduciary duty;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us arising under the Delaware General Corporation Law, or DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated certificate or our amended and restated bylaws;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These exclusive forum provisions may result in increased costs for investors to bring a claim. Further, these exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the trading price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified board of directors such that only a portion of our directors stand for election at any given annual stockholder meeting;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allow the authorized number of our directors to be changed from time to time by our stockholders or our board of directors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish requirements for stockholder proposals that can be acted on at stockholder meetings;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and allow actions by our stockholders by written consent, with certain requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit who may call stockholder meetings; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General risks</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions recently, including, among other things, recent tariff announcements, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflicts in Ukraine and the Middle East and increasing tensions between China and Taiwan have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of new tariffs, political unrest or war, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would not survive or be able to meet their commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget. We have experienced and may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq Stock Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In addition, Section 404 of the Sarbanes-Oxley Act requires our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. We are also required to disclose changes made in our internal controls and procedures on a quarterly basis. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. Once we are no longer an emerging growth company or, if prior to such date we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements of these rules and regulations are difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources. Effective internal control over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended and anticipate we will continue to expend significant resources, including accounting-related costs, and provide significant management oversight. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Market.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may identify weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we fail to identify material weaknesses in our internal control over financial reporting, if we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the trading price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the Securities and Exchange Commission, or the SEC, or other regulatory authorities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and research tax credits to offset future taxable income may be subject to additional limitations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had approximately $182.0 million of U.S. federal net operating loss carryforwards, or NOLs, $362.9 million of U.S. state and local NOLs, and $7.2 million of federal tax credits. U.S. federal NOLs generated in taxable years beginning after December 31, 2017, do not expire and may be carried forward indefinitely, but the deductibility of such NOLs is limited to no more than 80% of current year taxable income. Our U.S. state and local NOLs begin to expire in 2040 and our federal research tax credits begin to expire in 2040.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a rolling three-year period, our ability to use our pre-change NOLs and certain other pre-change tax attributes (such as research tax credits) to offset our post-change taxable income or taxes may be limited. We have determined that we experienced ownership changes on November 7, 2023 and May 28, 2025, each of which has limited our ability to utilize our federal NOLs and federal tax credits. As a result of these ownership changes, we are subject to an annual limitation of approximately $2.4 million on our ability to utilize our federal NOLs and federal tax credits recognized before May 28, 2025, inclusive of the ownership change that occurred on November 7, 2023. Due to the limitations, no federal NOLs are expected to expire unutilized and $10.6 million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership changes, are expected to expire unutilized. If we undergo additional ownership changes, and our ability to use our pre-change NOLs and other pre-change tax attributes (such as tax credits) to offset our post-change income or taxes is further limited, it may harm our future results of operations by effectively increasing our future tax obligations. U.S. state and local NOLs may be similarly limited. In addition, at the U.S. state and local level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase U.S. state and local taxes owed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Irrespective of the above, our ability to utilize our NOLs and research tax credits to offset future taxable income or taxes is conditioned on our attaining profitability and generating taxable income. We do not know if and when we will generate sufficient taxable income to utilize our NOLs and research tax credits.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may materially harm our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. For example, the IRA enacted a 15% minimum tax on the adjusted financial statement income of certain large U.S. corporations for taxable years beginning after December 31, 2022, as well as a 1% excise tax on stock repurchases made by public corporations after December 31, 2022. Further, the Tax Cuts and Jobs Act of 2017, or the Tax Act, enacted many significant changes in U.S. federal tax laws, some of which were further modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and may be modified in the future by the current or a future presidential administration. Among other changes, the Tax Act amended the Code to require that certain research and experimental ("R&amp;E") expenditures be capitalized and amortized over five years if incurred in the United States or fifteen years if incurred in foreign jurisdictions for taxable years beginning after December 31, 2021. For tax years beginning after December 31, 2024, OBBBA was enacted that includes provisions with effective dates in 2025 and beyond, and for some small business taxpayers, certain provisions may have retroactive effects. Among other changes, the OBBBA amended the Code under which domestic R&amp;E expenditures may be immediately deducted. The remaining unamortized domestic R&amp;E expenditures may be deducted in full in the first taxable year, ratably over two taxable years, or can continue being amortized over the remaining life. However, foreign R&amp;E expenditures must continue to be capitalized and amortized over fifteen years. In addition, it is uncertain if and to what extent various states will conform to the IRA, the Tax Act, the CARES Act, OBBBA, or any future U.S. federal tax laws. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future U.S. tax expenses.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#8217;, CROs&#8217;, manufacturers&#8217;, contractors&#8217;, consultants&#8217; or collaborators&#8217; cybersecurity.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we and third parties with whom we conduct business, including third-party CMOs, CROs, manufacturers, contractors (including sites performing our clinical trials), consultants, and collaborators, collect and store sensitive data, including intellectual property, clinical trial data, proprietary and confidential business information, and personal data and personal information of our clinical trial subjects, employees, and others. The secure maintenance, transmission, and other processing of this information is critical to our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our internal systems, as well as those of third parties on which we rely, are vulnerable to damage from, among other things, computer viruses, ransomware and other forms of malware, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, system malfunctions, cyberattacks or cyber-intrusions, email attachment compromise, denial of service attacks, phishing attacks, and unauthorized or otherwise improper acts or omissions by persons inside our organization, or persons with access to systems inside our organization. Any such event could lead to the prevention of access to, loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to or other processing of, our data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal data) or other data that is processed or maintained on our behalf, and cause disruptions to our operations, which could lead to a material disruption of our product candidate development programs. For example, the loss, corruption or unavailability of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More generally, despite the implementation of security measures in an effort to protect our systems and data, we cannot ensure that our information technology and infrastructure or any of our relevant policies or measures will prevent breakdowns or disruptions of, or breaches or incidents impacting, our systems or those of third parties on which we rely, or other cybersecurity incidents that lead to loss, destruction, unavailability, or unauthorized alteration, dissemination or other processing of, or damage or unauthorized access to, our data, including personal data, our other assets, or other data processed or maintained on our behalf, that could delay clinical development of our product candidates and have a material adverse effect upon our reputation, business, operations or financial condition. To our knowledge, we have not experienced any security breach to date that has had a material impact on our business or operations, but we and the third parties with whom we conduct business have faced, and we anticipate continuing to face, cybersecurity risks, including risks of security breaches and incidents. Risks of security breaches and incidents and other types of system disruptions, particularly through cyberattacks or cyber intrusions, including by hackers, foreign governments, cyber terrorists, and associated actors, have increased generally as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Geopolitical conflicts and tensions may also increase such risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any security breach or incident resulting in any loss, destruction, unavailability, alteration, disclosure, dissemination, or other processing of, or damage or unauthorized access to, our data, systems or applications, or inappropriate disclosure or other processing of confidential or proprietary information or personal data, or any other event resulting in unauthorized access to, or disclosure or processing of, such information, or for it to be believed or reported that any of the foregoing has occurred, could lead to us facing regulatory inquiries and proceedings, incurring material legal claims and proceedings, and incurring material damage to our reputation. Any such event could also disrupt our operations, lead to delays in the further development of our product candidates, cause a loss of confidence in us and our ability to conduct clinical trials, compel us to comply with federal and state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and subject us to material liability under applicable laws, rules, regulations and standards, which could result in significant legal and financial exposure and reputational damage that could have a material adverse effect on our business, operations, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notifications and follow-up actions related to a security breach or other security incident could impact our reputation and cause us to incur significant costs, including significant legal expenses and remediation costs. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident. However, we cannot guarantee that we will be able to detect or prevent any such incidents, or that we can remediate any such incidents in an effective or timely manner. Our efforts to improve security and protect data from compromise may also identify previously undiscovered instances of data breaches or other cybersecurity incidents. Any security breach or incident resulting in any loss, destruction, or alteration of, damage or unauthorized access to, or unauthorized or otherwise inappropriate disclosure, dissemination, or other processing of, our data, including personal data, or other information that is processed or maintained on our behalf, any significant damage to or disruption of our systems, or any perception that any of these has occurred, could expose us to litigation and governmental investigations and inquiries, lead to delays in further development and commercialization of our product candidates, and subject us to significant fines, penalties and other liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any failure or other disruption of, security breach of, or incident impacting, our systems or third-party systems where information important to our business operations is stored or otherwise processed, or any other unauthorized disclosure of information. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur increased costs and demands upon management as a result of being a public company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company listed in the United States, we incur significant additional legal, accounting and other expenses that we did not incur as a private company, including the cost of director and officer liability insurance. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and the Nasdaq Stock Market, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors, or as members of senior management.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B.    Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div><ix:nonNumeric id="F_2cb3fa28-d975-4f6e-b3f2-b03d1bf1830e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_2cb3fa28-d975-4f6e-b3f2-b03d1bf1830e_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1C.    Cybersecurity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3920ee7b-9952-46a0-9a3e-72c172346ea0" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_606fd40d-2748-45da-9a78-bd0e87176290" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e11aa698-34fc-464a-bd10-e0735db5d9fa" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_757c3ef2-efc5-4c06-ad08-8723bfa89d8d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> specialized third parties in connection with our risk assessment processes. These </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ce4fb98-c1c3-4eee-8537-f8078274f53a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties assist </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">us in designing and implementing our cybersecurity policies and procedures, as well as in monitoring and testing our safeguards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also conduct IT security assessments on our key third-party service providers and require them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of their security measures that may affect our company.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2cb3fa28-d975-4f6e-b3f2-b03d1bf1830e_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not previously experienced any cybersecurity risk or cybersecurity incident which has been determined to be </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06785609-6331-4c5c-b390-3bf32e4f4581" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, including the risk factor entitled &#8220;Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#8217;, CROs&#8217;, manufacturers&#8217;, contractors&#8217;, consultants&#8217; or collaborators&#8217; cybersecurity&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35427883-a395-402e-a99d-4625a3960e67" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_416bdb1c-ed4f-460d-85f8-f2669f63016c" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cb19957-994e-42f8-9c3e-11f91bb09252" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The day-to-day implementation of our cybersecurity policies and processes is primarily overseen by our Vice President, Associate General Counsel in consultation with our Chief Financial Officer and external advisors including our IT and Cybersecurity consultant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbfb4b45-843b-4871-8419-0c6b19ddab6d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President, Associate General Counsel has more than a decade of advising on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96c51d91-2318-487a-8548-cd8079a080ae" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8a01c89-23ea-4309-955f-d6cd7487eed5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our information security policies are developed and implemented, and are reviewed at least annually with updates authorized and approved, by the security governance steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb5c1cdf-953f-4ca1-958c-546ed3a31260" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the like. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c057350e-7249-439e-b047-314d1215c2cc" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee provides updates to the board of directors on such reports</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.    Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters is located at 345 Park Avenue South, 6</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor, New York, NY 10010, where we lease a total of approximately 15,839 square feet of office and laboratory space, excluding the additional approximate 11,588 square feet that we began to lease in the first quarter of 2026, used for our research and development activities, general and administrative activities and other activities. This lease agreement began in April 2022 and expires in July 2029 with an additional five-year option to extend at the then-prevailing effective market rental rate. In March 2026, the original lease agreement was amended to include an additional approximate 11,588 square feet of leased office and laboratory space at the same address as the original headquarters lease and to be used for the same purposes. The amended lease agreement began in March 2026 with an initial term of three months, which will automatically renew for an additional three-month period(s) unless either party provides written notice to terminate the agreement.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our current facilities are sufficient to meet our current and near term needs and that suitable additional or substitute space will be available at commercially reasonable terms as and when needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3.    Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. On October 12, 2023, Rocket filed a lawsuit in the U.S. District Court for the Southern District of New York against Lexeo and two former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges that while employees of Rocket, the individual defendants downloaded confidential Rocket company documents and other proprietary materials and that Lexeo used this information to advance its programs after the individuals became employed by Lexeo. The complaint seeks unspecified damages and injunctive relief. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain PKP2-ACM patents, breach of contract, and tortious interference with contract in connection with their diligence of a PKP2-ACM program at UCSD that was later licensed by Lexeo. Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. In June 2025, the litigation was resolved amicably and without admission of liability by any party, and all claims have been dismissed with prejudice.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Reserved.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5__market_for_registrants_common_eq"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.    Market for Registrant&#8217;s Common Equity, Related Sto</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ckholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has been listed on the Nasdaq Global Market under the symbol &#8220;LXEO&#8221; since November 3, 2023. Prior to that date there was no public trading market for our common stock.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 27, 2026, there were approximately 19 registered holders of record of our common stock. We believe a greater number of holders of our common stock are &#8220;street name&#8221; or beneficial holders, whose shares of record are held by banks, brokers and other financial institutions.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities; Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no unregistered sales of securities other than previously disclosed by us in our Current Report on Form 8-K, as filed with the SEC on October 17, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserved</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in &#8220;Item 1A. Risk Factors&#8221; and in other parts of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including FA cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, or ACM, and other devastating diseases with high unmet need.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2006 for the treatment of FA cardiomyopathy</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Clinical Data Updates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we provided an interim clinical update, which included baseline characteristics and safety data from the 17 treated participants across the two studies, and clinical efficacy data from the 16 participants who had reached at least six months follow-up as of that time. A summary of key observations from the October 2025 interim update is set forth below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in LVMI among participants with abnormal baseline LVMI (n=6). Five of six participants achieved &gt;10% by 12-month visit or sooner and six of six participants achieved LVMI measurements within the normal range as of latest visit. A 18% mean improvement in LVMI was observed at 6-month visit and a 23% mean improvement in LVMI was observed at 12-month visit, exceeding 10% FDA-aligned threshold for pivotal study. In the mid- and high-dose cohorts (n=3), a 28% mean improvement in LVMI was observed at 6-month visit and a 33% mean improvement in LVMI was observed at 12-month visit, suggesting dose-dependent improvement. Among participants with normal baseline LVMI (n=10), the majority demonstrated LVMI improvement or stabilization over time.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in secondary cardiac biomarkers. Fourteen of sixteen participants achieved &gt;25% reduction in high-sensitivity troponin I from baseline at latest visit. Fourteen of sixteen participants achieved reduction or stabilization in LWT from baseline at latest visit.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in mFARS as demonstrated by a 2.0-point mean improvement from baseline at latest visit across all participants. Eleven of sixteen participants achieved reduction or stabilization in mFARS from baseline at latest visit. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Previously reported data in April 2025 from ongoing SUNRISE-FA trial (n=8) showed that all study participants achieved increases in frataxin protein expression from baseline at 3-month visit, with dose-dependent increases observed across cohorts.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the data observed as of the October 2025 update, LX2006 remained generally well tolerated with no Grade 3+ SAEs and no signs of complement activation or other immunogenicity.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Alignment</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we announced further alignment on elements of the accelerated development pathway following a Type B RMAT meeting with the FDA including frataxin expression co-primary endpoint to be evaluated for any increase from baseline rather than numerical threshold.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, we announced Breakthrough Therapy designation based on interim clinical data from Phase 1/2 trials showing clinically meaningful improvements in cardiac biomarkers and functional measures. We also announced that LX2006 was selected for the CDRP Program, created to facilitate CMC registrational readiness and support faster patient access.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, in response to our questions regarding the possibility of a faster path to BLA, the FDA indicated openness to a BLA submission for accelerated approval that includes clinical data from the ongoing Phase 1/2 studies of LX2006 pooled with new clinical data to be generated in the planned pivotal study. The FDA also previously agreed to evaluate the co-primary endpoint of LVMI at a time point earlier than 12 months. Collectively, we believe this regulatory feedback has the potential to reduce the size and length of the planned pivotal study, possibly accelerating the overall timeline to BLA submission. We plan to initiate the LX2006 pivotal study in the first half of 2026, pending finalization of the trial protocol.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020 for the treatment of arrhythmogenic cardiomyopathy</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, or ACM, caused by mutations in the PKP2 gene, referred to as PKP2-ACM, is currently being evaluated in HEROIC-PKP2, an ongoing Phase 1/2 clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Clinical Data Updates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we provided an interim clinical data update for the three participants dosed in cohort 1 (n=2 at 12-month visit; n=1 at 9-month visit), assessing multiple cardiac parameters at latest visit relative to baseline. A summary of key observations from the October 2025 interim update is set forth below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Premature ventricular contractions, or PVCs, were reduced in one of three participants and non-sustained ventricular tachycardia, or NSVT, was reduced or stable in two of three participants.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">QRS duration was normalized or stable in two of three participants and T-wave inversions were reduced in two of three participants.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Left ventricular ejection fraction, or LVEF, and right ventricular ejection fraction, or RVEF, were stable in three of three participants.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, we provided an interim clinical data update, which included baseline characteristics and safety data from the ten participants dosed, including three participants in cohort 1 at the low dose and seven participants in cohorts 2 and 3 at the high dose. Clinical efficacy data were inclusive of those participants with at least 6 months of follow-up (n=8). A summary of key observations from the January 2026 interim update is set forth below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in NSVT and PVCs. NSVT reduced or stabilized in the majority of participants, with a 22% mean improvement in high-dose cohorts at latest visit (n=5). PVCs reduced or stabilized in the majority of participants, with a 14% mean improvement in high-dose cohorts at latest visit. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Four of five participants in high-dose cohorts report improvement relative to baseline on the PGIC scale, a patient-reported outcome measure.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participants stable across other clinical measures including QRS duration, T-wave inversion, RVEF and NYHA Class.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increases in PKP2 protein expression versus baseline at three months in all participants that had undergone cardiac biopsies (n=7) assessed by western blot. Dose-dependent increases observed, with mean increase of 93% in the low-dose cohort (n=2) and 162% mean increase in the high-dose cohorts (n=5).</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the data observed as of the October 2025 and January 2026 readouts, LX2020 remained generally well tolerated with no clinically significant complement activation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our gene therapy candidates utilizes the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease. Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, potential for lower toxicity given the opportunity to utilize lower doses compared to other well-established AAV serotypes, and low pre-existing immunity.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current and Future Capital Requirements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have funded our operations primarily through proceeds from the sale of shares of our convertible preferred stock, common stock, and pre-funded warrants and warrants to purchase our common stock, including from our October 2025 Financing Transactions, May 2025 Private Placement, March 2024 Private Placement, IPO and the subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares of common stock. As of December 31, 2025, we had $246.6 million of cash, cash equivalents, and investments in U.S. Treasury securities. We have incurred significant operating losses since the commencement of our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eventual commercialization of one or more of our current gene therapy candidates or any future gene therapy candidates. Our net losses for the years ended December 31, 2025 and December 31, 2024 were $100.0 million and $98.3 million, respectively, and our accumulated deficit was $380.1 million at December 31, 2025. We expect to continue to incur significant losses for the foreseeable future as we advance our current and future product candidates through preclinical and clinical development, continue to build our operations and operate as a public company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur net operating losses for at least the next several years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures to continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our ongoing and planned clinical trials as well as research and development of our FA cardiomyopathy (LX2006) and arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene, or PKP2-ACM (LX2020) programs and other product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate preclinical studies and clinical trials for any additional product candidates that we may pursue in the future;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to discover and develop additional product candidates and further expand our clinical product pipeline;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invest in capital equipment in order to expand our research and development and manufacturing activities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain additional clinical, scientific, quality control, regulatory, and manufacturing management and administrative personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other product candidates and technologies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operations in the United States and to other geographies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting, investor relations and other general and administrative expenses associated with operating as a public company; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure, either ourselves or in partnership with others, to commercialize any product candidates, if approved, and related additional commercial manufacturing costs.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of our results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales. If our development efforts for LX2006 and LX2020, or any future product candidates, are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, royalties or payments from such collaboration or license agreements, or a combination of product sales and payments from such agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred for our research activities, including our discovery efforts and the preclinical and clinical development of our programs. These expenses include:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, including salaries, benefits, and stock-based compensation expense for employees engaged in research and development functions;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with third parties, such as consultants, clinical investigators, contractors and CROs that assist with (i) identification of potential product candidates in discovery platforms and (ii) the preclinical and clinical studies of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of developing and scaling our manufacturing process and manufacturing product candidates for use in our research, preclinical studies and clinical trials, including under agreements with third parties, such as consultants, contractors and CMOs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to maintain compliance with FDA and other regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and research materials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments made under our licensing agreements with third parties, including milestone payments; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other expenses incurred as a result of research and development activities.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record research and development costs as expenses when incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. When third-party service providers&#8217; billing terms do not coincide with our period-end, we are required to make estimates of our obligations to those third parties incurred in a given accounting period and record accruals at the end of the period. We base these estimates on our knowledge of the research and development programs, services performed for the period, past history for related activities and the expected duration of the third-party service contract, where applicable. If timelines or contracts are modified based upon changes in the scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis; therefore, actual results could differ from our estimates. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external costs, such as fees paid to CROs, CMOs, central laboratories and certain outside consultants in connection with our research and discovery, preclinical development, process development, manufacturing, clinical development, clinical trials, regulatory and quality assurance activities. We do not allocate professional services costs and licensing fees and other similar costs to specific programs because these costs are deployed across multiple programs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business model and account for a significant portion of our operating expenses. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase for the foreseeable future as we further advance LX2006 and LX2020, and any other future product candidates that we may develop, into and through preclinical studies and clinical trials and pursue regulatory approvals. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future research, preclinical studies and clinical trials, regulatory developments and our assessments as to each product candidate&#8217;s commercial potential. In addition, we cannot forecast whether any of our current or future product candidates will be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We are also unable to predict when, if ever, we will generate revenue from our product candidates to offset our expenses.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense for personnel in executive, accounting, business development, legal, human resources and administrative functions. General and administrative expenses also include corporate facility costs not otherwise included in research and development expenses, depreciation, and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included in research and development expenses, as well as professional fees for legal, consulting, investor and public relations, accounting and audit services.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that in the near to medium term future our general and administrative expenses will decrease relative to those incurred during the year ended December 31, 2025 on an annualized basis, primarily due to lower anticipated third-party legal fees and related costs, while supporting the continued research and development of our programs and the growth of our business.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain on long-term investment</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gain on long-term investment includes non-operating income related to an unrealized gain on convertible preferred stock received that was recorded at fair value to long-term investment.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net includes foreign exchange gains and (losses).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest expense</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense is primarily associated with our finance right of use asset equipment leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income is primarily related to interest earned from our investments in U.S. government money market funds and interest earned from our investments in U.S. Treasury securities, as well as interest earned on interest-bearing demand deposit cash accounts and a cash collateral account.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization of premium and accretion of discount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on investments consists of</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amortization of premium and accretion of discount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on our investments in U.S. Treasury securities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provision for income taxes consists of U.S. federal and state income taxes in the jurisdictions where we conduct business. Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss, or NOL, carryforwards and tax credits will not be realized. Accordingly, we have recorded a full valuation allowance against our net deferred tax assets at December 31, 2025 and December 31, 2024. As of December 31, 2025 and December 31, 2024 we had no unrecognized tax benefits.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2025 and 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.477%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,797</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,091</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,294</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,460</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,675</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,785</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,257</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,766</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,491</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(109,257</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(105,766</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,491</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on long-term investment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,390</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,390</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(95</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(137</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,130</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,556</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,426</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(111</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(134</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income and expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,296</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,433</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,863</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(99,961</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,333</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,628</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(99,961</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,333</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,628</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses incurred for the years ended December 31, 2025 and 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.477%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development expenses by program:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,163</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,256</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,907</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,413</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,451</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,038</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,168</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,333</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,075</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,424</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,349</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total direct external research and development expenses by program</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,819</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,632</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,813</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee and stock-based compensation expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,707</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,011</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,304</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,550</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,367</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,701</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,030</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(329</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other unallocated costs, including facilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,020</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,051</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,978</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,459</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,797</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,091</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,294</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net decrease of $10.3 million in total research and development expenses for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to decreases in (i) milestone expenses of $6.1 million, consisting primarily of a $6.0 million development milestone for our LX2020 program that was achieved during the third quarter of 2024 and subsequently paid to the selling shareholders of Stelios, (ii) clinical trial costs of $3.2 million excluding an adjustment that reduced estimated accrued clinical trial expenses in 2024 by $2.2 million for our LX1001 program, (iii) employee and stock-based compensation costs of $1.3 million primarily due to decreased headcount, (iv) CMC expenses of $1.2 million, and (v) license fees of $0.6 million related to the Third Cornell License Agreement that were incurred in 2024. These decreases were partially offset by an adjustment that reduced estimated accrued clinical trial expenses in 2024 by $2.2 million for our LX1001 program.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net increase of $13.8 million in general and administrative expenses for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to increases in third-party legal fees and associated costs of $11.7 million, as well as employee compensation costs of $1.9 million primarily due to increased headcount.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain on long-term investment</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded non-operating income of approximately $3.4 million during the year ended December 31, 2025 related to an unrealized gain on convertible preferred stock received that was recorded at fair value to long-term investment.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized interest income of $6.1 million and $7.6 million for the years ended December 31, 2025 and December 31, 2024, respectively, primarily related to interest earned on our investments in U.S. government money market funds and our investments in U.S Treasury securities, with the decrease primarily due to lower interest rates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and capital resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. Since our inception through December 31, 2025, we funded our operations primarily through proceeds from the sale of shares of our convertible preferred stock, common stock, and pre-funded warrants and warrants to purchase our common stock, including from our October 2025 Financing Transactions, May 2025 Private Placement, March 2024 Private Placement, IPO and the subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares of common stock, with estimated net proceeds since our inception totaling $594.9 million. As of December 31, 2025 and December 31, 2024, we had cash, cash equivalents, and investments in U.S. Treasury Securities of $246.6 million and $128.5 million, respectively.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2025 we filed a prospectus supplement to the prospectus which forms a part of our effective shelf registration statement on Form S-3, dated December 13, 2024, which registers the offering, issuance, and sale of up to $75.0 million of common stock pursuant to our ATM Program. As of December 31, 2025, we have not sold any shares of common stock pursuant to the ATM Program. In October 2025, we raised $153.8 million in equity capital from the October 2025 Financing Transactions, receiving net proceeds of $143.9 million after transaction costs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our cash, cash equivalents, and investments in U.S. Treasury securities balances will be sufficient to fund our planned operating expenses and capital expenditure requirements into 2028. Our total future capital requirements will depend on many factors and are subject to the risks and uncertainties set forth in &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 1A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for the years ended December 31, 2025 and December 31, 2024 (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,561</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(81,151</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(90,252</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(94,077</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,795</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,776</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,982</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(86,452</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, net cash used in operating activities consisted primarily of our net loss of $100.0 million, which included an unrealized gain of $3.4 million recorded to other non-operating income upon receipt of our long-term investment in convertible preferred stock, in addition to $9.5 million of net cash used in changes in operating assets and liabilities, which were partially offset by $12.1 million of stock-based compensation expense and $2.1 million of depreciation expense and amortization of operating and finance right-of-use assets.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash used in operating activities consisted primarily of our net loss of $98.3 million, which was partially offset by (i) $12.5 million of stock-based compensation expense, (ii) $2.7 million of net cash provided by changes in operating assets and liabilities, and (iii) $2.0 million of depreciation expense and amortization of operating and finance right-of-use assets.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During year ended December 31, 2025, net cash used in investing activities was $90.3 million and consisted primarily of purchases of investments in U.S. Treasury securities of $195.4 million, which was partially offset by proceeds from sales or maturities of investments in U.S. Treasury securities of $105.5 million and purchases of lab equipment of $0.4 million.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash used in investing activities was $94.1 million and consisted primarily of the purchase of investments in U.S. Treasury securities and lab equipment.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, net cash provided by financing activities consisted primarily of the net proceeds received from the October 2025 Financing Transactions of $143.9 million, the May 2025 Private Placement of $73.1 million, as well as proceeds received from common stock issuances under the 2023 ESPP (as defined below) of $0.3 million and proceeds received from the exercise of stock options of $0.1 million, which were partially offset by $0.5 million of principal payments made on equipment finance leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash provided by financing activities consisted primarily of the net proceeds received from the March 2024 Private Placement of $88.7 million, as well as $0.5 million of proceeds received from the exercise of stock options, which were partially offset by $0.4 million of principal payments made on equipment finance leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses and capital requirements to increase significantly in connection with our ongoing activities, particularly as we advance our lead product candidates and other development programs. Accordingly, we will continue to require substantial additional funding to support our continuing operations.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing and amount of our future operating and capital requirements will largely depend on many factors, including:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, scope, progress, timing, results and costs of product discovery, preclinical studies and clinical trials for our product candidates or any future candidates we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our relationships with Cornell University, Adverum, The Regents of UCSD, and any other key licensors or collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization and number of our research and development programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we have or may enter into;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of securing manufacturing arrangements for commercial production;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our need to implement additional internal systems and infrastructure. </span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to raise additional funds or enter into potential collaborations, strategic partnerships or marketing, distribution, licensing or other similar agreements or arrangements on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your stockholder ownership interest will be diluted. If we fail to raise capital or enter into such agreements or arrangements as, and when, needed, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical accounting policies and significant judgments and estimates</span></h2><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and the disclosure of our contingent liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our audited financial statements included elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our audited financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with discovery and preclinical development activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with preclinical studies and testing; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMOs in connection with the process development and scale up activities and the production of materials.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record the expense and accrual related to contract research and manufacturing based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development, and manufacturing activities; invoicing to date under contracts; communication from the CROs, CMOs, and other companies of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses; however, we cannot guarantee that such adjustments will not be made in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock option awards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize share-based compensation expense related to stock option awards granted based on the estimated fair value of the awards on the date of grant using a Black-Scholes option pricing model. The grant date fair value of the share-based awards is recognized on an accelerated basis under the graded vesting method over the requisite service period of the award, which is the vesting period of the respective awards. Share-based payments to non-employees issued in exchange for services are based upon the fair value of the equity instruments issued. Compensation expense for stock options issued to non-employees is calculated using the Black-Scholes option pricing model and is recorded over the requisite service performance period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of highly subjective assumptions, which are used to determine the fair value stock option awards granted. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected term represents the period that our stock option awards granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected stock price volatility is primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since the IPO, each for a period equal to the expected life of the stock options granted, and we expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded stock price. Our peer group of publicly traded companies was chosen based on their similar size, stage in the life cycle or area of specialty.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The risk-free interest rate is based on the interest rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of stock options granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have never paid, and do not anticipate paying, cash dividends on our shares of common stock. Therefore, the expected dividend yield was assumed to be zero.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The fair value of shares of our common stock is measured by the stock price on the date of grant.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company and smaller reporting company status</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The JOBS Act permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an &#8220;emerging growth company,&#8221; we are exempt from Sections 14A(a) and (b) of the Exchange Act, which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency,&#8221; and &#8220;golden parachutes;&#8221; and (2) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer&#8217;s compensation to our median employee compensation. We also rely on an exemption from the rule requiring us to provide an auditor&#8217;s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We will continue to remain an &#8220;emerging growth company&#8221; until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates was less than $700.0 million as of June 30, 2025 and our annual revenue was less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (1) the market value of our stock held by non-affiliates is less than $250.0 million or (2) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million as of June 30 of such year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited consolidated financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently issued accounting pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations and cash flows is disclosed in Note 2 to our audited financial statements included elsewhere in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualitative and quantitative disclosures about market risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest rate risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and are not required to provide the information under this item.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 7A.    Reserved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and_supplem"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 8.    Financial Statements and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:92.92%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (</span><span><ix:nonNumeric id="F_f9187263-f794-4022-9929-996f9fec4cf1" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:AuditorName"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_6e10bc5d-b42d-4088-b72a-046e8b4d0924" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:AuditorLocation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">New York, NY</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">, Auditor Firm ID: </span><span><ix:nonNumeric id="F_cb0b1a84-77ce-42fe-be35-5c373a978a50" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stockholders_deficit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_fin"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:28%;box-sizing:content-box;"/>
     <td style="width:72%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img147150826_9.jpg" alt="img147150826_9.jpg" style="width:90px;height:43px;"/></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345 Park Avenue</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, NY 10154-0102</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and Board of Directors</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4a9c584-1d89-49db-9049-43dc8d232835" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img147150826_10.jpg" alt="img147150826_10.jpg" style="width:129px;height:31px;"/></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2021.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG LLP, a Delaware limited liability partnership and a member firm of</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the KPMG global organization of independent member firms affiliated with</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG International Limited, a private English company limited by guarantee.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11cd94bc-034d-4d5c-a68c-2c06bdbd1e5b" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee43894d-2f0c-4328-a95e-cd29f299a844" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,014</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36041f32-cdfa-444f-87d2-64a5e5fe39d8" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,767</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c296701c-1c2c-4bab-9df0-acfd95ce807d" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16816d9a-5b45-40eb-a5a2-10fa6bb6ea90" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,625</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2d7499a-661a-4fb2-bae0-bf66f420d1e4" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,603</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f490f37a-e7c7-4990-8276-832476fa2b6c" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcc0571f-4164-4980-8bdf-1d8dd82f9c54" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_138975e0-14a3-4691-9420-df4f7f0fda2a" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,801</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceb24957-b365-4052-9d27-1c70b76b6072" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4842e689-c071-4dc0-abb6-534e4008f72c" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,390</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ee9a83c-35c9-42b1-9282-15c1b97b2a14" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69aad6d9-d451-460e-a615-6d41e28e7a51" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,248</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a59a8bb-70e2-4a9c-9175-683e7a6dd96b" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,252</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eba6e54f-2fbe-4967-aba4-e2ce10623ef8" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,139</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f330d11-31a9-49ae-a1c0-375d974501c9" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease right-of-use assets - finance</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb0ae98a-c6d5-4d76-921c-c2ac63cc9abd" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,140</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de0fd2e6-eff4-46b6-8709-5e236eff56af" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,460</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease right-of-use assets - operating</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38bbc13-ea8c-42d4-a54b-f04d1244ae4a" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,578</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba6337ee-1e83-4514-aa1d-91c9ba3b777e" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,069</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16512271-359a-4331-8010-4758010c4c26" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268,688</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1eed479-1f2d-4318-a558-13b8d6a2e3e6" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,942</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f69f85bc-3d7f-4d2b-b137-0ef82da9623d" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,856</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef2b44d-ad09-4199-99e6-5941d3ee291f" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,417</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5798667-0dee-4ca4-a7fd-2ddf957722d8" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8963962-d414-42fc-82fd-279a94f5fb72" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,759</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad866abe-c681-41dc-83bd-6d53567cd8f3" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">518</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f097beb6-5e9c-45f8-b9a4-0901a47a1eb7" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ab2b583-828e-497d-8b16-1dc15975c33e" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,157</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368aa708-bed3-40e4-9736-1ef57894c7ab" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31b8d4ec-3c8a-4880-aeec-2d7771c4a840" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,808</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a33049ba-679d-43c7-a692-5a6befd48364" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,846</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b0c0abd-e52f-4eae-9370-0febd9a06695" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b2fb84-c480-46ad-8496-816e4dd4caaf" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f020d6f-721a-4b70-9a53-263bea9ae2bb" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,884</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b6dc946-8bc6-43d5-a99a-4baf367ea619" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,437</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9100e677-6bcf-4388-ab8e-c84ac1257d22" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,019</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_804c2b23-b8a9-4591-81ca-39765c7f22c3" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_ceacd56d-047e-42df-8382-2f180e72f798;"><span style="-sec-ix-hidden:F_368454f4-1de5-47d4-a463-ff48edb9c65d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 11)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb9534a0-503c-44ce-a758-0a0322ac3e81" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_400fa09b-1951-4349-a387-4ad5ad8459ba" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d24b4bef-032a-479c-8122-d4b42d61f0a8" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, 2025; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6a5b704-50d7-4bb1-975d-caae7845d8a1" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">73,001,766</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_949a5c99-b3c4-4365-8321-1e14d923c0ff" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">73,001,350</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares outstanding as of December 31, 2025; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_657ab82a-9f94-485b-8f1f-b6df4bed9e41" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c7ce63a-70a9-4223-a08f-271a1731ac26" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,079,209</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc22177c-8026-4649-b5af-67811874aee1" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,071,261</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares outstanding as of December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a37b0f0c-1899-485e-8afe-19f0e0f0276e" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a7693b-6765-4b77-8eba-d5c3c12bd600" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock, at cost, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c326932d-dfea-4abf-bea9-876770df2ab5" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d617b7a-3af2-4251-add5-29d8bb39d25f" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;common shares as of December 31, 2025 and as of December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e769f0fa-9802-4133-8978-7f2649272a43" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f06cc5ee-f461-453b-aa8d-8aa5df4c1c70" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7db15c86-8801-4bc5-a6f4-0192e00140ac" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">626,625</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70419780-cf1d-4daa-a821-9db99e09311a" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4431c10-149d-4676-bf16-8249d40af340" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60774371-b1b8-4895-b48d-f91a8bc58237" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0321b32-1e28-4d56-a90b-bae1eabe8d8d" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">380,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a61523e7-c4d1-46d4-86a8-9bb6dad242b6" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81e31564-23ce-4c3b-8980-8af9cb337951" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246,669</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dd4a5fa-1af6-418f-8d65-d06efb168cab" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,842</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7899df8-a28a-40a8-bdcb-b7f826368a73" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268,688</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8118d413-3d11-421a-bc48-5051f832a97f" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,942</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:64.52%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af7c918e-5403-4c30-b588-74bbde0b9801" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,797</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74465d86-4e2f-4ca7-aa25-ec78bfc5afb1" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,091</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32b5ff73-6d34-471b-aabe-2dba4917dc6b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,460</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b1df42-efd2-4727-893b-c603ac3d9533" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69e49168-9486-440f-aa9c-f6f0a2ae61f2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,257</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ac435d-ec19-4114-9451-3d7c58825a51" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,766</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeab5b70-1d49-423a-a835-19db70fafd03" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,257</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c63512c6-dbe2-4f1c-9c5c-ecde19989cc2" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,766</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on long-term investment</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0636fc8d-fa46-4834-9a4b-906f8036fc37" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:GainLossOnLongTermInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,390</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b99fde9d-977a-4e01-a1ab-e4181b929e43" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:GainLossOnLongTermInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7870828-2901-43a2-816d-c3ed73e2f47a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d128fb34-baaf-4885-87c3-c4a657d225c3" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f183d57d-95f4-4dcc-80d6-e46f0f0e4d2e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6215676e-5693-4d64-8a1a-c96d336f0634" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c394868-9bb8-4789-b905-f86a7792b7fb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,130</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_594c4403-ba0a-4a70-8fc8-09e27b89f6dd" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,556</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45d76906-bc2f-45e9-8e11-93b82efa1a06" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abfee1cb-3437-4222-aa0b-2c7fdf64377b" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income and expense</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80fdfbd2-c4d6-41a1-a26c-16facac6d2bc" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4862f17-608e-4732-8fe5-d242e820bf11" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,433</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f187737-bc80-4043-8530-18afa481460a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24180deb-ee78-4783-bef3-b0917264dc49" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dfeacdd-8e84-4e7b-926e-7cbd084300c9" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf843747-66a2-4716-9ab5-6479814962a4" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss)</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized gain (loss) on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51d8a6ed-78cf-474f-bd3a-b9d802267235" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4508b5c-9b08-4949-b54d-3fda4d556f6a" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other comprehensive gain (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_297110b3-ca72-4248-8504-90552c9c9978" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c62f26ed-d0db-44d1-acbc-b7bce22fcd08" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7001bd0e-95c7-4375-bef0-61cf0a2850fa" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,670</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68b3d33d-fee6-47b3-9e7b-6322aaabe1cb" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,436</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4da3ad9d-c46a-4ffd-bd7b-7bf7e60919c5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1f1ee703-c271-42ff-95f2-43e079acf5bf" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.86</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e147f05-641a-46af-922d-8df91ddd0b04" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b10529a1-1918-4c41-8eeb-ef2e7409632c" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.09</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares outstanding used in computation of net loss per common share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c46047c-3d36-48fc-be78-03b99c9ecef6" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bee34e93-6a25-4435-98af-00f68e594cdd" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,645,323</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e41677eb-9444-4470-acad-e704730c4e92" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1f8354d8-bb43-41c8-ac4e-de5ed225a894" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,787,491</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="stockholders_deficit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts of Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.12%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.52%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eab061b3-afdd-4482-b3e0-509cf9d7cd92" contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,071,261</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbf3ab88-d5d7-46b7-ad93-e6b49aebf8c4" contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c47092d0-66b2-4b12-9416-5c039d2f462f" contextRef="C_c98b542f-c785-4f70-99a0-bd604bf1c422" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec28fb7-0674-49a5-8435-f499a268807c" contextRef="C_d5204099-2478-4b5e-b1d3-d4947afd3ec0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be7b679-6f4f-4ccc-879c-8b338ee7c79f" contextRef="C_73d54a48-f66f-434c-bf6c-25a6a7ff448b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9cdf4f8-490e-4bd3-92d1-73b678bd1481" contextRef="C_bf8a2e00-8278-456e-a9f7-bbc406b2f028" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_facdff5e-37c0-4d28-919b-ecd2ee353678" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,842</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e9b9d2d-418e-43c4-b910-f67b55a7c4b5" contextRef="C_112bc5bb-417e-47b7-868a-20b951733299" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,300</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11538c6a-26e8-4bae-9c2e-d875dffdb4fb" contextRef="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b9fd2c-a4ae-42ff-a45e-f56904e77a1b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon vesting and settlement of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5cb9ef9-53d3-4852-8dc8-c111731488a5" contextRef="C_112bc5bb-417e-47b7-868a-20b951733299" name="lxeo:IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">101,448</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon vesting and settlement of performance restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35bffbcd-1a4e-4af9-8ea1-87ddc79cce0e" contextRef="C_112bc5bb-417e-47b7-868a-20b951733299" name="lxeo:IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,800</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under 2023 ESPP</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9247c9f6-dc4d-4dee-92f2-6bff7eabc3fa" contextRef="C_7c175820-3a63-46e1-a5a5-b8abc4c71645" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">102,837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23770fb5-46e2-4b03-a79d-a4948d9215d0" contextRef="C_c6ce4425-ba2c-49ff-99d6-85aeeb9dd72e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04494a20-9beb-4467-9055-3085d5196f23" contextRef="C_425a9b2c-585d-47dc-ace4-2331628255c0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f8c5157-a3f7-43f0-a891-520f6cb1a368" contextRef="C_112bc5bb-417e-47b7-868a-20b951733299" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,532</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dde38d27-11a4-4fd5-a11a-bfc495ed501e" contextRef="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80d8a434-062b-47a8-adc6-eaeae017d49c" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement, net of commissions and offering costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41c72c9f-7663-473a-9873-53606eb163dd" contextRef="C_5f0fb589-18d5-4129-b711-24379e2c8f87" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,917</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1aca9c2-d211-4095-b368-e78fc92fdc2c" contextRef="C_15d4c068-ac5b-4885-91c7-6d538b1e1b06" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,790,120</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0660f0cc-6141-4e75-bef8-b8f48e69e364" contextRef="C_15d4c068-ac5b-4885-91c7-6d538b1e1b06" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_246d2a0c-49f3-4bad-bf3a-255d688a7ccd" contextRef="C_29a85535-be63-45f2-b8b1-970ed18a0e41" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,080</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_657fdb4b-f8bc-4a9f-9bfc-e0b59ac29041" contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,082</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions, net of commissions and offering costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5bce218-74a0-4d7e-82b1-6e4df1b70c6c" contextRef="C_d98675e8-bd97-4502-824d-9b7f8f9d89bc" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,833</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_736b899f-3b0d-40f0-b1b0-6d795d99024f" contextRef="C_6efb2e92-a65f-43f5-9c07-dfb2973f3821" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,968,750</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18bba22b-765f-4f54-9d9a-44e6cd031c99" contextRef="C_6efb2e92-a65f-43f5-9c07-dfb2973f3821" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7f28e3-3d82-4157-8aa9-0c37a3ffe5a0" contextRef="C_4cdd6443-84d6-48d5-acd5-108c91102bcf" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,915</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f649258-3087-4370-9153-4e5d63e5ba46" contextRef="C_00ff945d-1722-46c0-8cb8-739f6c508cf4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,917</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7423311e-4168-4071-8fd3-62d2a4a13c99" contextRef="C_112bc5bb-417e-47b7-868a-20b951733299" name="lxeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">867,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized comprehensive gain on investments in U.S. Treasury securities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98bb721c-9f89-4daf-81cc-05dd00da8647" contextRef="C_f3a8649e-4f53-4947-a5b7-6b4f853ce45b" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35380284-3759-4f5a-a499-86ca0ac2f62c" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20413f96-cdb6-45ee-ac0f-72406c4bdc2e" contextRef="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e60075c-2d04-41e2-a6ca-1fcea783c9bc" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320091d4-ac11-4b06-b4cd-ca271e954bf7" contextRef="C_34b52306-94cc-4920-be25-ed2fc77dc45f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35ee62a4-aafa-4066-99f1-14074c487851" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed28f6a2-93f6-410d-9716-5b16b2fd735e" contextRef="C_e5d2a857-7730-4e56-882a-9078bd9748d6" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">73,001,350</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c5af0e5-0739-4ad6-8570-cb6a83fc7d8b" contextRef="C_e5d2a857-7730-4e56-882a-9078bd9748d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39499fe0-71b6-4ace-8065-1e4bd3ada84b" contextRef="C_f806ed52-1a8c-4157-881e-dbcb5b86b7fd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41999666-d7a1-41f8-acf3-b637d68230cc" contextRef="C_a87f627d-9dbd-40af-86cb-7af479bf48e9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">626,625</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_143b5e35-4237-4198-8ea7-0bd086e13cb5" contextRef="C_0869a89c-0354-44a1-82dc-7940298b2ae8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56811452-7ba9-4260-a67c-21e427438622" contextRef="C_04fb7643-33b5-4b2c-b8e1-4cf6f989f885" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">380,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_167152cf-046d-42d4-8819-0e1bc1494229" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246,669</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.12%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.52%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc26037-cc74-45db-be39-10de7cb86f1b" contextRef="C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,646,378</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e88b0b4-d095-41c8-bfe8-bff29f02124c" contextRef="C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eab4ffee-bfc2-4c4b-8b03-51fa0dbc73da" contextRef="C_44925c32-c071-4fdb-951d-3cec6e8d40c7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,372</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d290633-b538-4721-ad16-712046dcdb4b" contextRef="C_84571f91-58c3-4594-8881-2ecd5286cf9b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,840</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_662ac55f-bb25-4d22-acef-0d576b04c04c" contextRef="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,535</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53e87738-6cca-4220-b0c5-0288f69cf39d" contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,646</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40defbee-0168-4cbd-bd93-b3ba6dd40f7d" contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5b1d745-739e-4544-8211-57c0a77fff48" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_016de2cb-bc74-4a6c-b392-fe7542717336" contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e1c2a2-925a-48c1-8530-93cc13bd237f" contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2f1687a-6934-489a-85dc-daebae331732" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock upon March 2024 Private Placement, net of commissions and offering costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f3304f5-1d4e-4672-86c7-cc8db8cd8513" contextRef="C_0d4934d2-685d-4142-9a39-88dfc50f3990" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,287</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a29a6639-faf8-476b-ba85-e252d1942294" contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,278,905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3f9d51-6602-463f-ba17-51285c2457a6" contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,712</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c0e57c7-d5a7-43e8-ad19-e49f5b999db0" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,712</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional issuance costs incurred related to issuance of convertible SAFE Note</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ceedff-904e-4388-975a-443c14bda726" contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603" name="lxeo:StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07526941-8850-494c-87bb-9efc859fa5ab" contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022" name="lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da09ce65-2461-4ec3-b063-2593393fc12e" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48be89ee-53b4-4a19-8e09-f13c20a72612" contextRef="C_7e56c74e-cfef-48b5-b83f-54670366ec44" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_410030fa-e185-46e6-90e9-9125a8e41825" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized comprehensive loss on investments in U.S. Treasury securities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a267839-ec6d-4815-ae3f-be691d6042b2" contextRef="C_736d03a4-f8aa-492d-b0a2-7f25fcc32295" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c2f9297-0697-42f1-9a17-2a8a1e5496f5" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_923795fa-9ddf-4015-92dd-a67fb83db0f5" contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b363799-b2ff-43db-90ae-761cba3c5ec1" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1be0b22a-ef6e-4de2-abde-b181b9858bbc" contextRef="C_de179b0b-31a8-495a-bf4e-3b6ec6689dce" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_472cdfe2-4487-41db-8dd3-22d676b47efb" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d8c0210-22cf-4878-a19f-f269c554fd6b" contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,071,261</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b83934ec-bdd1-4f88-b8bb-07ae0d3e035c" contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ba7fd7a-6f02-4407-bbcd-9c3327a9e8ff" contextRef="C_c98b542f-c785-4f70-99a0-bd604bf1c422" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c70659a2-68ba-4fb7-ba74-63e4882b3ee5" contextRef="C_d5204099-2478-4b5e-b1d3-d4947afd3ec0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f81b5d6-3043-4d80-9e65-0433935222d2" contextRef="C_73d54a48-f66f-434c-bf6c-25a6a7ff448b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9336e11-45ce-45cf-a647-6980eadb3a07" contextRef="C_bf8a2e00-8278-456e-a9f7-bbc406b2f028" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d959a49-53d6-4d55-bbb3-85594d18ef09" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,842</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.033%;box-sizing:content-box;"/>
     <td style="width:1.58%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.903%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.58%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.903%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8834712-2616-406c-b09d-4c0782a6b322" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4efb90c-fb37-45dd-80e5-56ebc61a0c21" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, operating</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdb5d2cb-fd6e-4e1e-b93a-40a7b161c080" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f87397a6-f013-446d-a5a1-cd313421aa56" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48c3d67a-ac89-4e7d-b62e-dcc36c32408e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bafbe454-a396-44a6-8177-77d068313678" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f130ad-cb63-43c2-95fb-c2d0a260959b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59d9adc4-b966-4b33-b029-49603a371dd6" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c3be5c-0681-4396-8d85-af0353683565" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b42cab-34bd-45c4-8926-37826c3bd9a4" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash gain on long-term investment</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71abbca2-eac9-4ac0-af3f-d331c70777ac" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:Non-CashGainLossOnLong-TermInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,390</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized gain on investments in U.S. Treasury securities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f069d183-56ce-404d-84e1-79ccb8a44fcd" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:NetRealizedGainOnInvestmentsInUSTreasurySecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of premium (accretion of discount) on investments in U.S. Treasury securities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_379063fb-0b60-4cc5-8887-0a46affc1f64" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bd004c8-b345-45c3-9d1b-b3efe773ab2d" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60802085-d0e3-4b12-b6dd-4b4101b68f58" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7606991-4685-4319-82b8-ef129be70015" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5fe5324-515b-4249-84dd-14e28d814efe" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,561</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a906b40e-6151-4d8e-95c1-0ab4e6c55ac6" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,378</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_663f693e-34ce-40ce-9c12-af7ae80e833b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,445</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd54ef0e-3c83-4021-a2e2-118425fbba46" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,367</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, operating</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0a6968a-da58-4bd4-b8d9-7d00ec78ddda" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,496</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35f64803-d4fc-42e3-8335-47dfaa821369" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,336</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, finance</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e4e0309-d561-4898-9af6-1479541184ee" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:IncreaseDecreaseInFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf498c41-6e5f-456c-8cfb-653ace04b289" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:IncreaseDecreaseInFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99da0629-49bc-4d75-9944-b5e1e7778d3c" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,561</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b9428e8-c62b-4dfd-939f-d874c5db28ce" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb4445fb-2a6d-489d-86bb-2597f553e7eb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c0e199-b531-41ec-8c1b-8f1ed668e29c" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_528e28e3-92d2-4c8c-957b-92684f685359" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,382</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d268cfd-5b33-4052-978f-090999ec95ed" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,596</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sales or maturities of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2474a81-df57-47c2-8be2-52e402b9f2d3" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,527</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d2f8480-abf0-4a9c-8314-47469a105364" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90,252</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b10802fb-54b9-46aa-a6b7-5a42b5d872df" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c193c66-f75e-477a-a0ab-f22ccdf4ae10" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e52e039-433f-4836-b2e6-33563f072791" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on finance leases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ccefd7c-9288-4088-a27f-6bdca3b29f9b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">533</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58dd4593-4894-45c9-9f20-99fe2c670b3f" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from common stock issuances under 2023 ESPP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d43dfd3-d9b1-4a74-85ef-91a081d9a984" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdc30b41-6e3d-4fa4-9df3-b2dea8a095e0" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:TreasuryStockRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock upon March 2024 Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bdce0f9-6f4b-44b5-bcd0-84b910508503" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party commissions and offering costs incurred upon March 2024 Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_632f2e8b-c19c-45d5-848c-301be7fbb9fb" contextRef="C_1f1718fb-6b55-4400-93d6-9f15b60b4646" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,287</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f4fd527-d5c3-43b6-b1b8-59db0523c0d0" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party commissions and offering costs incurred upon May 2025 Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d30a1e9a-8d1c-4f9f-9528-8f25566638e0" contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,917</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e201160-205d-460d-991d-d2c37fe91407" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153,750</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party commissions and offering costs incurred upon October 2025 Financing Transactions</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64d30f02-c347-4185-af3c-bc0a969426ee" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,833</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3678e4-f233-47ac-b902-79929fccd094" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,795</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11d8000-fb97-4345-8169-669942c4439b" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,776</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec7df91c-0a8b-4a9a-b1b4-4c67afc87bad" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,982</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52d0b26c-d106-4d52-b9a5-fc7ac32920ba" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,452</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1be64c03-dcc0-4b0f-9dc9-9dbc31fecf61" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,266</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac4a2a67-067d-428b-aa47-14b1ff5869cd" contextRef="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,718</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_062576d5-d055-4322-b904-c81838e04dbc" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,248</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57c21e09-4f88-4ad2-bccd-760cee342765" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,266</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of cash flow information</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest paid</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acde7595-1341-4527-810b-f7188a5d32b8" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0df762a0-ec50-4a74-9eb6-5996a69d7710" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss) on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0f16817-5e7e-4399-8ba4-196c929a507e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc2b2be0-182a-48c2-b73f-f113567b3be5" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_648c4baf-86ad-4535-ae6f-d4e0504cc145" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91e0092-4938-4312-835e-964ba5f672b1" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unpaid offering costs included in accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea95e97d-1601-4b88-8858-94e2b9d2f69f" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassifications from property and equipment to prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe4c35d7-9bb9-46b7-93d5-e8e075dc15aa" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_832a25bf-cc5b-462d-bcc0-ac8efd9d420a" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease right-of use assets and finance lease liabilities recognized</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4256e468-0674-4ad8-9a18-b7dc6288d971" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment purchased in the prior period and paid in the current period, net of property and equipment purchased in the current period included in accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a0fa78f-b96b-4018-9fe1-e597fe114ca7" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes_to_condensed_consolidated_fin"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">otes to Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Table amounts in thousands, except share and per share amounts)</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07b461a2-4814-4ac1-bda2-486cd7529a7f" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description of Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Lexeo Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular disease. The Company utilizes adeno-associated viruses (&#8220;AAV&#8221;) that have been engineered to transfer genes to patients. The Company&#8217;s therapeutic investigational treatments include AAV-based gene therapies primarily in the clinical and late pre-clinical stages of research and development.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is located in New York, NY and was first formed on February 17, 2017, as an LLC under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company filed and executed a certificate of conversion to a corporation on November 20, 2020, to convert the LLC to Lexeo Therapeutics, Inc, a Delaware corporation. All of the Company&#8217;s tangible assets are held in the United States (&#8220;U.S.&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying financial statements and these notes reflect the operations of the Company that have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company has no unconsolidated subsidiaries. Certain prior period balances have been reclassified to conform to the current period presentation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Since inception, the Company has incurred net losses and negative cash flows from operations, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c2afbc-77e5-4b14-ad44-ebd4c629e7e2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_503cae36-5d13-403d-9a1a-7fab00a669ab" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">98.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025, the Company had cash, cash equivalents, and investments in U.S. Treasury Securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa135659-ca41-4113-805d-bbc5cf3005be" contextRef="C_464f0f91-9b5b-4c2d-9f37-9b998e5a31ca" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">246.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e8898a5-d476-4c41-b9d8-a8f3048d44be" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">380.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. During the year ended December 31, 2024, the Company received total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f033471-e1b5-4065-8be9-cb5221adca30" contextRef="C_1f1718fb-6b55-4400-93d6-9f15b60b4646" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc1a8f9-a108-4487-a355-32cb4e533e9e" contextRef="C_1f1718fb-6b55-4400-93d6-9f15b60b4646" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and offering expenses in the March 2024 Private Placement (as defined below) (see Note 7). During the year ended December 31, 2025, the Company received total net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_775e1ffe-22d9-421b-9289-26d80550cb96" contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">73.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c0ba0ae-510c-414f-9461-8e981350f92c" contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and offering expenses in the May 2025 Private Placement (as defined below) (see Note 7), as well as net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f7b3d3b-ee28-4498-8ac2-f6086724105c" contextRef="C_39a48e76-d9cd-4ef5-a9db-a32bb4c223a3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_938eafbc-aede-4e06-8d3e-3c3520b31fee" contextRef="C_39a48e76-d9cd-4ef5-a9db-a32bb4c223a3" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of underwriter commissions, placement agent fees and estimated offering expenses in the October 2025 Financing Transactions (as defined below) (see Note 7). Management estimates that the Company's current cash, cash equivalents, and investments in U.S. Treasury securities balances are sufficient to fund its operations for at least 12 months from the issuance date of these financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the ability to secure additional capital to fund operations, and commercial success of its product candidates. Any of the Company&#8217;s current product candidates and future product candidates that it may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance- reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd9251d7-d441-4586-8c90-32edc7e52c59" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#8217;s stock option awards. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0f8f576-bbcc-4184-86e5-cf9520df9881" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2025 and December 31, 2024, the Company&#8217;s cash equivalents were held in U.S. government money market funds. As of December 31, 2025 and 2024, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#8217;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0499df78-d87c-47dd-9372-6fdd1068c1fd" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments&#8212;Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of premiums of approximately $149,000 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2653fba8-e4bb-464e-80fc-7a10d713da51" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:InvestmentCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">39,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, at December 31, 2025.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_604d5608-7491-4afa-a586-ec1db37b5088" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company follows the two-class method when computing net income (loss) as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares and pre-funded warrants to purchase shares of common stock outstanding for the period. In accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the pre-funded warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During the years ended December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb97fa16-88c1-447c-9b02-dfbfbb9bc5c4" contextRef="C_f55932cf-ba63-4d0b-b12f-3a6366360e35" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,117,976</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fbe8c77-bca6-4943-815c-2b69d7d302cd" contextRef="C_25fca7a5-ade5-42ee-82c0-94f05ff45965" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,724,218</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> total potential common shares, respectively, related to the exercise of outstanding stock options, settlement of outstanding restricted stock units ("RSUs"), settlement of outstanding RSUs that vest upon the achievement of certain performance conditions ("PRSUs"), and exercise of outstanding warrants were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_1" continuedAt="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2db8082-7e6f-42f3-b476-cd8c1cfb293a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering in stockholders&#8217; equity as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8afa0537-69b1-4fca-ba24-c89eee6e8193" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e902b28d-681c-4906-9360-f2e8d33796e8" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent and occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d841078-4762-40c4-9576-dfd43fa259a1" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Based Compensation Expense&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of RSUs and PRSUs. The measurement date for employee stock option, RSU, and PRSU awards is the date of grant, and stock-based compensation costs for employee non-performance awards are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on a graded basis. Compensation expense for equity awards with performance conditions, including PRSUs, is recognized if and when the Company concludes that it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each reporting period for equity awards with such performance conditions and adjusts compensation expense based on its probability assessment. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award, and stock-based compensation costs for non-employees are recognized as expense over the vesting period on a graded basis. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation expense for all equity awards is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the Company's 2021 Equity Incentive Plan (the "2021 Plan"), (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#8217;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#8217;s balance sheet and statement stockholders&#8217; equity are reduced until such awards vest. Forfeitures are recorded as they occur.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant under the 2021 Plan and the Company's 2023 Equity Incentive Plan (the "2023 Plan", and together with the 2021 Plan, the &#8220;Plans&#8221;), and shares issued under the 2023 ESPP, are estimated on the date of stock option grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU and PRSU granted under the 2023 Plan is equal to the closing price of the Company's common stock on the date of the grant. Prior to its initial public offering ("IPO") on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_2" continuedAt="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6739fad4-b63f-4663-aabb-76d1649a82b5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.<br/><br/>The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. As of December 31, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against its deferred tax assets (see Note 10).<br/><br/>The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2025 and December 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24c82dd8-0a1a-4091-b00c-46a547ac77c6" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cdac3c04-4abf-4d05-a9e9-e06038826e73" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t identified any uncertain tax positions.<br/><br/>The Company's policy, to the extent uncertain tax positions exist, is to record interest and penalties related to uncertain tax positions in the provision for income taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d79acfb-72e1-40a5-88fd-14af0ee0a34d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are unobservable inputs for the asset or liability.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0e2e0c3-5e70-4281-a574-a7918ccb4416" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:LongTermInvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term Investment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for its long-term investment in nonredeemable convertible preferred stock in accordance with the provisions of ASC Topic 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received was based upon an observable price of cash paid for an identical security in an orderly transaction with a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed58df19-61ac-4ecf-8903-241902ce294a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#8217;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#8217;s cash equivalents consist of investments in U.S. government money market funds, and the Company's cash investments consist of U.S. Treasury securities. The Company&#8217;s cash, cash equivalents, and restricted cash are held with large financial institutions that management believes to be of high credit quality. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa79d0ba-7eb2-446b-a238-084cef2114b9" contextRef="C_d2859d77-9d6d-417d-b711-d050b24f282f" name="lxeo:LossRecognizedFromUninsuredBalances" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any losses caused by uninsured balances.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2d7bbbd-e065-4248-b1bd-e42534b407b4" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#8217;s Chief Operating Decision Maker ("CODM") is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer ("CEO") and its senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The CODM reviews the Company&#8217;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2025.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_3" continuedAt="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_4"><div><ix:nonNumeric id="F_1873d81b-8fef-43d8-aef2-c4ebb15f3fe8" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 6 for information regarding the Company&#8217;s capitalized operating and finance lease right-of-use assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95c5d1c7-77b8-46da-8093-cfa5ad4a3c43" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_95c5d1c7-77b8-46da-8093-cfa5ad4a3c43_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:50.94%;box-sizing:content-box;"/>
           <td style="width:1.6%;box-sizing:content-box;"/>
           <td style="width:14.66%;box-sizing:content-box;"/>
           <td style="width:1.6%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:12.8%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:1.6%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:12.8%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b92710b7-39a4-4e19-a971-96f7e64e1833" contextRef="C_8f865621-f365-4210-8b47-da03eb5738c4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5ac6a2e-1e6c-487b-b258-a43b4b74e648" contextRef="C_8f865621-f365-4210-8b47-da03eb5738c4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_054b2f83-d7d2-4079-a999-4b511d368817" contextRef="C_4c89430b-37d5-4909-a62c-9a1965b0a9b7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_19f16573-85bb-4158-be4b-03f72e4999a2" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb1f683-0cb0-4058-a13e-987cbe43569d" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3057a1f6-af34-4722-b029-480d02549459" contextRef="C_1735de27-a8af-415d-8fe1-67386826cc66" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">844</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b53a71ab-1a8d-406c-85d2-5b6fcb31a31d" contextRef="C_4bc16bb1-ead2-4dbd-aca6-b88278c3172f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca520350-145b-4c16-a336-2437d055f098" contextRef="C_4bc16bb1-ead2-4dbd-aca6-b88278c3172f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b0564f2-a7ac-4fcb-b14e-e3a15f1022a8" contextRef="C_db28a574-1df7-4c2a-a2c9-fa8fa1f5bb06" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67120918-74fd-4d6c-a70b-f08f0d8a14a5" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0207e682-d49d-4ccd-803e-e24da395b93d" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,502</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73790574-149a-4667-8167-bc8cf8d9193f" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">741</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dceee09c-34bd-44cb-99d9-19b50a922c1f" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c45d0ebf-db12-43bd-8f55-01f5aa0b48b0" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,139</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db863aef-cf83-47fd-a0c2-e206d9ea136c" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_95c5d1c7-77b8-46da-8093-cfa5ad4a3c43_1"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d5de7d5-5b3d-482f-8d4e-ba13ce4c968d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s leases include options to extend or terminate the lease. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31f10eff-b248-423a-90a1-53562b246264" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes&#8212;Improvements to Income Tax Disclosures, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which focuses on the rate reconciliation and income taxes paid (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires a public business entity (a "PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4283524d-7551-4b90-bb15-d2729ab6b502;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU No. 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in ASU No. 2023-09 prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for all periods presented, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December 31, 2025, the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fc1fd20-0cff-407d-8cfd-63e49f13e4c0" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU No. 2023-09 retrospectively, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ccf7dc1-37c2-4bd9-83f8-36c702f9e673" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which only impacted the Company's income tax disclosures with no impact to its balance sheet or its statements of operations and comprehensive loss, stockholders' equity, or cash flows (see Note 10)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure of specified information about certain costs and expenses in the notes to financial statements. ASU No. 2024-03 will be effective for the Company starting in annual periods after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued ASU No. 2025-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 270) ("ASU No. 2025-11"). ASU No. 2025-11 clarifies interim disclosure requirements and the applicability of Topic 270. ASU No. 2025-11 will be effective for the Company starting in interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div><div><ix:nonNumeric id="F_f916b79e-12db-4fb1-9ed8-ef9bcf3d8bc9" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_f916b79e-12db-4fb1-9ed8-ef9bcf3d8bc9_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents consist of investments in U.S. government money market funds stated at carrying value, which approximates fair value and is based on quoted prices in active markets for identical securities. Cash is stated at carrying value, which approximates fair value due to its short-term nature. The Company classifies its investments in U.S. Treasury securities as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The carrying values of the Company&#8217;s prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_a63b3892-c7e6-4020-a69d-65d97fed61fb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_a63b3892-c7e6-4020-a69d-65d97fed61fb_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.32%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce836692-84d6-4ea7-99a0-5ab86d9f8042" contextRef="C_80886119-480b-48c9-8ffb-65158995fa72" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,178</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_340d4635-30e4-4af9-8b65-72daa0cda89c" contextRef="C_357e96c3-27bb-4127-968c-48df3cab0274" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,178</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b33bb2b5-f112-4080-ae6f-6fb3a6960351" contextRef="C_9779ca0e-2456-4a3d-a96f-ccee925f0ee6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,767</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_337ecc9d-14a9-48a0-8163-3f9b7a480903" contextRef="C_fb7cdb9c-5e73-4b92-9e27-ac79a42a2be1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,767</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16bd91f6-78a1-4d21-9aae-ae505749ad17" contextRef="C_9779ca0e-2456-4a3d-a96f-ccee925f0ee6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,801</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4bf2334-fe95-4175-aad9-d1fbfe8e57d7" contextRef="C_fb7cdb9c-5e73-4b92-9e27-ac79a42a2be1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,801</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a008288e-d604-43e8-a9eb-e5045587c7e4" contextRef="C_e9b9062b-8c12-49f1-a351-c5a94c169bed" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,178</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b20bce-05a0-4a3e-903a-19ec334fdf49" contextRef="C_b80b39e4-ee70-4ac9-8254-8612c66068cd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,568</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed9ef1d5-ad4c-4e45-b432-38e7526eb105" contextRef="C_75647768-9be4-4729-b3de-fab3b1e0526d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,746</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:31.98%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52047b41-3be3-4dcb-ba4a-b79c62b14e88" contextRef="C_0c86e317-598b-4fc3-9ec5-6c3828cd4653" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,636</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fbbc0d5-5e31-4019-bac1-e8db81d93b94" contextRef="C_d1c75657-09b5-459b-b8d8-8d04ceccb855" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,636</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e0aa79-2210-4f25-a0a1-6521d9710a2c" contextRef="C_76a788a3-f953-4f3e-ab5a-d2f1c0ac015b" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cc7e6b7-35ee-40ec-9605-ba3c70b7dbe8" contextRef="C_9c4cb1e5-c1a2-4e02-af65-dbb6700815f2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ed63692-43dc-461c-b1bd-70f256cc6671" contextRef="C_76a788a3-f953-4f3e-ab5a-d2f1c0ac015b" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcc431c2-2650-4519-b8a9-b76a78325d5b" contextRef="C_9c4cb1e5-c1a2-4e02-af65-dbb6700815f2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83274359-65df-4523-8118-e9682465654e" contextRef="C_fc4e6f8b-c480-46e3-af2f-471fb85da201" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,636</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f9d18e2-7a9c-475f-ae15-c758d612ea40" contextRef="C_d6948e0b-b33e-4c10-b2f9-1d23d6fdb1f8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f7fa953-25e6-49b1-9bac-dd7ff8d7ff65" contextRef="C_5b4016c9-50ff-46d1-a19f-672dd8c141a0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,152</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_f916b79e-12db-4fb1-9ed8-ef9bcf3d8bc9_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a63b3892-c7e6-4020-a69d-65d97fed61fb_1"><div><ix:nonNumeric id="F_329f31e8-d449-4c3a-84c0-8445358c733d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true" continuedAt="F_329f31e8-d449-4c3a-84c0-8445358c733d_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:</span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_329f31e8-d449-4c3a-84c0-8445358c733d_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:23.745%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.763%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.763%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.763%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.763%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43b8e0a9-8023-473a-8496-1d197ac44a0e" contextRef="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,380</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c94bbc33-c595-4cd4-b4fe-9361841c043c" contextRef="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f9cce25-9d86-49a6-a28a-1a823058b006" contextRef="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,568</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a07f08-19c5-45da-9a46-096bd6609338" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,380</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d304f311-d08a-456a-ba27-1c12612ba872" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f35ef88-38a0-40db-89cd-64918ffc0294" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,568</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82074b83-094f-43e2-ac15-f1239d9448fe" contextRef="C_9610981c-dbfa-4244-b967-0edb48cea85b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,619</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bfccba4-e49d-46e0-8671-87a1f8b86f93" contextRef="C_9610981c-dbfa-4244-b967-0edb48cea85b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c8145ff-699e-43d7-ae25-538e38c25e5a" contextRef="C_9610981c-dbfa-4244-b967-0edb48cea85b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10896243-ea0a-4b60-bb4a-fb62b08d2ed6" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,619</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f575657b-647d-4f3e-9340-8c2d962f9441" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33811a91-1463-419d-8beb-ae5dd277d3f9" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments in U.S. Treasury securities classified as available-for-sale securities held as of December 31, 2025 and December 31, 2024 had contractual maturities of less than one year for the current portion of investments in U.S. Treasury securities and between one to two years for the non-current portion of investments in U.S. Treasury securities. There have been no material realized gains or losses on investments classified as available-for-sale securities for the periods presented.</span></p></ix:continuation></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2dee90cd-663b-43ed-a8c3-4c68b8b60878" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:LongTermInvestmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Long-term Investment</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, the Company entered into a collaboration and license agreement (the "June 2025 CLA") and a preferred stock purchase agreement (the "June 2025 Preferred Stock Purchase Agreement") with Tilia Therapeutics, Inc., now known as Myoventive, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a privately-held Delaware corporation (the "Investee"), to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. In exchange for access to certain of the Company's expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology contributed under the terms of the June 2025 CLA, the Company received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ba0add-ffdb-421a-a858-a1816ceb6b22" contextRef="C_ceb6a661-0f1c-4d6c-bf35-6817f0cf2a23" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Investee's nonredeemable convertible preferred stock issued under the June 2025 Preferred Stock Purchase Agreement, initially representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fa731f1-119d-43d3-9b31-741e25b680ed" contextRef="C_b108cd4a-1106-42e3-838b-ca809495548e" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Investee's issued and outstanding voting stock as of June 30, 2025. Under the terms of the June 2025 CLA, the Company is entitled to certain future milestone payments, royalties, and opt-in rights to certain program(s) (see Note 12).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its investment in the Investee in accordance with the provisions of ASC Topic 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe99505-1c25-4543-9c1b-4aede782e84b" contextRef="C_929d55a0-9e11-462d-ad46-1599e64792f2" name="lxeo:FairValueOfSharesReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b7d037d-97ba-4edb-95be-3ff7c10cba5a" contextRef="C_929d55a0-9e11-462d-ad46-1599e64792f2" name="lxeo:FairValueOfSharesReceivedPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">0.338983</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, was based upon an observable price of cash paid for an identical security in an orderly transaction between the Investee and a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_000d43df-4d35-4146-8878-ffe5f2b00f15" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18a748a0-ca5f-4319-afb5-552a018e2228" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_18a748a0-ca5f-4319-afb5-552a018e2228_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:72.793%;box-sizing:content-box;"/>
         <td style="width:1.274%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.693000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.274%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.965%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96128b8f-2bf0-4b37-99d1-e0ce064282ec" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,299</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c98e95-d7f8-45fe-a701-1491888e3667" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,696</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and other personnel costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfa5f565-1525-4371-a8db-86f6bb353328" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,066</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e086d2b-c727-45cf-855a-e3f0a173e810" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,112</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expenses and other professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3e0695f-6d9e-4043-a3d6-1fe3be5e7b33" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">839</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368b6e01-1d5e-43ea-8559-e0483b279520" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24ea29d7-89d5-49a8-b200-dfb40b5aa6a3" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d2f3bc6-454b-4e2c-a5d0-1174cfd19051" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">545</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7f282d2-89f1-45c5-9bf6-1d1c263e8fd6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,277</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feb770ac-e2f6-471a-a93e-73ec48512efc" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,759</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_18a748a0-ca5f-4319-afb5-552a018e2228_1"></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_11587ebb-2479-408d-885d-96b411205c69" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock" escape="true" continuedAt="F_11587ebb-2479-408d-885d-96b411205c69_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Lease Right-of-Use Asset</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7e9fda6-d374-4d30-a36c-fc3a0dd3f45d" contextRef="C_cf7275ec-9001-4e72-987c-f42dac6949d8" name="lxeo:OperatingLeaseAgreementEnteredDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into a lease agreement for an office facility and laboratory space in New York, New York that commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faa37477-2614-4ec2-9ce9-aeca5c2ecf6a" contextRef="C_3efbfffb-0778-4c28-91b0-3428da47503f" name="lxeo:OperatingLeaseCommencementDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afb41a11-38d4-43b8-bd7a-f149727db238" contextRef="C_6bba1c1b-df97-48f4-bb20-fa63b15d96c9" name="lxeo:OperatingLeaseEndDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2563a45d-2f4d-4e00-b412-52f8f376edd4" contextRef="C_40e7b7c8-b1b6-4586-9359-a5aa9b41336e" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4203fa42-0f4b-4159-92bd-2982d4807ac3" contextRef="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f88269a-2360-4de8-b2f6-2c99fbe4290f" contextRef="C_b95a7326-401b-4311-bbad-80ce85f07dc5" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend the lease beyond July 2029 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at the then-prevailing effective market rental rate</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon commencement of this lease, the Company recorded operating lease right-of-use assets and operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66d00ea3-bf17-42e6-989c-8ede531562aa" contextRef="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_94d4a640-6844-4905-bb2c-6a0a0c0b1fe8" contextRef="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the present value of payments over the lease term using an estimated incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c713b9-1283-4541-a06d-62ea344fdc1d" contextRef="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in accordance with the provisions of ASC 842. In connection with the Company&#8217;s lease of office space and laboratory space, the Company provided a security deposit to the landlord in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb3a5709-4bcf-40d7-b520-9f5a7558cdfc" contextRef="C_e09c5ca9-c296-43da-b854-8d0d1dd047e3" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The cash collateralizing the letter of credit was included in long-term restricted cash in the Company&#8217;s balance sheets as of December 31, 2025, and December 31, 2024. This lease was classified as an operating lease in accordance with the provisions of ASC 842. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0736cab-8983-4e47-882f-5bb20910a53a" contextRef="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_418b57e9-1f56-4d79-8e48-204de2095297" contextRef="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any right-of-use assets and lease liabilities associated with the potential option to renew or extend. The Company&#8217;s operating lease agreement does not contain any significant residual value guarantees or restrictive covenants.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The remaining lease terms and payment terms as of December 31, 2025 and December 31, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_769d32ef-e2fd-48af-9631-095bcdca5036" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4fd2d49-1232-446d-935a-9eec11bfbdde" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. </span><span><ix:nonNumeric id="F_65f77b9d-d0ac-4156-91ab-bcefb78e8077" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:ComponentsOfOperatingLeaseTableTextBlock" escape="true" continuedAt="F_65f77b9d-d0ac-4156-91ab-bcefb78e8077_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of this operating lease were as follows:</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:continuation id="F_65f77b9d-d0ac-4156-91ab-bcefb78e8077_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.64%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.099999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.099999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1820131-98a2-41e8-a713-be8fc988b437" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,147</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7271b16-7ecc-40b6-8624-c8903085eb66" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,147</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d5bbe24-dd73-456b-a5b1-2618e141e798" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b43c451-c8e2-4791-abf3-0c6bbeb288e3" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934e08ed-5765-4763-ac37-7b88f94448d2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,650</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1267d26-b849-479f-9c57-5058b0b9e313" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,606</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba691967-47de-48a1-a241-ddc3399e429a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,152</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97fd628a-c894-4109-9bf0-b82a60afe6b3" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,110</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_551ee565-5393-476d-80d3-b0dcade46103" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.135%;box-sizing:content-box;"/>
         <td style="width:2.641%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.224%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bbd241f-bf2b-4852-b15f-1f70bb3b344b" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,206</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a80c2a34-f8eb-4d1a-822f-4baae042eb29" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,261</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aa968f5-a191-4678-944f-da8c2c8bd1ae" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,318</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5faa0e7b-d0b8-4297-8be6-7f53172de91d" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfd03428-aaaa-4167-8406-7831c9200950" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8156e568-77e3-497e-a5fe-68ec64a97ebd" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: present value adjustment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ef75209-9499-4f0c-bb6c-21b5783760a6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_182df78c-4143-44e8-aef9-72d1fb8a9073" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,041</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256fbd84-fb2b-4bc7-b551-113e79ec11a7" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd1cb90-a8a7-49f9-885e-bd2ca360e549" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,884</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6fc30d-bb2e-4afa-b9ff-8e5509c56721" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,041</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_11587ebb-2479-408d-885d-96b411205c69_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing in April 2022, the Company leases certain laboratory equipment under financing arrangements accounted for as finance leases in accordance with the provisions of ASC 842 that are classified in the Company&#8217;s balance sheet as finance lease liabilities with related right-of-use assets recorded and depreciated on a straight-line basis over the estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_630c23f8-0b23-483e-aa8a-fc0e637a4fcf" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. In connection with the Company&#8217;s leases of laboratory equipment, the Company provided a security deposit to the lessor in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a327348-5edf-454a-be5c-28485bd73ad3" contextRef="C_3e5cdc3c-a4d4-462c-af4f-ff0564c0387a" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and assigned all rights and interests in the equipment to the lessor. The cash collateralizing the letter of credit is included in long-term restricted cash in the Company&#8217;s balance sheet as of December 31, 2025. The total gross, accumulated amortization, and net book values of equipment finance lease right-of-use assets capitalized under such finance lease arrangements at December 31, 2025 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78bdf078-3313-40e8-b05f-73e19f6788ef" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9811a8b-7f84-454a-ab2e-255e79735e5d" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e39bdcc9-1f67-4134-b6d3-4d8db605d5ad" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Under the terms of the equipment finance lease agreements executed through the issuance date of these financial statements, the principal balances plus interest for the equipment are to be repaid in full after </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5795f6f9-25e5-43aa-a4c9-0d22b1586355" contextRef="C_97bf9bb9-fd01-4c00-b07e-186f54c06f37" name="lxeo:NumberOfMonthlyInstallmentsLease" unitRef="U_Installment" decimals="INF" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly installments following lease commencement, with lease commencement dates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78e83308-325c-4983-807c-acfdf4f88558" contextRef="C_f0efe85b-fed2-44b8-8e9c-9573fb1386d5" name="lxeo:LesseeFinanceLeaseCommencementDateRangeStart" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cde0f60-7c14-4286-a424-c34768457271" contextRef="C_08eca4a4-adfe-4cb1-ad4d-04bbfa80f9d6" name="lxeo:LesseeFinanceLeaseCommencementDateRangeEnd" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, annual imputed interest rates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20c2d5ac-c41e-441f-8ca7-a8ddfce99117" contextRef="C_4295b1e1-3df8-42bb-8a20-af116ecee6bc" name="us-gaap:LesseeFinanceLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6673c55-4d77-4ebe-a389-ec06f8b39a3f" contextRef="C_7e067386-c3d6-4f06-8490-86af6f1f1e3e" name="us-gaap:LesseeFinanceLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and monthly installment payment amounts ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff9484e6-5217-4f2e-a3b3-85512c72f8e1" contextRef="C_4295b1e1-3df8-42bb-8a20-af116ecee6bc" name="lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8151eb60-3a9b-42f2-acbc-3d3a1c3a90a1" contextRef="C_7e067386-c3d6-4f06-8490-86af6f1f1e3e" name="lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The total aggregate monthly installment payment amount is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a85d9d7e-6fa1-4b2c-85d2-ea338e4ae3a9" contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003" name="lxeo:FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the Company's equipment finance lease agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2025 were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bd8b253-264d-4d47-be0d-0162c097bb3c" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95db7359-f894-4355-8b06-af3830e986bb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_322ef0f9-2162-4f5f-b301-675364694d76" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.61</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a19acbcf-4a31-4782-a5a7-0cc8fc5db8ad" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_072d1d62-8d1a-4fb1-9855-d4b316e180cf" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b74a0ae3-054a-42ed-9e7c-4c84717c63f9" contextRef="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af621183-5beb-4177-a735-855172c29368" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:ComponentsOfEquipmentFinanceLeaseTableTextBlock" escape="true" continuedAt="F_af621183-5beb-4177-a735-855172c29368_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the equipment finance leases were as follows:</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:continuation id="F_af621183-5beb-4177-a735-855172c29368_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.860000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.860000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c55b2708-95e1-472d-8a3d-15c1b8f768ba" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e38af33-964a-4ee1-b9c4-72c445c4d55c" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08f80b10-3683-41cb-b278-531e98d7d6f1" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6777c3fe-7b7a-4a2b-8ff7-daaf53aa23ae" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease expense</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a15c8e9-437b-4121-9971-336feec5a400" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:FinanceLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">424</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac7f25ac-f4d1-4de6-95f5-0f3845be5122" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:FinanceLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bfb35c6-1e37-42cd-945a-da8a857feca3" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">533</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef74cc26-1074-4ed3-bb24-6d942344e4f7" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a1e73ed-2894-4acd-b78e-c7e635fe8eda" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:77.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20.259999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a42e152-c874-45e0-b84c-e9f36edc6cb6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3da16d6-6911-44c2-8fbd-f73960ba6b7f" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41330d2b-ac18-47d7-a5ff-9396109f2220" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea402ee-6285-4a79-b0f3-dba17598a2e6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a35aba-cb1e-495f-bc8d-1d6f634525ea" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:FinanceLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74c7da06-d566-446d-9e4a-a846032e3067" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">907</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_451fbc25-b9cb-4eac-8087-85e47f3f0ec3" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efcb8fbd-662c-46c6-9700-590c414d16bf" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d95149b1-ee6c-431a-8990-ea7a11696c74" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">518</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ba6d10b-e58d-403d-a53e-35d2ba53aa61" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c97177c-a3f2-47e6-a775-8d0db6f74ffc" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_fbaa25ca-b72f-455f-9c19-2af2ca1b8218" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_fbaa25ca-b72f-455f-9c19-2af2ca1b8218_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Capital Stock</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and December 31, 2024, the Company&#8217;s amended and restated certificate of incorporation provided that the authorized capital stock of the Company was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0731794f-95d4-4f33-8cbb-8ca808706253" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CapitalUnitsAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_34d0bd87-8c98-4025-aa06-bd85f1db8f1e" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CapitalUnitsAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">510,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934bbea8-ed90-4bee-b950-50580e50ba42" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5c70ddd5-7b41-4937-9842-94a3df56855f" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86dfc34c-01c7-49e9-9911-c3819706c4ce" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_991f78ac-66de-4765-a3c8-83d94ab3f828" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of undesignated preferred stock, both with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b45ef07-191b-4c29-ae0a-b214a86d438c" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_adcfd0bf-53cb-4803-8f59-749fd6a8aa9c" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d1a27d2d-5715-437e-b171-44454759acc9" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3651ca3e-a87f-476d-be67-2db87e8beef2" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5ac5a0a-d9fb-4dfb-81e0-1fbaf4229fa0" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">73,001,766</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d89e75d0-f89f-4df7-8fb9-1a3cf4044d84" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,079,209</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company's common stock authorized were issued, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e727019-7c2e-4618-bbf2-34007dae06a6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">416</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24ea20da-b9cc-4ee4-aeb1-21d6518fe5a7" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,948</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, that were legally issued upon the early exercise of unvested stock options and that are excluded from the number of shares outstanding until the right to repurchase subsequently lapses upon vesting. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb94a9ac-8e0e-47d6-a12f-245351881475" contextRef="C_725ecbd1-08d1-4d48-b06f-22dc4a077218" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t repurchase any shares of its common stock during the year ended December 31, 2025, and repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2aa782a-7c08-426e-a2f3-5b0d283a7cdb" contextRef="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ecf6c0e-7682-4fd1-8b5c-8cd0236d35eb" contextRef="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 8). Each common share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company&#8217;s Board of Directors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f56bd61b-df54-444a-9307-590284933c61" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends have been declared or paid by the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 11, 2024, the Company entered into a common stock purchase agreement to issue and sell an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a58c3a-d4a7-413e-8e2d-9061d4127a9e" contextRef="C_fc0d444a-c280-451e-a6ac-f592154451d5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,278,905</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21dc31ce-4676-4b89-89aa-3b0186f18921" contextRef="C_ff8f1290-9480-4529-b296-ace3425207d0" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">15.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, in a private placement that closed on March 13, 2024 (the "March 2024 Private Placement"). The gross and net proceeds received from the March 2024 Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0371ae1-133d-4951-8f35-dcfb219b0b3f" contextRef="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">95.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_517790d2-72e2-41b3-bfb9-64be2e8df1f4" contextRef="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd" name="lxeo:NetProceedsReceivedFromPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a12efeff-12a9-451a-8797-c0924c04de13" contextRef="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and other offering costs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2025, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC ("Leerink") to sell shares of the Company's common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad1ea9c6-fa30-4937-8ada-8f3f6d6ab7ce" contextRef="C_3b196e9a-f7ba-488f-8a3f-bdc43e626635" name="lxeo:StockOfferingValueSharesAuthorizedToBeSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from time to time through an at-the-market equity offering program (the "ATM Program") under which Leerink is acting as the Company's agent. Leerink is entitled to compensation for its services in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6b9d3e0-6a0c-474d-9cf0-3a84e019a1c6" contextRef="C_890b7df4-85e3-41e4-b1fd-4859a5a3807e" name="lxeo:StockOfferingGrossProceedsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any of the shares of the Company's common stock sold under the Sales Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5b65690-3d3f-443f-96de-63c310046fa1" contextRef="C_e04e0666-d468-4c9d-9610-e8fa883f856b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock have been sold under the Sales Agreement through December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 28, 2025, pursuant to a securities purchase agreement, the Company issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4704a977-8480-42e7-b52e-c8feabfa8e8a" contextRef="C_a240413b-0d7d-487c-bc56-518232b357e0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,790,120</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e2d5fc-110a-46c3-85a2-c9536c227612" contextRef="C_1f09b079-161e-4135-8af4-e2998386a171" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,963,556</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to certain purchasers, together with accompanying warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a37073c7-4c81-4d25-bb99-43daf4e0c59d" contextRef="C_80d471cc-64f2-4ab5-9d83-c7f5596929ec" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,876,838</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb45166e-e8ed-43b6-91b4-f8ba522df4a1" contextRef="C_4bb6390f-6ce6-4793-8fc3-7a90375636cc" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.8825</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock and accompanying common warrant, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_970b615f-251c-440d-9b35-6736d6c41727" contextRef="C_1f09b079-161e-4135-8af4-e2998386a171" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.8824</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant and accompanying warrant (the "May 2025 Private Placement"). The gross and net proceeds received from the May 2025 Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_737479c4-9e8b-400e-a772-51de701f3125" contextRef="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bfdf372-a501-4985-b846-a86ef9b4cf72" contextRef="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7" name="lxeo:NetProceedsReceivedFromPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">73.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cfeaf9a-29b3-4b8f-aa93-57e802f9b222" contextRef="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and other offering costs. The warrants and pre-funded warrants issued in the May 2025 Private Placement are immediately exercisable at exercise prices of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9599e9ea-e665-47a0-82c0-1fc98504e46e" contextRef="C_80d471cc-64f2-4ab5-9d83-c7f5596929ec" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31bcd0b6-364c-4e7d-9625-ab3c341f8844" contextRef="C_1f09b079-161e-4135-8af4-e2998386a171" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively, except that the warrants and pre-funded warrants cannot be exercised by the holder if, after giving effect thereto, the holder would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac6462ce-2622-48da-a9e2-aff2e7f54b9d" contextRef="C_c6383d22-c520-4a85-89c6-6b07e625c012" name="lxeo:PercentageOfOwnershipConsideredForWarrantExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s common stock (the "Maximum Percentage"). The Maximum Percentage can be changed at the holder's election to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cbc19fb-e123-4aa6-b441-fedcc2fce7fd" contextRef="C_6b7cf2f5-7ba2-40f3-98b8-0a47a4bcab82" name="lxeo:MaximumIncreaseOrDecreaseInOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and any increase in the Maximum Percentage will not be effective until the 61st day after the holder provides notice to the Company of the desired increase. The warrants are exercisable until May 28, 2029, and the pre-funded warrants do not expire. The warrants and pre-funded warrants are classified as equity in accordance with ASC Topic 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging - Contracts in an Entity's Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span><ix:nonNumeric id="F_43526e0c-699a-4db8-915d-0ae427a939d9" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_43526e0c-699a-4db8-915d-0ae427a939d9_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon issuance, the total pre-allocated fair value of the warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e271c06f-689d-4e18-8d05-91f91ef1fd1f" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aa3ed6d-ab47-432e-b6fa-dd6f99d54cff" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:FairValueOfWarrantsPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share, was estimated using a Black-Scholes option pricing model with the following assumptions:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_43526e0c-699a-4db8-915d-0ae427a939d9_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.695%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.564%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_520922b7-f54f-4a03-93f4-69c3b275a163" contextRef="C_407ffdfb-fc65-4627-a3b0-cb0f4c4c5eda" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">2.74</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3538e71-1d39-4cf6-91ad-6598a22fcf69" contextRef="C_f6ffc1a5-c795-4565-95e3-4d24febe677f" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">2.82</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d42adf53-ccb0-4751-9033-f7cfdbaecd14" contextRef="C_b91348ae-b86b-4d6f-a90a-d0705420ee0b" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d82d4dd6-64ad-46c0-920a-8b70a1a4be8c" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d87e1b-6d17-4e35-b54e-33b89299e4d4" contextRef="C_bc5f8bd3-0209-4df6-a1d0-ca324664dc73" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">100.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f8483ee-d8eb-4c9f-a0db-f26329845416" contextRef="C_dcf1d763-8592-412d-b293-cc3b5ba5d13f" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pproximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9b62d15-f3ae-4a35-9d48-615e6d0b2e95" contextRef="C_a240413b-0d7d-487c-bc56-518232b357e0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">44.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57a80683-26d4-427e-80d0-f7872b3a04fa" contextRef="C_9ad9569e-82f6-46d0-91e6-51f179cc5dad" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8afa9588-c74e-4167-8d79-c8a66d567d26" contextRef="C_ab655c89-08d2-4df1-80c6-4cd7801eced4" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total gross proceeds received in the May 2025 Private Placement were allocated to the shares of common stock, warrants and pre-funded warrants, respectively, on a relative fair value basis, and were recorded as credits to additional paid-in capital, and are not subject to remeasurement. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0e4972d-47e0-4564-938d-7a5e6b0f18eb" contextRef="C_4e91b53a-c865-4846-b046-8b4dbf9ae7f3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_287234c7-46ff-4703-af9a-e74eaf652cc6" contextRef="C_8525b582-4e2a-4627-be2a-eadd8568fd9d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">867,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants issued in the May 2025 Private Placement had been exercised. In January 2026, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75d100dc-8f43-4f7b-99c7-2d7387d2d085" contextRef="C_d98866d0-7481-4b7b-bca4-1dd7071333f1" name="lxeo:NumberOfWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">867,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued in the May 2025 Private Placement were exercised (see Note 14).</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fbaa25ca-b72f-455f-9c19-2af2ca1b8218_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 16, 2025, the Company entered into an underwriting agreement to issue and sell an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11d0012f-c3d6-41a2-8a9a-268c2db89012" contextRef="C_601b6cb4-c759-4fde-8d48-72ad686bc4c1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,625,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d85e8ac7-b4a8-43df-a62c-faef9878e517" contextRef="C_6bf5181b-cf84-46b5-b3bd-e929f2acc332" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions, in a public offering that closed on October 20, 2025 (the "October 2025 Public Offering"). In addition, the Company granted the underwriters of the October 2025 Public Offering a 30-day option to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46260574-e8f3-49ef-992e-f72d66d238a9" contextRef="C_98d0b57c-8a4e-4d95-ac5f-068c0243f116" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,343,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c2afa1c-80d9-41d8-a271-17e34db4a807" contextRef="C_bc2c08ed-32fb-4bb9-9165-ff7bf6d493e8" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions (the "30-day Underwriter Option"), which was exercised in full. The gross and net proceeds received from the October 2025 Public Offering including the full exercise of the 30-day Underwriter Option were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbeaee29-271f-40e8-a2e0-21e571f2ec77" contextRef="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac87530d-5499-4a4f-a2b8-62cf95ffae57" contextRef="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d" name="lxeo:NetProceedsReceivedFromPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_067ddcb3-deb5-40b1-86f4-f5533e09c166" contextRef="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of underwriter commissions and other estimated offering costs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 16, 2025, the Company entered into a securities purchase agreement to sell and issue pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f57f457-348f-4773-b33c-0a9883c10490" contextRef="C_beac3254-3c89-4564-8632-f79760e1f8b6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,250,015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48cf869b-2590-4e29-af68-b2f95c1d45a3" contextRef="C_7b1bb5e1-9fac-4bb1-8736-1cc221d0c743" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.9999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, in a private placement that closed on October 20, 2025 (the "October 2025 Private Placement", and together with the October 2025 Public Offering and the 30-day Underwriter Option, the "October 2025 Financing Transactions"). The gross and net proceeds received from the October 2025 Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367b191f-e083-462c-9a57-2fd1d1cff84c" contextRef="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_242dda62-c759-4221-84a2-8d65aaace57d" contextRef="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f" name="lxeo:NetProceedsReceivedFromPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5538bb8-b766-4f48-a072-cbfa34ebc2fa" contextRef="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of placement agent fees and other estimated offering costs. The pre-funded warrants issued in the October 2025 Private Placement do not expire and are immediately exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76333f7b-2e38-47fc-af1e-96a217dc161c" contextRef="C_276b6562-55aa-419f-88ec-75b79f842098" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant share, except that the pre-funded warrants cannot be exercised by the holder if, after giving effect thereto, the holder would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13e1a7f7-468a-4b63-8134-1d11c72e668c" contextRef="C_f35a4807-02c2-465e-a506-734387ea3d75" name="lxeo:PercentageOfOwnershipConsideredForWarrantExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s common stock (the "October 2025 Private Placement Maximum Percentage"). The October 2025 Private Placement Maximum Percentage can be changed at the holder's election to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69974909-80ec-4172-8418-127669f89193" contextRef="C_51b02334-8c26-4f78-ac6e-af4cbca2320e" name="lxeo:MaximumIncreaseOrDecreaseInOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and any increase in the October 2025 Private Placement Maximum Percentage will not be effective until the 61</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day after the holder provides notice to the Company of the desired increase.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pproximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_133a3ddf-c0e2-4769-ad44-5dc9799ac6a9" contextRef="C_c8a465c9-e39f-4d34-ac7a-5fe710f82f82" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5134efb6-5e2b-4087-ad87-60cd6e1069aa" contextRef="C_9af02223-ca95-445a-b4e5-6659c2e7fccc" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total gross proceeds received in the October 2025 Financing Transactions were allocated to the shares of common stock and pre-funded warrants, respectively, on a relative fair value basis, and were recorded as credits to additional paid-in capital, and are not subject to remeasurement. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4665afd5-2b0f-498d-89b2-eecd35e59c9f" contextRef="C_ba4e7baf-9823-4208-bf61-fb7520c113df" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the pre-funded warrants issued in the October 2025 Financing Transactions had been exercised.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd39d219-31f0-4895-9cb0-7a7f933b07ca" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following number of shares of common stock for the exercise of outstanding warrants, exercise of outstanding pre-funded warrants, exercise of o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utstanding stock options, settlement of outstanding RSUs and PRSUs, and future issuances of stock-based awards:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.278%;box-sizing:content-box;"/>
         <td style="width:1.205%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.925999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.205%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.384%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase shares of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70678ca7-5741-4bb9-a2f2-72aedd91c3b3" contextRef="C_79952fb3-c2a3-4723-8ef3-9b6960397749" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,876,838</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants to purchase shares of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ecda13-6770-45ee-aa27-be3fbd6cfd92" contextRef="C_33a1d373-61e1-4dbc-8ca5-46559d2ba9d0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,096,254</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase shares of common stock under the 2021 Plan and 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2513ba9d-b7fc-49e9-8ef0-c525a5b98a21" contextRef="C_58b9ae1c-e54e-4971-8058-707bb52b2a1a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,396,860</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09144b14-8d02-4ebd-82b0-4f41b8731910" contextRef="C_b5e6a80b-0a90-4061-b5e3-d557692232e5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,457,918</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs and PRSUs subject to settlement in shares of common stock under the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c2ddb7-bf15-4143-bbbc-1eda51ea0de5" contextRef="C_2f5d2c9e-b849-4bde-ac52-df6ce3e72476" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">844,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24337c2b-8755-4af3-a9b0-bdd69250c0ba" contextRef="C_da57ec1f-8f38-4bd6-9e52-115625f9b6b6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">266,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe1dda9-6c6a-4561-85a8-bf9de802ba0a" contextRef="C_f5b4784b-582b-414e-b258-a9581e148ae5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,132,156</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ebd16ce-c9d1-4b76-a720-192ccfe9a566" contextRef="C_b7718c79-bbe6-4525-98cb-4ccd075faa86" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,185,328</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6011cd79-0094-43cb-b0f2-f165efa75147" contextRef="C_016a9c4e-9503-4416-a9e9-6e06fb5aba55" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">733,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3fb513c-d817-4507-bb14-58d087341854" contextRef="C_4883c806-04d5-4bad-8a04-6447a094163d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">505,284</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c684afc3-9339-4795-aa8d-a1f1f7c82dbe" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,079,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d51aa528-06e4-4ad0-97b1-96bab214f850" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,414,830</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. </span><span><ix:nonNumeric id="F_7f7f0bce-354f-46dc-9906-5e11225cde8a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span></ix:nonNumeric></span></p><div><ix:continuation id="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_1" continuedAt="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2021, the Company adopted the 2021 Plan for the issuance of stock options granted to the Company&#8217;s key directors, officers, employees and consultants, as a means to secure the benefits arising from capital stock ownership. In connection with the Company&#8217;s IPO in November 2023, the Company adopted the 2023 Plan for the issuance of equity awards granted to the Company's directors, officers, employees, and consultants, and for the issuance of shares purchased under the 2023 ESPP to the Company's employees, as a means to secure the benefits arising from capital stock ownership. The purposes of the Plans and the 2023 ESPP are also to promote the alignment of the interests of directors, officers, employees, and consultants with the success of the Company and to provide compensation opportunities to attract, retain and motivate directors, officers, employees, and consultants of the Company. Upon adoption of the 2023 Plan, no further grants may be made under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_2" continuedAt="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, beginning on January 1, 2024, and continuing through and including January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3df08ce-1aa1-40c1-aa99-bc36fce93ec4" contextRef="C_c0f2a034-41be-457c-99b1-4288da908b5a" name="lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company&#8217;s Board of Directors prior to the applicable January 1. The number of shares of common stock reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2024 and continuing through and including January 1, 2033, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb12b338-b5f4-42f6-950d-dc925f47c747" contextRef="C_b783d3da-cc32-4fce-b2ea-93ee7627889c" name="lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_849e1780-25fc-4bd8-9247-0b80e65431e7" contextRef="C_a707e4a6-c6ec-4da3-a440-f202623bc25e" name="lxeo:NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">477,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, and (iii) a number of shares determined by the Company&#8217;s Board of Directors. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full do not reduce the number of shares available for issuance under the 2023 ESPP.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2026, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_979b3b17-c19b-423d-a3b2-d1049044bfff" contextRef="C_c43d4a9b-6f01-447c-8344-401a3e883847" name="lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,650,088</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e47a685-7e42-42b0-8027-966e53b892fb" contextRef="C_0bf10b12-a23b-4f45-9d50-7e648eecff42" name="lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">477,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, to totals of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42246ed6-0090-4d12-9772-e87af2d81f44" contextRef="C_c43d4a9b-6f01-447c-8344-401a3e883847" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,804,770</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15d35f00-121b-4689-bcbb-0ebe572b3578" contextRef="C_0bf10b12-a23b-4f45-9d50-7e648eecff42" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,210,439</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63486fa5-3725-4b72-8b5a-f0b9bf22d137" contextRef="C_292ca90b-72fb-49a6-a3ab-69036c90f439" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,132,156</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d35cfe5e-5224-423d-a58d-508483e569a0" contextRef="C_59ff464b-49f8-40f8-92d9-92d1e9a17142" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">733,239</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future issuance under the 2023 Plan and 2023 ESPP, respectively. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e858896-4a23-447d-83a0-bc66a3506bc9" contextRef="C_59ff464b-49f8-40f8-92d9-92d1e9a17142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">102,837</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the 2023 ESPP through December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 4, 2025, the Company's board of directors adopted the Lexeo Therapeutics, Inc. 2025 Inducement Equity Incentive Plan (the "2025 Inducement Equity Plan") and, subject to the adjustment provisions of the 2025 Inducement Equity Plan, reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55abf72c-edf6-4bad-8949-a0f689a2b00c" contextRef="C_a31771a9-2900-4c49-8cb5-d8544ddd403d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock for issuance pursuant to equity awards granted under the 2025 Inducement Equity Plan.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock option activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2021 Plan are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d8787ee-93cf-4b91-bce3-9f4c5bcb153f" contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc" name="lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally (i) are subject to requisite service requirements, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a51e7ce-109a-4cc0-983c-55ae9f7650d4" contextRef="C_c104adc9-73de-4e0a-aec0-20142b5b14fb" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11d4489d-3002-4b34-a8db-17278407632f" contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57f955dd-4434-4794-b4dc-db340dac372d" contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) allow for early exercise subject to repurchase. Stock options granted under the 2021 Plan to certain of the Company&#8217;s non-employees vest in equal monthly installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_824ee549-19e7-4bfc-ab9b-95d8d55732bc" contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period or vested upon the achievement of a certain milestone event. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91c2d0a0-77d3-4fa7-b0c1-f6d79f382b40" contextRef="C_725ecbd1-08d1-4d48-b06f-22dc4a077218" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t repurchase any shares of its common stock during the year ended December 31, 2025, and repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6641b3a-21b0-499e-ae4d-5ccbfb079bef" contextRef="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e04ee4e9-bbc0-40ed-a67f-249686f9caa7" contextRef="C_3cd08b17-0362-4b62-b0f6-efc4c3963b9e" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 7).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2023 Plan are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dce42545-a742-4fe5-8daf-a1490d348c66" contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2" name="lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8ffe535-f1a2-4118-9b04-6b393d3ffd84" contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_881ec931-2a42-45eb-8901-6fb27c50bd17" contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fe8e78c-df17-4ce8-975e-e06abbe8cf97" contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after approximately one year and the remainder vesting in equal monthly installments over the following 36 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to requisite service requirements. Stock options granted under the 2023 Plan to certain of the Company's non-employee directors vest in equal annual installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c9cf7ae-45f3-45e2-aec5-d7e881f18d98" contextRef="C_a00433da-f67f-4690-982b-b7fff11be3f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period for initial grants or over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b24cc2ab-b18c-4f40-ab36-aed2c99ccc36" contextRef="C_304ec79b-72af-4cbd-af93-f335e40345bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period for subsequent annual grants, subject to requisite service requirements.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb9c8e41-9adb-4644-a3e5-fb609db2854d" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the year ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.791%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.878%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.298%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.878%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.398%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44734bfe-5fdc-4d05-bba7-a06dd68fe9be" contextRef="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,457,918</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eae7390-9424-45c4-9e88-7f879012a81a" contextRef="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.37</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_403e9d08-1b40-4cce-b962-47f90391e44d" contextRef="C_5f20fea3-e69b-4604-90bc-497426fe388f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d84773d-ac1f-4ea3-bdf7-725018e72298" contextRef="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,851</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d811520-64cb-4a33-a182-2c269969d423" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,450,904</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2e21ff3-78f3-4a2d-940e-f3bb2be9e103" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.57</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10cd3a73-68a2-46d3-b00b-5b2cbd62c0c6" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae5cf9d8-4d00-4ae8-9a61-0c6d2eee9b83" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.83</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_045258be-89be-4a20-bc7c-c020f7672b77" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1510903c-6ed7-44e9-8e68-518273a0ac3c" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">415,707</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d63bd412-426b-4127-a206-2d3c13a5d776" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.96</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cfd6a7b-cd5b-4c01-a51a-9651dd710b0d" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00395dcc-863f-4369-8c98-d7bda355259c" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.66</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73719c3d-0cb5-4177-b12b-0003db5272e1" contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,396,860</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdbcf500-0a15-4ae3-99a4-b2d0e384015e" contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.75</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_17cc78ff-d37d-4081-829b-0dccb43f1638" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.60</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef18e134-1605-40e5-9ee2-7f2ccbbddc0c" contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,304</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cecf1394-72d1-4675-9aa4-3f153605d17c" contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,556,582</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c53107b7-f029-4852-87ac-605526e0621c" contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.94</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2b6cf6ed-3aae-4696-8afe-8aa8bbba82d9" contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.69</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64349bab-a0e9-4ef4-bd36-a01ceb9530b3" contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,529</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of stock options granted during the years ended December 31, 2025 and December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22512593-2a9d-471c-b8d8-62e75523abf8" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6dc512e-60bc-4472-8bc3-4326e1c39820" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.58</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_896f1169-165b-499a-a88f-e25e04917935" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_3" continuedAt="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_4"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair values of stock options vested during the years ended December 31, 2025 and December 31, 2024 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2e2e4f4-b1b8-4dd7-9276-80ca7d80a679" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83ffcfd9-97c6-4ca0-9e80-ee2aa74891e7" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da008a81-2fb6-438d-abb9-43902b2593d2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions during the years ended December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.563%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.563%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rates</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_770e8d52-241f-42db-bec7-b08b83897625" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114c9d1e-a5fd-485d-8a94-def1fac536cc" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_113206bb-7053-4612-ad43-f77ebbb5cd04" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a3967c2-bfc0-431d-88f8-12cf7c500869" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years), weighted-average</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ae9d3430-4265-4162-9e26-27d3d7464404" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.79</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5f09b8be-3dcd-4c2e-8854-c8923243a295" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility, range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bbc9e47-3f26-45ac-a0f8-aed8ff9d18b0" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15ca8112-437c-4992-9a66-82d80edefb9a" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">98.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad0508da-6932-4bfa-aef8-f649471ff644" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.61</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8ac5d2f-e830-4fef-92a2-c981b0e1c74a" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility, weighted-average</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc0d0f3f-f73d-497c-bd5d-e335efacf909" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">92.25</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81946e7c-7a8c-4109-9ce0-67861105af6c" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">85.85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f23d8e7-fb1d-4b25-ad85-988d078dbb20" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a35e5e08-8cb6-4416-87f1-09e777f73693" contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected dividend yields are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd4e13f1-9968-488a-90e3-2249c007524c" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a799e73-8a11-4a1f-850c-2c0e952a7deb" contextRef="C_02c649ee-2689-4467-af86-e845ba2c5b89" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to stock options estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d5cadbc-2e63-4d8f-ab6a-a0fae195a922" contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU and PRSU activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs granted under the 2023 Plan generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbd54905-c7b0-4a6b-8ca5-1e4978c422ca" contextRef="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2def982d-580b-40fe-912a-eed367f9e87a" contextRef="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3ff910c-8688-49d6-ab96-a50eb735f294" contextRef="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to requisite service requirements. During the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2832fa3-0d38-46eb-a510-ba4f8fe06c61" contextRef="C_63a872cf-6e8e-4d40-9cbb-3023e8fdb46c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">217,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PRSUs were granted to certain employees under the 2023 Plan that vest upon the achievement of certain performance conditions generally over an approximate 18-month period, subject to requisite service requirements. Additionally, during the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a37124e-28ec-4790-b969-b9f25f25a2a7" contextRef="C_3bd640a5-6ed0-4cd8-a0d7-639661192341" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,650</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs were granted to employees under the 2023 Plan that </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e0037e2-614e-46fa-b126-8e8f9d0848a4" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7092d679-7cb5-442a-92b7-b05674a3d918" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d42bafb8-614f-4ea5-b02b-4594532c678e" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following four quarters</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to requisite service requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_434296fa-9c83-410d-a74a-f3611ecc4567" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true" continuedAt="F_434296fa-9c83-410d-a74a-f3611ecc4567_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.06%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.58%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f21c968-ed51-45eb-9e23-fc8278ccf590" contextRef="C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">266,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c8d347-ba21-4f8b-af4a-7161a5e44d70" contextRef="C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.59</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db25365c-a57d-4b1c-a52a-d1708233f5b2" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">664,684</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7b17619-8c75-4d87-8c3b-adab7eb40cf7" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.45</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed06f60-76e7-4efb-9c8e-d47954929e67" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">101,448</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d736255-17d8-4b27-8d51-01307f7e25aa" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baaf8282-3725-436a-b1e4-d15ab4c667d2" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">125,958</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bcc335f-43d6-48b1-b1d6-98c19366aa50" contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.49</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61ca445-d549-425a-aa40-3925d96ebfd5" contextRef="C_74917b61-bde0-47fb-a510-eeb410d819a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">703,578</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86af1cf7-d4ac-4f1b-9cf8-66265be9ae0a" contextRef="C_74917b61-bde0-47fb-a510-eeb410d819a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.47</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f170f75-a1e3-42ab-8ae7-2a2bbd61601e" contextRef="C_c8d1b98f-fda8-4237-9715-247e14f34e52" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to RSUs estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5d47c0a-faa5-44d2-bf26-0adf8b99df93" contextRef="C_e272bdc5-b039-4362-8f99-fa87bcc9aa26" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.66</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_434296fa-9c83-410d-a74a-f3611ecc4567_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the PRSU activity under the 2023 Plan for the nine months ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.06%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.58%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3daf70b2-74ba-4cab-b807-84aec32d5115" contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">217,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3ae2d65-5424-4c64-b3dd-0e25a37033d4" contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.25</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e08e7da-3430-4eac-a8b3-442e47a4e31f" contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,800</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211e8c65-2d91-4122-b2d3-1c7c133ee007" contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a61a859a-115f-490c-b303-385e84e2e4ec" contextRef="C_c04bdcf3-b841-4689-9b64-38b332249fe2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">140,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6604ca46-283d-4a6f-94ef-3f5526d5b5cf" contextRef="C_c04bdcf3-b841-4689-9b64-38b332249fe2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.33</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_7f7f0bce-354f-46dc-9906-5e11225cde8a_4"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 ESPP, eligible employees may purchase shares of the Company's common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_383568db-8ac7-4176-a481-7fe8b33b1c65" contextRef="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f" name="lxeo:PayrollDeductionsAtPrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market values of the stock as of the beginning of the offering period or the end of each six-month purchase period. Each offering period of two years will consist of four six-month purchase periods, subject to reset on the first day of each purchase period depending on the fair market values of the Company's stock. Employees may not purchase more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8656d267-9504-4db1-b512-5e0c022ad0f6" contextRef="C_cf9feab1-814e-43f8-90af-29fdc96653e8" name="lxeo:CommonStockDuringOfferingPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock during any purchase period. The first purchase period within the first offering period under the 2023 ESPP commenced during the three months ended December 31, 2024 and concluded during the three months ended March 31, 2025; following reset, the first purchase period within the second offering period commenced during the three months ended March 31, 2025 and concluded during the three months ended September 30, 2025; and the second purchase period within the second offering period commenced during the three months ended September 30, 2025. As of and during the year ended December 31, 2025, stock-based compensation expense recorded, as well as the estimated fair value of unearned and unrecognized stock-based expense expected to be recorded, related to the 2023 ESPP were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd4a072-da9c-422b-9ae4-624efbd7538f" contextRef="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f" name="lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material. During the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e286ebd-4170-4daa-8445-be7c3c9f5f96" contextRef="C_46c792b5-6c67-472c-9304-76b2d83ce68a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">102,837</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued under the 2023 ESPP at a weighted average purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c65a105-357b-489b-b1ef-8afffc2b8b39" contextRef="C_46c792b5-6c67-472c-9304-76b2d83ce68a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share with total proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f8bb8eb-c466-475f-97a9-74ed791941b9" contextRef="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received by the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ddaf99aa-bf9e-46b4-852e-a37e225bbb1a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true" continuedAt="F_ddaf99aa-bf9e-46b4-852e-a37e225bbb1a_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified as follows in the Company&#8217;s statements of operations and comprehensive loss:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a24bc99-8280-4474-b8aa-a93add2d4541" contextRef="C_8eaec952-271e-49b4-9770-a01b8320fedf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,524</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92a4d749-49db-4a25-bfd7-cadc4748c0b7" contextRef="C_26366915-140b-4c96-93b7-e237b4213687" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,001</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a59f6a8-4d7e-4704-9083-d2f301e66dc0" contextRef="C_0f7ea42a-4e43-4f1e-a004-b523e0aeb298" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,608</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_409744fb-5e1f-448c-ad5a-d96d6f2f5be7" contextRef="C_8d5bfde0-a484-4470-9cd3-618c66bc014d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,473</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7fe7989-9c1e-4932-96c5-c1e1e8befadb" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,132</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7e242c-1715-4414-891b-2175a56ce03f" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_ddaf99aa-bf9e-46b4-852e-a37e225bbb1a_1"></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54e25091-788e-44ff-a8dc-7aa0124486da" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e817e09-8181-4eaf-a477-374a7bc9745e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.52%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ee58ca8-d9f5-48c8-b1d9-5ee787bd4d6f" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_645e77e2-0214-436f-96ea-a593f6a9367d" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96af58ce-092d-46f3-88e5-b008b68e80b6" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_13b22d64-5767-4ac4-aea0-9716c7f8d36f" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,645,323</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_812c55d6-7606-4b84-9202-f785687dd506" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_93104e0e-e255-4287-a57a-cce89ba226a2" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,787,491</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2df25bcb-a9e1-4ccf-801a-085a1983ceb9" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b78b6786-947a-4ccb-b04f-a58e5d1d2663" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.86</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0b7b0c5-aedc-4cdf-890a-0c8d221e4448" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f84b27bd-10ec-4d0d-a2a1-1697b9c11ab9" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.09</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_39fcdd1a-92e9-47d8-ae09-e194779bf143" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_39fcdd1a-92e9-47d8-ae09-e194779bf143_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1312c9e1-d4f9-433e-bf6e-22de8c5da91e" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of net income (loss) before income tax expense are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f2b2534-f12b-43be-9404-2c665b3c03b5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c81fb4b5-2618-44af-87a6-165312a26dbe" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6c6f973-0d26-4eea-82cb-9e262f83ed89" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aae2103f-f11f-45e1-8d31-54a0e6d50ea4" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_39fcdd1a-92e9-47d8-ae09-e194779bf143_1" continuedAt="F_39fcdd1a-92e9-47d8-ae09-e194779bf143_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b4e9a52-c243-475a-b5ae-08812a816722" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December 31, 2025, and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.038%;box-sizing:content-box;"/>
         <td style="width:1.381%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.604000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.145%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.381%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.684000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.381%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.384%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pretax Income (Loss)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06fc9ad1-0873-4ca0-9ca1-10d6e64bc392" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_851a9a5b-5edd-4400-ba7f-d8b35b1270ce" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US Federal Statutory Tax Rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbdfe9ce-58a1-41fe-81c1-26979c21d310" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,931</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb2806e0-f367-4c75-be27-3464f883c5fe" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88e8174f-939d-4800-ae3e-0c1767465513" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,671</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c80a3710-67a4-4a46-870a-76efe2fa5fab" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credits:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credit - Federal R&amp;D Credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72f43e06-badc-4dd7-a749-00e108688043" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,523</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93ccf4b8-79bb-4a67-88b9-366ebc2419fe" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.54</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5578da52-5dbb-413c-a8b1-641cb3eae5e6" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">678</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9424377e-6ef2-4bf2-bd70-9f17d4ea7da0" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.69</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credit - Orphan Drug Credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd9a9b0-1010-4100-8b85-86dd78bdeee5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,970</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f9bf904-3854-4001-a3bb-3dd9f571582a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0effb244-f8a8-4077-a7d2-233506e3a4e4" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,995</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_415a87d3-b8a9-45ab-a9b6-eb0775d37d17" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">3.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d6fa13d-d358-4d7a-a032-d20b6c99e015" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,430</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9b87cfc-b591-4a61-9cf6-715b4aa22538" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">16.48</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a3e022-dc65-4f55-844a-3afbf60d1f7c" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,903</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_794e3f18-381f-4733-9062-1721a0dcc02b" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">23.27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39084d10-df6b-4ff6-aed1-fd2672ae93e5" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">948</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3e00751-f001-4fff-a4ff-9f97e73eb1d3" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce65855f-bebc-418f-bbe7-cb89d777651d" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6501ea7-2be7-4fee-847d-9547d00269ad" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.46</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02d323c1-3d58-4697-bd40-fdbd6bbe7d1a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_064c1bdf-ea0c-40fa-b1f0-a5f5cdd66de0" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7ac9e4-3ce7-4d8e-b8a6-d0129a620b49" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52e980e8-10e7-4dc0-9776-aa25810ac24c" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's effective tax rate includes the effects of state and local income taxes, net of the federal income tax benefit, which are primarily attributable to New York and New York City, where the Company has significant business activities. This state has higher effective tax rates compared to other jurisdictions where the Company operates, and together, it accounts for more than half of the Company's total state tax expense.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83a5b986-04a0-4144-ba5c-29e3e82cc52a" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company's deferred tax assets and liabilities at December 31, 2025 and December 31, 2024 are as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16c2588d-6a7a-49e5-b011-e76b5d5ae821" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,868</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7d4068-d01e-40b5-b408-ea76078a9059" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,295</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_993a8a78-ce76-406d-a2ad-dc72d73aba0b" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,190</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45c660be-f081-4111-807d-17d9abb3bb06" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,743</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangibles</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ebf57c2-faa3-4b1b-bfe0-65ec5588dfa9" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:DeferredTaxAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1b3ecc4-1c8e-4591-83c7-8b354ddb39ce" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:DeferredTaxAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,918</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eccf8581-61e7-4db9-9f50-7fc2f66b50d8" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,720</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9533b81a-f9cd-4403-83ee-ccbb84e7a363" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,338</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fb80c7e-6d8a-4431-81d4-16bfc4e96ff6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="lxeo:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b136398-feca-4f7b-949e-3b8055020d7b" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="lxeo:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,818</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c6e0b28-0fb5-4f5f-b741-29d758a2633a" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,225</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_872a42b3-3b3f-4c82-9357-68438705dc1a" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,292</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cdb2ca9-031e-4421-a055-fe1d575dc695" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,374</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec43ec4-503a-4060-8993-39e58f807c40" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,404</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42bd943d-2831-4963-a7a5-3282246edc28" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,935</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb81302-9ad4-4a59-9f73-73f13563ddb9" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,426</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31bae685-0bce-4736-96e0-5a13b66ca666" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,439</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d365fddf-0535-4a76-a631-0a9ba1e13d66" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,978</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9652a9e8-fd81-4d94-a7d8-e36f8a9cd430" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,059</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_650a08b6-4227-4469-a700-102eb346494a" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,663</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4addbed7-773f-4865-bad6-b1742f7c80b6" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e485aeea-3d32-43fd-ab03-0f16bcae52ea" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_132abf1f-34c8-4d64-b4c0-0d4abbf49f82" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,439</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b214400-32ce-4960-9991-2c5533b74c06" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,978</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d0222ab-5da5-406a-b8c0-3590cbaf5168" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9958904a-e655-43f3-81fc-15a6c5930088" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company had federal net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_552f51f7-41fa-4c87-ab36-ef0c914e370e" contextRef="C_ba541477-4977-4a4d-8ea6-08f08a69b3a2" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">182.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c96b0ec-36a1-4326-9256-c8f25f330391" contextRef="C_af7f7cbb-e358-4e01-9e01-445a10e44bc0" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which can be carried forward indefinitely. As of December 31, 2025 and 2024, the Company had state and local net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98eee0ba-d0bc-4c15-a052-c810015460ad" contextRef="C_487136e8-5828-4a30-8230-e11cfaee5e4f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">362.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d73cd22e-be40-4a7f-b879-33bb3ae09f41" contextRef="C_0eb85a0b-e29d-45c6-a281-a90d66d244dd" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">212.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fd60be2-f1ea-4fb7-899c-e3837b9f8d5d" contextRef="C_2d6d8b8b-f338-4359-9fa9-714c220f91b8" name="lxeo:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company had federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_917a4c97-18a6-43ca-b9ae-33f822509c8a" contextRef="C_ba541477-4977-4a4d-8ea6-08f08a69b3a2" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bce338c-3171-4bc5-a10e-edf57932b09b" contextRef="C_af7f7cbb-e358-4e01-9e01-445a10e44bc0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc0f6a8f-d0a8-4cec-9971-1d154ccf096e" contextRef="C_2917ec7c-ddbb-4d8a-a527-3f8895a2283c" name="lxeo:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_39fcdd1a-92e9-47d8-ae09-e194779bf143_2" continuedAt="F_39fcdd1a-92e9-47d8-ae09-e194779bf143_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tax Cuts and Jobs Act (the "TCJA") resulted in significant changes to the treatment of research and developmental (&#8220;R&amp;D&#8221;) expenditures under Section 174 of the Internal Revenue Code of 1986, as amended (the "IRC"). For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over five years and costs for foreign R&amp;D activities must be amortized over 15 years, both using a midyear convention.<br/><br/>For tax years beginning after December 31, 2024, the One Big Beautiful Bill Act enacted a new rule under Section 174A of the IRC allowing companies to immediately expense any domestic R&amp;D expenditures. For domestic R&amp;D, companies may either immediately expense or elect to capitalize and amortize over at least 60 months under Section 174A of the IRC. However, foreign R&amp;D continues to require capitalization subject to the mandatory 15-year amortization period under Section 174 of the IRC.<br/><br/>For domestic R&amp;D expenditures that were previously capitalized in tax years 2022-2024 under the prior TCJA, companies may elect to recover the remaining unamortized balance by either (1) expensing fully in the first year beginning after December 31, 2024, (2) expensing ratably over two years beginning after December 31, 2024, or (3) continue amortizing over the remaining life.<br/><br/>The Company has elected to continue amortizing the previously capitalized costs over their remaining life. Beginning in tax year 2025, instead of immediately expensing domestic R&amp;D expenditures under Section 174A of the IRC, the Company elected to capitalize and amortize its domestic R&amp;D expenditures under Section 59(e) of the IRC over a 10-year period. Any foreign R&amp;D costs will continue to be capitalized and amortized over 15 years in accordance with the requirements of Section 174 of the IRC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2025 and December 31, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. As a result, the Company increased its valuation allowance by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f95a8b26-a85c-43c1-9ad3-d767d8babf69" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_885dff74-86f0-452d-98aa-c47419dce9d2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:PercentageOfCumulativeOwnershipChange" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more in the ownership positions of certain stockholders during a rolling three-year period.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company conducted ownership analyses under IRC Section 382 as of September 30, 2024 and December 31, 2025 and determined the Company experienced ownership changes on November 7, 2023 and May 28, 2025, respectively, that limit the Company&#8217;s ability to utilize its federal NOLs and tax credits. As a result of the ownership changes, the Company is subject to an annual limitation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba55906d-e651-4588-98f6-5b829352cacc" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:AnnualLimitationAbilityToUtilize" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on its ability to utilize its federal NOLs and tax credits recognized before May 28, 2025, inclusive of the ownership change that occurred on November 7, 2023. Due to the limitations, no federal NOLs are expected to expire unutilized and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbeecf9f-b259-428c-b788-32988a53561c" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership changes, are expected to expire unutilized. As a result, during the year ended December 31, 2025, the Company reduced its deferred tax assets related to the federal tax credits, which was offset by a corresponding decrease in the valuation allowance.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2025 and December 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60a45da4-ed4f-4450-a26f-10c21744da63" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d80b9627-1a56-4e1c-8bc1-1d8a47022172" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any uncertain tax positions in its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying statements of operations. As of December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f70a58bc-69f8-47ee-a859-6b71225225ee" contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_34b2c76c-adad-45be-8f1f-fe786b0dbe73" contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the balance sheet.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_39fcdd1a-92e9-47d8-ae09-e194779bf143_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company's financial statements. The Company&#8217;s tax years remain open under statute from December 31, 2022 to the present.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_663d7840-9f15-4586-998a-bbbb4b8e04fc" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" escape="true" continuedAt="F_663d7840-9f15-4586-998a-bbbb4b8e04fc_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the Company's capital base and franchise taxes paid (net of refunds received) for the years presented below:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07de70fa-41b5-4895-b2b9-f435b17b54e8" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64257ac2-ec57-40d4-bdb1-2c6fb6d4a456" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cee69d5a-5801-4f86-a417-6851f6c2012f" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">551</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e448d675-ebc4-4c46-8091-c93fa2644a2b" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f66bf3-244e-4e4e-9519-f5876ba01aa0" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">551</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dca5255-838b-4351-bce9-974fa303dadf" contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the jurisdictions that exceeded 5% of the Company's total capital base and franchise taxes paid (net of refunds) for the years presented below:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.103%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c4ccd1d-b9b4-4ed7-bd73-9e100423fcf9" contextRef="C_23f2cf9c-eb2c-4874-9bb5-0b7e43ac44cb" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f8ebd1e-15db-4afc-baa1-a323ed22e1c1" contextRef="C_ac474d05-a4df-41bb-8c49-c9dddccf1523" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York City</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fbb602d-d37f-4605-a83e-fe0164ad8b99" contextRef="C_99561f6d-e4ca-4b39-a707-cdaeb6211e33" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_419ccec3-12ca-453d-896e-9dd6756e6f98" contextRef="C_80a79c85-4eb7-478c-9356-9eedeabc3701" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_663d7840-9f15-4586-998a-bbbb4b8e04fc_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0be18ea4-c95e-4582-885b-504cf3bcd544" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2025, the Company had entered into commitments under lease agreements to rent laboratory and office space and finance equipment (see Note 6).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2025, the Company had entered into commitments under license, acquisition, research collaboration and sponsored research agreements with third parties (see Note 12). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41ae52af-4461-4af2-aa87-ba1034f0e9aa" contextRef="C_1f3e3006-1af0-48a7-9634-48ce1dc96196" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afaa2a08-da17-408e-86db-08eede9b48d9" contextRef="C_84e826fb-ff2b-461e-a57d-ab9f5b605b0a" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-days&#8217; written notice, unless otherwise indicated. Further, certain of the Company&#8217;s manufacturing agreements could require early termination and wind-down payments due from the Company upon either the termination of its clinical trials or if the Company terminates such agreements for convenience.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company recognizes any associated legal fees as incurred and accrues a liability for such contingent liability matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings, except that on October 12, 2023, Rocket Pharmaceuticals, Inc. (&#8220;Rocket&#8221;) filed a lawsuit in the U.S. District Court for the Southern District of New York against the Company and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c77bbc0-42aa-47bd-8b45-b54e1ab96f70" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:NumberOfFormerEmployees" unitRef="U_Employees" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> former employees that claimed, among other things, misappropriation of confidential information and trade secrets. The complaint alleged the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they became employed at the Company. The complaint sought unspecified damages and asked the court to enjoin the Company from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, the Company asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. The Company's counterclaims sought equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. In June 2025, the litigation was resolved amicably and without admission of liability by any party, and all claims have been dismissed with prejudice.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. For all periods presented, the Company has not incurred any material costs as a result of such indemnifications.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_8eb75d59-3929-42be-b7c0-0863233ab782" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" escape="true" continuedAt="F_8eb75d59-3929-42be-b7c0-0863233ab782_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. License, Acquisition, Research and Collaboration and Sponsored Research Agreements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverum Biotechnologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On January 25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#8220;Adverum&#8221;) to in-license materials and technology related to the treatment of cardiomyopathy due to Friedreich's ataxia ("FA") (as amended in February 2022, the &#8220;Adverum Agreement&#8221;). In connection with the Adverum Agreement, the Company gained access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop, and the Company will assume all development and commercialization activities worldwide. Pursuant to the Adverum Agreement, the Company paid a one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82db6f07-1589-4107-817c-6668b17c2cd2" contextRef="C_75180180-4d90-42c6-8270-15e1f3cc0ebf" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is obligated to pay aggregate development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f40ec92-2cfc-4e19-b2a2-605f2466bea2" contextRef="C_e9dc71b0-9639-4d01-9da6-f620a88b25a4" name="lxeo:DevelopmentAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6056e926-e3e9-4bdc-aa43-d6af7f3382e7" contextRef="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023, and aggregate sales event and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_328d4109-03eb-4986-9598-3bb9a3528d90" contextRef="C_e9dc71b0-9639-4d01-9da6-f620a88b25a4" name="lxeo:CommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">49.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f452e53-9937-4175-adad-90bdc65a04ac" contextRef="C_38fa9b64-95c3-4a46-9bf4-5fef14d31d49" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5bac99c-1e86-4dae-ad9f-084a4f9e1c51" contextRef="C_eca6767a-469e-41ac-95c7-b2ab4461a834" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> research and development expenses recorded by the Company or payments made to Adverum under the terms of the Adverum Agreement other than the one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1584e20-5108-4d07-bcb8-d1c58d6383fb" contextRef="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98537fcf-7878-4141-8f96-2ce3efcf6a1b" contextRef="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Adverum Agreement remains in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f9a7ce4-3b7b-4095-92de-7a68422a9e4e" contextRef="C_75180180-4d90-42c6-8270-15e1f3cc0ebf" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach of contractual terms, or insolvency by either party.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On May 28, 2020, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee25079c-4089-4f9d-9d9f-69e200e86271" contextRef="C_3740bd83-e4cd-4204-8ee9-2432a933e74a" name="lxeo:NumberOfLicenseAgreements" unitRef="U_IntegerItem" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exclusive license agreements with Cornell University (&#8220;Cornell&#8221;) (each, as amended, the &#8220;First Cornell License Agreement&#8221; and the &#8220;Second Cornell License Agreement,&#8221; respectively; collectively the &#8220;May 2020 Cornell License Agreements&#8221;). The First Cornell License Agreement is for the in-license of technology related to portfolios for APOE-associated Alzheimer&#8217;s disease and Anti-Tau, although the Company&#8217;s license is not restricted by such indications and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh10.hAPOE2 vector to treat APOE4 homozygous patients who are at risk for or have Alzheimer&#8217;s disease to support development of the Company&#8217;s LX1001 program. The Second Cornell License Agreement is for the in-license of technology related to a portfolio for FA although the Company&#8217;s license is not restricted by such indications, and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh.10cUhCLN2 to treat children with CLN2 Batten disease to support development of the Company&#8217;s LX1004 program. Through the May 2020 Cornell License Agreements, the Company gains access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop. Under the terms of the May 2020 Cornell License Agreements, the Company has assumed all development and commercialization activities worldwide with respect to the licensed technology.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As initial consideration for the May 2020 Cornell License Agreements, the Company paid Cornell an upfront payment in cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a6af1a0-0029-4cef-848b-f6dad08411f4" contextRef="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852" name="lxeo:UpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b88bd0b-894c-4c42-9e05-c7a1122c6718" contextRef="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852" name="us-gaap:NotesIssued1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of notes (the &#8220;Cornell Notes&#8221;). In November 2020, the Cornell Notes with outstanding principal of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cdc8b95-56fd-4054-ac9a-31194e3f9446" contextRef="C_d3d8d14a-d897-4e92-bd97-3e0646e0e634" name="us-gaap:DebtConversionOriginalDebtAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were cancelled in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccf09982-2837-499f-b310-b2c463a506c7" contextRef="C_8453d8e7-a1f5-4915-bf2c-6ebc643f48ed" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,337,610</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of series A convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32438ea1-a118-41b3-8c34-b32f2bd273e7" contextRef="C_a71aae44-530b-4c44-887c-3235e51cb928" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">126,258</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO on November 7, 2023. As additional consideration, the Company is required to pay Cornell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c46de854-9948-410a-8153-ac4a3fe2c69a" contextRef="C_3bd21372-e009-4064-a11c-8bf9c564cecf" name="lxeo:SpecificClinicalAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific clinical and regulatory milestones under the First Cornell License Agreement and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_703a86c1-91dc-4f50-8ab3-2ddf18e715d5" contextRef="C_3d145bd9-a80d-4e38-8f51-01b475e8e55b" name="lxeo:SpecificClinicalAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in two portfolios and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03cd2bfe-8897-42f3-bd9c-bd7ab61b1205" contextRef="C_9b72a311-fda5-4b44-874c-7a79d1c0981d" name="lxeo:SpecificClinicalAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for a third portfolio upon the achievement of specific clinical and regulatory milestones under the Second Cornell License Agreement. In the second quarter of 2022, a clinical and regulatory milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c6d86f5-2778-49e8-bfa8-18e34428d64b" contextRef="C_e8b9a53b-cf8f-4ca6-984a-ef4b65858fd3" name="lxeo:PaymentOfClinicalAndRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized and paid to Cornell in connection with the Second Cornell License Agreement. The Company is also required to pay Cornell a flat royalty in the mid-single-digits based on net sales of the products covered by the licenses, subject to certain adjustments.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes non-exclusive and royalty-free. In addition, each of the May 2020 Cornell License Agreements may be terminated by the Company for any reason upon ninety (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_164ac19c-2c7c-4b25-a8e7-4e6b55d77cd6" contextRef="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; advance notice to Cornell and by Cornell upon the Company&#8217;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2024, the Company entered into the Third License Agreement (as amended, the &#8220;Third Cornell License Agreement,&#8221; together with the May 2020 Cornell License Agreements, the &#8220;Cornell License Agreements&#8221;) with Cornell. Pursuant to the Third Cornell License Agreement, Cornell has granted the Company an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell on behalf of the Company and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell has also granted the Company a right of reference to Cornell&#8217;s Investigational New Drug application for a gene therapy for FA cardiomyopathy.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_8eb75d59-3929-42be-b7c0-0863233ab782_1" continuedAt="F_8eb75d59-3929-42be-b7c0-0863233ab782_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Third Cornell License Agreement, the Company paid a license issue fee and an initial data transfer fee to Cornell totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72469ed7-39ec-4534-a8ab-b28ab32399b1" contextRef="C_aa8f2f22-e100-44a6-a895-7f6b95043573" name="lxeo:PaymentOfLicenseIssueFeeAndInitialDataTransferFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, the Company will be paying an annual data transfer fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68643639-23a0-4f81-806f-e4632d1649d0" contextRef="C_aa8f2f22-e100-44a6-a895-7f6b95043573" name="lxeo:PaymentOfAnnualDataTransferFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until data is no longer being gathered. The Company has agreed to pay annual license maintenance fees ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d1e0e9a-3ed4-4893-8fc1-80402212b421" contextRef="C_5c2eaa43-838e-4de5-ab2b-12e3438f3233" name="lxeo:PaymentOfAnnualLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71abd32d-e483-40d9-902d-08cdd8b93b30" contextRef="C_be3196c0-6c7d-48a3-80e1-3571e67be6c4" name="lxeo:PaymentOfAnnualLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until such time the Company commercializes a licensed product. In addition, the Company will pay Cornell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_751b0b7b-f159-4e32-9982-fa8273a3dc28" contextRef="C_be3196c0-6c7d-48a3-80e1-3571e67be6c4" name="lxeo:PaymentOfRegulatoryMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in regulatory milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b5e6775-7f7e-477f-8626-a046671dd515" contextRef="C_54cd63d0-b34f-4997-8bdf-7b733713a458" name="lxeo:CommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestones, plus low single digit royalties on net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Third Cornell License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, the Company shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell may terminate the Third Cornell License Agreement if the Company (i) breaches the Third Cornell License Agreement (subject to a cure period), (ii) participates in any proceeding challenging the validity of the licensed patents, (iii) publishes the licensed data without Cornell&#8217;s prior written consent, or (iv) does not reach certain milestones. Cornell may also terminate the Third Cornell License Agreement in part on a product-by-product basis if the Company does not diligently develop and sell a product. The Company may terminate the Third Cornell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e65e38c8-d047-4625-b1e2-f6b60c5b859f" contextRef="C_aa8f2f22-e100-44a6-a895-7f6b95043573" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; prior written notice to Cornell.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2025, the Company executed a Second Amendment to the Third Cornell License Agreement (the &#8220;Second Amendment to the Third Cornell License Agreement&#8221;), which added a one-time fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ffb155d-1b2d-4fd8-a14d-d3780d712002" contextRef="C_cddcf69a-38e1-41ca-92b2-1dc2813f0ff2" name="lxeo:PaymentToAdditionalDataTransferProcess" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for additional data transfer and processing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3e7c658-8611-4664-8b6f-a0cbd1ce09eb" contextRef="C_650a7937-a18f-466c-853a-cd74ae06db6a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb7985b8-27bd-48d5-adfc-ae5dcf9bca03" contextRef="C_650a7937-a18f-466c-853a-cd74ae06db6a" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the Amended Cornell License Agreements. During the year ended December 31, 2024, the Company incurred and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13ff7a41-494c-4c99-bb56-786b8d9b393f" contextRef="C_ce351259-df29-4736-b0f7-5bd85eaae4a8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0f1bfbc6-e224-43bd-bf0b-ace7042dcffe" contextRef="C_ce351259-df29-4736-b0f7-5bd85eaae4a8" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the Amended Cornell License Agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios Therapeutics, Inc. (&#8220;Stelios&#8221;) was an early-stage company developing novel adeno-associated AAV-based gene therapies for rare cardiac conditions including arrhythmogenic cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy. On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44ea8502-d0e1-4cb9-9a00-db8694206a76" contextRef="C_a404e138-86a1-415f-86fa-bd92d7670e55" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 16, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0358b61e-c6a9-4aef-a54e-6ce9645e2aec" contextRef="C_306cf451-d0e8-4733-9390-77a092116c12" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding stock of Stelios that was accounted for as an asset acquisition pursuant to FASB ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is required to pay up to a remaining aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cfce90f-0152-4968-982c-bd1860fdc6a6" contextRef="C_8be8bafc-0873-440f-bfc2-64f112f3e6ed" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the selling shareholders of Stelios upon the achievement of certain development milestones, excluding a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29139b00-aeea-4cb2-a1fd-20ca3a2101e2" contextRef="C_96240578-4334-4f1a-be14-256259efbda3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved in the third quarter of 2024 and paid in the fourth quarter of 2024. Dr. Eric Adler, the Company's former Chief Medical Officer and Head of Research, was a co-founder of Stelios and a selling shareholder. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88d7f06-2b8c-4314-b424-29b621564a8f" contextRef="C_a77def4a-c9cb-4e98-960a-031f93bc0880" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone payment, Dr. Adler received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f50be0-f4b0-4a1a-86c2-22c0cf238d6d" contextRef="C_248d415b-1dda-43fc-94db-d4c94d4bcf0f" name="lxeo:MilestoneReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Stelios was merged into the Company on December 15, 2022 and ceased to exist.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Regents of the University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios entered into an exclusive worldwide license agreement on April 23, 2020 (as amended, the &#8220;First UCSD Agreement&#8221;) with The Regents of UCSD to in-license materials and intellectual property related to a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The First UCSD Agreement relates to the Company&#8217;s development efforts for its LX2021 program. In connection with the First UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The First UCSD Agreement required Stelios to pay one-time up-front non-refundable cash fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65a9e850-8478-45dd-97d5-f66e0944c39f" contextRef="C_418db8cc-20a6-4c63-bc80-22f00e85ab78" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each agreement and requires the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b8adff9-ad79-4dc5-a263-4ac534e0f00f" contextRef="C_b7328e55-a04d-45a3-8322-e2fb9ba87bc8" name="lxeo:DevelopmentAndCommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low- to mid-single digit royalties and low-single digit royalties based on aggregate net sales. The only research and development expense incurred by Stelios or the Company, and payment made to The Regents of UCSD through December 31, 2025 under the terms of the First UCSD Agreement, was the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd39d6d-ea47-4f5e-ba8c-8fb04cc0c2a0" contextRef="C_f42c0641-10f4-40b1-862a-8bb73b4c2821" name="lxeo:OneTimeUpFrontNonRefundableFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has the right to terminate the First UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d53782e8-721d-4df2-8a4f-407046bd28c6" contextRef="C_250aa9ae-d108-452e-bc1b-21c4551179b4" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_8eb75d59-3929-42be-b7c0-0863233ab782_2" continuedAt="F_8eb75d59-3929-42be-b7c0-0863233ab782_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios entered into an exclusive worldwide license agreement on August 6, 2020 (as amended, the &#8220;Second UCSD Agreement&#8221;) with The Regents of UCSD to in-license materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy. On November 14, 2025, the Company entered into an amended and restated license agreement with UCSD, which amended and restated in its entirety, the Second UCSD Agreement (the "Amended and Restated Second UCSD Agreement"). The Amended and Restated Second UCSD Agreement maintained the Company's prior exclusive worldwide license to materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy, replaced Stelios with the Company as licensee, and exclusively in-licensed additional materials and intellectual property related to the LX2022 program. Stelios previously paid a one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6497f0ec-a66e-4653-add5-1e281b27ce32" contextRef="C_30c2f2ac-b0af-4f98-a1b6-41ccc4e13693" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Second UCSD Agreement. The Amended and Restated Second UCSD Agreement requires the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_face1615-3286-4634-861c-63edaa43ccb5" contextRef="C_a5a4ebfd-7511-4fbc-860a-5324a475f3a1" name="lxeo:DevelopmentAndCommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low-single digit royalties based on aggregate net sales. The only research and development expense incurred by Stelios or the Company, and payment made to The Regents of UCSD through December 31, 2025 under the terms of the Second UCSD Agreement and the Amended and Restated Second UCSD Agreement, was the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e83b6100-5c47-4d1b-a7fb-cb2e09f8d5c9" contextRef="C_773cd297-399a-44b4-b688-630eaee896cc" name="lxeo:OneTimeUpFrontNonRefundableFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has the right to terminate the Amended and Restated Second UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f8e4a8d-dcd5-4b64-b7d6-8757b020c56f" contextRef="C_30c2f2ac-b0af-4f98-a1b6-41ccc4e13693" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2021, the Company entered into an exclusive worldwide license agreement (as amended, the &#8220;Third UCSD Agreement&#8221; and collectively with the First UCSD Agreement and the Amended and Restated Second UCSD Agreement, the &#8220;UCSD Agreements&#8221;) with The Regents of UCSD to in-license materials and intellectual property related to LX2020, a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The Third UCSD Agreement relates to the Company&#8217;s development efforts for its LX2020 program. In connection with the Third UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The Third UCSD Agreement required the Company to pay a one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2629a2e9-f235-495f-b3fa-55ec85094395" contextRef="C_2c5a6104-de8c-4a89-b38f-5b76f25de136" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and requires </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_261b109c-65e3-4968-b597-07e153290a53" contextRef="C_f15ba613-2ee7-4a4a-a5f6-e7630c6a7078" name="lxeo:AggregateDevelopmentAndCommercializationMilestonesDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7475b10f-144b-473e-b793-bef179c21060" contextRef="C_1f5a81d6-9a7a-4e3d-81e3-123c0c43d34b" name="lxeo:DevelopmentAndCommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low- to mid-single digit royalties based on aggregate net sales</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Research and development expenses incurred by the Company and payments made to The Regents of UCSD under the terms of the Third UCSD Agreement include the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0266024-840b-4ace-8d2c-b76c109c55c8" contextRef="C_63514d7b-26f0-4ca4-a6a2-01e151213a0d" name="lxeo:OneTimeUpFrontNonRefundableFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_627fe77d-5411-4631-83f6-5fd6dbdcb4b1" contextRef="C_028187ae-2bdd-401c-9d01-a0eff189025b" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved during the third quarter of 2024. The Company has the right to terminate the Third UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8e345e9-3d8d-4cf0-8de5-b363776d0acb" contextRef="C_2c5a6104-de8c-4a89-b38f-5b76f25de136" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2021, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0aaf3bce-7e70-45dd-91d7-30a0cbce79a7" contextRef="C_09b1664a-a411-44c8-8629-2f95a673f0c2" name="lxeo:NumberOfResearchAgreements" unitRef="U_IntegerItem" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sponsored research agreements with The Regents of UCSD (the "First UCSD SRA", the "Second UCSD SRA", and collectively, the &#8220;Initial UCSD SRAs&#8221;) for the Company&#8217;s LX2020, LX2021 and LX2022 programs in connection with the UCSD Agreements. Under the terms of the Initial UCSD SRAs, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by The Regents of UCSD or resulting inventions jointly owned between the Company and The Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Initial UCSD SRAs each have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_186c9b60-79cb-4d95-906c-435009173a99" contextRef="C_e52cbdd7-cdf3-4600-944f-875c024f274c" name="lxeo:ResearchAgreementsTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ca1cc9a-7361-4cf0-bac6-a5e39d913914" contextRef="C_e52cbdd7-cdf3-4600-944f-875c024f274c" name="lxeo:ResearchAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD. The total costs to be invoiced to the Company over the terms of the Initial UCSD SRAs are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ee96976-33f2-470c-9deb-abf8fe6a30b1" contextRef="C_e52cbdd7-cdf3-4600-944f-875c024f274c" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company entered into a third sponsored research agreement with The Regents of UCSD (as amended, the &#8220;Third UCSD SRA&#8221;) for the Company&#8217;s LX2022 program in connection with the Second UCSD Agreement. Under the terms of the Third UCSD SRA, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by The Regents of UCSD or resulting inventions jointly owned between the Company and The Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Third UCSD SRA has a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7f2f366-7361-451a-9d9a-163b79485db8" contextRef="C_324cf665-a528-4a30-91f6-882210006248" name="lxeo:ResearchAgreementsTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_993fe38e-4bcd-4a83-a657-88137ee5dca6" contextRef="C_324cf665-a528-4a30-91f6-882210006248" name="lxeo:ResearchAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD. The costs to be invoiced to the Company over the term of the Third UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9e549df-77fa-4cbb-b80c-931e46c437bf" contextRef="C_324cf665-a528-4a30-91f6-882210006248" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and the Company may incur additional costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff2019a2-f433-4573-8b8c-2cdd0b31fd19" contextRef="C_324cf665-a528-4a30-91f6-882210006248" name="lxeo:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Third UCSD SRA if certain study objectives are met.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company also entered into an amendment to the Second UCSD SRA (as amended, the "Amended Second UCSD SRA") for the Company&#8217;s LX2022 program that extended the term of the Second UCSD SRA to December 2024.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each of April 19, 2024 and September 27, 2024, the Company also entered into an amendment to the First UCSD SRA (as amended, the "Amended First UCSD SRA", and together with the Amended Second UCSD SRA and the Third UCSD SRA, the "UCSD SRAs") for the Company&#8217;s LX2021 program in connection with the First UCSD Agreement. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to the Company under the Amended First UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef3bdb46-01f6-4c65-8ee9-b9f2f766f922" contextRef="C_10c07d1a-63f8-4282-9c3d-df142d9339e7" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_815fdf57-7cdf-4670-914f-a57520211c1c" contextRef="C_62dae8ef-bcab-47b7-8b50-1e70e0f56090" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ff7b866-112b-4c73-8691-85e6a8ba59b3" contextRef="C_62dae8ef-bcab-47b7-8b50-1e70e0f56090" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to The Regents of UCSD in connection with the Amended UCSD SRAs. During the year ended December 31, 2024, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_853e489c-7429-4735-8d55-4ef85cb30c54" contextRef="C_22f53fb5-b715-4275-818b-b00d6389e9cf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec4d0b8f-df39-4d23-a80e-05d379f80835" contextRef="C_22f53fb5-b715-4275-818b-b00d6389e9cf" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to The Regents of UCSD in connection with the Amended UCSD SRAs. The Company has incurred and paid cumulative totals of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c97ebfa2-ca8a-457e-ac23-836deca96b37" contextRef="C_f97419ff-d263-47c9-8d19-9400a45c4996" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_145846b0-a923-4a2d-a4c0-6d911978bd79" contextRef="C_e4a107b2-cde8-4301-ac61-de3823035653" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, to The Regents of UCSD as of December 31, 2025, in connection with the Amended UCSD SRAs.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8eb75d59-3929-42be-b7c0-0863233ab782_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Myoventive, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In June 2025, the Company entered into a Collaboration and License Agreement with Tilia Therapeutics, Inc., now known as Myoventive, Inc. ("Myoventive" and the "Myoventive Agreement"), to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Myoventive Agreement, the Company contributed expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform. As consideration for its contributions, the Company received a double-digit percentage equity position in Myoventive and will be entitled to future milestone payments, royalties, and opt-in rights to certain program(s).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Abiomed, Inc. (Johnson &amp; Johnson subsidiary)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of gene therapy. Under the Abiomed Agreement, the parties intend to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV-vector delivery to the heart by investigating cutting-edge routes of administration using the Impella</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> heart pump technology. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb69fd8-719f-4e43-a264-178c4ed11bf9" contextRef="C_4cb98960-d47c-4c98-b396-48e50d6696e0" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4f7c948e-c349-47e4-885f-a180bd53c164" contextRef="C_4cb98960-d47c-4c98-b396-48e50d6696e0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t incur or pay any research and development costs in connection with the Abiomed Agreement for the year ended December 31, 2025.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_f19cb4b3-33d9-416a-ba8a-a2b2f96227f7" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Segment Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75f9c2e7-1de4-4946-af58-da32a0cd7335" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_33986856-2fc0-46e5-a0a8-20e6e13001c1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO and senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All of the Company&#8217;s operating results are reviewed by the Company&#8217;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a037ea15-adec-409e-8c43-b3ef64e5bcf7;"><span style="-sec-ix-hidden:F_b1bf8275-7776-4ea4-af70-17f51659f92f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21194b07-f60c-473e-9e17-81e2675cbf9b" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_21194b07-f60c-473e-9e17-81e2675cbf9b_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.094%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.123000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.123000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_051c46a6-171e-4dae-8208-202a4508b31b" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="lxeo:ResearchAndDevelopmentExpenseLX2006" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c68ac81a-dd40-4c8f-bba1-47ca86e980ab" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="lxeo:ResearchAndDevelopmentExpenseLX2006" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,256</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_930dcf8a-dbfe-4d2a-90ae-d7feb7f12fc7" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="lxeo:ResearchAndDevelopmentExpenseLX2020" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,413</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3fadca9-40c4-4020-bd66-c1afab53c2c6" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="lxeo:ResearchAndDevelopmentExpenseLX2020" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,451</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe54bead-27da-47a9-aeaf-3cbe20c5975a" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="lxeo:ResearchAndDevelopmentExpenseLX1001" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,168</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_628483ff-009d-45c7-ac3b-e413acd4dccc" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="lxeo:ResearchAndDevelopmentExpenseLX1001" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b74e06ce-394b-434a-8617-eef0fa61684b" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="lxeo:ResearchAndDevelopmentExpenseOtherPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,075</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f14cefc-0001-4f67-9740-533b90adb5b9" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="lxeo:ResearchAndDevelopmentExpenseOtherPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,424</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04ae0929-38e7-49b8-ab95-263f2c7504f1" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,183</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2092c2c-f49b-48f4-b5ea-5b1b4adf6b54" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,010</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7394a62a-4d2b-4537-9b0c-b50eeca7152d" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,550</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2093c8e8-73ff-4bdd-8618-cd8eca12676a" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,367</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bee2f5c6-c0af-4c37-b510-486a7043d91f" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,245</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e530a1cf-dca7-4da2-b97c-90b1e9640166" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,082</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6639f4af-cea7-4d43-bdf8-1bf0bbf55c50" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,461</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83da1dd6-7e2e-469e-9884-2b4a69371571" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abbe3fac-7330-4c67-8533-17dea25c12bc" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,999</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb018f3e-7b7b-4a06-81e2-4033043fab9f" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,990</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81423b7f-dfb4-4a02-9704-de77fcd71131" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48c1fc4f-8dbc-4cf6-bdd5-5638b94f4a82" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,433</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8645e3d8-1a78-45d3-a262-db301c2504ba" contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,961</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0e4f5d1-ca12-4777-a964-b2def156a752" contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_21194b07-f60c-473e-9e17-81e2675cbf9b_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79ef6a36-7f61-44ca-8757-86074adfabb2" contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Subsequent Events</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent events have been evaluated through March 30, 2026, which is the date that these financial statements were issued and were available to be issued.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_127398a8-7357-41ba-a384-c7baf95b6631" contextRef="C_ddd009c3-4182-4517-ab43-5a05f6879a2e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">867,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91bc11b-abd8-47b2-8235-8b19412352f9" contextRef="C_1fd1bb70-d88e-4bd3-9f2b-0ae04cc83ef6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share that were issued in the May 2025 Private Placement were exercised with total proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a2a1d54-0fa2-42e0-bfa6-036ca6dfdf2e" contextRef="C_2d45877d-8c3e-4498-98ab-785fe7b33f59" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received by the Company (see Note 7).</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements_with"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9A.    Controls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of December 31, 2025. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) promulgated under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, our management assessed and conducted an evaluation of the effectiveness of our internal control over financial reporting based on the Internal Control&#8212;Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting a required by Section 404(b) of the Sarbanes-Oxley Act of 2002. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC related to emerging growth and smaller reporting companies.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the fourth quarter of the year ended December 31, 2025, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Effectiveness of Controls and Procedures</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9B.    Other Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_048fc93d-46e5-436a-8a59-2516eec8f7ce" contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Trading Plans of Directors and Executive Officers</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d393ce-a29f-40de-a71c-f00edc6ba18e" contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 13, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e90d4e68-356c-4402-add7-992bb0955c71" contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc050157-7e44-4988-8759-b85e1f367081" contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a member of our board of directors, adopted a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eef29a01-66db-49a3-9f0d-a41e81cee4c2" contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trading arrangement providing for the sale from time to time of an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_447ddffa-3023-413c-b5c5-5011e1e03ef1" contextRef="C_213bc6a0-4d38-4376-bd17-5ea5dbcd6e55" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">116,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, commencing on April 3, 2026. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b31d022a-740e-4046-8c6f-82aff704ac34" contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 11, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or earlier if all transactions under the trading arrangement are completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc4ed2c1-c164-4f0f-b787-08ee656f3506" contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_31bf3974-8980-408a-87df-9de93bef0fec" contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d521d87e-819c-40c1-868a-f224189fea37" contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_65facba3-b66a-44bb-afb8-eec4e2e89c7f" contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other officers, as defined in Rule 16a-1(f), or directors adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408, during the last fiscal quarter.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9C.    Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 10.    Directors, Executive Officers and Corporate Governance.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in our definitive proxy statement for the annual meeting of stockholders to be held in June 2026 to be filed with the SEC on or before April 30, 2026, or the Proxy Statement, and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 11.    Executive Compensation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="certain_relationships_and_related_transa"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 13.    Certain Relationships and Related Transactions, and Director Independence.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="principal_accounting_fees_and_service"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 14.    Principal Accounting Fees and Services.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibits_and_financial_statement_schedul"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 15.    Exhibits and Financial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523272430/d576843dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523272430/d576843dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (as amended and currently in effect)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.1&#165;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, dated August 10, 2021, by and among the Registrant and certain of its stockholders</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/lxeo-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 27, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525242652/d52644dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 17, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/lxeo-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 27, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523265646/d287237dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024095057/lxeo-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan, as amended from time to time and Form of Stock Option Agreement, Early Exercise Notice and Restricted Stock Purchase Agreement, and Exercise Notice</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 12, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/lxeo-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement dated, May 27, 2025, by and among the Company and the Purchasers</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 27, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525242652/d52644dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement dated, October 16, 2025, by and among the Company and the Purchaser</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 17, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523265646/d287237dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice and Restricted Stock Unit Award Notice</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523265646/d287237dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6&#165;&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024095057/lxeo-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third License Agreement, dated April 21, 2024, by and between Cornell University and the Company</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 12, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025108427/lxeo-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated May 21, 2024, to the Third License Agreement, dated April 21, 2024, by and between Cornell University and the Company</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 14, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, as amended on September 14, 2025, by and between the Company and R. Nolan Townsend</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, as amended on September 14, 2025, by and between the Company and Jose Manuel Otero</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.10</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement with Executive Officers and Directors</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.11</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2025 Inducement Equity Incentive Plan and related form documents</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, as amended on September 14, 2025, by and between the Company and Louis Tamayo</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.13</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Agreement, dated October 9, 2020, between LEXEO Therapeutics, LLC and Ronald G. Crystal, M.D.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.14*</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">&#134;</span></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Transition and Consulting Agreement, effective February 1, 2026, by and between LEXEO Therapeutics, Inc. and Eric Adler, M.D.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4, effective March 5, 2025, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, LLC and Cornell University</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3, effective April 1, 2024, to the Second License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, LLC and Cornell University</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Stock Purchase Agreement, dated July 16, 2021, by and among LEXEO Therapeutics, Inc., Stelios Therapeutics, Inc., The Cystinosis Research Foundation, Eric Adler, M.D., Farah Sheikh, Ph.D., Jeffrey M. Ostrove, Ph.D., and Stephanie Cherqui, Ph.D., and Jeffery M. Ostrove, Ph.D., as Stockholders&#8217; Representative</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, effective August 8, 2024 to the License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20*&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, effective May 28, 2025 to the License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated April 23, 2020, by and between Stelios Therapeutics, Inc. (as successor-in-interest to ARVC Therapeutics, Inc.) and The Regents of the University of California</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, effective June 4, 2025, to the License Agreement, dated August 6, 2020, by and between Stelios Therapeutics, Inc. and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23*&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement, effective November 14, 2025, by and between Lexeo Therapeutics, Inc. and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated August 6, 2020, by and between Stelios Therapeutics, Inc. and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, effective May 30, 2025, to the License Agreement, dated April 23, 2020, by and between Stelios Therapeutics, Inc. (as successor-in-interest to ARVC Therapeutics, Inc.) and The Regents of the University of California</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and The Regents of the University of California, as amended by Amendment No. 1, dated April 5, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">TNNI3 Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and The Regents of the University of California, as amended by Amendment No. 1, dated April 19, 2023</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated January 13, 2022, to the Second License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated July 4, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University and Amendment No. 2, dated July 1, 2022, to the Second License Agreement, dated May 28, 2020 (as amended by Amendment No. 1 to the Second License Agreement, dated January 13, 2022)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated September 28, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by Amendment No. 1 to the First License Agreement, dated July 4, 2022)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33&#165;&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated January 19, 2021, between Adverum Biotechnologies, Inc. and LEXEO Therapeutics, Inc., as amended by the First Amendment, dated February 28, 2022</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3, dated February 11, 2024, to the First License Agreement, dated May 28, 2020, by and between Lexeo Therapeutics, Inc. and Cornell University (as amended by Amendment No. 1 to the First License Agreement, dated July 4, 2022 and Amendment No. 2 to the First License Agreement, dated September 28, 2022)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-278566</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 9, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35&#165;&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Sponsored Research Agreement, dated April 13, 2024, by and between the Company and The Regents of University of California, San Diego</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated April 13, 2024, to the TNNI3 Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and The Regents of the University of California, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.37&#165;&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex10_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated August 31, 2023, to the ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and The Regents of the University of California, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38&#165;&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex10_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3, dated April 19, 2024, to the ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and The Regents of the University of California, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39&#165;&#134;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex10_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4, dated September 27, 2024 to the ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and The Regents of the University of California, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, dated as of March 24, 2025, by and between Lexeo Therapeutics, Inc. and Leerink Partners LLC</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.41*&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, effective December 22, 2025, to the Third License Agreement, dated April 21, 2024, by and between Lexeo Therapeutics, Inc. and Cornell University, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.42*</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Transition and Consulting Agreement, effective December 1, 2025, by and between LEXEO Therapeutics, Inc. and Jenny Robertson</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-ex14_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Code of Ethics</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading and Window Period Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of KPMG LLP, independent registered public accounting firm.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (contained in the signature page to this Annual Report on Form 10-K).</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy Relating to Recovery of Erroneously Awarded Compensation</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#165; Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit (indicated by [***]) have been omitted because the registrant has determined that the information is both not material and is the type that the Registrant treats as private or confidential.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16.    Form 10-K Summary</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has elected not to include summary information.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">145</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="height:7.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="text-indent:4.4%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p><p style="text-indent:6.507%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Nolan Townsend, Louis Tamayo and Youjin Choi as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that the attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:24.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:46.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:27%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Louis Tamayo</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Financial and Accounting Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Louis Tamayo</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mette Kirstine Agger</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mette Kirstine Agger</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Altschuler</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Altschuler, M.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Paula HJ Cholmondeley</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paula HJ Cholmondeley</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Brenda Cooperstone</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brenda Cooperstone, M.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Reinaldo Diaz</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reinaldo Diaz</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Tolga Tanguler</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tolga Tanguler</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Tim Van Hauwermeiren</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tim Van Hauwermeiren</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">146</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>lxeo-ex10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.4072+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.14</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.14</font></h1><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:10pt;margin-right:3.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><h1 style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSITION AND CONSULTING AGREEMENT</font></h1><p style="font-size:10pt;margin-top:10.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 30, 2026</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eric Adler, M.D.</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Dr. Adler:</font></p><p style="margin-left:3.333%;text-indent:7.125%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This letter sets forth the agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) between you and Lexeo Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in connection with your separation of employment from the Company, and your transition into a temporary consulting role.</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Your last day of employment with the Company will be January 31, 2026 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Regardless of whether you sign this Agreement, you will be paid at your current rate of pay, through the Separation Date, less applicable federal, state and local withholding taxes and authorized deductions (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). As of the Separation Date, you will cease holding any position or title with the Company as an employee (although you may be authorized to speak, and make representations, on behalf of the Company in your capacity as a consultant as set forth in Paragraph 2 below), and you will no longer be eligible or entitled to receive any compensation other than as expressly set forth herein.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transition Consulting Services.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:14.266%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning on February 1, 2026 and continuing through July 31, 2026, or on an earlier date if terminated by either party as provided for below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and the last day of the Consulting Period, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service End Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you will provide certain advisory services (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for the Company as a consultant, and specifically in the role of Senior Scientific Advisor, including the following:</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provide high-level scientific advisory input and guidance on the Company&#x2019;s preclinical pipeline around major milestones or at key decision points.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Offer ad hoc support for the Company&#x2019;s research collaboration with Johnson &amp; Johnson.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represent the Company at predetermined conferences and investor interactions.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You and the Company agree that the maximum number of hours per month that you will provide Services to the Company during the Consulting Period is twenty (20) hours.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation for the Services and as consideration for the promises and obligations in this Agreement, the Company will provide the following (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;): cash compensation in the total amount of $62,500, paid monthly (i.e., six payments of $10,416.67) no later than the last day of each month of the Consulting Period.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your relationship with Company during the Consulting Period will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. Except as provided herein, you will not be entitled to any of the benefits that the Company may make available to its employees, including, but not limited to, group health, life insurance, profit-sharing or retirement benefits, paid vacation, holidays or sick leave. You will not be authorized to make any representation, contract or commitment on behalf of the Company unless specifically requested or authorized in writing to do so by the Chief Executive Officer of the Company. You will be solely responsible for obtaining any business or similar licenses required by any federal, state or local authority. You acknowledge and agree that you will indemnify the Company for any tax liability associated with the Services provided during the Consulting Period under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Company&#x2019;s objectives, you will determine the method, details and means of performing the services required by this Agreement. The Company shall have no right to, and shall not, control the manner or determine the method of performing your services. You shall provide the services for which you are engaged to the reasonable satisfaction of the Company. The Company may suggest to you, from time to time, methods or strategies the Company believes may assist you in the performance of your services under this Agreement. Consistent with your independent contractor status, however, you shall exercise your independent business discretion in determining whether or not to follow the Company&#x2019;s suggestions. You may perform the services required by this Agreement at any place or location and at such times as you shall determine. You agree to provide all tools and instrumentalities, if any, required to perform the services under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Consulting Period, you will be in a &#x201c;continuous service relationship as a Service Provider&#x201d; with the Company under the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and in &#x201c;Continuous Service&#x201d; with the Company under the Company&#x2019;s 2023 Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and, together with the 2021 Plan, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such that any equity awards (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) issued pursuant to the Plans will continue to vest during the Consulting Period. Notwithstanding the foregoing, none of the Performance Share Units awarded pursuant to your February 14, 2025 compensation letter (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s&#x201d;) remaining unvested as of the date of this letter shall vest following the Separation Date. Instead, the PSUs will forfeit as of the Separation Date. The period in which to exercise any options issued pursuant to the Plans shall be extended to six (6) months following the Service End Date.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You and the Company agree that the Company&#x2019;s offer for you to continue providing services as a consultant following the Separation Date, constitutes consideration for the promises and obligations set forth in this Agreement, including but not limited to the release in paragraph 15 below.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Consulting Period, the Company shall provide you with indemnification coverage under the Company&#x2019;s D&amp;O liability insurance policies to the same extent as directors and executive officers.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term and Termination; Supplemental Release</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement is effective as of the Effective Date (as defined herein) and will continue during the Consulting Period, unless earlier terminated as provided for herein.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.13%;text-indent:13.544%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:12.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.530197141963075%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate this Agreement immediately upon written notice to you, in the event of your (i) material breach of this Agreement or the Employee Confidential Information and Inventions Assignment Agreement between you and the Company; (ii) misappropriation or attempted misappropriation of any Company funds or material Company property, or any appropriation or attempted appropriation by you of a business or corporate opportunity of the Company; (iii) engagement in misconduct that adversely affects the business or reputation of the Company; (iv) commission of a willful or intentional act which results in material injury or is reasonably likely to result in material injury to the business or reputation of the Company; (v) use of alcohol or drugs in a manner which affects your job performance; or (vi) arrest, conviction, or plea of guilty or &#x201c;no contest&#x201d; to any felony or misdemeanor involving dishonestly, theft, fraud, misrepresentation, or moral turpitude. If this Agreement is terminated by the Company pursuant to this Paragraph 3(a), you will not be required to pay any of the Consulting Compensation to the Company.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.13%;text-indent:13.544%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:12.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.530197141963075%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may terminate this Agreement upon seven (7) days written notice to the Company. If this Agreement is terminated by you, you will have no obligation to repay any portion of the Consulting Compensation that you have already received and will receive the full monthly payment for the month during which you terminate the Agreement, but you will not be entitled to receive any portion of the Consulting Compensation for any future months remaining in the Consulting Period.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.13%;text-indent:13.544%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:12.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.530197141963075%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You agree that on or within a reasonable time after the end of the Service End Date, you will execute and return to the Company a Supplemental Release (in the form attached as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hereto). As consideration for the Supplemental Release, you will receive $1,000 as a lump sum payment within thirty (30) days of your execution of the Supplemental Release.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation or Benefits. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits before or after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested stock options.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Property</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except to the extent any retention of Company property is authorized in writing by the Chief Executive Officer of the Company (in connection with your provision of the Services), you agree that, by the Service End Date, you will return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, sales and marketing information, customer lists, prospect information, pipeline reports, sales reports, personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computing and electronic devices, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof in whole or in part). You agree that you will make a diligent search to locate any such documents, property and information by the close of business on the Separation Date or as soon as possible thereafter. If you have used any personally-owned computer or other electronic device, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, by the Service End Date, you shall provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems; and you agree to provide the Company access to your system as requested to verify that the necessary copying and/or deletion is completed.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:7.052%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information Obligations. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge and reaffirm your continuing obligations under your Employee Confidential Information and Inventions Assignment Agreement, a copy of which is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:7.052%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of this Agreement will be held in strictest confidence by you and will not be publicized or disclosed by you in any manner whatsoever; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that: (a) you may disclose this Agreement in confidence to your immediate family and to your attorneys, accountants, tax preparers and financial advisors; and (b) you may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. In particular, and without limitation, you agree not to disclose the terms of this Agreement to any current or former Company employee or independent contractor, except to the extent permitted by Paragraph 9.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-disparagement. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You agree not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation; provided that you may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation. The Company agrees that it will direct its senior executives not to disparage you in any manner that may be harmful to your business or personal reputation. Nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures protected under the whistleblower provisions of federal or state law or regulation or other applicable law or regulation. You agree to revise and update publicly available information, including professional and social networking websites such as LinkedIn and Facebook, within one (1) week of the Service End Date to remove any indication that you are employed by or providing services to the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transition Communications</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company and you shall mutually agree on the substance and timing of any internal or external communications regarding your transition, including but not limited to announcements to employees, investors, partners, or the public. Neither party shall make or authorize any such communications without the prior written consent of the other party ,which shall not be unreasonably withheld or delayed. The parties shall use good faith efforts to finalize such communications promptly following the date of signature.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">References. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In response to any reference request from a prospective employer, the Company will only confirm your dates of employment and position.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Voluntary Adverse Action</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the Protected Rights section below) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the one (1) year period following the Service End Date, you agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages and attorneys&#x2019; fees) and will make reasonable efforts to accommodate your scheduling needs and in no event will you be required to provide such cooperation for more than one (1) full business day in any one (1) week period.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflict of Interest. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the term of this Agreement, you will not accept work, enter into a contract, or accept an obligation, inconsistent or incompatible with your obligations, or the scope of services rendered for the Company, under this Agreement. You warrant that, to the best of your knowledge, there is no other contract or duty on your part that conflicts with or is inconsistent with this Agreement. This paragraph does not prevent you from performing the same or similar services for clients other than the Company so long as such services do not directly or indirectly conflict with your obligations under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Admissions. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or any other person, and the Company makes no such admission.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign this Agreement. This general release includes, but is not limited to: (a) all claims arising from or in any way related to your employment with the Company or the termination of that employment; (b) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#x2019; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the New York State Human Rights Law, the New York Labor Law, the New York Wage Theft Prevention Act, Section 125 of the New York Workers&#x2019; Compensation Law, the New York City Human Rights Law, the New York City Administrative Code, the Massachusetts Fair Employment Practices Act, the Massachusetts Equal Pay Act, the Massachusetts Civil Rights Act, the Massachusetts Labor and Industries Act, the Massachusetts Right to Privacy law, and the Massachusetts Wage Act, all as amended, and any other federal, state or local statutes, regulations, ordinances prohibiting discrimination or regulating employment or the payment of wages. Notwithstanding the foregoing, you are not releasing the Company hereby from: (i) any obligation to indemnify you pursuant to the Articles and Bylaws of the Company, the Indemnification Agreement, applicable law, or applicable directors and officers liability insurance; (ii) any claims that cannot be waived by law; or (iii) any claims for breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">16.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADEA Release. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA, and that the consideration given for the waiver and releases you have given in this Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (a) your waiver and release does not apply to any rights or claims arising after the date you sign this Agreement; (b) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (c) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it sooner); (d) you have seven (7) days following the date you sign this Agreement to revoke this Agreement (in a written revocation sent to the Company, specifically to Jennifer Speer via email at jcspeer@lexeotx.com); and (e) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">17.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Protected Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the New York State Department of Labor, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Agencies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">18.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breach; Attorneys&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You acknowledge and agree that any material breach of this Agreement, unless such breach constitutes a legal action by you challenging or seeking a determination in good faith of the validity of the waiver herein under the ADEA, or its exhibits (if any) shall entitle the Company immediately to recover and/or cease providing the consideration provided to you under this Agreement and to obtain damages, except as provided by law, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company shall not recover Fifty Dollars ($50.00) of the consideration already paid pursuant to this Agreement and such amount shall serve as full and complete consideration for the promises and obligations assumed by you under this Agreement and its exhibits. In addition, except with regard to a legal action challenging or seeking a determination in good faith of the validity of the waiver herein under the ADEA, in the event that either party brings an action to enforce or effect its rights under this Agreement, the prevailing party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys&#x2019; fees incurred in connection with such an action.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">19.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You hereby represent that you have: been paid all compensation owed and for all hours worked; received all leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act and any state leave laws; and have not suffered any on-the-job injury for which you have not already filed a workers&#x2019; compensation claim.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">20.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You and the Company agree that any and all disputes, claims, or controversies of any nature whatsoever arising from, or relating to, this Agreement or its interpretation, enforcement, breach, performance or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), shall be resolved, pursuant to the Federal Arbitration Act, 9 U.S.C.&#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration in New York, New York (or another mutually acceptable location) conducted before a single neutral arbitrator by JAMS, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By agreeing to this arbitration procedure, both you and the Company waive the right to have any Claim resolved through a trial by jury or judge or an administrative proceeding. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will have the right to be represented by legal counsel at any arbitration proceeding, at your own expense. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law. The arbitrator shall have sole authority for determining if a Claim is subject to arbitration, and any other procedural questions related to the dispute and bearing on the final disposition. In addition, the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#x2019;s essential findings and conclusions on which the award is based. You and the Company shall equally share all JAMS&#x2019; arbitration fees. To the extent JAMS does not collect or you otherwise do not pay to JAMS an equal share of all JAMS&#x2019; arbitration fees for any reason, and the Company pays JAMS your share, you acknowledge and agree that the Company shall be entitled to recover from you half of the JAMS arbitration fees invoiced to the parties (less any amounts you paid to JAMS) in a federal or state court of competent jurisdiction. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">21.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement, including Exhibits A and B, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. You agree and acknowledge that this Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">22.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect the validity or enforceability of any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. Moreover, if one or more of the provisions contained in this Agreement is held to be excessively broad as to duration, scope, or subject, such provisions shall be construed by limiting or reducing them so as to be enforceable to the maximum extent compatible with applicable law.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of New York without regard to conflict of laws principles.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of any condition or breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any other condition or breach, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be executed in counterparts and electronic or facsimile signatures will suffice as original signatures.</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.306%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.306%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[signature on following page]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.343%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this Agreement is acceptable to you, please sign below and return the original to me. You have twenty-one calendar days to decide whether to accept this Agreement, and the Company&#x2019;s offer contained herein will automatically expire if you do not sign and return it within that timeframe.</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.343%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sincerely,</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:3.333%;border-spacing:0;table-layout:auto;width:39.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.256%;box-sizing:content-box;"></td>
     <td style="width:89.744%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">R. NOLAN TOWNSEND</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42.391%;box-sizing:content-box;"></td>
     <td style="width:57.609%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">I have read, understand and agree fully to the foregoing agreement:</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Eric Adler, M.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ERIC ADLER, M.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/30/2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUPPLEMENTAL RELEASE</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></h1><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIAL INFORMATION</font></h1><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND INVENTIONS ASSIGNMENT AGREEMENT</font></h1><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><h1 style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>lxeo-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3135+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.20</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:12.8%;font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20</font></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:10pt;margin-right:3.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:12.8%;font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.444%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENT No. 2</font></p><p style="margin-left:12.8%;font-size:10pt;margin-top:1.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.444%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO THE LICENSE AGREEMENT UC CONTROL No. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> BETWEEN LEXEO THERAPEUTICS AND</font></p><h1 style="margin-left:12.8%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.463%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.324%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Regents of the University of California </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#x201c;UNIVERSITY&#x201d;) represented by its San Diego campus (&#x201c;UC SAN DIEGO&#x201d;) entered into a License Agreement, UC SAN DIEGO Control Number </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;Agreement&#x201d;) effective October 4, 2021 and amended (Amendment No.1) effective August 8, 2024. The parties now wish to amend such Agreement, to be effective upon the date of last signature of this Amendment No.2 (&#x201c;Amendment Effective Date&#x201d;) to include certain modifications. These modifications are to be substituted for the relevant sections and/or paragraphs in the Agreement, and are effective from the Amendment Effective Date.</font></p><p style="font-size:10pt;margin-top:10.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For these purposes, the parties agree on the following changes as detailed below.</font></p><h1 style="font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 5. PATENT MATTERS.</font></h1><h2 style="font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delete Paragraph 5.1 in its entirety and replace it with the following:</font></h2><p style="font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font></p><div class="item-list-element-wrapper" style="margin-left:0.667%;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8929660837788047%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall be responsible for the prosecution and maintenance of any Patent Rights claiming or covering any Inventions, and UNIVERSITY shall reasonably cooperate with LICENSEE in connection with the same, including, upon the request of LICENSEE, promptly executing any and all patent applications, formal documents, assignments, or other instruments which LICENSEE deems necessary or reasonably useful for the filing, prosecution, and maintenance, of any Patent Rights claiming or covering any such Inventions, which may be filed or prepared at LICENSEE's cost and expense.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.667%;margin-top:9.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8929660837788047%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall keep UNIVERSITY reasonably informed of the prosecution of Patent Rights. LICENSEE shall provide UNIVERSITY with a copy of material communications from any patent authority regarding such Inventions, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses so that UNIVERSITY may have an opportunity to review and comment.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.667%;margin-top:10.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.731%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8929660837788047%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LICENSEE plans to abandon, cease prosecution or not maintain any patent(s) or patent application(s) in Patent Rights, then to avoid abandonment or other loss of rights, LICENSEE will provide UNIVERSITY with [***] notice of such plan and UNIVERSITY shall have the right, in UNIVERSITY's sole discretion, to file for or continue prosecution and/or maintenance of such patent or patent application at its own expense.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.667%;margin-top:9.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:11.731%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8929660837788047%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, nothing in this Amendment relieves LICENSEE from its obligation to make disclosures to UNIVERSITY.&#x201d;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.324%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for this Amendment No. 2, LICENSEE shall pay UNIVERSITY an amendment fee of [***] within </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of receipt of an invoice.</font></p><p style="font-size:10pt;margin-top:9.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.324%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All other terms and conditions in the Agreement between LICENSEE and UNIVERSITY effective October 4, 2021 shall remain unchanged and in effect.</font></p><p style="font-size:10pt;margin-top:9.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.315%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree this Amendment No. 2 may be executed electronically and in two or more counterparts each of which shall be deemed an original and all of which together shall constitute but one and the same document.</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.278%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, both UNIVERSITY and LICENSEE have executed this Agreement by their respective and duly authorized officers on the day and year written.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:79.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7.6%;box-sizing:content-box;"></td>
     <td style="width:36.7%;box-sizing:content-box;"></td>
     <td style="width:11.4%;box-sizing:content-box;"></td>
     <td style="width:7.6%;box-sizing:content-box;"></td>
     <td style="width:36.7%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">UNIVERSITY OF CALIFORNIA:</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jenny Robertson</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anthony Reza Razavi, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Signature)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Signature)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jenny Robertson</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anthony Reza Razavi, Ph.D.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Business &amp; Legal Officer</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Associate Director - Innovation and</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercialization</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/28/2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025-05-16</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>4
<FILENAME>lxeo-ex10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.4672+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.23</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1.33in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:18pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.23</font></p><p style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:14.413%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN</font></p><p style="margin-left:14.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p><p style="margin-left:16.587%;font-size:10pt;margin-top:16.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font></p><p style="margin-left:16.493%;font-size:10pt;margin-top:16.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR</font></p><p style="margin-left:36.413%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:25.898%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CASE NO. [***]</font></p><p style="margin-left:36.413%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:25.898%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CASE NO. [***]</font></p><p style="margin-left:36.413%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:25.898%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CASE NO. [***]</font></p><p style="margin-left:14.453%;font-size:10pt;margin-top:16.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Drug Development for TNNI3 Mutations&#x201d;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1.17in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:10.361%;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:14.343%;box-sizing:content-box;"></td>
     <td style="width:66.593%;box-sizing:content-box;"></td>
     <td style="width:19.064%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:98.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:18.307%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recitals</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 1:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Definitions</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 2:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 3:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 4:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reports, Records and Payments</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 5:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent Matters</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 6:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Export Control and Registration</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 7:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Termination or Expiration of Agreement</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 8:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Limited Warranty and Indemnification</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 9:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Use of Names and Trademarks</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Article 10:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Miscellaneous Provisions</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit A:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent Rights</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
    </tr>
    <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit B:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due Diligence Milestones</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
    </tr>
    <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:2.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:6.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit C:</font></p></td>
     <td style="padding-top:0in;text-indent:10.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.867%;text-indent:0;font-size:12pt;margin-top:6.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Technology</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:6.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.444%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:3.2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT</font></h1><p style="margin-left:9.827%;font-size:10pt;margin-top:13.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This agreement (&#x201c;Agreement&#x201d;) is entered into as of the date of August 6, 2020 (the &#34;Effective Date&#34;) by and between LEXEO THERAPEUTICS, INC., a Delaware corporation having an address at 345 Park Avenue South, 6</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor, New York, NY 10010 (&#x201c;LICENSEE&#x201d;) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (&#x201c;UNIVERSITY&#x201d;), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (&#x201c;UC SAN DIEGO&#x201d;).</font></p><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BACKGROUND</font></h1><div class="item-list-element-wrapper" style="margin-left:10.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7363795345500206%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The inventions disclosed in UC San Diego Disclosure Docket Nos. below (&#x201c;Inventions&#x201d;)</font></div></div>
   <table style="margin-left:10.935%;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:18.544%;box-sizing:content-box;"></td>
     <td style="width:42.008%;box-sizing:content-box;"></td>
     <td style="width:39.448%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:25.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:30.7pt;border-left:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:5.68%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Docket #</font></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:108.45pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:20.08%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:91.2pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:16.893%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventors</font></p></td>
    </tr>
    <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:18.7pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:3.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:1.013%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:18.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:3.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:18.7pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:3.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:1.013%;text-indent:0;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:18.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:3.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:18.7pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:3.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:1.013%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:18.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:3.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="text-indent:0;font-size:12pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:9.907%;text-indent:0.192%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were made in the course of research at UC San Diego by [***] (hereinafter, and collectively the &#x201c;Inventors&#x201d;), and are covered by Patent Rights as defined below.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;text-indent:0.148%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9942305558637528%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Inventor is an employee of UC San Diego, and is obligated to assign all of their rights, titles and interests in the Inventions to UNIVERSITY.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;text-indent:0.148%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9942305558637528%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research was sponsored in part by the Government of the United States of America and as a consequence this license is subject to overriding obligations to the Federal Government under 35 U.S.C. &#167;&#167; 200-212 and applicable regulations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;text-indent:0.148%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9942305558637528%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">D.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UC San Diego and Stelios Therapeutics, Inc. entered into a license agreement effective August 6, 2020 for the license of UC San Diego Disclosure Docket No. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to Stelios Therapeutics, Inc. (the &#x201c;First License&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;text-indent:0.148%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9942305558637528%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">E.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE acquired Stelios Therapeutics, Inc. on July 16, 2021, and LICENSEE became the successor in interest to Stelios Therapeutics, Inc. under the First License.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;text-indent:0.148%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9942305558637528%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">F.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE and UC San Diego subsequently amended the First License in an amendment dated June 4, 2025.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;text-indent:0.148%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9942305558637528%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">G.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE and UC San Diego now desire to enter into this Agreement to amend and restate the First License to the Patent Rights and Technology to LICENSEE for commercial development, use, and sale of the Inventions.</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree as follows:</font></p><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 1. DEFINITIONS</font></h1><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms, as defined herein, have the same meanings in both their singular and plural forms.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Affiliate&#34; means any corporation, firm, limited liability company, partnership or other entity that directly or indirectly Controls or is Controlled by or is under common control with LICENSEE. &#x201c;Control&#x201d; means (i) having the actual, present capacity to elect a majority of the directors of such entity; (ii) having the power to direct at least fifty percent (50%) of the voting rights entitled to elect directors; or (iii) in any country where the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of the maximum percentage of such outstanding stock or voting rights permitted by local law.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Commercially Reasonable Efforts&#x201d; means exerting the efforts and employing the resources that would normally and objectively be exerted or employed by a similarly situated company in its industry for a product of similar market potential, profit potential and strategic value at a similar stage of its product life, taking into account the competitiveness of the relevant marketplace, the patent, intellectual property and development positions of third parties, the applicable regulatory situation, the pricing/reimbursement situation, the commercial viability of the product and other relevant development and commercialization factors based upon then-prevailing conditions. Commercially Reasonable Efforts shall in no case involve a shelving of the development, marketing or sale of Licensed Products or a suspension of the diligent pursuit of needed governmental approval for Licensed Products for a period longer than </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Field&#x201d; means all diagnostic and therapeutic uses.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Licensed Product&#x201d; means any service, composition or product which is composed of or incorporates, or is directly or indirectly discovered, developed and/or identified using, the Technology, or that is covered by a valid claim in the Patent Rights, or the manufacture, use, sale, offer for sale, or importation of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or contributory infringement, of any pending or issued claim within the Patent Rights.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Net Sales&#x201d; means the total of the gross invoice prices of Licensed Products sold or leased by LICENSEE, Sublicensee, Affiliate, or any combination thereof, less the sum of the following actual and customary deductions where applicable and separately listed: cash, trade, or quantity discounts, credits, refunds or rebates (as allowed under applicable law); sales tax, use tax, tariff, custom and import/export duties or other excise taxes imposed on sales of Licensed Product (except for value- added and income taxes imposed on the sales of Licensed Product in foreign countries); transportation charges; and credits to customers, including allowances, charge backs or rebates actually granted because of rejections or returns. For purposes of calculating Net Sales, transfers to a Sublicensee or an Affiliate of Licensed Product under this Agreement for (a) end use (but not resale) by the Sublicensee or Affiliate shall be treated as sales by LICENSEE at list price of LICENSEE, or (b) resale by a Sublicensee or an Affiliate shall be treated as sales at the list price of the Sublicensee or Affiliate. Net Sales shall not include reasonable quantities </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Licensed Products provided without charge for charitable, promotional, pre-clinical, clinical, regulatory, or governmental purposes.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Patent Costs&#x201d; means all out-of-pocket expenses for the preparation, filing, prosecution, and maintenance of all United States and foreign patents included in Patent Rights. Patent Costs include out-of-pocket expenses for patentability opinions, inventorship determination, preparation and prosecution of patent application, re-examination, re-issue, interference, post-grant review and other administrative proceedings in patent offices, and opposition activities, and the like, related to patents or applications in Patent Rights.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Patent Rights&#x201d; means UNIVERSITY&#x2019;s rights in the claims of any of the following: (a) any patent or patent applications containing claims that cover the Inventions, (b) the U.S. patents and patent applications listed in Exhibit A; and (c) continuing applications thereof including divisions, substitutions, and continuations-in-part (but only to the extent the claims thereof are entirely supported in the specification and entitled to the priority date of the parent application); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding foreign applications or patents covered by subsections (a) through (c) above.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Sublicense&#x201d; means an agreement into which LICENSEE enters with a third party that is not an Affiliate for the purpose of (a) granting certain rights; (b) granting an option to certain rights; or</font></div></div><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) forbearing the exercise of any rights, in each case granted to LICENSEE under this Agreement. &#x201c;Sublicensee&#x201d; means a third party with whom LICENSEE enters into a Sublicense.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Sublicense Fees&#x201d; means all upfront fees, milestone payments and similar license fees received by LICENSEE from its Sublicensees in consideration for the grant of a Sublicense, but excluding:</font></div></div><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) any royalty payments; (ii) payments for [***]; (iii)[***]; and (iv) payments and reimbursement of [***]. For the purpose of the above paragraph, [***].</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Technology&#x201d; means the written nonpublic technical information, if any, relating to the Invention which the Inventors provided to LICENSEE prior to the Effective Date and which is detailed in Exhibit C.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Term&#x201d; means the period of time beginning on the Effective Date and ending on the expiration date of the longest-lived Patent Rights.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Territory&#x201d; means (a) for Technology, worldwide, to the extent UNIVERSITY may lawfully grant such Technology rights; and (b) for Patent Rights, worldwide, to the extent Patent Rights exist in a respective jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Valid Claim&#x201d; means (a) any claim of an issued and unexpired patent of Patent Rights, which has not been finally rejected, revoked, or declared invalid or unenforceable by a patent office or court of competent jurisdiction by a decision, which is unappealable or unappealed or (b) any claim of a pending patent application of Patent Rights, which claim was filed and is prosecuted in good faith with the goal of ultimately reaching allowable claims and has not been disclaimed, abandoned, or finally disallowed without the possibility of appeal or refiling of such application.</font></div></div><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 2. GRANTS</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the limitations set forth in this Agreement and to the extent that it may lawfully do so, UNIVERSITY hereby grants to LICENSEE an exclusive license under Patent </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights to make, use, sell, offer for sale, and import Licensed Products and a non-exclusive license to use Technology, in the Field within the Territory and during the Term. LICENSEE may extend such license to its AFFILIATES, provided that LICENSEE will be responsible for such AFFILIATES.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The license granted in Paragraph 2.1 includes the right of LICENSEE to grant Sublicenses to third parties during the Term but only for as long as </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:13.463%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.396535585934339%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to Sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the license grant under Sublicense</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the extent applicable, include all the rights of and obligations due to UNIVERSITY and contained in this Agreement;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promptly provide UNIVERSITY with a copy of each Sublicense issued which may be reasonably redacted; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of this Agreement for any reason, UNIVERSITY, at its sole discretion, shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all Sublicenses; provided, however, that if the Sublicensee requests an assignment, UNIVERSITY will accept such assignment of the Sublicense, provided (i) that the Sublicensee is in good standing upon termination of this Agreement; (ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and (iii) to the extent UNIVERSITY is legally able to accept such assignment. In no case, however, will UNIVERSITY be bound by duties and obligations contained in any Sublicense that extends beyond the duties and obligations of the UNIVERSITY set forth in this Agreement. For the avoidance of doubt, AFFILIATES&#x2019; rights extended by LICENSEE also terminate upon termination of this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reservation of Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> UNIVERSITY reserves the right to:</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">use the Invention, Technology, and Patent Rights for educational and research purposes;</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publish or otherwise disseminate any information about the Invention, Technology, and Patent Rights at any time; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allow other nonprofit institutions to use, publish, or otherwise disseminate any information about Invention, Technology, and Patent Rights for educational and research purposes.</font></div></div><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 3. CONSIDERATION</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fees and Royalties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this Agreement are partial consideration for the license granted herein to LICENSEE under Technology and Patent Rights. LICENSEE shall pay UNIVERSITY:</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a first license issue fee of twenty thousand dollars (US$20,000), no later than </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the Effective Date;</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A second license issue fee of twenty thousand dollars (US$20,000), within [***]following the date an itemized invoice sent from UNIVERSITY to LICENSEE.</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Paragraph 3.1(a) will survive the termination, expiration or assignment of this Agreement.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:24pt;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the following license maintenance fees per year and payable on the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Effective Date and annually thereafter on each anniversary; provided however, that (i) such maintenance fees will be creditable against earned royalties in any given payment period and (ii) LICENSEE&#x2019;s obligation to pay this fee shall end on the date when LICENSEE is commercially selling a Licensed Product</font></div></div>
   <table style="margin-left:9.602%;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:36.72%;box-sizing:content-box;"></td>
     <td style="width:63.28%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:1.25pt;border-left:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maintenance Fee</font></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anniversary</font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.056%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.046%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.046%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:0.227%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.111%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall pay UNIVERSITY the following milestone payments within </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of achievement for each time such event occurs with regard to </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]			[***]</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]			[***]</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]			[***]</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]			[***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:9.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]			[***]</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]			[***]</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Term, LICENSEE shall pay UNIVERSITY an earned royalty of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on annual Net Sales of Licensed Products by LICENSEE, Sublicensees, and/or Affiliates; provided, however, that in the event LICENSEE is required to pay royalties to one or more third parties for patent rights necessary to make, use or sell Licensed Products, LICENSEE may deduct</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the earned royalties payable to UNIVERSITY for every </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> LICENSEE actually pays to said third parties; provided, however, in no event shall the amount payable to UNIVERSITY be less than </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the amount otherwise due; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of all Sublicense Fees until </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at which time the percentage of Sublicense Fees due to UNIVERSITY shall be reduced to </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(e) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. LICENSEE shall reimburse UNIVERSITY for all past (prior to the date of the last signature of this Agreement) Patent Costs incurred in the Territory within </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> following the date an itemized invoice sent from UNIVERSITY to LICENSEE.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due Diligence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall, either directly or through its Affiliate(s) or Sublicensee(s) use Commercially Reasonable Efforts to:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diligently develop, manufacture, and sell Licensed Products; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieve the milestones described in Exhibit B.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.3(a)(i)-(ii), then UNIVERSITY shall have the right and option to either terminate this Agreement or change LICENSEE&#x2019;s exclusive license under Patent Rights to a nonexclusive license. This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2. Notwithstanding the foregoing, the deadlines for the diligence milestones set forth in Paragraph 3.3.(a) shall be extended for up to two (2) years by the proportionate length of any delay caused by an applicable regulatory authority where such delay by the applicable regulatory authority was not the result of the LICENSEE&#x2019;s actions or inactions and was not the result of LICENSEE&#x2019;s failure to abide by the applicable regulatory authority&#x2019;s instructions or LICENSEE&#x2019;s failure to provide data to the applicable regulatory authority in the form and manner required by such regulatory authority. For clarity, any extension of a diligence milestone will automatically extend each subsequent diligence milestone by the same amount of time.</font></div></div><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 4. REPORTS, RECORDS AND PAYMENTS</font></h1><div class="item-list-element-wrapper" style="margin-left:14.796%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.916482794235012%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress Reports. Beginning </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the Effective Date and within </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the end of each of LICENSEE&#x2019;s fiscal years until the first commercial sale of a Licensed Product, Licensee shall furnish UNIVERSITY with a written report on the progress of its efforts during the immediately preceding fiscal year to develop and commercialize Licensed Products. The report shall provide a discussion, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. LICENSEE&#x2019;s fiscal year begins on January 1.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each royalty report shall cover LICENSEE&#x2019;s (and each Affiliate&#x2019;s and Sublicensee&#x2019;s) most recently completed calendar year and shall show:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date of first commercial sale of a Licensed Product in each country;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.075309203129112%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of each type of Licensed Product sold;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense Fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.075309203129112%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the method used to calculate the royalties; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exchange rates used.</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If no sales of Licensed Products have been made and no Sublicense Fees have been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number: &#x201c;License Agreement between UC SAN DIEGO and STELIOS for case [***].&#x201d; Reports shall be submitted as an attachment to UC SAN DIEGO&#x2019;s email address: [***].</font></p><div class="item-list-element-wrapper" style="margin-left:14.796%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.916482794235012%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Records &amp; Audits.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products manufactured, used, sold, offered for sale, and imported and Sublicensee Fees received under this Agreement. Such records shall be retained by LICENSEE for at least </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following a given reporting period.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY&#x2019;s Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments or other compliance issues. Such inspector shall be subject to a confidentiality agreement with LICENSEE and such inspector shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an under reporting and underpayment in excess of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per year. Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE. For underpayment not in excess of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, LICENSEE shall pay the difference within </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> without interest charge or inspection cost.</font></div></div><div class="item-list-element-wrapper" style="margin-left:14.796%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.916482794235012%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All fees, reimbursements and royalties due UNIVERSITY shall be paid in United States dollars and all checks (should payment by wire not be possible) shall be made payable to </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and sent to UNIVERSITY according to Paragraph 10.1 (Correspondence).</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalties shall accrue when </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. LICENSEE shall pay earned royalties annually on or before February 28 of each calendar year. Each such payment shall be for earned royalties accrued within LICENSEE&#x2019;s most recently completed calendar year.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Late Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such interest shall be calculated from </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Taxes imposed by any governmental agency on any payments to be made to UNIVERSITY by LICENSEE hereunder shall be paid by LICENSEE without deduction from any payment due to UNIVERSITY hereunder.</font></div></div><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 5. PATENT MATTERS</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Prosecution and Maintenance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall be responsible for the prosecution and maintenance of any Patent Rights claiming or covering any Inventions, and UNIVERSITY shall reasonably cooperate with LICENSEE in connection with the same, including, upon the request of LICENSEE, promptly executing any and all patent applications, formal documents, assignments, or other instruments which LICENSEE deems necessary or reasonably useful for the filing, prosecution, and maintenance, of any Patent Rights claiming or covering any such Inventions, which may be filed or prepared at LICENSEE's cost and expense.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall keep UNIVERSITY reasonably informed of the prosecution of Patent Rights. LICENSEE shall provide UNIVERSITY with a copy of material communications from any patent authority regarding such Inventions, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses so that UNIVERSITY may have an opportunity to review and comment.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LICENSEE plans to abandon, cease prosecution or not maintain any patent(s) or patent application(s) in Patent Rights, then to avoid abandonment or other loss of rights, LICENSEE will provide UNIVERSITY with at least thirty (30) days' notice of such plan and UNIVERSITY shall have the right, in UNIVERSITY's sole discretion, to file for or continue prosecution and/or maintenance of such patent or patent application at its own expense.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Infringement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If UC SAN DIEGO (based on actual knowledge of the licensing professional responsible for administering this Invention) or LICENSEE learns of potential infringement of commercial significance of any patent licensed under this Agreement, the knowledgeable party promptly will inform the other party of the infringement and provide evidence of infringement available to the knowledgeable party (&#x201c;Infringement Notice&#x201d;). In a jurisdiction where LICENSEE has exclusive rights under this Agreement, neither UNIVERSITY nor LICENSEE will notify a third party (including the infringer) of infringement or put such third party on notice of the existence of any Patent Rights without first obtaining consent of the other. UNIVERSITY and LICENSEE agree to</font></div></div><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discuss and determine how best to proceed. If LICENSE notifies a third party of infringement or puts such third party on notice of the existence of any Patent Rights regarding such infringement without first obtaining the written consent of UNIVERSITY and UNIVERSITY is sued for declaratory judgment (or its equivalent), UNIVERSITY will have the right to terminate this Agreement immediately, notwithstanding Paragraph 7.1. UNIVERSITY and LICENSEE will use diligent efforts to cooperate with each other to terminate such infringement without litigation. Subject to statutory deadlines, if such infringement has not ended within [***] of the effective date of the Infringement Notice, then LICENSEE may initiate suit (or earlier depending on an applicable statutory deadline to file); and, if such infringement has not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ended within [***] of the effective date of the Infringement Notice, and LICENSEE has not initiated suit, then UNIVERSITY may initiate suit.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing: (1) UNIVERSITY may not be joined in any suit without its prior written consent; (2) LICENSEE may not admit liability or wrongdoing on behalf of UNIVERSITY without its prior written consent; (3) Each party will cooperate with the other in litigation initiated under Paragraph 5.2, but at the expense of the party who initiated the suit; (4) If UNIVERSITY is joined in any suit under Paragraph 5.2, LICENSEE will pay all of UNIVERSITY&#x2019;s costs; (5) If UNIVERSITY is a party to a suit under Paragraph 5.2, then the recovery to UNIVERSITY will be </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of net recoveries;</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any agreement made by LICENSEE for purposes of settling litigation or other dispute regarding Patent Rights will comply with the requirements of Paragraph 2.2 (Sublicense); and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LICENSEE or UC SAN DIEGO (but not both) sues a third party for infringement of Patent Rights, then the non-suing party may not thereafter sue such infringer for the acts of infringement raised in the suit.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Marking</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall mark all Licensed Products made, used, sold, offered for sale, or imported under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. LICENSEE shall be responsible for all monetary and legal liabilities arising from or caused by (a) failure to abide by applicable patent marking laws and (b) any type of incorrect or improper patent marking.</font></p><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 6. EXPORT CONTROL AND REGISTRATION</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Export Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of Licensed Products, Technology, and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Approval or Registration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preference for United States Industry. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LICENSEE sells a Licensed Product or Combination Product in the US, LICENSEE shall manufacture said product substantially in the US.</font></div></div><h1 style="margin-left:3.547%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 7. TERMINATION OR EXPIRATION OF THE AGREEMENT</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by UNIVERSITY.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNIVERSITY may terminate this Agreement if LICENSEE:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is delinquent on any report or payment;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is not diligently developing and commercializing Licensed Product in accordance with obligations under Section 3.3;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">misses a milestone described in Exhibit B, subject to the provisions of Section 3.3(b);</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is in breach of any provision;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provides any intentionally false report; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">files a claim including in any way the assertion that any portion of UNIVERSITY&#x2019;s Patent Rights is invalid or unenforceable.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination under this Paragraph 7.1 will take effect </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after written notice by UNIVERSITY unless LICENSEE remedies the problem in that </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by LICENSEE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall have the right at any time and for any reason to terminate this Agreement in whole or on a Licensed Product-by-Licensed Product, country-by-country basis, upon </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> written notice to UNIVERSITY. Said notice shall state LICENSEE&#x2019;s reason for terminating this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival on Termination or Expiration. The rights and obligations under Paragraphs and Articles 3.1(a) (license issue fee), 4 (Reports, Records and Payments), 8 (Limited Warranty and Indemnification), 9 (Use of Names and Trademarks), 10.2 (Secrecy), 10.3 (Assignability), and 10.5 (Failure to Perform) shall survive the termination or expiration of this Agreement.</font></div></div><h1 style="margin-left:5.72%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Warranty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The license granted herein and the associated Technology are provided &#x201c;AS IS&#x201d; and without WARRANTY  OF  MERCHANTABILITY  or  WARRANTY  OF  FITNESS  FOR  A </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:9.867%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PARTICULAR</font></p><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product or the use of Patent Rights or Technology will not infringe any other patent or other proprietary rights.</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNIVERSITY WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT OR MISAPPROPRIATION OF TECHNOLOGY, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY&#x2019;S INVENTORS TO THIRD PARTIES.</font></p><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in this Agreement shall be construed as:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a warranty or representation by UNIVERSITY as to the validity, enforceability, or scope of any Patent Rights or Technology;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an obligation to bring or prosecute actions or suits against third parties for patent infringement or misappropriation of Technology except as provided in Paragraph 5.2 hereof;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights, or any technology other than Technology, regardless of whether those patents are dominant or subordinate to Patent Rights;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an obligation to furnish any know-how not provided in Patent Rights and Technology; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.1901150690174873%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an obligation to update or provide assistance regarding Technology.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend UNIVERSITY and its officers, employees, and agents; the sponsors of the research that led to the Invention and Technology; and the creators of Technology and inventors of patents or patent applications under Patent Rights, and their employers (collectively, the &#x201c;Indemnitees&#x201d;); against any and all claims, suits, losses, damages, costs, fees, and expenses brought by third parties against such Indemnitees to the extent resulting from, or arising out of Licensee&#x2019;s exercise of this license or any Sublicense. This indemnification will include, but will not be limited to, any product liability. Notwithstanding the foregoing, Licensee shall not be required to indemnify any Indemnitee to the extent such claim is due to the gross negligence or willful misconduct of an Indemnitee in with the exercise of this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article. LICENSEE will not settle any claim against UNIVERSITY without UNIVERSITY&#x2019;s written consent, where (a) such settlement would include any admission of liability or wrongdoing on the part of UNIVERSITY or other indemnified party, (b) such settlement would impose any restriction on UNIVERSITY/indemnified party&#x2019;s conduct of any of its activities, or (c) such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims that are the subject matter of the settled claim.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance as follows:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercial general liability insurance (contractual liability included) with limits of at least: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.315%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the above insurance is written on a claims-made form, it shall continue for [***] following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date;</font></p><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Worker&#x2019;s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the coverage and limits referred to above shall not in any way limit the liability of LICENSEE.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall furnish UNIVERSITY with certificates of insurance showing compliance with all requirements. Such certificates shall: (i) provide for </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY has been endorsed as an additional insured party under the coverage referred to above; and (iii) include a provision that the coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried or maintained by UNIVERSITY.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.296%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 9. USE OF NAMES AND TRADEMARKS</font></h1><p style="margin-left:10.08%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of UNIVERSITY by LICENSEE without prior written approval by UNIVERSITY (including contraction, abbreviation or simulation of any of the foregoing). LICENSEE hereby grants permission for UNIVERSITY (including UC SAN DIEGO) to include LICENSEE&#x2019;s name and a link to LICENSEE&#x2019;s website in UNIVERSITY&#x2019;s and UC SAN DIEGO&#x2019;s annual reports and on UNIVERSITY&#x2019;s (including UC SAN DIEGO&#x2019;s) websites that showcase innovation and commercialization stories.</font></p><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 10. MISCELLANEOUS PROVISIONS</font></h1><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Correspondence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notice or payment required to be given to either party under this Agreement shall be deemed to have been properly given and effective: (a) on the date of delivery if delivered in person, (b) five (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party, or (c) upon confirmation by recognized national overnight courier, confirmed facsimile transmission, or confirmed electronic mail, to the following addresses or facsimile numbers of the parties.</font></div></div><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If sent to LICENSEE:</font></p><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:9.87%;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:12.36%;box-sizing:content-box;"></td>
     <td style="width:31.461%;box-sizing:content-box;"></td>
     <td style="width:5.618%;box-sizing:content-box;"></td>
     <td style="width:3.371%;box-sizing:content-box;"></td>
     <td style="width:47.191%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;text-indent:36pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Invoices only:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If to LICENSEE (other notices):</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If sent to UNIVERSITY by mail:</font></p><p style="margin-left:9.827%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:31.769%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:31.769%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If sent to UNIVERSITY by overnight delivery:</font></p><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:31.769%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secrecy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Confidential Information&#x201d; shall mean information relating to the Invention and disclosed by UNIVERSITY to LICENSEE during the Term, which if disclosed in writing shall be marked &#x201c;Confidential&#x201d;, or if first disclosed otherwise, shall within </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE. The Technology will be deemed to be Confidential Information.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE shall:</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">use the Confidential Information for the sole purpose of performing under the terms of this Agreement;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its own data of a similar nature;</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not disclose Confidential Information to others (except to its employees, agents or consultants who are bound to LICENSEE by a like obligation of confidentiality) without </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:16.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.9122245785557677%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the express written permission of UNIVERSITY, except that LICENSEE shall not be prevented from using or disclosing any of the Confidential Information that:</font></div></div><div class="item-list-element-wrapper" style="margin-left:23.204%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.203396010208865%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(A)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSEE can demonstrate by written records was previously known to it;</font></div></div><div class="item-list-element-wrapper" style="margin-left:23.204%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.203396010208865%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(B)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is now, or becomes in the future, public knowledge  other than through acts or omissions of LICENSEE;</font></div></div><div class="item-list-element-wrapper" style="margin-left:23.204%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.203396010208865%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(C)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is lawfully obtained by LICENSEE from sources independent of UNIVERSITY; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:23.204%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.203396010208865%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(D)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is required to be disclosed by law or a court of competent jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The secrecy obligations of LICENSEE with respect to Confidential Information shall continue for a period ending </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the termination date of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.87%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.138466659269944%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, UNIVERSITY may disclose to the Inventors, senior administrators employed by UNIVERSITY, and individual Regents the terms and conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the individuals not disclose such terms and conditions to others. UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the negotiable financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so, such as under the California Public Records Act.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignability. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE only with the written consent of UNIVERSITY; provided however that LICENSEE may assign this Agreement without the written consent of University to (i) an Affiliate of LICENSEE or (ii) an acquirer of all or substantially all of the business (whether structured as a merger, asset sale, exclusive license or otherwise) to which this Agreement relates as long as (a) such acquirer agrees to assume all the terms and conditions of this Agreement and (b) solely with respect to the first assignment of this Agreement, within </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of such assignment, LICENSEE or such acquirer shall pay UNIVERSITY an assignment fee equal to the greater of (x) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or (y) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No waiver by either party of any breach or default of any agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to Perform</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of a failure of performance due under this Agreement and if it becomes necessary for either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorneys&#x2019; fees in addition to costs and necessary disbursements.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, </font></div></div><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but the scope and</font></p><p style="margin-left:9.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application.</font></p><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A party to this Agreement may be excused from any performance required herein if such performance is rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party&#x2019;s obligations herein shall resume.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement, including Exhibits A and B, embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and signed on behalf of each party.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.731%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.286078277149409%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in one or more counterparts, each of which together will constitute one and the same Agreement. For purposes of executing this Agreement, a facsimile (including a PDF image delivered via email) copy of this Agreement, including the signature pages, will be deemed an original. The parties agree that neither party will have any rights to challenge the use or authenticity of a counterpart of this Agreement based solely on that its signature, or the signature of the other party, on such counterpart is not an original signature.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:16.493%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(signature page follows)</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:3.333%;font-size:10pt;margin-top:13.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, both UNIVERSITY and LICENSEE have executed this Agreement by their respective and duly authorized officers on the day and year written</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:13.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:13.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:13.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:9.87%;border-spacing:0;table-layout:auto;width:63.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:9.524%;box-sizing:content-box;"></td>
     <td style="width:49.206%;box-sizing:content-box;"></td>
     <td style="width:41.27%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.:</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025-11-14</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anthony Reza Razavi, Ph.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anthony Reza Razavi, Ph.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" rowspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Associate Director - Innovation and</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercialization</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025-11-14</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:3.333%;font-size:10pt;margin-top:13.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:40.707%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A &#x2013; Patent Rights</font></p><p style="margin-left:40.707%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:35.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B &#x2013; Due Diligence Milestones</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:16.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.769%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C &#x2013; Technology</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.33in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>5
<FILENAME>lxeo-ex10_41.htm
<DESCRIPTION>EX-10.41
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3293+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.41</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.36in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.315%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.41</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img47974566_0.jpg" alt="img47974566_0.jpg" style="width:419px;height:73px;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">          </font><img src="img47974566_1.jpg" alt="img47974566_1.jpg" style="width:189px;height:87px;"></p><p style="margin-left:71.347%;font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Center for Technology Licensing</font></p><p style="margin-left:71.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.389%;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1155 York Avenue New York, NY 10065 P: 646.962.7045</font></p><p style="margin-left:71.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">innovation.weill.cornell.edu</font></font></p><p style="font-size:10pt;margin-top:10.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weill Cornell Medicine Enterprise Innovation</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.315%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 17, 2025</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><h1 style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><h1 style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RE:  SECOND AMENDMENT</font></h1><p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the THIRD LICENSE AGREEMENT by and between Lexeo Therapeutics, Inc. (hereinafter &#x201c;Licensee&#x201d;) and Cornell University (&#x201c;Cornell&#x201d;) (each a &#x201c;Party&#x201d;) effective April 21, 2024, and amended a first time effective May 24, 2024 (the &#x201c;Third License Agreement&#x201d;) (CTL Contract No. [***])</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:13.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective the date of the last signature hereto (&#x201c;Second Amendment Date&#x201d;), the Parties agree to hereby modify the Third License Agreement as follows:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:13.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.480681101099652%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Paragraph 3.1 is hereby deleted and replaced with the following:</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x201c;3.1 (a) (i) a license issue fee of [***], and (ii) an initial data transfer fee of [***], each paid in cash within [***] of the Effective Date; and (iii) for the data [***] as described in Appendix B, an additional one-time data transfer fee of [***], due within [***] of the Second Amendment Date, and (iv) an annual data transfer fee of [***] paid [***] of the Effective Date until [***].&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:13.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.480681101099652%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lead paragraph in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix B: Data and Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is hereby deleted and replaced with the following:</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:13.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:2.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.480681101099652%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These changes do not otherwise change the terms and conditions of the Third License Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.36in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:13.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:2.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.480681101099652%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Second Amendment may be executed by electronic signatures or by facsimile and in two (2) or more counterparts, each of which shall be deemed an original and all of which together shall constitute but one and the same instrument.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, both Cornell and Licensee have executed this Second Amendment by their respective and duly authorized officers on the day and year written.</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:79.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7.6%;box-sizing:content-box;"></td>
     <td style="width:36.7%;box-sizing:content-box;"></td>
     <td style="width:11.4%;box-sizing:content-box;"></td>
     <td style="width:7.6%;box-sizing:content-box;"></td>
     <td style="width:36.7%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CORNELL UNIVERSITY</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lisa Placanica</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Signature of Authorized Officer]</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Signature of Authorized Officer]</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Placanica</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Managing Director</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/19/2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/22/2025</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>6
<FILENAME>lxeo-ex10_42.htm
<DESCRIPTION>EX-10.42
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.8987+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.42</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></h1><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:10pt;margin-right:3.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><h1 style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSITION AND CONSULTING AGREEMENT</font></h1><p style="font-size:10pt;margin-top:10.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 1, 2025</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jenny R. Robertson</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Jenny:</font></p><p style="margin-left:3.333%;text-indent:7.125%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This letter sets forth the agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) between you and Lexeo Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in connection with your separation of employment from the Company, and your transition into a temporary consulting role.</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Your last day of employment with the Company will be December 31, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Regardless of whether you sign this Agreement, you will be paid at your current rate of pay, through the Separation Date, less applicable federal, state and local withholding taxes and authorized deductions (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). As of the Separation Date, you will cease holding any position or title with the Company as an employee (although you may be authorized to speak, and make representations, on behalf of the Company in your capacity as a consultant as set forth in Paragraph 2 below), and you will no longer be eligible or entitled to receive any compensation other than as expressly set forth herein. The Company acknowledges that there is a Company holiday starting December 22 through December 31, 2025, and that you will be paid through December 31, 2025.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transition Consulting Services.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:14.266%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning on January 1, 2026 and continuing through March 31, 2026, or on an earlier date if terminated by either party as provided for below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and the last day of the Consulting Period, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service End Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you will provide advisory and ad hoc legal counseling services (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for the Company as a consultant.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation for the Services and as consideration for the promises and obligations in this Agreement, the Company will provide the following (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:20.115%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.204%;min-width:18.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.244809500656895%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum payment in the amount of $229,800, to be paid on or before January 5, 2026 (representing six months&#x2019; salary);</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:18.759%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:18.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.245512946507081%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">ii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum payment of your annual bonus for 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as determined by Compensation Committee-approved annual company performance, to be paid in accordance with the annual compensation review process for executives; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:18.207%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:17.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.790683480401792%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">iii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are currently participating in the Company&#x2019;s group health insurance plans, subject to your eligibility for and election of COBRA continuation coverage, the Company shall pay on your behalf the full amount of the premiums to continue the health insurance you had prior to the Separation Date for you (and your eligible dependents, if applicable) through June 30, 2026.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your relationship with Company during the Consulting Period will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. Except as provided herein, you will not be entitled to any of the benefits that the Company may make available to its employees, including, but not limited to, group health, life insurance, profit-sharing or retirement benefits, paid vacation, holidays or sick leave. You will not be authorized to make any representation, contract or commitment on behalf of the Company unless specifically requested or authorized in writing to do so by the Chief Executive Officer of the Company. You will be solely responsible for obtaining any business or similar licenses required by any federal, state or local authority. You acknowledge and agree that you will indemnify the Company for any tax liability associated with the Services provided during the Consulting Period under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Company&#x2019;s objectives, you will determine the method, details and means of performing the services required by this Agreement. The Company shall have no right to, and shall not, control the manner or determine the method of performing your services. You shall provide the services for which you are engaged to the reasonable satisfaction of the Company. The Company may suggest to you, from time to time, methods or strategies the Company believes may assist you in the performance of your services under this Agreement. Consistent with your independent contractor status, however, you shall exercise your independent business discretion in determining whether or not to follow the Company&#x2019;s suggestions. You may perform the services required by this Agreement at any place or location and at such times as you shall determine. You agree to provide all tools and instrumentalities, if any, required to perform the services under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Consulting Period, you will be in a &#x201c;continuous service relationship as a Service Provider&#x201d; with the Company under the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).and in &#x201c;Continuous Service&#x201d; with the Company under the Company&#x2019;s 2023 Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and, together with the 2021 Plan, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such that any equity awards (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) issued pursuant to the Plans will continue to vest during the Consulting Period. The period in which to exercise any options issued pursuant to the Plans shall be extended to twelve (12) months following the Service End Date. So long as you do not terminate the Consulting Period prior to March 31, 2026, an additional portion of the Equity Awards that would have vested as of September 1, 2026 had you remained in a &#x201c;continuous service relationship as a Service Provider&#x201d; or in &#x201c;Continuous Service&#x201d; through such date shall vest as of the Service End Date.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You and the Company agree that the Company&#x2019;s offer for you to continue providing services as a consultant following the Separation Date, constitutes consideration for the promises and obligations set forth in this Agreement, including but not limited to the release in paragraph 14 below.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If within the ninety (90) day period before the Service End Date the Company enters into a definitive agreement which results in a Change in Control (as that term is defined in the 2023 Plan) and such Change in Control actually occurs, whether the Change in Control occurs before or after the Service End Date, you will also be entitled to the severance benefits set forth in, and according to the terms of, Section 5.5 of the employment agreement between you and the Company dated September 28, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), namely: (a) a lump sum payment equal to $459,600 (representing 12 months&#x2019; of your base salary as of the Separation Date), (b) payment of COBRA premiums for continued health coverage for you (and your eligible dependents, if applicable) for 12 months following the Separation Date, (c) a lump sum payment equal to $183,840 (representing a bonus for calendar year 2026), and (d) acceleration of any options, shares, or other equity grants outstanding and unvested as of the date of the Change in Control.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Consulting Period the Company shall provide you with indemnification coverage under the Company&#x2019;s D&amp;O liability insurance policies to the same extent as directors and executive officers, and you shall be considered an &#x201c;agent and in &#x201c;Corporate Status&#x201d; for purposes of the indemnification agreement between the Company and you dated November 7, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term and Termination; Supplemental Release</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement is effective as of the Effective Date (as defined herein) and will continue during the Consulting Period, unless earlier terminated as provided for herein.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.13%;text-indent:13.544%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:12.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.530197141963075%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate this Agreement immediately upon written notice to you, in the event of your (i) material breach of this Agreement or the Employee Confidential Information and Inventions Assignment Agreement between you and the Company; (ii) misappropriation or attempted misappropriation of any Company funds or material Company property, or any appropriation or attempted appropriation by you of a business or corporate opportunity of the Company; (iii) engagement in misconduct that adversely affects the business or reputation of the Company; (iv) commission of a willful or intentional act which results in material injury or is reasonably likely to result in material injury to the business or reputation of the Company; (v) use of alcohol or drugs in a manner which affects your job performance; or (vi) arrest, conviction, or plea of guilty or &#x201c;no contest&#x201d; to any felony or misdemeanor involving dishonestly, theft, fraud, misrepresentation, or moral turpitude. If this Agreement is terminated by the Company pursuant to this Paragraph 3(a), you will not be required to repay any of the Consulting Compensation to the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.13%;text-indent:13.544%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:12.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.530197141963075%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may terminate this Agreement upon seven (7) days written notice to the Company. If this Agreement is terminated by you, you are only entitled to retain a portion of the Consulting Compensation representing the actual portion of the Consulting Period during which you provided Services to the Company and must, within thirty (30) days of the date you provide written notice to the Company, repay the remaining pro-rated portion of the Consulting Compensation to the Company, provided, however, that for purposes of this Paragraph 3(b) Consulting Compensation shall not include the 2025 Bonus.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.13%;text-indent:13.544%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:12.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.530197141963075%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You agree that on or within a reasonable time after the end of the Service End Date, you will execute and return to the Company a Supplemental Release (in the form attached as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hereto). As consideration for the Supplemental Release, you will receive $1,000 as a lump sum payment within thirty (30) days of your execution of the Supplemental Release.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation or Benefits. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits before or after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested equity awards.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Property</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except to the extent any retention of Company property is authorized in writing by the Chief Executive Officer of the Company (in connection with your provision of the Services), you agree that, by the Service End Date, you will return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, sales and marketing information, customer lists, prospect information, pipeline reports, sales reports, personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computing and electronic devices, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof in whole or in part). You agree that you will make a diligent search to locate any such documents, property and information by the close of business on the Separation Date or as soon as possible thereafter. If you have used any personally-owned computer or other electronic device, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, by the Service End Date, you shall provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems; and you agree to provide the Company access to your system as requested to verify that the necessary copying and/or deletion is completed.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You acknowledge and reaffirm your continuing obligations under your Employee Confidential Information and Inventions Assignment Agreement, a copy of which is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of this Agreement will be held in strictest confidence by you and will not be publicized or disclosed by you in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement in confidence to your immediate family and to your attorneys, accountants, tax preparers and financial advisors; and (b) you may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. In particular, and without limitation, you agree not to disclose the terms of this Agreement to any current or former Company employee or independent contractor, except to the extent permitted by Paragraph 9.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-disparagement. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You agree not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation; provided that you may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation. The Company agrees that it will direct its senior executives not to disparage you in any manner that may be harmful to your business or personal reputation. Nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures protected under the whistleblower provisions of federal or state law or regulation or other applicable law or regulation. You agree to revise and update publicly available information, including professional and social networking websites such as LinkedIn and Facebook, within one (1) week of the Service End Date to remove any indication that you are employed by or providing services to the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transition Communications</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company and you shall mutually agree on the substance and timing of any internal or external communications regarding your transition, including but not limited to announcements to employees, investors, partners, or the public. Neither party shall make or authorize any such communications without the prior written consent of the other party ,which shall not be unreasonably withheld or delayed. The parties shall use good faith efforts to finalize such communications within five (5) business days following the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">References. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In response to any reference request from a prospective employer, the Company will only confirm your dates of employment and position. The Company and you will agree upon the content of a reference letter to be signed by the Chief Executive Officer for use with any prospective employers.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Voluntary Adverse Action</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the Protected Rights section below) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the one (1) year period following the Service End Date, you agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages and attorneys&#x2019; fees) and will make reasonable efforts to accommodate your scheduling needs and in no event will you be required to provide such cooperation for more than one (1) full business day in any one (1) week period.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflict of Interest. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the term of this Agreement, you will not accept work, enter into a contract, or accept an obligation, inconsistent or incompatible with your obligations, or the scope of services rendered for the Company, under this Agreement. You warrant that, to the best of your knowledge, there is no other contract or duty on your part that conflicts with or is inconsistent with this Agreement. This paragraph does not prevent you from performing the same or similar services for clients other than the Company so long as such services do not directly or indirectly conflict with your obligations under this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Admissions. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or any other person, and the Company makes no such admission.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign this Agreement. This general release includes, but is not limited to: (a) all claims arising from or in any way related to your employment with the Company or the termination of that employment; (b) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#x2019; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the New York State Human Rights Law, the New York Labor Law, the New York Wage Theft Prevention Act, Section 125 of the New York Workers&#x2019; Compensation Law, the New York City Human Rights Law, the New York City Administrative Code, the Massachusetts Fair Employment Practices Act, the Massachusetts Equal Pay Act, the Massachusetts Civil Rights Act, the Massachusetts Labor and Industries Act, the Massachusetts Right to Privacy law, and the Massachusetts Wage Act, all as amended, and any other federal, state or local statutes, regulations, ordinances prohibiting discrimination or regulating employment or the payment of wages. Notwithstanding the foregoing, you are not releasing the Company hereby from: (i) any obligation to indemnify you pursuant to the Articles and Bylaws of the Company, the Indemnification Agreement, applicable law, or applicable directors and officers liability insurance; (ii) any claims that cannot be waived by law; or (iii) any claims for breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">16.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADEA Release. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA, and that the consideration given for the waiver and releases you have given in this Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (a) your waiver and release does not apply to any rights or claims arising after the date you sign this Agreement; (b) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (c) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it sooner); (d) you have seven (7) days following the date you sign this Agreement to revoke this Agreement (in a written revocation sent to the Company, specifically to Jennifer Speer via email at jcspeer@lexeotx.com); and (e) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">17.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Protected Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the New York State Department of Labor, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Agencies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">18.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breach; Attorneys&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You acknowledge and agree that any material breach of this Agreement, unless such breach constitutes a legal action by you challenging or seeking a determination in good faith of the validity of the waiver herein under the ADEA, or its exhibits (if any) shall entitle the Company immediately to recover and/or cease providing the consideration provided to you under this Agreement and to obtain damages, except as provided by law, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company shall not recover Fifty Dollars ($50.00) of the consideration already paid pursuant to this Agreement and such amount shall serve as full and complete consideration for the promises and obligations assumed by you under this Agreement and its exhibits. In addition, except with regard to a legal action challenging or seeking a determination in good faith of the validity of the waiver herein under the ADEA, in the event that either party brings an action to enforce or effect its rights under this Agreement, the prevailing party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys&#x2019; fees incurred in connection with such an action.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">19.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You hereby represent that you have: been paid all compensation owed and for all hours worked; received all leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, the New York Paid Family Leave Law, the Massachusetts Parental Leave Law, or otherwise; and have not suffered any on-the-job injury for which you have not already filed a workers&#x2019; compensation claim.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">20.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You and the Company agree that any and all disputes, claims, or controversies of any nature whatsoever arising from, or relating to, this Agreement or its interpretation, enforcement, breach, performance or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), shall be resolved, pursuant to the Federal Arbitration Act, 9 U.S.C.&#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration in New York, New York (or another mutually acceptable location) conducted before a single neutral arbitrator by JAMS, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-</font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employment-arbitration/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By agreeing to this arbitration procedure, both you and the Company waive the right to have any Claim resolved through a trial by jury or judge or an administrative proceeding. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will have the right to be represented by legal counsel at any arbitration proceeding, at your own expense. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law. The arbitrator shall have sole authority for determining if a Claim is subject to arbitration, and any other procedural questions related to the dispute and bearing on the final disposition. In addition, the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#x2019;s essential findings and conclusions on which the award is based. You and the Company shall equally share all JAMS&#x2019; arbitration fees. To the extent JAMS does not collect or you otherwise do not pay to JAMS an equal share of all JAMS&#x2019; arbitration fees for any reason, and the Company pays JAMS your share, you acknowledge and agree that the Company shall be entitled to recover from you half of the JAMS arbitration fees invoiced to the parties (less any amounts you paid to JAMS) in a federal or state court of competent jurisdiction. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7241250892238305%;">21.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement, including Exhibits A and B, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. You agree and acknowledge that this Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.407777777777778%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">22.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect the validity or enforceability of any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. Moreover, if one or more of the provisions contained in this Agreement is held to be excessively broad as to duration, scope, or subject, such provisions shall be construed by limiting or reducing them so as to be enforceable to the maximum extent compatible with applicable law.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of New York without regard to conflict of laws principles.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of any condition or breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any other condition or breach, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.517580973858711%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be executed in counterparts and electronic or facsimile signatures will suffice as original signatures.</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.343%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this Agreement is acceptable to you, please sign below and return the original to me. You have twenty-one calendar days to decide whether to accept this Agreement, and the Company&#x2019;s offer contained herein will automatically expire if you do not sign and return it within that timeframe.</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sincerely,</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:3.333%;border-spacing:0;table-layout:auto;width:39.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.256%;box-sizing:content-box;"></td>
     <td style="width:89.744%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">R. NOLAN TOWNSEND</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42.391%;box-sizing:content-box;"></td>
     <td style="width:57.609%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">I have read, understand and agree fully to the foregoing agreement:</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jenny R. Robertson</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">JENNY R. ROBERTSON</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/2/2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUPPLEMENTAL RELEASE</font></h1><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></h1><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIAL INFORMATION</font></h1><h1 style="margin-left:0.013%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND INVENTIONS ASSIGNMENT AGREEMENT</font></h1><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><h1 style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>lxeo-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3213+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:34%;box-sizing:content-box;"></td>
     <td style="width:66%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img238985936_0.jpg" alt="img238985936_0.jpg" style="width:93px;height:38px;"></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345 Park Avenue</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, NY 10154-0102</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-275374, 333-277816, 333-286040, and 333-291268) on Form S-8 and (No. 333-283781, 333-288025 and 333-291269) on Form S-3 of our report dated March 30, 2026, with respect to the financial statements of Lexeo Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 30, 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG LLP, a Delaware limited liability partnership and a member firm of</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the KPMG global organization of independent member firms affiliated with</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG International Limited, a private English company limited by guarantee.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>lxeo-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3316+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, R. Nolan Townsend certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lexeo Therapeutics, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 30, 2026</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer (Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>lxeo-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3164+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Louis Tamayo certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lexeo Therapeutics, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are  responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 30, 2026</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Louis Tamayo</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: Louis Tamayo</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>lxeo-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3088+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Lexeo Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 30, 2026</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer (Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>lxeo-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T15:16:34.3141+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Lexeo Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 30, 2026</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Louis Tamayo</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Louis Tamayo</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img47974566_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img47974566_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( 9D# 2(  A$! Q$!_\0
M'0   00# 0$             !@ %!P@! P0) O_$ %40  $# P($ @<#! P*
M" <   $" P0%!A$ !P@2(3$300D4(E%A<8$5,I$6([&R%R4S.$)28G)S@J&S
M&"0H0W1U=I*3HB8U-E24P<+1)S0W5V6#XO_$ !L!  $% 0$
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M/O/341BM;7+XP$L)M>X1<)NGE]=^U$>K>L>+CG\/&>3/7ESJ)>! *2-ZL6W
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M2ZW+C(/[NV"#E*2%%)QT(ZU!@:3O7:K)?>1<HPD@"?<&?*<CR-#+ENW<]/\
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M)3<%X5NJ351TA]AL*);84\G]T\9TESR( (\@=7*QRC1V1N:Y_C+@)0S&4S^
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M[R_[*J_6U-?HOO\ K6_/Z&+^E>G9^MOWJIQW_:7_ *H_A-$OI/4/&T;'6/\
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M*L')]P'Z=;;JV3V]M*V9U1EO.K<:846G)$LJYU\OLX'F<X[:5PAMQ;R&VP=
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I*:0I7,(R-C54.K"2V%>$[CO&U$P[:SI:6C5"EI:6EI4J6EI:6E2K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img47974566_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img47974566_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !7 +T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_.::&VAF
MN+B:*WM[>*2:>>:1(H888D,DLTTLA5(XHT5GDD=E1$4LQ !-?.7P@_:X^ 7Q
MXUQ=!^%GB_6O$,MY8>(M6\.ZU>_#?XH>%/!7C[1_".MVWAWQ-K7PK^(7C'P9
MH'@3XM:)HNKWUA;W^L?#+Q'XLTR&'4=-OS='3]0LKJ?T+XX> +WXL?!;XO\
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M]<TW4+"RN=*MWM]-DT?2]>GFU I%=6]G;$W:^_U^$NH?L,W?Q&\7?L&6MO\
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MFG!SQ$Z--\12^NNK@,YSS+H4,X?#M*&-RC%9C'$5,DH5<VH_T*T5_('^U/\
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MY\2+/1?VZ+_P1X:T"]UKX7>*OAIHMWJ7P]\206EIXETOPY'>W4NMU\\_ /\
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M!7Q6T_\ ;GMOV:-9^%_QE^)7[3FI_L<Z7^UY8?'[Q7^WG\3[CX;?$6R\;_M
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MMH(OXR?BL_C+PE\&?V/;?]LR?]DWPYH_@3_@FMXQ^*/[/G[,'_!23X(_$/\
M:F\ _&+XQVGQ-\57VF? _P"%OP_\7?&+]G_6];_:V\.?!2Z_9V^&7@W_ (2[
MX9_$G]H_P[H/CK7_  QX=^$5CXB\2?$?P_>_I+\8_BQ^P!\1?^"B7[+7A&?Q
M!^S'^S;^WO\ #_QG^S_\9OCG\0OBO\2?A[X4_:*^'&G^*/A9INA?#;]@SX)W
MOCS7O"_Q-\5:C^T!IGC=-%\4?";X4:)_PJ'0_ >I_$CQ;X^\.Z+\8OC?\/['
MXC@']%]%?DG_ ,%)A^R3\<_V<[76W^$/[(G[8GQLUCXE:]^R7^R!-\5OA=\(
MOVF/#G@C]JSXF>)E^&WB"S6U\1Z3XKMM)L?A%KO@G4/B'^T=X:T^ZTG5+'P5
M\"_%UKXC2WU#PM'#:?D+^VE\"_V,_P!G/0/VD_V7/BG9>$+;XF? W_@EY\ ?
MA)_P1TM_&\B1_&6_^.7AW1_C_HUCJ_[#MSK%S)J,_P"UAK'[0</P0F\6:G\'
M;@_%R?5%^$'_  FD[^$(/!TE ']<U%?S,_&C5/VG)/\ @JA_P3E^)?Q[_9-^
M/][JGAK]L;X@?!7X#^,=$\<_LEWGPD_X5!J/_!/']JW3OB;XM\,Z5#^U!8^/
MH?&GQ%\9/J7QV^*USXL^$W@*6W^#'P5\#?#CP3I7BGXG^%M#\._%7K/^"?\
MX:_9_P#@?_P4!\2^!?V>?&W_  3E_;(U;XP^)?VZ_B1\9_CM^S-\%/"6D?MG
M?LS/XZ_:"/QOTKP%^U7^T)X,^-'QIM?B!X.U/Q+X[O?@SX2\-^*= ^ _B%Y/
MACX/FT/P_P"+K3P7XNA\)@']'5%%% !1110 4444 %%%% !1110 4444 %%>
M2_'VZ>Q^!7QJO8X-/NGL_A+\1[I+;5M+TW6]+N'M_!VLS+!J6BZS:7^D:OI\
MQ01WFEZK8WNFW]NTEI?6EQ:RRPO^#UA^T-^U5H_PR\2?$CP;\?Y_ /@7]E_]
MFK_@F%XV\/\ P*\(?!OX!:=\./'MU\;-)T%?BGX9\:33?#*[\3Z#X'U30;%]
M*\):!\'-;^%-SX$N;V>YTC5YM(M=)\.Z;^N^'7@]FWB3EN/Q^5Y]D.3O 9MD
M^4.&??VQ"EB<5GN;9-D.5T:%;)\JSFJJ^*SC/LMPR6(PM#"4:4ZV*Q.-H4Z-
MI<&+Q\,'.$9TJM3GA4J?NO9MJ-*%2K-M5*E-6C3ISEI)R;2C&+;/Z.Z*_$S0
M_CK^U#;?'.S\=ZI^T-K^L_#R[_X*A>-/V,8?@ _PZ^#5C\.4^#;?#OQ;JND:
MO=^)[/X?)\:+GXI>'_&$%GJ%AXFMOBEI_A"[\,:7IOAO6OAWJFKMK/C#6OG7
MX8?M4_M@?'6Q\%>&?@/^VA9^/_VK?B_\ ?VD-?\ V@/V;KSX8_ 6YTK_ ()W
M?M#>#?#=AJW@3X=ZII.D^ =&^(OPTLO!OQL-Q^S9K&E?M7^+OB5K?Q6TQM4\
M:^$+O3;[PUJ>K1_8X7Z,_%>*I5\5_K=P+0R[!99@LSS/-:]3C2.6Y/'$X/B/
M,,3A\VQ5/@JI' 3RO"<,XZ>-QM>,<GKU\3EN!RG,\SS#&1PD.>6<T(M1^KXI
MSE.4(02P[G4M*C&+@OK/O*<J\.6*_>)*<IPA"+D?T>T5_-WXU_X*/_%SXM_!
MS1OVDO!OQA\0?LQ?!;]HCX\>!_A1^S_XJ\?^,_V>?V<?AA\+T^%W[/'CGQE\
M?9OCQ\>?VA/V1/VK[;08O&/QTM?&?P0\.:3%\(M3US5?B5\$/">D>'M1\ Z;
MK_C]=;X+X0?&?QM\4_B1^Q[^T1\>_P!J+4_!/C3X]?\ !+7XJVNE>!]4\/\
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M;$MOV?;[X(ZE\3/VEM#/[-7Q?_:,_P""K(\:_&GQSX<\(>!=$^-GQ%T7XO>
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ME]QE]0P/_0'A/_">C_\ (>2^X/\ AWK\!?\ H?OVXO\ Q9U_P4G_ /HLJ/\
MAWK\!?\ H?OVXO\ Q9U_P4G_ /HLJ**/^(L>*?\ T<OQ _\ $RXB_P#GEY+[
M@^H8'_H#PG_A/1_^0\E]P?\ #O7X"_\ 0_?MQ?\ BSK_ (*3_P#T65'_  [U
M^ O_ $/W[<7_ (LZ_P""D_\ ]%E111_Q%CQ3_P"CE^('_B9<1?\ SR\E]P?4
M,#_T!X3_ ,)Z/_R'DON#_AWK\!?^A^_;B_\ %G7_  4G_P#HLJ/^'>OP%_Z'
M[]N+_P 6=?\ !2?_ .BRHHH_XBQXI_\ 1R_$#_Q,N(O_ )Y>2^X/J&!_Z \)
M_P"$]'_Y#R7W!_P[U^ O_0_?MQ?^+.O^"D__ -%E1_P[U^ O_0_?MQ?^+.O^
M"D__ -%E111_Q%CQ3_Z.7X@?^)EQ%_\ /+R7W!]0P/\ T!X3_P )Z/\ \AY+
M[@_X=Z_ 7_H?OVXO_%G7_!2?_P"BRH_X=Z_ 7_H?OVXO_%G7_!2?_P"BRHHH
M_P"(L>*?_1R_$#_Q,N(O_GEY+[@^H8'_ * \)_X3T?\ Y#R7W!_P[U^ O_0_
M?MQ?^+.O^"D__P!%E1_P[U^ O_0_?MQ?^+.O^"D__P!%E111_P 18\4_^CE^
M('_B9<1?_/+R7W!]0P/_ $!X3_PGH_\ R'DON#_AWK\!?^A^_;B_\6=?\%)_
M_HLJ/^'>OP%_Z'[]N+_Q9U_P4G_^BRHHH_XBQXI_]'+\0/\ Q,N(O_GEY+[@
M^H8'_H#PG_A/1_\ D/)?<'_#O7X"_P#0_?MQ?^+.O^"D_P#]%E7U5\-_AYH'
MPJ\%Z-X"\,:AXYU30]!_M'[#??$CXG?$KXR>-)_[4U:^UFY_MKXD?%_Q9XY^
M(GB/RKS4;B'3O^$A\4ZI_8^DQV.@Z3]BT/2],TZT**\?.^-^-.)<+3P/$?%_
M%&?X&CB(8NE@\[S_ #;-<+2Q5.E5HPQ-/#X[%UZ,,1"C7KTH5HP52-*M5IJ2
MC4FGI3PV&HR<J.'H4I-<KE3I4Z<G%M-Q;C%.S<8NU[72[([BBBBOES<****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img147150826_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ([!.<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQUKOJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN-?#2>*)O%.IZA:VVF:H)C>260D3[)';L&&S>9/DW*XV%-JXQ7K_ (R_;O\
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M (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\ X5%C_P#':/\ AD[X(?\
M1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:H /\ AK'X(?\ 19/A_P#^
M%18__':/^&L?@A_T63X?_P#A46/_ ,=H_P"&3O@A_P!$;^'_ /X2]C_\:H_X
M9.^"'_1&_A__ .$O8_\ QJ@ _P"&L?@A_P!%D^'_ /X5%C_\=H_X:Q^"'_19
M/A__ .%18_\ QVC_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C
M_P#&J #_ (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\ X5%C_P#':/\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:H /\ AK'X(?\
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M)7;<H)RV#R",'%<]^W=^RE>?M4_"W3[+0-3BT;QGX>OAJ>C7=P2L328PT3L
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MPKITTPMXKO6[^*SB>4J6"*\C*"Q"L< YPI/:N+_X:Q^"'_19/A__ .%18_\
MQVNT\;?#OPI\2],ATWQ?X9T;Q5IT,PN(K36["*\B24*5#JDBL P#,,@9PQ'>
MN+_X9.^"'_1&_A__ .$O8_\ QJ@ _P"&L?@A_P!%D^'_ /X5%C_\=H_X:Q^"
M'_19/A__ .%18_\ QVC_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\
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M]$;^'_\ X2]C_P#&J #_ (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RK^P+_
M ,W&_P#99O$?_MO7U57RK^P+_P W&_\ 99O$?_MO0!]54444 %%%% !1110
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M5EJ/G>)M"M[>[U&Q\B1?(BG#&%MY4(V[8W"L2,<XKIZ "BBB@ HHHH ****
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M_'O@S2O%FAWZWGA_5+1+^TO7C>$20,NY7*R!648YPP!'>N*^&7[2/@OXJ?\
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M:&.6[4A+JS:V@BDC\N6/'ES/,#'(P)WJK'Q7Q/\ M'>+_&HUN/PQ\8Y=*^)
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M:5@3NQ@# '4\9J?[)_A'5?@)XE^$DVHZTOAO7[RZO;JZ2>$7B//>&[<(QBV
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M>J?#V\U'QYXT\21^ 98W\/V>IW-FL%JB6[V_ENL%K&9LHR_/*7D!C&' :0.
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M^%O$'A*3QEXRL/ ^M:A+JLOABQN[1+2&ZDF\]G20VQG*^;F3RWE>/<?N\*
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M]54444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M $)__E3B_P *ZRBBZ[!ROO\ E_D<G_PD?BG_ *$__P J<7^%'_"1^*?^A/\
M_*G%_A7644778.5]_P O\CD_^$C\4_\ 0G_^5.+_  H_X2/Q3_T)_P#Y4XO\
M*ZRBBZ[!ROO^7^1R?_"1^*?^A/\ _*G%_A1_PD?BG_H3_P#RIQ?X5UE%%UV#
ME??\O\CD_P#A(_%/_0G_ /E3B_PH_P"$C\4_]"?_ .5.+_"NLHHNNP<K[_E_
MD<G_ ,)'XI_Z$_\ \J<7^%'_  D?BG_H3_\ RIQ?X5UE%%UV#E??\O\ (Y/_
M (2/Q3_T)_\ Y4XO\*/^$C\4_P#0G_\ E3B_PKK**+KL'*^_Y?Y')_\ "1^*
M?^A/_P#*G%_A1_PD?BG_ *$__P J<7^%=911==@Y7W_+_(Y/_A(_%/\ T)__
M )4XO\*/^$C\4_\ 0G_^5.+_  KK**+KL'*^_P"7^1R?_"1^*?\ H3__ "IQ
M?X4?\)'XI_Z$_P#\J<7^%=911==@Y7W_ "_R.3_X2/Q3_P!"?_Y4XO\ "C_A
M(_%/_0G_ /E3B_PKK**+KL'*^_Y?Y')_\)'XI_Z$_P#\J<7^%'_"1^*?^A/_
M /*G%_A7644778.5]_R_R.3_ .$C\4_]"?\ ^5.+_"C_ (2/Q3_T)_\ Y4XO
M\*ZRBBZ[!ROO^7^1R?\ PD?BG_H3_P#RIQ?X5RG@#P@?A?\ \)'_ ,(Q\//[
M,_X2+6KGQ#JG_$[\W[1?W&WSIOWA;;NV+\JX48X KU>N(U#Q'J,%_<QI<;42
M5E4;%X )QVHNNQO2P\ZS:C+^ON+?_"1^*?\ H3__ "IQ?X4?\)'XI_Z$_P#\
MJ<7^%9O_  E&I_\ /S_Y#7_"C_A*-3_Y^?\ R&O^%%UV.GZA5_F_K[C2_P"$
MC\4_]"?_ .5.+_"C_A(_%/\ T)__ )4XO\*S?^$HU/\ Y^?_ "&O^%'_  E&
MI_\ /S_Y#7_"BZ[!]0J_S?U]QI?\)'XI_P"A/_\ *G%_A1_PD?BG_H3_ /RI
MQ?X5F_\ "4:G_P _/_D-?\*/^$HU/_GY_P#(:_X4778/J%7^;^ON-+_A(_%/
M_0G_ /E3B_PH_P"$C\4_]"?_ .5.+_"LW_A*-3_Y^?\ R&O^%'_"4:G_ ,_/
M_D-?\*+KL'U"K_-_7W&E_P )'XI_Z$__ ,J<7^%'_"1^*?\ H3__ "IQ?X5F
M_P#"4:G_ ,_/_D-?\*/^$HU/_GY_\AK_ (4778/J%7^;^ON-+_A(_%/_ $)_
M_E3B_P */^$C\4_]"?\ ^5.+_"LW_A*-3_Y^?_(:_P"%'_"4:G_S\_\ D-?\
M*+KL'U"K_-_7W&E_PD?BG_H3_P#RIQ?X4?\ "1^*?^A/_P#*G%_A6;_PE&I_
M\_/_ )#7_"C_ (2C4_\ GY_\AK_A1==@^H5?YOZ^XTO^$C\4_P#0G_\ E3B_
MPH_X2/Q3_P!"?_Y4XO\ "LW_ (2C4_\ GY_\AK_A1_PE&I_\_/\ Y#7_  HN
MNP?4*O\ -_7W&E_PD?BG_H3_ /RIQ?X4?\)'XI_Z$_\ \J<7^%9O_"4:G_S\
M_P#D-?\ "C_A*-3_ .?G_P AK_A1==@^H5?YOZ^XTO\ A(_%/_0G_P#E3B_P
MK)\2:SJUW8QIJO@5[NW$@*HEZ)2&P<'"*3TSSTYJ3_A*-3_Y^?\ R&O^%9^M
M>)M;:U46^J)9OO&9)$3!&#QR/\XIIJ^Q$\#5C%OFO_7H=%_PD?BG_H3_ /RI
MQ?X4?\)'XI_Z$_\ \J<7^%9O_"4:G_S\_P#D-?\ "C_A*-3_ .?G_P AK_A2
MNNQ?U"K_ #?U]QI?\)'XI_Z$_P#\J<7^%'_"1^*?^A/_ /*G%_A6;_PE&I_\
M_/\ Y#7_  H_X2C4_P#GY_\ (:_X4778/J%7^;^ON-+_ (2/Q3_T)_\ Y4XO
M\*/^$C\4_P#0G_\ E3B_PK-_X2C4_P#GY_\ (:_X4?\ "4:G_P _/_D-?\*+
MKL'U"K_-_7W&E_PD?BG_ *$__P J<7^%'_"1^*?^A/\ _*G%_A6;_P )1J?_
M #\_^0U_PH_X2C4_^?G_ ,AK_A1==@^H5?YOZ^XTO^$C\4_]"?\ ^5.+_"C_
M (2/Q3_T)_\ Y4XO\*S?^$HU/_GY_P#(:_X4?\)1J?\ S\_^0U_PHNNP?4*O
M\W]?<:7_  D?BG_H3_\ RIQ?X4?\)'XI_P"A/_\ *G%_A6;_ ,)1J?\ S\_^
M0U_PH_X2C4_^?G_R&O\ A1==@^H5?YOZ^XTO^$C\4_\ 0G_^5.+_  H_X2/Q
M3_T)_P#Y4XO\*S?^$HU/_GY_\AK_ (4?\)1J?_/S_P"0U_PHNNP?4*O\W]?<
M:7_"1^*?^A/_ /*G%_A1_P )'XI_Z$__ ,J<7^%9O_"4:G_S\_\ D-?\*/\
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M]"?_ .5.+_"C_A(_%/\ T)__ )4XO\*S?^$HU/\ Y^?_ "&O^%'_  E&I_\
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M_P *R='UG5H+[4GL? KV]Q))FY=KT1B1LMR"R@-R6Y7(Y]Q4G_"4:G_S\_\
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M^H5?YOZ^XTO^$C\4_P#0G_\ E3B_PH_X2/Q3_P!"?_Y4XO\ "LW_ (2C4_\
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M_P",T?\ #9'P?_Z&_P#\IEY_\9H#^P\U_P"@6I_X!+_(]HHKQ?\ X;(^#_\
MT-__ )3+S_XS1_PV1\'_ /H;_P#RF7G_ ,9H#^P\U_Z!:G_@$O\ (]HHKQ?_
M (;(^#__ $-__E,O/_C->L:#KMGXFT:SU73WDEL;N,2PO+"\+,IZ'8X##\0*
M#CQ.7XS!Q4L31E!/;FBU^:-"BBB@X HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR=7&3R>?I^=4MF835YP=N_3R_ NT445)N%%%% !1110 4444 %%%% !1110
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M;^(_Q,7Q?9/>^&_!5I/.T#7#1&Z=^+1"Z$$;U.X8(Y ![BMCX1?#'1O%>DZ
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M6[_*P4444CV@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>-P<AE(Y!! ((KI/^%4>-O\ H3M?_P#!7/\ _$T?\*H\;?\ 0G:__P""N?\
M^)H$\5AFK.I'[T<]J.I7>L7\][?W4]]>SN9)KFYD,DDC'JS,223[FJ]=3_PJ
MCQM_T)VO_P#@KG_^)H_X51XV_P"A.U__ ,%<_P#\30"Q6&BK*I&WJCEJ*ZG_
M (51XV_Z$[7_ /P5S_\ Q-'_  JCQM_T)VO_ /@KG_\ B:!_6\/_ ,_(_>CE
MJ*ZG_A5'C;_H3M?_ /!7/_\ $T?\*H\;?]"=K_\ X*Y__B: ^MX?_GY'[T<M
M174_\*H\;?\ 0G:__P""N?\ ^)H_X51XV_Z$[7__  5S_P#Q- ?6\/\ \_(_
M>CEJ*ZG_ (51XV_Z$[7_ /P5S_\ Q-!^%7C8=?!^OCZZ9/\ _$TP^MX?_GY'
M[T<M174_\*H\;?\ 0G:__P""N?\ ^)H_X51XV_Z$[7__  5S_P#Q-(/K>'_Y
M^1^]'+45U/\ PJCQM_T)VO\ _@KG_P#B:/\ A5'C;_H3M?\ _!7/_P#$T!];
MP_\ S\C]Z.6HKJ?^%4>-O^A.U_\ \%<__P 31_PJCQM_T)VO_P#@KG_^)H#Z
MWA_^?D?O1RU%=3_PJCQM_P!"=K__ (*Y_P#XFC_A5'C;_H3M?_\ !7/_ /$T
M!];P_P#S\C]Z.6HKJ?\ A5'C;_H3M?\ _!7/_P#$T?\ "J/&W_0G:_\ ^"N?
M_P")H#ZWA_\ GY'[T<M174_\*H\;?]"=K_\ X*Y__B:/^%4>-O\ H3M?_P#!
M7/\ _$T!];P__/R/WHY:BNI_X51XV_Z$[7__  5S_P#Q-'_"J/&W_0G:_P#^
M"N?_ .)H#ZWA_P#GY'[T<M174_\ "J/&W_0G:_\ ^"N?_P")H_X51XV_Z$[7
M_P#P5S__ !- ?6\/_P _(_>CEJ*ZG_A5'C;_ *$[7_\ P5S_ /Q-'_"J/&W_
M $)VO_\ @KG_ /B: ^MX?_GY'[T<M174_P#"J/&W_0G:_P#^"N?_ .)H_P"%
M4>-O^A.U_P#\%<__ ,30'UO#_P#/R/WHY:BNI_X55XVSC_A#]?SZ?V9/_P#$
MT?\ "J/&W_0G:_\ ^"N?_P")IA];P_\ S\C]Z.6HKJ?^%4>-O^A.U_\ \%<_
M_P 31_PJCQM_T)VO_P#@KG_^)I!];P__ #\C]Z.6HKJ?^%4>-O\ H3M?_P#!
M7/\ _$T?\*H\;?\ 0G:__P""N?\ ^)H#ZWA_^?D?O1RU%=3_ ,*H\;?]"=K_
M /X*Y_\ XFC_ (51XV_Z$[7_ /P5S_\ Q- ?6\/_ ,_(_>CEJ*ZG_A5'C;_H
M3M?_ /!7/_\ $T?\*H\;?]"=K_\ X*Y__B: ^MX?_GY'[T<M174_\*H\;?\
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M?ND^\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
M 6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UI
MW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_
MT&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0
MO^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (
MCH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\
MQH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A
M1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
M 6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UI
MW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_
MT&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0
MO^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (
MCH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\
MQH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A
M1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
M 6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UI
MW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_
MT&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0
MO^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (
MCH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\
MQH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A
M1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
M 6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UI
MW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_
MT&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0
MO^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (
MCH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\
MQH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A
M1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
M 6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UI
MW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_
MT&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0
MO^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (
MCH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\
MQH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A
M1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
M 6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UI
MW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_
MT&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0
MO^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (
MCH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A1[H>\'_"7:%_T&M._P# J/\
MQH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\  6/_  H_X1'0O^@+IW_@+'_A
M1[H>\'_"7:%_T&M._P# J/\ QH_X2[0O^@UIW_@5'_C1_P (CH7_ $!=._\
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M#:_^ <5&/"W_ $ ;7_P#BI>REV9?M<3W(_)\*_\ 0?MO_ R*CR?"O_0?MO\
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M=F'M<3W(_)\*_P#0?MO_  ,BH\GPK_T'[;_P,BJ3'A;_ * -K_X!Q48\+?\
M0!M?_ .*CV4NS#VN)[D?D^%?^@_;?^!D5'D^%?\ H/VW_@9%4F/"W_0!M?\
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MU_\  .*CV4NS#VN)[D?D^%?^@_;?^!D5 A\*@Y_M^V_\#(JDQX6_Z -K_P"
M<5 'A<G']@VO_@'%1[*79A[7$]S;_P"$NT+_ *#6G?\ @5'_ (T4?\(CH7_0
M%T[_ ,!8_P#"BLO=.3WC6HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N U/\ Y"5W_P!=7_F:[^N U/\
MY"5W_P!=7_F:[,-NS:GN5J***[S<**** "BBB@ HHHH **** "BBB@ HHHH
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MDS:EF.(]GA8J-*&UDE=]_P#+R]3\\S/&0Q-3EI*T5^/G_D%%%%?('C!1110
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M\0?^AZ\2_P#@WN/_ (NN-HH^J8?_ )]Q^Y![&G_*ON.R_P"%S_$'_H>O$O\
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M\71_PN?X@_\ 0]>)?_!O<?\ Q=<;11]4P_\ S[C]R#V-/^5?<=E_PN?X@_\
M0]>)?_!O<?\ Q='_  N?X@_]#UXE_P#!O<?_ !=<;11]4P__ #[C]R#V-/\
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MU/T[=*1$OB1IT444RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_P4&^$?C/X-:?>ZCX<\)Q+-X@\8C39K.W=4=V$+/(B,QV_NP",GS#@;58@
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M7^8?7<5_S]E][_S/"?\ AAWX)_\ 0E?^56]_^/4?\,._!/\ Z$K_ ,JM[_\
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M$3_\"E_F'UO$?\_)?>SQO_AD#X1_]"E_Y4KO_P".T?\ #('PC_Z%+_RI7?\
M\=KV2BC^U<P_Z")_^!2_S#ZWB/\ GY+[V>-_\,@?"/\ Z%+_ ,J5W_\ ':/^
M&0/A'_T*7_E2N_\ X[7LE%']JYA_T$3_ / I?YA];Q'_ #\E][/&_P#AD#X1
M_P#0I?\ E2N__CM'_#('PC_Z%+_RI7?_ ,=KV2BC^U<P_P"@B?\ X%+_ ##Z
MWB/^?DOO9XW_ ,,@?"/_ *%+_P J5W_\=JAK7[*'P=TVU26?PU);(7"AXM0N
MF).#QS(?2O<ZS]:-V+5/L=K%=R[QE)<8 P>>2/;\Z3S7,+?[Q/\ \"E_F1/&
M8E1=JDOO?^9Y7_PR!\(_^A2_\J5W_P#':/\ AD#X1_\ 0I?^5*[_ /CM>R44
M_P"U<P_Z")_^!2_S+^MXC_GY+[V>-_\ #('PC_Z%+_RI7?\ \=H_X9 ^$?\
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M7_E2N_\ X[7LE%']JYA_T$3_ / I?YA];Q'_ #\E][/&_P#AD#X1_P#0I?\
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M  CGBG_H</\ RF1?XT67<.9]OR_S.LHKD_\ A'/%/_0X?^4R+_&C_A'/%/\
MT.'_ )3(O\:++N',^WY?YG645R?_  CGBG_H</\ RF1?XT?\(YXI_P"AP_\
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M "F1?XT67<.9]OR_S.LHKD_^$<\4_P#0X?\ E,B_QH_X1SQ3_P!#A_Y3(O\
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ME^VE_+_7WE7_ (1S4?\ GW_\?7_&C_A'-1_Y]_\ Q]?\:M?\(YXI_P"AP_\
M*9%_C1_PCGBG_H</_*9%_C1[>7E^(>VE_+_7WE7_ (1S4?\ GW_\?7_&C_A'
M-1_Y]_\ Q]?\:M?\(YXI_P"AP_\ *9%_C1_PCGBG_H</_*9%_C1[>7E^(>VE
M_+_7WE7_ (1S4?\ GW_\?7_&C_A'-1_Y]_\ Q]?\:M?\(YXI_P"AP_\ *9%_
MC1_PCGBG_H</_*9%_C1[>7E^(>VE_+_7WE7_ (1S4?\ GW_\?7_&C_A'-1_Y
M]_\ Q]?\:M?\(YXI_P"AP_\ *9%_C1_PCGBG_H</_*9%_C1[>7E^(>VE_+_7
MWE7_ (1S4?\ GW_\?7_&C_A'-1_Y]_\ Q]?\:M?\(YXI_P"AP_\ *9%_C1_P
MCGBG_H</_*9%_C1[>7E^(>VE_+_7WE7_ (1S4?\ GW_\?7_&C_A'-1_Y]_\
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M.>*?^AP_\ID7^-+V\O+\2_;2_E_K[RK_ ,(YJ/\ S[_^/K_C1_PCFH_\^_\
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M?^AP_P#*9%_C1_PCGBG_ *'#_P ID7^-+V\O+\2_;2_E_K[RK_PCFH_\^_\
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M/;R\OQ#VTOY?Z^\J_P#".:C_ ,^__CZ_XT?\(YJ/_/O_ ./K_C5K_A'/%/\
MT.'_ )3(O\:/^$<\4_\ 0X?^4R+_ !H]O+R_$/;2_E_K[RK_ ,(YJ/\ S[_^
M/K_C1_PCFH_\^_\ X^O^-6O^$<\4_P#0X?\ E,B_QH_X1SQ3_P!#A_Y3(O\
M&CV\O+\0]M+^7^OO*O\ PCFH_P#/O_X^O^-'_".:C_S[_P#CZ_XU:_X1SQ3_
M -#A_P"4R+_&C_A'/%/_ $.'_E,B_P :/;R\OQ#VTOY?Z^\J_P#".:C_ ,^_
M_CZ_XT?\(YJ/_/O_ ./K_C5K_A'/%/\ T.'_ )3(O\:/^$<\4_\ 0X?^4R+_
M !H]O+R_$/;2_E_K[RK_ ,(YJ/\ S[_^/K_C1_PCFH_\^_\ X^O^-6O^$<\4
M_P#0X?\ E,B_QH_X1SQ3_P!#A_Y3(O\ &CV\O+\0]M+^7^OO*O\ PCFH_P#/
MO_X^O^-'_".:C_S[_P#CZ_XU:_X1SQ3_ -#A_P"4R+_&C_A'/%/_ $.'_E,B
M_P :/;R\OQ#VTOY?Z^\J_P#".:C_ ,^__CZ_XT?\(YJ/_/O_ ./K_C5K_A'/
M%/\ T.'_ )3(O\:/^$<\4_\ 0X?^4R+_ !H]O+R_$/;2_E_K[RK_ ,(YJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,W?_'W
M-_OM_.NFKF;O_C[F_P!]OYUO2W9K3W(J***Z38**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K'\4*S:?&%U5='/FC]^Q W<'Y>H^OX5L5A^+VMU
MTV(W&FR:HGG#$,0.0=K?-Q^7XT&<_A9N4444&@4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!CW2L?$UHPU585$1SIV1F7AOFZ_T_AK8K#N
MVMQXLL@VFR2W'DG;? '9&,/\I[>O_?5;E!G'KZA1110:!1110 4444 %%%%
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MM[FWN'MW0Q220B20AAMD93E0<$D9P2/O.@ HHHH **** "D9E12S$*H&22<
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MAXRL!+!.VI>2?*E7_5JN'X//7[W;N*WZ#.+W]0HHHH- HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "LO2%OA>ZC]JOH;J$R?N(XP,PKEN&P!SC'
M7/0UJ5@>'&TXZKK0LH)XK@3?Z0TOW7;<_*\GC.[\Q09R^)&_1110:!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 % ZT4#K0!U=%%%>><@4444 %
M?&WQ^\,?&GPE^V3I?Q5^&_PL@^)>DQ^!1X=,=QKUIIRVURU_).[KYSAB?+"+
MD+@ASSQBOLFOAO\ :]^*OBBX_:AT'X8V/QMT_P"!'AZW\&OXFDUR_>V1;Z[:
M[>WBMBT[*.!&7VAN0).#@$ $GAW2?V@?B]^UO\&_''CKX,6_PXT#PA%K,-[?
MVWB:RU W"75F4C1DC?>0LJ)@!6Y<DXQFON"OSZ_8D^+OB;]I?Q=X+^('Q ^/
M.AP:JB7,6F?"?0;NWMI;AT@F@DN+R#?YLC$+).J;2%&UU*K\M?H+0 4444 %
M%%<]X[\;6'@#PY<ZM?MP@Q%"#\TK]E'^>*N$)5)*$%=LJ,7)J*W.6^-OQ6B^
M'&@&*V97UN\4K;1G_EF.AD(]!V]37QA=7,M[<RW$\C2S2L7=W.2Q/))K4\7>
M*K_QIK]UJVHR&2XG;@9X1>RCV K&K]7RS+XX"CR_:>[_ $]$?687#K#PMU>X
M5]$_LWJK?#GQUD YC(.1_P!,7KYVKZ-_9HB>?X?>-HHD:21P55$&2Q,38 '<
MU&<Z8-^L?S0L;_!?JOS/#/!GBBX\&>*-.UJU :6TEW[#_&I!#+^*DC/O7T]X
MH^%&F?%/Q?X6\8631R:3<HLM^A&#,BKNCXQR3]Q@>P'I7S;#\-/%<MW:V[^'
M=4MC<S+ DES9R1IN8X&6*X%?5&F^)M"^%FI^%/AV")&N+<K).3A5D8G:6!_Y
MZ/OX[9'K7FYO4M.%3"N]2TEIK[MM?NZ>9RXR5I*5)^]9[=CQSXF_&"VN?B_:
MWPT^#6-(T R006LI 2:3:0TF=IZ/M(X/^K!&,UZA\&?B7<_&*#7;#6]&L%L;
M=4"I#&3&RON&Q@Q()P.HQWXKQ/QC\%=2LOBM_P (QI<):"^<SV<K\(L!R26/
M^Q@@]S@>HKUKQ=!J'PG\$)X3\#Z#JM_J%S'FZU6VLI'"DC#/N4$%ST !^4?A
M7-BZ>$G0HT</K-I<KO:RO=M]NOG?T,ZT:,J<(4]VE9]EW,/X0>%=#\-+X]\7
M/:I?P:)<W,%C&WS[4C!8E2>"2I4!NW/J:VO#'B6+]HKX?^);/6=.M(=4L1N@
MD@1L1EE8Q.I))!RC @'D?7%9?P0TR[O?A)X[\*F![;6]TW^B7"&.13+;JJ;@
M>1DH>M2_ C0=1^&G@GQGKFOVDVF1M&I2&YC*.?*63G!]2X ]<5CB>5NM4<KU
M8R@HZZVTV]=615M><F_>35OP.#\%?'Z[\%:'I6D:-X:T\R1-BXG?<TMT2W;;
MC#$$#)W=!QVKM?VL=$TR'3]#U5((K?5II6B<KA6DCVY.X=]IQSVW>]4?@3\*
M(M-TL>.M>LI[Q(E\[3K""%II'(Z2[%R2<_='_ O0C@OC%JGBWQ=K4FM:WH>I
MZ3IJ'R;6*ZM9(XX5[#<R@%CC)/?Z 8]&$*-3,E+#Z<E^9W^)OIYV_KH="C"6
M)3IZ6O=]WV/>O@]KOAS6/"_B*W\,:.=+TRS7RQ)-@SW)*,2[GGZ 9/'IT'Q_
M7U)^S=X<U;0_"/BB+4=+O=/EF8&)+JW>-I/W;#Y0P&?PKYHU;1-1T"Y6WU.P
MNM.N&4.(KN%HG*DD X8 XR#S[&M\L5.&+Q,(2OK'K=O37U-,+RQJU(I]OR*5
M%%%?2GIA7K_P ^$)\<:L-8U.%O[#LY.%88%Q(.=ON!W_ "KD/A?\.KSXD^)8
MK"#,5I'A[JYQD1QY_F>@K[?T/1+/PYI-MIMA"(+2W0)&@]/4^]?*YWF?U6'L
M*3]]_@O\V>3CL5[)>SA\3_ NHBQHJJH55& H& !3J**_-CYH**** "OS6_:V
M^*'AGX+?\%5O@YXT\9ZD=&\-:;X,D%U??9Y9_+\P:M$GR1*SG+R(.%.-V3@9
M-?I310!^;OQA\92_\%$OCO\ "/1/A?I6JW?PS\(ZL-;USQC>Z=+:VDA5XR(X
M6E56+;$=0, EI <!4+5T7[7/QM_95^)S^*_"?Q6\/:M9^/-'>YTW3_,\/W,6
MIW$D;,L;V=Q$A5XG8!D\QPC!@2N":_0"B@#\9?B?X*\?>!O^"2N@6'CV&]M+
ME_&<5SI=AJ 99[/3VBD$:.K<IEQ*X4XPLB\"OO7X0_L%^ _#'BKPU\0/$&O^
M,_B3XITR"*73+GQQK1OQIS[0085"(!M/*AMVT@$8(!'U+10!X]X-_9PTKPOX
MV^*^H7D]GKWA/Q_>6^I7'A?4--22"WN5A$=PY9F991-M1BI08*]3FF?%O]FG
M1/'7P.UGX7^$O[-^&VB:Q)$MY_8>DQ(I@$J--&D:&-5:1$V;^<!CP:]DHH K
MZ=I]OI.GVUC:1""TMHEAAB7HB* % ^@ %6*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\&_;<^+OB'X,?L]:UK'A$*OBR_N;71]*F=0RP
MW%S,L0D((()4%B,@C<%R",UR.B?\$X_A+%H-N^O1:YK_ (X:,-=^-I=>O4U2
M6YQ\TRR"7"?-DA<%1W!.20#ZGHKX>^.OB(_L$_&V;XNQ6][J7PQ\<VYL/$VG
MP,7D@UF&%FM;M0>-TZQF-SP,Y9B25%>D?LU^%I/@Q\)_%_QB^*=VEKXR\7!O
M%'B>[E((L+9(R;>R4CJD$/R@<_,S 9XH ^F:*_.+X::7XDUW]N?X,_%/Q?\
M:K+7/B!INO7]MHTY*_V5I4=LBV%L5[2>6S2R'CYY3D9%>M_M=>&/V8]-\4WF
ML_'G7[BZU2[L1/I^DWVK7FVUB1=FZRMX& 5F922V"Q8GD#B@#["HKYS_ ."?
MEAXNT_\ 96\))XQO;F^O',\EB]]<K<7"6!E;[,LCJ2"PCQP"=HPO&,#Z,H *
M*** "BBB@ HHHH *^!?B5_R4;Q5_V%;O_P!'-7WU7P+\2O\ DHWBK_L*W?\
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M\;_"6]T_7-&_:2\-?%O48]02/4_ UCX+:SL$@(;>T%_LS( 0 #O!^?/S 8H
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MC:EJ,6F0'0HHIW+R12RJ_P \B+LVPMR"3R, YKV&OR>_X* ^$?&OA#_@G[X
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MPSH]QXKM(?L]MKLMA$U]#%\WR).5WJOSOP#CYV]370T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?*OC/\ 9Z\1ZUXPUW48+W2TAN[^
M>XC6260,%:1F .(R,X/K7U57,W?_ !]S?[[?SKU,!C*N#E*5+J=>'K3HMN)\
MQ?\ #,_BC_G_ -(_[_2__&Z/^&9_%'_/_I'_ '^E_P#C=?3%%>W_ &WC.Z^X
M[_KM8^9_^&9_%'_/_I'_ '^E_P#C='_#,_BC_G_TC_O]+_\ &Z^F**/[;QG=
M?<'UVL?,_P#PS/XH_P"?_2/^_P!+_P#&Z/\ AF?Q1_S_ .D?]_I?_C=?3%%'
M]MXSNON#Z[6/F?\ X9G\4?\ /_I'_?Z7_P"-T?\ #,_BC_G_ -(_[_2__&Z^
MF**/[;QG=?<'UVL?,_\ PS/XH_Y_](_[_2__ !NC_AF?Q1_S_P"D?]_I?_C=
M?3%%']MXSNON#Z[6/F?_ (9G\4?\_P#I'_?Z7_XW1_PS/XH_Y_\ 2/\ O]+_
M /&Z^F**/[;QG=?<'UVL?,__  S/XH_Y_P#2/^_TO_QNC_AF?Q1_S_Z1_P!_
MI?\ XW7TQ11_;>,[K[@^NUCYG_X9G\4?\_\ I'_?Z7_XW1_PS/XH_P"?_2/^
M_P!+_P#&Z^F**/[;QG=?<'UVL?,__#,_BC_G_P!(_P"_TO\ \;H_X9G\4?\
M/_I'_?Z7_P"-U],44?VWC.Z^X/KM8^9_^&9_%'_/_I'_ '^E_P#C=5=1_9U\
M4Z? L@EL+LEMNRWDD9AP>>4'''ZU]15C^*5=]/C":JND'S1^_<@!N#\O4?7\
M*/[;QG=?<1+'5DFT?/\ _P ,S^*/^?\ TC_O]+_\;H_X9G\4?\_^D?\ ?Z7_
M .-U],44?VWC.Z^XOZ[6/F?_ (9G\4?\_P#I'_?Z7_XW1_PS/XH_Y_\ 2/\
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M*Y/_ (6#_P!2UXA_\ /_ +*C_A8/_4M>(?\ P _^RHY6'/$ZRBN3_P"%@_\
M4M>(?_ #_P"RH_X6#_U+7B'_ , /_LJ.5ASQ.LHKD_\ A8/_ %+7B'_P _\
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M%@_]2UXA_P# #_[*CE8<\3K**Y/_ (6#_P!2UXA_\ /_ +*C_A8/_4M>(?\
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M'/$ZRBN3_P"%@_\ 4M>(?_ #_P"RH_X6#_U+7B'_ , /_LJ.5ASQ.LHKD_\
MA8/_ %+7B'_P _\ LJ/^%@_]2UXA_P# #_[*CE8<\3K**Y/_ (6#_P!2UXA_
M\ /_ +*C_A8/_4M>(?\ P _^RHY6'/$ZRBN3_P"%@_\ 4M>(?_ #_P"RH_X6
M#_U+7B'_ , /_LJ.5ASQ.LHKD_\ A8/_ %+7B'_P _\ LJ/^%@_]2UXA_P#
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M;1)Z*@_X3:#_ *%37?\ P7#_ .*H_P"$V@_Z%37?_!</_BJ.?R#VT2>BH/\
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M'_0J:[_X+A_\51_PFT'_ $*FN_\ @N'_ ,51S^0>VB3T5!_PFT'_ $*FN_\
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MA_\ %4H\:P9_Y%37?_!</_BJ.?R#VT3L:***Y" HHHH **** "BBB@ HHHH
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MW4_(_P"-4Z*+L.2/8N?VI+_=3\C_ (T?VI+_ '4_(_XU3HHNPY(]BY_:DO\
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M ,#8_P#XJC_A./#G_0?TO_P-C_\ BJ^1**/K3[!_JG0_Y^O[D?7?_"<>'/\
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M[E RD'!!&>#785\B>./^1TU__L(7'_HQJYZU1P2L?29)E\<PJ3C*5K(^A/\
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M_A+]!_Z#>G?^!<?^-?,%%'UA]@_U:H_\_']R/I__ (2_0?\ H-Z=_P"!<?\
MC1_PE^@_]!O3O_ N/_&OF"BCZP^P?ZM4?^?C^Y'U OBW0W8*NLZ>S$X %U&2
M3^=:H.17R57L7PK^(OVE8M%U.7]ZHVV\[G[P_ND^OI6D*W,[,\S,,AEAJ7M:
M,G*VZ\NYZI11174?)!1110 4444 %%%% !1110 4444 <[>KIA\:Z>TMQ.NJ
M" ^5"O\ JV7#\GCK][OV%=%61<O?CQ):K'80R6!B/F7C8\Q&PW YSC[O;N:U
MZI]#*'7U"BBBI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=
M\,KIBZMK9L;B>:X,_P#I*2_=1MS\+P.,[O7H*Z*LC1GOVO\ 4A=V$-I")?W$
ML>-TRY;EL$\XP><=35+9F<OBB:]%%%2:!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 % ZT4#K0!T%%%%:GF!1110 4444 %%%% !1110 444R65
M((GDD8)&@+,S'  '4T!N4M>URT\.:3<:A>R"."%<GU8]@/4FOE7QCXLN_&6M
MS7]TQ"GY8HATC3L!70?%7XAOXRU8V]LQ72K9B(E_YZ-W<_TK@Z\RO5YWRK8_
M6<ARGZE3]O67[R7X+MZ]_N"O0/AY\/M/\7>'M;O[N>YBFLE)B6%E"D["WS94
MYZ=L5Y_7L_P3_P"1+\5_[I_]%M6=)*4K,]+.*U2AA'.D[.\?S1Y9X9MM.O=>
MLK?5998-/EDV2RPL R9& <D$ 9QGCIFNR\7_  DFT?QCIFE::\LUGJ) AFFP
M60C_ %F[& =H^;H.*\YKZP\&?:(/#.A6^KO'_:YM\HLGW\ =\\[@I4-[YJZ,
M%4O%G!G6,K9?*%>E*Z::Y?E=2^77R/%O$_@/PWI'C?3]!BU>:VB*,]]=7CH5
MB^4LJC 7!('?^\O7I6_I'PG\&^++:[30M?O+B[M^&9P-BDYP=I121QU!_&O+
M_%,&H1^)M2CU(%M1^T-YN ?F8GJ/8\8]L5[!X,T^'X/>#[O6M9;&HWRKY=GG
M#< E4^O.3Z#Z4X<LI.\=##'.O0PU)TZ\G4:2BE;WFW=O;:S]%H<-X&^%TGB3
M5M4BU"Y^Q6.ENT=S-'R2X)!"D\8&"23VQQS6SJGPKT#5/"][JWA35[B_-GN,
MD<X!W;1E@,*I!QR.#G\<UK^ [Q]1^$WC:\E(-S<2W<LA48&3"I/ZDU#^SXQ&
MG>)_,+?9PL)YSMZ2;OTQ^E5&$=(VW,,3B\7'VV(52WLI17*K6=[7OUUOH<YX
M:\)>"I='L;C7/$KP7EU_R[VQ'[KG #G:V/7)P.?QI_Q%^%4'@^[TV2VORVFW
MDHA,MSC="?4D8!&,GMTK'^''@&Y\<:PJD&/38&#7,YZ8_N+_ +1_3K]>@^-O
MCFW\0ZA!I.GL)+*Q8EYE.1))C''LHR,]R3Z U'N^SNUZ'=*6(691HT:KDM7-
M.UHK[/3?\?D:>C_#/P'J]_\ V7;>);J\U/83B!E"-@<[3L(/K@,>*\Y\:>%Y
M?!WB*ZTN203"/#)*!C>I&0<=C_A7H?P@\)IH,#^,M;<65G!&WV;S."P(P7QZ
M$$@#OGZ9\^\;^)V\7^)KS4RABCD(6*,]50#"Y]^Y]S2FER)M6?Z%8&==XZI3
MC5=2G%:MV^*^RLET^XP:***YSZ<*V?"7A:[\7ZU!I]HO+',DA^[&G=C6;964
M^I7D-K;1--<3,$2-1DL37U%\./ D'@?15B(5]0FPUQ,.Y_NCV%;TJ?M'Y'@9
MQFD<NH^[\<ME^OR-OP[H%IX8TBWTZR0)#$.O=CW8^YK2HHKU4K:(_')SE4DY
MS=VPHHHID!7YJ_M;>'?$_BO_ (*K_!S2O!OB[_A!/$EQX,D^R>(/[,BU'[+M
M&K,_^CRD(^Y%=.3QOW#D"OTJK@-9^ _@77_C'H7Q4O\ 0A<>/=#LFT_3]7^U
M3J8(&$P9/*#B-N+B;ED)^?KP, 'YY?'KX?\ Q*\!_MK_ ++B?$;XK_\ "TIK
MG7"UE+_PCEMH_P!B59[?>N(&/F;B5.6Z;>.M0_&'XC7'_!/7]K7XT7EHCV_A
M[XF>&9]:T8)&=B:P-^S)!Q@3-<$C' F3\?T4\=? CP-\2O''A#QAXDT(:EXB
M\)3-<:+>_:IXOLLC,K$[$=4?E%.'##CW-?,_[?G[+_BS]J7XG_!?1M.\+0W'
M@S2K^6X\0^)&O(8Y;:VD>(/ B&02-N2)C\J-\QCY&&H ^._V@_A'-\$?^"5W
MPE,B2VGB'7?&=KXDOI?F2433V-ZT6<\JRPK"I]"I/!KT[]L+X<?"[X3^-_V5
MK_X)V6F:9XBO-=MEL;CP\RF74[,R0!99G3F8LS;=[DE@\@)(SCZ,_P""FW[/
M?C;]H/\ 9^\.>%?ASH4>KZI9>);:]>T%U!:K%;):W418&5T7 :6,;0<\\#@U
MZGX$_8K^"/PS^(;>./#/P\TS2O$VYGCNT>9T@9A@M#"[F.$X)&8U7J?6@#\_
MHO"GCSXY?M\?'FQL](^%OBW7-.F%G::=\6X;J=(;!&*I]AAAR!A=C,V,C>&!
M!=B:7QE^"GB3X"?\$W_'OA?Q!XG\,^(8U\<V\]K;>%;^6\M=,#>67MMTJJZ$
M-\WEG)&[<22YK]%/C+^QO\&OV@=;BUGQYX%L]:U>-!']OBN)[2=U PH=X)$9
MP!P-Q..U6=1_9(^$6I_"(_"^7P39P^!3<K>-I%G--;!YU((D:2-UD9N!DEB2
M  <@4 ?'7QS_ &./A1\'/^"?_C7Q'H'AA+CQ)?Z#IE[<:MJDKWEP;CS4)G3S
M"5B<B>528@F5)'KG/^*'@KPKX9_X(YW&IZ#H.CZ5JFL>'O#D^JWFG6<4,]]*
M+^UP\[HH:1@6DY<DY+>IK]%]3\$:%K7@R?PEJ&F07OAR>R_LZ73K@%XWM]FS
MRSGDC;QG.??->1:#^PK\#?#'P_\ %O@G2_ D5IX9\5O;2:S9+J5X3=FWD\R#
M]Z9C(@1_F 1E')XY- 'PM\4OV?\ PU\!O^":L'Q%\"6FHV7C'QKX<T5?$FL?
M;II7GM[PP3SH5W;(T,A5,JH)5MI)W'-C]M+X3_![X??L,?"[Q/X!TK1-(\8&
M;2I=&US141-1OY#%NE9IHQOE((+$L3M91C!P*_32V^&OABV^'5KX#_L6VN/!
M]MIL>D1Z1=@W$)M$C$:1-YA8N B@98DG&2<UY+X'_8'^ 'PY\7Q>)]!^&FFV
M^M0RB>&:YGN+I() <J\<4TCQHP/(*J,8&,8H ^._B[X?\.^./^"G/PHTCXI)
M;26%_P""[,7^GZE(([>[O MP\<$JYVN#.J$1GAF51@]"_P"&NB:)X%_;_P#V
MC_#?PX@BT_P0O@:Y>_T[3%"V%O=K!;G:JKA5*R/* !]TO*!@9 ]C^,W['^J?
M&C]OO1?%WB?P;:^(?A'_ ,(HVFZA<7=U#M^T8N-J"(.)@P9XV#JO'4,"*^B_
MA1^R[\+?@=X;UC0O!'@^TT+3M80Q:ALFFFFN4(8;7FD=I" &; W8&3C% 'YC
M?!3X"?#[6_\ @E9\0O'%_P"%-.O/&"&\FBUN>+?=0&&5!&(I#S&O7*K@-DY!
MS6[\6-3N]7^"G[ %S>W$EU<'5[6,RR'+%4FM$4$^RJ!^%?H[X?\ V8?AGX6^
M#6H?"G2_#(MO .H+*MSI'VZY?S!*=S_OFD,HR1V<8[8JKJ/[)WPIU;0OA_HU
MWX4$NF^ 9TN?#D'V^Z'V&165@=PES+RBG$A8''/>@#X[^&7A3PG\9O\ @IK\
M=-/^*FG:=XIN-(T^*'0=)\11K/!%;A8BQB@DRIPC!L@<>8S=237WC\)O#7@S
MP?X"T_1_A_'80^$[22X2TBTRX\^WC8SR&9%;<W24R KGY2"N!C XSXS_ +(/
MP?\ V@]7M=5\?>![/7=4MD$27RSSVLY09PCR0.C.HR<*Q(&>*]%\#^!M ^&O
MA33O#/A?2;;0]!T]#':V%FFV.(%BS8'J69F)/)))/)H W:*** "BBB@ HHHH
M **** "BO/\ XO\ @GQOXWTS3X/!'Q(N/AO=P3,]Q=V^C6NI&Y0K@(5N 0N#
MSD<U\K_LWV_[07QINOB-)??M%7MC#X-\=:CX3$*>#M)?[;%:&+]ZQ\H%"XD(
M(&<8ZF@#[HHKX+D_:[^(?@+]M?QEI7BB_BO/@E::W8^%F'V6)&T:[N[1);:=
MI$C#M&\BR(Q=BJ[\\8&?>-9^*/B:T_;B\.?#V+40OA&[\#76L3:?Y$9+7:7B
MQK)YFW>,)D;0VWG)&>: /?**^"?@+^U[\0C^U)XU\._$34(;WX;ZKXYUKP7X
M8O!:Q0_V=J%G(KQ6SM&BEA-#,JJ9"S%X^.]>^>#_ (H>)=5_;-^(?@.ZU$2>
M%=)\,Z;J%G8^1&#%/+)()'\P+O;( X+$#' '- 'O5%?+G[-'Q'^*GQO_ &2F
MUVR\0:4WQ#N]5O;2WU;6;$?98(8]1:(L88 @9D@5M@XW.%W'!)KG]/\ '/QB
M^"'[57PS^'GBSXBVGQ9T/QW;:C)*AT&WTV[T8VT0D$P$!YB8G:"^>CC.5S0!
M]AT444 %%%% !1110 5\B>./^1TU_P#["%Q_Z,:OKNOD3QQ_R.FO_P#80N/_
M $8U<6*V1]UPG_'J^B_,Q**Z?P9XAT?P[!J<VH:5'JM^\:K9+<1+)"AR=Q<$
MC_9Q@'H>E;.I^+O"$FCZD=/\//!JM_$J%9DC:"V;G<T1^\#R>@'0=*XE%-7N
M?=U,35A4Y(T6UHKZ6Z>>ROOY6.2M/#&L7]L+BVTF^N+<\B6*V=D/X@8JO8Z5
M>ZI<M;V5G<7<Z@L8H(F=@!P3@#/>O4?@_K_B?Q%XNM_,OYY=+M("D\9XA";<
M(-H&-V<<]< ^]7?"VOZ1'\:O$%\+RVMK!X'59I'6-&8&,-@G .2&/OUK14XM
M)WW9YE7,J]&=6FX)N$>;1M];6>F_4\IOO"^LZ9;M<7FDWUI I ,L]LZ*,].2
M,57N-(OK2SANY[*XAM9O]5/)$RI)_NL1@_A7<^*O"GB^#PV]_<Z]_;^D9!D-
MK?R7$8&>&(; (!QR,XKTO2/"EOXL\%^#(KLJUM:QI<O">3-A,!?IDC/MQWIJ
MES-I$ULXCAZ<*LFI)MIVOI97Z]3Y\N]'O["W@N+JRN+:"<9BEFB9%D&,Y4D8
M/!'2HX["YFM)KJ.WE>UA($DRH2B$] S=!GWKHOB/XON_%WB*9YXWMK>U+0P6
MK\&( X.1V8D<_@.U:?AW_DD7BS_KYMO_ $,5GRIR:1Z3Q-6G0IU*D4I2<4UV
MYFE^"?WG%6=A=:@\BVMM-<M&AD=84+E5'5CCH!ZU)IVC:AK#.MA8W-\R8+"V
MA:0KGIG ..AKL?@[_P AG6O^P1<?^RUI>#KU=:\"+H.EZRF@ZY'=F8[Y3"+L
M$8 WCOT&.?NC\'&":1CB,=.C.<8Q^'EUUT3OJ[=%;\3S6ZM9K*=X+B&2"9#A
MHY5*LI]P>145;WC1-=AUKR?$1E;4(8UC#2X)9!G:=P^]WYY_2M?P]X5T*?P9
M)K^L7MW;+%?M:^5;*K&4>6&"KD<-DDY)Q@=.]3RW;2.QXJ-.C&K/6]OAUNWV
M.*HKN]5\$:5);>']4TBYNY-)U*Z%I(EUM$T3[L$9 P>,]NW?-6?$7@?P_8Z\
M?#FFW6HW6NR3I'&SA/L\89APYP&)"G)(X_6G[-F*S&@VDKZWZ;6=G?M8\[HK
MU*/X8Z->:K+HMM_;J7ZAD34)[<"S>102>,9"D@@'/YURVK>$X+;P5I^M6SRF
M?[3)9W\+L&$4@Y7& , @=\]10Z<D%/,:%62BF[NW3O>WWV?S.6HKNM4\'Z%X
M?U'3++4[R^CN'L5N;N*!%D9I6(VPQC'RGJ26R.!ZTGB;P386OA0:YIL>J6BQ
MW(MI;7544/R,AE( X[=/Y4<CU'',*,G!:VEL[:>7WG+:UH-_X=NTMM0@^SSO
M&LJKO5LJ>AR":SZ]>\;^%I/&'Q*T[3UE\B/^S8I990NXHBALD#N>@_&L6Z\!
M:5J&E:K-I<6MV5SI\#77_$UA"Q3QK][:0HPV.0#_ (D4Z;N['-0S2G*G!U?B
M:3=EHKZ(\[HKT%O"/A?1_#&B:MJ]YJ1?4(F;[+9A"Q8-@D%A@*!C@Y))IES\
M,HY_'%CH^GWIETZ]MEOH[N1?F6 @G)'&3Q^HZ5/LY'0LRH.][I+FU:=O=WMZ
M' T5UFKV/A&:UFCT.YU9]1214B6[1#'<9;!V[0"OK\WTZUTK?#+1[#4[?1KP
M:Y-J#[$DOK2W!M(G;H.1D@9&3G\NPJ;>P3S"E32<TTW?1K6RM=^FJ_+<\NHJ
M]KFDRZ%K%YITY#2VTK1%AT;!ZCZ]:HUFU;0]&,E.*E%Z,*56*,&4E6!R"#@@
MTE%!1[K\,?B&/$-NNG7\@&HQ+A7/_+91W^M>@U\G6US+9W$<\$C131L&1U."
M#7T%\._'<?B_3_*FPFI0+^]0=''3>*[J53F]U[GYUG65?5V\107N/==O^!^1
MU]%%%=1\D%%%% !1110 4444 %%%% &#>);GQ?8LVIR17 A.VP!.R08?YCV]
M?^^:WJQ+MV'BJS4:0LRF(YU+',7#_+G']?XJVZI]#.'7U"BBBI- HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L'P\ENNIZP8=3DOG,W[R%R2+<
M[F^49_$?\!K>K$T%V;4=6!TA=. EXN ,?:>6^;H/KW^]5+9F<OBB;=%%%2:!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 % ZT4#K0!T%%%%:GF!
M1110 4444 %%%% !1110 5X?\;/B1YS2>'M-ES&.+N53]X_W!_6NL^+GQ%7P
MEIIL+*0?VM<J<$=84_O'W]*^;W=I&+,2S,<DDY)-<5>K;W(GWO#N4^T:QM=:
M+X5W\_\ (;1117GGZ0%>C?"_XAZ3X/TO5;+5+6[N$O&'_'LJGY=I!!RRXZ]J
M\YHJHR<'=')BL+3QE)T:NS[>6IZ@OB3X9V]U:SVWA_4XGAF64DMNSCD##3$'
MG%9GBGXI7&K>.[/7;%9(K>Q*BWAEP"5_C#8) +9(..V/2N"HJW4DU9:')#+*
M$9\\VYNS7O-O1[[]SUC5?B5X5U#QYI7B'^S+UA!&ZW"R1IEG _=L!OP2,GDX
MZ+Z5=\0_$?X?^*KM+G5=&U>[E1=BDOM"CV59@!^5>-44_:RU,/[&PZ<'&4DX
MJR:DT['I7A3XFZ5X2UO5H;;3IG\,WQ!6U<@R1_+@\%B#GD$$^G/%6-8^*.A:
M?X7O-'\)Z3/IZWFX327!&0&&&Q\S$DCCKQ7EM%+VLDK&LLIPTJBJRNWI?5V;
M6S:ZL]A\,_%7PKI/@RWT.YT[41F+;<_90J"1C]X[A(K<_AQQTKGM9USX?NEF
MVE:#?6\T=U%)*9V+*\0.77!E89(]OQKS^BAU6U9BAE5&G4E4A*2;=W[SLWYH
M]MU_XK^!O%%M!;ZEI&JSV\)S'$I$: XQT64 \=,]*\P\97F@7NJ1/X<L;BPL
M1"%>*X8EC)N;)Y9N,;>_:L&BE*HY[FF$RVE@G^ZE*W9R;7W;!117JWP8^&_]
MM72ZYJ,7^@P-^XC<?ZUQW^@_4TH0<W9'1C,73P-%UJKT7XOL=;\&?AO_ &%:
M+K6HQ_\ $PG7]S&P_P!2A[_4_P J]3HHKUX14%9'XIC,74QM:5:J]7^"[!11
M15G$%%%% !117Y]?M+Z[KO[2_P"W5X9_9U&OZEX=^'FF:9_:_B*'2[@P3:DW
MEF41EUY*8,*8Z#?(W)"X /T%HKY\^'/[(_PT_9<U/5/&?P\TGQ%IHM]+N%N/
M#NG:G<WL&H8"N"()G<M/^[VIM8<N1CD8\R\;_M^^-_@^FD^(/B9^SUKO@OX=
M:E?)8IX@DU^UNKJ$N"5,MDB[H^%8X9QTXR2!0!]H45\A?M*?\%!1^SU\<%^&
M<'PUU;QKJ]WHD>I::-&NBT]Y<O*ZK;>0(F(7;&[F0%CQC8>M5M8_X* ZU+K/
M@/P;X4^#6L^)?BIXBTA=8U#PC-J2:?\ V-&03LFN)H@ V%)^9$&"F2"P% 'U
M+;?$7PI>Z]K&AV_B?1I]:T:(3ZGIL6H1-<V,9 8//&&W1J00<L ,$&I_"/C7
MP]\0-%CUCPOKVF>)-(D=HTO](O([J!F4X91)&Q4D'@C/%?FO^S%XX@\?_MO_
M +4'B+6_"E_I<%QX3D&H^&M8 CG7RTMXYH'*DC!*, PZJ01UKUK]F[]J;X2?
M!?\ 86/Q+T[P+)\._"<6JW-M!X:LM2DU.XNKPO@!9Y@K.S@9^;A50\X44 ?=
M%%?&,O\ P4&\2> =6\)3_%[X':Q\,_!OBFX2VTSQ&VMV]^%9\%#<PJB-!\IW
M$,=P ;"MM-=!\1/VX]6\*_M(:_\ !?PU\)]4\<^*+/3X+S3SIVIQ0)<L\:2/
MY[2H$MHD5L>86;+;1M^;@ ^KJ*^'_!7_  4?\2?$FR\2:1X6^ /B/6/B-X8G
MN(]=\.+JL$=KIZ0DJQ>\=!ND++(JQ+&68QM@'%/U'_@I[H]O\&/AS\4+;P+=
M2^%?$.O/X>UR6XU$1/H5PNULX$3"X4Q^8XYCX0#@DA0#[=HKP#XL?M96OPY_
M:)^&OPDT_P /CQ#J7BR&6^O+U=0$"Z59IN/VAE\MO,4K%.W+( (NISQY./\
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M[#XC^*+/Q#=Z;;Z>\UQ::=:K;+=7 Q).1U8^W3K[UM>'K;2KSX1R0ZO>2Z?
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ML)Y91]I&HFU;ETTM[NW2_P D['K%U\2M,LOB+9ZM;2R7.GMIZ6<[Q(RNG7)
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MUU'52^KIJ*F7Y8%()MN6^4X)^G;[M;58'AQ[5M4UD0:;+92";][-)G$YW/\
M,,_B>/6J6S,Y?%$WZ***DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *!UHH'6@#H****U/,"BBB@ HHHH **** "N>\<>,;7P5H<E[/AYF^2"
M'/,C^GT]:Z&BD[M:&M*4(34JD>9+=7M?YZGQMK&KW6NZE/?7LIEN)FW,Q_D/
M:J5?:U%<7U6_VC[R/%:@E&.'LE_>_P#M3XIHK[6HI?5?[Q7^MO\ TX_\F_\
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M2_&>B^+9M>7P_JUJUG=7,0$T154EVD';.7&?O;,#J*_6FB@#\V?VE+[XD_\
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M_P"K"X?(//7[W;N*Z.J?0S@[W]0HHHJ30**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K*T=-06^U$WE[#=0&3_1XX@-T2Y;AL <XQZ]#6K7.>&'
MTMM7UT6$4\=R)_\ 2FE^ZS;GY7GIG=^E4MF9R?O1.CHHHJ30**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H'6B@=: .@HHHK4\P**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*P[C_CXE_P!X_P ZW*HR:9YDC-YF-Q)QM_\ KU+5S:E)1>IFT5H?V3_TU_\
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M:7:6%]I-[=:K8_VII\%OJOF/>6?R_P"D0J)"9(OG3YUROS+SR*W?^%5>%O\
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M73/A[XN\;0^%KCPOXMU6RTRYT71["YBOM$-\P6U9KI[ATNMCO'')B"')8LN
M-IY?XE_M*?$^UT#QUXH\*2^#]+TGPSXRA\')HFM:3=7NH7DAGMX6G5X[N%0S
M?:!)'!L):,*WF#?P<TNX<D>Q]'_\*J\+?] O_P F)?\ XJC_ (55X6_Z!?\
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MU>]T[4X4@NV/B-+8I+(\ \[_ (EW^CR(!O-WND+9"*HW^J:W\7/%?C;XKP>
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MPM_T"_\ R8E_^*H_X55X6_Z!?_DQ+_\ %5UE%'-+N')'L<G_ ,*J\+?] O\
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M_P! O_R8E_\ BJ/^%5>%O^@7_P"3$O\ \57644<TNX<D>QR?_"JO"W_0+_\
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M"T#X<Z"WC5[S1O 'BU]=T.*?3RTL>G"&:*#3GD,Q+F(3D"?'*HB[.-U?1%%
M'RYJO[&^OW?A/7?!=C\1K:P\$:GXG_X2IK8^'1+J+SF_CO6AGNS<[9(_,3@K
M$D@Q&"[*K*_OFG:!XDMOB!K.KW?BK[;X8NK2"&Q\.?V='']BG0MYLWV@'?)Y
M@*C8PPNWCK73T4 >(_$/PUK&A_M/?##QUIMA=W^EWFGZAX3UDVD#2_98Y?+N
MK:=]N2L8EMFC+G@&5<D9K%T7]GSXE^'/BQXR^(%I\1O"FI:YX@9;>&YUWP;<
MW,VFZ<C%H=/MVCU2)4A4DNVU 9')=R3MV_1%% 'AWB+PUK?C/]K'P-=S65S%
MX>\#^'[V_DU(VK);W>HWQ6WCBC9N&,<,5PS!2=OFQ@_>&.M^,/PC_P"%L2^!
M'_M7^RO^$7\46?B7'V;SOM/D+*OD_?79N\W[_P V-OW3GCT2B@#BOC5\./\
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M_5]"T;1HH;:_$C!X+C$3(JR1-O&XJQ97VY7%>ZT4 >#ZQ^RY_:W[(=E\#?\
MA)O*^S:19Z5_;WV#.[[.\;>9Y'F\;O+QM\SC/4XKM/BO\(_^%GZ]\.M2_M;^
MS?\ A$/$2:_Y7V;S?M>VWGA\K.]=F?/W;L-]W&.<CT2B@#SW1/A(FD_&7QIX
M\EU%;N/Q+I.G:6VEO;8$(M6N26+[CO#_ &G&W:,;>ISQX[^P#\'+WX:_#WQ%
MK6JV^JVMWKNJRPZ;;:Y;/;7EGHEH[P:;;R1. R8CWR!2 1YW(SFOJ2B@#YI@
M_9#U9?V=M0^#4WC>R?PS#>V<VAW46@LEW96\&I+>^3<-]J*7!(1(@Z)#@ L5
M8G ]7UGX5?VO\;_#'Q#_ +4\K^Q-%O\ 2/[-^S[O.^TRV[^9YFX;=OV?&W:<
M[^HQSW]% 'S[X=_9/_L#X"_"WX:_\)3Y_P#P@^MZ7K']I_V=M^V_8[P7/E^5
MYI\O?C;NW-MZX/2NE\1_LZZ9XP^)_C7Q-K5^;S2/%7A"/PA>:*(-I$*RW#O(
M)M_5A<%0-HQMSDYP/7:* / -+_9L\3:C%X(T7QMX_MO%'@[P;=6]]IVG6NA&
MRO+R>VQ]C>^N3<R+,(\!B(XH0[JK'@%#\SR_#;5/"OB#Q_XLT[P[XJL?CA)X
MIU*^\/Z;;_#VUU'3I7FN2;7?K<NG.1!(C@R2?;81$KNH$?EXK]%Z* /&+CX.
M>+]/\>7_ ([\'>*-&\+Z_P"(]/M(/$NG:MHDFK6-S<6Z;89H/+NK:2)U5I(R
M2[JZB/Y5*DMJ:U\%;O7_ (@_"CQ9?^*)KV]\##4#,9[*,/J;W5KY!8F,HL6W
M[V C9Z<=:]3HH ^??B1^R?\ \+!T?XVV/_"4_8/^%E76FW/F?V=YG]G?9(+:
M';CS1YN_[-G/R8WXYQD]!XC^"_BJQ^)/B+QE\/?&FG>%[SQ+9V]OK%IK6@MJ
ML$DMNI2"YA"75N8Y!&Q1MQ=6"Q_*-O/L5% &1JWA:Q\2>$KWPYKJG6]-O[%]
M/OUNPH-W$\9CD#A H&]2V=H4<G %>6^!?@_\2/ 6D:1X7M/BI;7?@_2FCAMI
M+OPV)-=^R1L#' ]Z;GR&(51&9#:;BF>CGS![310!\N>)OV-_$&K>&O'WA#3/
MB/;:3X,\7>(9O$MQ _AT3ZDMQ+-',\3W1N0LD/F1C \E9 H1?,.W)]?\,_"/
M_A'/C=XX^(?]K?:/^$FT[3=/_LW[-M^S?9//^?S-YW[_ #^FU<;>ISQZ)10!
M\Q^+OV/]?U?P'\0?A]H/Q*'ASP!XMN[^_-B-"6XO[*6[R\L,=R9PAM3,6<Q^
M2)-KL@F7AAVM_P#LTZ=KGC]]=U?4_P"T-)N/ ,G@.\TC[+L^T0R2J\DWF[SM
MRH*[-IZYW<8KV>B@#Y]TG]F;Q)>:;X*\->,?B!;^)O W@^[M;S3].M]#-I?7
MCVC V0OKHW,B3+'M5F$<,7F,BEN-RMM1_LY;-!^.6F_\)#G_ (6;-=3>;]B_
MY!OG6$=GC'F?OL>7OZIG..,9KVBB@#R+4/@#]OU/X+7G]O;/^%;L[;/L>?[1
MW6#V?7S/W7W]_P#'TQ[UYKHGP6N=6_;Z\3^-3::G;>$]'T:TO%2ZM&BM+K7Y
MHGMFN+=R-LOEV2+&[+G#2@$@C%?4]% '@][^SQXJT75/'</@7X@6OA;PUXUO
M9-3U*PN]!-]=VEW,@CNIK*X^TQK$9%16VRQ3!9-S $,5K@?%WP)USPQ\>O@;
MI?PVEO/#6B^$O"6J:?;ZM/IKZA81X:S6."\^9-_F*KG EC<LFX-\I!^MJ* /
MG+5/V0Y=9\'ZFM[XQ^T>.M2\7VOC6YUU]+!L7O+9D%O ;'S<FU2*)(Q&9B_R
MAC(6K=\)?LZZK%XK^(_B#QMXPB\47?CG1;;1+VWT[2!IUO:Q0_:EQ K2S-M*
M7(XD9VW*S;BK*B>X44 ?/EE^S)XAN?AG\,O!^O>.-/U%/ .O:1JEA>V6@/:O
M<6U@@5()E:ZD!D<#F5=H'_/.O1;;X5?9OCUJ7Q*_M3=]L\-6OAW^S/L^-GDW
M5Q<>=YN[G=]HV[=O&S.XYP.^HH ^6/V*?@K<^!-;^*/BB_M=4L[>_P#$%YI7
MAJSUBV:WEL]$ANYYHECC8!DB>>YN74$<IY1[@#W_ .&?A_Q+X7\%:?IGB_Q7
M_P )OXAA:8W.N_V=%I_VD-*[1CR(R439&R1\'YMFX\DUU%% 'B_[7'A#6O$_
MP=DU#PU9S:CXD\+:I8>*-.L;>/?+=265RD[0HO5F>-9$51U+ <YKH/%6A_$C
M7KW^T?!OCG2?#VF7UE$/[.\1>%9+^6UEPQ,D92[MF0D,NY)1)@H,;<D'TBB@
M#Y=^*OP'D\,?L[>%?@GX1@U75K77_$-K;:IJ\T/FO%;/>-?ZC=W#JH1-X25
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MMY\W/E[\X3KCMFO4Z* /)_AW\'O$OPVT#X2>'M,\=8\.>#=';2M7T[^R(O\
MB?E;>.*WD\QG9[;RV1GVH6W;]I.!FO6*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img147150826_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '% Z0# 2(  A$! Q$!_\0
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M?V26_:A^*'[1OAK7M=\)Z=_POGP]\$UAO="O+^*71Q>>*O GB30)6EL-,O\
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M0Q%JU##1Q=:G4I5J4J>'E&$_:2]K3@O=C4@YQOST^:*J1BW8^^:*_ +]DO\
MX+R^#/C[\!/VT_V@/BQ^SGXB^!/AW]C/P[\)_$6M:)I_Q$A^)NN>.$^,,OC"
MQ\*:7IT5QX#^',>@ZI<ZOX:TW34COC>69/B.VN;N\L8;&YW_ %!^Q]_P4 _:
MB_:2\9?"Y/B1_P $XOBA\!?@C\;O"%YXW^&'QY/Q=\'_ !2T&;06\-W/BOPW
M=?$/PQX>\-Z+K7PP_P"$NTF&"+0H_$DS37.J:EIEC%%*M]#<-IB>'\VP?UOZ
MUAJ=#ZE)0K^TQF"C[\L-3QBIT/\ :?\ :ZBPU6G6E3POMIQA-.44]"*&=9;B
M?J_L*\ZOUI.5'DPV+?NJO/#<];]Q_LT'7ISI*>(]E&4HM1;6I^KM%%%>*>H%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!_)]^U[\./C?\5O^#A7PIX-_9[_ &AY
M?V7OB/??L76\UK\68/A9X6^,,VG:/;Q>.&UC2(?!OB_4=*TAI=9M6^S1ZNM]
M#?Z0ZBZL2)P"/(?^"G?_  3[T;_@GM_P3U\(^%=$\=?$/XJ^%OC7^W/\./'O
M[=7QD\0)<6FO>,M$N-,\5C34U?3_  [)<SZ+X'M=?GDU!(KB^UO59_B!K%C=
MRZ]<7FHZ1I]K_6ZWPC^%#_$N/XSO\,?AX_QAA\.GPA%\6&\%^&V^)<7A,S27
M!\+Q^.SII\4)X=-Q++.=$751IIFDDE-MO=F/5>(?#OA_Q;HFI^&O%>A:-XF\
M.:W:2Z?K/A_Q#IEEK6B:O83C$UEJ>E:E!<V%_:3#B6VNH)89!PZ$5]A1XLK8
M>KDZITO]CR_#8&EBL.H8>G5Q=3!NLXU'BHT77<:3J^UPM.K.I2H5XJK&FI-M
M_,U>'*5:GF;J5/\ :<;7Q53#UG*M.GAJ>)C24H+#RJJCS5%3=.O.G&%2K2E[
M.4W%)+^2GXCK^PVG_!6'_@G3??\ !,:^^&>DP:3X ^,&J?M3:S^RE)H$/@/1
M_@E:^#X?L.I>*9OA[%/I\7C6WT)_'(\1-J\,WBAM5?P''?12>)WTM#\N?L4V
M7[-O[.'[6O[)G[/FDV'[#'_!1;X/_M"_%/QK<_#'X\_#O39;']L7X:1>,-(O
M_#U]9_M(Z TR:C)X/D\/>)+_ /MCX:?$K3=4T>\T-?$VI0"TGTA-+7^RWX5?
MLZ?L^? E]6D^"'P)^#?P;DUXJ=<D^%7PP\$_#Q]9*%&0ZLWA'0](;42C1QE?
MMAFVE$(P57%'P-^S#^S5\+_&&H?$+X:?L\_ WX=^/M62>/5?''@;X3> ?"7C
M#4TNE=;E-0\2Z!H&GZU>)<+(ZSK<WL@F5W$@8,<]"XKP\</5POLLQK4?[.^I
M4YU\73^L8BHIYA5IU\3B*=.->#P\\<XT84:KA*A"5&M"HJB=/'_5VM*M3Q'M
M,%2J+'/%3C2P\_8T:;C@J<Z-"A.<J,E7C@^:K.K34XU9QJ4I0<&I_P SW_!&
MG2O@EX'^(/\ P4@\!>!/#W[+'A3]OCP_^U+^TOX;_9-\-?%GPUHFC>*_#UMI
M?A7Q3!H>A6EGH.G6_P 5M#^"6D:IH5[9?$'3?AZ+2+2M BU#3XX;;4=0TV"Z
M_H*_9)_X>#_\7 _X;N_X8V_YE3_A5?\ PR3_ ,+M_P"ID_X3C_A8'_"X_P#N
M4/\ A%/^$<_ZF3^U_P#F%U[=9? #X#Z9\4;SXX:;\$_A'I_QJU"VGLK_ .+]
ME\-_!MI\4;ZSNK9+*YM+SX@0:-'XLN;:YLXX[2>";5GBFMHT@D1HD5!ZW7BY
MQG,,SKUZT,.D\52POM)XFU:OAZM"$(SAA*RY>3#S<+N,H.4G.I>W-IZF697/
M 4:-*5:ZP\Z_)'#WI4:U.K*4HSQ-)\W/7BI6YE)17+"U^4_C)_8"_P"4!G_!
M73_LN'[57_JE/@56%\0?V?/"_P +?^#;WPS\9?@)\,-&T'XK?%+P7X(3]H/X
MI^'-%$GQ*\5?"W7_ (N6TOB?2/$7BZ%)/$5UX)AU#0?!EG<:!+>'PYH_AVTN
MX([*TT^XU1I_Z\M#_9X^ 'ACP)XP^%WAKX&_![P]\,OB'?:UJ?C_ .'6A_#/
MP5I/@3QSJ7B2SM-.\1:CXP\(V&B6_A_Q-?:_I]A8V.M7>M:?>W&J6=E:6U])
M/!;0HG9>'OA]X"\)>"K'X;>%/!'A#PS\.M,T:3PYIO@'P]X:T;1?!6G^'I8I
M8)=!L?"NFV5MH5IHTL$TT,FEV]A'8O%-+&T!21U/L3XNBL3.O1PU91GQ!ALY
MJ495E&%:A0P\*7U6KR)J3E.'.I.,H1:C)PDU8\V'#<G0A1J5Z;<,EKY7&K&D
MW.G5K5G4^L4^9JR46X.*E&4DVN9)W/XS_P!BWP-/?_ME_P#!/+XI?#SXP_\
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MZ2-=Z!+XJT;59-'NF>*-S<:<UM*7C1B^44C=\%?"GX7?#6[\5:A\.?AMX!\
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MA>//"]C^RU^SG9^&?BI+IEQ\3_#MI\$?AG;Z%\1Y]$U9-?T:;QYI$/AA-/\
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M9X;,*D8XGVE&#H9XLVE&@JG\-3I.6'C"G"E3A/FJ6E[6=JGPOB7-KZ[1E".
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M#?!GX/?\%D_V8/CW\6IK']F'X-?%;_@DU\,+KP/'\5M>&F:7X2BUC3!KNF>
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MGPMI%A=7:7D'C#PCJVHZ3X:N])M[=];6#2+3P7I_V:.\TCQ'X-EO+G2-3?\
MJAMOV?O@-93_ !,NK/X)?"*TN?C5=6=[\9+FV^&W@V"?XM7FGR7TUA=_$R:+
M14D\>75C-J>I2V=QXI;59;:34+YX71KN<R5/A5^S?^SO\"KC5;SX(? 3X+_!
MR[UR,1:W=?"KX6^!_A[<:Q$)(I1'JL_A'0M(EU",2P0R!+MIE$D,3XW1H0JG
M$V&JQS'VF'Q5:.-PN'H+!UYX:I@O;4,IPF7T\9)3H3KTL31K4)XB-7#U83JQ
M5&E.5-0DYNGD->G+!<E?#TI87$5JSQ-*%>&*]E5S+$8V>%3C6C1J4*M*K&A*
MG6ISC3E[6I%3YE&/M%%%%?&'U!RVN6GC:XNXW\-^(/"VDV(MT66VUSP=JWB&
M[>[$LQDGCO;#QSX9ABMVA:"-+5K":5)8YI6O)%G2&WQO[-^*W_0Z?#W_ ,-C
MXD_^>Y7H5%6IM*UH:=Z<&_O<6W\V9NG%MMNI=ZZ5:L5TV2FDMMDDM^[//?[-
M^*W_ $.GP]_\-CXD_P#GN4?V;\5O^AT^'O\ X;'Q)_\ /<KT*BCVDNT/_!=/
M_P"1%[*/>K_X.K?_ "SR_/NSSW^S?BM_T.GP]_\ #8^)/_GN4?V;\5O^AT^'
MO_AL?$G_ ,]RO0J*/:2[0_\ !=/_ .1#V4>]7_P=6_\ EGE^?=GGO]F_%;_H
M=/A[_P"&Q\2?_/<H_LWXK?\ 0Z?#W_PV/B3_ .>Y7H5%'M)=H?\ @NG_ /(A
M[*/>K_X.K?\ RSR_/NSSW^S?BM_T.GP]_P##8^)/_GN4?V;\5O\ H=/A[_X;
M'Q)_\]RO0J*/:2[0_P#!=/\ ^1#V4>]7_P '5O\ Y9Y?GW9Y[_9OQ6_Z'3X>
M_P#AL?$G_P ]RC^S?BM_T.GP]_\ #8^)/_GN5Z%11[27:'_@NG_\B'LH]ZO_
M (.K?_+/+\^[//?[-^*W_0Z?#W_PV/B3_P">Y1_9OQ6_Z'3X>_\ AL?$G_SW
M*]"HH]I+M#_P73_^1#V4>]7_ ,'5O_EGE^?=GGO]F_%;_H=/A[_X;'Q)_P#/
M<H_LWXK?]#I\/?\ PV/B3_Y[E>A44>TEVA_X+I__ "(>RCWJ_P#@ZM_\L\OS
M[L\]_LWXK?\ 0Z?#W_PV/B3_ .>Y1_9OQ6_Z'3X>_P#AL?$G_P ]RO0J*/:2
M[0_\%T__ )$/91[U?_!U;_Y9Y?GW9Y[_ &;\5O\ H=/A[_X;'Q)_\]RC^S?B
MM_T.GP]_\-CXD_\ GN5Z%11[27:'_@NG_P#(A[*/>K_X.K?_ "SR_/NSSW^S
M?BM_T.GP]_\ #8^)/_GN4?V;\5O^AT^'O_AL?$G_ ,]RO0J*/:2[0_\ !=/_
M .1#V4>]7_P=6_\ EGE^?=GGO]F_%;_H=/A[_P"&Q\2?_/<H_LWXK?\ 0Z?#
MW_PV/B3_ .>Y7H5%'M)=H?\ @NG_ /(A[*/>K_X.K?\ RSR_/NSSW^S?BM_T
M.GP]_P##8^)/_GN4>&-5\5_\)7XD\,>)[_P]JO\ 97A[PCKUC?:#X?U+P]_R
M,.I>--/N;2[MM0\4>*//\C_A%[>:">&XM?\ CZFCDA?8CUZ%7GNF_P#)5O&G
M_9/?AC_ZDGQ<JE)RC4NHZ135H0BT^>"WC%/9M;]1."A.DXN>LVFI5*DDU[*H
M]5*36\4[VO=>;/0J***R-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***X'X;333^'M1>>629U\??%:%7E=I&$-O\4?&-O;Q!G)(C@@BC@A
M0';%#&D:!415#M[KEV<5;_$I/_VW\27*TXPM\49ROVY'!6MY\_RMYG?4444B
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **_+KX->)/VJ/B;\+_  9X]O/VE5TVZ\3Z0NI36,/P:^'ES';.
M;BXA\M)S';F48A#%O(BR20$ %>F_V1^T]_T=&W_AD_AW_P#%5W1R[%SC&4::
M:DE)/VD%I))K3F[/\'Y7X99CA(2E&51IQDXO]W-ZIV?V>]_N]+_?%%?E1XQ^
M-OB+X=^+='\ _$#_ (*)_"+P+X[\0^1_8'@KQCX>^!'ACQ;KGVJ18K;^Q_#F
MMZY8ZQJ?VB5EC@^Q6<_G2,J1[F(!]?\ [(_:>_Z.C;_PR?P[_P#BJTEE./BH
MRE0<8S5X2E**4DK7<6W:25]6K_E>%FN!DVE6NXNTDH3;B]-))+1^3[>E_OBB
MORK^'/Q@^)'Q:\5_%CP1\/OVSQXA\4? [Q=;^!?BEI:_L]>'-,/A;Q5=:>FJ
M0:4;S6=+TZPUG?8N)OMWAZZU;3D8/ ]XMQ')$OKG]D?M/?\ 1T;?^&3^'?\
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MKJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\]^&/_ "+>I?\ 90OBY_ZM;QI7H5>>_#'_ )%O4O\ LH7Q<_\
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M2K5.=RE"K7G3JQ=6I2<VXTYWI3;FZB:=H_SX_$+X@_MB? 3X@?\ !7W]IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&I_@7_IRF9S^*C_ -?'_P"FJIZ%1114&@4444 %%%% !1110 4444 %%%%
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M_4W_ (:*_9]_X03_ (6E_P +U^#?_"LO[4_L3_A8O_"SO!/_  @G]M>5Y_\
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M \5PWCZ=-X8/A-=?.O#Q#%J"/82:*=/_ +22\1[5K83J4'XQ^(M<_9:^$_\
MP6G^'6O^%?'GPJ\,Q:[\)/BC_P +AURX^)>CW*I\<O$?B3QC877AWQ9JFM>(
M[S^P_&4X&D:5IO@B>?3YM.MAINE:1HEI:BUMJ^9_%L'P\^ ?[7/ACXP? /\
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MG_8B^+O_ %']0KC?V:?^3<O@!_V1/X5?^H)H- 'ME>>Z;_R5;QI_V3WX8_\
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M_:!^,_P>/[&?@/X<_M.Z)^QSX ^//QUU;P'\8OVA;W3/"VN:IX&T2U\-)?Z
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MV4#XL_\ JU/&5>@5Y_\ #3_D7-2_[*!\6?\ U:GC*@#T"BBB@ HHHH ****
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M[0DTB\U'2_B7^SM_9]W*EU<S>=:?:_B[!<^45F4#SH8WR#\N,$]QXQ\<^/\
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MM[FRO7TW6M%\):1INJV#7FFW-[IUVUG?6T]NUS87EW93F,RVMS/ \<K^IT4
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M_90OBY_ZM;QI5K^'+_'3_P#2:AE+^/3_ .O5;_TN@>A4445!J%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M KS_ .&G_(N:E_V4#XL_^K4\95Z!7G_PT_Y%S4O^R@?%G_U:GC*@#T"BBB@
MHHHH **** "BBB@ HHHH **** /E']M__DU[XG?]R7_ZL/PG7\^M?T%?MO\
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M2_CT_P#KU6_]+H'H5%%%0:A1110 4444 %%%% !1110 4444 %%%% !1110
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M/_5K>-*M?PY?XZ?_ *34,I?QZ?\ UZK?^ET#T*BBBH-0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OY?\ _@Y$_P";,_\ NXC_ -X97]0%?R__ /!R)_S9G_W<
M1_[PRM*7\2/S_P#26?D_CC_R:[BC_NB?^M%E!_+_ $445V'^>X4444 %%%%
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MGJ]%%%?SP?J(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSH/@#_ZM?PG2EL_1_D>MD'_(]R7_ +&V7?\ J91/]&"BBBN _P!2@KSW3?\
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M_@#_ 'S,/^P:E_Z=9ZO1117\\'ZB%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y[\,?^1;U+_LH7Q<_P#5K>-*]"KSWX8_
M\BWJ7_90OBY_ZM;QI5K^'+_'3_\ 2:AE+^/3_P"O5;_TN@>A4445!J%%%% !
M1110 4444 %%%% !1110!\'_ /!0S]MK_A@SX+>&/B__ ,*S_P"%J_\ "1_%
M#1?AM_PCW_"9_P#"#?8_[8\*>-?$_P#;7]K?\(IXP^T?9_\ A#_L/]G?V9!Y
MW]H_:?MT7V3[/=?C?_Q$B?\ 5F?_ )L1_P#B,KZ@_P"#AC_DR[X8_P#9T'@O
M_P!51\:Z_C?KHI4X2C=J[N^K7Y,_DGQB\3N..%>-*^4Y#G?U#+X9=@*\</\
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M3==8537#N1.#Q3=EAE+^QN5UV]%13]I?3E/Z./\ B)$_ZLS_ /-B/_Q&4?\
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M3O\ N2__ %8?A.OY]:_H*_;?_P"37OB=_P!R7_ZL/PG7\^M?TMX-?\DQC_\
ML?8K_P!5^5GY+QY_R.,-_P!BVC_ZE8P****_6CXD**** "BBB@ HHHH *_IA
M^ W_ "0WX,_]DH^'?_J(:/7\SU?TP_ ;_DAOP9_[)1\._P#U$-'K\6\:?^17
MDG_8?B/_ %'1]_P!_OF8?]@U+_TZSU>BBBOYX/U$**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSWX8_P#(MZE_V4+XN?\
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M_JU/&5>@5Y_\-/\ D7-2_P"R@?%G_P!6IXRH ] HHHH **** "BBB@ HHHH
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M<O\ '3_])J&4OX]/_KU6_P#2Z!Z%1114&H4444 %%%% !1110 4444 %%%%
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M8_4I0]A'VKJ<RYH?T 4445\8?4!1110 4444 %>?_#3_ )%S4O\ LH'Q9_\
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MC&#E&..BHR^U*"Y']]4445\J?0!1110 4444 %>?_#3_ )%S4O\ LH'Q9_\
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M4 %%%% !7],/P&_Y(;\&?^R4?#O_ -1#1Z_F>K^F'X#?\D-^#/\ V2CX=_\
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M_P#H2?\ F2RC_P";P_UNX>_Z&'_EICO_ )F/U<HK\H_^'G?_ %1#_P R5_\
M@!1_P\[_ .J(?^9*_P#P H_XAEQO_P!"3_S)91_\WA_K=P]_T,/_ "TQW_S,
M?JY17Y1_\/._^J(?^9*__ "C_AYW_P!40_\ ,E?_ ( 4?\0RXW_Z$G_F2RC_
M .;P_P!;N'O^AA_Y:8[_ .9C]7*\]^&/_(MZE_V4+XN?^K6\:5Z%7GOPQ_Y%
MO4O^RA?%S_U:WC2OAE_#E_CI_P#I-0]^7\>G_P!>JW_I= ]"HHHJ#4**** "
MBBB@ HHHH **** "BBB@#\'_ /@X8_Y,N^&/_9T'@O\ ]51\:Z_C?K^R#_@X
M8_Y,N^&/_9T'@O\ ]51\:Z_C?KKH_ O5G\&_2"_Y.-B?^Q3E7_IJH%%%%:GX
MB%%%% !1110 4444 %?Z@%?Y?]?Z@%<]?['_ &]_[:?UA]%__FN/^[9_]^ *
M_P O^O\ 4 K_ "_Z*'V_^W?_ &X/I0?\T/\ ]W-_[[X4445T'\GA1110 444
M4 %%%% !7]D'_!O/_P F7?$[_LZ#QI_ZJCX*5_&_7]D'_!O/_P F7?$[_LZ#
MQI_ZJCX*5E6^!^J/V[Z/O_)QL-_V*<U_]-4S]X*_E_\ ^#D3_FS/_NXC_P!X
M97]0%?R__P#!R)_S9G_W<1_[PRL*7\2/S_\ 26?TUXX_\FNXH_[HG_K190?R
M_P!%%%=A_GN%%%% !1110 4444 %?4'[$/\ R>C^R'_V=!\ ?_5K^$Z^7Z^H
M/V(?^3T?V0_^SH/@#_ZM?PG2EL_1_D>MD'_(]R7_ +&V7?\ J91/]&"BBBN
M_P!2@KSW3?\ DJWC3_LGOPQ_]23XN5Z%7GNF_P#)5O&G_9/?AC_ZDGQ<JX_#
M4_P+_P!.4S.?Q4?^OC_]-53T*BBBH- HHHH **** "BBB@ HHHH **** "BB
MB@ KS_X:?\BYJ7_90/BS_P"K4\95Z!7G_P -/^1<U+_LH'Q9_P#5J>,J /Y_
M?V]OV]?VL?@O^UE\5_AI\-/BNWAKP3X:/@;^Q-$'@?X;ZP++^V/AMX.U_4?^
M)CKW@_5-6N/M.K:K?W?^EW\_D^?Y$'E6T4,,?Q__ ,/1OVZ_^BZ-_P"&U^$'
M_P [^E_X*C_\GV?'3Z_#/_U3WP^KX H ^_O^'HW[=?\ T71O_#:_"#_YW]'_
M  ]&_;K_ .BZ-_X;7X0?_._KX!KU/X.:1\)=:\<VEO\ &[Q=XC\&_#NVT[5M
M0U;4/"&BC7/%&HW-G832Z9H&A6\L,UA:ZAK%^(;6/4=60:59H7DO)(4(E0 ^
MJ_\ AZ-^W7_T71O_  VOP@_^=_1_P]&_;K_Z+HW_ (;7X0?_ #OZ^C9_^"=7
MP<^(/C/]D:?X+?$?Q]IWPV_:2TWQCK^JV7Q//A)_B5X>T'P3HEOX@OKG3++1
M+72]*OY-01WT%WMX-4M]$U&\TK5O,UW2)[@VZZ!^P%^SO\9[3X4>-_@-XX^.
M%O\ #K6OC5XF^$'Q,LOB=HGAJT\964WAOPGK?BXZMX4-CI>CV$4.J1Z%%HEG
M'>:?KL]OJ'B6P.I6UG?Z!KN@D ^<?^'HW[=?_1=&_P##:_"#_P"=_1_P]&_;
MK_Z+HW_AM?A!_P#._KO=>_8I^&6F2>"OBW>>(?&WA#]FFX^ ?AGXU_$5]=UK
MP[K/Q,T+5_$VH:YI7A_X7^&KZ'PIX:T#6?$WC74],AM?"M[<^';:UMX8-<O]
M9M88=/LH]3_,Z^>RDO;R33+>ZM-->ZN'T^TOKR'4;VULFF=K2WO-0M['2X+Z
MZA@,<=Q>0:9IT-U,KSQV-HCK;Q@'WI_P]&_;K_Z+HW_AM?A!_P#._H_X>C?M
MU_\ 1=&_\-K\(/\ YW]? -% ']$'_!+S]LO]I/\ :(^/OC#P5\8_B0?&/AG2
M_A!KWBFQTP^$/ >@>1KMEXT\ :3;7WVSPOX7T34)/*T_6]3M_LTUW)9O]J\V
M2W>>&WDB_>"OY@/^"*7_ "=-X_\ ^R >*?\ U8OPKK^G^@#Y1_;?_P"37OB=
M_P!R7_ZL/PG7\^M?T%?MO_\ )KWQ._[DO_U8?A.OY]:_I;P:_P"28Q__ &/L
M5_ZK\K/R7CS_ )'&&_[%M'_U*Q@4445^M'Q(4444 %%%% !1110 5_3#\!O^
M2&_!G_LE'P[_ /40T>OYGJ_IA^ W_)#?@S_V2CX=_P#J(:/7XMXT_P#(KR3_
M +#\1_ZCH^_X _WS,/\ L&I?^G6>KT45^&WQ;_;#_:-\,?%7XF^&M#^(OV'1
M?#WQ!\9Z'H]E_P (CX%N?L>EZ3XCU*PT^U^TWGABXN[C[/:6\,7GW4\]Q+L\
MR>:25F=OQ_ACA/,>+*^*P^75L%1GA*,*U1XVI7IQE"<^1*#H8;$MR3U:E&*M
MLV]#[G.,ZPN2TZ-7%4\14C7G*G!8>%.<E*,>9N2J5:22MM9MWZ'[DT5_/K_P
MV_\ M0_]%._\LOX>?_,G1_PV_P#M0_\ 13O_ "R_AY_\R=?9_P#$&N)_^@_(
M?_"K,/\ YUG@_P"OF3_] V9?^"<+_P#-A_0517X;?#7]I?\ :[^*&OW.A:-\
M8/#FB)IVD7NOZQKOBW1/AMH/AW1-&T^2VAN=1U34IO"$IB@6XO+2W AM[B7S
M+A':-8$FFB]<U[Q;^W;X?\9>%O"-Q\8O EW;>,- U+Q1HWC6RLOAU_P@K:%H
MUNMWJVHW.MWO@6RGAMK&UFL[B28:?)%-#?VDEH]PK2F'S,3X:9EA,2\)BL^X
M8H8E4*F(=&IC<PC+V-*G*K4EKE=KQI1E5<+^T]FG-1<=3LI<6X2O25>CEN;U
M*+J1I*<,/A6O:3E&$5_OETI3E&"DUR\[4;\SL?K;17Y.ZUXB_;NT?7_!>DQ_
M&?P'KFD>.]+US6M'\<^'M)\%:IX'ATOPYIG]L:O>ZAK$?PYCN8;>'3BMQ;R6
M^G72ZAN\O3C=21S)'RC?%/\ ;9'BW_A&A\8/"QTL> K/XH2^/F\,^$(? ]OX
M!U#3S?V7B6XO;CX<PZW#;73C^SX+)] &JRZCF".P:-6G7&GX>8RM'GI<0\+S
MC[">)NL9F/\ "IUJF'GOE-U45>E4I>P?[YSA**IMIERXHH0?+/*\XB_:1I6>
M'POQRA&I'_F-^%TYPG[3^&HR3<DF?L;17\^O_#;_ .U#_P!%._\ ++^'G_S)
MT?\ #;_[4/\ T4[_ ,LOX>?_ #)U[/\ Q!KB?_H/R'_PJS#_ .=9P?Z^9/\
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M!'<:D+>RA33=1U+7-4L+A;=[G1HK&74)[;C?AG\4?#B?#GQAJ_C?PK'+X/\
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MF?\ W<1_[PRL*7\2/S_])9_37CC_ ,FNXH_[HG_K190?R_T445V'^>X4444
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M?'G_ )+E\9O^RK_$3_U+]8KP?!;_ )&F=_\ 8!A__4AGI<?_ .YY?_V$U?\
MTTCRBBBBOZ'/RX]S_9X^"E_\>?B-;^#+;48])L+/3;CQ%XAU#Y'NX-!L+RPL
M[I=,@DQ%<:G<W.I6=K:I,R01&=KN<M#;21O]A?%GX$_&?XO_ !1^&/P[N?"
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M_)#YW_W3?_5O@#Z'A'_DH<O_ .YO_P!0<2?JY7Y]?\%(_P#DAOA7_LJ^A_\
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M/U1^W?1]_P"3C8;_ +%.:_\ IJF?O!7\O_\ P<B?\V9_]W$?^\,K^H"OY?\
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M]G_2?@3;_!^\^'OBG6=7^**^-/ 'AGXV7W[27AZX\.?#7QIIWB.?X9ZQXO\
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MXO++3YY);(7@L[S-JD:WMO<)!)<0+%<2@']"'_"Q_P!EG_H?/@!_X5'PZ_\
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M_+U_I:_T=_\ "Q/V7/\ H>O@%_X4_P ._P#Y.H_X6)^RY_T/7P"_\*?X=_\
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MSB44?\06RO\ Z'6/_P#"?#_YA_Q%#'_]"O!_^#JW^7K_ $M?Z._^%B?LN?\
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MN/B_XFT'1X=1U_7VLM,L(IKRYTW1M,CN;N))+FXL=.M0TLMO"WQ=_P $Q/\
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M "/]#K_AJG_@GY_T<A^QS_X>#X*?_-%1_P -4_\ !/S_ *.0_8Y_\/!\%/\
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M'['/_AX/@I_\T5'_  U3_P $_/\ HY#]CG_P\'P4_P#FBK_/%KZ!_:2_9O\
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MS.>_]$QE/_A9C/\ (_T.O^&J?^"?G_1R'['/_AX/@I_\T5'_  U3_P $_/\
MHY#]CG_P\'P4_P#FBK_/%HH]@OYG]R#_ (F9SW_HF,I_\+,9_D?Z'7_#5/\
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M<&Y@,$CW0:3Y7_X8;_:E_P"B7_\ E[?#O_YK:/\ AAO]J7_HE_\ Y>WP[_\
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M=_PQ!^U#_P!$Q_\ +T^'G_S64?\ #$'[4/\ T3'_ ,O3X>?_ #64?ZU<,?\
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M_HF/_EZ?#S_YK*/^&(/VH?\ HF/_ )>GP\_^:RC_ %JX8_Z*/(?_  \9?_\
M- ?ZOY]_T),W_P##;C?_ )2?5W_!,3_FM_\ W37_ -W^N9_X*F_\HM/VHO\
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M_P#S,'P$_P#GI4<\/YH_^!+_ ##_ %"XZ_Z(OBS_ ,1S./\ YC/R_HK]0/\
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M/\/:=>NEEHVC6]E^67_#F7_@I1_T;?\ ^9@^ G_STJ/^',O_  4H_P"C;_\
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M'_S&?E_17Z@?\.9?^"E'_1M__F8/@)_\]*C_ (<R_P#!2C_HV_\ \S!\!/\
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MZ4)8CJ5QJ%K;PV(DC^U/%O7/P]\&?V-]4U#QO\6O%'QNG\7VWAV#]M?XE?M
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M?#&H2QCQ%J^@W8\4^*+S18M9\+V_B/4=5TZT\8^)9XEUC4JNE_ _]I+7]/\
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M+4C&4J]%4WA\1*$9K%4J5!MQH^TKU9TN>K!T*BI3A*2Y'[/VB_2?5_B)\/\
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M^%&J>++?]K.'X>>*O@]XNTWQ;\+]-\-ZA>^&M(T2PU?PCK=OXD\>Z)XJT/Q
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MJS^*@@U?4/$\2:!_PB]_X>\01L?$%YI$>O&WED\/'68KVW>Y^^?@#\)/B?\
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MUC_@I'\"-1U#]I3P?\)M=\#?$+XD?L\:!H6MVND:[\:OA!\.? OQ9_M?0/\
MA(=67P#\3-7\6ZII@TSP! DVE?$G7=<TC3=/\':_&-,O#+O$Z_GA\-OV'_VH
MKOQYX+U_XB?"[Q!J'AY/^"G7B']J'63\1/%_P(O_ !(/AKK'@;2X+3QWXPT?
MX:Z[;^ CXPF\0:?9)XC\/^ M*DCAUNQ>31=.O- M]/U*?Z ^.W[,_P"T%K'C
M3_@J?:>%/A1K'BS2?VQ/A/\ !JV^$GBK3/%?PPT[04\1?#/X33^"-8\*^)[;
MQ-X^T'Q3I&JZEJSQR:+?Q>&KWPW+:F234M=TMD59:487LVGL_B27Q1WVZ-WU
M6SMY?/5>)^-\9@8XFCD6+RODQ>(PM6C_ &+CZV85J:X8SG'4L51IUX5:>%C+
M.L/EV#HRGAL=1I8C$TJ>)=>G&=+$?IKIOQ[^%J3?#/P[XQ^(GPO\%_$SXH^%
M_#OB/PU\,[[XH>"[SQ)K1U^U$B0>#X8M4@N/'6GK?QWNG6&O>&K*ZTW66L9I
M[!FCRJ^2?"W]LCX;Z[\*]%^(?QQ\6_ [X :IK%[XT1/#VH_M*?"/QWHHTKP=
MXS7P7-K%GX_T+5[#PWJ<;:A>Z%;:Q;69:3PQKNNV/AC6'CUADAE^6?@3\ OC
M'\'/C]XWUWQ;^S]:_%/PM\:/A]^P]I]EXO?Q3\+FTGX+:O\  +POI7A_QMIO
MBNQ\1Z\?%4]]X7\0Z#:?%#P+<?#7POXSL-8\7V_AY&UWP[<QOX@\,_GUX%^$
MGQ=_9Z^,O_!/GP9XZ_9[7XF_$71+;]OOQ$OP?3Q5\+9-0U+2_%WC"+4M)U;2
M=>\0>('^'2WEOX?UR'7)K;5/$^DW$6EKJ-I'*VO+;Z'?$81:>NMD]U?X6WUL
MK/1W6F]R\;Q?Q+@G@,16RO%T*4\1B\MKTJV69A.C3JU>)L@R/+,7B72R]5L?
MB,5@L7B\VP.&RFOAXUH5*^!GAZU;#PQ%+^@_Q7^T%\!/ ?AWPGXO\<?&[X0^
M#/"7CVQAU/P+XH\5_$KP9X=\.^---N+&TU2WU#PGK>KZU9Z9XCL9],U"PU&&
M[T>YO+>6QOK2[21K>YAD=/%?[0GP"\!Z_+X4\<?'#X0>#/%,%YH^G3>&O%?Q
M+\%^'=?AU#Q%;O>>'["71]7UJSU&.\URTBENM'M7MA/J=O&\]DD\2,P_"35?
MV+?VYO"'[+'PY_9W\.^!9-6T_4OV2OBCX'\7-\-=0_9G_P"$AL_BS\3/C5JO
MC[2OAS\4_'?QJC'B%/@KX(\'^([BV>#X$WC:K<^-+"ZGTS5!8PZ)K$G0^,/V
M$_VFM<^&/[7VD)\)X+_Q5\3?V-_V(OA/\/Q/XP^&[7>L^.?A/H7A>+XH>'H]
M2N?%8ATE-%U;0X9)]2U>[T[1-<N-.M+K1M0U40VLH7)'K-;VW6UTKZ[:-MK7
M;<*G&_&$HOV/!68PJK+L-C*D*^79DZ=/%_V#F.:8O+Z5>E&2QDGC\+A<KHUU
M3PTJ6)Q2HRPV(J.BZOZV>!_VS_@/\0/VD?B?^ROH7BFT7XI?"Z+1_ML-YK?@
MT:9XMU"_TN]U77-"\"1V?BF]\1:]KO@&'3[J#XA:9+X>T^?PK=Q/%=[U221/
M/_CA_P %&_V7?V?_ (A^)?AAX[\9V;>+?"7A_P #:[K5EI?B7X<*UM=>/?'V
MG>!;'PN;77/'>AZI'XJT&TU*+XB^+M,N-.@A\._"Z*3QC>7GV:6SMKKAO@)\
M'_C7\.?VW/CG\4?&?@76=5\%?'?X-?L[:='\0]/\0^ KK3O#GC/X6^!]0T3Q
M?HOC+2KKQA9^-7O]0U587TK4O"_A3Q-H=W_:$3W>J6,<5U)!X!\>?V5?VQOB
M%^UAXI^)7A>7P!!X&N_C7^QG=^']8U+PDM^;?P)\"M7\>_$^7Q#?6"_M%Z!J
M-[IW@SQMJ^G:+XMT2/0M+\0?$:^O--O?!MGX,TC2M<U/61*%]7IRQ>ZW?+=?
MB]-T=>-SOC2&1^VP>7UZN;5>)LZP$*:R2JWALHHSS6658BI0K8VA&I3JTJ&7
MR^O1J_5YJNJ3O7NZGW'X:_;B^!_C3]J&\_9-\(/XO\1>/]+\,:[XBU?Q19>'
M1;_#?3KKPW/91ZQX73Q-J=_87FM^(+*WU32;V:3PSHNN>'(H=2M[6;Q#%JD-
M]I]II_ O]J^Q_:%UC6H_ GP5^,MOX%T#QQX]^'NH?%KQ#+\&-/\ ! \1_#S4
M;[2-7CAT>T^,>I?%26TO]2LA::1=#X;A96O+6:_73K47<]K\W^,/!GQSU+_@
MI5\,?CK8?L\?$:Z^$/@[X-^(_@=JOC=?%GP#BMY-1\4>-HM4A\<V6@7/QHA\
M83>!=+TZ9[O5?-\.6_CC;;3PZ7X(U2Z:V@N.<^'?[/'Q>\&?M0_"G4_@M\,O
MB=^S9\']#\2_'7Q?^TO#XA_:(F^*'P4^,VH^+_L"^&$^%/PSN/BCXPU.TUO6
M_$]UJ/BR7Q-KOPP^!MQX?TF&^2[M]5U(Z7X:F+1\E>*=^:]G9WO9WN^UM.QM
M1SGBGZ\U7H8NMA*'$^)R^5/"9'CL#6Q66UJF34LOQ5&6-P6-PKP&$EB<QGF6
M*J8_!2KT,/*M@\0I4_8/]8J^)OCS^W)X)^ GQ,\1_"N_^%'QI^(NO>#?@!=_
MM-^,;_X;Z?\ #*XT?PU\(]-\3ZSX4UC6KL^-_BEX&UC4[_2-0T6:XO=&\.:-
MK>H/IUU:W5E%>%+^*Q^V:_+3X\?L;^/_ (^_MQ>)/%NJ>(?B)\//V?O%W["2
M_ ?Q;XS^&NO_  PL=9\5ZY??&G7_ !!KWPLU"S\7>'_&?BG3-#U?PAJL>I:A
MX@\-Z#H$SB*/2K3QE;M+J6E7<QM=WVL?1<58C.\/E^'_ + I5:N.KYAA\._9
M4:59TZ-2G7<JM1UXRH4:$*L:7MJ]5<M.FY<KYY0/MVV_:5_9\N$^%XE^-7PQ
MTF\^-F@^%/$WPDT3Q'XTT'PMXG^(>B>.1:?\(A>>%/"GB2]TKQ+JS>(9;ZTM
M--M+;2FO9]0F73?LPOPULOG7QP_;@_9C^ GA'X@^)O%?Q;\!ZUJWPVMM2DU[
MX;^$O'OP^U+XH7%_I%]IVFZCH&F>#]2\6Z-<R^(+.^U;3K:YTJ]N+":WGO+:
M&<Q37$$<GY@?MJ_LE?M7^-)_B%\&_@5\*+N'X$6NG?LJZ=\%K#X?7_[-'AKP
MM<:3\&[64>)Q\:_%'Q(N[;]H75?%/A>+2]!\.?"FW\(ZU#X9M]#C0ZYJ$HN-
M7M;CUJ\_8Q^,>L?!G_@JUX73P5I>C^-_VH/BYX\\1_"6\O->\,NWCKPC%HFD
MW7@^*YO].U6]&@Q7FLCQ!9:=9^*FT:;3+S59[O48+&QN);NK48:-RTTTNKV;
MC]UKNZUVW/D\1Q1QG5JYI@,)P[6HUL)A\;&CF=;*LQ>#KXS"X+.I16!A*HH8
MRAB<;EF"6#Q$Z]%5*.:X>,L/*<(?6_MCX>_M>>%_BO\ $OX?Z!\/HOA_XB^%
MGCWX%ZA\88OB7:?'/X87/B72-4TOQ#'H>I^"KKX0Z7JFI^*;R'0MTD?BGQQI
MU_<>%_#7B"VNO"NHS+JL+5-XA_:[\"WFH?!X_!+7_@Q\<_#/Q&^,.G?"7Q3X
MI\.?M&_"?2;3P/=7^DR:OYNDVD^J:C)\2/%JV@BN(/AMX6F7Q9>V,PU&W@-H
MA<_G7\3OV1?VE?C5>^'+C3_A_K7PL$W_  3"^(?[,6H7/BGQ=\-IKO2?BS)K
M]C::9X4U9? WCOQ>LWAWQWI6C2SMK^BS:QI]CX6UY8]<6Q\0)>^&K?T#5O@-
M\</B!8?L&W=G^RU'\)+[X _'']GNX^)\FH>,?@S-XEN_!OPL^%VO>'=4\09\
M%^+M?T_5/ ?A?4=9AT7P#9)XLU7QU>I<:_+<?#WPII\%G=:^K1TU6VJNM'YN
M_7R[$0X@XOE"O0GEN9J7ML%5HXQ9/B:<Z].K5RQ8C#X6C++:U' T</3GB:E9
M9HL1B*E.K6I4,9#$8.4J?Z7^&OVA/@%XS\3V/@GP?\</A!XK\9ZI;ZI=Z;X1
M\-?$OP7KOB?4;31+O4;#6KJQT#2]:NM5N[?2+[1]7L]4FM[22/3[O2]1M[MH
MIK&Y2)-+_:&^ .N7/CJRT7XX_!_6+SX7Z?K.K_$RTTOXF>"]0N?AWI7AV2XB
M\0:GXZ@M-;FE\):?H4MI=1:S>Z^FGVVF26UPE[+ T,@7^?;]CSX*?&;XQ>&O
MV>+[X<?"C2= T?X)_MK?M*_&K6?C;K7B7PA:>&M?F@O-3T+2_"5[H^D:B_Q5
MGUO6M:TW3O#WB+'A:70(O!^B>'[J'Q1?W$CZ'X<Z[2/V1OV[O&.K>(-;^(GP
MR\0PZE_P[C_:(_9FM;"ZUC]D_P (^"-,\>>)=(URT^'7PV^$/AGX+:KI"Z5\
M)5MKK1+'PU?_ !#SJ6DW\&I+K<WA_1K32GN&X17VDM%HVKZO_+O9KLSEPGB!
MQ-B\%@,70X2QV*CC94YTZN$RW,YX.5"K@<MK2DZ\HJ=-4,3C:].&)A1Q.%Q\
M,'65&=%PG4C^R?Q _;5_9C\ _#7XK_$]/C'\.?'6D_!C1O[6\<:'\.OB%\/_
M !/XILKBXDN+71_#RZ8/%=G;6WB7Q+J5M+H_AK2=7U#2WUG5U_L^UD:<,J]5
MX2_:=^"?C+X"V_[26E>/?#47PI_X12#Q5J^O77B7PNT'A??IUK?7OAKQ/?V&
MN7V@Z1XNT:XO(=$UC0Y-9DEL=?)TMI7F:,O^6&L?L0?'G4WU_0M'\!:9X:T7
M7O\ @C3X>_9;>YCUSP5!IA_:2TC7KR^3P9?6FF:V]\0EI,(IO&<%E=>%$M[A
MC#K5[-"MHWVK#X1^.UY_P3JG^%OA[X>:AX)^.VC_ +-EO\*-.\%>-KCP#XA;
M5?$F@^ K/PA>066H^#/B[;^$K>S\6"VO;?POX@O_ (@:>_AUK_3_ !!XB\/W
M!TZZ\*WZ<8Z6EO*SUV6FOYGM9?GW%F(Q.82QF4U,+0PV18[$8:A#*<<WBLUP
MU>HZ4*5:K6IINIAYX>$,).4)XJI&K.A5BE-4L7P)_P %1/V4/'_@_P =>--,
M\1ZO:V/P]^&WPG^).NZ0A\*>*_%4\/QBU5O#_AOP;I7ACX<^+?&VL7OCW1_$
M]WX8\*>,] -K##X4\3^-_">B:IJ,=]>:A%IGH.C?MV?!W7/V9?AQ^U'9Z)\1
M3X7^+VO67@_X9^ !X?TFZ^*7C+QSJ_BC6/".@>"=)T/3?$=]X<&OZ]JVAW[V
M#WOBVTT6"P07NK:QID27'D?,?[+/P*_:?^ .D?M,:W\0O"=O\0FU[P3\!OAG
M\// _P .-(\%>&_%?BZP^&?P9\'?#J#7]+U+QK^T7J'@W1-'T&XO?$=IK=AX
MKU[1M;\33^'M2\9:+'I<6L:%X!;YX\,_L@_'_5_V _V1O@CX\_9NN]1\7_LH
M_M*?#SXJ^//A+XP\3? _6]%^.7@2U\5_$M_%7A[P3?V?Q+U[P;<O#X=^(D=Q
M>Z=\4[SP5INJMIFHZ5''J,-S;FZ?+#O]J*W6SC=_^3:-WT\K-GCT>(./:>&I
M/$Y=7J8JID/$%:5'_5[&TO99G@N(,+A<NJ5<1AJN/P\GB<FGB\5A\OIQ5>M+
M"^TA'%K%86#_ ' \!>*=<\8: NL>(?AOXT^%>HF\N;8^%?'M]\.]1U]88/+\
MK4&N?AAX]^(_A<V=YO;[,B^)&OU\J3[98VN8O,[2OAG]@;X)^-_@C\-OBO8^
M,?!]C\,-/^(O[1OQ:^*WP[^#FGZAX?O[?X._#;Q9=Z3!X:\ E?!MYJ/@;398
MI-(U'Q))HW@G4M1\-:4?$@LK2\DN8KQ4^YJS:LVKI^FWYO\ ,_2LEQ.)QF58
M'$XS#XC"XFM0C*M0Q5OK$)7:3JI87 \LIQ2J<LL%A)P4U&IAJ-12IQ*\]TW_
M )*MXT_[)[\,?_4D^+E=KJ6HV.CZ=?:MJ=S%9:=IEI<7]_=SMMAMK.TA>>XG
ME;!(2**-W; )PIP"<"N/\":?>O;ZAXMUJWDMM>\8S0:A/9S@"?1M#MTD3PWX
M>DVDJ)-,L9Y+F_5?E.N:EK$BDI*@%1TC-O9I17F^:,OP47?MIW1W3=ZE**U:
M<JC\HJ$H:^;E-<J=KI2:^%G>T445!J%%?E'^VY\??C'HO[7?['O[-7PB^,UU
M\#O"_C/P1^TE\:_VF?'FG>"_A]XUU;P[\%?A9X(L8M(OM&M?'OAGQ79:1KDW
MBW4Y?[#UR32[S2-,U:RM;WQ!X<\>Z+:W_@K5_P L?AY_P4H_:W\?? KP7JWQ
M$_:*C^!]Y\)/^"<GCS]N/XM?%:P^%WPEU'Q)\8_&'B/XN^-?AY^S=\/KCPYX
MG\'ZEX)TCPMKNE:3X=O?&=IX&\/^#O%?BSQ+JNG^&_ _B+0(=936]/\ ?PO#
MN-Q>&HXFG6PL85HTY*$WB'5A"M5QM"C*<*>&J<WM*V"G",*3JU$ZV'E*$85>
M:/CXC.\+AJ]6A.G7<J3G%RBJ*ISE3IX6K4493KPM[.GBX2E*HJ<'[.LHRE*G
MRR_J7UO6]&\-:-J_B/Q'J^F:!X>T#3+_ %O7M>UN_M=*T;1-&TJUEOM4U?5]
M4OY8+'3=,TVQ@GO+^_O)X;6SM89;BXECAC=UA\.>(_#WC#P]H/B[PCKVC>*?
M"GBG1M+\1^&/$_AS5+'6_#WB/P]K=C!J>BZ]H.M:9/=:;J^C:OIMU;:AI>J:
M?<W%CJ%C<07=I/-!-'(W\_.M>-/CE^VQ\+?V%_\ @GG\0/&M_P"*_B#\<?@7
M\-?VH_\ @I!X^L=(\.^&+[PU\!KP:5XLM/A))#X*TC2=!\)^+_BSXNN],\!1
MVVFZ1I\K^#O#^NZA)#?:9J]Y=3>-:3^V#^VYXS\7?#6;X+?M :3X&\!_&/\
MX*I_$?\ 9#_9\^$[?!+X.ZAX"T?]CWX2^$-;TGQOXUO+ZS\+6/BG6=3\':IX
M:M-2^&6BZ'XK\+P6<MOKVE>+]>\::-K.A6/@3:'#=:=.2^M8:%>G*M.?M)5E
M0^K0=:-&I"4*%2JYXE87&5Z<:E.DHX2A&O)VKP4<I9Y2C.+^K8B=*<:48J"I
M.M[>:I.I3E&5:$%&@\3AJ-24)U&\35E12O1FW_4)17\U'PA_;E_:K^),OP3^
M"]Y^TM=>'?#_ ,<_VRO^"@5IH_[7>O\ @3X%Z;X\TO\ 8L_8CM]$OHKJ.SD^
M'$'P&MO'7BRZO+K3-6\=:Q\(Y?#>DZ/9:[?G1K6]L[&=OK#]D7]I7X_^/?\
M@DU\9/VN/C#\:_$FK>*I?"O[4OQ5^&_Q0TOX??"KP=XBT+X7_"Y_%]GX!U*P
M\&2^"=0\#BYO;'P'/XG$7C+POXAEE.OR07S7=A%8"''$\.XS"P4ZM?"/FQ5'
M"PC"6)E*4Z]?%X>$U?#**BJN!Q49PE*->/LFW1M*'-K0SO"XF;C3I8C3#U<1
M*4E048QI4L-6G%_OW+F]GC,.XR472E[32J^65OVGHK^8/]B_4?C/^S]\'?\
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MWT<=ZVGB?[(UVB7!A,RJX\!\=?'V'PS\5/ GP]T[2_$%S!J+^*[OQM*/A?\
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M0_:+U+X^?"W_ ()'_#KQ5I7[0GQ'\,_$[3?A1\-=3\:^)Q=W'B#XM_$;Q?\
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MX]^.-,@^$FD^#M8\7^.=6^'.H^ _"TEIX]\::=#'H%K]A\&3>.!X6CO=5O\
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M_P"6_P!6?E?T*BO/?[-^*W_0Z?#W_P -CXD_^>Y1_9OQ6_Z'3X>_^&Q\2?\
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M@LO4\/C)TX4IXNA):TL3*E"%*5>FXU94X1@YN,8H]"HKSW^S?BM_T.GP]_\
M#8^)/_GN4?V;\5O^AT^'O_AL?$G_ ,]RERQ_Y^0^ZI_\K/2]I+_GS5^^C_\
M+?ZL_*_H5%>>_P!F_%;_ *'3X>_^&Q\2?_/<H_LWXK?]#I\/?_#8^)/_ )[E
M'+'_ )^0^ZI_\K#VDO\ GS5^^C_\M_JS\K^A45Y[_9OQ6_Z'3X>_^&Q\2?\
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MT*BO/?[-^*W_ $.GP]_\-CXD_P#GN4?V;\5O^AT^'O\ X;'Q)_\ /<HY8_\
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MK231#IPM+98O0_[-^*W_ $.GP]_\-CXD_P#GN4?V;\5O^AT^'O\ X;'Q)_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img147150826_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (- QD# 2(  A$! Q$!_\0
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MW%58QDJLZ/+43I2E4A)PDH1J*$IKF349P4H3M>$I+4]QHKX7_P""C7[::_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ\BO-1U6\@CU;4Y+W7+N;4)_P-_9_P!=T3Q#^T5_P3/\4V'B/X=^$/BAIO\
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M?AZR\174<NHZ=X=%MX;T[?HVFSVNF/>PW=[);-?7VH3W'#_\%$_AY\:OB?\
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M@RIXA\,V<GC3QAXC\5_8IO%-Y+J.M^+A%K^I3WTKIIUS:6-RT.@:/96^G_2
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M+"3I4?:2Q.'K\N'I4\9%4H6PZIN%9XN%YSJQA"K:2_A;N/V9?@/XM_X)<?\
M!9_]HOQ-\)?"&O?'/PA_P4#^+_AWP=\4M4TD7OC#PKX=T#XB?!*]M-.\,:K,
MSRZ#9-/X]\9?VO\ V0+0ZY#J;6NO/J-KINFPV/T7\=8_V>?AS^WS_P $E/VE
M/VM/A7X0U/X0?%S]@?P/9?$?Q1K_ ,%T^)6F?$GX]+\+-0TGP;!XFT:P\+>)
MK_Q7X[T^?4/AQI/AW4];L;Z]T&SB\.NNHZ=I&A&ZTW^QFBLWQC5G*K[3"UY0
MJRS"-H9A*%6EA\?EV%P+H4*KPTU2]C/"QQ,)>SE!S:C[).*J/1<,TXQIJG7H
MQG3C@G>6"C*%2M@\;7Q?M:U-5X.I[6->5"2YU)1O+VDE)P/XH]4U/X5?"7_@
MKW>V/P7\.:%^T[\0_BU_P4/FUWXF_ CXT?LT^+/"/[27[/WB"R^)^HOJ'QJ^
M#7[3>E6JZ3>_ BVU**#Q7X8L+_QI;^&M3\$W&C6OB_X>MILNL^(X_P!R_P#@
MNW\&M8^)G_!/GQO\0O!T4A^)'[+7C3P+^T[X!NK>U,]S9WWPVU8Q>)KH/&RS
M16VG^!=;\4:W,J;XY9M'M?-1-B7-O^R-%<-?B.=7'9/CH8:4:N51HQG[7$1J
MO%JE*/-"7L\/0I4J<Z4?8:4:E:5-WKUJ\TI'51R2-/"9GA)UXRAF,JLH^SH.
MFL,ZD96E'GKUJE2<:LO;?Q84E-)4:5&-T_\ /M^)?[0/QM\"2?$G_@K%I6F>
M)QH__!4*V_;C_99T31H%N"_A7PO!X3\%^!/@%J-M;LQ;5-8L_$'A'75@\NZN
M8;3_ (0=K>TM;HVLUMJG[ V?[,NA?L^_MX?\$"?V8M<T'3]7T[PC^RM^U[X3
M^(>A:S8V.JZ-KFO>(_V=/&5[\4+?5=-GBN=-O=(U_P 5Z]XC^U:==)=VD]GJ
M!LKE[Q'>2;^I&BNW%<7NO"%.GET</"&&S+"VAB6W*CB<#BLNRU2?U>/O95A<
M5.FI))XI+7V#;9RX?AKV,Y3GC95I2KX'$WG0LE5H8O#XW'-+VTM,PQ&'C-K_
M )AVW_&22/XL_P!@Q?@%\,_V0?\ @N'^SMK'PVT'P9^V?X.^'_\ P4<UZY$G
MPD?2/%_AS]F2#X1^"_#.D>$H_B='X:AL;3P5-\1+.;4-$^&UGXG^RW$UC)XK
ML=!:R2+5'S],^ ?P>^!WPN_X-P_C%\*?A7X3\%?%'XK?M*? ^+XF^/M%TAK7
MQ7XYB^(&M> CK_\ PE>NQR#4M:@E@U'49=*M=1N9['1K6>ZM=(MK32[B[M)O
M[7**)\7S=:M5CA:R6)KNOB:4LPE*%5RRRME\J6F&C:AS5OK$*<U4Y.7V;E)O
MVJ(\-05&E2EB*3>'I*C0J1P<8R@HX^CC8U/X\OWO+2]C.<7#FYN=**7LW^,7
M_!=#XN>*O#/[&EM^SI\+I?-^-/[</Q.\$_LK_#O3(S-YUU:^/M6@3QJ\QABF
M:/2KWPY%+X1U2Y\J9K9?%]O(D,C?,GY/:OX*_;/_ ."<?[=G_!.']I']JG1_
MV._#GPGU+0_"G_!.:]N_V3)?C';Z3#\.KC2;JR\#7/Q57XI:3:^;J>@W<MKX
MGL=4T.9VU#3/A_<V%[86UOI]@3_7]17GY?Q!' 8*. 6 HUJ%18]8V4ZC5;$K
M'4(X=*E45-K#*A3ITW"\:]ZBE-.'-9=F-R9XS%/&/&5:5:#P;PJC!.E1^J5G
M7?M(<Z]NZLY34O>I6@U&TN6[_@Z^,WBG]A_PIXW_ ."YFE_M*?!R]\6_'[XK
M_'CXS?#[]D/QM/\ "GQ!XR#_ !1CGU<Z3X9^'_C>RT[4=*\$>,O#OBOQ!X0\
M8>)T:X\.ZCK/@Z6/2UOM<2_@\/7/V7X _9HC\=_M@?\ !"_X&_MD?#JS^(-Y
MH/[!'C[4?&'P\^)^G'6[2VOO"NA>*-=\$Z#XTT#40]IJ+^$K6#P]IFH^'/$-
MM>6 N]+_ ++U>QNO)DA;^OJBO1J\83E25.EA*].?U>M2=2683J.E4GE*RFG4
MPB6&IO"TX07UBI24INK6M:K248VXZ?#4(U'.IB*4X>VI5%3C@HP52$,Q_M&I
M#$MUYK$3G+]S"HXP5.DW>G4;=_X0?%?PX\;V7['W_!7KX+_!?P+XNO\ X)_!
MW_@KPUSXL^%'PPM]2^U6_P"S[X>\7^-=&\0:!HVG6/G77]BZ7;>&/AS),+90
MNFZ?HUOJ^HSC3=/N)H_OS]EC4_V1_C[_ ,%@/V3?BM_P2X^%?_"(? ?X3_ #
MXLZ7^U9XJ\"?"7Q#\'/AW<3:]X)\4:-X!\(:_IFI>&O#=KKGCFP\7W_AJ[UB
M_:WNY?$,MG9:E#K&N?\ ",W%W#_6%14U^+G7HXJF\%4C4Q%'%T8RCCI>P:QV
M PN!Q%7%X?ZM_ME:*PWML-4=6C[&I4O*-5PC(='AQ4:N'FL5"4*-3#5&GA%[
M9?4\97Q=&GAZWM_]FI2=;V5>"IU55A'W72YFE_(#_P $S_V>?@IH_P#P0+_:
MP_:'L_A?X0C^.'BK]F']O_0]4^*]QHEK=>.9O#EOX&\<:-'X>LO$5W'+J.G>
M'1;>&].WZ-IL]KICWL5W>R6S7U]J$]Q\U:U^QU^S0/AC_P &ZL4?P-\#02?M
M&^/-*B^/6H6NB&TUGXM6GB*?X5ZKJ-IX]UZU>+6O$.G3?VIJPL['4+^6RTW2
MKZ]TW2H+/29I;0_W)T4UQCBHXO&8I4JZ^M9AB\:H+'U%[*%? XK!T<-SJC[T
M,++$JM3ERQ5Z2C"G3;4XCX9P[P^%P[J4G]6P>&PKD\)#]Y.CB\-B:M=Q=3W9
M8A8=TJBYI/EJ-RG-+EE_&!K4=S^SMX^_X.+_ (<?L_\ P \$^+/!/AWP[^S-
MK&@_L_VG@B:Y^'.G0ZGJL5OXBURR\!>&O[/M(M&\(>'?%_BKXA7&@6$%MH5W
M!X9M8-0LY= L7LQX#_P3CN?!EQ_P41\(>(OAA\7O#'Q<\->+?V#OCU;Z]XB^
M&W[&_AO]BWP!IOB6R\&ZAJ?B+X9V7ASPCHOANQ^+-WX'U*325UCXE:II/]HZ
MK>C2X9KB\BTS3KD?W>T52XP_V;&499>Y5<9AJ6'J5WBX2E)T\LP>7.K4]I@J
ME5R<L)]87L:U!MU94J\L0H4IPA\,_O\ #55C4H8;$5*\*2P\XJ*GF&(QWLX<
MF*A!1Y<0Z#]K2K12IQJ48T7*I&?XW?\ !OZK+_P2,_9*#*5)'QW8!@02K_M,
M?&5T;!QPRL&4]&4@C((-?E3_ ,$G?^"@/['G[*7Q,_;[^!G[1OQ57P)\1?BS
M_P %!OBJ/!O@^[^'7Q/\5KXAM=8\0?\ "'V\-U?^$? _B30-,6YUV.?2YK;7
M]1TYHP&FNHX[)O//]<]%>8\[P]6KG\L5@:TZ6>8KZVX8?&PH5,+..+JXN$55
MJ8'$QK14JJA)^QI.2C=.#EIWK*:U.GD\</BZ4:F4X;ZMSUL).M3Q$7AJ6'G)
MTX8NA*E)JGS1_>U%%RLU)+7^&;PM\,?'G_#4)_X(,7.AZK<?![2?^"CY_:8N
M+YK?R[9?V1])\&2?$V/P8UY=S-:#3]7T8V&H^9<V=['_ ,)I<Q6MM<75Q,NE
MS?</[;_[-EM^UQ_P6:_:!_9XO(&+_$O_ ()2ZQ8:%<R"-+;3_&&F>-K?6OA_
MK%U+/%+"EEI?Q TGPY=SR.$!^SF&.>WN&CFC_JXHKOGQ?7>(AB:6$5&M'+ZU
M"4HUV^?,L3/#U,3FKO15IU98:@WAUMR*]=G)#AJDJ,Z%3$NK3EC*56,944N3
M X>-6-#+U^]=XTXUZJ59[\[_ '*/X)/ -Q\8OVS/V-?V\/VOOV@-'OX[C]CW
M]ACX?_L)?"Z+5UEEN7\::%JOA_4OB_XNN(FA@^Q^,8[*VL[7Q!.4,KV7CJ6S
MGDD-H3#^HF@1R'_@IO\ \&]D@1S&/^">_BO+A6*#;^R=\0 V6QM&TRQ \\&2
M,'EUS_4O13Q/%OM_;QCET*%&=+,:&'H4\2^3#4LPRJ.6\D;T%S^SJ>TQDG[O
MM9U9T[4U:8J'#GL51<L;*K5A4P56M5G0]^O4P>8/'<TOWWN\]-0PT?B]G"G&
M?O\ P'\]_P#P<">,I_"_P\_9,L-=\-_#G2/A5X@^.]Y:_$C]HOXH?L_+^TUX
M8_9S@30(K/2O$A^$>IZ;KGA;Q->Z[:ZIK_E6'B'P]KOVZVT"[T[2[!KR[\V/
M\+O@/\)]/^(__!//_@N#X:\-:9;?'"/PAX[_ &?OBS\*-:'[/&A?!(F2.?Q+
MJ=Y\6OAW\!-,T]-+^#,VK?"VZUFYT^S\(V.E7,?@+4);"VCBTW49-./]\-%9
MY;Q4\MRRA@*>!YZE'$X?$>W^L0A&;P^9T,P2E#ZI+$)SC2>%E&&,C0=.?M/J
M[JJ<JEXWAY8W'UL;/%<L*M"M0]BZ,I."K8&I@VU+ZQ&BU%S5=.6&=;GBX>V]
MFXQA^9O_  2)\<_LU^/?V$_@OJ/[,.A>&=#\,Z-X6\(>%_B0?"OPWF^&ECJ_
MQQT+X<^![7XI:M?64WA[PVWBK7CKA33M=\<QV^HP>(M3TVX>WUS5H+6.Z;^/
M[XK2_LO7WQ2_X+,>!OC5^UG^U'\(?C!K_P"V5^T1J?P0_9M^$MOXQ\0?"3]H
M#Q+IGQ0\>:KX87XJ_#W3O &M^$?%!C\30:39V,OB3QKX2:RTZ=K^S6]$$:3?
MZ&=%9Y;Q)#+L;F6+CA<34CCZM*K!+'TEB*+HXJ.*BIXBKE]>%=2<?9S:PU*3
M@VX2A*TE>.R.6.PN P\L10C+!TZE.3>$J.C557#NA)QHT\;1G2<4^>"]O4BI
M64E-73_BH_;2^*'Q2U/P1_P2TTO]LWPA\'_V6+?7OV7/$,WBS]H;XA?L(Z'^
MU+'X1\7VM_<6/A[X/Z#^S_XD\,ZQX!\+Z[XC\):!X!U34O#UKX2TV]\-:QXN
MAAMW\,Z-H?V>#P7X2>#/A)K?_!'OPQI?QW^*7CWX.Z5\,O\ @IM\3]:\%_$3
M5_V<[WXK_"7PKXL\*^!-)O+'0/VA?@)I]MKAT3P1XEDNM:LYO"]MX=\26&E>
M(;V[T34M!U;1KO6;.]_O1HKMI\8JEAZ%"GEOL/98Q8N^'Q-"$4U7QE7EHQK9
M=B*D+QQ;I-5ZN*PZC3BZ>&ASU5/EGPPZE>K6GCO;>TPOU:U>A6E)ITL+3<JL
MJ6-HPE[V%52]&GAZ[E4:G7GR4W'^";XS7OQ+^,W_  3L_9!^(MY\)?#O[-W[
M.OAK]O#XO7GQ>\8?!']GG5?&_P #-:T*30? :>"?VG[;]EGQP8=+?X>7,@^(
M.DS>!KRPT'P3<:EI.HQP>&],NO$=KH0[/0_AA\*O#_\ P3B_X+%?$OX(?M)>
M(_VBO ?CSP;^S%%J?B;2/V*+?]BOX#WGBG3OBV8F'PJ\'Z=KD&A:CJVA:="E
MOXSL=!^&_@;3]%_MO0;N2?7KS7[AM/\ [IJ*O_762IPI4\O=*G3S&GC53AB:
M$HU*4,SHYG[&M4K9?5Q;J<]%4XUJ.*H48QY6\))0C$E<+1]I*I/&>TG+!RPW
M/*A6C*%26 J8#VM.%+&T\,H<E1SE3J8>K4E+F7UA<[D?RI^-(Y!_P42^%*F-
MPT7_  ;I:GYH*L#%C4/B7&?,!&4Q(RH=V,.P7[Q K\\;_P#9_P#@W\)_^"2'
M_!(K]IWX=?"SPIX9_:&\2_M]_"^X\2?%W3-)*?$#Q!;W7BCXYSQZ;JWB/>=6
MNM#2X^'G@F72]%-RNE:7/I@GT>ULKC5-4DO_ .[JBN:AQ=4H1PT882:C0GA9
M58QQDH1Q%/#4<QI.C42H6Y*CQZFU+GC%T4N63GS0WJ\-PJNO*6)BY58XA4Y2
MPRDZ,Z]3 S52#=:_-!8+E3BXMJJ_>CRVE_"!^WW\--$;_@I%^WM:?MG?M&W'
M[,VF_$\>$HO@-KOC3]@?1OVTXOBY\/+KPRFGZ1X9^"OC#4()=7^#WBC0(!IV
MCV>H^!;OP]<3:Y+JMKK'BO0]<T';>?UX_P#!.SP:_P /OV&OV6?!AUGQ]K\'
MA[X-^$+'3M3^*/@=_AI\0)-&^PB;0[7Q1X D\2^,7\(:AIFCRV.F#06\3ZV=
M/MK."#[=*% 7[.HKAS;B&IFF P.!=!T(8.&&BU&6&=*4L-A(X2,Z<88*CB8.
M<(\TXU\9BXJ34::IPC&*Z\NR6&7XS%XM5?:RQ,J[7,JZJ15?$/$2C.4\75H2
MY9/EBZ.%P[:5YN<G*3*X6\U#XF)=W26'A+P+<V*7$ZV5S>?$37[&[N+196%M
M/=64/POU"&TN)80DD]K%?WL5O*S11WERJ"9^ZHKYU-+>*EZ\W_MLHGLRBY6M
M.4/.*@[^3YXR7W)/S//?[2^*W_0E_#W_ ,.=XD_^='1_:7Q6_P"A+^'O_ASO
M$G_SHZ]"HJN:/_/N'WU/_EA'LY?\_JOW4?\ Y5_5WY6\]_M+XK?]"7\/?_#G
M>)/_ )T=']I?%;_H2_A[_P"'.\2?_.CKT*BCFC_S[A]]3_Y8'LY?\_JOW4?_
M )5_5WY6\]_M+XK?]"7\/?\ PYWB3_YT=']I?%;_ *$OX>_^'.\2?_.CKT*B
MCFC_ ,^X??4_^6![.7_/ZK]U'_Y5_5WY6\]_M+XK?]"7\/?_  YWB3_YT=']
MI?%;_H2_A[_X<[Q)_P#.CKT*BCFC_P ^X??4_P#E@>SE_P _JOW4?_E7]7?E
M;SW^TOBM_P!"7\/?_#G>)/\ YT=']I?%;_H2_A[_ .'.\2?_ #HZ]"HHYH_\
M^X??4_\ E@>SE_S^J_=1_P#E7]7?E;SW^TOBM_T)?P]_\.=XD_\ G1T?VE\5
MO^A+^'O_ (<[Q)_\Z.O0J*.:/_/N'WU/_E@>SE_S^J_=1_\ E7]7?E;SW^TO
MBM_T)?P]_P##G>)/_G1T?VE\5O\ H2_A[_X<[Q)_\Z.O0J*.:/\ S[A]]3_Y
M8'LY?\_JOW4?_E7]7?E;SW^TOBM_T)?P]_\ #G>)/_G1T?VE\5O^A+^'O_AS
MO$G_ ,Z.O0J*.:/_ #[A]]3_ .6![.7_ #^J_=1_^5?U=^5O/?[2^*W_ $)?
MP]_\.=XD_P#G1T?VE\5O^A+^'O\ X<[Q)_\ .CKT*BCFC_S[A]]3_P"6![.7
M_/ZK]U'_ .5?U=^5O/?[2^*W_0E_#W_PYWB3_P"='1_:7Q6_Z$OX>_\ ASO$
MG_SHZ]"HHYH_\^X??4_^6![.7_/ZK]U'_P"5?U=^5O/?[2^*W_0E_#W_ ,.=
MXD_^='1_:7Q6_P"A+^'O_ASO$G_SHZ]"HHYH_P#/N'WU/_E@>SE_S^J_=1_^
M5?U=^5O/?[2^*W_0E_#W_P .=XD_^='1_:7Q6_Z$OX>_^'.\2?\ SHZ]"HHY
MH_\ /N'WU/\ Y8'LY?\ /ZK]U'_Y5_5WY6\]_M+XK?\ 0E_#W_PYWB3_ .='
M1_:7Q6_Z$OX>_P#ASO$G_P Z.O0J*.:/_/N'WU/_ )8'LY?\_JOW4?\ Y5_5
MWY6Y[PCKW_"5>%/#'B?[)]@_X2/P]HNO?8?/^U?8_P"V--MM0^R?:?)M_M'V
M?[1Y/G_9X/.V>9Y,6[8O0UY[\(_^24_#'_LGO@O_ -1O3:]"I324YI:)2DDO
M)-I#I2<J5*4G>4J<)-Z*[<4V[*R5V^F@4445)H%%%% !1110 4444 %?.'[5
MG[4/PU_8_P#@SKWQJ^*$FH3:+I=YI^C:1H6BK9R:_P"*O$NKR2+IN@:'!?W=
MC:RW;P6][JEXTMRBV>BZ7JNHE)A9&&3Z/K\OO^"NG[*_Q(_:U_9*?P9\);1-
M8\=^!?B-X;^)^D>%C<6=G/XNBTC1/%7A;4M#LK[4;VPT^UOH]-\8W>MVGVN8
MK>RZ,-,@3[9?6SII149581G;E;UYI<L6[.RE+[*;LF[JR;]Z/Q+P.*L7F^ X
M;SO&Y#A?KN<8;+L36R[#*FZTJN)A3;@HT(M2Q$XJ\X8>%YUYQC1A&4IJ+^*?
M@7_P<$_"SXC_ !/\.>!OB?\  K5OA#X8\3:K9:';_$"W^)=AXUT_1;_4[ZVL
MK*^\3Z;=^"_!']E>&X&G>?6-8M=3U.XTRVC$RZ7>1F9K?^A>O\Y71?V//VI=
M7\;W_P .[3X"?$Z#X@:3HU]XEG\$:UX6U/PSXJNM(TNQDU6YGTC0_$,.E:IK
M5Q)I\,ES8:?HMM?:KJ:#&EV=W*-@_?/]FC_@KIXJ\22+X:^)%G/J7BS3I)K7
M6O#GB+Q9XQ\)>(DN[&1H;N"RU/3=6MM.'DR))#/%?>&I+^"9%CN0DQ*3>M+*
M,964%0P52->=)XBGADJJKXK"RE*,*^$HU6ZF*A"5.K&3P[J2Y82GR.%*M4C^
M'>$WBKFN85,=E?B'F$,+C*V)I4\BQN/R^GE,,96@JBS'+I5J.&PF7K$81RP,
MJ=*:IXB3Q4HMU'R(_IWHK\\_!7[:7P"UZ=-,\:-\2_ACK0,:3V_B/Q#XXO=-
MCEE1715U'2=:N+J.-E93Y^I:5ID05ED8K&=X^P?#$WP\\:V(U/P?XQG\4:>0
MI-WH/Q+\2:K#&7&0D[67B6;R)1@AX9A'+&ZLCHKJRCQ=MS^D-]CTNBN9_P"$
M2TK_ )^_$W_A:^,O_E]1_P (EI7_ #]^)O\ PM?&7_R^H Z:BN9_X1+2O^?O
MQ-_X6OC+_P"7U'_"):5_S]^)O_"U\9?_ "^H Z:BN9_X1+2O^?OQ-_X6OC+_
M .7U'_"):5_S]^)O_"U\9?\ R^H Z:BN9_X1+2O^?OQ-_P"%KXR_^7U'_"):
M5_S]^)O_  M?&7_R^H Z:BO/?"_AZSU'PUX=U"\O_$TUY?:%I-Y=3?\ "9>+
MH_-N;JPMYYY/+BUM(DWRNS;(T2-<[455  W/^$2TK_G[\3?^%KXR_P#E]0!T
MU%<S_P (EI7_ #]^)O\ PM?&7_R^H_X1+2O^?OQ-_P"%KXR_^7U '345S/\
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M\+7QE_\ +ZC_ (1+2O\ G[\3?^%KXR_^7U '345S/_"):5_S]^)O_"U\9?\
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M .FHKF?^$2TK_G[\3?\ A:^,O_E]1_PB6E?\_?B;_P +7QE_\OJ .FHKF?\
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MO_$L-YI^B:M?6DK>,/%LRQ7-I87$\$AAGUN6"4)+&C&.:.2*0#;(CH2I]!H
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MWMX//U3P9KND_$32L)YC1/X2\*>$[O69%4?-N;PK+X@@4J05:8,0RAD;W/\
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MG_IS\&UTU<S=_P#(XZ!_V+?BS_TY^#: .FHHHH **** "BBB@ HHHH ****
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M /T+HK\]/^&W/B+=?\@?]DGXLZEG[G&NQ[L]/^/7P)?]?;=1_P -9_M'WO\
MR#OV-/'MKG[O]I7/B9<>F[S_  +I?XYV_A0!^A=<SX3_ .07>?\ 8S>,_P#U
M+]<KX:_X:$_;*O?^0=^RLEKG[O\ :5_>KCTW>?>:7^.=OX5CZ'\4/V]Y[.=-
M ^ /P_6!]8\02O+JFJVB-'>7&O:E/J,&)_B9I65L[^2YMD)C.Y85.9<[V /T
MCHK\]/\ A)?^"C-]_P T^^$VC;O^GW2Y=F?IXWU7./\ @?3OW/L/_!1F^_YC
M'PFT;/\ TRTJ79G_ +A>JYQ_P+\>* /T+HK\]/\ A7__  45OO\ 6_&WX5Z7
M&WWHX=*TUY!R>%9/A3<'CVN5[<GFC_A2'[<E[_R$?VFO#]KN^]_9NFLN,YSM
M\CPII?KQC;[8P* /T+HK\]/^&8?VJ;W_ )"/[7?B"US][^S;/6EQT^[Y&M:7
M^FW]31_PQK\:KOG5OVS/BI<J?O0PQ^*$C'3(4R?$EX^?^O=>Q(.,4 ?H717Y
MZ?\ #"&L77_(8_:4^+.I9^__ *1=1[N,?\O6O7_Z[N.*/^'=O@.Z_P"0Q\5O
MBSJ6?O\ _$TT:/=SD_\ 'UI%_P#KNYYH _0"YO["SYN[VTM1US<W,,''K^]=
M:Y^Y\=^![+/VSQEX4M,=?M/B+2(,?7S;Q,=1UKXJMO\ @F]\!H2#-KOQ.O3U
M;[1X@\.H&/4Y^R>$;9@#_O9QW)YK?MO^">W[.D&/-L/%]YCK]I\4SIN^OV.U
MM/TQU^E 'GW[5'[;FF>!;FZ^'GPTM?#OC/4=0T25=<\1R:@VI:!IB:K;S0+I
MEHFCWEN;[4UM95O9K@:@MK9%X+5H+JXDN5L?5_V4/VL(OVA4US0==T2T\/>-
M?#UG#JDT&FRW$NDZQI,LZ6LU_817+3W-@VGW<]I:7=I=7EV9/M=K=6]PPDN+
M:R^1?VC_ -@2_P!%<>*/@79QW7AVTTEY-<\+ZIKJC5;.YL5GGN=4T_4-:N(;
M:ZL)K.-3-9RWJWD%XA-K%<V]ULL/H']BK]E7Q5\$KSQ#XY^(+V-MXHU[1T\/
M:=H>GWD-^=)TF2^MM1U)M3O+;S;*:\O+S3=--M'I]U<006MN[SSR3W7V>R /
MT$HHHH **** //?A'_R2GX8_]D]\%_\ J-Z;7H5>>_"/_DE/PQ_[)[X+_P#4
M;TVO0JNI_$J?XY?^E,RH?P*/_7JG_P"D1"BBBH-0HHHH *_.'X[W*>._^"E7
M[!7P@U2-KCPW\/?@G^V=^V(MG<I,MC+\2/AS=?LZ?LT_#_48L*UM?W>B^%?V
MM?B[,+:Y&W3;J\TG5H=M_!82Q?H]7R+\</V>M=^(/[17[*WQU\-'P==Q_"2W
M^/7PK^+'A_QFU\(/%'[/G[0G@?19?&.D>'(+71M:LM0\41?%OX1? 75_[*\0
M1Z?H.I^#],\96<^JVNH2Z9%<@'Y4_L)^"/VJOV5=>TC]C']H;4_$VJ?MK?%/
M]AWXE>-OAG^U-J'_  4>_;$_;F^#GQ-\>_ [5OAIX&^(?BSQE\#OVH_#OA32
M/V=?$T?C?XS_  J\9:)8_#?X=^-/#GBCPM=>-_#K>+-.D\,1>'?$GRM\/_VG
M/V@O@+I][\%?B9X/_;JM_ASX'^+NF_$WXO\ A*X_:1\'?M%?M;>'-#^#7[)W
MP>^+'Q'^#L7Q_P#$'[4_B/1K#PMJGC_PUX[_ &EOC%H>A_M(>,?B'I'P$\>?
M"?X/_#[X:6.I_M)'P5\(/Z!?V>?V(/V<OV7M>U'Q5\*/#WQ#N?%=_P""]"^&
MT'BOXO\ Q^_:"_:0\4^'/AOX<O)]2TKX=^!?$G[1?Q1^*NM_#OP$NI31ZE?^
M#/ =]X<\-ZSJ.GZ)?ZSIFH7>@:'-I^/X[_X)^_LG?$CX7:'\'/%/PXUS_A!M
M!\:>//B% /#?Q<^-'@;QCJ_BOXJIXNC^+%]XP^)O@?XA^'?B9X]LOBS%X\\6
MP_%70O&_B_Q#X?\ B7!K,T'CC2]>AM[-+8 \:_9O\0Z5HO\ P42_;?\  'A*
M=9_ ?Q>^ '[$7[;FEM8Q70TVX\;?%G_AH;]G;QEKA2>*&/3I_$?@O]E#X.WB
MVL<2-J%S;:KJMR@U&;4'D_3&ODGX*?L_^(O O[1W[5WQ\\5R^$HF^,,?P(^%
M_P +-$\(RZA(GASX _L_^"=;N/"6F>)TO='T:TLO%EQ\7?B]\>]9;3-!34=#
MT[PCJG@ZUAU:[U&/4XK;ZVH XJWTNQUO_A8^BZG MUINKZNVEZA;/]RXL;_P
M+X7M+N!_]F:":2-O9C7YR?\ !,K4[[P;#^T'^S;KMP\FK?!OXIZC)8B?"R3:
M3J<UUHEP]H  CV8U+PPVIAT!5F\01RJS1SQ!?TJT'_D*^-?^QFM/_4-\)5^8
MNK?\6-_X*BZ-J(S:>&/VF?AY_9MTXXLQXDM[86L<0C8@?;IM:\%:*[2(&8-X
MI<A\7%P@^^X1_P"%').-.'7[T\3DU//\#%ZR^O<-UOK52%*.K]I6RJOF4'RK
MFDHQ6MD?#<5_\)^<\'Y^M(8?-YY%C6M$\%Q%1^JTY5):>Y1S.AE\US.T7)OJ
M[_K!371)$:.15='5D='4,CHP*LK*P(96!(92"""01@TZBO@3[D_#/]L+_@D=
M!J/B;4OVA/V%]3TOX.?&LM>7GB'X;7"64?PF^)=O<&.XOM*31;VTNM"\/7.J
MSV\<ESHVH6%UX"UF[2VDO=,T&Y6?76_,'X/^-;R3XH/X)M[C6OV+OVTO"$_]
MGS?#[Q5JMWX2\#>/]5:;RC8?#[Q3K=T?["N=="0&V\$>-K_5/#/BFVG1_#OC
M'Q#%J-MH=O\ V%5\<?MA?L+_  #_ &UO!ZZ!\5_#OV;Q3I5E<V_@SXF: L-G
MXV\'33EI52SOVC:/5=%>Y8S7OAO6([O2+IGDGBAL]2\C4;?W\CXES?AZO.KE
MN,G1C6C[/%8><85\'C:&J>'QV"K1GAL90DG*+A6IR<5*4J<H3M)?C_%'AC0J
M5*N:\*TL+AL2ZSQF*R"O.IA<JQV)]URQ>6XK#<N)X;SJ7)&4<QRYQH8FI3I0
MS##5J3J3?R#\'/\ @I-K_@O7A\+?VR?!>I^!_$]A+'8/X]L-#NK6V>4847'B
MOPM%%Y]DLB 3MJWAB*[M)S-%Y?A[3[16NJ_6GPUXG\.>,M$T_P 2^$]<TGQ)
MX?U6!;G3=9T2_MM2TV]A;(WV]W:22PR;6!210^^*17BD5)$91_,-X]OOCE^P
MW)I7P/\ ^"A_@C4OVI/V29I[+0?AC^U'X4M9Y/'_ ,+[.0"&QTW^V;P7.HK'
M91H)7\ >,;^Z;]P[>$=?\2Z9I4&E-[IX2^'_ ,9_@;H4/[0G[!OQAM?CK\ ]
M?DDU"YMO#[/K5C,MJH6ZL/&G@6203Q:KI4/^B:A>0P:=XCT1(Y_M[^'9'^RC
MZB5'A#BS6C+#<$Y_4VI5)U)\(YC5=K^RK/VF*X?JSDV_9UOK.7P2C&-2@I>[
MR<.<99YA9U\!B:&89W++8K^T\EQT*.'X[R2G?E59T(.&"XKRWX70S/+94Z]>
M%2,ZD9U'R']#D\$-S#+;W$,5Q!,C1303QI+#+&X*O'+'(&21'4D,C*58$@@B
MOFGQ_P#L??L^_$/SY]0\!6'A_4YBS'5_!C'PQ=+(P.^9K33U&BW4SD[WEOM*
MNW>3+LQ9G+?//[.7_!27X3?%J:R\)?$R*/X/?$AWCM#9ZY=8\'ZU>,R1(ND>
M(KD0?V=<W,AW)I6OQV91I(K6QU/6)B6K](%964,I#*P#*RD%64C(((X((Y!'
M!'(KY#.L@S?A_%+"9O@:V#J3C[2C.2C/#XJD[.-?!XJDYX?%T))IJMAZM2&M
MG).Z7ZKD^>95GV&>*RK&TL73C+DJQCS0Q&&JJ]Z.+PU50Q&%K1::E2KTZ<U:
M_+:S/SI_X9,^/?PJ_?\ [/O[0NK1Z=;X:U\'>.Q)-I2)$21$A6WUK09994Q$
M"/#&EC(4/=1IAX?FC]H+]IS]K?P5#9?#/QY!I'P\\02VHU:7Q%X->./4O$6B
MS37%G97%MJ=EJVI0Z:HO;&[:9M+_ +)O7:*."XMK:W,T%W^UU?-/[17[,7@[
M]H?3]*.K:A>>'/$V@)<0Z/XCT^VANV6UNVC>>PU2PEDMO[3LED0W%I$M[9RV
M=T\DL,XAN+VWNO'/6/SK_8[_ &N?$V@>,[+P+\6?'!N_ .IZ?<VUCK7B[4=Q
M\+ZE8VC3Z>S:[?&2X72[R&U_LC[%=W(L[>XFLKFW>U*W8O/V6T?7-%\0V4>I
M:!K&EZYITO\ JK_1]0M-3LI. ?W=U933P/P0?ED/!!Z$5\&?!3]@OX/Z+X;C
MU7QT+GXDZAXFT2PE"WZ7.@:;I%O?0VU^1IMMI6I/?QZB';R'U0ZMO-NHCMK:
MT,ETUQ-K'[ /A32[Z36O@[\3OB%\*-:(#0O9:G-J5E$T9+1)');7.B:XJ!B0
M6GUN[V@[EC)W*X!^@-%?G5_9/_!0'X3\Z;K7@GX[:%;\I:ZE]G@UL6RG#^=)
M='PKJDMV5!=%76]=8,5VK,=T!LV?[>$_A*Z@TOXZ_!'X@?#:]9Q"=0MK26^T
MZXDP2;B*WUBWT&X%L0"P^P7.LL5&^-Y0> #]#**\(\#_ +3?P'^(?DQ^&_B7
MX<^VSX$>E:U<OX;U9Y3PT,.G^((]-N+N13D'[$MS&P!>-WCPY]V5E=5=&#*P
M#*RD,K*PR&4C(((((()!!R* %HHHH **** "N:\9_P#(G^+/^Q:UW_TUW5=+
M7->,_P#D3_%G_8M:[_Z:[J@#I%Z#Z#^5+2+T'T'\J6@ HHHH **** "BBJ&I
M:KI>C6DFH:QJ5AI-A#_KKW4KRWL;2+@G]Y<W4D4*< GYG' )[&@!=3TS3=:T
MZ]TC6=.L=6TG4K::RU'3-3M+>_TZ_L[A#'<6E[974<MM=6T\;-'-!/%)%*C%
M'1E)%<1X,^#_ ,)/AP^HR?#SX6_#KP')J\7V?5G\&>"/#/A=]4@R&\G46T/3
M+%KV+< ?+N3*F0#MR*\D\9?MD_LZ>"_-CN?B+IVOWD18"R\'P77B9I67.5CU
M#3(I=%4@C&9M4A!)&"<$CPY_VXO%OCAWMO@9^SSX^\:J[,D6MZQ#-:Z; 02H
MDNH=$M=6LTB+X!-QXAL I(5G#G: #[.\'_"+X4?#S4-1U?P!\,/AYX&U75XV
MAU;4_!_@KPWX9U#5(6F2X:+4;W1=-LKF]C:>..=DN995,T:2D;U5A^='[0_[
M77P"UCX@:!H>L_!3PY\9K;X:>)M1,?B+Q78>&[ZVL;UK6XT_4CX276/#_B%S
M:M?Q:5>G48)M.74+K0K2:**2*VTV_;T<Z1_P4'^)_.HZYX"^"&D7',MKIWV*
MZU5;9P=GD2VB^,;^.Y"E693KFD2!MP<PL##7YS_$;]D?XY^!/%S>'4\&:]XP
MMK[4)+?1/$GAK2[S5=-UJ-DGN([B5[1+IM+NGM[>YGNK#4GBN;<6]Q+F:T$-
MW. ?MMX?^(?P5^/_ ,,[75=43PIKW@OQ)&R:EX6^(%KH%W%#=65P!-IVO:#J
M[WVGM<V=S$DJ!UN()$-M>VDLL$UO.^5!H'[)?AOPMK/@:UT3]G70?!/B%X9/
M$/@Z#3?AII?A;7)+6:.YMY-9\/1PP:3J;V]Q%%<0M?6D[131QRH5=%8?)WP=
M_P"">'@N3P1I5]\9/^$A3QS>M/=:CI&B:]9P:=H]N\FVRTUYK:TO%O+R.!!/
M>W-O>&W6>X:U@,L=LMU<>TVW[ 7[-D&/-\-^(+W'7[3XMUM,_7['<6GZ8Z?6
M@#J_"6H_L4?"C4;O5_ %Q^S#\.]8O;)M-OM1\$?\*M\,:M=Z<T\-T]A=7/AT
M6=[<6375K;W#6LK/ UQ;PRF,R0HR];<_M1?L\VF?-^,'@=\=?LVLPWOKT^QB
M?/3MG]17$6W[#O[+]M@_\*S$[#^*Y\7^.IL\YYC/B80G_OW[>M;]M^R#^S9:
M8\KX3>'WQT^TW.M7OIU^V:I/GIWSGG/4T 07/[8_[-%IGS?BOHSXZ_9M+\27
MOY?8]%GSU[9_0USUS^W5^S!;Y\OXB7%V1_#;>#?&_)] UQX=MT/U#X]Z](MO
MV9OV?;3'E?!WX?OCI]I\.:?>_G]LBGS^.:Z"V^!WP5L\?9/A!\,+<CHT/@'P
MK&_U+KI0<GW))]Z /G>Y_P""@?[.$&?*UGQ1>8Z?9O"FH)N^GVPVGZXZ_6N?
MN?\ @HY\ 8,^5IGQ(O<=/LWAW14W?3[9XGM/_'L5]D6WPZ^'UEC['X$\&VF.
MGV;PQHD&,=,>58IC'M70VVCZ198^QZ5IMIMZ?9K&U@QC&,>5$F,8'3T% 'P+
M_P /&OAC=?\ ('^&_P 6=2S]S_B4>'TW>G_'KXCO_0]-W2C_ (;VFNO^0/\
ML\?%G4L_=_T1H]W7'_'KIM_CIVW=Z_0NB@#\]/\ AM/XLW7&C_L=_%C4,_=9
MF\21CO@G[-\.;T8&,GYP.#\P S6//^U!^TIJ&OZ9=V'[(WBRRNX=(UNWMK+4
M[G7P\]O=WF@2W-UF?POI3!;.2TLXG 3!-ZNYD(4-^D=<S=_\CCH'_8M^+/\
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MQQU]2MOXCMT/T*$>U=!;?L<?LT6F/*^%&C/CI]IU/Q)>_G]LUJ?/XYKZ9HH
M\&MOV7?V>;3'E?!_P,^.GVG1H;WTZ_;#/GIWSGG/4UT%M\!/@;9X-M\'/A=&
MPZ2?\(%X6>4?]M9-+>3M_?Z\]:]9HH X:V^&'PTLL?8_AYX&M-OW?LWA+0(,
M?3RM/3'X5T%MX<\/66/L>A:-:8Z?9M+L8,?3RH$Q^%;-% "*JJ JJ%4# 50
M /0 8 'TI:** "BBB@ KF?"?_(+O/^QF\9_^I?KE=-7,^$_^07>?]C-XS_\
M4OUR@#IJ*** "BBB@ HHHH **** "BBB@#F?&O\ R)OBW_L6=>_]-5W735A^
M*+.YU'PUXBT^SC\Z\OM"U:SM8=\<?FW-U87$$$?F2LD2;Y75=\CI&N=SLJ@D
M;E !1110 4444 >>_"/_ ))3\,?^R>^"_P#U&]-KT*O/?A'_ ,DI^&/_ &3W
MP7_ZC>FUZ%5U/XE3_'+_ -*9E0_@4?\ KU3_ /2(A1114&H4444 %%%% !11
M10 4444 <SH/_(5\:_\ 8S6G_J&^$J_.#_@J%H&I:-X(^#OQ^\.P@^(O@?\
M%/1]22=2T;0Z;K%Q9W4<LLT:EA&GB7P]X<ME5@0OV^5D(9F23W3XS?MM_LO_
M +*WB[5/#WQ[^*,7@'6/%6I+K.@6<OA'Q[XC_M#3;/PQX2L;FY6X\(^%M?M;
M?RKK]T8;N>WN&R'6)HR'/COQ?_:W_9%_:<_8T_:8\4>#?BS;:[\/?!?AF+3?
M%'B1O!?Q#L8?#WBN_FM+OP()]*U7PE8ZW?1S^*(]%WW&E:=>P6B%IKJ:VBBD
MDC^FX-S:GDG%.29C7<5A:..ITL<INT7EV,3P>81G>R<98+$5TT]&GKH=G$_A
M3XA<1\"8O'9?P-QCB<LSBG1H9!G6%X9SJME>/SJ6.IT,DP^7YC3P4L)BL5BL
M]IX; 86CAZU2K7QTHX6C">(DJ;_1CPUK^G>*_#F@>*=(E\_2?$NB:5K^ES<?
MOM.UFQ@U&REX)'[RVN8GX)'/!(YK;K\<?^"</_!1#]F[QS\-/@Q^SO?_ !/1
MOC>AU;P9H/A23PKXZSK&GZ,^J:GH+P:XWAD^&[1(/"MO#:[+[6K=S+IDB!$>
M>V@;Z&\:?\%5/V!_AYXQ\6> /&/Q]MM&\7>!O$VO>#O%6D-\.?B[?-I7B/PS
MJMUHNN::U[IO@"\TZ\-CJ=E=6INM/O+NRN#%YMI<SP/'*_DYOA*& S7,L%AL
M31QF&PF.Q6&P^+P]:GB*&)H4J\X4,12K4I2IU*=:FH5(2A)IJ2ZZ'TN4^&'B
MUF$<#A*_A9XC8;/JV2X'.L7D-;@?B>CF^#PN+<J'UC$994RN.-HX58ZEB,''
M$5*$:,L10JT8S=2G**_0BBOC;XG_ /!0/]D/X->&?A7XP^)7Q?A\,^'/C9X2
MA\=?##4G\$_$?55\4>%;BSTF_BU5+70_!^IWNDA[37-*F^QZ[;:7J"B["-:+
M)%.D1X$_X*!_LA_$SX<_%'XL^!_B_#KOP^^"UII5]\3/$*>"?B/8+X8M=;:\
M72YGTS5/!]CK.JBZ.GWGRZ'IVIO"(2;A8@T9;SRUX<>(;RVGG*X"XT>3UL9#
M+J.;+A;/'EM7,*F9K):>!IXY8'ZK/&5,X:RF&%C5=>>9M8",'BG[(^J?%?A/
MPQX[\-ZUX.\:>'M&\5^%/$=A/I6O>'/$&G6NK:+K&G7*[9[+4=.O8IK6ZMY!
M@F.:)@&577#JK#\&/BK^P-^TE^P;X[U?]HW_ ()F:YJFN^#KV^74_B-^R/KU
MS>ZWI&LZ;&2T\7ABVN;^*X\3VUM"95L+$WEK\1-&C+P^&?$&N&\;2$_1#X;_
M /!3[]A?XN^._"_PT^'?QVMO$7C?QGJL.B>&M#7X??%?2VU/5+A7:&U&H:UX
M$T[2K4NL;D2WU];0#&&E!(!C\=?\%0_V$_AIXV\6?#KQQ\>K+P_XS\#Z[J/A
MGQ1HMQX!^*ERVF:WI-S+9ZA9"^L/ UWIE]]GN(9(_M.G7MW:2@+)#<21NCLX
MS<;V::>C3U3OW_"S6O8\7B/Z/?'_ !)CJ.68GPT\1\%Q3E^#6;9;B<NX1XCP
MO$^58.=>6%CF6'A'+'BGEM3%*6&J*O1JY;B:RE0J1G5BN7X!^&/BW]C+_@J3
MIMYI]AIZ_LZ_M=:3:WK>+_AQ?QK::C/JFF^:NKW-A9RPZ7;^,-+MKJ.=]2O=
M/M-*\6Z4ZO+XJT<0Q6WVJ#3/'G[9_P#P3SU6T\.>++";XI?!B*X%KIUCJ%U>
M:AHGV&(._D^#?$X@FO\ PS,L6732KNTEM(E66XF\+Q>8MS4G_!2'X>_\$\?B
MGX4^$O[2ES\=8OV:/C%\4M(U'QG\"OCWX-\(?$&-_B$/#=OHETMWXRTSPGX9
M;74;3V\0>'_LWB.Z70?&NEK=6_V2YU2RTV;1*\#_ &0O^"T?AV.WO_@%^WM=
MZ#XX\.P0OH6D?M >&/#NI^(_#_BW3[4B*(_$'P@NB0:[=)?11K-9^(].\*6V
MK32&V3Q!X3M+T7VMU]?DW&&899A'E>*I8;/<@G)RK9!G"E7PU-N_-6R^LI1Q
M668E1E)PQ&!JTI1E+GJ0J['Y/B?"[Q.P/L<VXLX"XZRN+QU/)LK\9.&>$,]P
M^09AF-3.J7#>&R;BJ4,OJY9@\TK\13P^0O 9C*M@<7G,_P"R<'6PN-MAI?N?
M^SS^V-\$_P!I&TAM_!WB :1XR6W,U_\ #_Q*UOIWBBW,4:O=2Z?#YSVVOZ?
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M.O!/P7TF?!GTWP\EK/JT(?I]FN-,B\07P:-2V5_X3&UY(W%V 9+^F_\ !/\
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M9C'4X7JXU8!4\+*LLPP-">(PF&I8S&>J4444S\://?A'_P DI^&/_9/?!?\
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M##<VMU!X<M)(+B)9$S(@V>1?$7X!?M*?M ^,M8\<_M9_$G0='\3>(GLO[?\
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M)_:!_98_:9M+;_CVM=<T1O"%Y<PKS'#=SZ]X.^ 4_G%<)*\VMRMOW?\ $PF
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MQL<7]P4444S^<3SWX1_\DI^&/_9/?!?_ *C>FUZ%7GOPC_Y)3\,?^R>^"_\
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MM;X&_P#0V_%G_P 'OA#_ .86C_AVM\#?^AM^+/\ X/?"'_S"T ?H717YZ?\
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M=+7->,_^1/\ %G_8M:[_ .FNZKQSUCI%Z#Z#^5+2+T'T'\J6@ HHHH ****
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M^%GP+\(_"7Q9\=/'.B:CXDUSQ5^T+\4H/BMX]UCQ3?6&H74&HZ;\/O _PO\
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M2A7P^(I2YJ=6E42E&<7YIZII2B[QDE)-+I%Z#Z#^5+2+T'T'\J6N4Z0HHHH
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M!I<TVF0W$6DZ-I,-PMU-8V$UTL%SJ#:A=0V=U=75U9VAB^R6UM;VZB.XN+P
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MH **** "BBB@ HHHH *YF[_Y''0/^Q;\6?\ IS\&UTU<S=_\CCH'_8M^+/\
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ME)\\?:TZKDU%.3IJ<*E*K3J*DH2CR3J1E^LG[.'B3PYXL^"'P[UGPE\)-=^
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M_P"Q:UW_ --=U72US7C/_D3_ !9_V+6N_P#IKNJ .D7H/H/Y4M(O0?0?RI:
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M%OQ9_P"G/P;735S-W_R..@?]BWXL_P#3GX-H Z:BBB@ HHHH **** "BBB@
MHHHH *YG0O\ D*^-/^QDL_\ U#_"M=-7,Z%_R%?&G_8R6?\ ZA_A6@#IJ***
M "BBB@ HHHH **** "BBB@ KF?"?_(+O/^QF\9_^I?KE=-7,^$_^07>?]C-X
MS_\ 4OUR@#IJ*** "BBB@ HHHH **** "BBB@#F?&O\ R)OBW_L6=>_]-5W7
M35S/C7_D3?%O_8LZ]_Z:KNNFH **** "BBB@#SWX1_\ )*?AC_V3WP7_ .HW
MIM>A5Y[\(_\ DE/PQ_[)[X+_ /4;TVO0JNI_$J?XY?\ I3,J'\"C_P!>J?\
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M\%?\B;X2_P"Q9T'_ --5I735S/@K_D3?"7_8LZ#_ .FJTKIJ "BBB@ HHHH
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MBBBO$/:"BBB@ HHHH *YF[_Y''0/^Q;\6?\ IS\&UTU<S=_\CCH'_8M^+/\
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M475_ OBOP?\ $'0[OP_K[-://J-KXAT&]L;#6_#FLZ?:>T4 <SH/_(5\:_\
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M!_*EH **** "BBB@ HHHH **** "N9U[_D*>"_\ L9KG_P!1#Q7735S.O?\
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MNFKF="_Y"OC3_L9+/_U#_"M '34444 %%%% !1110 4444 %%%% !7,^$_\
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MIM]:U:,72HQ[RJSA%=6>3FF>Y+DE/VN;9I@,NBU>*Q>)I4:E1=J5*4E5K/\
MNTH3EOIH?H2O0?0?RI:_)X?M8?MO?&X>1^S[^RXW@C0;K"6_CCXJ2SHC6I (
MU+3QK#>$='<C(!BLX?%T8Q(B)-+_ *H_X8>_:@^-!%Q^T]^U=KC:7= O>>!/
MAFD]OHLB38)@D/V?PWX;AF@C_<EF\'ZPNXN([J1-TD_T_P#J-3R_WN*.)\@R
M!Q_B8*EB?[>SB#Z)Y?DSQ%.G)]L3C</9_$XI-KYO_76IC].&N&\\SU/X,95H
M+(\IDM+R6/S?ZO4J15[WPV#Q%U\-[Q3^T?B;^UW^S?\ "+[1%XU^+7A6#4[8
M,)-!T2[?Q3X@64$JL$VC>&HM5OK)Y'&Q7U"*T@4Y>6:.)7=?CF__ ."DGB+X
MB7D^B_LN_LV_$CXJ78E-N/$.M65QIV@V4H!_TB[MM#BUA4M"VT!]6U[PZP#*
M9#&[+&?H7X9_\$_/V5?AC]GN+3X:VGC'5[<HW]L_$2YD\73R/'@QR'2;U8_"
M\,J.#(LMGX?MI-YSNPD83[&L;"QTNTM]/TVRM-.L+2,16ME8V\-I:6T0)(BM
M[:W2.&&,$DA(T502<#FCZ_X>Y3_N62YQQ1B8_P#,1GN,AE&7<\=IPRS*95<7
M5IN6O)7S2'-'2<%K%GU'CW-/]\SC*.&L/+_F'R3"2S;,.26\*F8YI&EA:<TM
M.>AEDK2NXR>C7Y4_\*P_X*7?'@%_'_Q8\)?LW^&;S)ET#P$!+XDM8YQG_1[C
MP]=WVIGRX_E:.Y^)5M(K$ Q;S(Z=WX&_X)>_ 32+[^WOBAK/CKXU^)9I%GOK
MWQ;K]YINF75R@&V9K+1;B#5YAO&YXM4\1:K#* (Y4>+>C_I-16-?Q#XC5*>&
MRB>!X8P<URRPW#.!H92Y+_IYC:2EF=65EK*KCIM[MWU-:/ /#_M88C-88WB3
M%P::Q/$>-K9HD_[F#JN.6TE?51I8*"6RTT.%\#_##X<_#.P_LSX>^!O"G@NR
M,:QRQ>&]"T[27N0I#!KV>SMXKB^E+ .\UY+/-(_SN[-S7=445\77KU\35G7Q
M%:KB*U1\U2M7J3JU9R_FG4J.4Y/SDVS["C0HX:E"CAZ-*A1IKEITJ-.%*E"*
MVC"G!1A%>44D?/GC[]ICX;_#SXC>$/A9J:>(]5\6>+_$?AKPS'%H6D)<Z;H-
M]XMNX;30Y/$.J7][IMG;177G?:C;Z?)J>J+912W(TYD";V?&3]IKX;_!#6=
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MP5:M7Q&)HTZ-=8R6&ABL+["<J;H3=.G*I6PV-]EZ+1117P)]V%%%% !1110
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MO0?0?RI:1>@^@_E2T %%%% !1110 4444 %%%% !7,Z]_P A3P7_ -C-<_\
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MS/@K_D3?"7_8LZ#_ .FJTKIJ "BBB@ HHHH **** "BBB@ KFO&?_(G^+/\
ML6M=_P#37=5TM<UXS_Y$_P 6?]BUKO\ Z:[J@#I%Z#Z#^5+2+T'T'\J6@ HH
MHH **** "BBB@ HHHH *YG7O^0IX+_[&:Y_]1#Q7735S.O?\A3P7_P!C-<_^
MHAXKH Z:BBB@ HHHH **** "BBB@ HHHH *YF[_Y''0/^Q;\6?\ IS\&UTU<
MS=_\CCH'_8M^+/\ TY^#: .FHHHH **** "BBB@ HHHH **** "N9T+_ )"O
MC3_L9+/_ -0_PK735S.A?\A7QI_V,EG_ .H?X5H Z:BBB@ HHHH **** "BB
MB@ HHHH *YGPG_R"[S_L9O&?_J7ZY735S/A/_D%WG_8S>,__ %+]<H Z:BBB
M@ HHHH **** "BBB@ HHHH YGQK_ ,B;XM_[%G7O_35=UTU<SXU_Y$WQ;_V+
M.O?^FJ[KIJ "BBB@ HHHH \]^$?_ "2GX8_]D]\%_P#J-Z;7H5>>_"/_ ))3
M\,?^R>^"_P#U&]-KT*KJ?Q*G^.7_ *4S*A_ H_\ 7JG_ .D1"BBBH-0HHHH
M_.;]ML?\(=\?_P#@FM\;]2(B\&>!_P!KG6?A9XVU"6YDBM]#7]I[X _%WX'_
M  QU%[<R1VUS/KGQ_P#$?P?^&]F92T\5Q\0%^RI(9)4;YP_9[_X)^?M$_#[Q
MU^R?X"\>W7P'LOV>?V#_ (_?M*_'OX)?$[P!XK\9:E\=_BT/C9H/Q^\#>$OA
MI\1/AKKGPC\/^%/A-HGA?P7^TEXID^('B?PM\</BI-\4_$OP_P#"-^_A3PI#
MK]^/#7[444 ?F%;?L^?M:_'#]I[]G/XK?M3>%?V5?!_@K]DV[^/6I>%-7^"O
MCOXC?$GQG\>-0^+_ ,/M4^#EI8^*O!WQ&^"GP^L/@-X!'@G7=4\7^,?A_I/Q
M1_:"/B/QW8^!;%O%::9X'.K^(_S\^-'_  18\5^+/@MIFD_#;X6_L2^&?B=X
MPM_CQH_B+P%I.G:O\*OV=_V7)OB1X?\ %NC_ +.?Q5_96TOP-\$M7U#4?BG^
MPW>>+?%WC#X>ZC_PB?P+U_XL?%WXR_'WXS6/Q#_9\\0?$"WT/1OZ0** /SB_
M9<M4\7?MT_\ !1?XP:7/>WWAS2T_90_9/&KW!:.TUGQI^S_X"^('Q9\<76FP
M*D%C<KI=U^U7I?A36-7TJUBL&\3^&]=\-DC4/"M_:VGZ.T5XI\;OVE/V=/V9
M]$T?Q-^T?\??@I^S]X;\1:J^A>'_ !!\;OBIX%^%.B:YK<=I-J#Z-H^J^.]=
MT&PU/54L+>XO7T^RN)[M;2":Y,(AB=U /:51$+LB*K2L'D95"F1PB1AW( +L
M(XXXPS9(1$7.U5 =7FFC?&CX.^(K#X6:IX?^+'PTUW3/CG:&_P#@EJ.C>._"
M^IV'QBL%\*WGCIKWX67EEJL]O\0;1?!&GW_C$W/A*35X1X5L;SQ"7_LBVFO$
M]+H **** "BBB@ HHHH **** "BO#?C7^T_^S5^S5#X8N/VC/VAO@;\ ;?QM
M>WNF^#)_C7\6O /PKA\7:CIJV;ZCI_AB7QUX@T%->O=/34=/>]M=*:[GM5OK
M-IXXQ<PE^R^*7Q8^%GP.\":[\4OC7\2_A_\ !_X9>%_[,_X2;XB_%+QEX<^'
M_@3P[_;>L:?X=T;^W?%WBS4M(\/Z1_:_B#5]*T+3/[0U"W^WZQJ>GZ9:^;>W
MMM!* =\B)$B1QHL<<:JD<:*$1$0!41%4!555 554 *    *=7GOQ ^+?PI^$
M_AW3O%_Q3^)OP]^&GA+6-<\/^&=)\4?$#QIX;\&^'=4\2>++R+3O"OA[3M;\
M1:EINF7NN>)M0GAL?#^DVUS+?ZS>316NG6]S/(B'T*@ HHHH **** "BBB@
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MJ@'H=%<#X)^*_P +?B7?^.=+^''Q)\ _$#4_ACXOOOA[\2M.\$^,?#OBN_\
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M.OA./@-J/Q8\1?#KPW\0I;2Q_:,^ 6H_&$?".[\87EEXD>WL_!]KIU_\2_\
MA#9#';^&K>RNO%&S2X8'7]K:* /Y_?\ @IG^V'_P3Y^+'AJ+]CUOVG/V0/ >
MO_M[? [P==?$3]IOQE\:/@IX-\)>'?V)])\:^)'M/&7ASXH>(/%.D6WQ4\6:
MOJ.M_$_0?V8O!_A#6O$4'AKQ_P"*O%7Q;U.#1_!^A>);CQ!];_\ !7X:#XL_
MX)[^+%8:1XF\,>)OC;^PH&4BRUG0?$&@ZS^W'^S6""#]IT_5=(U73[G!!^T6
M5]9W'_+6"7YOU+HH _C1_;&T_P <^-_V-OVJ/V&?%MAXC;P)_P $:O@?\8I=
M?\0^([;6GLOBAJOCG0=<\!?\$XWL-=U=&C\>2>"OV-/$_C;Q7\6GDU'7(M$^
M-<?PS\02LOB/3=+OM+^X/VI?C?=6OQW_ &OK'5OVG/B_\//^"@?P[_:%_9]\
M*?\ !/?]E3PK\>OB-X'T3XK_  .U;1?@-K>AZKX9_9'TCQ-;_#']JKP'\4?'
M'BK]H+P[^T)\</&?PK^*=_\ "+P_H/CZRN/&/PQT_P#9ZT35_!7])U% !111
M0 4444 %%%% !7X-_P#!0SXZ?L0_!+_@I+_P2\\0_$/XQ_LJ_"+XR:=\?OB/
MJ7QEUSQG\0OA'X!^)MC\)1^P-^W'X0^$E_\ $W4]<U?2?%-M\.A\1/B-?>&/
MAS=>*IT\-#QIX[N]%\,R?VYXHFMK[]Y** /Y^[KXF_#?X+?MO+H/[%_[<7B3
MXF_&+]HG_@H+9_\ #6__  3KUO3/@/XM3PCHUW\/8/AU\;_C+<>%]/\ A%X.
M_:V^"?AOP!X'^$W@SQ]X1^*GC'XJ:Q\"_%D]EX9TC1=)\71?&SP5=7_HO_!7
MSX#_ /#37Q9_X)T?!"VUP^%/$'C?XK?M6+X"\:I%'//\/OBGX=_8:^/WBSX2
M?$BRBEMKV-]2^'/Q-T'PGXXTP/:7*C4- MF,$N-C?M_10!_*A9?%GQ3^W-\?
MO^"=G[>_CCP5K'PY@T7]O#X/?LA_#GX;>(=.%GJ'@;QOX'_9@_:U\3?MP7UH
M\PN;R2'4OVE+?3?@+>S#5;O2]6C_ &2-&\0Z3$;36%U;6/8/V0OC;J7C#XV_
ML3:CX5_:9^+?Q%_;J\=?%CXYZ+_P4\_97U[X_?$3QMX7^"'PFT_X??&Z^\33
M^*OV2?$WBJ\^'O[)VB?"7]H3PU^SI\//@3\2/!?PP^&'B?XF>&_$.E6,FM?$
M?2?B_P",/$VJ_P!)]% !1110 4444 %%%% !7X&^%OVB?V'_  -_P66^./@_
MX:_%7]F^+QQKG[%K:!XK^%WP@\??"BT^*'CW]IC2OVB/C!XK^)_@7_A#_"_B
M#3O$'B+]I"?3+--4\3^'KJ,_$7*VNH:XMO&B7<?[Y44 ?RL?\$AO%G@K5/CM
M^PSX=\.?&;X2_M$Z7\/_ -@3XL^"?A=\+/A'XYT76/BI_P $T_ /B/Q9\%O'
M&N_ C]LZ?PMX3T2\^*OCW4+;3OA1\$/#7CKXH>%?V9O%?AO5?@#K&EW_ ,!/
M'GQ.\1?%_P"+T/M'[?NG7OA#_@IEXT_:U\.V-W>>+?V%?V'/V1_VG)8-+MKV
MZU;6/@YH_P"TC^VGX&_:C\+6MKI:2ZCK$NL?LT>-_BGJ6@>'4MM0MM1^(7A_
MP)?-IUQJ.CZ7/:?T?T4 ?R4V_B']H+2?C?\ &/\ ;H^%NA^(1^U)^UA_P28_
M;S_:Z^%NAVG@X^+?'G@_P1+\7/V.O#W[)W@W2/AOJ.GZ@=9^(/@?]G/P7\--
M=O\ X22:'=V.N?'S5/'=C=>']5U?Q=KC:S^F'_!/WQ]\)->_:A\6^'?V+?VJ
MOB5^UU^R$O[+'@;Q'\0O&GB_]J+XE_MD^&/!_P"TC/\ $/5K'PU8:3\9_BMX
MT^)NO>&/B5XW^&(UO5OBS\#-(\:Z/I'@'3_#7PP\5W/PK\$7GQ&CU;QA^TU%
M !1110 4444 %%%% ',^-+OPC8>#O%E]\0)-"B\!V?AG7KOQM+XI2RD\,Q^$
M;?2[N;Q))XBCU%7T]]"31DO6U=+]'LFT\7"W2M 9 ?P4_90_:8_X)V?MK?%+
M]K#]K?Q+\<OV++KX%:S^R=X+_9_TG]GWQ7\5/@-K-YIO[$WPA\:>.?$&N?&W
M]K3X6ZCK]_#\*_"/C[QI\8YM&\*_"WXFZ5I/_"K?AI%X;3XGZ=X3^)_Q0\8?
M"_X?_P!"-% 'XV_\$.?C?\#?BK^QOXA\-_"+XO?"CXD:MX&_:L_;TU?Q7H'P
MX\?^$/&&H^#M ^*'_!0/]K'QK\+=3\0Z7X8U;4;GP_H_Q$\$3VWBWP!>ZE!:
M67BWPK-!KWAV74-(DCNS^;=Q\4/$?[$?[3O[>'[=?@;P/K/Q$N?&?_!0#XR?
ML0>-_ &@6+W<WB[QS\2?V6_V2O&G[$FI:R]N;>[AT_3_ -I33KSX"6EZMZ+/
M11^UOJNO:C;)8:;<ZOH_]6U% '\E_P /_!VK?L9R_M@?"3Q5\8?%7@WX80_M
M[_L!>%OV\_VFO!_B;6/A7K]OX4^(7["GPM\;?';XRZM\4O!@\-:S\%-&^-'[
M3&IZ#!\3_BSH&K> ;SX=>$_BGXM\2Z=XP\"7%C#XBTG]FO\ @F5XO?Q3X=_:
M?MO 'Q6\8_'O]DGPS^TO?Z-^QI\;/''Q0\2_';4/'7PJN?A!\(]?^)=IX<^/
MWC77_%WC;XZ?#_P/^TWK/QS\#>#?B+XJ\8^,+Z"UT"[^'NE>)M4\*^ ?#LB_
MIM10 4444 %%%% !1110!\Q_MB_'C]G;]F+]G?QW\?/VJ;KPY:?!GX57/@[Q
MIJDGB;2M)UJ ^,=!\<^&]2^%/]A:?K>S3?\ A-X?BI;>#;GP!J5S<Z<N@>-8
M-!\0C6=".E?VUI_X>^"IM3^.G[/7C:\^ ^@>$?VY_!7[:G[<GBG]H+_@HA\+
MOV&_V@/V+OBY9_";X=7OPR\!:5X?_9#OO$?Q)_:2^%'POUZ;XD^&/AA\(O!O
M[1VO:3XKU1/%VEZK\>;OPKX?M],^(GA+Q'H_]+U% 'Y0?\$0O$^M^*/^"8W[
M,,^M_#OQC\.9=*\.:]HUC9^,[[X?WUQXDTZW\5:U=0^*]%;X>^.O'=I!H%_/
M>W.G6MMXBNM \4I>Z3J$E]X:L]/DTJ_U/\,/V']/\<^ ?V5?V9?V'/A]8>([
M#PS_ ,%DOV?_ (-ZYI/BO0;;6H-*^%]W\/?"MO\ #O\ X*/:S<>(--3[%X!U
M3Q/^QYX0^&5_\)M0L[[0=2U7]H'Q)JNM6<K^(-1O-7']EU% '\H7[/'CGX2>
M!/@S^Q=\,/VH_CYK_P"R'^PSJ/B;_@JYJMGXU\(_M&>/OV)_!'B']I#P3_P4
M%\:Z+\*_A3XR_:,^$WC_ .$&O>$[*P^$'B/XP^*?A[\&_P#A8OAWPW\4KO0-
M?UZYT+Q1>?!O18]#_>S_ ()W>)?BMXP_8J_9\\2?&G4_&FN^/=4\&3RR>)?B
M3H;>&?B/XN\(0^(=:M?AEXS^(GAV30_#,^A^/?&7PR@\(>*/&>E7?AS0K^P\
M2ZMJ=M?Z1I]['/:Q?:-% !1110!Y[\(_^24_#'_LGO@O_P!1O3:]"KSWX1_\
MDI^&/_9/?!?_ *C>FUZ%5U/XE3_'+_TIF5#^!1_Z]4__ $B(4445!J%%%% !
M1110 4444 %%%% !1110 4444 %%%% !7RQ^UU\</%GP"^&VB>,?!VG^'M2U
M/4O'&F^&IX/$MIJ5Y8)87F@^)=4EEBBTO5M&N%NUN-&M4CD>ZDA$,DZM SM'
M)%]3U^>G_!2K_DA?A3_LK.A?^H?X[H ^3?\ AY5\=/\ H5/A-_X(O&'_ ,W=
M'_#RKXZ?]"I\)O\ P1>,/_F[K\]** /T+_X>5?'3_H5/A-_X(O&'_P W='_#
MRKXZ?]"I\)O_  1>,/\ YNZ_/2B@#]"_^'E7QT_Z%3X3?^"+QA_\W='_  \J
M^.G_ $*GPF_\$7C#_P";NO"_V9OA=X/^(&N^-O$/Q%;4)/ /PM\#:OX[\2:;
MI$DD.I:W'IJAH-)@GB:*2WCG1+J:66&X@G8VT=M%+ +A[NVV3X+\#?M%>(M#
MT+]GWX:R?"O4-*TWQ3K/CY_%7CJ_UOP=I_AS3GTD:1X@EU[5FN]5LV1IKRWU
M:UCTYXX9;O3C;FYMXKV[@ /6_P#AY5\=/^A4^$W_ ((O&'_S=T?\/*OCI_T*
MGPF_\$7C#_YNZT_@)^S!>>$?C1X)3QQ%\-OBEX&\;>$?'=QX>USP[=VOC?P1
MJ.HZ/IICDB,^I:9;VWV^PFF22"22U,?F)-)9W#S6-U]F\5U/]C+XN6FJ^!=,
MT:^\#>-(/'M]J^GV.N^#?$4^K^'=%NM B:?64\1:M+I=G!8BPBAO!*;47^^X
MT^[L8!+J'V>UG /5_P#AY5\=/^A4^$W_ ((O&'_S=T?\/*OCI_T*GPF_\$7C
M#_YNZ\KN_P!C;XC1ZEX'M-)\7_"OQ5I?CSQ+>^$-,\5>$_%E[KGAG3O$=CI>
MI:Q+I6L7MOH0O(+EK/2-1*K96%^(Y;5XKDV[,F[TOPI^Q'8W'AOXH2^+_B]\
M+;;Q/X2TS29=-&B?$6Q;P]X5U.XO]2L]2@^*<]SX9N+C1X(WL?LEHME-%)]O
MBNXI9'"   L_\/*OCI_T*GPF_P#!%XP_^;NC_AY5\=/^A4^$W_@B\8?_ #=U
M\K_ 72OAUKOQ1\+:%\3=/\0ZMH6N:II>B6.F^'KJWL3>:YK&L:;IEA'K-])/
M!=VF@QQ75U/?RZ2_]JL\-O#:F,2RSQ7OVD_!_ASP!\</B%X/\):=_9/AS0]4
ML[;2].^UW]_]EAET;3;N1/M>IW5[?3[KBXFDW7%U,XW[%8(JJH!]-?\ #RKX
MZ?\ 0J?";_P1>,/_ )NZ/^'E7QT_Z%3X3?\ @B\8?_-W4?Q-_9SOO%GC?X<_
M!7X;Z?X&T76/!O[/NE>./$FN7UNN@3^+]:N;M$UV[U#5[&POYKVYEFEL%T=-
M9>.VT^)KY)=3@MRF/(M8_9GT_P"'VM^&8OB_\7_!_A;P5XS\/ZSK'A?X@^!]
M+U[XI:'JM_HM[I-K<Z+';:5;:/>"41:J+E]0C$VGH(EA$TDLV(P#V'_AY5\=
M/^A4^$W_ ((O&'_S=T?\/*OCI_T*GPF_\$7C#_YNZ\Z\$_"WX(2?$WPUX;\(
M^(-;_:EFU[0_%4EEX+T;1]1^"D;>(](L[;4M.MM:\1>+M6@9-%N-&@\1WT]U
MI%RM[;7>E64 M[Q;W[-)]%W7P=^$'@[]JCP!\,8?ATECH?Q1^%FJZ=XH\,^(
MFO/%%CX2\1ZII6KZA#?>#_$>N">XO-4TVYTBVT\:UIEV?L;S7#V%[;W$LUI;
M@'G/_#RKXZ?]"I\)O_!%XP_^;NC_ (>5?'3_ *%3X3?^"+QA_P#-W7P/K6DW
M>@:SJVA7X07VBZG?Z3>B)F:,7>G74MG<B-G2-V030OL9XT8K@LBG*C,H _0O
M_AY5\=/^A4^$W_@B\8?_ #=T?\/*OCI_T*GPF_\ !%XP_P#F[K\]** /T+_X
M>5?'3_H5/A-_X(O&'_S=U^POPR\2W_C3X;?#WQCJD5I;ZGXL\#^$_$NHP6$<
MT5A#?Z[H-AJEW%917$]U<1VD=Q=2);1SW5S,D*HLL\SAI&_EOK^F_P" ?_)"
M_@M_V2;X<_\ J'Z-0!\__MB_M)>.?V>_^%=?\(7I7A/4_P#A+O\ A+O[2_X2
M>QUB]\C^P/\ A&/L?V'^RM=T7RO-_MJZ^T_:/M._R[?RO)V2>;\2_P##R/XY
M?]"K\*/_  1^+_\ YNJ]7_X*=_\ -$/^ZE?^Z!7Y1U_27 '"7#>9\)93CL?E
M&$Q6+K_7_:UZL9NI4]EF>,HT^9J:7NTJ<(+3:*/P_C#B+.\!Q'F.%P>98G#X
M>E]4]G1IRBH0Y\#A:D[)Q;]ZI.4GKO)]S]!?^'D?QR_Z%7X4?^"/Q?\ _-U1
M_P /(_CE_P!"K\*/_!'XO_\ FZK\^J*^Q_U$X0_Z$& _\ G_ /+#YG_6WB3_
M *'&,_\  H?_ "'E^?=GZ"_\/(_CE_T*OPH_\$?B_P#^;JC_ (>1_'+_ *%7
MX4?^"/Q?_P#-U7Y]5]*?LT_##PAX_P!<\:^(/B(VH2> OA?X'U;QUXCTW29)
M(=2UI-.4-!I,$\31201SHEU-++%<03LUO%;QRP"X>ZMN+,>$N"<LP5?'8CA_
M"2I8>,6X4J4ZE6I*<XTZ5*E#VL5*I5JSA3IIRC%SFN:48WDNK!<1<58_%4<)
M0SC$JI6DTI5*D(4X1C%SG4J2]FVH4Z<)3FTI/EC*T9-V?N/_  \C^.7_ $*O
MPH_\$?B__P";JC_AY'\<O^A5^%'_ ((_%_\ \W5>3'P9X'_:'\0Z'H7[/_PW
MD^%NH:7IOBC6/'K^*?'%_K7@_3_#NGOI0TC7Y=>U5KK5;0HTUY;ZK;1Z>\<,
MMWI_V<W,$5[=P>[_  "_9>O/#'Q.L8_&D/PT^)W@[QE\-?'=UX5\0Z#=VGC3
MP5<:SI4NE6K&.]U/3+>"WU+3Y+HF&Z^S */M36=T\EI>"#Q,;@/#[+\+5JXO
MA[!X7'4L-5Q,LHQ+I1QRC2]M+DD\/BL3A5.I2P]7$4E'$3=3#Q=6/NJ7+ZN%
MQG&6,Q-*GALYQ.(PE6O2H1S*@JLL(W4]DN:*K8>AB'&G4JTZ-1RHPY:TO9OW
MFN;!_P"'D?QR_P"A5^%'_@C\7_\ S=4?\/(_CE_T*OPH_P#!'XO_ /FZKR'5
M/V0/BK9Z_P" -"T>^\%^,XOB*=:&B^(_!VO7&K^%;%?#JQ/K<FM:Y)I=G;V4
M>G)(Y=H5NS<2VUS:60NKZ,6K:$G[&OQ'?5/!5CH_B[X5^*-,\<Z_JGA?3?%7
MA;Q9>ZWX9T_Q!I6BZMK]QI6KWMMH7VR"Z>PT34O+6ST^_6.XMFANFMBRD]3R
MSPO482>&R11J4JU>+;J:4L.\0JLIKFO3<983%14)J,YRP]6,(RE"26"Q_'KE
M**KYHY0J4J324'>=94'347RVFI+$8>3E!RC&-:G*32FF_3O^'D?QR_Z%7X4?
M^"/Q?_\ -U1_P\C^.7_0J_"C_P $?B__ .;JL;0_V-+)_ GQ2U;Q'\8/A/;>
M*O![>%8=-.G?$:Q?PKX;N[[5YK/7[+XEW+^';BXTRZG6*31?#$5A=1BZ\46E
M_8W#RQ0#/S9\(KWX;V6N7G_"P/ /B/XFW-Y!::=X1\':'K=QX>MM5U^^OX+=
M(]4U/3=VM1@PN8]/BTJ"YDN+R1(IH"C*\=8?). ,;1S&KEV08;,'EM2C3K4L
M/1<)U)5Z%'$4W0GBZ^&P\H.G63E4J5J5.')4<Y1@HRE-;-.,,)4P5/&YQ6P2
MQT*DZ52O54X0C2JU*,_:QP]*O64E.E90A2J3GS148RDY17U9_P /(_CE_P!"
MK\*/_!'XO_\ FZH_X>1_'+_H5?A1_P""/Q?_ /-U7B?[6?@#X??#7XMR^&?A
MU#)8:8GAS0[_ %C0I-5FUEO#?B&]6YDO-%-[=2W-V6BLETZ]>.ZN[N5)+U\3
M+"8H(?:OBI^SK<^,?BIH7P9^&5IX*\/W/PV^!7A[Q#X@U?58(/#O_"3WB7%A
M%K>N:IJFEZ7=RW^JW3ZUISB75C#;V]O:WFVYAPJW."ROP_>'RK%U.'\)AL+F
MF!Q&8JKBJ;I?5<)AHX;GJ5U&K4C=U,9AJ<?9SG!JI[2,Y05WL\?QC[;,,/#.
M,16Q& Q5#!.G0G&I]8Q->5;EA1<J<'90PU:;YXQDG#DE",Y-)W_#R/XY?]"K
M\*/_  1^+_\ YNJ/^'D?QR_Z%7X4?^"/Q?\ _-U7C>K_ +.&G_#_ ,1^'K+X
MO?%GPIX5\&^+_"][XB\+?$3P5I6N_$_P_K<]I=Z=!_95K;Z5!H]^6>VOQ?'4
MECDTT0B!8IYWN1Y4"Z%^S?X#\4:5<_\ "7:]^T?HUUI&L@>&-"\+^)/A65\3
MK/I4'AZRU74=4NKG5)]*U&&YU:22?P^DE_:WMC8QO;7,%U)$>B.1\ UHQE@N
M'/[1]K2J5:$L%E>83PU;V?M%.E',JL*.54JRG2J4I4\5CJ#A5C[*IR3:B\7F
MO&%.4EBL[^I<E2%.JL5C\'&O2Y_9N-1X&G*IF%2FXU(5%.AA*W-3;G!2CS,]
MK_X>1_'+_H5?A1_X(_%__P W5'_#R/XY?]"K\*/_  1^+_\ YNJ]"A^$WP3T
MK]HGPG\+K#P7:Z9%\6O@GJMMXC\%:W=CQ7>?"WQGJ>BW?B*PN+36]3?4;S3]
M?L[;26LX[BRO7NX#.E[ 8K'4H<_E_=6MQ975S97<3075I/-:W,+XWPW%O(T4
MT3X)&Z.1&1L$C(.":G)\BX'SES5#AFA02P>"Q]-8FFE.IAL;4QE&G-*EB*L'
MRUL#7BY0J5*<X>RJTZDZ=6#9F6;<5Y6HNKGM:M?$XG"3=";<85L+3PM:46ZE
M&G+WJ6+HRY9PA.,O:4ZD(SA-'W]_P\C^.7_0J_"C_P $?B__ .;JC_AY'\<O
M^A5^%'_@C\7_ /S=5^?5%>[_ *B<(?\ 0@P'_@$__EAY/^MO$G_0XQG_ (%#
M_P"0\OS[L_07_AY'\<O^A5^%'_@C\7__ #=4?\/(_CE_T*OPH_\ !'XO_P#F
MZK\^J*/]1.$/^A!@/_ )_P#RP/\ 6WB3_H<8S_P*'_R'E^?=G]7%?@7_ ,%3
M_P#@J?\ M!_L/_M!^#OA/\)_!WP;\0^'?$/P;\/?$.]O?B'X>\;:MK46M:MX
MV^(?ANYM;6Y\-_$/PE8II:6/A+3I8()=.GNUNY[V22]DAD@@MOWTK^-__@X8
M_P"3T?AC_P!FO^"__5K_ !KK^0*24IV:NK,^]\:L[S;A_@:OF.2XZOEV.CF6
M74HXG#N,:BIU:DU4@G*,E::23TZ!_P 1#'[:/_1,?V7_ /PB_BO_ //KH_XB
M&/VT?^B8_LO_ /A%_%?_ .?77X/T5T^SA_*C^.O^(K^(O_179M_X,I?_ "H_
M>#_B(8_;1_Z)C^R__P"$7\5__GUT?\1#'[:/_1,?V7__  B_BO\ _/KK\'Z*
M/9P_E0?\17\1?^BNS;_P92_^5'[P?\1#'[:/_1,?V7__  B_BO\ _/KH_P"(
MAC]M'_HF/[+_ /X1?Q7_ /GUUY+^R7I/P@^ G[ ?Q>_;9\5? +P%^T3\49OC
M]8_L]^!_#_Q=T"W\;_"SP/IY\'>'/&-QXM\0^$V>%)9;VYU2XTE[F>YMM1-R
MOAVPTJ]TBVU?4Y]1JVW[.GP7_:T\+>(OVU?BAXR^%?\ P3H^!VK^,/"_P?T/
MP]X-^'OBKXEZ)XO^*^G>%[>Y\4ZGX0\"Z%=^&I?"'A:]C2*]$%E/K%EIUU;>
M(7U*YC&FW>K:A/+3N_<T6E][O31)7;W[='TU/M8<1>*%?"9;+#<>XFMFN8Y>
MLY_LJI7I8*GA,F<L3!9AC,XS"GA<GPT8RP\7.G6QE.RQ%",:DZ\I48^R?\1#
M'[:/_1,?V7__  B_BO\ _/KH_P"(AC]M'_HF/[+_ /X1?Q7_ /GUU] ^!/V)
M-!^!?[*/_!13]F;X\?';PK\-_!6G_$S]FWQ!-\?5\*:GXFTN7PE=SZ-XK\.:
ME;>!]*U--=N-6U>X9/#:^'5U/SK?6;BX:TO-1TXVM]J'Q]XJ_P""0D/PN\5?
M&;5_C5^U#X5^&G[-OPFT3X<:K9_'UOAOKOBR]\;77Q-@B?1-*TCX5^'?$EQK
M=O=V5R)K;5%77K^4)<:-=Z;;ZC;7^H/HJ7LG?1>6C]ZZB]--_>MRZOR/2QU;
MQNPM' 5:7$F95Y5\/7GF=.KF&2X-Y)BL-C<\PU>ECY8C&KV.!A0R+$XE9UB%
MALKF_:8>GB)5*+=3T#_B(8_;1_Z)C^R__P"$7\5__GUT?\1#'[:/_1,?V7__
M  B_BO\ _/KKAK?_ ()$^'X/%WQ1B\0_M<^$])^$/@3]GSX7_M/^'OC-8_"_
M6M>TKQ=\'_B/J?BVR_MRY\-6/BZ/5M$OM.M/!6LZCI^F:=<>*I/$$4VDPQ2Z
M?)?N;:+]J3]CO]BGX7_\$^OA+\;/A5\<T\;?$K6_&WCK2/#WCN/X;_%;08OV
MC$TKXA'P]J.@Q>'?$'B;4/#WPFC^&WA[^T-676+S2X_^$T&A?8[::2\U:WF!
M:E=)1O=I:)Z-JZN]OENNVCMPSS+QMH8/,\=C>*)X"CEF7XW,JD,7G^1QQ&*P
M^ Q]++<3]2PU*O6KXC_::O+0J\D,+BW&%+"8BOB<5@:&*[[_ (B&/VT?^B8_
MLO\ _A%_%?\ ^?71_P 1#'[:/_1,?V7_ /PB_BO_ //KJ/\ X(\^'_A!X[:3
MP+X^^'7["OB>XU3XJS0>*+G]I36+/6OCUXM\'ZMX*MHM \&?LZ_#C6M+.B?V
MAI7B?2KW4M5\4-K)N+I/$$VG/IJR:787A^9?@9\#O#NN?\%;/#_P<U;P-J_P
MX\'Z=^U;XIOK+X<:W!:M?Z#X3\'>)=>\<>&/!NI+]HU:QO;"XT/1-*T>>\LK
M_4K'4](NC?:5JMY;7-IJ$CM33DG!>ZN;Y$PXA\3ZV6\+9CA^/,=6CQ/F]/):
M5*,9P>#QE6="$%6JU,/&E.-ZUG:4'*5.K[+VM*$JJ^GO^(AC]M'_ *)C^R__
M .$7\5__ )]='_$0Q^VC_P!$Q_9?_P#"+^*__P ^NL+QA^R)X6_:W\9?M<_M
M?_'K]K'0OV?_  SH?[:7CKX*:I<>(_AK?^,X(+&U>RMO!;:?=Z)XGT*6XDLK
M:^T#PP-/NM*M+6RT+2;_ ,4ZOXE5;.XMY<W2O^"=WP6^%GQ%^-WP<^.?PO\
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MW5GI/]G3Z1:6_FI-?W%WM,J2V2-);R?NO_PH/X%_]$6^$W_AN?!__P IJ/\
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MV=N]E;6D:5^P7_"AO@;_ -$9^%'_ (;OPA_\IZ/^%#? W_HC/PH_\-WX0_\
ME/55N/."\14KU*O"V8REBGBI8F*S2O"E7GC)XRI7J5J-/$QHU*BGF&,="K.#
MJ83V\EA944H**I<)<448484^(,$EAUAU0;R^C.I1CAHX6%*%*K.A*I"'+@L,
MJM.,U#$>QB\1&JY2;_"[X;?'C1/!MK\8-&\4_#:V\>^&/B_<Z1>:GH<_B>\\
M/G3[G0=9U77-)==0L=+NKB[2VO=365TC6P:62SA8R+&\D)I?L]?&O0?@=XAU
MGQ+JGPYM_'FI7VF+IVC73^(I/#=]X:,IG34+O2[^'1M8F@O+^VE6U-W:"RO;
M:%)%@NU2XG1OW>_X4-\#?^B,_"C_ ,-WX0_^4]'_  H;X&_]$9^%'_AN_"'_
M ,IZZZWB7PO7I9E0J<.YHZ6;+#K'TX9K6I1K_5:-+#T7%4L1#V$O84*-&M/#
M>QGB:=*$,1*K&*2YJ7 V?4:F!JPSK *IESK/!SEE].I*E[>K.O43=2C+VT56
MJU:M*-?VD:%2<I453<FS^>[XJ^,? WC;7;?6/ _PYN/AU')!</K=M=>._$'C
M^ZUS5[F\FNIM8N=5\10Q7L5Q*LHCFB4R":16N9)&EE>OK/XP_'30-.\9:C\0
M_#T>D>+(/CA^RU)\.-5TZP\5:<NH>!/$&NV]G::FNM65G;ZK<QW>B1Z?9E=*
MO(M,&IFYE:WU&(6TH'ZO?\*&^!O_ $1GX4?^&[\(?_*>C_A0WP-_Z(S\*/\
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M\5'0H_"K>,6L(_ OC:;QL=(32#K1LX_AI%X>?XCR^*C9@PKX%B\*/XV?5\:
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M27NEZI;6>IZ;=JDBK<V&HVEK?6<P>WN[:"XCDB6W4NJKN]/5Z/7[T_=^\</
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M<'D-7#TJ#P[S*KA,-AW_ *RRQ"I82GFV8QH0J5ZM7V.)J.K.HWSG\)/[-?\
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MOPI_^=C1_P (7XD_Z*Y\0O\ P6_"G_YV-'+'_GY#[JG_ ,K#VDO^?-7[Z/\
M\M_JS\K^A45Y[_PA?B3_ **Y\0O_  6_"G_YV-'_  A?B3_HKGQ"_P#!;\*?
M_G8T<L?^?D/NJ?\ RL/:2_Y\U?OH_P#RW^K/ROZ%17GO_"%^)/\ HKGQ"_\
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M^^C_ /+?ZL_*_H5%>>_\(7XD_P"BN?$+_P %OPI_^=C1_P (7XD_Z*Y\0O\
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M_P#!;\*?_G8T<L?^?D/NJ?\ RL/:2_Y\U?OH_P#RW^K/ROZ%17GO_"%^)/\
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MKGQ"_P#!;\*?_G8T<L?^?D/NJ?\ RL/:2_Y\U?OH_P#RW^K/ROZ%7YH?'?\
M8V\6_%O]KFT^+OB'PMX9^*_P:UWX;_!_X9ZSX6UO]J?]HKX"OX'TKP3\1OB)
MXQ\>R7OP@^%'A+Q)\*_VHM#\=P^+?"MU<>!OC/JGA?0YKGP-'X<U2ZN] UR2
M?3/NW_A"_$G_ $5SXA?^"WX4_P#SL:/^$+\2?]%<^(7_ (+?A3_\[&NG"XBI
M@YSJ4:L(RG3E2;3Q$)*,I1E>%2E[.K"2E"+O"<>9)PGS4YSA+#$4HXF$85:%
M1QC4C42?U:<7**:M*%2<Z<XM2DK2@[.TX.-2,)K\E+O_ ()S_%B\\?\ A'Q/
MXTT7X??&#PWXDT#XT:5\9O"D/[67[3O[-^EV>H_'O]IGQS\;OB=?6>E_"3P'
MKFE_M!>$O%_A7Q9X=\#ZY\+/B]!X6\)WFG?#'PGH,DTGAV98M'U?B5_P3C^+
M/C*/]K"&R\0_"N;0?&&H^*7_ &8_A_J-]XAL/#&GZ1\;_'_P\^(_[4=C\7;R
M'P1K/]D-\6D\ V?PJT,>&=!\;Q^"O >I^.;Z'^U$^)NN^$-)_5;_ (0OQ)_T
M5SXA?^"WX4__ #L:/^$+\2?]%<^(7_@M^%/_ ,[&O06>8]3A-5Z/-!WBG&NX
M1?MXUVX4I7I47*SI5)484W5HU*D*KFZDI/C_ ++PKC*#P]>TE:7O8=2:]E[*
MTYJ:G52TJQ56510JPA*FHJ,8GYV:;^RG^T[J'Q3\)_&WQM8?L]W?BG6OVX_#
MO[0_Q3\&:#\0?B1;^'](^$'A?]E"Y_9Q\">%_"7BN]^$LEYXY\9?"_7=7U'X
MH);>(?!G@72OB7XLL+*Y'B3X5:3=VOAOPYX)8?\ !-;XR-\$_C!\/O$'AOX6
M>)?B7K%[K#^%OBGXV_:Y_:<^*GAWXI:-XX_:.T7XQ_&G0?%'P2^)'PLUWX>_
MLR0_M ^&=&GT'XJ7OP<3XDMK&J:_J9U6T\1:>CF__8[_ (0OQ)_T5SXA?^"W
MX4__ #L:/^$+\2?]%<^(7_@M^%/_ ,[&E'.L9#DY*E"'LWAN106)@E'"2G*A
M!QA**J4XQJ3I2A44XSIN*FI2ITY0<LMH3YN:CB)<ZK<W/+"S;>(C!59IR;<9
MMPC-2@XN,U)PLISC/XU\&_L\_M%6OP=_;HU#Q1JGPCT[]I7]K#5/B%XC\(3>
M%=>\87?PX\!SW'P!\'_!_P"#GA'6O%UUX*T#Q1J]AX&E\(VB^(/&NG> =/U/
MQ DU]XGL_"FF7E_'X7TWA_B'^S7^U5X\_9.^"_PP\'V?P*^ WQM_9\\??#*?
MX5ZII/Q5\>_&#P-HW@[P'X'G^'!\43Z_J7P%^%&N3>,K?PSXD\32:?X,_P"$
M+.A7UWIVDVM]XXM;76[^71/T"_X0OQ)_T5SXA?\ @M^%/_SL:/\ A"_$G_17
M/B%_X+?A3_\ .QK&.95H351?57*-:G5A>E6<(JE1CAX4?9V]G.C["*I<E6-2
MT.91:YYN6LL'"47!PQ24J4Z<K5*"E)SJ^VE5Y^?GC5]JW/FA**<DFT^6%OS9
M^+7_  3R\:2:=;V_[.WB/P!X#U'X+?"G]DKP9^RAJGCH:]XE;POXP^"O[06J
M_%SXN>+?BG'9Z3%>^*3\3O#MEX,T.^D@U6YU;Q3K:^,-<\17VG:MK&GZUIS_
M  A_P3P\5^"/B7X7NM'\1^&+OX::)\<_V>_&FLWNK:UK5W\0?%W@/X ?"?XJ
M>*[?4_$]JWA(Z/J_Q2\>_MJ?%CQ)\6_%MXVN6NGRZ/?7OBB+5G\3S)X8C_2/
M_A"_$G_17/B%_P""WX4__.QH_P"$+\2?]%<^(7_@M^%/_P [&M%G&.5*5%XF
ME*$U)2<J<W-RE&BN=S=/F<XRHJK!MM1K5:]5+FK3;AY=A?:1J+"UHRBX\JC4
MI**C%U/<455Y5&4:GLY)*[I4Z4+\M.!^='[2O[&7QO\ CK\??BQKUO8? L_"
MWXU_"OX%_ +6/'^O^+O&\7Q@^&?P6^'WQ&\1?%+XM>'O _@+3_AE=>&M<USX
MR:WXC32'U>[^+7A2S\/)X3\%^)-3TOQ?+H-GX<@\YTK]AG]I.>>30?B3X3_9
MF^*/PZ\(O^W'JVF:5<_%OXK>#O%?[0WC#]KGQOJ6GCQ%\7/%.D? S4Y_A%:P
M_ WQY\0_".N:3X.A^+6IZ7K5MX9MM!\4W>B26\OA/]7?^$+\2?\ 17/B%_X+
M?A3_ /.QH_X0OQ)_T5SXA?\ @M^%/_SL:<,XQ5.E3HQGA^2G&,8KEQ"DFL/]
M4<U.+C*$YX:U*7LW"-_WT8QQ%ZHIY=1G4G5=+$\\Y-OW\,U9UEB%!QE*491A
M7_>+G4I/6G*4J-J9^2ES^P/^TQXCU?X):E\9=2\,_'_0_"WPH^(?P8\3>"M4
M_;0_::^!S>!/A_XR^+%GXAM/#D?C;X,?"'39/VMM/F^$FC^"/AU\1%^.'@SX
M=O\ %C4?AGX=\2^-3J&H:UJ5QIVW\1_^"=WQE\:3?%9M,\5_##08/B)I7[9.
MFVUO8:EXGT];"7]I?Q)\'?A-X2U!WA\&W4EC=_#S]C3X43^$+230GT^73O''
MBJX\.:+.GAS1[#QG)^J'_"%^)/\ HKGQ"_\ !;\*?_G8T?\ "%^)/^BN?$+_
M ,%OPI_^=C5+.\:I0G&KAX.#J<L8PK>R2JSG.<8T'>C3BW-\WLJ<)5'&,ZKG
M4BID_P!F89QG&5#$2Y^3FE*>']HW3C",9.JIJK-I05O:3FH>]&FHP?*?EE\7
M_P#@GE\2=7\<7'C/X<6/@1_#&@?'?P5X@\!_!?0?VB_CY^R9I5C\%OAS^R#I
M'P$^'EE:_&']G[P1K/CSP-XS\">/;SX@ZSIGAKP]H.L>$M4\ ^)[?0YM<TR\
MBU"&^_4WX3> ]$^&'PS\"_#_ ,/>&-)\&:5X4\,:3I,7AC1-=U?Q5IND7,-K
M&^I00^+O$5EIWB3QC-+J<EY<WOC+Q-8VOB;Q=?37/B/Q%$NM:G?9/^$+\2?]
M%<^(7_@M^%/_ ,[&C_A"_$G_ $5SXA?^"WX4_P#SL:Y,5CL1C*5&C7KPE"A&
M,86>(2:A'D@YP=Z4II.7[YT_;2YG&5245&,>FAAJ6&J5:M+#U(RK2E*=_JS:
M<I*4E&7/[2,&TOW:G[)<MXP4FW+T*BO/?^$+\2?]%<^(7_@M^%/_ ,[&C_A"
M_$G_ $5SXA?^"WX4_P#SL:X>6/\ S\A]U3_Y6=7M)?\ /FK]]'_Y;_5GY7]"
MHKSW_A"_$G_17/B%_P""WX4__.QH_P"$+\2?]%<^(7_@M^%/_P [&CEC_P _
M(?=4_P#E8>TE_P ^:OWT?_EO]6?E?T*BO/?^$+\2?]%<^(7_ (+?A3_\[&C_
M (0OQ)_T5SXA?^"WX4__ #L:.6/_ #\A]U3_ .5A[27_ #YJ_?1_^6_U9^5_
M0J*\]_X0OQ)_T5SXA?\ @M^%/_SL:/\ A"_$G_17/B%_X+?A3_\ .QHY8_\
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MX\TCPNVD_M/ZHDUYI_A2U?S?V5/C%I7P+\8Z9<7-WXRM])TZ[\9>/M<TJW\
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M****YS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img147150826_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'S!"(# 2(  A$! Q$!_\0
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M:Q[5?_!-;_Y7Y_GV9Z%17GO]I?%;_H2_A[_X<[Q)_P#.CH_M+XK?]"7\/?\
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M_P#E?G^?9GH5%>>_VE\5O^A+^'O_ (<[Q)_\Z.C^TOBM_P!"7\/?_#G>)/\
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M1E64IXB%-0JPK3]G#V"2ARU'7T:/ZFJ*_D$\??M&?%;]B:R_X+'_ ++GC_\
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ML;F]TO\ M'P_H.K:3X?\B#4K)_MOBF_T33I/.VPW<CQRK'_.CHDO[6W[<_\
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MWB3_ .='1[.7>'_@RG_\D'M8]JO_ ()K?_*_/\^S/0J*\]_M+XK?]"7\/?\
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MW^OP>%]+TCQ#H^A>&_"VM>%/"O@^?2],\/P^*=<NM)DODU;4XKV]>6YU&ZB
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M?!?_ ",GQ<_[*%IO_JJ?AC7H5>>^"_\ D9/BY_V4+3?_ %5/PQKT*KJ?$O\
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M7M2I*\I2=J<5>4ERRD[+64HMQDWJT[.Z/$O"_P"S1^SAX'O?A[J7@O\ 9_\
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M(+'4-4O+C2-+FN;J233[1H>S\0?#KX?>+? ]Y\,O%7@7P;XF^&VH:-!X<O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\]^$?\ R2GX8_\
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M+?B'Q!X5\&2?#_5=8\"?'?PBGPE^'VG?!KXP_P#"!_%3P9XTM?#G@SQG\<_
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M@[7;JVUN;5/AKX8\<VWACPFWQ 3P]:_!W1(?'_AWPI9:3+XDG^+T^E_MH_\
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MJ5OHEB^J>*/%%]IVD:7IYN!;:EK5QIND6D!+V>FQK WX)>/_  ;\2_A?X/\
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M=-0 4444 %%%% !7,^"_^1/\*_\ 8NZ+_P"FZWKIJYGP7_R)_A7_ +%W1?\
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M&:[_ /4-\6UTU<SKW_(5\%?]C-=_^H;XMH Z:BBB@ HHHH \]\%_\C)\7/\
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M2;2Y5@Z$O:8UQC!ULPK8B=3GY*<ETB]!]!_*EI%Z#Z#^5+4'W@4444 %%%%
M'-:]_P A/P;_ -C+<_\ J(^*JZ6N:U[_ )"?@W_L9;G_ -1'Q572T %%%% !
M1110 5S-Y_R.&@?]B[XK_P#3CX/KIJYF\_Y'#0/^Q=\5_P#IQ\'T =-1110
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M %%%% !1110 5S.O?\A7P5_V,UW_ .H;XMKIJYG7O^0KX*_[&:[_ /4-\6T
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M:=/$5KO$X^M*>*S'%R=G*>*Q^)E5Q59RDN9QE5]G%WY(16@4445\^>\%%%%
M!7,^"O\ D3O"G_8MZ'_Z;+6NFKF?!7_(G>%/^Q;T/_TV6M '34444 %%%% !
M1110!S.A?\A7QI_V,EG_ .H?X5KIJYG0O^0KXT_[&2S_ /4/\*UTU !1110
M4444 %<SKW_(5\%?]C-=_P#J&^+:Z:N9U[_D*^"O^QFN_P#U#?%M '34444
M%%%% 'GO@O\ Y&3XN?\ 90M-_P#54_#&O0J\]\%_\C)\7/\ LH6F_P#JJ?AC
M7H574^)?X*?_ *;B9TOA?_7RM_Z=F%%%%0:!1110 4444 %%%% !1110 444
M4 <S:?\ (Y:]_P!BSX2_].OC6NFKF;3_ )'+7O\ L6?"7_IU\:UTU !1110
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MWX1_\DI^&/\ V3WP7_ZC>FUZ%7GOPC_Y)3\,?^R>^"__ %&]-JU_#E_CI_\
MI-0RE_'I_P#7JM_Z70/0J***@U"BBB@ HHHH _./_@HOI?QJ\:>&?@W\+O G
M[-WQ3_:-^"/C/XEIJG[5GAGX0Z]^SAI?BO7?A/X'T\^(=&^$DUC^TE\>_@!X
M8N/"OQB\?KX8TGXE7FG:]XGEN_A-H'Q!^']WX9C?XBZ?XE\/_!?_  39_: 6
M_P#^"27[)/[.FG:7XS^%O[4/QF_8:^/5S^S/X.\26V@:AJ'Q&C^"GA#PWIVK
M?$;PYXE^'VN^/_!7AK0[7Q%\6OAT-%T[XD^(/!GCB_?4I9/^$*2+3=1-O_0A
M10!_.7^PC\0?@-\8OCI_P2DT3]E/6O!^K:I^RE_P3F^,/PX_:M\/^!(8K36?
MV?\ 3]>T;]ECPUX7_9^^/FF6$"W7PV^)&H?&+P!XCUC2/@W\0DT?QDVH?"CX
MC>)K?153PQK=V_\ 1I110!S-I_R.6O?]BSX2_P#3KXUKIJYFT_Y'+7O^Q9\)
M?^G7QK734 %%%% !1110 5S.O?\ (5\%?]C-=_\ J&^+:Z:N9U[_ )"O@K_L
M9KO_ -0WQ;0!TU%%% !1110 4444 %<SX*_Y$WPE_P!BSH/_ *:K2NFKF?!7
M_(F^$O\ L6=!_P#35:4 =-1110 4444 %%%% '-6O_(X:[_V+7A/_P!.GC.N
MEK\;T_X*Q>#Y_'?C.U\.?!7QMXF>YM=.T#P!%IFKVCZAXMO=)U36G@?4]+32
MI;SP_%J$&K/)%'IZ^*;V)K=(GM&-P[6VZWPW_;X_:\Q-\4?%5M^R]\)+\@MX
M*\-I=1^,M4TYV4&#4K2"]CUEFGBC:*\A\3:[H]O'*ZW$?A*6!S%7Z&_#?.LN
MY:_%>(R[A+ .$*GUG-,70KXG$0G&,W# 97E]3%8[&XB,9+GI1I4XTY<U.M5I
M3A.,?@5XAY/F'-1X7P^/XJQW-*G]7RS"UJ.&H2C)P4\=F6.IX?!8.A*2?+5E
M4J2G&TZ5.I"49/ZN^.G[=/[/7P):[TK5_%:^,?&EN6A7P/X%\C7M9CO,$);:
MM=QSQZ-H+B1HA-;ZIJ,&IB*436NFW@&P_)Q\2?\ !0+]L F/PKI,?[)OP>U#
M(&N:FU[!X]U739A)MDM)W@M/%$LLD+136UQI&G^"]-N$<&/7+I"2?L;X$_L5
M_ #]GY;2^\)^$(M:\76RHQ\=>+_(UWQ,)U"9GTZ62WBT[06W)D'0=/TV0JQ2
M:6;)8_6%+^W^%>'?<X8R;^V,PAHN(>**5*M&$UO5RWA^G*>!P]I)3HU<PJYA
M6CI>G!W0_P"PN)L_][B7./[*P$]7D/#-6I1<X/7V>89[4C#&U[Q;A6I8"G@:
M,M;3G'4^%/@G_P $]?@%\);F/Q%KVEW/Q=\?M/\ ;KKQ=\11'JT0U%Y&EEO-
M.\.2F;2+:5IV6XCN]236M8@N$$T6K*Y.?NE$2-51%5$151$10JHB@!550 %5
M0 %4     8IU%?)9OGF<9]B7C,YS'%9CB-5"6)JRG"E%Z^SP]%6HX:EHK4:%
M.G2CT@CZK*LERG(\,L)E&7X; 4-'*.'IJ,JLE_R\KU7>KB*KZU:\ZE276;"N
M9U[_ )"G@O\ [&:Y_P#40\5UTU<SKW_(4\%_]C-<_P#J(>*Z\H],Z:BBB@ H
MHHH **** "N9\%?\B=X4_P"Q;T/_ --EK735S/@K_D3O"G_8MZ'_ .FRUH Z
M:BBB@ HHHH **** .9T+_D*^-/\ L9+/_P!0_P *UTU<SH7_ "%?&G_8R6?_
M *A_A6NFH **** "BBB@ KF=>_Y"O@K_ +&:[_\ 4-\6UTU<SKW_ "%?!7_8
MS7?_ *AOBV@#IJ*** "BBB@#SWP7_P C)\7/^RA:;_ZJGX8UZ%7GO@O_ )&3
MXN?]E"TW_P!53\,:]"JZGQ+_  4__3<3.E\+_P"OE;_T[,****@T"BBB@ HH
MHH ***_-G]O?X[?M:?LR>'KGX\?#74OV<+SX+^"M9^"7AZ\^#GC3P)\2O$_Q
MP_:!\6?$[XP^'_AU?^ OAQ\1="^*G@3P?\'_ !5J<'BC0=#^%T=]\*_VA)O&
M'C?4E@U32O#UC%#;WH!^DU%?CM^UA^VI^U9X)\4?MN:]^SM9_L^+\,?^"</P
M<\(_%[XU>%/BSX,^(_BCXA_M!ZA>_#[7OCKXR^&/PR\9^&/B=\.O"_P&N]+^
M#>AZ5;>%_B'XG\&?'[3->\>^-X(-6\'^&]&\%ZB_B7P6#_@LMJ/AGXU?&S3_
M !M<_!36_A]H'A/XR7W@7X*:+'?^!/V@OA=XI\#>,?V?/#WP'MOVC/B!XD^)
M_BCX?Z'X/_:W\ ?%CXB_M*^'O&WB#X=?!CPU\%/V;_@A\3?BQKNL?$[X;_#;
MXK?$'P( ?T!T5XW^SS\01\5?@A\+_B$WQ,^#?QCNO%/@_2=1U3XF_L\Z@-5^
M"'C#7!#]FU_5/A?J!\5>-Y+KP>-;M[^TTF2X\5ZW>>3;;;V[%VLT,7LE ',V
MG_(Y:]_V+/A+_P!.OC6NFKF;3_D<M>_[%GPE_P"G7QK734 %%%% !1110 5S
M/A/_ )!=Y_V,WC/_ -2_7*Z:N9\)_P#(+O/^QF\9_P#J7ZY0!TU?+?[9?[47
MA/\ 8^_9\\<?&SQ0(+R[TBU&D^"O#LTCQMXN\?:M#<)X8\.1M&?.6"XN();_
M %>XA#2V'A_3M7U)$D-GL;ZDK^<J[W_\%<O^"@RV*$ZG^P]^QAJ)>[)%V^@?
M%OQY)<A'B)4BTOH?$FJZ:\,+$RQ+\-O#EU+&]A>^-0LE02;N_ACK)^7;U>R^
M_H?&\:9]B\IP.&R[)HPK<3<0XAY5D%">L*>(E!SQ6:8B-I/ZED^%Y\=B9<LH
MMPI49*]>)]1?\$D_V6O%GA7PIXP_;.^/HFU;]H_]JNXN?%US>:M!/'JOA/X>
M:W?+K.FZ0L5R2VG3>*YTLO$-U80!(-/T&V\'Z&D%I)H]U;G]DZ:B)&JHBJB(
MJHB(H5410 JJH "JH "J     ,4ZE*3DVW_PRZ+Y'K<.9#A.&LFP63X-RJ0P
MT)2KXFKKB,=C*TG5QF/Q,VVYXC&8B=2O5DY.SFH1:A"*17->,_\ D3_%G_8M
M:[_Z:[JNEKFO&?\ R)_BS_L6M=_]-=U2/<.D7H/H/Y4M(O0?0?RI: "BBB@
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M7?%&NZU>7^I7/TC110!S-I_R.6O?]BSX2_\ 3KXUKIJYFT_Y'+7O^Q9\)?\
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M6IB^*LZHNEG6>PIJEA9ZRR;):;Y\!E,;ZQJM/ZWF+2A[3&U'&4$Z$6<U:_\
M(X:[_P!BUX3_ /3IXSKI:YJU_P"1PUW_ +%KPG_Z=/&==+7PQ]J%%%% !111
M0 5S.O?\A3P7_P!C-<_^HAXKKIJYG7O^0IX+_P"QFN?_ %$/%= '34444 %%
M%% !1110 5S/@K_D3O"G_8MZ'_Z;+6NFKF?!7_(G>%/^Q;T/_P!-EK0!TU%%
M% !1110 4444 <SH7_(5\:?]C)9_^H?X5KIJYG0O^0KXT_[&2S_]0_PK734
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M&M=-7,VG_(Y:]_V+/A+_ -.OC6NFH **** "BBB@ KF=>_Y"O@K_ +&:[_\
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M>F:C-'X^T=;.'P_K'B>VD>VU,3W=NL-JUX?LX?\ !;C]E/\ :@^#7[5OQQ\
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M>7ZO1QV.PF&G)R4O:5X)1:;:_="BOQU^*O\ P6X_93^$'[)O[._[8_B7X?\
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M^'FA^'FM+%=V7C'4-2:6ZTM7TE$GNWLC]B3_ (+<?LI_MZ_$OQI\*_A!\/\
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MTZHHHKZ$_'@HHHH *\]^$?\ R2GX8_\ 9/?!?_J-Z;7H5>>_"/\ Y)3\,?\
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MP]^#W@SX1:OXKO\ 2-?N]7@FEU_2=4\)W>O>'@?L=P(=4.I:[I<=K8Q7<O\
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M34444 %%%% !7GOPC_Y)3\,?^R>^"_\ U&]-KT*O/?A'_P DI^&/_9/?!?\
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MP\<2^/O!$<LEU<_"GQF\4LR0ES-+'IRO+9Z==2LD8,UYHMSX7UFY;R[>.VU
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MI_V,5G_ZB/A>NFKF="_Y"WC3_L8K/_U$?"]=-0 4444 %%%% !7,^"_^1/\
M"O\ V+NB_P#INMZZ:N9\%_\ (G^%?^Q=T7_TW6] '34444 %%%% !7,^+?\
MD%6G_8S>"O\ U,M!KIJYGQ;_ ,@JT_[&;P5_ZF6@T =-1110 4444 %>>_"/
M_DE/PQ_[)[X+_P#4;TVO0J\]^$?_ "2GX8_]D]\%_P#J-Z;5K^'+_'3_ /2:
MAE+^/3_Z]5O_ $N@>A4445!J%?R;?M'?"SQ[\9_&OQ6A^(/_  ;K>//BI9^*
M_C1KOQ-U?Q9%_P %$/$GA)/&WC"WTW_A"K7QY#I_AJPLDT*+6?"NGV./#FEW
M*:%;ADE^R37R-?2?UDU^&_\ P7:^#7QV^,7[/_PCM/AC\//BA\:/A?X:^*T^
ML_M!?!?X.RZM/XZ\=>$)?"6LV?A>YM?#FA7VG:QXSTSPSXODL=3O_"VGW$L]
MY/)87IM3%I\E]8?1\,8I4<RIT6Z=+ZW*-/ZS4Q>883V"@IU/<> S'+?:3JRC
M&$(5ZZ@ZOLTIT[RD>)G^'=7 SJI3J?5U*?L(8?!8A5N=Q@^98S!8Y0C"+E*<
MJ5)RY.>\9V43F?\ @C]\!=$^$_Q!^+6O:/\ \$G=>_X)YQ:_X#\/VT?C_5OV
MNO%/[25K\2[;^VS>0^&K'2?$=S+%H"V2[=:_MC3U9;V/9;32!3 )/WNK^8O_
M ((&? G]I?PGXS\;_$CXR?!3XP_ OP1X7_9D^"W[/?AW0?C5X9UKP'KOBKQK
MX6UC6-?\6^(?#O@O7DMM5MO#EDLMK9QZW>Z?:+JS7EJ;9GGAU.STW^G2EQ2K
M9UB8O$0Q,HPPZE5A7Q6)5_80?)[;&8W,*\I032DI8J:A*\(Q@H\B.'G?*J#5
M&5!2E5<:<J.'H.SJ2][V6&PN"HI2=VG'#Q<E:3<V^9E%%%?.GMA1110!S-I_
MR.6O?]BSX2_].OC6NFKF;3_D<M>_[%GPE_Z=?&M=-0 45X9\;/VD?@W^SYI/
M]I_$[QE8:1>3VS7.E>&;0_VEXMUQ?](6(Z5X?M6:]>VFGMI;0:K=K9Z);W06
M*^U.USFOR^\7?M:_M3?M/V>IO\"]'T[]G/X&6TLUMK/QS^(VMV'AB..R60Q3
M3S>--3QI>C3)')%)/I?@F'6_$&G2@2?V^MLS,OU>2\&YQG.'EF,EA\IR2G+E
MK9[G%;ZCE<'K>%&K.+J8VNVN6.'P-+$UG)J+A&]SY7.^,,GR2K]3E.MF.;.#
MG3R?*Z:Q>8.*2?M*\(RC2P.'2:E/$XZKAZ,87DINUC]*/CK^U;\#_P!G:R=_
MB+XPMTUYH!/9>"=!$>L^,]15@K1F/1H9XAI\$R,7@U#7;K2-+FV.D=\TH$9_
M/$_&C]N+]MN1['X$^&G_ &>/@S=L4?XD:M=W=CK6J6BG)DL/%26:ZI<R/<6,
MJPQ_#K283I]S,VFZYXG>TD-Q7Q;;?'C_ ():?LJZA+KWCKXF:U^VY\;VG>\N
M(?!FA2^,/"0UJ9LK-9WFLW]IX%UUY[MF$FIZGXM\6WQ,:ZA;:597#P0R^YI^
MV_\ \%2_VHDBL_V2/V*;;X(^![U5BL?B;\<6>.1--";(=7T:/Q0O@O0IX-VQ
M!;:/X:^($<>UHHC.(I9(O;_M+A/AE6R# +B;-H6OG_$.&]EE6'J?SY7P_*3]
MLUI*GB<VG4<9Q4E@XIV/S#&\9_VWB)8/,,ZKTX/_ )I'P\AB.(<^KQ;LZ6;<
M09=3GA,%:SC6H82MA(<CE&>,;A)GWY\"?^">?P%^")7Q7XLC/Q:\=VYEU&]\
M8_$"WMVT:QN5-Q-<:AI?A:>>]TJP8*Z7+W^NW?B+5+2[MS?66K66XQK\@?M/
M?\%H_@/\#OVEO"GP8T_PG??$[PSX7UK2;CXB_%+P;XNT:\TKP]<Z]H%[:RV/
MAK2K&RU6W\9W&A6/B&WN-<5?$.@R6>J6M]H"Q2W]K.T?D6N?\$T/C?\ %I8-
M;_X*2_\ !1C6;W2)C'=WWPW\$>)-/\)^"X]S"6X>SO/%$7A_P98OE1"[V/PH
M08C4K=%(8D'16'[/?_!%K]GW6_AYKNF6WA/QEXC\%>)5U:36YO%WQ+^*TNH3
MV>EZI/8W>J:/HNI:GX!U01:Y%HSQ6SZ"FEI)&LAM4B:[=_%KQXLXPQCQE>AG
MO$6*DN2,\/@\7BX4H]*5"GAZ3HX>C'[-&A3I48=((,3F'$F!P%'!<,9=PMX6
MY?3Q5#$5<9Q5F^63S/&X:,OWM.KEF'I9C&&(K1DG5JXW,98R23IQK4)SC6C^
MGWQZ_9/\/?%"]C\=^!=0/PV^,&F7":AIWC+1S/91ZI>P!?(&OKIYCN/M V+'
M%KMD/[4ME($ZZG;1160\@\!_M&SZ=K$/P*_;(\(Z5I?B.(_9=-\9>(=*TV\\
M&>*H<B"VN]2^T6\FD0&\^ZNNV2_V+,^^'4(M&N894EY76/\ @JQ\$YKIM+^'
M?P]^+GQ(U8Y\B'3/#^GZ?:7'9=C2ZI>:R-Q]=!.!_M?+7C_Q3^,_[3_[47AN
M3POHO[!6IVVFR,\NB:Y\1;W6=/O=+NY%")JND:EJ=K\.(K*1@$,J1ZA<6-S&
M@@O3>6P:-O1I>'/&-%PKXO!4,C@K36)SK-LLR;V:Z3Y<;C*&)5N\*3:ZV/T&
MKX@\(U>>AA<96SJ;O%X?)\KS+./:=X\V#PE;#N^BM*JD^ES[I\8_L+_LE?$"
M-[C4/@UX4TZ2Z4317_@MK[P8091O6XAB\)WNE:=-O#;QYUI<02;MS(^0:^;-
M2_X)9^!-$NY=4^#'QN^,/PDU:0[TGL]6@U6VMY 28S#_ &6?"6L%$^7 GUR:
M0XXE7/'QYJZ_\%)_V=/ .D:7K'B9_ OPZ>Y2V^UZ9#X/\=/X629E7^SSJ L_
M$=]HEL25:RMXM5L]->?-O8723RS1/]"^ ?V._B!^T+X;L?&/B_\ ;P^(WCWP
M[JBCSM'\*MK5G8V5QM5KFQN;;5/%!M=,OXMX2>RN/"5I-&/+D9)(I(C7UN Q
MN;Y'#V>-\8,MHT+6^I8.IFO&%*R^Q]5J8"ME=M-O;^S?66I\KCL'E6=3]I@O
M";,*M:]_KF*IY9PE4O\ S_6:>-I9E==_8^U6JC'1D/BKPS^W)^SNCS6G[:GP
M=\4:19KN?3/C/KNAZ%K%Y&HW)NG\9V.J7"%E'S$>-+61BR@-+G<OE6F?\%8O
MBYX)U'^R/B9\-/A7XX^SOY3ZC\-O'$5K%<QJ=OVE+[3]1^(&E32.O[P1HMDK
MG">5;$D+]B^%O^"5_P"RMH3)+KMIX]\>S[O,G;Q/XQGLX[B5CND++X/L_"\H
M1F)(!G>3;P\TC9=OICPG^R3^S-X)\MO#WP.^'$,\./)O-4\-V7B/48BN,-%J
M7B--6OXWXYD2Y5VYW,<FNK$<8>&\J,J>;Y(N+<4T^;&X7AK+^#I5):>\Z^5Y
MK[=MZW<\*WM9]#FH<)>(<:L*F59R^%L-%JV#Q7$6/XMC".GNJAF>6>P45LE#
M%6O>Z:U?Y]ZA_P %BOAM%HHGTKX-^.+SQ'CYM*U'7M!TS10VY<A=?MH]7OF&
MW>03X:4E@JE0&+)\>>"O$/[5O[4'Q@T+]H3X=_!72_'MA\-$T_PAX#T?Q/JD
M+?#_ ,$ZCX?TK3Y+>:6?4/$'@Y-6\063WT'BB:47$2'6+RQNGL'M;/3]/B_H
M$\=_!OX6_$OPC+X#\;^!?#VN^$Y-K1Z0]DMBEC*C!DN-)N],:RO]&NUV[1>:
M3=65T(VDB\[RI)$:I\$?A_X-^&GPN\'>%_ GA^P\-Z%'HNGZB;&Q$K>?J&IV
M=O=W]_>75S+/>7U[=3N3+=WMQ<7#(L4/F"&&&-/-P7'G!.0X#&8CAK@B6%X@
MQGM\#*>;YIC,VR^.48F*6(A&I#$X#$0K55%4G3I4*<O92J1GCJL)2HR]'&<$
M<8YYC<)0XCXSCBLBPGL,;&&59;A,KQ\LUPTKT)RA/#8VA.C2YG54ZE:I'VT:
M<H8*G.$:L?S]_P"%<?\ !4WXB<^(/C-\+?A'IDW^OTWP_9Z=<ZI%N(_X][G3
M?"FMW68UW#Y?%T )(YD.'0_X=P?$#QK^\^-G[8?Q?\=1S_\ 'QI6G2:C9V,*
MD8>"V?Q!XE\26?E'YB/+T.TC&X_Z-G+-^K%%?-?\1&S^AIE.&X?R"/\ U)N'
M<IPU7U^M5\+B<9S+3W_K'/HKR=CZ+_B'^1U]<TQ.?9Z_^IOG^:XBG_X34<3A
M\);^Y]7Y.T3\\O"?_!+W]DKPV8FU+PUXL\;R18(D\6>,M4C#NO1Y8/"8\*VD
MG/)C:W,+='B925KZ9\)_LQ?L[^!_+;PO\%?AKIMQ#CR[]_".CZAJJ;>F-7U2
MUO=4/J<W9R>3D\U[I17B9AQ=Q3FG,LPXBSK%PEO2JYEBW0UW2H*JJ,4^T::1
M[.!X4X9RSE> R#)\+*-K5:67X55KK9NNZ3K2:[RFV10006T,=O;0Q6\$2A(H
M8(TBAB0=$CCC"HBCLJJ .PJ6BBOG6VVVW=O5M[M]V>^DDK)62T26R78YJU_Y
M'#7?^Q:\)_\ IT\9UTM<U:_\CAKO_8M>$_\ TZ>,ZZ6@ HHHH ***Q/$GB+1
MO".@:QXG\0WT.FZ)H.G76J:G>SL%C@M+2)I96 )!DE<*(X(4S+<3O'!"KRR(
MI /G7]J_X[GX,> /LOA\B\^)/C>23P_X&TJ!7N+U+FX"V]UKR6D2O),-)^T0
MBRB"/]KUBYTVU,4L+W.S#_9U^!*?!'P?X(CU@+=?$'Q?XJDU[QWJKR&XN'U"
M;P?XOEMM'^UNSO/!HR7$T4DOF.MUJ<^I7RL4NT5/&_V=?#VM?M(?%_6?VI_'
MUG<0^%M"O)M$^#?AV\D62*R33Y9X?[0,2KY4@T@RS2&X0O'<^*KS4+J%HCH]
MN@^_]>_Y"G@O_L9KG_U$/%= '/\ Q'^$GP[^+6DG1_'_ (6TS7X%1UM+N>(P
MZMIK.&!ETO5[8Q:C8."VXBWN$BE( GCE3*'X@N_V<_V@OV=KJXUS]F;QY/XM
M\(K++=W7PI\9RPS*Z%I9I8[%)9+32[N5^#+=:;-X7UN<K'"LU^V5?]):* /B
M+X9_MN>"-;U0>"_B_HVH_!;X@6TJVEY8^*8[BW\/RW>X( FJW<%K-HYE(:7R
M]>MK.SAC*1Q:M?.0S?;$$\%U!#<VTT5Q;7$4<]O<02)-!/!,@DBFAEC+1RQ2
MQLKQR(S(Z,&4E2#7F_Q+^#GPW^+VEG2O'_A73M<6.-X[+460VNMZ66#D/IFL
MVIBU"S"NYE:!)S:3N%^U6UPF4/Q3<? /]HW]FZ>;5OV<O&\WQ!\"Q2R75S\*
M?&;Q2W$<)<RS1Z<CRV>GW4K)&&FO-$N?#&L7+F.WCLM1.0X!^D=%?%7PN_;;
M^'WBC4O^$/\ B=IU_P#!KX@6TJ65]H_BY9K71WOL1J8H]7NX+-],DD9BXMM?
MM=-$:E(XKR]<AF^T8I8IXHYX)(YH9HTEAFB=9(I8I%#QR1R(2DD<B$,CJ2K*
M0RD@@T 25S/@K_D3O"G_ &+>A_\ ILM:Z:N9\%?\B=X4_P"Q;T/_ --EK0!T
MU%%?('Q=_;/^%WPYNW\->%S<?%/Q])*;2T\+^#9!>6T=^V5CM=2URWBO+:*4
MR@PR6>EP:QJL,P\JXT^'.X 'UY)(D2/+*Z1Q1HTDDDC!$C1 6=W=B%5%4%F9
MB H!)( KXQ^*O[;/P[\(:@?"/PXLK[XP_$&YF>RL=#\(++>:4E_B11!/J]G!
M>'4)HW0LUGH-MJ<K;'BFFLF!=?)4^$7[47[3[K>_&WQ/)\'OAI<N)(OASX:4
MPZS?VA,FR/4[5IIBDCH4\R3Q-=WSPS*9(?#=H&"C[/\ A7\"_A?\&=/^Q> O
M"UEIMU+$L5]KMR/M_B+4P#N/V[6;D-=O$SDR"S@:WT^%B?L]I"ORT ?&UO\
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MU%%% !1110 5S/BW_D%6G_8S>"O_ %,M!KIJYGQ;_P @JT_[&;P5_P"IEH-
M'34444 %%%% !7GOPC_Y)3\,?^R>^"__ %&]-KT*O/?A'_R2GX8_]D]\%_\
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M'0XJGF"2G5H1Q$XK"R_H@^V_\%&=/_YA/PFUS;_TTTN'?_Y4]'QG_@/X4?\
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M^'L$C3S?#+Q:4DU*VMMT;21Z?"9K6UGEV+([W/AVZT&]FD*1KHE^<JV%J/\
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MXZM]6M]4FU&^TI]/T/0S9Q:#)86D%VLT4XF?5+<Q2+Y<BU]LU^/O_!)'XD_
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M[U)=?N- T0W64DM;C2GF\:Z!:12S/8,?&OA^YG6?P_:V2?EWQQO]J._G'O\
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MJNEKFM>_Y"?@W_L9;G_U$?%5=+0 5\E?M=? B;XO^!8==\+1/#\3OA\\FO\
M@VZM%C2]U'[.4N;OP\)CAM]XUO%=:468"'6;:U&^*WNKQG^M:* /@?X$Z+\
M?VIOAS%J_BSX5>"5\>Z$\>A_$&WL-!@\,ZG%K<<;!=26YT/^S-12SUF.-[NV
MW3C[+=)?Z<C%]/=S6\:?L%? '3+2^\4Z7XG\8?"R+1[>;4)M6M?$\,FDZ5;P
M(SRW-Q/KUO<W\<4*C)<:U V!@NQ(KC?C=I6H?LG_ !RTC]HGP?9/)\-_B'J
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M\?#?#,__ $K)V'_$.>$NF!S"/^'B+B2';^7-EV1_-%_PG'BR+_4_MQ?M>/\
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M&&9PDL;+)&Q#H0R@U_,SI'_!";]K#X3_ !B_9TNOV?O^"BWB+PC\'/@)X?\
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MQTO]HOP7=E;*:0PQQ?%7X<2ZOJ<D;*^(HBT5M\2M.AA&R6XFGTF&,LQBA?\
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M9M7D2^MTO9(K[3?!A*#R8[3:#9SZQ:)B&&>SC33-$C1+30X@(1J$_P!NT44
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M-*OVBRU.")X[@ _3[Q'_ ,%!O@[:W7]E^!=$\<?$K5I69+.'0]"DTZSNF7(
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M[72?&.I:IKG]H&WFATOQ+YEMH^E_8;FS$-ZMQH@DU"YG:\6.UO[18[17<2D
M_0.BN=\(:_\ \)7X3\+^*?L%QI7_  DOAW1=?_LR\.;O3?[9TVVU'[!='9'F
MXL_M/V><^6F98V^1?NCHJ "BBB@ KSWX1_\ )*?AC_V3WP7_ .HWIM>A5Y[\
M(_\ DE/PQ_[)[X+_ /4;TVK7\.7^.G_Z34,I?QZ?_7JM_P"ET#T*BBBH-0K\
M7/\ @L-XO\;S?#?X$Z1X'_9]\7?ME_":]^/=OI?[2OP$^&OP,3X[W_B3P+X<
MMHKS4[)]9TW1_$M]\*/%N@:AY4VBZM;V>CZE=7<ESIZ>)_#ES' ]Y^T=?S/_
M !._X(6_M&:1\6?AKKW[+W[=NN> _A7X;_:6^(/[0EMX8\<>%-,U'Q#\$]?^
M(=M*NM^)/A=>6>CZI:_$/Q%.9?[+.C^-)_!FCIIL:7CZE<ZK)<SS^_P]]0AC
MEB,=C:6$>&3J48UZ.(J4:\O95DXNKAE*K0J0G[*5*I&*FI/GI35:G3A4\?.O
MKDL(Z.$PM3$>W<8594:M&%2DO:TFG[.NU3K4YQ]HJD)-Q<5R5(NE.<H?;7_!
M+'Q_\([B7XF?#3X-?\$Q/VB/^"?7A^SL]*\8:MK/QC^"M]\,]*^)&J2W<VE0
M:=;>(=7#:MXEUC1+:26XMK&YNKR'2M.N+IK46:W#I<_L-7PA^R3^S#^TY\!_
M$_BS6OCO^W=\0/VM=&UW0;72]"\,^,?A9X*^']KX3U.#4$NY]=L[WPMJ-Y<:
MA<75JK:>]K=QK#'&YE1]X*G[OKCS>K0K8^M5P]6-:G-4W[6%7'5U*7LXJ3=7
M,:=+%RDFK/VD+)JT&X),Z<MIU:6#I4ZU.5*<.9>SE3PE)QCS-Q2IX*=3#Q5G
MHH2;ZR2DV%%>2?&?X_\ P(_9P\)VWCW]H?XU_"3X"^!;W7+/PS9^-/C/\2/!
MWPN\)W?B34+/4-0L/#]MXC\<:SH6CSZY?6&DZK?6>DQ7CW]S9Z9J%S#;O#97
M+Q>D:+K6C>)-&TGQ%X=U;3-?\/Z_IEAK6A:[HM_:ZIHVM:-JEK%?:9JVDZG8
MRSV6HZ9J-E/!>6%_9SS6MY:S17%O+)#(CGS#O-.BO$?@_P#M,_LW_M"WGC73
M_@#^T#\$?CC?_#;4K/1_B+8_!_XK> _B9>> =7U"758+#2O&MMX+U[6YO"VI
M7TVA:W#9V.NI875S+H^JQPQ.^GW8A]NH YFT_P"1RU[_ +%GPE_Z=?&M=-7,
MVG_(Y:]_V+/A+_TZ^-:Z:@ KX0_;M_9RU3XP^ ],^(?PX%Q8?&[X-W/_  E7
M@/4-+"1:KJMO83PZC>>'HIP!(]XLMI'JWAT,7\K6K46D2Q1ZO>R'[OHKU<DS
MC&9!FN#S? 2BL1@ZJFH37-1KTI)TZ^%Q$-JF'Q5"52A7A]JE4DDT[->7G.48
M3/<LQF58Z,GA\72Y'.#Y:M&I&2J4,30GKR5\-6A3KT9V?+5IQ;35T_EK]D+]
MHW3/VE?A#I7BT^19^,]$:/P]\0]$3;&^G>)K2!#+>P6V?,BTK78\:GI992D0
MDN=-,LMSIET5^I:_'KXV:3J/["7[3FE_M(^$+&X/P&^-&I)H'QD\/Z99F2V\
M/ZQ=S?:[C5+2UB*HD]S,+GQ/H>T(6OXO$F@K+:6>KVL;?KMI6JZ=KNEZ;K>C
MWMOJ6D:Q86>JZ7J-I()K6_T[4+>.[L;VVE7Y9;>ZMIHIX9%X>.16'!KWN,,F
MP>%JX//<DC+_ %<XBIU,7ET6^:678F$DLPR3$2Z5\MKRY*;?\;"3P]:,I\TF
M>)PGF^,Q-+%Y)G,H_P"L.03IX7,))<L<PPTXMX#.:"ZT<QH1YZB7\+%PQ%&4
M8<L47Z^,_P!J?]D;X7?M$-X;FU:U/A3Q_/JWV#3OB7X=MH8_$EG#I_AWQ!JE
MC;:@-T,>N:=!>Z?:LMM>R)=VL2RII.HZ7)-),?LRN9U[_D*^"O\ L9KO_P!0
MWQ;7SF5YKF.2XVCF.58RO@<;0=Z=?#S<96;7-"<=85:4[)5*-6,Z56/NU(2B
MVCZ#,LLR_.,'5P&9X2CC<'65JE"O#FC=?#.#5ITJL&[TZU*4*M.5I4YQDDS\
MI/#G[1?[17[$NLZ9\._VM-'U+XD_".>5=-\(?''PZD^K:C:VZ3&.WCUVZG*S
M:J\5N!)/I>MFU\601QW$]C>>)[6.V1OU5\$>._!WQ)\-Z?XO\!^)-)\5>&M4
M0O9:OH]TEU;.R@>;;RA<2VE[;LPCN["[C@O;.;,-U;PRJR#2\1>'- \7:'J?
MAGQ1HVF^(/#^M6DECJVC:O9P7^G:A:2X+075I<))%*FY5="R[HY426,K(B,/
MRN\;_LB?&C]E[Q-J/Q<_8B\07EWHEQ</?^*_@#KUU-J.DZG:1(7DBT9;R\C.
MN)'&'CM+2YNK3Q98Q[H]%U_4)K@6(^X]IPUQMI7^I<(\53O;$1C[#A?/*SV^
ML0BG_8&.JO65:FI996J*4JD,-.JK?%^SXBX-UH_7.*^&(6_V>3]MQ+DU)?\
M/B;M_;N"I+149N&8TH.,82Q$*;O^M=0W-M;7D$MK=V\%U;3H8YK>YBCG@FC/
M5)895:.1#W5U*GN*^+OV:/VW_AM\?I!X/UB&;X9_&+3RUIK/PX\4R?8KFYU&
MV+1WJ>&;J\2T?5C#(DAGTF:WM-?L0DWVC37MH#?2?:]?%9ODV9Y%C:F7YM@Z
MV"Q=*S=.JE:<)?!6HU8.5+$4*BUIUZ,ZE*HM83:/L<JS?+<[P=/'Y5C*.-PM
M2Z52DW>$X_%2K4Y*-6A6@]*E&M"%6#TE!'SSXR_91_9\\<^=)K'PQ\/6=W-E
MFO\ PW%-X5O/-/\ RW=O#TVG0W,I/+&\AN5<\R*]?/5W^P2GA>XFU#X)_&_X
MD?#6\9_.6V>]DOK.208'DO+HEUX:N?L[J C?:QJ;%,K*LZDJ?T+HKS#TC\[/
ML/\ P4(^&'-IJ/@'XX:1;D%(+L65KJOV5?OB1YAX+U&6ZVAF4'4M:DWE0OV@
M 0UE^&OVX=5\ :+H&E?&3X#_ !!\(65II>E65OXCTR"2\T[4K>.TMX;:_MH=
M:M-"MC!.@20?8]:U(-DB)Y'Q'7Z3URW@^*.;P3X6AFC26*7PMH<<L4J+)'(C
MZ3:JR2(X*NC*2&5@002""* /#_!O[87[.WC;RH['XD:3HMY*54V/BU+GPM+&
M[8VQF[UB*VTJ5R2 /LNHW"ECM#;N*^C;#4=/U6UBOM+O[/4K*<;H;RPNH+RU
MF7UBN+=Y(9!R.4<CFO$?&7[+_P  O'?FOK_PO\,+=39,FH:':R>&-1>4])YK
MSPY+I<UU*IP0UVUPK!0DBO'\A^<]0_8#T70KJ75/@W\8/B1\+]38^:HBOVU&
MS$B9*1(^EW'AK4UA( 0M=:AJ#J"S$2K^ZH _0&XMX+J":UNH8KFVN8I+>XM[
MB-)H)X)D:.:&:&16CEBEC9DDC=61T9E92I(K\]?B/^R[XT^%7B.Z^+W[)FI'
MP]JZQM-XB^%[OOT'Q%:QR>?-:Z3;7$@M7BD.]ET"[>)(79I/#U_IES':V;Q_
M\(]_P4$^&/.C^*? GQLTBW^:&QU@6EMJLD2?>%Q/?1^%;]YG49"CQ+J+$XV,
M78H7+^VYXY\",L'QT_9T\=^$(XV"SZ]H,<]UI<W.UFM(=9MM/T]U4@X,7B>[
M#9QN4C+ 'L_P!_:J\)?&5I/"^LVDO@/XIZ6&@UGP1K9>UFN;JV&V\ET%[Q8)
M[M(I%=KC2[B*+6-."R"XMY[:'[?+]55^6_Q-\4_L@?M/I;Z[IGQ(M_A3\6[!
M(9-$\5ZS:7OA.YCNK8I)81>(;Z98-%U"""2-%M[VVUP:KI11)+6[6W0VEST7
MPJ_:U\2_#?6;'X9?M-36$J3I'#X3^,6@7-OK/AGQ#:(888Y]4U/3"]I>PXDB
M\_7K5([FT:2)/$NFV<YNM1H _0&U_P"1PUW_ +%KPG_Z=/&=?FG^V)96W[0G
MQF\#_ ;X<:-HU]X\\/6]YJ/BKQM<.T<?AW2I;?[0V@W]Y:K*YL;))8]3O(I8
M+F2'4[_3=/TT17M[J4$WU#^T)\>=)^"WASQ+XML+FSU/Q!XB\*^$M-^']I!)
M%>0:KJM_=^-)K74U$3LMWH^G6[KJ=S+$S0W*?9;-)5EU&V8U/V1?@=??##P=
M?>,?&PFN_BM\39_^$B\8WNH!)-1TZ.[FEO;;1'G(,BW&^Y?4=; *^;J]P\$@
MECTVTD !Y[^R3\9U\/"V_9A^)VAVW@+XC^ XGTG0K8HEIIWBVPB,ET)K20,8
M)M;G21]1DF@DDA\103/K%D\DKW<4?W[7S%^TG^SAH_QRT.VU'3+A?#?Q-\,*
M+KP;XOMVDMIXKBWE^U0:7J5S:XNCI[W2B:VN8BUWHUZWV^QSNN[6\\]_9J_:
M2UC7M7NO@=\;[=O#7QJ\+L]@DE^L=M%XUM[2+>+FW9,6QUP6H6[ECM2UIK5D
M1K.D%X&NK>S /M^BBB@ KF=>_P"0IX+_ .QFN?\ U$/%==-7,Z]_R%/!?_8S
M7/\ ZB'BN@#IJ*** "BBN+^(/Q!\*?"_PIJGC/QGJD6E:'I46Z21L/<WERX;
M[-IVG6VY9+W4;V1?*M;6+YG;=)(T<$<TT8 ?$'X@^%/A?X4U3QGXSU2+2M#T
MJ+=)(V'N;RY<-]FT[3K;<LE[J-[(OE6MK%\SMNDD:.".::/\^_ _@?QI^VEX
MTL_BU\6K.\\/_ OP_>2M\//AXTLL?_"2^7+L:^OF3RS-:3&,#5]7 5M093H^
MCF&QAN+B,\#^!_&G[:7C2S^+7Q:L[SP_\"_#]Y*WP\^'C2RQ_P#"2^7+L:^O
MF3RS-:3&,#5]7 5M093H^CF&QAN+B/\ 3&VMK:RMK>SL[>"TL[2"*VM;6VBC
M@MK:V@C6*"WMX(E2*&"&)$CBBC58XXU5$554  !;6UM96UO9V=O!:6=I!%;6
MMK;11P6UM;01K%!;V\$2I%#!#$B1Q11JL<<:JB*JJ /@[]JCX6W_ (O^ O@C
MXB>%!+;^/?@]I6A>,=%OK- ;[^RK2PTZZUF*!A&[-)8?8[37[<$$+)I#QQJ6
MN6#??%<KX0BBG\$^&()XXYH9O"^C130RHLD4L4FE6R21R1N"DD<B$JZ,"K*2
MK @D4 <A\#OBC8?&/X7^$_'UEY4=QJVGK#K5E$21IOB&P8V>M6&&Q((HK^*6
M2S:15:>PEM+H+LG0GUFOS:^!$DO[-W[3'CG]GO49'@\"?$IV\9_#"6=B+>&\
M:*>2.PBD<1H9+C3[2\T"YE8F2XU'PQID4$>;Y2WZ2T %%%% !1110!S.A?\
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M>#/"7C[PO=_;_#/C?PSH/B[P[? */MFA^)-+M=9TFZPCR(//L+VWE(61U!?
M=@,G^5W_ (*0^$X?B_\ LD_L7?M.Q1A[BU\.7?[.'Q'U"4EG1H3=:)X?U?4Y
M06+2IXJ\-W&NK]HVN$N89(08I=H_3C_@AY\=I?BI^QG9_#G6KEY/%W[/?BO5
MOAS?P7+ WI\+WLK^(_!MU*JDA+:UM=0U+PG9*5C<1>$F#HV!--\?Q!E];!3]
MC7UQ.68S'9#C6U:3Q&4UE1IU))7482PL\/0I)N\GAJC][63^%\.\PI9/XD\2
M9+3_ '>5<:Y=@^,\CBW:#J8JC'&5Z5&*LDG3Q>+HZ*W)E*7NVL?LC7,^$_\
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MM\*^*H?M'ACQ-X?\1V^T/Y^@ZUINL0[#C#^;I]S<)M.1AMV#D<\B@#H****
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M (4Q\);UM)^&^E7UJ$MM=UB!TN8[JZMYLAY%E^S^(=7#('1F\.:--Y\%K<@
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M.ZJ4_CCR_P#P3*\#?#OQ7\6/B!XBU_\ X*6_!#_@ICXCT&UL?&VBZ/I?[/\
M\(/!OB;X1^,=0O[?3[_XKVGB'P]XC\7:^VNZ_8V-CX<N]5C;3KAX;2Q2ZOK@
MP6,4/[P5_+G_ ,$!OVB-3^,'Q:^,^BZ[\'/V'OA5?3? ?X8?$G2W_9,_9_\
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M>DX1>@4445YAZ(4444 <U:_\CAKO_8M>$_\ TZ>,ZZ6N:M?^1PUW_L6O"?\
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M"VZ>8/,[,S.[,S$^QE.?\&\&RQ?]FRSOBZKC<+4P./H8R&&R3AO'8:JK.%;
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M0O\ D+>-/^QBL_\ U$?"]=-7,Z%_R%O&G_8Q6?\ ZB/A>NFH **** "BBB@
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M6OX<O\=/_P!)J&4OX]/_ *]5O_2Z!Z%1114&H5^1O_!6;XT^)/A3I/[(>@>
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M>K)4\+7]HZF1YQ/9/*\QFHJ-:;U_L_&>RQE/FA&*KMN1]]4445\*?:G-6O\
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M'N$OL3S;-8*A3J)73GALK5GK&;M=_E%_PS5^WK\>?WGQX_:,M?A1X9NC^_\
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MUU'X0TIK/3[Z&8+\]MXPN_&#L[RNURQ,0A][A_/\;PWCOKF#J4JL*M*6&QV
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MD#R8=/U Q#477*[GTB;48!N \[=D#U*\_P"1PT#_ +%WQ7_Z<?!] '34444
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M^'OC73-4UG2O#^E6^L>%[I_[-\4:5-9V4-M<&[T.\\J]>V2:&1%U&S2ZTR;
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M6UM]H-OZ14 %%%% !7,Z]_R%?!7_ &,UW_ZAOBVNFKF=>_Y"O@K_ +&:[_\
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M/$"9"NSS2?,ONO\ PYE_X)K_ /1M_P#YF#X]_P#STJ/^',O_  37_P"C;_\
MS,'Q[_\ GI4?N^\_NC_F'MO%;_H7>'O_ (>N)/\ YP'+>"=/_P""57A%H[G4
MOVGOV<_'>I*1(][XR_:4^%UY$\S$-(YTK3/%.E:3,COG$=[97K!3AY)'W2-O
M_M ?\%(OV!?V:_A5<KX6^)'PW\>?\)''?^'-+\#_ +-.K?#GQQJT$EQIMQ$=
M4U33_#GB33]&T32++S8A)=ZOJ5G-<M(8M*MM1FBN(HK7_#F7_@FO_P!&W_\
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M'@N"X@\F:&^2?XM>'_AU#'9W*K ]Q)#+O66&(U^*NH?$SPB_[<]YX/TSXN>
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MN6A3J2N^UCBQF99=ET/:9AC\%@86OSXS%4,-"RW?-7J05O.]CZ1HK\SO$O\
MP56_9OTZX&G^#M)^)?Q'U*9S%91>'O"T>GVMU( Q W>(=1TK555@I(\G1KF4
M#DP@!B.8_P"&V/VN_B%\OP<_8E\46EO+Q9:Y\0[G6K?3;H-RDW^E:9X(TU$
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M]6C2G0=/DBJE/FK1C[6FG5]JJM*F4445\F?4A1110 5S-Y_R.&@?]B[XK_\
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MK&G:="RVUI&\PM+2VL;&QM8H3<7#,T,MP\I>X95^A*YGP7_R)_A7_L7=%_\
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MV\!^5?R;_B'><8?_ )'&9<,\/]X9OQ#ET<0DMW]3P%7'XRZZP^K\ZZQ5U?\
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M &3WP7_ZC>FUZ%7GOPC_ .24_#'_ +)[X+_]1O3:M?PY?XZ?_I-0RE_'I_\
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MX*E^ ?\ A+_V6]0\100"6]^&_B[PYXJ5T7,PTZ^GE\)ZE$HZF #Q#;7URH!
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MNFUWQ)XRUOS".[VVH^(I[$9[K':1H>ZUY7U+PVPVE;/N+,T:ZY?D.79?!_\
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MP.F_[=-&'\O"47^3^2_V=_P5DC_YCWP-FQ_TQT89_P#*+#]>W]*/]18=.->
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MHKX4Z1\?]%^%VE3_ !G^!U[KFF^'=2^('@>#X8?%GXJW>@GPAJWB7P';>.O
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MMII@/GD@M)+J6VB8YQMADO;IT&.#.^2<C$] !1110 4444 %<SKW_(4\%_\
M8S7/_J(>*ZZ:H)K:">2UEFB222RG:YM789,$[6UQ9M*G/#FVN[B$DY^29QC)
M! !/1110 4444 %%%% !7,^"O^1.\*?]BWH?_ILM:Z:H+6V@LK:WL[6)(+6T
M@BMK:%!A(8((UBAB0$DA8XU55R2< 9)H GHHHH **** "BBB@#F="_Y"OC3_
M +&2S_\ 4/\ "M=-4$5M!!)=2PQ)')>SK<W3J/FGG2VM[-97YY9;:UMX1C V
M0H,9!)GH **** "BBB@ KF=>_P"0KX*_[&:[_P#4-\6UTU036UO/):RS1+))
M93M<VKL#F"X>VN+-I4P1AC:W=S 2<C9,XQD@@ GHHHH **** //?!?\ R,GQ
M<_[*%IO_ *JGX8UZ%7GO@O\ Y&3XN?\ 90M-_P#54_#&O0JNI\2_P4__ $W$
MSI?"_P#KY6_].S"BBBH- HHHH *Y7QWXX\)_#+P1XR^)/CW7++PQX&^'WA7Q
M#XX\:>)=2,BZ=X>\)^$](O->\1ZY?M#'-,++2='L+R_NC%%+((+>0QQNV%/5
M5^=G_!5\32_L$?&VP,,%QHVNZK\%O#'C:&ZD:*UD^&7BKX^?"[PW\5ENR(;A
M9;/_ (5KJOBK[7;2PR6]W;B6UN1]GFD( /KZT^.?P>N=9^%7A>;XD^#]&\:?
M''PQJ7C/X0_#[Q3K5GX/^)7Q#\-:'HVF>(/$>I^%_AMXJDT;QWJ:^%-&UG2[
M[QA:Q>'OMOA&.^MT\2VVE2N(ZQO&'[3/[-_P\^*O@KX$^/\ ]H'X(^!OC?\
M$FVL[SX=?!OQA\5O ?AGXJ^/K34;_4=*T^Z\%?#S6M>LO%WBJVOM4TC5M-LY
M]"TB_BNK_2]1LX&>XLKF.+\EOVTOCM^Q#\'?^"I__!/2Y\5?&3]E7X6?&J7Q
M;\:(?C3<>(?B'\(_ _Q1DT34OV8/'_AKX'Q?%&74M8TOQ8^E7^K^++W0/A3'
MXL8VEUJ7B6ZTKP@)+K698+GY!_:\\6^"-)M?^"T/[,/C[Q#X6TK]MS]JC]I7
M]FWQA^QC\-=9DL_^%M_&/P4?@A^R#X%_9?\ '7P1\)6L-QXL\:^%?@M^T?\
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MXJ^)W_!.']HG5O%^N^(/%?BWQAJ$T>B?M+_LD:?H7AO0)O%^N:Y_PA7P_P!
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MQ3KVI^(/%G_!+;X0_%?Q-^V)XCO+M#K/B3Q)\&Y-2^%7_!/&]\536D=MNO\
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M^*>D?MFZ7\*?V@_VG+3]B_QE\4_ASHW[+7Q7UOX\>,?CC\4->M/!/AS0-/\
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MNRO;2XU:.XM;NUN(Y(+FVGCCF@FC>*5%=645/^%^? O_ *+3\)O_  XW@_\
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M<FTO2M+TV75KJUEOY+#3;"S>X:WL[>..W_POSX%_]%I^$W_AQO!__P N:/\
MA?GP+_Z+3\)O_#C>#_\ Y<T >LT5Y-_POSX%_P#1:?A-_P"'&\'_ /RYH_X7
MY\"_^BT_";_PXW@__P"7- 'K->$3_LM?LR77QQL_VG;G]G/X$7'[2FG6SV>G
M_M"S_"+X?S?'&PLW\-7?@M[6S^+,GAYO'MK;/X.O[[PF\$&OI$WAJ\N]"*'2
M[B:U?>_X7Y\"_P#HM/PF_P##C>#_ /Y<T?\ "_/@7_T6GX3?^'&\'_\ RYH
M[/Q/X+\'>-HM$A\9^$_#/BV'PUXFT/QIX<B\3Z#I>O1>'_&/AB[%_P"&_%FB
M1ZK:W:Z5XF\/7P%[H>O6 @U32;L"YL+JWF&^N3NO@;\$[[3_ !?I-[\'OA;>
M:5\0OB'X?^+OC[3+KX?>$KC3_''Q8\)W7@N^\*_$_P 7V<ND/;>)?B'X9OOA
MO\.[SP_XUUJ.]\2:-=> O!=QIVIVTWA;0WL8/^%^? O_ *+3\)O_  XW@_\
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MKV[7.D:]I.F:QI\MOJ%A:W$7'?\ "^?@;_T6;X4?^'$\(?\ RXH_X7S\#?\
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MZ+#I_EOC?_@FG^QA\0K;P/8>(_A7K\6E^!/A'X/^ ,>B>%OC3\=_ 7A_X@_
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M+5/#ECJWVBP6U^VW8T;3]8@>TGA6QGO+T36</9_M%>)O /B;P7\#K'PA\0=
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M_P#<[?\ JQ/%M 'K?QY_Y(;\9O\ LE'Q$_\ 40UBOYGJ_IA^//\ R0WXS?\
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M]H?QU966HKI<6HW-O>7OB[P+9K%!<V-K)K'B"^T*Q;V[X=Z9\+O#GQJ\5_\
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M'JTZ%:I1^J2XEC&&*KQS&_U.<\APN'IYA"E4JU<1G>74E@%.K25?\)_@_P#
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M-Y2\@8%$8B7T2O._A]_Q,?\ A*O%K?-_PD_BC4/L#G'_ " ?#FSPQI'E$?\
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M/_E8>TE_SYJ_?1_^6_U9^5_S=_X=>?\ 5<?_ #&?_P","C_AUY_U7'_S&?\
M^,"OTB_LWXK?]#I\/?\ PV/B3_Y[E']F_%;_ *'3X>_^&Q\2?_/<HY8_\_(?
M=4_^5A[27_/FK]]'_P"6_P!6?E?\W?\ AUY_U7'_ ,QG_P#C H_X=>?]5Q_\
MQG_^,"OTB_LWXK?]#I\/?_#8^)/_ )[E']F_%;_H=/A[_P"&Q\2?_/<HY8_\
M_(?=4_\ E8>TE_SYJ_?1_P#EO]6?E?\ /'_AVQK7]BCPW_PT3JG_  CHU0ZV
M-!_X0.[_ +%&M&T%@=7&E_\ "QOL(U0V(%D=0\C[6;0"W,WD@)67_P .O/\
MJN/_ )C/_P#&!7Z1?V;\5O\ H=/A[_X;'Q)_\]RC^S?BM_T.GP]_\-CXD_\
MGN4<L?\ GY#[JG_RL/:2_P"?-7[Z/_RW^K/RO^;O_#KS_JN/_F,__P 8%:VG
M_P#!-O7=)L]6T_2OVB]6TRPUZUCLM<L=/\"WEE9ZU9PRB>*TU:VMOB-%#J-K
M%,!-';WB31)*!(J!^:_0S^S?BM_T.GP]_P##8^)/_GN4?V;\5O\ H=/A[_X;
M'Q)_\]RCEC_S\A]U3_Y6'M)?\^:OWT?_ );_ %9^5_S=_P"'7G_5<?\ S&?_
M .,"C_AUY_U7'_S&?_XP*_2+^S?BM_T.GP]_\-CXD_\ GN4?V;\5O^AT^'O_
M (;'Q)_\]RCEC_S\A]U3_P"5A[27_/FK]]'_ .6_U9^5_P W?^'7G_5<?_,9
M_P#XP*_0OX&_"[_A3'PM\+_#3^W/^$D_X1O^V_\ B=?V9_8_VW^V/$6KZ_\
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M"_\ T)*O_A?C/_GC_5GY7_.7_AV)_P!5O_\ ,:__ (?T?\.Q/^JW_P#F-?\
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M_P ]RCVDO^?M/_P&I_\ (!_Q #P\_P"@#.__  [+_P"2_JS\K_R0_P#$//\
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MSAJ$Y4^90E."GRRE!3GR-IN/-/EMS._\D/\ Q#S_ +:/_13OV7__  M/BO\
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MC^S?BM_T.GP]_P##8^)/_GN4<L?^?D/NJ?\ RL/:2_Y\U?OH_P#RW^K/RO\
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MQT_Z&OX3?^#WQA_\PE?KW_9OQ6_Z'3X>_P#AL?$G_P ]RC^S?BM_T.GP]_\
M#8^)/_GN4<L?^?D/NJ?_ "L/:2_Y\U?OH_\ RW^K/RO^4OA3_@G]^TCX(\1Z
M1XL\,^-OA#8:_H-XFH:3?37VOZHEG>Q*PAN19:M\.;[3YI8"WF0-<6LOD3K'
M<1;)XHI$R+[_ ()Q_M :G?7FI:AXT^%=Y?ZA=7%]?7<^O^,7GNKR[F>XN;B9
MSX$R\L\TCRR.>6=B3UK]<?[-^*W_ $.GP]_\-CXD_P#GN4?V;\5O^AT^'O\
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M_P#"R'E_T\]?Q\C\CO\ AVY\<O\ H:OA1_X//%__ ,PM'_#MSXY?]#5\*/\
MP>>+_P#YA:_7'^S?BM_T.GP]_P##8^)/_GN4?V;\5O\ H=/A[_X;'Q)_\]RC
M_B*W%W_05EO_ (0/_(/^(?<._P#0)F'_ (60\O\ IYZ_CY'Y'?\ #MSXY?\
M0U?"C_P>>+__ )A:/^';GQR_Z&KX4?\ @\\7_P#S"U^N/]F_%;_H=/A[_P"&
MQ\2?_/<H_LWXK?\ 0Z?#W_PV/B3_ .>Y1_Q%;B[_ *"LM_\ "!_Y!_Q#[AW_
M *!,P_\ "R'E_P!//7\?(_([_AVY\<O^AJ^%'_@\\7__ #"T?\.W/CE_T-7P
MH_\ !YXO_P#F%K]<?[-^*W_0Z?#W_P -CXD_^>Y1_9OQ6_Z'3X>_^&Q\2?\
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M*57Q1XIK0]G6K935AS0GR5<M52'/3G&I3ERRBUS4ZD(5(2M>$XQG%J44T4^
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MMN$F2/S(E2:3J_[-^*W_ $.GP]_\-CXD_P#GN4?V;\5O^AT^'O\ X;'Q)_\
M/<KP\_XUSSB7!TL!FF(P<\/2Q,,7!4<+*C/VU.E6HQ;DHMN/)7J)QZMI]#U<
MGX8RO(\3/%X##8R-:I0EAI.KB*=6/LIU*-624745I<]&#OV4EU1\\_\ !0#]
MGGQI^U9^R-\6O@'\/-4\+Z-XP\>?\('_ &/J7C.]U;3O#5M_PB_Q-\&>,]0_
MM*\T/1/$6J0^=I?AV]M[/[+HUYYE_+:Q3_9[=YKJ#^:?_B'G_;1_Z*=^R_\
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M\1_%WPM_9N^('C/X2ZK^U1H^J?'>+7/V@/BW\3OA3JO@GX _#?PW\)M8T/\
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MCAGS-1@Z$H<OV%&53VU2-I\RJ+D9YGJ7_!3S]E>U/A"+2O\ A??BB]\8>-_
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MX@R_M-ZC^U:VCSSMX>>S;P</B)J=QHPT^.QBUO\ X0M(=./B$ZXK^(Y.&/\
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M[\%>%?B%\=?&UYXG\6>#-4\>/X.\*^%_A5X"UKQYX[OM&\+^'O$_B'4[K0O
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M:T;X,^(3K$'C:6PNK+5/MGA[Q#9>&?$.FC2[[B-?_P"":7P(UWX0?$KX+?\
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M/L[/6]3M_B'\5?'WB/1Y(K+4H/#D'N^C_"Z^\2?!/P=\,_C]KJ?%OQ);>&O
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M^([_ ,#_ !2\)*UI8:U\-Y?"FH6\42:S?-XOBFTJWTW5/*-*_P""O&GZ-/\
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M_COX37]GJ.LC0O#:RZC<W/@B34;^R328H]'N[R;1X[O54L%U:]\PT/\ ;U^
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M/]5_ K]G>W^">M?$_P 67WQ8^*?QE\;_ !?U;PSK'C7QG\55^%]KJEU/X/\
M#D'A/0+?3M)^$7PQ^%'@_2K2TT"TL[*2*R\,1O=R6JW]U+-J-S?W=WQGQB_8
M0_93^.OPAN?@Q\1/@UX'U_P];^'OBEH7@OQ!KOA;PSXV\=?"FZ^,#W=WXS\5
M?"OQ7\1M&\9WW@SQ;<:S<V_B"QU6R62.UUC1]!E:SFM=%T^S@J$LDCBTJM+$
MSPT:F$]ZG5<H.G##I8I3A*&'KU%4Q*YE*$\+)TG)TXT)*,&I1S66'O"I0A6<
M,1>,Z:C)3E6OAW&495Z4/9T+IQE'$1]HHJ4ZJ<IKF?B?^T7^T-\.OCMX'^%,
M/P1^ VL^%OB8/BAJ'A#Q==?M0>.]!\4:5X0^%WP]N_%>M_$'XE>"IOV4+_PY
MX/\ !EKXMNO WPZUJ]T3XG>-M3TC5?B3X5U:VTC6=/36DTOY6N/^"L5MHN@>
M#]?\1>!?@//H.O?':3X47/Q*\"_M80>+_@1XN\.:?I'P8UGQ!XB_9[^+6H?!
M/PI%\<?'&A1_&"[TNZ^';^&? &B?V_\ ";XPZ--\2[:X\":HR?H+I?[-/@;P
MSXM\1>-/!&IZ]X!UBZ^!WAG]GOX=6OA&Q\#:?X8^ WP[\)MK-SI-I\&O!=SX
M+OO!^B7/]IZGIFIWEOXIT/QAH5T?!O@G19-$_P"$5\/0:!)P'AG]B[P;IUOX
MI_X3GXF_%CXQZM\1?B;X.^)?Q8U[X@O\+=*NOBR?AUX3M?"W@+P)XXT3X3_"
MSX8^#)/A[X:DTOP_XADT;P[X7\/:GXNU/P]8:/\ $'6_%W@:^\0>$-;TH5LE
MC&/UC"*IR4J49>SJ8RE6K5'*<JLU%U*M&'+3G"/\51E6HI1IQI5Y5J,5:6:.
M3]CB73YJE22YH86I3I02IJ$.;V<*D[SC.7\-M4JK<JCJ4HTJNW\%OVM_AS\:
M?@UXP^.OAV:'6O!7A7Q/XGT672_AA+J_QQ^(EE9Z#]@GL['QA\,OA5X=\1>.
M/"7Q3U'2-3TOQ%J7P/.BZQ\2?!FDZWHEGXRTG1?%4NL^&-"/"?[:G[/OCG7/
M 7A?PKK'Q)U?Q/\ $6\\5V.E^&H_V??VA+;Q#X6F\$^*8O!?B9_B_H=[\+;;
M5/@-9Z=XCG@L8]0^-]K\/;#48)X-4TNYO=)GBOG\\T#_ ()]_"?0/@A\;?@.
M/'/Q7UCPU\<8[+2]8UW7+WX=WOB/PMX,T'3-.T?PA\.O#UO%\-K;P;KW@GPG
MIEA+IL.G_%/PA\1]1\7Z-J>I^'?B=JWCOPY/#I%OP7P[_P""7OP<^&;?!JW\
M/_$CXD+HGP1^)NK?%[PKX>MO '[)7A:Q/C?7O$>F>)-<N=,U3X?_ +,/@[Q5
M\+]$U^31]-T+Q/X3^!'B+X2^%O%W@Z*\\'^+-'UOPYK.NZ=JD.ED<GB9?6,5
M3M6G]6@HMKV'U=RAS.5&;E-8GEIVE*DI4TVW#FYH4IYM'V$?8T)_NX^WFVK^
MU]NHRLE5@E%T.:=XJ;4[)*5N67T3XX_;+_9Y^'?Q,G^$7B?Q7XI'C>TO=#T?
M48O#WPB^,GC7POI'BGQ3H<_B3PEX"UOXA>"_ 'B#X>Z)\3/&6BQ6UYX,^&&K
M>*;+X@^+SK?A6V\->&M4O/&'A:WUCQ[X,?\ !0/P+XW_ &9/#_[4GQ9\,:Y\
M(O!GCOXA1>"/AUH6E^$?CS\1/&/BO^W]1ATKX?PVW@T_ +P7XXU7Q;XVU"1[
M'3M#\ >$_B#X5N]1>RT_PO\ $'Q==W;16_I>O_L>^$O$7QGNOBU<_$SXN6N@
M:S\2O OQH\7? RRU#P OP@\9_%[X9>$?#G@WP%\0M;EN_AW=_%NRU/PY8>!O
MAWJ$6@^%_BOX=\$:IK/P_P##=]KWA75EE\00:[J:-^R1\.-#^#OP'^"5IK?C
M>3PI^SSXP^''C;P7J%SJ6@OXAU35?AAJSZSH%OXHNXO#<.FWNGWETYCUB+2=
M)T2YN( %LKO3Y,RF%_8T:%*+6*G6G+"2KS51+V4%3K?6X44Z$8*4JWLE%SCB
M(QI\LHSE)U(0K_A4=:K)/#QI1CB(T8.%_:2<Z7U>=1JM*3C&G[1R470<IN49
M048TYRX'P_\ \%'OV//$^F>)]8TSXF^(HM.\)>&+OQ9J-QKGP6^.WA<ZI8:;
MXK\-?#_6-'\%P>)OAGI%Q\1/'.@_$;QCX6^&7B/X:^ (O$OQ$\.?%#7M,^&N
MN>%]/\<W*: >ATK]N[]FW7I?"]EH.M?%37=>\5ZMXVT2#P9HG[-/[3&K_$/P
MSJ/PZU#PKIGC%/B;\-].^$-SX\^$%KH]UXY\''^TOBMX=\&:;J%GXFT74=*N
M[[3M0M[I\+Q%^P7\*?$&@>'M$7QE\5="N_!X^,5YX1\2Z'K7A*+7_#?B7XP?
MM.?"O]KF7QC8-J/@C4M&N=>^'_QC^#?@F^\!6VKZ-J?AK^PK:_T7QQX>\;QW
MSSIS4O\ P3Q\#:AJWPZU_P 2_&GXT^+O$'@;XQR_'S6O$GB'1OV;I?%7Q&^*
M3ZIX;FA\1ZWXMTW]GG3/%'PU$'A3P;X5^&,VG?LXZQ\#M.UGX;:*OA[Q';:S
M-JNOZCJ^BIY!)-^UQ\/?K)1G.$I<D8S]C*\,"HMU)1C*:;BX.<:7*USXB$<^
M<)I.GA)^Y2;<82BN>4H>U7O8MR2@G)1LI<RBZETU&C4[SP/^W9\ _&?[,L7[
M6UX_Q.\ ?"!M7T?09Y?B)\'/B;X?\7PZOXA\7Z'X$T"WL?!=MX8U/7_%-IK/
MBGQ+H>D:?KG@JT\3>'I[N\N(?[66;2-<CTR\O[=7[,*:Y<:#J?CGQ)X9N+'1
M=0UC5-5\;?"#XT>!/".B7.C?"FX^.7B#P9XA\=^,_A[H7@KP]\5_"_PCL=3\
M?^+?@SK?B"P^+7A+P]HNOW7B3P5I;:!K,=C#X?\ V,_ ^A_ "R_9NNOB#\4O
M$?P^T3XE^!_B-X5N=;NOA[#XD\*0_#OXN>$?C1X4\!Z7J7A[X=:#9ZAX,L?%
MG@^UM)I_%&F>(?'-[H>J:M:7?C::].EZCI?DGC#_ ()>?LR^-_C7\4/C7K=A
M+)J7QDT?QUI/C_PZ/AQ^SE=R:B_Q'^%][\)?%>IZ-\8]7^!>I_M0^#KN]\-7
MTUU#8^#?CYH'A^TU5K@P:(FD:IK>D:FH0R*4\3[2KCJ<%4Q4L-[-PFG27L'A
M834\.I.K+FQ'M&W"%X4X\T$W4DY3S>,,/R4\).;AAUB.?FC:H_:_690Y:S2A
M&U+D24I+FG*T[*"],U+]O_\ 9BT31]"UWQ%KOQ8\+6&O0:QJ<:>+?V8?VH/"
M>IZ%X5T"?0+;5_B-XZT/Q'\'-,UOX;_".RN?$VDV[_&'X@Z?X9^%LLQU**#Q
M?*^A:XNG<M\0_P#@I7^RG\.]"^-^L7.N?$SQ-=_ /0/C+K?B[0_"WP,^,<TV
MO7GP"UM/#7Q7\+_#[Q1KG@G0?AUXW\2>"]:FMU\3P:+XVETOPEX;DG^(OC'5
MO#OPPTO6?&NF\1\4_P#@F#\+_CI<>!-;^-WQ=^)7QF\<^ +/6="T_P"('Q<^
M$7[#/Q-US4_!FK7FBZE'X,U'P_XY_8]U_P"'%C8:5J>DW5]8^)_"W@7PY\2+
MI_$&N6FN^.-9TUM*LM*]-\5_L!?!?QGX/\5^!];UWXCOH?C)_P!LEM96VUOP
M[;W;1_MQ77B2Z^+EO:W \)MY$6B'Q1J,/P_;8\^CPQVG]OS>*)8I99M(T^'H
M>P<ZN.J-SG]8A3G%0C",I.').>"IRFIQ48WY82O-S<:?+R.'/.9>U4:>$@N2
M'L93B^9RE&*GS1CBJD8N$G*5KSC:"BI3YN=>N^*/VH?A+X.\/_"[Q#X@'Q3M
MA\9=2?2OA]X7L_V??C_K/Q+U*\@TVZU>^.L_"/1?ACJ'Q2\%V>D:99S7NOZE
MXV\'^'=-\/P&W;6[O3S>6@G^>/V@_P#@HW\)/@IX/^)]WI'A/XN>*OB7\/;G
M0M-L?AQXE^ 7[47PYM_%EYXB^(.F_#.PUC0?%5Y^S]XA;Q-\/[?Q5JEC9ZC\
M0?AMX=^(VBK+J7AVQTI-8U?QEX,TWQ!Z9\</V0=-_:&^&/@#X7?$SXU?%;5K
M#P3JEOKNI>*?^$4_9HN/&?C?Q!8P26^E^*;_ %35_P!GG5=/^&WC70DN+Z3P
MSX]_9[TCX+^./"E[?SZIX8\1:1JD%A>V?A.B?\$J/V?=#\;?%SQW!XN^)LNL
M?&/78==\1NNG? S2-0ADMOC_ .$_VCK:VO?&7AKX):'\1_B/+;>-O!VFZ/!X
MB^-OC7XI^-8O!]UJ6E)XH&H7,>L6\82GD25.IC*V*E*-5NI0I.3A4IQQ,$E[
M7ZM3G'GP_.Y6Y972DITYR]C&L1/-VY0PU+#QC*FE&M424X3=%MOD5>I%\M:R
M5^:/V6JD5[674>+/^"F7[.'P]^'?CSQAXQD^(EWXB^%?@;7O%7C?PAX%^#/Q
MTUJUU+6_ MSH&C?%#P9\*?&OC;X5_#7PQ\3];^&/B?7X=%^(-K97&C:O\-8+
M#7-8^+NB?#:R\*^,O^$;^@?"W[6'P*\8WNAZ1I/BC7[3Q'XA^(UG\);#P;XI
M^&?Q2\#>/;?X@7WPG3XYP:!KG@'QMX+\/>,_#&SX3N/&EYJOB70M)T33M.#V
M^H:E:ZE&]DORUJ/_  2G_9IU#QA^T'XM$NK:>_[1^@_&S1_&=MI?PU_9>L?$
M>C7_ ,?[G5=3^(/B;PY\:X_V>3^TC<ZO+K>NZUJVD:;XU^-/C+P=IJW\?AS_
M (1:?P7I&@>&=)]5\&_LDWN@_M;6_P"T9XC\8W?C==!_9T\(?"ZPUG7VT*T\
M8^.?BC%XF\:'Q9\6/'GAOP-X'\!?#73?%%C\/)O"G@CP_P")/"6C6USK6B:]
MXI\.WVA>&M$\)^%QK3K4\A=*;H5<7[2-*K42G)*]24:/L*'(\/9QA4=9591J
M.23BXRJ14IP5*>;*I%5J>'Y'4IP?+%NU-2J>UJN2K:.4.1TTX)-W3C"7+":>
M+/\ @HK^R9X*\8>(_ 6M>,_B'<>*O"_B'Q5X0U#3_#'[.?[2?CBWOO&'@:Q@
MUCQKX/\ "VK^"OA'X@T7QOXN\(^&I_\ A-/$WA?P7J.OZ]H7P_MM1^(.IZ?:
M^"=+U+7K3I)?V[/V6H_%OAKP;'\2-0OK[Q7:>!KG2_$&D_#;XK:S\-[6Z^)O
MA9/&WPZ\/^)?BYI/@>]^%?@SQGXZ\*7&FZYX2\">,/&6A>-/$%EKWA<Z7H-S
M)XJ\.1ZI>L/V0/AKIWB=?%D&N>.7U%?B[\9/C.(9=3T!K+_A*/C?X$O/A[XK
ML#&GAE)_[ T_1;V6Z\/6OVG^T;35%CFU+5=6M UD_E.A?\$[/AGX>N?"^GZ=
M\6/CH/AMH#?"/5]7^#<^L?#.7P!X[\?? SX5>$/A%\,_B=XLO_\ A5:_$J#Q
M7H7A_P"'/PVU:?2?!OQ"\(_#K6/$W@'P_J6L>!;ZVFU[3]:B,,B:UGCX25&\
MFZE)J=?F::@HX/W8\D>:$9RM.<XPE6I1A*HZ<LW3=H8.2=6R2A-.-+E3O-O$
MZOF;C*48WC&#G&E4<HTR_H__  43_9S\=:7X8UGX7>*;SQ'8Z[XG^&MB(O%O
MPU_:)^'>KZ]X-^*D7C0^#/&_PF\/ZG\"=2USXP:;XKN? GB&Q\%ZIX8L(/A_
MXHO=+U*QC^(UAJ4%G8ZEE^%O^"GG[)_B/X9>%?BIJ&H_&+P9H?BC0?%?BZ32
MO%/[.?QW;Q'X1\#>"+NSL_%'Q*^(&G^&/A]XEMO!'PCTF:^B2X^,GB&_LOA.
M9K;6K./QH]_X8\3VFC=1H_[!'P>T6?X'7%KXD^)4C_ 'P-^S5X \'"XUCPNZ
MZEHW[++^.G^'USXF$?@Z(WFIZP?B!K(\93:6VC6NH"VTS^Q++P\8;HWOG@_X
M)I> K?P@? FE?M!_M*:'X9O? WCGX/>)K'2M1^!D4WB_X">.M7N-9G^!^LZC
M<_ >ZU&P\*^&[K5_%R>%?''A.Z\-?'33H?&_B(7GQ<U*:'P[-H&W+P[)N*GC
MX1]I!QG.I'G]GR5?:)N&#G%SY_9N+5**:]QVO*JLW+.DD^7"2?)/FC&$N7VG
M-2Y'%2Q,9*/+[523JR=_>5[1IOTW6/V[_@3%XHMO#GASQ(=5@TCXNZY\)/B!
MXAUKP3\<] \+Z/KOAKX;_%/XB>(-(\">-++X+>(_A]\3/'&C6/PQN[S4?"=G
MXRT#3K7PI=2>))?%BZA=>!_#'CZ/1/\ @H;^RGXE\.+XF\/>+/B3K5O<ZCX-
MT_1= TO]F_\ :6O?B#XOC^(?ACQCXU\#:]\/_A=;_"&3XD_$7P9XK\'_  \\
M>^*=#\>^!/"GB+P3?^'_  7XJU>'7VL- U2>UOZS^P]\(]:T&+PY+K7CRRTR
M#X_?$_\ :+@CT[4?#-L8/&?Q7^'GQ+^&FOZ)"C>$I;>+P?IN@?%/Q!/H&FI
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M$/C3]I[X">"I=/T/XV?$W]G5_$ND>(O%WV/5/"^J?&/X.V6J?$?P3HFMV_\
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M/Z]K7Q4\?V'A;P9\,+GPOH/A6\L;/7]02[EU?2\CP=^VU^T%XP_:%^ .@_\
M#4'[(.J? /7?VA_&?P2N/C!\/_A?>Q?"_P#:?O(_@M\)?B;HGAOX8Z]K?[2'
MC"W\.^.(/$_C;Q7\(/#R>#OB)\2;/4_B+X4U*ZO=-US4-'\1?";1/W%HIK,\
M$E4ME-!2G'$P4N:C)0553C0DHU,)->TPM.481FFE5DG7JQE7]G4I)X#%-POF
M-9QA*A)JU1.3IN$JL7*&(@^3$3BY2BTW3BU2IRC1]I3J?E%\=OVX?B'\,OBG
M^TYX8TOQ_P#LV:)>? SPY;7?@+]G;QSH/B>3X\?&72+SX/>$_B%JGQ^T;7[+
MXM:')%\$OASK/BCQ):>-;'PK\$?'MV^E?!3XCQR>.O#FHW0/ACQS3OV[?VI?
M&_B-_A_\(?B=^QG\3[.'5?C9)I'[3OA'X5_$CQ-\%/B-H_PI^!OPF^*\VF>#
M/!GA[]I[4$_MC1O$_CK6?AOXMUG3?CKXRT>WO+)-0%EI>OZ%KG@>;]P**BGF
M.#ITXQ>5TJDXT8TU.I.C*+JQHQ@JSA]44I-5%4K<E2I.,G5E"JZBIX=T*J8+
M%3G*2Q]2$)5'/EA&HG[-U7-TE+ZQ:*=/EI<\(1E%4XRI\CG657\!_&W[>7QD
M^*/Q.^!6C^&?B/\ "3X<:G)\:/@+=6/[+NE_\)4W[0'Q*\+>/OV1M%^-S_$/
M4O$-C\5]#M=>^ %S\0/B&_PLD\/Q_!N_T/4?$'@^TGU'XHZ;XS6^^'^A=K8?
M\%3M2\=^$_"NI>"OBM^RCX4T^Z^&?[$M]\9/C?XJ36?&'P?_ &8OBI\?='_:
MFUCXLZ!\9=-T;XO^#GT-M&UGX'_#CX7^%O ?BCXB^ ?$G@OQS\7-#NOB!XBU
M*SOM,TN7]PZ*UEFF7RA"#RB"]E3I0IM8BG[LHU.>I.2E@Y*JZBTBJWM+._M7
M7IOV1$<!C8RE+^TI/GG.4TZ,_>3@HPBFL4G34?M.ER77\-49_O#^?[QU_P %
M"?VD_@_<?M/7ES\=_P!ESXU6WAKXG_LT:9\/KGP]\./!O@KPO\/O@S\8_@S\
M*_&TW[1=Q)X^_;9^'/AKQ)\#O%GB;7=1^'7A#4/'7Q\\(Z/>?%KQ;97&E?&S
M4-.BT3X.-@?$#_@H1\<OB3X0^$.@ZG\3_P!G_P" OBGQ%K?[#.N?\('X4\4V
M?BOXI_M-VWCS]K32O"7Q(\1_LW?$3X4_M&^(O ^F_#'2/"_@Z[U3XB>%?#0_
M:?CL/!^K>,O 7C?Q]I%A;2>-+O\ H@HJX9Q@8^RE_8V']K2E0G[:,Z4)2E1I
M4*<KTXX3V"C6=*<YI4>:,JLITYPK)UI1++,7+VB_M.M[.<:L53<:DHQ52I4G
M%\\L2ZSE24XPA>IRR4%&I&=)JE'\9_V\OVK_ (D>%/BY#\"O#?Q@^%WP82P^
M('[#&HZ%X(U./Q/9_M$?M':1\2OVHO#>D_$6;X*^)-*^*7@^WTOP5X#\->'[
M^Q^*.GV?PS^+PUOPHWC/2_%=UX!T#4(-:'%>-?\ @JKXYTOP)J,'@RW^"?BK
MXW>!_ O[06H?&[X>6-Y9G4?@=XE^'G[9_P"SW^S=X0U;XCZ-XG^,G@/2_!/A
MK0_AS\4?'_Q5\>:?\3OB+\-M+U>P\$P:Y)\3/A?X'74O$"?N;165+,L!"EA:
M=7*H5OJTXU'>O&"K2=&%*K&IRX;VDJ=64/;-2J2J0J-1A45&$:2UJ8'%RJ5Z
ME/,)TO;0<$E2E)TU[24X2AS5^2,Z:?LTXPC"4+N5-U)2J/\ &;Q#^V5^T7XR
M_P"";VK_ +37AKQ]\"OA9X^\-_%WPOHFI_%+2[7X6_&/X5:C\+8OCEX6\':Y
MXPETKX8?M/\ QF^'O@)8_">M33^.],N?V@_B-)X1LM"\5QKX@T+4-0TCQ+X3
M[#X:_MR?$SQE^TUX.^$B?$+]F'Q?::Y\7M:^%^L?!?P;H?B:T^/%A\,]$^ _
MB/XHZ7^V&-<?XQ>*=+LO@G\2M9T+0)? VCW/PPN?#,GACXH^!=-LOCYXH\8W
M&GZ=XE_6FBLWF.$=/$0>64$ZM3&3HRC*FO8+$PHQIT[O#RJSAAI4Y3II5:;3
MJ.--T8\ZJ4L%B5.A)8^J_9PPT*JE&;]LZ$JCJ3LJT80E7C-1E[DU[J=156H\
MOXLV7[1G[5?PT\?_ +06HZ1K/@CXE> =>_:Q_:>^$7PZ^'WB?P]\0]?^(WA[
MQC\/?V./%G[1?@N71_&$?Q+@T _#F]UCX5W/@QOA!H_P[TO4()_$5SXITWXC
M1W&H2^';*WX=_P""B7Q'^/GC3X4^!?V8?'7[,.OQ?$CQY\ _ M_\1Y-&\3?%
MKPGX4U+QK^RM^U;^T/\ %C3;C2O _P 8?"#:AXD\/:E^S[H?AK1= F\4Z1<:
M ^M:M8^*9+R_6*?3?V;HJGF6#DG*65T766'C2IU%4@H1J15HUZM'ZNXUI)1@
MN5N*E:?M'/G]U+ XF+BHX^HJ7MG4J0<).4H-INE"I[92I1=Y^\E)QO'D4.3W
MOPUU_P#;4_:7TGPIX)^.FNZ+\-/%T^K)^WW<?#[X<^ ])^./A5-%T[]FT^-/
M#&BGQ_\ V;\9O$?A_P"+USXAF\&V/BO4Y+KX46UWX*L;C6-%\!V$VN%?%5_3
M^*7_  4V\8?##Q-\ ]!\)?M&_L@_M/Q?$'Q3X7M_$NL?!GX=^$?#7@OQ5H&O
M?%S0O &HZ1\/O%_BG_@H_K>O/XW\-:5=ZO=Z]I7PO^&O[4&L^'98='U[QQX0
M\&>'=;TEM2_=:BKCFF"YHRGE-*<8RK?NU5IJ$J4YU94J7O82<X>PA445.C*E
M*K.+K5G.HXN$2R_%<LE#,:D925)\_LYN2J0C252:MB(QE[:5-MQJQJ1IPDJ5
M)0@I*?X6Z]_P4+_:X\%_">\^*FM^'_@)XIMO'W@#XS>,/AMHGACP9XA\+2_"
MRV^#/[8?P+_9EU_Q'\4O$OQ&_:'T'P/XY\+VO@SXV'XR>(;Z^\4?LX^&?"%G
MX'UW1?$OC_3?#<T_Q$T;[O\ V&_VK;G]I'X5Z%J7Q \0?!P?%/4[KX@7^F:/
M\,?B+\(?$\/C7X=^#O%]OX:@^)>E>&?A-\?/VE-&\.:=%=:MHWA[Q5I%E\9?
MB/!X8\62#3[_ ,2I-JFGV$?W'16&(Q^#KX:5&&64:%:6(G56)IU+3C3]Z-+#
MJ"I1@X4X.,9RTE6E%U9_O)<RVH83$TJT:DL=5K4U1C3=&<+QE4O%U*W,ZDI*
M4Y*3C&[C3C)0C[D;/\$_V7OB]\=/"_[5/Q/L?#^L7_[<&B:!\-/BY?\ Q?D_
M9L_;(G_: L;WXHZQ^T-X.MO@Y;:C\._V@]7^"O[.?['GC?1/AY+\7X-:^"GP
MO^*^I6VHZ)X>!31XE\+>'I?$/I>J?M?_ +<&O>--=LO!ES^S'X.\-:A\4OVK
MOAIX7T?Q[\'_ (F>+/&/@[_AFOP\?&=IJWC#4_"?[26A^&O&FH>*[6ROO VJ
M:#X;C\*Z=X<U"X@^(.F^+O%5E8GX?:I^T-%;5,VH5*KJRRS#2DZ4::=23JRY
ME&7OR4X.E:-1QE2A"C35.E".&O*BHQCE#+JT*<::Q]9)5'-J$53BTY0]U.$E
M43E3C*-24JLW.I.5?2JVW^(>C_\ !2CXP^(/%WA=+2__ &<]+U'6K_P1IZ_L
MJ7FD^,+_ /:/UOP1XM_9>T+XX:C^TEHOB6+XEZ;;V_PA\+^)M>O=+N;$?!+7
M- OO#O@K6;6X^,VB>,]4GT3PKP/B[]M_]M"S^&WPR\6>*?C7^R?\%K?7M$_X
M)Y_'3QA\2;KX'>+%^''@3X9?MC^(OC7X:\0> /'Q\>?M(QV\^C^ =6^%VC/J
M'Q8M?%GPVNO&-AXCETG3O#_PRU2WM=<NOWZHJEFN!@XN&3T$DJ*?/.E5?[N=
MYJ/M,)*-JD7*+=6%6=Y*52=50A"*>7XN49*695FW[5IQC4IJ\XVBWR8F,O<D
ME*U.=.-E:$:;E.4ORC_9%^-O[02_%6W\"_$3Q1X-\<_"WXJ?'O\ X*?V7@%I
M]*\;'XM>!X/V??VU?'7AK0-/\0^/-<\?>(/#OBGPDF@ZI=^$/"/@[1? 7@U/
M 7A3PQX/L++7=8LXI=*L>(\2?MD_&[Q%XFUKX;:YX.\,:3JO[/O[0W[+GPW^
M.FHZ-J'Q/\(07_BWX[_\%#/@[\+O@B_@ZY\*?$S0M8CT#7/V8;K7_B_XR\#>
M+[SQ7H'B.Y^(_P +](\7:7K/PUEU_P +_$?]DZ*Q>8X>6(EB)9=2<G*,XJ-3
MV?+*.)J5&_<IJ+YL+4^KRM&,G5ITL6Y.<94YZ+ UU1C16-J<JBXMRAS\T70I
MP2]^HY*V(I^W7O-*G4J8=)1<9Q_GZM/V]/CI\7'U.R\&?$KX%ZU\3O"WB/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img147150826_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +0!$X# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?P]DT32R+W2O"?@RYDTSQ?92QVMQLBU*X /ZQ**_G>_X)2_\%<?V3K7]@_\
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MLLECKUYX \0VNL2Z#J+V\TUI%K&G'R=1T];L02M9RWEG#!>K!/\ 99)A#+L
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M!7A;0='UL^.['4+GP-X)A-G<B]U6![!+2:2W&B7,YGD20*@!^_\ 17P)HO\
MP5/_ ."<WB3XY0_LU^'_ -L[]G_6OCC=:XOABT^'FF?$#2+W5KWQ&[K''H-C
M=6\DFD7NL2RNL$6G6NHS7<L[+!'$TS!#]UZMJNGZ%I6IZWJUU%8Z5H^GWNJZ
MG>SMM@L]/T^VEN[VZF;^&*WMH9)I&[(A/:@#0HK^5/\ X(!?M??'7]KG4/\
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M?<_ZZK[P]I3_ .?D/_ H_P"9T]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\
M0W>&/_!_I7_R71RR_EE]S_KJOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#
M'_@_TK_Y+H_X3;P9_P!#=X8_\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\
MF=/17,?\)MX,_P"AN\,?^#_2O_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_Z
MZK[P]I3_ .?D/_ H_P"9T]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&
M/_!_I7_R71RR_EE]S_KJOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_
MTK_Y+H_X3;P9_P!#=X8_\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/1
M7,?\)MX,_P"AN\,?^#_2O_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P
M]I3_ .?D/_ H_P"9T]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_
MI7_R71RR_EE]S_KJOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_TK_Y
M+H_X3;P9_P!#=X8_\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/17,?\
M)MX,_P"AN\,?^#_2O_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P]I3_
M .?D/_ H_P"9T]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_I7_R
M71RR_EE]S_KJOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_TK_Y+H_X
M3;P9_P!#=X8_\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/17,?\)MX,
M_P"AN\,?^#_2O_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P]I3_ .?D
M/_ H_P"9T]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_I7_R71RR
M_EE]S_KJOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_TK_Y+H_X3;P9
M_P!#=X8_\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/17,?\)MX,_P"A
MN\,?^#_2O_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P]I3_ .?D/_ H
M_P"9T]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_I7_R71RR_EE]
MS_KJOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_TK_Y+H_X3;P9_P!#
M=X8_\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/17,?\)MX,_P"AN\,?
M^#_2O_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P]I3_ .?D/_ H_P"9
MT]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_I7_R71RR_EE]S_KJ
MOO#VE/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_TK_Y+H_X3;P9_P!#=X8_
M\'^E?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/17,?\)MX,_P"AN\,?^#_2
MO_DNC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P]I3_ .?D/_ H_P"9T]%<
MQ_PFW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_I7_R71RR_EE]S_KJOO#V
ME/\ Y^0_\"C_ )G3T5S'_";>#/\ H;O#'_@_TK_Y+H_X3;P9_P!#=X8_\'^E
M?_)='++^67W/^NJ^\/:4_P#GY#_P*/\ F=/17,?\)MX,_P"AN\,?^#_2O_DN
MC_A-O!G_ $-WAC_P?Z5_\ET<LOY9?<_ZZK[P]I3_ .?D/_ H_P"9T]%<Q_PF
MW@S_ *&[PQ_X/]*_^2Z/^$V\&?\ 0W>&/_!_I7_R71RR_EE]S_KJOO#VE/\
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MZNMYJ'@7PU\1?%7AW5/#US:>)+G6M4D\::!!!<#6]._L*XNK>'1(K4?W#_\
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MLGB;5-;GU_6;K4V3[7>:E)JERTDEV9S7T==W%]HW_!V_\;KOX<6UG)JFE_\
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M \+?#>T\*>(/ ]GX>M/ %MX@C\"SK:>%/$^L:+;7UYX?N-1AM)X-ET)+*S>
M _B2_P"".7P3_P""6/QE_;W_ ."R<7_!1*S^ _B+Q/X9^-?Q%NOA5X>^/_B'
M3;#1=/\ !6I>//B<OQ7\6>#-&\07UGHMQXITY]/\&Q2Z]91W'BG08?L,FB/9
M_:+B9_GW]@;]H_\ 9]_9J_X(R_\ !7)OBW\%->_:M_8GU/\ ;R^&G@/]GOX-
MZQXM\5^$?"'C#Q)_PD4'C[P/<^(/&6CWD?B+1?"^F6GPW\!>+O%\5C+/)XAF
ML+/P[J4-P/$=XS?J[_P3._X(,_#S]I+XY_\ !5N7_@I[^Q1XLC\*>*/VMO\
MA,?V<_&/C!_%_P -M?UGP_?>*?BGJ/B#4OA]XQ\(:WH'B"Z\*ZU:W?A&YU1+
M34&TC4\::)XY)[5EA_J4T[_@F5^PCI7[(%]^P99?LU_#R/\ 92U2 #4OA.UE
M=S:?J&J+J-MK,?BJ\UJ6[?Q)<>-8=:L[/68/&,FKMXD@U.TMKN+4DDACV@'^
M<C^TXGC#P%^U?_P2"^*]M\"O^"47[--]XC_:#^$?Q"\!>'O^"<.J:M<_$V'0
M+WQU\)-:T:/]H^5?'?B33;VXT_[4;+0;^"QT>_N]0/BZTO'N;9(HH?W1^,_[
M*?P!_;#_ .#N/Q9\+OVD_AQHOQ9^&VB_L@^'/B(/ ?B?S[CPIK/B7PMX-T"#
M0G\2Z-'+':>(M*LFU>ZN6T354N=*NKE+:2[M9UA5#^W7@+_@VU_X(V_#.[\&
M:IX/_9(AT_7O 'Q/\-?%SPOXFN/BO\9-3\367BSPE<PWFB6\^O:EX]N]2U#P
MI!>6\%Y<^#+^XN?"^H74,=S?:5<3*'K] [+_ ()_?LJZ?^VOJ?\ P4,M/AY>
MQ_M8:Q\.1\*=0^(A\9^-'L)O! MK&S&F#P0^O-X(BN/LVFV<)U2+P^FIE8R3
M=;I)&8 _D-_8/_95_9[\)?\ !<?_ (+H_L0Z#\&O UU^RCJ'P$\.ZN?V>=2\
M-V/B#X:R:AIFF_#'XF^'8;;PEJ5O>V2P^'/&^O7VK>%[.WA"Z+,;2'3%A2TM
MDCJ_\&I?PQ_88UW]@#X_>.OB1)\"/!/[3]EXZ_:%\+VOQEGE\%:;^T7\/?@[
MJ?P8\/C7M;\*Z[=LOC72_#V@Z/-XGUN.[T[&G6IM=2N9'"Q7&W^OKX:?\$^_
MV5/A%^UQ\;/VYO ?P[O=)_:7_:&T;3- ^*WCR?QIXTU2SU_2]'L= TZQM[3P
MCJFO7?A'06CM/#&BQ23Z%HFGSS&U9Y9'>XN&E^;OA)_P0^_X)?? O]H3QQ^T
M]\+OV6?#7A?XK?$+1?'OA[Q'+;^)?&]UX*&B_$[3;K1O'6G:)\-K[Q)<> O#
M=KXATF^O],NHM!\/:<D-CJ%];6BV\5W.K@'\2_P*\'?"O_@CS\7/V8/"/[1'
MP&_X)W?\%'?V;/B=^U#X4U?X"?MN?LY>,M&3]L/P7XFN?$VCZQX1U359]"UX
M>+;C2/#=Y;V.KS^"?$6F/HEU>R:MX?L?'VKVBV=C+_H8?MF-J]Q^QO\ M6MX
M:^T?V]/^S-\=&T#R!LNO[7D^%GBDZ5Y(<?+<?;&@\L,.),!AP:_//X(?\&]/
M_!(7]GCXTZ/\?_AC^R%X=LOB/X<UN#Q+X8N/$?C7XD>-O#7AC7[.[CO].UCP
M]X)\8>+M:\(Z5J&DWL,5UI%Q:Z,CZ7/%')8F!HT(_9?4]-L=9TW4-(U2UBOM
M,U6QN]-U&RN%WP7EC?026MW:S(>'BN+>62*13]Y'8=Z /XP/^""<ND2?\&PG
M[64>G^1_:=OI?[=D/BGRUVW']O'X?&>+[>3R]W_PCTV@X9LD6OV5"?DP/S#_
M &,O^"<G[%OC7_@UB_:<_;"\7_ 3P;XF_:;_ .$9^/OB[2?C3K<%SJ/CGPKJ
M7PJ\?76@^#K3P=JUQ<._A;1;;3=(BBU/1=&6TT_77N[^;6(;R6X#1_N=_P $
M)OV'/CU^R;JW_!5W_@F7^TU\#?B,/V2_%?Q:\4^,?@E\6K_3-2TCX??%WX>?
M$_1[GX>>,-/T+QII5U;;=<U;P#I_PZO9+'1[FUU'0KV'Q'!+):ZCITBQ?M]\
M/O\ @F)^QA\+OV(O$_\ P3L\$_"[4=*_9+\8Z1XUT/Q#\.I/B!\0-1U&^T[X
MA:Q=:]XKB'CG4?$MUXYMI-0U.\GGBGMO$,,U@C)!8O;P1QQJ ?R%ZSXH_P""
M?>O?\$;_ /@B?J/_  4@_82_:_\ V][V#X+_ !QT/X07O[,<WCE9?A9I?A[Q
M!\-M%\0V'CN?P5\6?A:SKXGTNR\"VGA(:J=>=H/!6N?9FT\QW1O^[_X)5WG_
M  0]F_;^_9PC_9A_X(X_\%'_ -GCX[MXHUT_#OXT_&9OB[=_#+P!JJ^"O$SW
MFK>+$\0?M%^--'CLKG2%U'2K:>^\,ZI%#J.H6;+'#)LN8?[1?V;/V<?A#^R1
M\$/A]^SK\!O#,W@[X2?"[1FT'P7X<N-;USQ)<:9IKWMUJ$D4^N>)-0U77-2E
MDO+RYF>XU'4+J<F3;YFQ55?<: /XE/\ @\<^)/PY\0?!7]B#PGH7Q \$:UXJ
M\(_M?W!\5^&-*\6:!J'B+PPL?@^XBD?Q#HEIJ$VIZ,D4H\J:34;6V2*4K'(R
MNZJ?;/\ @[)U+2/C!_P1G^''C'X3>*?#WQ!\*_#+]KOX#Z]X[\2_#[Q'H_BS
M2_#>EGX<?%?P0+F]U'P_?WUC')%XJ\;^$].6&2Y4B\U;3SP98F/Z8_'C_@V_
M_P""0O[2GQD^)/Q\^+_[-OB#Q%\4/BWXMU;QQX[UVR^.OQT\.VNK>)=<G-UJ
M=_#HGA_XAZ;HNF+<SLTIM-,L+2TC9CY4" XKZY_9X_X)/_L#_LO_ +,OQ,_8
MZ^%7P"T@?LX_&/5]2UWXF?#/QUXA\6_$W2O%VI:K8:3IUU-J=WX_UWQ%J@6.
MVT+2&L8[:]@33KJPMKZP%O>QK<  _@E_;/\ AIX-_P"">_A;_@FM^VS_ ,$Z
MO^"I7[2'[1_[7'[07C+X>SZ_\._$WQF\-_$BZ\2VVH:-X<O(=*7P#X+AT_6M
M+\/IKMW;?#?7OA_XYNO%RZZNK?V+'=VTEG=Q7'[L?\'!C[_^"Q'_  ;Y6WAG
M;_PG2_M6>";BZ^RJHU+_ (0=?CO\)?[>W.PP=._LR/7OM"=?+^T%?F(-?L?^
MR_\ \$#O^"3_ .Q[\7M/^.WP._9.\/:5\4="U(ZSX6\2>+O%_P 0?B2/!NL"
M226#5O!VE?$#Q3XDTCPSJEF976PU#2+&UO+!"HLYH3'$4^"/B)^R1^T7^V%_
MP<C_  N_:'^(GP;\>>$?V0/^"?'P,7_A67Q(\5:!+IOA'XJ_%[Q-INHSI#X+
MU&:1X/$%KH^L^-)-4GNK$))INH>!HX[X;;FWB< _I_HHHH **** . UOX5?#
M3Q+J=SK7B'P%X2UK5[SR1=ZGJF@Z=>WUR+>WBM8!-<W%N\LGDVT$,$>YCLBB
M1%PJ@#*_X4;\&O\ HEW@/_PE](_^1:]4HJU4J))*I-)622G)))6LEKI:RMZ+
ML9.A0;;=&DVVVVZ<&VWJVVXW;;U;>YY7_P *-^#7_1+O ?\ X2^D?_(M'_"C
M?@U_T2[P'_X2^D?_ "+7JE%/VM7_ )^5/_ Y?Y^2^X7U?#_\^*/_ (*A_P#(
MGE?_  HWX-?]$N\!_P#A+Z1_\BT?\*-^#7_1+O ?_A+Z1_\ (M>J44>UJ_\
M/RI_X'+_ #\E]P?5\/\ \^*/_@J'_P B>5_\*-^#7_1+O ?_ (2^D?\ R+1_
MPHWX-?\ 1+O ?_A+Z1_\BUZI11[6K_S\J?\ @<O\_)?<'U?#_P#/BC_X*A_\
MB>5_\*-^#7_1+O ?_A+Z1_\ (M'_  HWX-?]$N\!_P#A+Z1_\BUZI11[6K_S
M\J?^!R_S\E]P?5\/_P ^*/\ X*A_\B>5_P#"C?@U_P!$N\!_^$OI'_R+1_PH
MWX-?]$N\!_\ A+Z1_P#(M>J44>UJ_P#/RI_X'+_/R7W!]7P__/BC_P""H?\
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MJ_\ /RI_X'+_ #\E]P?5\/\ \^*/_@J'_P B>5_\*-^#7_1+O ?_ (2^D?\
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MBT?\*-^#7_1+O ?_ (2^D?\ R+7JE%'M:O\ S\J?^!R_S\E]P?5\/_SXH_\
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MOI'_ ,BT?\*-^#7_ $2[P'_X2^D?_(M>J44>UJ_\_*G_ ('+_/R7W!]7P_\
MSXH_^"H?_(GE?_"C?@U_T2[P'_X2^D?_ "+1_P *-^#7_1+O ?\ X2^D?_(M
M>J44>UJ_\_*G_@<O\_)?<'U?#_\ /BC_ ."H?_(GE?\ PHWX-?\ 1+O ?_A+
MZ1_\BT?\*-^#7_1+O ?_ (2^D?\ R+7JE%'M:O\ S\J?^!R_S\E]P?5\/_SX
MH_\ @J'_ ,B>5_\ "C?@U_T2[P'_ .$OI'_R+1_PHWX-?]$N\!_^$OI'_P B
MUZI11[6K_P _*G_@<O\ /R7W!]7P_P#SXH_^"H?_ ")Y7_PHWX-?]$N\!_\
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M^F:9-JETMEID.H7]K92ZC>N55+2PCN98WO+IV=%6WMQ)*Q=0$)89 -.BBB@
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M&\4^./'E]=ZHMXMS*]_#JEM;M!)#$+-7C>20 ^B**** "BBB@ HHHH ****
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M/\.:!916]CHGAGP_;37*Z3H>F65M)=W4PEG< ^SZ*** "BBB@ HHHH ****
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M$OB?XP>.K35!=8U>]\3W%]I,VM^(=:U$ZO>:L;MKM[GT?]IG]C35?C]^U?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%F_P"3GK'_
M +(3J/\ ZGVG5[U7@LW_ "<]8_\ 9"=1_P#4^TZO>JUJ[4O^O4?SD<V'^+$_
M]A,__3=(****R.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#F***/:@]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME4Q,U6?VC?@IX4^%_P *+*]\%6=U ;+QGI6H7UU>WDU]<O)+I]QIL/[R4_)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!?AO4?#NK^%=-M_$%]87']LQO:2Z@L,=M++JT44L4'E6%TVJ75S:/*"7C1I
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M$3R9'FR01PF4HKR!G+LW1:'\!_AGH/@W6? MMH1N="\021SZS]ONY[F^OKF
M)]EN7O T;PS6;11O:-:K L,B^8J;G<MI4K8>=:%>]1M.DY4G"/*N3E4DI<^J
MM%VCRZMZM)LQI8;&4\-4P:5%1<:ZCB%5ESR=1R<;TU3TDW*TI<[LEHF[7^4-
M=\(?";P9^RS;:C<:=X>N_%'B31;*YTW5I$MI]<N_$%[-"\G]GW8#W<,&EQ-+
M]HMH'2UBBMVCG4R2#?P7C>+78?@'\"?AS<M,NI^+M>EU.WLI5E\Z"SFN7@T5
M&210RI(VKM+%&@*%75@#\IKZUT']DKX.Z%JT&K?V?K.L-:RB>"PUO5?MFF)(
MIS&7M8;:U,ZQL PBN)9H9" LT<J$J?2_%'PE\)^+O%_@_P :ZM_:?]J>"'BE
MT2UM+N.#2Q)!=+>0/=6GV9VE,-Q'&R>7-" (T4@J,'18JE&4?>J5$JLZ[E-6
M]]Q<:<(QYI6BF[N5^FBMH8O+J\X2]RC1D\/1PD84Y73IJI"=:K.7)&\I*+48
MV;Z-MZOXN^/'PT\)^%];^!7PV\(:196>I:AK,45WK BC35=42YO],L'NM4O
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MS_\ 3=(****R.D**** "BBB@ HHHH *_+_\ X*=^ _V,]9\"_#[Q[^W%X/\
MCE\6_A+X0US6]'TSX-?"_P -_&[XC^#?%'BKQ)H[WEMXA^(GPG^!]A?:CXPD
M\-Z=X<U"'PKJ?C**Y\+>&-1U>XGA@AUS4-.O(?U KXO_ &HO#'[>EQXC\&>+
M?V,OB=^SO86.GZ7J>C^._A#^TGX+\7W/A/Q/-=74%SI?BWP]\1OAK<'QIX6U
M_2(UGL9M*N]%\1^'-7LI0#::;?J-14 _/G_@WSU,ZO\ L8?$.]\.>,M;U;X(
MR_M3?'<?LT_#7QKXWN?'/Q,^ GP%B\3+;^"?A%\1Y=4U#4O$7A'Q%H30ZC>0
M?#WQ-</KO@_2-0T_3[^:YF9YW_=:OS@_X)X?L3^._P!E%/VE?B9\:?B+X4^(
MG[07[8?QL?X[_&5_AIX6NO!?PB\*Z[!X6T;P9HOA/X:Z#J5W?:Y-H^EZ%H5H
M=0\2>(KD:[XGU2:XU/4;:VE;:WZ/T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)N7=LW+O"ABN1N"DD
M!MO7:2" <8)!'45\*^*/VCOB3X\UW4?!7P-\&7XN+.\N-.O?$FIV:RSVLD$S
MP2RK;7 _LW2%5DW"35I)[C9O']GQR*&'?_!;X#^+?"?B>3XC_$3QK?:]XMN[
M*YM7T^*\N;NTB6\2-7^WWURY-]+ JF.&"""*UMV5'AD=0JCIEAW3@Y59QIRY
M;PI?%4E?:ZB[033O>3OY'##&JM55/#4:E:FI6J8A_NZ,$OBY935ZLEMRP5K_
M &DM3ZFN4FDMYX[>86]Q)#*D%P46403,C+%,8V^601.5?8WROMVG@FOC+P_^
MR.=5U^Z\3?&'QI?^.+^6[DF6SM9KRVM;B(2;HEO+VX<WJQ;"8S8V(M(84"I#
M/LRM?:=%9TZU2DI>SERN:2<DES)+HI6O&_6S3-JV&HXATW6A[14VW&+<N2[M
MK*":C.UM.9-*[TU,?0O#VA^&-.@TCP]I-AHVF6ZA8;+3K6*U@7C!=EB5?,E;
MK)-(7ED;+2.S$D[%%%9MMN[;;>[>K?S-TDDDDDDK))6279):)!1112&%%%%
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MLAZR2E%!D<]V;+'UJ:BBLS<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB4=+LHHHK@/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >"S?\G/6/_9"=1_]3[3J]ZKP
M6;_DYZQ_[(3J/_J?:=7O5:U=J7_7J/YR.;#_ !8G_L)G_P"FZ04445D=(5_.
MY_P<N_M*?M%?L[?L*?#RP_9P^*'B+X&^(_CK^TU\*?@?XL^,WA*]N-(\1_#S
MP5XP;5WU35=+UVR>'4-!DN;BQL[.?5=+NK#5;>UDG73M0L[B19E_HCK^6_\
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M4:3\.?%3>'/[)T[3+.\N)_$VK:;I^F6GVO\ MJR\)R)I?^@/0 4444 %%%%
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M %%%% !1110 4444 >"S?\G/6/\ V0G4?_4^TZO>J\%F_P"3GK'_ +(3J/\
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MM+OX[\?:A^UIJ?B_6])\$:7HVB>&(+IX=)U5?[$=[K3RJB.ZFN]7DNI!<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY9](8Z<_]7- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M& 9<Y4E2,@9!'%<Y_P (]<?]#/XE_P# C2__ )4UTM% '-?\(]<?]#/XE_\
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M-+_^5-=+10!S7_"/7'_0S^)?_ C2_P#Y4T?\(]<?]#/XE_\  C2__E372T4
M<U_PCUQ_T,_B7_P(TO\ ^5-'_"/7'_0S^)?_  (TO_Y4UTM% '-?\(]<?]#/
MXE_\"-+_ /E31_PCUQ_T,_B7_P "-+_^5-=+10!S7_"/7'_0S^)?_ C2_P#Y
M4T?\(]<?]#/XE_\  C2__E372T4 <U_PCUQ_T,_B7_P(TO\ ^5-'_"/7'_0S
M^)?_  (TO_Y4UTM% '-?\(]<?]#/XE_\"-+_ /E31_PCUQ_T,_B7_P "-+_^
M5-=+10!S7_"/7'_0S^)?_ C2_P#Y4T?\(]<?]#/XE_\  C2__E372T4 <U_P
MCUQ_T,_B7_P(TO\ ^5-'_"/7'_0S^)?_  (TO_Y4UTM% '-?\(]<?]#/XE_\
M"-+_ /E31_PCUQ_T,_B7_P "-+_^5-=+10!S7_"/7'_0S^)?_ C2_P#Y4T?\
M(]<?]#/XE_\  C2__E372T4 <U_PCUQ_T,_B7_P(TO\ ^5-?)\^ASC]NC2X?
M^$A\0%C^R7K[^>;C3_. 'QC\-#8#_9OE[3W_ '9/O7VK7R1<?\GWZ5_V:1X@
M_P#5Q^&:]?*/BS+_ +%&/_\ 3<3@Q_PX3_L/PG_IP^DO^$>N/^AG\2_^!&E_
M_*FC_A'KC_H9_$O_ ($:7_\ *FNEHKR#O.:_X1ZX_P"AG\2_^!&E_P#RIH_X
M1ZX_Z&?Q+_X$:7_\J:Z6B@#FO^$>N/\ H9_$O_@1I?\ \J:/^$>N/^AG\2_^
M!&E__*FNEHH YK_A'KC_ *&?Q+_X$:7_ /*FC_A'KC_H9_$O_@1I?_RIKI:*
M .:_X1ZX_P"AG\2_^!&E_P#RIH_X1ZX_Z&?Q+_X$:7_\J:Z6B@#FO^$>N/\
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M!_\ 4K2OK>O8S_\ Y'&._P"OD/\ TS3.#*_]PPW^!_\ I<@HHHKQSO"BBB@
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MP_KH^%ULFF6^N?V;)J-M;W=C=0W32Z9>E))L/!);R!MA_9SX^_\ !([]@/\
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M7,:RV]W97MK)+;W5M/$RR0SP2/%*C!T9E(-? <4\'9]P?C(87.<(H4\1'VN
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M\G]D_P#:(D/;-SX)7\]NK2>WYU$?^#F?X.'/E?LA_M"/Z$WOA,#/_ +F3O\
MYSQ1_P 07\3O^B3Q2]<;E2M>V]\?YB_XB)P9_P!#R@_3#XU]NV&\S^F^BOYC
M3_P<Q?"YO]5^QO\ M 2>F=1\.#GT^6.2HS_P<N^ 6/[K]BOX^N/?5-&'Y[-.
MD]_R^N*_X@MXG?\ 1+5UTUS#*%V[Y@N_]:7/^(B<&?\ 0[I?^$N/\O\ J%\_
MP9_3M17\PK?\'*_A4Y\K]A_X\R?76-/!Q_P#09/Y5&?^#E+1V_U/["7QVD],
MZW .?^ >%)/>FO!7Q-?_ #3%1>N:9(NW?,O,7_$1>#?^AS'Y8+,GV[8-]_ZT
MO_3]17\OK?\ !R;$?]5^P/\ '%_3.OR#/XIX&?\ K49_X.1[YO\ 4_\ !/OX
MW/GIN\17@SZ?<^'4GMT!]::\%/$Q_P#--6]<WR%?GF:_X</^(B\'?]#C_P Q
M^:/MVP7G^#/ZAJ*_ET;_ (.0O$)_U/\ P3P^-,G/&?$NKK^J?"V3MZ=?UIC?
M\''OC4_ZG_@G'\9I/KXJU\9]/N?""3M]:?\ Q!/Q,_Z)VFO7/.'EV[YKYZ_,
M7_$1N#E_S-I_++<U?IJL#;7U/ZCJ*_EM/_!QQ\1V_P!5_P $U_C&_IGQ;XI'
MUX3X)O\ S_PJ,_\ !QE\6C_JO^"9?Q??/W<^,/&7/UV? 9\=_6G_ ,02\2_^
MB?PZ]>(.&UV[YNN_X/R#_B(W!_\ T-*O_AJS=O[E@+G]2U%?RRG_ (.+/C<W
M^J_X)??%M_3/C3QX,^GW/V>7Q^M?GQ_P46_X+6_M4_M(?"#2?AAH?[/_ ,2O
MV-_#&K:[,WC'Q))XD\82ZE\0;)+!_L?@RWUG4OAO\/!IFEY-YJ.M:?8W6H7.
MMI!9)+]EL+*\BO\ TLH\!?$',,RP>"QF!P.587$55#$8^KG.1XR.%I).4ZGU
M3 YG7Q>(FDN6%*E3O*HXJ<Z5/GJPX\?XG\*87"5\1A\5B<;7I4W*EA89?F6'
M=:=U%0]OB<'3H4HW=Y3J35HI\L9SY82_KJ_9%_Y!G[0I[']K?]H+![';XM5&
MP>AVNK(V.C*RG!! ^MZ_@F_X('_M;?%CX=_MP^ O@A?_ !$U&7X/?&^/QQIO
MBSPSXJ\0R2:''XJL_!NO>*/#GB;3/[7O%AM_%]_X@T+3_#_VB.4W>MVNLSZ;
MY-[?2Z<L?][->'XL<%8S@?BRIEV*Q=+'4\=@L/F>$Q5&G.BIX>I.KA7"K2E*
MI[*M3K82JI0C5J1<'3FI+GY8^EP-Q%A^)<CCBZ-"IAI8;$5<'7HU)QJ<M6$:
M=92A.*CSTY4Z\+2<(/F4X\ONW91117YF?8A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUSQ3H>J:3=:3>^&M7/Q0^'?Q&TR/2I([MKD2Z7IVGZDES'&1?^3OB< ^9_\
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M?W]S#9V=K"N TMQ=7#QP01J2 9)751D9/-?R_P#Q*_X+_P#Q8^.?B*Y^&/\
MP3<_9&\<_%/Q%<R36=IXX\;Z'J>L;1D0O>V7@+P=--%9)!O^TV]]XG\701Q
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MDG]2K:VM[.WAM+2WAM;6VB2"WMK:*."WMX8E"1PPPQ*L<44: *D<:JB* J@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >"S?\G/6/\ V0G4?_4^TZO>J\%F_P"3GK'_ +(3J/\ ZGVG5[U6M7:E
M_P!>H_G(YL/\6)_["9_^FZ04445D=(5_&_\ MD_LR_\ !63_ ()7_P#!2O\
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M4+%024)Y*DYVGN,4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKK+\/A(XKV\L'.G"G7C*JX0G0M.-/VD:W-+^?_PO_P $/OVS/VN=<T_X@?\
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M6>86M/L=[Y4?A'QS,R9G\-W+)IFK2L)O#=U(L\.GI^_%?DY_P4E_X)-_!?\
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M9%"(B DA%506)9B%  +$\DG')/)/-.HH **** "BBB@ HHHH **** "BBB@
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MFM+VV>&[L[A([BUGAFC1U_0^$>.YY-A*W#O$&"7$?!>/G?&Y)B)M5<%5D_\
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M#1-+TD:X^EZT--^U7FH1+]I&DZ@RXVK;2,P%7OV,?VB=2_:R_9E^$W[1.I^
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M$X2E^MU%?S=?%/\ X+Y?%3X7Z+I?Q.UG_@F7\>]!^ 6O:U'I&@_%3XB^,'\
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M %%%% !1110 4444 >"S?\G/6/\ V0G4?_4^TZO>J\%F_P"3GK'_ +(3J/\
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M&N?@_%XW^*G@WP_XB\ O\#-1T>\NIK_X=?\ "NK?14AF\4I:^.I-874[CQ=
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M%_Q$\?>*[_5/$GBO7I+2""SCNM1O6BM;2&.VLH+:$%#]0T44 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHG&,GB/$H91F]7-,ZS;%Y)G6*R[%Y-++'EV9YGEU;.:DL9BT\73RNO1QD:&
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MN9Y5CD:.+S/,<1N54A6Q\(_MX?M8ZQ\)_@EX6\/?LW:AX<\;_M.?M4^,[/X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /DG]N3_ )-H\8_]C=\%
MO_5X?#BOK:ODG]N3_DVCQC_V-WP6_P#5X?#BOK:O8K_\B#+/^QQGG_J%P\<%
M/_D:8S_L RW_ -2,U"BBBO'.\**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \%F_P"3GK'_ +(3J/\ ZGVG5[U7@LW_ "<]8_\ 9"=1_P#4^TZO>JUJ[4O^
MO4?SD<V'^+$_]A,__3=(****R.D**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BOF+]L#]JWX??L6? KQ-^T!\3M&
M\7^(/"7A>]T6PN](\"V&D:CXEO+G7=1BTVT6QMM>USPYI15)9?-G>[UBT5(4
M<H9)"D;?G9X0_P""^'["_C/XQ>"OA/I]M\:-.TSX@>(+#PIX9^+^N_#ZUTKX
M37WB/4;B'3X-,CUF?Q%_PD$T::O<V^DSZK:^&;C1HKF>*X;4!ITB7I^GRK@S
MBK/,OJYID^0YCF.7T)8J%7%X6@ZM*$\'1I5\33;B[NK3HUJ=14DG4J1<G2C/
MV=3E\;'<0Y)EN*A@L?F>$PF*J*C*%"O54*DHXBI.E2FD].252G*#FVH0:7.X
M\T;_ *-_M"_L[ZI^T%I<?AR?X\?%KX8>$G&C3:IX7^'FD_!.ZL=:U+P]XDTW
MQ5HVK7VH?$CX0?$+Q!;W=CJVD:>PM])UC3=,N;>W\F[T^X$LS2>O_#_PMX@\
M'^'8M%\3?$GQ?\5M42[NKA_%WC?3?A_I.NS0W#JT-A)9_#3P3\/_  NMM8J"
MEM)%X=BO75B;R[NG"NOY-?'[_@MI\#/V>/C)\0?@IXE_9K_;,\5Z[\.M>D\/
MZEXC\!_"3PQK/@_6)X[:VNOMOA[5;_XB:1=W^FR1W*"&YFTZT,I5F6,Q[7;T
M;PI_P5J^!OC#]D+XZ?M?O\/OC#\+_"7P4O+S0&\,?&OPQH_@KQ1XP\5R:/IU
M_P"']+\,V.G>)?$$&HP:WJ&KV.E12I>)=I.MX_V,QVX>3UZW!_';RC+(U<AJ
MK*\7B<&LLJ0PF6*K7Q.;NA2PO)7HQ^O5)XWFPT'[2;YU"C&KI1@H>?2S_ACZ
M_C73S2#QM"CB/KD)5\8X4J. 52=?FIU']6C'#6JR7)%<KE4<-:D^;]5:*_DM
M_P"";'[1_P"WQXE_X*=^!? O[4OQC\?W6C?&+X&^*_CO)\$M1U:X7PCX*TSQ
MKH=]XF\#:+'X>EABCTVZT?1_[-N8[18X9=-:X-E,K30RN_\ 6E7!QIPAB>"L
MSPN68K,,!F4\7E>%S2&)RZ56IA?9XFKB*/LXU*M.G[5PGAJG[RFG2J1<9PDT
MSKX=S^CQ%@ZV,HX7%8.-#&5L'*CBXPC7YZ4*53FE"$I\BE&M'W)-3BTXSBFK
M!1117R![P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '@LW_ "<]8_\ 9"=1_P#4
M^TZO>J\$E(/[3UG@YV? K4%?'.QF\>Z<RJV/NEE!90<%@"0" :][K6K_ ,NO
M^O4?SD<V'WQ/_83/_P!-TE^84445D=(4444 %%%% !1110 445\,_MD?MX^"
MOV-?$'[/_@G5_@Q^T#\>OB)^TSXO\:>"OA1\.OV=_"_@3Q/XMU75_A_X&U'X
MC^*);V'Q_P#$CX9Z1:6.G^$=(U34S+'K%S.Z6-PHMAM4L ?<U%> _LZ?'/6/
MC]X)O/&.M_L_?'[]G&ZM-<NM&7P1^T7X>\"^&_&UY%:PV\RZY9V/P_\ B)\2
M]&?0[IIV@M;B778;QYK:X$EA%&L4DOOU !1110 4444 %%%% !1110 4444
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M\)^(-#AU5K5]3M;#Q)X'\0>&M?ALK]K*U:\L?[2-G<&%?-@?YL@'Q;_P2_\
MVB?VB_B#\2/V[/V9?VAOB?X3_:%U#]C/XX>$/AOX2_:,\)^#['P/)\0]"\9_
M#C1O')\/>-O#^@23^$[?XB?#^:_71_%$_AR6&WNY+FVN;FPL;B4P+^O%>._
MG]GWX)_LQ_#K3/A+\ /AEX2^$_P[TBYO;ZT\+^#],CTZREU/4I?/U/6-2G)E
MO]:US4Y@LFI:YK%W?ZM?ND9N[V;RTV^Q4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
M7=(T>21E2-%9W=R%1$4%F9F) 554$L20  23BOG[X2(WCCQ7XS^,5XC-:ZE<
M2>#O :R!OW'A+0KEUN[^%7'R?V]K"RW!9<AH;6-XW:.<BMCXXZY?P^'-/\$Z
M!*T?BCXE:E'X3TIXB1+96%PH?Q!K&0#LBTW2?./F'Y4N+BVW JQKU+P[H6G^
M&-!TCP[I4*P:=HNG6NFV<2@*%AM85B4D#C<^TNY[NS'O6R]RDW]JJ^5:[4XM
M.3M_>DE%/M&:V>O++][B8Q_Y=X=<\NSK35J:?^"FY3:?6=.71&S1116)U!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117DOQH\5W
MOAGP9+::&=WBOQ=>VWA#PI IS(^L:T6MQ<JH(8QZ=:_:-0F*\JEOZD54(N<H
MQ6\FEY+S?DEJWV(J5(TJ<ZDK\L(N32W=MDEUE)V45U;2.3\!_P#%Q/BCXK^)
MDO[[0/"(N/A]X#)PT4TT$@?Q=KT!'#&YO-NEV\Z\O:Q3PNNZ(&OH:N5\#^%+
M+P1X3T'PKI_,&C:?#:M,>7NKK'F7EY,W5YKR[>:YF=OF:25B>3755522E+W?
MABE""?\ +%65_-_%+^\V^I%"FZ=-<W\2;=2J_P#IY/62](:0C_=C%!11169L
M%%%% !1110 4444 %>-ZY\&H-<UC4=8;XF?&/2FU&Z>Z.FZ'X_O--TBR+A1Y
M&G6$=JZ6ELNW*0JS!2S'/->R5^4GC/\ X*;VWP[_ ."GFB_L$>-?A:FC?#3Q
M'\._AA)I7[1K^+"UG;_'WXTR_$_4/A/\&];\(OH44&F6OQ \/?!?XE1>&O%1
M\33-?>--+T7P>-%%WXCTVX:HSE!MQ=F]'HGUOU3,ZE*G5252*DD[I-M6>W1H
M^XO^%#6__17/CO\ ^',O_P#Y#H_X4-;_ /17/CO_ .',O_\ Y#KY,^$'_!3+
MX.Z]\%+CXO\ QZO=%^";W?[0WQ[^ O@_PI8WGB3XC^(O&EU\$?'GB;PI<ZMX
M=\.^&/"<OB[5Y;G1O#K>)O$%KI/AK4++PI:SG^T=4>U6.]FL?$#_ (*K_LB>
M _B7^RU\/T\7ZOXRTS]K+P]XY\3> /B#X"\*^*O&/A'3=.\%QV42Q:Y)X<T+
M4]1BU/5M9N;O0)=(M[*75/"FIZ7>KXVL_#MN(IGT]O5_G?W1_P O+\^[,OJ>
M&_Y]+_P*?_R1]5_\*&M_^BN?'?\ \.9?_P#R'1_PH:W_ .BN?'?_ ,.9?_\
MR'7+Z5^VG^RWKGQJG_9YTKXR^%[WXN6^L:CX:_X1N.+65T^Y\6:1IHUC5O!>
MG>,9-+3P1JOCG2]+\V_U+P1IGB.[\5V-M::A+=:/$NG7YMNZ\)?'WX7?$KP%
MX_\ B'\*_%FD?$+0OAQXA^)W@GQ'<:%/-Y-EX^^$.J:KX?\ 'G@^YEN;>)H=
M5\/^(]&OM%U#$<D,=U [1231;78]O5_G?W1_R\OS[L/J>&_Y]+_P*?\ \D9O
M_"AK?_HKGQW_ /#F7_\ \AT?\*&M_P#HKGQW_P##F7__ ,AU^0/[._\ P6WN
MOCA^Q+X+_:1U;]GVS\"?&B[_ &B?V2_@O\1O@)??$2YOK?PGX0_;"^(GP\TC
MX4_%K0O&:^#;:;Q+X=U[X9?$:P\9:1$WAS38;WQ/H7B?P3/?V<NC7.JC]1+S
M]NG]D^P^*NM?!.Y^,NA_\++T%?%27GA^#1_%=Y;7>H^!M&FU_P 9>'- \1VF
M@3^%_%7C+POIMK?-KO@CPQK6K^+],O=-U32KO1(M5TO4+*V/;U?YW]T?\O+\
M^[#ZGAO^?2_\"G_\D=U_PH:W_P"BN?'?_P .9?\ _P AT?\ "AK?_HKGQW_\
M.9?_ /R'7S'^RU_P5$_92_:I^&_ASXB^'/%&L^!4\5?&*^^!>A^'_B)X7\3^
M&M2U3XAR^//B%X)\(:+I-]?:+#HFM77CB/X<:SXATJVTG4;RXT>PGM].\4QZ
M'KT=SI</M/CS]N+]DOX81>-YO'WQV\#^%U^'/Q4T?X'^-%U&YOQ-H?Q>\0^#
M=(^(.@?#J2W@L9KB\\6:YX.U_1-;TC2=.BO+C4H=4LK:S6:^G2U)[>K_ #O[
MH_Y>7Y]V'U/#?\^E_P"!3_\ DCL_^%#6_P#T5SX[_P#AS+__ .0Z/^%#6_\
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MAZA(;G[-J,BV-\UL>WJ_SO[H_P"7E^?=A]3PW_/I?^!3_P#DCT__ (4-;_\
M17/CO_X<R_\ _D.C_A0UO_T5SX[_ /AS+_\ ^0ZY7X9?MJ?LO?&%?&A^'WQ>
MT+6)/AYX(M?B9XTMK_3O$?AB^T#X=WTFN1V/CBZL/%>BZ)>R>%+U_#6N_8]>
MM;>XTVZ73+B2"YDC",_S3^WG_P %#/"/[./[(/P^_:%^%GBCPWJ<G[0/C#X
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M?=A]3PW_ #Z7_@4__DCZ6_X4-;_]%<^._P#X<R__ /D.C_A0UO\ ]%<^._\
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M]7^=_='_ "\OS[L/J>&_Y]+_ ,"G_P#)'TC_ ,*&M_\ HKGQW_\ #F7_ /\
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M"&:X/;U?YW]T?\O+\^[#ZGAO^?2_\"G_ /)'TW_PH:W_ .BN?'?_ ,.9?_\
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MW]T?\O+\^[#ZGAO^?2_\"G_\D>]_\*&M_P#HKGQW_P##F7__ ,AT?\*&M_\
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M=0-[H\#:?>K >WJ_SO[H_P"7E^?=A]3PW_/I?^!3_P#DCI_^%#6__17/CO\
M^',O_P#Y#H_X4-;_ /17/CO_ .',O_\ Y#KY0^/?_!6/]BSX$_#K]H'QO+\3
M1\0M8_9Y\$>/_&.O^!O FA^(]3UCQ;-\.5-MXB\/>!-=DT:+P=XGOM+U^2Q\
M,>)-3TKQ!=^'O VLZC:IXZU;PY;":XB](U7_ (*-_L=^'/AMX ^*?BGXM_\
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M&_Y]+_P*?_R1ZK_PH:W_ .BN?'?_ ,.9?_\ R'1_PH:W_P"BN?'?_P .9?\
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M^ROVTV]BU/3FO;2"Z:PU*".:*#4+(SQR&UO88KB>.*[@\N>..:9$D"R.&NT
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MS]HVU^-O[,/A;0+NV::#X@V6@^ +.X^#5[);"Z-C_:B:W$UO:)/'#Z=\'O\
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M?$FG'6=)U?\ L#6KVQDNFL=/-U&;1_Z%Z* /P1@_8P_:I^&?Q=7]I7P]\,]
M^)NH?#K_ (*.?M6_M"Z3\$XO'/A32-9^(WP<_:'^#/@KX8:-XP\*>(?$>HZ=
MX,\/_$KP7J>C7NHV.B^,M5T6.70I]?M4U:ROKVQCN]?X>?L/_M#W_P"TE\+/
MVG_&'P[\+>"6\:_\% /BU^UE\1?A7!XK\,ZPWP4\%ZG^R!H/[-?@.WN+S2Y+
MK0O%7Q-\4:GX(T_QQ\1+OP3?:KI-GXC\7WT6G:OJUMI$VN:C^Z]% 'YQ?LC_
M +.WQ6^$_P */VW_  C\0_!_A+6;WXS_ +8?[:GQ<^''A#7O%"3>$/%GPX^-
M?BW4=>\$V'BO4M%TWQ!<^&-,\5I?W"^*+./0]5U718M0U"XDT;4+QC:W'YQZ
M)^P[^V9KGP^UGX8VG@3QIX,_9U\,?'_]A'Q;\$?V>?VA?CI\-/CKXV^%>B?!
M'XRZGXS^. \&_%[2)-;UZ_\ @+;>#9/!NF_"/X8_%'Q[X\\:Z!J7A?Q#!H$7
M@WPUJVE>&1_1S10!^#?QV_8<_:AUW]I/]J?]H;P1X2\+>+=,@_;"_8%_:J^$
M'PTUKQCI&EV_QPTW]F_X'6'P\^)GA26ZNY3IO@+QI;ZFIU#X>ZUXPA31+CQ1
MX9\,76HW>G:2O]KZ=A_$[]C?]J_XM^)OBW^V-#\&='\#_%37/VK?V!?C?X4_
M94U'XD^!YO$OB3P+^Q!K&IG5SXH^)6@7^J_"[2_BQ\4+3Q7X@30&B\0ZKX;T
MWPOX3^'>C>(?$=C?/J<6C?T 44 ?SZ^&OV-/VPO&OQ:\>?&;QQ\(O#?PY;XB
M?\%7OV4_VO;;P=_PM'PKXJU7PY\#?A9^SUX9^&_B2X\0:CHY&D2^.=+UK1Y+
M?4O#.@7>LV,]T97\.:[K^E+!JEQS6F?L7_MHZ?X5_9F_9H_X4+X.N?!G[-?_
M  4\\,?M;ZO^T7>?%OP:+/X@?",_M#^+/B;-=>$O!D<%QXZC^)&G^'O'+P^,
MM+\76/A?3W7P]>P>%]?\6S7NGVLW]%]% 'YB?MA_#/\ :*3]L/\ 8S_:B^"7
MP.TCX]>'/@#\-OVJ?"OQ \(-\1O!_P /O&GVCXU7/P"TOPO<?#N7QQ]E\-:G
MX@MH?"'B34M1BUS7_".DQ^&--UVW'B/^W;[0- U_\XM-_P"":W[1_P /M:^"
M7QWUSP!\1_B+J5['^UE<?$_]G;]EK]K[QO\ LI^+_A#JW[3/QT_X7OX>;PC\
M3O!_Q9^"_AKXB:1X:@MH_!?Q1TG4?%EEI^I^)I;/Q5X.L-:L+1Y%_I8HH _*
M?XJ?L$77C/\ X)5>+/V&_@WX>LO@!JVO>!)'\,>#M0^+WQ*^(FG^'_$5Q\38
MOC#J/@[Q3\:+[4)_B7JMIXRUS^T?#_C7Q;I^I7^HZ7%XCUF;PU<:G9:?IC7/
MR/XA_8<^)WQ,^!_[26E>'OV._B%\._C+^TY\)_"7[)GB+QE^U_\ MW>-OVR]
M5\)?"KQ1XAO=0\;^/='T_P ;?&;XO:!'X?\ @W'K6M^-?AQI6C:WHOC/Q/\
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MCU%5\,#3 ?WIKS.^^,'P^T[XO>'O@1<:W*WQ1\3?#[Q1\4].\.6VD:S>1P>
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M,UTF6Z\/_%/ACX5?#'6?VQ_B_P#$3Q)\!]:^#W[4/[2__!+[X2^+/V?/#?Q
MU'Q3JOQ<7XT:E\&_C1H'Q0\(1>.KV2"/7_BIX/T6YTSPSXYU#4GLM<DDMX-7
MN[2SN[R5Z_IZJG;ZA87D]Y;6E]9W5SITR6^H6]O<PSSV%Q)$D\<%Y%$[26LS
MP2),D4ZH[1.DBJ48$@'\F=K\=_BO\6-+_9(T3]DO6_B[XA^/GP?_ ."'?[8O
M@?5(K/P[\0K-_#'[8FA_!_\ 9\TGP;X'\2W/B73+30[KXYZ-X_T/4A::%K4E
MWKUI?.+V=?L&J/-<^,>,-"_9X-UXD\8?L+:?\6[NPM_^"&G[>FE>.?%MA!\:
M[N:'XY2_"KP??:79:[KOB=':W_:7NKF*YO/&<&GW,7Q%N=7BLY]=1]1BM67^
MS^B@#^1G]I[PGX]\>?&_4M#^/G[0'AG]GG3+C]C7]F"/]B;QA\0_V=_VD/C?
MX^LO&TO@K4V^)GBO]E?4?@_^TY\$M/TW]I_P]\5?^$*O+SPSX@\(>/O&_B.^
MM_AG!96-WH$U_H^I_7UAJQ^$_P#P51\,3ZGXBMOVJ_B!\3]5\->%_&9O_#_Q
MH^$?[2/[*6F>#_@'X7M;_P 9Z%I5I_;'P?\ B!^QOXYF\.^(?%_B3PY-8>!M
M2TGXK?$R:73O$WQ0N5DTO0?Z**\E\:?'+X9?#[XF?!_X0>+/$,NF?$'X\W?C
M2Q^%NB)HNNW\?B*Z^'OAIO%_BV.;5M/TVZT?0QIGA]&O4?7[_3([]A]DTYKJ
M\(@(!+\$/C/X$_:&^%/@KXT?#*YUV\\!_$#2FUGPU<^)O"7BCP+KTU@EY=6!
M;4O"7C32-"\4:'/]HLYP+36=(L;HQA)A"898G?U6BJ=_J.GZ7;/>ZG?6>G6<
M;1))=W]S#9VT;SRI! CSW#QQ*TT\D<,2LX,DLB1H"[*" 7***\W^,/Q;\ _
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOX=?\.:M\$/&G@C1K3P_#HEAK'P\U[QM;6UWXMC_ *@[#X:_#K2K'P-I>E^
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MN]!_L6]\/>(+O5?B7XBM'\)>!A+YOX&^+?[2G[5-O>:YXD_:T^-_P[A\(_\
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MM*_99^.FG?'KP)X9^(6E6OA34/!FK>)_#OA;PQ;Z%J6BSZ2+CQDVK+^\_P
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MQ:^*_@K2?@C\)OV'O%VE_LT>&=<B\.?#OPY\2/C/\#_%6O?%2S\7V"6<VO\
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M#VC64*O)=W$&D:)I<%G8VT0>66YFBL[9$#R23.N79B =)1110 4444 %%%%
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MB7^D0Z+\,=:N/ /@V[^('A?6(=>L_$NG:=J.G,J?VO)); 'Y_P#_  6IUO\
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M+/PU_:BT+P78>-[SQ?X6\5?"_P ;Z=\2?A+\4OAOKZ^%_B5\+?'6G6UUIO\
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MU\./!MO>7AOM2L_#?A/1K70M'6YOWC0W5[%8V<)FNFA7SIPTIC7=M !_-_\
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MZUXPT3PIH6FZ+H_B6ZM&DO;W3_#S^-/%GB^[\):3>75AX8N=)2>1F\.\-?\
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M4OA\-)U3^S[+_A*+SP5XG\ S?V[:BWF_M73!H'B[5PEEYEOMO?LMSYI\CRW
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MSX1^"OCY^TA\2IO@M\;/"'[$7[,?Q U#2='TY_%7Q9U+PSXYF_:*NUUWP;\
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M_!O[&O@W6_"GQ+L/'^BZ)XMTC4H+^YT72=9T;3Y[#08(XI(9>N;]D+]IC4?
M_P 1/#_B[]CC6/'GQ&^)GCWX=?%#6OVCO%/_  4@T(_'[1_'WP<DM9/@]XC\
M'^*M!_91T+PSX4?X8_93'X9TG1_!EOX?N(;_ %F'Q)I&OQZ[K*WX!TG@+P%\
M+?#GQ._X*-?L\?'+XQ_%S1?V+OV2?$OP.^/FB-XA_:+^+6@-X#T+Q]\ M7\1
M^/?!GBGXR)XUMOBGJ'PYT77[=OB7I7A_4?B#YEAKES8Q-+<Z#%:Z-)S?@[XG
M?M!_#;_@DO8:)::W\1[#XS?M=_&'Q5\ OV&8?BYJ^JZU\8/!7P\_:6^*/B+1
MO@#K?CG5=<N)?$M_KOPD^ 5QJGQPU"'Q)>WOBS3/"/@T:5XFNYM>TS47'&^-
M/V$?VE?'GPRO_AWKW[+7CN35/$WQ\\(_M*_$KXI#_@I-X,N_B+\8/BI\/;73
MK3X>W7Q375OV.=3\ >*O"7@5-"\,7'A?X>MX"M/ VFZCX2\,ZO\ \(_+JNE0
MWI[_ $'X*?\ !2^S^//[/WQ-\;_ >R^-O@[]G;3_ (M^(O!VE?&+]NGP3K'C
MF7XQ?%+2='\$VWC"YUCP=^R!X(\-C0_!'PV7QMX<\-V":*NLQWGQ$\17%QJ4
MUF8[8@&M\6OVX8/^">WB+X5?LN?!+P]\+_$WP*_9VU3]DC]FKQ!\.O#'@+]H
M[QYX_P#"OAWXH^)? ?PB\*:CXQ^-?@7P#<?LU_ 3Q'I>F^)M)\4Z?X%^,WB=
M/$GQ"TO3IKW3[^SO_%OAV"X^G_ G[7W[37Q8'QY^-7@'P!\%[;]F#X+?$K]I
MCX/KI7BK5O&-M\;-?UC]FA_&'A#Q+\2(+_3'N_!D/AO4_BSX,U3PSI_@"XTB
MUUR;PLB^+&\907$L&AO\6?&#]B_]H_XT?$;QCX^U[]COQ%X:TOXB_$WX0?&O
MX@?"OP+_ ,%*]+\._"OQK\7O@=K7A+5_ ?Q"\0Z!_P ,JWFKWFK0IX&\+Z5K
M&DIXAA\):S8Z1875YX<;7;&QUFU[.R_9K_:PT?QY\1?%7AO]D#7/"G@SXJ>)
MOB#X_P#&GP)\-?\ !2?3M)^">I_$SXI>&K[PSX[^(C>'(?V6CXB.M>(8=2OM
M<OM F\6S_#V;Q=</XL?P4VO!+Y0#U']FK]N3]H[XR^+?V2_!'[0'@SX4_#[P
MW_P4(_9(\3?'/X17/P.\2>-+OX@?">]T7P-X \4ZIIOB?Q%XJL_[#UJZU'P]
M\0H=<\.:QH>B:._A;6+!-#O[/Q*(O[;N/._V)6OOAM_P4:\;?#&P\(_M(_LR
M?##Q9^R%IFK>&/@-^U?\8]=^,GB[XY?$CP;\5IH?%/QN^'>KCXN_M">!?#EC
MX"\+:_I7A;QAH.D?%;1_%_B%_&>AZWK'PRT_1M L/$%XG_#-O[2(L/V;]/B_
M8-LK*/\ 96_9T\:_LO?"B\TC_@I!+H&M6GPS\>_#KPO\+];N=1\0:!^SEIFN
M_P#":0>&O"&CRZ)XPT74=$U;0];2;6=-D@O&A:'D[+]E/]L>:?XA:[XY_9Z^
M*7Q2^)'C?X/Z_P# O0/C%XT_X*=Z!I_Q4^#?P[\5W,=_XIM/@EXE^'G[(W@2
M#P#XB\1:C9:)?ZOXVATR_P#&5U-X<T*'^W4LK-[6< [K_@L3X;UWPSX(\2_&
M?P)X5_:KL_B-X?\ "W@;4-#_ &F? _QFU[PW^SI^R;HG@_XAV>I^*OB)\0_A
M1X*^*-GXT\<6]EX=O-8U[QAIVD_L^_&:/Q#H.G6NF:E<:#I%M>WFG\+_ ,%(
MXIO!NL_#O]H;P,/VHO#^IW_Q2_90\<:M^W39_&;7!^R'\&/A,?%?@G0?%6A7
MWP4\$_%35-7UGPUXTT/3KS^W8=8_9OU[P@=6^+M_XH\3?%3PYH%C+>^%M?XP
M?LV_MH_&[[5HOC#]GGXHQ?#+Q'X&\'_#WXF?!?2O^"H6GCX:_%W0/"-K)ILI
M\<PZQ^REK'C&TOO&FB&WT/XAW'@'QCX(C\9V%HDVKP2ZG>:KJ.H1?$S]F']K
MGXM:]?1>+_V5_%\WP8UG7/!>O>(?V6+/_@I3H$/[.FO3> K7PW!H6C7?A>?]
MDVZ\8:?X,>?PCX>U+5/ 'A[QWHO@?4]0L9Y+GP\T.K:U;ZB >@?M??#_ $/P
M[^V1^R-:_L[?$7XVZE^V7\7?VF/"/QB\:V-A\</B)K/@;PU^QEX(@ETKX[ZE
M\0OA%-XD;X/:%\%KKPI/IWPR\#,?!NG^)==^+7B+PG<>'-;U+Q'9>(=5MOVY
MK^?W0?V5/VV-+_:/^(_[0?A_X6_&'X8Z_P#'+QOX*U_XJ6_A?_@H9\(=;\-S
M:%X,CBTKPYX0TW2O%/[#>M^)++X=^$=$EU*#0O &B^+M)TNVDU;7[VREL]>\
/1ZQK-W_0%0 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img147150826_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '? MT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.U74;;4;OQ#JME>:'I-O->Z;>+K%K/;:M::5"J7,GY'_ +0.G_'+]FWX(_\
M!-[X:_ #P)_P4<^!G_!/V[TKQ_J?QUT/X)Z*US^VSX2USQ!KNIZ]X6\-^.K[
M0+.>_P#!K75_JQN/L5E)IUFUM>ZGI\C76MZ;I$"8/["_P-\9>"?AA_P60UG]
MHK]C3]MCXG_"+XU:S\"=9\/_  P^,6F^(]8_:6^-'P[OY_B)<:IJMEXJN9+9
MO''Q3\(:-XATCQ3K\.@:[-K.A>([6WT*]O-/UR$>7OB<DRF.6\0XFAS)8?%9
MA#*I5L936.I_5.+\NR6EA<;236"HU9Y7BL1B5S3Q$:D:=+-I5L-@JCPL<\'F
M./J8S(</B)1E*MA\LJYDL-AYRPF*IXW)LQQU2O@ZLO\ :'[/%8?"T:D8JDL-
M6J3RYK$8C]^OVK_9G_X*:^%/C]I'CCQ;XV_9L_:?_9>^'/A#X37/QTL?BG^T
M)\/+3PO\.?%OPLM$MKFXUW0/$^E:SK5K=:C#I=Y;:V^BPI<2RZ/*M[9W-VC(
MK^!_#;_@N7^SYX\\;_"O3]=^ W[5/PH^#/QY\:#X??!']IGXF_#*QT'X,?$+
MQ3+>OIUA;6NLP^(KV^L+'6;V*2'2[V2RN2JJ\^LV^C6]IJ4MA^07[,OP&_:O
M^,'A/]O']EK]F.+]M&U_8*\6?LF^)= ^#FA_MS>')/!FO>'_ (YRSZ1=Z)\.
M_AQ>:FT4,7AV:*'6=#U$Z0-.T*VLKQ9O$EDE]'INIZEQ/[,'P9^%GCGP?^R_
M^S5^TS\"O^"W^N?&+X;^.OAWINJ?"74+[Q;??LI?#GQ1X:UR/2K;XBZ/!XF:
M/P[X-^&VBZ1<W.HM>Z79076EZ/=:EIVDW<]C/%J=SZU+AWA^6958U(5GAI0R
M6<,OHXAK,\/@,?BLXI8[%XFC5K)0S'"4L'@FHK$5<MI_6*.+KQ^K9C0AA?)J
MYUG$<MYX2I+$QJ9Q3J8V5&^7RQ>"R_)L1E^'H5(T^9X'%U\=CE4=6C''RE@Z
MV"H26)P5:I7_ *M/V[?B'XQ^$O[%_P"U-\3?A[K4OASQSX#^!'Q-\4^$M?@M
MK*\GT7Q!HWA34[W2]3@MM1MKRPGFLKN**XBCN[6XMS)&OFPR+E3_ "VW7[8O
M_!27]EK]BO\ 8R_X**ZK^W-=_'C2OV@/'ND>%_%W[+GQ)^%/P^@@U'3[R_\
M%0N8_"WB[1((/$UQ+%;>$VAGN-+M=#N[&XUBQF:ZN;>-["]_I\_X*%>%?$WC
MC]A?]KCP=X+\/:UXL\6^)OV>_BIHGASPQX;TN]UOQ!K^LZAX0U2VT_2=&T?3
MH;G4-3U.^N'2WL["RMY[JZG=(8(I)'53^3G_  2A_P""/G[,OAS]GO\ 9<^/
M_P"T#\ O'#?M.:#H#>(;SPS\:]8^(4-K\/?%MKXGU233[N#X0>)+ZRT/0-2@
MM+32]0MK/5O#LHM;KR-4@M8+T0W">#PMB<LP.%S''9G3HU:6'SGA7VE&6!P>
M8U\9@73XEK9AEM&AC90IT*680P]"EB<?3G[;!RCAY0A.4XV]K/Z.+Q-3+<+@
M_:>TKY=Q59QQF*R^E0Q:7#E++L=6Q6#4JTIX&KB*];#X1Q<,2GB4Y04)7\N^
M.O\ P5H\;_LD_P#!2[]M'1OBYX^U;5?@-\-/V4? OB;X/? $V>@V\VO_ !L\
M6Z9\*)M \/:+>P:0OB*?5-7U+Q)KDFK32W][#INB_P!K:F]H]OI,,45KXS_%
MK_@I?^S9_P $>?CU^UE\>/CUKVA?M0_$WQ9\-_&G@_PM8^%O!5A:_LY^!O%O
MQ#\/:;;> M(LG\-RDZQ?:#J\PUV/7#JEYHB-8Z5%-'K-AJNHW_GO[2/_  3.
M\2_ML_\ !5[]O72/B/\ "_QYX=^%GC[]DGP5#\&_V@K_ ,$^((? FB?&?P[I
MWPB_X1R\\.>-9=/CT+4]4TZ^TO6=.\0Z'IFJ/J5QX?\ ^$AT^2. 2-+'A?%Z
M[_;T_:*_X(I_M&_LN?'7]F3]H&__ &I?V?O&?PG^&=I>6WPN\<:W-^T#X0\/
M_$S0Y-(\>?#JZL]%GD^)$FE:+X?O(?%NM>%EUBTDM;72_%5W>*OB(K#W4Z>6
MRR'AV5"E@%F4_P#4AYO"O&A*;R.MQ7*EBI495-9XUXWV5#/IR3Q3RF670;C@
MIY@JG/!X^.<8RG7J8JK@:?\ ;4*%6"G#FSJEP9E]3#.M"G[E/+YT7C:^74Z?
M+06=+&RJ*6)A@'#HK/\ :7_;]_8G^/?_  3*MOB!^V//^U_\-_V_9/!-GXN^
M$WC?X6^!O#'B_P"'R^+HO L<VN>'-?\ "H;7+RSTJ3QYYUG?3RV&FW,GA^]M
MM0T>[\]9[#;_ ."MVE?\%'OV1/AA\1/VW;3_ (*::SH:Z7\9=.TOX8?LX^%/
MAKX;\/>!8?!7B3Q5<6GA;PN;^[O+K_A.?%&D>'%76?$3>)/"FI1W\&G:TCWD
MMO;0WC_HQ^P-_P $G_V1/V=-)^"_Q]A^#_B"7]H^#X5^"9;[Q)\5?%?C7Q;K
MO@'Q'J?A"Q_X2;3O#_AWQ7JMQI/@^_M+^]U*PQ;:-!JVC1M<Z;:W-I"UQ _X
MA_M,?%;]I_\ :)_X*$ZAX^_:]_X)P_M^_%_]E7]F7QIKVG_LX_ /X2?L^^/M
M5^'?C'7M URXTZU^*OQ$U^^T.#2_&4.O1:?!K=I:Z5'?:5?Z;<Z=HL=[_8%O
MJT?BGT)5<#B^)<)A<O6!IO*<9G.(S;,)Y9E-.CBLHI9UA\10R?+\')SPV,Q4
M<+3AE.$S2J\-BJU+%UZM6MAL-1E*KYU"&*P^08C&XY8NM#'Y?D^'P&!CC\?.
MNLWJY9C*4\SQE9*-?!86=>LLPQN H^WPM.6 HP]G6Q%6G"/]77[*_C_QS\5O
MV:/@#\3?B;HT7A[XA_$#X/?#OQCXUT6&UDL8=.\3>(_"NEZKK%O%8S%I;*(7
MMU,\=G(S/:(PMV8M&2?Y]/V8-0^+7[4_QK_X+@_M??#+Q?JWA[XM^%+3Q%^R
MY^R[XAL8[*_E\)6GPITC7=1M(=&LM6M=0TQ#XDUGPUX2OKL-93*;O5=3N$!F
MN"Y_HD_9_P#BEJ'QK^#?@'XI:K\+?B'\$]0\8Z.^H7/PK^*^@R^%_B'X+>"_
MO-/72_$V@S*DVF7CQV:7MO!)'$YL+NTE:*(R&-?Q!_X(56S?#KXG?\%3_P!G
M;7P(/%GP\_;2\2^)[JSN!MGN_#GC5]:LM#U01O\ /):7]MX9%U%+@H\5Y"P8
MB4$_-0C)XCCZKA\/2R[&TLAS2.#PM*4*]/+5B^*N'L#BJ="5.\)PPV$Q-7 N
MK2TG@Z]>,6J=25_:C-4L!P;'$5IYAA99]D2QN)K*5&>8K"Y!GF887ZQ[5>TI
MK%YE@<%BG2JIMXJE0C.,IQ43YXUC_@J1^T'K7_!"OX6_&WP7X\U6\_;-^)/Q
M1T3]F+3/%-CI?A^?Q1>_$Z'X@7[7=W;:-)I3:&=:UCX=Z1$ /[)6..[UJ*YC
MCAN&CD2UK_\ P5*^/6J_\$*?AW\=_"_Q U"+]L3QO\2] _9BB\80:7H+>('^
M*-M\0+J/4+]='?2GT5=9U;X=:1]I9%T@)'=:NMS%#%-L=/F+]F_]A;]J;PO_
M ,%/_#7[,6O? _XH:;^Q+\#?VXOB]^V/X2^)^H^!/%,'PIU,77A#3[CX;Z9I
MOC.YTE/!^H7%G<:5H&E16%EJT]XNHW6LPR6L<EI="HOA/^PC^U)I_P#P5 TO
M]EC5O@=\3[/]ASX:_M[>.OVV-#^)U]X$\51?"2]@/A.VUOP?H-CXTFTI/!]]
M(L]CH_A@Z=:ZM+>C49]4MFM$>"X ^PIX7AO'5E[6&!H4<\QN6>(L8QE0I2P&
M28&KD4<WX=YHV6'H5Z6(XBE3RJ"C4FL+AVJ4W.FCY^I7SK+H2=*6*Q%3A^CF
MO"5YPJUHX_-,7#BJ63YI4BY2EBYPE@.#X_7/WJC]?J1JU4ZN)<_VT^*'_!4K
MPQ^R]X@\._LO/\*?VE?VT_VDOA5\&_!OBS]HJ3]GWX>Z5XH/@F&/PWI<NL^*
M/'%T-1T"PL=6UR64:[#I&DZ>UI';ZE;1SW&FS3VUK)TWC3_@LA^ROHG[.7P$
M_:%\!:)\6?C/-^TYXLN_ 'P7^#GPX\(6VH_%WQ%X]TJY6Q\0>%-1\/W>L6NG
MZ5J'AO49;:PU7R]6U 7$U]I\F@+K=K?6UQ)^+W[1_P #/&?[-?\ P4X_:]^*
M_P ;=!_X*8V/P(_:8@\*^*?AO\6?^"=OB#QEISWNIV6E6EI?^!?BI'X/F@,Z
MZ=.-1LM#T[5;J*YLQ:PWMCI]UINL2WMGZ1\1OV<_V,O"7_!/S]GCPAK'[%/_
M  4_T3X6:K\6_B[\2O!/C3P_X6&I_M<_LW^/WN]-L=(\9>+?#6FL(]$\/?$V
MUTR"]TB"_M+VUMSIVEW4UN=8N;'5;7P8Y=DV)R_*<SQ%*O4K9I4R?&8MY;+#
MTJ<,7CJ^*K9WD<*%6I2P^$E@H)8; T%&.)]IA90E*3QN&]EZKQ68X3'XW+*%
M:"H9=#,,#A)YA&M5GBL-A,IISRO.ZM2E">(J_6<5#V^.J<TJ$:.(E24(XC#2
M]M]#_P#!1;_@L)\;/A+^Q/X:^,?P6_9N_:;^ 'Q7\1_%R;P%JI^/'P'T]M#^
M',?A270+O6;+QM+?ZS>Z;8+\0[#Q'9Q?"_4X[6[7Q.^E^(UMQITVE^8_V7XJ
M_P""NWPI^'?P'^$'Q.\<_L__ +6N@_%3XY>+M0^'OPF_9>\0?!E/#O[1GQ&\
M2:)#IHU/6M"\ 7/B2>U@\$S3:I8RV&OW&M![V"]MTL-.N[MA:U^(_P 2/A3_
M ,%&?VA/^"&_Q6T'XQ^#OCU\3_&/A3]I7PYXN^"NC_%#PKJ;?M*>)/V=?#-_
MID=KJWB[PJHU#Q3J6KVT]_J6II%?OJNN/I%O>W$%SJ.BVNEW<W7?MT1_%O\
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MHVNK?6^GRS6>LWWB.PO-1T>WN;VP62]GMM-NIUO;)M/T^^&HZ5_:'CG[;_\
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MGA:]EN(I7DGW?B[X0_:Z_P""F_@7_@FIX8_X*DO_ ,%"-0\575M\5W\$ZO\
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M:7<&XEU>_,VH^'M5M]=2WGO]&M?*_P#@I.?CE\$?^"NO[&W[7/@#]D?]I/\
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M!>V<_E2I/%YUM<QRP2^5/%'-'O1MDL:2+AT4CF/^%;_#O_H0O!?_ (2VA_\
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MNC_A-?!O_0V^&?\ P?:5_P#)=4?^%;_#O_H0O!?_ (2VA_\ R#1_PK?X=_\
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M_P#D&C]U_P!//NC_ )^O]+4_VCM1^^?EY>OX>9>_X37P;_T-OAG_ ,'VE?\
MR71_PFO@W_H;?#/_ (/M*_\ DNJ/_"M_AW_T(7@O_P );0__ )!H_P"%;_#O
M_H0O!?\ X2VA_P#R#1^Z_P"GGW1_S]?Z6I_M':C]\_+R]?P\R]_PFO@W_H;?
M#/\ X/M*_P#DNC_A-?!O_0V^&?\ P?:5_P#)=4?^%;_#O_H0O!?_ (2VA_\
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MT445D= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?+?A+]C_P"#O@7]JGXF_MA>%8/$FC_%CXQ>!=!\!?$:SM=:5?!7B6S\,R:>
M=%U^\\-_8L_\)59VFEVFFIJZ7ZH;%9HVM#-<W$\GU)16M&M5P\YU*%2=*=2A
M7PLY0;BYX?$P]GB*$FOBI58V4X.\9.,96YH1:BK2IUH*G5A&I356A74)*\56
MPU6->A52Z3I581G"2U336SDF4445D6%%%% !1110 4444 %%%% !1110 444
M4 >*^'?V=O@SX5^-OQ _:.T3P3;0?&SXG^'O#GA+QGX_O-6\0:OJE[X7\*0Q
MPZ)X>TFSUC5K_1_"FC0F**YO=.\)Z;H=KK.H11:IK46H:C&ETOM5%%7.I4J*
MG&=2<XT:4:-&,YRDJ5&%W"C33;5.E!RDXTXVA&[LE=DQA",JDHPC&56:J591
MBE*I44(4U.HTDYS5.G3IJ4FY<D(0ORQBD4445!04444 %%%% !1110 4444
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M(H_X7Y^U/_T;/\+O_$E-3_\ G$5T?4L7_P! ]7_P%_UU_/LSG^NX3_H(I?\
M@2_KK^?9GV_17Q!_POS]J?\ Z-G^%W_B2FI__.(H_P"%^?M3_P#1L_PN_P#$
ME-3_ /G$4?4L7_T#U?\ P%_UU_/LP^NX3_H(I?\ @2_KK^?9GV_17Q!_POS]
MJ?\ Z-G^%W_B2FI__.(H_P"%^?M3_P#1L_PN_P#$E-3_ /G$4?4L7_T#U?\
MP%_UU_/LP^NX3_H(I?\ @2_KK^?9GV_17Q!_POS]J?\ Z-G^%W_B2FI__.(H
M_P"%^?M3_P#1L_PN_P#$E-3_ /G$4?4L7_T#U?\ P%_UU_/LP^NX3_H(I?\
M@2_KK^?9GV_17Q!_POS]J?\ Z-G^%W_B2FI__.(H_P"%^?M3_P#1L_PN_P#$
ME-3_ /G$4?4L7_T#U?\ P%_UU_/LP^NX3_H(I?\ @2_KK^?9GV_17Q!_POS]
MJ?\ Z-G^%W_B2FI__.(H_P"%^?M3_P#1L_PN_P#$E-3_ /G$4?4L7_T#U?\
MP%_UU_/LP^NX3_H(I?\ @2_KK^?9GV_17Q!_POS]J?\ Z-G^%W_B2FI__.(H
M_P"%^?M3_P#1L_PN_P#$E-3_ /G$4?4L7_T#U?\ P%_UU_/LP^NX3_H(I?\
M@2_KK^?9GV_17Q!_POS]J?\ Z-G^%W_B2FI__.(H_P"%^?M3_P#1L_PN_P#$
ME-3_ /G$4?4L7_T#U?\ P%_UU_/LP^NX3_H(I?\ @2_KK^?9GV_17Q!_POS]
MJ?\ Z-G^%W_B2FI__.(H_P"%^?M3_P#1L_PN_P#$E-3_ /G$4?4L7_T#U?\
MP%_UU_/LP^NX3_H(I?\ @2_KK^?9GV_17Q!_POS]J?\ Z-G^%W_B2FI__.(H
M_P"%^?M3_P#1L_PN_P#$E-3_ /G$4?4L7_T#U?\ P%_UU_/LP^NX3_H(I?\
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M":?!_2_A;I6M^.?#N@:1X\UO4?$&L:EJIF\ WOB;0XO#V@1ZO-JBPWVGK/\
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M.#I8VI&57]Q&M' U,3]5>(?U=8IT/;WI\T7]'_&;]O']FCX:?";X??''X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?*?AG_D];XP_P#9M_P(_P#5A_'B
MOJROE/PS_P GK?&'_LV_X$?^K#^/% 'U95";5=,M[^STJXU*P@U348[F73]-
MFO+>*_OXK-5>[EL[-Y%N+J.U1T>Y>"-U@5E:4J&!/XW1>.?C9X2_:T_;_@^$
M_P $;3XOV6I6?PRC\37EY\5M$^'!\)01?#*=;:Y@M=8T/67U\W,4UY*8;-[-
MX#8K&S.;I&C\U_9<\<2>$_#W_!/-XO#GA'4[T? W]KK7H=:UVUABUG3I?#%Y
MXIU&WLM/\27%Q#'HFFW[*UKJTLJM%]CEE+20IO:G3Y986&,G+EI2R_!8Z459
MU8K%9!G^>58>SE*-10P\<D=&G7E"-/&*O*="SH.$_P >?BWAWG*R6.2XNE6A
MG^>Y)7Q6(AF=/!?\(_BIP3X:4*N!QE3**6!S6IF#XQ6:5Z&78W$/(ZV"IY=F
M,I2QD,33_>2YN;>SM[B\O+B&UM+6&6YNKJYEC@M[:W@1I9[BXGE9(H888E:2
M661ECC16=V"@D5-(UC2=?TVRUK0=4T[6]'U*!;K3M6TB^MM2TV_MGSLN+*_L
MY9K6Z@?!VRP2R1M@X8XK\9_A/^T#^T?\<=+UB\U3QK+XC^&>I?LS?$OQW\3[
M1O@==^"]&\(^,=2\/ZS8>&_AWX;\:W[6G]MVRQ7=KXAMM7LYO$4NH6&F2K),
M;;4A<V-7]C/XG?M ?#6W_84\%>)/%W@SQ%\(/CWX'\::1H7@W3/"3Z9K7@F/
MP3HDNLZ9J5QXJEOI[S7=2U0NAU*-[:UTVV$EQ:V=H^V"]7JA@ZCJUJ%1QIU8
M?5513=X3J59<1PJT9RBI6G)\/U)8.I!3PV)I5HUXUU1G1J5,<-XSY3C<5D57
M"9+G,\CSBCC74S&5/+W4PLHYAP#@,OQKI4<RJTZN55*W'6'PV82HU:N:Y?F&
M%K8*OE<:N&QJP_[9UD:-X@T'Q%#>7'A_6](UV#3]1O-'OY]&U*RU.&QU;3W$
M5_I=Y)933I;:C8R$1WEC,R7-LY"31(Q KXO_ &H/BM\9+'XR?L_?L^_!;Q3X
M:^'>N_%Y?'NNZMX_\3>&(O%\6F:5X"TBWU+^R--T&ZO;&TN[K5Y)WBG9[B.>
M*)(FMIH&9W/P'^S_ /&+XN>!?AQI?PR\':WX0T3XF_'O]NSXT>"M8^(SZ'-K
MWA?PPUDNE:GXDUGP[X>OKZW34IK^Z/E^';'5KQXC;.4N2TQ2:/##4Y8EQY%_
M&A-82%XJIB:T<[R[(_=4FH0H1Q>+Q%.I4J3A.,\,Y1IRHSC5EZW$/BAEV0<0
M5,FJ9=F%?#Y?5KX;-\QITZ#HT\P_U?P7$&"RG 0>*C6Q&88G"YKE#E*O1PV7
M4XYA3B\?[6ABX8?]XZ*_(G4?VBOVOK#PK^T+\/- -I\2_B'\ OC#X \+Z[\3
M/ _PVL]3\0W7PM\8:->ZYJOB+2/A6NMPZ/K7C3PVMI#:7&BVM]]D>*\8R0AK
M22^.#XB_;,^*FOVW[/\ \/\ X2?$O5/&6I^/O"OQ \7>*_BUX2_9VG\1>,[C
M_A$];N]'LO#-O\&)=;CL]&U*QND^R>,KI[N:&V6WCOM+$<%R@F(TW.,94FJJ
MFL+.FH*?/4H8O*(YY#%*G*$:D*$<!*4FZL:<ZF(I5L)AZ=?$TY4UG7\7N',*
MJBQ67YYAJM*%>G*CB*.54JE3-,-QC5X$Q.1X9SS=4L;F&&XBI/#XO$8*IB,F
MP6&J8?&8W-L/A\5AYU?V4HKP']F'QK\4_B!\%?"/B3XT^$+OP3\29?[5L/$6
MCWNC7GAV6X?2]6O;"RUI="OWDN]*37-/@M=3^Q2NRQ/<N(-MN8E7WZG6I.C5
MG2E*$W"37-!MPDMU*+:C*TDTTI1C.-[3C&2<5^B91F='.<KR_-L/2Q6'H9CA
M*&,IT,;0EAL90C7IQJ>QQ-"3DZ5>DVX58J4X<\6Z=2I!QG(HHHK(]$**S=9T
MZ35]'U72HM2U'1I=3TZ]T^/5]'EA@U;2WO+:2W74=,GN;>ZMX=0LFD%Q9RSV
MUQ%'<1QO)!*H*-^17[--O<_!.T_X*;+X0U'7M5O_ (<^)-3U'0M6\3:K=^(_
M$-_JNC?#?5]2M]2UC5;]I+C4]2N=0C%U<S2@))*Q2.&.$1PIG*I&%/,:D[I8
M#*:^:I)7=>.'QN PE6BM4J;C]?I5%.3:E;D4-93A\OGO$53),UX4P,LO^LX/
MB/-,QRO$8]8M4IY;4P7#>=\14IPP:P]66.^LTLCQ.'E'VV$5!SIU.>L_W3_7
MU+ZRDNY;".\M7OH(UEGLTN(6NX8GQLDEMU<S1QOD;7= K9&"<TL%[9W4EQ%:
MW=M<RVDGDW4<$\4TEM,1D17"1NS0R8YV2!6QSC%?AG^Q[=^%?"^I_ #2?B?^
MS_X=TSQ!^T]\,/B!?Z=^T9IWQ0O?$/Q&\3SR: VL^.;SQQ+_ &5I-]X?CUFR
MNF>R:SUZ\;0"EK&)OM45S/;=1^SU\"O"OC?]HWXP?$']E"ROOA1^S[I?P@\2
M?!:S\9:=?ZY/IGQ,^*%^E[:W/BSP\-2U&YN]7TSPG<2V\K^(!<[;S5-+@N+*
M:26]N+A.ZOA9T*E:D[U94<%F-=SH\KI_6<MJ8W#U*%1SE"="G6QV%H9=0E7A
M3Q,L5C%SX.%.C>K^?9-XLXK/,+PWB<#D."JUL]SS+\MQ&3_VKFM#/<OP&:97
ME.>4<RIX+'<,8.ACZ6 R3-5FV:XBEC*63TL+3P\,#F^85\=3ITOVIFFBMXI;
MBXEC@@@C>:::9UBBABB4O)++(Y5(XXT5G=W8*B@LQ !-16=Y9ZC:6U_I]U;7
MUC>0QW-I>V<\5U:75O,@DAN+:X@=X9X9497CEB=HW0AE8@@U_/S8>%O$OP,N
M_&GP(\3W%M?^!/$.L_!7P_\ &O0O@!<:[X@EUW67TDZ'I/PXT2]\8_\ "'06
M_P 3_P!H*^+^)?B9NN].T_P_X/LY4N=:O[S6[4)^WOP4\?\ @[XG_"WPAXT\
M :9?:'X1U"QN=.T?0M3TVWT>_P!"7PUJ=]X7O-"NM,L[B[L[*71M1T:[TPPV
M=U<V8%J#:7$UN8Y&F=&"I2KTJT:]!U:5*E4C%QYV\/"O5FXR=XP<JD8T$[59
MTH_6JM.C0Q6"EB/H.#/$"?%6/K95C<ICD&;8+ XC$X[*J^.>-Q-.M0S6OEU2
M.'G'!X6%;#X6-.@L;B)1I^RS'%U,JA">)RS,'3]2HHHKG/TDYCQM_P B9XN_
M[%C7_P#TU7=>0_LC_P#)JO[-7_9!/A#_ .H!X?KU[QM_R)GB[_L6-?\ _35=
MUY#^R/\ \FJ_LU?]D$^$/_J >'Z /H6O)]2_Y+?X1_[)CX[_ /4G\ UZQ7D^
MI?\ );_"/_9,?'?_ *D_@&M*>\O^O=3_ -(9C7^&'_7ZA_Z=@>L4445F;!11
M10 4444 %%%% !1110 4444 %%%% !63KVM6/AO0]9\1:FFHR:;H.EW^L7Z:
M/HVL>(]6>RTRUEO+I=,\/^';#5-?US4&@A<6>D:)IFH:MJ-P8[/3K*ZNYH8'
MUJ*3O9V:3L[-JZ3Z-I--J^ZNK]UN-6NN9-QNKI-)M7U2;4DFULW%I/6SV/CC
MP!^WM^S5\2?B;X4^#N@ZQ\6M%^(GCBP\3:IX2T+XE_LP_M0?!NWU[3_!NFIJ
M_BBYL/$'Q=^#G@?PU(FB:?+!/>AM81T:ZL[=%>YO+6&;N_A=^UQ^S;\:C\7W
M^%?Q=\+>-;#X#7ZZ;\5]>TA]0/A7PM<G2KO6G=?%US8V_AC7[&VTVPO;B]U3
MPSJVLZ98-:7-M>W<%U#) ORI^S1)9_M'?M-_M*_M@Z^+:Z^&7@%=:_9$_9\?
M4DC?2+CP=X U=KW]H/XAVWVE6M);+QS\4;4^$TU%"8KOP]\,[4,S6UPP;YP_
M8^^,'['?QK_:W_X*,_!3P'\6?@KXK\)_&;3?@CX9\$^"OAYXV\*/#XN\!>'O
MV<8O"7CNW\":=X<O@+C2O"L+7>E:G)H,)@T&2)HI#;-!A?=J9=1JX?'?5,/C
M7C<+PO0SOV3K4\31HXK%9GAGAX8F5/"4*D*+R'&T,17P\H4J^&QU#,8U*ZI8
M*=.7EPQDZ6*H0Q=;#K!SSZIE4J\*4J%2I2PN$]EC*="%3$U82Q-/.J6*PM*K
MSSHUL/3PLZ5&;QT*M+]%=+_;>_9LUSX8?$/XNZ3XXU2;PE\,+;0KCQ5;ZMX!
M^(7@_P 6@^+]/L=2\!PZ+X(\<>%_#/BWQ$WQ'@U32X_AS<:+H][8>.KK4;2V
M\,WFI2RX7ZETZ\.HZ?8:@;2\T\WUG:WAL-1B2#4+(W,"3&TOH(Y)DAO+??Y-
MS$DTJQS(Z+(X4,?YQ=;\+P?#3Q;9?&[P7\1)O$WP'\ _'OX._!'1/CI^U$NA
M>(?AW=^/?AYHNJ_#BT^,WC/2?AI#\"=!UCX-_LRVECJ'PQ^&%[>:SX=?Q-\;
MO&'B/Q_XH\::F?"OA/4KC]Q/V5?BOXI^./[/7PL^+'C70K#P[XF\:^'#JFIV
M&D0:C:Z)<F+4K^PM-?T"UU>>ZU2V\.^*K"SM?$_A^WO[R^NH=&UBQBFO[YU-
MW->999A*.%GCLOG7JX1XVAA4\3**Q%#VV6X?'4:=:$*5.*KUZ=66*G%-QHX>
MK@Z#;Q=/'PI9X/&XF>)IX+&QHT\5'!U<156'4G0J3IYA7P-;V$YSE*5'"UL-
M/"\SC"M4Q$,3.K0P]#ZC/%?05%%%> >N%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7PMXJ\<WOPI_:V\?\ BO5?AC\:/%7A
MOQ/\"/A'X?TO7/AQ\*/&/CS2CK/A[QM\7M1U;3KG4/#^FW5G;7=K9^(-)G>W
M>;SPEW&S1JKHS_=-% 'P/H_Q3^#&@>*OB3XUTG]F[]JJT\3_ !>BTF'XB:G_
M ,*"^-4Y\11:'I<NBZ6C6=S!-I^EBUTR:6VSHEKIIGW>=<F:X"RCR'5+?X 6
M/@K0_#_P[_9K_:@\(:]\//A[\3? ?PAUJ]_9^^.GB2S\$6_Q1T_4;?Q"]UI.
MM/>VGB>WO+O4)+B>+Q+'JTD<9>&RDMHVV5^JU%14@JE*=%N4:<\.L*U"3@UA
MXX7$X*G2@XM.$*6#QF+PU*,;1IT,5B*,$J=:I&7D5<@R*LTZF397*4:^*Q4*
MGU#"JK3Q6.S; Y_C,52JQI*I2Q6*SW*\LSO$8FG*->KG&78#,YU)8W!X>O3_
M )]?V</AUJ_PO\9^"]0\4?!;XV>%_!?ASX<^*O ?CO0OAO\ "_\ :L\2'XX/
MXET-]"&H^+M*\6^'= T3P?%8":?6+>T\,1WC1ZFT:V]Q!%!:/:_>&C^*/V>-
M 'P?&D_LO?M56G_"A+;5[/X3?\6,^.T__")VVO:>-+U:,&Y:8ZY]KL0(2_B3
M^V)(3^^MWAG_ 'M?HU1775Q-:K*,Y3M..O-#W&Y*KCJT9/E:2=.>98Z-",5&
M&'HXFK0P\*5&3IGS_#OAUPCPQ@7E^7Y1A:U#VJJP>/PV%Q4Z5J624U3H.6'C
M"A2<N&\CQ5:-*$'B\RRW#YMC)8C-%/&2_.+XV>)_@!^T+:^';;XI_LU_M9:U
M+X2U"?4O#>IZ;\"OC;X9UK2)[R)(+^.TUGPW!I>I)::C;Q1PWUHURUO.(XI/
M+6>&&6/BY=!_9)/PX'PHL_V2/VI=)\%P>,9?B%IEGI'P0^/=AJ>@>-I88;=O
M$?ASQ!#(->T"]6&WBB2'2M1M; 1JT?V0QR2J_P"J-%81;A&<(-PC.<:DXP;B
MI5(5*5:$Y*+5Y0K4*%:$GK&K1IU(M3A&2]G%\+<,X_&8C,<=P]D>-S#%X66!
MQ6.Q>58'$XO$X*5&6'GA*^(K4)U:N'GAYRP\Z,YNG.@_92BZ:45^5\.D_LOV
MOP_?X<6'[-/[9&F:/-XK/CJZUK3/A5^T18>.;[QDUG<:?)XDU#QY;7$?BS4-
M1EL;NZLY!>ZM/9_9KB2!;58RJK6U3PW^R?J7A#P-X,A_98_:XT*P^&TVJW'@
MG6/"_P '/C_X;\8:'<:_,T^OSIXRTB2U\2WTFN3LTVJ_VGJ=ZMW*1(ZAXXF3
M]6:*ISFW)N<FY3I5):O6="E&A1D_.E0A&C3_ )*48TXVA%17.^"^#W!4WPMP
M\Z:P;RY0>3Y>XK O%1QSPB3P]E0>.A#&.FO=>+A#$M.M&,U\1^ OCU\.OAIX
M3TGP5X1^!'[7-IH&BI<I91:E\!_C/XAU!GO+RXU"\GO=:\06FIZQJ%S<WMU<
M7$L]]?7$A>4JK+$J1KV'_#6GA[_HB/[5G_B-WQ._^4U?5E%*4I3E*<Y2G.3<
MI2DW*4I-W;;=VVWJV]3W\-AL/@L/0P>#H4<+A,+1IX?#8;#TX4:&'H48*G2H
MT:5-1A3I4X1C"$(148Q2C%))(^4_^&M/#W_1$?VK/_$;OB=_\IJ/^&M/#W_1
M$?VK/_$;OB=_\IJ^K**DW/D/5_VH/".N:5J>BZE\#OVL9=.U>PO-,OXH/V>/
MBU83R6=_;R6MTD-]I^FVM]9RO#*ZQW5E<V]U;N1+;SQ2HCK\W_#72/V4OA%X
MDU3Q;X"_98_; TS7-<L=0T[6Y]3^&G[3_BNSUJTU2U^Q7Z:OH_B[6M=T;4Y9
M[3-N+F^T^>ZBB9E@FC#-G]3**%[KJ./NNM2E0JM:.K0FI1E1J-?'2DIS4J<K
MPDIR3BU)W\S&Y+D^9XG+\;F64Y9F&,RFO]:RK%XW 87%XG+,2W!O$9?7KTJE
M7!5VZ=-^VPTZ52].#YKQC;\GO!WA#]D7P+=ZQ=Z#^RE^UL3JWAOQ'X.AMM5^
M#_[0NM67ASPKXNBN(/$FA>#;75+BZB\'V>KQ7=S'<R>'1IUZL<\D4%U#$Y0R
M?"SPE^R#\%?%>D^-?AE^R=^UYX:\1Z%%?0Z3=_\ "M/VH=:L[2/4K.XL+Q1H
MOB'7-6T.82VUU.@-QILQA=_/A,<Z)*OZNT5HJM5/F56HI>R]@Y*<E)T7*M)T
MG).[IN>)Q,W!OE<\17FTY5JCEY-+@;@JC/!U*7"'#%.IEV*>.R^I'(<K53 8
MV3PC>+P4_JO-A<1? 8"U:@Z=1+ X-*26%H*G^;$VL_LZ7?@'5/AKJ/[,?[6.
MI>&M;\7W'Q U>6Z^!WQSC\2ZAXXN=4.L/XME\8V26GBN+Q!%>;!::G::Q;W5
MG:0P6%K)#91);CT[P+\>OAE\,_"6B^!? W[/'[4OA_PKX>MY+72-)M_V=/BS
M<I;1SW4][<O)=7^FW=_>7-W>W5S>7EY>W5S>7EW<3W-S/+/*\C?;-%0I2490
M3:A)TY2@FU&4J-&.'HMQ7NMTJ$8T*3:O3HQC3A:"45ZV&R7)\'B:>,PF59=A
ML92P<LNIXRA@L-2Q<,!/$O&3P4<3"FJZPD\9*6+GA_:>RGBI2Q$H.M)S?RG_
M ,-:>'O^B(_M6?\ B-WQ._\ E-1_PUIX>_Z(C^U9_P"(W?$[_P"4U?5E%(],
M^-_$W[4^C:GX;\0:;:?!#]JIKK4-#U:QME;]F_XG*K7%W87$$*LW]BG:IDD4
M%L' R>U>I_LO:1JV@?LU?L^Z%KVEZCHFN:+\%/A=I.LZ-K%E<Z;JNDZIIW@G
M1+/4--U+3KR*&[L;^RNH9;:[L[J&*XMIXWAFC21&4>ZT4 %>3ZE_R6_PC_V3
M'QW_ .I/X!KUBO)]2_Y+?X1_[)CX[_\ 4G\ UI3WE_U[J?\ I#,:_P ,/^OU
M#_T[ ]8HHHK,V"BBB@ HHHH **** /%/C%^TE^SY^SU'H,OQU^-GPM^$">*;
MF:T\.?\ "Q_'/ASP@^N36OE?;#ID>N:A927D%@+BW;4;J%'M=/6>!KV:!9HR
MWKUGJ6G:CIUKJ^GW]E?:3?64&HV6J6=U!=:=>:?<P+<VU_:WL$CVUQ97%LZ7
M$%U#*\$L#K+'(T;!C^7T$O@UO^"EG[6R_%PZ!_9]K^PI\$V\'CQ8++^SX_A5
M/XT^-Q^,\EI_:1^SC19-9C\-KXS9 +9H8M$74B8DMP./_8V\?^ O _\ P2:^
M&%A\8]<O(M/M?V1?B9XTG\)6.J01?$[5O@1X>LO$DEOJ?A/0Y[N'6;L6/P\O
M?#EK87]O%]DL;B_T:*:YM_M%ON]'$8.%+)Z^.@ZE3%8>&"K<JL\-6IX]<224
M*;C%U%+"0X>E]8JWFIU:F-I*E167.KBN:E7=3.89=+EAAY35%S:O7]H\+PWB
M5."<XTY*<N((T%1?+*+IX.I[6?\ :"I8;] _A?\ M4?LT_&SQ3KW@CX/_'OX
M0_$[Q?X8@FNM>\->!?B#X8\4:UIUE;WG]G7.H2:?H^I7=S+IMMJ.-/N=1MTF
ML;>_(LYKA+EA$?>Z_G>_8HTKXN^ OCY_P3TL_P!I$> O$'A;6_V7?B;X,_8C
MO?A+J6G/K_A#PH/#WA?Q?K-G^T=;VNC:?9>+/$L_PGT+P9I-CXR^&]Q9?#BS
M\4VNMV]YX;N-4UK2O$TO]$-=6>Y91RK$TJ%&K.JI0Q:J2FX-JKA,VS'+9)J"
M7LY3C@85JM"7/]7JU:E"%?%TJ=/%U^/*<PJ9A1JU:D(4[2PTZ2I\SA*CBLNP
M6-C*%25O;TU/$U*5/$*%%5HTE.6'P]1SHTRBBBO$/5"O-E\6^+]1U+7K;P]X
M0T:_L="UB71'O=3\7SZ3<7%U!9V5W.ZV,'A75DCA'VU(XV-X[R;&9DCR%'I-
M>?> _P#CZ^(/_90=4_\ 3-H% !_;'Q,_Z$7PM_X<*]_^82C^V/B9_P!"+X6_
M\.%>_P#S"5Z#7Q[^TK^UG!^SKKWAO0YO DWBT^(M(NM5%S'XD31!:"VO#9^0
M86T/5C.7(\SS!)%M^[L/WJ]#+,KQ^<XRG@,MP[Q.+JQJ2A152C2YHTH.I4?/
M7J4J:Y81;UFF[65W9'-B\7A\#0EB<54]E1@XJ4^6<[.<E&*Y:<9R=Y-+2+MU
MLCWWP_K^L6^OV?A#5_"6C^'$GT#5-;TQM#UXZM:"'2=1T>QN[62V/A[0A:,T
MFNV\T+1>>CA)PZQMM+^BU^2\G_!2;1)-7M==?X)7AU.RTV_TFWG_ .%B *EC
MJ=UIMY>1&$>$!$[27&DV+B1D,D8B98V599 VE_P\\LO^B+W7_A?Q?_,;7U'_
M !#?C5[Y++_PORO_ .;3R?\ 6C(O^@]?^$^+_P#E!^JU%?E3_P //++_ *(O
M=?\ A?Q?_,;7IOP<_;UM?BY\2O"WPZC^%UQH+^)KF^MUU=_&,>I+9?8M*O\
M5"YL5\,6)N/,%B8-HNX=AE\S+;-C8XGP_P"+\)AZ^+Q&3RIX?"T:N(KU/KN7
M2]G1HPE4JSY88R4Y<L(RERPC*3M:,6[(NEQ)DM:I3HT\:I5*LX4Z<?88I<TY
MR481O*@HJ\FE=M);MI'Z$T445\:>X%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M85]/?L9?\G,_"O\ ["6N?^HGK]?,-?3W[&7_ "<S\*_^PEKG_J)Z_7B\2?\
M).Y__P!B7-?_ %!KG=E?_(RR[_L.PG_J13/Z(J***_C$_<@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR?4O^2W^$?\ LF/C
MO_U)_ ->L5Y/J7_);_"/_9,?'?\ ZD_@&M*>\O\ KW4_](9C7^&'_7ZA_P"G
M8'K%%%%9FP4444 %%%% !1110 4444 %%%% !1110 5Y]X#_ ./KX@_]E!U3
M_P!,V@5Z#7GW@/\ X^OB#_V4'5/_ $S:!0!Z#7XX?\%,O^1^^&G_ &*&J?\
MIZ:OV/K\</\ @IE_R/WPT_[%#5/_ $]-7Z%X7?\ )8X#_L'Q_P#ZAUCYOBS_
M )$>)_Z^8;_T_3/S.HHHK^IC\C"OI[]C+_DYGX5_]A+7/_43U^OF&OI[]C+_
M ).9^%?_ &$M<_\ 43U^O%XD_P"2=S__ +$N:_\ J#7.[*_^1EEW_8=A/_4B
MF?T14445_&)^Y!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M) /Z^J*_@V_X69\2/^B@^-__  J]>_\ D^C_ (69\2/^B@^-_P#PJ]>_^3Z
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M0G76(E42Y)QAR^S4&V^9.]^?3;8_I#\-ZH^N>'M!UJ6%+>76-%TO5)((V+I
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M5_&)^Y!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5_&U_P %'?\ D]GX_?\ 8RZ+_P"H;X;K^R6OXVO^"CO_
M ">S\?O^QET7_P!0WPW0!\24444 %?NY_P $.?\ D;_VA_\ L6_AY_Z=/%5?
MA'7[N?\ !#G_ )&_]H?_ +%OX>?^G3Q50!_1)7GWC7_D/_"G_LH-W_ZK3XBU
MZ#7GWC7_ )#_ ,*?^R@W?_JM/B+0!Z#1110 4444 >??$#KX(_[*#X<_E?5Z
M#7GWQ Z^"/\ LH/AS^5]7H- !7\LOC7_ )'+Q;_V,VO?^G6[K^IJOY9?&O\
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MM2;2PO\ 4[J6ZU34+72M/MK;3],MKR_N[B[U"]M;6&&VMI9&DF7*A0S#EO\
MA9>@?] GX@_^&K^)?_S*5ZV'SC$X?!X+!1IT:E+ 8[#8ZBJOMIQE4PF8YGFE
M*G7HJM'#UJ3Q6;8I55.BY5<,J6%E+V/MXXCAK8"G6Q>+QOM*M*OB\)5PDZE%
MTX5*:JY;@LJ5?#UO9NO1K4<+E^&G0Y*BI0Q<7BY4IUXT)4?B#]M#X5>'-4U[
MX7:_H/[*W[37Q5\=^%_"GB;PGX%\??LI_&_0OV>M5\':3J4FCK+\./&_B^/X
M^?!3Q);> /$LEAI]](]GIWC#2=%;17OH+6PU=;)+WQ'P[^P[XK\(_LD?LO\
M[-[?#'P!K?Q@@\0^,[OQ-\?-1TOP_P"/+[]E73?B1X[\3_&+XH>(/A?XR\?Q
MZAXWO/'\-_X@_P"$$^&?B33_ #-2N?%2Z5\0?$DZV^A3QW'ZF_\ "R] _P"@
M3\0?_#5_$O\ ^92C_A9>@?\ 0)^(/_AJ_B7_ /,I6=+-*]+#4<*XQK0HXZ&/
M3K5*\U*K"ICJOLY4O;*@J-6>8XKZU"%*+Q2G+VTI2K8J>(N>#INK4JPDZ'M,
M&\%R4848QA#V.&H4ZL9.G*I[7#0PM)X;FG*E1?N^RE1I8:E0_-K]FW]GC]HO
MX.?M)V.D66F?$+PQ^S]X*UKXP:5:S77Q?LM;^!_B#X)7?A_P?I_[/7@?X??!
ME/'NK7_A'X@^"-1LM4O?''B^]^&OA&_UZ[3Q!?ZEXU\:R^)H5@_6:LW1]7T_
M7M+L-9TJ9KC3M3MHKRSG>"XMFE@F7<C-;W44-S"Q'WHYXHY$.5=%((K2K'&8
MZOCOJLL1RRJ8;"4<(ZRYW6Q3I.<I8K%SG.7M<77G4E/$5HJ"JU&YN"E*3D\-
MA*6$^L*CS1IXC%5L4J3Y?9X=57&V&PR44X86A&,:>&I2E-T:,848S]G"$8E%
M%%<9U!1110 4444 %%%% !1110 4444 %>3ZE_R6_P (_P#9,?'?_J3^ :]8
MKR?4O^2W^$?^R8^._P#U)_ -:4]Y?]>ZG_I#,:_PP_Z_4/\ T[ ]8HHHK,V"
MBBB@ K^8KP!\$?C;\6/$_P"USX$_8H_X*0:G^RA\!M4_:3^,OAWXS?L^_&SX
M&_"O5_BI\.?&WB?43=_$?5OAKK%_XIO?%%EX#^(,VJ7VL^ ;W4+CP9?):327
MMD@O$EU6Y_>;]KS]HG2_V3?V:OC!^T1JV@7?BN#X7^$I];L_"UE=+8W/B36[
MF[M-'\.Z$M^T%TMA'JNO:EIUE<7_ -ENC96\TMTMK<M$()/YROV?/V,/V>_V
ME/VOO%OPW_X*5?\ !+_PE\'/C]\=O!'BK]I[P7XU\$?M._&_Q/X?\?V)\4:=
M;^.M+UO2_#WQHO=-\->*M)U#Q/97TMGITFGZ9]GDGAM="TNUCL#=?2<-T.>I
MF=>K%2PJRO%8>5.5'+L;'%5*,\+F^)HK*\TK4</FD,+EF6XO&XJC3;KX6,</
MB;.FY4ZOD9W7]EA\!"$Y0KRS;"UZ52%3&8=X=*%7*J=98[ 4ZN(RZK4S#.LN
MPF'Q$HJE6>(K8>37,YT_Z7_V=_@[X0_9\^!7PE^"/@&]N=3\'?"[P#X:\&>'
M]5O9X;F\U>PT73(+5-8NY[8+:RW6K2+)J-PUJJVOFW+BW180BCV6N+^''P\\
M'?"3P!X,^%WP\T9?#O@3X>^&-%\&^#]!2]U+4DT;PWX=T^#2]&TU=0UB\U#5
MKT6=A;00"ZU*_O+Z?9YES<S3,\C=I7C8_$2Q>.QN*E7K8F6)Q>(Q$L3B*<*-
M?$2K5IU'7KTJ52K3I5JKE[2I3IU:D(3E*,*DXI2?;@:"PN"P>%C1I8>.&PN'
MH1P]"I4K4:"HTH4U1HUJL*=6K2I*/)3J5*=.I.$5*<(2;BBBBBN0Z@HHHH *
M**_+/QW_ ,%=OV9_AYXX\9> -;\)_&JXUKP-XK\1>#]7GTSPQX,GTV?5/#.K
MWFBZA-I\]S\0K.XFL9+NRE>TEN+2UGD@:-Y;>"0M$H!^IE>?> _^/KX@_P#9
M0=4_],V@5^9/_#Z;]E/_ *$WX[_^$GX%_P#GEU5M?^"S'[(]DUTUIX$^.-NU
M]=/?7AB\(>!$-S>21Q127,Q'Q*&^9XH(49S\Q6- 3P* /V!K\</^"F7_ "/W
MPT_[%#5/_3TU;'_#Z;]E/_H3?CO_ .$GX%_^>77RA^TE^U5\.?VM+[PGXU^&
MNE^,-*TGPY::MX7OX?&>FZ1IE_)J"36.K&6UAT;7O$$$EF;;4H$$DMU#-YRR
MJ8 BI(_Z%X7?\EC@/^P?'_\ J'6/F^+/^1'B?^OF&_\ 3],^9:***_J8_(PK
MZ>_8R_Y.9^%?_82US_U$]?KYAKZ>_8R_Y.9^%?\ V$M<_P#43U^O%XD_Y)W/
M_P#L2YK_ .H-<[LK_P"1EEW_ &'83_U(IG]$5%%%?QB?N045G:OJ2:/I.J:O
M)::C?QZ7IU[J+V.D6,^IZM>I96TMRUII>FVJO<ZAJ-RL1ALK&W1I[NY>*")6
MDD4'Y _93_:UUS]I"Z_:&LO$_P #?%OP0U/X#?$BP\#R>%_%/B#1O%'C36M.
MUCX=^%?B1I&K:QHOA6"ZTSPQKUUI'BNSM[CP?8^(/%MQ872?9KC5OMYGL+76
ME0JUJ>-JTXJ4,OPL<;BVYPBZ6%GBL/@E549RC*JOK6*P]*4:*J3C[53E%4U*
M:BI4A2EA83;4L;B983#)1E+VN(CAZV+=.\8R4/\ 9\/6FI5'"#<5!2=2<(2^
MT**^#_@!^VGK?QKU?]JO2O$/P"\8?!JZ_9K/A6[M-$\>^)=$G\8^,-#\8_#Z
MX^(6B:AKWA[0K74++X>:A<Z7%;J_A^XU_P 3ZI8)>1C6H]*U6WO-%M\SX#_M
M9_'CXA?!"7]I7XM_L[_#3X:?!BZ^ TGQTT&Y^'W[1?B#XQ?$/4+%O"]KXSM/
M#>H^"M2_9W^%&CZ5?S>'I+HW%U;^-M7%MJT%OI\=I=V]T^HVN]; 8G#PQE2M
M&G3A@,+EV,Q4IXC#I4Z&:X/$YAE[C^]_?5<1A,)B*BP]#VF(IRI.C5I4ZSC3
MEG2Q-&M/!PHN=6>88G&83!QA2JR=:ME^)PF$QEK0?)1HU\=A(_6JG)AJD*\*
MU*M.CS5%^@=%?ESX>_X**>(-=\)^)M*N?@OH]A\?[^X^#.E?!?X6^&?B?)\0
M- ^)6J_M > '^(?@8W?C%O G@B[T"V\&^&[76?$?QC9?#>H6'@WPOH%[K6DZ
MUXEM[W2C=_IUIW]H#3[ :N;-M5^QVO\ :;:<LZ:>=0\A/MAL4N7DN5LS<^8;
M9;B1YA#L$K,X8FL9EV,R^=2GC*2HSIUO82BZE*H_:JA1Q,XITISB_9TL3AW4
M=[0E6C3;]I"K"GGAL=A<9"E4PU3VL*U#ZS3DH5(IT'5G0IU?WD8/V=>I2KQH
M2LU55"K*#<(J4KE%%%<)UA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7\;7_!1W_D]GX_?]C+HO\ ZAOANO[):_C:_P""CO\ R>S\?O\
ML9=%_P#4-\-T ?$E%%% !7[N?\$.?^1O_:'_ .Q;^'G_ *=/%5?A'7[N?\$.
M?^1O_:'_ .Q;^'G_ *=/%5 ']$E>?>-?^0_\*?\ LH-W_P"JT^(M>@UY]XU_
MY#_PI_[*#=_^JT^(M 'H-%%% !1110!Y]\0.O@C_ +*#X<_E?5Z#7GWQ Z^"
M/^R@^'/Y7U>@T %?RR^-?^1R\6_]C-KW_IUNZ_J:K^67QK_R.7BW_L9M>_\
M3K=U^V^#'^\\0?\ 7C+O_3F+/@N.?X>6_P"/%?\ I- YFBBBOWL_/ K]JO\
M@FI_R1[QM_V4J\_]1?PQ7XJU^U7_  34_P"2/>-O^RE7G_J+^&*_.?%3_DD,
M5_V&8'_T^CZ?A#_D=4O^O&(_](/T6HHHK^73]9//?B?_ ,BQ9?\ 8]?"S_U9
M_@^O0J\]^)__ "+%E_V/7PL_]6?X/KT*@#D/&7C_ ,%?#RQM=3\<>)]'\+:?
M>W8L+2\UF\CLX+B\,,MP+:*20@/-Y$,LNP<[(V/05YS_ ,-.?L^?]%@\"?\
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M>ZG_ *0S&O\ ##_K]0_].P/6****S-@HHHH *_E6_;M^('B71/\ AK";0?\
M@X,\">%M2T[_ (6[_9W[+3> /A -4T.:'^VTC^"(U[1_%5]XXCU*R /@R/5[
M7PW/X@AO$6\?3A>)(@_??]KKX?\ [6WCGP9X:G_8Z^//@KX(_$CPMXE.MZA:
M_$CX=V?C[P%\2]$.F7EF?!7B>79+KWA.Q:^GM=4'B'PM;W&L1O9_94C$=PTL
M?XJ^(O'%G\#=>UG7?^"FO_!$#X'^($U34[[6/%_[6O[*7P&^%/[1?@+7M1O[
ME[C5?&7CCPWK7AF7XH^$+6ZO'GO-2UCQ=JVIZS>SW'F_V=+-)B3W\BP\)U*U
M7V^$<W0KX98.JLLEB9N<L-4C5HT<]PU7*\1%J-2"A2E/'\\)QC25"=3VWFYG
M7E2A1@J&(G!5\/BWB*/UU48>R>)A*C6J936IYG1G=TYN:BL%R5(3G6>(I15#
M])_^"4?[1GP#^,/['G[/_@CX5?%W2?'OC7X=? KX91_$;PG?_$+0?'7Q,\&:
ME>:*EO-#X_;2;AI[6]?5;74+>(WEI92QI EK/:VEQ$]M'^FM?!'["'B[_@G9
M\4O"/B+XF_L >&OV>]*T:_ETW1/'5Y\&?A1X<^%/B&&[@BEU#2]$\>:%8>%/
M"7B6TGMDN;FYT^S\0:>L?[RYGL-Z-)(?O>HXDJ*MG>8XCZGC<!4Q6*K8RO@\
M?%0KT*V,J2Q4X*'+"2HVK1=%S3G*DXS<I*29CD%-T<HP.'6*PN-I87#T,'A\
M5A).<*U+!T:>&<JDN:476]K2JJJH-1A)<C2E&2/S"^*&B_'OX!?MB?%K]H#X
M9_L\^-?VC?!W[0/[/OPT^'@T[X=>)_A?H>N>"/BO\(==^(D_A]?%L'Q.\=>
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M\_Y)Y=_]CGK7_IC\*U\65]I_L^?\D\N_^QSUK_TQ^%:_0O"[_DL<!_V#X_\
M]0ZQ\WQ9_P B/$_]?,-_Z?IGMM%%%?U,?D85]/?L9?\ )S/PK_["6N?^HGK]
M?,-?3W[&7_)S/PK_ .PEKG_J)Z_7B\2?\D[G_P#V)<U_]0:YW97_ ,C++O\
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MW2,D<:EBJ*!8_P"'G6L?]$=TW_PMKK_YF*_+&BOU;_B''!?_ $)(?^%N9?\
MS8?'_P"L^>_]!\O_  GPO_RCR_/NS]3O^'G6L?\ 1'=-_P#"VNO_ )F*_07]
MGOXNS_'#X9Z;\0;G0HO#DNH:CJ]B=+@U!]3CB&EWLEHL@NY+2Q9S,$\PJ;=0
MA.T,V-Q_FLK]\/V!/^3;O#G_ &,'BS_T]3U\#XC\(\.Y%D%+&95ET<)B99EA
MZ$JJQ.,JMTIT,5.4.6OB*L%>5.#YE%27+9-)M/Z/AC.<SS#,9T,9BG6I+"U:
MB@Z5"'OQJ48J5Z=*$M%*2M>VK;5S[0HHHK\,/OPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OXVO\ @H[_ ,GL_'[_ +&71?\ U#?#=?V2U_&U
M_P %'?\ D]GX_?\ 8RZ+_P"H;X;H ^)**** "OW<_P""'/\ R-_[0_\ V+?P
M\_\ 3IXJK\(Z_=S_ ((<_P#(W_M#_P#8M_#S_P!.GBJ@#^B2O/O&O_(?^%/_
M &4&[_\ 5:?$6O0:\^\:_P#(?^%/_90;O_U6GQ%H ]!HHHH **** //OB!U\
M$?\ 90?#G\KZO0:\^^('7P1_V4'PY_*^KT&@ K^67QK_ ,CEXM_[&;7O_3K=
MU_4U7\LOC7_D<O%O_8S:]_Z=;NOVWP8_WGB#_KQEW_IS%GP7'/\ #RW_ !XK
M_P!)H',T445^]GYX%?M5_P $U/\ DCWC;_LI5Y_ZB_ABOQ5K]JO^":G_ "1[
MQM_V4J\_]1?PQ7YSXJ?\DABO^PS _P#I]'T_"'_(ZI?]>,1_Z0?HM1117\NG
MZR>>_$__ )%BR_['KX6?^K/\'UZ%7GOQ/_Y%BR_['KX6?^K/\'UZ%0!^</\
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M_P#]0ZQ\WQ9_R(\3_P!?,-_Z?IGMM%%%?U,?D85]/?L9?\G,_"O_ +"6N?\
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MQK_R.7BW_L9M>_\ 3K=U_4U7\LOC7_D<O%O_ &,VO?\ IUNZ_;?!C_>>(/\
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MR_Z]U/\ TAF-?X8?]?J'_IV!ZQ11169L%%%% !7Y6?$C_@B9_P $Q/B[X_\
M&7Q0^(G[,4/B3QW\0/$FL>+O%VO2_&#X^Z>^K^(=>OIM2U6__L_2/BGI^E6"
MW-Y<2RI9:98V5A:JP@M+6"!(XE_5.BNC#8K%8*JZ^#Q.(PE9TY4G6PU:I0JN
ME.4)RINI2E"?LY3ITY2A?E<J<)--QBUE6H4<33]CB*-+$4>>-7V5:G"K3]I!
M3C"I[.HI1YX1J5(QG;FBIS2:4I7XOX<?#SP=\)/ '@SX7?#S1E\.^!/A[X8T
M7P;X/T%+W4M231O#?AW3X-+T;35U#6+S4-6O19V%M! +K4K^\OI]GF7-S-,S
MR-VE%%9U:M6O5J5Z]2I6K5JDZM:M5G*I5JU:DG.I4J5)MSG4G-N4YR;E*3<I
M-MME4J5.A3IT:-.%&C1A"E2I4H1ITZ5.G%0ITZ=."480A%*,(12C&*222204
M445F6%%%% !7\.G[47_)S/[17_9=?BY_ZG_B"O[BZ_AT_:B_Y.9_:*_[+K\7
M/_4_\04 >%4444 %?:?[/G_)/+O_ +'/6O\ TQ^%:^+*^T_V?/\ DGEW_P!C
MGK7_ *8_"M?H7A=_R6. _P"P?'_^H=8^;XL_Y$>)_P"OF&_]/TSVVBBBOZF/
MR,*^GOV,O^3F?A7_ -A+7/\ U$]?KYAKZ>_8R_Y.9^%?_82US_U$]?KQ>)/^
M2=S_ /[$N:_^H-<[LK_Y&67?]AV$_P#4BF?T14445_&)^Y',^-?^1-\6_P#8
MLZ]_Z:KNK7AC_D6O#W_8#TG_ -(+>JOC7_D3?%O_ &+.O?\ IJNZM>&/^1:\
M/?\ 8#TG_P!(+>@"UK/_ "!]5_[!M]_Z2RU_*C7]5VL_\@?5?^P;??\ I++7
M\J-?N_@O_#XC_P >5?\ I.8GY]QUOE?IC?SPH4445^XGP 5^^'[ G_)MWAS_
M +&#Q9_Z>IZ_ ^OWP_8$_P"3;O#G_8P>+/\ T]3U^6^+O_)+4/\ L<83_P!1
ML<?6\&?\C>I_V!5O_3M _EM_;5_Y.X_:._[+%X[_ /3]>5\PU]/?MJ_\G<?M
M'?\ 98O'?_I^O*^8:_FD_4PHHHH _H%_X(8?ZC]I_P#ZZ_!C_P! ^*M?I+\>
M];\96WQ;\#7O@&\\3>+)_"FFV^JZY\/_  -X@C@U.SM(O%>A_P!MZIK/AJ:Y
MM+#Q-;:MX;N[G1+?3[F\CO=.O+FPU&.%+266ZC_-K_@AA_J/VG_^NOP8_P#0
M/BK7Z2?&KPI\ D^,>CW_ ,7?#'A_0+/Q%X,U&2V^(EYK.L^$DU'Q18:GIT$.
ME7>N:)<Z9!#JEIHR">WOM2OTNGLL6=MYL41C7Z'A>5*&;PG5HUL2H87'2CAZ
M&&ABYUI1PM5RIO#RQ.#E5@Z/M7*%&O&K*RBE*#J)^=FT93R[$0C.%/GGA(2J
M3J2HJG">-PT7-584JSIRC)Q_>.G*,(\TY^[%I_0?P4UGQ%X@^&GAW6O%4DKZ
MUJ,NOW$HN+C3+J[@L#XEUA-%L[^?1WDTYM1L=%73[/4E@=FBOH+B*X/VE)A7
MJE>,_L^7?A"^^#_@ZY\!Z//H7A1XM932],N-2NM9DB:'Q%J\&HW U:]>2ZU*
M'4-4CO=0MKV8J]S;W44OE0!A#'[-7G9M!4\US.$:+P\89AC81P[IQI.@HXFH
ME1=*%6O"FZ27(Z<*U:,''EC5J)*;WP4I2P>$E*<:LI86A*52,G*-23I0;G&3
MA3<HS;YE)TX-IW<(WY44445YYU!1110 R2..:-XI426*5&CDCD57CDC=2KHZ
M,"KHZDJRL"K*2""#7G\7PA^$\/A[P5X1A^&'P\B\*?#75='UWX<^&(O!7AJ/
MP]X UOP\LZZ!K'@K15TP:;X5U70UNKE='U#0K:PN],6YG%E- )I VEK?AS7M
M7U87-MXWUWPYI4>G001Z=H-IX=,LNH"YNY+F]NKO7="UQGCDMGLX(+>W2V6%
MK>:5VE,X$>=_PA&M_P#14_B%_P!^OA]_\P-5&<X.\)2@^>E5O&3B_:4'.5"I
MHU[]&52;I3^*FYS<&G)W4HQDFI14DX5*;4DFG3K14:L&G>\*L8QC4C\,XQ2D
MFDC;\1^"_"7C";PW<>*O#FC>(9O!WB.T\8>%GUBPM]0_L#Q5I]I?6.G^(=+6
MY21+76+"UU*^CLK^-1<6AN9)+>2.7:ZX;_"+X42?$6/XOO\ ##X>/\68M+_L
M2+XHOX*\-M\18]%\F2W_ +(C\;'33XE32_L\LL'V!=3%IY,DD7E;'92O_"$:
MW_T5/XA?]^OA]_\ ,#6/>6.O^%_$/@/_ (KOQ5KMIKWBFZT34=.UR#PD;22T
M'@WQ;K221MH_A71[V*XBOM&LF1UO/+,?FQO$X<%7&I4@K0J3@OWFD9RBOWT%
M2K;-?Q:48TZG\\(J$KQ20I0A-MSA&3:IQ;E%2;C1J2K4HNZ>E*M*56FMH5)2
MJ1M)MGK5%%%04%?QM?\ !1W_ )/9^/W_ &,NB_\ J&^&Z_LEK^-K_@H[_P G
ML_'[_L9=%_\ 4-\-T ?$E%%% !7[N?\ !#G_ )&_]H?_ +%OX>?^G3Q57X1U
M^R7_  2$^+_PZ^#^O_'75?B-XB'ARPU?1_ &GZ=.=*UO5?M%W%>^++F2'RM#
MTW4IHML*E]\\<<1QM5RV%K?#8;$XRM##83#U\5B*K:I8?#4JE>M4<8N<E"E2
MC*I-QA&4FHQ=HQ<GHFS.K5I4*<JM:I3HTH6YZE6<:=.-VHKFG-J,;R:2NU=M
M):M']-U>?>-?^0_\*?\ LH-W_P"JT^(M>)_\-O?LO?\ 14$_\([X@?\ S*5A
MZO\ MA?LL:O>^&KV7XKM$_AK7)=<MTC\&^/2MS-+X?UWP^8)BWA0E8A!KT]P
M"F'\Z"($["X/K?ZK\2_]$[GO_AIQ_P#\S^:^\X_[6RK_ *&>7_\ A;AO_EA]
MDT5\I?\ #;W[+W_14$_\([X@?_,I6MH/[87[.7B?7-&\-Z'\1DOM:\0ZMIVA
MZ/9#PIXXMC>:IJUY#8:?:_:+OPU!:P?:+NXAB\ZYGAMXM^^:6.-6=9GPUQ'3
MC*<\@SN$(1<YSGE6.C&$(J\I2DZ"48Q6KDVDEJW8:S7*Y-1CF6 E*32C%8S#
MMMMV2252[;>B2U;/H#7?$.@>%M+N-;\3:YH_AS1;1H5NM7UW4[+2-+MFN9X[
M:W6XO]0GM[2%I[F6*WA$DJF6>6.)-TCJI\^_X7U\#/\ HM'PG_\ #B^#_P#Y
M<5\C_P#!57_DQOXN_P#80^&W_JS?"%?R'UXAWG]OWBGXP?!?6O\ A'/LGQJ^
M$"?V3XJTC6KGS_B1X23=:6(N1,D.S5)-\Y\Y?+1_+1L-ND7 SU7_  OKX&?]
M%H^$_P#X<7P?_P#+BOX5Z* /[J/^%]? S_HM'PG_ /#B^#__ )<5_-WXR=)/
M%_BJ2-UDCD\2:XZ.C!D=&U.Z971E)5E92"K D$$$$@U^3=?J;J7_ "$;_P#Z
M_;K_ -'R5^V^#'^\\0?]>,N_].8L^"XY_AY;_CQ7_I- I4445^]GYX%?M5_P
M34_Y(]XV_P"RE7G_ *B_ABOQ5K]JO^":G_)'O&W_ &4J\_\ 47\,5^<^*G_)
M(8K_ +#,#_Z?1]/PA_R.J7_7C$?^D'Z+4445_+I^LGGOQ/\ ^18LO^QZ^%G_
M *L_P?7H5>>_$_\ Y%BR_P"QZ^%G_JS_  ?7H5 'YP_\%+?^24^ _P#LH2?^
MHWKE?B[7[1?\%+?^24^ _P#LH2?^HWKE?B[7]1^%G_)'X3_L+Q__ *D2/R7B
M[_D=5O\ KSA__32"BBBOT4^9.\^%G_)3_AQ_V/GA#_U(=.K^H2OY>_A9_P E
M/^''_8^>$/\ U(=.K^H2OP'QF_WW(O\ L%QO_IZ@?HO W\#,?^ON'_\ 2*H4
M45%<3+;P33L"RP123,JXW%8T9R!G R0N!D@9ZU^*GW9^?7CS]E7]IGQ;^UWX
M!_:;TK]IGX/Z%H/PST3QMX&\*_#:]_9;\4:YJ1^'?Q'U;P-JOB_2=:\>0_M0
MZ+!J/BJ4^!;*'0_%5IX)TO3M*^VW,EWX3U?9%&#XR_LJ_M,_$C]J+X4?M"^%
MOVF?A!X,T+X)#QO9?#_X?:U^RWXH\9ZB-%^)NA>&]#\<VGBCQM:?M0>#H-;U
M"Y3P^;CP]J6G>#O#\&AF\$=[IFN_9C)<?7&D>,O'6MZ5IFM6'P^L#8ZOI]EJ
MED9_&L$4QM+^VBN[<S1#07$<IAE0R1AW"/E0S8R=#^WOB+_T3W2__"Y@_P#F
M>KT*.9XS#_4%2E02RS#8S"8-3P>#JJGA\PGB)XR%15</-8EXB>+Q<IU,3[:I
M?%XMQFOK-?VG)5P6'K2QDJBJN6/JX>OB7#$XFFY5<)3ITL/*G[.M#ZO[*E0H
M4XQPWLH\F'P\7%K#T>3RD?LZB_\ VLG_ &H_%'C$^(&\._!U?A%\*/ !\/BS
ML?ARNO>(3XA^)GBY=;?6KXZWX@\?-IWA/1VEBT70O[%T+PTNG"75!J5Q+%P/
MQF_8]M_VA/$GQDU;XI>.+FYTKQ;\$_%GP*^#NDZ+I?V8?!O1/B3X9GTCXG>.
MK=KR^NK?7_B+XONY[6P_M=K;3K?2_!FAV/AFSA5=9\3W>K?2G]O?$7_HGNE_
M^%S!_P#,]6IX3\27GB!O$%KJ6CC1-3\-ZW'HM_:)J,>J0/)/H.B>(8)[>\CM
MK3?&]EKMLCHT"-'/'*N64*QYXXJO&-&,:CBL/A<3@\/RJ,70H8RKB:^*C1E%
M*5.=>IC,8ZM6+56:Q>)C*;C6FGT*G!5:E91_>5L1A,75DVY*I7P%/!TL)*<9
M-P:HPP&"48<OLV\/3E.,I<SEX5^S-^SQK?P,_P"%HZYXP\>:-\0/'7Q<\5^&
MO$WB?5/"O@.;X9>#[-?!_P -_!WPOT"QT'P7<^,_B#>6#_V#X,L;O6;Z[\6:
MB^I:K=7#VT&F:=#8Z9:_4=%%&)Q5?&5?;XB:G4]E0HIQITZ452PU"GAJ$(TZ
M4(4XQIT*-.G%1BKJ*;O)MO+"X6A@Z$,-AH>SHTW-PASSGRNI4E5G[U24YM.<
MY-)R:BGRQ2BDD4445SG0%>3ZE_R6_P (_P#9,?'?_J3^ :]8KR?4O^2W^$?^
MR8^._P#U)_ -:4]Y?]>ZG_I#,:_PP_Z_4/\ T[ ]8HHHK,V"BBB@ HHHH **
M** /E[X[_MB? W]G37-,\+?$+4_&VH^*]2\-:GXXD\*_#/X4_$[XP>)-$^'^
MB7*6>M?$'Q3HWPN\)>++[PMX(TR[<6LWB/7XM/T^>YCN+:PDO+BUNHH?:] ^
M(_@;Q5\/-+^+'AOQ-IFN?#G6_"5OXZTCQ=I<KWFDZCX2NM+&M6^N6DD,;S36
MLNEL+M56$W&W,9A$P,8_+KQO\;/A)^R]_P %$_VD?&G[2?CWPM\+_"/Q2_9
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MD75G>I#<1_)/$LXCF3Y9%9>*_16OS&_X*Z_\F8^)/^QY\!?^GAJX3J/YK?\
MAJ+]IG_HXKXZ_P#AW/'_ /\ -!1_PU%^TS_T<5\=?_#N>/\ _P":"O"J* /=
M?^&HOVF?^CBOCK_X=SQ__P#-!1_PU%^TS_T<5\=?_#N>/_\ YH*\*HH _ORT
MMF?3-.=V9W>QM&=W)9F9K>,LS,22S,22222222<UQGC7_D/?"K_LH-U_ZK?X
MAUV.D_\ (*TS_L'V7_I-%7'>-?\ D/?"K_LH-U_ZK?XAT >@T444 %?QM?\
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M"5_+W\+/^2G_  X_['SPA_ZD.G5_4)7X#XS?[[D7_8+C?_3U _1>!OX&8_\
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M+L!_V!87_P!,4S\&Q7^\XC_K_6_].2"BBBNTP/V-_P""9G_(B?$W_L;=)_\
M3.:_3.OS,_X)F?\ (B?$W_L;=)_],YK],Z_DKQ"_Y++//^O^'_\ 4+#'[+PY
M_P B3+_^O4__ $]4"O)]2_Y+?X1_[)CX[_\ 4G\ UZQ7D^I?\EO\(_\ 9,?'
M?_J3^ :^0I[R_P"O=3_TAGJU_AA_U^H?^G8'K%%%%9FP4444 %%%% !1110
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M?]C!XL_]/4]?EOB[_P DM0_['&$_]1L<?6\&?\C>I_V!5O\ T[0/Y;?VU?\
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M_L+Q_P#ZD2/R7B[_ )'5;_KSA_\ TT@HHHK]%/F3O/A9_P E/^''_8^>$/\
MU(=.K]G?^"E?_)D'QZ_[ WA7_P!6#X1K\8OA9_R4_P"''_8^>$/_ %(=.K]G
M?^"E?_)D'QZ_[ WA7_U8/A&OP'QF_P!]R+_L%QO_ *>H'Z+P-_ S'_K[A_\
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M(P.,5*HX2DZ5:C&=X3C-6<HR6ZUO'5=KZ?W'_P## G[2/_0N>'__  K-%_\
MC]'_  P)^TC_ -"YX?\ _"LT7_X_7\.'_#Q?_@H/_P!'V?MD_P#B3WQM_P#F
MXH_X>+_\%!_^C[/VR?\ Q)[XV_\ S<5]U]=XX_Z#N'/_  W8_P O^H[U_K;Y
M[ZQP[_T"9M_X5X;_ .9_7^GI_<?_ ,,"?M(_]"YX?_\ "LT7_P"/U[?^S?\
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M]M/_ *$WPA_X<#PU_P#)5'_#I+]M/_H3?"'_ (<#PU_\E5_*C_P\7_X*#_\
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M&69UDV5XB6)PN"S&51T94Y*KB*$XJ$ITVY6C2@T^912;=M4K7DK?V(?M+?\
M!,K]K/XF?M _&3X@^$_"OA>Z\,^,_B+XJ\1Z%<W7C;0+*YGTO5=5N+NSEGL[
MBY6>VE>&16>&51)&258 BO$/^'27[:?_ $)OA#_PX'AK_P"2J_E1_P"'B_\
MP4'_ .C[/VR?_$GOC;_\W%'_  \7_P""@_\ T?9^V3_XD]\;?_FXKXO_ (A?
MC_\ H:8/_P $UO\ /U_IZ>Y_KWA/^@#$_P#@VE_EZ_T]/ZKO^'27[:?_ $)O
MA#_PX'AK_P"2J/\ ATE^VG_T)OA#_P .!X:_^2J_E1_X>+_\%!_^C[/VR?\
MQ)[XV_\ S<4?\/%_^"@__1]G[9/_ (D]\;?_ )N*/^(7X_\ Z&F#_P#!-;_/
MU_IZ'^O>$_Z ,3_X-I?Y>O\ 3T_T&O\ @ES^R5\:?V6HOC@OQ?T;2-(/CF3X
M;-X>_LKQ!INN_:!X:7QX-5\_^SI9?LOE'7M-\KSMOG^9)Y>?*?'ZRU_E ?\
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M7R%_PUI^U5_T<S^T%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S24?49_\
M/R/W,/\ B<[AC_HB\^_\.&7_ /R/K_3T^O?^'27[:?\ T)OA#_PX'AK_ .2J
M^Z;S]@G]H^>[NIT\.: $FN)Y4#>+-%#!9)6=0P%P0#@C(!(!Z$U^+/\ PUI^
MU5_T<S^T%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25]-PWGV;<+3Q=3+
M?J4Y8V-&%;ZW1JU4E0E4E#D5.M1Y6W4ES7<KJUK6U\K-/I:\'9O&C'%<&\21
M5!S</8YEEL'>HH*7-S4IW^!6M;\=/V>_X8$_:1_Z%SP__P"%9HO_ ,?H_P"&
M!/VD?^A<\/\ _A6:+_\ 'Z_&JW_:H_:VNQ<-:?M'?M%W2VEN]W=M;_%_XESB
MUM(RJR7-P8O$+"&WC9T5YI-L:EU#,"PS6_X:T_:J_P"CF?V@O_#S?$;_ .:2
MOJ_^(G\5[<F2WLG_ +GBMKVO_ONS<6K][]M/(_XF9X#24GP;Q8HMM)_VKE=F
MU:Z3^K6;5];;75[7/V>_X8$_:1_Z%SP__P"%9HO_ ,?K]+/V+?@YXY^"OP[\
M3>'/'UC96&J:GXTN=:M(K'4;74XWL)-#T.Q21YK1WC1S<6-PIB8APJJ^-KBO
MY-?^&M/VJO\ HYG]H+_P\WQ&_P#FDJ:V_:L_:RO+B&TM/VD?VB+JZN)$AM[:
MV^,/Q*GN)YI&"QQ0PQ>(FDED=B%2-%9F8@*"3BO'SWC/B#B++YY9CEEL</4J
M4JC>&PU>G5YZ4E*"4IXFK&S:U7(V[V36AW9=]*G@G+<5'$X;@WB>551E3C&I
MF>63BU42B_=C0@V][:[VTUT_6[]NG_@G?^T]\=OVI?B;\5/AWX:\.:AX/\3I
MX*&D7=_XPT32KN4Z)\/O"GA[4/-L+R=+B#R]3TF\CC\Q1YL:),F4D4GY(_X=
M)?MI_P#0F^$/_#@>&O\ Y*KY$?\ :Q_:MB=XY/VEOVA(Y(V9)(W^,GQ(1T="
M5='5O$8965@596 *D$$ BF_\-:?M5?\ 1S/[07_AYOB-_P#-)7PRP4FKJI%I
MZII.S7<]]_3-X93:?!6?)IV:>/R]--:--.-TT[Z/M]WU[_PZ2_;3_P"A-\(?
M^' \-?\ R51_PZ2_;3_Z$WPA_P"' \-?_)5?(7_#6G[57_1S/[07_AYOB-_\
MTE'_  UI^U5_T<S^T%_X>;XC?_-)1]1G_P _(_<Q?\3G<,?]$7GW_APR_P#^
M1]?Z>GZ3_!O_ ()D_M:>#+C7WUWPGX8@34(=.6V:#QOX?N=S6SWAE#B*Y)3B
M="I(P?FY! !]W_X8$_:1_P"A<\/_ /A6:+_\?K\8?^&M/VJO^CF?V@O_  \W
MQ&_^:2C_ (:T_:J_Z.9_:"_\/-\1O_FDK[G(N,\_X>RZGEF 662P]*I5J1>(
MPU>I5<JT^>=Y0Q-*+5VU%*"LMVWJ>!F'TJN"<RQ,L7B.#N)U5E&$6J6:99&%
MH14592H2=[;^]J^U]/V>_P"&!/VD?^A<\/\ _A6:+_\ 'Z/^&!/VD?\ H7/#
M_P#X5FB__'Z_&'_AK3]JK_HYG]H+_P /-\1O_FDH_P"&M/VJO^CF?V@O_#S?
M$;_YI*]G_B)_%G\F2_\ A'BO_FW^KORMP_\ $S? 7_1'\5_^';*O_F;U_IZ?
MN1X$_8:_:%T'QOX-US4?#^A1Z?HWBKP]JM_)'XHTB62.ST[5[.\NG2))R\CK
M!"[+&@+.P"J"2*_2/]M+X6^,/C7^S%\5OA?X!M+2_P#%WBS3=!MM&M+Z^M],
MM9I;#Q=X?U>Y$U]=LEO;A;+3[EU:1@'=5C7YG45_(I_PUI^U5_T<S^T%_P"'
MF^(W_P TE'_#6G[57_1S/[07_AYOB-_\TE?)<29[FO%-7"U<R>"A+!TZM.E]
M5HU:2<:LH2ESJI6K7=X*S3C:[T>EO9ROZ6W!V41K0PO!O$DE7E"4_;9EELVG
M!-+EY:4+*TG>][V6Q]>_\.DOVT_^A-\(?^' \-?_ "51_P .DOVT_P#H3?"'
M_AP/#7_R57R%_P -:?M5?]',_M!?^'F^(W_S24?\-:?M5?\ 1S/[07_AYOB-
M_P#-)7S7U&?_ #\C]S/4_P")SN&/^B+S[_PX9?\ _(^O]/3Z]_X=)?MI_P#0
MF^$/_#@>&O\ Y*H_X=)?MI_]";X0_P##@>&O_DJOD+_AK3]JK_HYG]H+_P /
M-\1O_FDH_P"&M/VJO^CF?V@O_#S?$;_YI*/J,_\ GY'[F'_$YW#'_1%Y]_X<
M,O\ _D?7^GI^Q6A_\$^OVE['1=(LKCPWX>6XL]+T^UG5?%VB.JS6]I#%*H9;
M@JP#HP# D$#(.#6I_P ,"?M(_P#0N>'_ /PK-%_^/U^,/_#6G[57_1S/[07_
M (>;XC?_ #24?\-:?M5?]',_M!?^'F^(W_S25^FT/$GBG#T:-"G#)^2A2IT8
M<V$Q+ER4X1A'F:QBN[1U:2NV[):6^5G])W@.I.=27!W%7-.<IRMFN5VO)\SM
M?#O2[=M>WR_9[_A@3]I'_H7/#_\ X5FB_P#Q^C_A@3]I'_H7/#__ (5FB_\
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MBZ':P^&KJ\T>)=);4Y$U/3-3?1G.H?%O@O\ 8#_X)^_%>T_8^^.VF?%SXR?
M?]F[]H/QM\=?A;XNT#XY^.OA?%XOTWXB_";0%U?PC8:)\7;7P+H7@/P_X?\
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M "BBB@ K^^W_ (-7O^4?'QB_[/)^(/\ ZI+]GFOX$J_OM_X-7O\ E'Q\8O\
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M#?V>8_BAXWO_ (EV^M7GP+\,?$WP_P")H/'/P_T7PQXC^(?C346L=*^%^G>
M-4\(WWC.5]%MGM]:O]536,:OID-]<6PTVV:UN:]R_; ^"/P0^)6K?'KQ#INH
M_$;2_C1\'O@#\'OB1>HR^&(OAA>Z*OAKPCHSZ':V$5G)XDFU22PN[>]DU234
M;2V6[G,"6,D5H\EWXKXF_;N^&NO?!?\ X0"?P+XJUNZ3X#Z-\(-*\$^*=*^'
M6K>"?#7B+2]/@T^/XEZ7X]N=,NOBC<:I9O')J&E:*]Q96=E<R)!%=QPVUNT?
MQ3J_[3'QNUW4/'VJ:KXW:ZO_ (G^"-(^''CF?_A'O"D']N>#-!ATR#2=&,5M
MH4,.FBUBT?3D_M#2([#59_LY-S?3-/<&:<7"K6Q&8PI-PIQKX^IE]5/EA!O^
MU89:K6E_#E/+YXB4(N%7 *E1JJIC(X^E4^CQW%/AED>38#*L#E^$SC#YMDN1
MT\YI83+J<J]/'8/+Z\,=BZN)JXK!S]O/&8SFRR5;GS'"U:./K8OV4*F7*7T;
M^S/\$?@L_P *]/\ C_\ &C4_B5+#=?'OPI\(/!&B?#9?#>;+7Y;&W\1S>(?%
M2^(;2Y6_T>-##;II5A<:9>7(2=8[O?/$]O\ 27[1_P "_@HGQ3_:.^._QKD^
M(]_X>OOVH+;X,^&/"GPJOO#6A:A;:C=^%['7]4\2:SJ/B+0O$%L]I9V4BII^
MD6EC:RWUZA6:^BAEW1_G5\(OVH?C=\"]!\0>&?AGXPCT31/$E]::O>V%[X?\
M-^(8K37;"/R++Q%HI\1:3JC:'K]K#B*'5M*-K=J$A?S#+;6LD/4^'_VT_P!H
MSP]KGCCQ!%XUTO6;[XB^(K/QCXKM_%'@7P%XGT>\\8:=$D&G>*['0-;\-7FB
M:)K]C''$MOJ&B6&GR8BA\T2B&()O52GC*59*^'H4'"G3;Y9+ZQ5X4EF%&*2:
MC+%4\GSF*Q;FZM-YEA/9PIO#*5+YS)>,/#_!\'X#(,9D^+_M&IB:&-S3$_V)
M@<?AO[5R_+?$+!Y=FE>5?/<///*5&OQ1D-2EE%?"Y=A,-3RS'*=3'<\*6*^O
MO$G["'PD\)V7[0?AW3/$7C?XM_%/X6^(-<32_!/A#Q=X!\)>)-#\ Q^"=+\7
M>'_'>K^$/$ND7NJ>/K>.;5%T_P 46/A"^TNYLDL;LVD)N988TR/&7[$_P,\!
M_!LW_BCXJ1:#\69/@1I/QDTV]UCXM?!S3]"UW7]8T^+6[+X::3\(;FXB^+%Q
M->Z5(UMIOBN.>2RU#5HG%O8O"4MV^3-._;&_:%TO3_&-G!XWM)[_ ,=7GB6]
MU[Q5?^$/!FH^.!+XRMDL_%,6D>-KWP_/XGT&TUJTCCMKBST;5+&UMX45+"*S
M&<YU_P#M6?&K5OAS;?"_6=;\.:WX>L/#0\%Z=J6M?#[P#JWC33/""@K'X:TW
MQ[J'ANX\86.E0JS1V\=OK4<]K"WV>VGBMPL0Y'2Q;PLJ?M8_6)83*J?M>:2M
MBL/EV.PV/G3<8)1A5QT\OQT)2IRG7J4L5'$0>%=/!5.ZMQ9X.RJ8JK0X0S"C
M&='B.G@L+/ 8*IAL-2QF=T,9D]*M*><5,=7Q=/*GB\OQ&8/'<V"]G@WE=/#R
MK8FO0]H^"EJGAS]B']K;QQIX":]XD\5?!_X4R7L?%U9>%M4U>\\0Z[;)(/F6
MVUJ;3=/M+I,A9H[?8^X "O<OB%^Q3^SOH6D_&GPMX2\3?&B]^*GPB^%OP\^+
MUS<ZN/!D_@_4-(\7+X;-]X7L;&RTZRU>^U>./71/9:E->:5:B>:"SEM9DLYK
MN^^'_A=\:K#P7\(?CS\(/$&CWVKZ)\7=&\+7.CW%A<6\,GAWQSX)UV/5M UF
M=+A2)]/FM9M1T_4HH"MRT4\)B+!&4Y^K_M,?&[7=0\?:IJOC=KJ_^)_@C2/A
MQXYG_P"$>\*0?VYX,T&'3(-)T8Q6VA0PZ:+6+1].3^T-(CL-5G^SDW-],T]P
M9NFNI2KXJ=-:5:>&G0ES*/(J&2TL-2PSERU'3@L]P]7'XB,:<HSP^+G.U66)
MQ&'GY&7\3\%8;AOAO!9OE?\ :^)PV18S*\31CAO:SR_%U^)N,\?C,=3=3&8&
M/UK%Y7G'#=/"XJ#K3IO+)TFZ+P.$E4^O_B%^R=X&^"^AZ1\2=1\"?M5:1I7A
M_P 8>!Y]9O\ XM?#KX6V?@%-&N/%.DV^K1ZQ)X6^(GBG7)1/82SQ6=I;:%>B
M]NGBM9T2*5W7T?\ :?URXUS2O"G[27P*\1_ O6O@OX-_:&L[+PU+\-O@TWPE
M^(/A#Q!"6USPUHWB2>]\+>']2\1V*Z3'%YMU%,]K+?>1*UL[!I(/R9T#7-4\
M,:YH_B31+E;/6= U2PUG2KMK>UNUMM1TVZBO+*=K6]AN;.Y6*XAC=K>[MY[:
M8*8YX9(F9#]-^(OVN?B7\5=9^'.G_&C58M9^%_@OQKI/BV_\!^!O"W@WP)I^
MI36]W$VK7OV#PUHVBZ==Z[J%@+FRBU#4UG%HMU-]G$"S3"37#QDJ^73G75\+
MF]#%*<HN-*AAWB<GG7=6'[_ZU*-++\1+#J$<-/#UZRFJE6G*M2D8?C;A3^RN
M*LMP>2XSARGG>4X+#83#8+$2QE6><X%9TL'CZ^>4<3DJR_+83S6A+,<OJ9#G
MCQU+!4W1K8'$1I5Z>I^W]X6TGPC^U[\:].T2"*TT_4/$&G^*%M(0JQVMWXQ\
M/:1XJU*!44!4"ZEJ]VRH  J,HP.@^.J]9^.WQ5O_ (W_ !@^(?Q7U*U^PS^-
M_$U_K$&G&02_V9IC,MMHVE^:JJLO]F:3;V5@9515D-OO"J&"CR:N++J4Z.7X
M&C4@Z=2E@\-3G3;4G3E"C"+IN2;4G!KDYDWS6O?4^(XYS# 9OQKQ=FN524\L
MS+B7/,=@*D:;HQJX/%YGB:^'K1HRC%T(UJ4XU51<8^Q4U3LN4****[#Y8***
M* "BBB@ HHHH **** "BBB@ HHHH **** /V&_X(F?\ )U7C_P#[-]\5?^K&
M^%%?U%5_+K_P1,_Y.J\?_P#9OOBK_P!6-\**_J*KR<9_&?\ AC^1_J)]%#_D
MT6#_ .Q]G?\ Z>I!7D^I?\EO\(_]DQ\=_P#J3^ :]8KR?4O^2W^$?^R8^.__
M %)_ -8T]Y?]>ZG_ *0S^CJ_PP_Z_4/_ $[ ]8HHHK,V"BBB@ HHHH ****
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M &O$TL+2Y:-!?O*N+P."@Y.IR)KZQF&$CR0<ZO)*I65)T</7J4_V'_X=T?\
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M]@_PE^UUX,\ ?!WPS9:G^TEKG@KQ/=>-[Y=?U&/X8ZG^T3I'PN^'=CX(\->
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M7M[=32W-U<RRSSRR2R,QS_\ ADO]E7_HV;]GW_PS/PY_^9NOH*BL>>?\TO\
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M^9NC_ADO]E7_ *-F_9]_\,S\.?\ YFZ^>;G_ (*&^!-%;XF0^*_ASXQT2_\
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MGB,LR*>(IN*BW#$0P%3&T\-7BG%5<)7JT\9AIITL5AZ%:,J:^??^&2_V5?\
MHV;]GW_PS/PY_P#F;H_X9+_95_Z-F_9]_P##,_#G_P"9NOH*BL>>?\TO_ G_
M )GT'^JW#'_1.9#_ .&C+_\ YG\E]Q\^_P##)?[*O_1LW[/O_AF?AS_\S='_
M  R7^RK_ -&S?L^_^&9^'/\ \S=?*?[8O[5/Q!^"GQ9TOP;X9^('PQ\ :1_P
MI#Q3\3+0?$'PGJ'B>;QSXQT37DTW2/A]I(T[Q9X;OK>[\10EH[1M-AU._26*
M5X[&Y4_N>[F_;<'A.3X-:=\3_A1X@\*W_P 3++X96>KW8\4> (9=!\5?$>SL
M?(L[+P'J'BR+XEZGHFD:K>KI^LZO_P (Q'%I<BR1,;R2VF-:4(U<33HU*4FW
MB,2L)1@Y.,IUY8K'8*G!2?[OFJ8C+L3"-/VGM5?#N<(+%X5UO@L3Q!X7X'.,
M]R;'Y+E6#K<.JC+,L54X>P-?!THUL+EF+]I.6"HXK$86C2HYK@Y3Q&88;!X:
M:CBIX>K6IX#&U,/[C_PR7^RK_P!&S?L^_P#AF?AS_P#,W1_PR7^RK_T;-^S[
M_P"&9^'/_P S=?+7Q3_;R\5:3X+^('BGX5_ CQ=K>G_#SXLV'PFU3Q;XKN_"
M-EX5O/$,/C^T\(ZW8Z78)XXTOQ#?--;75K_9.IQP)86VIZM8KJJ):V.K&V_1
M31[Z\U#1M*U+4=(N] O[[3+&^O\ 0K^XTZZOM$O+FUBN+K2+V[TF\O\ 2;F[
MTV9Y+.YN--U"]TZ::%Y;.\N;9HYWF+J2P\<4I2]C.:A"3DU*7-A<-C83C!OG
M<)X;&8>M"7+K3JTZEE3JT95/;RE^'^=YEC<JRS(\IQ&)R_"8?&8BH^&8T,(Z
M.(S#-<KA[#&8C+Z6'Q,HX[),PP\_85*D>?#5(PE.5&LJ7B'_  R7^RK_ -&S
M?L^_^&9^'/\ \S='_#)?[*O_ $;-^S[_ .&9^'/_ ,S=?#6E_M]?$I_'_BRT
MU+X?V3>"?"G_  TQXDN#;:QX,GU";PG\&=-T6ST>U$VG^,]1N?M:^)3J::I?
MP:9/'JMKJ5A)H<%U9:9JUY;^]_L=_M!:W\99=1B\:_$_2]<\97_@OPSX\?X9
MVWP6\9_"W_A#M)U]Y,7F@>(?&-V\WQ&\,+/-#HT?B&QM6M9KZS:[AO'M+^U5
MKHPK5J5.M"3Y*F!P^/C>3<_98EXQ4XNG#FJ<Z>7XQ59*+HT?82]K6C>'-\_E
M_$OAAF>;T<DP>0Y9]>K9GF.51CB\CRG+8NMEM'+:U6M2_M)X2IBZ5>.:X'ZI
M2P%/%XVNJDJJPD:%.=6/M7_#)?[*O_1LW[/O_AF?AS_\S='_  R7^RK_ -&S
M?L^_^&9^'/\ \S=?05%9<\_YI?\ @3_S/T+_ %6X8_Z)S(?_  T9?_\ ,_DO
MN/GW_ADO]E7_ *-F_9]_\,S\.?\ YFZ/^&2_V5?^C9OV??\ PS/PY_\ F;KZ
M"HHYY_S2_P# G_F'^JW#'_1.9#_X:,O_ /F?R7W'S[_PR7^RK_T;-^S[_P"&
M9^'/_P S='_#)?[*O_1LW[/O_AF?AS_\S=?'O[7G[6_Q*^"WQEU?P7X5\<_"
M_P ):?H?P)@^)^@>'O'/A#4_$FK?%/QL_B[4=#M_AUH4VE>+?#^H6E]K%G:H
MUE)IMAJUU#+%+)):M SSVWLUW^V?:>&/&?PK\#_$#X7^(?"^H?$B;P'H,E^_
MBKX>37&E>,O'&@VFJ0Z>/ W_  EG_"QI/#^FZC<OH5_XEN_#%E:6^I021"*9
M DLETE4K4J=:$W:K6G0IQE*492J1Q6*P:BI.U-RG7P=:$:<:CK*]!SIP6*PW
MMO@ZN?\ AAALUSG*,9DF58.MD5?"X?'8BIP_@:^$C4Q4*,Z;E+ T<76PE&*K
M4[XC,J&!H24:M2C4JTL/7J4_7/\ ADO]E7_HV;]GW_PS/PY_^9NC_ADO]E7_
M *-F_9]_\,S\.?\ YFZ^4_%G[>WC"\^&.@_%#X6_L_\ C*\\-ZW\7O!?PUT[
M5_&=]X+L;7Q&-7\47_AOQ#%H&GP^/=/U"&\AO[%='T75M3,6BMJM[%<7P_LN
MSO;B/]';&]N+C2+/4K[3;C2+N;3;>]O-(O;C3Y;K2[B2V2>XTV[N[&[NM+DN
M+*1GM9[BTOKC3WDB>6WNYK<I,Q)58TJE:3E&%.LZ$DY/G]HL)A<;903<I+ZO
MC*$GRIR@YQC4C!SIJ?LY-+P^X@QE;!93D>58F=#+\#FCK2X9CAL)4P688O,L
M%A*M#%8G+Z-&LJM?*<8H.G)QJ4Z:JT95*:E*'AW_  R7^RK_ -&S?L^_^&9^
M'/\ \S='_#)?[*O_ $;-^S[_ .&9^'/_ ,S=?&_P@_:U^._QS^)MY\-M!T/P
M[X,34M(^.^J:1XHU&/PEXJMM#MO"?CFR\'^ KS4=&T7XAQW^K1:?<6>LV6O0
MV;P/KUW>6&JZ.?\ A';:XU(>V?LH?$OXX?$#QU\>M'^(OBSP3XZ\$_"_Q3IW
MP_\ #WC#PEX'O/!4>M^-+"S-YXXMH;6Y\3^)EN+#PY/<V.D//]I4S7XN&C"Q
MH5-0A5G&E/GY55R^>904JEW["EC/[/JQER.:C5I8N5.C.+:CS5J?+.7O\GB9
M;GOA]F^+P.&R[A"G7I8_.Z_#]'&RX;RK#8:.88?)8\02<Z6+E0Q\L)+*[UXX
MRA@JV&4H>QJ5(5)T8U/7/^&2_P!E7_HV;]GW_P ,S\.?_F;H_P"&2_V5?^C9
MOV??_#,_#G_YFZ^@J*RYY_S2_P# G_F???ZK<,?]$YD/_AHR_P#^9_)?<?/O
M_#)?[*O_ $;-^S[_ .&9^'/_ ,S='_#)?[*O_1LW[/O_ (9GX<__ #-U]!5\
M4?MF_'7Q9\$[?X*0^&_&_@?X:V/Q$^)S>$?%'CWQ_H)\0Z%X7T1/#&MZQ_:$
MM@?$7A>(DWMA;0,9=6M\K+LC8.P#)U))TX\TKU:]##PO.R]IB:]/#T^:4I*,
M8^TJ1YI-I1C=]#RL\R_@WA_*<=G..X;R9X3+Z/MJRHY1E7M''GA32@Z\*%"+
M<I13G6KTJ4%[U2I"$7)>J_\ #)?[*O\ T;-^S[_X9GX<_P#S-T?\,E_LJ_\
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ME)*RS)X/X[_8?^''Q ^*VL?%75/&/Q#TZY\0>)_AYXUUCPSI%QX-71;WQ/\
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M*5!33E3J):3=&G3IZM\LH5L;5:]H[S5*3Q%.4HQM4NI1IU*=.G&G5]@KY/\
MVXO^37/B?_W)7_JP_"5?6%?/?[5/@?Q3\2/@+X\\%^"]+_MGQ-K/_"+_ -FZ
M;]MT[3OM/]G>,_#NK7G^F:M=V.GP^3I]C=7'^D747F>5Y46^9XXW];ARK2H<
M0Y#7KU*=&C1SG*ZM:M5G&G2I4J>.H3J5*E2;4(4X03E.<FHQBG*3239QYI"=
M3+<PITXRG.>!Q<(0A%RG.<L/4C&,8Q3<I2;2C%)MMI)79_.'17UA_P ,._M1
M_P#1,/\ R]?AY_\ -;1_PP[^U'_T3#_R]?AY_P#-;7]9?ZT<,_\ 119%_P"'
M?+__ )H/QW^R<U_Z%F8?^$6)_P#E9^@O_!-S_DA'B[_LJNO_ /J'>!:_.3]F
M7X;^)?$>F?"3QS\*OA/XS\.>+_!'QP\8>+_BG\?O[3LM'\+^(OAIHFNZO/JO
M@BU@C\1S:CXKO[^W2/29+&;PW ()T,1FGL;BZN8OU?\ V(_A3X\^$7PH\0^&
M?B+H/_"/:U?_ !!U;6[:R_M31M6\W2KKPWX3T^&Z^TZ%J.IVD?F7>F7T/DR7
M"7*^1YCQ+')"\GT3\-_A?X$^$?A9/!7P]T%?#_AB/4-5U1-+_M#5M547VMWL
MVHZI,;K6[_4KYA=7D\LODM<F"$-Y-O%%"J1K^,5>/*'#N9<>K+HPS&OGN8Y6
M\'6A7E4RJIA,+@LZPV,^M2PF+H_7(3_M.A*AA:D<3@:\Z4Y8NG)4:=.K]Q+A
MR6<8#ARCC.:A0P,,4\92E!4\8E7A",%AG6H5?J]=.#MB$J>(P]U5P\XU$FOS
M0\'_ +3_ .T9+X:_9Y_:"U_Q;X*U;X>_'_XU6?PRE^#.G>#(;2[\(:-KVN:]
MH>EZEIOC5=4EUG5]9TS^PWN]3AOK1;)S.J+%&GW)H_C3^T)K^N?'OX;_ !+^
M(<OPE\>'P5\6M2\!?#O4?@NC:%?>%_#D<MSIWBGX>_$ZU\30/XMD_L"WN8=5
M2]-M+9W=\;^QBW:3) ?LCPK^QQ^SQX+\:V/CSP]X%EM=6T?6+_Q#X>TNX\3>
M*M0\(^&-?U0LU_K7AKP9?ZU<^&-%U&=G9TGL=+B%F^UK!+0QQE-/PA^RA\#/
M!/BS4O&FC>$[ZYUS4=,US1(F\0>*_%OBC3]%T7Q*SOX@TGPWI/B'6]2TW0+#
M5S)(EW!IEK;CR'>TA:*T=X&O%<7^'_/CZF"R%TI2PN)>62_U:R"%7"U?KU7%
M93ET_:XO&X2=++Z2H87,<ZJX.OG&<4'43JX2=%2QD87)>)Z=3"2Q.9^U5/'9
M75QG+FN91ABH4*E99MBXPIT:%7#/'4*L983)\/B89=@\3AJ+G+$4:E5+YJ_9
M5^*WBOX8_LJ_!C7_ (B+\4_C2?&NC)=>'(_AG\(/$GC#6/".C6UO"BZ7XLOM
M#OM>NM4E:Y\^:W\0ZE'I;WGF/91V0%B9&\CTGX+_  9^-'[4'[=>K?%[1(3;
M^%K+X37^C^*+W4=1\/:OX%AO?AS/<WVJV6HVU[8R:5=60L;6ZE^TEHHI;)4G
MB:,2QO\ H_\ !KX%_#;X!^'K_P *_##2+_1=!U'5IM8EL+[Q!KVOQV]S+#%!
MY-@^O:CJ,MA8Q10HL5E:O% &,DS(\TLDC>:>//V)_P!F+XG>-M:^(GCGX9+K
M_BWQ%-I]QKM_+XQ\?V5EJLNE6=M86!O= TSQ59>'IEM[2TMXO+;2O+DV&29)
M)9)'?GH\;</T>(N,LRPM;B')(\1X;'4<)G628/ 4<RPWUGB7(L\P\%E-#,\L
MPF#]E@\LQ678C$4,UKSQ<ZZQ5:C-U:]-D.'<TCD7#N75UEN83R;$Y?6Q. QU
M?$5,%C5@\OS/ UI2QM;!XRJXXBIC*.)I86IETJ&$C!X:E+V=&DW\$_L[?M"?
MM$?$GPC^S%\$M \>6OA+Q+XT\)_%'Q+JOQ@\6>&8_&^NZIX2\ >)M3T'PQ;:
M=I.KW]E9:CJ=_#9^7JFIZC+/<2VEM%?([3M.UQT=Y^U1^T[JWP;T+Q);?\2V
MU\$?&'XI?#+XZ?%KX=_#*#XBW6F:7X BL_[$\8Z7\/;[6+2W30=7DNYO^$FO
MX9YXM)CTZ6YM%MA-%92??_Q _9B^"OQ(TOP9I6N>$/[+C^'=O+9>!;WP7J^M
M>!-5\*:?<6\=G<Z9HVI>$;_1[NVTRZM8HX)].,CV;JH?R1,!(.?UC]CO]G_6
M/!?A7X?KX0U+0_"_@V+6[?1;/PMXS\:>&;I[3Q.]O)XFM-9U/1=?L]2\10^(
M7M8'U<Z]=:C-=/&',JN2Q[JO&_A_BL9#'5>&88?ZQF^,QV)P;X?R?'1PRQ./
MXAQ$\3#&3QN&JY@YX+,,GPM'*<50AE& Q.7/&PPN)A2^J8_"AP[Q+AJ"PT<V
M<X4\%2P]*I2S+&X?DA'+<%AI8*GAYX?$4Z:IYA2Q>-I9I*I4S&="K3P3G14G
M6H?$?C[]K3XY^)O&%MX)^!GB.^\11^&O@;X/^(@\4^!O@7??$ _%7Q7XGL5N
MK)+_ $6;5HYOAUX-O]B02SQB\U73-1N+FU=IC;+%%](?M,>(?$WBG_@G_P#$
M7Q-XQ\/7'A#Q=KGP5M=3\2^&9XI[:?0M<O;?3I=5TQX+AFN8!;7;SQ+!<LUQ
M%&%CG)D5R?3O%/['OP!\52>%IY/"&H^'+OP=X6M/ ^B7_@7QAXP\"WZ>#;$Y
MMO#-_>^%=<TJXU72HVRZIJ4EU<*[2.MPK2RE_6]<^%O@7Q)\-KGX1:YH9U#X
M>W?ANV\)7.@2:IK,;3:!:6\%K;V+ZQ!J,6N[T@MX5-\-3&H.Z>;)=M,S.WBX
M_BG@Z-3A.MDV35L)+)<ZP.8YA4GEF74,PQ%#"XM5\0GC<'BJ5/&SQG)"O##5
M\+1H8&JGA<%4P^#ARU?2RW*<_I5\;/,L?3KT\1EJPU.E2QF,JX:&(>$P-*\<
M/BJ52<%1KT<8XXE8B6(Q-/$>UQBKUYKZM\5?&#XY^-O@Q^S3^S#:_#Z&0>+/
MBD?A+\/;368O#4_C2]T&UU+P=!?:AJ>D^%(;FT_X237S#9"WT?2)KA(;RYF(
MDSL KS2#]IK]J#P#X7T+Q?\ %#1M0M? _AC]H/PWX&\6>*_&/POF^'.M>,?A
M-XWM8[6Q\6MX;GO)XO#NH>%]>(M-0ETZ62QN_MEE%M+13/<?5.G_ +"W[+FE
M>%]<\'Z=\-KFWT3Q!=Z#J-W'-X[^(VI7MEJGAAKYO#^J:#JFK>+;_4?#>HZ8
M=2O5BN]!N=.EFAN'MKLW%MB$=Q8?LQ?!NU^&WBSX37V@:SXD\%>.KE+SQ=:>
M+?&WC7Q+JNMW4(L1;SR^(=7\07.O6+VHTRP-H-*U&P2U>V26!8YGEDD[H<4^
M'M"A.C_8N*S66(SZMC<=BLRR'+*./KY;CL5AJF)^JXBGG6,J8+%8/!2Q^#PF
M&]O7P-6M]7S"4*&+JJ> X(Y%Q1*.#IK,:. IX7)(Y=3C@<QQ<Z5/&T,#F&&H
MXFI0E@,/#%4ZF)JY=BYJ2HXBE]4EAX5W14XXO\]=>_;/^.NN_P#"/1^$9O[.
MT7XT?'3XI>&/A?XA\-?#5_B%XETOX5_"BSM8+C4M'\)K?VD/BO7O$^KRW#1R
M7LWV?3K#3[Z40LIC>W9>^./C!XY\9?L07GQI\,ZGH/C'1?VE_B/X?LKS6/"E
MWX%N_&'ARP\)VTV@^+9O"MY-<2:'+JMM=&&[LX99+6*[M+C[.=N47]!]=_96
M^!7B#X=^"_A;<^"C8^$OAS.EWX!31?$'B71]=\(WJ&9C>Z-XJL-7A\317<[3
MS/>S3ZK<-?R/YM]]HE2-UMZ-^S-\&M%M_ D,7AO4]1G^&WB;5O&7A'4M>\9>
M-=>U6R\4:Y9BPU;5[W4=5\0W5SK4MY:*L)M=9>^T^W"J;2SMV52.F'&_ F%H
M0_LWAVM@L11GG6'IU897EWUVIA<1@,XRW*\3/,88^G5A6J8#%Y?1S; RAB,'
M+$X?$YC0=3%5G.<UN'N)<5*JL5FE.K2Q.%;JT/KN+^JT<3B*M7$8G"QP\L,X
M5\)0Q%6*P.*<</BH8:C2P_+1HT_8U?FS]E_XW?&'Q5\7_%OP_P#CYXGN/"_C
MR+3?$>JV/P4U'X41^&M.@T:R\10VFE^*/A_\3;?6;]?'6@)II^SZC]N@6Y>\
MN3+:.\%A<32?H;7S_P##/]F#X,_"/Q7=^-?!?AS4X?$MQI4OA^TU'7?%OBWQ
M6VA>'I[M+Z;0/#</B;6M5@T+29+M$F:UTZ.#.T1;_( BKZ K\^XOS'),TS:&
M+R'"RP6#>"PM.KA_[.P.5T88NFIJM]5P>!JXGDPW+[-0GC,9CL=.:J2Q&,KM
MQD?49)A<QPE#%4\RKJO4J8ZO6P\_K6(Q=186I"ERPK5:].C",XU564*>%P^'
MPT*'L>6C&JZSD4445\L>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !61KVO:/X8TF]UW7M0M],TK3XC-=7ERQ"(N0J1HBAI
M)YYI&6&WMH$DN+F=XX((I)9$1J/BOQ9HG@S29-8URX>.'S8[6SM+:)[K4]6U
M&X)2STG2+"(&XU#4KV3]W;VL"EC\TDAC@CEECX30?">M^+-7LO&_Q(MT@EL9
M?M7A#P$)4NM-\*$@B+5M8=,V^L^,&C;_ (^</8Z%O>#2@T_F7SW&*MS3;4%V
MMS2:M>,4^NNLK-16]VXQEC.HU+V=-*55I.SORTXMVYZC73?E@FI5&FE:*E.%
M*QT'6?BC>VOB'QS87&D>"K2>.]\,?#V\79<ZI)"XEL_$'CR$%DDF#*ESIGA5
MB]KIS".;51<WR^3;>V@ # & . !T ]***4I.5M%&*TC%;)?JWNV]6_DE5.FH
M7=W*<K.=25N:;2LKVT26O+%6C&[LM7<HHHJ30**** "BJ&I:MI>C6IO=8U+3
M])L@Z1&[U*\M[&U$DA(CC-Q=211!W((1"^YB#M!Q7._\+$^'_P#T/7@[_P *
M?1/_ ).IJ,GM%OT3?Y$N<(NTIQB^SDD_N;.QHKCO^%B?#_\ Z'KP=_X4^B?_
M "=1_P +$^'_ /T/7@[_ ,*?1/\ Y.I\D_Y9?^ O_(GVM+_GY3_\#C_GYK[S
ML:*X[_A8GP__ .AZ\'?^%/HG_P G4?\ "Q/A_P#]#UX._P#"GT3_ .3J.2?\
MLO\ P%_Y![6E_P _*?\ X''_ #\U]YV-%<=_PL3X?_\ 0]>#O_"GT3_Y.H_X
M6)\/_P#H>O!W_A3Z)_\ )U')/^67_@+_ ,@]K2_Y^4__  ./^?FOO.QHKCO^
M%B?#_P#Z'KP=_P"%/HG_ ,G4?\+$^'__ $/7@[_PI]$_^3J.2?\ ++_P%_Y!
M[6E_S\I_^!Q_S\U]YV-%<=_PL3X?_P#0]>#O_"GT3_Y.H_X6)\/_ /H>O!W_
M (4^B?\ R=1R3_EE_P" O_(/:TO^?E/_ ,#C_GYK[SL:*X[_ (6)\/\ _H>O
M!W_A3Z)_\G4?\+$^'_\ T/7@[_PI]$_^3J.2?\LO_ 7_ )![6E_S\I_^!Q_S
M\U]YV-%<=_PL3X?_ /0]>#O_  I]$_\ DZC_ (6)\/\ _H>O!W_A3Z)_\G4<
MD_Y9?^ O_(/:TO\ GY3_ / X_P"?FOO.QHKCO^%B?#__ *'KP=_X4^B?_)U'
M_"Q/A_\ ]#UX._\ "GT3_P"3J.2?\LO_  %_Y![6E_S\I_\ @<?\_-?>=C17
M'?\ "Q/A_P#]#UX._P#"GT3_ .3J/^%B?#__ *'KP=_X4^B?_)U')/\ EE_X
M"_\ (/:TO^?E/_P./^?FOO.QHKCO^%B?#_\ Z'KP=_X4^B?_ "=1_P +$^'_
M /T/7@[_ ,*?1/\ Y.HY)_RR_P# 7_D'M:7_ #\I_P#@<?\ /S7WG8T5QW_"
MQ/A__P!#UX._\*?1/_DZC_A8GP__ .AZ\'?^%/HG_P G4<D_Y9?^ O\ R#VM
M+_GY3_\  X_Y^:^\[&BN._X6)\/_ /H>O!W_ (4^B?\ R=1_PL3X?_\ 0]>#
MO_"GT3_Y.HY)_P LO_ 7_D'M:7_/RG_X''_/S7WG8T5QW_"Q/A__ -#UX._\
M*?1/_DZC_A8GP_\ ^AZ\'?\ A3Z)_P#)U')/^67_ ("_\@]K2_Y^4_\ P./^
M?FOO.QHKCO\ A8GP_P#^AZ\'?^%/HG_R=1_PL3X?_P#0]>#O_"GT3_Y.HY)_
MRR_\!?\ D'M:7_/RG_X''_/S7WG8T5QW_"Q/A_\ ]#UX._\ "GT3_P"3J/\
MA8GP_P#^AZ\'?^%/HG_R=1R3_EE_X"_\@]K2_P"?E/\ \#C_ )^:^\[&BN._
MX6)\/_\ H>O!W_A3Z)_\G4?\+$^'_P#T/7@[_P *?1/_ ).HY)_RR_\  7_D
M'M:7_/RG_P"!Q_S\U]YV-%<=_P +$^'_ /T/7@[_ ,*?1/\ Y.H_X6)\/_\
MH>O!W_A3Z)_\G4<D_P"67_@+_P @]K2_Y^4__ X_Y^:^\[&BN._X6)\/_P#H
M>O!W_A3Z)_\ )U'_  L3X?\ _0]>#O\ PI]$_P#DZCDG_++_ ,!?^0>UI?\
M/RG_ .!Q_P _-?>=C17'?\+$^'__ $/7@[_PI]$_^3J/^%B?#_\ Z'KP=_X4
M^B?_ "=1R3_EE_X"_P#(/:TO^?E/_P #C_GYK[SL:*X[_A8GP_\ ^AZ\'?\
MA3Z)_P#)U'_"Q/A__P!#UX._\*?1/_DZCDG_ "R_\!?^0>UI?\_*?_@<?\_-
M?>=C17'?\+$^'_\ T/7@[_PI]$_^3J/^%B?#_P#Z'KP=_P"%/HG_ ,G4<D_Y
M9?\ @+_R#VM+_GY3_P# X_Y^:^\[&BN._P"%B?#_ /Z'KP=_X4^B?_)U'_"Q
M/A__ -#UX._\*?1/_DZCDG_++_P%_P"0>UI?\_*?_@<?\_-?>=C17'?\+$^'
M_P#T/7@[_P *?1/_ ).H_P"%B?#_ /Z'KP=_X4^B?_)U')/^67_@+_R#VM+_
M )^4_P#P./\ GYK[SL:*X[_A8GP__P"AZ\'?^%/HG_R=1_PL3X?_ /0]>#O_
M  I]$_\ DZCDG_++_P !?^0>UI?\_*?_ (''_/S7WG8T5QW_  L3X?\ _0]>
M#O\ PI]$_P#DZC_A8GP__P"AZ\'?^%/HG_R=1R3_ )9?^ O_ "#VM+_GY3_\
M#C_GYK[SL:*X[_A8GP__ .AZ\'?^%/HG_P G4?\ "Q/A_P#]#UX._P#"GT3_
M .3J.2?\LO\ P%_Y![6E_P _*?\ X''_ #\U]YV-%<=_PL3X?_\ 0]>#O_"G
MT3_Y.H_X6)\/_P#H>O!W_A3Z)_\ )U')/^67_@+_ ,@]K2_Y^4__  ./^?FO
MO.QHKCO^%B?#_P#Z'KP=_P"%/HG_ ,G4?\+$^'__ $/7@[_PI]$_^3J.2?\
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<>[OZE)**LDDNR22^Y!1110,**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img147150826_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '"!#(# 2(  A$! Q$!_\0
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MRIM-\LK7LQ.45)1<DI23<8MKF:C;F:6[4>97:VNK[H[JBBBI&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%?*6@?MX?L.^*_$NB^#/"_P"V7^REXD\8
M>)-<TWPQX=\*:!^T1\(=8\2Z_P")=8OX=*TCP]HNA:=XPN=4U77-5U2YM]-T
MW2;&UGO[Z_GAL[6WEN)4C;6G0KUE-T:-6JJ:3J.G3G44$[M.;BFHIJ,K.5EH
M^S,ZE:E2<55JTZ;F[052<8.332:BI-<S3DE97U:[H^K:***R- HHHH ****
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M-+\/67Q3EN-?C3X?7>NZE:76G:-;>+6TB;5+ZVN+2Q2>XADC5?A3^TS^S?\
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MU:YN=1;2[3L?A1_P1[_:%_9VM+[X3?LX_P#!4/XZ?"7]DF\\47OB"W^!=O\
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MISEF4:N%C]8P#S;"5U0C)UEB:?L,%3<51E2C2I_5[4)3G4C%_E5\)?VJ[O\
M:\_X*)?\$./B1XABNM)^*?A[X>_MT?"GX^>%KQ/LVH>%_CE\-O@=XH\/?$33
M=2L8XH8;&35=1L[3Q996$:O]CT?7](MYG-S!(J?9'_!*34[7X:?MZ?\ !87]
ME;17GM_!'A7]H?P;\=O!6B1-,=*T6^^-.D:[J7CVUL;9I#;Z=#%<6GA&TLH+
M:-5EM+/RR$BL8%/M]G_P2-\'Z!_P5!\/?\%'O!_Q=U#PWIVG7WC[Q;K?[/L?
M@E+S0]7^)OQ,^$VL?"?QIXZT_P :GQA;'09/$MG>:1XCUW31X+U*;4M?TB69
MM7A@U!(K#G/^"4WP@^)W_"ZO^"D'[8GQ8^&WC'X5ZA^U/^TS_9GPX\*_$?PS
MKWA'QO\ \*=^#4>O:+X)\37WAWQ+IFFZMH]GXKMO$SF&.:&,WQT-;E(GTY-)
MO+K',,=EF)R[&_49VPT<BP&'CAY*4)8?,:W$>(S%86"J1BZRPF%K8B"K4^:$
MJ2DN?FD[:8/"8^AC<+]:A>M+-L76E7BXR5; TLDH8%UY\CDJ?UG$TJ,W2FXS
MC4L^6T4S]I*Y[7M:U+1_LG]G^$?$/BK[1Y_G?V#<^%+?[!Y/D^7]K_X2?Q/X
M<W_:O-?R/L/VS;]GF^T_9]UOY_0T5\(G9W:3\G>S^YI_<SZZ2;5E)Q>FJY;K
M7^\I+79W3T>EG9GGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?
M"G_YYU>A457-'_GW#[ZG_P L,_9R_P"?U7[J/_RK^KORMY[_ ,)IXD_Z)'\0
MO_!E\*?_ )YU'_":>)/^B1_$+_P9?"G_ .>=7H5%'-'_ )]P^^I_\L#V<O\
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M?NH__*OZN_*WGO\ PFGB3_HD?Q"_\&7PI_\ GG4?\)IXD_Z)'\0O_!E\*?\
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M11S1_P"?</OJ?_+ ]G+_ )_5?NH__*OZN_*WGO\ PFGB3_HD?Q"_\&7PI_\
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MOPQIB6MI97=M!;^'DNM-U._D^R?&'_!%3]D_QYX-^*^B^*/&'QVU#XB_%_\
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ML53?!C_@JEX\^)/BSQYI?QTNOBO\"=<MOC#;>-?V@?V>]'TW2+#3/#-K<?M
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M?BGXLVNKZAKW[/?QL^!>FVEOHEYX>NOC,_P<M;KQK8ZW'J$YN-(\/?#7XO\
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MI4LW&=N7FY>6,K_T)?\ #+7[/W_1+O#OYZC_ /)U'_#+7[/W_1+O#OYZC_\
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MNZ[I?AG2@FB>$[;7?$-^]YKFLZ98K'INDWCQFY$\ZQ6L4\\7BOC+XG?\$RO
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M:3J]G#J&G7B17-U#<1)<V=Q#,L<\,4R!PLL:.&4:W_#+7[/W_1+O#OYZC_\
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MBBBN<V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEFKPN8X7%8J>$C@>2I3=95'*%/W50E.-1\JCS.S>&TLG;%4O-'<>+_AS\$_
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M$?\ V4+4O_54_$ZE3^)_X*G_ *;D*M\$?^OM#_T_3/0J***@U"BBB@ HHHH
M*_*'X(ZK^U%X2^,__!0'XO2?L/\ QETF;XR6OA+XG?!3P]XY^*G[)^D6GB[Q
M3\(OV<_!WP]T[X5^)]=^'_[07Q5N? ^N?$/QMX8FL="\3/X>U_P?HVBW<>M^
M)]6TJ:)M)?\ 5ZBNO#8KZO#$T_84*T<52A1G[9UTXPA7I8BT/8UZ-G.I1I\S
MES/E34.5MM\]?#^VE0G[:K2="<ZD/9JDU*<Z52C>?M:52_+"K/E47%7=Y*5D
ME^7/[6DW[1WQ<\2?#CX3:Q^Q]\8/''[,=SX>\&_$CXXQ?"7X@?LNW/B#XA?$
M#1]<LO$6D?L^WDGQ;_:%^"]YHOPR\.:YHVG:U\2?%&C:?JMQ\5+>&T\ :?'H
MG@^\\67/B'Q/QG^SI^TIK>F?M%?LO6?P-UR?X=_M-_ME>"/VBXOVC#X]^$EK
MX.^&_P ,=8\8_"3XG_$SPYXO\&R>.IOBE>?%3PS?_#KQ%X-\):7X.\#>*_ G
MB:^USPMK&I>/=!TJ/7Y-._;*BNRCG%7#PI4Z.%PD(T;3@DL4_P#:(UJ=:&*D
MGBG&6(C.E!7:=.=.,:52G.G3I1ARU<LIUIU)U,1B92J7C)_[/_!E3E2EAT_J
M]U1E&<G9/GC.4JD)QG.<I?C[^R!\"OB=\*OB[\?K#QA\#?VN_!.L?%']IG]M
M'QIX>^/6C_M*_#WQ#^S7H?@/XM?%?XB>/?AUXPT[]G;4?VJ/%.C6/B^_T6^T
M&.RN;W]D/5-7L?%VI02^+[9-,?Q)J4/"^(?^"?W[3>N_"C_@H-X5N?V@_BUX
MSUCXN?%5O&7PE\+_ !/C_9=T_P %?&"\\.?"W]G.Z\-^-_&^J?";X#^%/%_@
M_6]0\8_#/5OAEY&DZMX-\.Z=H>@6'B._^'.IW5U<>(/$G[>457]N8M8B>)C3
MPRJ5/8<SE2E6L\/7AB*;IRQ%2M4I+GIQ3A2G"DHKW*<)VFI64X;V,:#G7=.'
MMDDJD:5U6I2HS4XT(4H5'RR;4ZD)U&W:4Y0;B_Q8^-7[,O[0O[:VE?MH^,_$
M?PAUC]FK7?B;^P_I/[*WPB\ ?$[QQ\,_%&N>)_&</B'QW\3_ !'XA\4ZI\%O
M&WQ$\,>&OA]>>(M;\(^ =#NX_%-SXLOK*+QIXBUCPIH4$/A^RU;VK]B;]GW5
M/ 7QR^+_ ,8/#_[)^E?L)?"OQC\)/A#X!C_9ZT>X^#,4?BSXH^%-;^('B+QA
M\7+K0/V>/&'BWX4Z38VFD>+/#W@#PWK374'C[QC!I&LWGBG1/#.F:3X8@U;]
M/:*BIG.)J8:K@U3HT\/4C"$:=-XCEI1C'"Q:@IXB:GS?5*3<L0J\X2YW1E2Y
MF7#+*$<13Q+G5G6IN4G.:H7J2DZ[3DXT8N'+]8J*U!T8S7*JL:BB%%%%>2>B
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^>_@CX&:?\3?BG^U9KUW\1?BQX1DM/V@H=(73? GB^+P_
MI$R6_P "/@=>"^N+-])OC)J,K7[037(F4/;6UI%Y8,)9^F'P)^$Y\?-\*1^U
M+\7C\44\()\0G^&P^./AX^/D\ RZU)X;C\<-X._LK_A(E\(2>(H9=!3Q*=.&
MBOK44FEK>F^1H!Z5^S[_ ,CM^UM_V<P?_6?/V?Z_-'XE_&GX.? __@NM_P )
M'\:OBS\-/A!X>UG_ ().^'?#FD:]\4?'?A;X?Z-JOB&Z_;#\67]MH.FZIXLU
M72;&^UFXL=.U"\@TNUGEOIK2QO+B.!H;:=T]/+L/7QCQ-.G5Q'-0P5;$TJ=)
MSDYRI.%J:A%WL^9_"KJVB//QM6CAE0J5*=!JMBJ5"I4JJ"48U%*\W)JUTXI+
MF=M;'Z)_\,CZ+_T6[]HW_P .9;__ #.4?\,CZ+_T6[]HW_PYEO\ _,Y7X.Z-
M^T'\;-5^,&BWD/QQ^+%Q_P % HO^"O%Y\)_%W[*%O\6_'DGA/1_V,K.QU30M
M0M_^&2QXH7X9CX#V/P-2R^)MG^T;-\/;:^O/%[V?CE?BU>>([N&6_P# H?VS
MOVK/V=O$UI_PF'QI^*OC#PG_ ,$H?B[\5/ 7[55UXB\3^.?%=G\8O"?[37Q8
M^)O@3]GC5_BW>ZEK!OO'[Z!HMGX-N_!NI>(IVN/#%O)!<Q+'JUV-07WH<-9A
M4]VGF"=7DC)4Y.M&524U4ITI4=7[3#XC&/"8/"XBT8UZN+BU&,:<K^3+.\##
MWIX*U-R:]HHTG&"C[.<U4NER5J.&>(Q.(H^\Z5/#23E*4XV_I?\ ^&1]%_Z+
M=^T;_P"',M__ )G*\ATSP!\#M8^-WBG]G'3?VF/VC;GXS>"_ .@?$_Q+X-_X
M2_7(?[-\#>*-5O=$T+7/^$AG\"1>%;S[=J>GWEM_9FGZY=:Q;>3YUYI]O;R1
M2O\ .^O7O[6/P/\ ^"(&I>)-.\:_$/QI^UOH_P"R7+\0=7\::UJ^K>-?B/8^
M,?&=K_PF_C.Z@U35FU;4KS5OA_I'B+6[3P^L?G0:1#X;TVTT>.WL-/L8H?QU
MN?BAKW@_Q[_P4.^*?["GQE^*GQS\5:=_P2\_9QU?PI\3]4\;^+_CWXNL+VZ^
M)-M:_%W5O!WCOQA?>*==\37G@W2KGQSXEN[=?%'B2S^'?Q#M/%/@FSO/#$7@
M@^#_  EE@,EK8Q8YK,)M4,3/!8>K"=2-"5:&+P6'C7Q-1J?LL/4AC/:4E;FJ
M*G5:G'V+C4O%YG1PSPB>!@G5H0Q5>G*%-UHTI8?%5G2H07*JE>$L/R5'?E@Y
MTUROVO-#^G#_ (9'T7_HMW[1O_AS+?\ ^9RC_AD?1?\ HMW[1O\ X<RW_P#F
M<K\(?$WQ-\2ZZ/VW_!/[&7[>GC&/]EEOV;/V6KCPU^UK\8/C_P#&WXS_  Z^
M%7[3&O\ Q<TFR\4^%-1_:,GUKQ?X[^$=G\0?A7-96GQ9NO#VN:;9_!2Y\6Q^
M,;J#X?S:=#;0^9>)_P!KGXM_%#PO^R1IUOXP\6?L\?LT>+;?]M?1HOB#\:_^
M"C/QN^$?P\\1?&'P9XQNO#GPUFT[_@H=X8^&>I?$SXO_  YT/PO+K?C3X*:!
MX^M-,MOB1J46NZ%XHUWQK:_#?PW)+<.'<?4491QM11<[2C.,Z56E%Y<LPC"I
M3J5HVQ,X*=.-",YJ$J<I5JM&$Z+JQ+.<%"ZE@Z;DHWBX<E2E4?UU8*4H5*=*
M5Z$)2A4=:48N49J-*G4E&JJ?]%?_  R/HO\ T6[]HW_PYEO_ /,Y1_PR/HO_
M $6[]HW_ ,.9;_\ S.5L?L8S_$:Y_96^!$WQ;^+'P\^.WQ%/P[T1/%'QC^%'
MB"+Q9\/?B5=Q))%;>+_#'B>#2M#@\06>L:<EG<SZQ#I-A%J%^UW=1P!)0S?3
M=?-5IUZ-:K1>(G-TJM2DYPJ5.2;IR<>:/-RRY96O'FC&5FKQ3NE[M*%"K2IU
M?J\(>TIPJ<DJ=/FCSQ4N67+S1YHWL^64E=.S:U/DS_AD?1?^BW?M&_\ AS+?
M_P"9RLG7_P!F;P1X4T+6O%'BC]HCX[^&_#/AO2=2U_Q%XBU_XNZ7H^A:!H6C
MV<VHZOK6M:OJ.AVVGZ5I.E:?;7%]J6I7UQ!9V-G!-=74T4$3NOV316:KUKJ]
M6LU=72JR3:ZI-W2;6S:=M[/8MT*-G:C13MHW2BTGTNK*Z\KJ_='YE?"]/V._
MC?XDF\'?!;_@H/=_%_Q=;Z7=:Y/X5^%_[67PQ\?^)(=$LI[2UO=8FT/PFVK:
MG'I=I<W]C;76H/:K:6\][:0RS))<PJ_2?$'P5^S5\)?$GA3P9\5/VW?%_P ,
M_&'CR:*V\#>%/B#^TMX$\&>)/&=Q/?V^E0P>%-"\1VVFZIXBFFU2[M=-BBT>
MUO'DO[FWLT4W$T<;?*7[)7Q5\'>./BW_ ,%!/^"L?Q9\1'2O@3X076_V;_@;
MXG?3=:UF/1/V9?V9+_4M4^*?Q T?2]!TS5=:U70OB7\54UGQ/9VNFV5WKDA\
M.?8WT>&YCAMV^ /^"F%OHWC*[_:V^(/P1^)G[+_Q[;_@HS^R3^R3X6^&7P$\
M1_%+Q!X7_:ZL;M?$\.J?##6O@U^SS%\-O%_BCX@:+XQC\1>'/'2V^O7GPJ?P
MUJ-CJGB'Q&^GZ9X-U#4;KZFAD[KYE]3>(Q]&E&GAHU:DI.:IXZK]5>)PCQ#A
M2H*>!I8BI4K*<8.<L-.C%Q]K3J'@5LQC1P'UI8?!5:CG6E3BH*#GA8*NJ&(5
M!2J57'%U*,*=)PE-1C7A5:DJ<X/]A?&K?L;_  U\='X7?$;_ (*%W'@#XF+-
MI-N?AWXU_:U^%_A7QT)]?BMKC0H#X1UUK#7Q-K4%[9S:3&=/WZE%=VTEFLR3
MQ,_T+_PR/HO_ $6[]HW_ ,.9;_\ S.5^+OP7^*%[\#_^"N/[7.B?$3]J;]FG
MX&ZCJOPG_P"">?A_QUI_[1"+K/BGXV7NC_"Q+3Q/H'PA\5:E\>_A FE^,Y)[
MJ^@G\27_ (:^+J_VCXCT#4KKPE*(9+#7OIJ?XL_MYWG_  5/\>?#*Q\*?"K3
MM&_X8-\&^(K/P!:_M8?%'5_A]X?TS4/VB_B;X?M_CGHOAO5OV7-.\-:O\=+B
MTLTT6\\!ZEH6A:'<Z)H>B6%Y\=);"ZDL]'PQ.45X2A&AC)V658;,JE7$8ETJ
M=3V^'PM:4*/M(48N--XAQ<J=7$JRC[1TJDE3-*.84)*;JX2%WF%; PIT:"J3
MA[*K6IJ57DE5DI35)/EJ4Z#NY<BJ0CSGU3X0\%_LT_$'X@>*_A/X"_;=\7>-
M_BGX#_M7_A.?AIX0_:6\">)?B!X,_L+5K?0=;_X2OP;HUO>^(O#O]CZ[=VFB
MZK_:^FV?]GZM=6^G7?DWDT<+;6A?"?X%^*/'WBWX4^&OVO\ XD>(OBCX MK&
M\\=_#;0OV@O"6K^/O!5GJ<5K<:;=>+?!VGZ?<>(?#=MJ$%]936,^L:=917<5
MY:R0/(EQ$S_@-^QKXC\23'_@DOX3^"'A:/XF_M4?L=_"?_@J#??M+?!RUU"P
MT/QEX&\<:AHGCOP[H7PZ^/%WK-WI4?P\U[XG_M%KHMG9R?$*^T4ZKJUQ<^,C
M>G2[AM9N_H#_ ();>%?BA\*/^"F/Q5\%_%?X/?%3P]\6?$_[%7@+Q=\=_$_C
M#6O@?J<EU\5_&?QB^('Q%\<^/]2N/ 'QM^(@O?"7BSQCKVH>%OA_;Z)<ZUXC
MTW2]*TFV\2>%_!VA6MM<1]>,R)8:GF$UF57GP>%J5Z="I6IPKU71S+%8&55T
MW5C-8>I1P]/$TN6#;^N4:<)U5'VE7GPV:JO+!1> I<N)Q%.C.K"C.=*FJN!P
M^+C34XTW'VT*E>I0J<TDE]6JSE"GS*$/V^_X9'T7_HMW[1O_ (<RW_\ F<H_
MX9'T7_HMW[1O_AS+?_YG*^LZ*^1]O7_Y_5?_  9/_,^D]A0_Y\TO_!</\CXO
M_9J\#V_P]^,O[4?ANV\1>*_$\-OJOP@F&J>,]736];D-S\/VN&2:_2TLP\<1
ME\F%?)'EP1Q1Y)4LWT=\3O\ D6]-_P"RA?"/_P!6MX+KRCX5?\G$?M5_]?\
M\%__ %6R5ZO\3O\ D6]-_P"RA?"/_P!6MX+I0;=6#;;;J1;;=VWS+5MZMA52
M5&HDDDJ4TDE9)*+LDEHD>A4445F:A1110 4444 %%%% !1110 4444 %%%%
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MI3ISI5:5Y4Y2_6^BBBO"/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"'CSXA>#M,^#'Q$@T/P!X)U2[^*J?$@>(O'GPP\+R^/&U"P\1_"+P7:Z-?\
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MO&!:PNKBT^':74]O?7@Z?9I^XIN]EHTG;=]^MOQ5W@?$>A.C6K9GD^/PL/\
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M_P!%F^%'_AQ/"'_RXH_X7S\#?^BS?"C_ ,.)X0_^7%?S/44?\06RO_H=8_\
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M &Q_^B4?LU_^'\^)W_T.-']O_MC_ /1*/V:__#^?$[_Z'&OIJBD=1\R_V_\
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M\0M+NO%?Q7\>>%->L(S\.OA[X&DTZ^TK2/@MXML XE\#O?K-!K4ZE-06 J#
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M9XI6A^SQO=>G_$[_ )%O3?\ LH7PC_\ 5K>"Z]"KSWXG?\BWIO\ V4+X1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:.(HTZ\8S@JD5)0J**G'HXS4)3CS)II\LI+LV%%%%<YL%%%% !1110 4444
M%>6_'+_DBGQA_P"R6_$'_P!1/5Z]2KRWXY?\D4^,/_9+?B#_ .HGJ]=V5_\
M(RR[_L.PG_J13.?%_P"Z8K_L'K?^FY'\S-%%%?W$?SN%%%% !7]+GP _Y(7\
M&O\ LEO@'_U%M+K^:.OZ7/@!_P D+^#7_9+? /\ ZBVEU^+^-'_(JR7_ +&%
M?_U&9]]P!_ON/_[!:?\ Z>1ZY1117\[GZD%%%>7_ !,^.'P6^"R>'I?C'\7_
M (7_  FB\7:H=#\)R?$SQ_X3\!IXGUI1$S:/X>?Q3JVE+K6J!9X6.GZ:;F[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 5Y[XT_P"1D^$?_90M2_\
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M^S9HOP<\5?$7XCZM\1?B3\;/BY\4H?"FE>+OBQ\6V^'D7BJ7PCX#M-1@\%^
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M[G]*]%?S1_\ "_\ XZ?]%E^*7_A>^*?_ ):4?\+_ /CI_P!%E^*7_A>^*?\
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M'O\ A%X+_3EU^#7-1OM,TK5VTCP9)=_V+5_!Q\:?V>/V5?A_XL_:>^*W@_\
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M_P#90M2_]53\3J]"KSWQI_R,GPC_ .RA:E_ZJGXG5=/XG_@J?^FY&5;X(_\
M7VA_Z?IGH5%%%0:A7XO?\%*OA_\ M#?##0/C-^V'9_\ !2OXV?LY? CX>^$=
M#U:\^#OPS^ WPO\ B)<V,UG#I/AQH?#FI>+/$/AZ?5-8\8>);N"6&'6;_3["
MTOM5$$VI6NFP>=#^T-?*?[<.@S^*?V3OCAX9M_V>9OVKF\1>#SH<O[/EMXTA
M^'5U\2;35M5TVPOM-L_',UK>'PO>Z593W'B.RU>VMVU"VNM&A.F/#J)M9X_2
MRC$/#9AA9<M*4*E:C1K1JT<#53H5*U/VJ@\QIU,+1FXJT:]3DC3NW.I&FYWX
M<QHJO@Z\>:I&<*52K2E3J8NFU5A3G[-R6"G'$58*3O*C#G=2R482GRH_)S_@
MGM;>/O@]^V?H7P3^)/[6/QW\:ZQ\5OV5H/VH]&^%'C[]G']G#X7>"_%>C^,=
M7TC39=;N_%WP/^)?C749/B=X%U3^T=+\0:/K.GQ:9?$ZEJ&B^(=?TR.QU"[_
M *#Z_EP_X)$>&--^#'[=7B;X2^/?V#OB[^SK\;M<_9EN_%?A[X@?M"_MEZ?^
MT5XOTKX(Z)XYTKP[8^ OAMX>M/A=X*TZQ\'GQ)###?&UU>_U[1H]&TQ)[5M(
MU">XK^H^O2XIAR9G"_(W+!X>3JTX9?3I5KJ?[VE'+:E;#J$OANZLZCE&3DU%
MPC'AX?ES8"7Q)+$UHJG4EC9U*27+^[J2Q].E7<E\6E.--*22O+FDRBBBOFSW
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OY3)_P#7S?\ 763_ -#:OZLZ_E,G_P!?-_UUD_\ 0VK]
MW\$M^)O3)_SS0_./$';*?7'?E@R*BBBOWD_-@K^@7]AS_DV'X;_]=?&?_J>>
M)Z_GZK^@7]AS_DV'X;_]=?&?_J>>)Z_)O&3_ ))?!?\ 8]PO_J!F9]MP'_R.
M,3_V+:W_ *E8,^LZ***_F@_6@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\]^)W_(MZ;_V4+X1_^K6\%UZ%7GOQ._Y%O3?^RA?"
M/_U:W@NKI_Q*?^./_I2,ZW\*K_U[G_Z2ST*BBBH- HHHH **** "O'/C_P#$
M'XA_"SX1^+?'GPI^#6N?M!>/M"_L'^P?A#X;\3:%X/UKQ=_:GB;1M&U3[%XC
M\2@Z)IW]@:+J.H^)[C[:/]+M-%GL;;_2[J"O8Z_*[_@MI\1_'GPH_P""7/[6
MGC3X:ZSJGA[Q;#X8\">'+?6=%GO+75+#1?'?Q=^'W@3Q=+97FGS07EE,WA#Q
M+KL0O8)HVLUD:Z9MD3 ]N6X?ZWF. PO+3E]9QN%P_+5=14I>VKTZ?+4=*=.J
MJ;YK3=.I"HHWY)QE:2Y<=6^K8+&8B\X^PPN(K<U-0=1>RHSG>"J1G3<URWBI
MPG#FMS1E&Z?X3_M _L]_![XP?M6_M&RZ5_P2I^/7Q_\ %^K_ !O^(_B'5_%_
M@C_@H_X7TX>.KBQ\8ZNEAX]T_P"'UMJUUJ?@_2;ZTAM]0\.^'KFWC?P=I$EC
MH4(MX].2-/ZC?V4/V1?@U^Q?\.M8^%GP-L_%=CX1USQGJ7CV^@\8>-O$GCO4
MO^$AU71/#V@7CVVK>*+_ %&_M;!M/\+Z5Y>F03)917(N[N.)9[VY>3^+?]I/
MX\_\$6/AM^SWX(U__@F\WCWP=^W'\"O%/PK\1_![XB6/A3XQZ!XB\=ZOI?BS
MP_I_CFW\<:OK=V=$OK?Q'X6NO$>KW5A-!'%)>01>'-&BM=(U*XTFZ_ODKZ[B
MR>-I8++*,O[2PV$J/$T/JV8K'T*M6>!A@U"L\-B\QQ])4.2O!T)4/8\LW7I2
M@U2@U\WP['"U,5CZD?J-?$P5"K[?!/!UJ=..+>(<J2Q&'P6$J.KST9>VC5=5
MN/LJD9+VDD%%%>"_M+^&_!_C7X/Z]X*\:>&/AEX\L?%>J^$=+T;X=?&+Q]??
M#?X<?$?QA;^+=%UGP=X#\5^(M,\-^-;VZTCQ+XCTK3K#4/"H\$^-;'QM9/<^
M$=;\(>)=!UK5-'N_B*4%4JTZ;<DISC&3BHRE&,I).2C.=*#:5VE.I3B[>]."
MO)?5U).%.<TDW&,I)2<DFTFTFXQG))NRO&$Y:^["3M%^]45^97_!,72=/\%>
M$_VI_A1;^&-#^'VJ_#+]L'XE6&N_"GX=/9ZG\!_A'<>,O!WPX^)&E?#_ . G
MB;3;/1+/7/ UIX>\7Z1XBUZ&\\%_"_Q#HWQ+\2>.K#5OA7X,M?[)BO\ ]-:U
MQF'6%Q-6@I^UC!Q<*G*H\\)PC4A-*,ZD;2C--.%2I"2:E"<X-2>>&K?6*%.L
MX\CFGS0NY<DXRE"<6W&$KQE%IJ4(2334H1DFD4445S&X4444 %%%% !1110
M5Y;\<O\ DBGQA_[);\0?_43U>O4J\M^.7_)%/C#_ -DM^(/_ *B>KUW97_R,
MLN_[#L)_ZD4SGQ?^Z8K_ +!ZW_IN1_,S1117]Q'\[A1110 5_2Y\ /\ DA?P
M:_[);X!_]1;2Z_FCK^ESX ?\D+^#7_9+? /_ *BVEU^+^-'_ "*LE_[&%?\
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MBV__ &I_V$O'_P"TA\7/VI?"GPFOOAK^T-X,LO!EI\%O&_Q.\0_M-?'WQ?\
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M?M<?MDZ1^QW'X!\0^-?@E\?/B-\,_%#>*(_&GQ)^"OP_F^(VE?!LZ'_PCO\
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M]\:?\C)\(_\ LH6I?^JI^)U>A5Y[XT_Y&3X1_P#90M2_]53\3JNG\3_P5/\
MTW(RK?!'_K[0_P#3],]"HHHJ#4*_/G_@JM\1_C!\(/\ @GQ^TY\3_@+K6N>&
M_BMX&\%:3XC\->(/#EA:ZEJVB6VG^-/#$OB;5(;.]LM1M'MK'PE_;MSJ4MS9
MS0VNF1WETX183*GZ#5\Z?M:ZQXBT']G;XG:KX4^.WPV_9F\06NDZ8-/^.?Q?
MM/#5_P##?X?FX\1:/:W-_P"*;/QA?:;X:N+35+.>X\/VD>K7L%N=2U:RV&2<
M11/VY=*,,PP$Y4Z=6,,;A92I5E*5&I&->#=.K&%.M.5.:3C-0HU9.+:C3F[1
M?-C8N6#Q<8SG3<L-7BJE-Q52#=*:4Z;E.E%3BWS1<JE.*DDW."O)?R)?$'_@
MO#^TY>_LV1V_AG]H[X/:=\<_A!\=_%P7Q9X2\!V9M_VE/A3X-MOA])X4L+[P
M=XM?59?#=EXPU7Q9XHL+V_T!M/U37[/P>PT=[3^Q_%FI3_VP>'=2N]9\/Z%K
M%_I=QH=]JNCZ9J5[HMV9#=Z1=WUE!=7&EW1FM[28W&GS2O:3&6TM9/,A;S+>
M%LQK_)=^S[\;OAAHG_!2S2?#_P"VK_P41_8S_:@^#ME^R3<ZIX4\0^$8?@#X
M#_9>T7XB:?\ %@WF@Z)XOM$\1-\-H/BQX<LI-=\0^#-4T_\ M#QLUCK]Y")=
M%TNSD&J_UQ6US;7MM;WEG<07=I=P17-K=6TL<]M<VT\:RP7%O/$SQ3031.LD
M4L;-')&RNC,I!/TO%L,'1>7T<+EU/"<T*^+EB*49QIUUBG2:HPE4P6!J26'E
M3F^6=%*E[;DI1IT[1/!X<EB:JQE7$8Z>)M*CAHT:C@YT7AU-.I)4\7BZ:=93
MC%RA4_>>RYYRG/WB>O#M _9B_9K\*1_$Z'PM^SS\#?#4/QLLM2TWXS1:!\)O
M 6C1_%O3M875UU>P^)R:=H%LOCVRU5?$&O+J5KXJ&JP7RZWJXNHY1J5X)O<:
M*^0A5J4U*-.I."GR\ZA.45+DDI0YDFE+EDE*-[\LDFK/4^DE3A-ISA";CS<K
ME%2<>9<LK-IVYHMQE;=:/0\9\6_LX_L]>/M;\!^)?'?P'^#/C7Q'\+%T]?AC
MK_BWX7^"/$>M_#A=)N[._P!*7P'JNL:'>7WA!=,OM/L+W3QX>GTX65W8V=S;
M>7-;0NEO4?@#\"-8^*>E?'+5O@I\)-4^-FA6R66A_&'4?AOX.O?BGHUG'8WN
MF1VFE?$&YT:7Q;IULFFZEJ.GI!::O#$MC?WMHJ""ZGCD];HJUB,0DHJO624)
MTDE5FDJ=1WJ4TN:RA-ZSA\,GK),ET*+;;HTFW.%1MTX7<X*T)MVNYP6D);Q6
MB:/ =!_91_9;\+?$^?XW>&/V:_@#X<^-%UK/B/Q'<_%W0?@Y\.](^)]QXA\8
M0ZI;^+M>G\?:?X<M_%<VL^*8-;UJ#Q'JDFK-?:W#J^J1ZG/=)J%VLWK%OX*\
M&VD7BV"T\)>&;6'Q]J%SJ_CN&WT'2H8O&NJWNA:9X7O-3\6QQVBIXCU"[\-:
M)HWAVYO=8%Y<SZ%I&F:1+*^GV%I;Q=-12G7KU&G4K59M0C33G4G)J$9<T8)R
M;:A&7O1BM%+5),<:5*":A2IP3DYM1A&*<Y+EE)I)7DXZ.3U:T;L>+>#/V;?V
M=?ASX$\7?"WX>_ /X+> _ACX_BU:#QY\.?!GPL\#>%_ GC:'7]&3P[KL/B[P
MAHFA6/A_Q)%K7A^./0M6CUG3[U-1T:--,O!-9*L Z'X6_!KX0? WP[<>#_@I
M\*OAM\'_  E>:M<Z_=^%_A;X&\,?#_P[=:[>VME8WFM7&B>$]+TC3)]6N[+3
M-.L[G4I;5KR>UT^RMY9GBM($C](HHEB*\U-3K59JI)3J*52<E4G%6C.:<FIR
M2T4I7:6B81HT8.+A2IQ<(N$'&G&+A!N[C%I+EBWJXJR;U:"BBBLC0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY3)_]?-_UUD_
M]#:OZLZ_E,G_ -?-_P!=9/\ T-J_=_!+?B;TR?\ /-#\X\0=LI]<=^6#(J**
M*_>3\V"OZ!?V'/\ DV'X;_\ 77QG_P"IYXGK^?JOZ!?V'/\ DV'X;_\ 77QG
M_P"IYXGK\F\9/^27P7_8]PO_ *@9F?;<!_\ (XQ/_8MK?^I6#/K.BBBOYH/U
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/?B=
M_P BWIO_ &4+X1_^K6\%UZ%7GOQ._P"1;TW_ +*%\(__ %:W@NKI_P 2G_CC
M_P"E(SK?PJO_ %[G_P"DL]"HHHJ#0**** "BBB@ HHKQSX__ !W^'G[,WPC\
M6_&[XK76N67@'P3_ &#_ &]<^&_#.N^,=:C_ .$D\3:-X1TO[%X<\-6.I:WJ
M._6M>TZ.X^Q64WV2T>>_N?+M+6>6.Z=.I6J4Z5*$JE6K.-.G3A%RG4J3DHPA
M"*NY2E)J,8I-MM):DSG"G"=2I*,*=.,ISG-J,80BG*4I2=E&,8IMMNR2;9_'
MG^U;X&_9+U'XW_\ !2;PYXZ_:D\1:[HGPDU;XQ_%OP7?7_[/GB/4/ 7[.7Q:
M^/'[4_[-.A_M%ZMH_C+1-;GUGX@?&GP#K?C[P#\/?"<GA[PU'#X2TC5=/N]8
MUBW@T5+:?^V^OX;_ -KSPM^Q'-^U]^T7X,UG]M7X_P#@KX%^,/V@_C9K/[1_
M[/FE_L<^.O%U[?>/O%GQ?^#?C+XYZ'X*^+UI"(&\/>.?B5^S%\+=3L=<ATV[
M7P_;>$;,:*FL:=JVIQWW]R%?9\6)K!Y%S3QDW*EB*BCB<+/#4Z<98?+8M4^;
M"86,ZM2K"K6Q/LI5Z2E5IS56<JLZE3Y?AW_>LWM##14:E"%Z&(C7G-QJXV2=
M1+$XB4*<*<Z=*A[14:G+3G!TXQIQA HHHKXD^J"BBB@ HHHH **** "BBB@
MHHHH *\M^.7_ "13XP_]DM^(/_J)ZO7J5>6_'+_DBGQA_P"R6_$'_P!1/5Z[
MLK_Y&67?]AV$_P#4BF<^+_W3%?\ 8/6_]-R/YF:***_N(_G<**** "OZ7/@!
M_P D+^#7_9+? /\ ZBVEU_-'7]+GP _Y(7\&O^R6^ ?_ %%M+K\7\:/^15DO
M_8PK_P#J,S[[@#_?<?\ ]@M/_P!/(]<HHHK^=S]2/YH_C_\ \ET^,O\ V5+Q
M]_ZE.J5Y'7KGQ_\ ^2Z?&7_LJ7C[_P!2G5*\CK^X,I_Y%66?]B_!?^HU(_GG
M'?[[C/\ L*Q'_IZ84445Z!RA7[7?\$VO^2*>+O\ LJ6K_P#J)^#*_%&OVN_X
M)M?\D4\7?]E2U?\ ]1/P97YKXL?\D?B/^P[ _P#IUGUO!7_(]I_]@V(_])B?
MH51117\LG[&?BC_P4E_Y+7X1_P"R6Z1_ZEGC.OSUK]"O^"DO_):_"/\ V2W2
M/_4L\9U^>M?V%P%_R1^0?]@,?_3M0_"^)?\ D>YG_P!A'_MD HHHKZX\,*_5
M?_@F+_K_ (U_]<OAW_Z'XXK\J*_5?_@F+_K_ (U_]<OAW_Z'XXKX3Q,_Y(C.
M_3+O_5M@#Z/A+_DH<N]<5_ZA8D_6&BBBOY*/VT**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O/?&G_(R?"/_ +*%J7_JJ?B=7H5>
M>^-/^1D^$?\ V4+4O_54_$ZKI_$_\%3_ --R,JWP1_Z^T/\ T_3/0J***@U"
MOCH_M'?L._M+^)OB;^RKKGQ$^!?Q4\4^'O$EWX"^)?[/GQ&CT"_U&_USP]JJ
MR7&EW7PT^(%C$?&=EIVL:;!<PZAI>D:YHHO+:SN[6]9_LLI^Q:^1/VDOV"_V
M0?VN87?]H#X"> O'6O"!(+/QT--?P[\2M*$,<<=J=)^)'AB;1O&VGBS\FW>V
MMX-<%FKVUOOMI%B51V8*6#C5;Q<\7222=*O@_92J4:L9)JHZ525+VJ23M&.(
MP\HRM)3>QS8I8EP7U:.&J.[52CB?:1A5@TTX*K!5/9M]7*A6BU=.*W*/_#NC
M_@GQ_P!&)_L;?^(P_!+_ .8>OL&TM+33[2UL+"UM[*QLK>&TLK*TACMK2TM+
M:-8;>UM;>%4AM[>WA1(H88D2.*-%CC554 ?DIX-_8$_:R_9J\9^%KS]E+]OO
MXDZQ\%[7Q7X?F\4_L[_M<Z7!\==%7P4NJ6;^)-*\ ?%=VT_XB^#9+?1X[V#P
MWI,1NK$W5RAU/4AY7VD_KG6V8-MTG'-'F=*2E*#F\5&K0=XIQJTL3'EISEH_
MW%6O3DE_%;5EE@DDJE\O6 J)Q4E%8=TZJL[2IU*#O.$=5^]ITII[TTG<****
M\T[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OY3)_]?-_UUD_]#:OZLZ_E,G_ -?-_P!=9/\ T-J_
M=_!+?B;TR?\ /-#\X\0=LI]<=^6#(J***_>3\V"OZ!?V'/\ DV'X;_\ 77QG
M_P"IYXGK^?JOZ!?V'/\ DV'X;_\ 77QG_P"IYXGK\F\9/^27P7_8]PO_ *@9
MF?;<!_\ (XQ/_8MK?^I6#/K.BBBOYH/UH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O/?B=_P BWIO_ &4+X1_^K6\%UZ%7GOQ.
M_P"1;TW_ +*%\(__ %:W@NKI_P 2G_CC_P"E(SK?PJO_ %[G_P"DL]"HHHJ#
M0**** "BBB@ HHHH _A<_:[_ &_O&'@7XX?MP^,+G_@I?^T+X"_:J^"7[<=]
M\//V<OV;?"4WCF[_ &2=0^ 'AKQOH^AZG-\2?#FB^&;WPQJ6L^%=%F\2V7C&
MUN9/[<NM=\&7%O8:+XPNO%,&J:#_ &'?LL?M@?LZ?MK?#W5_BK^S)\1!\3/
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M.V4^N._+!D5%%%?O)^;!7] O[#G_ ";#\-_^NOC/_P!3SQ/7\_5?T"_L.?\
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ML_LP_P#14(O_  DO'G_S+U_/A17TW_$&N&?^@_/?_"G+_P#YV'D?Z^YM_P!
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ME"U+_P!53\3JNG\3_P %3_TW(RK?!'_K[0_]/TST*BBBH-0K\Y?^"G,'P_\
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M_P#D99=_V'83_P!2*9]GB_\ =,5_V#UO_3<C^9FBBBO[B/YW"BBB@ K^ESX
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M^RH.I9WE*;I0]Z3C%<L8A1117D'HA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?RF3_P"OF_ZZR?\
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MJ>HQ221:CJ>E0+:K!I5RLDBW+2B5H56%E9WC^7?^'C_P+_Z%SXI?^"'PM_\
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MP97YKXL?\D?B/^P[ _\ IUGUO!7_ "/:?_8-B/\ TF)^A5%%%?RR?L9^*/\
MP4E_Y+7X1_[);I'_ *EGC.OSUK]"O^"DO_):_"/_ &2W2/\ U+/&=?GK7]A<
M!?\ )'Y!_P!@,?\ T[4/POB7_D>YG_V$?^V0"BBBOKCPPK]5_P#@F+_K_C7_
M -<OAW_Z'XXK\J*_5?\ X)B_Z_XU_P#7+X=_^A^.*^$\3/\ DB,[],N_]6V
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MCPMHW@'Q5:_%S1+SP3XKENO#_@;QAXP^$UQ;^)?#E@^H^,9].UV^BTSC7_8
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M %?GU_P4C_Y(;X5_[*OH?_J(>.J_06OSZ_X*1_\ )#?"O_95]#_]1#QU7UO
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M;I/0[J-6%>C2KPOR5J<*L+VORU(J4;V;5[-7LVK[-[A11161H%%%% !1110
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M7XH_\%)?^2U^$?\ LEND?^I9XSK]KJ_%'_@I+_R6OPC_ -DMTC_U+/&=?/\
MA/\ \EAA_P#L!QW_ *:1Z?&O_(BJ_P#81AO_ $L_/6BBBOZF/QL*^J?V)O\
MDY[X7_\ 77Q;_P"H'XIKY6KZI_8F_P"3GOA?_P!=?%O_ *@?BFO"XH_Y)GB+
M_L19O_ZK\0>EDW_(XRK_ +&6!_\ 4JD?T'T445_%A^_!7GOQ._Y%O3?^RA?"
M/_U:W@NO0J\]^)W_ "+>F_\ 90OA'_ZM;P75T_XE/_''_P!*1G6_A5?^O<__
M $EGH5%%%0:!1110 4444 %%%% !1110 4444 %%%% !7Y]?\%(_^2&^%?\
MLJ^A_P#J(>.J_06OSZ_X*1_\D-\*_P#95]#_ /40\=5];P)_R5^0?]A\/_2*
MAXG$G_(BS/\ [!I?^E1/Q,HHHK^PS\*"BBB@#U?X#?\ )<O@S_V5?X=_^I?H
M]?TPU_,]\!O^2Y?!G_LJ_P ._P#U+]'K^F&OYX\:?^1IDG_8!B/_ %(1^H\
M?[GF'_832_\ 33"O+?CE_P D4^,/_9+?B#_ZB>KUZE7EOQR_Y(I\8?\ LEOQ
M!_\ 43U>OR3*_P#D99=_V'83_P!2*9]OB_\ =,5_V#UO_3<C^9FBBBO[B/YW
M"BBB@ K^ESX ?\D+^#7_ &2WP#_ZBVEU_-'7]+GP _Y(7\&O^R6^ ?\ U%M+
MK\7\:/\ D59+_P!C"O\ ^HS/ON /]]Q__8+3_P#3R/7****_G<_4C^:/X_\
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M?'#X7^(?BIHNC>&OA;XN^'FF_##6_C=^T'X\\+6]_P",?%UOXIU'6[:T\?\
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M+7\'O^RI?#[_ -2S2*_IFK^>?&G_ )&62?\ 8#B?_4B)^H\ ?[GF'_832_\
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MDZBNFGIII8^CR3(Z624J]*E7J5U7J1J-U(QBXN,>5)*.Z>^IY_\ \+9^%?\
MT4OX?_\ A9>'/_EE7F_QD^)?PYU3X0_%73-,\?\ @G4=2U'X;^.;'3]/L?%6
MA7=[?7MWX8U2WM+.SM+>_DGNKJZGDC@M[>"-YIIG2.-&=E4_1%%?+X:L\-B*
M&(C%2E0K4JRBVTI.E.,U%M:I-QLVM;'L5::JTJE)MI5*<Z;:W2G%Q;7FKW/Y
M7O\ A']>_P"@)J__ (+;W_XS1_PC^O?] 35__!;>_P#QFOZH:*_8_P#B-.:?
M]"7 ?^%&(_R/A/\ 4#!_]##$_P#@JE_F?RO?\(_KW_0$U?\ \%M[_P#&:/\
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M2X#_ ,*,1_D9_P"H&#_Z&&)_\%4O\S^5[_A']>_Z FK_ /@MO?\ XS7Z\?\
M!/\ \5^%_!GPA\4Z9XP\2:!X4U*X^)&J7UOI_B76-.T*]GLI/#'A*WCO(;35
M+FUGEM7GMKB!+A(VA::WFC5R\4BK^E-%?/\ $_B1CN)LJGE5?+<+A:<ZU&LZ
MM&M6G-.C)R45&:Y;2O9O==#U,HX4P^48V.,IXNM6E&G4I\DX0C%JHDF[QUNK
M:'G_ /PMGX5_]%+^'_\ X67AS_Y94?\ "V?A7_T4OX?_ /A9>'/_ )95Z!17
MYL?5GXC_ /!0"^LO&?Q>\+:GX/O+7Q7IMO\ #?2[&XU#PU<0Z[907L?B?Q;<
M26<UWI;W4$5TD%S;SO;O(LRPW$,C($EC9OA;_A']>_Z FK_^"V]_^,U_5#17
MZKDGBKF&2Y5@<JI95@Z]/!451A5J5J\9S2E*7-*,5RI^]:RTT/C,PX,PN88W
M$8V>-KTY8BI[24(TZ;C%V2LF]6M.I_*]_P (_KW_ $!-7_\ !;>__&:/^$?U
M[_H":O\ ^"V]_P#C-?U0T5ZG_$:<T_Z$N _\*,1_D<?^H&#_ .AAB?\ P52_
MS/Y7O^$?U[_H":O_ ."V]_\ C-?I9_P3LUS1?!$WQ=/C/5]+\(C4X_ 8TX^)
M]0M- &H&S;QB;L61U6:T%V;475M]I$'F>1]H@\W;YT>[]=:*\7B'Q/Q_$.3X
MS)ZV5X3#TL9[#FK4JU:<X>PQ5'%+EC-<KYI45!WV4FUJD=^5\'X;*\=0QU/&
M5ZLZ'M+4YTZ<8R]I1J47=QU5E4<E;JDCS_\ X6S\*_\ HI?P_P#_  LO#G_R
MRH_X6S\*_P#HI?P__P#"R\.?_+*O0**_,#[ _)/_ (*)Z[H?C>'X1#P9K.E>
M+CIDGCPZB/#&HVFOG3Q>+X.%H;T:5-=FT%T;6Y^S&?R_/^SS^5N\F3;^97_"
M/Z]_T!-7_P#!;>__ !FOZH:*_3N'?$['\.Y/A,GHY7A,32PCQ#C6JUJT*D_K
M&*K8J7-&"Y5RRK.*MNHIO6Y\AFO"&&S7'5\=4QE>E.O[*].%.G*,?94:=%6<
MG=W5-2=^K:/Y7O\ A']>_P"@)J__ (+;W_XS1_PC^O?] 35__!;>_P#QFOZH
M:*]O_B-.:?\ 0EP'_A1B/\CS_P#4#!_]##$_^"J7^9_*]_PC^O?] 35__!;>
M_P#QFOI3]D%'\,_M%?#G6_$BMX?T6QD\4&]U?6U.E:79BX\%>)+6 W6H7XM[
M2W$]U/!;0F69/-N)HH4W22(I_H-HKBS+Q<S',LNQ^73RC!4X8_!8K!3J0KUW
M.G#%4*E"4XIJSE!5'**>C:2>AT83@C"X3%8;%1QV(G+#8BCB(PE3IJ,I4:D:
MBBVM4I.-FUJD]#S_ /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\
M++PY_P#+*O0**_(S[<^*_P!K[QYX'\3?LZ_$;1/#?C+PIX@UJ^C\+BRTC1/$
M6D:KJEX;?QKX<NIQ:Z?87EQ=W!@M8)[F810OY5O#+,^V.-V'X9?\(_KW_0$U
M?_P6WO\ \9K^J&BOT'A/Q!QG">75\NP^7X;%PKXVIC74K5:L)1E4H8>@X)05
MN5+#J5WK>36R1\QG?#%#.L53Q57%5J$J="-!1IPA*+C&I5J*3<M;MU6K;62/
MY7O^$?U[_H":O_X+;W_XS4UOX7\2W<\%K:^'==N;JYFCM[:VM](U":>XGF=8
MX8((8[=I)9I9&6...-6>1V554L0*_J;HKZC_ (C3FG_0EP'_ (48C_(\?_4#
M!_\ 0PQ/_@JE_F?S/?\ "AOCE_T1GXK_ /AN_%__ ,IZ/^%#?'+_ *(S\5__
M  W?B_\ ^4]?TPT4?\1IS3_H2X#_ ,*,1_D'^H&#_P"AAB?_  52_P R.$$0
MQ @@B.,$$8((4 @@\@@]14E%%?BSU;?<^_6B2[!1110 4444 %>>^-/^1D^$
M?_90M2_]53\3J]"KSWQI_P C)\(_^RA:E_ZJGXG5=/XG_@J?^FY&5;X(_P#7
MVA_Z?IGH5%%%0:A1110 4444 >??%KQR/AC\*OB9\2C9'4A\/?A]XS\<G3@V
MTWX\)^'-2U\V08O&%-T-/\@-O3'F9WKC(_-?]G7XL_M(>&OBM^Q?9_%_XZ:G
M\;M"_;;_ &<_B#\2M<\+ZGX"^%W@G1_@S\3/"/A_X9?$JSB^%-[X#\%^'O$U
M_P##BY\.^/-?\&SZ!\4=?^(7BU9]%\+^(4\<&=M?L=3_ %6UK1M*\1:/JWA_
M7;"VU71-=TR_T;6-,O(Q-9ZCI6J6LMEJ%A=Q-Q+;7EI/-;SQGAXI'4\&O@[P
M1_P3P\%>"=(OM)3]H']J'Q$^D? #QS^S1\#];UOQYX(LO$_[+WPR\?VVFV>L
M2? KQ)X1^&?A;6(/'ME;^'/!,&@_$[XHW?Q0^(&CVW@7PW9VWB+[%)X@MM=]
M7 UL%##8FGB8PYZG,E*6'C6FXSP]:E2=&HXN5"6'Q,Z6(J<DJ3K4X.#E-QC2
MGYV+I8J5>A4H.;C!)N,:SI04HUZ-2:J0YE&JJU"%2C#FA4]E.2DE%2<X^&_M
M*_&#]I/6O'7[=%U\'OCOJ/P8TC]A7X"^"_B)X=\(:;\._AAXOT+XQ_$+6? G
MC/XOZM9_%K4?'GA3Q1XIB\ 2^'O"^@^"[#3?A7KGPP\4V4VK^)]=G\4:A/%H
M-O8^+O\ MA?M%^-?A;\5/VY_#?Q8U?PC\-/A!^TS\(/A;8?LIQ>#/A9J7@CQ
MC\,-2USX+^%?B4_C#X@ZIX(U'XM1_$G5;WXK>(M5\'^)O"/C?PMX1T)?#7A*
MUU7X?:TESXC_ +0^[/BI_P $_O 'Q4U?Q%J5Q\9/VA/!=E\3/A9X-^#'[06@
M>"?%W@NVT_\ :1^'_@A=2M-.T_XKZIXC^'?B;Q=I^MZGH>O>(_"_B#QI\)?$
MWPN\:ZQX:\07^E3^(1%;:.^ERZM_P3]^%>I?$+6/$]KX_P#B]X?^&7BGXL>
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MR_Z(S\5__#=^+_\ Y3T?\*&^.7_1&?BO_P"&[\7_ /RGK^F&BOUS_B-.:?\
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M44U4FIN4G4U335DEI8^CR/(Z624J]*E7J5U7J1J-U(QBXN,>6RY=&GOJ>?\
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MG]0%%%%>8?[ !1110 5Y[XT_Y&3X1_\ 90M2_P#54_$ZO0J\]\:?\C)\(_\
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M3_%MOK?@V\UCP-<:;HO]J_\ "1VGT/H?_!7O]F*U\?\ P4^.5[X2^/NF>/\
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M7PK_ &L?!7AKPEX0^%FD^!?BA\+=>\5^#+GXL>$?$=[XSUS4->\;?$J/P_\
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M[ :W_J0C^8_I&?\ )&<-_P#93XS_ -54#Y_HHHK\Y/XX"BBB@ HHHH ****
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M_!/C_HQ/]C;_ ,1A^"7_ ,P]?9-%']HYA_T'8S_PIK__ "8?4L'_ - F%_\
M">E_\AY+[C^<;]J7Q1^PQ^S9\:?C1X$@_P""2'[$7COX;?LY>$/V:?'GQ@\<
M#P-\&_#7Q ?P]^T=\5X?A78V_P +/A8W[-NO:%X\\2>&+J=-5_L'Q!\6?AY_
MPDQ*Z-I-_%J4]JL_U5XST'_@BK\./$GCOPK\1/V1_P!FGP#JOP[\%?%;XB:S
M/XV_X)W7WA/0->\'? ^?2(/BOK'PQ\6Z_P#L]:?X4^,P\%?V]I-UJEA\(=:\
M<:I)IMW_ &K8V5WID%Q=P_3R_L#?"O5OVW?'?[:GQ"TOX?\ Q,U_7/ GP?\
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MC\A/CSXJ_9J^"OQ#^(WA2V_81_9S\5^&OA)X&^'/C_QSX@?P[\/] \02:/\
M$'QK:>#([/P?X3'P@UJP\0ZQID]];7J66J>+_#*:H#+96MQ'=?9Q<^^Z]IG_
M  3P\+:YK_A[Q/\  GX0>&]1\.:!\0/$]W+K_P"RA=:-I&J:'\*[(ZE\0;WP
MCXBU'X56WA_QV?#%@#>7UIX)U3Q!>RVX,MG;7*@D>LR?LK^"]4_:9US]H_Q9
M#X8\8WMUX0\&:!X5\.^(O NE:I=>!O$'@S5I=6L_&GA_Q-J5Y?RV6LO*\0MI
M--TC2[W3Y+>.>+5)6"JGS+J?_!.!]2\;_$#Q<_Q=T<#QKI7[2>FI>2_"2";Q
MZP_:)\+:IX9(\9?$#_A/8[OQM8?#M+Z&3PGI;:/H5M#91ZAI\1L7U22^M]5*
M#23E.+25VG+5VCI9WV:>J26J[(_'<7P_QWEV)S'$8#@SA'/L/C<_KX?+\!C<
MMX9P_P#8^18?-L9[+,%5P\LIJ8AX_*<1@E3PE?$8[%X:IEDJM9QJX^>%H;GA
M.\_X)^^./BAX:^%GAC]EKPAJ.I>+_ G_  L3P_XFE_8]&F>#M0\./J\6D6M\
MNJ:O\.["^BTC4&FBO=/\9S:5'\/+RTFM(H?&+:GJ6F:=>]C\?/A]^R)\"/#/
MAO7K[]DCX.^)[OQ7\0O _@#2=*T'X :'J\IN?%GB*QTV_OYQX3^&GBW4@VBZ
M')JNMV6EV^CW.H^*-0TVV\+Z+&^K:M:E.V;]FGQ?HWC;P)X\\"?%?3/#>N>$
MOV<'_9VO9M6^'#>)C=V4-QIVJZ7XST*/_A-]&L]%UK3]>TJSOFT[6K+QAI%Y
M8K+ILUNKR_;ETOB_^S;K'QI^'_P@\,>*_BQXCM_%WPSU?P]XCUKQ[X>37_!\
MWC3Q)HOA2_TFYUP:#X&\9^%;3PU?7OBJ>Q\7Z?+97M[+X:^QW6B:#+9PZI<W
MR3S1YH^]+ETOK)O3Y+LMMNFQ[*R'B%Y%Q!1EP7PO_K'SMY#C*62<.8;*?8U8
MY?#E]E4S3,<3+$8:57'UH?7*,*$_JD83G54J7M_@?PA\4/V5_'?B'X8^']*_
M8S_8Y\'/\2O B^.+"[^-#>$_A2EW]H^)&L^ M-\.>#+?4_V=]4N?'6NZO;:;
M:>(-*CL(]/LM02^GTZSNYVT]KVX_2+_ADW]EC_HVC]G_ /\ #-?#K_YG*\:\
M2_L>:SKOP!\$_LMVGQ-T;3O@MHWA?X>Z!XS6Z\!^(?$/Q*\277@[Q9IOBS6=
M0\,>-M;^*UUH?@JU\07.DVMMI6C7O@3QE;>"X))K?1)GTZWT;3='^Y:4I+3E
ME):O2\MM.5Z]>EEM9:OIW<$\)YC1CBZ/&61Y%C*GU#(ZU#%K(N&,+268U,/B
M(9W@<-A\KIU:E3#86O1PM:EF&,EAYXN6,J4J& PM+!J>(^?_ /ADW]EC_HVC
M]G__ ,,U\.O_ )G*/^&3?V6/^C:/V?\ _P ,U\.O_F<KZ HJ>:7\TOO?]=%]
MQ]W_ *K<,?\ 1.9#_P"&C+__ )G\E]Q^?7[2_@']F']GWX?Z7XRL/V._V>/&
MNHZWX\\&> =-T2[^'WP^\*67V_QGJJZ5;7U]K4/P[\4SVUI9.PFG6#1+V:1!
MMC0'FO/O">L_L1R^"_&7B7XH?LC_  E\"7_PX^(?Q9^'7CF+PA^SE_PN;PII
M5W\'KRS'B;Q1!XM\"_!EKBU\%II6JZ7?OKOC'PUX+:TNVU?2Y[,OHES=2?7_
M .TS\ +/]I'P!I'@#4==MM"T_3_'W@SQI?->^'8O%%GK%GX4U/[?=>';O2Y]
M4TF VVMP,]C/<337,4$4CF33[U&,)\._:-_83\-_&FP\':)X)UKP7\*_"WA#
MP;\0_!=AX(E^$6C>,/ ND1?$.:RN+[Q9X)\)VOB#P9I/@SX@Z=/%?SZ?XMMH
M=1N(+G4/MUM:VVH6RWDND91M%2E)-M\TKRT2M;JUTMHKK?HD?EO$W#7%6$S?
M.\PX7X4X6S/+,-E&4T\FR/&Y5PU3HYCFV(QM6&9UY5YPR_'4%E^#5*N_K&;8
M?#XA\F'PV&JU)U*]#SOXA^,?^";/P]TKXAZD/V??AAXZE^%\>@2^,+/X<_LL
M:5XHMM-3Q1'HUSX?DE\7+X%L_AY;6^LV&NV>H:3>ZAXRLK'5[:*_32KF]O+"
MZM8_J'1_V;?V2==T&S\1V7[,/P:@T^^L?[0@M]8_9U\.^'=>2#:S^7>>%?$'
M@;3/$^G7V%(_LS4-'MM2W%4^R;W16\9C_83B'PL_:$^&<OQ0D<?':S^&4$>M
M1^#%B/A2X^&GA3PMX=M9WTYO%4HU^'5;GPO#J-Q;+?:(]M!=R:?'=2R1+J#?
M5/A+P?\ $R"_\;3?$KXHV7C/1_%.D^&M/T7P[X3\%2?#.T\$7-CH][I_B^]T
M+7++Q;XB\9SGQ=?7-MJUH=0\3W&H^$IK-8=&U5_,\Z)2<;>[.5U:]W+72&VB
M5U+FW:TBM7H>EP]DN=5,QJ_ZR\"<+4,#BL*XX.&79/D*I99BZ69\2VGF6)GG
M&+Q>(IU\HPG#EY8# 5^;&YFDL/@Z>%Q[I?DO<?M$_L06FE>,=:N?V'?A5::?
MH/A?7]>\.S:M\%M"\,0^)+W_ (7-J_PB\ Z=>ZGXO^#WA[P_X>LO%RZ8?%6M
MZX=:U:V\&VUOXB\//;Z]XC\(Z_86GW;\'O@C^RU\4/!R>*6_9W_8LU(2:G?6
M"77P>TSX=?%_P<ZV?D@JGC _"SP0&U-'D9;[3!HF+'$/^F7!F*Q>(:3_ ,$S
MM"TWP/XK\.3_ !?\4:IXDU;P]\,-,\+>*=4C\8:KI_A#6/AWX]U?XCW>JKX.
MUKXFZKH^KZ?XF\2:M<2MH9ETY?#\-[X@ET348-3\4Z]J5Y]I_ OX/7'P@T;Q
MPNJ^)H?%OBOXE_$_Q=\6/&>L:?H3^%M ;Q%XJ.GVALO#/AF?6_$][HFBZ?HV
MBZ/9I;ZAXG\0WUYJ$.H:M<:EG419VCE*%GR2E>^FLMO=MOIIJM==%ILSY_@;
MAGC?^U<+_KSPQPK_ &;5RA2KK!Y3PK&GA<RAB\?3E&K+"4ZF,K8BK0I9?6I4
M\/#^SHX;$RG4Q4,91G@GG?\ #)O[+'_1M'[/_P#X9KX=?_,Y1_PR;^RQ_P!&
MT?L__P#AFOAU_P#,Y7T!16?-+^:7WO\ KHON/V#_ %6X8_Z)S(?_  T9?_\
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M4?"+6K?PW8:WX\L+*ST?X5Z=XR!\/6+Z5\0],TRQ37?$?B73?$UO?V>@P?\
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M\%^!?$/C37]>NKOP[\+?%<2)9G2M+L9+&]73Y%T[5-3\4M.- \(>);JQ^?\
M2_BE^RSK'Q*^'7P]L_V#O@!;W/C6X^!-C>:=K7@OPGH/Q$AE^,^B7>N:GK_@
M[X;:I\$K?4?&GP^^%MO9SKXW\;7.J^%;:W6*2ZBTX6GDS3_:G[37[(W_  TE
M'X3DO?B?XC\(:EX9\%?$'PI)>:3)XHCM=3O?'?AV#PZ^N2:+H/CKPKI,8L[6
M76H]3TN:UO;?Q1INKGP]K4\N@V\FGW?FWB/_ ()^Z5K7Q9M?']I\0;2ST.Q\
M4?!GQ#H\6I>"KWQ#\7/".G?!;0]/T31_!_@CXW:AX\75M#\->($TVVN_$_\
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M  CUG*L<3C6KF'[!WFFZ;8:-I]GI6E6<%AIVGV\5K96=K&L4%M;PJ$CBB10
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M=AX_\?:MX-7P/X:^'OBW4+&3PHNK>-]4\#6OB/3(8_V9_P"'='_!/C_HQ/\
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M;2/AY\2/B;\:?'?@[QEX"\0:[\)?#:^._@9;>&OA9I?PQU70_"'Q'U"]UWQ
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M[W3YO"&K?$#Q)XI^&7C*^O=(\2^*M-^$DW@!? WBOX@_?/[<O_!/F']MK3O
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MKC\QG3Q*X;PV'KXK^T8X+D6/HT\/5KYAA\2Z7SC/IWPEL_&/[/'A^[_X)_\
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MT[QM:7]_IJ7'A[3?#'B"*6QEO-9BU(:-:0W][^GWQ!\*_P#"=^ O&_@C[?\
MV5_PF7A#Q+X5_M/[+]N_L[_A(=&O=(^W_8OM%G]L^Q_;/M'V7[7:_:/+\K[1
M!O\ -7Y,U']A_P $1_LW^'_@/X/G\(^"]5T^#X1S>+_&6E?#32(M(^+>L_"V
M72)KBX^+/@S2]7T6Y\;:-XPFL+^XUC1]4\8/=)=ZD+A]:O6MYA?.,E:TI2NV
ME=.6BNKOJM+;6;VML>1Q3PKF\<VPV*X6X?X;J9;@<FS+%5\MQ&4<.JEG.<0A
M4AEV62GB<)#&X=5:DJ-66*I8_+\-1A1DJM2JYJFN L]8_P"":.IW?AS3-(^#
M/P?US6_%:>(VT7PSH'[(^K:]XM=_".MW'AWQ1;:EX1T?X17WB;0;_0-4M9TU
M;3M>TK3+^RLU75I[=-)EBO7[SX"_#_\ 8J_:)^&^E_%#P1^RM\+])T#5;J_L
MX+3QM^SIX(\,ZJ)M/F$,TENL_AR?2]:T]BRB+6?#>JZWHC7*W>EMJ*:SI>KZ
M=I^%^SC^PN?@#\0/#OCT_$K3?$3:'H7Q2TA]!T;X;P>"='>3XF^+-&\52/I%
MK;>,-<M]"TK0)-*;3M.T6"VNHC9S0K'=6JV@CG]1^ _[/WQ(^!_ASX5> [7X
MU:?J_P /?AM)\1+;4/#=G\+K+2+SQUH_BI[34/!\.N^(-1\7^)K[2]9\"Z[-
MXBOY=4\,QZ/IWBJRU>QTV^T"P;1C?:E4G%7Y9R;TLVY6ZW5N5=HVO;\#S^',
MIXIK8O+*_%/A[PEA,%6H8JCC\!E&4</SKX3%S?"M/!XNIB\1Q!7A4PM.IB>)
MJ]>GA*=:M3P>60I0H8W%U\"\3\E^+O%7['_ACXZ77P.M/V'/ASX@U2V\=>!?
M!2ZGI?[.\,QNV\2^#_&GC+Q)J5G:6WP8O-.N$\)Z=X;T>:WB77Q!XCTG7=1\
M46]_IWACPCKNJI-^RQJG[+W[2WB/5-%3]B7]F_P]8V7@/2O'/]K^'O"WP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;>[?=FJ2222222225DDM$DEHDEL@HHHH&%%%% !1110 4444 %%%% !1110
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M=?ULQF-&$ ?[)H^DPN6:P\/Z4)9(]-L58LSR7%_>//J-[=W$MI)+FEM]F/\
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M .!2_P P]C1_Y]4O_!<?\O)?<>>_\*Q\-_\ 02^(7_AW/BM_\VE'_"L?#?\
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M(7_AW/BM_P#-I7H5%'M*G_/R?_@4O\P]C1_Y]4O_  7'_+R7W'GO_"L?#?\
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M^*W_ ,VE'_"L?#?_ $$OB%_X=SXK?_-I7H5%'M*G_/R?_@4O\P]C1_Y]4O\
MP7'_ "\E]QY[_P *Q\-_]!+XA?\ AW/BM_\ -I1_PK'PW_T$OB%_X=SXK?\
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M]E#X@>%/&GAW6/C'I6J>+;+Q1I_CCX&:YX2^'UGX3UWQ7>W?@H#P+I&O>/\
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M^U'\9;;X^?''QWIOQ)\5?L[?LS_%R#]CWQ7>_#W2O#WP_D\<^ /#]S\3M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5.5U7I4Z52SG"3@^2E"TJ;A+1IR<6XO\JK[]AGXN6&JGQ'\/?%?PT\ ^,_\
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MZM:3UJR/Y]_V]?V>_C=X%^-%_P#%OX<:=XP&@_$[XOZGX@T_4_@;X:^(6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img147150826_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (8 WX# 2(  A$! Q$!_\0
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MW<DD[?TBT5\N7/[;?[(>D:=X"OO%W[2_P*^'EU\2_"GA/QKX-\/?$GXL^ /
M7BO5_#_CC2;#6O#%U!X:\4>(M-UAGU2PU*SDMXDM7:1YECC+L1GT3QW^T)\
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M%PH_6)TE&;Y:7-"-Y3Y?9J5ZE-^S<_:<LX3Y.22D_K"BBBN,Z@HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_&%_P $VO\
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MDN:I*4M+I(HHHKQCTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^?<+B*9)&C258Y VR0%HY0ISM=>"4?&&&0<$CBMC4]0F>Z6X6QM]*N'4S,+
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M76/#5Y>0R3Z)K=C=01S6=SIFM0;K*</$7\P>>9H7#12QHZL*ZSX-+I5W\1=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X=_\
M!R)#'<?\$7/VSHY3;B/9^SV[&YF\B'$/[57P-F^:0*YW90>4B*9)9=D4?SNM
M?Y-DFG7-M*_VZ&:%;8W,*6-_!+;374(<-'$MG*(Y87+9+!T0C;T)))_UK?\
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MS0&%U^55R244@[VQKV^748T9[:.&X@4J&MD6.)X2[NV^)1@,C2$!TPH0*I4
M9KH-.\7WB>'=8\,7^;RPOH(Y;(R!6EL;^V9!#+'(1O\ *:$/#)&6(QL*@% :
MPJ4*D*M'&T\,YXJ,HT<1%8F=).C5E1A5JJG'GHU73A"-:,)QA-\BC&I&5U+T
ML'FN$Q. S'A?%YU'#9%7HU,QR:K/(\/CZE+,L!3QV+P6 EBZDL-F67+%8G$U
MLOJXBA6Q.'3Q;K5\'6AR5:'/0WBR6T-A>/(;)+EIHUB8"2W>3REFD565E8/&
MH4 _Q+G Y)KM<"VNKI]-DN(;=VNH8#(ZFX-E-OC$<[(JHSR6[!)]BJC,6VJ
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M+J0Q]' 8:$I8+ TL%0KNE0IU98:G+%4J#J<N'Q.)E/F56J[>U:W\&_AEX?\
MV>]$^(WB?QEJ>N?%/XBR:N?!G@O2+:R>PL]$T>^FTW4=4UO5A.;^#4%OX0UO
M:>2"T05I%:.59#\B_P#"9ZB^CZ3X0U:&P@@T7?<:?>V-L$GO)Y909C?SC#S3
MQ?.L0D;$2L^W/ 'TEX[G^'7A[P=X2\%>$+D:IJ5UK6J^)-4\5S_+J6A/<3#2
M8M%D\MI(?L(TO2K36)?+'SW.HR;R!"!7!:CI'A.?PSI6G>'-)CUGQ0QN]3\3
MZW.L@,R+)-''I6G0*1;^1';B*_:Y7$TDDZC&U"3.0XB=+#U:N9O,,P6,SG'8
MC!5,7AZ.#_L[#1J8FEAO948\E/#8*CA8+#P=;VF*Q=6HZ]1*->'LHX6Q=:CA
M*]?.I9OFZS'B3-,7EM7,,'A\O63X.%;&8?!?5Z$.2E@LNP^ IQPL)8CVV.QU
M>K+$U4H8JG[#@;QXWA:]>[=[JYNMUS8S6ZB2Z2:)Y)[F$0J$55,0)'!3<"O
M85DZCH$&MVODJT=K%:1-)!?/@>4VW>(7=0"69<J(W)W8)ZU:@N%M=2N(;R.=
M;#3+F6&UN) '-OM+E(;@K@.#EXY6Y.S#'&6 =J^I1&5M.M%S;+,PC,+!A*KG
M=&';D2L6)*,5XC;@XXKZ>G[:G4I*A>+5JD:D>7DA3?+LHJ*<HPE%<DU)I2:;
M<5&_V]+ZQ2K4%AW*,E%5H5UR>SITFH\J2C&,93C3E&+A4<FE4E&5XJ"?C_\
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M:[7MQUBO0_,*JM4DKWLTF_.RO^(44451F%%%% !1110 4444 %%%% !1110
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M2,I1ASRBK&7>22:QX@GTO3KB;5K..[*6TK.\PN9<LD#-C[\-K$!($ V_(6Y
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M@U."9I;BW1=/NX&7=9W22JVZ2-N)()4W)( 58<%3D5C$X&?\_P"?\Y%*2/E
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M=N]M<3'#\L*^']E3=5W="$ZS=#71QYY5'&G]A.M6E5;7,X*,DW]^_P#!)O\
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M%\U, LH^8;3U JE=::8;2"YC8O$R(6?.278D,I Z!3P,XQC/6LURI8%LL!M
M<GLJ@!<]MHX SC P.V/I)*CB:<J<HJI!IJ2<4]8\NMGHGY6OMHM;_92CA\;1
ME2G%5:4DXSBXI-2@XI-)Z1=^F^RMN?I=\-_B#X.T7]G3QY&FH6S>+/&&L6.@
MVMK!J303Z?IXTZ6XFO+B"-A++MGM8HK5V;;AWW\A ?G+1[G0;KXAZ3!+?2G2
M1)IEC?R>>D#*EQ+&-1>%G.^%)G\]LQD/&#YAY;;7S9IMI->3,L65C4KYI9BJ
MX)P 2".2 2/3&:^C/#7PQM-1TVXU);VTE:T:(M+/<2123[W* PLJL %C >1G
M/W&5@<DBOS^KD679!/-L1/'XESSG$5*LVZ:;H3K4,-A:4(>\[1HTZ4%3LX:R
MG)IWDU^2XCA;)^%*N?XN>:XQU>(L75KU'*DI/"U,3A<'@J%.%IM1CAZ.'IQH
M_ ^:<YM2YI-?4/[0-UIVE^(M-\,Z#K.D:GI/AW1H%;^S;^.YTVW_ -%:5-.$
MJ!XKIHXHX1(V#BZ60Y#-7A44IME,]K<&.9MMS&/F\OSGWK,S1L=@>!78$@$A
MI%V\L%/*P:5=Z%<K'</ ()Q&;268^9"[!UDVE&PDGE LDR#:&V')YQ6WJ"W-
MW?7+[XG>:"!T\M!;I)+,1.;F!$)C2 K&C1# :5A"^#L.?'P&74\OP>%P4<3]
M:A3H^_BYTXTWB9^TBZE2I37-!.I.<G->T;C9IW?O'SN59/2RG+L#ED,8L?3I
M8=>TQ\Z<*;QL^>,JM6K17/",JE6K4E.+J-P^&7/).:YKQK9--8"ZEN7NIU(;
M$0BV;(!DL$4+(I.XN9"2&<MN"DUE^$_%LFC((;R"5+&=F9;FYAD=;Q[8!U@A
ME(<)/&S.OF(3RZ+)C(JMXINM?TRUNA=Z;((TC$=Q=!68Q>:_+L0?W<<[,$5B
MB]0A8_+G<T8I)I&B&<23Q36,EZ;!I,PV]O<7 ,=M!(-PAGN%@2YG8A6=3&F<
M*:^B4(K+:<*\:>(HSK2C%TJD/=2I^TO#E3BI*T;<Z2U3;3<&?7JG3CD].EBH
M4\7AZN(G&$J-6"Y;4753ING&4(S@XT^7GM%74FXR=,_U>O$,R3_\&Q&N7$9;
M9-_P0<U.:,D%7V2?\$^IW4D=0V&!(QD&O\CGPG+/)I6KZ1HJ7!\0:NJ6JQ6Z
MEGN])PTM[ 1\_P V$ "QQES'N)8 5_KAZV5'_!L)JY1#&@_X(,WY6,L9"BC_
M ()\2D(789<J,*6(RV,D9-?Y%/@CQ-K'A?Q5I.MZ%.+;5H;E(;*9D5E#W@^R
M,'1LAHV$QRN!G'Y?3YA1J5<KY:$(3JTL/3KX>G7J.%&I6P\8U:%+$3C&;5&5
M2$55E&$FHW<8\R1_1WAACL#EV>9$\QKXW"99BYX?*<SQ678:EB\VP64YI1CE
M^98O*J53$X6E/-,/@J]:6"C+$4*57$<M.=:-.<CF75X]RL%#1,1CG<"K%?+Y
M'\)'([8 QGBI4A6X;>8L%L%O*7"\#J !]21C!.3WKT7XF^"K/P1JMQI<OBBT
M\1>(&O9)M5BL;">"&R^T1K=-YUQ-,ZO<-/,\30(@,04NS ,JFE\.+F'_ (2K
M0+271;?Q ESJUI"-&GN([(7[/(H%J]Y-)%# DXRKO-(J+GYLBN>.:4J^4O-L
M&I8BA]7GB:;:GA/:THP]HY0>,C0Y:<^7FA5K*G2E&U1S5.S?U57@3,,KX_AX
M?<13P^4YG'.<-DF-IQJ8?/\ ZACJV+AA%1Q,.&ZV;^WQF&=54L3@<MEC,;3K
MQGA(X>>*C*E&_P"._@_XM\">'_"WBK6(]/DT7QE;+<Z3<V%R)]C&(2_9;L;4
M$-SY7[PHGFQXR#('4J."TBQM=3-VE[JT>GM:VCS6HN [K=2Q_=M(R 51VY*&
M1E3@\U]9_MB^)8+CQAX<\&Z?;OI.G^$/#EG'-X;@:)]+T?4KY1.\%E)"D<5R
MT5N4BDN@FUC\L)V<MY'X;MOA[:>!;'6]8CLKWQ':ZSJ3R67VFX>2Y@CM0]A9
MZKI9>!9;*XFW*E[8W<<L)W>?%)\I'SN0\09GB^%,KS?,\/6>-S:K*6&IY;AJ
M<IT</B*V(JY?[6-2I4HOFP<*,*U:$I4JDZL94KJ49'[/XL^$' _#GT@>//#S
M@;-L!3X8\/L'AJ&<8KC3.<71PN99SE&6Y+@.+HX*M@\'@\QA*GQ)C<RQ.799
MB:%'&X3#8&K0Q_)5H5:)Y[X0\&:_XXUZ#PQX9M%U36KHR"TM$FCA-P(T,DCB
M6=DB1(D!:1Y'1549)ZU4\2>'M1\+ZK>^'M8M4M=6TRX,%]$'65X9U7+V[NA*
M,8^A9,J2>"PP3>\,^+=5\&^)[3Q7X=F&G:K97;WEGY!/E0>86/V=3D%[8(QB
M:-R1+&-K[LD'=\8Q:SXCL(_B7J=ZFHS^*-:O8-4E$BM/;ZHH$BQS0I!&+?S(
M@3$ \H9$505"XKWYXG,J6;TE7G@X9/B,+3I8=-55CWF[G4J3I3:E]6>%>%IM
MT[14W73BI2BXI?DF&R;@S,?#G'U,KH<2XKQ*R?/<9F&<-2P$^$J?AO3H9?A,
M/CJ-*=*.<0SVGGN-IT\7S5*F%AEDZ=1TZ56%>53+TKQQ>Z9X4OO!KZ7I%YI-
M_J<6IRW-Q8QMJ]M+&FPQV6H@B>""4']Y%DJQ (4'FO.WQO8@$ L2 ?3)Q6AN
M(8XP<?*> .G'(XP?7H>.F:B>-F5CC!!W8(ZJ.N?;N>N/7L?5PV'P^%J8BI1I
M1I2Q=55Z[BY)5*SC&#JRB]%-QC&,FDKI+FU5S\_SK.,YSS"91@\QQ];'T>'\
MO_LO*:=:,)/!993JU,13P-&K&,:CP].M6K3I4JDIJG*K45.RDHJGT_'_ #Q^
MF>_;ZR18+A2<!B!GH/;/L::P8]L #ID'\:;V]\]?\^G]:[G:2:[_ (=>A\Q%
M\DXRM=1:E9IKF2>J]'JK^MM3U?X9P/;Z]-K9T277(= L+J^-N+:6>U@F5-L%
MY?!(Y$%M:LWGLC[1*%"[D!W53^(WCW7?B!KZ:IK,]E<2V-G;:-9-IULMG;FQ
ML\K HC7#.SEV+/*6<Y"DE57$7@CXF>)? MEXFTS2+B%;'Q=HD^A:NDD:O(;2
M8@K)!*</#<0MRCJW*[D;*DBN"!(P0<%-NW P<@Y##' ((!^N*^=HY;.6=XO,
M\9A<-S4*-'"Y5BHU95:WU:I34\7S4YTXQPDWB+QDJ4Y^VI\DJDG:,(?L68\;
M8;#^%W#W!'#F?9TJ&:9GF.?\?Y%5P5#+\N><X/%K#\/2HXK#XNM4S^A#*/9X
MBG4S"AAGEF/EB:.$H)5:V)Q7K/CGPSX<\(:+X=T^PU.;5?$U_IJZIXMS:A+7
M1+R<QR:9I5C<20QS,QM',M\=SH\A158@''DF3@#)P.@[#/7'UK:N[^_UB.YN
M[Z]2>XC,+S/<2,;RY542",*2&\X0HJKM)!1%4\XXQ?3G_P"M79EN'KX?#*EB
ML3/%XKVE2I7KSY4Y5*LG5<8*,*<8T:2DJ5""BG"A"G&;G-2G+Y;CC-\KSO/7
MCL@R3#\/9$\)@L-E65X:55JE@L#1IX"-?$SQ&+QE:MF..JX:IF&;UY5W"MFV
M*QM7#4Z&$G1H4[HO;QK5+#[5<_8DD,XM&F<VRS8YE6 GRPY'&_:6(]N*UM:T
M/5M!32)M4LUM4UO3(M6TUA+!*+NPF=TCN (I'*!GC==LHCD!4D)CFN?!/.,X
M&-S '..@]@<=!QG&!S74:WI%[H%KIBW=WIU\NNZ3;:C;-9W<=_)9VC2N8[6;
MJ;&[#J3-!A656P"03G2K-4J^&IPG1A[:I6YJ,J;]I7:ASR=*<9QC"=/2K4<Z
M=5U(KD7))J:Y\OH2QN4YWB\1A\SQ7]FX7+HT<QI8NG]2RF$\7"A0I8W"5L+6
MK8FAB]<%A(X;%X".$Q%58BH\32A+#S_T;?\ @R>M+N']D']K^ZGMYH8+WX]^
M$6M99(I$BN%A\%W22- [J$E1&(5C&S!6R&P>*_M8K^+S_@RK\0:MJ_[&/[5&
MFZA=-/:>'OCKX8L=*B*HJVMI/X.FN9(4V*K,#.SR%I"S98@$ 8K^T.NS#NLZ
M2=>-*%3GJI1I3E.'LU5FJ#YIPIOGE15.52/+:-1SC&4XQ4Y?.9K'+8XUK*:V
M-Q&#>&P$G4S##T,+B?KL\!AI9I3]CA\1BJ2P]',Y8NC@JGMO:5\%3P]>M2P]
M:K4P](HHHK<\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^4?VZ/@'K?[4?['_P"T5^S]X8U>'0_$WQ2^%OB3PWX:
MU&Z8QV*>(VMA?Z%:ZG*N7@TC4M5LK33=7N(TDDM],N[N:.&9XUB?^0?4/@!_
MP5@^)_C?XS_ D?\ !/:X^&VJ?';]F;X ?L9>*/B#=:M;6WP-\">#_@=K>AIJ
M/Q)T+7[1&\-7]OKFD>'X)(-)T7Q%K$^FAKBZT2T\275QI^DQ_P!=/[?OA+XQ
M>//V*OVGO!_[/]WJEG\8_$/P;\::=X#;0KV73M>N]6ETN4RZ3H&H020SV.O:
MYIRWNC:+=PSVTMOJE_:2QW5JZ"XB_D(^*_[./[3O[5'P5^(O[37Q.^ '[8GP
M"G_9!^"'[./[/G[!WP7BT3XD2?$_Q!^T'!XA\.CXA_%$Z--X:7Q5=03>(;36
M]4U_QW=P:5+??VQHWF>(]4\0^%5M[?\ 1.#:LJ>$KJ=?+H47C:<(+%TZE6MA
M\55G@EAZM.C2QV$G6IUL13P[G%QJ0IT\'6K3G"$)4ZWQ?$\(RQ%)QHXV=186
M<I_5YPITJ^'IQQ7MZ<ZM3"XF-*=*C.LHRBX3G/%4J<8RE-3I?W"?#WPC%\/_
M  !X'\!V]_/JL'@GP?X9\(PZG=1K#<ZC%X;T6RT:._N(D>1(I[Q+);B:-'=4
MDD95=@ 3V%<=\.D\6Q?#[P+'X^,)\=Q^#?#">-3;R02P'Q:FB6*^(S!+;,]M
M+"=8%YY<EN[P.FUHF:,J3V-?GU1MU)N4E.3G)N2M:3YG>2M96D]596LS[*"2
MA!*+BE&*47O%65HN^MTM'?J?B%_P<<^'M9\5_P#!&?\ ;#\.^'K5;S6=6G_9
MRMK"V>2.%)9O^&L?@5(=\LI5(U2-'=G8C:%)!R!7^6FOP%UR'1/%6O:O?VFC
MW'A]96BT'53/IDVL7]K_ *Z+2Q(!]JNV1I9HHBJ&=$=T9.-_^K!_P7XO[33?
M^"2O[5]W>ZS_ ,(_ K_ : :Q]DCO18W-Y^TS\&;.RD,$K(@5[V>WA:Y8G[$L
MAO KF (W^;O\>O$_ASQ=I&CRZWXF;Q%JVDZEIJQP65O:?91]IC5KR6ZN=/AB
M26X+VCI),Q"Q)+;IR0['\5\0<_S;+N)\GRW!TDL%C,!1JXC$PPU:M7IRCC<0
MI4U>E+#2I5H0A3F_;4:N&51U6Y*I23_G+Q:XKS_)^-^'\FRZA%9;F&58;$8O
M&TL)B<1BZ-2&9XQ3HQ3H2P52AB*=*E1J/ZUAL1@U5E7<I*K0B_R>N8=8M;73
MO$\4D4,.H7E_IMOLF5Y8YK V[3I/ ?FABEANH1&S?+.!-MR5<5U^D:?<^(;K
M3;>WTZ[OM5U%K:6'3-+ %N]O'-L>*XA $SFYDB$TOEE-RX5CSD>W^/?@)I1@
MUW7O"&N+_P (_I]LEY;VNI7%LSR75Z$F_LZU$;&6>ZM?-:%)#&&D2-55RX"5
MZC^RI9> K+XE:5H/Q%U75?#MK+I.H1Z7K5AID%S=VVI3::B645Y&C+-'IJ3S
MS&]E1C+:$>>J^:N!GF/%6#CD>*S7!4YXRM@:&(K2PM'#UXXR%.G35>&'E0@J
ME:I.E&=)3C2O-M2<$N:43#...\NI\+X_/<MHULQQ&687%XF>!P^#Q,,PITJ5
M%8JEA*F&I1JXBK4HTZE!584.:I)J;II2E*!\_>,?".NZ)IUIIVO:%)X>*L+K
M3]) \NSDM[QI/)N@&_?"X3"HRR;E*-P1S70_#[X?6EK>ZEJ$EU:74>DW=C#:
MW]I<R*SWB1I<2QPLN&EFCF7 *_ZLJ-IQBOOS]MZR_97NM'2?P=\7=2\5?%+_
M (2#0M,TD:7HDMKX,M/"ZVH&JW+7MTSWM[<6=Q&]I:PHL9FN9WE;*J2?S5TW
M7]6\)ZHFBVETT:2S)!<W\J/';WMO)<#R+B.W?Y[7R=K"6XP)F .[&,#Y[AS/
M<=Q5PU#%T*&-RG$8AU?:X3'X#&Y?*:C*C4JUJ$<;3CB*E)ING&HTW5J3JWIN
M$.:/R7!W%.9\=\%T\PPV#S/(<5BW7=? YKE6993*I&$L-6KU\/',Z<,75H-2
MG1A6<7.M5J5E*DZ<%./N_BOPMX3\4Z9'?>,-4U2ZN/MTT\>H2*)]8BM-1>&W
M\N<Q%!?0Z?<0M<[)%^TA)I>6&*R8?V;?'5MX=U76M-UOPS?>&=#TF/6[W4M.
MU.66XCT^\A\RU(M[B)!#J$3*JR:4LANF5@ZJ0$W5)K[5U8-JFD3)?O%%?I#,
MRVAGL'FDA>.&)B(BC2>7*+@,LZPL' *L=M.'6=<L]"?2_$NNW&G>!KG73K?_
M  AUI?2>3XDU+3H$MXYBP'F!##+]GCG8FW2&SN  ) I,TGG&&HTZ."S"C&E'
M$4V\/7I4\92=%SC.I#+Z5)TYJM[-55"4G##RJ2YZOLXTFWG1?$.%PU'#Y;F^
M&C1CBJ4OJF)P]+,:$L.ZD:E:EE.'P\Z4EBO9*NJ4IRAA95)JK7]E##N3\BO-
M,CTN1+<ZI'>BT@8W\L%N\UPT=TK2O-<&?_EM;*T< AA92C@D'=G%*R\)SZN5
MMH2+^;4+6YN+0BXL[66&6&2WB^TW)=_W-M()0&BD;+*&DQE#6O ^E2R7"1RW
M]J)VU%+5K^WCDB/G0O)%$JRF*2X5HT0><S[(P%,9+%17-2V]VFC0B)=.U*]=
M&V&!IH]1T^RMA)+<&[2/;"PD9<1[Y)7V+M SG/V=*=:R2K.G6YH)SJ4E%-RY
MY>T:C[*,8QG%N<56BN1>S5[QO^DT:F)Y5&-?V6(<Z474K8>,;\ZJ2]JU!T(1
MA3J1<ZD(XB*4%[*-[0YNO33K;PY>6%I>QZ?JX6"!+W["%%DR0$121VMSMS)]
MHN%C5Y]HS(#(O"FN"\>7\EPMC8VL>+>.:2VTJU@^<23.RB6%#_K'AB(4*S9
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MX2GEN'<,9&490E"A.A0QCI4I49>T=3ZOCL)36(IU(1YY1G3J^S2C[.'[K_\
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MM*527M).I7J*56<8J\_91I-QZ;9&V06\\=K,8T$4X=4N8F62,.IB4#.&)/S
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MGC[4M(\0:]9>#=(EA9[WQ%+I7AJVFU;5QINUIK?2;.+SM0N?(L6E@25[N/\
M?BU_X-,?^"P:PW;7/PO^$+W!0"T5?C-HHC$C,0SR?\2S(V+RN"06QD #F]!_
MP:D_\%D+;2Y=/@^$GP72:XE5Y]0/QHTAIWB0AE@"G3 J1AAN.TDD]3@5R5Z6
M)J3DH3KN#JPC**]A2C&G*-/VCA5LJCC%*4KQO5523C"I&,5R?095C<DPM'#U
M,30RN&)I8+$5Z>(E_:>-K5L70KXAX6EB,%[66"IXBO*5.C*%2,,ME@:-.MB<
M-6K3J?69-:_X(^?L-?##X[_M%-\6?BQ^T?K'[-'A/XL?L!_L\? C4? MS\.=
M,^+/B;XA?MP_ VU^+$/Q#^(L.N>'-7T/2O"O@JTT[Q'JJ^"=-LH-7U1KG1]"
M;Q);Q6=]K=QYE\7/^"/W[/OPB^%WQ;^'&O\ Q'^*MY^V=X,_9S_:Y_;!T+5=
M#F\)M^SD/A/^R9^TQ\4/@#J?P[U#0[O1IOB'=>-?&ND?!_QKXSMO$\/B>WTO
M0-0D\/\ AZXT74(GU;4K?]D/!G_!,3_@Y%\%_%3XG?%E/@S^Q9XLU7XJZ5^S
MZNN^&/B"?AGX[\"Z9XU_97\"Z%X ^ ?Q7\-^%?$_A_4K#1/B9\.=&T%)=(\3
M6>R:6]U/6&OHKFWU&:WK@+__ ()$?\')>M?L[>+_ -G77O!G[,&NV?C;2_B-
MX1UCXPZQKGPWO?V@8_AE\8/B5<?&/XJ?";3_ (PR^&SXNL?AUX^^*%]J'C#Q
M#X?AO!%<7VJ:O:120Z;JM]9S]5"G6BW*M/F:E648Q@H4U3E5<J-HJI-N4:2A
M"<YMN4U*4(THR=,\3-<7EE2-*CE>%="G*CEM2M6K8B>)Q4\93RZG2S%U:M3"
MX=0I5LQEB<1AJ&&4*=##3HT,34S"O1ABX_S"_ ;_ ()O_&S]H/1/V7=<\'>(
M_ASI]K^UIXX_:7\ _#I/$.KZS:W&D:Q^RSX!\'_$3X@7'BI+30KU;*QU31?&
MVE6WAB73VU.:\U*&\AOH=.A2*>;ZQ\-_\$0?BIXA\!Z!XTO?VIOV3?"%S?\
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MAZ)X?EATC1-2T_QM+X@O[J/4=1U#[?X:O_#<UI+%#HPTIH@8]2@ED:7^U)I
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MH4WGE_\ $+E=>3GR?^'!<_E9.3Y?_#O%O+R3U.W&2>IYK_(]NO'.O7WA/1_
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M4^(,WQV9YSA<-@<OQ6;RS[B'-J6/IY?@J.'P>(IU,%4Q&98JA6S+%^Y^&_\
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M-Y]E\1>)[K0/!7_":^(+;3Y_L^N^,[C1_#?]I^7J?B>6RLI]5;_-'_XA=/\
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M?\&NO_!=,$$_L.%3W_XR8_8]/O\ ]' \<_R_&OP9TZ:VLK\&_MVN(!')"T/
MD7>FU)$#D*Q0X)5BH9<@D'&/;/!>NZ5<//I$]S<?8K2WM[BW=H=MU);1LL<T
M$<9D\MYX#*45R4#Q<L[A2C<>(JRH*3A0J54HJ;DI65F^65GR3]Z.DN67+>-W
M%NUCY+$9A6HVDL/&:IP@W*TH0Y5))MR3?O1;3>D7.+E)-N+/U\_XA=?^"Z9Y
M/[#N.<_\G,?L?<COT_:!]?7WZ5^IG_!+O_@CM_P<1_\ !/7Q[\1?B-\+O@E=
M?"&[\;>%K3PMKVDZ?\:/V/\ Q1=>,++3[\ZMI\,TMS\7-;L=,AL;X&:&2*ZL
M[F:1S#.XM6DS_.-\-OAKXB^(^M:%X?\ !OA74?$-QXBOH[32[71M"O=;N#:1
M32-=2&TA\Z%XPT,SW/G")A#;7,\3Q) 7'Z#?M%_LT:K^Q)X=^#%[9?%GQ//\
M6_%#^(OB'%H'A.&>P\%>#-+6V.@6<VA:5<)J,ZZRNM0>(-,OM<8SN\5E#<6\
MEKYBN>+%X#$<09'FE6E4SG*LKP\*=+,,YRZKA\)C,.ZU:%&.'RVKB:%:%?&U
MJDE1E3H*->C"4JO/AW[*H_U/PJS[&<)XV7BSC.!.'>*N'>!JN$Q=;+>/\DQ6
M;\(9OFV,KT\)EN Q.44.)N&:O$,Z,ZE3'K+:&.Q%"5;"4*><9=6RS$5+_O!X
MC\-_\'L=UK>J76A>'=8L]*N-0O)-/LC\5?\ @GG_ *+8F9A:1%I/BL[%A!M+
M!F)#Y!8]:PV\)_\ ![UQMT363UZ_%?\ X)X _P#JU/ZGVK^1:ZM=3U2XU*::
M)Y]1G5I/L[+9F6YO+R1I/M<SRVVH13><S"0^9+:W:RN,A$(QVOP5^+2? OXH
M>$?B3K4.M0V?A3589M4N-*TY6U6WU"!I88;C0KCS383ZE96CS?V<NHN+!-46
MV>]@N;(212+*LTH5L1@\#-U:6&]I0HXC%NI]<KT,/^[C/$2I0IQGB9P@VTI5
M::KU%&+K+G=2/Y)AN)\/Q)Q''ZWAL+E>'S/,HULRQ&6X>I5P^5X;%UX5<7B<
M)E6'=.+H8:-2I+#X.E6P]"7)3H4JU&DU*G_5JWA/_@]Y"@KHNM%N<C_A:_\
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M3K9?5QV K^S5;"XNO0JTYR_U/?\ @UN_X)S_ +9/_!.;]G7]I;P)^V5\'O\
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M7$(50Z1312!7D#,L4KRL5^<D>\_\&;!#_P#!3/XQ2A0JO^ROXT\L=2H;Q_\
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MSM7"DXX;<<;\DC*@@D8R#@D$C)) .*DB^5B6.?D8D\8RP&%((P<^W/4U[/\
M"GX#>,/C!8>,M3\-2:18:?\ #W0;C7_%%[K=^]NJ6<%I>WJ+86T%O/=75P\-
MC.##&F%.V1VCCRR^) --L"(V" 451D_/Z#)))^7)R3@<\ 4\9DF;Y=EV49QC
MLOQ.&RW/8XR>28NK3E"AF4<MQ$,)CI85RLZL,+BI?5JU11Y/K$:E.,I2A+E>
M/X<SW*<KR'/<PRK%8/*.)8YA4X>QU:E*GA\VAE&*A@<RG@I2LZU/ XV7U2O5
MC%0^LQJ48RE.G4Y-R:2<:/;6S6B"W>ZEG2Y6!U9I4_<M$;AP(W 0;A'&7VXR
MV&XK];OV._ WPM\"?!6\^+U_XH2ZU[6OM@U.232/$L%MHB:!*ES)H.F7]AIB
MS3ZC);E9]3DLYKF!UN+5('W6\^/SH^ 7@[P_\2OB%I'P]\9>)[;POH>M6VK"
MUU/5-173M,MM9ATVYDTQKB65TB222Z2**)'>,7$CQPM(@DW5^E7[3I\2_LY_
ML?\ PL\!:#K\VF:KKE]_PCNL2:.BZ;#>V0L[_4M5*?8)ID8W=RN);Z2[EGO;
M>8QY2%W@7^IOHYY,\AP'&GC;FN5Y?F>0<$<(YKA\!4Q<8XW%8'BB-7(L'A:4
M,#1S7+949XFAG$H83$8I5Z52E+%JA"-?#^T7]I?1/X>?#.5^(7TBL[R;*\XX
M9\.>!L[PN65<=".88S+N,X5^&\!@J5/+:&=Y1+#SQ>%SZ=/!8O&+$4JM*>.6
M%IQQ.%52/Y)^.=4MM=\:>)M7T^ZO;O3[_7-1FL[K46D-]/9274HM&GCDEN9%
M9;<QH(Y;BX>- D;2L5K@F!5BIX()!!Z\''_Z_P *T0)"CD1@;F')XYR#E6R"
M.@)(...<DU1F.Z1R#U/.,8SCG'7O^>/K7\CYCB9XW$XC&U5&-;&8FOBJD8J2
MBIXFI*K-04I2ER1D_=YI2E9KFDW9O^%LXQE3,<9BLQKI1Q&.Q>(QM:,%*--5
M<75G7JJFIRG+D4I>[S3G/E:4I-ZO_4._X*"6ZW7_  9\?"J!I)HED_8!_P""
M4P+V[K'+\OB[]CYMJNX95$A78^5.49A@DU_FZZA;)9W=A!;R7T&F,Z375KYG
MVB[2(.HD:UNY[8()'4/L$L11'VD HVRO])7]O=%D_P"#0#X3J[B,?\._O^"5
MC!CG&Y/%'[(3HO'/SNJIP1][J.M?YO\ )KDB[;-/WD/FL8DD6,KD+B0";,<L
M>Y@"JF0JI)X.,#XO-'55>FX+FBJ3YH-V2YG-*HGROWHZN+=N6S::N[_-55B:
M57"8JA"G6A2K.,Z%6[IN3491G4@KJ<-.5IV7+S^\KGT)X&^%7@KXW:M?^&?A
MG\48/"WB?3M$CU/2_#/QNO?#_AO2O&FHPM,;_3/#WC2.YAT/2=4AM_+GMK+7
M19IJ&^807J/"8CYMI>C^)?$WB6?P-X=\+ZIKWC*SN+RW;P]X6T^X\5W;OI"R
M+J4EC+HBWSZC:P+!)<&\LI)8!&#)'+)$0Z\1"EK)?PW%M:>6LBDW E*2Q[P<
M!HWEB.%+@*I92,GJ 37LOP>\>Q_"#XB^'_B!H'B7QM\-/%NA6.J6@\1?#JXM
M1XCN)]25XXIS%>R06(TVZLKJ6WEM(&$3+"K2H_FLP^/HT:F7UJM3%XK,<RP"
MITJE+#1PN'K9GA9T^9XN4<11G0>.AB%"G[&E5PU7$4J\K?6WAJD:=#W<GPN
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M)W5NYY=2+C.491<91?+*+33BUHXM.S335FFKIZ!1112("BBB@ HHHH ****
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M;K,?B/Q7IGAK0M/\3>(8K=+.+7O$-EI=K;:UK,5I%'#':QZIJ4=S?);QQ1)
MLXB2-%4*.EK\^E\4O>YM7[RO:6OQ:I/7?5)ZZJY]E'X8^[RZ+W=/=T^'2ZTV
MT=NQ^+'_  <.?$-OA/\ \$@?VKOB*MC!J1\)ZO\ LSZG]@N)FMX;H?\ #6_P
M'MS"\Z0W#PAA.<2I#(T;8=5) K_(%^)GB>Q\8^.?$_C.PT]M)M_%.MZCXA.D
MF87'V2?5+E[N>WCN!%!FWBDD*Q'R8W9 68<C'^M3_P '0P)_X(6_MQ@#)/\
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MP7UC7=,?Q5H+ZAKNCWMW%IUEXFTR_P!0TZVN=(NFFN%TZ,CSC-!-'$L\[B2
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M6A2:MI^I@1S3!M"U&"_@\V^C^?3XVC*NUTRK:DEF9(ED? V[E/U1K7P-T_\
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MTBZO/VC_ -I#[1?V<BQ"ZA\@W<'VJ5II+4V[M;&VWW1E7^%&U5)9"J_NY-S
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M/VF"ZC)BF1XA+&Q1)$;:01G)P=7O)[^[DOKRX>6:Z)::Y?+&XF1<,!M "!R
M@' /!.!P/UW"<>U.&.':F5\.9#E7#N?8C"U,#G&=T\+BZV>*56I[V(R_-,;F
M5>>4U98*4,%5P^!P^'IOV^)JUG.O# 2PG[M@?$RKP?PG4R;A+AG)>%.)L7@J
MN69_Q%2P6.K\1J=:J^;%Y9G.8YQB9Y'7EETJ>7U\+EN#PM"2Q6+KUY5,7#+)
M8*K$JZ=:?:?.1[FY5XC'&0QMHFP"&'\,DA!7C.$!ZYYH?;)X;N*YLW,3VSHZ
M2AAN$BX+2LQQD[CP#QT%-B#3W<<6P9:491>06''7^Z!\WH2#@X-07"CSV@S@
M+)M? ^])D9!]EZ <C.<5^2U*LN2FZ-Z5.G4C"GR2DI>V@HSE/G>L92=IR:LX
MN,4N5**/PRI7G[.G*AS4:5*K"%+EE)3]O32E*HINTHSG)JI)KE<&HI.*4$[L
MNJW]^\LEQ/+)YLK3R#>ZAI#P'\M2(]Q[$*" .#P,_2_[/W[0WB+X,:O?:CI%
MMI&JZ?K&GKI/B?P[?0I VN::J^6/L5XJ/%8ZG'&3Y=S]G=Y6W&X\\.RU\ON#
M"JE(\8()8]_3.<_GC&!USFHP"TZ,BA%<@LPX4$\%B>P[X]A7N\-\5Y_PCG>"
MX@R3,<5@\YP-95J&,I3?M:=2490<U[2,X5(RA4J4JU*O3J4:]&M5HUJ=6C5J
M0E]+PCQOQ/P-Q%E_%'#N;8S 9_EN(6(PN/HU&J]*K.,Z<IQ=6%6G6C.G6JT,
M11Q-*MA\30KU\/B*5:A6JTI>Y3:M8?#7QY:^+/AWK=]:6MLEEKOAY=8AL9=3
MLGN 6FTO48K<W-C.;.02P>:I2.\MS%(T,#NT2=O^U1\:O"_QUUGP3XOT7PE:
M^%?$,/A9K#QP+*"UCM]4UL7(:&_2XMHH1<J;=797GC^T6R2K:L\HB#GY;N]J
MS;7=67.U,,2JJJC#$\G+EMY&3U_ 4F=BA7<?E(QC/3G)[ ]L^W7I7IU^/\XI
M9!Q+PCA%A\)PUQ)F&"S/&9.J<:^'PN8Y=B5BL-B\ME64ZN7U5&4\'*6%E3]O
M@9/"XE55"DZ?LXCQ0X@H\,\7\"X&.%P/"'%V:9?F^/R"-*.)PV#S7*L8L7A,
M=E,\0JE7*JT8RJ8&4L%.DL1EDW@\4J\:5%TG?[(P26P">0HY.3]<#/;'49-/
M(DA,;./-B/!'(0G/W<C!Y!!.W!P>#D<1Q*I+2/PL8W8.=S,V  N#SCC(Z"II
M;C!C+KNV+\D1X09R0S'')#$G&,GN1Q7PD;<KE*3BW;EMJDE)7<H]4G?2SOVL
MKGYI'E47.<N1Z<CW5E**;G'6ZT=E:3E9JUKM=WX9^(?BGPMH'B_PEHCQMHGC
M^VL[+7=,NK<WMI-'IUY'?6-U! [;$U"SG0?9;S:TL*/+''CS"3R%XALI2DD$
MZ3F-$B,L,ENC'9B615D52RJQ*J /O9+-T!33+V[L;RVN;6:2&[BECGCN$8I)
M"^5=#;L,F&0$*0Z@,",*1C-?4-G^TCK7BS6;%_B:GAKQ-86F@)X:L_\ A(O"
M>E7\FFVB((Y;F&>"*TO5O)"NZXNUG\Z><M.RM*69OMLGCEF?8/#Y?GW%.899
M6P+HX'A^E7RVEF&4X3"8C$XK&8ZG6Q-3-L'4RRE3QF*JXJ,,/@L;&KB<54G)
M4;3J2_0\@AD_$V!PN6<3\9YIDV(RR5#+>%Z.(RFCFF28+ XO&8W,,RA6QE7/
M,!5R>A2QV-K8R-/"9=F,*N+QM6I-8?\ >5)_T<?\&99<_P#!37XNEO\ HTSQ
MH3SGI\0OAP![8YXQ_7GQ#_@X_DC3_@MO^VA<SZ7)>_8G_9U%GB13!/<3?LE_
M $RPW,4@"^5#;F2=2K!C(J]J^V/^#2'6OAIKO_!33XH3^!/!<?@Q[#]D[QCI
MK+INJWNK:7KULOC_ .'TTNKW(U;&H:;J33M'&MLC7%L;7";Q)#YDWQM_P<E6
MEY)_P6;_ &T[A8A:6,7_  SRINUC65KN\/[*'P&>,X<F-&5(A9A64^8KD#D
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MS*3;O%IW>[****] Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)DGO+F:2:XD?'SL\LC%G)QEF8ECT['.:US<3(D2+^[A?>@"<EAQO+')P?E)
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MM]NN--TG]MG]D"W>6:4O+9V3_M"_#QS:0M*ZB#2DD?:MM;HL<N]YMA>5B?\
M8DKZ?AJFJ='%644_:TU)*?/*ZIIIS_EG-24Y*RNY.;7-)GU7"-*-+#XQ)1C+
MVM)3BI\\U*-*]ZJO[M2:DIS7+%RE*4VN:384445]*?7!1110 4444 ?YFO\
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M,^5U3!=%NY8 8V5<E@L@SN\L^63\I)S\_ .2>E5_LURI<#>5 RS1MN!0?Q$
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M.^AMM[6WVNZ:VE8H9'MFE9K4N(2T?F& H6$9=!(6",RA36!&60<[RJ-E1M)
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M(XF/LHQ]E*=>4E'DIWBJ2@FSIY&+2*>*9(093)"/DE=\ X<JKNBA0$5L ')
MYR>Y^&?C&S\(^)[;4=:@O-2T9HKBWU33;-K=)+ZUGA>-K=C=1SVX5F93F2&0
M*!E5#!2. E*B1W(PIV_+N&[!3(P 1@ X&",$TW:TC[4 +[?EQG@,!M &.6SC
M&,G=2P&8XK*\QPN8X&488G XFG7P\91=:FI49Q=.$Z52\:M)J/+*G44H5(.4
M9IQD[K+,UQF39M@LVRZ<:6+R[%T<1A(SC[>DI8>:E2A4HU>:%6BU'DG2JJ4*
MM-RA4BXR?-](>/OBC<?$#X=:#X5ATCPEI.G>&;]H=)DM=/BD\:ZG'Y\Z6EOJ
MFJQQ">2PTW3[R2"%'<PRF*(1IYL*&O %TRZ60Q-!(XC#[QE5*8)S\A(8'(.=
MV#CL2*?$;S2V*-'):W(+(C2H1-"V!YDC*1E& 90H894,",'IGEY%=G:5]\I8
MM*SEW<-QN9N20[<D]<9KUN(,]Q?$&+P^/SF=?$8^E@\'@*LY<E*,<-@*4*&&
MI>S]FH04*484HPA2A%4J<)2E4K3J3?M\4<38[BK'87-.()XC%9I0P& RNK.7
MLJ"AA,LH0PV#HJDJ*ITE3H1IT8TX4:<8T:5.4YU:\ZLW_77_ ,&:($7_  4U
M^+D!C*/_ ,,G^,W8%0,*?'WPZVX.2<'*G&>>OICQ[_@XTUJ[A_X+9_MHV$MJ
M][I:-^S@DEO)B=29OV3_ (&M(+9&RUH)UE,<TD0 $JQ2N"Q7/K7_  9FJ$_X
M*<_%X*Y=!^R9XR .>.?B!\.68=!G#=_IG!Q7UO\ \%L_^":?QM^/?_!7C]I'
MXMMJVD^ _A?X\O/@RV@>-[Z.:]M+?3_"?[,?P<\/>([K6GM#C2;5-6T/4[1%
MO,-<):&>/:AC>OCZG#^:<3XJ.6Y3E>+S/$*=.I.C@J7MIX;#J:P[Q=:2Y:5+
M#TJE>E&MB:TJ.'I*HIU:E.)\E@N!\_\ $3-HY!P[E-;-<9",\;5I4*F&IK!8
M#"7IU\PKU\35PV%A0PSK4U.I4K48.52*B^>48O\ EILO$FE>"9/%.JVGANRU
M&UU#3!%I]Y*\CR:.9KH^1-9,KA4U#; J1R2[L1W$A;#PJQKZ=_8\,-AKOB"[
MNP]Y-8?VNT<L=]JSZ5J<;I?2PV,CK"[0J6CMI$8FWAN;>5P&4U>^.'PVN_AS
M\6?B#\(M%\0^%/&&C^%&OKFS\4>&=2-QX5\6Z;H\!NI-3TBYE96N8[F&&Z2*
M *LPO!+$%,B!3Y)X=M[_ %F(K=127-I;7%I;HUFH^W/->3&"QT^"?:8W1W(*
MHWSE8@C A4S\-5P+3^J*JJF*H2E3Q=.$XSKU%_!IR3I3J4:KE.$FG3J55548
MU.:47S'P>/RFO["AE^'K?7*V63Q6$QZH4J,<55E4KUZ4*GM,*ZGURG5]E*5*
MI4K5G+EER.5"-W]M?$'XL_ *P\0S>'_@/\*;Z:QDT30-#^T^.;^:Y\F^TE1-
M_P )4\5DT;K=O-<O<RH9?*&W[NU H\1^('QJ\??$KP[!IOC3Q1J.L0:*LEEX
M7LXV2.PMK>.]227[%;J%"1$)+#&ZXV0*B\DY/NNI_L3?M$_#;X.M\7_%OPNU
M7PMX&NUM;&\\3WC*FMNFN7#OI<US:R-G[%<I%(CRQ*C)#(J@$CGY_P# GPWM
M_$NM^%[6:^T\)/<7RW.E2W<@E@T[2[>$_:04&88);EI&\XC+E6X*\U&(X:Q?
M"^(GA\\R_-,KQ\<)AL7AGFM.I2Q]6C6J-K$_[3']S2Q-/#5J:Y8QYJ<9QJ._
M+ UR[A_'>&N=2GQ5PWC\+FO]CSJX#"\3T*U/$XBGF5#%82&9.&(Y'AX*,*];
M#JFJ;=3#Q55M1C2E]<_M,^-O@O\ %3X+_!#Q-\+OAOXK\!>*?#WAZWT3XD:+
MJ-M#:Z#XIO;'2K32K7QAX:U1(T>>VNI;.>+4K60H\=[(B1[P"X_/%3%#=V-_
M8_VB+E&C^SO )%>VE/RO;M*,?OKAIF<;9!\K)EUVXK]6/ACXGTCP?9>(/ OB
M>./QK\,-;\,_\(S>^%?$DSW.E:=%=:S;:W:ZSX3O&4WFBZG%>62@7%INM72Z
MG$B .2>[\!?\$\-/_:TO-6\6?L;>-_ VBZ046WO?AC\1-4O=.\8^#[U;&.[O
M3<P/'-;ZOHC3+/;Q>)(V%G;(L#7,D<N0?8RW*/\ 7"4/["Q&!KYY6]J\9PY&
M$,JQ,%3CBISKX&,Z5#+<PP\L%A:>,Q#PM>.-A5Q56-3"2I4YXA_4Y?PSE?B5
ME_USAS,LMI\<_O*6/\/\'E\<DJUZ=!XJ57,\JK3E2R?-*<\NP\,?CZ.#EAL=
M1J5JJ>!J4(5<1'\@=?U]X=+72='ADETZ%)6EU.\MY;2474ZF"=GB#,)KJ/RU
M$$S?-(@0ME@2>ON[WP/X4\0^'/[#U$Z^VN^!-+;41/9745IX<\47,4B7MO ^
M\3W9M(5AO_[3&P_;E98TV1KG2^)7PXU/X9^*?%/A+5_$FFZEXAT?Q'J_AV[2
MQ;[?%!?^&KV:ROHM*N0'L;RPNKN&2&WU&+='+%$)(G*R[CYQ%I\VK7;70NYK
MJ(W=K826C&&TG+74R02VEIN*.HBF+NLJD1Q1X(!3BOEZ:H8>:C4J8BG3HU*D
M<13C&DG6JNT(JM5JT)N+I3<^6-*5*E.=U5A."C%_D,*>'P=7V5:KB:4*%2K#
M&4:<*$7B*K:IQC6KUL-5<)T:KFH1H.C0J5.95X5*<%!_9>H_MT?M'6WPLM?@
MY+\8%UGX;WKLUUX?UA;?7D73[=X9&T;4+NZ26ZO+6YE@CE:P<CRWQ)#)&Y8U
M\C:_K&E>('_M6P\.V_A9YH;5+EM-GNWLVOTNIKR*_M$G_>6!\NXM[>.V221(
M(H0PD=Y2!I2^$V\'VL#:C+IMUJ$]T[PZ9;M!=SVB7,2_9AJ]VN^.*\"QO,(4
M)\L%C)RQ%97BK4M-DMG@MXDT309I;:YU!T/G"&0*OV:7/+>=<O$TIMXC@ 1Q
M[5*YKNEF6+S3$X&A/%5LP484<OPV(QN*EB(87!4:T94L-2=>4_J]"/->G"$E
M23E-<T%*;E["S[,LUQ& P+QM7-*3>"R_#8G-*\,<L'@L%7D\-A,-4Q:J3P.$
M@L34E##T*D<--R:JO2YW\'[5WQCU[5]-/Q)\2:I\7K7PW:W.E^%O#WC)YM?L
MX8;FU_L]GM;.4%HU6VV"*>(K-&5$FXL@(\E\7ZY\5OB#<W@@L?#_ (*T_P"R
M2>7HOAJS32Y#82K-%);)+))->R0&WG>*6-I]KQ  @X%=W\)9-'\-WEAXBU"P
MEU;4X]3@EF0/#!<:?96\@N;72Y()L!H]1MU N98R'C=]C$<9]@^,?B3X=Z[X
MWL+W0_#A\/?VJUQ/K5C:SI*FEW%S?R1Q1(\0\J**W21F^SQ$^5%(%?#+QX\*
MN7Y37>7Y=EN$H4*,ZDJ5"A0I4L+1JTISG5>%H4Z:HTE-U)SE6Y(2K5).4VVZ
M+EK3XTK<,9?_ *F\+N679%0Q^:XM99@<)@<OP-"OB?JCQM3!QP5+GI0QLL.I
MXGGG&A5G3IS495*W-/Y(\+^"H/#_ )#_ -IQ?;C/"LZ0J)+H)<2)&\T+$$;T
M#R&$Y&V1"Y^[SZ5%KM]X4U79:7UTR:/?)%Y-J\D5T]Q"S">Z>8DRK=3.TH>;
M*F-61004(.T_A^!_$ESJNAO97^G>$KF![BYOIX+>%C-;126L-M"),:AY5S(Y
MMX06,GEDRE5)K-N=7T0VL%U<Z=(D$1N(-?G@D+R:I=77ER+.LO.V6&5&0HW#
M^:V3^]XG$X[ZY5II.6)C&C3]K3A*-X5ZL?:VG%RYHSE3Y.3E:;56FDH03DO"
MS?\ M"<,IQN*P6+E@LTP#KX&;2A#%RA7J4,15H<\DYJ.)PT\/[2E9*M^Y7+[
M&HX?M-X?_;X\'O\ #JWT6V\ _#S1-=\2_"S2/!^N^+?B9!;Z_<W>I>'4FM;_
M ,:6$4=J$37(-';6O#^BHYDG3^U'D,TDRPRI^(%['=)>W,VC0ZA+I.O3R0->
M7$8AEOK(7[B.Z;<8TFE$2QW"11XA1VBC*[D-8VOZ=XRG72==\0:)JMGX?OWN
M[70[MK9HM,NVT]X9-0TVPE.RW>2S$T8N(XB_EM(L;'<S$>B1Z)J]Y;PZG=O9
MFXTW3$N/[&U*9K1M.M5NH[2PL;>T/W&E.^[,R!O/@A0[M\N:[ZF)E0R^C#,L
M76Q2>)Q53!87V[6"P;Q52$ZL<-2]ZE!SKPC5Q%2,5[3&.<ZDN9N)VXC,9X;(
M\#A\YQ<L<I8S&XG+,)'$_P"R8#ZU7C*O3HP;J0HQJUJ4:M?V:IPJXYO$5;5)
MOF_8?_@F4G[#_P +/^"B/[$MS;1?&+XK>)_%/Q__ &9_#OA+^V-&L?#^B^ ?
MBWXC^+_@?3+?5M;CAN9CK.GZ3?WT&H:3=H%2W^PDL#--"*_U2J_QZ_\ @G,D
M=_\ \%'/^">6MV^K3W?VW]N_]CJTDMY1+#-!96OQ]^']Z(KERB0.ZZMF"%8B
MPN;6$E<[,U_L*5OP7ED<!1S"L\QSC,J^+K8?VU7-\9'$SIK#T7"G3HT:.%P6
M$PL8J<E4CA\+2]M->VK2JU92F[X&RRA@UG&,I8S.<54Q]; 1K0S?,ZN8+#O!
M8*-!0PU*5#"X?!^TFZE7$T\-AJ4*U>;JR6L5$HHHK[8^^"BBB@ HHHH _P Q
MK_@](BD;_@J/\!)/)>6(_L"_"^,E0<!_^&A_VIB.1W!9./0^]?S,_ ?XSCX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS6>GR74:RFW#DF 3;2OGB(\/\K'(JOIDC6L5W(-22WCF4VUQ&CA_,C.#LD4
MB5"X4@ ':P!R"N1^@\">)>:>%7'&6\5<&971RO,,OP=7"YCA<TJ87-\)BL17
MA66/<%&G@IX3#5(584(4:>)EB<+&E)K&2J2G&'ZGX9^+^<^"?B/E/&OA]D^'
MR7-,KP%?!YM@LYJX+/,#C,5B*5>.9>S4:67SP&#JTZU/#4\/2Q<\9@Z=&<EC
MY59U(P^]OV]/B5^S]\3M<TC7?A2;V[\;W%Q.GBW7!:WEAI=]IEK;B*QVP7L4
M;75Y.YB,=U !&;2$*Z[F4G\^K#5+I&6U0LRL2JJ%W2+N(WK&!\V'!_U? )QC
M!IM_(\Q@Q)NR&:-F# M$C%58$]$R#@8V\8Z\5%8W=QI][;7\:H9;9Q)&SA2O
MF( X!4\$C( R.<X-?+>(?'F8>(7'&:\9YC@LKR7&9SB:-;'4.'L \%EZ?LZ4
M:V(6&=>M.KBL0XRQ.*KUJ\JF+Q4ZE:<H.4;?&>*GB9F?BIXD9WX@9MEV2</X
M_B#%X?$9EAN%<MEEV5J7L:$,1B8X1XG$5*N,Q3C+&8W$U\3.KC<;5J5YU(.4
M5#5N$=?,*J6V.T95F ;S&P54QDY7.>5QGC!.:])\=^*O%]QX4\&^%?&FOZKJ
MJ^'-&VZ!H%VZ1P^&+.\D:6SABCB51S:L9F%P#<LMW!&6,40 \JM+V9]134[A
M$GE%ZEW+',,02.DXG9'6/:5C8@JP7!VG"XKTSXI_$FV^)NIP:[<:-;Z9J[V,
M4&KW=G%:VMI?36LTXM'@MK:&,KY5K);VKR7+R7#I;1!I-O X<OQV&HY'Q&X9
MMBL%C,9' X.CE=L1'"9ME_UJ6*Q,\5[":HSK83$8?+ZN'P^,C6H)O$8A3C7H
M8?G\W*LQP='ASBV5+/<9EN/S"&78##Y,_K4<#GF5_7)8S%U,:\-46'G7P.*P
MN55L)A<="OA4Y8K%1G#$X;"^T\D8P/$Q61DEP,ATSN/( 0*#M&<EF<@G)X &
M:9-#Y;I&'BD8 %GADWJ23]P'(4LHZ@'&6Y.0 9_L[M"CH(GC\QF+JN9=V/\
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M>79E#&5(8S+\33J86OA\3*HW5H?5L2E4I2A*T)0J\TW=*[;9_75_P9ISH_\
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M*E1EG52-+"U?:9%25Y9EC:SQD:4:3]G7Q&)H8B&&A4J4Z,*WX^_'*Z\':;\
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M!<;<-F[H#H==T.8Z#)XBC&I68ET""2>)M;2.>(OI41M8Y+L/>IFW+V\;S R
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M]\^M605*EF ,8(0$';AFR06SP3\I(!/(4CI7]P?@OP+\!_V2/C?XTT_XU?M
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO<VMRI"#]DS_ ,&K/[;IR3_P<%?M7$DY)_X5I\8,#)R< ?MS8&>?4<U<LO\
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M_@CXH_"/]G7P_P#L])XL^'NN_"C]I'X7?$,W7B_X5^'/#>G^-?#?CCQ[X_\
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MLO[0=J/]*_X+._M WF(T"!?AA\2;=1,HVM,X;]L&X+AP%^0%-N"0^6)JQ/\
M\&M?Q^N)III/^"R7QY(D \J(?"_XF+% 6N3/(Z*G[8BEG9-L"%V98U#-M<L
MOSM?AG#O-Z6:4\NS'Z[AL51Q=''4<UH4&J]&<94JD:2DK>Q;<HIQ5G!2M.:B
MSY&KP_2HYY0SC!91C:>982I&=/.,+FF%H5*U55E5ABG2JSDXU:-U"G.-*E.G
M3I1Y(NI:<L_PY\#O^"[&D^%/$4'BG]C3]GSXF^*)](^$"^"M.\;?%CP;K'PX
M\!>,/@CH>A>'? /Q#T#PA<ZLHC\6:)IVB^<D@O(K*^U34M4GOH);>X$(^.M.
M_P"";W_!?[QQ\+]?^ OQ2^#_ , #I/Q%L?B+X+\5?M 7OBOP)KOQY\/?"GXO
M^/[WXI_$SX6Z5XL36E,W@;Q9\0-0O==U;3SIKW:0:IK>DVEW%8:C(M?9-Y_P
M:U?M*7MS:W4W_!:7XY^;:33R1E/@]\28PR,X>TAD6+]LR.-X[,*J@%"9@"7*
M[L"]9?\ !KC^T187IU"'_@LW\?/M2R131!OA;\29+>.:*1W):";]L*4212*P
M62%G 8C=NP0H]?%Y?5E"5.GA\95:I3I1KQQ>"I5JBJ2E)N<YTIN7))\T)5(U
M)07+",?9P4#T<TP&(Q*E!87&XB4,.\+#%PQF78;$5J;^%UJDJ$G)TN6+IU*L
M*M2,5&*CRQY'\X_LZ_\ !,__ (*W?LV_!7]F?X._#?\ 8\_9LUCXC_ _XU_M
M9_$%OC7\9O&WA7Q)I?A/PY\>/!O@;P7IUO\ #&VT?Q)9:GI^HZSH/ASQ)I_B
M?^U[&^BMWO\ PS-9&.339FKV'Q3^P_\ \%H?!OABZN_@1\'_ (;:)XA\0^#_
M -EOX4^(;&/XM>&[!]/T?]CG3[72OAWXCT7.HBQBTGQUI%K'IOBO2TDENWMH
MA!<"(S KNP?\&L_[2JZYJ&MW'_!:GX\S-?W$TYM8OA'\2;>"!+@L9;:-6_;*
MGC%N[-AE6)'$8"1O&<,)-4_X-8OV@+YXFM?^"S/Q_P!/1+3[.\<?PP^),H>7
M:JF<$?M@PE =BL8V\QBVXF4[L#IH+%X>,:"RNK*+IT>3%QQN&5;!U(*-Y8::
M="I"JE>FZL8_O(\R=DTWVX2IC,+0AEZR2;A-8>?]IQS##O&9?4I*FT\'4C4P
MU2G4II2INM3IJ=:$JL9R<7"2_&[XX_\ !"K_ (+;_M%_%7Q]\4OB-\#? ESJ
MGQ7\?^)OB#XXTZS^.O@^RT"WU#Q+XBU3Q(^GZ%9-JUUY%GIU_JDHTC[0)3I]
MG#;6T4@5#GR(?\&X7_!7PE]/_P"&:_ABFG/;VENEV/C3X"6YB%E<J^_Y;PDR
MWL0D%U(=P<.%&TQK7]$'CW_@V)^-WB6X\*_\(C_P5V^.G@2P\->$]+\.2VL7
MPZ^)NNSZW?6CW<VH^(-3O9_VNM/,EYJ<]RCK"("+..WBB$UPN2.&MO\ @U?_
M &AXH(TN/^"T?[0-S-'#)")A\+?B1"&\R42!WB'[8<FXH-R+\X^5CSD#'ET\
MMGBJ=.OB<GQF'J37-]6GF>$J5,/-UIU&Y2HSJ474TC)RIUJR::C=M29XD<G>
M-Y:^)R7'X:4^:<,/6S7!SJ8:;Q%6JY36'J8BBJDTJ<YNEB,2O?C!RDXSD?S$
M? +X)>/?V<?^"P7[$'P+^)?ANT\"?$3X8?M]?L<Z1X^\,Z5KMMXBL;7Q%J'Q
MH^$^K1^5K%D6L;Z&_P!'U*UO9&MF>.">ZDMU*NK"O]9*OY$/@9_P:OZU\)/V
MD_V>_P!I#Q+_ ,%#]9^)^O\ P0_:"^$?QYU>UU[]F^]BUOXB7'PJ\>>&/&D/
MAS4O&.J?M(^);_3/[7A\,P:+'K=Q8:_)I4<RW8TV_2UCL7_KOKVLHH8C"X1T
M*\)PY*U7V*J585JGL7-N'/4A)J;MKS.TFG[R4KGNY%AL3@\"\-B83A[/$5U0
MC4JPKS6'<VZ7/5A*2G)J\FY6F[KG7->Q1117JGLA1110 4444 ?YC'_!Z-=S
M6W_!4SX"FWFF@F_X8"^%VUX9I(BRM^T1^U2KIE&4DD# ZYR1@\8_D(2.5]OE
MHS$YD8KNR,-R&)  VXR2."".<YK_ & _^"G_ /P;V?L8?\%9/CYX1_:*_:+^
M)W[3_@OQMX+^$&@?!72]+^"GC3X4^'/"UQX6\.>-/'_CJQU"_LO'7P5^(^KR
M^()=7^(VMV]U=6VN6FG/IUII4,.E07,%Y>7WYR?\067_  2WV[1\?OV_PO7'
M_"T_V=>OJ3_PRKDG\:ZX8E*$83]I*,$^5)I*+?+=J]TF^57=KNRNM->ZEBU&
MG"G4]I*$$^6,6K)R<7+E4KJ+ERI2E9MI15O=N_\ ,<N4E"1[DP-Q)(P2P8)@
MY4D8./NYR."?0>A:OXS\0R^ ?"WPZOK:.QT/PUJ>M>(K:T$<L5W=ZGXCBL$D
MU&^WL27^PV5K!9LD<:);EB0QD8G_ $J8O^#+K_@EW$I0?'[]OQE)SM;XH_LZ
M$;AG#\?LK EADXR2/:HW_P"#+;_@EW(_F/\ M ?\% #(>K_\+3_9U#-CH#C]
ME7! [<=..@&/4PN=5,#2Q\,)6Q5'^T\)# 8R$904*V"CB<-C)X>LU[U6G+%8
M+!UE%2IINC:=TTCV<'Q!5RZCF=/ XG&X?^V,##+,PITY4XT\1E\<7@\?/"U[
M+FK4I8S+\#74%*E%RP]JBFFD?YE!L[06<-W'J)>>4X:Q%O*&B^8KCS0=CG@-
MM 'RL!R0147D31SE)$VQK&P+2!H\JRXR%/S$GCT&.I"\U_IPI_P9=_\ !+I&
M#?\ "^OV^&8$'+?$W]G+D@8Y"_LJJ#^(R3U)K17_ (,R_P#@ESLF23XW?MWS
M><K+OE^*/P!,D188#Q,G[,2893\ZJP>/<!E&7Y:SCB\%4Y>:^'<(P6D:LHU)
M0C[TIISK-.K))R4.6,?LI+;*&-RZIRMIX64(P5HPK3A4E3B^:4U*I7<76FDY
M1A:$'\$5%V7^9]XS^(.H>,-'\$:'+;6MEIG@;07T&SM]/1K:TG\V]FNY-4N+
M-2+==3O/,1;V_6/S[[R(&NI':--OGAP"O'*\9QN!Z\<'H,GGD'^7^G</^#+;
M_@EP,_\ %_/V_.1C/_"T/V<P?S'[*HR>^3GFD7_@RT_X)<*<_P#"_/V_&]0_
MQ/\ V<V!]_F_94)SWR"*,QSG$9KB7C,?B*V)Q,Z6%H2JSA"ZHX+#4<'A:22D
MDH4<-AZ%*"7V::;NVQYKQ!BLZQKS#,\37Q>+G0P>&G7J0I\RP^7X/#X#!4HQ
MC*,53P^#PN'H0BDK0IIMMMG^8FJL=O!&>>0.G'I]>/H1UK^NG_@D,/\ @@E\
M-_V,-%_:&_;@^'WQDN?VDO 'B/QEIGBWQ?HTOQ(G\/SI<ZF[^%X?!NBZ1XHL
M] O=:M-!GLH9;K3=)AO+:ZG9YKCS%,T7]!LG_!F!_P $NYFC>?X\_M\3-&R'
MYOBA^SP@=(\!86$/[+,8$>!@^6$?DD.#S7TOX\_X-:/^"?OCCX6:5\&K?XP?
MM@^!? >G+9K<Z9X$\;_ G3)==^PI (&UN?5OV=-<^TR--;17=Q+;)9RW=V#+
M=/,-JK]IP'F'!^58G.<]SW/>(\LS3)<IKXK@JCPY1E0S#%\6<K645\1F2JPA
ME>!RS%1IXW%U:=5XNHHJ&#:J7;_0?#+-> \DQ?$'$O$O$G%N39SP_DF)QWA[
M0X2H3PV:X[CCE:R+%8G-XUZ=+)<MR;&1I9AC:U*L\=6A"-+ /VRYG_-=X@^+
M'_!G-XHUO5/$/B'X<?MM:MKFLWLVH:IJ-[JW[0<MU>7EPQ:2:9V^)62WS;4&
M L<:I'&JHJJ,,^,_^#,AP$/PD_;-(+$Y-_\ M $ACC=DGXD$G/&1SZXK]RC_
M ,&67_!+<DD_'[]OXD]<_%']G0_^^JTO_$%I_P $N, 'X_?M_$#H/^%H_LZ8
MYZGC]E49)Z$G.17Y[7Q4\76K8C%8C%8BOB*M2M7K5YRK5:]6K-5*M6M5J5'.
MI5JSYIU)R<I3FW*3<FV_RO%8VIC<17Q6-Q6,Q>)Q5:KB,3B,34E7KXFM7J.K
M7K5ZU6K*I5K5JDI5*E6<I3G4DY2;DW(_"Z3QA_P9C1L4?X1?MF@CIG4?CX R
M]B-WQ)!*GJ#BNG\#?&S_ (,\OAGXS\*?$3X?^!?VW_"7CGP+XATCQ9X/\4Z/
MJWQXAU;P[XET"^AU+1=:TV63XC2QQ7VFZA;07=J[Q2(DT2,R,!@_M0W_  98
M_P#!+9AM;X^_M^L!C&?BC^SID8SC!_X95SCDC!R/:H_^(*S_ ()9_P#1?/V_
MO_#I_LZ__0K5RODN^5SL^Z5[=G9N_KZ:::\4O9W?(Y\KZ-*ZUV=G9[;^FFFO
MXI^+OC!_P9T>/O%GBCQUXS^'O[;7B3QCXU\0ZUXL\6>(M3U7X\RZGK_B7Q'J
M5SK&O:UJ,J?$>-)+[5=4O+J_NW2.-'N)Y&5$4A1SP\:_\&8@Y'PD_;-!QC(U
M+X]CCT_Y*5T]J_<W_B"L_P""6?\ T7S]O[_PZ?[.O_T*U'_$%9_P2S_Z+Y^W
M]_X=/]G7_P"A6I>[WE]R\O/U_#MJO=[R^Y>7GZ_AVU_#7_A./^#,?C'PE_;.
M&/34_CX/_>EU^/W_  5GUW_@B;K&A_!@?\$D_"'QJ\,:[!JOBT_&B3XM77Q#
MN([S27L])'A)=(_X3CQ/XA@62*\&K&Y.FK:RE'C%R9%\H+_:7_Q!6?\ !+/_
M *+Y^W]_X=/]G7_Z%:C_ (@K/^"6?_1?/V_O_#I_LZ__ $*U/FVO*;M^EO/R
M_+MJ^;:\INWZ6\_+\NVO4_MYZC:Z3_P:#?"#4+V6ZM[6#]@?_@E&);BS=DN;
M?SO%_P"Q];I<1,K*P,$DJ3, RED1E#+G(_AM_9L_;4^*'[-'C7XE?$+P?HOA
MSQCXC^)OP%^)?[.^JS?$ >)M<TVR\"?%[PT?">OZQI9TCQ)H=V_B&WT@!_#U
MU>ZC>:9:7TAFO-(U&W5[8_ZE_P"T9_P2_P#A7\??^"7=G_P2MC^(GC_PC\(]
M$^#/[/7P0\/_ !&DB\.>(OB/;^&/V<-8^&6J>#M4UA1I.A>%]5\0:O'\+M'M
M_$<]GH>BZ;/+?ZC<Z;I>FH;:U@_GO\/?\&8?[./AVTEM+;]N+]H"992S%I?
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M4_VP$CG8H3#JWQ])MW&"JW(/Q]C$9E7+QG++( V#D%:Y4?&7_@S(BR%_9?\
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M_P#!'#_@B5\,O^".A_:-;X=?'3X@_&I_VC3\(3K;>._#OAS0#X</PB_X6?\
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MK?[7<(9;/Q_%\'KS7;Z;[ MK<B";X:Z>ANYKBR^TB&VCU"[0:I\7?^$(-^?
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M(;2_BN)+VV_E2C_X/4O^"64A('P%_;]4@$C=\+/V=_FP1\H*_M4-@X.?FVC
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MQ1;QRR*-5>U\(:=\%/%FDW;V41=]/CE\;V2ZG(JQ7,FDJQF3^9'Q/_P>&?\
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MIIF@_!;XF6U[9_9A!*+Z;5K"<SR2V_\ 9PCA2YG_ )6&_P"#TO\ X):JI<?
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MX5?L[[$O-29Q:6RX_:H8O(ZQR2OCY8HD,DK*N">:N/\ @]/_ ."6]K-+;S?
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MO!5I;FYN%:6R\?0_!Z_UW4)A9K:3K!/\-M,1KF>XM3<+%:Q7EW_*1_Q&K?\
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MPHU[::;K5[HWAV\U:QM[@R16NHW6@:-<7D*I/+IEB[M;QZ5% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?@3_ ,'0?F_\.+_VXO)#&3'[-)&T%BJC]L#]G\R/@=0D89SVPISQFO\
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MLP554;F+9&  ""2<#&,CGM7M7A+X3OKEAJ]QJ]U=65];60NM/M;:W%Q-?SR
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M8WT>HZ59WMU:7-ND=LT7VJ&:::>-&%M(.;T_PGX4^+WCO6!_PF$OA?X=>#M
MUC7KWQEJVB3M<7$MA$SV.D6FF(W[W4;^Y:""*R$X=O,E89\M5/)VUUJ^FP:M
MHOA/QMXAM;/7);.RDTR.UEM(]47[455+BTDO[BU@W+(LPD0DK(B(S+AG;]!]
MA26$_LW+G3R_%571Q>?T\1@,PC3KT\;A7A(IXO#NA]2S&EAJ=/$IPG4J4/94
M%BJ-.-6G4C^LK#45EZR;)Y4,IQU>6&S#BRCB\KS:%/$T<SP+P$$\=@WAGEN<
M4<)1H8M2A4K5L+['#1QN&I0KT:L/TG^)/[)GP_\ VH=3UOQ[\(;_ , _"Z2^
MEDO+;X>ZUXYT^PM=$TVV0R7O]G:UXDO;=;L27:BWLM/^_!#<6B;CYQN'_+OX
MU_ #QQ\#K^PMO%=DB6NJR7Z:5J-I>6&IZ=J2:=<M9W,^GZEI=S>6-Y;)=1S6
M_G0S%6FAE4#Y":^W/AW\'OB!!\-O%'Q=G\5^&]1'@OQ&O@O7O"6K:W::7XRT
M=M3CM+73;Z;P]+);RWVE:K=SC3;6^TPW0%]:F.X2)&B+?&WQG\;#75M-+74(
M[HPIY-Q$H9A9R6EU<E(M^]D+2"0.9(@H90B2@LF:\+@&OGF&S6>3X3B2AGW#
MV5U8X"IAZ^%KUL=E\J>%4XT)YI5Q3KUG"E4PM>-?&8>=3$TZBG[6<J\:S^8\
M*<5Q1@<^GP[E_&6%XJX2R2LLJKX3$X'%U\TRJ=+!QJPPM3/*^.EBL1*G0JX+
M$PQ.8X2I6QM*HJCQ%66*CB7\\$D]23@8&>P]/I1117[@?TX?Z_T04_\ !K3&
M'.U#_P $!$#M_=4_\$[0&/X#)K_()$@BD9MH*G<-O.<9."??U_$5_KZ+_P J
MLZ_]H Q_Z[LK_((E+'!( !/'?IQS4-)NSU3BU;;9IZ=;O]#HIR<*?/%)3A4Y
ME+EYGJHJTK^[RKHFM7)WOI:,G))'&23QVS4R3;8V3"YSD$CD?0Y^G'3O4%2)
M'N(X.20 /7/ZX^E.2BU[VR:[[K\612E44_W;]Z2E%KNI:/3[MM;I6-JRO+86
MZVB6$LU[)<#RI$+22.K[0L20J,NY?[@ YR!C.*[GQEX[_P"$MT7PMIMUX>TS
M2;[PUIB:2U]8*8KC4K>!B+=[Z$1QQI+&I96*;F8@%R6)(XW0=6N-"U.QU?3P
MD6IZ7>6FH:;=2*)/LUW8SI<0R^2X,4PWHH:.0>6P&".:['QGX(\9:3IVA>,M
M?L ;+QY#=:SIE["J>5./.=KD,D0"6\D;L)&@XV1R(P 4BOG\7' 1S/+WBU0I
MU?:59994JXRI#$5L9*A5^L4:&'O&%6FL'"=6493G\$YJC'V<:K_7^'JW%E3@
M7B^GP_+-,=EZP&7T^.<%E_#6$Q.49?PU0S?+(Y'F69YMR5<5@L9+B2OAL#2K
M4L-AN;ZU0P\LSJO&5\"N'N)91;00R$LBAMB$DA0QY*J?E0%CDA<!B2QYS5>&
M9HF#*[HRX*%200?J.0/H?IZTVX+94-O0JJC#J5(&,@8.#@C!'8]1P<U7+ Y'
M0=R><]N!]>1SVSZUZL(+DLTO>;D[+2\G=].O5];ON?GV(Q518CVBE/FIQITX
M.4FI)4H1A%7O=<G*DD[*%K<MU8^BO'GQ+\-^(-&^$5UI-E.?$O@?1+&PUNYD
M BN)[G2[Y'M(UN"K"XA6TACCM)6!:!6*$-C%,^)?Q#TWQ9X9\.Z1I^H^*+VQ
MMKFZU35K;7+>S%O8ZS?0P)/):2VI$UTSF-\2SA=R;2 79L> V-K=7US':6<?
MF3S;@JYP"%4NS,Q.%554LS< #GTJ0:A=0PW5DDF8+GRQ,CA20T+$@HQY5@S,
M,CJK'(KYJCPOEF%J9?[!5)U,KQ.*Q>&5:LISI1S#$8BK43<Z<Y1A1GB,0\(J
M:I\JC[-RE%2/VS,O'GCC/<'Q?_:TL)AL%Q[DV09!G=3+,MGA*&.J\'Y3DV"P
M<^6AC,-2KXG,*&4Y2N(*F*^N^VG6>,A1I5I46G3V[Q!I&!1$VA%8%3*C?=;Z
MXYYY!^H%):)%Y\)=P^X@H I8[R 50@]L\$BHI[RYN8UBFE,BQ@!5XR .F2!\
MV#U[>PXQ77<I5@IRO((.,$'((Z],$X(]:^EC&;@XS:4FFO<=U:UD[N*=^KTZ
MVNTD?B=2OA88N%3#4ISH1=.H_;QY9<ZJ*4URTYSC9*T(J[^!2:BY3OMZ]=I>
MW-O(+2*V+6\7F&& 6_F2[0LA"@D,JNI52 I."2,FLBXN;R[:(7=S<7"6<2VT
M GEDD%O"F2D,*R,PCC4YVQKA%YPH/-;\^KV]_I,-J=+L$OK.#RFU%YIC=77F
M3AUECCXB6:)08W8DJ8FS@-S6WX)L_!CKK9\8G5) NF^;IDFDE9%AO!. T]\C
M?>AVD1(.,/(K$X(KB]O' X256IA*\GA9>RA1H1AB,1*,ZD*:J45&;?+*$U-I
MN,U#F7(G%P7T\<JJ<3\14<%@^(<KHT\\H+'8K,<SK5\FRFA5H8.KBIX/,IUL
M-%>UHXG#SPT)QI5L-/$RI2AB'3JJN=9\&?BCJ'PF\46%[=QW5_X>>9+W5/#P
MDC6+4TDM)H;:8I,KQ[T2YW)D R1_NW(!X]O\9:1^R;XVFU;Q19>.?$7@K4M4
M4:E_8L6C"[LK&\G7?<V=M:HBEU\XMNCCD58\YBR@P/E#3_[*_M1KY[&ZU/1;
M2YMFOHOF27^S6GV21K/\Q@GEA#16LFPK',P^7"UW?Q,\$>#/#,%AJO@OQ>GB
M72=6"/!!<V_V:_L))((KJ:QG="8);BQ$ZVMTP.%F0J"6!KY#-<GP&(XBP>-H
M8_/LASG'X=8:IC,FC3CAL=#"RAB'ALQC7PF.PD*].-12I5,53I5:M&4Z=.M4
MA!TX_P!&^'WB1Q?E/@UQ+PQFG"?A-XL>&O"><2SG"<.^).(Q-3.^%\3G=*KD
MRSS@O$Y9G_"W$6*RK'5L+*AC\)D.-QN#P>8T\/B\9@,'B<72Q=;Q>]CMX;NY
MBM)FN;5)Y5MKAHS$T\"NPBF:(DF)I$ =HR<H25[55ISD$G"XP3WR>O&?<=*;
M7Z/!-1BFW)J*3E*W-)I6<GRI1N]W9)7>B6Q_%M:<*E:K4A3A2A.I.<:5+VGL
MZ492<E3I^UE.KR4T^2/M)U)\J7-.<KR?U;^P<YC_ &X_V,Y%QN3]J[]G=QGD
M97XO>#V&>G&1SR*_W2Z_PM/V#E+_ +<?[&:*I=F_:N_9W4*.K%OB]X/ 4>[$
MX'N:_P!TNJ,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/A?QE#=?LX_&6TO-.UO1O-$.AC3/#K:KJ-GJMC&!>:A:6=C/'(UVTT/YD_\
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MSP-7[?J-_%:6%Q?7,UK:AEM;=Y'D@M@V6;RHB2JD\YP,\\U]$_%S]GB/X=Z
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MU(^R]DT^95>>$HQ@O=G%*:G+D562;A2=*+GR0DIM0O4DVX''^'8_6@,P! )
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MR>!R[ 0G6JQI3E4KSIRPN!CB:RL?,^7C8#)!7!(P0R]^XR,#Z?042+(Y,K2
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MX $D[N,<"OU*TK]G;X;?$7POJ_A'P39>/?!7[5?@[2I[_5/AIXOU&QU#P_\
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MMOX!?3U1+"Y\+G4/VC[@Z5J%A%''!:ZG:E-2MK>&&WBNT@ACC7T_XC?\$"?
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M-])T7]D[]HBSLO$NG0V=_JEI%::K#&MW#';ZC?1*D@"74RX<\G_P<D2V<?\
MP7Y_;C6^M[:YM[G3/V>[,K=!BL4EU^QA\ 8HKB$J"5N8'(D@8='')QFKQE=X
M;!U\3&FZCH4I552@U&4N2+DHQ;:2;M97T\NWV/"^61SO/LHR>>+I9?#-<=A<
M!+&5X2J4<+'%584O:U84_?E3I\R<E#5)76Q_.*02>>,\\\<>_P#GVJ6WG-O)
MO 5L @JP#*P/L>V,\]:DO8A'=3QIDK'(R<G)RG#$GH23D\>N!TJI72FJD$[>
M[.*=GVDKZGE353"8B23Y:M"M)*:U]^G*UU?=73W6J>J6Q;N)S<2M*  6(.U<
M[5 & HSSCT&<]\\5-8W4UE>6M[$D+2VLT=S&EPBS1,\+AU\R)_DE3<HW(V0P
MR#D9%55SA1C!QCW_ /U__JIV.GJ>,=Q]?2LI1AR.ERIPLX-2UO%JS7HU=-=5
MZLZJ->O'$1QL*M2.(A5AB(U8-0E"M&:J1G&RO&<9VDFM+K162.C\0>+?$7BG
M4KW5-<UBZN[G4&S< 2/':K&I'EP0V<96W@MH@JB*WCC6- J[5& :Y^6*)%3;
M+YI8$NNTKY9!Z9/7/M@#'O7I]AX'T_2;.67X@1ZYHJZK:VS>&-1TP:?>Z>\\
MS1222:H4EFD%NEJYD6*,Q3LP8#[K <AXH\.2>&M4EL1>6VJ63*L^FZQ9"3[#
MJMG(%9+FT:558A"WDSH1NBG1XSG )\K X[+G.."P')3I4J=L/]6HQA@JU*C"
ME&<<+7I0>'G]7YHTITX352G*G.+@X4Y-?>\5<+\:PP=;BGBI8G&XW'8J-3-I
M9OF->OQ-EN,S+$8JO0K9]E>.K1S;"O.(T*V-PV-Q6&J83%4L50JK$JOC,-&>
M)<P6B06CV]RTTTT3-=1-&8_LTRN56-6Y$J,F&# #&2.O-4R@XP.^.,GK_G_/
M%2  D ]R!^9Y/^?_ -?V?^RO^S;X:_:[^.WP?_9;^&^O/X=^)_QM\>>'?!7A
MWQGXZN1:>"-"N=3C=KZ35X+&-KO[/')%((I8Q)*Z^6D<1E< ]E7%2P\L/3]E
MB\2Z]7DYZ5.,XT5.I%<^(FO90IT:2FFY6E4<(2:C.46SYO+\DIYW1S;&O,.'
MLCIY7EZQ+P^88^OAJV85:&%JS^JY5AW#&5\7F&.GAI)4VZ6%ABL31A4K86C5
MIJ/Q>8MJY['&3QP0>G^?KTK](/\ @E1XB_9H\/\ [9OP:/[3?P;\0_'SP]JW
MCWP+H7@GX;V?B.T\.>#[_P =:YXQT;3-/U/XDF:TNKK6_!^D6MQ<7UWX<L/(
MDUFYB@L[F46;SHW[NC_@SL_;)Y!_:T_9* YY_M_73_[2[_CZ]:ZCP)_P:0?M
MU_#3QKX2^(?A#]L+]DK2_%7@?Q)H_BOPWJ3:UJUP+'7="OX-2TN[,$]L\$WD
M7EM%+Y4JO&^W:RE2178HN6DDI=DTFM;:.Z>NG3K>^ZO\\ZL:3YZ%2=*\;-QD
MXRC9IO5..CUNG9/STMS-IIOPP_9.UW_@HK\?_!'[,GP$^+OCO4O^"Q/AS]C&
MQT/XJ?"VQ^(7A/X?_ GQ9J/BS4O$6@>$/">QK3PWJ?C:6RM?#UKK4<,5[9P+
M%;Z$?M@"O]7K^SE^S%^QG\:/!?P+^&/[+7P*^+/@7]L[_@KA\=/V2_BS=?%'
MX?V7Q'UKPE\!]"\._#[4-%^&7PWULF:;X?2:'>^/M;U6VU'3WBUM%\-6BS/]
MGLKUD]H^"_\ P1-_X+=?L_?%/XZ?&'X6?\%(/V5= \8_M'^);SQK\7%N4M=:
M\/>(_&MUJ-UJ]MXRB\-:SHE]HVE^*-%U&]NKO0-<TZTM[_1Y9F-E-&, ,^!7
M_!$__@N9^SEHWQAT/X5_\%/OV=M+@^.7BC7/'GCN\U?5#XFU?_A8GB6*[M]?
M^(OAK5=?T?4+[PEX[U:UOKJTO?$WA^:PU&6UF:$RA  +6W^7X?@<\G=MJ]V]
MWO?3HNSO:WEV/Y4O@=^PO\+?C9^US^W_ /!*X\3>*="\&?LP?#?]L_XD?#VZ
M\.OIM_>ZO+^SY?\ B)O!NDZI/=PW45QI.IVNF6T>J7-D!<R1%I;29"0U?8GP
M5_X)+?LL^(?V?/A?^T'\7OBC\<],\/:[_P $V?CQ^W+X\TSP#9^#)M7B\1?"
M'XU6WPVL?!WA)==L&M/[)UO293<376JO+-!J3"43?9(VC/[T_P#!.+_@WF_;
MD_8#^.'Q5^/%G^TS^RQXO\:^-_V?_C5\*_#]]/XANK\Z3XU^*.@2Z9IWC'7;
M77;6ZL]>T[3;Z62\UG2[J*235XI9(_,C=B[:'Q)_X(I?\%L/B_::KI7C'_@H
M'^QQ<Z=KG[/GB_\ 99N-'T71-,T+3+?X'^.O$%CXF\0>!M+TW1=#L[73K.;5
M].LYK6XLH(;NTCA$,$JHS KE2UV6K>MNJ?2VBM\C55)R<$FV_<@DE=NRBDK6
MNVWHK7;U6R1^'7QV_P""1_[$'A_X?_'%O@U\7?VG9?BAX&_X)X^$?^"DO@Z#
MXCZ?\-Y? ]K\-O$TEJH^$'B5O#^FV>MZIXV2.6\F_P"$NTN33=#C\BTA&F2M
M+<,O\T,2J2&)!).""VW&3USSQGWST/ )K^^'6?\ @W]_X+!ZFWBJ/5?V^/V2
MVD\9?LI:+^Q5XA22-H7O/V=-!YTKP0%_LP&%X/\ H,QA=4D'WKHU\+G_ (,Z
M/VRN!_PUI^R8,=O^$@UL?^T,TK)Q]UZ26\7=->J>M^Z?S[MSG"HO:Q<I4]'"
M:<7&2:NFI)\K5K--.VBLK:?R#3S2/A68E1D@9)'/'?KTZ]Z_U\O^#7'_ )04
M?L,_]W,_^MA_M!5_GU?\%./^"!OQ_P#^"7_P,\.?';XI?''X&_$G0?$7CRR\
M!6^B?#?5M0N]<M[^_P!.O=1BOIH;R..-K%([&2.5H]SQR/%OVB1-W^@K_P &
MN/\ R@H_89_[N9_];#_:"IQ2BDDDO3:_5_,SJU)5)N<I2DW;63;>B2MKT6R/
MW^HHHJC,**** "BBB@#_ "&_^#H)K.W_ ."ZO[<,UXAN@P_9F9+6.41M\G[(
M/[/PQ+(%8Q(Y1@<8<JP*CD,/PP\-7@U;66L%@BB&HI]F2*68S11@<1K&\^6C
M$"Y,*AEPRKG(!!_;K_@Z-_Y3K?MS9SC_ (QFQ]?^&._V?OY9Y'OFOP0TQITO
M;=[?<)D<LNT[20H+$!AR#C(XYZ <X%<>*PRJ4JS<FJDH2Y)R<N2FU[T7R)J/
MNM1;?Q.R=]K>?C<)&M0Q$G-JJZ4_9U)RE[.DU:4'[-24+1E&#D[<TN7XEI;]
M%M)=='UD^'-,T\V-GH^DSQZ0N#-J A6!KF2YN;EU5$GOBTC-<_NDA$JI  P4
MMP'C/QK>Z3H>KVT]S;1WNIVT=O"NTM=V]O=2NMQ#;3,H\E9(RT;W2.-X7:CC
MS%8^8:3\=_%FFV\:1MIYEN--DTB2X-C;27&I1D*D4=Y<7$<_E2 +;JUU$L<L
M<=NFT+)AJ\<\27=YJ&M74ET5/E^7"$6:26" H@211([EI"C!UW9PW!XS7YWE
MW"^(>.<\RC0C""I55.,W7J8FK1J7J3E[2,9052I)3DG*JY-RO)2;B?D&3\$8
MN69NIG,,-&G2AAZRJ0J/$UL97P]7FKU)RJQA.FJU:<:D^:59S<IN4U-R@784
MM9'ED\F03P1L,1,',LB*6_>-(0" HP6!.WACNS@1QK=/:W5\;F%(I]Z26[*\
MQ0+'*TLW[H("8E"@)CRW,JMAMI NP*UI;P_:5NG,EL\ZOL27R[) 86FCC8A<
M)("/.D4@!6Q\BG*:?%I>H2:I)<:REI9HGFPVT8"_: BLI65-L8!(C5#L0AWE
M!1 F67[%SLIR?,X1<%SJ#K77.DX02C)ZR::35THN^FI^ARJV5234Y4X.G[ZA
M/$-I5%%P@E"<DY3::TYH<CU2U7/:7K0TQS=18=D5HX5;&XE@=QD4 '80,!@2
MRD ^M:AUB_\ $\L$.NZFT5E&LC)-(JR2(8H2BPQ$LI1) $3?(3@*I);8%&==
M/HLCK:V-N8XI$#&]NG>,)(%)81K\Y,?1!D,2V" JYRRXM!IEM(+?5-.O/M-K
M$TT<1<SP.S[C#$VTH\J +YC1,1L8@,<,1U2A0E)5/9.EB9V5*=2"E4A%Z-QE
MRU(TY+FO:=KM)-*YW2I8:I)550E1QE2T:%6K2C*K3@_=DXR4*L*,ES-N-1+F
M:Y6ES(L3:79V[Q7#W_VG3XI%6;#(TJH0"I0!RDL3,-OR[64G#+TK,U'44O+F
M2.&(O!Y0MK82,Q=563>)%56"AV^Z !@+QC.<9WE2&%94CPC.T052S9=5#'/7
MJ#GL./QK^D[]F;_@@K^S=\=?@+\(/C=XG_X+/?L#_!C6OB3X'T7QAK?PG\?>
M+O"5EXR^'UWJR.9O"_B6WNOBII5W;:O8,ODW27.GZ=,LI9?LRKM9^J-%1]Z=
M256<4XPO:%G=.S2=G-R5N;9K1];]U/#J/OU:TJ]2FI0IWY*?+*Z=N6$E%U7)
M<O->S246D^9O^=WPIHNGWT-Y<:@A+Q[4L/-,OV5Y4;=,9U@42OL7"A=Z+F1=
MQ(!K^H_]E']CW_@GU^TK\)?^"2MGH'P#UVSM?B/^WA\7_@W^TAXI\=>,+>3Q
MO\==5\"? /X7?$J_\,6=QX,70U\%_#?5O&&N3^"_ WA31;W4O%,&D32:U=:]
M/XIU^6WL-#3/^#=;]EK2I6:Q_P""^O\ P34V.Y\V*7QOX&D1T#913N^,;#<1
M]XD<'[N<U[;I/_!%/X=^&O#'A#PEH'_!QG^P5X?\/?#GX@WGQ:^'^DZ+\6?#
MNCV7@7XH:K:Z)8WOQ \,/IWQLMKO1?%EW:>'?#]L=:L[F"[$6DV B=&MXV'+
M4ABHXFI43]I3J<GLX.HXNGRRA=*+:<>:W,[-J4K-IKW'Q5:6/CC*U6,O:TJO
ML_90=7D=+EE23BH<T7!2MS/EE)3D[M-/DEY<OP/_ &:_^% 0_P#!167]@+]G
M^T^/2_L)?$+XJ-^Q6GA[XR#]GW_A+_#'[?'PU_9ATWXOW?PBNOB0GQ)>QTGX
M4^-M?N-6TD>*X?"-[XG\(OXHNDBN$U.-/@?XM_\ !/OX4_$'_@L/\?/V)OAW
M)KOPB^%5A\+OB!\9O#WA'PT+GQ1J7@7Q'H7[%9_:BO\ X2V'_"27EYK$]AHG
MCZ*_^&TD6L7EUXATW2[1K>\,FKV<D=?LE)_P33^(MU\?X/VI9/\ @ZR_9=D_
M:+M?#G_"'6WQ@'[1UI_PG-OX.\J1&\(PZN/CF)D\*N99KB7PZ!_8TU[--J$U
MF]]-)<NG[+?_  2K\!?LJ_M33?MB>'/^#@W_ ()O^/?CG<:+\8+"Z\9>//B]
MI=[XCNO$/QD^'_BWX?ZYX]NO%5O\<1XCG\9:0GB^\\2Z5JLVH22R:_96DMZ\
ML)E5O15.+2YXQG).,FY)-J227,M--M+>AZ_L824?:1C4FG";<E%M3BDN>-U[
MMK:6\UU9^.GPT_X)B_LY:'^R[X?_ &F_CK\5OCCI/A.\_8E^%'[5GB3PS\-/
M!7@C4?%O_"0?$_\ ;IUS]D33?!_AO_A+=:T+3H](DTRRT;Q=#XBU6[:6UDO[
MJ9+#5+6&VM+OB_\ @I=_P3%_9]_8Y^'OQ=\8_!KXR?%[XF:S^S[^VY!^QE\4
M;/XF^!/"/@[2_$.N>)?A-XE^,GASQCX%G\,>+_%%ZFG:1I?AF]\*^(;/Q!%;
M7.J:H\&NZ9_9]E,VE0?LY\2O^"4.J?&F+7[;XK?\'0W[&GQ%C\5>#_#G@#Q%
M%XJ^-GAS6AK/@?PAX\C^*'A7PG>K=_&:4R>'O#?Q @@\6:'I6?L>F:M;P36<
M<*01(G#?$O\ X(L>#?C#9>,],^)W_!RE^P=XXTSXA_$ZT^,WC:P\1_%CPA?V
MOBCXK6'AV_\ "-EX_P!9@E^,;)>>*;;PSJFI:)'JDF;A-/O;FW#;)6%)4H*3
M:5G)/F:E)-_"E>S71=+=;;L2HTXSDXQLYQ;G)2DI-KE46[-/9/56U3ZMG\:T
MES+(T;%B!$ (D'^KB );:BG( R2QXRS$EB223 3G)/4G.?SS^=?U=G_@V\_9
M.'!_X+Z?\$U0?^Q[\#_G_P E@_SBOSA_X*6?\$J?@M^P/\*_ /Q%^&?_  4I
M_9/_ &UM6\9_$#_A"M0\!_ #Q'X>UKQ'X3TX^'=:US_A+M:AT;QSXIFBT07.
ME0Z,99K.VB^WZG:(+DLPC?1)*UDDK:6[;_\ !-HQC%)1222LK=M_^#YO4_T7
M00/^#68$C('_  0"!(]1_P .Z^1^-?Y Y<DDC"@G( ' ]AGL*_U]_P#G5E_[
MP __  .NO\@6BR>_I_2V*YFE9.RO?Y[;[_+8G1CC.<'!''KQ^7KG\J>1\JGZ
MY/XC'T_^O4*@CG(Y.#WQZ?0]L>_X4\G@C) 88]CWY^F,CGFLY1][U^=MNGEV
M73LCJISM#7M9:K5OE:?SMJ].N[N-SDG!XP<]L8ZD'')]!^N<5<N+62V9$E"Y
M=(Y5V,&W)*BNN,9YPW0\@G!&<XJ1$#KTY))Z# Z?R-2A2T9E4K@$Y4, RG_=
M.>N 01GZ=J4DU*-FE%:.ZW;2L^9-6M9WT=[JUFM=*'(Z=2\)3JRM.+C-)4Z<
M%>K>FX2<N:\.5J<.3EDW&:D^5DH,9 4@XZ]\>Q[?E_\ KA!PV3GWR,=003C\
M3BKIG618HUA19%4J7<\,">"1D98<X)/4].!53< 2'&[!/?'J.W;//?V]:J#;
MC:4;;Z75VKVNK-Z/>]S.O"FIQE3JJ47RV?)4C&$N2$G#5<S<>:TK1:O&Z;31
M926)(_+>'>2Q*R @,58+U&"20/N].M3&]$,5Y:V0_P!'NS$TCS(K7 6+D1J_
M.Q0QRQ7EL G &*SR0<8) Z8YZ>OO_/BOJ?\ 8I^(W[-_PD_::^&7Q#_:W^#.
MK?M!_L]^'KKQ!+\0?A#H6KQZ'JGBZWOO"FN:;H<-MJ<E[IR6W]E^);S1M:F!
MO8#-#ITD <F0*4Z4&US)N[C)J3O%RBXRC*S?Q)QO&VB=RX8W$4URT7&$E3E2
M56E"$*RI5*4Z-6DJD%&3A5IU90J<R<IQM%RMS7^5NH[\<#CCKT^O.?\ (K]-
M?^"?WBFY^"7[0WP!^*_P5^,WAKPQ\6(?%.AQZ]>^+/#.ASVGP^\.W.MZ9_PD
MVK:)J'B:SU+3[3Q';Z3'/:Z;J]O9MJ5C%<W=YI4UM<QQ74/[%?\ #R[_ (-I
MN2/^"*'Q9P.O_%W+,=?^YW-36_\ P4V_X-J[6430?\$4_BS'*H.UQ\6[%BI/
M<;O&IVGT8?,.QY-<&:X/'8RC3_L[-*N5XFC*=2$XX?#XFA7DZ4X0I8NE6IN<
M\/&<HU7'#UL-6E*$5[91YHOZS@/B/A7A[,<4^,>!<#QSDV8X?#X/$8:OFV<Y
M)FF5TH8_#8G$8_A[,<KQ=/#8?-JN&H5<!3K9QEN=Y?2HXFK/^S95XTJM/[>\
M._'KX&>$_P!HWXM>/;7]NCX0?"#PGX._X+>?%?\ ;\^(M_<?$75M"3]HO]E6
M\\.:#HO_  AOA*#0P?\ A:.N+J?ASQ3X=A^'^I+);7R_$NWOX8&M)]3D3XH^
M('[7G[.NO_L0^.OB/I'[3?@F#X=>)/\ @ECI/[$>B?L.GQ5JR?$*R_:ELOVE
M_"WCJ;Q[)\(E3_A&(?#]IHF@:YX^3XHHHGG/B2/3([E]1EN84JR?\%,_^#:J
M9V>3_@BG\6W=V9V)^+MH<NYRS8_X3; +'EB!DGDY-1_\/+O^#:;_ *0H?%G_
M ,.Y9_\ S;5TX&EBZ.&IT\=BJ>,Q,74Y\12PWU6$XRJ2E2BJ'M:RBZ=)PI2D
MIVJR@ZO)3Y^2/C<4X[A[,L[Q6+X5R/&<-Y)4I8*.&RC'YS_;V)P]:C@<-0QU
M:69O+\LE5IXW'4\3CJ-"6%O@:6)C@O;XI4/K-7)_X)W?L_?LNW7[*?\ P2]_
M:._:!\0?LO\ PX\">&/VJ?V];'XUZA\<]7TGP_K'Q2\,VGPK\$0^ -$TNQOK
M6>;Q_%X;\67*6L&EPDMX?OO$%A>N%@NWD5UY^US^Q_\ #/\ 9B\5:-\/?"W[
M$VO^.OAI_P $S?V&_'/PND\0_#/P[XG\7ZM^VE<>/O"'A[XWKJ5W>;6\1^.O
M#WP]UCQ,NM^'KY&TJUATZ'4[RTOKNS:27L;O_@JO_P &YE_X?T?PE??\$<OC
MI>^%/#M]JVI^'_#-U\;EGT'0M2U\6*Z]J&D:7)XZ:TL+S6ETO3!JMQ;QI+?#
M3K$3LXM80N&?^"E__!M*<?\ &E#XLYZ?\E<L_P \_P#";<G\*ZSY]6W[>>M]
M-G^.W^9^'G_!4D_ !_V__P!J&Y_9<E\$R_ ;4/B9J6I_#MOAO+YG@0:3J5O:
MWTZ>%L%EBTB/4)[Q+6W0F.V1?(C^2-:^ J_J_P#^'EW_  ;3#K_P10^+(_[J
MY9__ #;4?\/+O^#:;_I"A\6?_#N6?_S;4"/Y\OV"/^3Z?V+< $_\-9?LYX#
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M]NOXY_'7]M7_ (*>G]G?]IGQS_PK+_A9?P>_X;4_8Q^$@\(?\(S\'OA]X/\
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M_I-.?_%C?_!.S_YS='_#@K_@UF_Z33G_ ,6-_P#!.S_YS?M7\!5)_GZ]R/\
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MXOB7+.(LLHTEB<LRK&9!FGU:&,_M:G*KA:^5XS T<=5I5*=>=6I6PCK8;V^
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M'_#!W_!GO_T._P#P3._\6-6W_P!%!7^6VK*L<B&-79]A20E@T95B6VA2%/F
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MJ>'A/#TY3Q+Y<#1Q6']K5JN<8NK.<E\3@.-/$#BF.3Y7B.(EE.3X3,LNR?\
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M=_ )/C'XC^#>A:II&M>"?C!\/;>Z\">,]0U&WDN/!'C"WADU*RCFN2MNMO\
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M_JF_X,[BH_X*]SAC][]E/XUA!@G+?V[\-V.#@X^16.20, CJ0#_JEU_E7_\
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MNX 0]8Y0?E20#!(8,?\ 6>_X("0M;_\ !'G]A6!X_*>+X7:ZCQYW;&7XE>.
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M-*ACL/FD\=' 8_+,92]OEF;9/F/M,/5A4P<O:_ZX?_!KI_R@I_8:_P"[F?\
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MW5CIUW:8T75%O8-,F@OHY(=01X7FL[AKJ$V[H0ZPY4RI\M^$/#=_9W/B2_:
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MC36J:T:/]OG_ ()<?MS_ /#RC]A/X&?MK?\ "KO^%+_\+H_X6;_Q;3_A-O\
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MQH\>KE9;R)+"S2Z*N)?)M-0NPFQ'9(1<*ODR0R2_37[2W_!+O]H?]D;X^+\
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MK*U\.^&/"FDV&FZ?X;T<F'2KB]T^U6Q;7[JU1(XO[7NX(T2X=0R_+D$L69O
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M)DUC4KP27$=SJ<UW-##IEO<6\-O RK(TBGR0W[.ZO_P5Z^%O[17[/OAKX?\
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MA0@7CZ'I-UJ5QXEEB"@RFSALGA%_MQ%ME@$Q"E2/KKPO\?OAQ^SA_P $[/\
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M%76IZ'IJ3-)K%[>6.B:9-<0H':VM+W5)[:.^NEC/,=N752?WKID9Y3X8>+?
M'@O6[6]\??#&Q^(^G"'YM.O=>UC0EBD,L+H\4NE.HD:%$FC,%RLL,IEQ,I"A
M3ZC\3_VNOBC\0[_3K6PU$>!O ^@36\'AOP)X,:;0M#TW3[8-%##-]DD2>]N&
MM'>WFN;F5U*R2+%%#$1&/UGA++?#3#8&>=<><0YMC9RG'"X;@SA##SP>=59N
M,7+&9GGV<Y96R/+<OI)J=.&7T,^QV*JIT)8? P_VE_M_ V4^$.$RVKQ%XF<4
MYYCZCG'!83P^X#PU3 <15JKC!U,?G/$W$.35^',GRFDFITJ>5X;B7,<;73P\
M\+EM-?6W\OZGIMYI=]>:=J5N]E>Z=<36]]#*H22.:W=DDB(&06W@@,"5;&02
MIS7T-\)M&^#'COQ=\'_"6IZ/XDT>YN=?6U\=ZS=>)-/_ +'UG26MI[V5]/M9
MM,4Z)-;SVXMF1[J\CN[*0(JK>2;ST/[57Q%^%'Q>O?"GQ"\%V6N:1\0O$&E0
M6_Q"\/W,5N^CVVI:5!'9Q:A8ZA''!-J%UJ:1F:XE:)4\M8W8+.\J#Y+,@B9#
M"\N!'&79@ 4DQB4(%;!4-D!B<G )"Y(KBS!95P!QOC,)@<1D''W#F%Q^68FC
MC)8?#UZ&=Y*L7@LXP]%2KT:U;)L?B<)3I8/-J5*,<7@:E7&9=BN>$L10J>?F
MD<C\+_$7'X++,5PQXG<)8/,\GQ>'QT\+A<3A>(N'HXW+L^PF'4\5A\1B,@S/
M%X&E0P.>4*,8X_+JM;'Y7C.>D\3AZO[@_P#!(#Q/X"\1?\%ROV'-3\%^"+/P
MAX4?]I/PMI^AZ#IMU*EK!<6MAJ5FFLLCF38UW)%+?2V$12WCFN D9$: -ZC_
M ,'.<S1_\%S?VXQMADCV_LTJZ2'YAN_9"^ .& XQ]<]\8)/'RW_P0NL9+7_@
ML-_P3O>0Y23]I'P<\;E64NKV>JNIVN V3C!;&T'N<@GZ8_X.@;I(?^"Y'[<,
M<<:M/(?V: Y())3_ (9!^ /R@=,XY!&2#UZU^=<59ABLYS3'9AC,/A*&(Q^/
MQ..JT<%@\)@,-2J8NK*O.%##8*E0P^'P\'+DP]&C3A1HTU&-*$(*R_*>,\TQ
MG$&=9EFF8X7!8;%YIF6+S&MA\NR_!99@Z-;'XB6)J4\-@\OHX;"X7"4N=PPM
M##TH8>A34(4*<(:+\,[5R8/+<G#RJ,'"JT*ALM&6X9T/"^O?H<^]?"GPKJ_Q
M&?1/"?A>:UM/$=S?75F_]L7UGI4-_!JDL%O;11WVH-':0I%&S&;=(NSS!-D(
MA->#:1G4+-[66Z:*&,2W-O'Y:R/YZ(6$:?==%;+;B21GL3Q7K?@J2]OM&MI[
M2(&VT.\E>\OY%$?EWEP"MF\4RL)%/V:"3AE(RH!YV@_"8NZA4M"I-T:L:DU3
M;C[BC+F;DZ<XI2A>+ERS5.:4VWRI'PE6-.C3C7Q&'GBJ-/%QJU:&&Q*I570I
M1DJL9S5'$?5HSA*WM*E"48NU17Y-/KVX_8]_:'TSP_J_BC0OAYK_ (U\+^&]
M0LO#-[>Z2VG:]I$VKZA9WNI"TMH[&X-Q?&*UM[V\62SCF58X_F8[X@_8?LY?
ML]>,O&^J_$W3M2\,^%]*TK4]!TWP_KGB[XF:+=:;<^ K_5=2M'TBY\"65Y%;
MWW_"1W45JT, CMV7^SFN&FDB1LGP'1_BS\18=&DT32?&GB/PY;:/-#J>G6NC
MZIJ%E!<7-LS)',(XKA8OM8A8E)B"TBDQMA6VUZQKG[2/QO\ &_PJM?!'C+Q9
MXN\5:'IT]C<Z)=VLMO%J]A+9WOFB*[N[6/\ M#4TO5O)XB;W>UFUO9B%UA!6
MO%B\LG1JT\RAC'4C*"IT(.G.EC:BQ=*KA85ZU*OE];"4Z5.,*TZN'J8J=:K0
ME15&,:_)1*.)\.:M&H\\RGB>-:EAZJI9;3S3"8O 9OF<<5A*^3PQF*H4L@S#
M+<NPSC+$XR6#Q6/Q.*E0CAJ,:/M9I:OCSX&?'3]C7XH:EX6\<MX<T#XC>&M$
ML?$.D6ESK.EZBT^A>*-.-[X=\1:?=:7=7UDUVEA-;W\=E-/'>6-YLCN(5:.0
M'YMGEUO7[VWU4275WXFAOM/%D+#,DNIWKVIAN'B$6%6Z'E6S2SA09)Y&E;#9
M!_77PC\)?V//VHOV1M%G76?"GP2_:?\ A=<M-\4M?^*/Q1\4:WJ?Q5\&PZ;?
M>7JWAS1M3\^"T\16FJPV>G#1[2[M;:WT]YD%N[P0J/$/A9^UKX$^!'@*7X+^
M#?A-\//%>HW/B>'6)/B/K6G-#X@U+38I;-K_ $2+6I8;B2TM]1@AELK*6V13
M"EU<,Q$QC9>_,L@E@*<,XHNC.CF-"-;+ZJQ.$G4K4J,J?ML'B9X:#JT)TJE6
M?M:5?"PC%5.:G.JN69>><&2R'!95Q=A,=E\\'GD95<JK87,\'5S.*R^O2^M8
M7&TL-&GCL#4H.O&I"=?!TL/-U6L/BZE:G7^K^^_#+]DG]GWXXZ)\,[#]H']L
M/XHZ-\=?&NB:/:ZD_B?X?G5/!OA7[!9PQZ5X5UC7KS4;76;VS\/:+':VPO;"
M;[,3";>VCE.,>!_MY_L(?M ?L'P_#?6/%.MZ#XE^#/Q#.LZ_\%/BS\/=2GE\
M)^+$T>>*":X@N<)>:9KMFDMM.=,N76YMU.R-R\4Q'CG[77QTO_'7Q-\1Z]XB
MT^+PYJ%EI6DP:7X7\%SS6WAO0;F.)0=/0RL;NY%A (%%ZS12W$A+,J@!:^:O
M%GQO^*7QA\,> ?A7XK^*/BS4?A3X%N;Z^\.>#-1U"[U+3O#]SJEO!-K^H:7:
M7,C16LVH7-NL<:(1DG)(&[.<\55SV6'S#&JE1G1I*K4KX2GBZO\ :-1X7#Q=
M:57&8FK7<ZC5;$SQ?L85:M6I.'LZ=+EI4^6KCJW&7-GV;_4L%BJ#I8F=7 1S
M&M+.*E7"4H5J\9YEC,5BJDYU:=;&XC,:KCB:E>NZ4J2C45.CWM]^U1^TCXVT
M32_"7BWXX_$?Q3X5L=-_LC2=(\0Z_?Z]9Z=H\\J"6RL3J1N#I]K-]DS(D4RF
M5(XX\X)KR*36Y+Q[6"]N+VXB@>]LY+"*YF95!E1X62.1WA&'VEU1 -N!]=J(
M^)-+\+:;<P6]U8:%XHFFM]-L9+=)TU.'PU')&+E&EC:1A:?VA<*DH(3SIF )
MV#&)IVF:A-JEG<)I_E7*ZA<2/9RJ1*C1/'%(CH!]Y6C\EUDP6DR!@YSQ5<2Z
MU6M-UW.DHRHPFZDI2_<RJ*5.?,M.6M[6ZA.:A*[<E*4H'F9AF$*L::H9QCL7
MAXTL6JT,1>%+#XJ&)K4ZU.@_K%=UJ=2G1HSKXCEHU(XE5:$J<H485:W$?$R_
MLX=+O;73;&6UE:T2V:]EF822QS3PF99QP&(*21Q@<@,!RH(KQK2;L:9;:5=6
MRK]JCO'D:)2#))(&\IPX(.4\EMB#^ZQSR<U]/?$WPS#:S:M%JEK/!!IFE8U"
MY5A)#>7MN\-QL7:2&6*XE6V+1D88)NSE@?E&&TU&Z>[CCB73[;=$9'DPI!C=
M?+,;/DQ, 06VE0P)!S7NY5["MEM.,)MQ;<ZO/)M24XI2BW)R<ER24E&-M6H\
ML>:[^AR.GA,1D=.4*\ZGM545;FA*I9RI\\%)N;4H58N*;BXN'-/]TW'W_;O#
MWB;4K^9- TVTO;Y7#B6& K$(I5+32QRF)OFBCC5>.%!/X'["_9L^$_Q2^*?C
MBQ^'_P #? 'B7XD_$/Q5"MOI/AWP_IO]J7'GM"LD$\LVTVMI';N7EDN[MXH(
ME4.TB>7NKR;P=X_^%1\)_!_0-*\ 74$/A.2^O?BAXB.R+6/'-WJ,ELM]IMK<
MJY:73K<VS&!R$,9=4^7:Y;]C/%G_  5[TWX1_">]^$O[ 7P1\"_LIVOC-M-?
MXE_$OP]#=:O\1O&U@8;6.'0K77]=FN]2\.::LS:N=2L=+N88[SS-P9$<*/+I
MQPN.K4\/FM'$9+A4L75JTEAZU7&8VEAL=]7HR@Z$)X"&(QL%#%8:EBL5AYPP
M\_:5FXPG&/O<)<(9)Q%E6(SSB[-<OX3R3+LXEEN.R.>+@^,<UI3KXOZKF>!R
MBC"K#%83%4<"Z\*L)16%J8G"T,SK8%8NA5C\)_ME?L<?M(?L)^.](T+]H?X:
M0>%7\8^&O[:\/2:5K6E>,-"GLYVDMTMW\0Z)-=6-OJ7VRRG^V:?-+'<+LD>*
M.6V'FGYN^ OQ$^!4?B?Q5X;^.WAWQ;XMT?7M%?0/MWAC7O['?P[+J3V\)\0
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M0_@Z7]J#2_$[^!-;MQI&I7WA?5YM)UCP3-K5J88/%NG21K>6VJ7.DWC6%_\
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MTY3Y(*,>6)_4U_P9XC_C;Z?^S5_C9GD=/[8^'GKR>3T&>YQ@$U_JGU_F"?\
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MP[7R:EQ+C\SR>EQ+#Q#I\60XCS>OG57(J^6KP\XEIYA2P]:72^"OV;;WP/\
M%/X;Z!XGUGPI=>+/%&N>/[>S\)>)?!@\8^&CX6\.>'_$2V_BO6+1?$ND&Z76
M;BS2;0-*<VLENQAU2>],^G3:8_'>&?V;-#U_0/"WBKQ%\5M)\&0>-?%OB#PA
MIEA)X4O]1E?Q!8Z[)H^E65BEGJB1M::D\-S+<W5X^GVVBHMK$\EZ+AI8+]E^
MUO?S^(_A[XU\6>"8/$?C/P#K/C*YBUVWUX:*-4\/>+M,UNR'AN:RCT*^2"/1
M9]5MI=+OS+<F.ST]K(V@EO[F^KSR3X[/)X8^&OAP^%U!^'GQ&O\ X@_;?[9.
M-8:^UR76AI/V;^RO^)>(C*UM]N^T7ID $OV1#F,Q2P?BK5JQJ5ZWU/%UJ.#P
MV/QN"7#=2BEAL1QO5F\NI8NG7E]5E&OPM[-XS#O%_O:BFO<QO+U8_B3Z F"R
MZM@\JRQ<1\/Y;F/$6=<)\,<3S\:L'FDJF=91]%O T(\8X_A[&Y7AY9]3JY7X
M\O&PX<SF'#K^H85X22CB>&%7X74_AAXDL?BA=_">T2+4_$D'B=_"]LUN)([:
M\N/M/D0WBF5!)#9R0E;R221/W%L6D?(0D_57QAT3X5Z)\$-+3PKX6T34#\/O
MCEI/PZUSQ5;6MK9:YXX.E>!KO6_%)N=?M[7^TEL;[7+RZL[51/<00P:?97-J
MGEQVZ)\U^(OC!X@O_B[JOQA\,)_PB>OWFK3:MIT8>SUS^RI)[#^SI(]^H::E
MG?;K9I4+3Z8B?O25B5E5AZEJG[7OQ*\0^ CX.\4_8O$M]<>+[#6M3U?4K#0(
M].UCPI80VTH\#:AX<T_P]90-97.L6L>I76KP:A!J,T#2:60+5V8^MG.6\;YA
MB>#,;'#X6I2R^GEF(SO!4\[JY9B89I5BHYM5E3PV#KX3&X?#4%.CA%2Q]/EJ
MXC$2C1JIT*]#\^\-.-OHN<'Y)])?AFMF^?8+,.,<7QMD_ACQ+B_## \<Y-7X
M%R_$>W\/\#0QF<\197Q#PUFV=9I*CF7$<\=PEB_;Y=D^3TJV98"K'-,GS;V+
MXN>%/#-_^S[KOB6Q\'?!2[U?2?$.C+INM_ IXK^'POHEQ+:+)%XVU=Y;;4=3
MOI4:2SED>TE@2XN8)GMK9HVNSXA\'@OAWX)?M$^.X%4ZN^B^&/A]ITJC$MM8
M>,M7-MXA/F$$HMQ8I;A#'\YD@VDH&#BEXB^/7AM_ GBCP-\.?A+HWPW@\=2Z
M9)XQU&W\1ZKXBFU--*N/M5M;Z?!J5M FD6JS-,J6T4EQ##%<W*P)'-,\]1_"
M+7M"N_A1\=_AQK>K:7HUUK^@Z'XK\,SZI?6FFQWNL^#=2.H2Z-;W5])%;R7^
MJPM!;V5GN$]P!<K;Y<Y3RL'D^=Y;PGC\+F>&QT</4XUX?QL,-BJ]'%XY9!_:
M_#DLQC7IX+,<WPU*A!T<?.I2P^-FZN"53$XBG3Q&(KP/ON)/$;POXU^D%PEG
MG V><+5LXPGT8O%SABOG60Y7F/#_  K+Q<_XAQXRX?@RME.+XHX/\/<[QV:X
MA9EPEA\)C\XX9PJR_B:I@LERC%8[*,HRO$KU'QAJ?@?]GOP]\,/#%M\*/ ?C
M_6O%O@?2?'/C#Q#XYTE]5N9DU]KB,:7X>G\R)M&-FUG/'%<Q"41PBVF>S:YF
MFF?C=$_9UTWQKX:L?BAI/C6ST;X>W%CXMU?QI*^CM=7?PWNM""W$'AE;676K
M>7Q-/>+<P6^EW:SZ5)=PA;F2UC>:&&2EI_[0WAO4O"OA/P_\3_@_HGQ*U'P+
M8)I?A?Q!=>)=5T"YATZ *MG9:Q;6%I<IKEK;1QPQ"VNIX[:5(BSPF>6:>31T
M#]J"W\/Z-I_@ZU^&^FCX?7.B>*['QOX1AUE+>/Q;K'BV19;G6H-0&@R2: FE
M-%#;:'80VU^^GZ:C67V^9EMKFUF&7<=Y?@YK*<MS&GG\LRQ4\YSC$9MD^-P&
M>8"4LUJPJ9;A<?F&)E@\53A4P<<LIU\!EM##8KV&&QD:N4TL1?>OQG]%#C#B
M3#3\0N-.#L9X1T."<AP_AMX<91X?^(_#7%7A=Q;0H\ 8'%8+C3/.$N$LFI\0
MY!C,1@^)*O'&,ROBSC7-<YR&.:9YPW4P''^891&GZM\'?ASX%\-^"=7T3Q=X
M9T;Q#\0/'/PL\:?$JW;7-,LKZY\&>$M)T\6GA)K>"\AN?[+UGQ!<WUUK/VBR
MF%Q#;V=O#.ZR0V[U<_9GT+P1XN\)6FEZKX)^"&O6PT;Q$-4T26]CU3X\^(-5
MLWGECOM*BU&33X= TMH7BAMDM;M=L42W*7D#NV?(_!?[9OQ<\,M=VVL:F_B?
M1D\.WFC:#IDEIX7TF31+XPPP:-K$FH67A-Y]5?2(XB&L;I4M]29RURR$"LGP
M5^T3X;\(/8>)7^#/AC5/BGI<5^MIX_77-4TJ"XNM0%RDVIZIX3LK?^R[W4Y8
MKF5+B\AN+*64O(T!M0Y4>3FG"_'V)PW$T<3A:M?&YIC,#C<NQ64<1*K2IXJG
M1S2$$Z&/J\/O+\!A*=7 86;P\L3BJ'L*6)PE',,4JF(C]]P+X\?1'R/.? RM
MDF>X#*>%N!>'>*.&N,N'_$;P:E@LQQ>0XS,N <5B*D,UX3R_Q@I\6\6\08W+
M^+L]PL<VI9+D6:?VCC<BS_,N$<CJ8/**]A+"XU[]D_7(=5@ECU+X2?%>-+!I
M55)K+3/%-M;VFJZ0ZR'S(U.N2B]G1%#>>L6Y2J2$?*E?3EYXNTZP_9LU/3)-
M<TS4?&7Q4^*MQXAUK2[._MWO]+T30X$83ZKIMM,\E@^H:X@GL8[NWMDNK67S
M[82I;*R_,=?J'"-/$0CQ&ZU-TJ-3BK-*F$@HSC3Y72P<<?.BII2=*IG4<TJ1
MFTO:N4JBOSW?\*?2&Q63XFKX+PR[&1QV98/P%X$P?$.(=;#U\7[>&.XCJ\)X
M?,986=2C3Q^"\,ZW F"K855*DL###TL%-QEAW"!1117UQ_.Y_K]?\&N/_*"C
M]AG_ +N9_P#6P_V@J_?ZOP!_X-<?^4%'[#/_ '<S_P"MA_M!5^_U !1110 4
M444 %%%% 'X!_P#!T7_R@J_;E_[MF_\ 6P_V?:_R"Z_U^/\ @Z&C:7_@A;^W
M(BJ6.W]FIL+UQ'^U_P# "1CT/W0I8\= :_R"!D'W%;03Y;]')J_FE%ORT377
MJ;0B^12:?*Y2BGYQ46TO-*2^] ">.< '/T^E=;H>D'7+E;:*^L[6X9'.VZ%W
MM6*&%I'N)9H+>X*Q@C;PK-O/*JGS#DL'\#S@'J!^?3WZ5<65UVRH[HP79N4L
M">H9=PVG&T@$=P:[L'5I4JT95Z/MZ2E!SH\\Z;J04E=*I#6+Y6TGJM=4T>EE
MU:C0Q$)XFA]9H1G"56@ZLZ+J4T_>BJD&I0=GI*TEKK&6B/I7P;^SAJOC^SFN
M_#.LRZX-*/F^(IO#OAO7->LM(LT7<\D+6D"WFJW6"@-O:V4:1.LGGS+&%D;J
MYOV7M11[:.T^+7PPLM O--_M6ZN/$E]K&B7^CXD%LD.NZ+_8U[J6G:A+.72*
MV@-T%C5I99(X\&OE?1==UK0YTNM'U?4]*NE+;+C3;ZYLYE$B%'VRVTD;@R*2
MCC.&0E6R.!:;5==N);F:34+ZXE?BXEGNIVD=GW,WF.S'S&)W,6<G)Y/<U^G8
M#B'P[IY?AX8C@+&U\U;<<9B*7$N8T<-45-Q=-4:=.]2G1KPC*&-P\_:U*CE*
MKAL9A8.%"C^QY9Q3X4TLJPM/%>&&88G.FY+'XJCQ?FV&PE54W&5+ZO1I7JTJ
M&)I*=+,<+4]M5G)RKX/'X.FZ>&H?4OQ>_8W^*'P8L_#VMW3Z9X\T7Q&(5TG5
MO!#7NK0273P?:'M7M&MTO64PG?!<1VSV\Z*3N1OD'R?,MQ"TL4T36\B2DO%+
M$Z/&49@R2*P!#*1AD*C!!!P17K7A/]H?XP^!IHW\+>+]3T>ZMX#;6]S"Z.UM
M;,B(Z10RQR6RJRQ1AOW!+B-2VXJ"/*/$/B'4O$-_=:GJES)>:EJ%Q-=ZE?2%
M3/?WEPY>:>9D1%!=R2VU5R<ELD\\_&^-\-L7*GC> \%Q+D*JRDL3P]G%;#9G
MA<&E0P\92P6?1JT,=BY5<1[>?U?&993^JX=TH_7L74YDN7Q&S'PCQ\Z68^&>
M6\7\,QK3:QG"V?UL'G."R]1PN&A*>7\31K8?,L>Z^+6)J/"X_**7U/"NA!9C
MCJO,EB2S'S7<E9"6P7 P..,^HX[<YQZ5Z]X4\3^"V\)KX7\2^&+)]1@UF?5K
M+Q;;RWD&L+!);1P?V)<^1.(9=.$BM=HR6TETLS%%/E_+7C!P.,9^IYX]0#CC
MH!Q^M.1PN""01_/'4$]/Z'\Z^%RK.<1E.*J8BE3PM=5Z-3#5Z&-PM'&4*E&K
M*$IIT\1":C/FA&4*U-PKTYQ4J=2+O?\ -LDS_%9)C:N*HTL#B5B,/6PF)P^8
MX+#8_#U</7E3E4A*EBZ510J*5.$Z=>BZ>(HSBI4JL'=O]%]*^!'[+7CGPL9?
M#?QR'@[Q]?Z5::I8:#XRG^Q^&;*]VNVHZ5=ZS>Z/8R2N5B>6WN()Y# 6BAE2
M<N'KL=8^''[ OACX5>)M+E^*&I^*OB;9:<5MO$>BMK;1R:Z]LTT$>D:88;71
M+[1XKJ,6EW-.\DRPRM*DQD\ME_,N"XN70,TC.L9"*C88J">H4G@9YR.>M-NI
M@\2J%8%>&< ?,22>1V)YP!P?Q-?MF&\8>&,'@Z\Z'@GX95,RQ63U\IQ&.Q^$
MS_&8>5.M2J1>8X+*JN=RP.7YPJU:57^T,-&'LX4:%+!4,#&G)U/Z)PGCUP;@
M,!B:F&^COX.U<XQV0XC(\5F.:8'B?'X65+$4:T/[5R[)*W$;RW*L_5;$3K/-
M<)&'LH8?#4,OP^70IS=4FF668N%B\N!$A14'E[T0;5D88.^1\;W).2YR<]:I
MP,S7'FAB#&=ZG/.Y3\H'U/;&,>U0#!^\3TR"1C/4@#!Y]/49J[8Q(X<.ZQAM
MQ61PVT/$ID5?E1VS(?D&!@,1N(7)'X+&<ZU6%[)N;F_>2][[+;TY4G:*N[):
MMK5G\RQG/$5Z;=DY5'4OS*/O:<NNBBE[L4W*R6K:5RPYDD #R0J4+,-PQEB?
MFX4'&2202,<&FJJ;V.=P RA P&;@C !(QG.%!/'TIPW&-F*Q!@RJ&<LI).23
MMX!V]#G."W!.:M:9%'<RQVCC:SEB)-P # .V<M\H!) !S@D$<9%=4(.K4IP3
MO.IR\O.Y-RD[1C%W;6K>FRT5VSMITW6JTJ:UJ57%0<W)N4KJ$8-/2[TM962B
MO>MO4GDD9;=FP#&LR*0. 1R<$#=G# <DD<=.@I<C.[/0$@]3SD=0..<<=_8U
M9O,1':8S&T;[",DDL$ 9SN./GZ\9 .<=*JM,F.$#,>I.0,#'8'.<CG)QC'%<
M]:24VI2UCRIN5W=J,8;6_NVVV23V1RUII5)JI/6/*FI<S>D(0>CBG?W4M8II
M*SV9^MG_  0EEEE_X+#?\$\&D=FV_M)>#T#.20%%KJ>U 6)  '"J .V*^N/^
M#G2TM)?^"Y'[;KW<9 :/]FYH98Y CM+#^R%\ B(G'4;OX6.,$*0"#Q\??\$(
MG9_^"Q'_  3PR3C_ (:2\'X'11B#40,#/IW^N??[!_X.A[2?3_\ @MY^V;JP
M@:2&^'[-R GE-\?[)?P)@1L>Y@D0=,LF,UY&/DZB24I*4II*5[2E)Q=E>^C=
MNKE=Z6NT>-CW*MS<KFY-KWN9J3=MW).Z6F[?756T/P@T]KBTNK:46WS"-F@=
M!EW7<2DQ!&R4;59'!RO4<,.?2/ ZB?5+K3IY;^T750YNY=.C$EC!;W $L=U=
M6K@(;.V;<9@A21!E(W4UYOILUSJR0V*KY/V.2><R%\3B!B@EAB&X*R*V957A
MB2^1CIT'A+7]5MM:M+ SW"P:I#+H4CP(&>>QO3L$+*" Q#A9 A<$'HQ'%>!B
M:<YQKJ*@JD*<G).4KVBY3B]I<UTN91779JUU\[B5BOJ]6*C!TU[2HZ=2=3V4
MYTHMIQE%N[Y;-PIN$DY1]Z/NM?HG\.?@/#JD'AN#6O$GA2PC\<6R6VC2N;F]
MU*[CN=0DTZTE@TF/REA>>X@D#2/J49M8<,RLP(/WUI'_  24^+G@1+K4[CXB
M:)\,?&[Z8GB3P-K7BY+C3/!]_IL<C7,4]GXHM;G4]&U+6KS36:/^R(K26*TO
M8F@>59(F9/QHMKG48;JTMEN+V.'3U']GA+J6.YB2T+PJT,BR[(7DN(YF418Q
M)&SGY@0?9-0\;_$_5O"UE91?$+QQ=:6EW+HUIH]SKFL:K8VU[=W4#Q06T4]Y
M(MBUW]JNYDE@10SI)&BC(KQX8S)X0G#&99"K5K25I/$XWZO6YN2\,13ABUR*
M,(24.2,J+;G"O1KJ4)4>+"9[PK1PM>CF?"6!Q=?&3M]8>8YZHU(SC#FI5(PS
MAT:*I*$G0D\/B:#FYT\31Q,*D/8?J1IG_!#7]LWXV:;X]\>^'?B%\'?BEXW\
M)IHMWXJ\$>"O$,]WXDO;O6;234;2*\_T;3[(3WEM!,\EY:QW%F^H$V<DL4AW
M5^4'Q'T+XH?#>ZTK3-9^&^N>#-+T[6-=&@?\))X>O[1M1$5];'4+2RU.]MH8
M-:M].E2,&2SGN((TF299"LT;/[;HO[4/[3?[*&OSZAX)\<:UH.OO_9,0EM-:
MNYR\.B7\Z$:KI\DRR;7U$2.D5Q]R+R%( 62,<#^TE_P4 _:H_:=M])LOC]\1
M+WQOI_A6$KX/\/ZA9Z?;:9X6CF2)99-'M+*TA-NDD-K##(HDQ,(XQ)D UZ>#
MQ.2YK@*,?[%HX"KAJ$EA,;@L=B,50Q[E.C3IQKY?BY2C@_94'5A/%X3$R4I-
M4(8"G"3FO0P&8<,Y_@*5'_5K#Y++#T:CRW,<MS+&YAA\P4JU"G1ACLIS"52.
M&=#!RQ%.>-RW&4U4JS=&GE=*$N=?%7CK5M3N;^ZN-2U1OMFH7ES<75NKF29U
MGVS(3+N;.[)')_=L @P *]!_9?\ B9IGPR^.G@'Q_P")/ WACXE^%_"VOV>H
M>(/AQXOFE7P_XNT3YH-0T'5);9HY[>&_MYI(VN+9XY[9BLT3!D4U\[:C*^H7
M$MQ=1R-*S$(7<1(QW,Q944LX5>  , <#'6L^*[M8)E(#6R @3^6TF7DR<$-P
M?G /7 XR.AKT8TFJ*IT[*48)1O3BX1MRM*,5+6*5DHW:5FKI7OZ5.G4HTH0H
MRIQE"FJ<83I0J4XQ35HRIIVY=;*GJ[;N+W_IE^!-K_P2G^-PUF'XMR?%OX,P
M6*-X@\%V7A+Q3<76F:?%>74:>*_ UC<ZU#>"2TEM)2=(OHPLUD+-1>><9L'[
M;\!_L _\$=/A+XFE^,7Q4_;JOOBQ\#M?U&TG^%_@WPWH^HR>*-/MKORH]2M_
MCAK>EPZ=%IC>&M2N(K>6YT&4R:F$.H"-#(D+?R&^%_%^G/)##J$>KWRVD4JV
M\5G?-: (V2R$\X#L07( 8A?F8]1Z!;_$?Q+#HD^AM+JMUX7B:ZGM]%NI2=-B
M:YF$OF%5"I,6>*,L6SNFB\P<@8X,/"G@H86%#(<!B<1A<?&O7Q69UL7/#XK#
M57B.;#5<++%5J&*]G[2E4IQ=# 2G7N\5B<93_<GZ'PIA/"O 9?EF)XFR>4\;
M@XYM54<LS3&8J>.S5QI1RG#\1Y?G>#Q>7T<@]KB,3C:]7*Y8G-\77I1H5%]7
ME!4OMK_@H/IW[(.K_M47WP^_8.\9:OJGP5\?7OAJSN]8^)$LRZ?X0\2W5ZUG
MKFFZ)KMT_P!KU+P,-1@MM:L=:OHK>^EL)WM+F-5MLM^?'Q[^'5S\*/B%JOPH
MC\6^%/'-QH%PL5[XB\#Z@VJZ%J#HJ,SP7C8\TP<K* S*&5@C$<UYMJ!U&ZOG
MNQ9W:6LTWS1PP?Z/N+%6"LH#$KDDA2=N.#@9I;.*VMO$6FP6[S![G$=]*8P\
MUJ9&)D,:L3N;RE(/F=V.1Q7975>KFKQF&GA<)E[P^)E+)<+A*;H+&5*M*I3K
MQQ3G*K2AAJ<:E%8:$73J>U4G)2IPB?!9DZT\ZJ9AEM;#X+)ZV'QCGD.$P5)4
MI8J>(I5*.,IXQOZQ0IX>G"O0^JTZ?LZKJJ4FG2IP7KV@Z+?Z=H%K,K))IZ22
MVELRIM9[N= 9U#<%TB$J9V]6?<<'!JW<7<JM;V,OEXL)'99$3$C *$"2'@-Y
M; E0>LKDCK@^AC2+A7\.Z;ID\&I6&K6EEJMN8EV1VU]J*!M3C((!CDTY;7RI
MNB@PL4!&W/,W"B;5[R2\L6NK0?VA&_V:)VD"1R@1W-P4 ,40(5HI7V(\I12<
MN!7A+%K$5)RK<L[.;BTVI4X-J$?=?*N;E4KIN+<UR\JY=/F*>8.K4DJT8U+2
MJRC-2J*=.G*2IPY8.T7>$)1::NYQE&R<6T_5-,BU/PU?P6UM- H\&:L4;.#<
MWEBUUJ#R?.>0( 8\  A ",L&KR[P]]HFL8;MI?(+):*([7<C1JT:")#$!M\K
M&YL@,6?)()Y/TS\0O!-UX3\)> O$RM#>Z=XM\,&Y5H)8WDL;U;O6--N["^CA
M(V2RV]KYBJ^7EC=)"2&X^2/#FNQQZ>MFRF2ZBE5(D"$2RQ1;]NUP0$:-2RD-
MV&1EN1M@*CQ.#K^RJQJTHXF235VJ;52I"M3ES*ZBITXMW32TV2:5X/$RQ>!Q
M'L:\*M%8N45R\TX4^6K56(I7DFU&,X1YO=235E:*?+Z3IUL-/GN( LEJMW(9
M+EG;$DTZJ2VQ 0'SG:I8?(HR2#FO];C_ (-_VC?_ ((Z_L)M$5*?\*MUX*4<
M.OR_$OQRI =>#@@@XXR".U?X^.I^,;B_MYU4FUCB 7>VYI)]@8&.-RVZ-5!Q
MG&7V@G )K_7P_P"#=E]__!%C]@-L!<_"GQ%P.F1\4_'P)_$C/MFO9RW#U85)
MUJTFYNG&G:[<4KQE=-M]ME=+5.SO?W,)@J]#_:,35E*M5@H1I-RM3IQ4&I6E
M)M>T=FHV7+9NRYFC]IJ***]<[@HHHH **** /\BO_@Z&LKV3_@N'^V[)8VUS
M(DY_9J6[N%AD^SJZ_LA_ )8[9IROD[]BK,8RV[#@XQ7\_<<#Q2K]H&TA]H#Y
MR>,@Y(^[V]R>U?UH?\'&/QK^%M]_P5;_ &YOV>?BKHM[HNF7&O?LYZ_I7Q)\
M/6MO=7NAZC-^R+\!9H)M<T\QB\U2SA>1X6%M(TJVCQ(%_<**_EW^*WA70/!/
MB"^T#0O&VB^.[. 6,^G>(?#QD.GWMO=VR7(D"3JD]M/#O6*ZMY$#17"NI((X
M_5,[X/R[ \-Y#Q1DO$F6Y]A,3E>5K.L+&K0R_,>'>(,10K5,1DN(R?$XAYAB
MJ$(X:=2AGF%I5,MQLYRIJ=#$0>'7[7Q%P'E.6<(\,<8\/<793Q-@L;DN3+B#
M!4Z^&RS-N%>*,3AL16Q/#N+R'%XIYIC,/"&$G5PW$F"H5LGS&=25)5,-BH2P
MRX:XMY+6=6F4B:9%E1">?)D&5;KD!EY4=<$^M?3W@#]EGX@>/?A3K7QBTW4O
M#5KX9L)KZQ6UO;QVU.YFM 3<E;>)&BL3&$/EO?RP+*-IBW;EKY::ZCN84DN3
M(+A (Q*!N5D08!P3D'G&,XR*^LOV5?C/I/@C7+SP7\1;Z34/@SXS@N;'QMX>
MO()KFR#21?Z)J]I#!NGCO[*6-6CEAV[L[9 V%KTO"^AP/F/%^&RSC95X9+G&
M%Q>!P&-AFD<LH93G>-IJEE.:9UB/8U*G]DX3%2YLR]E3<Z>'E+$QAB(X>6%Q
M'K>#6&\.,UX\PN3>(JQ-/A[/L%C<MR[,:><QR;#9'Q%CZ4:.29SQ!BO85JO]
MAX'&S4\W5"FYT<+.6,A3Q4,-+!8GY6ET^\G,-A&KR2"9K:RM88B\MW<M)L.2
MH.99&(" D\$ <&OK']E7P5\"_%6M>)O GQR/B31?$.NM8Z-X-O=/CFB;2M3D
MD9+N.YC6.5C<2R-"D:7$30B)9"=I(=.1^+6K_"0ZV?\ A4FE:M;Z+<QWYDB\
M07#R7&G:DE\3::II,L'D/&LEG%$8HIVE,/F,CCS "O+?"KXDW7PU^)_A3XGW
M=M#XDG\/:L-2EL-2N) VH3?9IH!OG9)Y%>/S/,2<H[(Z*<8PR^CPU2X?X)\1
M,FJ9Q6X<XIRG!9OA\#G%;$86OGO#%;),;3^I9AB_JZ^IXS&3P6#Q3Q6">&]E
M6IXBA#EA3Q5"/-ZW"%'A?PZ\5\@JY]7X3XTR/+L^PN79_7Q6"Q/$O!N(X=S"
MG_9^:XY82/\ 9^/Q]3+L!C)8W+Y8-T*]+%8:FZ=.EC</%S[_ .,G@'7/V7?C
M?J6A^!?$FNZ?-IBR?V%K]Y:OI6IR:;J4!AE=7*^5<6\T;NB75N?*F7Y@$88'
M@TNH2^(]>>Z\4:O>SR7-S_Q-]>D$FHZBV5(\Z4.P>YVE54@N'$9R"2!7UQ^T
MC\=M(_:@^Q>);'3/#WA76])T>SM-5T_4;Q(-4FGM9II'ETV_G,27ULR2")80
M#,L:(&C4_,?BI(I(BRNQ$)\PL8T+QR2KP%\P JP'&6!(Z@=:?B@L@P'%^<83
M@;,)9GX<XC.\3G7#6&A4Q]/*H8;%N"^KK!8K$>VH5L/"%/ XFM-TL<Z5&-.4
MHN,;/QE7#&6<>9_@?#;-:F<>$V+XBQG$/"&$IU<SHY'3P>.=-?5EE^,Q2Q&&
MQ&%ITZ.78RO4E1S%T*$*,Y1<(VV_$VB^&[?4'_X1C5[W4=+@M;$O>WMJ+.:6
M_EB_TV."#<S"WCFW+;22'S'CP753Q7V^?#]C\;/V8?#-UX(\5SZ;X_\ AG)#
MH/CCP3?>*;R+1M5\/1W+OI/B./1KRZDM0;9I@]Q-!&MO$TDC&&)D=C\"&&XN
MIXEA5IRRJJ)#'N).-S!8E&2549;&>!DYJS::S?\ ARXD-I>3V4\D<D%PUO-+
M!.(I@4EA9HV5G2:,LLT1)5T8HZL"17E<*<7Y?P]B>)(YAP_1Q60<4Y/B\DS+
M"87$5L#5P4JM>AC<#CLFQM1XNKAL3E^*P]!JG4EB(XO!3Q6%Q+=/$NI3\3@K
MCS*^%<9Q;'->%\/C.&.-<AQ_#N;8' XK$9=6RZ5;$X?,,NS+(,PJO'5L)B\J
MQN%P_+2K3Q,,=E\\=@<:Y4\8ZM&74;2ZL=3?2-4ADBO;>\-O?,S([&5&P[1,
MK%6A"_/&RDAEVL" <U4NW6/S=/M+@R6IN69Y2Q42[>$61=Q0!.?7.3S7U7\*
MD^$7C/P/XN_X2/Q3X=\-_$!;AI]-B\2Z?=F?6[:.R,=M9Z/J=N18Z45D9BR3
MQ$W$P!=TC"BOG#Q#X6E\.74,5W>62PW\4LJ*+E)S\DCQ\R1%EP2H<<C<I&>.
M*XL[X7Q&791EF>8/&X#,<LSJE5Q$*V#Q^&Q.*RRA'$O"PP.;1HU5/"8N;Y75
MIXJAAZE3F]I1A5H3C4J>=Q%P;B<JR/*.(\!F&5YMD_$-&OBZ=; YE@L9C<GP
M\<6\%2RW/(8:M[3 8^I+E=>EC,/A:U52]MAZ=;#5%5J\U87(T_4;.Y:*"Y2V
MNHI5@G5I+:9HI!)Y<T:,C/#)C9(H(+*2 1G-?:O@SXNQ_%6RL?A=J7A+PEH,
M^OW*Z3>:]:6=K&=/\/,HEF.@0:N_V#1-1GN8XS=74-Q$/LX=@ P<M\/R_9XF
M!,PDPZY*%3]T':,#JO\ >91[<&I5U4VSF6UDFCE (5HGVGD$,>1D#&1V_6N7
MA'C3,.$<17A1JJ65XYPI9UEJ^KN698!N,:^%6)J4:]3"RJT?:488BARU*:JS
M<7=N_%P+X@YIP+B\3"C7C/)<RE3H<09/'ZK?-\LO&.)P2Q=3#XBK@Y5J'M</
M#$X5PK456GR2;NCJ?BMX-;X>>--5\(?V]H7B$:<86:]\.:@FJ:9&TR>8+,WT
M0$$][:*5BO3!NA6X#+&[*,UYOW[X[_Y_R*D9VFD9Y'9F=LL[$L22>>>I-2SB
MW  @#'!^9V.<_1!TYXR<D^E?%YG7PF,S#'XO X3^SL#6Q5>K@\OGB9XN>$PU
M2K*5#"_6*D83Q#H4W&$JTH4^=Q<N2%^5?GV<8C!9AFF:8_+<"LIRVOC<16P&
M5SQ=3'3P.$JUISPV"6*J0A4Q3PU%QIRQ$Z=)5'%SY(<R@H7*@GRRVTXZ]<_A
MT&>!^M-9F;!8DX  R2>.@'-(!DCGMU/ISGZ=B<>G(P**X+[]+O9;?\,O,\MR
M;OT3?PIOE[Z*[T5]+G^OI_P:Y_\ *"K]AK_NYG_UL/\ :"K_ "NO'/CB_P!5
MUYO"D-LMQ*MU/)K=_LFCL_/M8A&HCCQ'&EOH\"-96K>8L3R,\K*99A7^J+_P
M:Z#'_!"G]AH'_JYGK_V>'^T%7\<?[0/_  3+_9Y\=_"WX5_$3_@F]<6WQ.U+
M3/A9IUM^U#\%]?\ &5K>?'/PW\2?#^G2ZIXP\3V%CXD\M?$7A744BO6=/ +W
MD6FRV,L?V"+?%N\S&82->,J].$*^,PT*BPV#@W/&5857#V]7#8:"=2M3PL:<
M*F*FG&E1A*'M7>I3.2I@85Z=;&T4J^9X&#6!P%%SJ9EB*6)DEC*N"PM*,IU:
M>#A1I5,95E*&'H4I1]JVZM-'\]/A'3]0U'4+/1+"_8O+Y4<$-TCR1328ENK1
M9D";1:17PWPK&#YEPQ*JY0BO8?#-EXRBMYM+OI[O7-6OM4GU&/3W\RZ6PO[6
M)+2YG^<,#*(K2,L(R586\/+; !YUJNKWOP8^+>A:G<:>NGRZ5<V#:KHUPOVP
MV%G.GGP2+!)O6>,1W!+PS*TAC:.; E*UZSX4^)D'@KQ)I7C#0]6T[Q!J=AJJ
M:U YECDM1J-WMNH4O;*Z,1D@0RS1O:281D0+.&C,BGX[,EBY4L/.A15?#SHQ
MJ4TZ2G*.(E*4W)U(M1C&KS4)IJHN:UE)1N?$YY+-'1PKP]*6(PLZ$*U%2HJK
M4HUZLG5E4=6+25.LGAITW&JN91M"2C*5^X^)$WBOX>>"=%N_%OA/Q;X175;?
M8;_6?#U_H5QK&BQM):V-YX?DUK3;*]U>TNHXGCBN;7S+;^T)FGE+B((/DI+K
MPIK%CXXE\3^&9IM7\2-:'PC')J"K-X;M(+CS7A91&[SR7-OOB<?N3'<.967>
M=M?UR_'&?X=?\%9_V//!'CKQ)\8_A/\ !7XX?#WQ#X2\(>,="\5-H]MX'US4
MO$-O'9>%_%-UXEL=..LZ#=:>]CK&GZMH>G17^EZ?-K\&H7;BWMKAX/YN;OX*
M:=IEUJFD7^GZ8\EPMV\TK0V,6HZ+>Z/>75RMUI>O->%XK"^T^+SIS,L<TQF^
MR"QE\F&9OH,TR#)<HHNO2QN.HY5CXX;,LMS7$WP6)S6CAHT:\)87#4*KQ;PL
ML;3^I5:4HPE"+JQQ%*6&I8D_1\7D>$\+\SQ.-BX4L'F64UZN69CQ%@<LQSSC
M YSP^Z#Q6794YX]N4(X]T,#7E1CC\BS",,=!8;%Y7*O0_3NZ_P""'G[2_P -
M/V3_ (<?M?\ @"3X9_&?X4WWPY\*_$7QYJ7A/Q;I/B#X@_#.;5S;EM!N?#X6
M&>>[TN*ZM8I[31;F>5[J95GMQ+',J<YJG[4VD?%']C'2/V;_ !7\&]*U&+P)
MXA\4ZEHW[1_B ^*IO'&BQ:K<Z)?6WAFQN%O8]'N[2V&FWZ2Z&+66PQJ-[=LU
MI=&2XF_2C_@CI^UW^Q=X ^"'QF^ /[3GBVPL=;^.%Y>>!O#ND>++>\O] T[0
M-,\,C6]$U+2;&[>30K;79/$-K,=&O+^!I4UQ=(G1UB<2+^&?[4UEJGPVU3QG
M\/\ 2I/%]A\--.\16^O>&/#WB2.>TUHPWEOF]::0CR;N,W5M=V<M^(XQA+>5
MK>W><Q5XG$^'Q&!EE6,R?$>QI\49=%5J$\;2Q\L%%XN#JX3E]G.=/&0Y<,Z:
MJQP]6E"5:\5!J6)^&XYPN-RF>39CPSBJM'+..LJHPKT,1BZ&9K M8U2JY<XN
M%9T\RH2IT?8RK+!5Z5)XIQH1HN,\9X7X._9_N?&OA7QO\16NK)? GP_A$\NM
MS:C;Q7UY=+>6EM'91Z>)9=0A97OH;L)) T5P,Q0-*8WDA^Q/^"5/PX\*_M$?
MM7ZS\!?%^@_#K5?#_P 0]"U_2_A-_P +6TWQ'+H]Q\2M,TJ6Z\(Z7=2^%-=T
M/7=$TO7YVDL9-0M9M3E2[%HK:+?H)H:_/3P3X9UBXL[WQ1>+=V?AZ_TN_OGT
M2RO]R2VD%UY:KK"IB1@\Z&6-'#R;5C?>HD\L^N>&_&&N>%[JQU+2VN]"OM%U
M+3O%3^+O"UXUOK^A+I6FG5=-M;2YB-M-!)9-''>7 6X@N7DMS:0SQRXSS.OE
MF$S2%2O+%YO2C/!0QF&G5P<\/0A0K8>IBZN%HO#4^;&PG1A4H0K5,1'V\HPG
M[2DU27ZEFOBEPOPSA/#[+N'^%:U/B'(<OY>-<WS'$8;.*N=3S+$XVM+$X# 9
MA065X>G3R+,\)'+\OE@:\Z.80ABUC:U3$56_J'XBZ/:?"_XC_&OX77_PH\*?
M!O7M/\2>)--\6ZUJD>L0:7X6FT>Y:QO_  =\.;/Q*9-5G@GU%#':O=>=<+;/
M&;WR%581\I^#)=5T+Q!X9^)MY!I2> [+Q4]A+>W^G0:]:S-H-NM[:Z;/H5VU
MO;W<FK+%!;RW4R(5>[:7:/(V5]R:I^UA??\ !0_Q'\*OA5\9/B3X>?7_ !5X
MH\+>'I/&GB6'3K;Q/_PE-[:+8ZYXFO)+J2SCN-5U'2K+1M"O7.HZ?:ZW-IVC
MW5[,^I-=:D;'[=_['/B#]GF72O &BZ?X@3PKX=TB;Q7-I?B#["VKSQZI=%I=
M;@&D7-UHVHP-81V$MI?6-[,+BWANC)'$D4ZKYN.RRK@,1B\?&CC<3EV:YE7P
MDLRQ."=*$:E2-3E]JG&6'I8K$0Y)4L'3A#!4HPG'#T90IU.?\!SG)<3EN+Q^
M<K#YAF&39]G.)P<L]Q&75J%!8BM1=2=*M[2C'#4LQJPQ%!_V?2IT\OI1C)8*
ME6H0=2M\@?$CXE^+/B1XLUSXS>.9K&2]U1D&AZ2H*:=IFEV=O/:6.F:/8PMY
M%O:::B0/:A8A&UQ&9_F8*3^C?P'_ &A?A9\4?V<].^!?[0/QA^(,GAB^U0WO
MA+P_=Z;:ZCX3\,:Q#'J-C;ZOX->VDEUG3O$LB6]Y"UQ+<)HVH V^GWFE/-,N
MH1?EQXKTW5/^$:2YDT=9]*UG08--TB.2W#MI4%C+/<ZAIT5O;.\[ZC)]AD#W
M<_E%5FD2,B,%U\)\%>*4L-$TK[3?:)';65_'';1W%^'-LT6I-?+]O6W)DDBC
MNW-VS00N$5YXVD1=L:Z<+U:F6PKU,+AJ-;")TLMQ>4SG6I9?BLMBX3>!J4,)
M7HRJ<E>@X1C6YZ<:]*594YU(4G'T?#K%K(*>.Q4LGPV8Y37A2R#%Y3B)X_#Y
M=5RV$\/5JX6CA\!C<)1Q.(PE2BJ2H9A#$X:%64L0L(\1'"UJ/U#^V1X=^+/P
M@\*Z/XP^QZWJOP4U[6)-$^'&H>)(+6]O(]-M3>+HFH>(]2T*PL]#A\57MG87
M4MM!+*E[<62W+FW:"%BOY%^(?$&I^)M3EU35;F2ZN9 D8>0Y*0Q#;%$N,!41
M0%50 J@8  XK[X_;"_;W^.'[1O@7X>_L_P#BGQO9ZY\)/A%>7%]X4T/0;:XL
M]&DURZAEMY=5DMI9'>XO$BN)X(9G ,4=Q.L>/.D+?/'A?]GJ77/AEJ7Q0U7X
MD_#_ ,.V5BE_%!X1OM2NYO'6H:E:2B.&QM/#]K932'[3$Z7L,\DL<,ELP5)/
M-680?8T:F3Y+0CC)T*67QS#%7A1H8%T8PQ&,J3E##T,-AE5G"DD^6FYI2C%I
M5N61^I\25_#_ "G%X*IPA@ZF2Y/F='(Z4Z%>A[!5N)<9@*$,TJT<-2I)X'!8
MG,GBJF$PU9SIY9AZBPT\97ITEBJVBOP!O?!'PE^&?[2'C:Y\.>(/A;\0M:UW
MPYIFA:#XKL$\9)XF\/>>UYINMZ#D:E8:8L,<4[:K#NB!N;:%S%)/#YF'\8_B
MY9_%FUTS7-4\%^%= \8266DV-YJWARP;3IM6LM$L8]'MM0U=$=X[O6;ZVL8&
MU._8K)=W22W+HKS''B=YJU]=V=OILS 6]F^8HU4J0V-K$H#L61N/,**"[#+Y
M.,:MQIT(TBSENTN+*[ACGB43_*)E$CSHPCDP^,2J@"  #!8]2<Z.5U(XJAF&
M;XE8S'T<;CHX"MAJ=3"1PV6XBO.KA\$\/#$U85I1HQPE+&XCEC]<J8:C6E0I
M6C"/RN7Y;B\)BYYGFV+IYCCWB,SP."Q>'PD\'2P>2YAC?K>%R[V'UG$TYUU1
MPN!HXW&Q5&>/G@*5?V&'C'V4?Z@?^#/2^O'_ ."N<=C)<S26=O\ LM?'-[:U
MDD=X+:2YUKX:O<R6\3$I#)<&V@$SQJK2K$BN6  '^J+7^5G_ ,&>$<A_X*]N
M_EML'[*OQK??@A0HUOX=1E@3C<!(ZQG;NP6Y P<?ZIE?0M13?*DE=O1)+F;;
MD].KDVV]VVV]6>VU%.2BDDY2;44DG)MN;=NKDVY/=R;;NV%?X@W_  5B_P"4
MIO\ P4L_[/\ _P!LC_UHKXC5_M\U_B#?\%8O^4IO_!2S_L__ /;(_P#6BOB-
M2 \+\"?LP?$CXC_!7QQ\<_"\_ANZ\,^ =2U73M8T&6_U)/%UTNA:5H>MZQJ&
ME:='H\VF75AI^EZ];7=PTVLVUULM;T1VDCI;K<\5XY^#WBCX?^!_A7X^UN\T
M2;2/B]I.NZSX:M=.NKV?4[*TT"_M=/NAKD-QIUK:6TUQ)>0S6B6%[J2M!N-P
M]M,ODG[D_9Z^+4OP1_9)\+?$#[*-0TRV_;2O-#\5:20KKK7@O7_@7%9>)-+>
M)\QS&2V6&\MHY!Y?]HV-B[D*ASZ#^U5X7^!'@S1?V7_#?Q*OO'^H_">P\)?&
M.;P7>_""?PW<^(+C1]3\8^&=4\!2S7'C*:?3[FQ/A&\A75;GS/MEQJ2QRPI#
M&TT,?]<2\%^!<Q\+)\4Y9F7]G<1Y=P!P=F.=QSK-OJV58+.N+>-N&<ORK/IU
M/82E#*\=DV+XHRVOA5[2& Q>38;&2;ECJ<5_=4_H]^&F:^"U3C3)LW_LGBW*
M?"_@#-N(H<19Y]3R3+N(>.?$3@_+,EXFG5>&G*&2YED&.XRRG$X)>UIY7CL@
MP>/E>6948K\A**_:WX&+JT/P#^T?L+1Z--JTGQAOU^(:_%Y_ W_":?\ "O/L
MJ1V*>-B98M-305C,,MXGAYUNVL#=-H8?56OU;ZH_9@\.7EG\-_AQ8:GXB3Q+
MX0\2)X]@\1Z3X%TGX-67P4AU/5M>U^?_ (1S6QJL+?$_6KIKC4'M-!D\.S2)
M>?8H7\3V\,,TPN?5X*^B'7XPQ7#N$I\8YG3CGG#,.(9YYEG!=#-^%(2Q.8Y-
ME^&PV49W5XPRNOG^'P,\W;XHQV$RNC/ANIAG3JX+&PK1KP]OP[^@CB>/L;PG
M@*7'^<4H\2<'T^*:G$>3^'N&SS@B$\7FW#^583"9%Q'6X]R;$\483+9YZY<9
MYE@<EH5.$JN$=*MEV84\1'$4_P"=[X;^$#\0OB)X"\ C4!I!\<>-/"WA :J;
M3[>-,/B77+'11J!L?M-G]L%E]M^T_9/MEK]H\KR?M,&_S5]]\<_LNOX,^&'Q
M:^)*^-TU-?A9^T3XC^ CZ.WAPV+:XOA];?\ XJQ;\:[>#3FNWNHU_L V=Z(%
M#O\ VW,0J-^H7P0T[QMX>^'W[-UE^SVWP_B^&%C\3?$\'[1]UKDOAS^UC)IO
MCG[)9/J<^O>7JSZO'8VMP/#4NA*-0_M6#PU)"1X<VEO/-8^+?C#X*_ _]J_Q
MSX$NM-LO$UI_P4%^)UE:76I:78ZND$-ZVB_:_(M=0BFA2:YM8)K-KA$%Q':3
MW8MY8966:/V\K^CMP-D'!53,>-<5F^,Q.+X6SGB.?$N#R3&T\#EU)>'V7<3X
M6?"5*'%F"P/'&'R?&8^>%Q&*Q?\ 8%&OG>!S#*,1&.'PKK2^BR7Z*/AMPOX>
MULU\0\9GV/Q>.X*X@XMGQ?@.'<QI99E5#_B%F5<8X*IP+1I\<9=EOB1A<@S#
M,JF#Q6,QSX8H8GB/+<TR'%0CA<&\1+\3Z*_I9TWPUX,T#XV_M.S>"8-7MOBS
MK4_PUUFWM?AVGPIA^($&A7GA+3X]0D\+0?%9(_!B6&HZG:7VI>(Y;T/-<W-R
MT\LC7#Z<J^,:IXF?P7XL_;<\<:!X!N_A_P"*]!^#OPD\5R:3XUL/ &I7,GC7
M39_%^H6'BZXL?!FO>*O"-Q=RW%MHVKQ/%>+)_;%H+JXL()@H?CS/Z&[R6E0K
M9GXBS5'^W^.,IQN*R_@K$X_+Z&%X,P?'F-E4P^8QX@HX2MGF*H\$>TQ7#N,J
M9;5R^CF]"K1Q^9O!XBG+@SGZ +X>HX;$9OXL35#_ %H\2<BS#&Y7X>8S,\KP
MV"\/<O\ $S,9U<-FT>*</@:_$>.H>'2JXSA3,*N45LKP^?8:MA\SSAX'%4I?
MB1JG@7^S/ /ACQ[_ ,)EX#U'_A)M3U;3?^$+TOQ#]K\?>'O[*FEA^W^)_#GV
M./\ LG3-2\KS=)NOMEQ]LAEB?RX]^!PE?NW\ /$FI>,O!_[%/B_7YH+G7_%7
M[0_[0'B36KB*"WM8[C5]<TOXMZGJ,T5K;I'!;)+>W1=(((TBA5HHXD5%C4>(
M_&[QGJ?Q:_9'^-]_XNM] DF^$?[3;>#_ (>+I&@:/HT?AWPK:'3],M=$L5TZ
MU@/V-+74KQF=R]S<DK]HGFC@A6+YC//HZ9'#@^/%N5\8XFC4J<$KB7+<FJ\,
MWAF?]D>&7!_B#G%7'YE/BFO+*:^+PW$E:G0P^'P69T88S#1I0=/#XCFPOQG$
MGT3^&Z? <>.<FX_Q>'JU?#M<791D%7@]RIYQ_87@[P%XIY]7S/-ZG&F(GD6(
MQV#XNQ%'#X7"Y=G&'IX_!PH4W2PF*Y\%\%>"O@BWB?X*?%?XVZKXE'A_1/AS
M?^&]!TC3ET?^U9_&/B;Q#=QPMI$5Q_:NGC1X],M;FSO[N^>VU+=;W#"*V+0M
MGN/B3^QO\6?A?J/PGL==O/"&H0_&'5])T#P[JNA:EK%WI>E:WK3Z4+'3/$TU
MYH&GW&FW3P:Q;7H2UM=06:SAO);5[@VSH>UTJ"]NO^"<_B<Z;( NF_M9V-_X
MBC1B)&T.X^&.E:?8B<*C%H&U^>Q:%9&2,30LRMYBA'_13Q'XIT7Q-\>M"_9[
M\2?9(QK'A'X&_&?X7W\[1(VG_%OX>VT5V^GB68-'"OC+PEH[:!/,6CD2WMS;
M6S"XU%77VN#?!CP[XDX;RFAF%#&Y;GV9\+^&,\IS=9EB:>&SCBKC7/\ Q$QE
M3#8FA5E7PT*>8X'AO+N!\KCA*>#I87,_99ABG4K2QE:?T' /T??"KBWA+(\-
MFF&S'*.)LXX,\':F1Y]'-\73P>>\:^(?%'BMCZN$Q>&K3Q.$A2S;+N$<I\.,
MFC@:6 H8+.?99GC75KRQ^(J?A]\2O .L?"SQYXJ^'GB"YTR\UKPAJ]QHNI76
MC375QI<]U;;?,DL9[VSTZ[EMSN&Q[BRMI#SNB7OP]?O7;#XD?VE^U7/^S5_P
M@S_'U?VI%7Q.->;PT=:7X/1^'-)VB'_A(B+5-,;Q(=32[:5E8Z>GB%=,(UU-
M/QZG^ROI?B*T\'Z5?ZKXB6[M->^+_P :;+QSX>^%]C\(8/A5INKR?$/Q-IB6
M/B2^\91R?$75]"U:_56\"P^#KDZI_9>HZ39ZE:-IHAGE]'+_ *(E#B/C!9-E
MG$O$679;F$^)\?AL=0X)HYSDN7Y=E?&7^J^$P&'SS$<8Y1//L?ED:U#$<6PP
M^!P^(X?HRA7>'S&C*O6P_L97]!'"\6\>KA_)N,.*\JRG-*G&>9X/,L-X=X?B
M#A[*\JR7Q _U-P.687B/%<?9%4XFS/)HU\-BN.H87+<+BN%L/*GB7A<VP\\3
MB,)_/%X1T$^*O%?ACPP+H6)\2>(=%T$7IA^TBS.L:E;:>+HVXE@-P+<W'G&'
MSX?-V>7YL>[>/JOQM^R,?#%G^TC_ &/X_;Q)K?[.6L>%8M7T3_A$FTMO$7A?
MQ-%;F3Q/:W?_  DFH+8-H\SWGV_2O(U#;9V8O#J$;7,=LOZ0?#'3?%OAGP!:
MZ?\ LYV_PXL-/TG]J3XH:;^T$NJGPC;_ -F> M+\=ZO;:/#JXUUH1;:;;>%;
M72X[2'25&I1H^F/I<20'49%\VU?9%\7_ /@I[=WBN=+3X,:M9R-YH2(:M?\
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M_96_9-^'O[.W[.'[9G[$EU\=-.^#'QM\??'CX(Z]\.?VC]4\#^)O'GAKXA?
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M*Z)\+]2_LNUT7P].D]A?:7H=MI]_J2A&%K_:.J")9[E8M[C[W[QPS.Q/(I_
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M1\ISGH,5^^'_  =%_P#*=;]N7/./^&9N/^[/?V??R_S]:_ :)2\BJ.I('?U
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M*L;B\OQ7LW&=3"8FO1<E"K-,HHHKS3R0HHHH _U^O^#7'_E!1^PS_P!W,_\
MK8?[05?O]7X _P#!KC_R@H_89_[N9_\ 6P_V@J_?Z@ HHHH **** "BBB@#\
M!/\ @Z*./^"%?[<IZ?\ )L__ *V%^S]BO\@YP1R<=AP<]L]1QZ^G\\?[5_\
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M52ZV]W%$DX7S+=YT&X^1B5HHW?R8GFD(CW2#>X')RD> ,C[I8@YS]WT_N/\
MAY_P:5_\%)_"?B+QCHNM_&']B#5_@G\0#>:=XE\!P?%G]H 7$&ELV[1]4T87
M?[,4MK:^)M!DC@EL;O[0FZ-'LY+LPR>8/$/'?_!EA_P4*CUK/PV_:/\ V--2
MT [I(SXV\:?&_0=7M69CBV*Z%^S[XDM+Y$3'^E^98.Y)'V1<;C]+Q1E_"<<O
MPN<\*9U3E3A.KE^;9#C\PHULRP..HU7".8Y3*>%P4\SR',Z$H5\+4A0_M#+J
MZQ6$S&G[.EAL=C/L.,\KX'AEF"X@X'X@I2IPJ5\KSOAG,\TP^(S;+<RH57"G
MFN23J8/+IYQPSG&&G3Q."K0PW]JY3B8XW 9M3]E2P>99A_)/X-^'FO?$;^UQ
MIVH>$=$T[PMHYU?4KSQ1KVG>';86JDQ%;8W;BXU"\DD!$5G:Q3W#?+A/G0'Z
M9^%'_!.+_@H!\;O NB_$SX&?L9_M)?%;X9Z^^HQZ!X_^'?P@\9>*?".OMIE[
M<Z1J<FE:]I>DW%E?+;:A:W-E<&&9C%/!+%(%D1@/Z%6_X,N_^"HY/R_'S]@9
M5P04_P"%H_M#NN".G/[+0/7IZ=1S7[#?LL_\$H_^#HW]B[X&>"_V;_V<O^"@
M?_!/;P+\(/A__;/_  BOAFXT_7O%,VG_ /"0:W?^(M5WZYXL_8:UO7[T3ZMJ
M=[<H+W4[@0"7R8!% B1+\IBL?@)X3"0P=&5',*3KO,,?6QSK0QO-4A]5AA<)
M'"4G@:>'HQ4))UL3*O-2JN=*+C1A\/C,SRN>!P%/ 8>IA\UI/$O-,SQ&9.O3
MQZE5B\'3P>"A@:/]G4L+0BJ<XSKXNIB*BE5=2E!PH0_BCN/^"0'_  54$L4\
M?_!.W]L9B01,1\ ?B'N.<84@:*W0<;N.?O'/%?I)\,/@G_P5R^"W[,O[,OP6
M^'/_  2P_;!M/B%^S!^W%J/[;/A7XE:M\'_B'>Z/JNN2:)\/-.TOP9>^#(O!
MMI<I96MYX#,VHZFGB>1M2L-5>QAL+"6V%Y/_ %GZ5^R-_P '<KW*KK?_  4Z
M_8!MK3!+2Z;X!L]0N2PZ*+>Y_88TJ(!NA?[3E>HC;I7MOQ#_ &8O^#FV?PGX
M;M/A=_P4"_8TL_&-I;/'XFU;Q?H.F_V5JMP\2@7%G9Z?^P[J36ODSAVBC2*"
M-H66.5)'0ROTX#*(YEEV;9C6S_AC+8Y?2IUJ>!S'&XF&9YG.I4A1G1RG"X;
M8N52O3C+ZQ5^M2PE%TX3=*K4JI4WV9;D4,WRG/,VK\3\'92LLH4L12RW-<QQ
MD,WSBK5K4\-5P^1X/!Y9C95<32A/ZU7>.J8&A*C3G*CB*U9*E+^9OQ+\3_\
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M.[YOV!05/08 (QD\&E3]DC_@[]$<F[_@IG_P3Q,NP^5_Q1T6S?Q]\C]@52%
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M&=I3+!\2_CXTL8E619/+C?\ 9DBC+99'52RKN5AD;LU]5?LQ_P#!MA_P6/\
MV,_BWH7Q^_9N_:?_ &'O WQB\/\ A_Q!X6L_$EWXL^,VNVDFA^*0UMK5I/IV
MI_LTW%J[36*P+#.\#R12P*J%5/F"YPK/FISIX]NM[!QK4:M*-*@N>O4Q,)T)
M4'.I[:3H1C.->DJ<(M2A/F_=QA,7@</A,TPF89+C,TQN8T*%/+\UCF]?"4,B
MK>WG7Q&(CE^'HPCF%2HX4Z"6)KO#T\/5G_LSJ1IU:7\YOBS_ ()E?\%*_%.A
M_8M8_87_ &F-4U&WTM=,M7F\!HZ11VJRRV+)*VH@_(\C; ,% S*W'%>H?\$]
M?V1/^"F7[$/[7?P)_:DO?^";7[37Q&;X+>*K[Q$OA$>%9=!&O"^\+^(/#?V-
MM5,EP;!8CK@O!*MO*"UN(\#?O']E-K^R7_P=/J%6Z_X*!_L$/\RAWCLO'Q.P
M$ LJ-^RT@+E<G:S;2W\0ZC[B^!?[-'_!97PWH/Q ?X__ +:?P>^)GBK5/"R6
MWPYB\%6MUX&\.^%?%DOF?:;_ %R67X':KJ.O:; #$+0+!;-(8W>6QC\T+'WY
M)@J7MJ>!3^I4:E1*6*S"T<)14I1M.7L?;58TX2M)>RH3E%1<N6^HN'LMHU:T
M,"JV&RRBY<M3&9O54<'!5*D8PJ>SHQQ%:,:3E&25##SE3C3=5KW6S^-#]D23
M_@H?^S5\+OA)X0^(O_!%[XS_ !Z^(/[(GQG^)O[07[$GC_5AXN\*6WP>^(WQ
M8AT.X\1VGC'P_H-U-8_$'PG:>*/#6A^-]*TNYDLYK?Q)9K)),]LJ1C;^#OBS
M_@IYX(^$WPXN?''_  1U^-/C[]M/X#_"3X]_ 7]GS]K*XC\5Z2/ _P -/VCM
M1\?7_C&X\1?#>TG30/%'BSPDOQ3\>VW@359Y;:#3K;7)DO;>Y.[/]"FL?LC?
M\'7MQJ=[)H__  4)_P""?=II2J8]-@N(/B(;E_WIVSW[)^R=(BR^3@&.!WC,
MG.2!D^A?!W]FS_@Z,\&>-+36OBA^V5_P3Q^*?A-(#%>^%7U/XJ>'6FD;;F:'
M4M-_9-6>.10"L9.5&XL4) %9YC4G@:.+J8?!8C-*N&A5=*C@/J\*N,DDFJ>%
MGC<1@J"E.R5-XBK0IKE2E-)7//SBM5R^ECZN&P-?.JV&A6E2H99]3IU<PG&*
M:I8*>88C+L+%U;*-.6*JX6BFESS@KL_G$_X)Z_L-?M#?![]FS_@J'X-_:;_8
M-_:0\=:!\:_A!^S9X1\$?"70['4O!/B[XBW7A?X]V&O7T7A'Q38?;(M*U#P'
M9/:^.IA?"*TO+31)M/=)Q=&%NT_:6N/V_/C?X#_: ^'GA/\ X)+?M(?#[PU\
M=/!7_!/CP;HFG2)/XD@^&^B_L*:1XGL+#3O-O9$OO$<?BG3-=M+"*XO9DO+)
M]-\RYDO+BZ>0?T ^/?V8O^#HG7_'WBS6O!/[;/\ P3_\%> ]8U&:X\-^$7O_
M (FZW>^%;%UC6.S76;O]DY)=5*,LLADN4B&9 B@+&N?4?!7[+G_!Q#I6@RGQ
M?^W7^R3XA\5RQW;QM%IGBJ'0;6=X56TA5(?V?K"YN+9)U+RR26\=PJ,P0O\
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M];?>NQ^A5%%%, HHHH **** /\@K_@Z,_P"4ZO[<GH/^&9^__5GG[/W^>:_
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M/6/M)RY80]G%)7E)I7=G)\JER?#9*3YDY<SBN9JSZK_@MI^UA\,/VL/V=O\
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M7\<TQ&R%9),*?UL;_@UN_P""Z1>.3_AC33V9=K#/[2W[*9*LI.!EOC9C P&
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M$NN76J^ O#EMH5QXL\0:K'XDUGQH=7AU*YUK^6>OZ_?^(*G_ (*F_P#1?/V
M/_#I_M%?_0JT?\05/_!4W_HOG[ '_AT_VBO_ *%6@#^0*BOZ_?\ B"I_X*F_
M]%\_8 _\.G^T5_\ 0JT?\05/_!4W_HOG[ '_ (=/]HK_ .A5H _D"HK^OW_B
M"I_X*F_]%\_8 _\ #I_M%?\ T*M'_$%3_P %3?\ HOG[ '_AT_VBO_H5: /Y
M J*_K]_X@J?^"IO_ $7S]@#_ ,.G^T5_]"K1_P 05/\ P5-_Z+Y^P!_X=/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img147150826_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &%!(,# 2(  A$! Q$!_\0
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MD_V^?&.KGQJ]Q)K<<D#?V+X26U2T>*1+MKI9;;XQM_\ @A%!I?[(O[+?[/\
MX=_:OUCP]\7OV1OC1XT^-/PM^/5M\%]"U71#K'C7Q$GB*ZTW7?@MXC\=:UHV
ML06%WI_A]K66_P#&%S!+)I5R+K3YK#5[K34]JIFV08VIAUBZF&BL/+(HT\3_
M &:IUO94,EK4,?"M.>"K.O2IXZ&%I\F(I8J$4O:X?#5X1E&?E4\NSC"PK/#P
MKMUEF\JE#Z^X4O:5<UI5L'*E&&*I*C4GA)8BIS4*E"4F_9UZU*4HN/Q]^R#_
M ,%8?VBOB%X?_P""J'P^A_:M\.?M86_[-7[&'Q/_ &A_V;/VJ]/_ &?-,^!F
MKZCKWA/X=7FI3/JOPEU/PSI>E1P>&_%^LZ18)I?B;PS>Q7=[X7U"<W?B+P]K
M%O(>#D_;\_X*O?#G]C+]C7_@I%XT_:9^%'C?X9_%CXM^#/A/XL_9MM?@1X,T
M9O$/A][WQ3X<O?'7B'XE6FGVNO6OC'Q7J7@'7[O4M"\$VWA3POX<FU;2KK1E
MO;&.YT&V_3+X<?\ !&OQQX?\<_MM_%3XL?MK^(_CC\4?VXOV2_'G[-'Q \:^
M(/@EX<\+7&AZUXV\/:?X6C^(.F:/X7\<VNAOHGAO0=%T/2]#^&]E8Z+;VMEI
MJ6L7BN&W,$=KU7CC_@CS!XR_X)Q_LY?\$_!^T+-IJ?L__$KPY\13\6?^%5)>
M/XMDT+Q%X]\03Z2/ O\ PL:T&@)?-XZFM8;W_A,-::R&FQS/:WIN6BAUGF?"
ML,3%TZ67SHU\;ERQCEE?M%'!K+*E+,)4+Y;A51;QL:4U+"X7"5)5&ZM##T82
MG%3# <0RH-5*F-C4I8;'/#*./Y&\2\?3J8*-7_;L1[2V%=2+CB,1B8*%J=6M
M4DHR?YU_M]_\%(?VN="_:4_X* ^ O /[<7PD_86T/]BOX>> ]:^$OPH\;_"G
MX;>-?'O[77B+Q/X-'BJ\L/"VI?$W1M7OX-2FGDM++24\)Z+JMI#:>(/"T^H:
M;_97_"0^+M.X[XT?\%6/VL_@9\&?^"='PB^*G[6NB?![XE_M5_!X_M(?'G]L
MSQ[^S#I/BC5_A+X"\7?VKJ7@7P5X8^ /PY\/ZMX>\2ZI ]C=>%HM8E\*P3>(
M&'AK6-9M? MK?Z_J&F_!'[4?B[1O!/\ P4%_X*/>-?B!\8O#?[+/Q$D^,B:E
M\!_AG\;O^"?OA3]L_7OV@-4\&V6H>&O#>M?#GQ[\0_AQXEM_@[X>\7M:Z7?Z
M'>Z!=QQW6D>)]*MYS>GPQIN/W2\ ?L?_ +1G_!1S]GG]AK]MCXH?$3Q7^PK_
M ,%#/@_X<\<6OA_XC>%/AQINJI>>#-=U?7M"T:;Q?\&_%%YHEE8Q^*/!S_VQ
M_P (^FI6&FO8>-/$-K>Z7)H^M66A:'Z5?#Y/EN$R>KCL'@(X.5+#J==X.E&L
ML94R.]*3J/*:TLPPGUUU*^)K0JYQ2I5Y4J=;#SC3CAUP4:V98[$YG3PN*QDL
M4JE;EI+%3E2^K4\V2J)4UF-&.#Q'U50HT*<H994J48U)TZ\93=9^>?\ !._]
MOO\ :W_;F^&7[>_[.GPK_:3^''Q7^/?P6T_PS=?LS?MI:A\'I/A/X1\::9XZ
M.K6]IJOCOX3ZCX%U"'PUJ7A^]T&XAAMF^&VJ6T[7UPL^F:U;:1!J&L_O_P#
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M9%JW_/RE_P""I?\ R[U_I:^>_P#"SO#?_0-^(7_AH_BM_P#,71_PL[PW_P!
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M6%JW_/RE_P""I?\ R[U_I:^>_P#"SO#?_0-^(7_AH_BM_P#,71_PL[PW_P!
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M6%JW_/RE_P""I?\ R[U_I:^>_P#"SO#?_0-^(7_AH_BM_P#,71_PL[PW_P!
MWXA?^&C^*W_S%UZ%11>G_+/_ ,&1_P#E86K?\_*7_@J7_P N]?Z6OGO_  L[
MPW_T#?B%_P"&C^*W_P Q='_"SO#?_0-^(7_AH_BM_P#,77H5%%Z?\L__  9'
M_P"5A:M_S\I?^"I?_+O7^EKY[_PL[PW_ - WXA?^&C^*W_S%T?\ "SO#?_0-
M^(7_ (:/XK?_ #%UZ%11>G_+/_P9'_Y6%JW_ #\I?^"I?_+O7^EKY[_PL[PW
M_P! WXA?^&C^*W_S%T?\+.\-_P#0-^(7_AH_BM_\Q=>A447I_P L_P#P9'_Y
M6%JW_/RE_P""I?\ R[U_I:^>_P#"SO#?_0-^(7_AH_BM_P#,71_PL[PW_P!
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M6%JW_/RE_P""I?\ R[U_I:^>_P#"SO#?_0-^(7_AH_BM_P#,71_PL[PW_P!
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M6%JW_/RE_P""I?\ R[U_I:^>_P#"SO#?_0-^(7_AH_BM_P#,71_PL[PW_P!
MWXA?^&C^*W_S%UZ%11>G_+/_ ,&1_P#E86K?\_*7_@J7_P N]?Z6N-H&OZ7X
MFTN+6-'EN)K&:XU"S!O-/U'2;N*[TG4;O2=2M;K3=6M+'4K.XL]2L;NTG@N[
M2"598&^4J59MFO/?AC_R+>I?]E"^+G_JUO&E>A4II1G**O92DE?>R;2OMK\D
M52DYTZ<Y6YI0A)V32O**;LFVTKO1-MVZL****DL*_@J_;0\$^,M'_P""A?\
MP5!_;&^%D4K?%+]@SX^_L?\ Q_T81%V-_P"$?LUMX=\9Z+<1+N1]*N9KSPUK
M'B RP741\/:!JMO/;26ES<BO[U:_+WP5_P $RO"VA_M#?\%#/C/XP^)!\<>$
M_P#@H'X)T7P%XE^&+^!X=(7P-H5GX0U#PCK48\4R^*=:C\6R:Q:ZC+<6Y?PQ
MX;72RJQ,-1;$Z_3\,9OA\GJYC7KN[K8.A1A1Y)R6)C_:6!J8K#MQBXP57!4\
M2G*HXQ:O%2<Y1C+P,^RVMF<,%2HJWLL55JRJ\T8O#R6!Q<,/72E).3IXJ=!J
M,%*5]6N52:_GH_X*\?&;1/\ @I3XN\9ZA\--4DU;]G3]AW]@VV_:;U>Z0K]C
MU+XS?M.:=X+;P'X>OY[%)4;5="\$>)/#7B*VMIKQ18:KX;\:Z1,D4T=]:7OH
M'B;_ (*:>/?V5/V2?^"2?[+G@+XW^%/V3M-^+?[+'A;XA_%G]JGQ1\)-6^.]
MU\,?!=A8:II7A^Q\*?"K3=%\0IXDUCQ!K7A_5=.E2ZT6^B6\N= 6XO?#6D-K
M&OVOZ8?LY?\ !"_P?^SS^PE^UG^QU8_'JX\2>+?VL9H(O$?QQ?X61Z._A_1M
M#MK"/P=HD?P^'Q$U1=8M?#EZ?$FH22MXUTR74IO%%[&O]GI;0;NU\:?\$<6O
MOAS^P^_PE_:G\8? _P#:@_85^&I^&/P\_:3\+_#G1=;M_$N@W>C2:1JUOXD^
M%.O^)[C3I-.NH[S6TMM)_P"$MN+<:;XE\0Z/K<GB"SOH1:?3K.>&%2PN62J>
MWRW+L976"=7#5>2<997/EQ]>G4P>)BXU,UK5I.G4PN*G&/LY5,)7IP<)>"\K
MSYU,1CU#V..QN&I/%>RKT^:#CF%/FPE&<,50E>&7T81YX8C#PE)SC#$TIRYU
M\+?LB?\ !6?XU?%WX!?M]^%-1_:__9_\0^*/V9K_ .%>I_"3]O/XI_"/7/A-
M\,O%7P]^(OBM-(US4?&/P<L-"TC5;3QYI&FZ5K5GX"\+:?X55?$OC+4=+T>\
MBU'3+,ZMJ^;_ ,$_O^"IWQA\=_\ !2/X3?LHW'[>/A3_ (*#?!OXT_#SQ_>W
M?CFU_95/[,FI?#/XC^#_  CXP\='P]I.GCPUX9OO$5A'I7@:9%UJ\DUK3-3L
M?$,906&JV.Q?T7^)/_!*+XC?M&?LK_&SX ?M:_MV_%S]H#QQ\7/$G@#Q5H_Q
M/N/A_P"$? 7A3X7:K\.+N_N]&3P3\$_"^I#PQ:6&N?VMJ%OXUM5UR!_$$":3
M+;3Z1J&BV5^O+_!/_@D?\8_!O[9G[-G[:?QY_;RU_P#:.\=_LZ^$/&WP^TWP
MY>?L]>"?A7X;O?!&O_#KQEX \+:!X:LO!'C(Z=X.7PP?'&L:YJU[<:5XJN_%
MMVMM%+)HK++=2\<\;PK/#YSIA*=6O0Q<<+1A@^>*Q,<LP\<+7PN(_L*A6IQJ
MX^%:4H1J911H3FW]5J4*G[KICA>(8ULLUQ$Z=&KAI8BK+$\C=!X^M+$4<11_
MM>K2G*E@Y4XQG*&9U:T8V^L0K0O/\E/AQ^W3_P %>?C!^P=^TW^W#H'[8'PT
M\+>'/V1?C%XN\&7/@:[_ &>/AIK'BGXQ6^C7W@O7=6LO$FOGP]9Z#X1T/PYX
M9^(/A_3?#)\*Z OB+Q#<66M+X@UG3[@6&K7']7/[,/Q7U+X\?LU?L\_''6=,
ML=$U?XS? WX2_%?5=&TQIWTW2-2^(G@'P_XOOM,T][J6:Z>QL+K6);6T:YFE
MG:"*,S2R2%G/YB_!W_@CQ;_"7_@GU^UE^PDG[0LVO#]J+XF>.OB,_P 4F^%2
M::? \GC+2?AQI46D+X)'Q&OQXD32T^'<$TEZ?%V@MJ#ZI*JVM@+5#/\ J3^S
MK\)%^ /[/OP*^!":^?%:_!3X.?#'X2+XH;2QHC>)%^''@G1/!PU]M%&H:N-(
M.L#1AJ)TL:KJ8T\W/V0:A>^3]IE\GB''9/BZ52.74L'3E3S2L\,\+@%@W++9
MX7#\OM)1H4?:6Q2K.*KN5:G=J*C2<4>EDV$S/#3IO&U,3.-3+Z2Q'UC%O$J.
M.CB*M_9IU:BI_P"SNGS.DE3G9.3E44F?Q?\ _!+/6=1_8ZU7X+_M]V'G6WP4
M^*/[4?QD_8+_ &NHVD']FZ+9^*_$V@^-?@A\8+M5CG-I%H'BK6SH/B/6)8,6
M&@Z+9Z+:7$<_C"51U?PM_9(^.'[:'[#O_!5?X2?L_3V-WX\TO_@J9XO^(,G@
MG4M;;P]9?$_0O":ZB;[P#)JKW5C8V]Q>W>H:?KNFKJU_IVFS:KX?L89]2TV1
MX=0MOZ"_V?\ _@DSX!^$W["/[0/["7Q"^(TWQ=\'_'_QE\3O&6I^+/\ A"8O
M!MWX:O\ QW;^'W\.W&EZ&WBKQ7%<ZO\ #_7/"^B^)]'U2?58X;W6K"VEFTRU
MMXS _BG[/W_!'/XN?LV?LX>./A1\+?\ @H;\5O!WQH\:?M-M^TE=_M!>%/AE
MI6EG4KEO -]X*G\">.OAKK/CSQ-I_P 0?#NJWVK7_B_7DUGQ3!9ZGXALO#%W
M'I%E<^'_ +5J'TE?B;+:M?'XNAC*5''?7\#'"5Z^%Q=2AB,'A,6\7AZ]:-.B
MZL?8>TK8>I%QA7]A'#>QC.<'R^%2R''4Z6#PU7"U*N$^I8IXFE1Q&&A6H8K$
MX>.'K4J4IU%3:K>SIUX.\J7MI5_:N,9J_P C_L7ZS^Q;^TQXM_:#_88^)O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \]^&/_(MZE_V4+XN?^K6\:5Z
M%7GOPQ_Y%O4O^RA?%S_U:WC2O0JNI_$J?XY?^E,RH?P*/_7JG_Z1$****@U"
MBBB@ HHHH R=?FUVVT+6KCPOINDZQXF@TG4IO#ND:_K5YX;T+5==BLYGTC3=
M:\1:=H'BO4- TF^U!;>UU+6K'POXDO-*LY9KZUT#6)X$TZY_.0_MS?%KX??%
MWXJ_#W]H3X&_"#PEX6^!O[+/C+]J[XN>.O@I^T?XV^-4_@;P=X<N;R'P_P"&
MM7\->+?V7?@7$GBSQ_::!XWUKPO8CQ&(WT7P+K]]>/;^9I$6I_IC7YV>#?V+
MO$_B/X(_ML^&OCIXG\/+\9/V[IOC)I'Q*\5^!I=9\1^'O!/@+Q/X-U;X._!W
MP=X5?Q!9>$=0U>P^&GPE71)+I;C3/#_]J>-;_P 6W:R""_BOG]+ / J%=XZ$
M)1;HTZ<E*NJ\95:L54J0C3J*#A1P\:U1N=.I>M["#C*,Y(X<8L6Y45A)SBU[
M6=1<M%TI1ITVX4YNI"4U*K6=*"Y)PM2]M+F4H19S.F_\%"?%'@&;2;K]K+X#
M:9\"?#GC?]ESXH_M7?#C5? _Q>D^-6H7OA3X(^'/#OC7XL?#KXA:3/\ #'X8
M0>!_BOX7\&>+] UVTT_0-7^(?P_\0M;>*M/TOXCO/H5DVNFF_P#!0GQ1X!FT
MFZ_:R^ VF? GPYXW_9<^*/[5WPXU7P/\7I/C5J%[X4^"/ASP[XU^+'PZ^(6D
MS_#'X80>!_BOX7\&>+] UVTT_0-7^(?P_P#$+6WBK3]+^([SZ%9-KO"ZK^Q'
M^T+^TGI>D:!^U=J7P;^'VE_#O]CCXX_LM>#)O@1XQ\>?$J;QMXL_:0\ >'_A
ME\1/C'XML?&_PY^$,'@C3_#'A;PC;'P/\+M(N_'LMS?^-?$,FL?$N%/#>D'6
MC5?V(_VA?VD]+TC0/VKM2^#?P^TOX=_L<?'']EKP9-\"/&/CSXE3>-O%G[2'
M@#P_\,OB)\8_%MCXW^'/PA@\$:?X8\+>$;8^!_A=I%WX]EN;_P :^(9-8^)<
M*>&](.M>O[+(O=]JL/3TJK&>PQ.(J>P?[_ZG+ 7KU?K'M?\ 9_K:E];]CS3M
M'#VER^;SYMK[.5:>M/ZM[:A0A[9?N?K*QEJ5/V*I_O\ ZOR_5_:6C[U:\>;W
M?X,?M@_$[Q-\5OA#\*_C]\ =!^!]]^T9\&?$'QF^!E_X6^,LWQ@.I0^"5\&7
MWCOX;?$^S?X6?#>/X?\ Q,\-:!\0_"VMI;>'=0^)7@'6X[?Q;9Z3\0KBYT"Q
M&O\ WY7YR_!C]GG]I+6_C#^S_P#%+]IR/X*^&T_96^"'BOX8_#W2O@AX\\>^
M.Q\3O'/Q,L/ ^@^.OB=XT_X37X8?"Z'X>:3I'AWX<V5IX,^'&CK\2)OMGCOQ
M%<ZQ\0F3PQI$6N_HU7C9C'"QJTUAHTH/V3]O##U:E:A&K[>NH>RJ5*E:4E+"
MK#SG^]GRU95(^XXNG#U,$\0Z<W7E4G^\7LIUJ<*5:5/V5+G]I"$*48M8CV\8
M_NXWIQA+WDU.11117GG8%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117!^.M1\5:1:V
M%_X>U#P_;0S:SX:T2XM]9\/ZCJTK2^)/$VD^'TO(;FQ\3Z$D,=BFI_:FM7MI
MVNV@\H75J)/,CVP]%XBM3HQG"G*K*,(2J<_*YR:C&+]G"I)<TFHI\O*F[R:5
MVL<166'HU*TH3J1I1E.<:?)S*$4Y2DO:3IQ?+%.37-S-*T4W9/O**J6*7T=I
M FI7%I=WZQ@75S8V4VG6DTN3EX+*XO\ 4YK:,C $<FH73 @GS3G MUDTDVDU
M))M*2O:23W7,HRL]US13MND]#5-M)M.+:3<7:\6UL^5RC=;/EDU?9M:A1112
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GOPQ_
MY%O4O^RA?%S_ -6MXTKT*O/?AC_R+>I?]E"^+G_JUO&E>A5=3^)4_P <O_2F
M94/X%'_KU3_](B%%%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 45
MP%AXYN[[Q-<^%SX%\7V=S90:?>WNH75QX';3;73=5N=7M--U*0V?C2[OY;>\
MGT/4E2"VT^?4(1 K75E;K-$7[^@Z,3A:V$G"%=4U*=.G6BJ=>A7_ '=6*G3D
MW0J5%'GA*,XJ34I0E&:7+)-E%%%!SA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'GOPQ_Y%O4O^RA?%S_U:WC2O0J\]^&/_ "+>I?\ 90OBY_ZM;QI7H574
M_B5/\<O_ $IF5#^!1_Z]4_\ TB(4445!J%%%% !1110 5\T_#']KOX$?&*YU
M\_#_ %_QGJGACPYH?B+Q/<_%75?@W\:/"/P%UCPUX6U2/2-7\0^"_P!HCQC\
M/M ^!7Q"T,S2-J&DZMX#^(?B2P\1>';:_P#%?AZXU3PQINH:O;=G^T3X.\1_
M$3]G[XZ?#_P>_E^+?'7P<^)W@[PM)]J6Q\OQ'XG\%:WHFB/]M>:W2SVZG?6K
M?:GGA6WQYS31A"Z_@[X(^#7QE^)OPDU3X-?L]^'?VV/ ]EXB_P""9/[07P?_
M &B/ _[66L_M)6'PWMOVB_%_PS\,>!?@GX4^#Y_:8U2]\+P>(=)\4_\ "QY=
M7UK]G6]LO@II'@6#2XKW7+6*_P#!^FWGLY=E^%Q="M4KXB5&<*L(*?-3C0H4
M^24Y5<2YIRM5M[+#J/)&5=*G.<?:1E'S,;C,1AZU*%&C&K&5.4G&TY5:L^>$
M(TZ"BU%."DZE9RYG&E><8OD:E^R_PE_;>_9E^-NI:AI7@3X@ZG!=6/PUC^,]
MO+\0?AM\5/@[IOB7X-R3Q6Q^+O@+6?B_X(\"Z1\1_A;;R76G->_$/P#?>)/"
M&GP:UX>NK[6;>U\1:'-J!\)?VWOV9?C;J6H:5X$^(.IP75C\-8_C/;R_$'X;
M?%3X.Z;XE^#<D\5L?B[X"UGXO^"/ ND?$?X6V\EUIS7OQ#\ WWB3PAI\&M>'
MKJ^UFWM?$6AS:A^6'Q<\!_$K]N/0/ 6@_"3X._&3X=:G\(/^";W[8OPD\677
MQM^$GQ"^ T=K\9/VG/@MX"^&'P]^#G@V^^)^C>#+#Q[=:;KW@OQ#K7C;QCX$
M?Q'\,O#-KX=\*S'QN7\5Z!]J/BYX#^)7[<>@> M!^$GP=^,GPZU/X0?\$WOV
MQ?A)XLNOC;\)/B%\!H[7XR?M.?!;P%\,/A[\'/!M]\3]&\&6'CVZTW7O!?B'
M6O&WC'P(_B/X9>&;7P[X5F/C<OXKT#[5Z']CY<^7GK8C#<RJ^W]K7H3_ +-<
M/;^P>+M0I>UCC_9TOJ]OJJA[:/O5[QOQ?VECE?EIT*_*Z?LO9T:T?KRG['VJ
MP]ZU3V;PG/5]M?V_-[)^[2M*WZN?!+]LK]G?]H?Q)_PB/PL\8^(=0\0W'@.P
M^*F@Z?XN^%?Q<^%G_"<?"W4[^VTRR^)GPRN_BIX%\%V/Q4^'<M]?Z3 WCCX<
M7/BGPO!_;_AJ2XU6*'Q+H,FH_4-?D5\'KCQ#^T+^TG^Q%X[\._"+XS_#/PY^
MRA^S/\6M(^+NH?&GX,_$KX+?V?XZ^,V@?!WPKX>^$/@E?B)X>\+1?$N]TJ?X
M<>+==\:>)?AW!XL^'6A6_ASPJ(O&$\_B[P]'>?KK7C9CAJ.%JTX4E5@Y4G.K
M0K5(5:M":KUZ<83G"E1C+VE&G2Q,/W4+4Z\%[RM.7J8*O5KTYRJNG+EJ*,*M
M*$J=.M%TJ4W*,)U*K7)5G4H2_>2O.E)^Z[QB4445YYV!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5PWQ#_Y .G?]CS\,?\ U9'A2NYKYY_:"^(FI>!-&\/>3\,_'GC2
MPO\ QW\*;9M7\)WGPVAL;+5]2^+'@W2-#T.[A\9?$/PAJK7^NZM>6.GV-S9:
M;>:-:RWD5QK6JZ38Q7=W;>GDN%K8W-<OPV'5)UJF,PZA&K7H8:,I*K!J"J8F
MK2I<\OAIPY^>I-J%.,IR47Y^:UH4,MQU2IS\BPM=/V=*K5DN:E-)N%*$Y\J;
MO*7+RP5Y2:BFU]#45DZ#J5YJ^CZ?J>H:!J_A:]O+<37'A[7IM"N-8TF0LP-K
MJ$_AC6_$>@27"@!BVEZYJ5KM90MRS!E76KSIP=.<Z<G%RA*4).$X58-Q;BW"
MI3E.G4BVO=G3E*$U:4)2BTWW1DIQC)<R4HJ24HRA))JZYH349QE9ZQE%2B])
M)--!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Y[\,?^1;U+_LH7Q<_]6MXTKT*O/?AC_R+>I?]E"^+G_JUO&E>A5=3^)4_
MQR_]*9E0_@4?^O5/_P!(B%%%%0:A1110 4444 %%%% !1110 4444 %%%% !
M1110!P.F_P#)4/&/_8A_#?\ ]2#XJ5WU<#IO_)4/&/\ V(?PW_\ 4@^*E=]0
M>CFG^\TO^Q=D_P#ZJ<$%%%%!YP4444 %%%% !1110 4444 %%%% %/4+&'4K
M.XL+A[R."ZC,4CZ?J%_I-XJD@DV^HZ7<V>H6DF0,36EU#*!D!P"0?.?A;I,5
MMI6IZBVH^(]0NW\4^/='WZYXL\4>(8H]/T+Q]XDTC2H8+77=8U&UMI+;3K"T
MM6NK>&*[N5AWW<\\KR._J5<#\-O^1=U#_L?/BI_ZL_QA0>I1K5H9/CJ<:M2-
M.>/RY2IQG)0DIX?,I34HIJ+4I4:,I)IJ3I4V[NG&W?4444'EA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'GOPQ_Y%O4O^RA?%S_U:WC2O0J\]^&/_ "+>
MI?\ 90OBY_ZM;QI7H574_B5/\<O_ $IF5#^!1_Z]4_\ TB(4445!J%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SC^TQKFB
MV7@SPSIM[K&EVFHR?&?]G#6TL+K4+2WO7T;P_P#M$_"[6->U=+669)VTS1-(
MT^_U35[\1FUTW3K*[OKR6&VMII4^CJ\]^)O_ "+VD_\ 90OA1_ZL_P (UV9=
MBY8#,,#CH0C4G@L9AL7"G)M1G+#5H5HPDUJHR<%%M:I-VU-:&"P^9U89;B76
MC0S!_49SH3A3JTUB_P!PJL74I5H-TW4Y^1P]_EY>:%^9=MI^H6&K6=OJ.EWU
MGJ6GW<8FM+_3[F&\L[J(D@2V]U;O)!-&2" \;LI((!R#5RBBN,B7*Y2<%*,'
M)\L924Y*-_=4I*,%*25DY*$4WJHQ3LBBBB@D**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** //?AC_R+>I?]E"^+G_JUO&E>A5Y[\,?
M^1;U+_LH7Q<_]6MXTKT*KJ?Q*G^.7_I3,J'\"C_UZI_^D1"BBBH-0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH X'3?\ DJ'C'_L0_AO_ .I!\5*[ZN!T
MW_DJ'C'_ +$/X;_^I!\5*[Z@]'-/]YI?]B[)_P#U4X(****#S@HHHH ****
M"BBB@ HHHH **** "N!^&W_(NZA_V/GQ4_\ 5G^,*[ZN!^&W_(NZA_V/GQ4_
M]6?XPH/0I?\ (JQO_8PRS_U&S8[ZBBB@\\**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \]^&/_ "+>I?\ 90OBY_ZM;QI7H5>>_#'_ )%O4O\ LH7Q<_\
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MI"M"HZ&#H2G356LX1E*TJE.G%)RJ5(1]X^I_VY/VL+K]C;X,Z/\ %>Q^&_\
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MR2DG6J)Q4"BBBO,.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \]^&/\ R+>I?]E"^+G_ *M;QI7H5>>_#'_D6]2_[*%\7/\ U:WC2O0J
MNI_$J?XY?^E,RH?P*/\ UZI_^D1"BBBH-0HHHH **** "BBB@ HHHH ****
M"BOCK]LOXY_$OX(:#\"HOA3:^!IO%'QG_:5^&?P$-[\0=)U_7-!T*S^(]AXJ
MC3Q%_9GASQ)X5U"]N=&U32M+O&LO[7@BU&PCO],$UA<7MOJVG?,_@K]NWX\W
M>@>);#4_@KX5^(/B_P"'OQK^./P6\7^(/!'A[]KBU\*:IJ'PG\<3Z!I^MZ+H
M7P?_ &7/VN_^$;@UC1YK&2YTCQ=\08-5%_;7=Y80W&FW<<=@KV_KS2_4_1LF
M\+.+^(,@PO$.38;!8[#8S$U</1P<<PP^'Q_+1GB:57%3AC)8?#1P\:V%G1_W
MIUY3E3<*$J;G.'ZNT5^-OC7Q;\6OA5\:/!O[2OQDTGQ?XB^%/[0_Q:_9F^'_
M ,,/AWX)_:D_:E\#:Q\&_%_B7P;9Z)JVG3_LV>(/A[\)?#/Q*T?6O&NEW>JZ
MQH/C31O#WB:ZL?.N=6\!+=7FM:5;?I=^T+HOQA\1?!3XDZ)\ /$^A^#/C)J7
MAB\MO /B7Q%8MJ&E:9K+/$6:2($K:W=U8K=V6E:M/;ZC::'JMS9:S>:/K=I8
M3:1>LQSO@*IDN*X2HU\XP,,'Q/'"4JF=XF>&CDV4Y@Y8&EG>$Q5;+L;FN.4>
M&,5C7A,YG7R["8CVF&K5L!@\;A*F%Q.(Y#PQ\<?A%KG[3OQ-^#6D?$+PQJ'Q
M1\.?#;X=W^M>"K;44DUJQ@M]:\?W-XK18$,UWIMKKFAW6K:?;337^DVNM:/<
MZE;6L&J6,EQ])U_GT_"CX0_MGG]KN/P/\-/#_P 1+#]K3PEXOU37;YIKY+3Q
M+H.NV,KWVM^)O%'B/7;S^Q_[&OUOS-J6NZ]J=SX?\6V>N0P/=:Y;>)+:'4OZ
M-8/V_?\ @J#\&H(;?]H+_@G%JWCR&PBCAU+Q#\&=0U:XC=84$<VJ3GPE%\8]
M&#/M-S.L=QIM@79DC-C"5$4J7=-;]&^WE_5MS^E_%[Z)E;AW,>'<-P%X@<&<
M6XS,N&,GQ>(R7->+>%>&L^Q%2G@Z.$AFN2X3-<UP>'S#(<V="=;+JM/%5*U+
MEG0G5Q24,34_>&BOQ(\+_P#!=K]EXZ@- ^+OPT^._P %O$,6S[?;>(?"&GZS
MI]D6)4[VTW6(O$QV,K@[_",.X+\FY]R+]J?#W_@I7^PE\3OLZ>&OVF_AG8SW
M.T16GC?4KOX:W32M@"W$/Q$LO"[27!<^6D41D,TA"P>;N3<TT]FOZ_X?[]#^
M?L^\#/&'AF#K9QX;<7T<*H\[Q^$R;%YKEG(U=3_M3*88[+W"2=XR6)Y9*[BV
MDV?<=%8F@>)?#GBO3X]6\+^(-$\2:5+CRM3T#5;#6-/ER P\N]TZ>YMGRI##
M;(>"#T-;=,_+*M*I1J3I5J<Z56G)PJ4JL)4ZD)IV<9PFE*,D]'&233W04444
M$!1110 4444 %%%% !7 _#;_ )%W4/\ L?/BI_ZL_P 85WU<#\-O^1=U#_L?
M/BI_ZL_QA0>A2_Y%6-_[&&6?^HV;'?4444'GA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'GOPQ_Y%O4O^RA?%S_U:WC2O0J\]^&/_ "+>I?\ 90OBY_ZM
M;QI7H574_B5/\<O_ $IF5#^!1_Z]4_\ TB(4445!J%%%>#?M%_M._ C]DOX?
M1_%3]HCXB:9\,O $WB#3?"T7B+5-/UW5()?$&KP7]UIVF16?AS2M9U.2>YMM
M,U"=62R,,<5K*\TD:@$ZT,/7Q5:GA\-1JXC$5IJG1H4*<ZU:K.6D84Z5.,IS
MG)Z*,8MOHC.K5I4*<ZM:I3HTJ<7*I5JSC3IPBMY3G-J,8KJVTD>\T5_%?KG[
M?_P^_:@_:/\ VK=;^)?_  6H^,G[)?PN\.?%>VTW]FSPQ\#_  =XVM?!WBGX
M0SZ)'+I>O_VAHOARSU>37(Y4-IXETWQ%86]_::TMS<K<WUI>6B6']9G[)U_H
M.J_LT_ [4?"_QB\0?M">'KSX:^%Y]'^-_BM+N/Q+\4K%]-A,'C37(]0@MK^/
M4M;7_2[J.^A2\CD<I=;IUD=OI^(.$L9PYAL)5QM2JZV)5#GHO+,UPU*C*OA8
M8I4XX[&82AA,35IQFJ=:GAZM2=.I&:::A)KQ\JSW#YO6KPPT(>SH^TY:BQF"
MK3J*G6='F>&P^(JUZ4)M<].=6$8R@XM/WHW^A****^3/<"BBB@ HHHH ****
M "O%OVDO"7B#Q]^SM\?/ GA+3_[6\5>-?@M\4_"7AG2OM=E8?VGX@\1^!M=T
M?1M/^W:G<V>FV?VS4KRVMOM>H7EI96_F>==W,$"22I[310=V68^ME699?FF'
MC2GB,MQV$Q]"%:,I49UL'7IXBE&K&$Z<Y4I3IQ52,*E.3BVHSB[27XF?"G]@
MOXQ^$?%OABP\%V%E\ ?#OB/]BC]GS1_B]XDT;Q+XWMK?Q-^U'X+\5^*+OQS-
MXIMOV>OVB?@7\1_$WC#^Q_$$[7'CQO&][X6U1+V\A>YU^>9HX/5/BO\ LN>-
MM ^&<.G3>#/CE^T;\<]!L_C%J7P5^+WP6^._Q.^$-S\(]>\=^"_"WANWL-<\
M1_M#_M\^+OB+/8:IJOAS3[ZYAT36/%O@R#3K>_4_#VTU&]UF3QG^K]%*RZ:>
MGR_R/U;%>.O'N-S?#9MBL3A*GL)TJM7 T_[2PE+'5*>"GEKEC<RP69X?B*K"
MOE\_J.*P]/.Z6%Q.!7U&O0G@YU:%3PSX;^"_BM#^SEX1^'_Q+^(EV?C.WPCT
M[PMXP^*'AF*PGU&P\?7'A9=-U+Q;H1U;3YM-U+4='UB5[_3[_5=&%IK%W9Q7
M^H:+#'=S:;'_ !:?%K_@FQ^UUH7[7,7[.4^@ZI\0O&GQ!U+5/$?AGXHROJ#^
M%_&7A9]1637?B5K_ (DO/MTNE1Z7-J$<_CN#5+B\UK3-:OH;)!KEUKGAZYU_
M^[ZOG;Q!\:/@[I7Q?T'3-4^+'PTTW4M%\/\ C/PKK&GW_COPM9WVD^)]>USX
M=7&A>'-2M+C58[BQU[6K?2-6GTG1[J.+4-1ATO49;.WF2RN6BZ*&#Q6,<HX7
M#8C$RIJ,YK#T:M:4(N<:<935.,G&,JDX4U*5DYSC%/FDD?4^"OTD>)?!G..,
M\?EF7<-8BGQG@LTQ=?"8S"T,OP^#SC!87,<RRW$X&6%C1K1P&!JU*\9Y)3JP
MP=7"3E"D\)5IPQ,/R6\/_!K_ (+E_ /0])T'PA\:_@1\??#?A^PMK#2-'\3S
M6UWKOV*SB6*&UU#Q!XK\&^"?$&H2A$$:W.I>.=2N&CV;[R,C8FQ_PW1_P5C^
M%G'QE_X)OP>/HK7BYG^"^JZS<O<1Q_>EB;PMJ?QM16=1O+);,@))$"#]VO[M
M45SV\W_5NZ?;\SSZGCEEV<5*D^+_  7\'^(7B)SJ8O%X#(,UX,S7$5*DG*I5
MECN$,[RF@JU63E.I6>!G4E-N;E=N_P"%UE_P72^%WA>Z@T[X]_LO_M'_  9U
M.5_)>&XT+2M7M[>8 EUE_P"$CN_ &JNB!6W?9]'FGXS]FQNV_3/@?_@L/_P3
MY\;^3%_PO$^$+^;;_H'CCP5XWT#RMV/]=JXT"[\-IM)PW_$[.,%N4^:OTNO;
M&RU*UGL=1L[6_LKE#'<6=[;Q75K<1D@F.>WG22*5"0"5D1ER <<5\S^./V)/
MV0/B1YS^,OV:?@KJMU<;O.U2'X>>&](UN3=UW:]HEAIVL]<D8OQM8EEPQ)):
M7=/Y6_)_H1_K)]';.=,S\,?$#@Z?6OP;X@X//*%]-5E_%W#M2OR+7]V\Y<VK
M?OXMZ=AX'_:<_9Q^)GDCX??'KX.^,YI]NRS\.?$CPAJNHJS?=CFTRTU>34+>
M8Y'[BXMHIAD909&?<NO2OR6\<_\ !$O]@#QAYSZ5\/?&/PZN)]Q:X\#?$7Q.
M=CMG+PV?C.Y\8Z9!C^&*&Q2W7&%A R#X=_PY3UGX?_-^S?\ MX?M)?!P6_S6
M-M->SZG$@3F."5_!'B3X81>6P C=ELFC"DL;65<PL7?9?)^G>WK\@_U1^C]F
M_OY3XP<6<+2EI'"<;^&U7&1BW_S\S/@W/<Y?+'9RAE4FU[W+'X3]VJ*_"7_A
MF#_@M/\ "GY_AM^VS\,_BUI5MQ_9?Q+TF)M8OT7E%-QXD^'GBJ=';&'8>-;-
M\G!GD!8@_P"&E?\ @M=\*?D^(G[&/PK^+^D6W)U;X<ZM;_VU?JO^L*V_AWXB
MZ].A(&8U/@6T<LQPDHPB%^Z:^5_RN'_$"EF'O<+>+G@SQ+[37#X5\9OA;-*U
M]H?4.-,NX>2K2Z4X8BK9;R5G;]VJ*_"3_A])XK^'V5_:0_8%_:/^$"VV5O;V
MVM+W4;?:GW[F"/QKX4^&T'DNH,D8_M*6(H5*7<J$2GVSP/\ \%N?V O%_DIJ
M_COQO\.)I]H6'QQ\./$<OENW1)KGP/%XUL8>>&EDNUMT^\\RH"P.9=U\]/S.
M''_1R\;<!0>*CX=YWG&$5VL5PM+ <88::6O-"MPKC,XIS5M;QD]-3];Z*^5_
M W[<?['?Q(\E/!_[3/P5U*[N-OD:7=_$#P]H6MS;NGEZ#X@O=+UE\' ?;8G8
MS*K[2R@_3EAJ.GZK:0W^EWUGJ5C<+OM[VPNH+RTG3^_#<V[R0RK_ +2.P]Z9
M^59MP_GV05?89[DF;Y+7NX^QS;+<;EU7F6Z]GC*-&=UU7+=%RO-/&&H^.=/U
M[PK9Z!K'A2TT_P 4:W-H2QZOX3U?5KRPEMO"WB7Q)+>M=V7C;0X+N.8^'Q9Q
MV@L;5H1=FX:[G,'DS>EUY3\0O$&@Z/XM^"5AJ^MZ1I=]K_Q)U33]"L]1U*SL
M;O6K]/A5\29WL=)M[F:*;4;Q85:9K:S2:98E:0H$!("<GA.>,G&G0AB)K 9I
M65.>&IXM7PN6XK%QJ*E5IU8_N94%5E+ETA":F_9N:?J40E6*(3O').(T$TD4
M30Q22A0)'BA>6X>*-GRR1//,T:D(TLA!=I***#RV[MO35WT22U[)627DDDN@
M4444""BLS4]:T;1(?M&LZMIFD6^"?/U._M;"' ZGS;J6),#N=W%>1ZY^TU^S
M=X8W_P#"2_M!?!#P]Y>?,_MSXK^ ])V8Z[_M^OV^W&#G=C&.:#T<%E&;9DU'
M+LKS''MNR6"P6)Q3;[)4*51M^6Y[?17Q;KG_  49_86\/;_M_P"U1\&;CR\[
MO[#\7V7B?./[G_"-?VMYGMY>_/;->-Z[_P %B?\ @G9H6]#^T NKW"9_T?0O
MAO\ %;4M^/[EXG@B/33D\#-\,YR.,D*Z[K[_ .NZ^\^RP'A'XK9IRO+?#/Q
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M"5)M15ZM.BWRKV&BBBOC#Z\**** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_"+^(],\8^&?^$BT/3-;_X1WQ=HGG_V-XIT+^T[6Z_LCQ'I'VJY_LS7-/\
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M2R-.MIK=QHFCZ1IWBV;0F:$+)=>,K_X26L(:1O[2/E;)'6W_  2H_P""G?\
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MI2J0;Y;*=.K"<&[J6EG_ #H_LR?$S]GWX)>+_P!AOXG_ !FT;2_V8_V?9?\
M@G)XV^''P5U#X_\ B=)?"VC^+[7XOZ)=>*K'3_B5XV\*_#S29?$OQC^&>F:'
MX[\/QMX5\"ZKX^\".J:+X,TS3;-_#]I^F'_!+GPQKO@_]A#X"Z+KVB:MX:S:
M?$'6O#'AW7+&\TK5-"^''BCXK^._$_PIT>ZTG4++3;W1_P"S?AEK'A*SAT:Y
MT^RETFWABTYK2W^R^4OW]179C\U6-HSI+#SI.I7IUIREB)5TE1ECW2A!2IQF
MI6Q\_;5)U*DJLX*I:#G)/FP>7/"U(5'6C45.C.E%*@J3O5C@U4E)QFX<M\'#
MV4(4X1IPER7DHQ84445XYZ84444 %%%% !1110!YYI?_ "57QO\ ]B%\,_\
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M85*>/A@<11G[3].Z***9^%A1110 4444 %%%% !1110 4444 %%%% !1110
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MU-?>&_AIIFJ:;IMM?6'P_P##U]<7%YH?@VUGB\.:3=3S7%AIMO-*[MA_%GX
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MXOL8;<V=NVO>(_"FEZGJ&H6EB8H3IUCK$]PVKV.FE6_LZTOH;+SKCR/M$O\
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M?J1U;X7P6GB*S_L(U7]M[]HW]FZ+PWX@_:OTGX,^._#'Q)_8U^/'[4?AJU^
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MO$/B;1]1\/:=XE\&ZGKNC2:U NF/>)>W%K#-],_&OX<_\+A^#7Q;^$G]L_\
M"._\+2^&7CWX<_\ "0?V?_:_]A?\)OX5U7PS_;/]E?;M,_M/^S/[3^V_V?\
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MM$DC1)12BKV225VY.R5M92;E)]W)MMZMMA1112&%%%% !1110 4444 %%%%
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M_D6]2_[*%\7/_5K>-*]"JZG\2I_CE_Z4S*A_ H_]>J?_ *1$****@U"BBB@
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MM,W_ &BPFU?1[@N(+>/*7%OH=V)+N^GQJ'B=YYW:Q/Z2@         8  X
M'  '  Z4M%>+G_$&-X@Q5.MB(TL-A,+26&RS+,)%T\!E>#B_<PV$HWM%:*5:
MK*];$5+U*LY.UO8R'(,'D&%J4J$JN)Q>*J/$YEF>*E[3'9EC)+W\3BJKU;W5
M*E&U*A3M3I1BKME%%%>$>X%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7@O[5/\ R;%^T7_V0OXL_P#J!:_7O5>"_M4_\FQ?M%_]
MD+^+/_J!:_7M<-_\E%D'_8ZRK_U.H'GYM_R*LS_[%^-_]1JI[U1117BGH!11
M10 4444 %%%% !1110!Y[\,?^1;U+_LH7Q<_]6MXTKT*O/?AC_R+>I?]E"^+
MG_JUO&E>A5=3^)4_QR_]*9E0_@4?^O5/_P!(B%%%%0:A1110 445^,/_  5M
M^(>K:UX/UO\ 9TUGP?\ &^V^!^K_  &^*/Q=^,'Q ^'OP$^._P 3- \6:IX3
ML+YO@_\  P^./A'\/_&VA>"M.UGQWH__  G7QKO?'%_X6TJ+X9>%]-\)W][=
M>'OB=KTVE=N7X.>/Q=+#1DX*;;G-0=24*<5><HTTXNI.RM3IJ4>>;C%S@FYQ
MY<9BHX/#5,1)*7(DHQ<E!2G)V@I3::IPNTYS:ER04I*,FE%_L]17X#?"#1/@
ME^U1\3/V&OA_\??!VG>/O@QH_P#P3#C\<?#[X7?'KP)K>@^&;OXI>'?%/@CX
M:_$3QU_PK#XJ:)HC:OKGAKPA;6\?A/Q?J/AZYCL_!OB:7QMX!U.3P[XMM_$-
M_P#?/_!+75]?UO\ 8-^ 5]K^M:QXC1;'Q]IOA/7M>U&XU?4]8^%^B_%;QUHW
MP?U*75KN\U&ZU2WO/A38>#9]/U&XO[R:^TY[6ZDNIWE,C=6-RKZGAY595I2J
M4ZU*E4I2H>S2]O+'*#A-U92E*/U&:K0E3A[.I-04I\LF<^$S'ZU6C35*,83I
M5*D)JKSM^RCA'-2A[.*BI?6XNG)3GSPCS-0YE%?H!1117D'I!1110 4444 %
M%%% 'A'AW_DYKXO_ /9#/V=?_4]_:@KW>O"/#O\ R<U\7_\ LAG[.O\ ZGO[
M4%>[U[6?_P"_4/\ L2\-_P#K.Y4>?EG^[5?^QAFW_JUQH4445XIZ 4444 %%
M%% !1110 4444 %%%% %/4+&'4K.XL+A[R."ZC,4CZ?J%_I-XJD@DV^HZ7<V
M>H6DF0,36EU#*!D!P"0?!?V;[!!X-U[59;W6[R\/Q9_:!T ?VCXAU[5+5-,\
M,?'[XE^']'2+3]1U*ZT^&[BTK2[*&]U2&U35-7N$FU'6+R_U&[O+N?Z&KP?]
MG'_DGFN_]ER_:@_]:7^+=>M1ITWD68UG3@ZL,VR6G"JX1=2%.K@\^E5IPFUS
M1A4E1HRJ0349RI4W)-PBUSRQN,I8VA@:>+Q-/!8C!9A6Q&$A7JPPM>K1Q&51
MI5:V'C-4JM2E&I4C3G.$I0C.:BTI2O[Q7Y>_MO\ _!(+]BG]NV+4==^(?P\3
MP%\7KF.1[3XW_"M;+PIX^-\%E-O<>)A':3Z%XZB6=XS-_P )9I6I:HMM$+;2
MM8T@L)T_4*BN/"8W%X"O'$X+$UL+7AM4HU)0E;=QERNTH.WO0DG"2TDFM Q.
M%PV,I2H8JA2Q%*6\*L%-7Z25U>,ETE%J2>J:9_+$(/\ @M3_ ,$A\FW9_P#@
MJ!^Q?H&3Y#_VS+\<? 7A>T)8[,?\)%\0="6QTNRV@H?C+\._#NDPD_9_#)E_
M=?JK^Q!_P6"_8I_;J33O#O@/X@#X=_&.Y5(;OX'_ !8-EX4\=MJ($4=Q:^%I
M9+N;0/':"Y:9;>/PKJM_K8M8#=ZMH.C%C GZD5^5'[</_!&_]BO]N1]0\6>*
MO!$GPI^-MP[7MI\<_A MEX5\9SZLKM/#?>+[".V?P[X\9KH0-=7WB+3)O$ZV
ML"VFD>)]%R)D][^T\HS;W<ZP?U+%RT_M?*J4(<\G]O'9:G"A6NVY5*N%>'JM
M_9FSQ_J&99=KE>)^M8:/_,MS&I*7+%?9PF/]ZM2M%<L*>(5>FOYH(_5>BOY6
MAXE_X+4_\$A"L7B[3G_X*<_L8Z 40>(M-.LS_&GP+X:M3;Q+)>ML\0?$#0EL
M[&&61UU2'XO> M$TRV"MXC\-K)^[_7#]B#_@KA^Q5^WC:Z?I7PN^)$/A+XJW
M-NCWGP3^)IL_"GQ$CN!'$UQ'H-O)>7&C>-[:)Y&Q<^#M6UF6*!1+J5IIKL8$
MY<;P]C,/1EC<).CFN6K7Z_E\G6ITUNEBZ+2Q&#FE;FCB*4(INT9RW.G"YSAJ
M]587$1JY?CG_ ,P>-2ISGTOAZJ;HXJ#=[.A4E)I-N,3]-:***\$]<*_&W]KO
M_@F1JE[XY3]J7]A#Q+%^S_\ M-Z'-?:M?:7HDT>B^"OB;/<>;/J$%W:E)-(T
M/7=;9C#J0O+&?P;XJ+M#XJTN":\O?$"_LE12:3W/M.!N/^)_#O.'G'#6.C1E
MB*$\%FN68RC#'9'G^65DX8G*,_RG$*6$S3+<33E.%3#XB#<'+VV'J4,3"G6A
M^2G[%7_!3?2_BYXJ'[-O[4/AJ7X"?M:>'KG^P-1\,^(+:71/#?CW5[8*H;PM
M)J$C'3-=U!&2Z@\+W5S<1ZM#-#>^$M4URTN3;V/ZUU\.?MI?L"_!7]M;PM!:
M^,K63PC\2M!BSX(^+_AJTMU\6^&YHW\^&ROLM;CQ)X;-Q^\FT'4+F+R&DGN=
M$O\ 1-2F;4!^;WP?_;9_:(_X)]^.]!_9B_X*+:?J7B/X:W5TVD?"K]K#3TU'
M7+*_TF#RH[-/%%^89+WQ#8V4+1+J%Q=Q)X_\-[P^N6'B'3+FSU:W+M;_ '_Y
M]O7;T/UK&\"<*>+N#Q7$/@[A?[&XPP]"KC>(_!JOB95\3.-*,ZN+S;PUQM=J
MKGN6**=:KPO5<\^RM1JPPBS#"?5C^@2N,\>>(M:\)^&]4\1Z3HNEZW#H>FZG
MK&JVVHZ]=Z%*+#2[&:]E&GO;>'M?2[NY%A>.."Y&GPABI:[ )"[F@>(-!\5Z
M)I?B7POK6E>(O#NN65OJ6C:[H=_:ZKI&K:?=();:^T[4;&6>TO+2>-@\5Q;S
M212*<JQ%<O\ %?\ Y)=\1_\ L1/%O_I@OZ9^!Y?02S;"87&8;F7U^CA<3A<1
M[>C)<U>-&K2JJG.A7IS@W)-*<)PG&TMG%]7I$NM362R:]8:7INH&20-:Z1J]
MWK=D(@1Y3K?WNB>'YVD<9,D1TY5C. LLH.1J444'!.2G.4HTX4HRDVJ<'-P@
MF](Q=2=2HXK9<\YR[R;U"BBB@@**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** //?AC_P BWJ7_ &4+XN?^K6\:5Z%7GOPQ_P"1;U+_
M +*%\7/_ %:WC2O0JNI_$J?XY?\ I3,J'\"C_P!>J?\ Z1$****@U"BBB@ H
MHHH Q/$VHZKH_AOQ!J^A>'KOQ=KFEZ)JVHZ-X4L+_2M*O_$^JV-A<7.G>'K+
M4]=N]/T33;O6KN*'3;:_UB_LM*LYKE+C4+NVM(YID_'#P/\ !C]H_P#:,\!?
MMI6G[1G[//Q4^$/[1/[7O[-OQ&^#-OX_\:>*OV;_ !#\!?@CX*O_  CXI\+_
M  ^^!OPUE^%?[07Q6^*M_I=CK'CO6/''CGQ_J/PQ\//\3?$ZZIKVKZ/X4L],
M\ > ]%_:JBN["8Z>#A5C2HT'4J2I2]O-576IJC4C5C"'+5C2Y)584YSC.G/G
M=.*;Y;Q?)B,)#$RINI4JJ%.-1>QBZ:IS=6#IRE/FIRGSJG*<(2C./*IR:]YJ
M2_$?Q[^S/^TG^VEHGA?PY\0_@MJG[+J?"O\ 8._:<_9Y&H_$/QM\)O&D/Q!^
M-?[4GPH\*_">2X\#O\'?&?Q-U&R^$?PXLO"&LZWJ_B7QQ!X*\8^)9O$W@V#3
M/APS:;XB_LH\>_LS_M)_MI:)X7\.?$/X+:I^RZGPK_8._:<_9Y&H_$/QM\)O
M&D/Q!^-?[4GPH\*_">2X\#O\'?&?Q-U&R^$?PXLO"&LZWJ_B7QQ!X*\8^)9O
M$W@V#3/APS:;XB_LK]N**[8Y[BH>S]E0PM+ZNJJPO+&O+ZJL1[7ZS[/VF(J>
MT]O[:KS_ %GV_)S?N/9<L;<KRG#RY_:5<14]LZ;Q'-*DOK'L?9^P]IR48<GL
M?94^7V'LG+E_>^TYI7_+GX/?#W]H'XM_'O\ 91^)WQ<^ OB']G31?V1O@!\0
MO!^J1>,/&OP?\;7?Q4^+/Q@T;X;>%=1MOAN?A/X\^(,]G\,? ND_#G7M2O?$
M?Q D\ >*?$U[XK\%067@")=-\22Z1^HU%%>=BL5+%2IMTZ5&%*FZ5*E1]IR4
MX2K5:\DG5J5:LG*M7JU&YU)-.?+'EA&,8]N'P\</&:4ZE252:J5*E3DYYRC3
MIT8MJG"G!<M*E3@E&$;\O-*\W*3****Y3H"BBB@#E=.\"^"-'.@'2/!WA72S
MX435XO"YT[P]I%B?#<?B!Q+KT>@&VLXO['36Y )-733OLRZDX#W@F8 U<\2>
M%?#'C'3&T7Q=X<T'Q5H[S17+:3XDT?3]<TQKBW+&"X:PU.WNK5IH2S&*4Q&2
M,LQ1ER:WJ*W>*Q+JPKO$5W7IR<Z=9UJGM83E4G6E*%3FYXR=:I4JN46FZDYS
M;YI2;P6%PRI3H+#T%1J14:E%4J?LIQC3A1C&=/EY)15*G3I)232IPA!+EC%*
MAI>E:9H>G66CZ+IMAH^DZ;;16>G:7I=G;Z?IUA9P((X+6RL;2.&VM;:% $B@
M@BCBC0!40  5\V>*/V>OA+K_ .T1X-^).J>$[.Y\2IX7\4ZS<Y &F:EKGAW5
M/!%EH6N:IINW[/?:KI5OK=ZMM=R@EG2PFN%GFTS3Y+;ZBKA]0_Y*3X3_ .Q'
M^(7_ *?OAC7H93F./P>*Q57"8W%8:KB<OS.CB*E"O5IU*]*K@J\ZE.M.$E*I
M&<XQG)2;O.,9_$DUP9K@,#B\+AJ6*P>&Q%+#8_+*V'IUJ%.I"A5I8W#QIU*4
M9Q<:<H1E*$7%)J$I0^&33[BLG4- T+5P1JNBZ3J8;AAJ&FV=Z&'3!%S#*#QZ
MUK45Y4)SIR4J<Y0DMI0DXR7HXM-?>>I.$*D7&<(SB]XSBI1?JFFCRW4O@=\%
MM8W'5/A%\,M09LYDN_ GA>:;)ZE9GTLRJW^TKAO>N"U']D/]FG5-WVGX.>$(
MMQ)/]G6]WH^,_P!W^R;RQV#G@+M [8P*^CZ*]6AG^>X6WU;.\WP]MO89EC*5
MO3V=:-CS*^0Y'B;_ %G)LJQ%]_;Y=@ZM_7VE&5SXSU']@+]EF_W&'X?WVE.V
M27T[QEXQX)[K'?ZY?0+_ +JQ!!V7K7":A_P33_9YO"6M-1^).CMDE/[/\2Z3
M*$/5<?VIX:U%B%..K[L?Q \U^@]%>O0X_P"-L/;V?%6>R2Z5LQQ.)7I;$5*J
M:\GH>16X$X,Q%_:<+Y)%O=T<OP^&?K?#PI-/S6I^</\ P[LTO3/^12^/GQ>\
M.[?]7_I]M/L ^Z/^)8^A9V\<KL]@,\+_ ,,:?M!:1SX:_;3^)01>8K/5H/$T
MMNF.@);Q_>P'. &VV"\#D$<#]':*Z_\ B)'&$M*^98;&1^U''9-DF-YO*4L3
MEU6;VWYD_,Y?^(=\(QUHY=B,(^CP6<9U@^7_  QPV84H+TY6O(_.+_A17[>V
MC?\ (O\ [4?AK4MI^3_A(M++[L=/,^V^#_$O7N#Y@]<T'1O^"EFB?\S9\(/&
M&S_IVTFU\W'?GPSX6QG_ +9^P%?H[11_KYC)_P"]</<%XQ]9UN%LLI3?K4P=
M/"S^Z2\@_P!1L'#3"Y_QC@X](4>)\RJ0CZ0Q=3%0\M8O0_.+_A8O_!2'1<_;
MO@=\+/$=NGWI[#5-.CN&QW1(?B;;R?,,G TQCG'W?NL?\-/?MA:-_P C!^Q]
MJFI;/O\ _".WVKR;B.OE_8K+Q+G.#@+YG;EN_P"CM%'^M^55M,9P'PG475X1
M9WETG\Z&<.*?^&*79!_JEFE+7"<<\54VMEBWDN/BGZ5\H4I+RE)OS/SA_P"&
M[_'^E\>+?V1OB[X?V<2,$UF8*1]XC^TO!.BC'4C+ 8[XYKXM^.7[??Q*\9^.
M?#.J?#N*\^'FA^!-1?4=/TF_2TOM1U36WL;S2K^;Q-')"]M);+8W^H:5!HT8
M,4$5Q<W<T\M_):MIG[X5\._M!?L@_"OXL?$WX<>,=4AO-&O];\4/I'C2+1#'
M:Q^,--L/"OB+Q!;B^==KVFI[_#UOIDVL6F+V;2KB6!V^T6VFW5E]9P;Q/X=X
M?-Y5LTX*I8&"P..Y*]/'X_.L.FL-4E5ISR[,9U8OV]"-6C"K[2I[.<XQE&,)
MRK4OE>+^&O$"OE,:66<9U,;/Z]@.:C4P&!R?$2OBJ4*-2&89="G)>QQ$J5:=
M/V=-3A"34I3A&C4\N_8/^%_AKQQI5U^TQXVOM:\<_%;7M?UJT;5_%6GS16_A
M^YLI%@EG\.FX#6NI236LD,$>MV&+/281-X:TN#39--U.&3],ZS-&T72?#NDZ
M=H.@Z=9Z1HVD6<&GZ9IFGP1VME8V5M&L4%M;01*L<444:A551ZDDL23IU^=<
M49]5XCSK&9E/VU/#3J2IY=@ZM2$XY?E\)-87 T(TJ=*C2HX>G:,:=&E"-^:3
MYYRG4G^@\,Y%2X=R;"9;#V4\1"G&IF&+I0G&689A.*^M8ZO*K4JUJM;$5$Y2
MG5JSE91C'DIQA3@4445\^>^%%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ5=SQ.*Q$94L//#J*Q6)JXEPE&>(Q/,X3JRBIJ4$XI7@G=LHHHKRCM"BBB@
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MEH>AZD^EZP?UC\/?M;? ']H[]EOXE?&'X:?$'1I_!^G^ /%0\5'7KRTT#5/
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MMQ^CZ***\H]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO@K]I;0/A98_L ZIH7CGQ)\(O^"2/[97PR\>Q?!&XMIKOX;1?$GX+?"_P_\
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MG@/PCHGAW_A4-_96-O9:A\0]*T;PQIMA%K'@CQ)=12ZYXUU*>"XUKPMXAO\
M4-7OKBY\'WA?P?\ W#U\J?MGZMX/L?V=_BOIWB3Q19Z!K'B#X9?$?1_!>FW'
MB^?PS<^*/$EYX.U2WL]%LM/@U;31XGDEFG@672;B'4;00R-)=VPMC*]?6\$8
MW&X7B/+:.#E4MF&*H8'$TH47B.?#UZL%4E[%3IMNBKUE44XNE&$I-NG[2$OG
M>*L+A,1DF.J8KV<5@\/5Q=*M4JJ@J52C"4HWJN,THS^"4)1<9N27NSY)Q_DR
M_P"";7_!-[_@N;^SU\$+;XQ_LO?&/X8_ ;3OBZ+7Q3J?[.OQGN;J[U?5M-CM
MXXM#\1:SX/\ $'PN\:^&/!WB?6]/2V9EAUCPOXPCT*+3+#Q)>V4UO_8=E^BG
M_#8G_!Q'\"/D^+__  3T^#?[07A^SY.O?!W6H/\ A)-51.)66S\(?$_Q9=1%
M@H,*GX86$FYSB*;B./\ HM^'VO>"/$?AR+4_A]XKL_&7AU[JYB36++Q==>-4
M%[&4^UV4VL7NJ:O=1W5HS*EQIUQ=K+8.?)DMX'RE=O6V9<35<1C\6\SR'**]
M1UIQG#%Y?6P>.IJ+Y8TJM6AB:>(52G&*A^^G5E&UF]$EC@,AIT<'AOJ.;YC1
MA[&$H2PV-IXK!S<DI.I3A6H3HRIU&W->RA3C+FO8_F?C_P"#C*3X6R1VW[8?
M_!-_]KS]G.:)T@OIX]);7((I-PC::./XD>'O@HQB=OG1%FF8(0L4MR=K/]7_
M  P_X.$_^"6?Q(-O!??'/7_A?J5R%\O3?B?\,O'>D[&; *W&N>'-&\5>$[4H
M2-S7/B&*,\E'< D?M=)''-')#-&DL4J/'+%(BO')&ZE7CD1@5='4E71@5920
M002*^3_B?^P9^Q1\9_M#_%#]E#]GSQC?7)8RZUJ?PG\%IXD!?.\P^*+/1[7Q
M%;%R<N;?4XB[!6;+(I'#]=X7Q&E?)<?@7_/EV:>VC\J.88>L[>7UAM[)K<ZU
MA<_HZTLUP>+_ +N-R[V;:\ZN#KTE?S]AH];-:&K\,?VV/V/?C0+=/A3^U'\
M?'UW<[1'I7AKXL^!]1UU'?&R*Y\/QZW_ &W9SL""L%WI\$Q!!"8(S].@@@$$
M$$ @@Y!!Y!!'!!'0U^'7Q._X-V/^"6WQ$-Q-H_P@\:?":^NMS2WWPQ^*OC2
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M_JUO&E>A5=3^)4_QR_\ 2F94/X%'_KU3_P#2(A1114&H4444 %%%% !1110
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M.WA3XH_&WQ]\)O&_[$OB/XI^)-+^-WQB^)GQVUG3OBG\,?C/\/O VE>-=/\
M%GQ5U[Q7K7A>X^(?AKXCZ];^(/"OAG5M%\#WMWX)L=2T?P=I%W::A<WOZ?U\
M[_!3]E7X(_L^ZEJVN?#;0/%3>(]9\-^'O!=UXK^(OQ7^+?QK\86_@CPE<:G>
M>&O NC>+OC3XY^('B7P]X%T.^UK5]2T[P5H&JZ9X7MM4U._U--)%_=37+_1%
M;X_$4\36A.FZD^6C3IU*U:$:=7$5(\S=6I"%2JE*SC37[VHW"G&3DFW&..#H
MSH4I0FH0YJLYPI4IRJ4J,&HI4Z<Y0IMQNG4?[N"4IR25DFZ-]=W%HD;6^EWV
MJ,[%6CL9-,C>( 9#R'4]1TZ,J3\H$3R/GJ@7FLS^VM2_Z%'Q#_X$^%/_ )IZ
MZ&BN6,XQ23HTYO\ FDZJ;UZ\E6,=-M$M-]=3HE"3=U4G%=HJG;_R:G)_CU]+
M<]_;6I?]"CXA_P# GPI_\T]']M:E_P!"CXA_\"?"G_S3UT-%5[2'_0/1_P#
MJ_\ \O\ ZN_*T^SE_P _JOW4?_E7]7?E;GO[:U+_ *%'Q#_X$^%/_FGH_MK4
MO^A1\0_^!/A3_P":>NAHH]I#_H'H_P#@5?\ ^7_U=^5CV<O^?U7[J/\ \J_J
M[\K<]_;6I?\ 0H^(?_ GPI_\T]']M:E_T*/B'_P)\*?_ #3UT-%'M(?] ]'_
M ,"K_P#R_P#J[\K'LY?\_JOW4?\ Y5_5WY6Y[^VM2_Z%'Q#_ .!/A3_YIZ/[
M:U+_ *%'Q#_X$^%/_FGKH:*/:0_Z!Z/_ (%7_P#E_P#5WY6/9R_Y_5?NH_\
MRK^KORMSW]M:E_T*/B'_ ,"?"G_S3T?VUJ7_ $*/B'_P)\*?_-/70T4>TA_T
M#T?_  *O_P#+_P"KORL>SE_S^J_=1_\ E7]7?E;GO[:U+_H4?$/_ ($^%/\
MYIZ/[:U+_H4?$/\ X$^%/_FGKH:*/:0_Z!Z/_@5?_P"7_P!7?E8]G+_G]5^Z
MC_\ *OZN_*W/?VUJ7_0H^(?_  )\*?\ S3T?VUJ7_0H^(?\ P)\*?_-/70T4
M>TA_T#T?_ J__P O_J[\K'LY?\_JOW4?_E7]7?E;GO[:U+_H4?$/_@3X4_\
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M_P#-/70T4>TA_P! ]'_P*O\ _+_ZN_*Q[.7_ #^J_=1_^5?U=^5N>_MK4O\
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M[1^&$M_NSN^VV7@2ZW9ZY\_7Y,Y[YZUWM%5#$.D^:G3A3E_-"IB8/[XUT_\
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M_P":>NAHH]I#_H'H_P#@5?\ ^7_U=^5CV<O^?U7[J/\ \J_J[\K<]_;6I?\
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MW/?VUJ7_ $*/B'_P)\*?_-/1_;6I?]"CXA_\"?"G_P T]=#11[2'_0/1_P#
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MR-J36 LU2\M7,P6XA+_G+\)OV5_CSX9_:V\&_$[6_ GV+P/I7[8O[?GQ4O\
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M.^#[GXD^&_A-KGPRT[Q;J4VBWOC&&;0_$CZ-XM^T;_PO:_\ VT/V5?'/@O\
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MI8>"=E'GO3G4G-7Y:4</*6F)C)_J31117SI[04444 %%%% !1110!Y[\,?\
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MF\0_"#4[C4;6]\1^&?B@;>Z;0AXGNO%?_"J(?AGH5I<2:%J7CX>(8[*PU/\
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MO@=X%^!G_!1W1[GQ9X6GO?!VA_ [Q^/B)X=U;18]+U[6=&\;ZI\9/AU?^/\
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M481=.4;UH2J0Q$E.7Q0E4B_9+:5"-*LM*USL:***\<],**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M//?AC_R+>I?]E"^+G_JUO&E>A5Y[\,?^1;U+_LH7Q<_]6MXTKT*KJ?Q*G^.7
M_I3,J'\"C_UZI_\ I$0HHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** //?AC_ ,BWJ7_90OBY_P"K6\:5Z%7GOPQ_
MY%O4O^RA?%S_ -6MXTKT*KJ?Q*G^.7_I3,J'\"C_ ->J?_I$0HHHJ#4****
M"BBB@ HHHH **** "BBB@ HHHH *^7?$W[:'[-'@[Q%K?A3Q#\3(K+7O#NIW
MFC:S91>$_'6I)9:II\[VU]9F]TOPQ>V$\MK<QR6\YMKJ9$FCDB+;T91]15YC
MJWP2^#&O:E>ZSKOPC^&&M:QJ4[W6HZKJW@'PIJ.I7]U)S)<WM]>:3-=74[D
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M_"&_\*F^$?Q/^%?_  L#[%_PFDO_  D7]O\ _"Q_[=_X13[7H7]E?V-_9?\
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MK2/A_;_!/XD?%/P:GBE=2\,>&_L?Q(O_ (M6=MJ.H^!O&>B^%_%WBKX4>&_
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MOX2T'QIIFEZQKWPYU[QEX=ALM7O_ *I^#?Q,_P"%Q?#/PI\2O^%?_$WX6?\
M"5V=W>?\(!\9/"G_  @_Q,\-_9=3OM-^R^*_"OV_5/['O+G[%_:%K!]ON?.T
MR[LKK<OVCRT^4?A%^PW_ ,*KTK]@#3/^%H?V]_PPQ\+O%?PV\_\ X0K^R_\
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M6\*Z;J-Q<:?_ ,)+<:W%H=TD4VOV>IVZO _TY/\ M[:;X>^+?Q3^$!\'^/\
MXS_$73/VB;CX&?#+X5?"GX>^"?!OBG49M%_9W\)_M"^++VZ\<?%3]HS3OAQX
MAT;P]X3\0_;;WQCXCU/X(32ZE<VO@O0_ 7B'5(K/6_$&CX8_8._X1S]E']CW
M]F+_ (6K]L_X9/\ B#^S=X[_ .$W_P"$&^S_ /"??\,]^,-*\5_V5_PC7_"8
M3_\ "+?\)=_9GV#[=_;_ (C_ + \_P"U?8]:\K[-)\#?MM?L?>)_"?QTT#XL
M:/XA^*LVD_%;]IOXB_'?4_B)\+_@Y^U=\2;GX$:G_P ,I?#OX :-X-O/!7[#
M?Q2^'7[3OB&]^(%GX5UZ\T_XG^'/B3\//A[X5TV;Q%X(^(7A7Q;/XJ\*3U[-
M&&0XO%5Z-)2I0D\RGAXN%2JZCA5IU<'&*C1H5%2E1IU>7#TYPQ,HWH1JNM5A
M&7F5)YQAL/1JU'&I./U"-9\U.FH*=.5+%.3E5JTW4C5G%NM*,J"E:JZ?LX39
M] ^.O^"A?BSQCX0_X)]?&[X+_#?XW:+X)_:*_:4\9_#[7O@YJ?A?X.:A\6_B
M5X8T7X*_':_TKP];0IX\\3>$O!#7?Q*\$Z%>RZUJWQ)\!'PW::+>W7Q!UOPK
MX2BU^4?HG\ ?COX<_:$\%ZKXMT+PWXR\$:CX7\>>.OA?XX\!?$*QT2R\9>"/
M'WPZ\17GAOQ-X=UIO"OB#Q=X0U/R[BUBU'2]<\'^+?$_AG6]$U'3=4TG6[R"
MZ^3X;_9R_9X\4_$_X._L,:_XG\)Z1^SO#^R%\:?B'XM\%_#S1?ACXL\'6_Q$
M^&>G^#OC/\$?AMK=[\/_ (@>.=:^(?P0UOQ[X+\=Z-\5-?\ #'Q#\0_$;Q]H
M>M27VA>,[JX\2:EJ6HZ;]G_L_? C_A17_"[?^*J_X2G_ (7'^T'\2?CO_P @
M/^Q/^$<_X6%_8O\ Q2O_ "&-7_M?^R/[(_Y#G_$K_M#[1_R![+ROWOGYE_9D
M:<Z%"$:=?#U:T8<GM)2E'Z_BU&E5J6=.JXX65"?M7)RT5-22BZ:[,!]?<XU:
MTI5*->%*4N;DBHR^IX6\Z=/2=-2Q"KQ=/E4=7-Q]Y3E^<'P<_;9_:[M?V;OV
M4?VS/CFW[.WC3X&_M"7GP4T+XA^$?A1\*/BC\,/'_P $;C]H'QIX3^'_ (*\
M96?B?Q-\<OC9HOQ3\-^'O%WBG3-*\6^'_P#A$/ASK,^FZI'KNA:K=WVE_P#"
M*ZW]6_$?_@H/\,_AQK_Q.6;X6_''Q;\*O@7XN\-^!/CQ^T-X0T#P#<?"#X0^
M*M?N-"34-+UV'7OB3X>^*_B]? UCXI\-ZQ\1-2^$OPM^(VD^#=-U8_VM?QW^
MC^(['1O&/@__ ,$ZOBEX:^%'[-G[.?QK_:1\$?$_]G;]F._^&WB#PWX%^'_[
M/&J_"?Q3\2/$OP;UG2?$/PR/Q?\ &OB?X^_&G3M>\):'XATFT\2:KX4\'>"_
M +^)=<T[1DU/6_\ A&K75?#6N]9\2OV O&7CF3]H?X<Z5\?]-\/_ ++W[5OC
MNW^(/QJ^%&H?"&3Q%\38=2U6V\-6/Q,T7X6_&E?B?HFC>#O#'Q0L?">G6VM:
M?XM^#_Q+U'01JOBB3PGK&C2:EI)\/]=660U<5-SJ4?9>WKN,\/1Q>'HO!RQ=
M%48*G##PG]=I81XB4)2I1P\G[#V]2K.,XSYZ2S>GAX*,*OM/945*-:KAJU7Z
MS'#3=63G*M*/U2IB%14U&I*LE[7V,*<90E'WOPS^U]X3\8?%+XQ> ?#_ ,.O
MB1=^"_@!XBUKP?\ &'X^W-_\']*^$O@;Q9X>^'^B?$?6-"U+2M7^+5C\;[HV
M>A^(M(MCKNE_!J_\*3ZC<3&UU^;2['4-4M>=^"/[<?@GXU^,? 'A-OA/\;OA
M1;_&CP%XA^)_P"\5_%G1/ &D^'?CCX$\,2:!+JNM>#;7PG\2/&?B[PU=KH?B
MOPUXLM?"WQ;\+?#3QE>^%]7&J6WAV0Z3X@@TCA_&_P"PQJ'Q6_:AL/C_ /$C
MQA\((=%T;P]\3_!4.F_"GX!ZQ\-/C3XZ^'_Q'^'VO_#F+X=?&_X^W7QN\9GX
MF^!?#%AXDN?%>D>';#X:>";:W^(6B^$_%.FMI(T.;3=3YG]CC_@G;I/[)'B7
MPW?:?I7[&>LZ9X+\'WG@OP[X[\#_ +#6@?![]J+5-/$-MIVF:A\0/C]X=^,F
ML:+XKUF[T6W^S^.[W2OA!X23QQJLCZRUOH9DGLI^24,C^JU)1K/ZS]5H.G3C
M3Q7^\>SKJJO:S7)*?MHT)U).E"@Z%1T:,(U8RQ$>B,\U]O"+I)4/K%7GJ.>'
MUH<]%TW[.+YXQ]E*M"$54E556"JU).FXT9?IK1117A'KA1110 4444 %%%%
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MV7_B/\,IO$S_  [^/W_",0^/?VT/%'[4'Q!@_P"%5Z#K7_"5?#CQA8&WU_X
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M:I>>.M9\,^&-6B^ /CJTT8PZ/>:KHFO[+U+CNO#/_!0GP/X\\!_LU^(?A?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRMHZCZM74%[L&[RE,HHHJ#4**** "BBB@ HHHH ***XK4?AK\.=7O;G4M6\
M>"=3U&\D,UW?ZCX5T*]O;J4@*9;FZN;"6>>0A0"\LC,0 ,X IKE^TVO2*E^<
MHDR<DO=49.^JE)Q5O51G=^5EZG:T5Y[_ ,*C^%/_ $3'X>_^$7X;_P#E;1_P
MJ/X4_P#1,?A[_P"$7X;_ /E;56I_S3_\%Q_^6$7K?\^Z7_@V7_RGU_IZ>A45
MY[_PJ/X4_P#1,?A[_P"$7X;_ /E;1_PJ/X4_]$Q^'O\ X1?AO_Y6T6I_S3_\
M%Q_^6!>M_P ^Z7_@V7_RGU_IZ>A45Y[_ ,*C^%/_ $3'X>_^$7X;_P#E;1_P
MJ/X4_P#1,?A[_P"$7X;_ /E;1:G_ #3_ /!<?_E@7K?\^Z7_ (-E_P#*?7^G
MIZ%17GO_  J/X4_]$Q^'O_A%^&__ )6T?\*C^%/_ $3'X>_^$7X;_P#E;1:G
M_-/_ ,%Q_P#E@7K?\^Z7_@V7_P I]?Z>GH5%>>_\*C^%/_1,?A[_ .$7X;_^
M5M'_  J/X4_]$Q^'O_A%^&__ )6T6I_S3_\ !<?_ )8%ZW_/NE_X-E_\I]?Z
M>GH5%>>_\*C^%/\ T3'X>_\ A%^&_P#Y6T?\*C^%/_1,?A[_ .$7X;_^5M%J
M?\T__!<?_E@7K?\ /NE_X-E_\I]?Z>GH5%>>_P#"H_A3_P!$Q^'O_A%^&_\
MY6T?\*C^%/\ T3'X>_\ A%^&_P#Y6T6I_P T_P#P7'_Y8%ZW_/NE_P"#9?\
MRGU_IZ>A45Y[_P *C^%/_1,?A[_X1?AO_P"5M'_"H_A3_P!$Q^'O_A%^&_\
MY6T6I_S3_P#!<?\ Y8%ZW_/NE_X-E_\ *?7^GIZ%17GO_"H_A3_T3'X>_P#A
M%^&__E;1_P *C^%/_1,?A[_X1?AO_P"5M%J?\T__  7'_P"6!>M_S[I?^#9?
M_*?7^GIZ%17GO_"H_A3_ -$Q^'O_ (1?AO\ ^5M'_"H_A3_T3'X>_P#A%^&_
M_E;1:G_-/_P7'_Y8%ZW_ #[I?^#9?_*?7^GIZ%17GO\ PJ/X4_\ 1,?A[_X1
M?AO_ .5M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M%J?\ -/\ \%Q_^6!>M_S[I?\
M@V7_ ,I]?Z>GH5%>>_\ "H_A3_T3'X>_^$7X;_\ E;1_PJ/X4_\ 1,?A[_X1
M?AO_ .5M%J?\T_\ P7'_ .6!>M_S[I?^#9?_ "GU_IZ>A45Y[_PJ/X4_]$Q^
M'O\ X1?AO_Y6T?\ "H_A3_T3'X>_^$7X;_\ E;1:G_-/_P %Q_\ E@7K?\^Z
M7_@V7_RGU_IZ>A45Y[_PJ/X4_P#1,?A[_P"$7X;_ /E;1_PJ/X4_]$Q^'O\
MX1?AO_Y6T6I_S3_\%Q_^6!>M_P ^Z7_@V7_RGU_IZ>A45Y[_ ,*C^%/_ $3'
MX>_^$7X;_P#E;1_PJ/X4_P#1,?A[_P"$7X;_ /E;1:G_ #3_ /!<?_E@7K?\
M^Z7_ (-E_P#*?7^GIZ%17GO_  J/X4_]$Q^'O_A%^&__ )6T?\*C^%/_ $3'
MX>_^$7X;_P#E;1:G_-/_ ,%Q_P#E@7K?\^Z7_@V7_P I]?Z>GH5%>>_\*C^%
M/_1,?A[_ .$7X;_^5M'_  J/X4_]$Q^'O_A%^&__ )6T6I_S3_\ !<?_ )8%
MZW_/NE_X-E_\I]?Z>GH5%>>_\*C^%/\ T3'X>_\ A%^&_P#Y6T?\*C^%/_1,
M?A[_ .$7X;_^5M%J?\T__!<?_E@7K?\ /NE_X-E_\I]?Z>GH5%>>_P#"H_A3
M_P!$Q^'O_A%^&_\ Y6T?\*C^%/\ T3'X>_\ A%^&_P#Y6T6I_P T_P#P7'_Y
M8%ZW_/NE_P"#9?\ RGU_IZ>A45Y[_P *C^%/_1,?A[_X1?AO_P"5M'_"H_A3
M_P!$Q^'O_A%^&_\ Y6T6I_S3_P#!<?\ Y8%ZW_/NE_X-E_\ *?7^GIZ%17GO
M_"H_A3_T3'X>_P#A%^&__E;1_P *C^%/_1,?A[_X1?AO_P"5M%J?\T__  7'
M_P"6!>M_S[I?^#9?_*?7^GIZ%17GO_"H_A3_ -$Q^'O_ (1?AO\ ^5M'_"H_
MA3_T3'X>_P#A%^&__E;1:G_-/_P7'_Y8%ZW_ #[I?^#9?_*?7^GIZ%17GO\
MPJ/X4_\ 1,?A[_X1?AO_ .5M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M%J?\ -/\
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MA3_T3'X>_P#A%^&__E;1:G_-/_P7'_Y8%ZW_ #[I?^#9?_*?7^GIZ%17GO\
MPJ/X4_\ 1,?A[_X1?AO_ .5M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M%J?\ -/\
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MK?\ /NE_X-E_\I]?Z>GH5%>>_P#"H_A3_P!$Q^'O_A%^&_\ Y6T?\*C^%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img147150826_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! (<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4#\M-+#I
MUQ0WS<=/>OGKP;X-U#XG>//B=)J/C?Q;IT>E^(#86EKI.JM;P1PBVA< )@\Y
M=C^-:4X<UY-V2,IU'%I)7N?0F1_=I=P]_P J\L_X9]C_ .BB?$#_ ,*!O_B*
M/^&?XQC_ (N'\0/_  ?M_P#$U?)3_G_ GFJ?R_B>HL^W&!^E&2>V?PKYG^(&
MEZM\*?%5Q;:9XS\4:C!<>#-=OS'JVIFY$<\"P&*1 0,,I=N?>NP\)_!%]6\+
M:+?7'Q%^(!GNK*&>0KKS ;FC5CQL]33=**7,Y:>A*J2;MR_D>TY']VD9AZ&O
M+O\ AGV/_HHGQ _\*!O_ (BAOV?D_P"BB?$#_P '[?\ Q%+EI_S_ (%\T_Y?
MQ/3]P'?]*?N']VODW0UU[5_$&A^#IO&OB=;$^,]<TY[Z/4BM[);V]J9(HVEQ
MD@-STKV#_AGV/_HH?Q _\*!O_B*TE1C3MS2W\B(U)2^&/X_\ ]2)]%IN2.WZ
M5Y?_ ,,_(/\ FHGQ _\ "@;_ .(KC/C-\+;OP#\*_%/B/3/B)X[.HZ782W4
MN-<9XRZC(W+MY'M6?)3;LI_@5S22NX_D?0@8GHM*&/<<?2OG7PGX9U+XH_%+
MXG1ZAXV\6:9:Z-?V-M9VNCZH;:%$>P@E;*A3DEW8Y]Z[C_AG]#Q_PL3X@?\
MA0-_\33=.$=)3U]!1G*2NH_D>I9']VG"11[?A7E?_#/L?_11/B!_X4#?_$5S
MO_"*W_PY^-GP^L;7QCXHUC3]8CU);NTUK4C<Q'RH$=" 0,$$GFE[.,M(RO\
M\ ?/*.LE^)[S[T4BT5@;C/XA]*\A^ O_ ".GQD_[&QO_ $DMZ]>Z,<^E>+_
M_4+6U\;?&19[F*%O^$K)Q)(%/_'I;^M;TKN%1)=OS,)64HM_UH>VTRHEFA9
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img147150826_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img147150826_10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  O ,(# 2(  A$! Q$!_\0
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M;,3.50H(TP"D2DYX+$G(K]&-)_X*5?LWZJX"?$FVMF+!<7=C=1#/KEHL8]Z
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E8X]K!B5'SN60#G'!KZPHH :J@@';@TH4 Y P:6B@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img238985936_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238985936_0.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5HN:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!G,#!A,#,N<&1F)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" Q,"U!=6<M,C R,R P.#HP-3HP,"8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P.2U!=6<M,C R,R R,CHS-3HP,"8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@
M96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S
M<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($--64LF(WA!.R8C
M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,RTP."TQ,%0P.#HP-3HP.2LP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C,M,#@M,3!4,#@Z
M,#4Z,#DK,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R,RTP."TQ,%0P.#HP-3HP."LP-3HS,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG
M.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3 T
M/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O
M-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!
M045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!
M25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$
M0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX
M.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&8O.$%!15%G06%!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!
M2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"
M05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#
M0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1
M:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.
M:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ
M3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K
M9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ
M<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%
M1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%
M>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K
M9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q
M4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y
M3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K
M=B]A04%W1$%104-%44U2040X03E5-'%X5#@Q=B]*8BM9+RM91V(O)B-X03M!
M26IM4G!0-S)0=EE:4'!,1B]++S5)9FQF9F579$EV8G)29E5U8G%Y=#5P-5!R
M3C)V2U-32E=9,%=9059*-T1,.'5U>6E205!8=417)B-X03M-14LU2FXO>6]4
M.'!V*W)&+W="4%8U+S%7>4@U+TXO3RMW9G%4-$5/-3,O2VA0>6TO=T-R1B\P
M.5AN+U9B2#@O;2]N9EE0,4PT14\U)B-X03LS+TMH4'EM+S9S6"]!13E8;B]6
M8D@X+VTO;F994#%,-$5/-3,O2VA0>6TO-G-8+U0Q968Y5G-F>BMB*V0Y9R]5
M=F=1-VYF.$%+:%!Y)B-X03MM+S9S6"]4,65F.$%68D@X+VTO;F994#%,-$5/
M-6A0-7-F;&8U1CAS84QP96\V2'!N,4\Y8E9B5T9P9EAU2F8S8F-Y4GAL:V1E
M<6IT)B-X03MM5G!.5FMN26E2<V-*-VU%.%59,%%/<69F;D)O=6TV,S4X+TPW
M4SE4:"MS5T8Q3'%+5'<X;E1K;VIH86Y*0W)$8V1J;$]J;5DT-6MC)B-X03LY
M=C!S<W-16E)".# T+S552BM5,R]6:2\V97)Z+W%T;&8U+TXO3RMW9G%4-$5/
M-3,O2VA0>6TO-G-8+U0Q968Y5G-F>BMB*V0Y9R]5)B-X03MV9U$W;F8X04MH
M4'EM+S9S6"]4,65F.$%68D@X+VTO;F994#%,-$5/-3,O2VA0>6TO=T-R1B\P
M.5AN+U9B2#@O;2]N9EE0,4PT14\U)B-X03LS+TMH4'EM+S9S6"]!13E8;B]6
M8D@X+VTO;F994#%,-$5/-3,O2VA0>6TO-G-8+U0Q968Y5G-F>BMB*V0Y9R]5
M=F=1-VMN.'(K569,)B-X03LS;&(X-W!.4#!',"MP,F-V;&\S16M8<5-Y,6MA
M+U9#,TM6;F(W2TQT5VU76F,P<VU#-4=Z>"]O67AG235+2&-H=$DO3'9Y9#5R
M."LK)B-X03MD-71F,"\V-TQA,S!#44XV,#A81E=T=U-+4E!'1'5/*U-N<4HT
M.&-/13%S;G<T>6MB6D0O04UQ12]+8B]!2W-8+U0Q968Y5G-P+U U)B-X03MV
M-3,R1#E39D%H,T\O=T-60V9L3B]W0E=,+W V=E X07%T:BMF>F9Z=G-(-FPX
M0TAC-R]L46XU5&8Y5TPO<#9V4"MQ,E U+TXO3RMW)B-X03MF<5AW261Z=BM6
M0V9L3B\Q678X07 V=E K<3)0-2].+T\K=V9Q6'=)9'IV*U9#9FQ.+S%9=BMN
M<3@O-G)9+VXX,S@W-T(K<&9!:#-/)B-X03LO=T-60V9L3B]W0E=,+W V=E X
M07%T:BMF>F9Z=G-(-FPX0TAC>$@X=6M64'E!.#!O;V]Q>&%U1DAS3&-J36I5
M9C1X2"].67@O=7HX)B-X03M59"M8+W=#5% U839T-4HP6%5T43!F,7(R-W1)
M-6)I6#9Z9$IY9&A5;FEK<7%0;T=2,4=T>7AY14$W03EW5T='2FE$5$E0.$%L
M46XU)B-X03M49CA!5FDO-F5R>B]!2W):5"MF>F9Z=G-(-FU89U$W;F8X<44O
M2V(O04MS6"]4,65F.59S9GHK8BMD.6<O579G43=N9CAQ12]+8B]Q)B-X03MX
M9CA!5#%E9CE6<V9Z*V(K9#EG+U5V9U$W;F8X<44O2V(O<7AF.5!6-2\Q5W@O
M4#5V-3,R1#E3*T)$=60O=T%Q12]+8B]Q>&8Y4%8U)B-X03LO=T)6<V9Z*V(K
M9#EG+U5V9U$W;4@O;34K568U9658+T%-=DY7,6933DHK<F%H8F96+U%N*W-8
M36Y(,4QM2TYV:&ML9%166$DS1UI/)B-X03MK,65395%2:V1V:#-.95A&15)*
M064T6G%N2UEP*V$S+T%*3&9Z2"]Z07IF.%)Z23!N.3=(,W--;C!L379*4#A!
M>6AM9R]W1&)/=% K)B-X03M40UI$3CEC=F5756538S55;#)+=7A6,DMU>%8U
M;"MF+T%0>6EM:R\Y='%Z+T%&4UIN840V>B]63%9L-40S:&0K63,O:S!0>3(O
M=T--)B-X03LK;R\X;6]C9$XO9%I09VEF,7@K3#!V349U9&ER<U9D:7)S5F1I
M<GHO05 X04LK+RM#<"\S8V-Z4"M1+RMF*VAP+W=!<"]M+W!89FPY)B-X03LO
M=T%P=C4K+S=A1G0O=T)1=W=A:BLW:#=V,'-O8WHW,F9::4YJ<U9D:7)S5F1I
M<G-694IF;#<O-4E0>E@O=T%9.5DO-4U.;3 Q2"M-)B-X03M2+WI82&HO9&XT
M=E%V>7 O.&QV-6,O-6=99CA!:4]997(O=EIE.71X+U-'5C5J<S-9<3=&6%EQ
M-T98;B]!3V9F+VMP=&0O-DYF*V]Y)B-X03M(37I19C,P9FHY>&%C+S!&-D)M
M1S--52].8B]Y5R]M4"]M0FTO=T-)-6MA5"LY:C<R1U0V4VU8:VXO;$1.0B\W
M6C%P+WE95$E:=G)L)B-X03LW>7EJ>51N2VMU>%8R2W5X5C)+=DUV>B]!4#A!
M;$9.2B]W0S(Q6B]Q:WI/,$@Q;BMQ5W),>4AV0S<X>'8O2F]F;'0O>&XQ2"]!
M2DY1)B-X03LT-F(K-GEF0D4O<FHX6'!E64QC-T9867$W1EA9<3=&6&XO.$$U
M6#,O04U&5"]U-#5M9CA!268X07HO,$Y0*U4O>F8P<G9Y*R\U5&9Z)B-X03LY
M+S(P3&(O<4='1%5F,V-09"ML;$1M9F5Z-TU2<V1I<G-69&ER<U9D:7)X3#AV
M9B]!0U%F;78X031X-G@O=T%M1WIA86HO1TDO=T-A)B-X03LT.&8W<R]&-D8K
M5E O:W0O3&XO341$+WA(35!6+W="-TPS='50-E%Y=DUD;3=&6%EQ-T9867$X
M+R]0=B]!36Q.<G8X03!A+SE2:T]:)B-X03MM9R]V;R](-VDP-2]O3#!$34YU
M67 K83,O:W0O368X07I!>F8X4GI),&XY-T@S<TUN,&Q-=DI0+T%#:&UG+SA!
M8D]T4"M40UI$3CEC)B-X03MV95=595-C-55L,DMU>%8R2W5X5C5L*V8O=T1Y
M:6UK+SET<7HO5DIM9&]0<E Y57176&M0948S-6IF.$%K,%!Y,B\T>C9J+WEA
M:'@P)B-X03LS.3%K*T-*+UA(-'93.'=7-3)+=7A6,DMU>%8R2W90+T%0>79V
M+V=Q9CDS2$UZ+VM0+VXO04M';B]+9C5V-E8S-69F.'!V-2LO=T,R)B-X03MH
M8F8Y47=W86HK-V@W=C!S;V-Z-S)F6FE.:G-69&ER<U9D:7)S5F5*9FPW+T%/
M4T0X,2\X63E9+S5-3FTP,4@K35(O>EA(:B]!2%HK)B-X03M,,$PX<68X07E7
M+VQZ+VU":"\T:FU(<2\W,EAV8F-F,&AL95DW3C)+=7A6,DMU>%8U+SA!;C,O
M-4MB6&8K:E@O04MJ26-Z3D(O9E(K)B-X03M0,T9P>B]16&]'66)C>%0X,78X
M07E7+VU0+VU";2\T:FU2<% W,E!V65I0<$M:95-F*U5-,$@O=&Y7;B]!0UE4
M25IV<FPW>7EJ>51N)B-X03M+:W5X5C)+=7A6,DMV379Z+W=$*U55,&XO='17
M9C9P37IT0CE:+W%L<7DX:#=W=2]-8B]Y84@U8F8X6CE2+S5.430V8BLV>69"
M12]R)B-X03MJ.%AP95E,8S=&6%EQ-T9867$W1EAN+R]!2E@S+W=!1E0O=30U
M;68X:"\X05 O43 O=T-5+W=!,SE+-SAV=CA!;$XO4#,O8E%T=CA!)B-X03MQ
M1T=$568S8U!D*VQL1&UF97HW35)S9&ER<U9D:7)S5F1I<GA,.'9F+TI"*V$O
M.$%J2')(+TIH<S)M;R]X:5 K830X9C=S+T8V1BM6)B-X03M0+VMT+TQN+T%$
M07<O=T1%8W<Y6"]E>3DW8FHK:TUR>DA:=7A6,DMU>%8R2W90.$$X*R\O04-5
M,G4O.$%2<B\Q1U$U;6%$*RMJ.&9U)B-X03M,5&XK9W9137<R-6EN-7)F*U,S
M.'@O.$%-1$XO>$A-:E-F,W-F97=Y9E-5:CAQ9FTQ*UA.<#58,&4P=61D=#0W
M:3-S8F%+84UH-G$V)B-X03M1<7)+84PR27DS3'!-<&U323E736-S835S:S!0
M.'AV2D=U-F=U;C92<3!.-65U<D]S35EE<%925FIU;T<R57HP,E-!=5%O37A-
M2&M7)B-X03M2-5%Y63=R=C5I95-D0G9J66%V<D5&<&5"43=135=,0E<V8V=O
M86QE=2M863E0:VU,:4Q$17I!-6Q,=BM6>69L:B\Q349T.3!N+TY/)B-X03M4
M+THU9C5R2'A9.39B*UAV4$AL5'I(3DQ$;VUO<&9344M(;453=E)15%%667%"
M=C)'5C5-131F54M:4FM$>5E:+W=!-4-3>'AE54Y-)B-X03ML:UE,2$AR1F]Z
M<V5G5E9K2D]:4%HT.5HO<6QH;35F1FHO;FHX>"]*1B\X06U"-48Q1WHQ94=A
M>3!Y82MA+VY8;GAI17-C45%T5F8R)B-X03MI<#9:9&<P,E%9-6=J8S Q>FY(
M:6IV,W,X+S582BM74"]5=U<S,U-F.# U:69K.'8X,70X5U!E-R]L8VXU62\Y
M5$)B9F1*+WI4:BM4)B-X03MY+WI6.%=096Y7:BMD4$M/<WE#3%-T6G,W>6,Y
M24EP:V%88B]!27)R>B]$2S4T6G@U9VAK2D$X:6Y/5DUK=#$O>DAO9FPK>$8Y
M<DXT)B-X03ML;&%--&E785-T0S=!:TQS0V$P53502&IL33%%5U5'44A.:C,O
M2S50>7@O-FU#,BLV5"]M;DQV>658*V%W.%=097=Z+T%*5U@U12\U)B-X03M8
M2BMM=C!X1"MI+SA/+U5V<F1(-&974'(S<2MN.6UT94<K6E@U8DHT2$17+TAF
M,DYF:5(T-W9O;C,U5F%R<"MR95HO4$=O-F1/='I:)B-X03M81CEB3D1/;&5,
M05<Y2VET3S1Y;E9235E10C4P>GAK16UN<$=95&$W1E=(4V9N0BM78V-J4G8U
M9W1G-D5Q=TA--V<P3S17;5I),&58)B-X03LK87<X4U!E="]W0U9Y9FQJ+W="
M5$)B9F1*+WI4:BM4>2]W03%(:7@W,5,S+T%$9"],931N:G0T3F5G:VUM6EDT
M;S%%:$Q->&]O2'<Y)B-X03MY8U1P36\S-%4K2DAV6F9M37IE2F9L-R]!3U-$
M.#$O.%DY62\U34YM,#%(*TU2+WI82&HO04A:*TQ-+TEE=C9*;V8U5V588GI6
M-S9')B-X03MX=&A9>%5K;F-*56AE:6<W<V998C5J6CAC<%I:0TEV9'-G44EI
M,D\V,R]Z:W@U1G-M85!464QV5DA5,$5I24E94U X05=L268O:$UU)B-X03MH
M,EIK4$]G,7DQ35%X938O-7ER=5,T*W$K6$520C%-=#!72B\T1TIA9FIL-#=+
M2%=8,DU$<79*8D(O>FQ896E4.2\U8VEE4'=J=6U1)B-X03LO95EN=VYS;V1*
M9EEJ.#$U37(X=2]W1$]3;FMJ55I&:#%31S0P959I0C9K9T4P07(T=D@X42ML
M2UIJ-4]Z8VME5S=B2%524&LY6'1R)B-X03MM,G5R94\T='!5;G0U5D125%)S
M2%)L4%%Q>3%"1V$X9VI9=#=!+WHW+W=$2E1A-R]!3D=V+U5:1&U8;U W-E!X
M*S1T3V8V0SE!>D1B)B-X03MM2&9N1&515VXU6BM92DHR-'$Y<5E6.3-M65)O
M4"M#8DUN4FDX<V9E,354-E,K34TV6C%J,WHO;D9N>3EY=4Y:.'=Y3'1'<5=&
M<S%.)B-X03MQ<U),3CE)0W@O9FUO-U5Y8V\O1GI.3$AM6&]F-74O;7):*U-D
M2SE#,DMZ95E,>$0Y4W1Z=4DQ-F5T2U U4BMY4#)J-U9Z1#!M;$]5)B-X03LW
M+U-'-TQL-%(U=FMI+W9R>E5,,F4K=EI7;G4W;#)L;FUC,5IN63%*3V1&1TE!
M;V-N6$5K;7EN4&MJ>5)R9FY(5S0Y3#!U4'=A-G5M)B-X03M".4]#3W4W=68Q
M1'%4;%=F4$A(1WEZ>#1Z23!(,D8U3#AM-E U4C!+2%-.350T12M+93191#%*
M<%0Y<5)Y3R]H-$1B3V)Z6G!:2F-2)B-X03MD:D-!:4M$>7HO;DM46%5I,%!3
M3D159WDS5G<Q,TE0,F=K0T9&*VAM;% X07=/8D1S=D@V:DIO,55T<69.*V)P
M=U968E,V6E%Y=W5Y)B-X03MN8T5+4T0K1T1I0V5%<EI)<%DR-'E)>4U25VI!
M9S K;D-#<$9.4GE01S9Y4G-59$-#<G%A145D0T--5F96=C5!969T43@P*U=R
M;7HQ)B-X03M347HV;&\W>'AV8W1U,&M-;U!P334W=5!4644Y-D$Y835Z*W8P
M-'AY<V-I-2M$2GA$9&AN+T]5,G8X<FI29DPX8D=I2SDO8TQ866QJ)B-X03LV
M55 S8UI0=GI*-TQX.#5F0G(Q575194(U=#-$9&ER-DXO-7A7+S0T,G8X02]-
M5$(O=T%18DY,,G(Y55A/,'8P;#=N;7%C;#56*V8S)B-X03LU:68T8SAU9F]7
M>&LT-GAR0TUL5BLQ1F)(-%I(.6DO,D8K:SES,D=G,"](3&E024Y'9DIW:GI,
M-55Z9G5V9&ER3E!Y8C!K-G K6F5G)B-X03MW54)31S0K=$]4,$%T;$UW*SAO
M0FU,<DHX3TM48F=&>40W37IM;EI0;#=4=GI.,'9Y+SA!;$IQ2&QY2E)D87AR
M13DO03!684Q"0D]0)B-X03M437)N*UDQ4$)F<$\S6&5Y,'AN;45V-%)4:&Y)
M0D-U=3=Y939V-S(W14EU6C5*;'0T,6AG5U)I=U-.4E)544@W2VIW1V)%4D$U
M3TM3)B-X03M3<$EJ=7=21DQ/>&]Q9U9*2C=!659:2&(O;'(K64YX0C8X4&PS
M54=I241+>'0U1G%$,$MH9T-F;WEG-FY'3G5)37AI;#-*1&575C=9)B-X03LS
M36QR93(X;')D4DAJ3$)-:E)Y2V9";%E!:DQO>4)&:&=14GI534M(=5 X07IJ
M4C4R=F]T86TX<#-5<E-71GI%.#EG:D=V<%12+T4V)B-X03MR6&]R<'E9:GA(
M=6,Q6&%706-01T]B;#9A9E(V9BMF9B]K<'1D+S9.9BMO>4A-2%%F,S!F:CEX
M8G,O,$8V0FU',U!$9BMC;R]-4&\V)B-X03M0<$]G4G5/9#--,3-C2T]O:FA(
M0DLK>DTU+S1(3G(R6&IU4FPS3TYQ6F)5*V-C,U1G=G!B4E!.3VUF;%@K5#)L
M3D]I>6$W<7-B6&QT)B-X03M9:S=Y4U0O17)Y53-6231Y9V(U538U;S4T:G%-
M>'(V434T:TUC0C-V;F983F(Q4%A.5G5D5C%/9')I.75N3'EY3C0Y9T(P0W%.
M9T(P)B-X03M'8FU%0D%53U1H4VM38DM0.&TK5&1B.#-A,T9P3VMX8W!'*TME
M9'%I3T=-2#1P2D<W069E5'--:FUZ4GAX<W!H07E.0CEH95)F22MJ)B-X03LK
M5'1#:3!R5%8U3CEU-G4R045K.' V=3%0=55D:&Y.-3@X<VMR3'-O445245I$
M;$Q*.&@O;C$U:2]44#5K6#9)>&$S,'-,65%G-U5-)B-X03M65$PO04UL5V9/
M:C!'4&AX1'HS9&9Q2EA*-2]"0DQ04$A"17!E5U9G:V%J<5=9,$$K+TUS;6UK
M0S,S9F]E;5(V5F]T:'!K6D)J<V)E)B-X03M+,E5J86]I44I8.$TU3V-U2U)0
M93=50V=X2#@W,#!V+T%*5FYR370O1$A+630Q1G%804Q,33AI;VI)5'5$53EU
M,EI/:'9X4E1$3EA#)B-X03MB9DA79$DV>#<S+WII<&%Y1S4X>#-84TY5=%EV
M;5=-<F9H>'I59'%N84DY-VUA56,S;D@U>#8Y*VTO>D@Q;3569S!&=DXY5&=)
M3E8T)B-X03M7=SE);%0T37EL=G!Z3S!E4&AX04Y/959Y3$=.13!Q-#%B5V)(
M4S=C5FYV<#0W95 O5VQC2T0Y1F-V;E!H:5-E:EA%5V%15U-9=F\S)B-X03LO
M;D9B+VIJ82]W1#AX34@O04)"<S!V878Q4F,W4R]36'-U=38Q<"MH-E!D-G9Q
M36YP5U9L1UI:;3<P2%)60G!6;4]Y:G5C,7-)1U5G)B-X03M">DQK13!,9D4O
M;DAZ5'%(;6YZ2&4V,V9':W0P.5DT9V%I3TID;S0Q.6Q88C,V-3 K2$5-8U)%
M3W-N4&E.<&9:-F)D,VM.,U!#;%EB)B-X03M'3#$W<5$O6E)#-GAR6#-A4U)6
M2'5C;DM11F5A0D<P3&MM3#)J+VY&-U-"8V5B3E0Q4FLU3%E766E2=7EY6$1I
M:"MF0TIX;7,W56Y5)B-X03M!3SAU5G!2=5,Y>B]!1$8X-E=V:R]W07$S97-3
M:%AU1DAP5TU$9C=S=4@K=W9Y1S=.-T$U<710:$]366DU5U-F0TQF13!J=$I)
M,&IF)B-X03MA8VQJ.'EA-3%!1')#55AO=6HV:')7<3)U;&%D15IR,CAK155%
M63)Q5#-*-T%$8VYS36I/66E#5'E#67A*3D(Y9"]L=BM5,VPS>5A:)B-X03M2
M=7-36&UT<W8K:S9M-C%B:U)U<TE0.$%D<#AT>C-Z;DY4<35:5#-2-VY9-#A1
M:4=C6FET:GE8+T%*>4,O3"]54$UU:V%D96%*<#5V)B-X03M.6G1R:C!N.5!I
M<B]!1EHP6FTU1FET47)Q=%!N;7@W4#%!:$EI4G%,4FYX;5$R-79$=CA!;%,O
M-6]F.$%5=GHO05!"4F8X,35T4'IU)B-X03M,*V,T=F=4-VUE+VMJ*U8O;EA2
M=E Q='%M<S9:3%DR9')"3V969&]Y0S=P-EE8-%=9+W1K+U)M2G)T5FIL:G%*
M<W1U1$9)4W-V5'9Z)B-X03LW+SA!2E1A-R]W0D=V+U5:1&U$;U W-E!X*S1T
M,F8V0SE!>D1B;GE"*V4S;4@Y32]M5'%14G56=G!V2%0T4C1E:%@Q4B]W06IM
M9D]J)B-X03LP1U!H>$1Z,V1F<4I82F=-5%)R2VI3<5AJ1$%U9U!%;&$W9TAE
M;&-Z0S!H379-=FU452]-5W)Y-FYQ1&=Y4%)9;U5Q2319;#)32TIF)B-X03LR
M55%B069X>79&:D5"45I4;5I'>7%E579+5W1E871A:#!J4TEF56YK,VMK3E)(
M1D=$.%5K:F1L2#EG,W=:<S!C8V)+=V=:1V<K=W9))B-X03M(:TQ34$IE:$IP
M;&=056UE:C-T-GEG4U1Y,#9M;E)2,%9E=SDV:S@U<4TX<W-R3'-9445245I,
M;$1.3"]!1$1R14=I-D1Q1W)Z,#E+)B-X03MW=#5,9V=M;DEX<5=#+TYJ<TUN
M:FAX4T5E.4).0S-W<&1833$Q9%1853=&-34S85=6>C%,=5-Z12]-;D]R06]5
M-F]M>7EJ.'%2;W$K)B-X03MF=$IU9&%U-'),5')+6#8S2DY-=U9E8TE,>$QV
M-'E"8V\Q9D8T6D526DQ::')I,V955C$K8U@U6E=Y8S5034YQ=W!7:UA/62]D
M1W)N)B-X03M.0TY(;% X04-83T]74&4X1R]/;C@T;V9/26@P:E(P:VDP4S)F
M,6YL;$A'4V5506A4>'%E2TM#84$Y97!Z8F%,4BM(-G!F531U8DYX)B-X03MB
M1&LX<'I93TTK;R]Y>3!U5#AV+T%-;G(W5S<U0D9F,T5-=7!U:FIC9G4V5S!2
M.3)O=3-9=%1.1'%:94YM15)Y-69R9&AI2$)#>2M8)B-X03MP2DAK9'!(67,W
M:W-Z2'%39'EC,W=C0794=CA!;DA845 P;BM9:TXR-F-O3DIG:W5M<C U:V5L
M1U!N5U1K4&QM0C)J:S1C9&0W9G!O)B-X03LS2RLU-69M930W-DXO=T-C5G8X
M06IJ82\O=T%X34@O14=Z4SEQ+U9&>G1,.4I9.2]Z:V(K66XV4C%.9DM7;E,Q
M<W1/8U!Q5'%D<$QK)B-X03M$84]O-U)!-R]W0U8O<35D,F1P-DA'95HU34Y4
M:R]H1'A6160S5D55<S=%0E9!<5-4<T%!33)J:5!99D\O;%-0>4HK5#%J<&LT
M<'(S)B-X03MM2SAI;C%-*T5C0TTV=R\X.&U:2R]W0U54-UIR8T=8>&-X4#A-
M4G,U530X14LV;#0U;7EC5CE/9C@T=V%2.5<X;F%H<51#:C,Y-%58)B-X03LS
M:G0P04(O-$XS>E)D<'IU64AC2% P=SE,0E K8VQV3E1A:C5U9S!'2C8R=6I2
M07EG56]B:6-",C9F>7@X0C='=5IF6G5+;V-893%A)B-X03MM9&UN:C)B2GA8
M,$0O=T$T=V5527EU;V5A-VA!6$1'>'-#93)W95IX.#9Q;U K=&UN-U1Z8V]$
M,W5:<&]D6'9S,'-C351Z4W-%:6I5)B-X03MU-VYO1E562D]A9T,S3&559CE$
M32]L,R]!3#0Q2"]K4D8O,59Z669Y6FPX;6HX>$8S+U%Z4#5D+S<T,4@O:U)&
M+W="5F-F-4UY*U,O)B-X03MM274O-D=:+TQV.$$S>'%0+TEI3"]Q<FHO2FU8
M>5@X>$9N6&MN>G1P4&Y(4C,Q8E-O-30W5DIM="]W1%-55D=,27%S4T%R4#A0
M># V)B-X03LU:35S2GAY;W1S2FE1<TUE+U!V+T%-;$YR=CA!,&$O.5)K3UAA
M1"LK:CAF=4Q8;BMG<W4X>38Q1&]F;"]59%EM;U5S3&539FEX;T=:)B-X03M&
M2E9F.6LQ0FU.:FAX4T5E.71K849V:%<T;FQU3&E7-&U9=DQ--U-3365P6FI5
M;C=Z;E9G54MD551A;FA1-T98=6XU0F9M4#5(.'0V)B-X03M$<49J<F-S5VTS
M>EA!:U<W36-J=&-2<W1!<$M+-2]D1E0W9D9T,WI5-B]46DIY0FIU2$TP*U-)
M1D8V;B]!37)W+TMV+T%+=CAF+TEM)B-X03LT+S9P-6=F:W-V.$%.8B]':C-U
M+S58:"M69CA!,68T+RM23G@O=T)5.&9Y5U@K879J4C<R069N8BMB;FQ45B]*
M16UK95AD4U<X=4PV)B-X03ME2DQP5FIK5&I!:$UH3EI&6'$V2TYS>DY&<$IX
M>6-5:%9.3V)+1$=G6'IV;35C2C)+=7A6<T-P<#0T<3E3+TQ$4U!Y<3 R-V@Q
M:GID)B-X03LU9W1R:31I264S,&Q)<FE32EA(4G S.4]J,"]L2'<K2E!43F9Q
M<#5P1&AH12LY>6-5641C;&U8-31F;3$U5#%N>55D2#AV86M,>31V)B-X03M,
M:4U84V]K<4)9239Y1W!D539Y2VU9,F@P:S0U3TM1<6UZ4&Q":E%,-39Z8W5%
M.7<O=T-C9B]/2&M4>7)P1W S1W0V<$AA86QF>F]I)B-X03MW=$A+-45%2S%5
M.&M2:#A4>4YT6'1M<3=1=S5-:V=):7=(3# X;WA'-65(-718165O+VQL*UID
M;C5-.&HK63%I:W)R,35,175M4493)B-X03M256]Y;59J5&I33W1A9'I43416
M85DU8VMF-6\U=51I>4--5#-V35I:6DI:2&QL679*27A:,UDQ6FU*<5-3935Z
M4$%C9&XS-4U0-4ES)B-X03MV37<Q<GI8<45D<D9P,T=3>'1N4U)Z2F-(-TQN
M,#!C56EP6&8Y<6YH;4AR9D5-94=!-70R1&AU>6Y(+T]16&XW4E!.3W$V5$1O
M;#1,)B-X03LS5#='0U(R:U9844-A6G='53@Q56UI>$PY*U8Y;C1*67=E2553
M>3%%=V%P-4YM=V-:.5!F;&8X06UD*U=N;#-Y1F\K:S-E='A26&M-)B-X03M*
M939J.4MC;%I:;F%6,4I%6D)+;#9:;W16<'-S.&A)1WIS365326E"8C4R.#%A
M>2MT95ID53%:=BM0-C9L;E5E0W4U2VIF=U=G>F,T)B-X03MO8TU!3S1/1D]6
M>4I3<DQ'1#9B+T%#<R]->CAS=DQN:TQ39$MU9%IJ9W9)-#)K=31Z1D]32G!8
M3'-#5E%G,#55-CES,%=Q,#)795%K)B-X03M$6GHX5U-):4)A2R]-3#@V=DES
M+VMN5V)B4F184S4Q3S5T;70W9499-6Q*.6%K8D5&,%92>%)I,UAT:V10;W-G
M>4%Y1WE:-6\X2F]V)B-X03ML<DXK-CDR2W5X5CE09FQJ*UIF-5EE5W9)=6LV
M5&-A,T9(9'A1*W!E24E:>5).37AK9%-22%%L4S-'=G1M:3%7;7EZ>44Q<S=$
M2&MI)B-X03M)9U=H=GIF+T%$53AG83<K6%=R859P5W)P9%@Y>#E8.4=!4GI+
M5S18355J8G5I<G-Q:SEC;&\Y3&MH;$)),B]9>'I:26U*04M0+S5Y)B-X03M7
M.'<O;R]Y4$1P36)%5&%X8TMJ060T8F5K:B\X4#9E43=.>#-K=G5:86E64G)V
M9DQE8C4Q-S9$.&MF;$YA-C,K4C!Y=$%N-F$Q3C5.)B-X03M1<TIY;T5I3D=E
M14UF32]S>4Q(+T%-3EA.4&XQ6FIN+T%+23)C,D=+.&1D-S4K:VIE3C)J:U5O
M-D5Q-FM524DR24EZ8T]';G9K6'I$)B-X03M"-68X,5='<#-50UA6;$A*=W9B
M95)&:U9O2"M'5#170DA*4653*S1'534X9DA!9V,R94]F1$LS,EA$-60X<512
M2DY$<&1J2D9);V5/)B-X03M264E3<DMW<4-#1C9%6GI2>51(575Y;TPO=T1#
M+VQN+T%+=$9L+S!J>&8X04Y/1'A:9#57;GI"+WIK2F9A82]N=S9:<'1V0F(R
M*VQW)B-X03M2>%-,8F]I0G!P4#-R:SA!3G=R2W8P6G9U>C1N=S=05G=D4V96
M5'I(335X,S)F-40X9S9*<%!K-U-,0S@P>3-L=DER6D=U;FUG:F%4)B-X03LQ
M<% S:V=*644O0S=%6GI/9E!+57E19&YA46A1050W+T%!=C5:+S9T1FPO,&IX
M9C@P-50T<W4X<W%D+VAF>7HO04Y7:7DO-E(T=CA!)B-X03MM;DAX6F0U5VYF
M-%@X<R\Y5VEY+S92-'8K86-F1FPS;&%F35 O3U$Q-7!R9690,%IP,71$8E%A
M6F)X>%-,06E)1VUL+V5S5'=!+UID)B-X03M2.4=B,W,K2CA/>C%C2%5N,54X
M=WI08V0Y;BM1+TEE:#98-4XP97AV3DUT<&)Y3S)2<G U64DR9C%P0C9K9TI9
M13=/>$=C>FYZ>6Q-)B-X03MK2&$S85%H44%F1VQX1W-D>$Q'=%-Q3WEI=E=G
M3DTV54A:,6A&1E1W;U1N>68U6#%$>E(U:7,Y17-2*SEU;F\X:$96:FI'-WE.
M-TMU)B-X03LO=T-'5EIS;WAX36EZ:$1I3E!S;E-F279L4%1.371T4&<P=3)E
M2S%J5TI:2EE9,VMB:5!T3WA7<%DY5&Y.5'IZ:U-B3'-H14%5*U1F)B-X03MZ
M9'4W5S4O36)80F%1>#(Y=&)82#%33T=&46E,.5A54DY25F].,U%K-3!/:D)'
M25<V+T]B:U=.85)P,'5P871:861#0UIB,F5+,VI!)B-X03LS4$M6=V<O6&PX
M-6-)2C=M15):<#EW4BM5+TLX8V%X<'!&;4910E9R0D=444-G,TLQ>FQV1FXS
M;#)L0CA-,U9U.71C>E<X9W!*0S=2)B-X03MU1'1U<&]F,5HQ44YI,U9%56%5
M<TM(,7(K5$DX<2M94'DK,'5:=%!S-7)Y>6I&;F4X;TEI-&MH*T93-30W;&\K
M3%8Y.#4W5SAC36@S)B-X03M.2&0R5T5G>$1/4#A,*U=F*W)26F8Y23A8+TY/
M66YI>3=Y,E5S;CAU*U9)25I*-71,<U5I:55V235T-'%"5D935#A065E2:VUE
M<%=G)B-X03LK271B,4%A:G)&.7%#>')#=#-C4WIR0V=#<6=K8W-&54190E%A
M6C%-23A-44\U,6-J6DI6=DQ/:TYR4&U,5$Y*6')F6%5.=5-/>7E/)B-X03M&
M62]11%A";&YW>$HW9W-),E%(,C!02S-L:T%!85):041O4'$X6"].3V-V-'-U
M.'4P;T\O=W8U6B]W0W)26F8Y23A8+T%$5&<X5UAE)B-X03M6<#@P9C@U2"M9
M=C!L-2LO4C!B8V].2&=30V<V971,*SEK4#--<6XU6G9/>F-F1&IV=F-,57EU
M5F1Z>DQ4<D,T,4153&%W=&Q,,T8S)B-X03M+:T5+1&-L-4=#<4YV8S5N>6M!
M0U0P8V-#>E0W=#!N5&)F5$Y,<SE.=&A3,W-O23=E168U15-H1B]!6GEC-4=2
M2E!6,F]&4&PO=T0U)B-X03MY1SAK+V],>F8K;4Q74&IP,G5C<'1U:3-+,#E:
M9CEL55 Y2CA-,W9:,F9J:'=N;D9W=%)#:F9E.'!Z64]-*W%0*V-D9D]N-F$X
M;W1O)B-X03MT,4QY=CE%26E112]%,7$K.%(S-CA#0VYS079J;6<W4G<X32M)
M8W!F93=$5'IU3F1Z,4LX=31,3WIN=DQH=45&=$<X,'HK0TEP6FHY)B-X03MW
M>D%!<S!'.3A+83EQ."MS-C-F-G1C9C,Q.6-36$1J=TUJ1G%$,D9A6C%E3TA$
M14%D2%93;%IT3W9Y=SAV9C1G."MA3G!J3'EH9317)B-X03M7-4AB,%E+>7E!
M;C-62UI8<7-N0FI*6C19,TE0=&9/6&1K-T9867%S;FUI9VAK;FU92D9%<&52
M>C!#<4MK;C5$0T)A=FA4>DQR375T)B-X03LK6613,658-V0Y8WEZ,#A!-VMQ
M=BMX1S)D6&EH=WA%934Q53574U4P+TQ845 P+S4W,%A41UAN1$IC<DIC3"]X
M5$0K.6LK.45)>795)B-X03LU3T1'4WEX4G519F)78W4W3CA#,W8K.6LO=T1X
M:V8X031K8S8V4$HQ575:56-,1CE6+VM$*UA8*T<O3'8V6G8T*T]S87=I=GA9
M9D9$)B-X03MB2#1O-"]9=#ET=F](8DY"<CE2>'DT4CE)9&AG>#A).'DY3S%#
M.6AS8D,U=G!Z4T<Q:65E52\U36%L;2]!6F=2:EIP=F9";#5D4S-D)B-X03LS
M4&141W-T>$DP<V@X5V1I>"]%-3%S4E%P,4I.;3)C9FM8<$$Q4#A!33=3038Q
M:7-Z2F5353=E:6A+2"]!2D=C8WAD9%!H>$AZ8G1/)B-X03M,:RMW<S5T,D0U
M3"]!1#8X:C-0;#=Z;F-A;$9%9C!6<E1T8W=39V9#<WIB>E)N=U!).&@W2#)/
M9$1O331N0W5S6$$Q14ML9F4X>GI/)B-X03MC9% O04-D-30X>"M53E-.+V]T
M>C943T%S.$1J;D1+;TY1<VED+UEI:$A9-51M=U)Y0W!--%I$13=05W),+VY+
M=2M304,Y.'525'HO)B-X03M!3%1W,U11;V9K:E)42"]H<S$X=7EH,&PY:FMF
M;79*2G9.2"]!1&ML-6DQ;E,W,U1,5%,W87AT-S9'4S-E479*3DMS8V]+='AB
M.3)V)B-X03M,:65V2$Q-6%IS66M%;3923%5K:7%E4#5S;D9E;F8X04]/,FDO
M<$@X>6)E-5IE55=M45188E8V8VE04E0V955T9F]Z0C=2;G<T<3<S)B-X03M)
M,#!B:RMS<S4U>C-9<2M63F0O2E X,CE9,7$O,5<T,'50,3<K-&MU2D(Y870V
M07EU5V]0:C9#=$)M+W@V,T1'24%03'EC1U=#6DYP)B-X03LO=T1L5BM32&Y,
M4V903VXV<C5G<UDT3E!S4S@T26UI:TIL0T520VE->#)C:'9O>7)6839%<UI%
M5'5794Q!4DMY*VI-,')L<U4O32]Y)B-X03M7;FTO>61E855O2#$Q4C8K;D]D
M=4YX1T1X1E0P1&=L1#=(36I3-79$;40P-G--:T])52MC4"MH9F9Z52\V=&-F
M+U-68B]W1$YE8G(K)B-X03M535AF.6IH9FPU370O2S,X<U!Z5CAO96,W3%9:
M3DY55T1%,BMO<71Z06$R.&UZ1V=F9F=A3T(T:DUF5F%R1&MG4F4O5%IT>%EP
M4FQB)B-X03LR4#A!3D14=DU/<"M2.5,P=E%)4%@Q1R]28F-+6D5J06ED:#9P
M2F-Q3C0V<CE/83-3>6I(241,:TA)>4%M2D%F3B\X03!,-RMA;B]6)B-X03MR
M:B\V4W)F+T%*<GID9GEH:3<O<V-,.'9*-F(K4E U4RM9+TLK=E@K<BM98E9,
M95%7-'0W14-33U5K>4YY:V(Y,E<T,$-!8BM/64]U)B-X03LQ8V-K4D=*8CA'
M27A.;#=B;7)C;#)+=7A6:FXU:5=E=3,S:W)6<D11;W97,4\Y9TYT0VAD67AX
M;$E343AN2V=5:DQ:9' U4D5W6F-G)B-X03MX;4-1869.2"]1=G8U<68Y5W50
M+T%+4W)F+VUV3C4O2T=,=BMX=V9Y.&YP6#5&+VQ*-6TX<V59-WI6+TU.;VQU
M5G1V47-G2EDU4U=K)B-X03M91C(O9',Q2TML3B\U<W=T9'$T-4EI35,S-$U2
M:6),,T1.535,-4MU9GE!+TY+4S5L9&1,:DMS-TUP*W,R+U%M=C@K9$-/,$U6
M8R]S)B-X03MC039E5G-J+T%#-"\U>"LX>7AE86)A-S@Q,F-C3VLR9C<X>$-7
M2U@Q<$5)-%)L54PO1%AD<3E12V0X<#%0845406E",TQ02'!Y1%IF)B-X03M3
M5V%2>D=/9FU.<"MT86PU23%J5'1&:CEB57)Y03(X35ID639R2W=35#1N2W%0
M,UIB=FPR;FQ'3U%'6$E-6F=K14(X,&8Y0RLO;7 O)B-X03LQ830O*VMQ,R]W
M0V$X,VXX;UEU+S=(0B],>65O9FM.*U9N;69Y<')7<#9N<CEQ;',X;'-T=&%H
M6EDU4W=E5&Y*+V1S,4ME;7983418)B-X03LV<4=32457+T)I35-B93%:<DA*
M4S=Z0C5D,&)Z1'!C=6PV=F),9%=5,S)K8G%R1&\V34XQ661I36YJ>5-G8FIZ
M4DM)26]V05!.=CA!)B-X03MZ:D9R9'9-."]L:3EJ=G)5:VQB4S90<%1Q2S=+
M2$$Y3B]M95!Y>F(T=3 T;C9X5&E4,#-C=T,Y+THW.'I,2C)36'DY9$]6-FU!
M3$].)B-X03LO07=S-$]::V1::5 X46%49VXS259F>7<O359M0VIY,W%.5'1V
M8GE!9F52:W9Z5TPK8T8X1UAC;49L*U-N-6\S:'!(;T5Y94IM94=%)B-X03MD
M868W<V1-:$Q7-&@O16YW2CEZ271.+S5X;R]-2S9O8G53>7-&,G%*6FUK9C9"
M16IR+W<R57DW5'AJ;%I::E1397AF;$HK56$K42]R)B-X03LY>%!F<G%&-V9R
M1VA:66I'<U-2;&E656QM3&-I=W%30C!Z5S9V5BM,5S%!3U)I>&-$,%A-2G5D
M:7(O+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB
M;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C-&,#-$
M0D9$,C$S-T5%,3%"-T(R.39#03=&,3 U.38V/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C-&,#-$0D9$
M,C$S-T5%,3%"-T(R.39#03=&,3 U.38V/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y
M,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C-%,#-$0D9$,C$S-T5%,3%"
M-T(R.39#03=&,3 U.38V/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C-%,#-$0D9$,C$S-T5%,3%"
M-T(R.39#03=&,3 U.38V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&
M1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,T,P,T1"1D0R,3,W144Q,4(W0C(Y-D-!
M-T8Q,#4Y-C8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#@M,3!4,#<Z,S(Z-#(K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C-&,#-$0D9$,C$S-T5%,3%"-T(R.39#03=&,3 U.38V/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(S+3 X+3$P5# X.C U.C Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A
M=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P
M4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @
M(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(87-6
M:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S
M/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-S(N-SDY.# U/"]S
M=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XS,"XS-SDX.#,\+W-T1&EM
M.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI
M=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y"
M;&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO
M>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P
M+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  F %X# 1$  A$! Q$!
M_\0 '0   @(#  ,             " D'"@ #!@$$!?_$ #,0  $$ P$  0$%
M!@4%      4#! 8' 0(("0 3%!A8E]81$A46.'@*(3>WN#9Q<W>V_\0 ' $
M @,! 0$!            !08 ! <#" $"_\0 /1$  @(! P(# @H) P4
M 0(#! 4&$1( $P<A(A0Q%18R-%15E)72TR,S-4%Q='6TM211LS9"@8.V_]H
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M_P#7_P J=;.7O]-9-_<3U]_RSNSY\S_SZ#^BZ;_^=Q74H_J'_G,C_D+71$_
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M4QI+&@.Q>R3[V('ZU'F+XRT\%*U8ABK1K&5AD9%9D0S32$ @$IR968^?&/\
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E6(I>,\,UAF++)(D)C]"I'"(QNBJFP* #?8@@=7Q?GDCK4NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>lxeo-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-30T15:16:36.5078+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.lexeotx.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:lxeo="http://www.lexeotx.com/20251231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>75010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1" id="StatementStatementsOfStockholdersEquity1">
        <link:definition>75040 - Statement - Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical">
        <link:definition>75050 - Statement - Statements of Stockholders Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>75060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity" id="DisclosureCybersecurity">
        <link:definition>995455 - Disclosure - Cybersecurity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" id="DisclosureDescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>995465 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestment" id="DisclosureLongtermInvestment">
        <link:definition>995495 - Disclosure - Long-term Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities1">
        <link:definition>995505 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3" id="DisclosureLeases3">
        <link:definition>995515 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1" id="DisclosureCapitalStock1">
        <link:definition>995525 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>995535 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995545 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995555 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies1" id="DisclosureCommitmentsAndContingencies1">
        <link:definition>995565 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" id="DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements">
        <link:definition>995575 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1" id="DisclosureSegmentInformation1">
        <link:definition>995585 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995595 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995615 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995625 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995635 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995645 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables" id="DisclosureCapitalStockTables">
        <link:definition>995655 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995665 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995675 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995685 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995695 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995715 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>995725 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995735 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" id="DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails">
        <link:definition>995745 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails" id="DisclosureLongtermInvestmentAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Long-term Investment- Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995765 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails" id="DisclosureLeasesComponentsOfOperatingLeaseDetails">
        <link:definition>995785 - Disclosure - Leases - Components of Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" id="DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails">
        <link:definition>995795 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2" id="DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2">
        <link:definition>995805 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" id="DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails">
        <link:definition>995815 - Disclosure - Leases - Components of Equipment Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" id="DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails">
        <link:definition>995825 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2" id="DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2">
        <link:definition>995835 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails" id="DisclosureCapitalStockAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Capital Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails" id="DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails">
        <link:definition>995855 - Disclosure - Capital Stock - Schedule of Fair Value Assumptions of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" id="DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
        <link:definition>995865 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>995885 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai" id="DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai">
        <link:definition>995895 - Disclosure - Stock-Based Compensation - Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails">
        <link:definition>995905 - Disclosure - Stock-based Compensation - Summary of RSU Activity and PRSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails">
        <link:definition>995915 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995925 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails">
        <link:definition>995935 - Disclosure - Income Taxes - Schedule of Components of Net Income (Loss) Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>995945 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2" id="DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2">
        <link:definition>995955 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>995965 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995975 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails" id="DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails">
        <link:definition>995985 - Disclosure - Income Taxes - Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" id="DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails">
        <link:definition>996005 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" id="DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3">
        <link:definition>996025 - Disclosure - Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996035 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets" xlink:href="lxeo-20251231.xsd#StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="lxeo-20251231.xsd#StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1" xlink:href="lxeo-20251231.xsd#StatementStatementsOfStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:href="lxeo-20251231.xsd#StatementStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="lxeo-20251231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity" xlink:href="lxeo-20251231.xsd#DisclosureCybersecurity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="lxeo-20251231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" xlink:href="lxeo-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="lxeo-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" xlink:href="lxeo-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureLongtermInvestmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureCapitalStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails" xlink:href="lxeo-20251231.xsd#DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lxeo-20251231.xsd#DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" xlink:href="lxeo-20251231.xsd#DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lxeo-20251231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="lxeo-20251231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:href="lxeo-20251231.xsd#DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lxeo-20251231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="lxeo-20251231.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestment" xlink:href="lxeo-20251231.xsd#DisclosureLongtermInvestment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1" xlink:href="lxeo-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3" xlink:href="lxeo-20251231.xsd#DisclosureLeases3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1" xlink:href="lxeo-20251231.xsd#DisclosureCapitalStock1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="lxeo-20251231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:href="lxeo-20251231.xsd#DisclosureCommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" xlink:href="lxeo-20251231.xsd#DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1" xlink:href="lxeo-20251231.xsd#DisclosureSegmentInformation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="lxeo-20251231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxeo-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lxeo-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:href="lxeo-20251231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="lxeo-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables" xlink:href="lxeo-20251231.xsd#DisclosureCapitalStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="lxeo-20251231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="lxeo-20251231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="lxeo-20251231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lxeo-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails" xlink:href="lxeo-20251231.xsd#DisclosureLeasesComponentsOfOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" xlink:href="lxeo-20251231.xsd#DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" xlink:href="lxeo-20251231.xsd#DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" xlink:href="lxeo-20251231.xsd#DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lxeo-20251231.xsd#DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="lxeo-20251231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2" xlink:href="lxeo-20251231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2" xlink:href="lxeo-20251231.xsd#DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2" xlink:href="lxeo-20251231.xsd#DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AgreementExpirationTerm" xlink:label="lxeo_AgreementExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" xlink:label="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentCurrent" xlink:label="lxeo_InvestmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationPaymentDescription" xlink:label="lxeo_ShareBasedCompensationPaymentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdUcsdLicenseAgreementMember" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LongTermInvestmentPolicyTextBlock" xlink:label="lxeo_LongTermInvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" xlink:label="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellSecondLicenseAgreementsMember" xlink:label="lxeo_CornellSecondLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdPortfolioMember" xlink:label="lxeo_ThirdPortfolioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TaxCreditCarryForwardExpirationYear" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommonStockDuringOfferingPeriod" xlink:label="lxeo_CommonStockDuringOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfFormerEmployees" xlink:label="lxeo_NumberOfFormerEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseEndDate" xlink:label="lxeo_OperatingLeaseEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentNonCurrent" xlink:label="lxeo_InvestmentNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" xlink:label="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfWarrantsPerShare" xlink:label="lxeo_FairValueOfWarrantsPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AnnualLimitationAbilityToUtilize" xlink:label="lxeo_AnnualLimitationAbilityToUtilize"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025PrivatePlacementMember" xlink:label="lxeo_October2025PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PayrollDeductionsAtPrice" xlink:label="lxeo_PayrollDeductionsAtPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AbiomedAgreementMember" xlink:label="lxeo_AbiomedAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfMonthlyInstallmentsLease" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025PublicOfferingMember" xlink:label="lxeo_October2025PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoPortfoliosMember" xlink:label="lxeo_TwoPortfoliosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OneTimeUpFrontNonRefundableFees" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfSharesReceived" xlink:label="lxeo_FairValueOfSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NewYorkCityMember" xlink:label="lxeo_NewYorkCityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LongTermInvestmentTextBlock" xlink:label="lxeo_LongTermInvestmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfRegulatoryMilestones" xlink:label="lxeo_PaymentOfRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmendedUCSDSponsoredResearchAgreementMember" xlink:label="lxeo_AmendedUCSDSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Non-CashGainLossOnLong-TermInvestment" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonredeemableConvertiblePreferredStockMember" xlink:label="us-gaap_NonredeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LossRecognizedFromUninsuredBalances" xlink:label="lxeo_LossRecognizedFromUninsuredBalances"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SteliosTherapeuticsIncMember" xlink:label="lxeo_SteliosTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_WeillCornellMedicalCollegeMember" xlink:label="lxeo_WeillCornellMedicalCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAgreementsTerm" xlink:label="lxeo_ResearchAgreementsTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfWarrantsExercised" xlink:label="lxeo_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" xlink:label="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfSharesReceivedPerShare" xlink:label="lxeo_FairValueOfSharesReceivedPerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Thirty-DayUnderwriterOptionMember" xlink:label="lxeo_Thirty-DayUnderwriterOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UcsdSponsoredResearchAgreementsMember" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" xlink:label="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfWarrants" xlink:label="lxeo_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseExpense" xlink:label="lxeo_FinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellFirstLicenseAgreementsMember" xlink:label="lxeo_CornellFirstLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredTaxAssetsIntangibleAssets" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfLicenseAgreements" xlink:label="lxeo_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:label="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdCornellLicenseAgreementsMember" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAgreementTerminationNoticePeriod" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UpfrontCashPayment" xlink:label="lxeo_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PotentialFutureProductSalesMilestones" xlink:label="lxeo_PotentialFutureProductSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentToAdditionalDataTransferProcess" xlink:label="lxeo_PaymentToAdditionalDataTransferProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PotentialFutureProductDevelopmentMilestones" xlink:label="lxeo_PotentialFutureProductDevelopmentMilestones"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfCumulativeOwnershipChange" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PerformanceRestrictedStockUnitMember" xlink:label="lxeo_PerformanceRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdverumLicenseAgreementMember" xlink:label="lxeo_AdverumLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellUniversityMember" xlink:label="lxeo_CornellUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLossCarryForwardsExpirationYear" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" xlink:label="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfDevelopmentMilestone" xlink:label="lxeo_PaymentOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountDueUnderAgreement" xlink:label="lxeo_AmountDueUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentTerm" xlink:label="lxeo_PaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SecondUcsdLicenseAgreementMember" xlink:label="lxeo_SecondUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommissionsAndOfferingCostsMember" xlink:label="lxeo_CommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountDueForEachQuarterUnderAgreement" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmendedFirstUcsdAgreementMember" xlink:label="lxeo_AmendedFirstUcsdAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfResearchAgreements" xlink:label="lxeo_NumberOfResearchAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfAnnualDataTransferFee" xlink:label="lxeo_PaymentOfAnnualDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdverumBiotechnologiesIncMember" xlink:label="lxeo_AdverumBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_RNolanTownsendMember" xlink:label="lxeo_RNolanTownsendMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MilestoneReceived" xlink:label="lxeo_MilestoneReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfOwnershipConsideredForWarrantExercise" xlink:label="lxeo_PercentageOfOwnershipConsideredForWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommercializationMilestonesDue" xlink:label="lxeo_CommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GainLossOnLongTermInvestment" xlink:label="lxeo_GainLossOnLongTermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchCollaborationAgreementMember" xlink:label="lxeo_ResearchCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ComponentsOfOperatingLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellLicenseAgreementsMember" xlink:label="lxeo_CornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseAgreementEnteredDate" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FirstUcsdLicenseAgreementMember" xlink:label="lxeo_FirstUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_EricAdlerMember" xlink:label="lxeo_EricAdlerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseCommencementDate" xlink:label="lxeo_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments and Receivables, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments and Receivables, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Acquisition, Research Collaboration and Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Acquisition and Research Collaboration and Sponsored Research Agreements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and acquisition and research collaboration and sponsored research agreements disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All other research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Use Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credits:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Parties for Pharmaceutical Manufacturing and Research Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Parties For Pharmaceutical Manufacturing And Research Activities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third parties for pharmaceutical manufacturing and research activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Two Thousand Twenty Five Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May two thousand twenty five private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2025 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">May 2025 Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in the balance sheet:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends, common stock, cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock, Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum increase or decrease in ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Increase Or Decrease In Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum increase or decrease in ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents, including restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation payment description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Payment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation payment description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Facility and Laboratory Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Facility and Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office facility and laboratory space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted cash included in long-term assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted cash included in long-term assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Return To Provision Other Adjustment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation return to provision other amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return to Provision - Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third UCSD License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third UCSD License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third UCSD License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025FinancingTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025FinancingTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October 2025 Financing Transactions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025FinancingTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October 2025 Financing Transactions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025FinancingTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">October 2025 Financing Transactions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LongTermInvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investment Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LongTermInvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investment policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LongTermInvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan and 2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one and two thousand twenty three equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One And Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2021 Plan and 2023 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition percentage of outstanding stock acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Voting Equity Interest Acquired, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and commercialization milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Commercialization Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and commercialization milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents (money market)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">US Federal Statutory Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock, at cost, 3,827 common shares as of December 31, 2025 and as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Description and Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment To The Third Cornell License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second Amendment to the Third Cornell License Agreement [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment to the Third Cornell License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current portion of investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellSecondLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell Second License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellSecondLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell Second License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellSecondLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell Second License Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued upon early exercise of unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares issued on early exercise of unvested stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued On Early Exercise of Unvested Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Simple Agreement For Future Equity Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible simple agreement for future equity note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible SAFE Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third-Party Commissions And Offering Costs Incurred Upon October 2025 Financing Transactionsmmissions and offering costs incurred upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third-party commissions and offering costs incurred upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party commissions and offering costs incurred upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Third-party commissions and offering costs incurred upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPortfolioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Portfolio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPortfolioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Portfolio [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPortfolioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third portfolio.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Risk-free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or Nondeductible Items:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LX2006</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense LX2006</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Expense LX2006.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockDuringOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock during offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockDuringOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock During Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockDuringOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock During Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares outstanding, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares outstanding, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Investments Classified as Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfFormerEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Former Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfFormerEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of former employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfFormerEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of former employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease end date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease end date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Rollforward of Changes in Fair Value of Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, Federal, after Refund Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Paid, Federal, after Refund Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Derivative Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of convertible SAFE Note liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid offering costs included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, equity component of convertible debt share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE Note into common stock in connection with initial public offering, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment in Equity Securities of Investee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment in equity securities of investee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Imputed interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense Employee Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expense employee compensation expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Federal Statutory Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales or maturities of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leerink At The Market Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leerink at the market sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leerink At The Market Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfWarrantsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfWarrantsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfWarrantsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Termination notice period (in days)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AnnualLimitationAbilityToUtilize_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual limitation ability to utilize</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AnnualLimitationAbilityToUtilize_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Limitation Ability to Utilize</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AnnualLimitationAbilityToUtilize_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual Limitation Ability to Utilize</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October 2025 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October 2025 Private Placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2025 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, by Individual Jurisdiction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Estimated Fair Value Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PayrollDeductionsAtPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll Deductions at Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PayrollDeductionsAtPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll Deductions at Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PayrollDeductionsAtPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll deductions at price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AbiomedAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Abiomed Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AbiomedAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Abiomed Agreement [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AbiomedAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abiomed Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease right-of-use assets - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of unearned employee stock ownership plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Unearned Employee Stock Ownership Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Unearned Employee Stock Ownership Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Paid Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of monthly installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Monthly Installments Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of monthly installments lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October 2025 Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October 2025 Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_October2025PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2025 Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoPortfoliosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Portfolios</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoPortfoliosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Portfolios [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoPortfoliosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two portfolios.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from Computation of diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating And Financing Leases Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating And Financing Leases Disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time up-front non-refundable fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Up Front Non Refundable Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One time up front non refundable fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest Over 18 Month [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of ROU assets, operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, range, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Shares Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of shares received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and other personnel costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workers' Compensation Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on fair value adjustment to convertible SAFE Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Fair Value Hedges Recognized in Earnings, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NewYorkCityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New York City [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NewYorkCityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New York City [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NewYorkCityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York City</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury stock repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock repurchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options unvested and expected to vest exercisable weighted average remaining contractual term1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SAFE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SAFE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreement For Future Equity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple Agreement For Future Equity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares unvested, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares unvested, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LongTermInvestmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investment [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LongTermInvestmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease liability payments due after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All other general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued bonus expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term grant date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate total net proceeds raised with issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedUCSDSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended UCSD SRA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedUCSDSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended UCSD Sponsored Research Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedUCSDSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended UCSD Sponsored Research Agreement [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, conversion of stock in initial public offering, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Conversion Of Stock In Initial Public Offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Cash Gain (Loss) on Long-term Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash gain (loss) on long-term investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash gain on long-term investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash gain on long-term investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonredeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonredeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of Internal Use Software into Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of internal use software into prepaid expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of internal use software into prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly installment payment amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Monthly Installment Payment Amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease monthly installment payment amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized comprehensive gain (loss) on investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net unrealized gain (loss) on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LossRecognizedFromUninsuredBalances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss recognized from uninsured balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LossRecognizedFromUninsuredBalances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Recognized from Uninsured Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LossRecognizedFromUninsuredBalances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss recognized from uninsured balances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Return To Provision Other Adjustment Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation return to provision other adjustment percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return to Provision - Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Annual License Maintenance Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of annual license maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares automatically increase in available shares of common stock under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, by Individual Jurisdiction [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in finance lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 11)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average grant date fair value, unvested, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average grant date fair value, unvested, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, conversion of stock in initial public offering, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Conversion Of Stock In Initial Public Offering, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SteliosTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stelios Therapeutics Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SteliosTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stelios Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SteliosTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stelios Therapeutics Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities - finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Effective Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares outstanding used in computation of net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2023 Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_WeillCornellMedicalCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weill Cornell Medical College</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_WeillCornellMedicalCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weill Cornell Medical College [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_WeillCornellMedicalCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weill Cornell medical college.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreements term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreements Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreements term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and regulatory milestone paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Clinical And Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Of Clinical And Regulatory Milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock at par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Payment Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease weighted average remaining payment term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest Over Two Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Remaining Equipment Finance Lease Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Inducement Equity Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty five inducement equity plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Inducement Equity Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfSharesReceivedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares received per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfSharesReceivedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Shares Received Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfSharesReceivedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of shares received per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition date of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Effective Date of Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Thirty-DayUnderwriterOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Thirty-day Underwriter Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Thirty-DayUnderwriterOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">30-day Underwriter Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_Thirty-DayUnderwriterOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">30-day Underwriter Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UCSD Sponsored Research Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCSD Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UCSD sponsored research agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued general and administrative expenses and other professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Expenses And Other Professional Fees Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative expenses and other professional fees current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance of Common Stock Upon Exercise of Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of pre-funded warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options nonvested weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Options Exercisable Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested options exercisable weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury stock repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchases, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellFirstLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell First License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellFirstLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell First License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellFirstLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell first license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options, share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pretax Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) before income tax expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excercise price of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Common Stock Capital Shares Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in common stock capital shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in aggregate number of shares of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Adjustments:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, weighted-average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense Employee Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense employee compensation expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of Financial Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Option, Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units and Performance Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units and performance based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs and PRSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Realized Gain On Investments In U.S. Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net realized gain on investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net realized gain on investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of use assets and finance lease liabilities recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right-of Use Assets And Finance Lease Liabilities Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease right-of use assets and finance lease liabilities recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Exercise Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized capital stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units, Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LX1001</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense LX1001</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense LX1001.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Cornell License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third cornell license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell Third License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specific clinical and regulatory milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specific Clinical and Regulatory Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specific clinical and regulatory milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease amortization of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reduction in the carrying amount of ROU assets, finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW YORK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares outstanding used in computation of net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, range, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Compensation Arrangement By Share based Payment Award Options Nonvested Options Exercisable Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options nonvested options exercisable weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and commercialization milestones description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Development And Commercialization Milestones Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">aggregate development and commercialization milestones description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PotentialFutureProductSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Product Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PotentialFutureProductSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future product sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PotentialFutureProductSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future product sales milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operation segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">All other general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment starting after period of execution of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Starting After Period of Execution of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment starting after period of execution of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand Twenty Four Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March two thousand twenty four private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">March 2024 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2024 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Orphan Drug Credit Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation tax credits orphan drug credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit - Orphan Drug Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Tax Credit - Orphan Drug Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentToAdditionalDataTransferProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to additional data transfer process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentToAdditionalDataTransferProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Additional Data Transfer Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentToAdditionalDataTransferProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to additional data transfer process.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options exercised in period weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments options vested in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Adopted and Not Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Remaining Undiscounted Contractual Rent Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity and PRSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued during the period upon conversion of convertible securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of automatically increase in available shares of common stock on beginning of each calendar year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Automatically Increase in Available Shares of Common Stock on Beginning of Cach Calendar Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of automatically increase in available shares of common stock on beginning of each calendar year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Financing and Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payment of Financing and Stock Issuance Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of financing and stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time up-front non-refundable fee paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of One Time Up Front Non Refundable Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of one time up front non refundable fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rates, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs incurred for research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PotentialFutureProductDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Product Development Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PotentialFutureProductDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future product development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PotentialFutureProductDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future product development milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Cumulative Ownership Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cumulative ownership change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cumulative ownership change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amounts Reclassified From Deposit Liabilities Upon The Vesting Of Early-exercised Stock Options Previously Subject To Repurchase, Net Of Proceeds Received From Early Exercise Of Unvested Stock Options Subject To Repurchase And Recorded As Deposit Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financed research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Net Income (Loss) Before Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected Dividend Yield [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireSoftware_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of internal use software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PerformanceRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PerformanceRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Restricted Stock Unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PerformanceRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issuable Upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Converted shares into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yields percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adverum license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adverum License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adverum License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell university.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry forwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares on conversion of debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued on debt exchanged</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant date fair values of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offering Value Shares Authorized To Be Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offering value shares authorized to be sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AntidilutiveSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AntidilutiveSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AntidilutiveSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Vesting And Settlement Of Performance Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon vesting and settlement of performance restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting and settlement of performance restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of series A convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining lease payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Lease Payment Term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, by Individual Jurisdiction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, unvested, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre-Funded Warrants To Purchase Common Stock Upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Due Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount due under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional costs incurred for research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Additional Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development Aarrangement, ontract to perform for others, dditional costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net book values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease right-of-use assets - finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rates, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second UCSD license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second UCSD License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second UCSD License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Deferred Tax Assets (Deferred Tax Liabilities) True Ups Other Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation deferred tax assets (deferred tax liabilities) true ups other percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DTA (DTL) True Ups - Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commissions and Offering Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions and Offering Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in the balance sheet:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years), weighted-average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: present value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit - Federal R&amp;D Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax Credit - Federal R&amp;D Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due for each quarter under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Due for Each Quarter Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount due for each quarter under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income and expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other income and expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedFirstUcsdAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended First UCSD Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedFirstUcsdAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended First UCSD Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedFirstUcsdAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended First UCSD Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfResearchAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of research agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfResearchAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfResearchAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of research agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual data transfer fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Annual Data Transfer Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of annual data transfer fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting and settlement of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Upon Vesting and Settlement of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon vesting and settlement of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, $0.0001 par value, 18,125,051 shares authorized, 1,660,650 shares issued and 1,633,206 shares outstanding, actual; 18,125,051 shares authorized, 15,220,250 shares issued and 15,192,806 shares outstanding, pro forma</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, commencement date range, start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Commencement Date Range, Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, commencement date range, start.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Orphan Drug Credit Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation tax credits orphan drug credit percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit - Orphan Drug Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax Credit - Orphan Drug Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adverum Biotechnologies Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adverum Biotechnologies Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adverum Biotechnologies Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equipment Finance Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RNolanTownsendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">R Nolan Townsend [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RNolanTownsendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">R Nolan Townsend.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RNolanTownsendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R. Nolan Townsend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MilestoneReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MilestoneReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfOwnershipConsideredForWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership considered for warrant exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfOwnershipConsideredForWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Ownership Considered for Warrant Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfOwnershipConsideredForWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ownership considered for warrant exercise.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions, accrued interest or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues Additional Offering Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares new issues additional offering costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issuance costs incurred related to issuance of convertible SAFE Note, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additional issuance costs incurred related to issuance of convertible SAFE Note, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Unobservable Inputs Used in Valuation Model to Estimate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Significant Unobservable Inputs Used In Valuation Model To Estimate Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of significant unobservable inputs used in valuation model to estimate fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Received from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds received from Private Placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective income tax rate, Amount Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury stock repurchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchases, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from common stock issuances under 2023 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Fair Value Assumptions of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid, Net of Paid Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital expenditures incurred but not yet paid, net of paid amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">property and equipment purchased in the current period included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LX2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense LX2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense LX2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A and series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A And Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, State and Local, after Refund Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Paid, State and Local, after Refund Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total aggregate monthly installment payment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Aggregate Monthly Installment Payment Amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease aggregate monthly installment payment amounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues Additional Offering Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value new issues additional offering costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional offering costs incurred related to issuance of common stock upon private placement offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additional issuance costs incurred related to issuance of convertible SAFE Note, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DTA (DTL) True Ups - Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Deferred Tax Assets (Deferred Tax Liabilities) True Ups Other Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation deferred tax assets (deferred tax liabilities) true ups other amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares purchased at public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes with outstanding principal exchanged</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Original Debt, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Additional Information On Company's Net loss Including Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingGrossProceedsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offering Gross Proceeds Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingGrossProceedsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offering gross proceeds percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingGrossProceedsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock offering gross proceeds percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercialization milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercialization Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercialization milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current portion of lease liabilities - finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining amortization term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Amortization Term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Amortization Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease weighted average remaining amortization term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GainLossOnLongTermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Long Term Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GainLossOnLongTermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on long-term investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GainLossOnLongTermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on long-term investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit - Federal R&amp;D Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax Credit - Federal R&amp;D Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Equipment Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Equipment Finance Lease [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Components of equipment Finance lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to selling shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts, placement agent fees, commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Operating Lease [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Components of operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, commencement date range, end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Commencement Date Range, End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, commencement date range, end.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current portion of lease liabilities - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease agreement entered date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement Entered Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease agreement entered date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium (accretion of discount) on investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium (accretion of discount) on investments in U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense Other Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense other programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts, commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts, Commissions and Offering Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Discounts, Commissions and Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description of Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FirstUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First UCSD License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FirstUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First UCSD License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FirstUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First UCSD license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_EricAdlerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eric Adler [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_EricAdlerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eric Adler.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_EricAdlerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eric Adler</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of License Issue Fee and Initial Data Transfer Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of license issue fee and initial data transfer fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee and initial data transfer fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Labor and Related Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab-related costs and supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, weighted-average period of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, including restricted cash and investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" xlink:to="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:to="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AgreementExpirationTerm" xlink:to="lxeo_AgreementExpirationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" xlink:to="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_InvestmentCurrent" xlink:to="lxeo_InvestmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationPaymentDescription" xlink:to="lxeo_ShareBasedCompensationPaymentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:to="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" xlink:to="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdUcsdLicenseAgreementMember" xlink:to="lxeo_ThirdUcsdLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_October2025FinancingTransactionsMember" xlink:to="lxeo_October2025FinancingTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LongTermInvestmentPolicyTextBlock" xlink:to="lxeo_LongTermInvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:to="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" xlink:to="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellSecondLicenseAgreementsMember" xlink:to="lxeo_CornellSecondLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:to="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesAConvertiblePreferredStockMember" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" xlink:to="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdPortfolioMember" xlink:to="lxeo_ThirdPortfolioMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TaxCreditCarryForwardExpirationYear" xlink:to="lxeo_TaxCreditCarryForwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommonStockDuringOfferingPeriod" xlink:to="lxeo_CommonStockDuringOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfFormerEmployees" xlink:to="lxeo_NumberOfFormerEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseEndDate" xlink:to="lxeo_OperatingLeaseEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_InvestmentNonCurrent" xlink:to="lxeo_InvestmentNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" xlink:to="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" xlink:to="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueOfWarrantsPerShare" xlink:to="lxeo_FairValueOfWarrantsPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LicenseAgreementTerminationNoticePeriod" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AnnualLimitationAbilityToUtilize" xlink:to="lxeo_AnnualLimitationAbilityToUtilize_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_October2025PrivatePlacementMember" xlink:to="lxeo_October2025PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PayrollDeductionsAtPrice" xlink:to="lxeo_PayrollDeductionsAtPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AbiomedAgreementMember" xlink:to="lxeo_AbiomedAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:to="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfMonthlyInstallmentsLease" xlink:to="lxeo_NumberOfMonthlyInstallmentsLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_October2025PublicOfferingMember" xlink:to="lxeo_October2025PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoPortfoliosMember" xlink:to="lxeo_TwoPortfoliosMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" xlink:to="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OneTimeUpFrontNonRefundableFees" xlink:to="lxeo_OneTimeUpFrontNonRefundableFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueOfSharesReceived" xlink:to="lxeo_FairValueOfSharesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NewYorkCityMember" xlink:to="lxeo_NewYorkCityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TreasuryStockRepurchase" xlink:to="lxeo_TreasuryStockRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesBConvertiblePreferredStockMember" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:to="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SimpleAgreementForFutureEquityMember" xlink:to="lxeo_SimpleAgreementForFutureEquityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LongTermInvestmentTextBlock" xlink:to="lxeo_LongTermInvestmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfRegulatoryMilestones" xlink:to="lxeo_PaymentOfRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmendedUCSDSponsoredResearchAgreementMember" xlink:to="lxeo_AmendedUCSDSponsoredResearchAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_Non-CashGainLossOnLong-TermInvestment" xlink:to="lxeo_Non-CashGainLossOnLong-TermInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonredeemableConvertiblePreferredStockMember" xlink:to="us-gaap_NonredeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:to="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:to="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LossRecognizedFromUninsuredBalances" xlink:to="lxeo_LossRecognizedFromUninsuredBalances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" xlink:to="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:to="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:to="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SteliosTherapeuticsIncMember" xlink:to="lxeo_SteliosTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_WeillCornellMedicalCollegeMember" xlink:to="lxeo_WeillCornellMedicalCollegeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAgreementsTerm" xlink:to="lxeo_ResearchAgreementsTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:to="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfWarrantsExercised" xlink:to="lxeo_NumberOfWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:to="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" xlink:to="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueOfSharesReceivedPerShare" xlink:to="lxeo_FairValueOfSharesReceivedPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_Thirty-DayUnderwriterOptionMember" xlink:to="lxeo_Thirty-DayUnderwriterOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UcsdSponsoredResearchAgreementsMember" xlink:to="lxeo_UcsdSponsoredResearchAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:to="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" xlink:to="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueOfWarrants" xlink:to="lxeo_FairValueOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseExpense" xlink:to="lxeo_FinanceLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellFirstLicenseAgreementsMember" xlink:to="lxeo_CornellFirstLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DeferredTaxAssetsIntangibleAssets" xlink:to="lxeo_DeferredTaxAssetsIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfLicenseAgreements" xlink:to="lxeo_NumberOfLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:to="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" xlink:to="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:to="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdCornellLicenseAgreementsMember" xlink:to="lxeo_ThirdCornellLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAgreementTerminationNoticePeriod" xlink:to="lxeo_ResearchAgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:to="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UpfrontCashPayment" xlink:to="lxeo_UpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:to="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PotentialFutureProductSalesMilestones" xlink:to="lxeo_PotentialFutureProductSalesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeMember" xlink:to="us-gaap_OtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:to="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" xlink:to="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentToAdditionalDataTransferProcess" xlink:to="lxeo_PaymentToAdditionalDataTransferProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:to="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:to="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PotentialFutureProductDevelopmentMilestones" xlink:to="lxeo_PotentialFutureProductDevelopmentMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PercentageOfCumulativeOwnershipChange" xlink:to="lxeo_PercentageOfCumulativeOwnershipChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:to="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireSoftware" xlink:to="us-gaap_PaymentsToAcquireSoftware_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PerformanceRestrictedStockUnitMember" xlink:to="lxeo_PerformanceRestrictedStockUnitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdverumLicenseAgreementMember" xlink:to="lxeo_AdverumLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellUniversityMember" xlink:to="lxeo_CornellUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLossCarryForwardsExpirationYear" xlink:to="lxeo_OperatingLossCarryForwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PreFundedWarrantsMember" xlink:to="lxeo_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AntidilutiveSecuritiesMember" xlink:to="lxeo_AntidilutiveSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:to="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" xlink:to="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" xlink:to="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfDevelopmentMilestone" xlink:to="lxeo_PaymentOfDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" xlink:to="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmountDueUnderAgreement" xlink:to="lxeo_AmountDueUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:to="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentTerm" xlink:to="lxeo_PaymentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SecondUcsdLicenseAgreementMember" xlink:to="lxeo_SecondUcsdLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" xlink:to="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommissionsAndOfferingCostsMember" xlink:to="lxeo_CommissionsAndOfferingCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmountDueForEachQuarterUnderAgreement" xlink:to="lxeo_AmountDueForEachQuarterUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmendedFirstUcsdAgreementMember" xlink:to="lxeo_AmendedFirstUcsdAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfResearchAgreements" xlink:to="lxeo_NumberOfResearchAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfAnnualDataTransferFee" xlink:to="lxeo_PaymentOfAnnualDataTransferFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" xlink:to="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" xlink:to="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdverumBiotechnologiesIncMember" xlink:to="lxeo_AdverumBiotechnologiesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_RNolanTownsendMember" xlink:to="lxeo_RNolanTownsendMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_MilestoneReceived" xlink:to="lxeo_MilestoneReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PercentageOfOwnershipConsideredForWarrantExercise" xlink:to="lxeo_PercentageOfOwnershipConsideredForWarrantExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" xlink:to="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:to="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:to="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:to="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:to="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:to="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:to="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" xlink:to="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockOfferingGrossProceedsPercentage" xlink:to="lxeo_StockOfferingGrossProceedsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommercializationMilestonesDue" xlink:to="lxeo_CommercializationMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:to="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_GainLossOnLongTermInvestment" xlink:to="lxeo_GainLossOnLongTermInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" xlink:to="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchCollaborationAgreementMember" xlink:to="lxeo_ResearchCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ComponentsOfOperatingLeaseTableTextBlock" xlink:to="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellLicenseAgreementsMember" xlink:to="lxeo_CornellLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseAgreementEnteredDate" xlink:to="lxeo_OperatingLeaseAgreementEnteredDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:to="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FirstUcsdLicenseAgreementMember" xlink:to="lxeo_FirstUcsdLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_EricAdlerMember" xlink:to="lxeo_EricAdlerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseCommencementDate" xlink:to="lxeo_OperatingLeaseCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:to="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GainLossOnLongTermInvestment" xlink:label="lxeo_GainLossOnLongTermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lxeo_GainLossOnLongTermInvestment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" xlink:label="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_31"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_32"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherComprehensiveIncomeLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_32" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommissionsAndOfferingCostsMember" xlink:label="lxeo_CommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_CommissionsAndOfferingCostsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Non-CashGainLossOnLong-TermInvestment" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_8"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireSoftware" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_TreasuryStockRepurchase" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lxeo_Non-CashGainLossOnLong-TermInvestment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_RNolanTownsendMember" xlink:label="lxeo_RNolanTownsendMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_EricAdlerMember" xlink:label="lxeo_EricAdlerMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_RNolanTownsendMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_EricAdlerMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LongTermInvestmentTextBlock" xlink:label="lxeo_LongTermInvestmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lxeo_LongTermInvestmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LongTermInvestmentPolicyTextBlock" xlink:label="lxeo_LongTermInvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lxeo_LongTermInvestmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ComponentsOfOperatingLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_ComponentsOfOperatingLeaseTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" xlink:label="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LossRecognizedFromUninsuredBalances" xlink:label="lxeo_LossRecognizedFromUninsuredBalances"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentCurrent" xlink:label="lxeo_InvestmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentNonCurrent" xlink:label="lxeo_InvestmentNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_LossRecognizedFromUninsuredBalances" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentNonCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" xlink:label="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonredeemableConvertiblePreferredStockMember" xlink:label="us-gaap_NonredeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PotentialFutureProductDevelopmentMilestones" xlink:label="lxeo_PotentialFutureProductDevelopmentMilestones"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PotentialFutureProductSalesMilestones" xlink:label="lxeo_PotentialFutureProductSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfSharesReceived" xlink:label="lxeo_FairValueOfSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfSharesReceivedPerShare" xlink:label="lxeo_FairValueOfSharesReceivedPerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonredeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_PotentialFutureProductDevelopmentMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_PotentialFutureProductSalesMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_FairValueOfSharesReceived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_FairValueOfSharesReceivedPerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseAgreementEnteredDate" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseCommencementDate" xlink:label="lxeo_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseEndDate" xlink:label="lxeo_OperatingLeaseEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfMonthlyInstallmentsLease" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseAgreementEnteredDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lxeo_OfficeFacilityAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseCommencementDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_NumberOfMonthlyInstallmentsLease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseExpense" xlink:label="lxeo_FinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_FinanceLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025PublicOfferingMember" xlink:label="lxeo_October2025PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Thirty-DayUnderwriterOptionMember" xlink:label="lxeo_Thirty-DayUnderwriterOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025PrivatePlacementMember" xlink:label="lxeo_October2025PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfWarrantsExercised" xlink:label="lxeo_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfOwnershipConsideredForWarrantExercise" xlink:label="lxeo_PercentageOfOwnershipConsideredForWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" xlink:label="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfWarrants" xlink:label="lxeo_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfWarrantsPerShare" xlink:label="lxeo_FairValueOfWarrantsPerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lxeo_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lxeo_AntidilutiveSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025PublicOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_Thirty-DayUnderwriterOptionMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025PrivatePlacementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_NumberOfWarrantsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_PercentageOfOwnershipConsideredForWarrantExercise" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_FairValueOfWarrants" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_FairValueOfWarrantsPerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_StockOfferingGrossProceedsPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_NetProceedsReceivedFromPrivatePlacement" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:label="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lxeo_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" xlink:label="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PerformanceRestrictedStockUnitMember" xlink:label="lxeo_PerformanceRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationPaymentDescription" xlink:label="lxeo_ShareBasedCompensationPaymentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PayrollDeductionsAtPrice" xlink:label="lxeo_PayrollDeductionsAtPrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommonStockDuringOfferingPeriod" xlink:label="lxeo_CommonStockDuringOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lxeo_PerformanceRestrictedStockUnitMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationPaymentDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PayrollDeductionsAtPrice" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_CommonStockDuringOfferingPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_22"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_31"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PerformanceRestrictedStockUnitMember" xlink:label="lxeo_PerformanceRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lxeo_PerformanceRestrictedStockUnitMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredTaxAssetsIntangibleAssets" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lxeo_DeferredTaxAssetsIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lxeo_DeferredTaxAssetsLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLossCarryForwardsExpirationYear" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TaxCreditCarryForwardExpirationYear" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfCumulativeOwnershipChange" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AnnualLimitationAbilityToUtilize" xlink:label="lxeo_AnnualLimitationAbilityToUtilize"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_OperatingLossCarryForwardsExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_TaxCreditCarryForwardExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_PercentageOfCumulativeOwnershipChange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_AnnualLimitationAbilityToUtilize" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NewYorkCityMember" xlink:label="lxeo_NewYorkCityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_NY" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lxeo_NewYorkCityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfFormerEmployees" xlink:label="lxeo_NumberOfFormerEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_NumberOfFormerEmployees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SteliosTherapeuticsIncMember" xlink:label="lxeo_SteliosTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoPortfoliosMember" xlink:label="lxeo_TwoPortfoliosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdverumLicenseAgreementMember" xlink:label="lxeo_AdverumLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdverumBiotechnologiesIncMember" xlink:label="lxeo_AdverumBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdPortfolioMember" xlink:label="lxeo_ThirdPortfolioMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellLicenseAgreementsMember" xlink:label="lxeo_CornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellUniversityMember" xlink:label="lxeo_CornellUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellFirstLicenseAgreementsMember" xlink:label="lxeo_CornellFirstLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfDevelopmentMilestone" xlink:label="lxeo_PaymentOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_WeillCornellMedicalCollegeMember" xlink:label="lxeo_WeillCornellMedicalCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellSecondLicenseAgreementsMember" xlink:label="lxeo_CornellSecondLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommercializationMilestonesDue" xlink:label="lxeo_CommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdCornellLicenseAgreementsMember" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FirstUcsdLicenseAgreementMember" xlink:label="lxeo_FirstUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SecondUcsdLicenseAgreementMember" xlink:label="lxeo_SecondUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdUcsdLicenseAgreementMember" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentToAdditionalDataTransferProcess" xlink:label="lxeo_PaymentToAdditionalDataTransferProcess"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" xlink:label="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfLicenseAgreements" xlink:label="lxeo_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UcsdSponsoredResearchAgreementsMember" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UpfrontCashPayment" xlink:label="lxeo_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmendedFirstUcsdAgreementMember" xlink:label="lxeo_AmendedFirstUcsdAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmendedUCSDSponsoredResearchAgreementMember" xlink:label="lxeo_AmendedUCSDSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AbiomedAgreementMember" xlink:label="lxeo_AbiomedAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchCollaborationAgreementMember" xlink:label="lxeo_ResearchCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfAnnualDataTransferFee" xlink:label="lxeo_PaymentOfAnnualDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfRegulatoryMilestones" xlink:label="lxeo_PaymentOfRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MilestoneReceived" xlink:label="lxeo_MilestoneReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OneTimeUpFrontNonRefundableFees" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfResearchAgreements" xlink:label="lxeo_NumberOfResearchAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAgreementsTerm" xlink:label="lxeo_ResearchAgreementsTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAgreementTerminationNoticePeriod" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountDueUnderAgreement" xlink:label="lxeo_AmountDueUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentTerm" xlink:label="lxeo_PaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountDueForEachQuarterUnderAgreement" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AgreementExpirationTerm" xlink:label="lxeo_AgreementExpirationTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lxeo_SteliosTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_TwoPortfoliosMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AdverumLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_AdverumBiotechnologiesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_ThirdPortfolioMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndRegulatoryMilestonesDue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_CornellUniversityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellFirstLicenseAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfDevelopmentMilestone" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_WeillCornellMedicalCollegeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellSecondLicenseAgreementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_CommercializationMilestonesDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdCornellLicenseAgreementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_FirstUcsdLicenseAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_SecondUcsdLicenseAgreementMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdUcsdLicenseAgreementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentToAdditionalDataTransferProcess" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfLicenseAgreements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_UcsdSponsoredResearchAgreementsMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_UpfrontCashPayment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AmendedFirstUcsdAgreementMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NotesIssued1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AmendedUCSDSponsoredResearchAgreementMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AbiomedAgreementMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ResearchCollaborationAgreementMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfClinicalAndRegulatoryMilestone" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualDataTransferFee" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualLicenseMaintenanceFees" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfRegulatoryMilestones" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_MilestoneReceived" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndCommercializationMilestonesDue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_OneTimeUpFrontNonRefundableFees" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfResearchAgreements" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementsTerm" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementTerminationNoticePeriod" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueUnderAgreement" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentTerm" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueForEachQuarterUnderAgreement" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AgreementExpirationTerm" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lxeo_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingGrossProceedsPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" xlink:label="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" xlink:label="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherComprehensiveIncomeLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommissionsAndOfferingCostsMember" xlink:label="lxeo_CommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_CommissionsAndOfferingCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Non-CashGainLossOnLong-TermInvestment" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireSoftware" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_TreasuryStockRepurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lxeo_Non-CashGainLossOnLong-TermInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_RNolanTownsendMember" xlink:label="lxeo_RNolanTownsendMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_EricAdlerMember" xlink:label="lxeo_EricAdlerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_RNolanTownsendMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_EricAdlerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LossRecognizedFromUninsuredBalances" xlink:label="lxeo_LossRecognizedFromUninsuredBalances"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentCurrent" xlink:label="lxeo_InvestmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentNonCurrent" xlink:label="lxeo_InvestmentNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_LossRecognizedFromUninsuredBalances" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" xlink:label="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonredeemableConvertiblePreferredStockMember" xlink:label="us-gaap_NonredeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PotentialFutureProductDevelopmentMilestones" xlink:label="lxeo_PotentialFutureProductDevelopmentMilestones"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PotentialFutureProductSalesMilestones" xlink:label="lxeo_PotentialFutureProductSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfSharesReceived" xlink:label="lxeo_FairValueOfSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfSharesReceivedPerShare" xlink:label="lxeo_FairValueOfSharesReceivedPerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonredeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_PotentialFutureProductDevelopmentMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_PotentialFutureProductSalesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_FairValueOfSharesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lxeo_FairValueOfSharesReceivedPerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseAgreementEnteredDate" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseCommencementDate" xlink:label="lxeo_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseEndDate" xlink:label="lxeo_OperatingLeaseEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfMonthlyInstallmentsLease" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseAgreementEnteredDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lxeo_OfficeFacilityAndLaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_NumberOfMonthlyInstallmentsLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" xlink:label="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025PublicOfferingMember" xlink:label="lxeo_October2025PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Thirty-DayUnderwriterOptionMember" xlink:label="lxeo_Thirty-DayUnderwriterOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025PrivatePlacementMember" xlink:label="lxeo_October2025PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_October2025FinancingTransactionsMember" xlink:label="lxeo_October2025FinancingTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfWarrantsExercised" xlink:label="lxeo_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfOwnershipConsideredForWarrantExercise" xlink:label="lxeo_PercentageOfOwnershipConsideredForWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" xlink:label="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfWarrants" xlink:label="lxeo_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfWarrantsPerShare" xlink:label="lxeo_FairValueOfWarrantsPerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lxeo_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lxeo_AntidilutiveSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_Thirty-DayUnderwriterOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_October2025FinancingTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_NumberOfWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_PercentageOfOwnershipConsideredForWarrantExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_FairValueOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_FairValueOfWarrantsPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_StockOfferingGrossProceedsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_NetProceedsReceivedFromPrivatePlacement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:label="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lxeo_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PerformanceRestrictedStockUnitMember" xlink:label="lxeo_PerformanceRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" xlink:label="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationPaymentDescription" xlink:label="lxeo_ShareBasedCompensationPaymentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PayrollDeductionsAtPrice" xlink:label="lxeo_PayrollDeductionsAtPrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommonStockDuringOfferingPeriod" xlink:label="lxeo_CommonStockDuringOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lxeo_PerformanceRestrictedStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationPaymentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PayrollDeductionsAtPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_CommonStockDuringOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PerformanceRestrictedStockUnitMember" xlink:label="lxeo_PerformanceRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lxeo_PerformanceRestrictedStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OperatingLossCarryForwardsExpirationYear" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TaxCreditCarryForwardExpirationYear" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PercentageOfCumulativeOwnershipChange" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AnnualLimitationAbilityToUtilize" xlink:label="lxeo_AnnualLimitationAbilityToUtilize"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_OperatingLossCarryForwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_TaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_PercentageOfCumulativeOwnershipChange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_AnnualLimitationAbilityToUtilize" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NewYorkCityMember" xlink:label="lxeo_NewYorkCityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_NY" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lxeo_NewYorkCityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfFormerEmployees" xlink:label="lxeo_NumberOfFormerEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_NumberOfFormerEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SteliosTherapeuticsIncMember" xlink:label="lxeo_SteliosTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TwoPortfoliosMember" xlink:label="lxeo_TwoPortfoliosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdverumLicenseAgreementMember" xlink:label="lxeo_AdverumLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AdverumBiotechnologiesIncMember" xlink:label="lxeo_AdverumBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdPortfolioMember" xlink:label="lxeo_ThirdPortfolioMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellLicenseAgreementsMember" xlink:label="lxeo_CornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellUniversityMember" xlink:label="lxeo_CornellUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellFirstLicenseAgreementsMember" xlink:label="lxeo_CornellFirstLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfDevelopmentMilestone" xlink:label="lxeo_PaymentOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_WeillCornellMedicalCollegeMember" xlink:label="lxeo_WeillCornellMedicalCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CornellSecondLicenseAgreementsMember" xlink:label="lxeo_CornellSecondLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_CommercializationMilestonesDue" xlink:label="lxeo_CommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdCornellLicenseAgreementsMember" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FirstUcsdLicenseAgreementMember" xlink:label="lxeo_FirstUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SecondUcsdLicenseAgreementMember" xlink:label="lxeo_SecondUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ThirdUcsdLicenseAgreementMember" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentToAdditionalDataTransferProcess" xlink:label="lxeo_PaymentToAdditionalDataTransferProcess"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" xlink:label="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfLicenseAgreements" xlink:label="lxeo_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UcsdSponsoredResearchAgreementsMember" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_UpfrontCashPayment" xlink:label="lxeo_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmendedFirstUcsdAgreementMember" xlink:label="lxeo_AmendedFirstUcsdAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmendedUCSDSponsoredResearchAgreementMember" xlink:label="lxeo_AmendedUCSDSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AbiomedAgreementMember" xlink:label="lxeo_AbiomedAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchCollaborationAgreementMember" xlink:label="lxeo_ResearchCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfAnnualDataTransferFee" xlink:label="lxeo_PaymentOfAnnualDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentOfRegulatoryMilestones" xlink:label="lxeo_PaymentOfRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MilestoneReceived" xlink:label="lxeo_MilestoneReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_OneTimeUpFrontNonRefundableFees" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NumberOfResearchAgreements" xlink:label="lxeo_NumberOfResearchAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAgreementsTerm" xlink:label="lxeo_ResearchAgreementsTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAgreementTerminationNoticePeriod" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountDueUnderAgreement" xlink:label="lxeo_AmountDueUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentTerm" xlink:label="lxeo_PaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AmountDueForEachQuarterUnderAgreement" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AgreementExpirationTerm" xlink:label="lxeo_AgreementExpirationTerm"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lxeo_SteliosTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_TwoPortfoliosMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AdverumLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_AdverumBiotechnologiesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_ThirdPortfolioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndRegulatoryMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_CornellUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellFirstLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_WeillCornellMedicalCollegeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellSecondLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_CommercializationMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdCornellLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_FirstUcsdLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_SecondUcsdLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdUcsdLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentToAdditionalDataTransferProcess" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_UcsdSponsoredResearchAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_UpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AmendedFirstUcsdAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NotesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AmendedUCSDSponsoredResearchAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AbiomedAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ResearchCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfClinicalAndRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualDataTransferFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualLicenseMaintenanceFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_MilestoneReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndCommercializationMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_OneTimeUpFrontNonRefundableFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfResearchAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementsTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueForEachQuarterUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AgreementExpirationTerm" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_PreFundedWarrantsMember" xlink:label="lxeo_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" xlink:label="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lxeo_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingGrossProceedsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202309Member" xlink:label="us-gaap_AccountingStandardsUpdate202309Member"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="lxeo_GainLossOnLongTermInvestment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GainLossOnLongTermInvestment" xlink:label="lxeo_GainLossOnLongTermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireSoftware" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lxeo_Non-CashGainLossOnLong-TermInvestment" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lxeo_TreasuryStockRepurchase" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability" order="19" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Non-CashGainLossOnLong-TermInvestment" xlink:label="lxeo_Non-CashGainLossOnLong-TermInvestment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" xlink:label="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" xlink:label="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" xlink:label="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_FinanceLeaseExpense" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_FinanceLeaseExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_FinanceLeaseExpense" xlink:label="lxeo_FinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" xlink:label="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" xlink:label="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" xlink:label="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lxeo_DeferredTaxAssetsIntangibleAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lxeo_DeferredTaxAssetsLeaseLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredTaxAssetsIntangibleAssets" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_LaborAndRelatedExpense" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20251231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lxeo_AnnualLimitationAbilityToUtilize" name="AnnualLimitationAbilityToUtilize" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_NetProceedsReceivedFromPrivatePlacement" name="NetProceedsReceivedFromPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SteliosTherapeuticsIncMember" name="SteliosTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_SecondUcsdLicenseAgreementMember" name="SecondUcsdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" name="ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_DevelopmentAndRegulatoryMilestonesDue" name="DevelopmentAndRegulatoryMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" name="Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AmendedFirstUcsdAgreementMember" name="AmendedFirstUcsdAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AmountDueUnderAgreement" name="AmountDueUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_TreasuryStockRepurchase" name="TreasuryStockRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_FairValueOfSharesReceivedPerShare" name="FairValueOfSharesReceivedPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AdverumBiotechnologiesIncMember" name="AdverumBiotechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" name="IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_OperatingLeaseAgreementEnteredDate" name="OperatingLeaseAgreementEnteredDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_MayTwoThousandTwentyFivePrivatePlacementMember" name="MayTwoThousandTwentyFivePrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ResearchAgreementsTerm" name="ResearchAgreementsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AdverumLicenseAgreementMember" name="AdverumLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchAgreementTerminationNoticePeriod" name="ResearchAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CornellFirstLicenseAgreementsMember" name="CornellFirstLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" name="AggregateDevelopmentAndCommercializationMilestonesDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_LossRecognizedFromUninsuredBalances" name="LossRecognizedFromUninsuredBalances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseLX1001" name="ResearchAndDevelopmentExpenseLX1001" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember" name="SecondAmendmentToTheThirdCornellLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TaxCreditCarryForwardExpirationYear" name="TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" name="CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" name="SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentOfAnnualLicenseMaintenanceFees" name="PaymentOfAnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" name="ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_CornellUniversityMember" name="CornellUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ThirdCornellLicenseAgreementsMember" name="ThirdCornellLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ThirdPortfolioMember" name="ThirdPortfolioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PotentialFutureProductDevelopmentMilestones" name="PotentialFutureProductDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" name="ResearchAndDevelopmentExpenseOtherPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_InvestmentInEquitySecuritiesOfInvesteeMember" name="InvestmentInEquitySecuritiesOfInvesteeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" name="ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_DeferredTaxAssetsIntangibleAssets" name="DeferredTaxAssetsIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_MilestoneReceived" name="MilestoneReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_StockOfferingValueSharesAuthorizedToBeSold" name="StockOfferingValueSharesAuthorizedToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities" name="NetRealizedGainOnInvestmentsInUSTreasurySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" name="IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_OfficeFacilityAndLaboratorySpaceMember" name="OfficeFacilityAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" name="FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" name="SeriesAAndSeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" name="PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" name="GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" name="AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_LeerinkAtTheMarketSalesAgreementMember" name="LeerinkAtTheMarketSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ThirdUcsdLicenseAgreementMember" name="ThirdUcsdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FairValueOfSharesReceived" name="FairValueOfSharesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_GainLossOnLongTermInvestment" name="GainLossOnLongTermInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" name="IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_NumberOfFormerEmployees" name="NumberOfFormerEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" name="AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_Non-CashGainLossOnLong-TermInvestment" name="Non-CashGainLossOnLong-TermInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PercentageOfCumulativeOwnershipChange" name="PercentageOfCumulativeOwnershipChange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FirstUcsdLicenseAgreementMember" name="FirstUcsdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" name="IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" name="PaymentOfLicenseIssueFeeAndInitialDataTransferFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" name="FinanceLeaseMonthlyInstallmentPaymentAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" name="IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PayrollDeductionsAtPrice" name="PayrollDeductionsAtPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AbiomedAgreementMember" name="AbiomedAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AmountDueForEachQuarterUnderAgreement" name="AmountDueForEachQuarterUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_NewYorkCityMember" name="NewYorkCityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" name="FairValueOfUnearnedEmployeeStockOwnershipPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PotentialFutureProductSalesMilestones" name="PotentialFutureProductSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_StockOfferingGrossProceedsPercentage" name="StockOfferingGrossProceedsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FinanceLeaseExpense" name="FinanceLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" name="TemporaryEquityConversionOfStockInInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_RNolanTownsendMember" name="RNolanTownsendMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" name="ConvertibleSimpleAgreementForFutureEquityNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_InvestmentCurrent" name="InvestmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ComponentsOfOperatingLeaseTableTextBlock" name="ComponentsOfOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" name="LesseeFinanceLeaseCommencementDateRangeEnd" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" name="StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" name="IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CommonStockDuringOfferingPeriod" name="CommonStockDuringOfferingPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" name="IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_LicenseAgreementTerminationNoticePeriod" name="LicenseAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AgreementExpirationTerm" name="AgreementExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FairValueOfWarrantsPerShare" name="FairValueOfWarrantsPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoThousandTwentyFiveInducementEquityPlanMember" name="TwoThousandTwentyFiveInducementEquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_UcsdSponsoredResearchAgreementsMember" name="UcsdSponsoredResearchAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" name="NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" name="PaymentOfOneTimeUpFrontNonRefundableFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_OperatingLeaseEndDate" name="OperatingLeaseEndDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" name="FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PerformanceRestrictedStockUnitMember" name="PerformanceRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_October2025PublicOfferingMember" name="October2025PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PaymentOfDevelopmentMilestone" name="PaymentOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SimpleAgreementForFutureEquityMember" name="SimpleAgreementForFutureEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseLX2020" name="ResearchAndDevelopmentExpenseLX2020" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AntidilutiveSecuritiesMember" name="AntidilutiveSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_CornellLicenseAgreementsMember" name="CornellLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_NumberOfResearchAgreements" name="NumberOfResearchAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" name="GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_InvestmentNonCurrent" name="InvestmentNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentOfClinicalAndRegulatoryMilestone" name="PaymentOfClinicalAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_WeillCornellMedicalCollegeMember" name="WeillCornellMedicalCollegeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ShareBasedCompensationPaymentDescription" name="ShareBasedCompensationPaymentDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CommissionsAndOfferingCostsMember" name="CommissionsAndOfferingCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_EricAdlerMember" name="EricAdlerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_OneTimeUpFrontNonRefundableFees" name="OneTimeUpFrontNonRefundableFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PaymentToAdditionalDataTransferProcess" name="PaymentToAdditionalDataTransferProcess" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AmendedUCSDSponsoredResearchAgreementMember" name="AmendedUCSDSponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" name="CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoPortfoliosMember" name="TwoPortfoliosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_CommercializationMilestonesDue" name="CommercializationMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" name="LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchCollaborationAgreementMember" name="ResearchCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" name="SpecificClinicalAndRegulatoryMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" name="RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PaymentOfRegulatoryMilestones" name="PaymentOfRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_CornellSecondLicenseAgreementsMember" name="CornellSecondLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" name="TwoThousandAndTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" name="LesseeFinanceLeaseCommencementDateRangeStart" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" name="TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_October2025PrivatePlacementMember" name="October2025PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseLX2006" name="ResearchAndDevelopmentExpenseLX2006" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" name="IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_DevelopmentAndCommercializationMilestonesDue" name="DevelopmentAndCommercializationMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PaymentOfAnnualDataTransferFee" name="PaymentOfAnnualDataTransferFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_Thirty-DayUnderwriterOptionMember" name="Thirty-DayUnderwriterOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LongTermInvestmentTextBlock" name="LongTermInvestmentTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" name="PaymentStartingAfterPeriodOfExecutionOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage" name="MaximumIncreaseOrDecreaseInOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_NumberOfMonthlyInstallmentsLease" name="NumberOfMonthlyInstallmentsLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" name="UnderwritingDiscountsCommissionsAndOfferingCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember" name="MarchTwoThousandTwentyFourPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LongTermInvestmentPolicyTextBlock" name="LongTermInvestmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" name="ComponentsOfEquipmentFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" name="FinanceLeaseWeightedAverageRemainingAmortizationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentTerm" name="PaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" name="ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" name="LesseeOperatingAndFinancingLeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PercentageOfOwnershipConsideredForWarrantExercise" name="PercentageOfOwnershipConsideredForWarrantExercise" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" name="StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_IncreaseDecreaseInFinanceLeaseLiability" name="IncreaseDecreaseInFinanceLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" name="OperatingLeaseWeightedAverageRemainingPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" name="ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" name="TemporaryEquityConversionOfStockInInitialPublicOfferingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_October2025FinancingTransactionsMember" name="October2025FinancingTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LEXEO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text"> 0001907108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-4012572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">345 Park Avenue South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">547-9879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,087,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2026 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2025.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="nump">$ 35,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">118,767<span></span>
</td>
<td class="nump">86,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,625<span></span>
</td>
<td class="nump">4,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">188,392<span></span>
</td>
<td class="nump">126,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Non-current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">64,801<span></span>
</td>
<td class="nump">7,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Long-term investment</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">3,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Lease right-of-use assets - finance</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease right-of-use assets - operating</a></td>
<td class="nump">6,578<span></span>
</td>
<td class="nump">8,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">268,688<span></span>
</td>
<td class="nump">146,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,856<span></span>
</td>
<td class="nump">6,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,277<span></span>
</td>
<td class="nump">13,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of lease liabilities - finance</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities - operating</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,808<span></span>
</td>
<td class="nump">22,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - finance</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - operating</a></td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,019<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 3,827 common shares as of December 31, 2025 and as of December 31, 2024</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">626,625<span></span>
</td>
<td class="nump">397,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">188<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(380,134)<span></span>
</td>
<td class="num">(280,173)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">246,669<span></span>
</td>
<td class="nump">116,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 268,688<span></span>
</td>
<td class="nump">$ 146,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares issued</a></td>
<td class="nump">73,001,766<span></span>
</td>
<td class="nump">33,079,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Outstanding</a></td>
<td class="nump">73,001,350<span></span>
</td>
<td class="nump">33,071,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common shares</a></td>
<td class="nump">3,827<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 63,797<span></span>
</td>
<td class="nump">$ 74,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">45,460<span></span>
</td>
<td class="nump">31,675<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">109,257<span></span>
</td>
<td class="nump">105,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(109,257)<span></span>
</td>
<td class="num">(105,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_GainLossOnLongTermInvestment', window );">Gain on long-term investment</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">7,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income and expense</a></td>
<td class="nump">9,296<span></span>
</td>
<td class="nump">7,433<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss from operations before income taxes</a></td>
<td class="num">(99,961)<span></span>
</td>
<td class="num">(98,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(99,961)<span></span>
</td>
<td class="num">(98,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized gain (loss) on investments</a></td>
<td class="nump">291<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive gain (loss)</a></td>
<td class="nump">291<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (99,670)<span></span>
</td>
<td class="num">$ (98,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding used in computation of net loss per common share, basic</a></td>
<td class="nump">53,645,323<span></span>
</td>
<td class="nump">31,787,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding used in computation of net loss per common share, diluted</a></td>
<td class="nump">53,645,323<span></span>
</td>
<td class="nump">31,787,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_GainLossOnLongTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on long-term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_GainLossOnLongTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>2023 ESPP [Member]</div></th>
<th class="th"><div>May 2025 Private Placement [Member]</div></th>
<th class="th"><div>October 2025 Financing Transactions [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>2023 ESPP [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>May 2025 Private Placement [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>October 2025 Financing Transactions [Member]</div>
</th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>2023 ESPP [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>May 2025 Private Placement [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>October 2025 Financing Transactions [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,646,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 113,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (181,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, Value</a></td>
<td class="nump">88,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred', window );">Additional issuance costs incurred related to issuance of convertible SAFE Note, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred', window );">Additional issuance costs incurred related to issuance of convertible SAFE Note, Value</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Treasury stock repurchases, Value</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized comprehensive gain (loss) on investments in U.S. Treasury securities</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">12,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(98,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,071,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2024</a></td>
<td class="nump">116,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">397,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">(280,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits', window );">Issuance of common stock upon vesting and settlement of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits', window );">Issuance of common stock upon vesting and settlement of performance restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="nump">20,790,120<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 73,082<span></span>
</td>
<td class="nump">$ 143,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 73,080<span></span>
</td>
<td class="nump">$ 143,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants', window );">Issuance of common stock upon exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized comprehensive gain (loss) on investments in U.S. Treasury securities</a></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">12,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(99,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,961)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,001,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2025</a></td>
<td class="nump">$ 246,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 626,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="num">$ (380,134)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options, share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon vesting and settlement of performance restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon vesting and settlement of restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues additional offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues additional offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember', window );">March 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember', window );">March 2024 Private Placement [Member] | Commissions and Offering Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member] | Commissions and Offering Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">6,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember', window );">October 2025 Financing Transactions [Member] | Commissions and Offering Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 9,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_CommissionsAndOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_CommissionsAndOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (99,961)<span></span>
</td>
<td class="num">$ (98,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of ROU assets, operating</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Reduction in the carrying amount of ROU assets, finance</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">12,132<span></span>
</td>
<td class="nump">12,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_Non-CashGainLossOnLong-TermInvestment', window );">Non-cash gain on long-term investment</a></td>
<td class="num">(3,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities', window );">Net realized gain on investments in U.S. Treasury securities</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (accretion of discount) on investments in U.S. Treasury securities</a></td>
<td class="nump">111<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,004)<span></span>
</td>
<td class="num">(1,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,561)<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(4,445)<span></span>
</td>
<td class="nump">3,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities, operating</a></td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseDecreaseInFinanceLeaseLiability', window );">Lease liabilities, finance</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(98,561)<span></span>
</td>
<td class="num">(81,151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(397)<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(195,382)<span></span>
</td>
<td class="num">(93,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales or maturities of investments</a></td>
<td class="nump">105,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(90,252)<span></span>
</td>
<td class="num">(94,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(533)<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TreasuryStockRepurchase', window );">Treasury stock repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock issuances under 2023 ESPP</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement</a></td>
<td class="nump">79,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions', window );">Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions</a></td>
<td class="nump">153,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions', window );">Third-party commissions and offering costs incurred upon October 2025 Financing Transactions</a></td>
<td class="num">(9,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">216,795<span></span>
</td>
<td class="nump">88,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">27,982<span></span>
</td>
<td class="num">(86,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">38,266<span></span>
</td>
<td class="nump">124,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">66,248<span></span>
</td>
<td class="nump">38,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="nump">291<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses', window );">Reclassification of internal use software into prepaid expenses</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount', window );">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized', window );">Finance lease right-of use assets and finance lease liabilities recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Unpaid offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount', window );">property and equipment purchased in the current period included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember', window );">March 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of financing and stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,287)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of financing and stock issuance costs</a></td>
<td class="num">$ (6,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditures incurred but not yet paid, net of paid amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease right-of use assets and finance lease liabilities recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncreaseDecreaseInFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncreaseDecreaseInFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net realized gain on investments in U.S. Treasury securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_Non-CashGainLossOnLong-TermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash gain (loss) on long-term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_Non-CashGainLossOnLong-TermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of internal use software into prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Third-party commissions and offering costs incurred upon October 2025 Financing Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_TreasuryStockRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_TreasuryStockRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (99,961)<span></span>
</td>
<td class="num">$ (98,333)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Trading Plans of Directors and Executive Officers</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 13, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a member of our board of directors, adopted a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trading arrangement providing for the sale from time to time of an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, commencing on April 3, 2026. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 11, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or earlier if all transactions under the trading arrangement are completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other officers, as defined in Rule 16a-1(f), or directors adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408, during the last fiscal quarter.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=lxeo_RNolanTownsendMember', window );">R. Nolan Townsend</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">R. Nolan Townsend<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 13, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">January 11, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">605 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">116,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=lxeo_RNolanTownsendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=lxeo_RNolanTownsendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1C.    Cybersecurity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.</span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> specialized third parties in connection with our risk assessment processes. These </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties assist </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">us in designing and implementing our cybersecurity policies and procedures, as well as in monitoring and testing our safeguards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also conduct IT security assessments on our key third-party service providers and require them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of their security measures that may affect our company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not previously experienced any cybersecurity risk or cybersecurity incident which has been determined to be </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, including the risk factor entitled &#8220;Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#8217;, CROs&#8217;, manufacturers&#8217;, contractors&#8217;, consultants&#8217; or collaborators&#8217; cybersecurity&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. </span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The day-to-day implementation of our cybersecurity policies and processes is primarily overseen by our Vice President, Associate General Counsel in consultation with our Chief Financial Officer and external advisors including our IT and Cybersecurity consultant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President, Associate General Counsel has more than a decade of advising on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our information security policies are developed and implemented, and are reviewed at least annually with updates authorized and approved, by the security governance steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the like. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee provides updates to the board of directors on such reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. </span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The day-to-day implementation of our cybersecurity policies and processes is primarily overseen by our Vice President, Associate General Counsel in consultation with our Chief Financial Officer and external advisors including our IT and Cybersecurity consultant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President, Associate General Counsel has more than a decade of advising on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our information security policies are developed and implemented, and are reviewed at least annually with updates authorized and approved, by the security governance steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the like. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee provides updates to the board of directors on such reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President, Associate General Counsel has more than a decade of advising on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description of Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Lexeo Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular disease. The Company utilizes adeno-associated viruses (&#8220;AAV&#8221;) that have been engineered to transfer genes to patients. The Company&#8217;s therapeutic investigational treatments include AAV-based gene therapies primarily in the clinical and late pre-clinical stages of research and development.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is located in New York, NY and was first formed on February 17, 2017, as an LLC under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company filed and executed a certificate of conversion to a corporation on November 20, 2020, to convert the LLC to Lexeo Therapeutics, Inc, a Delaware corporation. All of the Company&#8217;s tangible assets are held in the United States (&#8220;U.S.&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying financial statements and these notes reflect the operations of the Company that have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company has no unconsolidated subsidiaries. Certain prior period balances have been reclassified to conform to the current period presentation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Since inception, the Company has incurred net losses and negative cash flows from operations, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025, the Company had cash, cash equivalents, and investments in U.S. Treasury Securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">246.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. During the year ended December 31, 2024, the Company received total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and offering expenses in the March 2024 Private Placement (as defined below) (see Note 7). During the year ended December 31, 2025, the Company received total net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and offering expenses in the May 2025 Private Placement (as defined below) (see Note 7), as well as net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of underwriter commissions, placement agent fees and estimated offering expenses in the October 2025 Financing Transactions (as defined below) (see Note 7). Management estimates that the Company's current cash, cash equivalents, and investments in U.S. Treasury securities balances are sufficient to fund its operations for at least 12 months from the issuance date of these financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the ability to secure additional capital to fund operations, and commercial success of its product candidates. Any of the Company&#8217;s current product candidates and future product candidates that it may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance- reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#8217;s stock option awards. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2025 and December 31, 2024, the Company&#8217;s cash equivalents were held in U.S. government money market funds. As of December 31, 2025 and 2024, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#8217;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments&#8212;Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of premiums of approximately $149,000 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, at December 31, 2025.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company follows the two-class method when computing net income (loss) as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares and pre-funded warrants to purchase shares of common stock outstanding for the period. In accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the pre-funded warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During the years ended December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,117,976</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,724,218</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> total potential common shares, respectively, related to the exercise of outstanding stock options, settlement of outstanding restricted stock units ("RSUs"), settlement of outstanding RSUs that vest upon the achievement of certain performance conditions ("PRSUs"), and exercise of outstanding warrants were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering in stockholders&#8217; equity as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent and occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Based Compensation Expense&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of RSUs and PRSUs. The measurement date for employee stock option, RSU, and PRSU awards is the date of grant, and stock-based compensation costs for employee non-performance awards are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on a graded basis. Compensation expense for equity awards with performance conditions, including PRSUs, is recognized if and when the Company concludes that it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each reporting period for equity awards with such performance conditions and adjusts compensation expense based on its probability assessment. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award, and stock-based compensation costs for non-employees are recognized as expense over the vesting period on a graded basis. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation expense for all equity awards is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the Company's 2021 Equity Incentive Plan (the "2021 Plan"), (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#8217;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#8217;s balance sheet and statement stockholders&#8217; equity are reduced until such awards vest. Forfeitures are recorded as they occur.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant under the 2021 Plan and the Company's 2023 Equity Incentive Plan (the "2023 Plan", and together with the 2021 Plan, the &#8220;Plans&#8221;), and shares issued under the 2023 ESPP, are estimated on the date of stock option grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU and PRSU granted under the 2023 Plan is equal to the closing price of the Company's common stock on the date of the grant. Prior to its initial public offering ("IPO") on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.<br/><br/>The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. As of December 31, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against its deferred tax assets (see Note 10).<br/><br/>The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2025 and December 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t identified any uncertain tax positions.<br/><br/>The Company's policy, to the extent uncertain tax positions exist, is to record interest and penalties related to uncertain tax positions in the provision for income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are unobservable inputs for the asset or liability.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term Investment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for its long-term investment in nonredeemable convertible preferred stock in accordance with the provisions of ASC Topic 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received was based upon an observable price of cash paid for an identical security in an orderly transaction with a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#8217;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#8217;s cash equivalents consist of investments in U.S. government money market funds, and the Company's cash investments consist of U.S. Treasury securities. The Company&#8217;s cash, cash equivalents, and restricted cash are held with large financial institutions that management believes to be of high credit quality. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any losses caused by uninsured balances.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#8217;s Chief Operating Decision Maker ("CODM") is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer ("CEO") and its senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The CODM reviews the Company&#8217;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2025.</span></p></div><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 6 for information regarding the Company&#8217;s capitalized operating and finance lease right-of-use assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:50.94%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:14.66%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:12.8%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:12.8%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,880</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,502</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">741</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,139</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s leases include options to extend or terminate the lease. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes&#8212;Improvements to Income Tax Disclosures, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which focuses on the rate reconciliation and income taxes paid (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires a public business entity (a "PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4283524d-7551-4b90-bb15-d2729ab6b502;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU No. 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in ASU No. 2023-09 prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for all periods presented, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December 31, 2025, the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU No. 2023-09 retrospectively, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which only impacted the Company's income tax disclosures with no impact to its balance sheet or its statements of operations and comprehensive loss, stockholders' equity, or cash flows (see Note 10)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure of specified information about certain costs and expenses in the notes to financial statements. ASU No. 2024-03 will be effective for the Company starting in annual periods after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued ASU No. 2025-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 270) ("ASU No. 2025-11"). ASU No. 2025-11 clarifies interim disclosure requirements and the applicability of Topic 270. ASU No. 2025-11 will be effective for the Company starting in interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents consist of investments in U.S. government money market funds stated at carrying value, which approximates fair value and is based on quoted prices in active markets for identical securities. Cash is stated at carrying value, which approximates fair value due to its short-term nature. The Company classifies its investments in U.S. Treasury securities as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The carrying values of the Company&#8217;s prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.32%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,801</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,801</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,568</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:31.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:23.745%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,568</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,380</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,568</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments in U.S. Treasury securities classified as available-for-sale securities held as of December 31, 2025 and December 31, 2024 had contractual maturities of less than one year for the current portion of investments in U.S. Treasury securities and between one to two years for the non-current portion of investments in U.S. Treasury securities. There have been no material realized gains or losses on investments classified as available-for-sale securities for the periods presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LongTermInvestmentTextBlock', window );">Long Term Investment [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Long-term Investment</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, the Company entered into a collaboration and license agreement (the "June 2025 CLA") and a preferred stock purchase agreement (the "June 2025 Preferred Stock Purchase Agreement") with Tilia Therapeutics, Inc., now known as Myoventive, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a privately-held Delaware corporation (the "Investee"), to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. In exchange for access to certain of the Company's expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology contributed under the terms of the June 2025 CLA, the Company received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Investee's nonredeemable convertible preferred stock issued under the June 2025 Preferred Stock Purchase Agreement, initially representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Investee's issued and outstanding voting stock as of June 30, 2025. Under the terms of the June 2025 CLA, the Company is entitled to certain future milestone payments, royalties, and opt-in rights to certain program(s) (see Note 12).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its investment in the Investee in accordance with the provisions of ASC Topic 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.338983</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, was based upon an observable price of cash paid for an identical security in an orderly transaction between the Investee and a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LongTermInvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LongTermInvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:72.793%;box-sizing:content-box;"></td>
         <td style="width:1.274%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.693000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.274%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.965%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,299</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,696</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and other personnel costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,066</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,112</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expenses and other professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">839</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,406</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,277</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,759</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Lease Right-of-Use Asset</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into a lease agreement for an office facility and laboratory space in New York, New York that commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend the lease beyond July 2029 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at the then-prevailing effective market rental rate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon commencement of this lease, the Company recorded operating lease right-of-use assets and operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the present value of payments over the lease term using an estimated incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in accordance with the provisions of ASC 842. In connection with the Company&#8217;s lease of office space and laboratory space, the Company provided a security deposit to the landlord in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The cash collateralizing the letter of credit was included in long-term restricted cash in the Company&#8217;s balance sheets as of December 31, 2025, and December 31, 2024. This lease was classified as an operating lease in accordance with the provisions of ASC 842. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any right-of-use assets and lease liabilities associated with the potential option to renew or extend. The Company&#8217;s operating lease agreement does not contain any significant residual value guarantees or restrictive covenants.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The remaining lease terms and payment terms as of December 31, 2025 and December 31, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of this operating lease were as follows:</span></span></p><div style="font-size:11pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.64%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">459</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,650</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,606</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,152</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,110</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.135%;box-sizing:content-box;"></td>
         <td style="width:2.641%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.224%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,206</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,261</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,318</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: present value adjustment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,884</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing in April 2022, the Company leases certain laboratory equipment under financing arrangements accounted for as finance leases in accordance with the provisions of ASC 842 that are classified in the Company&#8217;s balance sheet as finance lease liabilities with related right-of-use assets recorded and depreciated on a straight-line basis over the estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. In connection with the Company&#8217;s leases of laboratory equipment, the Company provided a security deposit to the lessor in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and assigned all rights and interests in the equipment to the lessor. The cash collateralizing the letter of credit is included in long-term restricted cash in the Company&#8217;s balance sheet as of December 31, 2025. The total gross, accumulated amortization, and net book values of equipment finance lease right-of-use assets capitalized under such finance lease arrangements at December 31, 2025 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Under the terms of the equipment finance lease agreements executed through the issuance date of these financial statements, the principal balances plus interest for the equipment are to be repaid in full after </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly installments following lease commencement, with lease commencement dates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, annual imputed interest rates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and monthly installment payment amounts ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The total aggregate monthly installment payment amount is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the Company's equipment finance lease agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2025 were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.61</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the equipment finance leases were as follows:</span></span></p><div style="font-size:11pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease expense</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">424</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">533</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:77.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.259999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">907</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Financing Leases Disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Capital Stock</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and December 31, 2024, the Company&#8217;s amended and restated certificate of incorporation provided that the authorized capital stock of the Company was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">510,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of undesignated preferred stock, both with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,001,766</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,079,209</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company's common stock authorized were issued, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,948</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, that were legally issued upon the early exercise of unvested stock options and that are excluded from the number of shares outstanding until the right to repurchase subsequently lapses upon vesting. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t repurchase any shares of its common stock during the year ended December 31, 2025, and repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,827</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 8). Each common share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company&#8217;s Board of Directors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends have been declared or paid by the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 11, 2024, the Company entered into a common stock purchase agreement to issue and sell an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278,905</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, in a private placement that closed on March 13, 2024 (the "March 2024 Private Placement"). The gross and net proceeds received from the March 2024 Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and other offering costs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2025, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC ("Leerink") to sell shares of the Company's common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from time to time through an at-the-market equity offering program (the "ATM Program") under which Leerink is acting as the Company's agent. Leerink is entitled to compensation for its services in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any of the shares of the Company's common stock sold under the Sales Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock have been sold under the Sales Agreement through December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 28, 2025, pursuant to a securities purchase agreement, the Company issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,790,120</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,963,556</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to certain purchasers, together with accompanying warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,876,838</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8825</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock and accompanying common warrant, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8824</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant and accompanying warrant (the "May 2025 Private Placement"). The gross and net proceeds received from the May 2025 Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and other offering costs. The warrants and pre-funded warrants issued in the May 2025 Private Placement are immediately exercisable at exercise prices of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively, except that the warrants and pre-funded warrants cannot be exercised by the holder if, after giving effect thereto, the holder would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s common stock (the "Maximum Percentage"). The Maximum Percentage can be changed at the holder's election to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and any increase in the Maximum Percentage will not be effective until the 61st day after the holder provides notice to the Company of the desired increase. The warrants are exercisable until May 28, 2029, and the pre-funded warrants do not expire. The warrants and pre-funded warrants are classified as equity in accordance with ASC Topic 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging - Contracts in an Entity's Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon issuance, the total pre-allocated fair value of the warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share, was estimated using a Black-Scholes option pricing model with the following assumptions:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.695%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.564%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pproximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total gross proceeds received in the May 2025 Private Placement were allocated to the shares of common stock, warrants and pre-funded warrants, respectively, on a relative fair value basis, and were recorded as credits to additional paid-in capital, and are not subject to remeasurement. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">867,302</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants issued in the May 2025 Private Placement had been exercised. In January 2026, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">867,302</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued in the May 2025 Private Placement were exercised (see Note 14).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 16, 2025, the Company entered into an underwriting agreement to issue and sell an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,625,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions, in a public offering that closed on October 20, 2025 (the "October 2025 Public Offering"). In addition, the Company granted the underwriters of the October 2025 Public Offering a 30-day option to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,343,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions (the "30-day Underwriter Option"), which was exercised in full. The gross and net proceeds received from the October 2025 Public Offering including the full exercise of the 30-day Underwriter Option were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of underwriter commissions and other estimated offering costs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 16, 2025, the Company entered into a securities purchase agreement to sell and issue pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250,015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, in a private placement that closed on October 20, 2025 (the "October 2025 Private Placement", and together with the October 2025 Public Offering and the 30-day Underwriter Option, the "October 2025 Financing Transactions"). The gross and net proceeds received from the October 2025 Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of placement agent fees and other estimated offering costs. The pre-funded warrants issued in the October 2025 Private Placement do not expire and are immediately exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant share, except that the pre-funded warrants cannot be exercised by the holder if, after giving effect thereto, the holder would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s common stock (the "October 2025 Private Placement Maximum Percentage"). The October 2025 Private Placement Maximum Percentage can be changed at the holder's election to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and any increase in the October 2025 Private Placement Maximum Percentage will not be effective until the 61</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day after the holder provides notice to the Company of the desired increase.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pproximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total gross proceeds received in the October 2025 Financing Transactions were allocated to the shares of common stock and pre-funded warrants, respectively, on a relative fair value basis, and were recorded as credits to additional paid-in capital, and are not subject to remeasurement. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the pre-funded warrants issued in the October 2025 Financing Transactions had been exercised.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following number of shares of common stock for the exercise of outstanding warrants, exercise of outstanding pre-funded warrants, exercise of o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utstanding stock options, settlement of outstanding RSUs and PRSUs, and future issuances of stock-based awards:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.278%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.925999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.384%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase shares of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,876,838</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants to purchase shares of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,096,254</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase shares of common stock under the 2021 Plan and 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,396,860</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs and PRSUs subject to settlement in shares of common stock under the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,132,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,185,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">505,284</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,079,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,414,830</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2021, the Company adopted the 2021 Plan for the issuance of stock options granted to the Company&#8217;s key directors, officers, employees and consultants, as a means to secure the benefits arising from capital stock ownership. In connection with the Company&#8217;s IPO in November 2023, the Company adopted the 2023 Plan for the issuance of equity awards granted to the Company's directors, officers, employees, and consultants, and for the issuance of shares purchased under the 2023 ESPP to the Company's employees, as a means to secure the benefits arising from capital stock ownership. The purposes of the Plans and the 2023 ESPP are also to promote the alignment of the interests of directors, officers, employees, and consultants with the success of the Company and to provide compensation opportunities to attract, retain and motivate directors, officers, employees, and consultants of the Company. Upon adoption of the 2023 Plan, no further grants may be made under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, beginning on January 1, 2024, and continuing through and including January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company&#8217;s Board of Directors prior to the applicable January 1. The number of shares of common stock reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2024 and continuing through and including January 1, 2033, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, and (iii) a number of shares determined by the Company&#8217;s Board of Directors. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full do not reduce the number of shares available for issuance under the 2023 ESPP.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2026, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,650,088</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, to totals of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,804,770</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,210,439</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,132,156</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future issuance under the 2023 Plan and 2023 ESPP, respectively. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,837</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the 2023 ESPP through December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 4, 2025, the Company's board of directors adopted the Lexeo Therapeutics, Inc. 2025 Inducement Equity Incentive Plan (the "2025 Inducement Equity Plan") and, subject to the adjustment provisions of the 2025 Inducement Equity Plan, reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock for issuance pursuant to equity awards granted under the 2025 Inducement Equity Plan.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock option activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2021 Plan are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally (i) are subject to requisite service requirements, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) allow for early exercise subject to repurchase. Stock options granted under the 2021 Plan to certain of the Company&#8217;s non-employees vest in equal monthly installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period or vested upon the achievement of a certain milestone event. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t repurchase any shares of its common stock during the year ended December 31, 2025, and repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,827</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 7).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2023 Plan are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after approximately one year and the remainder vesting in equal monthly installments over the following 36 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to requisite service requirements. Stock options granted under the 2023 Plan to certain of the Company's non-employee directors vest in equal annual installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period for initial grants or over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period for subsequent annual grants, subject to requisite service requirements.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the year ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.791%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.878%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.298%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.878%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.398%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,450,904</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">415,707</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,396,860</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.60</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,556,582</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.94</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.69</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of stock options granted during the years ended December 31, 2025 and December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.58</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair values of stock options vested during the years ended December 31, 2025 and December 31, 2024 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions during the years ended December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rates</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.78</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years), weighted-average</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.79</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility, range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.90</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.61</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.19</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility, weighted-average</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected dividend yields are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to stock options estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU and PRSU activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs granted under the 2023 Plan generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to requisite service requirements. During the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PRSUs were granted to certain employees under the 2023 Plan that vest upon the achievement of certain performance conditions generally over an approximate 18-month period, subject to requisite service requirements. Additionally, during the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,650</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs were granted to employees under the 2023 Plan that </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following four quarters</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to requisite service requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.06%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664,684</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.45</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703,578</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.47</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to RSUs estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.66</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the PRSU activity under the 2023 Plan for the nine months ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.06%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,800</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.33</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 ESPP, eligible employees may purchase shares of the Company's common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market values of the stock as of the beginning of the offering period or the end of each six-month purchase period. Each offering period of two years will consist of four six-month purchase periods, subject to reset on the first day of each purchase period depending on the fair market values of the Company's stock. Employees may not purchase more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock during any purchase period. The first purchase period within the first offering period under the 2023 ESPP commenced during the three months ended December 31, 2024 and concluded during the three months ended March 31, 2025; following reset, the first purchase period within the second offering period commenced during the three months ended March 31, 2025 and concluded during the three months ended September 30, 2025; and the second purchase period within the second offering period commenced during the three months ended September 30, 2025. As of and during the year ended December 31, 2025, stock-based compensation expense recorded, as well as the estimated fair value of unearned and unrecognized stock-based expense expected to be recorded, related to the 2023 ESPP were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material. During the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,837</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued under the 2023 ESPP at a weighted average purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share with total proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received by the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified as follows in the Company&#8217;s statements of operations and comprehensive loss:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,524</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,608</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,132</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.52%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,645,323</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,787,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.09</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of net income (loss) before income tax expense are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December 31, 2025, and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.038%;box-sizing:content-box;"></td>
         <td style="width:1.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.604000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.145%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.384%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pretax Income (Loss)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US Federal Statutory Tax Rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,931</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,671</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credits:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credit - Federal R&amp;D Credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.54</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credit - Orphan Drug Credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,970</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,430</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,903</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.95</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's effective tax rate includes the effects of state and local income taxes, net of the federal income tax benefit, which are primarily attributable to New York and New York City, where the Company has significant business activities. This state has higher effective tax rates compared to other jurisdictions where the Company operates, and together, it accounts for more than half of the Company's total state tax expense.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company's deferred tax assets and liabilities at December 31, 2025 and December 31, 2024 are as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,743</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangibles</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,338</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,818</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,292</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,374</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,404</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,935</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,439</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,059</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,439</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company had federal net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which can be carried forward indefinitely. As of December 31, 2025 and 2024, the Company had state and local net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company had federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tax Cuts and Jobs Act (the "TCJA") resulted in significant changes to the treatment of research and developmental (&#8220;R&amp;D&#8221;) expenditures under Section 174 of the Internal Revenue Code of 1986, as amended (the "IRC"). For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over five years and costs for foreign R&amp;D activities must be amortized over 15 years, both using a midyear convention.<br/><br/>For tax years beginning after December 31, 2024, the One Big Beautiful Bill Act enacted a new rule under Section 174A of the IRC allowing companies to immediately expense any domestic R&amp;D expenditures. For domestic R&amp;D, companies may either immediately expense or elect to capitalize and amortize over at least 60 months under Section 174A of the IRC. However, foreign R&amp;D continues to require capitalization subject to the mandatory 15-year amortization period under Section 174 of the IRC.<br/><br/>For domestic R&amp;D expenditures that were previously capitalized in tax years 2022-2024 under the prior TCJA, companies may elect to recover the remaining unamortized balance by either (1) expensing fully in the first year beginning after December 31, 2024, (2) expensing ratably over two years beginning after December 31, 2024, or (3) continue amortizing over the remaining life.<br/><br/>The Company has elected to continue amortizing the previously capitalized costs over their remaining life. Beginning in tax year 2025, instead of immediately expensing domestic R&amp;D expenditures under Section 174A of the IRC, the Company elected to capitalize and amortize its domestic R&amp;D expenditures under Section 59(e) of the IRC over a 10-year period. Any foreign R&amp;D costs will continue to be capitalized and amortized over 15 years in accordance with the requirements of Section 174 of the IRC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2025 and December 31, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. As a result, the Company increased its valuation allowance by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more in the ownership positions of certain stockholders during a rolling three-year period.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company conducted ownership analyses under IRC Section 382 as of September 30, 2024 and December 31, 2025 and determined the Company experienced ownership changes on November 7, 2023 and May 28, 2025, respectively, that limit the Company&#8217;s ability to utilize its federal NOLs and tax credits. As a result of the ownership changes, the Company is subject to an annual limitation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on its ability to utilize its federal NOLs and tax credits recognized before May 28, 2025, inclusive of the ownership change that occurred on November 7, 2023. Due to the limitations, no federal NOLs are expected to expire unutilized and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership changes, are expected to expire unutilized. As a result, during the year ended December 31, 2025, the Company reduced its deferred tax assets related to the federal tax credits, which was offset by a corresponding decrease in the valuation allowance.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2025 and December 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any uncertain tax positions in its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying statements of operations. As of December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the balance sheet.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company's financial statements. The Company&#8217;s tax years remain open under statute from December 31, 2022 to the present.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the Company's capital base and franchise taxes paid (net of refunds received) for the years presented below:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">551</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">551</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the jurisdictions that exceeded 5% of the Company's total capital base and franchise taxes paid (net of refunds) for the years presented below:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York City</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2025, the Company had entered into commitments under lease agreements to rent laboratory and office space and finance equipment (see Note 6).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2025, the Company had entered into commitments under license, acquisition, research collaboration and sponsored research agreements with third parties (see Note 12). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-days&#8217; written notice, unless otherwise indicated. Further, certain of the Company&#8217;s manufacturing agreements could require early termination and wind-down payments due from the Company upon either the termination of its clinical trials or if the Company terminates such agreements for convenience.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company recognizes any associated legal fees as incurred and accrues a liability for such contingent liability matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings, except that on October 12, 2023, Rocket Pharmaceuticals, Inc. (&#8220;Rocket&#8221;) filed a lawsuit in the U.S. District Court for the Southern District of New York against the Company and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> former employees that claimed, among other things, misappropriation of confidential information and trade secrets. The complaint alleged the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they became employed at the Company. The complaint sought unspecified damages and asked the court to enjoin the Company from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, the Company asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. The Company's counterclaims sought equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. In June 2025, the litigation was resolved amicably and without admission of liability by any party, and all claims have been dismissed with prejudice.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. For all periods presented, the Company has not incurred any material costs as a result of such indemnifications.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Acquisition, Research Collaboration and Sponsored Research Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock', window );">License, Acquisition, Research Collaboration and Sponsored Research Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. License, Acquisition, Research and Collaboration and Sponsored Research Agreements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverum Biotechnologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On January 25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#8220;Adverum&#8221;) to in-license materials and technology related to the treatment of cardiomyopathy due to Friedreich's ataxia ("FA") (as amended in February 2022, the &#8220;Adverum Agreement&#8221;). In connection with the Adverum Agreement, the Company gained access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop, and the Company will assume all development and commercialization activities worldwide. Pursuant to the Adverum Agreement, the Company paid a one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is obligated to pay aggregate development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023, and aggregate sales event and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> research and development expenses recorded by the Company or payments made to Adverum under the terms of the Adverum Agreement other than the one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Adverum Agreement remains in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach of contractual terms, or insolvency by either party.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On May 28, 2020, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exclusive license agreements with Cornell University (&#8220;Cornell&#8221;) (each, as amended, the &#8220;First Cornell License Agreement&#8221; and the &#8220;Second Cornell License Agreement,&#8221; respectively; collectively the &#8220;May 2020 Cornell License Agreements&#8221;). The First Cornell License Agreement is for the in-license of technology related to portfolios for APOE-associated Alzheimer&#8217;s disease and Anti-Tau, although the Company&#8217;s license is not restricted by such indications and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh10.hAPOE2 vector to treat APOE4 homozygous patients who are at risk for or have Alzheimer&#8217;s disease to support development of the Company&#8217;s LX1001 program. The Second Cornell License Agreement is for the in-license of technology related to a portfolio for FA although the Company&#8217;s license is not restricted by such indications, and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh.10cUhCLN2 to treat children with CLN2 Batten disease to support development of the Company&#8217;s LX1004 program. Through the May 2020 Cornell License Agreements, the Company gains access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop. Under the terms of the May 2020 Cornell License Agreements, the Company has assumed all development and commercialization activities worldwide with respect to the licensed technology.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As initial consideration for the May 2020 Cornell License Agreements, the Company paid Cornell an upfront payment in cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of notes (the &#8220;Cornell Notes&#8221;). In November 2020, the Cornell Notes with outstanding principal of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were cancelled in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,337,610</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of series A convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,258</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO on November 7, 2023. As additional consideration, the Company is required to pay Cornell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific clinical and regulatory milestones under the First Cornell License Agreement and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in two portfolios and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for a third portfolio upon the achievement of specific clinical and regulatory milestones under the Second Cornell License Agreement. In the second quarter of 2022, a clinical and regulatory milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized and paid to Cornell in connection with the Second Cornell License Agreement. The Company is also required to pay Cornell a flat royalty in the mid-single-digits based on net sales of the products covered by the licenses, subject to certain adjustments.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes non-exclusive and royalty-free. In addition, each of the May 2020 Cornell License Agreements may be terminated by the Company for any reason upon ninety (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; advance notice to Cornell and by Cornell upon the Company&#8217;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2024, the Company entered into the Third License Agreement (as amended, the &#8220;Third Cornell License Agreement,&#8221; together with the May 2020 Cornell License Agreements, the &#8220;Cornell License Agreements&#8221;) with Cornell. Pursuant to the Third Cornell License Agreement, Cornell has granted the Company an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell on behalf of the Company and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell has also granted the Company a right of reference to Cornell&#8217;s Investigational New Drug application for a gene therapy for FA cardiomyopathy.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Third Cornell License Agreement, the Company paid a license issue fee and an initial data transfer fee to Cornell totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, the Company will be paying an annual data transfer fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until data is no longer being gathered. The Company has agreed to pay annual license maintenance fees ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until such time the Company commercializes a licensed product. In addition, the Company will pay Cornell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in regulatory milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestones, plus low single digit royalties on net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Third Cornell License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, the Company shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell may terminate the Third Cornell License Agreement if the Company (i) breaches the Third Cornell License Agreement (subject to a cure period), (ii) participates in any proceeding challenging the validity of the licensed patents, (iii) publishes the licensed data without Cornell&#8217;s prior written consent, or (iv) does not reach certain milestones. Cornell may also terminate the Third Cornell License Agreement in part on a product-by-product basis if the Company does not diligently develop and sell a product. The Company may terminate the Third Cornell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; prior written notice to Cornell.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2025, the Company executed a Second Amendment to the Third Cornell License Agreement (the &#8220;Second Amendment to the Third Cornell License Agreement&#8221;), which added a one-time fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for additional data transfer and processing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the Amended Cornell License Agreements. During the year ended December 31, 2024, the Company incurred and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the Amended Cornell License Agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios Therapeutics, Inc. (&#8220;Stelios&#8221;) was an early-stage company developing novel adeno-associated AAV-based gene therapies for rare cardiac conditions including arrhythmogenic cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy. On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 16, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding stock of Stelios that was accounted for as an asset acquisition pursuant to FASB ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is required to pay up to a remaining aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the selling shareholders of Stelios upon the achievement of certain development milestones, excluding a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved in the third quarter of 2024 and paid in the fourth quarter of 2024. Dr. Eric Adler, the Company's former Chief Medical Officer and Head of Research, was a co-founder of Stelios and a selling shareholder. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone payment, Dr. Adler received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Stelios was merged into the Company on December 15, 2022 and ceased to exist.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Regents of the University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios entered into an exclusive worldwide license agreement on April 23, 2020 (as amended, the &#8220;First UCSD Agreement&#8221;) with The Regents of UCSD to in-license materials and intellectual property related to a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The First UCSD Agreement relates to the Company&#8217;s development efforts for its LX2021 program. In connection with the First UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The First UCSD Agreement required Stelios to pay one-time up-front non-refundable cash fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each agreement and requires the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low- to mid-single digit royalties and low-single digit royalties based on aggregate net sales. The only research and development expense incurred by Stelios or the Company, and payment made to The Regents of UCSD through December 31, 2025 under the terms of the First UCSD Agreement, was the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has the right to terminate the First UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios entered into an exclusive worldwide license agreement on August 6, 2020 (as amended, the &#8220;Second UCSD Agreement&#8221;) with The Regents of UCSD to in-license materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy. On November 14, 2025, the Company entered into an amended and restated license agreement with UCSD, which amended and restated in its entirety, the Second UCSD Agreement (the "Amended and Restated Second UCSD Agreement"). The Amended and Restated Second UCSD Agreement maintained the Company's prior exclusive worldwide license to materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy, replaced Stelios with the Company as licensee, and exclusively in-licensed additional materials and intellectual property related to the LX2022 program. Stelios previously paid a one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Second UCSD Agreement. The Amended and Restated Second UCSD Agreement requires the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low-single digit royalties based on aggregate net sales. The only research and development expense incurred by Stelios or the Company, and payment made to The Regents of UCSD through December 31, 2025 under the terms of the Second UCSD Agreement and the Amended and Restated Second UCSD Agreement, was the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has the right to terminate the Amended and Restated Second UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2021, the Company entered into an exclusive worldwide license agreement (as amended, the &#8220;Third UCSD Agreement&#8221; and collectively with the First UCSD Agreement and the Amended and Restated Second UCSD Agreement, the &#8220;UCSD Agreements&#8221;) with The Regents of UCSD to in-license materials and intellectual property related to LX2020, a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The Third UCSD Agreement relates to the Company&#8217;s development efforts for its LX2020 program. In connection with the Third UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The Third UCSD Agreement required the Company to pay a one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and requires </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low- to mid-single digit royalties based on aggregate net sales</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Research and development expenses incurred by the Company and payments made to The Regents of UCSD under the terms of the Third UCSD Agreement include the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved during the third quarter of 2024. The Company has the right to terminate the Third UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2021, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sponsored research agreements with The Regents of UCSD (the "First UCSD SRA", the "Second UCSD SRA", and collectively, the &#8220;Initial UCSD SRAs&#8221;) for the Company&#8217;s LX2020, LX2021 and LX2022 programs in connection with the UCSD Agreements. Under the terms of the Initial UCSD SRAs, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by The Regents of UCSD or resulting inventions jointly owned between the Company and The Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Initial UCSD SRAs each have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD. The total costs to be invoiced to the Company over the terms of the Initial UCSD SRAs are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company entered into a third sponsored research agreement with The Regents of UCSD (as amended, the &#8220;Third UCSD SRA&#8221;) for the Company&#8217;s LX2022 program in connection with the Second UCSD Agreement. Under the terms of the Third UCSD SRA, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by The Regents of UCSD or resulting inventions jointly owned between the Company and The Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Third UCSD SRA has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to The Regents of UCSD. The costs to be invoiced to the Company over the term of the Third UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and the Company may incur additional costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Third UCSD SRA if certain study objectives are met.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company also entered into an amendment to the Second UCSD SRA (as amended, the "Amended Second UCSD SRA") for the Company&#8217;s LX2022 program that extended the term of the Second UCSD SRA to December 2024.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each of April 19, 2024 and September 27, 2024, the Company also entered into an amendment to the First UCSD SRA (as amended, the "Amended First UCSD SRA", and together with the Amended Second UCSD SRA and the Third UCSD SRA, the "UCSD SRAs") for the Company&#8217;s LX2021 program in connection with the First UCSD Agreement. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to the Company under the Amended First UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to The Regents of UCSD in connection with the Amended UCSD SRAs. During the year ended December 31, 2024, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to The Regents of UCSD in connection with the Amended UCSD SRAs. The Company has incurred and paid cumulative totals of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, to The Regents of UCSD as of December 31, 2025, in connection with the Amended UCSD SRAs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Myoventive, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In June 2025, the Company entered into a Collaboration and License Agreement with Tilia Therapeutics, Inc., now known as Myoventive, Inc. ("Myoventive" and the "Myoventive Agreement"), to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Myoventive Agreement, the Company contributed expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform. As consideration for its contributions, the Company received a double-digit percentage equity position in Myoventive and will be entitled to future milestone payments, royalties, and opt-in rights to certain program(s).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Abiomed, Inc. (Johnson &amp; Johnson subsidiary)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of gene therapy. Under the Abiomed Agreement, the parties intend to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV-vector delivery to the heart by investigating cutting-edge routes of administration using the Impella</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> heart pump technology. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t incur or pay any research and development costs in connection with the Abiomed Agreement for the year ended December 31, 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and acquisition and research collaboration and sponsored research agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Segment Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_33986856-2fc0-46e5-a0a8-20e6e13001c1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO and senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All of the Company&#8217;s operating results are reviewed by the Company&#8217;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a037ea15-adec-409e-8c43-b3ef64e5bcf7;"><span style="-sec-ix-hidden:F_b1bf8275-7776-4ea4-af70-17f51659f92f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.094%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,451</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,367</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,082</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,461</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,990</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,433</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Subsequent Events</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent events have been evaluated through March 30, 2026, which is the date that these financial statements were issued and were available to be issued.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">867,302</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share that were issued in the May 2025 Private Placement were exercised with total proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received by the Company (see Note 7).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#8217;s stock option awards. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2025 and December 31, 2024, the Company&#8217;s cash equivalents were held in U.S. government money market funds. As of December 31, 2025 and 2024, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#8217;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments&#8212;Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of premiums of approximately $149,000 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, at December 31, 2025.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company follows the two-class method when computing net income (loss) as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares and pre-funded warrants to purchase shares of common stock outstanding for the period. In accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the pre-funded warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During the years ended December 31, 2025 and December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,117,976</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,724,218</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> total potential common shares, respectively, related to the exercise of outstanding stock options, settlement of outstanding restricted stock units ("RSUs"), settlement of outstanding RSUs that vest upon the achievement of certain performance conditions ("PRSUs"), and exercise of outstanding warrants were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering in stockholders&#8217; equity as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent and occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Based Compensation Expense&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of RSUs and PRSUs. The measurement date for employee stock option, RSU, and PRSU awards is the date of grant, and stock-based compensation costs for employee non-performance awards are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on a graded basis. Compensation expense for equity awards with performance conditions, including PRSUs, is recognized if and when the Company concludes that it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each reporting period for equity awards with such performance conditions and adjusts compensation expense based on its probability assessment. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award, and stock-based compensation costs for non-employees are recognized as expense over the vesting period on a graded basis. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation expense for all equity awards is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the Company's 2021 Equity Incentive Plan (the "2021 Plan"), (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#8217;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#8217;s balance sheet and statement stockholders&#8217; equity are reduced until such awards vest. Forfeitures are recorded as they occur.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant under the 2021 Plan and the Company's 2023 Equity Incentive Plan (the "2023 Plan", and together with the 2021 Plan, the &#8220;Plans&#8221;), and shares issued under the 2023 ESPP, are estimated on the date of stock option grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU and PRSU granted under the 2023 Plan is equal to the closing price of the Company's common stock on the date of the grant. Prior to its initial public offering ("IPO") on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.<br/><br/>The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. As of December 31, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against its deferred tax assets (see Note 10).<br/><br/>The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2025 and December 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t identified any uncertain tax positions.<br/><br/>The Company's policy, to the extent uncertain tax positions exist, is to record interest and penalties related to uncertain tax positions in the provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are unobservable inputs for the asset or liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LongTermInvestmentPolicyTextBlock', window );">Long-term Investment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term Investment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for its long-term investment in nonredeemable convertible preferred stock in accordance with the provisions of ASC Topic 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received was based upon an observable price of cash paid for an identical security in an orderly transaction with a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#8217;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#8217;s cash equivalents consist of investments in U.S. government money market funds, and the Company's cash investments consist of U.S. Treasury securities. The Company&#8217;s cash, cash equivalents, and restricted cash are held with large financial institutions that management believes to be of high credit quality. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any losses caused by uninsured balances.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#8217;s Chief Operating Decision Maker ("CODM") is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer ("CEO") and its senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The CODM reviews the Company&#8217;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2025.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 6 for information regarding the Company&#8217;s capitalized operating and finance lease right-of-use assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:50.94%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:14.66%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:12.8%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:12.8%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,880</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,502</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">741</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,139</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s leases include options to extend or terminate the lease. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Adopted and Not Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes&#8212;Improvements to Income Tax Disclosures, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which focuses on the rate reconciliation and income taxes paid (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires a public business entity (a "PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4283524d-7551-4b90-bb15-d2729ab6b502;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU No. 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in ASU No. 2023-09 prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for all periods presented, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December 31, 2025, the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU No. 2023-09 retrospectively, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which only impacted the Company's income tax disclosures with no impact to its balance sheet or its statements of operations and comprehensive loss, stockholders' equity, or cash flows (see Note 10)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure of specified information about certain costs and expenses in the notes to financial statements. ASU No. 2024-03 will be effective for the Company starting in annual periods after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued ASU No. 2025-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 270) ("ASU No. 2025-11"). ASU No. 2025-11 clarifies interim disclosure requirements and the applicability of Topic 270. ASU No. 2025-11 will be effective for the Company starting in interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LongTermInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term investment policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LongTermInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:50.94%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:14.66%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:12.8%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.6%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:12.8%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,880</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,502</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">741</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,139</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.32%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,801</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,801</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,568</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:31.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of investments in U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Investments Classified as Available-for-Sale Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:23.745%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,568</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,380</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,568</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ComponentsOfOperatingLeaseTableTextBlock', window );">Components of Operating Lease</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of this operating lease were as follows:</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.64%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">459</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,650</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,606</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,152</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,110</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Remaining Undiscounted Contractual Rent Obligations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.135%;box-sizing:content-box;"></td>
         <td style="width:2.641%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.224%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,206</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,261</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,318</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: present value adjustment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,884</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock', window );">Components of Equipment Finance Leases</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the equipment finance leases were as follows:</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease expense</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">424</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">533</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Remaining Equipment Finance Lease Obligations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:77.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.259999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">907</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of equipment Finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ComponentsOfOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ComponentsOfOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:72.793%;box-sizing:content-box;"></td>
         <td style="width:1.274%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.693000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.274%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.965%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,299</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,696</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and other personnel costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,066</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,112</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expenses and other professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">839</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,406</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">545</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,277</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,759</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions of Warrants</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon issuance, the total pre-allocated fair value of the warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share, was estimated using a Black-Scholes option pricing model with the following assumptions:</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.695%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.564%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuances</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following number of shares of common stock for the exercise of outstanding warrants, exercise of outstanding pre-funded warrants, exercise of o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utstanding stock options, settlement of outstanding RSUs and PRSUs, and future issuances of stock-based awards:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.278%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.925999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.384%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase shares of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,876,838</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants to purchase shares of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,096,254</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase shares of common stock under the 2021 Plan and 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,396,860</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs and PRSUs subject to settlement in shares of common stock under the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,132,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,185,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">505,284</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,079,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,414,830</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the year ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.791%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.878%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.298%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.878%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.398%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,450,904</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">415,707</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,396,860</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.60</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,556,582</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.94</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.69</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions during the years ended December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rates</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.78</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years), weighted-average</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.79</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility, range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.90</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.61</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.19</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility, weighted-average</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity and PRSU Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.06%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664,684</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.45</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703,578</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.47</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the PRSU activity under the 2023 Plan for the nine months ended December 31, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.06%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,800</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.33</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified as follows in the Company&#8217;s statements of operations and comprehensive loss:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,524</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,608</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,132</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.52%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,645,323</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,787,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.09</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Net Income (Loss) Before Income Tax Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of net income (loss) before income tax expense are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December 31, 2025, and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.038%;box-sizing:content-box;"></td>
         <td style="width:1.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.604000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.145%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.384%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pretax Income (Loss)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US Federal Statutory Tax Rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,931</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,671</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credits:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credit - Federal R&amp;D Credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.54</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credit - Orphan Drug Credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,970</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,430</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,903</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.95</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company's deferred tax assets and liabilities at December 31, 2025 and December 31, 2024 are as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,743</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangibles</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,338</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,818</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,292</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,374</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,404</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,935</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,439</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,059</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,439</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived', window );">Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the Company's capital base and franchise taxes paid (net of refunds received) for the years presented below:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">551</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">551</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the jurisdictions that exceeded 5% of the Company's total capital base and franchise taxes paid (net of refunds) for the years presented below:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.072%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.103%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York City</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary Of Additional Information On Company's Net loss Including Segment Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2025 and December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.094%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,451</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,367</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,082</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,461</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,990</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,433</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>May 28, 2025</div></th>
<th class="th"><div>Mar. 11, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,961<span></span>
</td>
<td class="nump">$ 98,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(380,134)<span></span>
</td>
<td class="num">(280,173)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents, including restricted cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember', window );">March 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember', window );">October 2025 Financing Transactions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 143,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">106 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LossRecognizedFromUninsuredBalances', window );">Loss recognized from uninsured balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operation segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate202309Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_InvestmentCurrent', window );">Investment current</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise of Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from Computation of diluted net loss per common share | shares</a></td>
<td class="nump">19,117,976<span></span>
</td>
<td class="nump">3,724,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_InvestmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_InvestmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LossRecognizedFromUninsuredBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss recognized from uninsured balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LossRecognizedFromUninsuredBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,880<span></span>
</td>
<td class="nump">$ 1,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(741)<span></span>
</td>
<td class="num">(474)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,222<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">$ 118,767<span></span>
</td>
<td class="nump">$ 86,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Non-current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">64,801<span></span>
</td>
<td class="nump">7,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="nump">223,746<span></span>
</td>
<td class="nump">111,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents (money market)</a></td>
<td class="nump">40,178<span></span>
</td>
<td class="nump">17,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">118,767<span></span>
</td>
<td class="nump">86,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Non-current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">64,801<span></span>
</td>
<td class="nump">7,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="nump">40,178<span></span>
</td>
<td class="nump">17,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents (money market)</a></td>
<td class="nump">40,178<span></span>
</td>
<td class="nump">17,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="nump">183,568<span></span>
</td>
<td class="nump">93,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">118,767<span></span>
</td>
<td class="nump">86,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Non-current portion of investments in U.S. Treasury securities</a></td>
<td class="nump">$ 64,801<span></span>
</td>
<td class="nump">$ 7,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 183,380<span></span>
</td>
<td class="nump">$ 93,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">183,568<span></span>
</td>
<td class="nump">93,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">183,380<span></span>
</td>
<td class="nump">93,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 183,568<span></span>
</td>
<td class="nump">$ 93,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Investment- Additional Information (Details) - Investee<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lxeo_InvestmentInEquitySecuritiesOfInvesteeMember', window );">Nonredeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares Issued | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueOfSharesReceived', window );">Fair value of shares received | $</a></td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueOfSharesReceivedPerShare', window );">Fair value of shares received per share | $ / shares</a></td>
<td class="nump">$ 0.338983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueOfSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueOfSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueOfSharesReceivedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares received per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueOfSharesReceivedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lxeo_InvestmentInEquitySecuritiesOfInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lxeo_InvestmentInEquitySecuritiesOfInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="nump">$ 6,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation and other personnel costs</a></td>
<td class="nump">4,066<span></span>
</td>
<td class="nump">4,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent', window );">Accrued general and administrative expenses and other professional fees</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">2,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,277<span></span>
</td>
<td class="nump">$ 13,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses and other professional fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2029</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2034</div></th>
<th class="th">
<div>Aug. 01, 2029 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,578,000<span></span>
</td>
<td class="nump">$ 8,069,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net book values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,140,000<span></span>
</td>
<td class="nump">$ 1,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm', window );">Remaining lease payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm', window );">Weighted average remaining amortization term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember', window );">Office Facility and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseAgreementEnteredDate', window );">Operating lease agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseEndDate', window );">Operating lease end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">additional five-year option to extend the lease beyond July 2029 at the then-prevailing effective market rental rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember', window );">Office Facility and Laboratory Space | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember', window );">Office Facility and Laboratory Space | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Total gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net book values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfMonthlyInstallmentsLease', window );">Number of monthly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeFinanceLeaseCommencementDateRangeStart', window );">Finance lease, commencement date range, start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeFinanceLeaseCommencementDateRangeEnd', window );">Finance lease, commencement date range, end</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts', window );">Total aggregate monthly installment payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Imputed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts', window );">Monthly installment payment amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Imputed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts', window );">Monthly installment payment amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease aggregate monthly installment payment amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease monthly installment payment amounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease weighted average remaining amortization term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeFinanceLeaseCommencementDateRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, commencement date range, end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeFinanceLeaseCommencementDateRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeFinanceLeaseCommencementDateRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, commencement date range, start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeFinanceLeaseCommencementDateRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfMonthlyInstallmentsLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of monthly installments lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfMonthlyInstallmentsLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease end date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining payment term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 2,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total operating lease expense</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</a></td>
<td class="nump">$ 2,152<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">8,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(1,116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">7,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Included in the balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities - operating</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - operating</a></td>
<td class="nump">$ 4,884<span></span>
</td>
<td class="nump">$ 6,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Equipment Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Reduction in the carrying amount of ROU assets, finance</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseExpense', window );">Total finance lease expense</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</a></td>
<td class="nump">$ 533<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Included in the balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of lease liabilities - finance</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - finance</a></td>
<td class="nump">$ 327<span></span>
</td>
<td class="nump">$ 817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 16, 2025</div></th>
<th class="th"><div>May 28, 2025</div></th>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Mar. 11, 2024</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000,000<span></span>
</td>
<td class="nump">510,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,001,766<span></span>
</td>
<td class="nump">33,079,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions', window );">Common stock shares issued upon early exercise of unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="nump">7,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends, common stock, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueOfWarrantsPerShare', window );">Fair value of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,999,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember', window );">March 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, placement agent fees, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NetProceedsReceivedFromPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember', window );">March 2024 Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember', window );">Leerink At The Market Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockOfferingGrossProceedsPercentage', window );">Stock offering gross proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember', window );">Leerink At The Market Sales Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockOfferingValueSharesAuthorizedToBeSold', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, placement agent fees, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage', window );">Maximum increase or decrease in ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NetProceedsReceivedFromPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,963,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,790,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,790,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,876,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May 2025 Private Placement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfOwnershipConsideredForWarrantExercise', window );">Percentage of ownership considered for warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PublicOfferingMember', window );">October 2025 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, placement agent fees, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NetProceedsReceivedFromPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PublicOfferingMember', window );">October 2025 Public Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_Thirty-DayUnderwriterOptionMember', window );">30-day Underwriter Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_Thirty-DayUnderwriterOptionMember', window );">30-day Underwriter Option [Member] | Maximum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,343,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember', window );">October 2025 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, placement agent fees, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage', window );">Maximum increase or decrease in ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NetProceedsReceivedFromPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember', window );">October 2025 Private Placement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember', window );">October 2025 Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember', window );">October 2025 Private Placement [Member] | Common Stock [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember', window );">October 2025 Private Placement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfOwnershipConsideredForWarrantExercise', window );">Percentage of ownership considered for warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember', window );">October 2025 Financing Transactions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, placement agent fees, commissions and offering expenses</a></td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember', window );">October 2025 Financing Transactions [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember', window );">October 2025 Financing Transactions [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | May 2025 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | May 2025 Private Placement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | May 2025 Private Placement [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued on early exercise of unvested stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueOfWarrantsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueOfWarrantsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum increase or decrease in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NetProceedsReceivedFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds received from Private Placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NetProceedsReceivedFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PercentageOfOwnershipConsideredForWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership considered for warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PercentageOfOwnershipConsideredForWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockOfferingGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offering gross proceeds percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockOfferingGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockOfferingValueSharesAuthorizedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offering value shares authorized to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockOfferingValueSharesAuthorizedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_Thirty-DayUnderwriterOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_Thirty-DayUnderwriterOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_October2025FinancingTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Schedule of Fair Value Assumptions of Warrants (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">2.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">2.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">100.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">28,079,625<span></span>
</td>
<td class="nump">6,414,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">6,096,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">13,876,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember', window );">2021 Plan and 2023 Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">4,396,860<span></span>
</td>
<td class="nump">3,457,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">733,239<span></span>
</td>
<td class="nump">505,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">2,132,156<span></span>
</td>
<td class="nump">2,185,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | RSUs and PRSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">844,278<span></span>
</td>
<td class="nump">266,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1">59 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,079,625<span></span>
</td>
<td class="nump">6,414,830<span></span>
</td>
<td class="nump">28,079,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,079,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in aggregate number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="nump">$ 11.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant date fair values of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yields percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting period, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate', window );">Contractual term grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member] | Employee Stock Option | Non-employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationPaymentDescription', window );">Share based compensation payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a four-year period with 25% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear', window );">Percentage of automatically increase in available shares of common stock on beginning of each calendar year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting period, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationPaymentDescription', window );">Share based compensation payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a two-year period with 50% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following four quarters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a four-year period with 25% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Restricted Stock Units [Member] | Vest Over Two Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Performance Restricted Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Performance Restricted Stock Unit [Member] | Vest Over 18 Month [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,804,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in aggregate number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,650,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting period, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationPaymentDescription', window );">Share based compensation payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a four-year period with 25% of the options granted vesting after approximately one year and the remainder vesting in equal monthly installments over the following 36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate', window );">Contractual term grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Employee Stock Option | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Employee Stock Option | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan', window );">Number of shares automatically increase in available shares of common stock under plan</a></td>
<td class="nump">477,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PayrollDeductionsAtPrice', window );">Payroll deductions at price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans', window );">Fair value of unearned employee stock ownership plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Weighted average purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Total proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear', window );">Percentage of automatically increase in available shares of common stock on beginning of each calendar year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP [Member] | Minimum [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommonStockDuringOfferingPeriod', window );">Common stock during offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyFiveInducementEquityPlanMember', window );">2025 Inducement Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CommonStockDuringOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock During Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CommonStockDuringOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Unearned Employee Stock Ownership Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PayrollDeductionsAtPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll Deductions at Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PayrollDeductionsAtPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of automatically increase in available shares of common stock on beginning of each calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ShareBasedCompensationPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation payment description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ShareBasedCompensationPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lxeo_PerformanceRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lxeo_PerformanceRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyFiveInducementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyFiveInducementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - Employee Stock Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">2021 Plan and 2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, beginning</a></td>
<td class="nump">3,457,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="nump">1,450,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares</a></td>
<td class="num">(15,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(415,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, shares</a></td>
<td class="num">(80,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, ending</a></td>
<td class="nump">4,396,860<span></span>
</td>
<td class="nump">3,457,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable</a></td>
<td class="nump">2,556,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 11.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">8.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">7.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">9.75<span></span>
</td>
<td class="nump">$ 11.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 9.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Options exercisable</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning</a></td>
<td class="nump">$ 2,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending</a></td>
<td class="nump">11,304<span></span>
</td>
<td class="nump">$ 2,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable</a></td>
<td class="nump">$ 6,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rates, minimum</a></td>
<td class="nump">3.78%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rates, maximum</a></td>
<td class="nump">4.57%<span></span>
</td>
<td class="nump">4.57%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, range, minimum</a></td>
<td class="nump">88.12%<span></span>
</td>
<td class="nump">84.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, range, maximum</a></td>
<td class="nump">98.90%<span></span>
</td>
<td class="nump">88.19%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years), weighted-average</a></td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility, weighted-average</a></td>
<td class="nump">92.25%<span></span>
</td>
<td class="nump">85.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of RSU Activity and PRSU Activity (Details) - 2023 Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares unvested, beginning balance | shares</a></td>
<td class="nump">266,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">664,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested | shares</a></td>
<td class="num">(101,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(125,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares unvested, ending balance | shares</a></td>
<td class="nump">703,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, unvested, beginning balance | $ / shares</a></td>
<td class="nump">$ 15.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">5.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested | $ / shares</a></td>
<td class="nump">15.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, forfeited | $ / shares</a></td>
<td class="nump">7.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, unvested, ending balance | $ / shares</a></td>
<td class="nump">$ 7.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lxeo_PerformanceRestrictedStockUnitMember', window );">Performance Restricted Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">217,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested | shares</a></td>
<td class="num">(76,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares unvested, ending balance | shares</a></td>
<td class="nump">140,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 7.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested | $ / shares</a></td>
<td class="nump">7.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, unvested, ending balance | $ / shares</a></td>
<td class="nump">$ 7.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lxeo_PerformanceRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lxeo_PerformanceRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 12,132<span></span>
</td>
<td class="nump">$ 12,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,524<span></span>
</td>
<td class="nump">6,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,608<span></span>
</td>
<td class="nump">$ 6,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (99,961)<span></span>
</td>
<td class="num">$ (98,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">53,645,323<span></span>
</td>
<td class="nump">31,787,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">53,645,323<span></span>
</td>
<td class="nump">31,787,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Net Income (Loss) Before Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (99,670)<span></span>
</td>
<td class="num">$ (98,436)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">$ (99,670)<span></span>
</td>
<td class="num">$ (98,436)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax Income (Loss)</a></td>
<td class="num">$ (99,670)<span></span>
</td>
<td class="num">$ (98,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">US Federal Statutory Tax Rate, Amount</a></td>
<td class="num">$ (20,931)<span></span>
</td>
<td class="num">$ (20,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US Federal Statutory Tax Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract', window );"><strong>Tax Credits:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Tax Credit - Federal R&amp;D Credit, Amount</a></td>
<td class="nump">$ 5,523<span></span>
</td>
<td class="num">$ (678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Tax Credit - Federal R&amp;D Credit</a></td>
<td class="num">(5.54%)<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount', window );">Tax Credit - Orphan Drug Credit, Amount</a></td>
<td class="num">$ (1,970)<span></span>
</td>
<td class="num">$ (2,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent', window );">Tax Credit - Orphan Drug Credit</a></td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Amount</a></td>
<td class="nump">$ 16,430<span></span>
</td>
<td class="nump">$ 22,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(16.48%)<span></span>
</td>
<td class="num">(23.27%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract', window );"><strong>Nontaxable or Nondeductible Items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other, Amount</a></td>
<td class="nump">$ 948<span></span>
</td>
<td class="nump">$ 1,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.95%)<span></span>
</td>
<td class="num">(1.46%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract', window );"><strong>Other Adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation tax credits orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation tax credits orphan drug credit percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,868<span></span>
</td>
<td class="nump">$ 33,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">7,190<span></span>
</td>
<td class="nump">10,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DeferredTaxAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">5,167<span></span>
</td>
<td class="nump">5,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">43,720<span></span>
</td>
<td class="nump">39,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deferred tax assets</a></td>
<td class="nump">6,225<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">121,374<span></span>
</td>
<td class="nump">98,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(118,935)<span></span>
</td>
<td class="num">(95,426)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(2,059)<span></span>
</td>
<td class="num">(2,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other deferred tax liabilities</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(2,978)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfCumulativeOwnershipChange', window );">Percentage of cumulative ownership change</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AnnualLimitationAbilityToUtilize', window );">Annual limitation ability to utilize</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Federal tax credits</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Uncertain tax positions, accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">182,000,000<span></span>
</td>
<td class="nump">106,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TaxCreditCarryForwardExpirationYear', window );">Tax credit carryforward, expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 362,900,000<span></span>
</td>
<td class="nump">$ 212,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TaxCreditCarryForwardExpirationYear', window );">Tax credit carryforward, expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AnnualLimitationAbilityToUtilize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Limitation Ability to Utilize</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AnnualLimitationAbilityToUtilize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PercentageOfCumulativeOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PercentageOfCumulativeOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_TaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_TaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">State</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes Paid, Net, Total</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">State</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lxeo_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">State</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidFederalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lxeo_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lxeo_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Employees</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfFormerEmployees', window );">Number of former employees</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember', window );">Third Parties for Pharmaceutical Manufacturing and Research Activities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">Termination notice period (in days)</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember', window );">Third Parties for Pharmaceutical Manufacturing and Research Activities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">Termination notice period (in days)</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfFormerEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of former employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfFormerEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 19, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 13, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2021 </div>
<div>USD ($) </div>
<div>IntegerItem</div>
</th>
<th class="th">
<div>Oct. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 28, 2020 </div>
<div>USD ($) </div>
<div>IntegerItem</div>
</th>
<th class="th">
<div>Apr. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,797,000<span></span>
</td>
<td class="nump">$ 74,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember', window );">Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfDevelopmentMilestone', window );">Development milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Asset acquisition date of acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Asset acquisition percentage of outstanding stock acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payment to selling shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_MilestoneReceived', window );">Milestone Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payment to selling shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember', window );">Adverum License Agreement | Adverum Biotechnologies Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfDevelopmentMilestone', window );">Development milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms', window );">Royalty payments description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember', window );">Adverum License Agreement | Adverum Biotechnologies Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndRegulatoryMilestonesDue', window );">Development and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommercializationMilestonesDue', window );">Commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember', window );">Cornell License Agreements | Cornell University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfLicenseAgreements', window );">Number of license agreements | IntegerItem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_UpfrontCashPayment', window );">Upfront payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Notes with outstanding principal exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember', window );">Cornell License Agreements | Cornell University | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember', window );">Cornell License Agreements | Cornell University | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on debt exchanged | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember', window );">Cornell First License Agreements | Cornell University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue', window );">Specific clinical and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember', window );">Cornell Second License Agreements | Cornell University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfClinicalAndRegulatoryMilestone', window );">Clinical and regulatory milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember', window );">Cornell Second License Agreements | Cornell University | Maximum | Two Portfolios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue', window );">Specific clinical and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember', window );">Cornell Second License Agreements | Cornell University | Maximum | Third Portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue', window );">Specific clinical and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember', window );">Cornell Third License Agreements | Cornell University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee', window );">License fee and initial data transfer fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfAnnualDataTransferFee', window );">Annual data transfer fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember', window );">Cornell Third License Agreements | Cornell University | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfAnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember', window );">Cornell Third License Agreements | Cornell University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommercializationMilestonesDue', window );">Commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfAnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfRegulatoryMilestones', window );">Regulatory milestone to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember', window );">First UCSD License Agreement | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember', window );">First UCSD License Agreement | Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndCommercializationMilestonesDue', window );">Development and commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember', window );">Second UCSD License Agreement | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember', window );">Second UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OneTimeUpFrontNonRefundableFees', window );">One-time up-front non-refundable fees</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember', window );">Second UCSD License Agreement | Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndCommercializationMilestonesDue', window );">Development and commercialization milestones due</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementsTerm', window );">Research agreements term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementTerminationNoticePeriod', window );">Research agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred', window );">Additional costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription', window );">Development and commercialization milestones description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfDevelopmentMilestone', window );">Development milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OneTimeUpFrontNonRefundableFees', window );">One-time up-front non-refundable fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement | Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndCommercializationMilestonesDue', window );">Development and commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember', window );">Second Amendment to the Third Cornell License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentToAdditionalDataTransferProcess', window );">Payment to additional data transfer process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember', window );">UCSD Sponsored Research Agreements | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfResearchAgreements', window );">Number of research agreements | IntegerItem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementsTerm', window );">Research agreements term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementTerminationNoticePeriod', window );">Research agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember', window );">Amended First UCSD Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AmendedUCSDSponsoredResearchAgreementMember', window );">Amended UCSD SRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AbiomedAgreementMember', window );">Abiomed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate development and commercialization milestones description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CommercializationMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercialization milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CommercializationMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DevelopmentAndCommercializationMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and commercialization milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DevelopmentAndCommercializationMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DevelopmentAndRegulatoryMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DevelopmentAndRegulatoryMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_MilestoneReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_MilestoneReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OneTimeUpFrontNonRefundableFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One time up front non refundable fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OneTimeUpFrontNonRefundableFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfAnnualDataTransferFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of annual data transfer fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfAnnualDataTransferFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfAnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of annual license maintenance fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfAnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfClinicalAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Clinical And Regulatory Milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfClinicalAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of license issue fee and initial data transfer fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of one time up front non refundable fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfOneTimeUpFrontNonRefundableFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of regulatory milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentToAdditionalDataTransferProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to additional data transfer process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentToAdditionalDataTransferProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAgreementsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreements term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAgreementsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development Aarrangement, ontract to perform for others, dditional costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific clinical and regulatory milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_SpecificClinicalAndRegulatoryMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when acquirer obtains control of acquiree in business combination, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_AdverumBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_AdverumBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_CornellUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_CornellUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_TwoPortfoliosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_TwoPortfoliosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_ThirdPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_ThirdPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_AmendedUCSDSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_AmendedUCSDSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_AbiomedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_AbiomedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The Company's CODM is its CEO and senior leadership team. All of the Company&#8217;s operating results are reviewed by the Company&#8217;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a single reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income and expense, net</a></td>
<td class="num">$ (9,296)<span></span>
</td>
<td class="num">$ (7,433)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(99,961)<span></span>
</td>
<td class="num">(98,333)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseLX2006', window );">LX2006</a></td>
<td class="nump">18,163<span></span>
</td>
<td class="nump">14,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseLX2020', window );">LX2020</a></td>
<td class="nump">15,413<span></span>
</td>
<td class="nump">23,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseLX1001', window );">LX1001</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseOtherPrograms', window );">Other programs</a></td>
<td class="nump">2,075<span></span>
</td>
<td class="nump">3,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses', window );">Employee compensation expenses</a></td>
<td class="nump">15,183<span></span>
</td>
<td class="nump">16,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Lab-related costs and supplies</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">All other research and development expense</a></td>
<td class="nump">10,245<span></span>
</td>
<td class="nump">11,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses', window );">Employee compensation expenses</a></td>
<td class="nump">8,461<span></span>
</td>
<td class="nump">6,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">All other general and administrative expense</a></td>
<td class="nump">36,999<span></span>
</td>
<td class="nump">24,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income and expense, net</a></td>
<td class="num">(9,296)<span></span>
</td>
<td class="num">(7,433)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (99,961)<span></span>
</td>
<td class="num">$ (98,333)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense employee compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense employee compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseLX1001">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense LX1001.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseLX1001</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseLX2006">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense LX2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseLX2006</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseLX2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense LX2020.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseLX2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseOtherPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense other programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseOtherPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 28, 2025</div></th>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember', window );">Leerink At The Market Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockOfferingGrossProceedsPercentage', window );">Stock Offering Gross Proceeds Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May Two Thousand Twenty Five Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May Two Thousand Twenty Five Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May Two Thousand Twenty Five Private Placement [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">6,963,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember', window );">May Two Thousand Twenty Five Private Placement [Member] | Pre Funded Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Leerink At The Market Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockOfferingValueSharesAuthorizedToBeSold', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | May Two Thousand Twenty Five Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 44,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | May Two Thousand Twenty Five Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">13,876,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | May Two Thousand Twenty Five Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockOfferingGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offering gross proceeds percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockOfferingGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockOfferingValueSharesAuthorizedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offering value shares authorized to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockOfferingValueSharesAuthorizedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_MayTwoThousandTwentyFivePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lxeo_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>241</ContextCount>
  <ElementCount>440</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1</Role>
      <ShortName>Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Statements of Stockholders Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Cybersecurity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity</Role>
      <ShortName>Cybersecurity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Long-term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestment</Role>
      <ShortName>Long-term Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies1</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements</Role>
      <ShortName>License, Acquisition, Research Collaboration and Sponsored Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Long-term Investment- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails</Role>
      <ShortName>Long-term Investment- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Leases - Components of Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails</Role>
      <ShortName>Leases - Components of Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails</Role>
      <ShortName>Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Leases - Components of Equipment Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails</Role>
      <ShortName>Leases - Components of Equipment Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails</Role>
      <ShortName>Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Capital Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails</Role>
      <ShortName>Capital Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Capital Stock - Schedule of Fair Value Assumptions of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails</Role>
      <ShortName>Capital Stock - Schedule of Fair Value Assumptions of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails</Role>
      <ShortName>Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Stock-Based Compensation - Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai</Role>
      <ShortName>Stock-Based Compensation - Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Stock-based Compensation - Summary of RSU Activity and PRSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of RSU Activity and PRSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Income Taxes - Schedule of Components of Net Income (Loss) Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Net Income (Loss) Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Income Taxes - Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails</Role>
      <ShortName>Income Taxes - Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996005 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails</Role>
      <ShortName>License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3</Role>
      <ShortName>Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lxeo-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lxeo-20251231.htm">lxeo-20251231.htm</File>
    <File>lxeo-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img147150826_0.jpg</File>
    <File>img147150826_1.jpg</File>
    <File>img147150826_10.jpg</File>
    <File>img147150826_2.jpg</File>
    <File>img147150826_3.jpg</File>
    <File>img147150826_4.jpg</File>
    <File>img147150826_5.jpg</File>
    <File>img147150826_6.jpg</File>
    <File>img147150826_7.jpg</File>
    <File>img147150826_8.jpg</File>
    <File>img147150826_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="659">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lxeo-20251231.htm": {
   "nsprefix": "lxeo",
   "nsuri": "http://www.lexeotx.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "lxeo-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "lxeo-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 340,
   "keyCustom": 100,
   "axisStandard": 30,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 41,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2025": 8,
    "http://xbrl.sec.gov/ecd/2025": 1,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 241,
   "entityCount": 1,
   "segmentCount": 82,
   "elementCount": 847,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 659,
    "http://xbrl.sec.gov/dei/2025": 41,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 12
   },
   "report": {
    "R1": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
     "longName": "75010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
     "longName": "75040 - Statement - Statements of Stockholders Equity",
     "shortName": "Statements of Stockholders Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical",
     "longName": "75050 - Statement - Statements of Stockholders Equity (Parenthetical)",
     "shortName": "Statements of Stockholders Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_1f1718fb-6b55-4400-93d6-9f15b60b4646",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0d4934d2-685d-4142-9a39-88dfc50f3990",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
     "longName": "75060 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_72e10212-d78b-4f0e-a46a-69781278fac8",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_72e10212-d78b-4f0e-a46a-69781278fac8",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity",
     "longName": "995455 - Disclosure - Cybersecurity",
     "shortName": "Cybersecurity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation",
     "longName": "995465 - Disclosure - Description of Business and Basis of Presentation",
     "shortName": "Description of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestment",
     "longName": "995495 - Disclosure - Long-term Investment",
     "shortName": "Long-term Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:LongTermInvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:LongTermInvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1",
     "longName": "995505 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3",
     "longName": "995515 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1",
     "longName": "995525 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1",
     "longName": "995535 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995545 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995555 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies1",
     "longName": "995565 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements",
     "longName": "995575 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements",
     "shortName": "License, Acquisition, Research Collaboration and Sponsored Research Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1",
     "longName": "995585 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995595 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995625 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995635 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:ComponentsOfOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:ComponentsOfOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995645 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables",
     "longName": "995655 - Disclosure - Capital Stock (Tables)",
     "shortName": "Capital Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995665 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995675 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995685 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995695 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)",
     "shortName": "Description of Business and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_464f0f91-9b5b-4c2d-9f37-9b998e5a31ca",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995715 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_d2859d77-9d6d-417d-b711-d050b24f282f",
      "name": "lxeo:LossRecognizedFromUninsuredBalances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d2859d77-9d6d-417d-b711-d050b24f282f",
      "name": "lxeo:LossRecognizedFromUninsuredBalances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "995725 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995735 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_75647768-9be4-4729-b3de-fab3b1e0526d",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails",
     "longName": "995745 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Long-term Investment- Additional Information (Details)",
     "shortName": "Long-term Investment- Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_b108cd4a-1106-42e3-838b-ca809495548e",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "lxeo:LongTermInvestmentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b108cd4a-1106-42e3-838b-ca809495548e",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "lxeo:LongTermInvestmentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995765 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "lxeo:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "lxeo:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_3efbfffb-0778-4c28-91b0-3428da47503f",
      "name": "lxeo:OperatingLeaseCommencementDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3efbfffb-0778-4c28-91b0-3428da47503f",
      "name": "lxeo:OperatingLeaseCommencementDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails",
     "longName": "995785 - Disclosure - Leases - Components of Operating Lease (Details)",
     "shortName": "Leases - Components of Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails",
     "longName": "995795 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)",
     "shortName": "Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails",
     "longName": "995815 - Disclosure - Leases - Components of Equipment Finance Leases (Details)",
     "shortName": "Leases - Components of Equipment Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails",
     "longName": "995825 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)",
     "shortName": "Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Capital Stock - Additional Information (Details)",
     "shortName": "Capital Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CapitalUnitsAuthorized",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CapitalUnitsAuthorized",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails",
     "longName": "995855 - Disclosure - Capital Stock - Schedule of Fair Value Assumptions of Warrants (Details)",
     "shortName": "Capital Stock - Schedule of Fair Value Assumptions of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
     "longName": "995865 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "shortName": "Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_33a1d373-61e1-4dbc-8ca5-46559d2ba9d0",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e272bdc5-b039-4362-8f99-fa87bcc9aa26",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "995885 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_29e7aba1-e6b3-4d85-8383-eedc450375e7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bcddf2df-722a-4a3c-bd72-c6695de021e4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai",
     "longName": "995895 - Disclosure - Stock-Based Compensation - Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
     "longName": "995905 - Disclosure - Stock-based Compensation - Summary of RSU Activity and PRSU Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of RSU Activity and PRSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails",
     "longName": "995915 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995925 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails",
     "longName": "995935 - Disclosure - Income Taxes - Schedule of Components of Net Income (Loss) Before Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Components of Net Income (Loss) Before Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "longName": "995945 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "995965 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995975 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:PercentageOfCumulativeOwnershipChange",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:PercentageOfCumulativeOwnershipChange",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails",
     "longName": "995985 - Disclosure - Income Taxes - Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received) (Details)",
     "shortName": "Income Taxes - Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lxeo:SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lxeo:SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:NumberOfFormerEmployees",
      "unitRef": "U_Employees",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "lxeo:NumberOfFormerEmployees",
      "unitRef": "U_Employees",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
     "longName": "996005 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)",
     "shortName": "License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a77def4a-c9cb-4e98-960a-031f93bc0880",
      "name": "lxeo:PaymentOfDevelopmentMilestone",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3",
     "longName": "996025 - Disclosure - Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)",
     "shortName": "Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9ad4d83e-62ad-4f4d-afe5-59f007561415",
      "name": "lxeo:ResearchAndDevelopmentExpenseLX2006",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996035 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "lxeo_AbiomedAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AbiomedAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abiomed Agreement [Member]",
        "documentation": "Abiomed Agreement [Member].",
        "terseLabel": "Abiomed Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r155",
      "r156",
      "r157",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r255",
      "r256",
      "r293",
      "r295",
      "r296",
      "r313",
      "r314",
      "r317",
      "r356",
      "r357",
      "r358",
      "r359",
      "r443",
      "r444",
      "r445",
      "r446",
      "r497",
      "r498",
      "r499",
      "r500",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r553",
      "r554",
      "r555",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r591",
      "r592",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r638",
      "r639",
      "r660",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r957"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium (accretion of discount) on investments in U.S. Treasury securities",
        "terseLabel": "Amortization of premium (accretion of discount) on investments in U.S. Treasury securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonuses",
        "label": "Accrued Bonuses, Current",
        "verboseLabel": "Accrued bonus expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued general and administrative expenses and other professional fees",
        "label": "Accrued General And Administrative Expenses And Other Professional Fees Current",
        "documentation": "Accrued general and administrative expenses and other professional fees current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities And Other Liabilities Current",
        "documentation": "Accrued liabilities and other liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r135",
      "r746"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive gain (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r64",
      "r141",
      "r742",
      "r769",
      "r773",
      "r1230"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6",
      "r15",
      "r594",
      "r597",
      "r684",
      "r764",
      "r765",
      "r1119",
      "r1120",
      "r1121",
      "r1137",
      "r1138",
      "r1139",
      "r1140"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1231",
      "r1267"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs, value",
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, equity component of convertible debt share.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Share",
        "terseLabel": "Conversion of SAFE Note into common stock in connection with initial public offering, Share"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options",
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options.",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options, Share",
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options, share.",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, share.",
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Share",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, share"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, value.",
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Value",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdverumBiotechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdverumBiotechnologiesIncMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adverum Biotechnologies Inc",
        "label": "Adverum Biotechnologies Inc [Member]",
        "documentation": "Adverum Biotechnologies Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdverumLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AdverumLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adverum license agreement.",
        "terseLabel": "Adverum License Agreement",
        "label": "Adverum License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AggregateDevelopmentAndCommercializationMilestonesDescription",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and commercialization milestones description",
        "label": "Aggregate Development And Commercialization Milestones Description",
        "documentation": "aggregate development and commercialization milestones description."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1005",
      "r1015",
      "r1048"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r997",
      "r1008",
      "r1018",
      "r1051"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "lxeo_AgreementExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AgreementExpirationTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement expiration term",
        "label": "Agreement Expiration Term",
        "documentation": "Agreement expiration term."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1043",
      "r1052",
      "r1056",
      "r1064"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r447",
      "r457"
     ]
    },
    "lxeo_AmendedFirstUcsdAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AmendedFirstUcsdAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended First UCSD Agreement [Member]",
        "documentation": "Amended First UCSD Agreement.",
        "terseLabel": "Amended First UCSD Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmendedUCSDSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AmendedUCSDSponsoredResearchAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended UCSD SRA",
        "label": "Amended UCSD Sponsored Research Agreement [Member]",
        "documentation": "Amended UCSD Sponsored Research Agreement [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmountDueForEachQuarterUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AmountDueForEachQuarterUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due for each quarter under agreement",
        "label": "Amount Due for Each Quarter Under Agreement",
        "documentation": "Amount due for each quarter under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmountDueUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AmountDueUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due under agreement",
        "label": "Amount Due Under Agreement",
        "documentation": "Amount due under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts Reclassified From Deposit Liabilities Upon The Vesting Of Early-exercised Stock Options Previously Subject To Repurchase, Net Of Proceeds Received From Early Exercise Of Unvested Stock Options Subject To Repurchase And Recorded As Deposit Liabilities",
        "documentation": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities.",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AnnualLimitationAbilityToUtilize": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AnnualLimitationAbilityToUtilize",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual limitation ability to utilize",
        "label": "Annual Limitation Ability to Utilize",
        "documentation": "Annual Limitation Ability to Utilize"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from Computation of diluted net loss per common share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "lxeo_AntidilutiveSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "AntidilutiveSecuritiesMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Member]",
        "documentation": "Antidilutive securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r104",
      "r137",
      "r167",
      "r169",
      "r170",
      "r212",
      "r225",
      "r243",
      "r247",
      "r292",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r580",
      "r584",
      "r648",
      "r729",
      "r730",
      "r738",
      "r826",
      "r899",
      "r900",
      "r914",
      "r957",
      "r960",
      "r961",
      "r972",
      "r1164",
      "r1165",
      "r1252"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r142",
      "r167",
      "r169",
      "r170",
      "r292",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r580",
      "r584",
      "r648",
      "r957",
      "r1164",
      "r1165",
      "r1252"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "terseLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r943"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1001"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1001"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1001"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r303",
      "r737"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Available-for-sale securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Available-for-sale securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r303",
      "r617",
      "r640",
      "r641",
      "r642",
      "r643",
      "r724",
      "r878",
      "r943",
      "r946",
      "r953",
      "r1149",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Current portion of investments in U.S. Treasury securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r303"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Non-current portion of investments in U.S. Treasury securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r258",
      "r303"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r776",
      "r923",
      "r924",
      "r1221",
      "r1223",
      "r1224"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r776",
      "r923",
      "r924",
      "r1221",
      "r1223",
      "r1224"
     ]
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition date of acquisition",
        "label": "Business Combination, Effective Date of Acquisition",
        "documentation": "Date when acquirer obtains control of acquiree in business combination, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r930",
      "r931",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition percentage of outstanding stock acquisition",
        "label": "Business Combination, Voting Equity Interest Acquired, Percentage",
        "documentation": "Percentage of voting equity interest acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r930",
      "r931"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to selling shareholders",
        "label": "Business Combination, Consideration Transferred, Equity Interest",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r932",
      "r933",
      "r936",
      "r937"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred But Not Yet Paid, Net of Paid Amount",
        "documentation": "Capital expenditures incurred but not yet paid, net of paid amount.",
        "negatedLabel": "(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable",
        "terseLabel": "property and equipment purchased in the current period included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized capital stock",
        "label": "Capital Units, Authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents, including restricted cash",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r132",
      "r879"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents (money market)",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643",
      "r1233",
      "r1234"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r90"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash and cash equivalents, including restricted cash and investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r74",
      "r164"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r74"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r123",
      "r155",
      "r181",
      "r255",
      "r313",
      "r317",
      "r356",
      "r443",
      "r498",
      "r508",
      "r509",
      "r553",
      "r554",
      "r573",
      "r591",
      "r605",
      "r606",
      "r638",
      "r639",
      "r660",
      "r679",
      "r680",
      "r762",
      "r763"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r182",
      "r196",
      "r294"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r138",
      "r139",
      "r140",
      "r167",
      "r170",
      "r201",
      "r202",
      "r204",
      "r206",
      "r214",
      "r215",
      "r292",
      "r328",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r369",
      "r372",
      "r373",
      "r377",
      "r380",
      "r387",
      "r648",
      "r784",
      "r785",
      "r786",
      "r787",
      "r791",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r814",
      "r834",
      "r852",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r1088",
      "r1131",
      "r1133",
      "r1141"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r214",
      "r363",
      "r372",
      "r373",
      "r375",
      "r377",
      "r380",
      "r385",
      "r387",
      "r590",
      "r784",
      "r785",
      "r786",
      "r787",
      "r915",
      "r1088",
      "r1129",
      "r1131"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Excercise price of warrant",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173",
      "r388"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "lxeo_CommercializationMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CommercializationMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization milestones due",
        "label": "Commercialization Milestones Due",
        "documentation": "Commercialization milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CommissionsAndOfferingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CommissionsAndOfferingCostsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions and Offering Costs [Member]",
        "documentation": "Commissions and offering costs.",
        "terseLabel": "Commissions and Offering Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r95",
      "r739",
      "r813"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r319",
      "r320",
      "r874",
      "r1155",
      "r1160"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total shares of common stock reserved for future issuance",
        "terseLabel": "Common stock, shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "lxeo_CommonStockDuringOfferingPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CommonStockDuringOfferingPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock during offering period",
        "label": "Common Stock During Offering Period",
        "documentation": "Common Stock During Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r963",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r1137",
      "r1138",
      "r1140",
      "r1231",
      "r1264",
      "r1267"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, Authorized",
        "verboseLabel": "Common stock shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r814"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares issued",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares issued upon early exercise of unvested stock options",
        "documentation": "Common stock shares issued on early exercise of unvested stock options.",
        "label": "Common Stock Shares Issued On Early Exercise of Unvested Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, Outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r814",
      "r832",
      "r1267",
      "r1268"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.0001 par value, 18,125,051 shares authorized, 1,660,650 shares issued and 1,633,206 shares outstanding, actual; 18,125,051 shares authorized, 15,220,250 shares issued and 15,192,806 shares outstanding, pro forma",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r361",
      "r368",
      "r740",
      "r957"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ComponentsOfEquipmentFinanceLeaseTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Equipment Finance Leases",
        "label": "Components of Equipment Finance Lease [Table Text Block]",
        "documentation": "Components of equipment Finance lease."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ComponentsOfOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ComponentsOfOperatingLeaseTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Operating Lease",
        "label": "Components of Operating Lease [Table Text Block]",
        "documentation": "Components of operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total",
        "terseLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r145",
      "r147",
      "r153",
      "r727",
      "r753",
      "r754"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r167",
      "r168",
      "r174",
      "r177",
      "r212",
      "r227",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r732",
      "r899",
      "r900",
      "r1164",
      "r1165"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r167",
      "r168",
      "r174",
      "r177",
      "r212",
      "r227",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r732",
      "r899",
      "r900",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r377",
      "r966",
      "r967",
      "r968",
      "r969"
     ]
    },
    "lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ConvertibleSimpleAgreementForFutureEquityNoteMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Simple Agreement For Future Equity Note [Member]",
        "documentation": "Convertible simple agreement for future equity note.",
        "terseLabel": "Convertible SAFE Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellFirstLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CornellFirstLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell First License Agreements",
        "label": "Cornell First License Agreements [Member]",
        "documentation": "Cornell first license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CornellLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell License Agreements",
        "label": "Cornell License Agreements [Member]",
        "documentation": "Cornell license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellSecondLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CornellSecondLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell Second License Agreements",
        "label": "Cornell Second License Agreements [Member]",
        "documentation": "Cornell Second License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "CornellUniversityMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell University",
        "label": "Cornell University [Member]",
        "documentation": "Cornell university."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r175",
      "r176",
      "r342",
      "r375",
      "r685",
      "r705",
      "r736",
      "r880",
      "r881",
      "r882",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1226",
      "r1227",
      "r1228",
      "r1229"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r1163"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r1163"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1075"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1075"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1077"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1077"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1079"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1077"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1070"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1071"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1071"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1072"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1074"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1074"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1075"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1078"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1076"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1073"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of common shares on conversion of debt instrument",
        "terseLabel": "Shares issued on debt exchanged",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r26"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes with outstanding principal exchanged",
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r26"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r48",
      "r92",
      "r94",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r954",
      "r1129",
      "r1130",
      "r1132",
      "r1136",
      "r1156",
      "r1157",
      "r1158",
      "r1246",
      "r1247",
      "r1261"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r954",
      "r1129",
      "r1130",
      "r1132",
      "r1136",
      "r1156",
      "r1157",
      "r1158",
      "r1246",
      "r1247",
      "r1261"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r93",
      "r487"
     ]
    },
    "lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "documentation": "Deferred offering costs included in accounts payable and accrued expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized R&amp;D expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "lxeo_DeferredTaxAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, intangible assets.",
        "label": "Deferred Tax Assets Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other deferred tax assets",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32"
     ]
    },
    "lxeo_DevelopmentAndCommercializationMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "DevelopmentAndCommercializationMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and commercialization milestones due",
        "label": "Development and Commercialization Milestones Due",
        "documentation": "Development and commercialization milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_DevelopmentAndRegulatoryMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "DevelopmentAndRegulatoryMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestones due",
        "label": "Development and Regulatory Milestones Due",
        "documentation": "Development and regulatory milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r408",
      "r439",
      "r440",
      "r442",
      "r926"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends, common stock, cash",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1001"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1001",
      "r1044"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per common share, basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r154",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r199",
      "r201",
      "r204",
      "r205",
      "r206",
      "r211",
      "r359",
      "r445",
      "r515",
      "r577",
      "r614",
      "r615",
      "r728",
      "r755",
      "r889"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per common share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r154",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r201",
      "r204",
      "r205",
      "r206",
      "r211",
      "r359",
      "r445",
      "r515",
      "r577",
      "r614",
      "r615",
      "r728",
      "r755",
      "r889"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r208"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r207",
      "r209",
      "r210"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate, Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "US Federal Statutory Tax Rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r172",
      "r471",
      "r501",
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r929",
      "r1129",
      "r1135",
      "r1206"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r1129",
      "r1135",
      "r1206"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other",
        "negatedLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1129",
      "r1135",
      "r1206",
      "r1207"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r929",
      "r1129",
      "r1135",
      "r1206"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Tax Credit - Federal R&amp;D Credit",
        "negatedLabel": "Tax Credit - Federal R&amp;D Credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1129",
      "r1135",
      "r1206",
      "r1207"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, weighted-average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Exercise of Outstanding Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment",
        "label": "Lab Equipment",
        "verboseLabel": "Equipment Finance Lease [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r115",
      "r122",
      "r123",
      "r149",
      "r150",
      "r151",
      "r178",
      "r179",
      "r180",
      "r183",
      "r191",
      "r193",
      "r195",
      "r213",
      "r293",
      "r297",
      "r314",
      "r358",
      "r389",
      "r445",
      "r496",
      "r497",
      "r511",
      "r512",
      "r513",
      "r516",
      "r576",
      "r577",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r613",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r661",
      "r684",
      "r751",
      "r764",
      "r765",
      "r766",
      "r791",
      "r852"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r507",
      "r648",
      "r1090",
      "r1091",
      "r1092",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership Percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r648"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFVNINoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investment",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "lxeo_EricAdlerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "EricAdlerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric Adler [Member]",
        "documentation": "Eric Adler.",
        "terseLabel": "Eric Adler"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1005",
      "r1015",
      "r1048"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1002",
      "r1012",
      "r1045"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r630",
      "r943"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r630",
      "r943"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value Assumptions",
        "verboseLabel": "Schedule of Fair Value Assumptions of Warrants",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r620",
      "r946"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1234"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r629",
      "r630",
      "r632",
      "r641",
      "r692",
      "r693",
      "r694",
      "r878",
      "r910",
      "r911",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r943",
      "r946",
      "r953"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r621",
      "r943",
      "r1236",
      "r1239"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r625",
      "r627",
      "r628",
      "r629",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r723",
      "r943",
      "r947"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r394",
      "r399",
      "r400",
      "r618",
      "r630",
      "r641",
      "r692",
      "r878",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r943",
      "r953"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r394",
      "r399",
      "r400",
      "r402",
      "r618",
      "r619",
      "r630",
      "r641",
      "r693",
      "r878",
      "r910",
      "r911",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r943",
      "r953"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r618",
      "r619",
      "r620",
      "r621",
      "r630",
      "r641",
      "r694",
      "r878",
      "r910",
      "r911",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r943",
      "r946",
      "r953"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Rollforward of Changes in Fair Value of Financial Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r626",
      "r631"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r621",
      "r943",
      "r1236",
      "r1239"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r629",
      "r630",
      "r632",
      "r641",
      "r692",
      "r693",
      "r694",
      "r878",
      "r910",
      "r911",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r943",
      "r946",
      "r953"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1239"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "terseLabel": "Fair value Disclosure, Total",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1234"
     ]
    },
    "lxeo_FairValueOfSharesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FairValueOfSharesReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares received",
        "label": "Fair Value Of Shares Received",
        "documentation": "Fair value of shares received."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueOfSharesReceivedPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FairValueOfSharesReceivedPerShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares received per share",
        "label": "Fair Value Of Shares Received Per Share",
        "documentation": "Fair value of shares received per share."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FairValueOfUnearnedEmployeeStockOwnershipPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of unearned employee stock ownership plans",
        "label": "Fair Value of Unearned Employee Stock Ownership Plans",
        "documentation": "Fair Value of Unearned Employee Stock Ownership Plans"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrants",
        "documentation": "Fair value of warrants.",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueOfWarrantsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FairValueOfWarrantsPerShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrants Per Share",
        "documentation": "Fair value of warrants per share.",
        "terseLabel": "Fair value of warrants per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r649",
      "r650",
      "r878",
      "r953"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Option, Disclosures [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r649",
      "r878",
      "r953",
      "r1245"
     ]
    },
    "lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total aggregate monthly installment payment amount",
        "label": "Finance Lease Aggregate Monthly Installment Payment Amounts",
        "documentation": "Finance lease aggregate monthly installment payment amounts."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FinanceLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease expense",
        "label": "Finance Lease Expense",
        "documentation": "Finance lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails": {
       "parentTag": "lxeo_FinanceLeaseExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on finance lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r670",
      "r956"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "totalLabel": "Total finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r676"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability [Abstract]",
        "terseLabel": "Included in the balance sheet:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities - finance",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Remaining Equipment Finance Lease Obligations",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of lease liabilities - finance",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "lxeo_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liability Payments Due After Year Four",
        "documentation": "Finance lease liability payments due after year four.",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FinanceLeaseMonthlyInstallmentPaymentAmounts",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly installment payment amounts",
        "label": "Finance Lease Monthly Installment Payment Amounts",
        "documentation": "Finance lease monthly installment payment amounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r673"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net book values",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "terseLabel": "Lease right-of-use assets - finance",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails": {
       "parentTag": "lxeo_FinanceLeaseExpense",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease amortization of right-of-use assets",
        "verboseLabel": "Reduction in the carrying amount of ROU assets, finance",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r670",
      "r956"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gross",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of use assets and finance lease liabilities recognized",
        "label": "Finance Lease Right-of Use Assets And Finance Lease Liabilities Recognized",
        "documentation": "Finance lease right-of use assets and finance lease liabilities recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average effective interest rate",
        "terseLabel": "Weighted Average Effective Interest Rate",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r956"
     ]
    },
    "lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FinanceLeaseWeightedAverageRemainingAmortizationTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining amortization term",
        "terseLabel": "Weighted Average Remaining Amortization Term (in years)",
        "label": "Finance Lease Weighted Average Remaining Amortization Term",
        "documentation": "Finance lease weighted average remaining amortization term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining lease payment term",
        "terseLabel": "Weighted Average Remaining Lease Payment Term (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r956"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r355",
      "r385",
      "r590",
      "r603",
      "r637",
      "r647",
      "r650",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r735",
      "r752",
      "r907",
      "r943",
      "r944",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r958",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1232",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241"
     ]
    },
    "lxeo_FirstUcsdLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "FirstUcsdLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First UCSD License Agreement",
        "label": "First UCSD License Agreement [Member]",
        "documentation": "First UCSD license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1052"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1052"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1052"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1052"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1052"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "terseLabel": "Loss on fair value adjustment to convertible SAFE Note",
        "totalLabel": "Gain (Loss) on Fair Value Hedges Recognized in Earnings, Total",
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1225"
     ]
    },
    "lxeo_GainLossOnLongTermInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "GainLossOnLongTermInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) On Long Term Investment",
        "documentation": "Gain (loss) on long-term investment.",
        "terseLabel": "Gain on long-term investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "All other general and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r836"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "GeneralAndAdministrativeExpenseEmployeeCompensationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation expenses",
        "label": "General and Administrative Expense Employee Compensation Expenses",
        "documentation": "General and administrative expense employee compensation expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "GeneralAndAdministrativeExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "documentation": "General and administrative expenses.",
        "label": "General and Administrative Expenses, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "verboseLabel": "Initial Public Offering",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1001"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r171",
      "r470"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Pretax Income (Loss)",
        "verboseLabel": "Net income (loss) before income tax expense, Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r99",
      "r103",
      "r729",
      "r731",
      "r748",
      "r883",
      "r885",
      "r886",
      "r892",
      "r899",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r318",
      "r586",
      "r587",
      "r588",
      "r589",
      "r623",
      "r626",
      "r631",
      "r649",
      "r650",
      "r651",
      "r759",
      "r761",
      "r837",
      "r877",
      "r878",
      "r930",
      "r932",
      "r941",
      "r942",
      "r945",
      "r953",
      "r1220",
      "r1222",
      "r1263"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r586",
      "r587",
      "r588",
      "r589",
      "r623",
      "r626",
      "r631",
      "r649",
      "r650",
      "r651",
      "r759",
      "r761",
      "r837",
      "r877",
      "r878",
      "r930",
      "r932",
      "r941",
      "r942",
      "r945",
      "r953",
      "r1220",
      "r1222",
      "r1263"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r471",
      "r472",
      "r482",
      "r493",
      "r929",
      "r1211"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r471",
      "r472",
      "r482",
      "r493",
      "r929",
      "r1211"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r172",
      "r465",
      "r471",
      "r478",
      "r479",
      "r480",
      "r484",
      "r491",
      "r502",
      "r504",
      "r505",
      "r506",
      "r734",
      "r775",
      "r789",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "verboseLabel": "Effective income tax rate, Amount Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r111",
      "r167",
      "r194",
      "r195",
      "r212",
      "r230",
      "r247",
      "r469",
      "r471",
      "r503",
      "r757",
      "r883",
      "r885",
      "r886",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r493"
     ]
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "documentation": "Disclosure of information about income tax paid by jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r493"
     ]
    },
    "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidFederalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, Federal, after Refund Received",
        "totalLabel": "Income Tax Paid, Federal, after Refund Received, Total",
        "terseLabel": "Federal",
        "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r492"
     ]
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "totalLabel": "Income Tax Paid, State and Local, after Refund Received, Total",
        "terseLabel": "State",
        "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r492"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r467",
      "r468",
      "r484",
      "r485",
      "r490",
      "r495",
      "r783"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r929",
      "r1206"
     ]
    },
    "lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DTA (DTL) True Ups - Other, Amount",
        "label": "Income Tax Reconciliation Deferred Tax Assets (Deferred Tax Liabilities) True Ups Other Amount",
        "documentation": "Income tax reconciliation deferred tax assets (deferred tax liabilities) true ups other amount."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncomeTaxReconciliationDeferredTaxAssetsDeferredTaxLiabilitiesTrueUpsOtherPercent",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Deferred Tax Assets (Deferred Tax Liabilities) True Ups Other Percent",
        "documentation": "Income tax reconciliation deferred tax assets (deferred tax liabilities) true ups other percent.",
        "terseLabel": "DTA (DTL) True Ups - Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "US Federal Statutory Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nontaxable or Nondeductible Items:",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1206",
      "r1207"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherReconcilingItemsAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount [Abstract]",
        "terseLabel": "Other Adjustments:"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncomeTaxReconciliationReturnToProvisionOtherAdjustmentAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Return To Provision Other Adjustment Amount",
        "documentation": "Income tax reconciliation return to provision other amount.",
        "terseLabel": "Return to Provision - Other, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncomeTaxReconciliationReturnToProvisionOtherAdjustmentPercent",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Return To Provision Other Adjustment Percent",
        "documentation": "Income tax reconciliation return to provision other adjustment percent.",
        "terseLabel": "Return to Provision - Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract]",
        "terseLabel": "Tax Credits:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207"
     ]
    },
    "lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Tax Credits Orphan Drug Credit Amount",
        "documentation": "Income tax reconciliation tax credits orphan drug credit.",
        "terseLabel": "Tax Credit - Orphan Drug Credit, Amount",
        "negatedTerseLabel": "Tax Credit - Orphan Drug Credit, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Tax Credits Orphan Drug Credit Percent",
        "documentation": "Income tax reconciliation tax credits orphan drug credit percent.",
        "terseLabel": "Tax Credit - Orphan Drug Credit",
        "negatedLabel": "Tax Credit - Orphan Drug Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Tax Credit - Federal R&amp;D Credit, Amount",
        "negatedLabel": "Tax Credit - Federal R&amp;D Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1206",
      "r1207"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r76",
      "r1127",
      "r1209",
      "r1210"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "terseLabel": "Income Taxes Paid Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r163",
      "r492",
      "r493"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDerivativeAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Derivative Assets and Liabilities",
        "negatedLabel": "Change in fair value of convertible SAFE Note liability",
        "documentation": "The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "lxeo_IncreaseDecreaseInFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncreaseDecreaseInFinanceLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, finance",
        "label": "Increase Decrease In Finance Lease Liability",
        "documentation": "Increase decrease in finance lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities, operating",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1125"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "documentation": "Increase in common stock capital shares reserved for future issuance.",
        "terseLabel": "Increase in aggregate number of shares of common stock reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1043",
      "r1052",
      "r1056",
      "r1064"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1068"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1068"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1068"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r883",
      "r886",
      "r1124"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r161",
      "r162"
     ]
    },
    "lxeo_InvestmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "InvestmentCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Current",
        "documentation": "Investment current.",
        "terseLabel": "Investment current"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_InvestmentInEquitySecuritiesOfInvesteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "InvestmentInEquitySecuritiesOfInvesteeMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Equity Securities of Investee [Member]",
        "documentation": "Investment in equity securities of investee.",
        "terseLabel": "Investee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r228",
      "r247",
      "r899",
      "r1123"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total",
        "negatedLabel": "(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net",
        "terseLabel": "(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "lxeo_InvestmentNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "InvestmentNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Non Current",
        "documentation": "Investment non current.",
        "terseLabel": "Investment non-current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Long-term Investment",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r779",
      "r780",
      "r781",
      "r782",
      "r858",
      "r859"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Investment",
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1234",
      "r1238",
      "r1240",
      "r1241",
      "r1242",
      "r1243"
     ]
    },
    "lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock Upon Vesting And Settlement Of Performance Restricted Stock Units",
        "documentation": "Issuance of common stock upon vesting and settlement of performance restricted stock units",
        "terseLabel": "Issuance of common stock upon vesting and settlement of performance restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting and settlement of restricted stock units, shares",
        "label": "Issuance of Common Stock Upon Vesting and Settlement of Restricted Stock Units",
        "documentation": "Issuance of common stock upon vesting and settlement of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Lab-related costs and supplies",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r885",
      "r1122"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r677"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LeerinkAtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LeerinkAtTheMarketSalesAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leerink At The Market Sales Agreement [Member]",
        "documentation": "Leerink at the market sales agreement.",
        "terseLabel": "Leerink At The Market Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LesseeFinanceLeaseCommencementDateRangeEnd": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LesseeFinanceLeaseCommencementDateRangeEnd",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, commencement date range, end",
        "label": "Lessee, Finance Lease, Commencement Date Range, End",
        "documentation": "Lessee, finance lease, commencement date range, end."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LesseeFinanceLeaseCommencementDateRangeStart": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LesseeFinanceLeaseCommencementDateRangeStart",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, commencement date range, start",
        "label": "Lessee, Finance Lease, Commencement Date Range, Start",
        "documentation": "Lessee, finance lease, commencement date range, start."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Imputed interest rate",
        "label": "Lessee, Finance Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r678"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r678"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeases3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating And Financing Leases Disclosure [Text Block]",
        "documentation": "Lessee Operating And Financing Leases Disclosure.",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental borrowing rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existence of option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Remaining Undiscounted Contractual Rent Obligations",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "lxeo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "documentation": "Lessee operating lease liability payments due after year four.",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1130",
      "r1136",
      "r1261"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to extend",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r55",
      "r167",
      "r169",
      "r170",
      "r292",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r581",
      "r584",
      "r585",
      "r648",
      "r812",
      "r891",
      "r914",
      "r972",
      "r1164",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r96",
      "r744",
      "r957",
      "r960",
      "r961",
      "r1129",
      "r1134",
      "r1154",
      "r1244"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r131",
      "r167",
      "r169",
      "r170",
      "r292",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r581",
      "r584",
      "r585",
      "r648",
      "r957",
      "r1164",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r1233"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LicenseAgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LicenseAgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Termination notice period (in days)",
        "terseLabel": "License agreement termination notice period",
        "label": "License Agreement Termination Notice Period",
        "documentation": "License agreement termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, Acquisition, Research Collaboration and Sponsored Research Agreements",
        "label": "License and Acquisition and Research Collaboration and Sponsored Research Agreements Disclosure [Text Block]",
        "documentation": "License and acquisition and research collaboration and sponsored research agreements disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LongTermInvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LongTermInvestmentPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Investment Policy Text Block",
        "documentation": "Long term investment policy text block.",
        "terseLabel": "Long-term Investment"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LongTermInvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LongTermInvestmentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Investment [Text Block]",
        "documentation": "Long term investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Investments, Total",
        "label": "Long-Term Investments",
        "terseLabel": "Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_LongTermInvestmentsAndReceivablesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestmentsAndReceivablesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments and Receivables, Net",
        "totalLabel": "Long-Term Investments and Receivables, Net, Total",
        "terseLabel": "Investments, net",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r321",
      "r322",
      "r323",
      "r326",
      "r459",
      "r908",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r321",
      "r322",
      "r323",
      "r326",
      "r459",
      "r908",
      "r1161",
      "r1162"
     ]
    },
    "lxeo_LossRecognizedFromUninsuredBalances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "LossRecognizedFromUninsuredBalances",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss recognized from uninsured balances",
        "label": "Loss Recognized from Uninsured Balances",
        "documentation": "Loss recognized from uninsured balances."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_MarchTwoThousandTwentyFourPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "MarchTwoThousandTwentyFourPrivatePlacementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March Two Thousand Twenty Four Private Placement [Member]",
        "documentation": "March two thousand twenty four private placement.",
        "verboseLabel": "March 2024 Private Placement [Member]",
        "terseLabel": "March 2024 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_MaximumIncreaseOrDecreaseInOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "MaximumIncreaseOrDecreaseInOwnershipPercentage",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase or decrease in ownership percentage",
        "label": "Maximum Increase Or Decrease In Ownership Percentage",
        "documentation": "Maximum increase or decrease in ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r322",
      "r323",
      "r324",
      "r325",
      "r403",
      "r434",
      "r435",
      "r436",
      "r459",
      "r621",
      "r721",
      "r758",
      "r760",
      "r774",
      "r804",
      "r805",
      "r857",
      "r860",
      "r861",
      "r862",
      "r863",
      "r870",
      "r871",
      "r872",
      "r873",
      "r875",
      "r876",
      "r906",
      "r915",
      "r925",
      "r930",
      "r934",
      "r935",
      "r946",
      "r947",
      "r951",
      "r952",
      "r959",
      "r1166",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "lxeo_MayTwoThousandTwentyFivePrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "MayTwoThousandTwentyFivePrivatePlacementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Two Thousand Twenty Five Private Placement [Member]",
        "documentation": "May two thousand twenty five private placement.",
        "terseLabel": "May 2025 Private Placement [Member]",
        "verboseLabel": "May 2025 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise Price",
        "verboseLabel": "Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1196",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected Dividend Yield",
        "verboseLabel": "Expected Dividend Yield [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Expected Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r946",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Weighted Average Risk-free Interest Rate",
        "verboseLabel": "Risk-free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock Price",
        "verboseLabel": "Stock Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r619",
      "r620",
      "r621",
      "r930",
      "r934",
      "r935",
      "r946"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r620",
      "r621",
      "r930",
      "r934",
      "r935",
      "r946"
     ]
    },
    "lxeo_MilestoneReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "MilestoneReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Received",
        "documentation": "Milestone received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r322",
      "r323",
      "r324",
      "r325",
      "r403",
      "r434",
      "r435",
      "r436",
      "r459",
      "r621",
      "r721",
      "r758",
      "r760",
      "r774",
      "r804",
      "r805",
      "r857",
      "r860",
      "r861",
      "r862",
      "r863",
      "r870",
      "r871",
      "r872",
      "r873",
      "r875",
      "r876",
      "r906",
      "r915",
      "r925",
      "r930",
      "r934",
      "r935",
      "r946",
      "r947",
      "r951",
      "r959",
      "r1166",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1173"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NY",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flow from operations",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net Loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r77",
      "r100",
      "r123",
      "r129",
      "r143",
      "r146",
      "r151",
      "r167",
      "r169",
      "r170",
      "r174",
      "r182",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r203",
      "r292",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r359",
      "r362",
      "r365",
      "r370",
      "r445",
      "r515",
      "r577",
      "r615",
      "r648",
      "r750",
      "r833",
      "r850",
      "r851",
      "r883",
      "r885",
      "r886",
      "r970",
      "r1164"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NetProceedsReceivedFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NetProceedsReceivedFromPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from private placement",
        "label": "Net Proceeds Received from Private Placement",
        "documentation": "Net proceeds received from Private Placement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NetRealizedGainOnInvestmentsInUSTreasurySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NetRealizedGainOnInvestmentsInUSTreasurySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Realized Gain On Investments In U.S. Treasury Securities",
        "documentation": "Net realized gain on investments in U.S. Treasury securities",
        "negatedLabel": "Net realized gain on investments in U.S. Treasury securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Adopted and Not Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NewYorkCityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NewYorkCityMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New York City [Member]",
        "documentation": "New York City [Member]",
        "terseLabel": "New York City"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_Non-CashGainLossOnLong-TermInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "Non-CashGainLossOnLong-TermInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Gain (Loss) on Long-term Investment",
        "documentation": "Non-cash gain (loss) on long-term investment.",
        "terseLabel": "Non-cash gain on long-term investment",
        "negatedLabel": "Non-cash gain on long-term investment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1043",
      "r1052"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income and expense",
        "negatedLabel": "Other income and expense, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income and expense",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonredeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonredeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonredeemable Convertible Preferred Stock [Member]",
        "documentation": "Capital stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity and may be exchanged into common shares or other types of securities at the owner's option as long as it is in accordance with the issuer's terms. This security does not have redemption requirements."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes issued",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "lxeo_NumberOfFormerEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NumberOfFormerEmployees",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Former Employees",
        "documentation": "Number of former employees.",
        "terseLabel": "Number of former employees"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of license agreements",
        "label": "Number of License Agreements",
        "documentation": "Number of license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfMonthlyInstallmentsLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NumberOfMonthlyInstallmentsLease",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of monthly installments",
        "label": "Number Of Monthly Installments Lease",
        "documentation": "Number of monthly installments lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operation segment",
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r1144"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r1144"
     ]
    },
    "lxeo_NumberOfResearchAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NumberOfResearchAgreements",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research agreements",
        "label": "Number of Research Agreements",
        "documentation": "Number of research agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares automatically increase in available shares of common stock under plan",
        "label": "Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan",
        "documentation": "Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Exercised",
        "documentation": "Number of warrants exercised.",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_October2025FinancingTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "October2025FinancingTransactionsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2025 Financing Transactions",
        "label": "October 2025 Financing Transactions [Member]",
        "documentation": "October 2025 Financing Transactions.",
        "verboseLabel": "October 2025 Financing Transactions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_October2025PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "October2025PrivatePlacementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2025 Private Placement [Member]",
        "documentation": "October 2025 Private Placement.",
        "terseLabel": "October 2025 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_October2025PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "October2025PublicOfferingMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2025 Public Offering [Member]",
        "documentation": "October 2025 Public Offering.",
        "terseLabel": "October 2025 Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OfficeFacilityAndLaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OfficeFacilityAndLaboratorySpaceMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Facility and Laboratory Space",
        "label": "Office Facility and Laboratory Space [Member]",
        "documentation": "Office facility and laboratory space."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OneTimeUpFrontNonRefundableFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OneTimeUpFrontNonRefundableFees",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time up-front non-refundable fees",
        "label": "One Time Up Front Non Refundable Fees",
        "documentation": "One time up front non refundable fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r883",
      "r886",
      "r892",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "lxeo_OperatingLeaseAgreementEnteredDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OperatingLeaseAgreementEnteredDate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease agreement entered date",
        "label": "Operating Lease Agreement Entered Date",
        "documentation": "Operating lease agreement entered date."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OperatingLeaseCommencementDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OperatingLeaseCommencementDate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease commencement date",
        "label": "Operating Lease Commencement Date",
        "documentation": "Operating lease commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails": {
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r956"
     ]
    },
    "lxeo_OperatingLeaseEndDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OperatingLeaseEndDate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease end date",
        "label": "Operating Lease End Date",
        "documentation": "Operating lease end date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1248"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities",
        "terseLabel": "Current portion of lease liabilities - operating",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Included in the balance sheet:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities - operating",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of lease liabilities - operating",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r673"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "terseLabel": "Lease right-of-use assets - operating",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Reduction in the carrying amount of ROU assets, operating",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease terms",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r956"
     ]
    },
    "lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OperatingLeaseWeightedAverageRemainingPaymentTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease payment terms",
        "label": "Operating Lease Weighted Average Remaining Payment Term",
        "documentation": "Operating lease weighted average remaining payment term."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OperatingLossCarryForwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year.",
        "label": "Operating Loss Carry forwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248",
      "r899",
      "r900"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Description of Business and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r124",
      "r125",
      "r127",
      "r777",
      "r778"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLocationAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Location [Axis]",
        "documentation": "Information by location in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r631",
      "r878",
      "r953"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLocationDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Location [Domain]",
        "documentation": "Location in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r631",
      "r878",
      "r953"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Total other comprehensive loss",
        "totalLabel": "Total other comprehensive gain (loss)",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r11",
      "r144",
      "r147",
      "r152",
      "r191",
      "r652",
      "r653",
      "r658",
      "r726",
      "r751",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) [Member]",
        "terseLabel": "Other Comprehensive Loss",
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r953"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "All other general and administrative expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r1266"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r940"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "All other research and development expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1007",
      "r1017",
      "r1050"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "lxeo_PaymentOfAnnualDataTransferFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfAnnualDataTransferFee",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual data transfer fee",
        "label": "Payment of Annual Data Transfer Fee",
        "documentation": "Payment of annual data transfer fee."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfAnnualLicenseMaintenanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfAnnualLicenseMaintenanceFees",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Annual License Maintenance Fees",
        "documentation": "Payment of annual license maintenance fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfClinicalAndRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfClinicalAndRegulatoryMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and regulatory milestone paid",
        "label": "Payment Of Clinical And Regulatory Milestone",
        "documentation": "Payment Of Clinical And Regulatory Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfDevelopmentMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone paid",
        "label": "Payment of Development Milestone",
        "documentation": "Payment of development milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Financing and Stock Issuance Costs",
        "totalLabel": "Payment of Financing and Stock Issuance Costs, Total",
        "negatedLabel": "Payment of financing and stock issuance costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfLicenseIssueFeeAndInitialDataTransferFee",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of License Issue Fee and Initial Data Transfer Fee",
        "documentation": "Payment of license issue fee and initial data transfer fee",
        "terseLabel": "License fee and initial data transfer fee"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfOneTimeUpFrontNonRefundableFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfOneTimeUpFrontNonRefundableFee",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time up-front non-refundable fee paid",
        "label": "Payment of One Time Up Front Non Refundable Fee",
        "documentation": "Payment of one time up front non refundable fee."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentOfRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory milestone to be paid",
        "label": "Payment of Regulatory Milestones",
        "documentation": "Payment of regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentStartingAfterPeriodOfExecutionOfAgreement",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment starting after period of execution of agreement",
        "label": "Payment Starting After Period of Execution of Agreement",
        "documentation": "Payment starting after period of execution of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment term",
        "label": "Payment Term",
        "documentation": "Payment term."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentToAdditionalDataTransferProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PaymentToAdditionalDataTransferProcess",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to additional data transfer process",
        "label": "Payment To Additional Data Transfer Process",
        "documentation": "Payment to additional data transfer process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of Common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Net of issuance costs",
        "verboseLabel": "Underwriting discounts, placement agent fees, commissions and offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to research and development",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of investments",
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_PaymentsToAcquireSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireSoftware",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of internal use software",
        "label": "Payments to Acquire Software",
        "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "lxeo_PayrollDeductionsAtPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PayrollDeductionsAtPrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll Deductions at Price",
        "documentation": "Payroll Deductions at Price",
        "terseLabel": "Payroll deductions at price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of automatically increase in available shares of common stock on beginning of each calendar year",
        "label": "Percentage of Automatically Increase in Available Shares of Common Stock on Beginning of Cach Calendar Year",
        "documentation": "Percentage of automatically increase in available shares of common stock on beginning of each calendar year."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PercentageOfCumulativeOwnershipChange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PercentageOfCumulativeOwnershipChange",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Cumulative Ownership Change",
        "documentation": "Percentage of cumulative ownership change.",
        "terseLabel": "Percentage of cumulative ownership change"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PercentageOfOwnershipConsideredForWarrantExercise": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PercentageOfOwnershipConsideredForWarrantExercise",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership considered for warrant exercise",
        "label": "Percentage Of Ownership Considered for Warrant Exercise",
        "documentation": "Percentage of ownership considered for warrant exercise."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PerformanceRestrictedStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PerformanceRestrictedStockUnitMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Restricted Stock Unit [Member]",
        "documentation": "Performance Restricted Stock Unit.",
        "terseLabel": "Performance Restricted Stock Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "lxeo_PotentialFutureProductDevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PotentialFutureProductDevelopmentMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential Future Product Development Milestones",
        "documentation": "Potential future product development milestones.",
        "terseLabel": "Potential future product development milestones"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PotentialFutureProductSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PotentialFutureProductSalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential Future Product Sales Milestones",
        "documentation": "Potential future product sales milestones.",
        "terseLabel": "Potential future product sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre-funded warrants.",
        "verboseLabel": "Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuable Upon Conversion",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "verboseLabel": "Converted shares into common stock",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value per share",
        "terseLabel": "Preferred stock at par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r372"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r814"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Offering [Member]",
        "verboseLabel": "Private Placement Offering",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock issuances under 2023 ESPP",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "lxeo_ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock And Pre-Funded Warrants To Purchase Common Stock Upon October 2025 Financing Transactions",
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds Received",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Aggregate total net proceeds raised with issuance of convertible preferred stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Gross proceeds from private placement",
        "verboseLabel": "Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "terseLabel": "Proceeds from sales or maturities of investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Total proceeds",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss from operations before income taxes",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r129",
      "r143",
      "r146",
      "r159",
      "r167",
      "r169",
      "r170",
      "r174",
      "r182",
      "r191",
      "r194",
      "r195",
      "r292",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r359",
      "r445",
      "r515",
      "r577",
      "r579",
      "r582",
      "r583",
      "r615",
      "r648",
      "r729",
      "r731",
      "r749",
      "r790",
      "r833",
      "r850",
      "r851",
      "r938",
      "r939",
      "r971",
      "r1121",
      "r1164"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r677"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r134",
      "r747"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r677",
      "r733",
      "r747",
      "r957"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r109",
      "r110",
      "r745"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r677"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful Life",
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "lxeo_RNolanTownsendMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "RNolanTownsendMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R Nolan Townsend [Member]",
        "documentation": "R Nolan Townsend.",
        "terseLabel": "R. Nolan Townsend"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r322",
      "r323",
      "r324",
      "r325",
      "r393",
      "r403",
      "r434",
      "r435",
      "r436",
      "r442",
      "r459",
      "r621",
      "r695",
      "r704",
      "r721",
      "r758",
      "r760",
      "r774",
      "r804",
      "r805",
      "r857",
      "r860",
      "r861",
      "r862",
      "r863",
      "r870",
      "r871",
      "r872",
      "r873",
      "r875",
      "r876",
      "r906",
      "r915",
      "r925",
      "r930",
      "r934",
      "r935",
      "r946",
      "r947",
      "r951",
      "r952",
      "r959",
      "r964",
      "r1159",
      "r1166",
      "r1236",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r322",
      "r323",
      "r324",
      "r325",
      "r393",
      "r403",
      "r434",
      "r435",
      "r436",
      "r442",
      "r459",
      "r621",
      "r695",
      "r704",
      "r721",
      "r758",
      "r760",
      "r774",
      "r804",
      "r805",
      "r857",
      "r860",
      "r861",
      "r862",
      "r863",
      "r870",
      "r871",
      "r872",
      "r873",
      "r875",
      "r876",
      "r906",
      "r915",
      "r925",
      "r930",
      "r934",
      "r935",
      "r946",
      "r947",
      "r951",
      "r952",
      "r959",
      "r964",
      "r1159",
      "r1166",
      "r1236",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of Internal Use Software into Prepaid Expenses",
        "documentation": "Reclassification of internal use software into prepaid expenses.",
        "terseLabel": "Reclassification of internal use software into prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1002",
      "r1012",
      "r1045"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r175",
      "r176",
      "r342",
      "r375",
      "r685",
      "r705",
      "r736",
      "r880",
      "r881",
      "r882",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1226",
      "r1227",
      "r1228",
      "r1229"
     ]
    },
    "lxeo_ResearchAgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research agreement termination notice period",
        "label": "Research Agreement Termination Notice Period",
        "documentation": "Research agreement termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAgreementsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAgreementsTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research agreements term",
        "label": "Research Agreements Term",
        "documentation": "Research agreements term."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional costs incurred for research",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Additional Costs Incurred",
        "documentation": "Research and development Aarrangement, ontract to perform for others, dditional costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r1205"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs incurred for research",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments description",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Description and Terms",
        "documentation": "Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r1205"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and development",
        "verboseLabel": "Research and development expenses",
        "terseLabel": "Financed research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r877",
      "r883",
      "r884",
      "r899",
      "r1260"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseEmployeeCompensationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation expenses",
        "label": "Research and Development Expense Employee Compensation Expenses",
        "documentation": "Research and development expense employee compensation expenses."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseLX1001": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseLX1001",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LX1001",
        "label": "Research and Development Expense LX1001",
        "documentation": "Research and development expense LX1001."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseLX2006": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseLX2006",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LX2006",
        "label": "Research and Development Expense LX2006",
        "documentation": "Research and Development Expense LX2006."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseLX2020": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseLX2020",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LX2020",
        "label": "Research and Development Expense LX2020",
        "documentation": "Research and development expense LX2020."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseOtherPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseOtherPrograms",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense Other Programs",
        "documentation": "Research and development expense other programs.",
        "terseLabel": "Other programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "lxeo_ResearchCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ResearchCollaborationAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration Agreement",
        "label": "Research Collaboration Agreement [Member]",
        "documentation": "Research collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1003",
      "r1013",
      "r1046"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r993",
      "r1004",
      "r1014",
      "r1047"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1011",
      "r1021",
      "r1054"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted cash included in long-term assets at end of period",
        "periodStartLabel": "Restricted cash included in long-term assets at beginning of period",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1105",
      "r1128"
     ]
    },
    "lxeo_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units and Performance Based Restricted Stock Units [Member]",
        "documentation": "Restricted stock units and performance based restricted stock units.",
        "terseLabel": "RSUs and PRSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r84",
      "r743",
      "r768",
      "r773",
      "r788",
      "r815",
      "r957"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r122",
      "r123",
      "r178",
      "r179",
      "r180",
      "r183",
      "r191",
      "r193",
      "r195",
      "r293",
      "r297",
      "r314",
      "r358",
      "r445",
      "r496",
      "r497",
      "r511",
      "r512",
      "r513",
      "r516",
      "r576",
      "r577",
      "r593",
      "r595",
      "r596",
      "r598",
      "r613",
      "r660",
      "r661",
      "r764",
      "r766",
      "r791",
      "r1267"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r212",
      "r226",
      "r227",
      "r241",
      "r247",
      "r251",
      "r253",
      "r254",
      "r390",
      "r391",
      "r392",
      "r722",
      "r883",
      "r886"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares Issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r197",
      "r404",
      "r1089"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Investments Classified as Available-for-Sale Securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expenses",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Net Income (Loss) Before Income Tax Expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r929",
      "r1206"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r507",
      "r648",
      "r1090",
      "r1091",
      "r1092",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r170",
      "r289",
      "r290",
      "r291",
      "r292",
      "r648"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r167",
      "r170",
      "r289",
      "r290",
      "r291",
      "r292",
      "r648"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r677"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary Of Additional Information On Company's Net loss Including Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r86"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of Estimated Fair Value Assumptions",
        "terseLabel": "Summary of Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model with Following Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity and PRSU Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Unobservable Inputs Used in Valuation Model to Estimate Fair Value",
        "label": "Schedule of Significant Unobservable Inputs Used In Valuation Model To Estimate Fair Value [Table Text Block]",
        "documentation": "Schedule of significant unobservable inputs used in valuation model to estimate fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r82",
      "r83",
      "r84",
      "r138",
      "r139",
      "r140",
      "r214",
      "r372",
      "r373",
      "r375",
      "r377",
      "r380",
      "r385",
      "r387",
      "r590",
      "r784",
      "r785",
      "r786",
      "r787",
      "r915",
      "r1088",
      "r1129",
      "r1131"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuances",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SecondAmendmentToTheThirdCornellLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Amendment To The Third Cornell License Agreement [Member]",
        "documentation": "Second Amendment to the Third Cornell License Agreement [Member].",
        "terseLabel": "Second Amendment to the Third Cornell License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SecondUcsdLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SecondUcsdLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second UCSD license agreement.",
        "terseLabel": "Second UCSD License Agreement",
        "label": "Second UCSD License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r898",
      "r905"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r212",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r231",
      "r232",
      "r233",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r893",
      "r896",
      "r897",
      "r899",
      "r901",
      "r903",
      "r904"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r233",
      "r247"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r250",
      "r253",
      "r894",
      "r895",
      "r902"
     ]
    },
    "lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SeriesAAndSeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A and series B convertible preferred stock.",
        "label": "Series A And Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series A and Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date",
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date",
        "terseLabel": "Contractual term grant date"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, vested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments options vested in period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, unvested, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of shares unvested, beginning balance",
        "periodEndLabel": "Number of shares unvested, ending balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted-average grant date fair value, unvested, beginning balance",
        "periodEndLabel": "Weighted-average grant date fair value, unvested, ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Number of shares vested",
        "negatedLabel": "Number of shares vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected dividend yield",
        "terseLabel": "Expected dividend yields percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, range, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, range, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Weighted average risk-free interest rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rates, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rates, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility, weighted-average",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for future grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, exercised",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award options exercised in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercised",
        "verboseLabel": "Intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired, shares",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited, shares",
        "terseLabel": "Forfeited, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, Unvested and exercisable",
        "label": "Share based Compensation Arrangement By Share based Payment Award Options Nonvested Options Exercisable Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award options nonvested options exercisable weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, unvested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award options nonvested weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, ending",
        "periodStartLabel": "Aggregate intrinsic value, beginning",
        "verboseLabel": "Aggregate intrinsic value, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, beginning",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares outstanding, ending",
        "periodStartLabel": "Number of shares outstanding, beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, vested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Options Exercisable Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award options vested options exercisable weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award options vested weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Weighted average purchase price",
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options unvested and expected to vest exercisable weighted average remaining contractual term1.",
        "terseLabel": "Weighted average remaining contractual term, unvested and exercisable",
        "label": "Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vest Over 18 Month [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vest Over Two Year [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Based Compensation Expense",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r412",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ]
    },
    "lxeo_ShareBasedCompensationPaymentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ShareBasedCompensationPaymentDescription",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation payment description",
        "label": "Share Based Compensation Payment Description",
        "documentation": "Share based compensation payment description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Non-employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, unvested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedFairValueOfOptionsGrantedUsingBlackscholesOptionPricingModelWithFollowingAssumptionsDetai"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years), weighted-average",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, expired",
        "documentation": "ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value",
        "label": "ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, unvested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, ending",
        "periodStartLabel": "Weighted average grant date fair value, beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant date fair values of options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "terseLabel": "Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r1108"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166"
     ]
    },
    "lxeo_SimpleAgreementForFutureEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SimpleAgreementForFutureEquityMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SAFE",
        "terseLabel": "SAFE [Member]",
        "label": "Simple Agreement For Future Equity [Member]",
        "documentation": "Simple Agreement For Future Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal Use Software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SpecificClinicalAndRegulatoryMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SpecificClinicalAndRegulatoryMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specific clinical and regulatory milestones due",
        "label": "Specific Clinical and Regulatory Milestones Due",
        "documentation": "Specific clinical and regulatory milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLongtermInvestmentAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r138",
      "r139",
      "r140",
      "r167",
      "r170",
      "r201",
      "r202",
      "r204",
      "r206",
      "r214",
      "r215",
      "r292",
      "r328",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r369",
      "r372",
      "r373",
      "r377",
      "r380",
      "r387",
      "r648",
      "r784",
      "r785",
      "r786",
      "r787",
      "r791",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r814",
      "r834",
      "r852",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r1088",
      "r1131",
      "r1133",
      "r1141"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r61",
      "r62",
      "r115",
      "r122",
      "r123",
      "r149",
      "r150",
      "r151",
      "r178",
      "r179",
      "r180",
      "r183",
      "r191",
      "r193",
      "r195",
      "r213",
      "r293",
      "r297",
      "r314",
      "r358",
      "r389",
      "r445",
      "r496",
      "r497",
      "r511",
      "r512",
      "r513",
      "r516",
      "r576",
      "r577",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r613",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r661",
      "r684",
      "r751",
      "r764",
      "r765",
      "r766",
      "r791",
      "r852"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r213",
      "r360",
      "r361",
      "r363",
      "r366",
      "r661",
      "r722",
      "r779",
      "r792",
      "r803",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r814",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r835",
      "r836",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r852",
      "r885",
      "r886",
      "r965",
      "r1265"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r197",
      "r404",
      "r1089",
      "r1093"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Table",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r213",
      "r257",
      "r360",
      "r361",
      "r363",
      "r366",
      "r661",
      "r722",
      "r779",
      "r792",
      "r803",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r814",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r835",
      "r836",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r852",
      "r885",
      "r886",
      "r965",
      "r1265"
     ]
    },
    "lxeo_SteliosTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SteliosTherapeuticsIncMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stelios Therapeutics Inc",
        "label": "Stelios Therapeutics Inc [Member]",
        "documentation": "Stelios Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1006",
      "r1016",
      "r1049"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued during the period upon conversion of convertible securities",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, share",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r58",
      "r61",
      "r84",
      "r349"
     ]
    },
    "lxeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Issuance of Common Stock Upon Exercise of Pre-funded Warrants",
        "documentation": "Issuance of common stock upon exercise of pre-funded warrants.",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares issued and sold",
        "verboseLabel": "Shares purchased at public offering",
        "label": "Issuance of common stock, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r84",
      "r784",
      "r852",
      "r865"
     ]
    },
    "lxeo_StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares New Issues Additional Offering Costs Incurred",
        "documentation": "Stock issued during period shares new issues additional offering costs incurred.",
        "terseLabel": "Additional issuance costs incurred related to issuance of convertible SAFE Note, Shares",
        "negatedLabel": "Additional issuance costs incurred related to issuance of convertible SAFE Note, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised, shares",
        "verboseLabel": "Exercise of stock options, shares",
        "terseLabel": "Exercised, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r84",
      "r418"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, value",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r61",
      "r62",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, Value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r84",
      "r791",
      "r852",
      "r865",
      "r971"
     ]
    },
    "lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value New Issues Additional Offering Costs Incurred",
        "documentation": "Stock issued during period value new issues additional offering costs incurred.",
        "terseLabel": "Additional offering costs incurred related to issuance of common stock upon private placement offering",
        "negatedLabel": "Additional issuance costs incurred related to issuance of convertible SAFE Note, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r57",
      "r58",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, value",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r61",
      "r62",
      "r84"
     ]
    },
    "lxeo_StockOfferingGrossProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "StockOfferingGrossProceedsPercentage",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Offering Gross Proceeds Percentage",
        "documentation": "Stock offering gross proceeds percentage.",
        "terseLabel": "Stock offering gross proceeds percentage"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_StockOfferingValueSharesAuthorizedToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "StockOfferingValueSharesAuthorizedToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Offering Value Shares Authorized To Be Sold",
        "documentation": "Stock offering value shares authorized to be sold.",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Repurchase of shares",
        "verboseLabel": "Treasury stock repurchase",
        "negatedLabel": "Treasury stock repurchases, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r84",
      "r787",
      "r852",
      "r867"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Shares repurchased value",
        "verboseLabel": "Treasury stock repurchase, Value",
        "negatedLabel": "Treasury stock repurchases, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r84",
      "r791",
      "r852",
      "r867",
      "r971"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, value",
        "periodEndLabel": "Balance, value",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r78",
      "r816",
      "r832",
      "r853",
      "r854",
      "r957",
      "r972",
      "r1129",
      "r1133",
      "r1134",
      "r1154",
      "r1244",
      "r1267"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStock1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Capital Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r371",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r389",
      "r590",
      "r604",
      "r855",
      "r856",
      "r869"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r687"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r687"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r687"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r687"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r687"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r688"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)",
        "label": "Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)",
        "documentation": "Summary of Capital Base and Franchise Taxes Paid (Net of Refunds Received)"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "lxeo_TaxCreditCarryForwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TaxCreditCarryForwardExpirationYear",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forward expiration year.",
        "label": "Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Tax credit carryforward, expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Temporary equity, balance, value",
        "periodEndLabel": "Temporary equity, balance, value",
        "terseLabel": "Convertible preferred stock",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r360",
      "r361",
      "r363",
      "r367",
      "r456",
      "r458",
      "r741"
     ]
    },
    "lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TemporaryEquityConversionOfStockInInitialPublicOfferingShares",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, conversion of stock in initial public offering, shares.",
        "label": "Temporary Equity, Conversion Of Stock In Initial Public Offering, Shares",
        "negatedLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TemporaryEquityConversionOfStockInInitialPublicOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, value",
        "documentation": "Temporary equity, conversion of stock in initial public offering, value.",
        "label": "Temporary Equity, Conversion Of Stock In Initial Public Offering, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liquidation Preference",
        "terseLabel": "Convertible preferred stock, Liquidation Preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r363"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Issued",
        "terseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r363"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Outstanding",
        "periodEndLabel": "Temporary equity, balance, shares",
        "periodStartLabel": "Temporary equity, balance, shares",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r363"
     ]
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of series A convertible preferred stock",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "lxeo_Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third-Party Commissions And Offering Costs Incurred Upon October 2025 Financing Transactionsmmissions and offering costs incurred upon October 2025 Financing Transactions",
        "documentation": "Third-party commissions and offering costs incurred upon October 2025 Financing Transactions",
        "terseLabel": "Third-party commissions and offering costs incurred upon October 2025 Financing Transactions",
        "negatedLabel": "Third-party commissions and offering costs incurred upon October 2025 Financing Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdCornellLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ThirdCornellLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Cornell License Agreements [Member]",
        "documentation": "Third cornell license agreements",
        "terseLabel": "Cornell Third License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Parties for Pharmaceutical Manufacturing and Research Activities",
        "label": "Third Parties For Pharmaceutical Manufacturing And Research Activities [Member]",
        "documentation": "Third parties for pharmaceutical manufacturing and research activities."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ThirdPortfolioMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Portfolio",
        "label": "Third Portfolio [Member]",
        "documentation": "Third portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdUcsdLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "ThirdUcsdLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third UCSD License Agreement",
        "label": "Third UCSD License Agreement [Member]",
        "documentation": "Third UCSD License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_Thirty-DayUnderwriterOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "Thirty-DayUnderwriterOptionMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thirty-day Underwriter Option [Member]",
        "documentation": "30-day Underwriter Option [Member]",
        "terseLabel": "30-day Underwriter Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r355",
      "r385",
      "r590",
      "r603",
      "r637",
      "r647",
      "r650",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r735",
      "r752",
      "r943",
      "r944",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r958",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1232",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, common shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock, at cost, 3,827 common shares as of December 31, 2025 and as of December 31, 2024",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r61"
     ]
    },
    "lxeo_TreasuryStockRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TreasuryStockRepurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Repurchase",
        "documentation": "Treasury stock repurchase.",
        "terseLabel": "Treasury stock repurchases",
        "negatedLabel": "Treasury stock repurchases"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoPortfoliosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoPortfoliosMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Portfolios",
        "label": "Two Portfolios [Member]",
        "documentation": "Two portfolios."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoThousandAndTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityAndPrsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty three equity incentive plan.",
        "label": "Two Thousand and Twenty Three Equity Incentive Plan [Member]",
        "terseLabel": "2023 Plan",
        "verboseLabel": "2023 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyFiveInducementEquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoThousandTwentyFiveInducementEquityPlanMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Five Inducement Equity Plan [Member]",
        "documentation": "Two thousand twenty five inducement equity plan.",
        "terseLabel": "2025 Inducement Equity Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan and 2023 Plan",
        "documentation": "Two thousand twenty one and two thousand twenty three equity incentive plan.",
        "label": "Two Thousand Twenty One And Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "verboseLabel": "2021 Plan and 2023 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty one equity incentive plan member.",
        "verboseLabel": "2021 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoThousandTwentyThreeEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 ESPP",
        "label": "Two Thousand Twenty Three Employee Stock Purchase Plan [Member]",
        "documentation": "2023 Employee Stock Purchase Plan.",
        "verboseLabel": "2023 ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Equity Incentive Plan.",
        "terseLabel": "2023 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r918",
      "r920",
      "r922",
      "r943",
      "r1262"
     ]
    },
    "lxeo_UcsdSponsoredResearchAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "UcsdSponsoredResearchAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UCSD Sponsored Research Agreements [Member]",
        "terseLabel": "UCSD Sponsored Research Agreements",
        "documentation": "UCSD sponsored research agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "UnderwritingDiscountsCommissionsAndOfferingCostsMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts, commissions and offering costs.",
        "label": "Underwriting Discounts, Commissions and Offering Costs [Member]",
        "terseLabel": "Underwriting Discounts, Commissions and Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "lxeo_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid offering costs included in accounts payable and accrued expenses",
        "label": "Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses",
        "documentation": "Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on investments",
        "verboseLabel": "Unrealized comprehensive gain (loss) on investments in U.S. Treasury securities",
        "label": "Net unrealized gain (loss) on investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r483",
      "r928"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions, accrued interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r928"
     ]
    },
    "lxeo_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment in cash",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r216",
      "r217",
      "r218",
      "r219",
      "r729",
      "r731",
      "r890"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails": {
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r956"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r963",
      "r966",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureCapitalStockScheduleOfFairValueAssumptionsOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of shares outstanding used in computation of net loss per common share, diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r206"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of shares outstanding used in computation of net loss per common share, basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r206"
     ]
    },
    "lxeo_WeillCornellMedicalCollegeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20251231",
     "localname": "WeillCornellMedicalCollegeMember",
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weill Cornell Medical College",
        "label": "Weill Cornell Medical College [Member]",
        "documentation": "Weill Cornell medical college."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and other personnel costs",
        "label": "Workers' Compensation Liability, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-22"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-6"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-7"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001193125-26-132085-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-132085-xbrl.zip
M4$L#!!0    ( .B,?EP53ME&>2H! ""? 0 2    :6UG,30W,34P.#(V7S N
M:G!G[+P'5%/=MB^^:2)=D-Z"% %I2I4BP4(3:2J]1$6!4$2D!0@$44"Z@("B
M@(" @/1>)-)%!*1+)P&D2P(2 @G)B]\Y]][SG7/>.?>><=_XW_][WR9S#,98
M<\VUYF_.-=><>^V]R=_("\")JWJ&>@ 5%15PB_('D*>!RP --?6O'^6BI?SH
MCM/1T=+2,=+3'SO.S,C,S,3(Q,3"RG&"A96=E8GI!/<)]I.<7%Q<S&P\O-R<
MO!R<7)R_A%#14/K0TC'0T3%PLC"Q</Z7+_)'@/TXM2;M"@V5*$#-3D7#3D7N
M!$  0$5']=L%_/FBHJ;,\1C]<09&)@I#[0F FHJ&AIJ6YM>L*:TAE': EIV.
MX]2YB\=.FM^F%_7F5'R4E'-<[%)E&]?U(8RXTIV'X0R,W#R\?/P2IR6EI,\H
MJZBJG5?7N'Q%5T_?P/#JC9L6EE;6-K9.=^\YN[A"W7Q\_?P#8(%!CY]$1$8]
MC8Y)3GF>FI;^XF5&;M[;_(+"=T7%5=4UM77U#8U-[1V=7=T]GWH_#X^,CHU/
M?)N<0J$7EY:_KZRNK6-W=G_NX?;Q!X>_]*(":*C^[?J[>K%3]**FI:6AI?^E
M%Q5UP"\&=EJZ4^>.<5PTI[_M?5)4\=%QSDM).95M#&)*US%<=QX.,7*+*Z,D
ML+]4^TVS_YQBX?^29O^NV'_H-04PTU!1C$?##H"!HQNY,5+ '_0'_4'_B';-
M"<9P84^SM3PT\M% KL19@7-H3?!Y U9&CUVE!O8X)V6JM9LW1%,EHR6BQPUF
M+\OD?+H5="(X)@3@-->ED*/16](8DG&OGP=]K-P%79-N@N$<]$*K3WU>IHM[
M:G^V0X_Y=?="X.WJ!*4D'>%:71\0B[8$WGV1[=%/)"\,?-/8O2,CHWD*(F[*
M^TRLQG/G4_'GRWG2S%2?5$:^4ND&KH0A7!6BR "GEA]Z_AC>J=/;K54<\_;[
MO$VE46">:A6]ZV1 $QU<HRHY(DSLV ?6,$:I,B9T?0^$!LY.!IX@2"<='K@B
MI_?["M8::[,0VJ@FR1])=7L@I5O!7^F#=3G-J/YE4IEUT@NX59PG$?V19KPA
M4V"QL,.+'19+H+F*CT YF#K.5A/D!VWK,C8""I^7V6E_>\.*CMDI,9U*085L
M[7?:G6^Y'KF(VO14B![;_&$&76_>">#]F"YL1P:*%49F7-[A;;!V[4A^(OMM
M-!F@6^\KQ?OC/]7MQS(_^R&U+,B99#$:>?VLSMJ:CI GIU463 WW"(_ TJ--
M8[1H4&2 O>L=OKD#O,,]8CEW5Y4,G+VQ6T4+/P=L.K>=/_^&[?)OQF\ Q9(!
M(2(+AL=HV \DM)%WJ7K,*\6X^OG4H/?W&<7J,W?$'[9('[R@ZK'=?O<_P%?_
MZU0<U%IY^PUT!+*>/C[E&2>F..OPI5*7=T#Q2R=5[[:5##J$!K65N-5(N (W
M&".&[J[/LV@+;ABC/'G:0WU*XP=R&&G\_!X4Z[]8'^"ZB:$"5D!GZ;\FAXXA
M:7.3DDCG8'1"AI:6V M/1?9I VNR,>-@6O!J%1Q,!MIS>\A PHCH47(K?0>_
M*%$0PV!!==&+>?(<T3!6<AU*!C"]\Q3F>.(O9D<*<[P9%1E@<<)<)L5*=I !
MXAE9!'X+]#<BA\@ <R:%Z>G\+R:)301^#/2'J%^B;(<14.3C*5+)O0)H-A>1
M[=VZ5;5$;6EFX=/-Y8Q A_"WKK&G9+]T F\X# $+"/[N=CCHIQX)1 90"DYD
MH+MX/(6@"!?^JF(G9WH-;[X0HGF]ZJ6\IY><EKH+Y]>K<7SB^M9MEI9 ).T)
M'=&P"_)(+J3+2VT:78(,Z:LDV@UF2+SC9WS%-9RHXU<Z[P(1VVP\PLUK$I#R
M ?<7_4)')SK %6J;UO.L6N!%S>Q8)'.+%NGTJ\X1QS6UILS:A+P':07*4T.?
M"R[SSK9L?1)96G .T])$66U988UPUXX2D2X-$QV&Z.B6&T7KW'53SN].JR7;
M,)S<3)JNN%T=F+(T4Z;*.=70%40&XI#WR4 L\AA)"!;:A_8*:U%"F<8*RTP4
M5 YYE/MQU0_+^2XGS,1.-Q(/J","/W/-12TY172S!1+\B#38GFY3(2+5J)9
M3EF)$\J+\W1."7AJX?%F'=K.>3Y:R&A!CRCBU&.B:W6$!-_SXH(_& _EARVV
M93C&HC,A;5951N (K8L5MFZX'U@E/2-BYITI"\SQAP\9PW3.A5*'SDW5E6.[
M5U#IG5NFJ%*"X5OC4EL8$O6]YKYO1 )GH$2"?^ITW[T$:8=8Q:WC#/9GW?8A
M?*'?P Q$%<Q^5]:9X19OU#:?0I3RRFB9[S:K._=$NNRC5)[E^(&OPUK0!@Q3
MW,0+(H"W*76;4\Y:Z0)7(3L4'I.$-!RZ,GMK"<=RWLVUO#D5;SLEH?LH3[$D
M;^7!+0WGYL189&5YQS8O7!#;\P3.@P(QP9BLL-POQF6*U_CE/I10BQN:WW5-
MLLE3U.6[O?7Z+B. !KL@XQ$UA5W?B*<60VY\;*6MP3NA;;AO5E>/RA^K=7)>
MV&Q,>GV@R$KC:<8;"9+:VG791*(3\9?@)PG^[F1@TM:YR7?VSN$JM*D?.25;
M=E5E;>=[HEB0X*TR/?V@0S:<0PHN'1^ FJ>!*V#9VLO9H',@S';J[8!%?2SG
M#7V?VWP?=SS%CA:>OP&4GBGUF@^W;*,2-_.Q^AU(9C+@82QIAOGTV R[-_LS
M2R"*<&FL=:X<5QHE>DET,"-[@]%):_%8&(L1;A%KU9XX:86#81&11 :4!8+7
MS<6D&3.7[H&S3&JO:CJPO&58=\PSCYDP>C+YK94?:GNJ;U$R#.$&HH/+X7M1
M"L<GK6%3<X:^KP89[6>NXN[3) E^OQ'-R\789:$_P,M!Q;4LK'"42))S0U9M
M;W:AF"",T5J7%V;ACAMUB"G+QYL/7L[N;RMNIC#JLZ=ICVTA:[P^>@GB]W'#
M>/K%?B9=GE9.3$_V43D"UR!&4#64(=0_V'Y-!JCK6Z5H4O&FA)MK<P+X1H+U
MW(8V(Z8[*A]&#:GI?X?W,N(^S"IC_P$0;N9_RKAD1B<N13<0A!T.'20#P@BH
M:;QJ%A=V%\;TL0[)U'(1%M,$#XIOWTBK,S[=X3LPW_A,B@X7]O[C+2EQ*Y8%
MY+>1'@TRT F:.ISH]#="]=.@+>]\]7OLS?(Q7=%DXU2,.M.[Z]AD06F19Q>:
MO"8?3N->XPU17G1PJ3$2%_[A!7J=QH3AE1XV]/FE2,_SQHV=ED^UYC7[9(L'
M:P, &YT!G;-(5]#TR467-L+\2;=KVHRKMH[QROUL$2K;'"VM8J-R20.3H@GJ
M7#1-MSOA%3/'&!8.!K>ZL([SB]EMR$G3GK3Q[,FU,GSN^%8I;2Y$U/2Y5O!'
M@;J*VZ]9,^FO+GD@;P_&S?%B$KL4J&?@?)B 3CF?SH )*W\$M\JLY;C1BSN^
MYG52;X4??NFR2=UY=/=YFCCS1,@BVS<">KR(H!#ZQ?%$+::J'PTZMM&^[U!#
M&JH%.3T9V&X.?"[[@M:;SVF5!0AQ*8%;X#.A!$?75JI:C'XVIFSC4O &DNLH
MQF=ICDV)/1#5DK/O),#X0W/W->.>@@#\"J:PPUA1R*B+='JH1:;0^&Q]S+8=
M,F: YWG)6=U OHMWN!*H!CBSQI:;ZHGRVWCW?IY-L L9B& _>D(&O 8G \B
M:^CN?2524O:>@_:U^X,JZXZJE+5B&AUT5\,KEJB4!RLQB;SMS550?YMK25K*
MTFP]60;XJ,3\Z/4YH54:2KH368D_109T4R@Y$HF+&TST3\2[@R@[@8WVKYW
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M/9L6QG05 YXF<;MER$XTU<=J]VB&Q*Q9+KUU?. EK7@GS/.>+/P'&Q?6LI;
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M4H1:O3.T)R-%!5L:]DH3&='HQOV8+I/PVOO8'E8B6>\&IFU1"48/1FELM?A
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M+IR\"*7[L![KE\8F3Y<F)=((>WFY5SS"/BKPK P2:[6Y>WMQ/D);#*,6 W=
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MFX=2:8W'LG7.7<#,QVW_J-G UV;3"ZE=5:\+S&D84=#N8OUI]32L(#AS2#N
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M"!-1;(@H@=7OT=:J;FQ-L<8^L:74 Z:B K"(UP_U>9[GT%!?*6WV437@[7G
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M829!]&1@U8L"U3V*T?G>@"MV(8=TE-449D1,=,UM@9 $Q!;(P!$+Q5;76LC
MHC*BXRX<1+$^D@Q(IV<3G</^9Z@2U/VX;!+_2J]ZS'<_V4Z@H;.BI:)%]G.0
M4 (-6R<CJY8))*ZMR^BDGIGI?=?:@[Q+,5)O%O[I.W7_5=KUM"-=2L_>H_CN
M3S''%(@JOAP7AP_,P1=:CY3#+R\Y3LX9>VE![C1X)HNEWD[BHZ<5OMA%WYAZ
MVQU=*''IU2NC7*\=S4.9/C#JG38?XBLE*"3S0'Z]9NO&%@GYJ818BI@@ _QO
M#DTW7_>0'JW\R4HW<ENJ2?R/4>E'S/,'I_S^_*6(-_A[%'#42 8."&PQ#4'R
M' 5Q"I*_X3>Z6B[[URQ_-608J?<+8E48\<M$>QK_=$;@*A_0(7WV;SY@$K,S
M^/OFO+^:'MO_3=.GU$0"NI6)6Q5&6HZWVKM&!86#$H,6D+\?L&@]NX8,=.#J
M(16P+)57#WK3VC<$'B#6TLND"XOB/?+.^4X=4A@P#.#VGO(A1QO*DKF(Z2-%
M>A&?-5$6W4U$AQE<D;+H*-%57!Z)'Q/S^K\)PO_7IO^A434;DV0;%6[9LC/0
MJS]COOL@\!#W0\:V)1PRA4"1 =QK"2U3T#=_$D: J72Z<8U0GF__US(]7XQ\
M5N)<)O5?H*AD]'-B])]K^=;S*.4%)<QJ_?(T1-*ZKU7:7SL6"#,*8D:N4G*J
M7J9RDHH.XNYW\$\V,)$:LA24R;6<_?MF?:(*?8?"(1]RY]+&KZ\A@B;5$X]H
M!LD D'X@7*@;Z/+[=O._=FMZG(D3&="A[!(?)4CZ17_K^!:3>*6>*?I..0VC
M;;9U\W75(63ZJ9MW[WI=>D\)ZSX7(SR.*;&Q06WC\H1_R"E\R/MU&'3^TE^>
MFU3Y^KAZU2I4M\E>CP8'#?OZI"WY[!$W;(N^Q0YY^^$*XMKM]JDT(GHW\'<R
M)E_T.WK[;X_T8>3-=3GC_^F93&HHYG#X>OD<R!;8.R.5^WCY[W*U@'%Y1V]$
M\"HH)9?"3U6PPNN7ZI)6CB[]5#J+V]3,S@_(YB9)0\''X3R!Y>L)#!>KIKZ!
MLM W]LT119M*D+0L,':\!"O6E4X2&7>!;M^?]U?:Z<[[D9OPF1ZX[K(Z<ZHC
M4;5\[_W5HR\@$BTA2![I'148H)H3H-+_I?1"Y\#=9"MUESL/#;4;W[TKOX-7
M(&C6=[,=@Y5#^/'#B(IG%?6JH0%95SSPLQ_\CV9\+T!!7ZU;'$$*>5N5',OA
M59,?9M-Z][3\8]:T!?"6?3W"ZD,_62Y;.3!.FV=OD@$O5RW4R6?^U*_2-;/=
M]GAGL\9FB=>/,O:VHQ"<OHAC4_U'-5.#:<J$Y7K7Y.O]M8_E[>YW]#U\T. T
M_EBC,9([X=1M-Y,1[X?5K7T!P78FQ?MU=95+G%:M^!'<30@KW 8SV'&DV<W=
ME%5:<EFBJ[.>VWE.4VJ(;^=;P,S5GE,TB4U*89-"$>6;<NYH(7D2A!EN,D2\
M_,XF.=G.;KHH7J*M72M:Z;E6 *0]5MC"1.)ST24N2<O/;FL[?<Y3QH2FTR.U
M6S[+9V3&6ME"![)$\?7H(SM=JT3=6#TGX<+ AVJQ <R?3TB!E3A*9YBEU=>R
MIM'TFP&242TT[V#5[5G*(RV>A6MM<UN>8M8X4<3[,WVR,5WT$H;TP-YY6@UW
MEY?^H!,5M3(2:O?CRX/=:]Z7#V^!U(<<-S!1.*LF?/1"$?QV.2RCIRV4?\92
M8'J)[7O8M$V" Y=5P&<&CV0V(89^_"Y!Q0U!^_YGOXV*NQ<[+-C,ZXR0WJQ6
MB\'-JI+3WWGOT8;S/J[YN2BRF+F\VW6DIV)5TVQ973N^CEMNV@K.4M<-D41Y
M?6L/P(24/]7R7O14^GC6(0)VNS7>)NP68S13+Z\>&7 13R NL0GCZS%;VCRP
MN6V=6)O:B9R8\\L)AU]O.SC0,,>]%@ZZB[NPJL#T^I;WV')4Q^CWY-;>:>,M
MF8?-D#P7 5W.ZQ>>Y<;\S Y#TM6"XD-5'QL]]N6WIS5ZY[@H*E7]%5$S"Q"#
MS7SN>"M7^-Y[6BZC=V8K*YYP*G2@!^W<DB4YX3E-8H_7@"2K\?*DL%XB%&-,
MES<@.:NQ_&=$G^CR,N8!;%<',!-1RF3@^*JJK7:J1UU&R.M+4G<N?F5;#TJQ
M]7/9Z49DC@V>NU]3$SXL4T6IDB9(OXZ50<I<!P2"=NC(?*W+EFXA+,\*8Y*-
M\3$=_FE\QT$B!1)ED>!_C_%CXAG]ZZI-NTD#L/*O9XA9OSV(((__L%A.#]=O
MQ@=BFTE<D>EL,3]$&T:0J)/58Z0AM72^77CO"T5BOI7KXO)@$' XB/MT5*05
M3-#&>Z%:(Q:.V*Y@%;H@W#,O$-7?$Z >N([C[NGQEE?@]+[3C:T_-I=B9O$,
M! M3;#E.K0E?([>Y@&6)3'UG^,YZBOI4)&Y2*";"^0Y7>%Z8=685<PI$TFU>
MV*2<#- )3L A/@L(0:+Y$(EW#82)M\FF<85,R;'FMJ5!O^NL5]YW;KG8*WFK
M9Q:M@)?<?UI:&JH,A^'9BU9#3V&\(HGWN,:K<UU;3X_T1QR]5SR68# E:L+;
M)@Y3%XF%)]10S<ZM"DMA$HD<S9<FB*#%4JMVM:^N;&B'J]O&@*.;TDQE9OH6
M[?;3P.1D&^T[G,!-YV9PHD;F]T2,%<X67S!QP][]D+4>M>L7K!6W:V\[;_>>
MY^D70XFWK&]34I)2,J8PD,W8]T3+HR0X&Z8>G5:)SJ:>Q0>IUTSW(1@VSNH+
M%WD*U#QX:6!C:9!Q2L#CUG&/)6]3;/KFRS*H(PBO@.GKF"J,ACLL9(IUF\$2
M[2;@%B67_2YDYK\.?E-E3J@[]XE@8:E\2C7YP3D=D.-_Q^=3K):RNP</9.<H
MFVO%$1D@/3>$E*8>2&*K249JB8A-,((,Y'-<=]EH%20#'^Z VY%*L;DQ9TSG
MJ&/V2MEP9O@B] 7N#LN1%CE<O#9I3K,D$%DC=P-^/R>I8CA<\?AY$?X594AX
MEA*6+<$/1 \]5)O2TB\L^3"6/I4#D94VZPE\$$67GB=<,ZBJ7D -)]8N'*BD
M?Q#BR6J"#XC&;!*Y,#[=('8%%3L(VVI_B'PZ&0#E%\9P/DX^ZZAG,?AYAN;;
MA)B[N]S6J"I&\J7R@-@5>H$7KZD.AC46G^:I7V7/N*_:U-346GQ45M>Z=-.R
M)[9%K 1V\G^Q]]YA377;OG 4$)3>FX *BE(%1$ #$9$F0J0W(0(B34!$)$ @
M*-*;@*" $!40J5%Z#[TC'224$((@/4%*@)2;=]]SW[W/^YY[]][?^;Y[OOO<
M_4=\'A_6&&O\QAAKS-^8<ZZYVBTS^.K=]D0L^@L'O9<D,IDO.OPZ*P6]#U5?
MG2C';[7; /!4P/336O/*(^AF17MXFDM=_#>.P@^2$J^.OQ+.?GV\W=A=T=0B
MK<B\L'*S?J4T2UD-+3W2 #Y2(>GAO9[[E+C/"61@C*KN_NH1:5>Z<AL>/2R2
MKEM[VA^I_/Z=AE2$G!PT,,;-#5HQ.<]CK,VH]WLX[%2>-XFY:]":O9=A1]<\
M7.%?K\3&NR]OR/75"3S;,FM]5SMSF8VQIO1AV,7QE\M2/H&=D]M-+=H\=]W_
M4V?:?*=5@O0"DBP!:),7QA_^Y8U%+JF\*UMS?T>]*/%CF-"8V\*EWE1S:*,0
MZ Z,'R>KU-4D4CGQ-+U]HAPI3LSQ^MGVE;<6@@#1-RE 8!<('"GR&K%/6[QE
ME5K$,,93D6LC3<2AW3YY+K>K==E9C]]86%Z42# #<L!+C(E\0<ECO=(K)6HP
M^9T0#\),HS:/J<;]_S%9(2VN;7L67I!ID?1)D4($W9CR0B1XV!=8*4_5UO-S
MZ/)H4@%/>\8[P9*(_&6SJH?<EN]$ZG>V2<P5QMKZ-7\O\?]"9VZ;'[6MW1#-
MH_D0]OZ/5YB+^-I^Q4\D!A2N6BI,?;=N'S4$1IZ*.:%?E!NJ".4](!\Y4H9=
MNC+:L]GQY"Z2Z1Z7XRIT.K;V^0IE86\7.!0LJI4\\8W@_O)*S 3XMXH]] N"
M%L;%[W=BA/2AUO-#&R=CP>5 ACOD/;$YK_S1Y_:6VKR2NSK<S+H,-P4".2L<
MB]_L$L.#DXYX:314\+=#(NY-4P'ZB\CXM57V*<F%_><-#/,H0==LA8G<D1/%
MO5_?;N2]+A.8$G@1-<^9C4,%<OZ"F>N4P$H?YS!>\M6<NC"7;/BS4@-B(=7\
M0O/TB^N6JXA63E\<.%*4CL >>^6G<,>S/9V@@(=G^GY] %\Y#?NDUUL.4)U-
M&-^^$L)&3G]*!AO45A&?E]IUL:+U?1@VWB%YDN2L/C"[YB^=D6?\H SJ *&'
M9F$AM,<G"JCB*]L5#@1%.47SYO#[=#.BA9T\SR2%WYUE<7?5< 'E0:*#LUC.
M"[:T&!F9QN6,])[:(\Y1;B^_A)E/["(Y87J$\S0M.:Y^!?)YMF\%EGN</3]>
M#GIYBB?H(K($Y0QG@;=ID&0(_.W>@KU/ISV-!#+F>FI2/]IUJ%)(X?BBGXJ!
MA#[H5B>*KL'RZ!;4N]/4X\2^3MI),8OH8KE;CDL2QV>S[@2]4P&$TS]4J'_A
M.PYS(&PU0^*KJY)I!)[;CRCKR<_AML>7HNL5/[M7F</5]4D?^+1#T1=H+R[V
MLFU>E"_WTNU+8Y5J5U]#6G@]E6U1Y2XEO50 O?**'W(J$^<=G<(7&)$35&AW
M.;PVUJ]0%; [W_U=&7%T_)[R5GC3A95J1:_1B>LNVYG"9MUO3BT3F!KA]?>V
M6A#Q$#8*WUJV"EZ]8W:I"#]J[;1GIP.USFW3+C,^1V_1QJ;(P5GA\TTG+9^0
MB;5L@;^DG,4OMS9JW9W8]?0-5/\Q9J(S=,*D/A;HMF^6]9ZNIT?=5?7KVSN&
M>@M?S+[\(I,*>KE^/(NSE-Y'3/G<'E W0%5X"(M]QV -&RO"S[QUVY#ZT/SD
MT6RWZMJOTV1M/U'V"! /I4N,_>-XU6R1AX5%BS-@4[,HX*Q/P@L@<BC8(Q0O
MWXF,@'.&G%C!L(=<G+/_N>UVGJ&$G"NW6.C%6<:CBVX1^,"2RSD8HA2B1AFV
M/QW;.L>%A[3QO?U9Q]#.C_#*OJHIWNXKM'%?L,FI,9I.4N"]3[.3>Q"PUCCY
MG71O3J;]EER)LEQUW6@P^V-R#HD;W]9)!7!47 >+$I?O#N\R5AD$@VZ7.YN;
M;%]]X.CXN/X;OZ^GV)GEF /IO22BJ 8#<8%5#KUGJ&706,5O4=[/HW=BH3@Q
M(9?S7>@Q%O6UG^Q<,%LB R'%%+\<2[+][&ZC&_6T9NAJ]JL[MS*M:N*GQ)V=
M6:Q>%.<O+0]!53;4"648G'\[TR[KM9.>.Q[,/FZND@#],S/6N?>O/7AW+*4U
MX662UG6H8YIS1(DN^WECT[@'G_)Y/F;M+#Z;K/=W>66LK<$D49NAZA"?EZ;#
ME/2^3XD[%+#I#AY_=A7(/[]AVD6Y\&7HJ<?#VC%Y"<Z/"3'7RT5[&24F5\&T
M. ="6I#TTZZ!@<5O&/>KWV0^GN3F[./^>>W8=TL$I1=2W@]A@BF12XIN"'<$
M)M,I.*1XB!ES'8JN!T,W[ _,$I<U+B^ -FYC3-L,]B\'40%*6S_K@LFTSN]3
MR*._C +-I#-$SGGOT#K[DGPH]TTAWNPBV&'JXLW5H,2KV%1SA&)]*E:W-Y?M
MFF6P-N QY)0&/5%X_L4:KB508'C:OLG3P"2I-+\V>0E;5P_\MGX-\9KCA#Y=
MRET/L?*M4.6MN R5#MM9 "AQ)\C4Q;E8UQ^H?59:*M5U1%.85*ZGN&HD+#CO
M-/Q;(RE56E0XY6KCO)178*^9OS+QN+%C8':LB.?RK1CK17_'XX6?)9(? R2&
M& JE$VJ) WA*7YN-950IT _[&0@J[%MT.ZRH:ZQ#V^LG7]6Z%)Q\U3R")R55
M(_7[_^1XM/MM. S+/6(KKM4'FJC_IN,JGKF@XDI3%$;W9*>$*YTW\R_Y?ATU
MT<K&?[<M5/3\D3M)E\#>"IKR[YJ3QW]Z?P7%L?(L2=\%>C_!^U(&]%56LO39
M ZM=QI(',%6B+N$C\X"TY205X!JOVR[TH*IC::3KY=-ZSR4]/9/S>MNGKDLG
M,)T'G'FA?9?&S!-HU3[EMS43I !HIU!HC*AR)$8Z1S0.?D^<;*.(U8_Z35\'
M*<C+*9-O0D?[0W-?=BFWZ>A,>A5U&;\X!A#5?D]!AYPC6N)1"_SA31)O_9 )
M]FQCW+I?RB)F[].H189!56>F#XL>H#W]8%SCYTVH#(,Y.0\8?'2+)$HTQH,T
MAX!VWD4DJTF_DP[CF^='/85D;SI7!X6Y%IX[59#T0_J,SEFS-/H4>Q?<K%('
M7 QF6TJ9S&;Y$K'9A9W=L:!PC@C-GB2PO7FX'7_SV2.^OHKDMWH_;MUBF-%$
MNA&Q!&9MXE<<9(JQ4U2DCC]#KG(AHJ'JM1]ZXHFSU3-G-0O[#Z_#1D)E8<_(
MI<HB8,K)M2+8(Z(GG!R.% [BRG[ ^6V/7Q;.T#C&EOS!Q/)I09J]CH#?B284
MLC>1>+$J,N!(F>BT,!BY+OO0.U*,?^!3T8,D.<=1/Z)\25X=9,\$*NZF!BQS
MN''*8]?^SY/:I!3B%!5P/K,+M2>&H@)&HJ5WRU 2E*OPGH>$+7+D%A6P\_'V
M';)_&V*_6)=HN?0()HS EF8Z+7@:+##D'G:,5W"R2FHG6+^W[1&H3D]W%+LP
MQ+W%H>'4<JZ>G:L#S];7JB$QMJ.V*Z)K,^:9(V01Z<?;[IW;[]N0_OSD1<'3
M"MZU&#4DW<>D0_*C\FE+/W*CWFR^L[1.+]H&?6%\VL)KP_Y;UV1@8V0;%8!6
M:L6<:I!F;/<(9F[/N!K/^KPL\TZ&=L:S" :%:*N/)UA%+S,_R)8"3X&QW_+Q
M.7LYDR3EHBM/[&Q<1U(S3J^G"ND)VOFNLAMUB5<^UF A/L?+MQYNIBR$XU&Q
M]R=I/:@<=*=[TR&CQ8N;7O69PZ4VECA",Z[R'C'HR QM'3)D@VF'\*Q,.J*I
M +#'Q4<5E=8V#+-\'7UEQP%QBX1DW^?O $0;HDP+UD<5>.7"SYK;O>[\RT\:
M/^**;!HWZY6&4*X_:HFZ>&&#89*@0,I-POG^<H]KZ[*1V;H'#677PN'I 3^_
M;J@;A>C@(TGQ&?+DD!8J((>OL0O[9D,8>\3.1$2UV%\;56:%M-I4;,]8G\_0
M^84&)E@];QP#"'N\8&<YN>POIA%M6#F4C+;FZ3SZ^!J6<!GJ=;)EJP4W$;:B
M*',>=EZ(>.>6^N;# RH D?F0A,-7EI5]78-73I+>6<;!UTI0E!1M^W#<EG!^
M6[SI7B!!)@WE&6N$_U%1ICF;(N")VKB?K-Y<ZM].!?"&<,.LQV2!VCA/YG8T
M/ ;X&8<2%4N>06,4 1^^=VM=.GL#]QXG*5CJU"G&O\,>!>*]DF5[#]^'8'!+
MB\Z;=K6HOJ F7G'+.9%-X9?T5=)CU5-&:N^Q.1$E-@G"[#8O2W2X3*?G]M5D
M^8,#*MU^EM3KNN"\(^Y"E]CYH?M82%S>A.<FGT>CDU9J-N;N"T&V ]X(>)#
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MT.VORGN8A0UFIG BV*W<X)X-8_'%-Y4"/AO]&E00L9Z-EDA9]>BG A["IZ@
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MG0;XFDX0[";N.:HKW4VO2QBJ!1%72.SN1VPHQOZRU:F'9X>*&\5TZA''HMO
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MJ:F2''8EWA3;U881(MTB!*_7N43(C\N=\^CRGHO:3Y>['+@IPR-:K+DWJ$0
M8[=:MOA#QD7%)AX04)&9K38[OA#WKVCWQTS)2[R,CY)/M#LZFOUZT:Z?8*2;
M1QD*5 G34)UR.Y3-[\(P$DU;G^E]N&*K[_G T@]K\*7NQLTXS[OOV7V[!Q6Z
M[G9@+]X7-QQ]B1-UZ9/L$T"%6ZL$Y?^8+%#-V%DSSH\T]HE+KB]_9O"Q;.[G
M$A7@@N$\H +*NW[[9+C-31$5TS$_68M5P9I?#L>_&W(,%J9_3X1-0$C<R\8U
M!/\V1$PV__B#HX>OOK:W"O;X4%)$6OO9P#?%31--@CU4]J"$_+:M2"Z8 5%^
M <S_?8[H8>["EWT^/.VZ1Y)L38)#@U(AQ]6-\U&]U6K-UZHTSA#=CLZ1! CQ
MB>&D@'SH<D?3658>KA4D3SA;IUYUU&QK<=!LF>V21*A:QQ/'E5H9"ZXL-;7Q
M5!7#;53XD[4@M][2K/7).2<;E;T*)_X!%7Y^EZJL0&M_#5.B\T<H9H%&G& J
M6%E^D[%->[2YA^9>NI"LXN4IMS&O=O?TV:0$/;KD8T>)>^\)%O$+6_$@1HJ0
M! 'CSH?>K<HK..[/E",P+9R0F6O7)=@MK"_@8 TO.R(I$[WQU]2N(*.:>/'[
M"95KFK)+.86STSW*N9&Y#_E2V;C+DA5GWNT@68CQ>%P;@LDO6'[!.;+34WC!
M):IXM\]VY>G:PY<S]Q3[EI32;*/9%$/%WIRF\&+L&X&#2F[Y[,X#0AYIEJ\7
MBQ=GBU/WZG^Y:-].ZG L)L_9?OZYZUVRX0'[-KG72\@NSZ%,S#%=??.K->.!
MA>*T3K)BH=*WHV_'*&?#O>]>AA9B\*:L0G.8!?:7RK?NRGE5],@NBA=8_>A-
M&20K>V$0 CMPT14X/44#=A./:)^B7%JQ4;3294=7>/1@8VS#8W22>(H3D()]
MO-ZI9>^=1,#]B"J5SD80SJ4C)>#C];[W*\^*'-R4CC>%"*;_ ,2%6G]1FM+$
MJ>8EMYK[6)UG4JV[G)RU,(&\56FS5HI8$A"H'7^?PU=[;JRBNF\7*!5S$3G&
M7LASO!V@"+XAO1.[=Y;\-K*MD0LD#$V>IDC9Z0#1MMT-4S?:"J@ STB(YO,U
M>_4C5DH_8V=@K@:(H/[^&N_KVM&2A_=B:U]3 <6T\?PXPCY_!?(QE4@%"/@P
M;*5AG2DJ5$ 5C5//SA#[EQ4:\16((C*HGU9Q25%$_%_&%'[BU-$#F"@Y"V;@
M@J6EOOUE"/L:_[-8."MRSV]VV)6YCK%?0570=>;^JQ#3CB#M$'?*!(:G00%O
M2SF%Q/MVVBN.40%?&U0^$17!E7/D;&L2ZK+[L&0/5_F[ABA5T[A%_,GW[%44
M/LHHG)FB#/4VGX3QXH1%@HQ&/BIA#J0E?&VZ*JI6SOI9\W"4Q"&O&RG%@%DH
MHQ 6$@0?2"/5V6\6/COC>6/Z)X7:]T:;OQ[HL@%K.1](J@(8^KB.+R9!&$,&
M#[6[.B#HG+TH(F9^X]3^+:)A =%B\UOO]L+ AOA8O@>4#NAZ8T9P/L-"7=-O
M4!9RF<1 X,%P :7QDO/^"5YR,$E\F.TD4KZT4A7!7&)W,LK <9ZR8=[N-G@V
MGTWG.,>QPVDD91IT BB+KV]#<?I!!"K?A#5H =/0]CD74H(SW]QL(7"$]0-X
MO-]^-GW^XHF2[SQF(Q;OC:.4'8)"27[.)>Z]\6>^))_<D!.Q3+MTFI"C2I=2
M<=JR%X$W_[P#B6SB)![_TG(B$;O!W7%Y(P(MH^WI>4JR]W/.9J$\@&WFU)(?
MDM=-K$J7Q".,%8NCL+KMUR5& B6Y!A;8!>*O>ESW-_-W8 9&Q75Y;S:+2_:K
M"IM' 0ZG.Q'5F'4J '_4\8OH=(_XYM/TVMT[$[_:O!DZ^A_WYGM()'<(Z\3E
MGXEP>,&DVA'T*;;$C2(Q(E-I)[7':G"G,5Q.%BG[@$O[RJ-CECJG%5]ITENV
MH?!FW@)$R19$.2WFIRI*3GS[U=FD,G8F6%)K9'WR&Q<Y[T'REB/+YD-6 ?$E
M_]>);[U+][%='?+TE&9,N6XKA GVD'"3&&3UQBB5TZ1W%2]H_K)<]ZTX+ #N
MJMW3K%YVD6XUWM2T8OAI7Z,.!2O[R/-L4/3R:ZQXO%FY@GHH -':,#KOO:&/
M1^TE4[[3FD/?A=<$;C=1RVG3=<NK)1PIS]JJH$-?K@NG=@LL5\)^'3T-&;51
MB04Y?I>C"+M+VGG'\+MAL[C,7NC98Q\DX6K:GTBI"CLE:]Q8TEYE0E["5S_?
M -U'34]C'R:Z6DRWT%I"H*P'MJ]V;$&M\J+QV5]7W\$&9)ZU9ZO5^LZ\.+;O
MWRF&9L=.-HM(L6HM,,;* )49.K?.77\Q M:8\=K&QEU)C(O;,(U+M%D"LAZY
MP/B)J5AV+B*B+>1ZQ5@%G!6M3BE>0"]<*I$=XWK@*JK\&MGK$ZZVD7&@A;V0
MY4% 4$[U$&R..H8Z"A'T*^?43WS[H=7E\66Z4\)<O2M3>KG\ME[+\28$N;SA
M>NYT2#]<T.]M19]J90!),IB^[H7M^YID!6Z.^#/",6'?3G:ZTGTFBAR!20KD
MW+/CN43?A<\-VN37PR6+CA-!;F?GV%I-7(=CLDHB '$OE)+,-*Z&3"*84"Z&
MWD;#E+/03C'VU8R78N[5E4>\ V/Q? OUW1$JZ+S44-FXC4<N)U J**>3DWMN
MQ)*C:\1FE:D&!=KP."DJ-I:@I_E9^UD/-TZ@Y]RPYCQI^_1NJ=;>AUHJ(.(Y
MWG^#F; -WHD7 G&LS+'AV_-3^5[I";G<V6&/@FB4=5^DVV7N@(CZ7431&.]Q
MTC7\>&5"WB<,],E1A\V/E@1]+[Z.JQT>>Y[%_$]3JD[>;Z.CHU^JV8J$5[''
M ,&$:@/B7SZ+;I/?YK'%Z?9&"!&)]%,W8NZLB3DO0?[(].7^([K7<E:B;(JL
MCYO$/ 9/4=!PUMW4*FN,/?$<6B>)N5N<W[)JTG@6:)L(3GJ]_$5MXV[(P#5(
M5Q0%:(@#Q:+H6M?0O?I.OC@+@A?B?%5D_F<W\<J*+[&^+^5X%'X)?J]:>G3\
M(MU/]BD#G$X!813+(K0<55Q<@>']OLJ?<;7:.=_K"*B2-EKA)3YGP"#%&>JH
M-QN77;FNO#U(XN[E_DQ2(D8O_#1ZBA2$:4TV:'Y*I3];E>P7?1M>=D=&1]UC
MU?U/ZSM+%'&8-GZ_%4*_VB1'L/]X!<'NYA/M+<^B:/CCTOWWZ_'6TTOW+Q];
MLW? [^_-$B4)NAUI(8)X*B#A7/"S?8JZ3*6(QA;8(V7*445!1Z3FJ%!_KQ1.
M.76="K@ )H I#?>I@)'/'MT:%SPH9\C(G<%P6LQ0K6 A:-"1F/VH7R:&'SJH
M0^D+,WJ!6?)]]&UZ,0G/0R_0LKA_E[WL*3R:(CA)@B^(T7]W=\2U4\1>H)=-
MOVZ?AY1WJ<J>G#,3]SIEQ!LM0KA7LKRAB>_L:\N^-KE(N*D1/1_[P1FYRF%]
MSX A=S'4R5*O._UU602G-UJ/-0S"0AE&<<-T\;B]/")!-!'8)#:\^[WA4HY'
MDV(XK T[?>ECDNCBF66?;\UDCB_JSR;K*=]!K#!Y?"SE9 <.?HIX=40:PF[E
M=K7/R_%LW$'=R_2L+HR_1#GHB?Y[=C QZ,B+Q$W,6>@#L1#A79P:]4%4@&B:
M30+"/[^R9_VK\-L<MIG@<8DC"T0'$KV%96_>\#_B[PRY4C6RZR.082 @6RI_
MX852=X %TTQ[[OT71SI,N\C,D'_:?9!B#3GB<@N"#LBX@!0AQJ!'T&,WA0@Y
MSV'DVX8?5>^OI-M1K,9.[XH YNGR\2[Q3^6CL@6^$/@C_#SLO+50B0-5366O
M@$_D'C_6?:Q)+ZI)?YK3UN^7/XD;AY6KQ_OO.0X]17%9PYW=#^,'OGV]D-I]
M=/R>GKTJTQE/9\/Z-W0>?")%*T+_?B61D(*;)+T!1:'V%%9!A^;G0P8F<9)=
MR ,Y."=\W6D,OE-XFPP.A<]YT ITB,LX+<<([H$A><@PVH.\NQ7/6J*?-[=R
M32<KYV8*9C5P?+BZ*E3M_O.WTJ>S2J;%+O6<MC0OI71A.(#R><1ZTW'<Z,Z&
M4EM:S[/)\CL4P\.K/GN63%K5 (>85]:^$PV18()H2>Y*703"J=!^RLI=*C;(
MP_LQH>,I3_+'6XQLQR3BFW$72N>(1^V';R*Q0UXDW2([U\?AG&XID-M[P^%'
M'QQE*YRJ&'D/\VRL7Q:IF13P,I><MGTV<HCQ+T1/>!1JE/FTJ\TIWM;(H )L
M$4[0%&PNI'RR#7/2+5N0J.E&N-X9F)<_[1>L93;\8_Q<!4B^6]S\0%.FMT:Z
M]<&FQ*3XT748$+_5@8D3!1*\8QK$/3ZXS@E5&!3 +K&P\G .?HD3Z*:_N/W
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M6[AY_^-Y_@8-0A2[LKQ36>6JUC);ME[JV=(,P?-M'=:WG8<W6ZV=\^*'#W[
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M)'@B?_$I!3HDY[?M(P2;D?]$K1[N[EZ7_T7A_W8*A01HNKIU9LO!B'CF_5>
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M, SJ^-P4"5A90F5]*RQUT+/DZ*O6[/VI^)!*2._CQZ%>?;(3DHTFQYP$")*
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M?#2^^4H6(V!Q35@4S-AET%R=^YFWVF*><U:K0'3R).5BII+2:X]78=#F^(K
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M!+=T^+W6<<&  3T<,I2W__*@TM ;/9-+C5?X/1SX%:A"%R>Q3*<H?@['')O
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MBY3)CDOQR^J?8:PL9OY@OOA]@^/@2(AR"3K*.F<07,^*$,8)P]-5[<]FO4=
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M(?,&;O7OUR,"%2!?\9HZ)B<\1R;G"\]MOS^9];BA<&.?-YS*HD]+.S-U8]!
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M P05I=\D$Z$:.&?=LHR6YZZ!^GZLWUG$/]HN\;H]BT&AR/%D$/$,L17*0*#
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M"[& JZ'H:'%I;=Q B18":XQU=<26]DSPI==RM:HSV]4V\G$U\XEYF+"#$EP
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M?6^7Y?."QZTDB!H%'N%($ 4B0510& G$&I2(@#.+?ZE+^;N^UC<,M,: CXD
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M9)IY.*F3L:>,V/&F!'+(76SG2V4;E.XY9ZMKF#>]'MFSIT7@QFX>R7*ERZ/
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MD2-$@-"^HB#<ZO)]8RW4VQ[+>ZY.QD6D/'^3Y*9F;;\]XK6&65<VUI42AHB
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MN*^O"\]-D+'\%,C4&,D8:988+ODR;M7FA3J[YUB*4MXA&:./SD<9E_B/1*V
MQVT>8AGE%QG1QC.VZ)&6.DA8$64GOMP,C;L0MY:)^S07?#AV/8OU"O"A%CJ9
MU0]!&ODF,$Z#XT89PQ.ZUB9"&:)6[S/M[90N]DO,FAAE6(@6Z1Z(_ WN/@WA
MG8"P,6&@$)+0W[%D_N?XZ"6O(&:[STF#Y]E7$*I-HI]#V\<*_'DM_['V0IP$
MVFY&M7'V#$SU'AH'2K5=WJ,EW2[,5$>0'\9=F.U85D]S?Z%,?&1G6_)<2<36
M._C*2#^XHI>=BFU!;1Y816W))?TZ)LU_G]NO1 F,+".79/:YV C(G5*1,&6
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MG>VMY#/S/RL](7Z:P!:@VW/6IOEN N^M)M)",7N'2(Y#(6]^2=J&7*=D]B#
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M?KU*L!;X\-M?85@6*T,Q(EL^-H-HBC_ X"*^I53.X7Z$;A:]0D.=^$$,7\K
MK2#+N>6;H&D?6BG7\D_K!"CY\8/80\3":0DN1+U79 A,EXM_K;D(SX06!].S
M8^FILQ;WZ7P&I[ D*(JOR@B_.G\4V/\KKD<O=1ZF_M60AAMMPOO:J_I/SHC_
M8GO_Q^3QJ=^_B_R/D'.KEY%.9SVR].:;',(0*Y<_A#,3;U:YO$W^<-FL)*6Z
M-=A.@YS?8#/EOI7,<W:MGS[C]*; X(T[]7B5ZS[EQZ5<EFND\4>8W42@#U^:
M1^F#)_>H,;LB^&X\U?ZQ5.+^&049LQQ5PGDPB0.7P@=YW%_4"WF>< [+UZ+7
M+GF]CI8;[1I'M'UH,/(Z^/K0U<)3[\.%=N(Q./#D!Z^2< <\(3%_K8O/G:QY
MZB(7X!S!L#E^U(IQH<5Q+,W:'Z70%M[MY<$T&PFF>%FC*FC>/K]K+7Z?US_A
M??=[5HBZ<HW,E'N%CG.D:?W'@C.O;2?KYC-D7IC79)>%&;AF-C@YG(C5474U
M<$GTBLF-7)8)^[3:U#064MD5SJ"TAJS^XL'25-DRHF-\]L)L!E%_Z08FED8P
M [X,2)XIG'+0;"7<_4?D$WB71FUX4>"QUD36*>WR\.S39SC6/;8>BSV_;Y5O
M0Q8:>INQ:X9\'O?+*A^0".)VLI&DO7L'M0X!1>2?, 4\C^-$3^U!+1-UD@;B
MM*)6/\=6B7Z?1>1D%-[="49Z\+6?6VA13(I93U)=9>O617_=3L7>I^W[>21Y
MP$$M[!(]T"%_&Q)KVSBE/YV+0]F_9IVRK\VO 8:<@I'7%!2J9+BA0Q[+SME*
MR[8_#?I-W*B:US^K-7DNM?;HVZ G]QD.=ND*[8EO>Y#\;TT _14;AI+%CW&)
M]P3T-3992Q&D+D3)XW_9"/>._A*T)VTDW/XQ8!'W;M@<>YU9(3RS&%&PAAAU
M+7-PLFTZR\S+R,V^X" WY#MD;W^<IU,?C\IB*1]Q,7>^4>PTV&%OKV_,_>!G
M_Z0A=DJOLO<X:8&V#0'<MJS%,LTUH@,O)B3BZ.482]$+G&V4.(>+K1-&/=K;
MD/Y.BFW.*PM44F/ V/Y,0,C=S?H\*K)8?&?T6TMS 7%([-[NYJ3<?>N/&V<:
M1Y0=]R16-UP)CQ%:1-88. 2^+5U^^]/0N4ROCIG\^<Y;?=:;M>KO@UP /&QY
MT=. VE+A6%0>IFR &#O#S*YP,*7IZK\]Z7 R\ILP@-(XY=4G_R^D$J&](L6_
M2'TVQ3-KQ$.2!RI *U/Z>2[/Q.^U?O-^FRO1VK/NMW*<20J2-88TYTV@VLR0
M4_SU^MZ0/PS[2 M%,,!CQS9DS^%Q4JBEUP!V)TP0W;U5+K+F=,L.^!+I? NX
MUOD;B#FTDO_\!_:RJM9.$(]$;>[N4>Y-<FE_T=J5[E)XNXL\4JCS53S\=T]#
M]E"7T8R&R8#1\5/55 >3^T>F4N#!JY]=/&AZ4[2]8^^MP@Y$QT2[7AP68G:N
M<&Z,R*MB-6RX)\:SPNP]'E<8E#/+SC.3_8_IV[$<#A">N3C5%JUD*W.W(?NW
M(3CH>S;/L_D)/GZ!/=R;**'$-LGU8>T>[7'Q(9$K@,Y!Y$ 'E2>]1XZ_J,7[
M!4Q'W7K([<X]=U9++!OK2%/XF%90<,"V2>@M'K&0'M@#.CT13[(A9MB,'$+Q
M%8+9=,\I@@6SYS=4C?9ZA%9YCUP7_S#J6/B7%QF.MUK5<674;*[WWVEOSH@;
MTK\4H!MF!7_F()>$!J7\E+PO^7?N5&F8_5/L,'KNW=+FX 'OL3G73_DOCJ%Q
M!WR<!9^S7C1^3CCK%KD%)4G&EXM9TQ!:BM1G6N%R!"RX#H1S,&DB%W5'3MDN
M+F80NANOX<M7<O5_'7*X6*6 FQ#CV#/-R_VN'^&R 9HH?PO*W7/</5CS,$GB
M8QWYRBCH(/\<9[57I0;H!.?1*1,@DQ'%5\'LZ7[5@E&E)GJYHHZ39+O?JS30
MGSR\5=AQ=,?MX'-A"2E$#W205ZY+/@\=@O*QDM,?=9B)3L(YV+.,JUD=6VTF
M(=!P3/FI+/\[O+]K$/C!H5^NN4Z#B-N%Z>42&YO]9<U4:+ZTJ3I 5\**Q]&[
MKQ-,@:"!\(7U+-31+K!IX5R$+,<NL\23_!_L/I'#].)L'@: I\T%="39!$ '
M5=4#:V-Q'*8-K>O!D0A-J. >*,N-YN\&PWEQ_?"#.<F]5]'*SF2^;E_G4_ J
MG-/]HAE]T"FU[0;RD& NP=REG"E60*^R6ZTOQQN=FYRYG=UU^HBNKM6S+%_7
MO)IS-KTA5]G&><29@KQIH<-MD'>K82)"QS?OIE-UO=6:27PK_791"^UVJW]>
M;__:2JO7 Y$!*)EU&*]5O7NL#YI-V2L^Y1>J:!U%]R<8@ \6V&DW0HM4CUI'
M2='AR;%E@9:GP^_MKU6CJZOFVQS)]@L*^B$KWI<BF2$OH'VU0'@:7!_N?;8^
MT/N^B <;)D% 89^6,A_-,/8;VHS+>=*E4XO/=.ULGEKO\EN@D"D'D98\S:/Q
M=W[+F&0Y60F=VA,%BR>C-1D1[7E4F<*@YHXW>/4S=S/E79LL_-N.6(25UK^V
M/="23XJ5^M2]5-TVN:EV)1J\:*)>:](4&K_O1IESJ(-I3+;9AVDSRKIV+G$U
M<@-]+91>3CPN"N!+2X8F&)J&U;K5C;:E# 8J;I43?/AQSI,_]T8% Z+YW\9[
M-+#@FS%,=R)KD^F29YOGTG:?M:B&.!<^^RSD KVBM*E?%"#AE\\2Y51$0&W5
MDX)[WX]QH<.]&;TM.0PT"\TCH)#Z0(@M>*\2[^8Y#6/ 5)$)P+I=25\O5!3"
MBP@?COMS>9.4' %'-L<V'HKZ\E*E16WWC2%KXR'W?L\A9O6R2T5&J@)5YXLK
M(L2V[=8_1TL$8>5:50685&/M^:K"<W+[G8R,EO4\FLCEQRF(*FEG9;W)\$>M
M+SZL,%U2O[]\/KS<K?QE_B#8#C1PH6F$& YL!\$)3."1E$4GIB,VX.E$-8"<
M)3K+Q1X4(6?6M<3GG&##%B;9M,#E0(7I2(K#M (;,[O6*GS!=NKUK@@*N7$,
MF\I60:D0K@&KY7 0S8=SMB&#43*#M/FON6 5ISVKZRR/?F"X<:E2L6Y)(9RH
M.M7FA$"<VQ&]H_MI^(/8,-WD,25B6.2G H-FUYLUK@:'2[]=RG41-'^I^9OE
MWS.)VH!'XE<TFIQ37$M+W<.LG/U%- ?CD?<]OJ4TRSO:4R%1*4N&IN-Z]+?L
M=Q2!D"P8! >%-T0ZF!17PKD\P4EPJT%T("\P2@.>J<@]M40\SM^&I!8-ZM?F
MR( 17=JS"O@#\<_'1W^E_ZY/LSDX<SP\[@Y!@^<E4@X?5-F&M,&R2$'T=R4"
M*SYU[26_@7/M86?.D-1DCQYHO4!A1)'=E+.K)Q#P=!1B,K;I /:@;^LXZ\.[
M@.-%NXL;1BIQLYWW6R[7OWMW5_YUC/Z5AC_$=+59QC@U?2#^HJUZ@;K:W=8E
M#ZKO<X.:T,LXJTMT>ZIK:\+2T %FEY=2R\7]-S::4>_?%-QMJ;#+S;Y;$.Y)
MM?BSS,+[[JV:P.I\FOND4@V^;S10Y8%0U88H+YZB #[8=/:SL5?H>[V*75%"
MB.CB)-%(= 5\S1U+_"':S1\>F(-)AZN?;N>4.*'"G4(8*)/)'BW\#(,+)8M<
M8NK?^X Q;I,;$28C+J2V+G,3XPE=8<XK-'")GJQE+NGI>!O)&!^,#\^&<;I[
M^\8.BC"SA!.;-07?FFI6Q I.CA?Y4$9F@DO0\]8IQ#M1='4@7M>N,]Y/OB'L
ME+?S=:.>=\97ZE]HX6Q3]E\$VBO2!T=V6=48O+O+;\C(^H)Y;_?.LVYKB5E,
M/5U@T=7$+)WLH"V^3_"=KK.6#YLZ,3$X0W4M"'.EDO,OHW'P<&?9C]D7S@Z)
M-OZIK+<U?B=<S!#MW)+P^4)7SWY0""@*F%N/44;$M\2CH"*'_6Z,T2LCLFD*
M+28-7" >7RD_@\DZ!?8/]Q<'EBD/_U=\>/CQ<I%%;VKK1\2Q'O/"JZ!DKK]]
M']+0*-N&7"(.LX%+4%:F()=?U/\)?""9<"Y8 :@NY RM[PW$LSGDX3Q^7-\V
M1*GU4*L*\'$L0V0>*TF%EA8PG]E$D*C@Y)?VJ7M;]43VIDXQ]6&^P5DN#NWC
M'TX_+(>-/B7Y;<ZHET%I]E:]K4-_5*V/R&'4:.,2/M^&A-<]G<;-%"#ASTLO
MFWU6VCB:&EO()=)7#=_29_(*M"Z>-A;6=P$??O9&BT>E TN7]+F6^<%Z;2HS
MU.4U)9= _>4]2B[_^=^>L->_UN(!'H\T& 6>\>HOE_M7&8?>(06OI_UB-\=V
MS?2J_ 'Z<**R3'$LRZ[ ,Q%!%\A]/?"I6TU':F8B_%8GEE<2Y,1_+ILT7BC=
MB22+]\5)\B><Z%TH9P,8[%[0ZW?^[  ZHT<%G!7&B,[PU]>F^7D#,M$X.G[D
M]PXFTM-L:OK?MU:O8U"9"_$!Q#N(W1E<H=]T"'BOT?OC"-T_,,S"EA*^%=G>
MCTZ!\DW06>O ,(<GNDQF4/OE"=Y1>\"('IU!CJE9D70_'UQ=H@[*<)C11BUE
M\K$NM8^J<]TBNM_G>'!A!T#28.=Q*H>N_-77/+WK;!/+D;J"@O$// J6]$UW
M,D_1)^RN9\V>T92M:D9ZQ)/'A8>D#R1[O7/AOGEW]X4%U7$K!\[X W?EZ;+:
MW=CHV!.1+=EV&=FJ 4-Y#6LW6I??UA@H<^N'BO,B1*.!AVM\RZ\MNTNJ/#0[
MZ,Z8N=ED@0_#/YQT362\J:\:=7&[M?*V]+)KDW[\6:=![=Y<2MJ*4(XJ4B:+
M99@)DOP-]8 AU7W5X"Z>%$WH%HY^EE^\&[5K0BSC"Z)@3Y<#]4LXJVY+?/P,
MVXIT.$?^-'W_O%Z$ATA:<\,57[;1BC8A#I[&MD2M<H2^XM>4EL6\R\+]$I7<
M Q6/]RJ)PF. 8=X8H_NT'VQ.E5,=>&(2+K),"!%>^"IW*NP4'H6!XB63)@SB
M4 >:S-TGULT0_-,UD%;*!2=CTC-V"K:%NOH/H/,3A]I+D '-@4@G/&U6&_0
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M.3URH-W"MXJFY?G?IEL=L\T]F&(M_"Z7KLG<'YR+PTY=X[$-X=2.*61<$]Z
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MQ#[^;I"JU<")&X3M$UH+IVQ@@"=".GBRZQ0 <^"LOW(V8B &D+DVYIPZ$+@
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M,HG\K(1B08%I%FFKM0O]*T9@4&C;[20<4NX?$?C-F]6A:,7@D@BR9+ZGFI]
MV%AN%Q;_\6O'[]&$_N-,R/^T_8S@'A1!\CU L9V]> FQ=9U*MA T48[B+@*#
M62)(V/IMZF_FQMMI"#G"%:0LV/@6H;G"M4CX2+W;=8)A;>DX92XX33\]L?_E
MWU3*R^<357GO4/X?:+H)H9\+E-;BXR0FBZN$??1OX80=B-7S:2*(B_*&![=*
M4/1(4!D"QC8LTO=MK">+S86-'/;N9A\":K,?B^^5"6+;OI@,^9OHW=HQIM<]
M[BT<<14.C6M=2*V\HC)3[Q'/S0_P=_SM^_1 Z?H<F8%8G>3X]_F@U/&*V)5
M -<NU&T&J^. ;Z90L-=4PN\*=TQ=';$-S55&0:?[GF-3CT4J;.6'=T12,N+C
M8_6[)W2>M[;S?+@)')=N-NDV:GM7)*MT?0TI#](8O])  21Z\(S+BKFYW2RH
MQ&)'&_D6U]AJ?AS9P@NJB(N*XOJK._F?)!P;:FU/W7%N^I,(HH8?1+4H$VV@
M()E9G(&(1,JM6)'[C*]](<"P^1= :Z;1&LP3R.Z 6\78[ 'H2;]S9')J[D3:
MKF+J@I;Q&I.,#LJ+4.)0N[1N_JT#/#.^+F?ZU7I* H*&T.!?^'4I*^Y0FY5E
MLOD(>,J,(!Y5@ @JGP6X:8_ Q!X19*;#IKI.! D702Z9Y,=&BR"[=]82HNI1
M(LB5GY9C0U?9)7] [^ A^)DB@C0U#+H;%PNN$#A.@YO4%C'A(3+C@F3&X2<U
MA&8O@<+6QLYG5ZQ,[\:4R7M-M7#'S(Y? AKZK YF,=--@Y5+ZJ].C<9O0C$_
M\'=XEU=(RGBMB')]02DB;%T=Y\BA)U&T:0R$%O]W,(=%W,V7X1"3&NBV$ZT&
M7:=J U8V;73&+N6>Y/E;JUFKG;SW['5T=.*A)O^#^=?S^-.\8\*A<C..9._Z
M7104'FU#!>;<!5F$<)(*F.7@'/:JI*J-H-!ECF:5TA70<4*M*4RLS-ZA0.4
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M%/6<LM"&:3"5BU OKES,;6Z17Y]X<^6'.<*/Y%"D%/=7@-KUZOLBG3(82=:
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M9>LV;&;!\+UFZ^DX5#L7/'=I7V5XI+Z=_Z/X7][LDWX/G..3D<?X'W%[N*X
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MSN8\^9CT((GA%M<)M\<5+D^K[!9/N*L='PX]V,B,T6HNR0Z0C3ORP,-F76]
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M& /6='LT75?1=O959#<[_Z<MO3@-ECC3+XES'G-B$'X2M*? C;[7/0(B:J=
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M8$*R Q4UH+_6G_ZTB/Y4;<30=O=RZ0L)N,XU\B5\D>JK_G5MIQ$D:E![L<O
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M,)"36TOK+6A0P<12-(UY!VL%(ZQ'N%Y9[![1/B&!Y82N=5"_19$B+=12=#H
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M ^"CCK98K]D.<;V+;/$O_YDMH_9\9Y9RU.9;K5$F.@K$TN"XTV\)C8A#<BX
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MZC"FQ491A# $)A'NP'VU8LPV03<0FIA*N0/7 9NP&F2DRX<B]$9&G84PK_M
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M;IZ<&SK<+9)G']-Y":6ZT$GP0'LM&_.JPXZMS:1"FE)W$4;G08RN48": L$
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MYEL1T&'!,(]X(YU72^LA(V^Y#ZBU'(N*$#9WU:.R%S9%K'=;<A$J>;'YZ.-
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M*>9.:,R% MDR%PUG^5N%2YJ#>3KW7H=I:#C%OJH#5W)3UO!N0!)[&T3_/G\
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M<BO+T0@'-J&12RFVGR:?=QPP/1ZZOY*(RJ&2XY;3[M2X&:<_(\XO,Z6[M6_
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MW.D?_Y%5A'B;R=&I?7A!M9H=GWED&+);EDA-;96D8D@LV@.LM&F8J6K6A.R
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MM1M3!$V_!%ZK(T!&V%&[P1^QLHQ^:2'79?78ULN*Q&311"(WB*WU?<)WN;M
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M1CO%Q?UZ,TV[RVGC_TCLSG2W]V8[+FHAKU@8Y4\4WQ#&7JB?SG_,()4[]A^
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M4R,ERS(D9VJ0J!6SIJ;&=*C$DW@"7/8\P8,.-42FB$F;IP]2#5RUK@%\CO+
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M*?#B7&-> E+;.OBQ?[GMP1WE3V>5K7BHO!_4E:V3WP6I*S;3**L6=#9:Z^F
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MUF[PV\IUO*7(LKM_B\*&#?K)JB7VG2+A7\:D%F$N3FDVLZ:VJ=&1I$W8.41
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MK]<HGI;MP4Y]@KTN:7Q0!(9,#K@9;BAS(_HIQZE0XKYI-D,XG[P"(^P WR8
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M8/)^^1BV[;,[H[.YJ83U;/4N"8.F*(^H+.Q#N+C:"-^KP,IVTR2U!)L5?T4
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M%^<YD!'A%>.;N]W/_=I46KD%=&[#2X0&N/**I5K1M$+E9IPIWIM' C+P;2&
M;BY"K"^#4"0.X E%@EC83.(<%;'UUM0N3*)($?BV8RN1U?)^,@SY?,XT2D!C
MC4>I4XT6I[Z)EA4&6O(*L%(*_;!34K*\8+-*$?>/J_>R6_IY[&W*=Z8>7&JJ
M,<0$]%C9JGP7"+$M1(8P/6K _;ALT\1,9@ B+;)9IIO-6,P,+2EETV-,\\E<
MZ9.CXB/'7/J#5@N4=GB*/%BUFEL5YU:;"D0S" .X932BA;* K)[\./[AU&7X
M+L)U,%42"8:G'&$U8Q(J8X@G!-2_OERZ_?E4H>^(5V=[\,31J^SH=VW:DJOO
M_>I#<YM@30_/Z4#R+/WH#4'=4H"Q,S!@S]"-RC 'FDZ,=>5AIZWN%4^E;RNW
M?<W8$3M4Z>]H%=%DTCYBO>*XFF=JXGK"PM=Q]BR[I3*OTN6L/"ZO<JN;IR.[
M+-OFQT7P_DJR<@*]@6"V<C;:>^4H5T:10--5>03W(6:9,[EKB+65L&WP.XZ\
MIM9JN1 B[3@"]07:_IIOH:ZSR& _F17J)&02$E<?R4REO.9S>9K?0@=V#+2D
M^ NY!=23RO>D%M*"!S"NJO50('!1_DH6Q5UUD!]?S4A84Q.,]PI-26(4\>T0
MOEF"ZZ&;M-(P(F0&<=M_&]*(FV91VBH9 F+/OK=\-NC8@=LT2S)A^M7/.2=F
MP*!9_)\YH;/&Y>+<F*OHD%<,_R]Z_CVP/=;!IME/;W.249ZNO1I>6F/?WE6Z
M2]6]]M>D4\6AQ3]9=H="?.T/)6"<']9</^R*M-P?;.OC"2>>Y)0\SO=T+U;>
MKKM373O3OKNX!NO\KNQ"Q?1/G[S)ZKK9]I*)SHSB*DSK9L^$E)H88[Z_&S;R
M0B36H,TI,7%_#R[V-W\?QRS3 [I3ZS@(?98UX>AJ"_/("EH1*XOJSK/L031Y
M*+8(NZ MB]VDU';X?8!ZK(TB6>RFZGI+Z%D(;<=,V&+&Y/91II-H$0)Z=RT[
ML79XKYX@> /\K*5_!UJ09M,0TP'^\8XF.G%8")RQTY+O!<=6PA2115^$*HRF
M(,Z;([N+;J3*7+JHSP-IHK*5H\0!I=V@(_)VJ,=\GXB=QJ?J$S 2W52B,=!+
M<?31F_-=I2?T&^*+>^__4WFT$;PR]3F0;_N];TTMT.;;^]L\T<M95XO#9TH\
M_1\T'?K'<X@;@=-8O83J_3"2L*,<*NQQ\]H7=[7YYSG&;N AZV3*I6L/MIMF
M.^X=H+30,Y?+EQ(64F@PC</>RSZME1;K5_>""!YJ,Y@NSM/G3?XB"\I07!/U
MZWWHJ</']4SJ\AW9>N %])"E[?;A>)]DM_;.04;8UNQGV5]X7Y)O:C[SU-%Q
M]E(&*NV)P^C6PBZZ%G&490P>EO'=0;08]R&.PP:0[+%F,?HO@CG@(?J-:*;R
MZP"%]R!!/U+FQ+7!1 )]_H,MNN31_^&KE+I;0,M7SCARY6!"K .7#]5>ZE<'
ML2?X!(04.8T6&U77@JJU6=@I,4,*2!R$*6$=3L+>@-_)I:Y7R0T"/ 01N6B,
MAW)R,+(#')6(IZ8G'/'N(>Z6D>_ 5MV'>MJK\J3@]^(UM75C>0=.##H^I%F\
M9 T?:OH!.Z=MD5FP(VUZV#>^7+?A766)*ZO3.0$Z<L'+T(+\IF9DZH'4ZWN3
M0>=3NFE\3(+HFQ?^9;MU7O1(JE_-I_GM6K72/>^N(K=8WZNJ%\4,/4^MQPS4
M_CWCE;#]>ZQ!D$HAL+$Y"'7B>[8647O&5#V788XXTPKFU2G.%CC<HFY3'&W$
MM#N1'>O-D)IH_&8\B8/3S7+L#.KY^2"PB)X=;^["@YL^?];THK6=-7B%_GVN
M5X8\_?-;-^2_^IP3'^[!+;5^WX+3QR<'M1UL;TV5:._O"QE(</&?G1KW&UPR
ML;^,B^U[>CAC2N."??;X]2=Y6BXN/O#!40YG5,#C\ 1:+C8VAW:TMC2WM&9%
MM#(8K>G^9LE8O-^.VQOO[LC>%2P-<%,C6E%RJ'JLWWT J?12OFQG;VA4#MR"
M*/R)X*#)DVHM,F'FO*L6%G#@&+=74>D8T\_</(B2SQ5(T..8Y79RKN),;712
M8S/NR#N*>6EEI=N_&B1W=LR:FA'>I0N]23],5IT%WSW3VHPM:#<FNYH!Y&[3
M_@Q"LNQ";^BGDE5J*M$<C#L#/+X*BADI'L%?&2Y:#IISSB[G^BJHX$FAZI^D
M*0KAE^\CAC]V2GZ1(<2D^3- 'X=DSMI#B!DE880&TRS8 -P4KR_^?&>I7C=3
MZ0"62_"+4X"MZ6(6TZ9F#.1V&U$UYG$T'#.(1)+T@T=C144+A( JL->? 1QY
MN6H,&CY1_ &PN]@9* A8+]G*/".#G@0";T5)?:Y+3GZQ[)#]ED1 "+8@4\S^
M6:7!TKIG!N>>OWS)+QU@%#/#T:>>K!N9_K_Z#CYC>DB..'':S_X<I4&:+/*:
M=[QQ1.B Y!ZGO[?=G=*VY)JBFNJ86_X*34Y['FU7OB$L:T>N47WZX9''F*&T
MV;./'T3X;HE[_,DRFK<O^_J#XH%=Q;@360_*-[Y\YY=[OOA!Q? % T9LV\5[
M8:WS>8(^T]W9L"K9[X..39+=@_P3L7B,/#4TUM!^<M4Q8\25VF9NYU!Q;RG^
M&V+,:&%2=&SWI;AOEK>)^U0%D?*J?PO^+<QF\1<P8P@YJC@)JW<@)RF<427B
M6(>PX2N7>3DITN*;!!L)#7T::/S?7$(-9EE04%P1$WKO7#AFMXM;<_LL^Y(&
MX\.:FHJ=U+ H&#^A)"QDI"6,;1#3_CF;D;SJ+O?V02E7 H8^%ZT$O2@X>?GW
M]U//C%[3S2MNW*WX>V-B$3)*__[YKXJ#SHT[GI>C-1YQ+6FIV0WU9_.]8'.O
MZXK3K)#:RG?E$,_A?(]#/AS'3UZ5OIK!/TWJ7D3[I]9ZL?3PT^?-JF9X>VN]
MBLC6#ZI-V9U3A(';V;E/*ZUJ>=!C ^C'*&T9+I<9*2OL<K+L)5JW#1$B96B)
M>A9SIZ1E1!&%!;Y)U#D4#? Z?QZA2X !7R*;!Q82L#Y\6N,<<=?[^ ?[,8E)
MRE0)VVQB(J2AM!> H[?.0LU)T5LDR$S!8EY\_T:G-%>GJG%G51D'0X?\1AH:
M$Q90YC9<H[B^JF"?)[SV&^ER/K83)2OO?#&,F[KW;TO)PTF3VEOE6;5!YFY(
MK0+_-S&GXZ]MJ77 //*PCL?TW1WT+;5[7>(6&K_/X),OS?EA:()58)[KWA_,
M?0<J32)FKX_V]&N9E@[>S[UYE6):#7M3C1EH>3+#J[2R<O>C[7FG@P[W<S/\
M^OG9__=R5L.">!^#.6_)\0I,5+=W96MFNVQH0:>EW6:B<F5&J^XFXHIIF-##
M? XC(3V'"2RZTM[425\1$F1R%0:?!2RY$R[>LO5O3'/ QD7>($7%+/I+M&/C
M)P<<_PX[1>5@GDX7PS[0&1TU=@ZP/(BP.RD@G7E]E4:K+)@03M&WJ%09.R>7
MNKD%:0(6>O-A#H+"/\ C@) ;BLN$A3MP_? >W&6>T,^9G[Z NW^2?\7UJ,UL
M*#6389Z,'/ER>6'PW>"HI,^3D3$(K>X#+^SOYN6'WL-KFC!=+=T9P0%^=?42
MFXB9H2(OUV?WN('=(P^*<_=>#?@1M;"'4TW)>@L\*#GI9NOC91AI^D D^FAN
M'5_W&M.ZN*=]>.;HKN)NSR'F36LO:,7WH#Z$"DMST&J8@Y -0ZZ>D6**"7ZR
M_W018C,JQOG&8Y8!T%A0FI@)FPL:;J1M[Y 9CM0A*_!.7AGX+W3FT6L&LGT^
MSM&5/^K%QGE+BT;14$VFI<I-6 Z=P!<*D"RQ['7(FOQ]B$F2;%0$T1XR_1KP
MB4??7Y3%WJ'C&H-)'*NMQD[./BQZ57!_0G6/$5VKP@%[+=C>@"=Y7C.U9&T+
M-TV(,KV:;WV_/DC7-\.^H<G@WJ>TSLK+NP!\DN^U_%.G1%/3[XEC#>X)Y/(\
MO$G/2+V)VVNO:[G;_0.BC_H7CWH7&$I1%3]"\_;TY?L^C>?/3!B*V<WN]1):
MG C!U4;SVMH$A9D,W4U=<7$UL\0+,<9RA[BX57+R3=>_[T^>"X\^[E,:[AYG
MQZL8-#^67%S;B)I"7Z>O,T\O4#?+[?*]6N\*L=F2GN_ETYY@0:YW]B\Y.'A%
M_^KU5(R34>/](ZY'(C.Y[[OWO-;L- UX8'D%;_TL=S@2VQA=&QIXH_V&YIZG
M+WUN9^]Y\NO_^=62DG6*+R37?+3X6" W*G1J[HV(2*D3>FHW.+C61E;.W. 7
ME5;>^,?,CI%1@DE(N;G/.]D;\V77G=U@3C>;@6IPU5[Y Z2X#RRY[!1UHM!:
MBL.E<^)%2H-:9_81K>.L8450PYQ@%]&X>9C&1-+^L:"F,W:K<GIRLFY33/O9
MM[:)0?#&D'M36YF/KY[=-HR-B/:J>)!_:*1'8A51T_76W1,>PQHD_>-N:'UD
M9U1O3J_XJI6KFYN1./1I=O/]=,TS]7X5@AD=E3*!>1ZS":H6A-K?*L-?>3,S
M:3X07Z*.Q!87\YX-Q(\?L7\S,>EUJ:/]8.O>KE]>MC\JPCYZ?;/Y-<\SY/']
MT)&O4(Z;S)*L/(*GOUK74^H@\R6+V:FH7U[(F"R+_[J3%Q^5>9P>QE4IAP>K
M^?:+_60)/_[@2^9]CR'WO.IW U]23X;%.O?/OT1#+&4Z'3)+#D031$K1$(<>
M)S[30:*-XI^4:2]1;Q$A"L1@94&X[UR/X.!C>9+14]:.E]%1.;ZR 'IF0NPY
M2WE*?>B,\4'GR&62W&#N4HZ&*R%2\X7US0?-FBVS7\]P1\LV':/G^OKG:\88
M[CP<\/C?B<-GK@;8!%0?.]>W+W<O<2*BZ,$^/8ZMHZ4.)B ]Q#]^.L3"_]S
MM5R#"YA:JT,<O1K6P%/V(8;00'&<(F%EX>KFH(8M)-,Y!".RX):X7S=-QJ(
MRW[@NB<: J6$-Q:[P(* ?\4X!\<>#VG',!!Z.U=+$\)L\(T6B'+&/\47E_;7
MB"J= =K2:YV6F]OW].QYP?-]7+$0FEK\P(I/L8WQS3_[](%^P0?;^&OTS>6^
M9Y5TOS.$MP>_%'MY8GVK[2JMKW?D1FV8^'=05=9E=P#Z_[DQ>\=DY9I:I);D
MLY*&,PTJ"_H_5V;?Q?G_UXQ(%J>"^;8\:S[P2>E,^NESW(H$H:XFT=;4*M\?
MT<S>4P/3W$._18I>'/<AZBKBP"V BO$,98VUM:"TUW1(X3EB)B>NEC'C,!B@
ME[.FIFO/#&_H!]IQ9*5F>RM(EMQDQ)[I$KA-J-1NE&RJ4.3I -OHFE".R=W-
M'!#XS-/Y7USGAPZ^NO@A6O)MFYLK3$-R]>$AWXIR",'=:0M2^]CCFY\,QFO]
MO*[,G*DTS:^2^C[^ES7T O!(M5>$5^.5BQRX2;MLZF[Y)#[14\;@W:KTD2PX
M<'^FS220RC"3N^ZIHL,.\G/6\25SR(Y^_OG+$CW,DYL&>V?F?LR!?;)^J64W
M5C=W3<U<L5WF(J&F$X+$B^ >!*?_PXH\ DP64PW!SUV3IMD.OX+-)R@\&2@4
M^]"F\LO!%7_POIU*A#;"5E0(9R0+;*J>$1RIRL)43_\\4OGV/I%&G!"LJ>42
MMJ]8*K R^FVB=0Q4G8'^#6_6#;=_(;N44X8Q%6;B;./M($H ].;>Q^;^3"3#
M^DW0E61R R%PU#E_ZC9N<M&+D1JP8E1=/92S'+!T9;(8<<3!!C/B CW\EV3>
MR$:WV^0-'!UR^O55MN!>B97X@FVOKM74V0LA7I5>!IB@>N2>@AW[NH.&UF>^
M.EL;:&A]MNSX7)V-[+@\9Y@%)Z@^X+:'PED6F+]RC. !]'<O.(D]N.%('LO2
M.!'R.]@F,^M94S-HB)^PYG<)$KO1^K.)D!T -P0O[0UT6C;]<A=W37JXQ4'+
M[6ET4F&&OV3JBP-_D4R$C+A:J!3!*Y8!'U:_IJ:')6X%$C-<CS3@<\X.+R[1
MD.@1QW"]7I]A&,TC>$1C> F[ZO]%@)U[B_3;K51*;MK3-5X4'/?DO5Z>Y4_@
MOAUQI<-O%CCC-2(_Y%IXA=@C'X_4AC9"KF:_0]D[7ATX6^=;7K)5=.WL[+N&
M/9/Q8>F'_?.=[\]'/\V^/WWL_TW--NK=RIU#BIU/8E@6([%+<YTN[@QL7P=N
M$SZL6WF0/Y6^]6Q5OABQ 6.ZII:=,/[TG&'3@&/LL:7A Y4=.USVG/JL>37?
MZU[N]HVOXQ[_6[[QF-5K_P<5@[GG[U^_C]E5?.7OR48<!ZX-D/]R142*$;^
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MCN<  C/"KJ4\F)8+##<WUPFY=>T[HHU/99,26!4U>9*<_CE5W((K8/38P\>
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M.M@+,S<2761  R)'SA&:ZGP[%]DTH-A<H>_FAZR?@LO'UM189)I$L/N[EK%
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MT*] %7<_<!292'$C: J>DX6:3 48WQ7PV !)2SNTC[^LK1"^%?PDM"\8:OU
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MM)%VL&#7^\',X;2[/O/ZQ9<GM'.3_OBH_2\[NO[O'QO]_P]02P,$%     @
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MHF?*]LUJB# Q@E8N(0=G)HCPF CEM.=OQYT%O2F@AKM@+Y6[&;SO+*4W)A4
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MV[GXJ9@MR(XMB+BH.W3SST[&1? 9SH0*FMFC=N3OAVY7/-.-X05"H67% B.
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M_1M7##MA+E<\BC!7/6/NDYCH\_G=-T8<L-\D[[<@$#CO&GB(I"W9V\FZG'\
M_(.N@E.=5>F/4GKX+V(;;%(0TI\>X!N_4M&H_%!.7HY:28_ 3 >>!<N @1 P
M5S .OTUH+;]*;X/>14! ](S95.=<)PNS%V2$/+5)0FBUW1D(D>-<ZK:NQ9T5
MN*V^J_Z;)!M76S90^L>4OT;QE;(/:@EY"FK&5QKJ!XL1 \Y76#5C>$*XL5?-
M6,!(26O%@J-*#KK[HV?N.K;)-@(6UW2M=M72M_#@EV_7'= UGF07CX7<:O3Y
MPK(VSZCIK]$F Q(X_CT=0C.URO;D^@[ [VQ!5#"OW@[R_P9O",QZ\>;QLB>R
M'I8P3;A#\6@$/#PPYC;#1SU-X5K6_FRWY[/0+4AT_F0F;YAXM%L6H KS0$6!
M^<#)8T'!(:"YE!*86Y#,&7-!>$7[HT_)"<G<V;W83/2XZ5Q'2-SAXB&]M$0]
MPWKL)1=A"6,BA&GDW6-,G'1T$22;P1.<H\N;2L<B ZAGO@6T&ZQJ>:VBH5,6
M*QS+'Z6IEEIMZW:?LW^^61;VB^\U4=?%1W\(Z\3ES99V@4P8_;9%L\TRG\ X
M?5V,8E7">S+=)KH/D*=<>4G/>P2.6?4? S]$_]K9=B6Z*W8%F)J9.FM+T<+*
M,JF@L<9*.H 4=@.$E3"!&4_W(3?^KL08R)DQX72'-H%D;@L1>,G]=X@\L]1E
MEH;0Q^:'"+X6-&.=6!)3MNF*)50.BU]@6"FV^&.)#"N?B8,Z<4/3 ?Y7$=WE
M1G\)S,LCQUIX]9S/0@NU)8XSTPJ6XN(6,E0O<C,H^C-.N="KX4*D_=%F&V/W
M)M/5:/JGWK9/M7:\BC:WE3+D64/J;R_$5?AM_B)4)ZB7(F#,B:FLZTRG-M A
M49JGRSA4E[,I_F-^_)QF<JT@:$GX^XR>0\V3&,SZS3\Q=DEX<Y ,#'"'MB!W
MDJAW,4K=LG-VGCRSK*9N-6#334 BBI#<ZUL0'7 0??]4TIH<]N1P(.=2G"V*
M%VOO7Y4]>&9$CS865U-L<7O4,5E6UO[996*UMTN-7>VIKD3WRZTXP*>[ZN]9
MB[BFLIZ"D]Y1ED;&A5-I+_0Y_$CWQ2O.,R-%4T$M[U9-HO.^97]?CB=BY*FX
M&-YPQCA!!0$/%CD NL0P'DH;W#7-PFN36+0]P%=RO-I,&15L[1N)1K6 *0X<
MTXC;GP>\QX\<68E;_9P=:7#?6BG_GQEC\4N10:S@CC !&&8$YM\DJ.*WXY*!
M8>::6O1L6PAI,T2TYWV3K5$-3IN]43:L%HW8"R9?;_B$)?)]B%6#CZ([)#83
M.)EZYSK<J7RW,3/;0,MR6/!:4;.VNO'+PJB1DI?NWH%EN8;?'',$&IZ-AO;H
M"E@BQ46IH")<O9YU)>H4);O*V<"&Z,\J/8^F'+WFG:X8YN;N<JP1O8]RLM H
MT<#G?.[4YE*VZ"Y0(E+;%&+%CZ2^GS[MQ(>OO.8IZO)YI)6GP+ P3Y!1 E!Y
MQ90YIL",J#&7PI@FJ'S N;4!3K<0>LLAA\8EV\$[_3;#F2)D+#\F]NSOL-R5
MDE]_)"[:_*?]GGA3J"-^@=?!L^D[Z1&#:_MQ:%"#+&'#526*H"</0T3(8D\/
MV*C1B18O-IIW6O;8+SB#,0U8:K! G)_);S,C7/I5$&VVMRQK@1.GYWGYD^4W
MW("B2WL &-!6)/\F/=+%;,JSH&:9\D;N).6Z90I:E-56]M)Z\2(6MF'D67V7
M[#%>LXPN_[O"FNGE51YF,LE9N.HET2^X^G[S<_8K042V!7('-K!?ZCOMUE,Q
M&:(#7'$$4_< Y_-P 3DR=5=%8F/TQ"C?8+#M2=OSY[CM5UD)0WAWJ4BT0,XU
M=1%$JB8LNJH$'D/8EAP_N<P,40 PMQ'&6!67"5M"//\Z-1LN9QN?6!\PA5WJ
M.X73XD)7_"P6,S.5)4-[7\0]P];UJ8[!(@W.YNZA:][MXPG:(E]P+R,&E[V]
M%@<F-Z.N>+8=MD37S@NN&Z(FZVH][YM:-0==A&7H*:8W>MO3S*:.V"'\:81P
M-:,9#V*:!7ZMK=#Z$W]OE'[)BJ+:3XU-<^E!W7'F?&@NO&,+PB!-$7AF*PN
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M#.3A'-32.UKY4(V8*V>C%(4O;H351,&2\L/)B^/.X;7^#FJ%L=KY!IQV9ID
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MO/0-JH0SG^A6$KBN[GMW]*#?_*A3!NTW+,:U<JS&CTFCJ+4_*!U7OX=0!4<
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MFJ78' U,9*PF#VM_P-*V( S?5.9FX*=!GN:EE7;#Y-Q$B5(9\3FAR=B$TR_
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MCO6PVW3.;/08HAX37Z^%/A^9]<A'/]/_NEN-7C=E<DN@$U'^V9]1M6J05_W
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MJ61GZH1H-VIK/*D-27<>[>,]X:#['-,:G?;5.YY@>@O'[-HC-]67O!.R&X<
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M-KXSP$PA3P;;'7*XYAX'-**LX,)E: VN):^QG_ R9_=MJ?SK(E%_]Z\)MW%
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MXZ;0B)M_,5;% "1YYQP%#YRS6Q6F1MQ**M?5HN[,X]9R&'>4<WIOU%WDUJF
M((8VIA\*WA:K+//#!K\#[.A<PGJ^KE$R<+JD7]XVQH\I(M"UJP<_Q?1GY=;.
MQ4)K[%;+:!,$H_:)!\S3]< VM8+<$\/TG.@ "V&(N!KY\"T'M/M[U$->%TG'
MJE%=2]$N?"1\3Q!VM8+?J."7-BYBBRCN0"R>6A98>N[\!'.+W8$YQ"K&>[B$
M&K,2L=Y^L,ZI@K4R&HPN#:11D-'86LVWW'"387V$WD=&X 31H50=6\!G'AF+
M4:)E?-J82B&T"0U#O>""1A0L-X4<:?%X9\_4 H(IL&.HO(X)5RWJ"JK:(I5P
M'!7<B5-$0UD%4&_5)TUA&^WPN%PPJZF,2^8AY/5LFA:9FQ_*H3X0'LP0O+8^
M1AT: :\*;M](@!QG'^NB_3VSJ!8:NX4 \_KF0JD3R=S$A$QTE(EA&*-ZR#+/
MJ8(]N,-L,%,?\'$O8@\;M<,/0=_ )Q?I)UBO\1YKH98TNXX4,-J@D>;"C9@M
MU>A!5 7WCCT;4[ST9S18C+XD\/!WF)DI$#P/%\ ,884P"BO88\S]32^'ENW8
M1ZG2.S&Z6J7+VI@X;.E25M1L^-O^ @JPP3[,8,BCC0&7MTPI&HR0%,#F]^/I
MSM4%HD#4N2YBDLQ!6G(%&1]?1/[%5H*C"&1D./LD$$SV2KG7IM1%(8H0:'97
M:?@$I@&) XKS1ZA=H22IND;/]BL_T470D;1C:>\XH/9K>#\."(0R#<)]PHJV
M@3"=\+J?Z>,77/@T*=US(EC26[P74AP1)1\OMK7$-)K'3QK,KY&G>@0TWP;X
M%2_7G]40K^5)W>IN,P'.,:! PB=\3?":"VVSZR%@*@<0()]2HKB 1!UVJ*_0
M.%<*V,?]C[Q3 S4]DQS8.K2%,%,5<4:[ *VT#0<_M2OF1@8C+;+%*.UQ:<<-
MRQ3K^.D57Q"Y;*M9&LD6T4\H^E3O>+^BI"ZCT GZO>$CGJH:M:8RCZ5[/O61
M17IJ_/G" >WO'=UHD02O\3 T5^K!<F54)#DW[TPLCO?TE$6!QGB</_T)*,53
M0_6HY@?I/;9(?B.%:B/=*UC3&@@774RPNQ$PE@'Z#/Q54SW3?@Y04$DJ3)Q"
MN=,S@1!6=B EX0+9+-0-(755\T18DQ^BW5&Q)E8\ I7_&>WL?(*Q?IQ;0*12
MDRX%,48Z?XQN,H^Z5NWN\(WOCAE;)5=,V?:6_+R)+LDRO> X">'KPE)QKZD8
M3$TT1"O7, EQC>IL:+1<LV#E&/HR0%L</:%6XYR]O+';;AYH<CSON<W0V/.A
MT8O:YQ5Z>S]%V^Z/MCITXMEU/NUX0' =QB4'O.S#T@?SR'YF]$A6U+:>ZOQB
M=]5$1NY)P,\_W9(I!V0@_=T;VH93#5MKF@9;] **B4BI#&W-MVY!\\J>7(S;
M.J(NF89S07Z%1+ U6E+)$8#<+,61E8#W4ST$8^&T"!O"OO48 :I6RK9M=J\F
M!-QB738#657,"3Q]<+I=1A,_IJM&SO898NI0(/Q=A=/>C[A)UP;]@.&&Z>"Z
M%P?DA^0I#Z?!"7A/FD6:1P!RGAB7M9?@14'RF%_VL5':F-),L1ER74B<:),<
MEVT>5LG\D7OVWK:JK&7]SF_],_W XY;EA88O0TG>#%U;F0=1:!G-Z"(2[9O"
M4*ZD^%637A7AHB]=IE8%9RV&X2E<IJ>N<*LDBUJFI"(IL*+KJ7BB0ON5<XET
MW([SQY#[BGQ]<:269>?G+P.D&KNCY?*U;WX]/U:DG8H]P93B!G J@LT[$=,Q
M-RW?_AC'96=N2H_ E&F^8\OCDPMBE@_(>%Y#4=S=JA."=66DV/(U>37#!2 4
M5F/;5#&.XT/A"+D7A]0Y( $ YCR,-B&Q; \TC@3E"+"GK4:0;O>2Z#N/7I@=
MS;87>FZP$6^(>G_KN;C1)A]E>B,97OD]R^X3!P2<Q3[54)U*I9MDA2KSD%+6
MC$AF#C^X6:J#<1D4W6/.GFP1U8[O\9 X#/\D<P'?A/RN@S*"TU0R\Z_D:S6A
MS+C1WHT-;Q*"ULBO2M*B)R@5G_0P)AJ\V4AP]8JMFG)Q5%,EK2#\[C.82$F^
M 3NNT-7@8 Y9[[@L;FV#- E9S5L^8Q1YJ=KQ(L'? FOM:R-OA99]-?8(7U7*
M^J 8LSQ@CO=R6KF,%DATMWJ:T?R%\-HCU\T+OB?N[2NOAWUW\#6_G0//DH"-
MTP48&X?!B&C>^-]S48-??T]:5[@*RVH_SS'ZC#5(;>?[>G'ZNX%PIZ"LH;I@
M]PN"TOTC+0][3MQ]+FUR-#'?7N#0J38?KLRK80Q]IL'FXJCN 3<2R^+.UR#L
MP0O4KN'/GS8RR]2W)91'!RQVTAFFS<&I*E\=7M<3H=493*$,DE9746G+&=K%
MLVPPVC@X>7!R)<.>BJE%?7U^:DGF5",_ULOY^^=@N;2*'D_+]_'C/=;C<F=*
MML(=' S.'2W=IWCN@(/QYQ/)AV2?&>U_J/A#K31"B\2TZO $)+YIIZ;4Y%T^
M2P3'OU^EP'GBWR_&= V^\"G^]KCV9-GKU"9X\8\_/VUP;KF*"MW#72.)C0K=
MNH.=;L4EL\FJ?#8&QZ/*1++2%+:6^AV9==50;2PI55^/J<#BBLI@7%T>6AH'
M$' >U*J)YLNXXZ>O1?EMEQUT\+AQ[1"U._VBD-ZH3TS,SQ1N87G-*F,*\V40
MH#)7WJ-U:?OK\FPS.EWY4)31%L-W_1I=.6E==04>);XWEXI5[]V?\OR[YP+I
M\BZ9-P&!"% 7Q=:.;<+6A!D74#KTF)&MO!)?T5PIFN:3#/Y?;-F1M;?-'K7-
MWK.A?%8=#LKXFM7T:UHBSY777M<%PTY7#IQL:*UOHA'MF2LL;JU$X 2]9=2J
MJ*I=."E)/&CY<5A_;7(M><WH ;4MW]U[9&EU:HWV@A38_-D/6Z7?%?Q0:6U=
MKJJQ/M2J_LXFW<EH0AW./VE4Y"W1G5'NPUUF,7YHF]?<HM=B#VMF[.7()R8_
MQ@&\7R;2KAUW 'H;'[&K&DT90P>J8$XOR\@-*9WAQ61H'\Q^[S1GX(>YGNV7
M[PO#RKR3;HD9.U;6,EV8/#4U^"5P0A !J01'J3<O:51$X 7;3J+/CL?R\4[Z
M!OC:6JK?K3&12I_0EFLH%'OF&'9_PULG_6*PXA/,DR%X#GP22KT)B60N-4T\
MQ>AXVS+SR_/I*(V/]PK BR:!:,5BLT>W1 U=D"ZWNQZ5]@0>[,>MD:"1Y6^&
MV=K,XT X=6K[]=4@7H0)LF8E[KQ)0_R<??W@_0,?096, P-57=>!V9LH$.OH
MNQ99;N37S'W"QF)N8"2!#!*QCA@NDU;FC(_>]GI)'204 $_U-,GKAI=Y5LT"
M)$&N6BCJXDQ:VIB+V,7*HZ7O+U95?O:0/?'TT(FG5WA./1'Y'P\Z&BO$N40-
M1R8R1&KG6!HS=F;.$UPL]0-&\V(E.&ZPL]8+][UWC?@%35,^M06YPBSR_G?=
MO+=%ODVN23YR;TM];27,(Z$K%4&*?:&2Q@WR.QE:5H9'_ __>>U_>-5[3Y">
MFOEXS<J,K,-(:9"?O%5=5I_EB(:.62A+FSU .AHLDE%G9]GG%^2G>V^H?S_-
M1*BP2UK<1+@3I3;/36NP&'#A%^HF"4FHV/.EI(L>YL 4GT\Y"KAL&U^4_#+J
M9#"BY$A7_@11^=&;"5K[7'&:EK&6RM!&J?8G+Y)5<BIFK]GSJO*T!Y$]TS(N
MVV_S73P7:',BT=//BM]$3'Y_RC'L=$)7VZ7@.D"<H0LPNHM7OXC4EQIHE&?O
MV5_X8EE:8,*VVCAA7O !61+T/LKKV*,GX.H6"#6!9$3H-[ <8^ZA$DB+X;4N
MKIHQMJ-,R'P%'^!U<^RDSPO2NU%DH(MF[T^Z9NZEQ;N-Z39JUU\\;[6)631:
M S-<T'O']4]X2\A44ZT)./&R-@E4MN4%(*'KD8QD6]W'5H13$M1*7\#%G< ^
M&> [0?.Q*[!\ZG<YB+?LR+#WNQ>*?IJL5JDE"/4F-HZYK+WXI.V0CZA4'Z(@
M+'[%QLF+Q^NY\CN@FZWS+-_AY4K6M?!ZGO.5YR<6H9W(20@%%Z[K/"L-.XB8
M/5_7-GJZ?DC7A%2FLFDS$E0X*=^03+:K,?LPO)X[._LSM(3/A-Q8+[(C\!-Q
MA>_[/*1N%@+$4.TH'!!!Q\7N%NP(8I:7=OI>5D94VPG'7Z(/#((\_/=//6I]
ML[P15E#;G_/51(''*?:T@5^HCU*E.5)GX<H;S!>,)+6N>A[A(D@/&D0+DD6C
M8?R -I\6Z4,&R>^AF4->8WVJ W7+O_W],A+Y0,B.OW;[_9K04(^"<* M1!XM
MS2W"*)0*;+^/W9PXE'02)C5;L^.8_/P=8MS?9TJO^4M=GWE(69FJR._?E_AA
MH0%(E-]X:'3MDS[IJAGG4//ZU0,,S2LI6@3,B=8>> U0[W2#A>EYX+/K7C#^
M1!M_V!?ZT:@CZ?J&'?5 SRJ!NF'?6N6GR;"D&C$5YH[Z3CP.@/&-?'-Q!@(=
M9K\[:(R5M1(<>XG[G)T(YQ*_'+FX70^M%5W=],%I47C"YZ0Q_:6$T)61U3OH
MK37<J-UQ/\8Q=A_]&Y1:VKD*C5_L8FMGZRZ^(L9%RK-9C,?CK/K5"(:FHWLO
M8$[:Z8'5?%^Q:\O!3!;#<G,V<P-&!_>+0NN@JT/<JY/;$H$5NI]J9P8^X]N6
MP^9$'=; >9NX-L8X[[38!\0]>&1$G49I=3-Q_TS(2-<;;(-3'F\E(">SZ6$U
M/6G48!*#4C"%OEPPR\;>BT>S+Y<_G9X/;G?2#4LE\1!X'VJKZ^^AEB*W59IN
M/@S[(C_[1#_X;X,IG#W []4[CK8,^=M@^O FNPUW3Q-7KLU"_*O_E(S>$Z%O
MFTD[M2.MWT^:$=8*TY\DA\*8H<)TPWI"1<RX/0,2KBOI\W=R=]S!"R,R-O'N
M,F.#T]Z[ANGZ/?D^==F/P[*ZQX^ZB_6D";B+2>L= *&YG!<L ;@'<4 GL-$<
MD$B0$HL(O$2%:3W&]E3$;K# YC-G.:!H>M8*^Q\.J+JG*\<,&LPZGC<S :&M
M?)BC%/C-K&RIQ(/^-G"B1X#JH.X4AC33?E1MQR&[\WDR(+\Z=PQY_>!%C/\E
MZ/E]&BG0M2L,4U\)=F:P&T,65=6[+BWK5%]7-;H>1-V<GIGU%O@^XXGE7;HA
M,F!F=NGU_G:MDL9G47R[1L[]<\QD;1Y6 D:) QK!17CO(U4 <'A=ZP8S@DL#
M-2>@P0R898/SX_N;V_VJ(Z_7UD:X.N-591^1#N. 9'![],7M3W) Z1E9=;B?
MJL[H*J9M5 I[G];@/OC;P)L\BP5TXK]Z5![0R"G-C=V0X?Q)'",SZ!X%NK:U
M\?WOJ7]/$^>P7Z>IV==G.""+*>=FM138T>7&'B;OVY5N[-5?;\!$*&"+H]Y<
MV0"8P ZUMT.-*?+8/.95YK*::,<KF#24LM"\N8RGOL7ZA<[].<0>=0PJQ^S0
M[^?X-VQ/__#.@I.2\%&8J*%_(+DX:B^W'BWL,".Q]Z"BCG_;7.EM)YR]RN=D
MNQSA%@^26GEN4+$$$;3]O_I.:S$T]YL\&V?A B<6"P\NDI5_??H!3A7KZ=6V
M^^4BM.=?+:SCRA/,:*CWOSI4.[O61LWE6,J*%9X5,#<1P9;^0NU881MP";G2
ML@.# Z)I4;="6[E_( 0#Q+:-B93!IK/[YA%(0![R2>S"SV7L\8T+$VOZIX92
M@R=6,>+_:C=9>\,K[58WSG! L6OK6TB!.:/\%4VZ)MZ;9I$G&2* "KTZ^MKX
M7MN7UOZ!M_[!? U78P\*">[D!&B+,J/0/AR0^QD<^RU;^ TX6QGOAIQ\.B?)
MEH8],J(Y WT]TF&FTT#R#'CP+=>=G3 ]D&K##[H541)JW"@+@@JX<J-LO(!(
MR=KUC =1$<C)8'K(WS#$?B(FXWR&WK9NK= )^H^#!T*(UBX'ZC_!PNM0FG,\
M^J+7">]QU'"4PP*$/FZN_&.-Q6[9KG!X]^02 AD-X5/Z2(?&Y!ZLF=[!]).4
M]QX-TRW3NP#87?$C$<$.[JN/19+^AMKPZNV>D=[P"X!MOQ HOOB-0J'-OCVW
M0* MT.T]6_G_UGNGXIA/-Z"KGC0<.W]W(7#L*P!C7PG&T=501 [(BO7PO^Z\
M7\9)< %$-GF.(1*TP=)PF3"WQYRM;AQ%:Y"5]0>@VK\95\=*U]SFI#!^_6-1
MG?Q&/TV_""#3QH(_+TDL!E05GK[_;V_>\N0R93F@%];4'O:7C:<<T+;D"&*P
MA(CA\N8OY_YN&[V[TX[=35JJ_643!(VS9C[D@(8ST\#SEAQ0Q2T.:"LV2LCR
MIJ^0I2'HWX\ ;3#7? BN^30*V&_;!"H&P(""2'B1]^PA0(?&(%1&D%7#.2"A
MK3 3>:NA&NW['Q]X!4E5]4ND'R^(0^N1^CQL]ZM.+]P]F?D"%@CT,_S8?5RH
M7)]0"P.C0X$\T2=!*<*^9J6_1!X"1CUMLNS!D7O,"R1%R>RT!FI*5"W#":NP
MLG-=LG%M7?+DN%QBC+X.#4NO9SW'^A"_C=!?T8PB,$K3"#P8+4IZ53,GA'K>
M(DH[U@T!H\K9"#/\WL-;978=MMHS6P' .SW1L.ZT M=V[Z@/35E39]^_@'Z8
M_SZ5:])U6<[=I<O-FU(TW'.NV7#A6R<U)-(K5%[\]D?A$=CUW";IUS 2+-;9
MZ-.KED?P3]_=X_K4X@.][XJ/BT8'%$^Z0K73M7..IH(S?JI3K3KN?+0OI>=*
M[HG*BRFS*D,'YD7E'2:?+L(/I? A=H/CF9??H J,,XC#:+-W/H[L#"U(VTAM
MMIB&Y#G4:<SOJ9_R\\^)^Y,1]_%2V/G74*HE>+*Y!\JG?Q0SL,,!"0ZU:;T=
M:Q%_ UC!C@ KVMVX//VBHE^J!QMFQ?4E:XQU%9%\Y7UKOC-?F^[&'I<)]9;\
MA93 MMM ;V-C<B_0O)[HNM/HT]=IP>$MYA4HG2Y' _1EH!D]91?+5"N>\6[Z
MF371A'RBJKY"<"^:='',+M/_O=X[W_5SRIFXKT?QS^4V@>A]&E\K[>^92WE*
M'D[N<JL$6O1\4?%B64(E T(7A$JL7A:-%CAF11F;"O@4J31!S%X";N1Q-ZEC
M OBH7%FWZN5)%1[MKA\:#9"X7S\!717EWICQ"^(>-\HO35VR2<Z/;>\Y;A7I
MW7?\:IE8_VC!V8K!>$7*W[>KJ3>AD^#YB6B,,$ @VW4!:#42,2E7(*8'?E1#
MG@KK#+-!6Y*<$O3DV,HVRH%0GN7@)N-0\P#3[-7':W49A6>;#XTGG+9^;Q0.
MG7^#K8)T$F.@0A@E $)F:F\0-IZ.9]GL=!+Y"YYB9+^I1BL'U;6XJ'B-:,!X
MOJUH%S9IARWVO5V:RNXX*4>ZPR>.U*TE]<0BE0M>E^^E&*6.=QNHY&6KB!!E
MG.S.%V66IN<>S+U\&U.BZW&#5/I!S'XL:#&S]DFBS#F&[#).&( 19'2HL[7S
M&Q*HT.LT>)2ND9M^6@4JH%,BJ+SLW8I$4.]:+A?=5]S)&E^>O?+4/4MN3YJ+
M_W(I]*"^ OO37$W&JB2E%4Y/XI8K3T36A^;YE>F%4;8LYO/N=O]Z_7N$]KV[
M-334G:F?;,44P6FGJQY.O((A")K@]<06?7':P0:DI#%L",P% E3KC6]P\D8R
M4Y4Z0IKK02"/H^:Z'Y=JRT?7: !A-+B9'^Q6@YVWW_6W92A!B^$RL]+[U^HG
MQ@>/NN7O?^).FV *@^F"@ \%*8+6IO7TE*B" >*GW?4\$D[(NUYF#U#T<,JS
M_OWW/J]"!]X5\#Z7I8PYKX9H8_9(@>O,E.G>+WR=SYMT+O5WTWT*\F"W-N:H
MU8YT75?973T:!R3@7KCP"L>G:]3^P (>X5#G%-?78!1+;8&EW5YTM;?_:8\R
M4D(5I(]VG7,K5MCR76C(ZKVE<#WH3B-F#^!.GOO6QSZ2^F'6AR[QF#V KQU/
M13R>504>8"6F?-66LY!93:W]4:\KEQZQSP^OE>?E;"O.Z(^8TNZ_7/X-E!CQ
M=_G1"]6),IA)KHY@>K8CA%RERFQR1GML^8'R'/="%U=?"?EO=XZQ81%HBQ-9
M7""OIN00.%R^=J8FSM8IKD55]%6]ACQ3*(:TP13L(>.B] 78PQE0Z3NL+/T+
M:*MA#8@X\PBP,S]W"'TEB7T2S#?]*\,LF**LUH$1]PN2A"'Y4=C56=DF%Y[N
M)L<9)]:+Q5M5(YY#BEP">U<54(;$N-?C@0.,4)=?^I>HJ_QM4>\Q@S)BU/4"
M,A0,U,-J3YU-Z80<4HD[V!R8,72]V@%(L:#FUY6I1T_J7B'IF V%E4U,_/CN
M]LKCE5$:N<BM^OO3AP_+GGD=L:&.3N,U[K55O7S@X'GFNI5_YVW?X9<>*H^?
ME7S\HR_?L2%8J=^C21[82RDM5Y6&R?4R[Y)R^8G^?PZZO1H=*/*?E90C%QFH
MEJ3?WC1E&NKJ7Z6*)Y;<?A#RE9ON_8,J&Z;=\ADXAB[[V]Q^#LA'TMB/*4W>
M\Q[UQ>_K!!>A,DW'N<E1^:MER8Q9 6%1KPY?\,E$C@,RROUE*-*#?]IA]UMT
M.8OMCCEKS@'M9P$]M'V$=.Z5>=9.^A0P'6CP./49M0Y7D+X84)#'9]V5]>'M
M40F-^FBT33&@<Z-FZ/[=EA>G:^'\R^ETFD7?.9I,II] QV4\/[;=_N]3C>>H
MDGEH,MKKS1<:3WM3M;==FSP-%ED;9MVC+YW;A5MS#/L^/*495>8L-1V[+>UD
M-E80&J!3N\9P=G*9VL4M+QZEB:K(1ZLQCYE=-H4X?;G4##':HR20;6KC?[GO
M:8<GREAS[?#5:/<CEE;I,C7OLQESV_(]%I"OT,I+&>TX@<U$XK*PFM*9^\+S
M,G+=E(^-80I#A#"D* $!VM1M Q\_Z[:0%(E8N-@UEG0@/D_Q&ONUKC '= H9
MB5]U&,1NC?FX:&#UL%5>3.$- EN&_87* :U94\).$3\YUL5<IL([LY&'?/O"
M_(+SNA!2COH?WZ.@!MD#(_?OI;T8W]4[(LD(,W0WZVFN;?&I(8ZI1D/J)U93
M:!F$.2&T'76$PI<2MP5^R@8WTS8Z9ZZJ'D$QS.&\@&EWC\UH>6V<WS;NR-+$
MX]?^D]Y9[W].&-:/5GQS?&EFFVXO ']%UH=T^P_XZ)9(P_?$E4B(H6]<$+^O
M(O;U#%I?)1%!6K$J$3[\>RS_TJVG)18O%RS\B]\LW2JXS!#G.?J@_KC_]X9J
M'M(.A%2E[9"N*M=)J98Y1O1'H6603_H7GKE?_&HA9W_N-BF9X/4LU]P)+'5C
M$:81^7LR/[G *A+343R1;OLXJ73<,2J_=CNG(R18)..981!"]^Y3*T3($#GM
M,&@MT.,SCY1=>^XQ;B[-P[2WZ=-@44QA$F2*UWB,:4F!\O^:%:(./&L["F1X
MZ1>1P?S+CZ;TDPI.-Z4\75,N^]$V6KY6EI?U.S34^VO)Z9&N0SX'=SK_]I<Y
MH%5KJE=/KBS@3M.B?$@EP:51ILN\JOP 9K$#QX\L&+E_O]0O2!&5NV%"36/G
M0+/=0Q'^%8@0W5"YF\Z7/.!'5AJWB!T50K*OC,YE1#-#I<91VIF1%WO:F5>K
M#\^?G<B/+DM./KPPYY!^+%VN]:C>#=/WOSI:?6_E:UB]EU7]AX9?#6#HHE8&
MTC=)=!R)\2=!BYX1D9]-$)1M,_NL%/C37,3+4R>SO*;Y*?SGLE-P9/VJ.\V,
M-*+. 8'PWG@1U*/94X[3!'VED'5USQ,_56M-/L0%QCT*&[Y+#>PYVN4O_KS5
MO0M>CUM-F\=%X< 8350>128C'ZT"E 053Z+V=560B)+.4T#\BD%#4\V86W1W
M'T%+NS5U\KN#RS4.:"HK+/;YFX##SQ^]V(B"UJ>L9M#:1GHFYGCU+RRY*M<"
M<)(B41JU;H8\!DS ]"'47)QPYT33UX\(?8F1#VW1LSH.F?,CLJTM9VQL9[*,
MQPCQKC(/F!>9%G[Z!RF'%NR57-!X\<R^Z(#"!> &1E*:E1'7?N=!Q?[*T0LH
M-)$M6$(J'HWRM=^@FSY+EMWQ>H'M&&$ULH5^H#9)!Z-H6,-Z\50'JD'IX];A
M#^AQ^\ #C;G"4_O6,SX-GCV=IK3O5)"K"-==GC"EVYK97VCKJ135J-U1BX^N
M3D#,M891);_\>Z#HL#/R8]8\,:']Q[[<='L5]=U.GH"EWIK[)MDU>VH0?8XT
M-R5K,(J^0@Y#F%'I,045D?JGIS78'\O@5SXLI=_YN=F>3G_T<YG^\]#^'3M^
MIVOPK[G>[VR#L&N'&?<XH'8H<Q\%RX^69KW#G 1DN-S>1KUF0E>5G!(SJTQ3
M;S*>"#37ZLRR3-[M:6_JSJUR\=[MSBGL4L%AAIVR7]JA[E->7.HK7[S;HD33
MOQRE],%5ZL&/ ,=OVG^2I*J<3W8JGB_)()60J-]>ARD)]K55<^7HI)Q_]1@H
MM H\9]?EMG3KM:]=OGA8PCP'%(<_QCYQM1J0[YX5HUTZUTH:VLZ6[/LF=/1Y
M<$'/A;9J_P;/Y.59<6'C.V_X80'PQ#E!-Z[N? RHJ>W8FJ""KAD8"4[ QCYF
M%[U%@7MFQ6IHK/'4$B#5H'G\WK:B?0NT" 5W&-_:] HBL3QUE<NC[J_=WO#Q
M'VJY#N<9AOJE[ <DYBR; 2,.Z( X@*"T@@VJ4F]F$/ BI6@[THSI<L>YJRJX
M=^T4(AC^I1@N*V2_-0=&V#Y^.5ABCO2LZ[AFO3W]=?.C\^$>,:F*\P.T%LDN
ME&[&N:X[_I?+D?&D[W/@M(57WV54&5#1B*]J1QHNN9VW+U6!LA($8SK'"VRC
M55E9I;).WZ%O)7ZV>''S,38!NNHX@=V:"((_G85P):4S3P_9*#/#2!]H#O^(
MA!F1:I/Q!3?V2HFFF-""2FWM5$\E_8$?G[HFF7C6[R/[/->V9M#Y/->SK#K]
MT_GUA%:CGED!5FZ@LNR-*NK<$XT_RNI.25X.Y\/RG&FPA"T77I>)P-!^5S-&
M0HZBT;/E^J%)U,/QR=OQ'1NW)@36\X15:][5/?1S@'NT;10$+%PBRM-$(U?<
M?K]6C62?>0 6=:>^>DU0)$G5/P7>.;1!E3Z-=[AM*DWE''%043S.2DVWZUD
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M1T_QN7?@0XY70)#<G\%7I-OA.-_T #-N4(K=&Y'4/T+^=OOW9;*/EWVC_VR
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M0$K!P2)W40E&R/*9N1)NYANS1-6I&3477&U5Q5,SBEK:*7+NLI$KZQ:WK^
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M2)&Y5A=9]?./N,\5M"+-Y_Y. JL"R]Z:7IYR5V)._2K7_)I28FUQ;'QDRW$
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MZ8E&]L'40-]_:[,M<[6T;;H<E%5V2?/Q'7\FAT! JWEH-((OVZ$%*".31%W
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M*$IMCMXBB(#=4^1UJ&<T95<[*UTDOZ;+A_D^PR\WO[%W.B_Q\E&A%)MF6Y1
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MF3 !1O?H[R)BR_53<-;40DG4]-)#:#3;G99G;$@YY;XT*[\',1LN?L>YRDE
MHJ%3J\P83CI1!.=12"WL+)3%_J(T>^C7,AR*Z#S@UP(5/,N7"Z ,Q5W'."-K
MZKIAY]Q^+FS:OW"ZZ:M'3\7O.V#(Y:;68>_6H:R?PE>LK(_V'M;6O_*%Z3(S
M;?;TH7I%QG1@2HMW3Z%X2,HO_OI(W0%?>46DE1YUZIT>NF#!J4(6Y[ _OBCG
M2]J9> EZ_>UW5A(YUSN-FL7(Y]TM)^2='O[L&KNN-81R6-J#U(FN=;W$P1F^
M'3,R\_%DCCXU+&U;6]^)$?^X6O=2,;"9T&BMLFE%'(8U6AV9UM&YC=%U/T:;
MO7C!XA[KUAXDRXMD& I+W8, 9M")17I!4:F5+S!.A?7 8A_&SN:%!K]D\_@Z
MHA(;<'5T2TX;YM4PCC.<%T:9OYCUD__.<W+9BDRP0OBDYYF3CT<1QF )GC$^
MK\^6%&S/M5GS!8KGFZ,1QFS+AK>MG&*\+^KQ'D0>AV)(S#-)\^_W8?32Z9@4
MHOP(R1<3[2$+&E>1?:K=YJ; 9JNQFE!:*T6>!MXR)"BCW'$FK RN@"T-)89#
MCR)OD4 -4GR)O$W*'L0?)NTWJPY.S"H3WXT&LA6 L]2M51I4[I-(4; GE94\
M'>CJ.*0C<W'D6+QIA!>,W]_ ?B//]]B[@W5)N5=.K+S E&0DN31M9>6B [?J
MS_: /V@Z,#6ZO+.YQ&++R="3/W[D- F>[@XV"W@6'.G]XBKYAY/;@85?"/ER
MU)GN[@?WW?-Z3I-I 3>.VV'])VY[B.0+F4R TP"+>Q@ZCXKW4.*\X<+9!N"%
M$A!*C_B202.(8N>N M 4PC9*81;W[[ :HR2M7#3VGK7\KRZ2_^C6=&)HM:DO
ML-[0ZI?YI58IYGL/RAU,9SIRGI+\1 78IT9Q=D!(>^$1(VWJP%]^#U&=RXWY
MRIM]@VT'0THGOBT]C,P^..PR^Z=+\62?%S#E\6_V$<T*:\6[B=*DOW@*[(T+
M(1$.5<1AO[*]6?#(009.BE- /+",XM^#^-@< 7VIA\K# !ERZT[B#8 ,\A)-
M0HI1*#XBL&3YO\FEKR[L<T!)=P*\Q=&F,7'SY5#H\P4+?!%L<G\W%,CG]I'V
MM?$D/S\I!:? ),0I2[WE:4M\3ZL&6Y6HT<1M'_8"]B#305N%C1X/#"(;.=F<
MYI=NG")2 \[XS;)+UL?(R>_=)0>*Y<*"6(@O2$/,0G71*C"7IJRZ^ *5_HGA
MYDFYZJ;]./J3%MF0YN+$AON-$IXNPN]DGCX?4Q353M.\>N_.];=)$M59O2DK
MX]4"-9D"7 5.&M)GDQ^[OWM.T.@L8-4^I4\F)8JCZ\#5#J;+O?)7V )W%;\-
MW4FXE4.+Y\FL$%/))P:ZM^6/[TB+O92-_(L3LP>Y*1K+A7UE1P [S @PC J3
MP_HO;]Z#BBU-N8U-%62':C<P[UJC]:>>JWX*" D.^NT@+#FD^I=LTFYO4K).
MSY)-6LO,\.=RQ&E:F=7Y3 M?R;DC"QL% 9HM+D[R=9^+MK^XW:NX\6:P8P1;
M8C\@:):E;#U8Q@]+:[/AL1>+DVR$IJ&.@#U=J'H\V3B,PCTY#L>(@QFNI,$?
M62RG\<9I5JJ=TRCFIHREVOL1N&!E\OML@:*%G(E]+QRR*:A)":8OF!,&Y'40
M$:#V/$821%&S'QE=H Y EG)KG@]-@(X7WV:W/PS,RBY1L58P10=Z^P8&2@;]
M#$P[^F7A/J9J]7]T(3^(,*:7V\ JP.%DI<ME^3[V4+%%D0=>Y7%9(J_Z%A@O
M)G1P:B6QA:/YB-NZ)1<=7W^S.0*DKX6R8*!H!]$8?#"_&84X".Q$(8Y/33CC
M+@)?"DO;'CHF:]\C->Y!?,F5[<.D@J;"H/>GI&[>//ONR_TGO2",>8"32E3"
MDBXP=AZ3? GQLS*,]-AM63A&='77.G.]<2.CW/6OMS-37K^++*Z>%?'R">S_
MX!H\,+YEZS,AHQS<Z_S4S;<KT5>?.VZ54!]3[TI%SZ.8V2Q?5BB@ZS<_-_:A
M&F@HI\YMH+L%_W<M,(+DM0=)0&@R1-.,T"Q#-H(ADXQSK/18):J,API:7]AL
M#$39YM3 "!M3QA=UT1N^84\O)B0YITG>JRGKGJM-7VMF\&A(I$V87AA5(,30
MCXD41X?MPLB!?';-'Y[V=.PZO,F]_# V[;_:V1ZU.^[F1>C#*GUJ/8&Q+=>*
MKFR6^;W$K^Y!E.:TLW=7N]HFX3R8A^Y^>C&GN=!YO=V*!>?<!Y5O"_NW:&RC
M?'#J+L]]63F]H@O(_9'=J+HY,DH09PK8/$8<!F%D92FP^;6+'U1<UUIOC'&2
MC2IVZJJ\@"[S[W3]=#,<>W0<?M,T[M(56.DWRIK6)ZP)]_ F2QH4[$(H,YJC
M2;ZH^%EE!BIF.Q])458<O\=R-S-<5W4>JBEN&VX4-(\P'?1M;(T[7ZR3EO??
M(8=K%UC'DDZ^%P[>@RB?N&7G%MC5^Z 'QFS+%O<UFB0<$R_X"SEU;7>=\:U%
M_OK;X-WARKZ8,AN1:C.QJ-_[>U!OH6N!C+-=4WN0=%PXRQC<WZ5\FF'*6BGX
MFW&H#!VYLUM3I**&";W'\!<S&ZHSEW_ZY&5GFE8QPW?-FZ4-KK;/_@6B:9L\
M:X^S^8!6;3/1^%E94O.'#&O@M4']Q=V4AR[J*U;R[HUMQVQ/UNU!*O]Y_T]7
MQ'G3 WL00EMH7Y8YYQ[MBUMFM[,1?LR(GGWBV:G,4V)93L1WM_>G'6J\+>DA
M=2W@L$.IDDO*#[Z?.X_P7@.3OM2@)PS1?\!PP+$3(3$8J04Z;'8@Q>[UJX>>
MJV([4UU7K58%JV7LXJS-[/7JG5<>QKX+P*N$6O6E/BU_DAJ,^","[W(I""&&
M1GR;)Q4_V=?^$);8=J(&C5 '-NIOP6O#7J^V2G&(Y:_][Y=:>USJZH\K"L"$
M[KMW3YQ2\B3[;P[!5$NGS[IA8@AQE,'VOR7EW6/D*?^N =T#+U<^]B7S\A?=
M.XR.H31/>.I"=W>6^.G.8:=L6Q-1V:^IY>H2WZ$)I+?Z:V$,3'?N)L4F80\"
M:9.@S2E@"VBSJQX,Z=)6TO2V8;*K@KO>K&MAO?]_%XA:"EJN/B<$_OJOYD+@
M9_]/+*G(/N63P#6<,@/:@3KLOP<1XBJ 1!JK??;(>_EB=('\^S'<Z9?N*QGH
MKE#)UD,_%[@;S@X!.5?E$DQ-K]NS5/YG9?*@SV0$10=);[32>MDRGFPOE':]
M[.F@F\4+36<C +1L$9#H7:["'$-IGA,8?7N]).:ZNY&Z2XO?N<'RX\C]()HE
MQ>V#\GDQGD&%B *@50? O@A\V(QJ"Q#)@MMH42*E1^R'=DQ'O%M'@L36=<0M
MI-BUBATW0RVN&^YO7RH$K D3ON3<+T]H2H+,($ DNWK)(#^NL7C%H<S=JMK0
M?FB#1AS>K'ZQ>D"]J^3;D6\7*4?JS,KX9 DMQU_UU0T'ZL'3$XA_=S892H@8
MT(][G;TT&.?K8623W]WD+60L$U\D%&J?9M?5'7MHR39-Q5[*0'LH*D4A\:<-
M97/"A&D"]M-3,33'+M%'7$%&85J;!2>/\X[F[N3?<W6$5+N5BOQG&/$UL-$0
MB_RZ%0&S>9M\\P0KV6DG*.+SE/SBFC5+"YM!M8DA\@7@#[9IX8'"]MS9(AJ2
M'WOT^YC7T#TEC'VAX[N14,%CS:,J;>(SWP*F*,-JS=<Z;Y)R8FXD,".L3:7=
MGSS#LM*H)IJ=Y%1LT[G;2=B'.<?DC<Q?F,79V!V.+7_<::/YJC:I &6D(]#H
MIJSL=&DP4U';Y?G#(%W?X\A,HE0D!557UB&X*>&/$H@4!'T['&?/ *7%\WB)
M;^@P@ZW4*JR=0^X8W78PZ"G+\7V*J[NUS^T-X+6C@-=?YY\XDQ]TY_!(KYL3
MK1MA93.Z-3!)Z)!^F)49CBY'[SSQP);U-Q)K"PPKK9XW8Q]G?XZB'?]AW=OW
MSNR"HN.LI%W=&D94'/=O64*/]PG&CKQ=U\*=(ILS729)(1]I9P6P+B$E<65I
M!,6'E<EQRIDN#6\NME68I1IDQ,)EOUBP,QG>3''.$^YY[+0MF,[PG0^+-0JD
M1[C,76D8P9E6N 4,>LQ,+^M=79ZZ=ZTZKM8W,-E* :M=K/57;1I\UCG.NM^$
MJ<+)A*-B#*#MUN;SI+@@[A%L0%<(EGX!4&MV80SI#D@-'*H-T*L/5%E9C=2Y
M&4V1[]7%8)ESC%/YE*.]=1P[TT-B] W#.!FM]C_&ESWYM%2^QBHZ76Q1K/.'
MU)U[OG&=]KW JFRYS_:IEH>-IT T]:C9]>,C^9I73KUXQ74$35ABW%[2/IQ)
M!4B@\G7@A; R%(.YN$8HW\I4069PC15\)RXTH!JQ8SNX:&WB\.'1U,P,V@4W
M%)CH,Q>@/"D9)/P#P'?H[$%N6*&+WC5S<MJ$A9@_>XS.E&PFC=*R-,3-54XQ
M1$Q4*^H**/M1.%O3;._2PD0/5=LN^NFMECU(:KEWO0#6_QS;!Z$YX)G<<ZVC
M8K!CJ-M+-=V^5A=X0G%,DY<J._?5?E734J#J-]$*[&()1'["0]EH?0HR!7D0
M9T@OE'=#C\E?WN66O &SQE:L#:W,TSHG7PTU]B.^5C?<-5#E%'[6O+,QX>:U
M!*V%K=6_88M@'C7/\34H%,8XX,7;[&DLU &+<FPV2T]4;')U:B$CL,+\;NO$
MR)A3 WN:GSC#]"IY[>?B@!:=_!\-W3*S;X8,T[E&)=%]9W9YU#4"R*F[P7%Y
M^VT2SSZ_\3,)/&Y9(-+D')<&MVVW[[P8$B=?*BU9=E'\&?K<"5WN?1#.$N;V
M(NOG4FPHHM&H0SCD/%(V_QC+Q& ANQR;N_!]V2!CVB+BYJ!_ZP].41+-RM#7
M*_!STM<B<[L7OY%L@S+NX5^\#+1O?I.MA)W;@^3F<OA>)>OT;9C;PR3:+(M3
MNVY=QUVD\R2&09J$:%K/$.TSMT!?+K[=R*3]:Y=7T7--,.F<1G)7F[KFJ(;0
MV2XO)=F.L?+^G^G=J(D0IBWG)=LYD%Z84GC(R)A.DG;QNZ^LT#RV;6Q"R6H^
MO91[<R=;3_J@;C7&IAF[7CH"4U)_*IW?1B-HJ9B]R9I[.[=6[ N$V8+[ @%?
M,H.M/(IS*CA/ F#,[,3"RRV,FW><IH_5,W/@W:,J+4ZZT\?9;S#T1L05^CZT
M.AI!X-W&Q^]E/=_"S ]F^S3P0!WM,VF,T],XWK?,4 X6DG9,[+ 8X$OH>UO;
MK2DK#UHTGX2[P0WLCUN\N_9,X=U/9*<H#QTO@8?I 38)<_P( 6QX.Q=>6S>B
M.^V.OSQJ9!L<(I56&108*HC1L!O'5,T:/A?I^:6=G[V/?GRERHCXBWO8EH<J
M[!&=#<(F\M: T$!8>(CQS$@_#9-@.>SFUCML<^(ZX^&K'/7[=\7L+YRSWP^)
MC.%%M\\.WOW)M%67J/@2/5@N'RIV;B7+.X5,O?.\K3-;>G&+T5)U3 ";]-Q(
M3U5&L<.1$-]YO=MK,;;8X74Y=3&)8OG,4W/;K<+):0I]7]K%)T9EMN=*0U-M
M7;-#F).V]E&K<*Q)[X!J0E'J$=VTC8Z[:Y\M]):J^@.L WW-1AMB1AJ-Y;;=
MS^Q!K*V]30L4W'TM U:= QVO#04%:6^LKV\;2AQO?5L0[OK<JS7IA'ISCE3Q
M+=QE5&-%ODN-9LF_*V.YF>;*#\*W;V8NZM7\4".<,)Q:+WR&.HC$;"I@R=0]
M2!=ARHKFSHVGSCW:@PAK@)]HKDA^$,_T *G2S;3-.*X0XU@M%?,7*8:$1DFQ
M+P\1#X*$'GENF7)&8&B1WZP"$DVR-ONR("K@6L(MH6[Z\[1[5#I.)6N\VQ;%
MAH.+K[#-G5P54('J+D']4DY%\14JXLS&\7XS&G8,T4YWPPX]E[#T;25EP?5P
M<BNBN,;_(2:MD71@I4"RKBE+5,II:>K%M0GU:BCW\/;\S%EF^#M.%@%QGAT^
M3N1'Y%/[56V M->1!YVL7RT3E1BE^?3H !^:J!!.$-A)(,BXCVSQ) 4VRAIO
M/U;Z86BSD;_Z1_V'? QMDI&])@:0NQ'Z#'/*+_IF,D()S*0A4XE"X"]?>JJH
M+7"PNYIJ(X/=WQZ"TP>Z,Z@<)&4/(M)F3JTD')[ >CP('+=@W(JF)9>TW"_0
MMOS[LD] V:OA7^/L:BYJT#D.V7ZY!_ZE+*$HC3S_(\>[F(R?U*UUNJPCH=ZY
MH'C64:5SX2KY^P,/E89?0L)!)XLHLKTC9]WF#BS](.Q[?FLX]?S([W$J<GV'
M5L[5P%UM!A_/IR<C_D:*(=$$F<B!POJR=J0@Z$W%<<\#666 *M4CNHKMAA$+
MJ 5)YL#HC]C-),+&^%6&\0 %)04ZFI"B5E;F* :H1X%YKM&CU:3Y4M0A.&G_
M,E</L"$34O%'Y")%L+_HBREL+6JJ K6_.3%2%J<-AM+RO3MRF1_H#W".#"19
M63J+N\A3_PRIIFAJ^D&PL%OYQ'C@/4..S97!TF'3#S,]><Z\C D>"A/!.8/H
MT'G1-*0$[C!021V/02 #Q+!D*T9D?"7WJP&A&S\ET>6"*S@]L@EC.P+U%&7A
MO'_P!SITLOF2=50+:0=KB@->]V/.C:R;)TD,$9#SS^?JU^[C)PK$&3)=^'B$
MV"A1"O2>)U&0?* 6Q4,VWA*L!EADQ-_O&4>'V@(JP?B.2!5&?NIBPF:CL)FH
M=  "PK!YO!UXM\^6&!7^<99F84%@"^\T[FZ--Q=_W0ZI()D;F<%@7?"DZ.K8
MOIMO?&3=!D0?%\?U!<M]L4&)OKCQYGJ90Y;^*>J:OO#B.<>H;EJ(D*/$'L2_
M+S'$4O?TKR[%VZ3FGBA=5")>#'?/",.PH4$[6]+7JH&>]CT(/^XH$-T1".^A
M#$R9F.1US\J/&L%H.3C' %Z.&9 =*=LRG)[(5JI8WH4 ;_W6[P7J4UJ[/C^9
M=F",LR4#W$E$4*L()P$*,T2=&6%_3KH*Y2,'YHZP%>B&F+@CJU.:;+GZ]T2P
M@[>=1=R=<:%#;/40NJ?HQ&L@/A':];",[!D06&-3[;\:<2CSM3^1_BJR'740
M9TPS5J48>-0S!&9T,5,JT\QG#5\EG( U#R6,K!^1+YJZ&<6&J:<H2\11<?MY
MQOWOMX?H8#5!>SO XD=FHS7>(;JW.04H7),!R.U3V>W5F$ZB(5A9$C"WCW@4
MYP6F%Z]>9%&WMQ=3MS%INP/,;$H$DG; )9N<UX_X93VR1=:(60O":7M386++
MRHI/LJ^,SX^-:0>=]=B#C(XOX]M^%H3,:VL^QUD;52H]I[W-<3L%^CO7B#1)
MP*J3.N]XH+/GZ;E4,#++K59R)?B*H&;/+5GP8E- 2ES(^@K-WT:GNT=FYZ"D
M[65N\/^7Z4'[\Q@V*6U'YP,$A1V[B5K 7/36!SM*@200E%..+7,;8B,]WX"D
MG@*U(;;"/%[ R<-_W"%KIT"-49B\W2_362#Y=?U[QG6&3"(\%68RI(V!6U\<
M&@MZ2CJ_![E=&A'&+.7!IAL;.9)2UBG?O&[+L.O9[<_05;4>;S,%"IG&G"*V
M"< R'RE^<"T@>\C(.=R7H64>I9YY=#Q2"=WZ[(U(O@0L.;(?*L2& CU<0;X]
MR,$#34!J3:T".,R$<V(11[%EMG^.+MSIJ6&N#%0BUQ#?<4%^E[E#B3PWCC,E
M-!66H9D/47%M&M3O(QGD@H. 632U$ )J6 "\E;6=IJ[OOPSA/'Y%>HX_P.V1
M]UT;9_A:@"8 P8,3'ZFVB@3L9B2X CX^ (G9#^JS8-,X.*>9*/P-YU '9K/,
M)MB6#)OUHZ]PGF"]Z+H@@*<RR^G:JO-?6X8:;**MBU#?< ?2A$VNW^)V92_T
MRW1[Z'.RC0QIKFBDK^@DR8[SE"B N\XI1MX6MF+>!@49! \@>^V]1B)/I,)B
MD/Q57#AZCH^-J8K\T@K/IN0@?3>3\0)!D:= #/5^-1 _/_>(JQXYBQ3C'IL!
M"31S<@[2^SZ8RAC9O[O"N[]DM@9M;#RCDZ@!;"86=A)52+R=,TS>'<NK:HXW
M<BXQ12/*J:D/[JWF912#R=91W.X CLQ5Z=W,%XY93]U<S;*/U&_!?W>Q]-UT
M4GF6%^!9+!6K_V]=05\G\2@0MF;.^L=_GR=+*7.\"Y; /0A^ .*[QC.<WEGE
MX8_T\:[/# (-E>MV[C>-GYDDOSK9NRD(CTS[RG?V_RY@K\SYBO^N14>QY*J1
MV\) YKV1?0 ?6_(]=1A<93HQ$-6^8A'>U-+&(O8_PZ\3I%K2! ]_']QN2KNI
M0$\3%G09@<LYWC$+1,C\+^K>*ZJI]UL;C14$,:(4J1&EB#25)A"(@H" @(!T
M(2(B38A("QH2I2I544!!B'21)EUID1H!(70D""%!Z9%$("Q(""?^]]Y?^?_V
M..,[8WPWY^*]R$56WLQWK3F?9ZXYYX/(/I.EA]W!MIPJZL1&P'E;3FWE.F,%
M -4K+:,.1_5]:<2"Y*?O#NO1ZL;+@L7N=\B["<U=N6WU:%48\#2G5T2Q+&>F
MW/8W&,=#=<N0OC<2/GP*A]T<+@_J[?Q.4CB.");=,Y.=;S\/81V;[R!&%[5#
MGI'V->DS428T'0JZ/O>'D]#)B<6&T='9L%-R6\.2\D/0FRM(KF_7;UQ\0 HW
M9@NBM+JL@4IQF0Z!\P,(^\,E3Q?P7$\38)\/$_9$OFV0OUV+7K>BC>+(JAV'
M)> QL0(_U6DV9MYS*)CS,C+,C#G<&_#I:SF]W:MYC#"\=":W93_S^7_),U1
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M8]1)L:Z"HU#=X!RDG"/M5^*O7VF1'Y!WVZ\U#U*5?_O5;%')V3<P(;F/]4(
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M?P>O?VZNCUOQ%AUMR<OMK/^J\;+-0<.X@_3=$C^M04=!CJ$4F)9 +'F^(UD
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M]WXMH?!Y5R<^4WC)ZUBSTXA 204>>4,GS2 ZP+'"'AU<UM6U:;N@:Y^?1Z"
M6V-*Z_('/H-F'$B^UVS-NO[\S&7'V#YJ-#-C>I>NEOFM^BD?Q0?XAAX.%1KN
MNBHC&^&!+-"_)./B:+(O#D0C[$>/0/:@3SY]V4XZ#M62^/G.;VAC.9W6__X.
M5.V\XU]-:;//U^=A;DSK<P=F0Q,0%7SC&'_<8]'0CD0="]%RW'OO!K^DQCQ7
M9-&UP93E]LH?<#B O@RU#F_0=?K3_\-;,\(Y7NG4SYL'XLRU$.\^Q=BOMIQE
MX^'[49B<96H!P'6)-A[_.ZCLJM?#_L?**"T_WW(S3^W%\5!B2 +-.S1D&370
MAU16FWPF<UF*Z]MM/ UA!P3,]H$[+6<2+=OT3M;1;S5HO !0BZ'6/NFJ"/XN
M1:I;DJ.*]<\J]?RZ;)3]B][]=15J-FV_]^SH>SL59I5[9X34YKM.+FG;E7GX
M%GO7,U(.^57<4W$SRS0K"1..C4%*F[B[C3J(XN#II"/H@^@IR8,T6,P]E 0]
MM+5!$GLDG>\;FH<N6&/_<@'N[SDB._CS4Q/-HAE"]"OZ_$+Y&.]Z?01&0\PW
M)N+B%-.2B@#.$&+#]$0 J]E*R$W+ J>PUH?/#^)F_O &?^''&DJ<V;>N$<=:
MVP7%/-VIK %OB7"X@T')RBZ(P[NX"Q@YRJS@/[CJ(GK( ]7$%L1%YM2A71#?
M!$4"DBR._H839"E5/ZODH^+3DYN[*LBX(_,GH.<MWF;\U0MOX1[&S.3N@O:4
MDWI&UG%/LR%O+":,"LC4"T&)L599*O 1N9.86O]D]I<*TR&,'V$BW8Y80I=5
MTKO;Y3;:I$5IY'O3I7FS-V<GMH++;]A]_]O#Q_9L^ G./O2D\M,@]I<8\!-H
M<?&$I[]9\)S%X1?+C'"C/T-H'?9J$E#NV0FKQ:Y0R0<"BU&VM#[6^XN1[:HW
MD77VJ,-&8NW7?9X;;4DY$S*D$S^E#G.!((96<*S]7X5$./=2NK4WB5=/$&4&
MI!9+$9\3%P<7Q]94/3U3&?OIDA\$Z6-^DG+] 6*W.=2N;6BG24]*HN4HH$#&
MQ&3<:4\T[CJ>YY.6V4)&JF=9]X02#RER1=V52I\[]#QA#R.T4^79M!!P>:;,
M&8]6R4:N9RD:B$XZXL6):47AP2?CALV'E7ZE[<_^\ZM;RM4K-X9[OO%SFIAS
MV%PR&1?U=W<J>P$L?AP-H4.B@B%<WX'VCA"K1:>U9;OMVM2R$>+=Y!RB<JV8
M-]'&>\S&K"@LA817HCBIC^A3!&N3YAA'8)2*E6KF3=0UFFM!,)UK]DCL+)_9
M-:^-,CDR.Z7$+9?D<Q01>WM:(XL<+MFS/6G9T"*4+BR*HC5U$)M_\M_L?HC=
MSSJQ@T5YTB,IAUUYAV?B>B8M<$^1]3:/)@6U99,E.LXO:=;1NB^&&U$N%AK6
MU-:8)&RJ7I(Y-\D;_Q0$RR<JK VS)<IHFNP84CP,T*7%[H+.U6#::ULXG')@
MDLZ!A%Q_QP?-"3V&Z2]4$"R!D/HOI&VQO\F#F<TV"*N-$\"/C %BNR #1">6
M)0D8[()>.X%V>'-QNC RD;0/L^#W=T91)(D;L\9KS-)QGD'L\.&$,+1'9##;
MS6O?NG+<7PGF6%\4WRXHIYY"8(-14KN@;TH0&A7Q!+>N\3=ST;H:!=N*?@<>
M:/C_LM_E?\M$H-3_N[WB!_[V\9/V;^AH_9:CPSNO(&N3CWHO28VQI#^X#=5.
MF9G5WP7//#N42EVAA+T^9_0FWVM(34'T,?K%(#P;^X]-YOUS>WNVA0W1#_^[
M32;_PYP#7 LN@G^%C_^YT7^:\Q(D)\A^ON@?1OWOS E"1_\?[W>2/4*JQ4:V
M',:'S>S)=T56=(G.Q_Y.[,)ZAQ_)<L^=\*D;UP@9]G&*=R8UD$S%J/>]*R=4
MFY\+:PH+E03<5F;N@B8F&5FT4"JX:"GOZL<FVNJSH/WUF0ZTZ;R  Y-*!9/:
MES$%I Y.M"+:*9R*?_39J:??6:<N2?[=T1^.-UW0;N@A>"4XCGT"CB]%*0Y#
M;6=Q>UHRJEW[3A&7)64&@[GWESV2V$F++W+H#BA4;])G\)F2KCDHC?1YHP9-
M!&O&2=?07W#5^ Y(K#8^3D\:N7FUF58YRH)"57.\M#->JYME/BJSP-N,!"L9
M6'@Z)ZJN#'LQTM+NDRY+C'[]U/C&/6;T5MKZOO6E_^O9IO]US05!MGB <7:7
MK^6. 4K&1?V?N8S'/%M81A> V 7Q.C.\@&;RB;+._GRH?"A%Z=BY_&_;\U%W
MXCNV[PBMO*LR#P_(+\]\\9CN:B(0VY-R"?TZW\/>SM@VR.-LSY<+51_;%>2_
MGKU\,H+[Y S=9>*N7IW]ZQE5J$[=:94N<D"-"Y7Y0\G+OBBD0>NRW*_ ^/-?
M!K_]884X/[7/26ZEW ].?;DS+9NPT-^]897IVX_'PSZJ="0#CMBJHK8^_4>1
M>L7D<&4XR(<YB7KQ ZEQ=RAH54/?#%HO*9ELV/*"-'^W4:97PZ4%7]$# >3H
MB"B<.,979>+AS&M%UOE98_IJY+WN,Y:QOW^?'LIO.I>B+Y:X=XV\CI6ZU7*W
M[7>N!JQD=!T5_CCO,>4;:2E^)_9<B:56;X9=U$>M49ZP;!%]X@.;&(7OY?V9
M]B&?UUA\B66)Y'LERY8[]7M,"ZV2S:<#NGYN?/#XE/1HF6"-1/BL-KPON//:
MRE"0CA^+%K"Z=("SQ D1N)_FM/2=>&TP.Z-,H;#<LQ7^1Q8P8W=F<>V"S.U2
MA_^E1;T_T(#OVX7)'X8"C+5.:=56-5]%58.SK]+D;]_OEK8^?<%$K$2A1/#6
MY5,X,3TI -&!HUG $\^S7(% M_=+V"I\IX0K$4^!1=P;G8__0BSKJ/A)*.RZ
M:>Q31U4<UQ-L?(4__#$3QP7OY4\WQJ4S7#]";<@(#@EISR!$-3GF.RY/B]&/
M8 ,*EK6-<B"9ON'N0=$R<9=X&BY2KLI%SWZJRSKUN2Y-X6G>"SUL-!#/Y#W^
M-"^A?1?D]=.Q3":2<.&-R1GW<V_'HYV4%HW/M9KON.^)2U9<&$]\-:J=>GRK
M1?HKK(ZVKN"FL ORG _SL(_O#KR*ST!>L[9+/5OLZ[PO(8)Q8D7M<XY30OG,
MO$6F<723#7E5#!EHQ#G1C4>ZC]K14L/4#7,Q^^&?:WZ(4O_G4.NNJ_;&XGCH
M<6D.S,RO&S]O&"#PHG 'K8:"TN6>86;>XD3O  9TH5V0U2C,(SE.M+9OLSU9
MS%7UA^&,G]V< VM!77XO-]5NJB".U&GW@IN<ML][5HP[]X*OT#%V=[N:YKG.
M (2BS21!(/ R](+BQ[[#'R3E;Z?R2K^XFE A_O1;>:F(R7[1B]A8S,?*BP^_
M0XT928890\AOR1H)?H?O\C>:IMZIR7M]JY!=D=S6FU8@2F^,<K/.].2;WP5-
M(A^N!P3IY63]2K4[KMWS2X' %?>KR6<(X?3]\!WAL7,77Z_IUXHXFO<+'DN)
M.U/Q6N^Y0@8=RWK&YGCR2E^77="PRVA0;1^2P+ZR"Q+"?*\MYSB"\J7'VH8+
M>I%;UD,JE]<A/6G_>Q)<81Y.G'2FC\?L@NX2$AYNML/Y%UV/T>M29WJ7^XYW
M.(T5%7K5.3D;JN,FYY+MQN[$F@W7RJM5AR-RIZ;[#I];5G70RI#E/<6V1;?B
MCNE)LZX X^5 :!N\1AC/FW5LE?$@UFY,#4?T=:JEHW$(NJ=+4M\MNF<[C-L%
MGI^!?8S2#3OE<_VJ\OKWU9K)J&%$^6^A/[Q?'\."*Q1+-\2\[]7RFCDO:XW?
M8:2GT5V<K\5^,-N_0+]:Q"Q/T"VAS5.*5L!T7P/Z2!IZ[\=AE E9 N/<&-^>
MCIUTLLL,+B3V"C(*CF25.OO4VQU3GTJ,3OV:-FN9-#>T>"ON:H;(;_-$W"#V
M8^PS]DD'EMU./4N>;C\+CF^1<62=I<]'!?4B^($UIQ=JU MCO!!1\_(E;?\7
M2I->>GQ#Y<1NY=]!.S)*]Y24ROQ2O.6$XN\_)!!]&2TT=N+?@=N9C&" R90"
M<!UHL;'5#27[+]-J );L+4?7?3X0?&9,B:N#"._8.=C>GA%EE_C!R;FS;#&C
M(*VBQ.?AA42#JT+'B,N/3[ YX3H"@=0;;R-"LV7II 2U7=!3D\,I/L3T*'4)
M/15P9Z#T$/2^-V,[)DK=1*HVLCNZW)4Q^KO(I!P:C_R51)2,9Y^8G[6,H4V#
M=LKT3CIT0K:S5)S,_7WYDQN;VBG%I9D21X)L6B_.I.H=H@^S>93RD$R&*N(9
M%@2]'$"&2P*Q>$D^P'F63[%3J&@V.:H^6ZENK*)BU4\-:-/()<9DD:G6I%:T
M3%7]'W7]\6.+LY9TC<1B[VVY*$R[/3@2 H)YY],@G1#BZ@T 7SC!4JBL'\3=
MXW6VH6#VFE#\G%9-1UA^,TQ8K<_0]T71U)C2]'.+3H]3YKK^D-HU^3O?._<&
M/+BD]V<7%"7,YA$D6P3AXC@8!17J"=DN,;?NZ1*;.$]T+&=!"OO20>!,U^?[
M7KZ2KH;0ZC$(%1XZ!3&QV:8G7Y?,=D6I8,1<?IR9J4\O!!IO!KOW[QDZ>>_6
MUI4'*!R#&WB2"V==I\<^4=&31T^P3]'_H#2&48ZE2$U&14T<WO)35;BG101<
M$J4U+#VRH61F,%!1.%JJ=*]F<MR%(3SXK5[83< 973[ -9_,TH0DL'3_L QW
MTMEG %MWBN_[XU:?HA\O2YN5 )[ZL6XB"O&+UY^\."^>]-*0<[:Q;$+&R[,^
M<-I;I-M:G54IX*,3_:RU/0(%*_9](&B#W;HC_N2;#TDI?/3F7.W,*C?P_ (0
MWS8M/CX:(Q)<!KXVNN^P^V&5,L_][@GB"=>YXA<PM?4K9 H?U@VH)<<'RIY3
M[\+1QH8>:=$EDEX5)_WZNF_\A/J*D]S? 1)^6%HB@&^;/KEVG@,=;B-C34;K
MYPL)'UU^^/<;:<QK49K2;^Z\PGE:'EUE8MI4N)U7^U=7=$Q8J@D;$QQ&.-7_
M\M?&;.]DTO<O%9+CL)EL;'5=2=,BH^4\K?L>E=U)U_G!3?#+ZPAYN'7RH<[Y
MTRUA(,@#*W@VC-:&EJ+M@F!'8-Z8N&PP_]IA:[.PH,='7C1Z99^D]?BY_:G\
M(W+?XG;P%@^'6*7O-*"4"-$PKU4^((W[\U&@X4MS9QMX9JH8@'<>EOAXT"+O
MD#A6UU*:PU[_\=KQRS8NF0-QWY' 05F6MF.L/;3>KH<6+XI<24NB96_3,%[U
M-95U:7.4/SHZ8$$O^\#7N<\*SK7F_C Y:2-^G\NCXFL?G&*<7(L3A"766@HC
M8V8["Q?+A^':63^TLTKG+,_S97V[8"P3YWRAJ^Z%TXG;U4DG3M5>O5T??1K$
MSO<^Q,-[?L\EZ91+H#TI)E 0EW0VJ*(7&ZM=09VG-WYABXZK68H@(5]:A$:"
M?D9,=MBGA1BXCE'7%Z6'YD=^2[%[Z$HKFIOU&C86?_0SI&V^=CWRJ*]-._DH
M>">&Y3A[2@889!JC#.GY#YY[#JE]+E=2O.U:QE?:,)=3/E%Z)^UTSX"?NW7'
MUOZ4JUQC+0K !@W>*GD;P%)"(]4FG]:'I?&6.Y*62NK+@[(TS/HL*\2=Q#^>
MO7!9<"WT*6XF![:O9HO=3C93$4/N@JZG?K,+6-"3?,3K^P8DS4=<W[Z;+_A8
M!Y4E2[%T>-PM@8N&N7&@-ZYM^F;B3"A=Z<>C@#!*L[O-:.@LUV9&4*A0QNG?
MIY6R5$:-!%)A5Y&AK=E@6A3$@X:-1FF1,\.?'-8^^*QP@5YUV,TQB.E[G_78
M8B4E3#K;:]\:TP:@,DU8#@;"3W!WG"^6SHLI;:C$A?0%^BHJ??F4X%N)5.YX
MS_6@-#1T\*!+8U&KP7P]KK*">H!NBJE%_EF=L6^?U.IW);1AP$V*Q,X6BMGO
MAD'4>8] O8'[$7#A'VY/%*IE2!L<4,R:HN%8QRW)Z.P/;"4Z(:')[/X[CZ#W
M-16'OS<&I##^7*Z8CF8O%19&>:;Y+ 6K '(J7W0Z=T'Z(RU2"T,@C>;DIVK%
M73,7/<TMV\=_1H3=2N9G+RN%K_TMWL,S#RP1>59H8*H,W::-._9<_H.;/97\
M ]3!X%T0W]Y+^U[QK\]*Y.^"8@)W/@:!MX1@/HNUX=BE71#Y;-5(P512MB<C
M FC46FWLVP4]L5_P$-@#;#&O.K$G6XX 5N7&=!6\JR =]GB5$XT4X"VTZ*S4
M\ORT>OM]*\OAZA714-5 OX*I*;R?.W*)^W/*$I]>H*)P%5YN'AS)<JQ *G1J
M0^)1.H\"/<N]'A:4E[A#+UP,^5SW$I-^-K$-Z<^?7]\089NBD.D]7Y^M)95Q
M!;%D9CM4TQ=HT3RX4:;=:S=4*Q:FA%B?,AWCG>2=]#::4/I=IFS-@85X/O'W
M/8^2#J!V0;1A1@B@, ,_@2SJ0 L#F'SO[;&L"H.#F1@H,;M$]O5+ '&I)76]
M8TQEE3Q<Y)O)[!*VL[K\X,6//O^4LL;7[_>@1=ECL+UH^?#L20-Z;=J+TA^"
MMK35> UDH,.%C_N=)^,G,-6U\E^[_ZPG&ER_:*<K,+NPM(6GV*]DT>0HZ43E
M8,+^"6_1OM:["'ZDI6>L>J3"7K[.UJIXIH[UVP2PJOWPQKYHJT$CO0#.(03L
M%+$/O8!]@22L4DA')B4&D5SX:0?#QWL/I+Z$BU&% ZGZFT(/ ,//)R].O '!
MC,]4$/@T&3\X!Z#B5P,AVLS@G[$A<%.V/O#R<DWV6OMFU0&=@MJ:EC=1=5^M
M]8<6MC>?BC_6[[CFAZW4@[#< 3C=8L(?M6\VG*O#PGWMSC#U=V==K9_DP.2J
MFMBOVK%[XR)BY:6W]6TC*HG?0>L-_RMNFT/)[8).-A*8(G]?H16C/W.XG-[Q
M7=!SE_F=A&G57= ([N:[(QG_R2;_UW7$LPO'H1GU')KQB$,S[(.'[55GX5O'
M4<Z<.-#?O LJ+&E8?/]?11G["&C^75"W/."^"[JSV8K93ERL7;"=QW'O@GZ^
M8IW?!54]FL'M&*T3U\\V8#N*V5J8Q6L]L;0SNZ#Q#YCM*_HM>D )$XW&8_:S
MU9$VC" @DS[;IB<&3,X:#^4-M$@4U#]5GPK\-KZO)2%C@C:76/(=L*V]ZLXT
M?TPWGTMD-)KX54B1?(/]U'"WQNG-3'=T;_9Y8'P7=  &3'@PQ="#V"K-9V@5
M&!X1@1%FP6GNL[@X*)RV1N&@!K0<ZSP@7[J@D0&.4?)GJ2"X.DDQXY+"= E2
M?*V)GO@TD#+;YN?KE[]$S>O>UUW*1,'29JJA%F>S=?CM^8QB> JE; L_W_I@
M5"8:P-@H,*TY,VB:][;@8J=YEUKJ58M\Y[7 A!"Y/<9@J(QH\-)8ITWN8E^]
MYB']_%\KWF=?S=N5_+2RBLJ,\\^+RA-QWOX!F-,19#P>'ILM"E32DCL;X$EL
M"607\?=:NZ3BH'GKL'JF+Y_IIG%CQL!4J]]]:SY+B^;J0&G^ETI-F0:R8PC#
MBAXX(*V2#//84658TR KQ31>1@K'M_!1DB<BVRL!7TI2\0R.:F;FU61"D<!T
MB+++WB_4-4PE9865()4Q_"3?AY@8E%41/K3 9TSHJ*GRV)QQO>7HA[5 \0NM
MLY5(KZXF[Z$*.S5TM6F0KR6X?UJRP#0P6LMP-)=LXV"T9&\BF_1#,#2NS6VY
MY\;;):NBLRUM^3Y#B?XW2FRBR/)=IEFN2&]YY[2^.@'[MRPSH'H&'"4:&KT!
M?^JTO!"2K0XDTIADS>@T/HC+>$5P!81E1;?(FB$=6+#+\(Q5ZX-;3X27^3PW
M^;!\C&B8@[2Y5#?*<J'T61K0LB/+?1^&JLPD$]T9]X$W=$T\_ !:'#T VX\^
MB;H#P!DDP!%S",5/=_Z2K0!DTE:9FM:11B,8LC9-,K("#A2UP6^-*9?5E)"H
M.PJ63.6"@ ,);)>1P8X?GE;4$?MOTX=V:C'NB&<8_B9SVB,R@>K+O/!W^@XI
M8I8.G3X/.,]@DV&\4%NZ6%L \BQM<?I">L<T]T"3+8;B=Q!VR ?T'<C:,+\P
M&B3VQ:_6QAO6[6(?!?.NF&BD@-MU=68M'^.\5"(D-0&M4B36B&;Q@N[9!A%D
M<5'@,0^+$EB&LQ(*Y/%8EDP1<LUH?!6E%$X)#Z4<:<Q%"AL-^-4Z!KO8=&EW
MI9+C%4PVFO6'NFZ!$;E-\U]@0BT0E.4(6M9;\B"=Q_=A12OIZ3CV$.=S7^&R
MJ.UJ5,O)[X!SF^O%]/9Q!G$,6V2F^@.IB<_FHUMD%CLH32>7>DG*#&ZXR%UO
MKFJ*<U\8V?-M ?9'D%ZQDS"&W8X!3!M\_I$M^E>9!MJ2%4)H50'.C*\PZ2ZP
M0:@.O?TR)B9;^E6DN+T3D9_\VI4R(YCH_J06'CN^WY3;<%@Z!*-R$#+&PYKF
M@-X<0&C-=2>K#'W2J^6.WDE =Q8!1K;U;W_?%^I7-/VC(G:UZ6V,E%O+2)"+
MTUU;6?6A_15/\YZ/_X#S- 5[TS7)V,=HJ>^O.W$)K-/OD,F]"2EUPTL-?LVC
M4R^Z9>Y4-J8\TKJ>8NT@<4@F$![>@:$5M4%%LBO0Y3Q).E'5AU2JH1^JNG[Y
MF&T5I=T]7R3T^\?]N@GI%N%83L#5C/N$DT93%3WN"0O,W&:/J&JK''CS9\O@
M?.\OJX)<9/ZF7PN;P[J?Z"W\CVP:2G 7= H1A5MQ',"LCWK_=<'_7L+R/SPV
M%#N+:*TXR'H(!%2PU.F=.9FF8V[''$E?*B6,+XWYC5FN]&&NIMD&QUH-%[QX
MP[M/L*\I74/86REUZML%]$-V#T8$Y<V\R#).9IS9R?._E#(ZI/*$=/37!>54
MBB[/G,GQJQQ439R_NW=HQ8B&1/2_^%L2\ALE$2R7=?#E7G:E?2^D-GFE^5]%
M*;L@AM*W02]7*&W6\@,*2L]0*.N*+J4::80^F$RNZ7ZW1-C/[W/?L.6JI(*+
MQ9!FRS UM64R1O4;3_OMB\Y/?VG=G_9VM$V2/<JH_7-X_.7$0/_' *" N\3Z
MV_U*WV4'/0^!I>'" GJ32<JLZZG88[1U-TFI7F]MZ_9^TZS#FPKSC-0_J)L9
MOQ)^#A>G4SS8RW'5?M;%FI#BA8I^PO<21@Y=,P$13)H@S!)-<MD#<%YBN,;,
MT@/%4#WMP?4.0^U\_PZ9WXV>/FX-(S)UWN[C:F_\FJSNK+7JY8YA<X-GYB<D
M=6(#ST[<U3L7+/_>-N=IGHKWW]H>PQMMLQ^#TQOAO,_R1TUM3T^U^0BZ733^
MT:U:*H1)M_KV\4)&D55_EH]@W@K]HJ*+R(/;]QT:5*;SXMIM+;*<$!]L(E.U
MVA[\'R5<F@+'_E]2+M"_0WGE\]&#L(/00)KOS3%U"'AQ6KUR^)V?KVF2_*K:
M9)_8S2&6<<&44LW*"Y?)PN*\B?AEV31PW??,3-O/==YI%%AJBPB[ \+/DJ/O
M)5'PR1@?I4 *O /!S9(=TQ- R8PEMQ%X 'MS ..&*73QWO8O"\]Q\MDNPR7\
MKO%6_METM=8L7G/T[EW1YJDYJ[R=X[F/8;HX3_!WTJS<%VR"W@6@H!P]PL%N
ME??0<DLO?4F"4/E=$ ^L;9H#!:(F76+-QY34S,V8(81.T8YI,38>-R8STH(G
M]\$LJT>@N,JI-K=@K^9&1A;@08=0YF-1\C.8/2SXRYFIPEJ*V#+L.#+>F)9/
M7$WP5UN$JI>I.B(]G205:2Q)(=\L/277MFW NZ'E'?6]PX_%32=/AM\W4=QP
M\+=ETA\!&GPG81RV_119_ECO"AV_(DC#W-S)N(>YB]NK3FHWE],?KT&( )C.
M;;\:[8JGM^F_DWJ*NK*E+O0688\M:V>56+J]AVYJZ"N(*)4&O2SX[NUD7I">
M:KX+VC]33Z^(:='D4,XU@$R!Q6,%]-06I@4&YH$TE$0>4@LJ[SGS:%+)K#W6
MB(9.+9[VKC@UM5@G7Z(*GTPT[1(I(PL=)RT)I\,+1ZYS=>*J-U>P%$(T22!X
M-1$CU**+?#D[WS%E1I[+HN5='5>'\RRB>3\.-!UP*W'R32PH?UFX]/ KKN7S
MZ#TEE:+1.TWU&93?YA;;VPI3QG:-S3#O_ZR/^Z\EM>>)W9[4)X?S]W*?WG\4
M>3*)&\H//^2+^XC]PF=,,<IZ7YY.X=,Q'RFM[;N[UD:\6Y/6(I%":=L%M=/C
MD7D:%WP8(?:G[9HN3$[X"DT;N25;/#IQ,DZ:V?#O!'K@8-W+ F^B4'J15X-N
M:DM6_J*01H/_FR+BNSAB3UO7_KJ:VHCS;0;[^?.M*CRL4BS5<PP%0%;_MOY1
MP/NWH1+W4V'6DBG">8HVP+0R4- (YU]9C=3T:3I6?1H.#M?#VPZ7#^"#BY;L
MTC;'[,^_?"G163;RH/7"L3WRTO<^2RC,$IY"/A:UPH5N2KBWW5\B\4+-Q'9R
MAVUHMI.7BSI#\E_/A1_YE5];?W7M#SZG+^?3K;+Y^ZWL0<YM?K$KDAG(X@8M
M/)Q+9%Y!7OAVV&&)28C+J[V6=TXSW:[E9,K/=Y:RO'ZAG?(B[4HOS[S6=)LA
M3(Z3^Z;?0;7H[NVN9P%-RNLZXS!?BJX&8\TT)N2 ONXW#;OMOC?>@D_\S"[5
MU$6;OE'A=A316RG7Z8*#47QTL*4V/)$E]P[([?55#%@6#:[]43>99#;AHAU>
MWG9O/;L'*2M.N?SRDFBV!-TXI@E>V%F*M(</-AD77-N3?'U07<'<8O#9]<G#
MC$!ST:][MB@ACD=_N0@^V1?2 J(+KTCE>V6\;9$%#M#ENF#<4'T]K[*3(ZL;
M$L<NE7Y+BZ'H-+J$*-@?&>Q1J=CXZG3!JO2G_7.]0T 9TY/%JV??"8DA8KJP
MAQRICE"7F9?5=D*#6<D!,(;AD[2+Y/A[Y=OUD2O0.4+F!_\+O2>X%JB"?Q#M
MF$G[&94.HY@N^''8DXT)D=OAPG@KXYP7]RVZXB3<^S\->,@BIMK%ENZ[FKWJ
M>^O?I;[=()+S.48A/NQV]J%9$[=L$2&'NW&&?.(OKD:G7)VZ>B?H=FF^H/11
MK[VF_W\A-;@D B"OTIK,A^+:^8R^R'(=P/F" ;G52)0M'4P1;E4AJIK3BO!]
MC_!ID)K02)0[;9F<_JP) FXOX27$HH7&,60)P)ZN3^H0GI8:1:B;E9T--]6Q
M/.0=.M;G#F%)B\8RY. ]PE0.\$S 55>P!'@9]4"[!U,*_04BS!)F&EK2BFQH
MC *F#WJ 5-V7_.S=9YIF! ?#2([4$F*W/3L2?=M=3],P,4W7?RD%(WBF)GR^
M++D*UN*JQIW-F;)9'ALW(5;M$@FU#@98T.R*G/TAP]N[H,ES*4&V-]UOS,P*
M++?8RO>H%? )9$(E92*RA7D?6J<KGX?YBB(S*OA0>J?TQB?(Z=#/F3?25:WB
MWQ>5Q.F&LKEA3'Z4$^?Q,., D=,=KN<!*0X)B[3?!56'I-).SVPFM'#[$L<J
M\EFWJJN ;@I!<FD7=+2VQ,7SRL#J^I1E^^;:3>0I2ZK.1?]5F;K/OL[(E5N.
MY9A"GBUWABS]8#$%.X$@'\&5(;EFQMNHEM:#ZH[^30>8>LCXMA9%0(O<E=RQ
M36T*F3Y(!T<H5Z 4BKTWS[5+YH3+)H;J-FEW3A?X2B<&[M_8T W38NBUN&?,
MGC^1>L#*-DO,YOZK&UZF-V97A_VS3$S[K8O-F5K=]29&6.G3"[].:%]4Q/$9
MQ6=&%HG69Z2@1F\7[DP47#1T'8Q:O=@I8]6#&L*\Q=:),.%4#">.Y T%FR>2
MNV$^L&31J9IC_11>PE-1\(H4TQH65?:SZKP)XB$C6Z*%SFZ^.]R@&Y.3Z^0C
MA%NT&VS"B*..[Q3A;E<0"6P>^QD)R P!;SF!:=O67#%W8UJR^('+M.1V[''T
M<2^,.%J//> *PYIA&7&C37PT,_/Q63HU^0LDDBT!N%/,MW?P4:7*>EHH_4]T
ME4XXV+FBE1 ]?0AX22_9F)^U_(([Q'H02PZ@RQ90=+EL 1UZ$9F$M]S+,62H
MMGGVYP*@FKRST_/#NP5=F[L\AJ4E(9FM&?AXMA"P39SN(=F-Z$DBESLS_*/+
MD*%.31_'UTG>%2?7D^>PY-0B#K-!78ME'-E)Q" LQ=C#\.H*JDT1IM4H"$M<
M981_K@/V452.L=N=0O'GZ3H4^Z?LT\HX&HG,U49*(NUE!8"I*G2YZX!'#DIU
MI[B6)+Z4\:L^N;91E^OR\"I:T'7)R?YKBPY022]BW*_^N//1OT6)W0_C;P)3
M5)Z2:F!XR&.]D_3-+[L@$=0%0(1IRT%9(-Q=. AUB):43#M-/I+%U.<00B,@
MCVD"B,W,I=(J&,)T#GH[AM;2?'H0RS1!#[GR (;T1@-@BW-O(6;F&3(<SO,
M37@P;;P+.B#.H3!/'8F.\3 ^$DIV)Q)JB\X.\M-D*>XX7]K)A>I0OJ[FU*TI
M=N4@:)NM)*Z3:4MBC5V?:I)Z(-!)1R+/CEB%,.!(4VF#'4(YTH?QVK)Y%//
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MK 6IGG,TP4TZMEXL(\GU&UXLJB=\1GOM@#YZ7&4$]-'PD0(4V"XGKT=R9:6
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M.3"R>5'!//RHR9Y&9ZH1_X"V7&US=99\%:$JS8+Z@7E@Q4_H9&1_\"/.X]=
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MV(+A "2Z:&MN%CMIR]0&4AE2[60>@C1GE%BEGLA1!=0@PKTT<"3A +!.K^J
M"34KB#_!'\RB*2)-9^/Y.FPY)_O=Z"FO!!*CR59#JK:7FO=-6FLGL9)'$%>8
MZ>P,PE&6QA!!$^!C/@&.T=#AZ5W1&_ ]"V QY#$&["U*'O H1O2UNYP9),@@
MT&T.P8F:OJAO;6,S"F.HHTN-"H\#?;GCI5J/Z+F5>KD<J:S&.@ZKJMQEB0'N
M7G1,!TSX&#N<Z :;'.K< 56/+2]M6RV0Z>99"LPF-M;/EP "8MN);T:S&.^1
M9C].6'G:@V?I )?H=;2ZMT3I*]LF+*-A?0E/&/\.R-LWN$NWH,&7MN+7=ZD_
M<)L<:=N8DOQ5/8&C@O1B9ZHL0^Y)X6/158GM\-U +%5G19#1-2OX5"^,#NF$
M\1/VH49@U="WZN.I;\%_0Y[(9>T'KN!0_:D<Q0'"*<X@:A]P/A^IS(YDF4/:
ML0FFU%TXSB"L.O4)00CIU\_11_5E2P'G=K'O(GBH8Z2UZ*W$]MX3;V>.F<)_
M9"5(KE/4VWO/5T^[&;?04]NEP'P(DZ[#P"/.I,/0QL+=T,1]P'HK07$H2'EO
MT\!F_.[V1OV2O$7Q6MOG-\(DB><A'@UP+FX_24"W7E594>G 1JT1A%&MV4I$
MJ*YV!D<,5?8*-2 KP[@3W#\9DN)VLPX(G5T+?V82)#!-<W(P=!?,]BU=V8N*
M_Y?.!/B_;-FN[Q@N4S.D$W)YVO 8L)2>?I/>CP[\?IAR1Y=["LN/'C8$>>SZ
MK?'9P@Y(U"R- @*YV\P_HRAON+423@TA_2F"?(@AP[ M:"SRPFL@XX9OZ_KM
M\H7:B:P"YU_XV_@*28=XW@ON?D4AZ",O)%+[6N'1Y(/I\BFT#A3_Z ;[M/9@
MQ5*1YS<4N/X8P9+I_& 2VM"JC%78U4_!]$#H-]:>)M(2QWU(C:K+<1-]))E@
M9P!=V*']J>&ZRGRBX\#59]V8ZV4;OGX]-Z)K(]0+>@^QES64V)MPP)H^?\ Z
M]&/"8:HD=T:;SY;+O68$RD-629IO76FR,79EHG,G.6*I+'D@/+: /041O:/I
M?Q_N]3GSHOUMGT[(3+9C0IO10NG]">+#4^S=KV.49Z&-_^$&^:G!G]//1?%_
MX>7!2W"G TOMVQ:K(;.UIFU-?@XR%^[.<PG_ DE6/;X!OL0J\OP/'X\"=[,(
M$,!(XR&SYPR>5A=Q1G963;)JL]%KKZW&R91/W5[R<\V5XV;[^5/%7ES1\]O=
M=;Q^S\-AFVJ?49)U)/*B=[6R)7)XR;Q(U_JV?'6.Q4$NI:(.:91=2SB>^64L
MWXS+J%+RE89I-IG4;W$+O<9GH=5)AI]Q"9#9W\![X9O"5&@X1Y&Q]A8O>G5-
M-?Y;I%;3M*U1=?J5ECD356.FZJ/#<KP#'04 _D9M=(#T?:7]$4Z0'[R#;HD>
M__:YGV4T2YY(Y!+:TQ5CQKA8@\*VZU][T/Z4-2$HTHHGZERS";47C]E6&4\1
M9[N])HQBGMJSBJX(9'6I4TNE3_1(2IL\P:791#S:EGZW4>6M44=20LR]VYP+
M#@86I_8^OUS*.*]9P3H3F_$YV4^F<[AGP<Q9]%[CR(/&@48S\^P#Z_=F1EG-
M]#&6R%J;Y,DB\<@=D"<Q G*8L ?X[6]U@H5>XA.C<04G[>8:/-V'-M#"'7LB
MHEU-((*+C&+MOEK3IW/8-4'N;N <8CG7BL,$4,<!:">X:?U.Y6!0J,>HJJ54
M55C.A_XEW9")8%_"F[I[ 7&V[E3X?L"VL]%I AR'U'J%P%_+%-).HEX$0T<W
M%H(5+5QZ+.H:ZNY.7)]RF]HU&P-<H>JPA)69]QE!/3[ZO'4,2"M9V%!AHDP+
MLFO)=K=9U":T^X)G.LG[T$1G^&KK*V?/7?;6@P;ZMY)@OI09__Q[:D&M'XL\
MBV\5JQWO?DG,1MRS>M-0<Z0E; +1[!-3\S*N)14\ISO8_HGE')E0GJV606%1
MRI\G* A(V]@ZF#33Z[441A6^_(D\X]^?H"=R>"]M0U@[(#Z..A#,C*,GIYX&
MW*A'O[*N:(JQNH12VW489(,CF&]&^[",8SJ'A%3//G/[BJ$FKHQOWV 9,EX#
M.9SCB/"W#*^Z%?UX"FS/XB,L1E/UB*%([>L9$Q/'/*P5]EWVJG)&B[?CY'C*
M*G4ZW\2@KJ;N6Z7@_HIFJ$O5[P V:EV:$*]E@9@0K8@5,K96>[/A'^)^3U7%
M[W"9GT."_@1O4KQ2<[+'N7.RLB'46L&H+P/V9 '&05ABF7G;$>/A^PF1=D-S
M6QU.:NXFHK8\,3C#[/07^>H^O1;8BTK^Z6GL6P,P<4XK&JQGN7T5^;<J!CR^
M/0"H(\V<'&&)EB_V3Y#<!)^J!3:I*EC7CEJ\&SVBJNJ>839VKPSO5FU0$W9Y
M<!5QO#;!O:IN^S)1\\.#3!>#=-I7Y(,?N1W%]0Z<=V:!^;H6=1<5:\25@DYX
M#3V(4^B6[]MOS("]GI,H$+_0<_I\[8%>2@"_EHKU7AN]9#?>"NB+/.$7\<9^
M]/2X?%E/@OT[[:13KV/6H5?_T7O[\_G*@2/OI[GH0GN%_EA'[6.?![3_63Y'
MH/IW7F"(TVD"85]A*?_P48NS(I%>W)F7QW)R.*+_S$>-/< =7VV=TPGGPM@B
MK/P'YD5PX4L\A'NK#A?(-M7'3OVEFWIW&@//BB:H_G#IN/QPZ4S_\#:/<:Z2
MQ79 'ZOPZ(7BU?\M)+-.CD!_-48=V0&-7Z3#.+F/?!^)AJRU0;[+0_C1R]F
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M')$'8#3'ZG<&8FD7W]=&49</5YC*I0O&(2]I&GSXVLA_M)*=O0]*F(4POS/
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M CC6B>Q=]+N)U!U0C(M^0UU+_0C7NF*R]S+NYN=X$HZ/EBYK"IA@?_2, 79
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MO)&034Q(Q59H[F*M+C,I?RG=:2FHP$<W**4$YX2;KJ\8]GW=7)UU__JD:O/
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M!-KS8BA-$,/A S0HL&6*^LH9>B+W:YU0NP"AV1W0I/ 5 #(+V8U8ZB332W9
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M1IQK\^3UU4)\;Z(TNO4FX6\+MN2/$+YJF S+AZ$RJ"DFYG*X7UVS]^PJ99<
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MZYN;#'MK3&T(P%S(8U0_DSE58=Y7GS^Q^M-<SK]D]G."LN0XK/4P6A);*$S
M2AI= 71P2*F7R$7H>!P"1*9*\ ^A <&YT55=\LF4<!2;MV;".[[VA= 1B^:W
M8/<)_I18^9=8)<[MM_#U]/9$XZ[9-(0<,'NF[JIO_/"U&\KM]X)#*1\^:@SM
M:7^\<6>ZPHJ'PB_0$N(<:W Y*3U1%)(J*I?F!DH+#A:;I5 1#F '/TYR3HNC
MM1M*"=\L,2*JHW657-!([M87IM<[J7UZ:?22QOU_>5\<EV&A%T !/_#K]<C9
M9)Z:3(^RMQ>WC=QS&"(!W5QNO@7 NXG!Z5,.#+B?[<*N'/,A*H=>I<A,P:(G
MM3]J,_GARRR4(HYZGK7,VKWZXV/Y!UTGD2DX8XDI@$^1H2%D&TN5(L='ZDB\
M>BTJ#/C$..PQ(7H=1&NEJ5D0UX4PAJF;>G!H*-J]-]R"MF%":UTZO/2QH>WL
MK*N9[[.+:,4\^Y7%LV%-_Z*0C..?00^ 'E<HL5*BWT/5)Z..PL*<IC2NMQ.T
M8BMB-+^A:,H2&SY2V7?D0S#.:("BL>J!8;(Y76DRNA_5[WVP_G%(UN+9PNC
MZ/# *//^'GU$M%O?@?U3CTN[=UQ9\WB5P^I;B9<09BU[A&F[S]P\<'+ZJ'R\
M9*>T!'^6F)Z_&QQ@T^/PU<17C%2:L@PU<G*0X@2@V>A4%E(2(\0G1M=Z5[R/
MOQ+R*ZX\.-:5]7SC,N=+;WX<K*\;F(K\>:HOW"QR_!AF8Y;ZM)G,5++]"93W
M2*+&@O( 4;O0DL6WF=7[1E0PDX3P7Y"2AP:N5[?_* SU,^^FK+1\E&_4VVA8
M/'%MO&[4H*J[J&L:TUR5_]WF^N=.^0?'3BJQ6FGQ=0PU"_2-?@8\]5$@W0&(
MS^:8$OD6K#2*#9[S#O/*.J-D:V(Q)#P&Z'BGDHNX+:C%WN/CFGY;ZKL?=IVO
M.?2I9^SE[6DM%=Z_&#P- 7XE+80QR!+=J0;U'HBM99WX%53<![+-\;HNB6\L
MX"&HNR;;/D3V\&A,"9DV9ZI\A+3]!OP[YXT?A\]LK7O:.]H_0;Z?<^CAF>0W
MUV*B+%0,5@;8VYO,[-]VU,\A9/,E!*+ZMLVAZ;Z1NW]F;<[7YC-:,0EX+8I&
M@>0PM!?4?L70I.I "<Y^NG)<6--)B##PZ$+&)W-_ZY_'*(5U!<N,@-H'I=^\
M[^48)LW%$MF+C9<]?M3F5HQ[9V62-[&>-MPPDFG^BG>NWTXH&9AMQL,!3^8*
MY%NTW\FY0%5C1$7R )NZ":2W2.U:KT8N<N.GX. *<.R=F6>M]"/?<:RM[S-7
M)*E^&+\3IA75N-!PZ>2P_>;29=\B/>3&&"DPNE&W\*"O3M!%T/ 57MD"GX##
M-$$QH+$+0(!G7P ;]\0F7/?T=.4\7@[ZTK&_ES2#-11(K?M%[[^(V=Z2J]2:
M$%)TN$7K'Q<[U/"Q_]68:[PA?^7FRT/^8S"W2/9#V4+,&@H60,;-E55$MS;M
M 3N2JND*9'S+T):4*]D-'4D2)^9HR*)9<J$7]\?(KVL%%84-E.ZWJ>\N+2&0
M37LE:E -\!Z3CE\CVR$Q@>X"EP0]?JPX00=[-@FG"C+8>\LIIM$T?T',Z\8K
M_'?$XT!U5KY.4W>-D^E5OH5[XJ$7/:3I&OFZG/=\ \0\ZD"FWEZ5,QGV9VY;
M'?WV;:RLH&QY>?FC,N/EZU57;^PI^QU <M#+*"< 4F(3[#5!UDW<9@H.O)RG
M^92/UR7+<QJLTK#:@MBM9R,3W8"%9(EMS.-O.?UYQES]UM@BWLGA0Z\G;M\N
M7X5AL])X\C(,>1<)Y@D%F3'%$L:"[Z,_?'LJL5> 6:X?"F3&;>S%8J(O^@O"
M%!J/\2M<73L%C<#T?&%?UHO0A7;<K>CPB^&/MS1VODY9-F[NH0((!4%L6AI5
MH1.W1:(/Q8W14QCKL![AME_CFS92]H!^<4+Z"BCK?;_HJW-]0R?6@Y\J==W?
M'UXQKVW<KO"UASES.D74_:7?P6LLRWSZV_^6G6C)KV..YY0C2XCX?>!7F4*X
M< D!!9,&>2)/69NT@!:\FL6/EO5Y&THVX^4:#:4E8BU)1'?3.\&(H0Q%GQ**
M<ADJTBJ9"E.I3F(ZN_:GWI:^ZKN2])AVV:O>)00)-F>?%<<2VY@W:7)8;=@Y
M4$!6&S&%MIJJ Q-GA/C*$J+966)K.+U30-0B!_#KIL1@J5(,GS'-V$*?5@ F
M_4"7!X\@CQ8X"7"VY/;6B#"68K4Q084<Q[[<;SUS!T[699!0 &<T7QMD).-+
M,'+D'Z]@N)>@^;PDHA(VD ]+E65@0F98)>3$U5L%:MX2\.2AX@--A%WM7L!L
M<J3B.SO[_KFRU[(87[LC+QNJGQ-RMN==J:S\NYF5^<-#8J;@;"%%\27J1Z):
M-6E8K8U8E<C]R3K-&'PV +L]X/! ,[&*F1:YA!B.X2[JU8CM1O!3XV/I\D*'
M%HRNY!AT2X!1E5SJI2#AA-.0[)#^V4@#ZK@*2 YS!13'L:KZ. JC3R=^/WZ,
M.;2E+H-V&IF(TX;B^=.XB9XV=&VV1$W[ ,B--WOKG9 9 :NZX6%1Z!,0DUAY
MV,G<JH'2Y3LZ7J6>XUD9?K?VS3<^?3)>?9DD0M9]6^((58DM*([2NU3#82CE
MQR%XY2V"FS1A:0%G/I3?=AFM <]QAY 8)].2O>8IE\]/?@C_!*ZJ>02ODNW,
M>5CD. ;/S3\EH&3]5 TGVZ!CO9+MI5-B8R&AK9T.!>/3^ZMDO?@-V%]-DE%
MQ_0P0.0O3.6*-P8O(?1P^F0B.]]:FCTK<0#<1V8BF1^^#'/<\8K4O104R&JI
MB!82,G"[93U4$\A'^,Z);R^MXX3O1Z925Z6.(1,KL"NEAG_?5T2_M>7&14X;
MBMY*<UF!I$&FZ+7TU\FW#VT5_-!'97NI'VBJN+44'+0W0(@9:A=YTUM12PBT
MS)#:C=/_995^N>NAXOA&!7XP)0(D>DKSY[9AP\469#Q7MI&6[+<,VA^5%QIK
MX->/GF!"QHFOWA%%J=!/\2K)3B!SOB@5M'0V%+T&.YJ1ZL2#SWS(&-$-Z!C
M;":J4Q&0('#7;]/R<;(=$+[9;].+%.VR[97EU>)<\Z8J\;[G] 5K.*A.2*Q
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M:]J9>WNWK'[O;/@/L4#_&\9ZI$\L(:H2&, 2@D/5>P:]!(-:\C4 4JH$$R/
M*%(. .Z9E1("(*NS+1S-DQ>=J&C*7$6G>DTS6\'>K+WF7:NOG\Z/KM=S4WQ
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MNDIH05YC/$&WS@X'M1(1C2O%!R3'<H7S]*F%,1I2XMMI*B$!5:\6KP#1B=B
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M3QJ?O./5K*9>-%/G>\=][5YS[AZG7>]AAV"V00Z^4A+J6=>10+2:B,%P"H\
MW>DBA&4*(S1DJ3T;:1BS_ZPZR8#5&[^2?\\&:ZQ&Q:X:=3IKAV)\D@<U=+]8
MU6S!;I#YIT02WS\Q_K; )]\=*\E!%X=_SD(*Y#EMUIE+/H(;ER1('(J_@Y)
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MZ]H^^W;$;E$%.9AXL-\BU/0'1D+;9[$"84Y(I02#>6<$N,S>GT#*+RP$SC)
MPW\?8Z-Z=*/&\-WL2,>"NK*O>Y=9+CZ;$#W ,30)KP)#7KAQ/+CZ V2?U/R0
MGI9.1=^XG+K\ NR[A_DY1Y@[O2VZM-YZU,[>;L_E6+N\8U98ND3+'#*,O*50
M[/044__@8K%6_O,HD0V F-^4)%D,,)2""L$,KTT@ZP"V$),R*I:5 U^W\.KI
MB<QHH-"8+&!0.D91B23IS2RDHDAUL!ZE-1=@#:S%2MRTT99KR;7Z"2HH%>V#
MPOE;L#2Q:A_Q;MD,R4#"FX3< *.Z-?).<HM=+3-0.%I@*V[/Q<QW;EA"<\+%
M-S),'Z",QV5+MXEXV\G!\%B4NFU0$)VPSN,[I(M<RF>11R'ZQCFH[HU8"?R4
M4T*@MJ^-'P;(E,\65 THQ>/^B$1P_9 CECT !&!2>7M(NT<('H*"E8XV3,H6
M3)VT&S(2J)91)X9)VB&Y:RW;/]2S=:'[D1Y"!J@NVK?*5HQ,X<4V7:]&Q$^R
M!I"'((^V]9B&3*+-$\ND<EH;0J)"'I#V0@PP:&*RG,(Z!#5RR=)XL31$YN;2
MX\WQ<@&$8$^0WL%+MH:WHG="<JTCZ>5"N\.+/N#9/$$:R4Q0:AU9FU1RIIA0
M=S[6M]_6@X]0(H2?GZM\%/SP=OS>[QY7N656W.Y4-LP\NJA5Y+!&57H\&=_^
MI:]H <N#>[Y3F>F-FY2.MU7S5-6\V&Y=JWJE:MQ<U9J1K9Y;_K+"2G^($Q#9
MG+_@2SLR>[%2OQWW-WR8O*H_R)0'RU>=0?4V_#"JA5Y*U(>V@2.\4^!%WZ@W
M,6$=JT2H'#RSFOD2&B@BG.[=#FJ %O'E'-YN/WL^.JZ)W=J%:-."/\C@%AKT
M+OO8JI;@FI9S<SQ!]*H^R.;R1C!^FT4,=,*(YQ8L77FU8Y/&,$W0/3:XTB7E
M_A+RV; F;H/0)5"MD)L+LQ9%L32I G:'#BH "$XWI\I^1&C/26*Y)P,O,+9>
MX_AB7_>(ER'JQB6B''0*C&I%[!0;2"J0O8?!VTMP%W)9NB \G8F>V(+MA*PW
M+I"59PK5@+7[QA9D98CJR!P@[2,,?IGS90'4^&4[4T^:1Z](4S":ES1_[?FS
MQO[U5UNP&^SA+T,"UU(@9$[8V/(:G[)N?CHFB'_^VY%0RG!N@>%.X*G8QH=A
M*N58:YI\Y I^N^]?T!^.D:5<2FO#$A2'F$^\RL18^Q2&&G9K5#@Z-2B]<$\]
M=IPR,)5"R!T(VAB^W3':99@N[FIK<S4=<>Q^<7+O*X_UNJ>YI4DE?UTSE UA
M_MQ3Y)1?XVK<^;'C+Z\IMEE<SL&+**EEU,>,U=QFP&X+EHR>3ZF$I(52I"Y=
M*0@'KG$'V4HD*5_13YO/D09$E\TBTAY"W>I[\!Q8'H<TM'OU< O&1\2SC BX
M">\4EA[1 : FUBRSDTD'@)I).B?-Y!0V:HW\IGN8)Z"V4H>+5U?94-#&"8+S
MZEU)SQOE8E289S90Q.V :SGPFI.+CEU.P=Q'*D"A@-^/K)PW]YJ'6KMWX'++
MDYBH"FA-8$RG,+J".2,.7(0F8<Z]E\%3N?37\.P(;<0;T1 \3\9*P T-U45M
M>(F[LMFR*WBEOPAF3E#.+;";3T3 5U :OCZ.E?Z0!QK,9!E@]@1 V4.NR7X;
M:;*C[AD7$]Y9F90P+BF6*,RB&-Z<&C.!=S)2:VPXI"%*=Q>8"YFU(X\,,A83
MD,I >JP%NT4;35W_W-2H:P91^%UD[CU$G*W44\(5LB9<FA#-O3>50&OS1=(K
MIW^%K.6CVJQ/#"R='U76["O<F?]]E?52;(+)L<DB;WGK3"UZ4F:PDP7?\:6%
M87VI9V^I8<2GRJ<5$\=GE=+.79FRL@Y)O5J:D/FJVJ-&P],U;8=^?Y:!BT%9
M97^:A7M)L+X5+8NE)FGZ/GPJ56P XKFT> 0#Q:U$ROKX3_->+'(1\5I3\]I/
M"%$ND >?_DLNFH-*8&V#\""\G;0/0"Q0@3GN^L5[])1#KR%RM! E*^ZV9*OK
M@7"N<6CD[TR_&D(&UW8QEGT%D[@>',N^QMY!GT?S?\_@-W;@5:%<.W@'1IY\
MQ4<L,TXT %')1)T)9W8BHL'[/E,1O#[)X(WB[2&;"2.T"L%22)WG\&DJ,^5M
MIL4S35SKX 11("C]QEI]GD%?<-DX-@Z9MF_!E(ZP;_!^62/O$6OBW*!P@0,U
ME&1*1+X$,)Q%A<[H:^7VCR%>VS&"1/S*S+F':&47!.KFT#&7,'8+FUE5;X*;
M[A]<P<M KUM)2& P28C^#J)QQLV!J*3ZN= @#ND(4,@H@ZB<@.][\0J.V*H;
MN9^IX7=+9T<B^Z\ZAD8'1MX*M5;H<7H7[F:[9/[ O3JA?,<.5XKYS!5LJ2'A
MWH>_L5ZIJHY];1=KW T.3Y[LTF^S5]]=;IIQJSS@]NWPFAO]158GWS.LPC'#
M3JZ*V;HJ18?'BM6E#X\&G[%7\7ZO^_%_)[Y\5[\,N=:][C<M=\89R6$734VN
M'73 XW#*W;=LX[X[;:]DF_[#0<.,V,O>G-=&['D<37'V6;UU=YJ%#-$E>G?5
M]L$34;?.2%.6[R*##=<=*#7UG4:97E]&W9PW,L]U==9X@E,B=)C(;D*?%0&J
M"D-(^]W^0$M#)#]<C:OF#_(;S>'N.>> N?86VSD=M#NA!!YB?\\>P]G>U.TM
M5EG&6!T>$<]C/ XM#N#G>R]7BUDN>GI;L+"6DESQW=K[_^MN@O]Y;N-;'%)[
M,-)FL.D%N 5+(=IL2S?7"DN[-N$XG_6K0M^1PN\!K]<57Q].'=_)OG%*ZEWR
MOE]OL_ERH-ZF:G<B!C*&/+9@[]MK["W(V!U_]W]F35NLG;@^=7#D8I5YX4QO
MW9)W14&S^[U0QJ9L\A(/.BURW(+9APO4Q7(DE2W8TO-BL0);B=QS&8K?@CW@
MQ:-$\S<FJ2(194QB-BMEQ%E,'-B8WH)]X<UVOQ/'V]]=%.TC'=R"/7D%RDGH
M,UN6_/5CSQ9L%R8)-5U+/+T%:\&WTL1WS&]WB$EG/E=NP=YQ_FOCOS;^:^._
M-OYKX[\V_FOC_[X-3"Y"Y]L)-6HBO\W:4*0)1&D=UX3H ,X?P@-D?F$=/Q2_
M6K[YA/4=^_XR?;OH+)0D1.B^C09B^0YQ3$> OOKD@R@*GD(TBKPU@4]=+X]?
MMJHERB,H%L[5S5*7'\:8??Y7O )7+I=8&9L_ZU:]ZUW$I&,]J/ PM50S0-4@
MVOK9P\S]BS(=C_1DECSR^4>.J10GQ05ZQ3MH]*?]2!LH5]<OJ]&_F#_SWMC)
MJ3>VKGY"Z'XT5Y3Y;3M1N.@2\]N;'B):Z*+.7VN'RT,9/T ]I<3K0 F*D;-@
MLV$Y<^<>M8,]$MR!TF;I87QFR#*VTK58<KUZ'!/#QZ@1HMZL3[5VIWP@^+5&
MY49Q$#+3QUWT*-<OU<=@DC" *RH%>9RZ^BRADXN2_?2!&%@!E6[!KJ,HZVEK
MB3=MCY7/(+1%9&!)@%IP" +O?$%LQZ&&Y4&LK50P4'U&5_,#$8]XP)2NA#ZM
M(Q9^A/)JH3..FUZ2$9MR:<O>R'WDB48^>@MFHX7Z!Z=KWE$8U,^W"*":ZPCR
M<2_M-PA#82JE]RY>?CIS,4O#(_)&?Z5L;5A)";0%>P'4'H_E#-5GE2X&]N>N
M!KSKR\TMN%A?K>KEJ6+8JE3VI%B#5I"+GR_?<)U%J(CTP,;V043=&"\YDCY*
MY;#K46VHG3=0"J2#?A#Y''2*3QX^/;5Z"]"+%QT2O.;%O0@@3+5CY%;&,&[0
MX^SQ?4#P_0AZ$NG(LQ>O= ]"GB5C(Q">4R@3N 7;/@C]P=LN/DI$@M()8C5"
MCB#@>?135#S+ !I=?;59CC0D1 FRTX34$1M[J ,L/P4ZM)@F(>0L>!1VW4%4
M/3PA KN,2,YA2RL+G'%:9>S* J\^KN\]*_9F^K]R6F;XTZM65H87*'6$,/L=
M20_<6IUN%TEK.!F6GFPOF7%251%:AQF&N)>[7KC=>0.=EYN^__)LHZ7ML[I0
MP8$=7MBWC9J-N[J<]IB8N?_\(E^(2B-J;]B*>[S8TN2PM#-M6N6M=C:K69M/
M+=") 0> N''5(69@%"!\$_X7<1M ;MF"Q18J#C+](R=JI-JTFBGW2X&T)U!L
M>U/4+Q&;:*Z,Q5K2O,B@+ #3P8^QI$"4#0OQ0(#M9@9+3G04B*&]H?_"TR8'
M=R.(QVG\@,H2D2>XV Z7NC&^!T#<GX)^)KHAV97$'9!;K8O0B+P;RN#V8L6[
M)7XY,NT]=.].!BY&F.+G'R;V5UZ6^R>O_P_^:[?*NN%R$>-Y.RTD,O">9_[^
M2K=T7968@N;\Z8U=59>S@MP_?'+#%8;Y=DK+V+=P5#(K7?-KW!]DYL]N8#VG
MIJ;2,"%_?2W2+S^8A\Y6$PU##$D&? %+<B.;V?,+ A2, '>#C('R52<@>+ZH
MBC"-&S^$EX,X$_2%'56BR] K 2_YUO#,L0"H1.0*+.3$FMO,?#\0%HE7F<,)
MY<.YWB-W:IYBUP?S)8A';K&U]9Z@)I'4FWI$#OP4=D*N7@=J>+$]M^MS30W.
MFZQ ])] _8*0$1L2:GD>H%TUX=ST.KO-5%<\0E.S=03Q;8UIM;XS7Z;7AECZ
M*5YDY3\+-:C+U'_EIYY@C4FGBP&',XLL#ND9AH??SKQ1&V6)?O3^^).JEH9^
MG"?=TR2D+TS7/W[UMXIGC&+]EU\J^DN>%*M[_.7F>??B-:W"]XY&31=G3HOJ
M)T@1I%[V\QR)<D]G(TA'<(.KB.^Z6WEI9%GQ#M%W@[9D.O2Z'23^! 4#?OPU
M+EZ1Z XQ^(M2D!P:NA;)KPF_#+VM@=+,*0.?Q<8$]V[.6SYJ!Y3AT2O"F,0&
M\_^PG7+:3"!CK:8R3D$9?-1PGH#*H>]B+W148W,]N]O8R>-[0,R"O! ^,M6^
MGEUH:P^&MUD[O.ER)<=Y/1/)@U-<U*ZY7'1L$<2HG+DWT)@06H]0&9M^Z-?)
M1PW\*Z3'<DZV>92ZI@93_B[7:#?*42C)Y6RZ=;F:'(^;2F 81%ONXJWUI-Y2
MKS*8[ ]VC_0_@K;]>W0-Z/(9O!0OK>GDEAF(64LI<$+[WLZL&'GTU2!\0TK<
MIWM@0"P3@M&,--TM(G\0&0/% D0+59E@='&S'H6EW^^:0%/$QZ'GP0)M]!X'
M(3X6L2MB&(4+1>+C<E$/D#K$'S'INKNA.ULP-0M$ DD'-$US+:K ^6:U%S2"
M"+',&)C3GD'T"C5K(^\VUT#NQV(:7/-"\8&5!!K:3X:,)2L1=2 7OO&I<<3.
M,<>@*&!IU1QR0\49'_Q 0^>X@AW)M;963]X7[NV9MPW6FZ7\J[YMX6S37GGZ
M5C4E-K:R4Z.U\873TRFK=G.=Z;Z4<.+XN_Q#;NUF55/NAE<E+2<P/UCS M>9
MEI'K7H@8L70]FGIUMK*J#GO*;\0U1'<96]'RA9:-4=^"311BE"+)>R\3NOEM
MU/L(CI9T!WD'(?8-><<R8L14.#7_J/222 T*W_A^!K$-J>OC*PK<I#$5GT)+
M;\;- #TJ'OG]G'5P M/N\9RNTH"ME" Z9D]H^'EFRH6$C15+ON4OR^@$Q&Z1
M'+ %XXQK]!(U2PD>'"W7#/4$<Y<H;] KK^0R!Z<]>^&,8%'1!SM^$$SMG;T=
M<'D<ZN0.GF =!B.7AY '0!7GFI"HX7\"./6?&59[WLM&,;7T;-H](%/_[+'X
MPGV'BW3/6;6,9Y9EY"P6H$)-@C4O9EX,TLW5"+D4DA72R^E/K79R+Q _';G]
M,#/S6O?"@9V]FR.T%Y<;4U7R;B\;&G63_]7OZE[:@G7_$3. ^NHSL'!H"X8,
MV5PF?\6O!$^23S]AKOTKZ+ *VH*A]JU=W()-!O[7QO^YC1 Y^C;<4/:06A1"
MC;6?T=RO[.?Z?%ADVOA;4>&)9#>=MD;.I;#O;Z>V7&_,-GART];]8/+3/?\K
M;K#5C"T8315YNW@+UHF9J^,YT^^'U\[J'@3_+K&U7A!,B[4.7G7@F^[I#,<%
MW](\*&KZ]-RDKK:D8K_9S%"3T_GX!<7J7L/2^+2R1T'7RC[^D#UH'5G:G)95
M_U/BPH+Q/N?H&P>V/U32#SK7K^0ZH'FXIC?C4P;._HESO7N]QY+CP8TL5Q,%
MQ]>=WH<;PC-N9_AG9-SQ5\WYX4FRH?/_=W7'Z\T*<A@^D5W'7D (:)0O$*9%
M';,S@C:<P=$UH[9[KS9M0%0.#8$\C-N"(>JI<8-(_>C0VZ..KR!OP0)FHB"'
MDX$/"BJ'"E&)WZZ]T]SNVS=C72.<YE5D\5'*J.OX^S1-=4$^69FX+4@PS;(@
M'NP5[R0Z4RX,$,^HZ.Z' HMF"\V&S/V_.WDD,OI<A-'" 5\H5M#L=Q[TIBB?
M ^,32LG8&!S=/OS)C>/8@H^R'YTL2H^$RG@7&Q+SGS6:7Z[R^%2I_4[&527+
MP76AK7\R=>A QN67383<S(>M VF&SVF6YGF3#U/U;CCU9$QFN=K;&%6$GV1=
MS?AZ@$,#W,;VK[46:@Z8('<2KX&X66M2"E][$4$P=86PI2*C@2W8C>C%^P#Q
M&OX!2QNC1?3O%1_P'9\57&+J%4,\7^"*:%\?T8.,*X*H@M*4CW.6@[KA_$7H
M"/I-XLTM6+ S(H4&%UT#PCL0")8V40G*%2L/B?>+WZM_(5A*G,J88\N)3@Z&
MWAP57L\"I06%%($\QJ6?L8/"-^60-0@;K;IP+>\DEJG(!KH4V67CG#%?(+6J
MMYDK,A7Z*W?DFOZR$AV*YKR8:6Q"4\JA/%!"D8/P="QR&X4?24G]!%E6$@1+
M?)TU[DD68K2-?Q=Y,$1W5Q,X.5A8,D9(C\YY>.<=0)LWVK"&%%D(]H-YL1GA
MHNAXC\B23Y.3EUZMV*PR9^2TZNX>7$$K$(S>L$R=T:F@'A=/&9=A#T7.D7<2
MI 3[H?*60J4>BX4H#E+GPS)O#\ZW,"MR>H.D6__J&6'84N/DR[<>#VG&U]R-
M-T,BOGID&9QVRF$*HUP5XRH%)_WWSHU-M@5ZYF>XN]ZZY5XB-(H)4/Z$]4Q]
M,HO5)(;G%[NG2R]$;YPE.D*288Z(+@#D>)JD50P@S44'(-_<8"XZ89W7@1M3
MMX=B01Z'+6M*],%]NSP22B>B0:W5)<X]9N%Q /U I"F\P?1[:OPYJ3CDGM<C
M =;"=/<P@9V FGC">7.<" /4%VPF7,YPR$IB.VB><*"EZ7T>JI4=FR+ P95$
MMUB0'5#<S@8Z>7O9-^3@(QNMSPE?>J=:Q*9#1.TRD05$JQ0=[6,Z']$]/K0O
M@R,^:(T:MV:WX"F%^X#:^(ENQ9GUM:0(A#SQ1V"J+525Z"*DZT(IWO7@4!SR
M@)_(&VBH$A\:9+K$"/Q&$7#"^/OVC;/ V"H]G)^&.OOL&1#3D(:(O1EJ_NV,
MQ$3:B^X63#);B6@!!K?G(E),F%@^EK47C36A@$&"J5C;8S7L5KAN@ @-^;)L
M(/($6X= YF_!N"^)VT ICWZF-]^9G,C2 %U8*=6SZGT^]DIC[Q^&\T$KWR<5
M@F<,O0V1O8]7J49[5;GASPFZ^=I5Y:HRT4X9GH:##T(4+^1E?@KU3;#KC[QQ
M99_Z?,4ICXI)_?#V,,_R@Y4O+?4K6DU49MXN.2Z=TN="O7C(X$Z10 :ITCU!
M'G86CK$?D(Y#04)*HJT5Z-&6PZX3>5F?_0W .?0N6J"TX0F#M'K5\A1;--_&
M9N$T$-+D^:EFPE1M5LW7QH4O;\D]BM.*^8*?XP$7U!"[B*%"LJS$]455,ULP
M>:02X4 [39%DTP$L\K.Z6\G2$+M-0GMLY<&JOE9ULNP*;:2Z!:-F,4;::)$P
M=AV2.5YZ5GP0J+T?*=C4<^YG&8UWE>*&O'B.(9CGC?.+E5 P'Q/[-W#]5;G$
MA?4!AQA0)$[BQ22>JL@TL@1;>+SQ85];T\[J:@*N?=WUN1"^FY [@M;S!QI3
M%T6G^&->)VOB/^=8#AL3"Z/=-F/9UW5<+' ^1&VAC9TR%_E=#U*;0&NU1G0@
MJ+I[ 7@*TYC/WC'#WE._$\SA=,-%Y_MLX4*X"E9W5T^$J?PEP@9W'#% O(LO
M@\B<G@Z!V^'8$L=KS%M6JA/CRHJ[VMWOI*HZF#]W_SES['Q8'<%2P[SF],G$
M):>T&_ZVS0EX+$;Y=)B3]:O;MQLI#_)_*HKO1?AZ/ Q;*5![4M67_=>.(9&*
MZ1NO@'T@*^,N@!,&%$AFNFN.5J\>N]R=I#6V^ :^6V0%=DN4\/4\M.+L%DS)
M5O/QG%@/6BJ^#%U9(%KRX<I0N0/HW=9LQB_GW(TPEKN8YP6RJ-'7;@4A'F$Q
M@!<Z5O<P<(<BA'\GTH%F0$.[,^<VBVQ=!/*F_-KR#7-HP1;.AP\GD52Z)59&
M>&E,BPV'682,R/&)ST?1=<!B/&4+)LL1(+@Z'KZ%7Y9^:.Q3;\L.Y:\M+TH4
MFI58ZN,L2C.2G:1(H K*Z&!*.P_!=/@YMS&=932#5 >NIX!+;9;6JW7!$_!M
M9T 3"0_&P%G[9GRO9K,05"&5$Z/<@E#Y'+I0]NKY4#VZ<6R$70GA5O4W\VV-
M0JM; B<6E6<;=?<!.>VF4KCUH32D*?$Z1!$41'$PB,>0'PX,Z_8%R536]U!.
MFW4-+\68)2LZ%KL1L@6[]')P69]IJD7 N?7D7!S:6386@(AM'  C\WW7BKMV
MN?;/TAG)GE:7)YW08^6'9]Z6[NH>/E@Y=7QH-'"F?/4:]IUE@1XY"M[Y9[%6
MI0FVO2\YS)U2'X$*1H_D>&T6B7PV[ FDSHF<-%OYQR(XE$O2@8(%TDE,-V!]
MHW4+IOJ0#(,0'2->S\NQXKW@8;J0NJNSZD:A=0]C>KE;D6#K@.6[!'-R+'.?
M(JWSVA%[B')+K,:-BZ3^$=1\O 1Z@_(X&)ATV^(O/"6QZ0W?<=I>FF(827N&
MI00%386XCV*]%L*O"21XLO^:,T:ZXZG_+&I7?=?E\<M$!SP<BL ^EW12U@B@
M/K\!U/$I242RH'O;C,21J^4@TG0//>W(@GB?Z&P3P"JZR\?(W"!M[[48LVRQ
MIJ28VFKR::HT&4(PITDR;+C<#2W39*9#:-&,.R'ETD#83>-R*J=/++.X<9S.
MH2=B9/ZNAQ;N3J"2Q[]'JQ!/]ZR@1N56WPR$,=V>YL5<&77+E2"@5DX'CJWD
M$"PXM]+9#I;]%EP]BM6U+I37FFOWTEH8HA!1)QZEV9[UT/KLSNF_>/?+UW;:
M,\_2D&/)'?9-+R>O>;F&/V 6NWVI/!NG7F=>L+>MU\VSLHGY^Q_O2 -]WA6C
MK6_U [7"<MU2"S(K:X,U/3,^&8I'V/7T5/%W;8!?*V]/S7FD"?16.(;[ :_:
M#4@+*0NHH F:',&AQ7<QU6(S6*Q"GI^++"=Z@.^K*P(NW0C0Z@N]:4'?/:UU
M4.M3J:!;@9#T/;# IC =TZ(DXDY^DS9OJPI\PN\@K/VP624^#+U?XWO'L_D!
MI"[?1DXB,RI2@$XN5'@-.L1;='GPV5QR2M.AJ5:\'*%JU*5PS256X)W*S^.L
MCL3'LQ@UE]MP%7.*T=UIY.OP.)H"41W8>#-N2!7XC]%:._O[F=*",4MA=P=U
M#S'@0^2VQ[,LC:9F3/JX%I110L3UUT:2X7/WRC($F@PR8A8N\+-IH'*E/;[P
MCZU(3Z!;\9 ]2P':C]AYZ2/D/&%2/K'@QU>G++_N\G/LLU6^"VQP&@N5@9"9
MP?7K13<:O:SA%'QM1+6+T47+=;_1^M#P8-O!U2]M^4;70N)W72Q*JO3*GVVJ
MB9:]4'VW/Z+T\*OG>Y8WLZQZTNY%\+&N>SQN1YIG'6D9K#GI620;?G' ?//I
MI&M/6=59@R\] 6N,_!"GS"FC=C.G$Q>@;@X*\* F!.S_<'C(!+F#U%NHF><.
M3%$8=(JN+@A/8*G"E8@_#49NP5)&U-^H Y:_U"_ A7L:5:G)YNA4\<%>HGSU
MF,B^"8 _^#LY"EQ-$FP&\\\?)X A<VS 8Y%"TDFY'.NV64C&M@@P%+$RU"WD
MI;'D*6>A X=? 48M&-@*6GZ$> Y43X_<"<T7*H 73UBCTFQU!)MP1\A 0$V1
M2%9,@L@>+T'D\93*N29,XK*=\HP.>M5\,]^"#!\A7%_D;_[E&Y#'WZ#+8Y6P
M+%N(6HRS5HWO;G.1$Q(MQW5 $ZI@#JX(17/746WTW83H#I8Z6)M4]9'0T8K\
MOB=BE"XWUV0]<D;K0^\6[(KI<)ZC1&$G,BWAG$V/"W4@E8-.0>P2!5424@3>
M;1A5J+$=N1,25@WC4"KS(G\A71GB>8.-R1:+JAAL[I6WPIAHKA8E/:( Y=*W
MG";-O1>0<0T7I#;;<.K.9%P[6<WK078RU=08%2,(FUJ==<CPE80I7K_)K*VW
M:_52OB4@>)4?N9KCGC>YJC;9+)3N*K6I],@Z6\69#/46R^X#7438$@+Y].:O
M+$.-(^0PE KI[;UT*CP1*4O(D8PNHAF^>@WZ"OZ.(\OI($] 'IQQ>7!/AL T
M85RZGWB)="3$-SCN*7(O(7EAN2#\$GAFSDN\;;U8K&TTL<+FX'^AJ3/N"\A[
MB"<W'U]ABMM [T3S,4O7/I%T3!#0V8Y2/=3+.FPP6/+R0]AD#U-*4"#;.^=
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M,^W$!D5_%/;1V-7EG#6[HM1(6QF?WDQL'O)Z\>[17]PN&0K:SWN"VT!R11G
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M$9.L5)P>A)>&C!:0/"^O;.E,0KR!TDYP)E8RZ,\5#+54/++DNS9AK@,RR>B
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M_K*_.4&=DDD86968UM<M(]_KU^]8C55.*Y*X&B)U0#Z/'L,U:51Q=7BVXYA
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M_X4W*X W.^.:2I+"[O?)>%]E2F<,LKW_IK]J^ROL@L/"@,>2K6PVBKCOKXF
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M/M76#@3\JBQG:!5_[)X7RR2IU-C:1.F12_N+[DW<&02QW<])__H0!7G5H4+
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MK9WC%OZQ]6$<'TQR70SDL(CX% T"0I4+282PO&6.F4)VC3=,+TYJK4M4?*M
M%_NVU&QCMT"SB5]HI8[LI\/6W-B#G"H SHSX0TV57V$DE5H8H U<HJM0CD@E
MT^0MSK%I5UGP+)+]K2B$%8$(Z%QK& DX"KXZ2G(L*76*D3RI*![LBO?I..-:
M99U9'K_US3HZS+;SV'F-4@>/4\B!DA>9+]R>OMW4<CCK6FKV))M\:J#<M4!I
M\IF.AT>X0_07Y3\+M$G+SO+'U]6-?:5\<+KNM8QGSP(O., G]MVCR K4D2:+
M-"I1A><-I%?Y+Y-W U'T[. ^M.%D;1/X"%#\4)&JIM90XC9EG/A"1&^3O$N8
M"/S*Y([B3CI^Q:N1&AQA.7CI'^HIXN8<"R,X^$(4!=EQBXO<W<A&9M$[VHP)
M%;,'L_C<56H/SPC7%7 *>!K#EJ7BCMSEF88MJ+)AF;W?B57+\;&)(F^@,F?I
MZ\1"%P0S)!/L6>-3RLZ=3 G+^%&5THO0Q5P1]Y(Q(= ,*,N%D@HGB3R -,H&
M4,&+Y&83O&LXH^VJE18PQL HB'Q9](X6G7_I':7Q68!YQ[B%,1T[DP ;TY@Z
MSOKZB.C;RTB0%PQYCKD-47XG4+VS](XY:ZJD==OF2+I6N1J=.UMEQD8._&6V
M]<H]*<S:>'FBW+7$+1-KGIQ?KI-D.'LTH^G,S=#?U;UD5JUE:JSO92OI&EMX
M*!>\T!1O,]::2!K+A!45\^K GY:HPVEJDD##(F0_"@;$$GV0Y>\P1SH@+X#A
MKH53#8Y_U<50))%Y3BT33>'.1R$W2.1FQ0>*]ZY.%DTVMTSF#(4G(")BY%X3
M N$9&%9$1":)J(#ITL8$+V^W3J[PM.I0/JR<I_<NXT(>*EX%\(SV3@,)0MPM
MKW K53NNP7CWGW9J)4&!XNF5&;XB37=K^SWO8D2H"A#A.$)",.]EZC6WUB\
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M8CJE*6*=PJ8LSA?TKT^P4]^9+:53PC!JJQ@YGGVYB *N6$BRZL?ZH&)-8%4
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MV)_Z@9&$+N;@0 +5 /0GY8\OV,.<-H#$P,W".3?9L6LOV)?Z<"I69T,P,JC
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M!(9%"0R[F>II?B#8E58Y1607':JD'GPB\40VMTA2[27)6_%-:K)O^>]C&[=
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M N,OU@#3\=(SMY.?8Y [1_%R\L>IKN$0HU2[]=*KX*Z4YE&<&>.*9IA;^)4
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MXIP,VR/9Y9IU+8@+8[(JN<&%ECL])Z9X:;9N5[_O#91J,3;9:W5QM,AQM,1
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M.BG.."2 GB+4T+X+6">U3AZ$P\'PM@S72V1%(F-M$[U<P(<)Q5*6F0%;-E1
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MLKO(6>.^YM@S$. )RG+:#!%4\6E+=MJ<F)ENL[H&E\>/(+4&8]IHZMP#;9]
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M<^G:&\B$OYTR!E#M?)@@&,Z0IMK(8.T9\+NXJT6NB^2#K*Y[S2:%V(96GNH
M(NW]JU&<$</CI^^7!\):U%91>6.7AQ"!59KB<XD^GKX[*_*;(3^VK+.EAPMB
M.:=P1  T^SYXE!75.2VT+EZ(LP?"V_BP1-Y.%O1*EO6CV@ZOA11!$D:=DAA;
M#T"W-CX86;/RL=3U/%8S%&A:4.AW6QE1^]&C0[JA7_!_6K**I[40TO5 4?+2
MIPV]&<;Z_^SP_[GJ4)*;%H( ]AFTYN6#VVL.A=*QH!@(8?L):R.8OU/IX1$2
M%((KW"1/<2@$2QXN%E7[C4$A&,[K( E!>QCJ#/M7P.)8K!IV.2BSA7*[B#^.
M9=K4C;9[!C1$K]W2(1WRW.V(K?>];3WTL</P]<]H?[%BS*NK=UL$+I)B4I:E
MMS"\T4<W"3=2XLH 9WHZZQ2A;0*\>YPWV/PJL\<^HK O#!-R[3DCU<27@\@'
MRU=IEU//DS[^F=TU.GM8,G?NM?=3ASBXRCM[]Q]S$1[>X]YYW;$69:-=5@L%
MECO,Q.WL-B+LD<ZZS+W9ZNW-9/'V&^-4SSG+M,L95_^88K=$AA)?M9[U,'#H
M<J+:VVZ\R4*9D=5QP: -8&9F.-TA=M@7+UZ/G;(TLNR)1M:51USM44YY-J[T
MX64YV?9)DISJJ"X?YCI0?05_$TR"0&]QR\S?U2<>Y46*SJJ4O5/=%"RZ[6*=
MV/4T8^?IC[3)VLZIP3E38#+G]_FJT@4IP$^VNJ%LLF//>7KIM\L3[Q8I(JB9
M;.+>T(!?L8M,2H+Q^:WS.+.FT*9A'3%9CRF]N%BZ0+:A\49# VTF>>IB$C;-
M8?BFIM>5(@_9SK,O[HQ'%<_3M,D[!M>2D3T60R=Q9W5:'N46TUJ]KOH$P:,Y
M3@=%W"RO,!H:8@6%)$[EG_B:WX*N_@VU3]T;-,S!9%%Y7M\CPWX[;&":/V(I
M^N1<<-<-6VM6T"E27)&1ZAT[FH+/B/[0 YTNQCR =SD#&#A:7/EVI$JP.5BF
M<KY'(/-=89;+G;TF5SRZ%IU'\+>Q<)[0GSS-L2K>$=X811)R!SV=Z),4X-'$
M0F1N?'3HTA^Y2P>7DXM)$;^^,OEC.30[:,_\A$VZYM/3R;V;)G24(-;^;99\
M25RS-+U7O*U1(#&V;F!-5'?(8HAA=$ 67>/2(1$4K-89%_5TYR?WTRM9YH<S
MSBA)?G\S+?&E^=Q\EU;7<%G<\V)IQ'-A[*4:0<G"JS$]P,NBF&<%\/ LB9;"
M5/?O:<,;JX$R[TY+ZF7,8(;:G9K:F8L6V,HN:14?5<9+\*ECA].MU+G@=+2/
M-/ZBB>]V.>['RE_LFE$;D:WQE;!YL^Z?=BV7;K,EM8;BZKK^7VSQ_P]*=W\=
M\?]6C/Y>(-HV\D3._174T@T6D5>T.?M?([Z^2/N60K\CYLK2>Q"F;@7_!?B6
M5KK8.$<BJ+5Z%?ENFN30XDK*/#],G]3-T'7Z_NF3Q?3)W]J_824Y/WCOD HC
M?-A,";Q!.I$/"R0]R/+HYV;S83Y5OV+5V3Y 1EU F'Q> T->@;ZRUB?^SLM(
M[NJ= DMM3[VQ:4P&2M*/+#Z0.K?:TQ9R5KJ T.J /PTRF6/ME+AIX!)\G,$A
MI2!_GIZ7;>BRV3\ATE /Z%%K?<,J O2NI+[+N++D,Z0QR\I,7([N"$;%W]0^
MHR#9;"-=5X%OQ0F!&C.$\6DZ_!YR+\=@*,T:R+Q;JWY'H3W -J1T,C J%^TY
M/(DE7F'M)@7?J?(;VRFB^_S.;U_+9"Z.F7PSW;*PZ.D^@ZZHR\PHY71!&5BF
M0:I+ ]U,QPMW#+;/I8*E<QSG/9W58B<)-ZKECI7H,X/[YX(C8B]I*E3I+7D'
MN5;[=Q)65< :7D=5.!]F%>XX.*;#1/T0YT"A=FVT"5KNIO+W7/UYZ6>;8K.6
M%UL$^PEJKO^V*G-U*S^$0#U>IQL18@1'#XW_62#ZSSVZN2#4Y]_Z44L>+#0O
M!P?WT/GOY:%G^[+^^2:S[;;/YQQ$#0W)J*5K-=MXT[8^Y/P_ZD-_K3JV;I^(
M,Z]C$IH&J]'MWO^]/O27NN-35A#G?A447X SK]A5=-O"_;TZ]!^/)?Q].H:P
M:K%=&1X_ Z!Y!9$!D9+_LSQ41=B'9D+71^'PZ4S6/!\V5CZ]Z;&S'SIB].5_
MV<#O*3QA1!''CU42AQ?E: (J2Y,L&W8R>)R)2L"4XT?R9,#S)/R';3LR'<,3
M'.I[$!H4DW:%-XA6X,&PUYAME$/->/*A0;R2)X:VD3#;!%H]PYT%">'T/Z89
MFD0&Y/BW/ZHWSGT&X15/2&E+D?<AZW8F$Q5+J1/K#/KHSQSI6^J;63GHYBL;
M]YPEB[J?MQ^8RJW F0)?$O!P?S(*<(ZK-4(?P+F"H=H>1@R;!\8RS*2-X:(T
MWO[")*MA*\K:41,8P8#P(J4=?A?R9X:$5E5MFW$;5P!?58[O1@/600]1^U!^
MTV+@P4-5.L1Q/LQFK#8(\EN>TEPB&8G)V*\Q1@U*D(WO1,"P*5<&D:*<<U;P
M3JM2W DPF>%_1]*>*CLYP8>9/OG?VI\/VXB,%H!$!(KDTJ DJ+?/-B&3[E.6
M;D"1/*S74?LWYMVN())^B&_?+KSV(1J*D J+;>&!W#WYX+9,G84.ZECT=PH*
M<:*LZOM3V!I8&RAF\[3^#WOO&=5DOKX+QQD1$2$B E*C(M+! M)",NH@ D*D
M2Y$,(D) 0 0D0DA&Z7T$@1&02 <IH044,1%"8! 1)!2E)R!(DT0A/)K""3-[
M[__L/;/><_[G/6>M]\.[5OB6POK][ONZK^MN3VTV69[&WT.=^<H-GS5!BF.D
M6"V)!?.C-@/0'=(/J\9@A8SQ256'D0+AH?6FP=(V)M<U1JZQYT!$!%#&/M9R
MH>!M*H78O(PQX)'@_J^M6>94I^F&S0ZKSZ)H30HJ#))"M#9Z?R;:KND>V]0[
M%UWL2SC,.OV\>+Q;LZ83NS];^(3SQR *9EGG X&*3GD>4R>^KW(CGR9SEJ0J
M(=)UZN9+[SM1%YU,Y!-2KCU;/)]E2,O1-QY&V4BF8(70\9GS"D-H)#B=41VN
M5\E#:G6,%,<5JO6T(Q0?>E72F9>-]V=@B-YV)>7R-EG&OSRXQJ\%%CFA_'[D
M=ZYKEL-<)]()5NDS7^>7?*'/^JO735[ORQXC3H1T%_OJ'/6-&?E65KRK[,@#
M:_^RJ1UUW'R,Q19(Z#M>G4AZ1^M%7$-0^^JY0_ZY>1[MLY/.UK]:-%M93(DB
M#EAI_=)D[^:.DL/=6Q^/N>DUJO-+!K8+D.1(<4$\?/8@IP.[+]F5%=90#!%(
M]-]&,1=5+SW$VV1;H9M6A5J.G1D(Y9T^6VV'NM[CM1&KN\J7HD^'Q)T,6DWI
MD-,YS$ARJ#HOZ3;<B\;FE]^EC%G8I+IWU'JZ&GOD*PYL@>J>YL$WG^88\E^]
M1#C_PNQS?> ^L\&^$Q=I=[QKM,TMUN_R'K3<R1%:?ACL *"ZO78#$&)FS\,E
M_,>N]%.G(8+X%MC*"N^T5:K9-^1Q/MNMSX22\; I&>5ZVRWAT\;1$6*"SCYK
MZ>I:&^SBCQ>&;:5L)1PE),X^.?*SE.,/.P0O!Q (M",I3.JS"^E.OL^[G)0W
M(0I.7@G#9R_G-N2KFRVO,-<=*^B5OC7G8XU#BP=W?ZNN4GEU"WJRPUL6*[_C
MG+D:?;'B574.MXW@.%5[I&K9J6W)(<>E[@\O*!<$^I7KVT+Q'#6,]I>$[N?T
MB_\"QS\ \G^>Y?H31 K^C!Z)\L^2] 0?R.C? ET2R,-1:_<WL=L^*8=[U^,C
M\$E<K'_9O_#]N[]4X+??_Q\^[/M]V?^-SA%"'WY\>K9E%<4YB8Y8F.VF7+%B
MWVP#=&=J?&9RX@DP<33M)7Y_&X)%8=]E^72NI< @0!AN1C<>(A&JFU2PDXEK
MWP))^=U$%Y\9X,N81S$)[)B\+B6#H6PQ>TOF1LJE\:F?L9FVR+1I8OQJ)<<)
MK4J%-,^_X)BX\/N3F=U\$0HSI ,N0](72,G^:)@R4,R K I7>'!AHR1CH)>>
M3M&5!;P8X12"*'?7\T&^V,<(QY98_F$ WXZ'-/5%=I,,[HFYM?/EW[;)5) 3
M,=)@0*NYF(Y/1<H++D#>G7M@A _Q59($>J)FD/=RM<+Y.WF/23+H\I=3)WAX
MJ"E3:9R= MQE(!+Y:@"N$("S6YC"U/0$<A,AOBV  8Y'[H+J,^W900)Q:L#H
M>EZ-L0&"F..,ED[(=R#<#Z'.J?Q^^#[S[8<&B_(/&W3V1^,.?FJSG^&IV@[#
MCO'[C7\>QNY&4]SW\?*0PS"9)6&JAT'&<ONL6PNY:?#:4Y9'RYVY\8 7SV7\
M]4Y$JOQW>SE@ CWYRY4%7LK4*8$YD]VWZ;- 4/ZF\X7?%20KL&=D[25A:Z0V
M_SV.*+/]E)VU]U^Z(?+02X?:G@]JG\^<(8CW*7=-Z;#8-6(=:"_*_2:?-Y=U
M= YE;X&<G\;H-2M!:,0HB_WG?.I))80%C34<5ZJ7OV=OLYI-.0>,[9)+C&PP
M&_\(D>;>4?G-/"'KR. WR'Z_5G^*J*26%7.<DF/7Q19<K:C*F6.?^ >753^,
M#Z^0^/%=K+*HY%<W#6\\/Y:B&6RPCZ'D^,NE@KKRA <*+)>R(Z<SOV4C8A>Z
MKWKWJK7L<;A&\% =0C(MX._]J052S/(4^(VU]*( -W8Z[\DG'<R5D#M59Z 1
MA!B^DG]X;_5BZUGJ+2L4#5T;VL 2&X[9<8BV+A\D_!$E5))K.OR,EUE6=-2O
M(JDBX4E"0J&CQ ][GCP&;;\$@ .B&C\HF1O',7N+OBJUB%\SM)'KJ7.!B;TJ
M.3[PH(KAMYS0[:5I,=SEQ3H5\(QQXM?$(8*3C<T;/PF_?4EF(1Z"&[@/IPJ$
MC#_YFW]K;?8S@N "?L,S^CG2Q&F>_J2=*:7$(_HC/$O[CPJD[[]2XKD"4:(Z
M,\V1#<1M2+ <0XE]_M.?)9E!O)06^+<$X$FKZY_ J&V[-O7#=EF/BOL6S(P2
M@-$4[C?Z8]R[YPPRSQ" _0T6;>_FKT_JWZY*BOX3BH($4$3=AJ+TV.4_0Q%>
M:/N_IB,Y,J%(GH&;X.W]V\((P23PDEMU^7DU'_\%1 *F225_WM.TG5-M1WY[
MZ*LO0%/&]%<A5P%JS1!X%YOD_L0S_\\-7OR+%_\WB_'_08&(M+\(1-#?(/^?
M&= _D/]/J9\_G?97?W8;KWB=_+Z<KE3.J)^; D;=41@X<^UL5 .IE.'_Z\'N
M2-,ZV+56FUA9N>P*!Z$'*LV_JB0MVQ.UU]-::E P^;=$Y+[EL=CFK"+?B+!/
MA*JE\(;= 7H\ YN6C$_LS_/V'6<" @YD7ICX)>&FR$O";UN@NZ['*CFAV,'6
M\E6CV2@8FB^,.30T39D6XIZH'+_0_&VJQNM$:\N(3D#)ZY-6WB=:6$K-TX8!
MUP.$?]P_Y>+K;*OZGAEG'=TYU.7S?LZ;7\-<5V<T[B[OU>J5,=+/F4/?<9EJ
M]O* $O.=/QV_V>F<7_FY S%G2#"@TA?I)Z'9MEN@RR%?AR@_'1W5N[6BM1_-
M79:0(BJ04IY5JG)ON'^TC;G^0:V@GB.$?74)<[CE.9#*4C6_MS:+2]'3-J#*
MQ<X7!LB,0Z6"&,M;H/U1Q6?J8K\;O^P7[I0M34/?8TQ-R5?4UJZ%7OC [[\[
M,KO>\*P*^55!?YHCW2:@'.4(V5$KCV-1!?,*YKF,QANOJBH3.ON>MAM%*FCO
MG*YOI_\T[E#W%*UODZJV>+#J^1N[!R_RTU5>WN2[Q+UJ6+)\M!>Z_\&8Q[CD
M%:K&N[:+@S:UJA(J_:[%PSUC&L=3O/8GJ1$4-N[]*S87B&['YNVR/ECJG[$9
M(7"4=WW;*>CXI#_YQ#\4&/*S*MJ>3WT!%BBP[&U+V^;7;>H"RYR*%_#K7M=_
M-[7M%/,>@,;OLH+SSG$U!8K06(8;BQ&8LY<*GE_(EZK-_9-\_/<*^/:;_[VG
M[[_D(U@@T[@I>!GX2B&*_.T)]N!HH;- IO'/(Y+Q[$M-TSQ'^%[_@2=+&"NN
M@."L3UQ<Q.CR24X"8V\4_-3C ;5JGIM]\]O0&L3E%U]2"S++I_S"<3[WK/+2
M&R^[683![P?L:1N5O&,+S]II.6C)\3+3>@FAUICS]Q Y-NAOQT:V0-ZZP-'^
M51]6SLO!HIY2]"BCZQF=_+Z@N_.FK,2N<GK?*:HQ/$7?VLKLZ;FC8U&<,T':
M0_ZR&:]&,07FM\$ZU-FO4W('\E%/GV1I,FX^M;P40CYZY<85OP,/2GMU+G_Y
M8F*B+7[1R4 L>H[].3?+QF>W72%2PLY2H:W/CC)895OQY?Q:=D\3H9+C;X:]
M@%': MW+X]H/DU30HG3G50&;V_F)5T7V[O-A(!/7D4* ?;=8F>#,#V)%59/"
MWC.(M/7T_5P;9FEM:@#]F:[J@V393^NHGW)%(WOS<AJ2WMS"UVP<;!-7_=Z0
M(KG;;"C=U,B^YIR$94G0=;H;V*Y&MF0=TW@[PD0JCCI [;(O-+(XZ]Z8:NGH
MZQ!3G6M?ZG%@J;V)YC[@[.:N^<6?_8"7 ??K%\CSI@4*,EV@' 7_R,]8.:9!
M>[^8%SWH)3F-W #OQ*5A#S!]J*OFG' $"]+=&V!.WP*M%G-.4VJY%FW,N :H
M*-VJ7P8=V7F)>XI) U(P<'[[<%O4[ O[3DA)D_/A0>QE[""$B0 G(F4Q*(YY
M/W.9_>M;TCZN.N\I5@: T&56LV;\R7<;@"U0%U:-.1K7!J_A&K+@"3@??*(5
M"]?>#/].P+_69KH3 OGRTT!\-T1@Y+[:PF<RSS&#DMO@=%'3H/,CPHDO9&8%
M1%M6IIO&.KR!2QSX^/8<,YY"%B5[IXM19]0VP-]A^\;2XBM06,TA[ITG@"_0
MVL5AC"9 PQA;(#' Q(S5=*X3(OXXZ)[2O@; :J:%:5/,("1N@?:1#F%C;7^
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M&]PC;YP<V(Y[_Y[*U?NON.=<P%7> F78,[OY/=M-,AOR-/^!JK])Y_H#M[9
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MP,! %C/Y981W<U&KQW/&M#2ZA9Z3,J@KXMLZDEE.B-/=N #U?,P=YVAA![9
M!]WX(E5T_%@0.Z9^B#B=,*4(R+.4&=CB\$K #A)/.@;<G^G_'B+K1]Z+B6+@
MOZ/Z%+J@Y;N1,B0I7ZP8:S,5JNQ="""LF.3D-I=JW];P6,SA\G?C0+@E"^'
MDRPB"]2$=WH*G!@>P]?#=C1OS]GYKB+9T<PU[H'OV0Y 'BNZ<TIL!"N/46*"
MXTD@#)()BV9Z,<)BXU\FK\61P5R56<W^Z%&2'%#,V +MG$3[SZ8GD4Y@SEA
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M)X6):3H"\71PG#$B5IO.S(D+0THM654@T4&SPLEAZ%*\S=M/GO5N 7M6C[Y
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MD07'N.K%'N,5Z^/'^AG2#[7@N_ER?@AZ_UW!<69<;VX=:JKL9.<NC[^R;FM
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M"=T")5JQQ4(GEF":N+O7K;1A7RA'VP-*=1-*#9R/^SN7(U(/WULLX3D0N@B
M\EK[%9.9Z3B8T?BB@!];7PGGB_RFSXM\V6A5M$QN:DF$^WZ%:2J:(%@:QRJ#
M< R7TF?,(K35:JHO.WOI%[\:@D@R-%M+DNW4-K&9R7&661ER,*J\5>$0>WD+
M]%W6JEV!=UZ'ZQ3[=?#I<&L:ZFWYY(,O6R ?SV=?GSWSP?I:YO&UK3PD7WYH
M2,N>%CJ[[&8-1YU,4B,<7?_70TGG9/BB?<STBP(#L>0> WJ8"QT%\DRH0-T&
M4$?(.+JUI-7 41:XLU=7 6CL=!U-XI[-M:XI'&FSJAE;;D:.&_,KV:D(Y[21
M@T&!M79"E[FC,\BN*EP"3/&MODC9Z=RFI/O5B\J=K*7FV!_995=>+8<IO%)Z
M,[-OU!9Z$M.B'<]+%YSYV+;NCBWD&*"3J:>-KTXNXT7+F4I$*3;7RK/(/YQO
M.$AX''?R]F]C+0GV'=+:GQN+ZG^RA78C%WS8KHW,_E@<W64)(D%4+L4(\8J(
MBDCZY'2G6L#:M?@9GVZ"L&E66_C8@TS#EN<THK:F*S,\$>I57MWL)$/:S7KY
MM.GZ"%_ALOME?OP#Z,.9XPZGQD)<=$+.U^SY=44;CDK\K;%-".G)*XPK?[W@
M"A:RUZW*^RF_J/Y!?5+H["KSG0YB+O#PZU,$<2ZR+]@(6DG['^R]9U13[[LM
MB@41D=YK5)I*B2)-2O)#1(0(2.]$14H(100D0$B4WJ,@("!$I7>17B,E(" B
M74!*@H#T1"0L(82#^YQQ]W_O__EPQAUWW$_G>[)6RO/.9\YWO<^<?=M]US%N
M<1_),D4N0)QZNOX)M1B\%.+^2S]KLU1Y3_.]K*Z2VA^4H6Y)FM^1&JKUV3A!
M 3I/)5(E'5NKGD8P>JF:^N1X;AY?FK_1$\VUK(L628(FC=7^[98NS,_VS4F'
M3'0^+#&Y[!&P3/(JC.&6#&P:TSH1ZN<5>%+@AWRZM01HU+CDQOL_"2D>F0]/
M)@]=-'D!U3S_]9")9 &0M^=E-XP*X("Y93TK9P1$P?V1N)Y9WRTNA%WJ#^9[
MN![,V8:X\V)WDK\!Z3";R BUYX.%,-+D/F<,E!GM17F)R*15%^J1<<=79_5V
MHS!2@-Q=Q&]MXUE;]+1<O )F=I:DW+\6]:MO"CE^:OUDJJ?D><@H!!F#"A3O
M?/6-Y.N=&BP49TITF4P3P$P<R[SG@80)AU6T3KU<*BL4OVR:O3*6X%J&-?YQ
MG<$6<^5Q%\G23N6G!<JS$TS4G73^\-T3&A_1?1>SH_$\<#&M9NW&V"7#NPA\
MM1/+03W6#2[ZQQ0D7!^^M3C->+80+ZP,!@?"U:ST6RED+RW5@ H(I<^E=%5;
MSGHXH/]BK0*OQ4AMHH;O*_#OTFFO&WWWG_KQC^55ZYSKO/1'2HLKF!L^6!@>
M( [O/N^E4#/(C$8QWQB<WQ*S+8S&*"C;7OWPTTER9$<<VM5V/J7PFWP-6!#U
M;E,H9<-:0J J^HON+,JX9Q[=-%K'$ '2J3ZTVT B7SS_> HY=BL RJX;_%3C
M6V*(\5$G=K8?F>]4Z@7'1=;XONVU[8]Y2#%Y=##_;S$P?P9+U@CU/AT$5@^)
M"\-T@WE04AM;.*RQL9:JF,J<UEALBYBU[U8)07FF_#.J$N3Y*JOXM ]?ITC'
M+T?6LK>O9'S6<_>]IKYD5D9@(*CD?D-"\YC4*/TJN;G\L@+8I,7+:=NT>;QL
MI_'W=$@H^(Z-RBE>&Z=>!-*U8VES:G65%^GY@0E39&JY 5908;,/F68K#9F6
M*TH.L6\V(#?6-H;IL8N-[W)5$Y7-+IU-OK6>D,<O)5+UOZ9,_MN\3'G(C/F=
MD73,VZ)OWV2N-=$V9\=\UYJ")(5VO\CU:P5134B1^$BTB4\@%?3Q23TO"FL7
M=5$1#2?]E$E#**^]6HA2SQ^UG+5^S"UIJ?CE1I'4LW\D/O[/<1M*_-94("UD
M1&=?OQMTK+?&C\8>/&*Y<C"WWMTR\]MA0AB[[X7Y;(<AR7;MAZ0[D#4YV5'=
M^[[B:?8^G-H$\LAEO!W37DD<<,3E&&>X]Z]/+J_OI<<'./COLT16.,^L0VLV
ME6<)&UX2>=9RLG0^'Y)V?XT=RU.,'/)Q$I.1:"<E5^U>FWXL>+G]D,ECQOX@
MY?N)WS)Q]",TCEJFNN8>,EWH66^D.CO.,"IW[5YJ'D!_@$A&;I6@P$"G:_IT
M%="&?BGV$R?M'RH$3XA@S#9-I'@'!^&1E*WHID#9?I ATS[^WTS+)\BR/>#X
MN3KO2/(<!]V &A5.AD?9"> "'NQ!4O+*B3W/WC69:G%*-'EM[K"Q;>A;&(#?
MH51Z,1/2"</3WSK%W_/O&[Q!3NG'*1O)=04STT5RXLN_V:T&.[WUG)YO_M 2
MZQKV4.J4V:=Y+>]2*6.1ZZ92M^X>J_R_1NFF=SWX@;_15.4'.5GDK790!('W
MZ'6)>*8V-B"%A@'>!I('.;]C1F;!=11P^Z (C(P_O081:J44O"6'I)^X0XV@
M?<B:.WGG^7?O,077*!TD7V61+6-P@M1#%RB=[^GB3&"('*0&#$9"3VBQ[1NN
M@4X0W/=]1%'5))^NRKBYTUHLE$[[K^\H!0?6'1+0X38Y5%:G@,:/M@LC 0J0
M4'G$[D1]ID*CFEUTU$XBR,&MGM;PQ%CXRRG#EBM]UXH6[0JK+$8=1>+NOJ[B
M+;QUM5S@Y_71UQ:AA4KH7MG%95B6'+'GVY=FWT(/_X/2K.1RHV*B:<1J[S#"
MTC1":K&W;T+.\X\:X_0)2H@.!9? D$/UV!T48EVA"5#NW[AG<V?:V-SA'$<D
M!"0V RPSN+%1$LQC 9HO%D#B'IF12:^&D1!)*OL/*]I[A*I/P3?[&YBA %H6
MX%E&*,RDNQR1 3@!-]<#Y</%_YVIA7Y06Y=V;^,=8BY,@+IN@1@#.>!Q=,#C
M@-A %+)K''M"Q,MLXL[[&-5B%[]*F/BS9NNX\>O>XE.@R9*)V+5!WM=DI/%=
M[[MOZ1K?M&Y>2!62%AK[^*5 /"]MZ'5!]IC^X&>7Y\.)9S]$7KPD+6Q)T)8W
M8E5=-6@TS%&\4I;5EA[Q8*Q14#KLB#$QT6[\?^ @-@\%$3SAS[#5KWFG47/$
M2T5 [7D>>]2)#C*[,W$D@^?2?;4TI"][0?C)KU_2N690<;N&4:O?;X^?^F7!
M54]6ZYH1I'T\*,-<Q'8: ;PD7!<GVT_?&00W_:H5]>R370UV0K2RV^BYE';H
ME-E/NXHJ6G^VJ U5;%="8*A"P=ZNI;DN=KDYF1^_U>#\M"IH420CR0O7^:CB
MYOL=M^@OVY5NT>T+OLCT;_,4W\J8CM&NIOK7A7#.C>+AR$NEQM6%MPH[?67%
M2(_M1BG"3BR\77^F*XV%$K)DEROCVTEPM3HB>>:,T*O[J7*WKN3&T,Q+-9Z/
M\Z4:CAXRY4_)48[X1SV=#T:K:VIM'-HA3&YU'C+Q5=:\N 9'Y)SP<M.C1KRW
MXP&[>HG,+G0+^HE:,7LO?J!\OCN9'>MWUEL'&SJ$G2^!G]X F^L#Y91^\EQ'
M-A*GP6Y^HVY,?N/]D]ZE%+^\M1YGKE.#'*JW_*K>E_-2YN+<A"WZKP <Y][R
M+6XTA*CV^X7DC]VG-&0X"ZP9W'^WYYUI">)J<.5)E._G3OI4VCO];7G2RCG5
MME6E,K93__3$:U\E1Q_7K /==VT.%.N-TGTY8+_7D67!)ZR\0G9*LIJJM\XX
MTX*P9]A(25RI^SJ+J$?'/0]Z=^N0R6SXDA74<&4J)ZO,3J\((1*95'Q??89Y
M,SO0)Q2A1/ULK3H,.QO^HN^Z6-R?.QCS3!<_6E"./:Z_Q+'BSA-.[H@LY+O$
M8/_I/Y*KCVP+;#,ZIUPFDUA QA/+[0]^/LCUWK2X;*0POMZJQV>=$_B_2;!J
M.W>0?\B$@/E,-M,"*>/%>>NM0/H"B-.=(0JXO#W ;WQP7!M>$6"%5*H\/SLA
M@HTF-\9MVK0T\NS>S3(<MK7>OW,[)\H\=<&OI9_YY>)HMJ<WI.7*[_,E..7:
M5,-D@U^F^<R7:TM4^@U?RIHYK=NK7[LSR)+B GP> 5F:ML\7];4&;?YQ=A&Z
MH>:PXS'0G2J"V+8H53?'M4JAU_;OHY:/1%_-8+<)!^:H!$X'"+\9,=L<Z0))
MM)@[*QFXY?^LXYERJHO7[+9U]-=+'M_;^Z+/&DJ.)W#\]!X?F8*_/="D"#ZC
MJU!&VH]D"F?X[YUAN@K)2&9"?UA^="N@KO:.\L0U+I$EVB_7M%^,39VE6:=!
MWX"K"-<G4%E&)[;:<O C+EKP"('>AVPE$/B63?C1>F,^59!"9Y4U@Q D*;KY
MP:_;>^AT:\'@T;?3&SGG6@A^\K3Q<7;0]-AO.CSSWELQT)D?EI8.T=&+IEH6
M@I>_;)?$ZE[]4B(UIRQ[\<!>T>SE0=+Q5!56:3OW/Q6\_5>3T\"QVTW&.8$Y
MW5DVB#:WE(>_IW/@*2->BK8=2GO=VMU7:-]64_SB_7//O6N9)N*%,=P %^R0
MB;60R!G-X$<]EF#'$O=.I08T/'*&P?J!"I=TK=.YL3]DGT9,?&Z3/\++1,8G
M#-^V)(AW,+92<H8138*R RDV<_6,H%6C KN?/BD=ATQ=HVZ5,W]*.S\^FN!V
MK6,,?*I&!Z>6:\DXQE<:#Y86&R<4=T-G7[Y$#_J NFQ/66,WQ+8N?VR8I1!=
MA>Q4%)LN!USN?IR^ZRQ QS7\K.R;/$+F8H@$56K8CBYRD,U0IILV6EWMKEH9
MW_/TZ^,X_H:R#KG>;.&<6 !3SCKI_<Q^L8A >GOTICP0UR,")^'A' ?JU)<%
M!AQSP8.G)]2%US^E?Z)%?SX=8?VTSY^M3O*)PK6^T#-'2_ABOOQPCN7SD>"F
MC,V0ERX5VJ'KVI[.Q'*-4*>MAUE?*: 8M(IEPV+M-:U?!7TY!LE+C6'I '*X
M0UYNAT:#60V/'BC]^U0=4+TOS/@,KR7\?19=: ?$4P,M0Z&P=(.Q'9"XD\'"
M$;%GI_+385ZE4^YUY(D[;<VOC]3-W#[BX=A&S5:58L+YNG\4WQA $:4]Y->X
M8YU_4K4X'/&+=/U;*'E5F0*H0G7G<*5]MF5[XZU:E'&^A)[LQ='FR-LAAOX>
M^X97=AK<-'K<)D/O>$,O]%!VW)VO"KG?\Q,MTS-43E4S$<B];.$B9+7\TL)!
MOM 8G5)JDES6=_%=F^?>N?]L*?_-D9CLLR&&YV7(8B:"9W#MK6XV5-7Z>62H
M_,_W*\%AB/<HJ-E7?W?O@%;%+WN,S1%C^^J2J55!WNX4N9FY[PXK!=?S:E.9
M6#92^2D]G?CI\([ IGKZ>;AH"[08S4]=K"YO'74Z'[8*9A^\KOA.I\A1EWT\
M4:SY;-Q4%UM!GF>.4VW \YZ-?5BS_;X[V-/;:TM^\YW!1L6&3!)YBLS*I^RG
MHR5/->*+TY5ZT2QYB=F 1?G8@W\Q#_W7[(;_\ []5WN5?YU2?=?0$#;,6E%1
M&#4U-75)MJ&AX<7YL-,7=*6JC903JHA\M__&^1;%_$><;SCF&F,R1]"]%A>%
M/>$5,!=[R,03,*-I/J0\H-MNVJ^8\<9#K>Z#+;%D<O6Y3H!,56!^KU9P9#U-
MN[;[U99/W;)-]>4NIM"4@ED[Q&Z.5ANAJ>[#A]J)C<*FEN8<.:2]NR0E,-+.
MH$)1YF&<T L=MV1]B[NL#YC1*51!&IGBFEURR-0A3''6&8.HH#87IZ:&YSH?
M.4*C'S3T52P4VT]_=T2R@5Y].%J4:<.A$ MK Y4L5>:>7OAQP@.3.(FKK51V
M?'>V7Y<3!\53)#MQJ9(4"NU*RXPJ)&=C8/9&9L);SC4M8_Y9)I(FHY)!.VP_
M-U7<EQH%WML3+WP?]-HKI"R39#LK(Z;N#FL=(QF!.RD:%QQGVKGQ5J-QS%V9
M.97^(Q[66ZG?WRTMW29+Q4C&7GES@BSG,SE-BSEX)QMN<Y"/.6<TOW6Z5S[P
M+EJ.<N=Y9]V57GE?IS(SQQ6K#V_D[S>-R5*=*H^!V50R_EAO^$3A62"BZ/,C
MT&H("# W^AKQ0CZP*>Z6=VVKB7>'O?FX]Y37+>J=&&D;J89]*1Z!?866TS<X
MC?[_=Z:4^U-SR!0>V<;$&(:*M%RG0)9)<QWX!"@(P_H3P@?L%P"=).MV>VTL
M?.(OE<=(41Q3HS_ZQ#I=H$ CEZ)MJ;AHNC39)7,QYV+M1;0:7_#K$<3NH[5K
MB,SZW^GP,#C%;C 2#@J8L:;Y _64%%H$($GQZ61P#$/4Z)H3&VT0NE<M(#Z_
M 7($6DFBG.SN>,'?Y>:F8\HSLD3,)<#E85-%_=L5M0[:MNYX>8U7X,V1+6^!
MC?M[$@(E/Y<;+K\HOO'R79582M<M;[S6^]I<H4)CTVR-9*];J3:]&@%B;@CI
M7K!HS*621N/+K]_:Y3W\Z7<K/@Q_N<OLL9>%602)[W6)^4N[XI,+J+F<([5V
M4@DPHNYW!'-N2%.M%^ =?UT2F6MPL<.8@5DN(' >G"!BM!M)]^5/_U@9IH'M
MG.-#;@.:YBG[NIV9J@3R\>V?U-FI20<GXLF1&L5XL6$,S9H$HG/SSD]$0%BG
M&=]R1(ZN7T_2)X*>I8,$M%C!'00.]#5@>WXK:2('5#N"/N-OPH/6I=8NAZ-M
M%T2AS$#T@G=]02^Y5PL$*;^P BYTF+2I25-]]/[@>QF0YE$0F)#Y6E;@?0D'
M7[[>9=]VTH(Q3Z%&JHO(R_E<X]( UWRK:R\?+DA9Z0F>+643%+X%FVZ\9)%X
M:XFJDG_]UJ-(]09CKR_9Q1VCBT(UF?>/:%-$\/\3[CPP5P/N;*?:DWIZ<-$K
M#U5$M[C1Y]['Z]: WQN00]CP8AYM_*$S+3@>FQ5K(:VK\8B/,H27<]\D2=@(
MAN8JJ+:0SMO?(Y@6;$0@XCGMT:X 2\6J@J^\$P?03&%HXM>G9RX,GVAR&].2
M(R/FJ68=/"%;9P!=RY&%M$O2AHR>_VJ! ^\>W. ."MEGQ[;?I,M1L;=KFD=^
M5T;@Q2K*:S45M+A]_2B578(C<Q4OQ.+*8X_T(4-J7/GYL%3X@>HY[HZ8Z<W'
MAJ"IUY)=*/6UV$]4=8ES'41M3'%L<I]?H.M,KDA*KR^_M%"E'QO8?6JQ?GLY
M4=U3QO'U(VL^9_<;=;9GK>2BMP%CM43/+.6"E0>7-*7^Y(9WN084JTFMC!<:
MET-L>[(QV9BNX+24?3<Z+[5P77K?:LH!%4C+/WBQW$II2R3+O1\!>M&7\K[W
MO%UQD@P+^9!8WOYFIAP723?Q< OAY'+W(HG[.XG#K,/-/\23>HB'3/'X][@N
M!=@\9\\ ._H^I=,F69<]FRSSEG3(Q.6>;BYDW07A:1R3%'C,EF^6/N7RJ^?D
MKIQ,1D7[_9*;Z>,S<#K_"9)U/.84^C9@>U3"9@>9Y^I'T084LN.9G@5O7('1
MHSVW+I.HI@C5/:MT,OLM+\T!^VP9(X&?*-TNZY_I/+KOX"AGI]I]#< *5K6G
M5X(*F8?^E2D("C9>P3$ = :UI8/K:CM--2I[A.TPF \-M@B! =Q?;FKDQ)9,
M.[I#+@U)O2C;4E1>R[K4Z^[E/6\KR'UOG)6RS#-2&D]Z;6EKD6^6;-Y#68(4
M)']^7 QS,E#-3^R?MO!]^>>UL\B*H>.D(CQS?EO,U3*"V($7?50A@ANM4L]0
M)ZFOA2TJWJFPQ2NDWG$2N,KX7(X+2W40T$B\_B7?T";5)T,K<%\(K0;TDDJQ
M<8=,'Y9C/3TE1T=G>T@AI1D3-Y(WM?K]7%S\SJ6;4PJJ?2YQ]^9YL*J\Y'U%
MULV=*OF$<<:3)Y):6-'XLP0/:-15NL'0[V_#XYI04:("#J<,.W5!!=\!Y_)B
M'5VN8EU2J0-OK7L;EEFETUZ$K2VW\5'K>P8!V>AN83HK>>[W(1/GJI)\'<^@
M]">*3Y<)9R<XQ2O$[7'_^:K1C:$(UB<E 4;'-PZ9JG<N>O]>2=:LG"IGL00$
M]Q_25>)6MPS?4R5RPOO;A@.XGJ-RV^V(72<UI =JPG9A32ZW5)L2(S]6CRF0
M-:4:G[D]T\)<('UVXR 7FY=KV'P^I9H^_N'U].GO%.&*,T:/R5?&- S5[G;=
M7_;X9E=?: 4]6[C7IM,E=.>0B=TL_Z)EA_/[5$AYIHM-WMO$_JLOK'- W":P
M;KM^SI@P?U_E<K.7^%8A!AH%_[CGE/]F+0=\$ =1!SKU)Q9&EMO&,"QKNU53
MJ$S_J[@ZF2SAAJ0>ZX8/M;92'W(T%7QVX\]> <)$:8FBLAU0#J@GZ A,.3?I
MVF23:!%H@K_@>*U5]1A#Z64MM2"^."LCQ58$4EB$M+-.*'L0JE>8O)B7.)\,
M.,HK=LUT/2:XSWW#'PDD9L]:DY@VI@DW*LLSY<(D\HK;<UN@N5-@POJ*#5%J
MR^-]9[EMC\(H O*V,#^?V**X[;#B.Z7C%WSA(![KX:4V/YY; H#)[%^*&"Q4
ME<5(8E*1;.:OD?:FDM 2N?Y&Y5H#&2]-6]ORI'SM%&7:8$&[QJ0C:R&J#;V+
MNTF!KV_O^],%A@)@E=$0F>$RKPSI##JH$!5N-"'YO"K()?W.4(MEOB/P1&[+
MEM00?K?QCR2/P]73Z$.F3JPPUAW$!WQ8;H?R8A'L\/G"F/,97E.<@H 5E',J
M8S+NCY(30L,5SY'V\3CC2>5!QKU/YKVMJ:\4,+,KP149%8AQN[;$(MO5)JM<
M'_Z9J-S"[YU!+B%(I>@X\O@J2[(PZ<5M.2GOOE!D.)!*"2$1B#/@?;D>!O](
MP&B2&DQ!9T%U:CS-06VP "E0('YKD&,6J2O>,^D68!K@HW$\XL1"%G92<B&'
M<%(MF+"133VU]&7SXG*BOPY9IJHI[*&M9!KK.^I!>=GS3PD2EP0&AH;"ST\%
MI3.$SDR8'FD(_,(<,3$D<&_P]R?2+"?\SVF'-?7!??N#;5M!$!/6?7"R(V@'
M.]G9PP/LMW/W2X\-=N"%6\P^/T^_!I-X7:F0DQT@)W5O(.C==P!NV^BC.*OI
M]4]R^<H<VR&35V4T0V:40.( WA:L@DYASDU]3K.>TH]/1CH*;[7I7=4KG6EW
MW7-(6L2O3QU49%;EZHM9UU?H7F%1<#EJY62 ]T10^M1R5ZO=K27=(#([AY3K
MYC\?**UE;T"T@B>'3!YU*MAO)K1'7^EJE:O<@+4MX:BI:%O]FK(_9!) A;/Y
M(>_[:BDI/Q$<YVZ;-+7)/9]85?N\^-P!D:_*08^/ A/[:B0".SNDT<M7=?OM
M4=OB^F @%M,^]#75Y?S+YSH5(?_5']?B&*D)NQZTKX)HAPQ2\+HI[D+[H8=,
M,2H.O_?GIH);E[9")P<QM=,VF$'X<>69@I'YK4X]E^Y)60H\>DO&3+-L(DV0
MI_B0R5T=LK/.]A]3C&\XC#L_0IB'J0<9\P16Q+1O_;J$V- Z->G5OO9K5/>I
MJR-BUN9BOEWQ8J9YID4=/2(E%W!ZEL?^H3&9__R?W%$#>$$*Y>UN>O*"!.6>
MU"]RQYP;4U$ F]<\YYRU=T2I$=T'1.=?>9]_4#WU74:ZKC%)+B;#)5$(#=M7
M 7(=#O!ME]?P'W!=L,F"H4K%BH#*\+9S+9?$!&F"P]^_)ZJ(O1!SMN8>U%+]
M-*V -D"6(:HR%MMJ*]O^J_LO7),QCCU> +3/V]1BV:)J@.QY5GB7T^E1+\X4
M;(!*17]I]G'-U,O4NC?CE,$"@U;,0-G4MT]24:R*_4]#[?70D_N*=/_H!5QG
MD<^.0EV;)J7EA;N3UG!+B@?%@UH6SU$H7LKL[J52]"9Y4?);/#)$(+?P(O2^
MXIS!U_^[6\]/S\(,S;%IA5#QW03^MT#X(=.I-=0V.1\?QU!&$G@#L )Z1Z#+
M196-2.F>O5(_@B6=J:7^T,!&E<FGW(BWI53@G7$<B,!+;^VC##"]*K]4?N/'
MC3"BATSM3]K8T4\ XCZ4+ED#.%.VR='=N$B&"% .J=[700L"FHKET*26 !(K
M6KIL$G!:FNC,Y*=EEZ$&[U &XW]4C6[1%0J_P[1__+)QRC(7P$OO1 ]1NB^9
M?BX>\LX&E_<I,ZK-!5_=UPX+RS;QG;\F5C]E7)8K=(-_K4BC;>#22$L>*H,A
M/O;Q2XEY\4[ I?W3]RDVD?;9W9P9SE=L%D]W*)J]+C9[_&.YQ<V%-^.0*0R*
M9AZ"\-)U@-I*]T,FBL%,"(-U68 P#^6<UE\XL*<U44TVI)%4Q>E]SUE=4JFX
M;%>@$O&-0O+&.*%.><>E%>=2,\Q\A14:4OHG_NARI]"L!_ETV06H*/TVT$LQ
M7^#\2#B)@M,> @K[VD"@#C!&RD9^#-Z*:T&2O)QM)NCV9! ' ':">5E-=Z;!
M%,I?!\]LXMV;JIWLLER#2*/KO^=6AM/Y2MUL7K7<O*J4<&75\CZ</]::QH7.
MF19._"S7=]?HTJ4'!6_E.JZ&X2ZH!\U=?C,F?-<LU5KD<6[TF_55V"S-QE/Q
M3)Q9(**'4U :H:;Z)^.([W_)^?9_ZD!I'87V/,C#L#,&,TUH^*XM81N$8,JT
MRI=44I;N03YYQA<[+""9C\*,9>YL%.1,V>N4S)3GQ/KX"\AM&$]<K^S?$L2,
M$VK5-J!NQ82/K2#C@]>,4_8PE;IJZB!9M?X^*6;A@^U9<Q.U1!4M1+!RK]@+
M TCZ_*L  A=B^)DL;6_ZFM*!$ZR]L=LO.LU9.KKOL>'CQ?*<9?ZVW-3V-91I
MJ7K3JZF-"AL21;E*Y75F?(2/WZ)?VY7>7X8$\Y=KKM>KP[.U\'(%54'A<0;[
MAI2$7-B):(-B$]ZDTNA<(2=#[W&H(42#,48X<<CDAI3%QK1=J3<*>L,[B9+5
MX5Z#7!NU#*MQU181)HN@>24%P^].>-<D*GHEO9A3?G,+JV72C9N.ITV_6,><
M!!!'%\"%JWF:,J0\)@*?:(P7NQ?*P#CYI3-7TY6TB0FE9[$<-:^,\7[7$$W+
ML;/#NKYP@6DTZJAF[#!]31%-NTEM,DAXW7(W+7M+\3S%-1*<H"6E4IPEIY*]
M5(U%S#L&+#>[\G@$X^/1]N@[R")[A)4UYTFE_4S,]%'=6A"F8B]4'R1#'V3Y
MA$%86BWC>L@^/0*H'T;*,I\"0D6@?."PWY?F9ZJ8ZW"DRACNGMIW,5\NI-UN
M)6PH\I)2/<.9&K)4(ROQ5 [121>;8/Q@*H6>=U!M9Y@CJYJM+TPTN$?.QGV^
MVN)V4!^3QGGE2^G($6)DZG=^>J >#:D46%]Q_:Z3;I[#RXQ4'W\;41X1+?G2
M+<&;QVT.?QP[GX,]ACF=2H7'2T(%6@*]749]T,[4X[,S-4C15#5>!P\1>&1A
MSJ[A^WL5Z6!LQ0P0;U'37*\V;E>;MB!"?[9O@FUW9YR@<QSDMURB.)M0LG>[
MMLX"<+MA;\@%NAG%)[X&.2#7.:%!>Q:"5,!%U92**EC-=0>*\.-BO#95B'"N
MGTJVJVGU4\>)"@=E&Z 72#S%B#/QJ-6GL?LPSL".8$YHW,<_-B$P<(Z=SDTV
M@G9@V'!^K-X27[:)W"AL>QHXE:OY&_VB3LQH^=#M!SI#1YT:2]&KG-RU!X(J
M5M)F>:GI,71^LN58WO@2-;"+$#>\RCNY$IQ'4PLNP+U;M<,_#= 1:!1(H-I#
MPC+M#$0^>9G)- =2D3WQZIU"U-2?;BUZ<<D_$BB EI,B7^YPZAE4L'&21 )F
M0(1OQ33Z]KFN)3&#9Q]-VQ]U.W;,"BS^IEI<Y?=];9FUF/*9VN#>OUNSNO@J
MV#;A?DRYL*Q5A=K5-"4##=_R&WZ)[@P\.O@@A:Y-O4&#B@."=Z'L;5<0Z:Q%
MB%FEH<\TT]7T]\R_3K4U!24M;)QXT"/0_!!:J_#RF<;JDR&]AUKA'[$UGGM/
MJC@_5DY+=F@<R45UW*3_G# JVG#$1TN87/3X7%WS:-N0C\R+8RW[I1638)K\
M8)OX#061)6$S)VN;H](N0_-FKM00HK&<&$7T[;$D=(S_(.?*7FA^C\NWX=7T
MS$_?0_UYGS$F^IV@5),%Z 9TWQ3E;<+VD_#>JM"KX-.@8FP%6J]UW']_1G%3
M[W1FQ8MBCR<$C@L?7CS5O:Q?Y&#SO3N,;23(4T3U-P+EUZWL($>F6"BIRQD]
M\"N;EN]MS5R!.'@K14G;MUQ2;?IV<*HR1DO2.B=*4-A>(ZO%"23;MRV_,!6(
M4^5DM>?8>E=3DK?GL%_8#7U/6$^E'E=K&(6PH\R-DU=N#L$!A<H6(9V7/O8Q
M#RC9FZF%1BVJU&4[!QV9C<^XY\BE 1B#U6W>B&?3T7R^IWLK <JJ@N#XG3-H
M%6Y95_^<Q_G*(9,+GA7)S+OX$>^0J9LD[4"E+E40*&;8R9&/&K?2RU 9=#;*
MRJ;9]$;P0P@G=02PE7$YDAU%;%#N.?>TKE2D'*K67EME>: U<MA$?@CZM>W8
M01+C'.9KFV@5]>^#81_.F%EMRF91[I<A^N6IL>S$U.XQ9)9HEI<Y\=3$'4(\
MRF"]0DL:H>S<_R+Y=E[,Q/C\U<8V?4ZW1&JX0NZ-\;TTC@)D-U]96\^8QSTY
MER<C/C[K<[8>Z I-EE0W<]HK,&OUF=I*;,6#XL77TF:'3(,[F:@IV]0)K/.&
M5<G5H>= :2>T7G9]$Z=2N%%,"22*Z&5NAEY;@#2__6E'_.&A)K-"=W,N<3CO
M KHJH5S[(OXBNV(@.!6!IUB!XW-81[$?(#)H9<!Z 5=->+F'Z_01TT/R?_9X
M<I /KCG0)Y]*54XBM'"_FY1[+9OJ:<!& T<2YE./1'Y=1*]B,V)A3F*P^7-V
MB\F"\/I"0VK2"ALX?)T.OGCKP>U3@2D^G,J)Z3X%6K+[4HS/LZR_ICOG3K2)
MZ6JI__)1,6&?1.%,8RJN#'DX21K9,=06,G@6'1N_]\@T58G=)[44]>7X)"LJ
M$)7_5#4XB?0#&I;2A2UKBT&5]5YK@5IR(;:_KQ<]2H_Q+3V38?48L&<7* \G
M^@I XYU/KVR6".?8KO-9]>KR(V=7RN'+LV^/D"8.\!*(DQUN8P?(VUVH/S7E
M^DY?_0?X5!<_.6*FM)W^1,W\X"7E2X<5WQ7Z@ Z:K^0Z:DVU+-WL;+0(()!B
M#:-N1'?>'*&?G]<&=>WE*?P=5M# 1?\NA\""\O%WJ2SA*594YI0Y'7)LOB#W
M^7&PO'=.^X;G[P,(^"=O#_840X .HR2TG: 2GJ&U*P!CHW*)YS38@S2EW%.P
M1)FM.TBY Y&-)QN"F49CJ5\3\^*__,I[(5+8#HIFL ,(2G/[K"!%-GI=2^VM
M_KN5O=BJ*IYZ?)''DR>[@;N[Z=9*@T&A(0&:*0HS&T1BYP4BYZOS44(C ^V^
MRR=_J)]UE8QJN&#C=*X[!'VV,&OIU>=I<))I;)Q-S*V\J^IG;\I9FEID:UA<
MZI\TS'-+*F4U3&@5<SOIFQ24V'&7#+F6)'>A(^2LY_U4EX8[E2#Y"7:YKZ_?
M:JFJ1OP<7@JP6+4J!GF)/(XZ\YHD4D4_.&2*]#WZK8V V,$8R#6T J!?8,0@
M&%$.<K+]2O0:<,!NXPCZ4OF,J\IW"%SP'U;)# YQ3B"0I8M3A+&]X+813<7V
MF X>,H%$K+)E<MV<S[R(#INDZY#A/+9_])<D^[]N2(KB]E0?#^Q5Z:$GZ#<]
M&5$9QJ+1OTX?<?&LZ,>O5>#P<NL.LN_K?A/LFMB>7.^W/3 0_4<\U.^.<6@.
M82]K^4_%!3R#U[2+1$EC+(_]T;Q)_T7!TWEV:8:4R=A:,#NJNON77I@4U2VA
M]G9GT^^@>Y17E/*\U[^<D7YL_J@, [L]MPYLM>#ZUCQ6H05,L2959/ER:#7O
M4I)P11[%]04JH6;CNQ:00C4WV924@9!\?K*KF"/Q>J'29_5X#6*'_7!IQH,9
M]D##L)(B(F2HX,7Z/,H\ZO$7ZZ>?E-#RN4C+_'22);(\JV)%8QC94C#)QZ7C
M=?8)[2O1YZ0AS\5[B1>BI,1YU!?.Q.1^*'FJ>28M3F[9WJMN9GJLOCET<BLO
M^8,5[&9:[Y/K_Y8WYO!O P;_RUQ3CK<KY\)0B^0;I(0LE?VWAG?LFY4)NX+"
M$$WF)#;8[4Q;F^,ZR=9G),/X/M?SMCRZ42D?DW=B&3Y%6&@$KLYS?@#0\8.Q
M$+5D$TY U/"9$WE'T?OX] RR%\'3DL(NN\$5?S$,.K43GZTZ2I0'^U5ST@(
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MUO,)'][K2FSJ(G,FD;'[VGERO[ZR=(\?,AW#NL]-&:,"L%/7NE/0VA2I%/T
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M>(=I4+*T$>BA0:@"]4=H]>6@7LM^GQE]>TPQ_R ' T&R=!\R50LFJ,1N9D[
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M\?FTRU=,ONYQQM$5R*786L"YJXDE9N-)U+YQ>!EBBM@VWBWZ96336W+J\97
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M_XO4E[T5HWU<&%OCM _QG.WU*K7V[TOV]C_<7_JU5ZDH.?ANA30/JQD+!6T
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MK!-9_)[TC1!G!JYB(=G3AL2 $T. ,B- :_>Z\(&..UHX:3G53G]1>3UZM+-
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M/[A /[ X-@;!;3^>5#6(\%FTRA4Q4#D[4S0;?W9J,(56R560_>^'4'R\WKT
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ME8.I-W)LR77#*MI;D6$QI?Y%QK"!N@^KDIT%P=)&#G[=,Q+\4W!1!H&"B#Z
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MQ*+UN[%W\=R7.J9+1O\*47"%X8LO(+%Z\:T8K/<\F0\W2@ LZ\"J/0LPDND
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MC"\'QG[1Y/S^>OX1QJIK;PA^WGGS3EJH<N6_T:Y?,F?$&B::# 0$? 7*.7+
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MI6\L$USC+KW]Y9^HPH^N-*H*]RSDBX;4K\[,N1IX8MS;6.P(]^_?BO+=J(-
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M=9HYE O>S"1MG?9UNPIH+IBG)T..A:1/#]!0@!1UIK=%HFOK*4H8X4Q7<4#
M0,R:4DR_Y5,4/X)W$3NS?A- 4^+O8=L!>SH<U:EAP,LD'$0./ CQ@9:;4G"]
M!V[9"VA15^*0D*L4GF5C#^@F<,B-B0>O'H25^AB *)N%H]RDUQ&'SO];=5&"
MO2HKF$IEM1^!'H[$8'?7%YU62X\O'8%FC+^ *9^Q'O,I<\)I7'5NG0MT+.]J
M8.G@2!EPW5O/V8OSDVCE_A/O^0?W3O,H$;I6!EYV,FV0&H A4A;9G27\TWM?
M&/L%G+P#][+->:T7"CD']N:4Y_Z@5Y@WZO +PH<X'Y*89];S"JK\Z$3?LO%A
ML<M,9SA,OVC<5+]^_/K,[ WYN#1O6:,D[T(;G/3+6JFRA;*+>Y@E',FRZW4K
M4$6W1?8(?\TA Q\6P,FHLVJ"'DI+:&'@G[7%'@FNO:Z@YD)+P$C9J<<;=P=W
M_]3%'M=4NN;Q2>8HA9YV/9[/KL$X8: )RV;:+FMY[C MD+]^7R;[0=Z97+7%
MA# +M^L,WN[*5UJS^Y<"%#(2G[1-Q51H&S@<AOJX:Z'R-CW>W4WU0M7&^U+'
MS'?3F:>+J$O,:TQ\/A\EORJ8 *]=T&@L0\A,D/+>N*9R67+[,D_G?7CHI&N.
M.KN6U2'2H'<J&V?ORW?GD?UZ)NKBWQX%L-1L" ?8#\W'$*6>7>XU/_S($ BU
MZ_<Y>ZV;:D_"MW242/MA$CXJ\37BJW0$C?H"+J--XZX//HQEN?XD1K9$O(.+
M:P1WMIZ4QNK]^DPGU?U?DTFM+O5E9GP// DIA+N]DP 8/6"P<*=H*@.^D6=Y
MJ5?NQUWU)]UGX&%6YG,K94_SSU7.MJ_HO&K_,0.P,<^@*+)X5)WEA@4UG;3U
MK$T,NHA*N#<#0+O=3HP6R6>O5\'=NW4,BLIFO7G4:FJH)_*Y+7E]B*YU3]@F
M+H^+&,NI121WJO1C*;</%6@]WSK8$;=9(,173+>WQ3A&#<+CG6O?&:5 SJPN
M\%B,NBYF(!9 Z(V(= 2>25&52F+] LB4"4Q\58C68EUC6[);O.GM1M/[R'%[
MU?^9Y;NTO._BE]M.6&MH;_?_@[Z10#JKA%3]0BV\!C T5-@S[_=#_[NZ$ZMW
MSMUP@$]>M=?P%M$N2]RAI;9$R*+[?DGLNW"Q4^7!XU:&IGL]$HD(]??P@7\G
M&$KD*DF<&^5WN[O!VTKO@W?L0>XHC\>M'G'P=__1X#]O?L;)&ZNIB(X68!:7
MRTH0=UD4TA/8=@W#4==1W&!WC C4F]B0,J:^C*%,W1^7,;$V67J1L(GY=YM4
M,_[(6VV>K_."CM%G6NY&A.?'(U#M7D;U+R?-Q%U_&UR'Y-A&2#N'T^<F0HB_
MK$U#TC;.JJ8U]6-3?6M#CIO<ARP-^?[^2.XX4'H9J5HFRXRJ)1HJK(TYM_SN
MQ="V[UA@++R;N2404];!I=K%@+NX*IA=-^/3+FO('J0*G#/6=D $</ J8L #
M+B6OEW<_%NE<SZKM(I?]^A0>>GGVS3L9\QZK@,=+I1GPN>/4K1CD9<#2D-K[
M+&1 A1ON#JES;M>T^93Q1.>5G7-DPAO%R;#)#+:&CD\M:0JM"J5+C<UQV@7!
M_&U>1R!)5#)XPVD*M3L5 GF1+T>!L4(=<'DD'68@Q;C6.*F'HLL"C;:Q#-B"
MH[),Z[@>>V"(9*?8C[8=U=.7&T]IJ<&X[]C-V\9>I*PD%3IW%D)A!\\*$>84
M^^[YYQ'9Z1T2ZUG$(U!<R#P[M-;)]4OH$.SZ:IAY4(FO!B;Q;R%5EYEY!Y>/
M+LYWBEQ#7WM.)6IY"GDH&@1ED(MR*1T>VL8J@\WWH0\JBD9LY(?*C.]<]HE+
M[^;/5+15WWNGD*FI93T0#T\+SW3Z8P2+2[/'-P=+*2)=!Y>,N0T['#S#71V=
MUQT#)"%G)]8>E(,KR/=]K_278#!_RT&V92P*=*H<0SRF#':(4JNS/O<)?STP
MP'I^NH6!(S?'GX44S:L]X3/2M1A*6== 1W"?G*BK$E61J/J_?YS5<?N@=MO8
MY0@44T +C83$2=3UQOP'S-/U?_Q00L=T7!PJKJ=A2*=+=-T;HS=_["DI>S^T
M6O9>M(K>OB(51,ISVAZ;WMW?Y>":AEJ-*3T T'1!!JQU=/?0\=0'&&G3W-K?
MN:NEYEZUDO#.UY;4?/Y4_[<65*/$<E?GV:PX&K/O0PAD-"_HYFB;1:&O,%M"
M\("2E^&$?_Z(]=B>"/QW)4:IL.=72;3MH_].VQM]@?^\GZ7AR.V #(07+,QW
M8Z857,<[I)##L'#R5NP^C+8EQ+@ROMPTKJQ81?KNU4IX'=#:GG::.[:CRE,"
M,K9@LCC^<"KXZ^]94, JI$$%#XG5B6V,0_G"8@X:XQZ%(P=@BR-GG$3:V:P\
MYDX43VUJZD1-3TN@0R['5[D,?GA3'!^@@3>8H4C@YUG,B;=N9!,% AH-J?JO
M8E6/0%ZNQ\,?N7A(C=?UX77RLU7_$;Q12G0:O!^W37MAF8>0 :8H);37E,RO
M8Y,X*]1G?+X\12)1R>_W5C!!#M2+*IXMG&S)SY;&^5<7G0AR='E@;5G[HW+R
M!5"2#GX .SF[AJ9D(P2H&NT4YYZL#8*3)8G>.AU\^<WK)]&C*DKU2DJ7'YW&
M68QG]5P(!4]KGODH>8RF_/<8%OC4$>C[0- 1J#0]J6)YGJA"R_\,V,M@GB).
M_J<71"W >RKHLW5E<?>57GZIOM_G$UE]PW,NTOPR22DM6:0W/.*95]Y&I9AR
M(:! AG5C9\*^B&M1MKJBH,ZN]OB73<E=+9AXAD(A1$*@K_S[CU6-EF)TZ>RO
M>Q8A81ZP4E?'UL.L'G/GII_H^W$^9 '+@V-T'>3 @6QGPN\V6[+"SB(DV>TB
MSPA90FB^KM$?*K.RI>*GIJVBZ2JM:C((JS=/\75JS8I\#O-]6//T>-HA&NMQ
M:&-(/8$61NKY0BAO&9X3/\W7@]M?*6QJ=L:\WW:O(W*^.^C^^%#0JS95;8A'
MS=SBW,5+PBQV$3!J"(*7X-'3,PM3W<_T.E0IE]/#RN^>VSKO,ZJ12KZXDOG*
MPLL<ZCR 5?K<=^Z#S(]JQ_U_^W^++&EC'TFD@-F+LJT.<SNTUX5=<_OW.190
M(B;*:CXUR];Y?AIA1+'Q[5/P DVD0/T+_L'<=TCW?O3'W7MLI(GX9*86<A E
MN@R4445(J2-QP6#^'YR:O;0.H7HN$A=/U7B^_W)%@>N-4HAW*%,R?)$YW_#9
M_^YWTU*#@C.&13X'J4-56"(-W8C:V*N []^,IT/QP@$Y O'U3254_C+2^MLH
M\;D=ZXR;[7%='G'.J2XN1FH5R3Y%%C(;R#'*:=CE6&(P7:"'R?G-X!+<THUB
MGZ1D,/,>2+?,OCM^\2R/K>F9-DV-L4S8Y>W^92V87_4_GQI;&Z,]K-W_P:(Q
MIW LT+O2 ^.'HQ8U8T.P";G&SQBWR'FG9G]E9U&^NZT)BVUVQ[XFIL=OV5OZ
MWQ0*4'(9X%VG3;Y4JZ E*]T]G:_[E(NPQ<TB_#<ZSA%_H#P @=O47GR5D]VC
MVOA;WPH)E;]SGH"X*M0[:C1%_;?KA(;9%<O_M5O<4TD_ C6HI/B5C.M)46[]
M"UB2ZBTU4#R,>^.O.NO6[;325E>HZO.Q_ET:2WZ8^*U.ZS-E=]H?P(/(X$V1
MQ5;(QOQT!2V$,M*I<MI%OM! B7HNM7A59K.&7W?&I#KX4.5.:\JGLZON[X'"
M^%OT%3FY:IS%87S]EIA;9S5S=%Y8SYG*S]36V_NF!AU(5OIGV*)036/**<F,
M2NQ8&8PP2B5-BKRI^.>W"5OW_'F#*P#!-J?N""3.G'#:2JG7S3D!H<0SV @8
MKS'EHIR&6R4CU?_JL9/Z7G[F'2+XM3G2O[3^U^S):Q?V'/7(,@7,4Y2V?@/P
M C\+AI85-(M? >JK9LTKFUX.OC(]S!'/*]'?4.W-3A^DW"F?Z=1Y*V":34.1
M]CLAL1".2R:,DPO^QW$[E4ASWQ=$CO90..VU7!!FC3.L<K;@G^DTZ$J*0%2I
M9D/4S:=@:?5YX'+F)B9:94O-,N&6,Y!ZFNY?C5;.\/\(V#$D^Z0/].YXMK0T
M-.<D*:45Z=5\9S]_*Z2$>$.[Y?,^=IJ#/(_K34+%Y**?,L"4R$6!^,;5EI5X
M_[KD*+XV6Z6D92A=-U%@LS$WX3;=\'=.5$C8DYK-#D))&Z&Q'CV7N0W>-*=K
M_4+Q,;11B_ZG. ZER///ZY+;[;LBMN)M/TRJ)[>+S[G>LJ#LC4:;R#1'OFVR
MYI3<NVR^*4Y[E#_F?JRYMAET8'[S"/2B,16\\;#V"#1NW+5'L%^$?($15VBO
M/Z'XBBLH!=U'(+$"@5 KMZ&/O^P/[,I(AVZ3_9QJM\K= %@GL;LM/?!!R2W1
MAI8T-!]]UEE]:H9#?<QBUY*A >ZU/+@.20;OTWLD&"SRL:N<Q-AE1?E>8/4(
M9&1.]6(>@>"X(U">N@3E^]]RC?\7;V\>U-3VK8O&K6Y$!$1Z$%!::2/229=L
M<0," DK?9R/2!6,V H(0B(KTG8# %H0H?1<B0@@@$"$T"B+2!0G2)"@]D@C$
M)23AQM\Y]U7=>WZWZM2K^]X?5*4J<X4YUUSC&]\WUAQCK+R+TS@ S6])H+<K
MGPNB -*^&DL6^$ P:/^1-/4GX^K@^Y+S]+=)-F3*'8GZ]F2WD@$/Z6F;8I>Q
MI>6AZS*=DRV7!?/!)H;['G'#U2Z3M[CR+.L1^2R1YEP[8W./-JQBEW[E[N73
MI&M3FB:MV4)B'V"BJV(O588JIQ_>W47_URF4<:3E%JO8DN ^S#Y[49 3/G&H
M;@&3"GLEN"GCI_*HX_+"%B^ [)WZXC$;Y=A7J%5$G0V?4TP*CQ9,:=YMR@G!
MZ!NX]1?43H<$F*Z;)K2_96 @$^@ >SF60LO'+NVX00_\<&8=.$GW-5<@Z$Y\
M6YH(GS_5S3S7<%O87NK11H2@]IS5[]G5WII?'*TT]GZO"[Z+J,\:@383,E#F
M#%=2="(!R^GKT@0B:'R6A+8.X$6U.X#WZ>\W-'O?7I\-R/6074OO,&;ZPG ^
M/J0@1?EC)LL9BZM$+IF3B)ON.@J$5 (_2!RY+J"8WJ9UNYY*O]LZ95 BGV8]
MOIAE5)48?V8J,4LQQ\J_*D-[M\YMJ?%75.>4IV+DJ?NQBW0>9@T=V5_,D9Y
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M>\IAYPY ]89'5JEAO$I#ITG\%PGW/P1I-8=)"2U7%] ;_^Z]_L1W2 2&2S\
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M<+B[/SS5H>:$[EH="M9$T^(G9TU=Q"6>13+O01&];7I*!R"(\B;[]</R9J<
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MZ?[.%"A/"-UN3H?^&7[:/(Q:X#[O-;;+I_O8,A#Z:-?S;15:KX$%9JKD3Q^
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MO>WIRRN9$GZ1?[UXVH@7_><^&LR1"=HKV+1G^#FS2UF!5:]8^O2D5)0V%9K
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MFX2ED!K4>H4Z5W&?"W5V>MIN%4E5'FX:HL<OU/BXI5N765<U,:_55D&"N,Z
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M/+<8KY03=W+'6?U;C:XENZ/1MFK1_433/;]_:P'<1FW(4=6E.NW6$2'S0G/
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M?#!AM\M9^3LDF(*5)$[H/%( 3HD_38O2UJH0GV:Q5[P?80(\F@*3G*%A#@'
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M/'\'.JYQY,)+JLV::<-(C9S]";:Z1PXK-GNS'RGG+CBM_@*<\NUG[1:NC#P
M1Z!)%E@\B)^\#^K8![$R^G6Y6X[V?("#N8"LLU*+MRP]^"?Q17(<7&U/R$*F
M*<XO=#Y>3NNA2L-#WQ%<!9L-W_[X)J67IWMK381C0V9TN,&\Y]/%SJ6 )+.;
MUKBAIN$>9XTV1>T^?XL41='/#VB6]AJG$3DL$FGMP576 0BO=K?*^-U,;3TO
MI:KU$;H(,RI#"'[M&6(H,IAX/(PF<"BNC^TII<[5-13^X95^9K[V'-[A_7OU
M<Z,;B@_.V86=LTO\7!&%%M$5A0M1DNJ "NK1?5"[6_$JOF#F 9 R[P-ITRQ&
M7"+K)!G5\5=-K<A)5$2=KQP3^EK?C/'CF')<X2\1K<Q>5>>^6&LVO!4Y1[H%
MF=[%I76[ /'!"QSQNM)9Y@&AA?!1QP;,J*+?X>)W VDY?3Y!CTY_J]&<K2SK
MHLEM68-"EPG@(W"ESX(.'EG'2&F1VN#<O\R -+B7WFB-L8''6'&/O&902Z.)
M^BG?K#O;6BHJ32H7=;LLT22_8WW\] SYK=CBA8>8"Y?VSGZY6V4JU'VWN.22
MS>>Q"+?$3JJ,[E/N8E) @;E,V]4Z/RG5+_78V(5PQG""2?N;3_!B^#=V;W&R
MP."9^4J>=$\K_T]9SL_;&RN=4G(,[Q$N:9RDWLQ#=:,BL$(H7[^9&!U/5'B6
M.F!-NMZF:?JAT;=JS^1KL(L2)L(#\=/!;O,\&1R=D_30R7[5YA-<MY=B[!A5
MYCLX7?Y\%W5  RX@A6<]HXF)B5AN77'$4[+QFY#IH'Z_V\,U&:GR]U-ETG4,
M+,E.7^Z+RQ7$;*0D!P@%N@M=A,"4IH.[YXXW!T,VG*E_B<&0BE6P+88X3>'3
M\]QA&BQ?.S:@Q'DE7:'I1IH?G+-@@G;Y>)K">F_C9*3+8(<Z08TC%\F"G$$?
M;;U(TQ15'FNV_8#0G51]S5L0ASA'+'N$,QL+U+'*_E))O9\ZLN9@O98;GP>=
MOC+XL)A2QT=I3&D9?Z,[$9KU ([($EB.3&J[_^VBC>JGZ7CYM$.1;<O3DNK^
M<<BRS*6+U@&R-6O]&B^^KMPK(E3*%%O$RP['2?RX_T[1&:J>:MQ=(I!!5I"R
MY4P;'[BX0WXBZ?\RKJ&U.MEM8Z2OR"J'+U5%L2BB* JGNJIO[=%KF?@DCS&P
M#SK$ 'MB3R^2_-KV09&"[)O)Q">YHSLA9B<\$BL<^\#A-(.'R8EGG*8'RWH>
M)<\XWJI3\>0R%:][WI&1'5<QK/;'G.S.8.5VS4-8#/W>!X%^-FK$MHH [N;5
MS6,[DYJ8\H(*LX \YVE/KP\U2UU"9U6IH0Y+$_RMHWXVN[>KJ3<LV75O?L5^
MS#H,5)-FB.'O6D@<<;^5N,]_2/+R$OJ4GOE1I-YK0W3%9\>+;?,VR\:;H\EQ
M]SFA<<3*^J]!9E[QG43_E"#ZIFR+DY[94U.+W3731Q,F/6NE&7XVTWN;0L?#
MVBPI=MJ*0B>-S;[?+;3(-KOQL:77/"PPQMS!(\GX1N+UCS%R;U?^T5;J!_GQ
M< C"A.90QGL$F$ET-="_+GF *8I Q3[(5)?C7T3W[ZHL]W_7RU;)1GUQ[$)3
M+MKO@U;%"$]7_J'.^P_]JS;4+RG EM'YG7\?9#)Q\.YY[!]NFMP^Z-YF[#XH
M?^WI@?Q5L^O"7)>)T+P?+M2]"_^NKG[,'%)-NYC3+Z:/7X[:S'DU9<>AM(M]
M$&>@0,DY?V9H92+-XIS*B=>?=5WHY8@0(D>4BS1I;AU-:I]'<\$G0K3040YO
MSMO$XF;/TK__<G#I.<0NK#R=X^7P]4YN8MYUUWLO_,O>>FTH1>J"2+OM^R 6
M..ISZ]E:1Q\Q'(43KS]C[=[:>#EU'V35+->1AL]<&PQ]O+"H,K FF&LLJ-2'
MK>QN^^Z*>RI:2<X@RJ3N$@LZNWU\&4M_A*$P4=$Q"9-KHR:!KXYA&L;R?F'D
MJ&YV$WB>D1H<FU*^9MT,#\A6A3CWA\4!-=4_7T&_52.X4O)?Y)5!!_8MH+_/
MW_^;]-I!A648ZI<1DHE(IG5(4$;.4Q\'AC"VVVP?9%CHIK0PN@^JL,;^;CR>
M;:['>RP;^AI+LO&+UQ4'+',97YX>?P9Q-WL!$6'((V[3BVAB3%+5.+?!+:1'
MJB,H=9XR$;,90R@0IX/L1$>HQN3X;R4ZB6&+HSO.ZN1:SQ%'H;62D%#UK9U>
M; KX.99DA 6D_#:>4-U1;5<1_$2.9PZMD1^0 UA>A JA1^TFXS+-!MV=I4[&
M=N@H69 38YK-2F")Y9UY\)!V%/[U*E\67\RL%C7SP3FUL;K4_'9'&.-EY,J=
M%(2^%EB3C%NLR8G*U+P$G[#F]8P]R:*QL\Y[LW"RXNHORR 1N^TN3YZQ7)KW
M4K[<M'G[G06]B6[K@ZJ-3*GC1DK<4BP[VD[BWV75;%7'>"\_ZM7>]H_>4V)"
M_'HZ\['"MJ:[NZ""?D@-9-_<I^/K.X0M\$HC+[UL'[0>X$J6'.QPD2+KHHM7
M']%C.PT7T+Q >OMD.]XZH:2P/P?V5!"F7LL_.1+K=9VM_!P]K6)Y'\0XF4/5
M9?1#JX[3>!PI1/I;W5,T,;,3JUFG $N2:Z<F-+&4(0G?[E(&(C]GJ2B5&A*P
M9X'@SL;4G (@I--!LC+ 52)E,U$NOSKGBU^<YCU3^;D]4"D0WK 44+RT6@QX
M\YWG%>$H:7Q3<E=Z+$_*<.'B)J3IC75>])N:ZGCU!K$GLK<_ZZ//Y_^<Z!C.
M5+.=D;;*BRIB?4U!6[<5A:R:KH99MHSEIV=(?XPA#=H=G'(N^4!^/)K$KMN3
MTAB9""_FO%='_[KL-4>1!XR9\[Y5K3S]V=\+Q,$/K8Y>N@^:SVP$=V-C'R+,
M1EK%YP E9_+;FF%,R2GTZ8*HFC\8G2/M_#VYJX^3)1L^#A9<\];6*)B:G8[:
M0O1H]P$/8JY-_$+F_JU]9]L&I:@X,]<*(2*>\NNTV$ ]5'A;/E9$_IBZE>Q=
M=^8FL#-&VG$S#9(Q395,\52)*S!Z/ZFFOJ#Y\+V3&\]D?!:)8M91+Y'F#I=>
M^/2ZPHR;U:+$Y67$^3>>UWCOVK+;Q'N87BBQ$-VXD7>R5]E4&<:P+M@X1'W
MZ*Y2S*0:PCF942E5@Y)4BD6RRBEB[MXODS;<"<FMJXTPL$N]<)?\.#/[V[=;
M'1P\T-<-V"NMK(Q1, O60^22"TV%7)Y9#.T^<:!1RM]/3R/V2R/:6N<^N/"T
M_#)/2=Z@> 7G&_4B!T.5:>.;50;"PSULP[F51HG"E3=CR#U"1;8)-^Y8#X^E
M!-ZQ?O/JZM$8&@.89H;D.J!#YC='"2)4&\9TC]),Z]*-J1S<P)'0B*2]=UQ5
MWUW@3P>([7*&Z8;VN2VDQ:7PIU_[%3K2W*7G+.E%;=],-I??<NR8J6>A9YX<
M$YCH*>F?F?L*1V6:L0=6:$[KV169^OH=':G<ADR_=\1E48R9 -U!N1[U-4.G
M0]:^Y81<R#MD2"\AJG8H)WW$1U\6XF3RC7[T(_:<Y<(^:".3*GJS,7A#;-X6
M6"%E#=/>MBH TM%!9;H]#C[)J[M>/CX\":]+[^"(&UHWZK/N70.R ,+,[^/S
M!1L728Z4YZ-ZRSB(X,I>?K;P>9_K./YNJE)GNL6/"(T]EAF)Y:2X4K1?M6._
MHLWQ]=W1TU[= W"5R[T7^I3S/_WI,M#PM-\TMG?]U5W7Y))WJ7B*M:='W^KB
M[X?C5EN\ @[+96_\D>;I1$CUJK:^Y?M.EWS#]^9PX4Z_)[?#]5=<85H:@E.R
M]3&^3+;GYSKK\3'FC\KJM08T"^I+!D&)RA<(IJLYV)K\ET8XZ2-+$+P!108P
MINIE3RI^2/N,Y2X[:L'D<EPT!5;'-<YO^*H>CZ"^F[F8R YURB_Q!U(-Z7,V
M-7;#JM]=VC3D:-'9C!%43>(ZM!3&.$(O#V0W)D+;^V+#1YFQ,XJ34RPIO'X<
MO7A%;:T(D5/<^XIH6/,]@*K562+HY(3_!J3SU-G20TOC4;@]<$R-CS&N57+X
M]W?4E0F%^U7C@3[W>N?,1]6$#/V7'&?MG;L56CIN7?%)TO^L7!*G7 3V>N,?
MMG)GY3["X$4B)VE=I)!P44U$&R>[9*C9('K_3<E\GI"^V2DEV//2CP2+L">+
M:N3I@I/7\I7S@W!3#0\9*-5,;QO1]*)G_9>#K*K?-Y)SXF(GY+C![O$Y7PM8
M?_V(8S,[A+A&,NL$LTT!W83=Z!HT']S=8E8AR.?\O!E'INB<YLB2Y,F NRAO
M9YLML]87^+WA*8G^9M/'DV[09(8N/08IBQQD2(XAE1@X%X7&85]QY>] ['Q6
M2PAE[O0:Y0NBZ].P:9[4M%+.3(M/X'<D4>':EQ[5=*D8^67U"==I)N6>F?S,
MY)9!.:1N8FVR_T$M,OK1GDO._!SOJ7C(K;&=FX?E7WDT)A3QEN ]N9N.Q>(:
M1V96P[Z\6JGVNNNRA/D*UST;)^*]%G:QBLB6]<;9R04\W94:FH1#.LTHO'Q3
MH'_R%W-GN--2RYH3MBQUU4$2?EHAD\U9&!U#\O\2\+3*BH2AYQ2]7N:>UJZX
MF!X3#VM!59.S^@3,TCECRF=>[X[SF$-90XOZ'?9!7PCE^Z I# %"UX0/-#HL
ME:%^/)Q$K3N0T(Q,;7=GA;_W]K_W=Y)?M]D4KAW,B[SX$\(9!.;QW/,6E1[[
MW:_1V<B">:^R#_)DY\"E);(U/B[>-5=/I&2JX";2?=J%1*XO![>$$Y,O:LQ:
M?UV;^\5#@M+C)B%[4?#R9QH;_[-^KT,Z//\A$'E0X7<P)4Q)!?38IV!&AH+7
M/WI#I>"6C,X6#B:&2_U'_\<A4L5&)VG7IIY4$<&X!,BK81-:3WG6XE>=KY0M
MFQ$P32^()"/.!16]7*B>7U&SKY%B.A[/&1MY?!4=#CWS&QV#Y4#(+=#/%M:0
M15/8OTVT3>B/[ISM<_1L="K-?:F>470]R.W<X,#=;7[953,?E*M[L=WL2GIX
MLVVJ8'Q>9_Q.[EJK4(E6O<OLTNQ];6U+G%CG>71SG,%3VBK]K=*6[A'$(R">
MJ@A_L629O5H7+*H*V <%2R+'80H-]:F]_$_.]J@M11\V4;Y1PN.0%JE6%: P
M^!<X]^"1!&CRT\(1L'V0JP2:D<W@+4]OR#S%N-9ZH#*3-+@/NLUDXI,F5U@0
M"M2'M!OC9<URA,'GLZQS 0O8>,V\UK#43RHG/Y!FON-\GKI))]R-M6].95?X
M\5#,1RVH3IZEB7.796,C/],]N!#Z30_F>M='9V-Q;)-+R,O8+BLD-OH]Z?5U
M-C_Q!+B5A=EA[&74?TAB#OY3$O/*WY*8&[[_DL2,1S1X_PY)EJ<:2U'JHH/.
MQXG7"%W1G?]_R9G]UF2B_'^7@3=Q&CCP^X*R,"%K\#ZHT"_6XTC^?T#\_Q_,
M??\39N@&T(L9( Z\XWQ7"6E@M!-%>@8O'NS<!YUB2-$T@#!5#;(,B;\3^@++
MC1 CAQ#0L>(DFN9RA-1DS8925^O)85,LX6>SX8=$;O@C9U=<L&9>66I9X,XP
M=GV&JME'+@;C3<V>H5CNTS^6_4[^X$@+95+N8ZCXVQXF>7W9M;$<G>I#B0GW
M1DQCM?<NCR8[.ZKD]2MFW:6*)YZDI$L?Z4 1WNV#W#D 9S1I9(XT.'<41<A!
M5:,JL034/JB]B"1%4QQ<9R[]@#X3JV,)GON@.\R_!],S]D$GMF@WD3AZ"P7*
M?#GE#_0NO1/"'%>U[?HR^3AA, K) =^=YV@S$Z*)DX-CU2I$@0J"7RR#%^#O
MP)Y&F"TP.<W +E$CJMF="#[JI<F^%1%4P>>U#SJ#43#H3I^,PB@H+]N-:[NC
M0HBQ:ST[345;N91&YF:&/<H8>*S+1<]%2B*')D7_JAL#=X*/,\[03@+^\SX0
MW,.?@E+MT(A]$)N:F0@<;3$:V."#<2P)O;</ZA95('^KV\.L/S5]R9(028 <
M 1[AN^X/W1\+XLC[GY1O<40RD>/'UD/[H+!=RBT@Z5SDP)BV8*-98LT^*"TX
MA7ESOM-,2DVZY:IQ&@X_O^ENKM?U-+8J[(->Z,/;^SJ01X$YDJ7#M$[,[!20
M/]MER^:G.L@'LP"@'<.R9XS:0,.!UJ\X7O44\[$*O*];+XAIUKE+W&*#)[8_
M_;@UJFWV88W)R"P]0BF"$VC__%G%D2L^$[O*[+G/IMO^$F1XHN:SLB2QP&6J
M.PS)/GG6OBX*V@4YJ7TEH=-&P51 O+'RF9AK8!)0@7OJ''?GV:JOHX#$:VS
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MJO\Q&UZ#_A%6FZ/R-4LQ$9B9P*0Q- %=B=W8)1LO0#>.^)&:B ;/FB^[^5?
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M]PQK:FO;1>.RH")&I(F4+ LBS:@TI20V0&0!(@)2(R)2(J "$B$D-GI;@("
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M+HV;I% IH>&+=X?'T%?T(,OP3Q,B WQ09 2]YV,/4E$[29H-&2NAH\ZE?L]
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M;@E;9D ;/L8)WS8?@9 !2W@8D,T8RB[$[&..+L\D<S28A X&=&J"L@J11<#
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MWP?[AW9?,GELDUND#2*F3A2=8-&B6^YP3[()H(F1\2IDR^-7WQ$4T5\4UX3
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M]@S?I%7(YO(RML1ZMP$CN<#@(A1X:N(T::!://M7Z- 'C1\+(G&4"KMP8J_
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M3F!3D-&)_:TA7^2$1DN<-^!6<,'BD=K)27TH"]QU&;1A[T%(.*JG4S?"'S*
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M$BYM^ZJ:GRZ>C85"VJRZ,"YU/F8'+#1^CO*WY%G%M(3;IM]_-:8B/?[UT_Q
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M*OY<8POPI+:5E!$NRYM^*K)B+> ,A-&K,@I4I-R?T96Z*71C,-)DN,-9QK9
M=R1K5B3<C=<TF0AVWF^TTZGC3ALD.T"^R('S2EQ%O$BE&@>4U?[#8@VP'"5K
MI!/5..'XP9!O)+#>2X?=>2KY!2]R+E##;%4.F.NBD K1N4<'!S#_3M%ZU#H
M#4,^:+:70@T6D0F'$&EFQ4/OX#,4OUM#6V<9MH30YW Z^ Y@["%](#O)<-E$
MB.N(44E;R$ZXK6GP1MU%F-DJ.&<B6 D3X.CFE \2\--)9EWP6V .6@8%\CA?
M&CL=Y%QA@DKIR)$9/?JL6_>!-M4>9E*J+9+'91R"!%9C1DMD>:%LN(H0<K"
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M&GA K%(!1"(?6K0*EV;Z C ^V 6J;4;9^"?<C+*9P$O39%L%:U!-GHQ$ @^
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MMLT5VJF&Q.][JD:YO'U:R;XE37%03J[SL(26)[^'R)M(&:0E(G-4JF,BM1E
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MFH9G?S2-*JBA=P[1MATS72M>;PF#[:N50"#8@]BN!E:+!**(=@-%OPQL*.H
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MIM]*(->%KA)(;@][7JP*W87[_K74UN+;[M62  GD7ALJ)2'M6:#OF0BQVZ;
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M,!R6:@$5'(MO9\?#EO#&S_&44W4Q.IRA880K'UM3XOEE6JDIN!#7;-@D[SL
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M/&XY\<79]I&:0_= +R"[6VB.[4@41-%"B;XYR+C,)T&]^_W[M$$+4R(PG*G
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MC:=B\^_->5]K:EAVO-_<7>?]U]SPL&&=Y;1C65EJ_G1L'?-VC>>Y%HM]IVT
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MQFL]AX/:CKA2<B)])(]9V,ADACXO&B?]=MNB_YPY6= !D_/Y]F!3 %EL%3^
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MH_<<].I??QS!^ST8HAF#C(UOT& XGDG84/_MC,:49/'XV.,LI1 U8?B.T>V
MJ2<D*[I1,JGM"W:]^B:Z9_DP)8GH KM/+"1;SFE, #VPKY>:'^, ?:PV'Q@6
M:?#(H5J:S\"=?W"1(_.$V'5EJI3@8=_!%)IU\S9J(@XB>Z68.>]=FEA\J&[8
M ?<S!3\@_2I&+M%N,E'X(%3C"#%*B3L 1B]Q"W*[:^^5%9U-]]@&K>W"@KU$
M5V%V),D(,(X>^;)A5W,+JML(' KHDGU14_<$:D4BG/X\DYI/LU5\.Q#C]!N
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MIRA>8'HUSK*SZ6L'T[^P7SV6WI ;M#->R\/5=^@.L[A5A-50O]*E&!*?Z.Q
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M^[L@:<='YC(YD?[#D O=SE?EQ-!%ZF=[)IV0(&6_29)@PQB7B$/ZR$.T \H
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MA=Q%+;:2BA6=CPL-R=I4TT2%W<&O?7AF)K,X_;&>-N D,#9K[&C;M5,KVOC
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M&9(]H>MR*H)\;$)C0TH7X1#46(:IMHKZQ=[@3:J1]"5"4/HF5A8]F&$I6\\
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MVMJS;3V&V0Z"BJ>^K<J@K-UE;-5/(2&);:]K]5)F-@87[IR0MY>KB)3)F+V
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M@@G\#L_*ZB +PN0[ /[D9]"KC:ZO)(-8N0<Y,7=QGB1#4X1-FXFR.0(N"L:
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MP!$]'EF#^/LP/*!&5;^_A:S[=VA6L?_7'98C! .H0?J^6D&,L-K<-SVA)S2
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MBB8?38&,(>)?H'@T16A\E$0,UR^C;85>I@BMJ:?S$A)!"QN-99BNY"09F74
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MLX#3A!Y&KVYR448(\5C =7LA;'V%$Y"83J*!Z+B#BG!58*\WLQ5/U"$5TN4
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MZ8&-,?;EQMJV)A<RTE;3"XI:*C*F_C:Y+GRO"JP'#PCH;.L4;J#X55)8C2L
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M2?"1)PI8IITR.+GZ[7:E].-$$7&L.*44<JND>1"YW6UP6]ZE(#=MG.ZQ/B?
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MN7(>&QGO<N02'4D+DHWVKWC&;*9LBYMB9,UL[9SMV#+8- =T6UJW)Q*SS=&
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MT#=A3G>T\!VR(-B?"7R<#;F#)6B83YEF>/%I-"FV.+EWN&Z+KZC7A_5?EK3
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M+34N07M$2D[P5Y"E3*HDA&R-=!<6:'[6Q=D3\AP/OI\L4RO+G#]F44<[04<
M;C20(^KBIG5K0W2-^H.L)G7A@L;CARP#4/G;\A0T:4/\C1ZO:J98U*JEQ;7
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M^ZUL092Z_=SM76&CZ>RYK?^-O?>.:JI[UT5C105$D5Y5>A>D*" 1%3 @(%U
MR*> $&) J5$"47I'J0I"I(0BA%ZD1KIT(10)-0%$2B!1"8&$</.=^\<==__V
M'OO<N\_>OW/&V'_,C(RU9K+6FG.NYWV>]UWK?;>/OGL];SZ5>0CH5&&',H\
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MLB<KU8=[^:F< XGLC\QLK3:VM36^DIGV<B:K>W-,PGB\/29+CW9>WHO-RAZ
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M3['UR"L89>G-:@?)>I/*_P4I7O_+4\*&L$"GW0OXU]Q5*N,@3IG!SM4#/(,
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M@OTN8DA%HJE.Q,TS.;9"1$_8)(AG_O)+9>BP,TE'!_VU@-3\TXZ\O@']^'.
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M/ 2<@HHI98#&_;O&'B6:;\XI:<V9X4Q%SJ_48]..]LG7_M[S>9?'090[=<J
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MIG:\N8;*C#.TT0D)K=G=M5,%Q9];7I?SM*C- \8>RJE=^JSG$\'Q<VXD]!#
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MU,W]>,#D)$5F+E'@LG6BAL@'^?AD4)_D1'_WM9+?LO/R=A8Y#;&!%FF88/6
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MZG%;_N(G'](RNJW@0;<H/FN4:5J".K0T0?K'MFFB7!:5^N9_Y(W] OCKR$_
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M_OMRAW9#6@'ZT="4PKX98:45V*'T=NBPMR=>E0SO'"@1"^XY?)GT=*UNX22
MNF;6U9CR3Z%#/^&,_JU?SFKG)MV/*_>NO,E":->>C/MZ*<BIU,7?]OGW"CV#
M:5[/&T%2JY[K8ZM=I.I/\BI=KI=4+]:=PVI^SZI;&XVE[QFEQ L,8ARLM&@W
M\$:UG\:"C#>OJ9O5Q@\&H]&!'+FY%0HO1F>='+7]KPNG'$NQL1(2TIYDDCM%
M@<[4.A37)4QT%4KP/XI.'_B)4BTI?%]3[:812SV'XL45OD)GV[8S7[2*J8[8
M28K0"7ZA)+3 ==%_);Q1XK8IGDDBQ>@.!:9>+UMH'%_&QN 6F<JL/G2U$_Z/
M\^!^(V!,U +4VJQ%GJ4J>0F$(\4"/U O#_.3!&Q;-VGPKL:&70D.W>N7]8^C
MLHT[<ZQMC 3;M4GLV2^K:V)+JA$;"]..>LZIX\8<K]U&RV." ?B$/''9U"3D
MEI(OA; 4*SB=@B?WV+P)D/)L-XC&6Q[F69J&EKN_^=29&&>UY6)G GWJ<'E/
M9+^ &<?GZ9\QM0+[B:\9(!Z')?7$A]IKV1WH4_<;* X=(?P_CI2QI";EK5:A
M]]69][*TVH*PUC(JUUT>]]^'9=B@R4P)IFA&Y=79".79/T?+>D#+HPO ^Z2J
M@6RL+F_SZQITAN$JD+XTH\2#YZ^)"]C_LHT\3PR>(#WL<"G=4!&\C:O"U>Q0
MN0KV3],R3F67,M&'K[@+*[(^P --0EW4%M>8B/B*&!R,S SR88EXHO)#>:W.
MZ9\>6-H#GA2T165EY=8VL:ZN,7)B8EHR;'YZ6G:QL3%2BE7T(IZ[(D!/&%0J
MZET2^T\)Z)@]NF)>A(QKZ9R5<8BM%7YNH+T4TX.0,O?35N=8]&!7+;VJ[.TG
M%IV+\/R ?6*PKRZP:K]JMZV=RGIM]YM(7*)4!RUKJD=:I:(H?4DMLD#X<4OM
M%'9%ERA#%1FOH!I1>"$\S*5^CZXWZ (GSJLV)_OY466(8B'VF@&?D*K5WF@N
M;5ME;5TT>\</XVCJU7<('<]EH3BK3W%:1_ (#%D7][V J+Z]39RQW:9? #8[
M#M4[6[")XN)D@22D09%WN\AH*SR?:CCR^YIX/[&.=MQH''F=.'AE_J?6FR=8
M;F_-BLS@AC[IC\_*;@SZP4?_D_=6O.40Y;T'!8,N#M&4-XZ*-8Y!\@CV!E65
MV5/":5Y5MUS\/\G?]1KVC_.W>I=QOM=P(MER,5'@<P5[Z;*J@DVB:T3.1]N^
MNSWWRTW&'$>Q<"[-U+(/DY=?80V-;0DQ/_%$:&?A$8Z=#@$7AVMKP#*R+9(B
MT.P"Q?BD8\QOJ-JPC%RG9;X#OPD*^C=?--.AQF$'$MNA$>"#7\;,A("G)HHB
M+P$/<<'$G9>3Z\1K)]!*.A_@D0P0Y^1/@*W#A[X347>)6N%3]SYSXB/L-Q><
MJ0GOKC=.@UWU?(U2&*!/S.E*O(: 6T_@@CO$ST+,.#SQ!W9WPS^C6. MBPMG
MP,513UY2*S;+F?^_!/E%;Z1S8$S:AVGIT(,_9@P0*.E ] O9)MSF)V",EUA_
MMZY[8'\WO%.<VUF@DRYV?-@SZQ[=>GS$W'AF@@'"C*/)#QB@KZAOF%U=!NA8
MTH&@1.>\(+R%.'@2E:6?!TMO,]*^2EQ>?[=6L%[X/6GYY,,1X^GQD+%2!NCE
M +6W#_PCB?X/[DN_,'\T+EA_-'.]V!Z\S'%+-4$*]3.S&#K:_QTM6ZX?ZSR*
M'H)169DG3#D*SX -0)K0R29/MJ^AMB.8,V[Q ='-8U_;VV/G&AHAMUPA?=[=
M?-JC(7VTK:=.F;,7];A_)U[ZK0?Y8KGV_G5GJR4S06RMD^'[!4!0"5(.V%E4
M@I $7NZQO8$RI4V]><")0U2Y9ZJ>1\5:5N6K_:RJJ$J[WD#_C*RJ]&=>H?^8
MJ1AH&#ZPWF]60"HK\(1UF7<O4OC(;RK4;DW@2?[C'KI<-RH@JO(CE4;FI:8?
MA$TOOTI+'5=ULT\0U9-/N\1;.IEOS9EKKY8OG%9VPV@TPBC0XM625$%\JLFC
MI.7L.\P@=!;U#2?<SDF]'[X?TC2.8J4^!.R.#*FNPSK"B)X_7?-R%/YT= $"
MUL7E@/#I1"GZ&IB/J=DJ/2R(Y2H"RF^]1D09MEF-5:$;.O+ZEXSW(<Q#UB/A
MM$RZ+'2+.<.3=PE!X., 'F\QO:;#!NQART4<9JXWS-PR$]NH+O_NDP<9>V^;
M?1,H*#)4JBBCV\3>5*SQ'CC*_^^K0CMIC>A[N!?H1@Q>)"EJ0?#W,<Y:UY-?
M\TX!R>_Q/N"$UN/E1@G+\VO-KT8T9[]K%YH6OO-FTTDNPS=K90=E#GR*VX\!
M7D9]I=C^%*"("[8R0%$;I*MD.US=?JLN7J-L;#UP267+R?GYFQS%W,+8 9_^
M)V4]<J,V21_+#WX@K*O.1(I<)0K=Z?]UR]R\Z][59RHY*Q%7!S+!<?EL^@D/
MJDKNK\M^XZA7]PJY%9KJ4F++Y+WG>9DA7J5>S1%U @W"$1%?U3/4)X(O54Q,
M/@U^NB,I<&7R;+/Q"?(7BK&(0H%*M?0<&K)P!N8%FQ&@G[:A.-RDY3! /M=@
M=L#4$<_F85K# F>[M.?3/YE88INRX=ULW DGN-&VQY4WB3(4EDXG;XKSK&JF
M#M^8_:G84+/#1L" $D5,ZL6 $&A24B=8V--9APR)V>;?,:#POWS::)TJ=WRP
MH2GZ53.A7L% QX2>67+=I^2[H\+,O(.N2@TX>HGS5"^Y%N^Z=E]V%7DY2\92
MBN38=G7QTMC<=(&=L\7G%=64M !!=ETKK[$(/18+U66IWV]9N(F!.-^(4J,B
MIYQ%C+1K*BG+MD)U'&N1/7+?/]57T[;,L#,@3<3\L>&A%:\YG#/TW/\D=Q<B
MT"(,4(/9?_2690:@,!MF'#5B@+R@@.P0E4=DT3WIR(4*HM4]?.+KL;2Z]?OU
MAG!CG/95BH!QO5[[&)'<$%.ZCKHX7M \<:J8A&$#4CL2J@:\H+%(0V(2%_!X
MOG/R5OL$NN;,+C8!+MK.2?\&X]36I:"7AKIPIZB2@"O1]EUFE[@&9:7%E;@#
M]L)YYRH])&8<TFU3C <V2^_75W]LY'%><#(4:RML)6CF@^AR:I 3Z X_V&([
MO ZZ54Z$SBCLJV;NL]"B<1YF"3HBP/+2=ZHA<8<7(=+E#)VDGB-4?N!_#N^*
MZZ4,Q=1G'RDDV/P[O/T;R[G>SC?J&Y3=!K?#^;QY*)-Z5'73=MR<5_Y"V87$
M?\I>\/V[!0*!O:GW1F"+Q 5 0B9Z;QN"%Y;9GB.OWIE4HWF8DNG)K@+A=&7H
M3)"O/5WLLEF]\5N4N(&7\*SSK.[9IBS$MH3-K^4\#;Y"^/1)MR ;"R';4]86
M9VJJOYQ+/'TN[/1BHN<QS_^!&E^%Q9T9-)UU\$@5-=\.3M4#.H@WJRF5$0G=
MC:]TE!#W%1S $,#(SN;/_05SQ(,HN]$,/0/,OY/GVT=7[W2XA!FH)+5Z8G45
M!@,54\6BON[&/Y51[B6ZE]WI)GKWIWL_WFAZ3ULS<5:3&S3*O:5^)CE-DG00
M\$E4W#6R/+S7I81$KB\8L(Y R!%2UK;VTYP_YOC*&LKI%:7"DBHO]RZ0S8>
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M>%MV%1.?(A_[KF!QV7&+B]T]48LT)3^J355S^O3 !\_)0L&2T)9(= X<<&*
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MO_UZ)/Y5UKU)&<:3L2+H%6C11?36##1:[\^9J"[7+TPIOU'AH5\1.OTZS<&
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MZ=L33P5L+GKE'2>7I,@YL_B= <RGK]B E48_)>-\8>X00!J^97XD85 \1[T
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M.7ZG<?>,!'$^I-JCISHJZMX>XIL)!03\5LL6=:469G7+,J7[Y 5-87XTPB]
MQ14F)GD[ 'C%%&=)VT81NS+Q]5BOH8!PW#5$I(Q$Q_,WK*]51!6'''7UDU Y
MS_^M25)J"*T($F)>#TT$MP>\QAUGRW*JN\-I8&ED%01H?K+A@%RX_I+YY_<=
M+VSW&F.;W#%C7) ?\LQ[UAU^@G=0A0_)(OW]V)Z%(<W84MT!+TEALE[=_9&6
MX</PE3.F.L2;+V(JD@'32.OH:9"T\^2(D95$N9]SL*:P::TE>)/9;UU%G')6
M4>W_\9(,8@H_+U*Y&6JTZ%B;C7.?KBJQ26\^$PC1QJ7$9PF95190RXQWU9Y.
MWGOV6276XXZ^C,=^"?=8' 7##QSE"LPQTJT9X/X19;IL<FT=LI;4U?&RLO_I
M_%JY%%.NITYH).#U/99Q?T]!X\TEL9=GQVG2'#"DP+-.^57RI(?7PI#V1A(Z
MBA>3"P=\ON=^>JVB1UPJ^+=-8?+9W8[/@ H7)B[#](I_0&3-Y\S&(*:'9Z;A
M'Q--7[244VPF0C0:MZJZ7ESP7G=(1=SYJQ-V:DE^3)"MG'7AA>E0AE'A^2'F
MKNYU<4-C,NWY7)+'2:)3_SCN09F%^_LDM0OQA;KV[5*F8_8E6-NW?>":T"7Y
MDXEO=(*UU(6$Q15$"GT#7?H<GVY<3EQSR)#5MW]7E=^(VU9S[Q2[B!T>5'F"
M=V+]GZ]MCMT):=S67&U[%2]=;_/4O^-EQ\M4Y<Z7G652JH_+)9VKBB6K;F>Y
M5;M<^Y<1/^BKZGX4IO=WO#)*"$@";Q%X;*%I2A^7 A:/D'[5B.FOX#=5-PV=
MVW@X?, 'F_IB+@<KE)QHHA!(.7"HL+Y*DYYWF ]T4^4L_A^]5Z-K VE[Y:?I
MPJL)S*_]*Y&JDSSIP8'J#38_W!MP+J&L1#H>+:)\Y)3%.&145VG?:U16M<ZC
M+.)H 8^.0$EGW-X/](766_K,\&<1A^;\GI])G$A6$'B0]@EK-'@A!"ZP@S5Z
MJXCHQP!*46QQ(5Y_R>D@\*-UW!=0TIS&;X<K;&=,!>JMS/^I KX<\%ESWE7%
M4>[7M7C-;YPT-MF0.S)Y9D/*\TM.[ZZ)[,X">M*5%L4^3>0>VZ7(+_SJ69%5
M<0A! 33WO0#,VVD]B/3GKY G@4NF4Q%5K$SCY0$'F'6G![HKYTE-/KWL(J;]
MVP_KS$OZZJ9DB3>\!N;*%MNG6?4>\#VP1Y,P#*<1=5? EYG^1W<;8SN)>P%H
MF5:7EHT8'$)4SZ/^Q'<JV_A/%@Y*:9-&M.#9QY'W;\7;.M $OH#;M? +>E3A
MDHSS9\J5&4ME5YV)CLBLWR@>[69X>.[F.EW'U=_1X*W34ND_R(:SH1F4R9XR
M^=+>@!_)E]*J<L,B*&O3Q57Y87IGZRBMQQ\2/ZE37W_2U(S&;L)?O7BK/^K(
M&F5]Y,FO0&8V)W.9G["+1!GA&NL_0A=B N]@;FN++7K:B/7WD-/0 J.'&5=;
MB'HZ//Z(..=HH>&?<[4Z,W_\S]M6ER6O.8C$14)+72=^&]*N96L$$'[ZBLR,
MS^@.>'+_UEGF7!V!K!IRCSL!F5'5W#=@07.1P)W<1G8PL%KIWOCPGD77A*EL
M#73CE]*:3_[9_88^HADJ67\(+P6<LCJ!6<3,=5(_X/K <U\I%41I18$0BG92
M.3^C+4CA1)(Q.$5OXR+?@U,*O[I5"%3DA<T3%'@]K G#L-.>)[)6 -R^ 9).
MD<_D'@6BK@#\\$:XP3RT?\2U?[H&(KONH\A@M1['RN4_9ILQFQXUP. (JJV@
MZN/)3^V+#,B=Z0G/11.I+88N5V@&A]('>BG;TNCQY>;DRGKDZFMB[Y+@9/=%
M&!TDZ(74V7>9CIB@@20N-082#C5LSSBW,\KPS96?72INO6I/OS'CZ/'/UA<]
M3Z>7'.LF4941MA$E(U>DOUNW@';^44%D<<#L]2')M*JTVO1AYFRP^/&P*JM#
M/F+B$IK$9U.E&PY!I_+^JMG"I"6AT(?27^3J-/X3<&;0F1%]3T@#ET@<J[OL
M=-XMZ$4Q(U+M)FQ0;EG:>:)VR!KV5EE9[![&;)GAADC?,Z\_X./G!YC,=);Q
M-,KY& -*A/^\HVP[2LH^7#T&H)=)>,7G>,"1%JNBWVCZ0&%B]X."TT2W6%3T
MN>E59^:I]>2^:&O%6>X+#*6@X@CZ,/LX)QE]I)]AU M.ZH93O$5ID%13_WL%
MSX/PFDS(@[;ZV.43\!@.Z?J81H>AD%(NXHX2/$3=;B)DLQ*A=>0?KA^@R^LL
M,0RKOE% Z?N _.S.AOU[_=%T@AQ;.0[#-*15*3W6B(2D=6QP:BGU0%--6YQ_
MMSH%<J+7+_Q)?]BM[W=/$Z:T-(KW';M2\8@)WK$7$Q@.!WS'>4W[/-ML7QBX
M0L>]Q@@AIT=I63U*KVB9T@,\-;/95F9%L<3!GZXGO"Y84DJAW@22YUD0L74E
MDPTC4Q,8S#!YB];B'0!?G(?LHB D4_7^1>W<T'N>I&\[&?(BS..>_W03#?*O
M=G]/>?[2J\YAE*FW-N&L#/DERZW__FMK:[U0H,MTZ5WUQS6DNY9SV<>+T[ZD
M,]T%R+T? XX9P]SZ^S?@&B-PNJ_Q(V?)=W=.%JB+[$:E]JMT.C0*%JPFGBI,
M^#F/"H8A3F%Z[=$J@"M7H'5?"%9+L_RG$J!#F&"R?(;X7V\9^Y:OWEN,E+7)
M,QX29:8K&.E([^TONR)^[EE6WN'>"9 Q4S,1-FL%9UK!&N54F&H^X?+(XC5Y
M0/%==G1<$TH.<*Y%0AV9(3U[G")DRP&?!S-X?CFK/;9(A[5AT/,8@#M=I>MX
MM\<''1E1Q&BT+5_F#A[P,>SD 4WE303E*5X&]2LPL\^'%.V;,2Y>-^9\-!=G
M'FFE$4X,[SS-V88RE; ,OJ#YW9'&II!OG[>W$\4?/B,B6)'1LG@>GL0G_@16
M0F!V=H7<SXOCA4,L=V". DE9;B/T>A^R?K^M;?X[K N+2^R^$ET]%!:.H)D$
MC+5!)*0%9'&[)D+;H$7@[@'?=<+X-O\K+\^VN]+9C@(D+WVB>XT5<0XB&LK1
MDAC:P:MRR<.!?A=F%QUIPT25\J,@DI>-D7];Y7T6P:,^Y?58;]QM(S6?<9TZ
M?3%%,E3UG6Z&N'\Q?2=XNB8J;>!C!;3/J3*9>(/;U_?I!&EJ\"ZRVVLE]:.3
MGZNHH^BF_X.Z(<5C'33NSU&A[V\(X@18-J TLUE&#0Q996J]9)KLA[K#N X?
M8%V(5/8U*OCH_)#&'WKB!@8=76@L6LZM0*510^N.C#3\]GP%P_)%X;]&O7-X
M<;'"!(-.#\S7-%8#!">&Q'TMW-N"U3_>1R+$UJ<-7#J6[@K\%L%P3>R^B#7,
MZZ">4B]B8R5.*<;A]J5_)C[> (ABU4YB[N 6Z/2 )+PI>OQ\8 LR]G4QY+[>
MJR%(2CE?6_&[5=O<&Q-0QW%3LW/?'\(*.UE29OD5R1%P,]E(6<M-?&5LN R+
MH.*!Z57$4*HPK58#\O/2CIQX3! A 0KB@M!C'MS:!GA'Q0D-E)5$5O<%^+,@
MXWRV0;&..Q(T("Y2CPR+]!P242!->WQ*B0OW_\AY(@3/TY43E/PN>,#WS&CY
M. /EF.?;7&0N7E4X3O-R"I>Z:*DK71)V3K=<M9=ZX>3K43$-'>*-U]3/3G5)
M-<T[5>Z6@L=UXISO=F_OQX+ZBS)R93U!#]ZMWZS-'4-:%^V="3Y^8X>=>](C
MES20"#>>"M,/&M"O88R5F73JC;.!&:[1^C2A$\06Q[$F&+) _ 0UH$]>%*7&
M(#SX%MWG:4/KP3@QM#</^*C[(TH_I$\%W6, '@=\_>*&XA,JFOZLV>%_VGQ;
MP/Z-)ES!_'T)7J"-].7GERG*J0=\ = 4Z"]:BB4T0FI#>]FAZTS# 4SJ/8GY
MCW+BZ2Z3GZ;9ZO5NF6!(X*EEZ[$G3+O46)&,&8D.*51AX7>=1?066XMW[CHH
M72",UPW9P,B^M&'6E_8*.7;,??W1!V"IU;'A* ESTXD[C?K:(C[N@=D8_6&T
M)(.SDG'#HL8K:&+9QW,I:$87:A6%YB?TS1]EGUSF"OK1*Q*X_)Q,M EW3O[H
MM^79H5ZI]H:AQVS=\>XK=>PK4]^D95UL?18L7A:Z,;23? -]NPJNZ;W1AXIN
MQ* S3:Z8N*_7P<1:XX[+9P'2LDFD%<8P<%?2Q;.,\0Z:EG)ZQ6C8\QU2._FN
MAOF1LNNMAX3U Z?(T^2&."]98>LD+[VP\PU3:L\TH_61?JFA4Y]IV(01;-:
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ML;@30 YCP;-G9<P77NOF>3EW>;T+.V<EWG6[$![]U&OS86_(;U;J["%>W+S
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M)+6WOKYG^QOXL3Y0@O-$V0.O>+$QX_RMMYSJ(9$8<<"7NMP:M<ED$NA6 RM
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M@@Q1U2"VHX&VN+1Q0=PI5H1THI_:F+(I\E+ZOE[3DVJ$4\C3M$[N:5-7%*J
M^J%!1^_4&>@G508=F__SQ\?P#/4N+*-.J-PCEEW;<)?2)U<N-HW$4%],X[&T
MA$;00BB(TKQ";F] L[T]K?H)ED4MG 5[TME^XLX25M*:%J(MD"=7'R;R_R'$
M:&3^:-YXMF\(3J33ZS8M/CB3X_QA?607)0X8*:\;%6&U[!).OO<MY9(+]KYA
M&AY/"^HONU1<XG'G8:8'9<SVHWHR=Y^:R>FG^/*>1+W+':'17D8??W=^UNM8
MIO':Z+%M0QA_9\>QWQV#=GLEN8E-B'L)7VI2SAP)\%@A T*,- U:FGWYI7G
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MW^(C"K5;[:TW@FT#4TEU'!M^[8&>21)V$K]UV9!:>]KU_HW_VJL[8OX7*C?
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M>=[0=SH\USPM>7JE@GZ?L" 4K+4@U;1+T,YQ: I  S_LI:$CBDQ)?$1_)MO
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M4KIK97VQ@G=Q2AC#*^<;%2WJX<GWET05(V-GG".$$TZ&I,37VBDE?3'Q1!
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M-P(IS?!)D'I*JM\%X[^3-CC[^4,FL&5_:%]BCF1- .-*E9RL^DAZ,J1P;&L
MC[> O7039 >)B=O9^/@IY/F+E5*2UG4=.!Q3%CX<1KY<.)/N?]/-.7(DD-N?
M.!F^TMW$)+-F>FK/@Z8CZH9K49.(N8*TS'!C_-L*%M-^+<@1+J*6?]@7N(*I
M1"^#4XZ %>FS9UQ<SO.*[1R_-N"J6Y'7+H[+19=W>:_Z-MQZ=Z4BB1R=_#WZ
M[3V-:^N WHK^%_ZQ<7NJN>8.+ %GE!73KMJ3]%[^4E@+[69D]YVEI2E3YPUY
M"5R1 E8@HYV_>]#Y+5-!KX58XF([#/@KJ<--1XW@][G7[O[[3 -V_1&*)ER_
M2J*6VTT.+:(:C85V(:J"3+T/X@BOTAXC ?MA.XC3Z773W@$B9?FX7P%GVL;<
MH>3K#7([68!IA2B<DVZ/AP(R 2NKG+X=O'!".&/U9$B(85@:#HQ,45C#0@V-
MU\O?0OMY1H%MS^&@@;-#5B*Y!=>6E3YFS/:'BU2'6B,.^_A!)H2";R@8&TI6
MY5927:WJB+O37.OI9JNE26;HK\&8ZS[6H%IH$W"=;D\+$!K<=PQS>JS_(,A*
M<S-UZM!O['6.?E;XD1#O\'7/])[$6H\Q0G5.3D'&WWT;QU17RJ._^G:J#?,/
M'C&O)L'W0%NE,;(^X<27$X/0V;B=X,QT3!GR/7Q:S<ZPWRKE5K.^'#DQBV5B
MUM,WPSL82VG^74<:F<(Q!["N5DGQ#E+9.A4,(H&4Y$J,V9LXLS=.A\> M;IG
M=$>X2\E"UAL'W-/<XD'&8OQ-N2D^EK*(DA$.LT0R4_E-(*8.<-45^L1X5'F*
M FW&S!G1E30GU2LVQ;)L6?[5LX6DG N&.L@Y%ZHL[&4\K,9D8$P36T@KALEL
MM(]I12APH%"E5LZ5L6YP30BDI<0K!N%)QJ?%3\_"*E T%.Q9D!]B%IOUPV=9
MQ-F1O[O7?"KY[.4X]1\0+8S<)@5B#(F 6>F#5Z/7PQF+*/'8%B@R"^QO+PS)
M<I^QC&N\RB]Z1&.'#EUP.^,>&"3RRF=S)AL]%P;G!A;NO"UNJI:].?MB11GM
M-HKA*S=M(,J(X;J;>,4MOMN ()XJ\Y]18:9U$%9#N:<6L-#9B18"HC&M6D$2
MH:TGZ*OAF#+391\PZ+X%6813X  2\&"\*U*:9+>BJ]-SZ"LXMZ*%7J)F=TJR
MY<OI+OIAC(FA[C+%N+7@;OT !B1@A^7B191MDO5LBB 3LYJ_'CD'AY3'RM?S
MMY)H^LEOP]]!^2U?O28?A="=YG$,,#<N;"JLH234)/Q'UH)E$YP$+O03P,M9
M% 5QQ4BL8.V__>]@1FDX''6(20#W- ?>*(PLP*9QX:G@?J$9N?G'?K(LY<.O
MKQN*;CP-'=DX/5JRCX)9P[>%LX<Z-9&;X51%[L\O5=&YC060??\9L#RM2H9\
MW;]G5ET:1A[S;&I]7(RU>"T;WR.+:"CG%6A LFCXL,V(N06*CJ*_9EC.X#:=
M@1,T5(.2GT4BOCB%$&7,M"?T.01FJDDC(1WX)0A>,6VDK"M3%+E,='4RN,E,
MO2D2#J=!!(.DHA$_=74*>@U@V=+#>$(%?%4FK2$J4F8MIB-RA=E_!-?XSOH^
M=D-@Z[OG*J*L7\T0/@,<# 03JOMC$47Y:Y:3YC7/Y%E53+*Y 9ES$EG=WY]5
M.$XRFEE'K9N]IR4N&_]M,G)U!H&X@E8S,A[B]>K73W#RD7#JA[4SFN]T!0WH
M533O-D]#I":W$>1+ >\!:@.+:7"FL"_XZ7U'Y/+!!N\J;(-S4/O8IGM"3@D<
M=7( &YW_:4%[J/[)\Y;F6X2LM[="8G YT6"_\E7A4& %S:C=*X5$.R5I2ZZ-
M5D:L'N08PCWPT5FR?DWSWC/^%WUVG<,]KR7&*(<)'S3U%)O2QZ$E$U;Q>XT_
MFZ1H3]%'V0WYSQ^B39"3(+Z]V^_+^E^&_H4  YC6P#F:UH$O'4573PC6X_8#
MG@,\HEIR<X%S@\L9CE&7%T&3;<76<'I9&!QT CQ?JV*LA<.%E@N690\EI3DL
M:X\: 6\1A>+$M,!ECR)I(QIVGWX+<E[*.#\S_#X89FJ]:7@QW6: ;PUX\2E4
MB_(2B*WLRB@XVJ_?3-;;PB]5H4DMMJ8,L3G_7NTX?57?@[Z:&JR;[I2'AKA!
M_XI4/Y3GC*PBJTG7,"MXY\C@DZTL92XGFV[U16P-=CSJ!EFU$5FUMO;!:)=R
M62;9ZT26#Z[Y:J=;-_Y[S ^-G]Z!I#8!$[<,?@#%J#V8I6]>0$[J</A;K!U<
M?7K )<GWF_?^H/T=C]\,"&]"WO&VT->\HWE9<G/#7%Y:Q39+THC-N^<UQVY-
MV)0-?%P"RPWRA($"ZV&.@IB3R,EDU'>)T-?P)GC%PT744X\6%7%8H/AXV_*.
M]BS\4I/1"#<H&2O&QV/4VR!FCAMVPV3Q:J@@RPV=%;D/CB&#)>V1;E" D+V<
MTFQ9 A']^HZ7["B98C<1Q>P1HC\<HAC%!S6"I*E:_,U%5+S@];SB?9I^![(2
M5C.@>YUA[Z_AG "@AV>J@CBT!)7CE!P4"OGH5A[86&';52Z^ IE)"2//IVW&
MH_I5K0*="VE8J_@*.<52WT+,X$,"&V6H%'/3"1QI+U']3D@H>4.[JHR"K[N1
M8,+)BVXF+;5K?VI^9O9AWM/FQVLUY;=6S#HG"R,W08<L/?@[0'V6RBD>&]H'
M'"X?H32?SN"L*%*9+M4X$[X9NG!N8/.SO/[0WJ2-FP?<BHZ/1K7V<\YE3[RB
MQ>1N0V'^B>F4V^I[2?4S&0S%0]Q><&@Z5_LM18-_3)PVU3JBKQL^HR*7ZTN7
M+:+\X!>5B.DSN$")SY%URPUEN0FW!TX.:X1<6LXI)]$;Y6?9*PY6O72YMB=D
MZ8$@'OQ>ZP?\6!#PY6!4?4^CO $K(C$%W(*I:NUWXVQC00QV&',,LBPJ!7PA
M;$;-0_BX(9+P8L$*EYJ0[^"&2OH 4=T=I^GONDW8+B[C9,W&\K:G5HC!A0!,
MC[0*[%(V/J>J[@52E#/7YE*(FT;'0_0>#8,^CO<G+/5[^3VY=WMF?(*6C['=
M(C>W].85513M5@>'/^>JHV(T <RIG@MB*6X%L@%"BU*-U?8"D*&\^!Q*[I!>
M(H]MA*MJ #Q87&& VT+ Z,2ZUQ]P^UO['"'<;S$K!QL.6M2Q'X6W;QQH0&4N
M?ROY8PGR"3@"CVJ/T"Z^U+S2/;+2%, O+!914Z.&$/T!]M/Z +[P/OO6AV'(
M)BY\4OT<_V.$21?=& K)^*%'WZ_Z:VXC[BNX^/WAEJ$D[WLS*R?7G2'!E\-=
M/4HLYG]!+L#$,IJCPABQ6DBAWOSR!"C$:CI%X>N!-H'5J@MZY[[I6;D9XJ.[
M-C?JJCJF-QK:ZE&P\#9W6@4S#D*X!Q3?/XLM>A,9*QFE9\B',0M/FPV6NV^A
M*Z)OQD H-I^/00'9SL E5;S79$?8<C$KDT?^8>%08R1V*'Y'_Y@\!#K\9S&F
MY\>&H;F5']TIR;UNS(QIV\#ZO6J#S3+BKZ:EB?A;H>+6+^/7I$9OC/6PMX2H
MV7,,IMY\@$=0L=:00QJ]B@N4DO64IL)#LO*F^^/->7?+)RQM_"N2DBJ&Q\8U
MGI<UD(1,W?8]IECP5)Z)VP(X&X+F.KV'_117"^6HF)U$YF5#4F.F^K4G8CWE
M&WD$JDIN 8=T"=;3=^I[Y&N0Y/(/7KPP.MN7?3UI$IUA;R;=X^,RZ7)/V7W>
M.4J[)CPT[E:8\+,T'6)K;C[3E<8S%,6%!6*)-3N;;JOCN;-R/?5XJZN).$<I
M7E'4&VNB]8?#3%JN591$P#\8<%W&PSPI+TF(OUB85K1")_NT#?V3H.EG&J.]
M^7A+)4T382[TBLFZZ&:*%Q9R<K?U)U;[7F:8?)B79925Q7HQ,V4;9][VN+42
MS@Q29W4N[R#NI.UTT(GFQNN[9NI^S%_I8ZTXBGPOV%#+VZ7<Q6,D*/<#ENSU
MW_=PR3[G+BE./A)DQB,[^"YY Y.GX&.4A!=U?O=S#W(O/?IGH3!,5^?_YR\,
M%YRU[B'N0"SC2?+4.>W7%+R-^X@DS5"3Z?9 "C0T;04*%<Q.4@8;A8]]?@HK
MLTBD+@$N&I"^06<>".*[T$P\VL=5*<FD8R!BNVUN@E().7\LJ8@<]^2[0>ZM
M[(P=3[2$57IO&D;USB \V20SGK.2M&01U9ZPB/I!YQTPB*Q7[<>9=3^@N79Z
M&6*?_;,[QWSTP\+Q/T%*I'4SM&9L6X_[C-G,(+!%59V)%<M\<QNXI+Z+#=H#
M=$GD]@;0O2"3;X18#TWQ-TZ$%'8)PPV9S;CN'DYB-O-+4N*KXFPXUVIGN =4
M8'%9:N5PJ'R,%+NJ8C0B4A8>0722+#OE>+06V08'J>*-.W$6D*,0R^1O!@4B
MPKL!_68:-1PD9<Q%&'>%W>Z*,IFPW]<[,SN2BQ?-=UO>+1<-71UMG1,&5+Q^
M\&MMZ=*]:,/(4069_-TZ-FX)_67A_"_Z7;2"@^!'MC9.WZY?"6=!#M]!&VQN
M+K#;J1;Z'MP2D"FRIF^F"4_EA9,-B,,RG;CUFL816?6'=?G8W+S=.E=_;#OF
M3X'YE]TE,B=U@(@([RQ(,_SS?J\5566 L^Z)($:P%B:TK=/W%-O"5M7PI%)_
M3;N'T2&"GVAQP H8'+.'CA>!$I7!P5R*)JMJ_4X-U%S<\]%MVDC,MY3.R8W)
M-M.+J*Q9[ ?J*3C9X!C.@&[R->Z,I;#W:9ARZ7Z7DL)B%A9DN!%FC(C*S/B2
M>J;P-NW;B<Z(I1$KG(X\;& =2?7EPM,E><N;UF^M_,R"S[.'<X) YQDA&SZ!
M63*'R;CZ>^'N.)S1(BK]-+@PT];T"3YXN((9/-^QB'K]5:S5*5K$EO (BY@G
MOW%/9_K]X'SCW-?&GQ_4T ?QW(#I:+4D8\P87@XE=XXMA8E1VHWM4)"2WP+)
M-:V-NER#(^&(^X%0. N4B U*S,[1V]-?,;CL-#V> -(91C3&-P-3;IQU78JB
M;^R.#W5YM2ZB<I20+K_,/F0Z$"*J)&+YM2_[N9VM- ]T#<YZ&UJ!PA$Q^ZP,
MR00<'B KH!DFL@]TT%R'F 8L'5:K##+OK3I<?E>5NF*,D4-?"=]5YW@SF/8K
MGQ9W2$<.]L]M9#SF3KN*K33)/RVBOM7O_V]'4$%6,_J&CQ/DJ AHYV1&;H13
MEP7SEX+O\W &#!(7HJ\[WZ^O[[_?!&:P.+')"XR,^TQB_]2>'YC^34_SO+UM
MO;\[N9R[LU"_#W8$8[Z<((97XS,Q*_4;X<E.>_/Z >Z,"8W3B5L*<K(0@K(6
M'WJ=$A$I%"Y\;"J5QQ6Z%U?')URB5H6-#P7WD [Z]$9L>_+W1!LFZ\OC2N-P
M^*5^91H8\PHBY?)V%P9D"!1_%CQY0W,0AQ1;%/^G 7N37<]D2NV^???//EY3
MO<V+P=G*TN47>(<K8F6\ \_[E<89\)Q:;AMK4X%L(!P?PL=+\O!+W!=1L./[
M#CQ35C#%>? &\:OW)*TO-03!;H$9EY.]B+)THZXC)\CU_5F0DVJT5M+QDK4F
MLE;7,$6W' 2<2H7H3)_C_>@/KB= YK6D&31Z:5RQ%5A<KPST\EV]7C'J=[AW
M#H,^<_C^F]<3D=:9M*LJ6;R'U-?R\[?]U-EMEK'-2:^*HI(J,J/KKQ_Y#]L:
M60OO@C#BR/70D AK2%03X(J:P9S?&PFC.W&N,$.)WT"K;O?,'P+C\H?HZZ&U
MSTM)<7K;YTT#T[4-&QU[.7O*LO5C)L]&+V[-.XQ":G6_ H>A>4VZKLF0G'8)
M:KR8DZU?W4=?B>S0,7D19?IN>^NAK>![H6"M0>4E(%X<-B\FX*U>;__3 $59
M-0Y#SB49$N'55X\7SA=5GF&0W<PG3#;TT)C3$C6#9<6P7T0IRLUA@H8-#X,5
M0O93-&+.451,.X/LMD64Z9S._" XQ=CXKD##'7@+87)PO0])<9%;04T5%1SZ
MIL_GL"+W&Q .$06?/'R)\4.2G=,Q7H,.?@)*,F9;8\Y^:2:G,S\.H;.&"$2S
M2:G7Z?3R>M6&WLV%0X<C$KYK:LK3!D=LE;Y3C1#"__-Q!7O99[_8+7DAP?\,
MT#$P^LQSZ/ [CH*]<J* [@G.-=T R$F5,-6?_QQBW)@J.!V.7T-[F')O5_00
MXAO;_+&Q4>92,W3U@DG-Q$.G'VW27_]A])\:N%4;J)?BGZ8/=1[P,?ZR/LR0
M7A; %V/S]0A==EZNRI6R5,ZN[1B[1,9-_@J0F 4P#,/9''"C;@]ON:+,D/"M
M)-(@;_G#V#!!6F(.<2DME3NS]GA^<OX"BU@!Q.DJ!3'H=/PF)!YR5)>SU,0;
MQ4[P2?#X2-N8+1RM31RA][/M:W![#=6CMASQ[=%O'@$BX"*M$V+5@S-"UD,?
M69R#%31F1$L?0#D'+LP+YXOW@3C6BH=8KE;RH0.[%-YJ&CDD6D?S[G@\*<59
M,)8.4R[14HZP0NK!8P4>34]I7D.G".Z\)K"F(#\XA*K\<#YP2UV\<PS%U9EW
MO)BA% S7:Y) Z@U>M *]$C""G93$I<!A2@:<IN"8(GM CW0EUJ[A[9/Z%JHU
MC4KHJ4VDFC<,WO5H,@Y_RG<=,5]6]M [UN@_3\"0Z>W:X+BK)!'F%S-Z'WTS
M./A%Q15U<@/[=,6K24P&Y@(C#FUF"/.*3FR:?@44(Y(S]R%TJ*!])J.@V.-W
MF'UVZ ZCB6]S9C+2J.5/.$ZZB#J-LZL?W*&[_*5Y'6T1I;*=E#?)V^3FAI\-
M<V7%G1DF:AX/X#8B^R!/47>2STEH[>>.2 ?8&LQ1.U<P$:**\S1TC/(IMGD1
M)4HE^?<VV 7N&!@ZR#S&;6Y^1CG]NZY7R?J%M!2P* ^-Y9O"3F!!1YC'O;I8
MG&,_E[T&V ]>3BL_0[O=T;B77&P%F=[)N%,2%B:;++;MCX_GZHR#K^^<F4VQ
MC75VT^:DT*)R4[H=.L8V@KKYS"1?(V'A6F85K24X,$5\->.W4O)"_'S6W%^S
MDW;VOC$BS\O!(+$VKG?<YOR]LO*2JJ,)M.;+[*@?ZDTH!%H)2G^9;D,?W ='
M:;9"DND1*%G3!X\F0R^_G*R-P^=]Z3VXDM:OK ZE.8BN6HE7@&XX>Y@")JOL
M[R24(WL&]*O/CL",PU)>5 VZGJRYFO]$M8BR:ZR*2;F8\XE? B6HC[?$0),*
MC%B2Z1'IW*M?;0"B0X8)RPEC920^$Y!SY+()=9N,+1+(*A2:!RHV^@V2(.5;
M )N&&HY>='$;]0ZZW1'&3M]!7#T6>?9@^:25-/FOQXNHDYI%5/U\6SC1G/:Y
M,U^PC+\^G-:E*F>E*F>R]'N:X'C%:R 0PGP]T+=QSAG=53AU=?=$,;9W;N7T
MM)K?[^.75#D<4;JN5F2VYXBE(%T0@Q^>:9-M!H>NTY<!-B"#N:)*J?N)QNB0
MK_%9K]2MHT2:#T8- 4XUIDY'>Z;W&-XMNK@QB8V>6(IN^""K.3EADR@=NE33
M9@1I#=Y<C+4!@H@R5W5,+IXBR2Q>J;L/>$):32=LK< .D[Z%Z-=*8)=45V5R
M&G]'&.(,IY0"=M+$R=:@$*A;GNYSH Q(3>LJ=)%OG)B.<CA8Z9DF:$A\R;HS
M1QUQZB1MX)O3V^Q7$V4;:._F53/(>D_-([C:P./G7XH6UM:FJF8R%_!3+\$L
M!X@ILC7UC9R0D/J!^$K:PMC7D^4YJ9<#Z7^G'"Z6'C%XB-)8O2FPF:GZ;A%E
MK81/@S+L34\OHL94(J8AILI,_?:SL?3O@@WT4@^/)SY1926RMZ[<HG]U^S0%
MOWMCR:?+_MG/</:Z/QDQG%41DR'Z#3 :C!%:Z;<]A[:_S^0 OJ"@W<9YK#59
M[71F"B EU9X=;[;CRLHDV34/LB6BVW*?3Y/Y3P*H50T#1RI1^#LSLG"-$&X%
MZS6GP!VUH*,J.1M9SJ%W"L#C\M<4E=1P<VP9]1O8%.S$KT/\P,NY*4H[VP[Y
MBBG^6L1?BJ>D<*P.*P\D,FQIC"X#,:4J36WZ/KX4&G!WZ>15?9-'T<0BBAN2
M,:*,R6,HE)B<9G0G-5M#6H_X:G?!)BK'#)]=*D;F;S"S(QFK8@Q/JNPY]H_I
MMK3\SOE#0V[H)7'-B;*87\X)^AN<,1V6EOVQ/:M^R/Z.,XX1?7F -C6MILA-
M)NBN\"HP7"PKN.Z#TYN#D0]4C'3^BB$.L$49>J&T_T=0DOYQ+F+UQU0CX2=R
M/^'[!8\[V\O_U)QZ$2?M-(Y])?BR%G<#Q,JZ",2H9OXKX$%J$_D*.7* !Y$R
M]1B8>!9RE@M'0Z:-O@.WOVJI&K<**]6;#J2/]@A 41/Q861JN7K:\JLK?1=1
MR%>Z!_JO8+6(C_W2MRK.WD7WF+]-__(J9RH<-%$ZYC'.$U?!GF(;S[19C$T$
MG*,X";,=Q50;&N%DWSL,QHVX 8AX_!P^:G4M@IJ8:=[>+,G@:L^X2ZSJ.9E(
M!#RM#8-OMV/ DU29N8C$17>RTB+==+\NHJ(-0=.OEESGKX0=0_I\O!7HU4@(
MQ&S; +,@S&$H+X?Q<,*+D\5SK:,T1W3>?@2[BIKOC-VFFG9/_W,BX%'F1Z4^
MSR<&=%0P10R#[H@%Z_BFR&[H?3;?3F(Z)%Q$F=,DRO<W@),J]-(W(Y%A$Y;S
M]FNE2=WVVI.@""2]'B;Y>60E1&T+R;_<M/.E.\^ER+("5"O?<8OWL<Z F#3W
M6/W6T%"R8)UY$,AGTHL/]'-'#KA->PD[G9*B=L.%?PN)^>&V3A&QI(.4F#WY
M/0&;UO[U-7[#!4$L-2L2K>/SC%7X'+8E<%HEN('!\$A*3(9\V11N!1)OF' %
M(XV_![,,L*ZCL12":7>M,R7L?)$J<8#GIW*'RR K@NX^8LNA?9KYNK= V&QU
MTPV?L>#!+HMK'IJ.$7*R\&@ZEH8]"+/ ZDY#4K$,9D7L\302IG2.&0_-2C;0
M0DCUV>\H!RYR4U/\G_/ZW6UI'Z?KG(LIA+M1H8K\K>WJZ(W[ !-XN['('+J(
M21.8;($?);J!+^![5D+YJ@!H&7S1U]?M#\0'.%_X-831V) O=967W]:5:9;W
M]^X1/VL\?3-);P.^O^&SJH1LOPZDIRD%*^ 48C8EU;A#;],W*T''2D]4OTB^
MM.*WA^2?0E^/'+(/O7@^^]7P.I];QR8+SF^VV_Y_MBG_'Z_OXMV<]OS$?5+3
M5\T]Z5J9?YI%_:.W\TC,F7F73_=OO&EY\MNOJW8^S$;]]ZJ\ ;I)+M0?&EK?
M>>L%ZK<UO6('KRX'D>W5+@?_B;R_+88W[=I^W-9ND/O$!SI[<,]Z[HMMO=VV
M8MN1E@ O7K;8XGYBXMTS:>8E3NF[OT859^?M^J%XY_OK9]YE_'CT7*%CZ-;\
M QN^.KHI,]3.[LB/2=M#CVS^]6#5_[-'*?N XH]_'G=OJ*7NNIZ4=^C7]OV'
M?A?N/77LY\RWV7ZVTS_=<E!3JC:;]?Y_=ZN=/.AC=:+K4KQ;B.7GS;>L%;_M
MR#CS.CKR0-3Y /]-&<&[ _Q.]2SY[X:^_^$B_1Z)>4HT2#'X'78$[3>4%)\<
MP-30#8YP&6(+IU;!5\?=!.MI.*K, $5FN"U !!1S(TGB\G8VERK*+T;!!\ON
M_57+FR3C,*^[[UJ]/*V+X$@$UO07.">I@,*^*=_@AC6/*]X(G]0&Z;L:!4OX
MKG%\-)0D3^<[TCQ56"%V RU-;T'*X]N^<;E3*9/%%;*O\5V0(WT-@:GG&YM[
MW+'+89MW3L[?G3W0WX;'X=8C:\$ \8R-0>E/T5<"&(,709OKVPTA^RI=ZRTG
M0&B50(2_J=_0JJN;K752)3)LDMAI8R[P Q7'$J[K!HR4J>%*!A-(PN5R!,P"
M55[6_CY<NXIH2KGUHM7@1)AP@5H">P:(Y=R?H.1L@[122(;B=B5V;,\@[Y*R
M-B0,G,^)1RZ.&?4Y^Q!4@>:A?=L>#W%'"2<&2P8X4YS9Y_%)RSW)[C>SG X)
M)^*--:N@KJEV[3Z " =I=P)7X%YU?"1^6-O)6&6@8U?XLP$K'R,.8$!FPZB;
MC)8B3K;B+X==[].:M 3_ ?M PBDIML$N^814_*X!5V*G>?Z(0?&;"6$\GN\@
MK:-WV(0@YI_%MRGS#.,M.C;@I/6A>!9C!JR$^FT#/EBE9/4X;F/!R:<#P2:#
M_>X1A]V>I&R;7#9I(18]\]]X'_WWEQ-9YTC#U9WX!JLN["^-<EN^';W3$H/2
M&\<6NM)'F9IG/;SMU73IV';XM\H/-OPF,$<IGS:^/TEJ8.>L8!MJ1R@H+I((
M.4:T\[(A-8=UNT..YEN3A&K3\%-#-?OEUH:9\L?'<VX6KP0SV."]4W $6&&8
M> :\R[,-,\Q1K16H)-<%W!AAA+F*<<.@JU3AV-Z>[V\;4*<SA[@,B863'QY/
MJB4<A#[>49D$54_F>T5D/%>0UH]KFO\\A1Y=1,E,_A='UQ[6Q)GU8RDB(D1$
MB((0%14M0JIR:2$D551*$:.BHB!D+8N $;-6D2A#HB($1,Q:5JFP$A$!42%5
M;A9" @3(MJZ&.Q(JR21;Y18S4S&\-9/A&[Y_>1XF,^<]YW>9]YUS3&<0&\-Z
MI)&:'1_4C.Z]637!WX!0;D!>.KGU5,(WJ/RR-!.1=WX*NRY=H!<MYAR(.>ER
M6[8:4>7YA00?J ^Z4?0H)?K$IE3_2%^\0Z<;8MW:+- 643]+95"Q;Y%,5:=
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MI&?L:28YI>]E8N+2*X>CM/+/YDA_FR/E:.H^3@=XV(,[Z(>#@%4V(=O8*_/
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M92)1++4(GB76E/-2 (O:65>W02LLU_U5(V(%/V  7\/A^Q<J!<OP-= 9EE5
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M4>@0N(E,Z=,5<C+T[? YKGU*\;I(V&C#:^K J8.TVGI#U)&BSN+XF@S[RH*
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M!UH#YXM=QJV.HO(">J359%#KRX&+);25,!EL&NXRYHKK35F(4[LCY(BRA+*
M6'[?19MV56[I*I!JWL]"AMO'O@;659HW_RE6*>7+0%2[_'/"<6>Z3!I#A\^1
MEX_R7\G6"P\B@MSI]^?^>MO:U"=I6&BVVD7<\P]8,"+JEMAB9Q$;)5G-:O/P
M1)HZY%?DGS] C$)ZDC968@-$,+NMJ)AM"VC'GJ)A"J;C5,"GO77^8V7, B:\
M<ECZ]5E=Q.._?-\]OS+9'U&L\(1ML&5&+;F=>TU@*]L DI14CX\<Y@ANU,'
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M^\8:WZV_SX[CCX9\.Q#QH'974M>G_=.3]N^'V\&AR#<].?I<<(#5J:QD;CB
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MQ;3RMO1AISGIY2[K7R,Y^8YU[^#XH([O3*?NOYMTM/!8QW@VJT9CX,]3PQ\
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MZ.I;B<T!2<2$B\GG]ZP]NI,3$-G<?*8A:(^J]9._+C7NN3EV(\T9/^.<=,1
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M#U"&95R;*51( VE?#@50MD)<9$#467'74O<&B+Z=\+?YLZ.YX\-R4?N<I&K
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M9S$T-S$U,#@R-E\U+FIP9^R[:5!3:[LM&D5$08Q(#T*6(B)ME%8ADJ6(+$!
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M+G3U:NS%QM]%^^_H'JV8<?!._L[R[1TC>]@^BCSQ]53\*;.!7G_Z,9YT+7Y
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M;[M?=R]9+B5%R.?M:&O%ZA((2T"B4_ZN9;%^/#=)6WX6/RK&Y4W_R]9(CAV
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MD).%@J[N1 +L 51_Y<X9G!.8%<,HO3UG"MXG!+-FW3$)A!;R'>9-K^]AEF?
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M<.*A?QY'O/73\P6M+ZB-F_8">T(28?4>N"Z$.!,@] :/W&7TAC=/2PBY-#!
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MG[<EA/2XX)5 ;4=PEI63AI 2<=&$Y"^4UD7:_%3Y-Z8:BK!Z'RA9[YO?#[?
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MW$$Y]#XTZ;F?S%:G((;BGZ7'6K]%AA-ZK/2%D& 9!O0 UMN;7X@_"AIQM5Z
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M7' $=[X#+&9)#,GB8*,4IB>VE+K"J&V5+Y*WF/XX!)VGM")7:W?^Q(],PG5
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M.B<$^+O\X[V8+(W2?&8X\.FD%[7&N$A7YO$\T;(ZSBM2I\<]R&=R@@=3*.+
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MZ22\GHSQ',//E-/89Z%WA'OMG)U;1\U1/"]A#VI+J[QP /?+&%65E_=R!!O
MRI1>]%7.8V;&&812U&/Z;#TX-\B5BZ:UGZ)IXX-]F@=^K.J;:SE146%QUR/T
M&+D[JWH/)A<4/A_1<$O?\T/:7:_#HF(X-EX'">N7Z#+.D1CF3H4&^KJ46$HF
M[+_JR@8:DDK71RS5WS#]=$VJ DPJOT8$1MF'!NN)O7&2*PI,(BJ<62,():QX
MEMBM )VGCNL7;@=<.5'6G)5TG!I6$@B =81)3/-/O\=&<HZTY>=\3<G]?H;%
M'0Q5B?$>&PF)E,*D?R%FUY1)H$^2B1W($-@\&2O#VXYI%DJ,<VS;X?N! AX$
M@^;&#-:A-R(FY;K="=MP\ICK#&227W.L3J2TX5G.UW@_!E("DSL8\V=C8^/0
M$O\4Z2F^I;&8?M/X >S5PK$'3\A%7X]E5K*N*AAY5'WH <RQ+GKOR6F5^BXS
M);T2ND?)2A9]QWNRTCZ5E3W*.&4WT'/X6&1*.R@(KJX=QF#=9.VODFW%+8N5
M>\H:B4K>$X-5514FNZVO&1.5-;Y+,1-2.2LS2LO)'#3W-A#(,P?&N.GLJ.6M
M/#C?&, 8KR3Z:@&HDL7B[0"%G>@#)",2QSJ?8^TY8[>79P \<U*5^8L416[.
M%+ZWY;VAL??]Z,?G\MPR3T[?06V!P_G:@BR<HK!+L?X';M?PNN$XO9NK?D10
M@=6@ /[.+X!3G(*.L:] D+HZ6Y%TBP@4=#[ 7P9H'3<S[C#UY +*/*T8,9'#
MFK5-PTL=^')Y=[GNXS/%VYZI0KURS@W&1P^[-G)VT9W>Z5PH<3U=MS=7.M#U
M"W+\=#YY_?RO1F@YFYR;F&(1I/H:J]C/ANIE\I%XK")&:[M+W+44YT)_MQP[
MM,.;"H?\K =QX9C-[%LYP2]OOD1U(\=KN0<%%? MPG$$U-P6SW%NP^D*"'!U
MW%^Y!+&GE#KHW>(];-G)[G+@ZZS3(&Z/!5&K,U,.R.]UJ;N.9J6?8>[9O%&*
M?IK=^/X9IV+:#DNHB7"T//%;YR64>Z[!8-$?YD:'N<]+;=)M^I4>LFIM1L+5
M>P['VPQVL!:GGL2=?_QXX?IHI.YPFJ8X-#9R2LTE3J]%ZQO1B^SAE"%UJ.U+
M]CZKB7?7TQ15MUHN..>4?=K+."U_>?#_G#N_W$EOK_B)(LN(\>]"ZR_3@HR;
M8\*'?#V4HOL$OG:6G]5+X^U9IPB, +?_8A5U_8"%@N /G*7"WTDREOX/;#JU
M@[!J/PM&M8-]^/5MC9,Y(LA?O8= .%[2$I8Y(Y[H@A"<AOR4$0@&)4V@0=A9
M! 8E._=(-!VV:H")$;Z^B13>\Q[YUU?O N8T3S%R16#B,T+9@?^+RECA;9E'
M;)X*^UTEJF';X+MO2WNOH]'A5W<5E;PU,K\C=6%9ND&YK>OZW4':01ICUJM;
M(#-I*H)(H2G"2WKK=\%QW8-7@]SOXXK@8"XM1T40UBY4?7,L5GFHCVW497[@
MQ7IB:*MF9JWKJ,E(P\BBX]=9KHL0CK[&JV^F=7$N!67V^FY=\$@\\U'?O8YJ
MYGK\50%]%:]8N!P:C3WZ:KTU<<$8QG;B?72^.CHM9NQ]H_EE3'.I>)IFW*=)
M,RO53Y]V\_7+T8D9VJ7199,:!\(K+U8\]@#C31$:MF85,<TW>$;;>$CI5=%;
M#P,2]RB)(*?/X1FAH,W[$KM%D*<;*P+Q7E#'LVG\TM[OW_J'5X#HT1H1Y&R4
MG0C2/K$H@CQ*$8@)BH6'^CET1G$!9]OLZ53Z@P65#,K%B)<FXL.LI*"H%U[Z
ML=]L;16O'T8>KFQPB%O>\>$3/K]'P!;<07S^V'(<C(CBJ8BU]9-8:!)?@]ZH
M>,I6.2=@H/UBP"._.9NJ#I9N@TV$D7/V<313M\W7968CVR7/(,NZ3IB9<*2P
M__#;P#/**9&5^@9>*3MSML=P*BUUW4DVL@,V-F/U9.KUY9_Q=P<(&/_5ZO9_
MSK%&"AZ,_7-UQ]Q6ILU/.B3X!-ZW!YPYTSPP@G]H8'\'"4^Q+J7=[#\X\Q@Z
M]^ ?V-7/Q@3_<1'M]Y4D-:P,>+DXG="S^9.>_6\,#&1]?RO:6#?Y6UJ6.[T-
M,86Y*VP)F-Z\KHA5 A\.:B""J.N)(-:/KQL[6N"X.(S"/R9;%=#_5.%QG4GB
M/]A-X>UX+8+,K]U";,?_M9 GP'3@Y\7GJ""!ZR4M:OT#N?*-X2"$%JF&//56
M1?Q"/_O6304([JH(TF:+_YP-0(4]LO@%TV?NS&7< /YOQ_". .A5!W!RPO:?
M:_OO:ZSZ'OI90Q*V^3T1Y+3G0',)Y#>R6GY>=1#!Z!9D%H.*=CC1GK(@2\NC
MQ1-6G85[\!\V&%#!N8@%88D>&Z9,F[YFR!/K @>Q(#[7(LW?T2UL_<G>4DI
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M5>M>C85JO3(T?(0FU"LMN[/]6;#4;[A]\RB9%FOBPI26H 0KQ0B+*]8"W(F
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MBO_<)3P$QM S_XN]]X!J:GOW16-%4(R(@#2S48I216DBDFT!1(1([T1%0$!
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ML0_]I*Q$@?Z4%TYKK,9"X$W_=*#VA$[LG#!KB0?@#L.6BGL!NW^PGU9ISXW
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M_O*$)]A]I>E'[.^4FFQ/$[,XU'QA\GPQZU3_F8#A9BNHK^7';DEW!:G@PFC
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MY4F?[D$F70*OC.Z!WK$V9SWC/<9YXW':6#1'WY'0\4WVEOE<PPP9>*B403S
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M[[N#RZ" JD&%GJE-VO[!PB,]_N52]Q6Z=EL\ROQ:JN(46%6V>*8K0W:AF6Y
MW6HOB(W0B[0J>UPP\?U(L.=+):'XM#I3C9M"2_'UO68CA"[@[_F)!#1S@%AM
MSY/IFH'C+#J+ ?>*UGV ZD3HQRX$H:LDH#T!,31NCSWL(%LPC*ZO;P'FZIEF
MG91^6AHY"%(,^(/R,YE!X1[UP'([5RG2BT*_C?9&K4@8H/F(2$^86-NGR* U
M9R<>8!:VHJ)&#PP$"V^715'=#)G7*26=R-B%K-B+O<$!(MY#B0OWCN]J,_UJ
MYNSM*)<@<>^/4YL>"*V^2OI+NN2NA2DO2 S,+L9^NR=ZER;%)FQR=644%4R-
M\V3D&:.:^2JZGKVFKW-:>U<P5V65[T^:1-259CX:UZ-IOQMJD,][EBZK\ZRZ
MWS7$OG?E Z_!$(D;'^^:IK $Z*'4+.EC)JV0W"OFI2&/@B=%0Q-V*8KQXP%(
MWXSO9E/M9KBS-PG9(7L%SGO<LY/OJ(^#;JUA2^]2_AX.D-Z3_Q\07)VU$<VF
MHA:,?M# JQU\Q#(*3OW%V;_G%>3^.H26:X5CGQ<L=?8M'?S;N< IF&<+\G)_
MO*K/-CCR>&,FX\8YW7BM<TV7TK)/KKOZN]Z^WW:N^VE.4(4?_.\T &M.O<'V
M:^YM[>L@Y!]Q=S<6(]<:E]ND"=K</R*FWW?#.42A,U2EU&E@\%VG87J#;%9;
M0J"+=,L]&YDOQY(\TIM&GX9GZ&H?H(W955-DUXJ]GVO20BDPE,NN>24!M\>$
MT!UJYNV_%.H7P (8+HR!GD.E"IU-\2VJ<K6)V6+?4Z_XN)X\J'K8>:V((Y.@
MO8#8S-N445CDO634O"9!G,I '][L,&8?I.CU1X\57KHU3JV*R'YF[]G_+'6E
M.LM^8-C5;7#--%FH9*N!1\:)X93M7'-Z%\KALX-/)C%1/:3T=%F(M*N%[O/4
MDQ^GK4PRNT>U@@+=KQ8HRC67D'7J2%\'UVI<00VO%.VKTA'CIP;?:6COY"3C
M5-3HT/ XLJ7XEU*F\5:9<U2)F$S32]?EK+3L/"^N#[=0:>_"=<7HQ6OD."8Y
M7KFZJ&Q5-"HM[);M=M/**MPJ1['LRE#_-9W92P/1UUT7BL<>U8K)6$A'X')L
M;3PL-(L??DN-M]T9O^1^0OCUS#-VKRO:F>)/!)6 F6.L878^F,6RIM.B&HX4
MX= M$V-/\EQI(/54S[-O^DK462'<K7/S5S24S&(,7F-,&Y+0FB994O)O[]\S
M7=ZWEJ@0X2-\44,U2KBOO'S*Y=-?$Q_*)T*'\*=-3$[8=O<W&$LZ.HAYG!>Z
M>QP1%[ 6YN(/-9F6EMSSGLRTZ P]MK302;\_A!<C*F9GXKBOM082M<:#>\G)
MM2/_10FG";3\N-K.$[FQ!,D<@@/3!!;]A-35"=KP2]! SK:Z09HKDQCUF_D)
MV2-^F4AID/ CR/D8_;Y>W-?[C&#ETTW++S<BPFC_"<%!>OFFK@M-GZ[/<?S#
M\=+SA1+;8HD8JGVQ[;NJY1\W3HJ>47.MWO6XK-9O$B<9W5,:'J1ZM@*7M)T1
M8F=YQRD_T^->Y!,Q,0_EG:$U$)M4_<\71"0O.+7$ 44S/N(.C@3Y0<^XY?!5
M1'4;L0LF+"PD^X($>:Z^/GFY9R,OBG+95: -$A[41B%_6DZLZ,8U'"NAO47%
M:<5>2NJRZ)^>5<_>:]KQ9FJC>H?4^@^-RN&G23WH83-Z0(*A-O0>*T:6 #?W
M]*Q67U7M#9;VD^I96:&=K<YT1DK@ /N7HEC7%\[#D2]Z?[DZ&:\;L=->SC8"
M]A+_)G6^#52\E<DR=U%S>3OV1%56OVHBS"[1R;2M[,F!H)*T4M=1H4Z]H5F3
M_->/2!-^39]/^9[<VM1@JN!V[CZOQB.]LW!CS[=O^5M53$>77J>W_]/E$'[P
M7T+R<-_?)@'T_SZ_Y4X>YB.(]S@/UDJ ULL $T,:<FLWZE%]9J!+_U97V;/
M<>S'NS[5+QM@WVU5CG(.+]N0BVB\^_L;/>WB_Y2BF:@R,&4\.B:E=8"J]/7)
MF>S=01<TU5WNTW>;/"R[^*HJQ%NE9CH]?=F1IX3;GO?#RD6VU:7W4:&*YTM7
MDM+[&?S1GIEA-YK&YUGP/&;(!(KL0L(2W1%V(:P5]%^AG17]MTW0X%_C'K6V
M#7 FP!YZ8P/ -&LFZ_0T !?<+]PH!\.IYWI[VJVK^GK,?,/TAL_TF%[^57$P
MXX^DDR+SZ^(X%U<7!<I+M*,2L:)H;ZST3ZP(=!!O"=Y^,H079JF3?'-QPPR!
M> /[?&>?YS@./?N15#8YF^0SR+XZN>,SC>;4>DM&)4BV>N:+H')KT"'*0A V
M\\?#*!7M3DW')-U//"^)_38E12=L)I2DSN6+;;$(D<]0TQN=3QNAW>-YT'6E
M/;Z$-=6=Y2AWL![Z"U]DU0GA7,)\M%G*#F=*<ZX5GSA8,'[$9LDJSELMY._-
M+C8,_>M>M!6%-8HV_N,WL![+#$%R\U!CL[R'M=19GBNE2AO02N.I\1%-?>BY
MNT $A>U)0U(6KT,?^^$X6:@5!-[JIO(1GV30"\6H&)8$-VE>@[,%6#FU/FX_
MZ:G!N7\YN'7#XA0[ L30S4T@09@P-J:\9%(B\7*/<4N,P02T#VT[+J/-KEX\
MK<"7H%@7/^YV&PY:871\PW%O;_'B\N'+.DN 9^^'XI#K6AVB\N(7=\>>7 AM
M)8&*E&EKNC'OA:$4#M.&KJK"BE'&B#<#FBEB>%\6*:X:':U$'VRE"/N.RC$'
MDEGJO3#'!O,1FXZ3P WV/4\&E8B-J;[0/E:9?G&-;=^57SLQVFC=U4-]-^WC
MO2!+X]=7\A[@Y5CVQI7@OD)OMT/=P90M/D0!: N8LW2Z%_K-=5("4DLV81'C
M"#*^;D=[U+6=1ZS8$P$+--$AVD3OVUV9MIWQ3D.[5;DP9H2G$3[!P&\HZ4,3
M)"OBS_568[>"!>BM)UGK^8C38 ASL)F@#19*W.[9S95%M6)B#,68Z<GCV!A+
M7*#?F)^AQB[?S 1,X$;=VN+0L&WV!^:KF3=Z6NW2=SZ3TO/^<6/42T#5%F=;
MBCG\X>!RU'J].#,!O;8DZSL.7+6S]3E[;0YC2">T5<;&(W/M#+_)V-G\_.A0
M@HNUC4(*WREZ<B(A5RK89]PC/E&R0T2<)7E?4\_!NMTBP>?K7..[?"'<8/S]
MRU MKA?:HD;_J84=VHZ.IHEP \O!WK-@+W/6@I<6+&P<L/T#10SP2M[1P3S&
M]66I.#JCMCN1BV_0MV*3">)FB9CCQ%,]<O7=U;=U4K6NW;[ 1%&[/IF-D=HP
MH/*'<@X2?Q2,';\#2C_A8EAPAO\BR/E<PP&V+'8NO>N.F]3 (B#CZJUQX:DW
M&46T&PA!"?G6&$K<O6SE-'0\M."+F^,DX%DGX69.GP65B3,<.E:$*\/RC^2<
MFK)S^PW<P*RU 368F2N8S=S#9.PVO/9 N9:O&H9:*^X4'?ZLS,!<H9\2'2RF
M/QOO%T(3:56\5XC93-K%OON.J(37 .DLY['V5MIV/ [T'C>WIJ+$\0<8IGCG
MI^"'356O*=&N];ZI82&A <7.;MXKC_0SW=R<)VNDLK-'H@J];X1XA_D=JVZI
MT!J[*LD3JA97TLYWNG^M@2H<6;K_E@]QR#HWHF,.]LC'N_,M\O9_?/=\N4T#
M*=50'71EUJ"YJ4',0-;;6$,BS:Y)KZ?1(ET'UZ#FDU*HX6YTX5'@@P:J8#2Q
MJM0J#O>EV?&Z4-E$_Z-##:6J+38UB@4JVP%S*8WI1(X281!XH3%MRJP=\ZQD
M#38"E>\(W<2:@!8-21^LJ)_!IE+NM>J/D#A>K:?!A-&YE;HJFJ?Q:F5N4_%/
MAJCTTM+./0H]SM;WM(\=M@Z3_/"$%0"C\GDTJ#3;>@OSB3->\Y 5-*[4"'Q^
MQ8Y@U;9C(\GJ'PV/@%-TO)M&+V$O5_&CA#TS,2J6=7VPL5[B#RX:SN]877L=
MJ6,?7C. S5@GG+7-HR;Y^N2AWQP,E5E8KE@\>XD%)!C*X(:6QE,F]$G-R-U3
MD#[HY4%'1Z.%N KP!;;XCJIT6U-']YNAD."M)J?K&;>>XI)-18>GR-(#?M5H
MY&0E=G)P:>C*2A*I>&1D#!</"5W@N. *V\GK6;\J&%W1<R2JK&@K09J)H;XQ
M%,"+58&:N3]S#.2X 9X$86><$#IJZ,ZHVD.K'R[]VAK"(U.Z]IK.9^$D]+CD
M!U[V.+*HW#]Y4E+J8$N;]B[WY.R;G_!G&AE7TTH_5%^IZ&W'B&[Y=O_JE,CQ
M[@ZE\/3SQ9YB2LZ""3/E#[[V'^@N7#3%3,ZUM'5ME=(JO5#J*5;Q *\E9X::
MN1HO:"V"%8TA1;><%,DT+NUX7>!J<;#-FG>:2>'N5!G;GEA$^ CL(!O"NF,W
M69BK"8:RT'2-9N(FKC:+-F/)V<O581UVP?_.-*I-A!5YC#VERJ1%6-<,U!CO
MVC(T$61:Q#W:W2"=.X2+:-/Y,3V8[*Z>6FZ&[  JO*:[F=$F,%#U<95X1.YA
ME@05)4O8#DJS_Z#TXP^P-ISJ"\;L (,8XA%CP@*V8#P]-BJ7SGDUBYPL#PI\
M.K'B7S9DV[?BT<F5J'!.EKOC.Y\8S14[R?Y4RPIM <0G*3OQ:N/[(94AW(F.
MMAP!UE+3; 2D"]J&^C'9C=Z$]?&G05L&=H./(0)^5+EZG+/YI@9-.D]NAK[)
MRS>QZU4;>2LTX(8&[3E8W 9V,T5<_T=2@QK+ZRR837*<R+2(I*L=;D&Q#NT$
M4T]5=N.U\R<(LDR(^.SRO(^4P74GG62/ F_VT@4U5?<HA9A0#W"/7&'<HXHC
M:4+!W](P@I%I4G69\8(/,)O2SSU)*)8QTD]3X5FCHM\';7*RY;UV&,\6^O5:
M&>=P'G?8P,+26;W<1#B\U. L:T]/7HGU$Z3?<8/6#VEH#[T3<:23(G\TURMG
MO""ON^@^K6+7:B:VDL4,8KOQTM#>Q*UNA$^4&MT$M+<W'LLQ 9I,&FPYVNWT
MV0A[VO;RW\QO,;2D,/%:%+$IJ8PD@V.E(]X#A#T-@]KI_7[3]/[\?C5ZC]:,
M8?N9.?]9I5YF+7>G0&/&S=DVY'8WW%9(")9#D%A&.S8!):3*]64BQ_B(:1X#
M'5W_/8LYU59?&%4U55>-EN7Z,PT;AKZF7S]'B?&#A=.>VN?5?4,XK>5G?MV7
MT _X"!'@"BTFF8$2P=T:2Z>4X43'U(D<^RE:=6TS.CIS('+,S]J6:=(2_ZH6
MB_25J*=_])^M]DU$&INI*7&D9BT;F-GO/I>_KY?^8J::.*_;TA6[1PNDLI!M
M-#'ROBF3%H(A&,\(\VUS.S3X@9CO;>+ 4HH)^-&WF'AZ(E,VZ6$N'-R^K^LR
M RHF;H:D19+Y".6!@2VV^]SPBLY9MU15GL3=<).$DXO9V+$TJ\%V#-AFW?S1
MYL+TQ+MR&4^)6/&]98'V:0:>0A^J+DY<"-O6?O#=Y$7-GG345/^/K(N:6)?D
M7P.'LEVZXGSL,VJ(VJ=[2\/;KG8\$;R0H>:R65.OYYIM(+H;SK8]  (WT,4(
MF*YD9!]EN["HK8^A[AS9C^A+-!FHJUZ;.(-AC;>L$.*+?2")@1!B\NAOW?X&
M8O2PDU2K_,[L_*1LEKP+CC!(M:=<^%B0?M0<MUK_^^<\KA 2U.8(<G]GF;\:
M!L?I$NVT(6>V3[AS[BO+K*:#+M[H'0LC>QF>:O(#9-&!V<5$-";YEI%G?62+
MII^]D.&?.[ V:?$J :^NR!UX&="(==*4F1RE-7*XQ4DINKK(4)*K08'34TVT
MM79P*",V&!#D8OH-9&^-SR(_^0Q%Y0,W69]P44K/ZU]ECINF8AY&)'F-PP^3
MSS7E9<#RD?8YM=E-=B!8;>N8<.WJ7!1NW'X@8,;_!TS+K90XZ(#4LUK&_KW5
MDK4]P8D;,-U5QV0#+H4=YR,8[FJ-ELH2*M]V\Q$S]HD6:6=" F6.6&B[6W(<
M!M]YM(@%OFQUVO/N_L$IZ;3QDDLO\A<3NL2D7L(#V6*BVMS#=CSW_BI@M5)U
M?Z+^&L, \^*J5:&JH5]$TX7G+R_YS'<,-QAZG]R499UPV0/T\=4@)3S2E$P\
M_08DPUJSS##X7T]TX\SP$1'VE&\HU&[*]!SA-SYB,H67XPON),W60L)N?,1]
M//XB'U'Y%HS@(TK,V#=(42Q1R+2$QI:X XOESXOXU?75=< GG7USL<L/.4[
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M.+CJ;3Z@A)/,]9_]G5< Z>$N#C9>OXE*VM,V3,^(,O ;HVUH,3A&/WKO"1C
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M1=Y.*E\<'3^[O+EK%"JC,S"#:M6GS&BR7KGV&825^)!U?4OAAX.V],""ZSL
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MDAW+ZR4819'G[(\ET%(&+,W/<*(5+KP D!U8WKUZ"*W^V4TLA@0+K N;<EI
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M4KJY<4S-R78\SX#HUGW:'&P&#LT@PD1@)4Z/L@,V-6U*'' R'[;-&[Z!EQ9
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MRFE(^CG:YG1T?Z:%4R9JK,K)Y^U8YD/XO"M;IO$JYSDBVS7QK<!HH6VMK;$
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M8Y4VGS<XY?GMA.KR]F98T$,.\6N7^W9G^*1E[U7);XN;SLP\"8XQ(,@<D4.
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M[_IB.F)ATB0Q5G"Y3=W(Z*KC%Q.)1LATTJB>0_3E$O[_PU?%_[;MWZQMK7I
M[S/^V(B'"34%"['S2S8V-S=E: 9[.\+-FZL'E,NKNK@]V36;6,R53)[RA2_B
MFV'SK\,D#5RED@EG-#L$T9$A"D>YW!](],LQ]L/*SD:KG7$>4MU#&#=E8WB
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M"V6;,?&50BJ6^02X-E5'VBNX-6'J#]4G4\#?0X/V;*D\1 YD&#O5T7\NSYT
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M45/  .C*, !SOLQ691\5Q].#:.^D(A@ O=%76'+1H.Y/C81_%NW574RG_\8
M?-:N /[\:<8 '$_X^1/=O.99J4GGE>Y@QD[19A$&($*'Z6I[\?^H&&_( ,AC
MR7ST&^M>B($O"*HP8J _=-E=WW>67*4CQ@!\WYW;I,GLF-%-\_Y-/3^SGP\8
M@.?8+0YO8WJ8%?-*YNEAWIN:@G+QS&.B_EK&%(D^@2"8_8G8@HG]HV(2H@](
M8V$ W@0[@+>W<N@GQ+:WP4_'!IV"_DE4\3\+"O_GS7\U,<0 Y*0P .3KS#;C
M\%MW]#R6X!:BRP#DKK;-4JU^Y-!0!O^FY$+.5A\#< RQ(#J23J,5,0 O>FBT
MT9E 99#(OR-+]Q\U)1B -#"5G0&X\(O_7_S_XO\7_[_X_\7_+_[_'^=?I0?>
MUSWA\>K1>C91#F5F/^RAJB-"'GE;IE-#/&/\F.#M^MC^IAY;H@H]]\G@V$IM
M;B54.NXWY'(- Q ]P?+1T:OU; .N^2EQW3X?J4_>1.XZRO5O\H.91MN^M2:-
M>(9+[^/9)# $!#]V)W)(KJQ!_$4%5>W3QQ_[Z3JR%!-:F#AEKP* -!^Y92(2
MG^S>]-7L+-7AV\WU@A^VZ#X_*,SQ.737L  U'\]F;N$TS&6\UF$C@^V_ 4L'
M;71O;%R5K<Q;>#\OO4<*,2_$X R\\%XS5TP'78Z,I?F_I4=H<94,E/7,HU]?
M<X2X7+UJ+)I8Z%!M\A[.V[YP3 KUOOQ%&*[43)3+CB)<53%]>-P'HA" MY/8
M-;I<DI*%FM6_GS9H?#_]%E:S+G!2.5S<5*NJM7(K.2AE83\EQUY3X9E$DJ$$
M,SY9I_W78M&66%S NNW4!"20UR&U!/9F$CS1]O2QLY+%5[7SO0(!$JEN#4Y9
MY^URR*^H0'H$!U-+<Z^8G7+!B'2Y,--1M44(/-*W(=G.&93B-AO$/3LSR&2L
MG6,.>\"M!60 7IYAJB#Q,@,0+M:&V+D,!S, OPLR57 )9*&OXX50;MT_"@ _
M:4'I_MSGH+'J+O@Q.\G_?B)=P@DR^(A-E(\!:&--9DHI%6]AH(S-  ?3&X'U
MVK^PO["_L+^PO["_L+^PO[#_WV/OKTRP1N0U)ZT(2B46&"J=7$HVQ3U:<[&V
M:K TJ(V42N1IO5=^Y\2;:PYX"\O)X*:#E*3HCX:*O1*M"TR_=_R__EG098S_
M!U!+ P04    " #HC'Y<AY$%>/<_ @ /B@( $@   &EM9S$T-S$U,#@R-E\V
M+FIP9^R[:5136;0N&LL&!#$BK2"D;! !(2H]1E**@( 0Z06$B(AT H6 1(R)
MBJ%O2NE*$%*(H<=($U (1"! E10@O8 2DI0@361OA; UW4N=]\9YXXS[?MQQ
M[QOCO1]G9ZP_>ZW,M>9<L_F^K!7)>\D\;(^CG8,=;,M/6V!7I!^89!9F ]OR
MO_G\*^1_5\86R1N8HNR6[FTGMVXY"/M)<<M6Q2T2)@P!@VW9_G\.@/U?SY:?
MMF[;OD-&=J><O'0 ;0_LIRU;M_ZT;>OV[=NV27OO2OMAVQ2W[SUPXLP.)==
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M11D8*\%[Z2V8%O))%^07"X)3*/<?E*C]WNKJ))_6WU(GRM<W?)=#WF^^9ZQ
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MF_:_\QAL7%:G8R<C=#$[&NL6#[@^K#V+J]EG>.ST_D-QW*.C+D[;EMN>/JH
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M?2L?.A'<W/3US_-U5]QY?")PGB7S&0%X(.#$+GLZ DRX",R55&)Q@MXVUJH
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M\QWV7*U/K![>U6&7PE_:WZ$<0HYY%[HN:QR:.5W<0;P^ =4"2F)9$E#+#^D
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M,C<P-MCP><.?HX.[9@]3L#+[[1 R&14-EWZ\F@'^^A47;WYLMT:!_U$V%YX
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M<"7:L[!UP33L_EJP;W;H,T^6_2_5QQ8#O/8Y[:TZ[/*Z3#DM\\S1M3F)1KB
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M3@K;)?*C0RN<V%Y44L FR $0GA"7BDZ!QU9X"G.]9BDZ2@#[3HS?#'V[\Z8
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M(LTN4&.,(%^*_Q4J<-.D?)'"1,HZ0MYF*>PY.^4Z-"FX"]D([4.V"NY 13%
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MRGQQ7K1,XA!^ZP#F>MA3KQ>91$NPJQ(HX* 2$5B.&'<.)#-M_;AY]\L69A6
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MI7'Y6!-\^I;Q'&XJ?XT_.'D[!D*%V!Z4PEQ!TX?@QMX;.KL8DUK<!:B:15%
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MR,-$+<D@NYF8RK6&[A:Y\?56T@$W135!+)^^,EH!G@=GN*J)<S1R<M>^R8<
M;%ITD;-Z8XZ<Q0'T4NA1QM8.!H@3'Z=W%2EF+ =RY@O7J?%+-B?LQ)61SM%?
M6!H6*VO"GQ>U#X]%UEN?&D/851$N 9U)[7%EBWOZ57,K_$($Y,8CF,17^126
MLNOB=.0&-/#*_@A*TS%#?9C_\)G<6ZV;\&?!KSDO3@8<_.OC&>B]^;$:^Y+
ME$S,E_HLEC!PU:WF2+1M@Y&FY6FSVM'*A92"QQ2WR)KK[N';>S;[F? ,VP.
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M6R1P^"[WA]J0ELEH3"E%W$B5#$9O9L^L:]J<EHQ(OJPB@SI:.MOO<!T//GL
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ML]@QN"<0_VIWWMO#PWXX "M;E[TBI[GE3"0'VANGP\%F^X]W(&L6;0UER/D
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M[Q:>(;YA/XF1:78H,J.-OI(*% D:"WC8U71^/*=U)9'+3MT4W 9>C;(*31C
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M5.:E$"7;DP15\$BI=@$/)OOG1"E$KAR(KHY$R@T )_HE2GP-/!GCJF2>S5D
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M"_V'*K8E6:3DWCMK-4G4%BF)RPC!_'2_UQU.?#B+K;)RI /-+\6ED.4B=W1
M^60[\ H=3)I@/]\HW,AL=B1H!H9RLG> X5((EY1"L"D+;GVTO"%1YZ\WY'Y
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MENSP18VZC$J,EDIUP!@N3BUX<Y9:MCRKPV>D((+Y!;ULA8[0.GQHK]JFA^3
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MU\]__?<5UTAF2@0B^/%P'C2#K/ROO7]!M&V ?T&VGX0HND-V/;]FM'KRS!V
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M4I1Z#H00 .<1#:H UD[FREJS]7FU%I+OL"^,3(@I9N<8![ P",[V'\,>#A7
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MQQ>+OIUO;VZKMQN)M0/C]3PJ/Z2O\$R-(%U4Y52Y'L><BP-F5I7IJW&#Y0<
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M3!!WNV4;[<4T2><.,'UK4J/KU:R<V;;.-@XG8GR["4== PVJE&[C5EAD;H0
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MX+&7N<K@Z0QG<AK92B[X;&SM5(WBI "6;N5V2-.JP="?=VJ25;>9.W4=IRN
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M<]YS@WX/V.=V.O67/"@)RW[E8)^ \=GPR*DP.595[R)NZZ;QPNITV)L6U^4
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MHJ3  J"GBW0(QZ'CV_R0$QMHTG/"<B_TQ0V* )[T'!$C@ >$4$ZJA?PQM*P
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M-GF1=W?=D!Q^7U ][' @L\NU;*M-KXPV)E M][+;'IU3AC;:$_M_.I_D$>A
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M+MS!C1B3S*&1C98O6:*GX9CU.PJKFC ;CH!YS[Y<49X_[ALWA0CKZ-^XIIL
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MAIT3%,;-WZ@<!]T3HF_$WHAFISM/#S]_/CPMLOE<5T?+-#7X-)O^/B]P(X/
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MW?='+0BL5&5_N[[?\&77MZ$;.8+S=5>\B>T**33;89QM*\[GSE"%X2YUK<8
M9Q$^]O7R_APUYH=M;X5&@GF?_/!AVK.#1_=%W'-ZP@FH/_??F:F/G!&J#'Z
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M8=6SW09#>(O&TNUO=MX>G!S7"@W-.+0S]*B*5IJGF/D?Q/+?*C J2:S3?Z_
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MUF#\)Z ,<(WF5T+^O@WF/\0>A5G]6\\:[#535<8BM>3;_Q(8NY-7"T@Z1#=
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M@2+E96*CW^8QRC,J4(DRBB@V;Q.2-THL(9I@(&7\]_A/M7A0?XC?GJ'*O$3
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M+?>P*$L8/ 67GR5)(M8OJ/S'A(+.MB4>M\Q/B1)WG1CZ=,X0-["3D+NQ7R^
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M@\RA7*E!XS-1VB]/C(Q=+CH8^8[V@G5[%3/J<UF4)W2!QQM[1H5RX9M]5>6
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MNO^@BF6CE;K-AJI%45953)R1ZPLP_F[$U1>S56ZEG?SI/H@ET)]'*)$0PM^
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M[>8*\#MM5S7?QD4>LR_^?^US'/Z?^!SF9E CD>Q-W2'T 17850(ITOMAIC3
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M[7'R;OJ_.YU8<FWAK<.$>VRQ(^W<X38)[F=D90IEL_E&HF+2,6(T%"$P$]J
MB!8X51X!-U8@!W Y(P9<SE^AY7^,.8-#A0)C(6Z8:%DZY[%GZ'H(7+J]C.SI
M9VBLBJA\WBCYX7::WP?.]BF)2AI!WYHY5?$-='$3ZQ>QTARZ^C.%*>N/@M6
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MS2@\XMYV(I:$%=7\K"B[L5N4I,N)K6/^7($5(.[*1;^$"J?@\K['1PA&?'V
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M$A\DKN8K.M-=2U,3!DOM\^P:1VWM<5KS7L,.#<<[EA>\=Y<;/G1R3WJTWZE
M*5=C4RQ]*R\Z.^5TF][LVT?71I,O9UF-6B[3TM ;B#B!-O%\0]\4V+V@!2B_
MYI,.0BI7P,]L9]6M4/!CHO= (%$O')1B*J/B2B#/,Y#*8T(NIQ53T>&G_["0
M$&P)XFI+KQSZ5(D]@\H.#30ID.9 ZH,#S'U5U9 :D/'=!?1@39&E?7,57HC^
M7DWJ5NKF8>(_F^)5?,-SM]1 ILBDE6@,6UZLUH=<M;;Q.?L\2UL]8C76N6]%
M9+[<7]B'OH+<#(7S[0?683YPF;E<10E W1&:YD'6MB"UM5R96YM>X(\R? F0
MDQZ#-LFY^CUE>J4!2[)^=3?*OU/H*XT.K=\863J5I:/LHM\S^X_0 6>^Q+#C
MS*:Z-Q(^BV67=HQ+B&S_%&U4NHT#)!$LN"$>OP)/);]!O22$'QI(A0*LDMHF
M?L-*?U&5DGAM!?$A^=;5A_CK>LI14OFUV39I%P8HA_T'9FK\C]M:S2)#Y[L"
MWG9&9]K2[DP_0O/D-V><N=5V [_)N[]E\N9U\Z@<SQ.I*OR'W@:*C[A%/GOE
MXCJ/NZCL\^&;6U6>^N+4_.?@47/UD.<#6E,>B@Q<]U],*5$"V9>VB=P</DD=
MP7#;TIZE8"[UN<+WD;I498'\_LM?1B=*GUPVB1M<BKO6L_I&:?[<2[]K +^R
M5$7=7 ESQ\$<E*M]\G2$0&N5(?-1$![LZY]\A*U$-[-VOQ]E-<M(7P1ULH%?
M)]Q4C!RA8C+OH>K[C7U,Z?G(P%*=."YF!S(!Y]3IC@;N=:'HCV?;I-=A6P@O
M;+3FR+=I5=];NF_S29N!U$RPZGPCA)WL5B Z#%<(U;8T-UAK![<9&K38.+2(
M#_6M8'83VB^ N0Q^'5,&]$EP<ZH9$AYY GF;!+YMTT8X] I?Y==76'B($JJ1
MN\0]]X@A@Z@#A*Y%;_!SO# 4>1M'M 25;6L,5/= $3RDE&^8G7]6>$NI=8!7
M/\."9\22^]"->VRJ$I_U7;SI174,.XO/K+]GGWB??N34R/*H?6._D\U(B'MY
MG>= VXWO<E<)/O%7_IK\NO=UT!_OEA\9[!ENG=YW[#G6+M=9\V$!&IEG(9O5
MQ/7U=O3EBD]YZVG$M%QD>]&E76/S/]$D^<AY"8?/\^#-*@K\DY",#Q>_C>!$
MEH/<>-=H.\3*[J["WY_W&^.+A09#@2LYFY&_M,LP$[8D,XQX*6C+X=] ^6)\
MQ:79G7,9P)G-3Y1,5SG_^@S@!EJ:[$FF2"(C\V03:,H55_)2M-BNX<TR:*YM
M C CX<YUV"ZB3>&LM!<OQ:=EM[_^6EVB,+I"ZXOWF&-JIPU@Y,L^TU.S5X=A
MD:^K5%M,^#P_][#3L>.(:V?84C1R.%IN,9_?JS9WRB!.RU23KGJ2*Y;/O5%U
MOOE"[H:C;_W_G/@U]#X0U/PVU>5V%MLN.=]49O4M>A0.MTH&!S6OYMM;?%Y:
M/#D)'XGB1T+>3%2UB$KVH2MAW0FLIHD=_2M:5 H9;HSTTUY*UAMSWRU=VA6(
MI$RH9_4-O?FH_)"8LGO-)?;JGA2#A[+O&2JEXM9@R+H]2S(HY(@T%WX+*58D
M6D$YP'";'0')CT K"4]Z!0$EVJK?6SPTDUK$FZ'#=6$><*K-</7L])"Q&Y<N
ME:15/5 MN'.VWJN%LH <Q4^JT!?5@#Y$_/=ZH:K*"]7C #DQ\&L@PP21L(A?
M)&J7GRGYZ)MI>'&TXNZ>OP-VG>6?M-%^5]FTKVS))^Q5' /#3Q3%&Q\',ZT
M-$6XJX2 X#K',79Q:0D>"L\!4^&!7H;;I-8OH(X1N8Y0VCP!KP*WW%ZA2A.^
MFS6XFSKT&CML=XW-R,K-UW]<^P?H&G'92_G0$4L#C0@/5[/#RXNAI3:^V4ZL
ML\1NV1O#>[C!R5/'N"0Y[O5VK>9/(V=/$*F*Z3<&#4_GXN^T\_QFTKU<\XUW
M&-[N?(YV:C7 ZK.OE+XTE8YC.Y4ZU1#1640SD"*4#?B)A>66+!]6O(=!-O?]
MP\E%SU97,KM[Q.T\>#0R,&=*9/#[D! 1'LJC0F>.$C<4ND&4LZ JK6360*D]
M:64LVGSOJK*U8F"HS0D!)F9.!<''B>Z%CF_N;@G#5L&;BG0%\XC%K=JKU)%A
M-E-E^)Y,F=C]<QSQS"3N9,M:*'\/=:'+U*)VH$X.\P(?X@3.LJ[<J4 I":.A
M<&3+C^,@JYFS@6&D2D?$.&+B*E#;B"B ?!L7NN4Y?L\;O0_$,\'<O:%)29L8
MO5C,;;Z-II'@U7YW>TRQ\9')=5C"C3F4+HUGT:J,W/MEXG"/\'B!KU@9H-U^
M!OGY338(9 P<7X"IQ4\":DG:H$+R-.K8J\;G ]JR%T 3B9G$JO<-AKB[C,X6
MW$E+:1QY.S?<D%%OBMM=GZF_Z"=7VK-"(!]\[^_M.+S[!E+:[O557]N]<IG7
M1K;[3;],/$V7+0D]>=3L_)1"$ATCFW;EE+]]QI9?W!F!OIF#P$7@P3K,ZX=6
M-"C@HY3@J34B-?XVR,RD,):(+"&\:,/O(B*J@<"'Q;-!0L(KR(#[H\8&[PIM
MU67!Q^:S'/.[DRN0\E.7:OOTI'&F7(')]X1J7+#@Y!(F]N<Q+UZ2@9.VUX+7
M.569"Y[1*M.KHIK\I69M->Y2:_=F=[</[[0?+C*N2?)UX8XJCEE(IOXP?]>7
ML@S9W]4,JM[T'33^_IK\H?.2*%<-1%5.LI)NSC.-!H72DTL;OF0-4U?(=U2U
M@-RX@*=0(1;$)G[U DX*?2M3Q>@]_AX'6 U]90LUBSL)1@XTNX'K.J%PR-+8
M&4>/ZGZ-N$V9S(V9R@[@[+;@L62)YZ'R*5:RA^[0T1 YH#96? 0<7Y%U'R4$
ML'&EA/AOYCT+UZ_KSI_37L7LAJ@.KQH2O]DW#$Y']>*O3Q\>6>[X,EB3,S&^
M8ND6O3+F';%/KOG1I<J'N$"]-Z?"0HZ?=E(_G2$M<_=&^CYUEP=7*M.GXNC[
M/';H@=""K2<EQ,M86_/BBP65;1=*P'NM Z6WX[#_MC0&JN.G8$:F)JFI.*$,
ME_X!S_<"NP;(FT@'A3<&EU9%TJ])O]14 TOL4ZI+3GUEJ"X WS8?788=,SWR
MW&#Y2[W_.[74;Q=JXW)GD(.:/P)X/@OE$G&258F;P*3VYP1L:SW\MO$F'G*S
MA!OJP/!;(32Y6:4<?EUQ4[$K@;I8WS7=FI,^\?=50KE$EV-)7WU.ZE;.R1<>
M[I<*6+)RJIK77KL^[#6H78.J2GYI[OC"MY>[/>VW9A^YX*,EV:W6&F_VW1@A
M2O+7A\X!QSN#'D1H7D(&&.SE!O .YG7&%\R?<FL+Z<1#&HT@<# R<V$):&CN
M%YKW"8V*"'Y"!\&1IOPOLAQ"WFL?GGDFU\^8R-H12%+JF%( 7F!. UW49'KH
MZ1IIOY6HPX&KQS)>!$5BD\F3CSP.@(AFW(9F<A4Z1N@2 .9&DSA-N9J]:$\W
M&F3F@]_A,CK.>3<:7PCTVS0,+#R)HE?.N5+B===A.R\1G&:&+Y"5+T-7.S$-
M#$H9.+P@JY&",ADG^N$3E<X?ORP\UT,ZJ)U:#M2/8<'I^UF(&!9W%V:3'V?/
M03 G;IK"[GLQ[L^?D*\%/H;U^&M[Z7VL3Z[W*F/7 .2%F#("W$)T;Y%H!*+/
M1WOR+]> &6FB)^5$5#VKWS@XC_#-U@:!I0@.M+>OV0S'AYZJ7L4OI)@*\"WR
MM>')=0KU3H6_*AN4-G=\>\\?=/_R ^L6;N<:.4=-BK=K#PUZD"@+"&X!+[>K
M!VP+.=[;L6QLKJ7WUM='>)I"N&,GYA1:2[DI_#W(,VX+F;>/G3+64=YB>^JZ
M=9ZQ(WE4FDM9> C(<A6224?&Q1W8C<0+$XJ5J=9PN!]MH_"WY7FE\ND6)T.G
MG*#H9X0-+2=],\(SO^]TZRX?]PO^\$'*\?/V[CWV1&HT2.%K&=3;)A2*W]!>
M?(\/+2?SPEM9FV;#.2K&6ES$7\QM-0"K^;A,11YO:1<4TX;>I*.WB' :KIEO
MP,KXH:0D#J<R(J"BJ6(V<H:>[X_:-WB4)_C6CJT:3B!)W'XU9 1:\V;H//)N
MQ&[?R(D&4,VB5P/8.+J:F@)N1NPA>V*X^ U0YMG*>$6&AH)P__.&.6>GH='8
M,)0!#O7Y<G_Y 0PM_^>SSNY\0GB3T\0VJ#4H'V*SLQ3:.=+S$O.GQQO;@9KL
MEC6%=D'V6$K0E1X]5N)0.$IU8$61?I#57[$@- V]4AHPK%31R'-7<V8-U<@_
MB'V<V7C$X!W__KV:3*U^]^& Q0^7G=F, +>3A=A8R)1R+.+0^:2#+=U2"6\)
MJ-H@4X.,<$OO']&5>CZW"/4N>GZOWI]:>^6LOP-KWS;8,E"HM X[Y\MZ\7FA
MIN3+J&W!SX)R"Q^6BF8S%!;6D,T<BNM0\F)$@!Q;/ZT,L=7OLU/_WC<V\077
MC]J(BA._C(PI$N_WK\/B;409Z"^C:)]UF/ D=@?KQR/Z14 AIII.\=@,^+ 7
MM[D)4F1?,V6!I9CJB%7+J?J!F3[&\;R1+UG$^I1WQUQ;@\B'\I.1X<9.0V#7
MC;YS?Y\M4_-X4363^<UZB?SY$W-J]1%2^A-<.IY0H?1F?V+(8<;Y_>G3@VK;
MOCYR]VU[=N/^E/WQXG=Y>K99]ZRL=MJ8D<Z,055\7TG^P@Z:E%[Z8,T/IC3]
M+>[# N\L>0($G&C( J_GGJ@'WDT<Z-=;AT'.P<)#_>68V$_7$ON=&VO!P4%^
MDG1GM#HMK'A3XW 9)X %G.]2[W9C##-W")6!#F!)>$"FQ$^L+;JWBI::+PV8
MZC)?.@?D%GMRNW<3U?I619YG!U>UE)/TAJNC]27,6O7@#SUI@5E]S<FHGZ2!
M:/*0 MO;X7>&E[^L#:>2=*"I5I1FCS#<9U*D80;% >WG06?*$T T<8N+5;9!
MU929 QIC^ ,#U]^G!7[C6!WJVZOH2KXG1*[#-C+(\+9.C3:DS,';G$E1X4,N
MZ_8%Z/*<-9#9)L_4%H^ 1Z@\CT+D'>(5WH\K6?"=A-PY7^^(F<3%ZY]N#ZF@
M:F<*Q!^GO%0>U9"6].><7HSAG,;4P(1/*+7I^T^!C[)-CTR=$:D\P[Y+PJIX
M7P9U"R7NW(VOBM%63+/MEX,&\ZQJ'(F!!^(V?^$='Y@;X#_ >D(!>20V0HYT
MB##/Q?^L=L'9ZB?^#=A$B5_5=OW6RGFA1XL)\2L78O+5Z9Y[7X&(OZH%7=O$
M1A%R"E9@+HV+<W#6"@KF9IN$VU8.(,M/8T>O(CY\X^.RFVO7: M! +7U)I1F
M!J7SI&@6D'0>QB_?C[Q#N(%.>/55![F"B"-I5(V12V='S2G%)@-#.R%GB\&O
M0GQYI^JM)^,_)GZ4D[I9LMHD->%-* %@3WD_!+X*I@)I0)M1@HY8SI70[P(4
ME -]RMJ:6EWJWQW!'!J%7MV]DW ]P- V/W^.N>LEHZ9A4'O5W<BU-LW&S8U!
M'J7Q4?UDOW%3]EK<4@M\%Z3[Q6,[V!Z;4I =SGNU(N! YRL8^C+"48_T*?+V
M63?M:IQ12Z1.J9=>W!O0AGZGS'/HJ_=SH(U6\/&/^Q%Y$9T9HZ4=U3^<&I U
M-?3:^DO?OZ$0O/#FD?&C=3&$*V"8LG[QT3PYX\SX&R,>5^ZC-%I-X1BX507Z
M>(ZQ%9>AK\K4$IB?TC&CYF'@3LPKE)9Z[*GN0N*A*I"Z '(%+$AC';90)<H6
MF/O;M7,'8RS[%HE1W,8-&&"\+M'8BX?<0Y!NH549Q'.?4YKE%7[5:M@,VH^[
MC]M<45(.9837"'S^=>G&TU[F+TU7P%F2OG_NX7IP(PH!V>4+-:!@+L[I_7?[
M!L [-W/*#D3?"61<J0@8':KDX66ADG-'<<C0S@]'5X,+QBS]BN8,V1.7;4EQ
MQ?=KIW%^Y8_J?C 3M*OK^ZT1&/8^Q#:[KL(6%UN;A.!W'T^4.-ZT58[)R[SR
MG'#>N/2(U\/HK6\54Z]@5!Y<*>9Y.<C%OW9NNE*Y+5<]G<"ZSX@6&(G?3FP"
M-%*(@>NP%YS7,C;&*ESD+JBX>A R V9Z:S8!?&I4:4WB.&W;QR2G!GGO7V[@
M/N]\:,S>_B3,X UBJ[&U0(LPNLQKYR$6C "-IIM=@ ,7TYXCPU0A'N]!&79%
M2: ER;EVS3LA;RY2(8ZYS9=YO)^!\R.3"_+;*=6<[83;1ZY[,8:N#L2G^,F(
MEF:_MR"V24@H?!*I#*DMKL-&L,!#@FD+4T[<+T".L:I8W/V]]!!JG2AI49Y\
M78 80_7RL36CHKS.96:OA*'T2.<'R%<D+L!"8 "1)]$QGP'J[55W%#PVF,!J
M<W5FVQS05N--5 &U[@<"DJA)J.U]J]'RG]M&#9+5G[->#NE&.[3!0S(C_WX9
M[;]:/J/P_H13=;Y6;7I_1N+<4DG?F$MC>>6G(,RV&;#K^8<*>:Y8N3AC\N;U
M3CFL=HO7/L-BG],M^^T5PUR.\&[\W<8==+V7YW2IY)*0)6.^YUK)0,E,<<6O
MW3]/YO"="R?MZ]>EQJ"WK';A6_UX^KW$DX]);]9J&WG#Y*WSX:HJH%EM/E<%
MP963D+VR:,/%FAP]G)%'7W6G0$O/W34JI,\K<570_=?/-Y%7Z:,:7&8F:-J$
M>%'7+-+X?3"0OC!9#=8MS$Y2M\\]Q:&N;.]S*Q/OHUD/5?.//M7V84=6U#W5
M>SL^BRLJJ,J?6PNCQ0E.B9L_3\);X#N@%:%5/_'LJ&H<:'TN>HLYA-]R.R0\
MC8=/TL7+G5LS*Z]+UNN,EK;J.=B7;=M??4F[XJE^\!^5XZ[ECU/)=A!<@":>
M@Q#<[CB/#3708.'<.@Q.4K8$=X]= ,9IS?/:![ZUNZ(3<_LO $3#I3MZ" 4H
M2V ]1)2NZ.)I_0C%;&_/FYW0?#&X$#*V^&M3M6=T\<5'CC]\U%>J IWF0P,=
M1_4;61NZN>\*$P.N+K\5.G"7I*X<<RRZ6C0%*)K;L;_18UN[@')C59T"Y*X6
M.:Z#M&V!1D+I<&%LH6N-L:K+M@M/4EJ'7S,P'20=T'F!S*6F9F(WE*.O=%-0
MOPUJ,T(GL9MT"O/%[X%W@6,M3#A8F,RP+'89=2/N9?17R#9'AL>O1)3SW(EG
M>"8:[@-$.SRYD.#9;/BU)(W4J52XT"BP)E O]CKP#XFRA2:>7I,F6NWH4;$J
M4,=>AZE:<'^L8O?,BY62?FYT+J(T4Z7="-*\FZ9/T'>VQ"I< +?3G[S'V_ L
MMCT4==N)*+KNSE,5E6#;%(_:(JUB[01F)@@O9052>%B5V:I9M4N0^S.A4<]B
M=;0Y&8'],.I!\%XUQM#9(6L;U]PG,GE:9%@[5X1NRMKGZK5('0GG'ZL1/1+:
MB[6S6YF*PZ&'2?)?.-LF,1N%NMCX"X3;PYCA"N,S180IWB6\(C2$525:#GS=
M3/-F'MD-1>-T(3WE"-WYH8&\>Z]O4G3N91H<C>SD]6>7N.O^< M0U<$V?R1!
M=1N_Z>SC>C5W)IQ*N9H7_Y9@IL%.N:)Y8V7N_267&=MGET'=BS=ZXS7)SIA]
MDX7;O@E2$P^78;[<H!\'&WD!]:DID^Z';&8J<G\#L(FKF>;K,#- ',>E*?BI
M'A38%A[>KO9JB'8VS;KWNL6:S:=EF_":Z]>1&E2?5@^UQJJL,7:N4KSTDL(<
MP*@-NKPE2D;6UGG9!U1OF#[!B,25SAA9.Q*^AI;_KI/C_59^^>M;"0X1M;VX
M[B@W7_67K 'D5ZS=<&@GCUX\7U_]-BFHB/,FL6AOB<6F_#(ME8(<3YE:FN=V
M^;">EBR+C]43WQD*60*,H'A1V.5V[9WWN/FL!7>TK$&=14$L=9A@/R2Q6G@A
M W9FWM?_UQH&_[LON9GZKZ^*(*KS*\ B-O!934:/N;$G+_N&(O$D+DCI;9;Y
M0[7-\5@%?_WW+\XH[E:/\=3T_][[T+MO$5E!2',;J)'F _A8GTLUKPXDNH=?
M7L[@#3>-NK]1-WJXJRE^JL4P]DI\3+[EJ]]E2OV/IQANY;)FC4VX(B1;R9%)
M??9[S^CO7G<G7%2C&CH;$I2BNOX0S]GW>\PI#",/=2U^6OAV^?*Y9:-KDZY6
MT@_I$:5-88.N]N[E0*O0C17VEM!13[VWH\>F),U5?VAE<J@[U#Z "UW]\75V
MI$\WQ^B/_NLK*>I#1B:HMOTR-8RH.XX?WR];JF7<B_B</A&5_3#7.JDTX=#+
ME_<L\^^9]SY-C!_#U86MXKYRPOSO61[\^7&RU-YMZ7O/[;>GB8?W_EM-VO\=
ME[,RCR6'2N0;ZE,#5,MYBS?.UZNF]IWXH_*U7>!J^55?MDGJK?R(RL;5H?Z#
M?1V;<ZY6^2MD].K1]T#I1#0>)U.>YS_QV^!T%!KN>^&-&LV!<1%^\-Y;Q]:,
M],(VL_?T$JN437%%6ZX/.XRZ?AP ,F/?Q^)KHET70ZD* 6V*H:+K;9[F.[<(
MU*G/FJ>SV.RU"QGG5L;DKKY;OHR=,%Y+61QOJ;UGG>46_6 ==A)#_^Y4%U7W
MM7WQU/1I*WM^R#A-R* )!;;O.T/F+-&A1D5TDE_%N?=+\<9Z",KBUVNY<S;.
M[H,%;MT[ X:W%H>6<#9^R/:T[_ I&+$0)SV;O5$WLC*O=ZFGT^CCQX\28[$?
M2\,UU(DB#V8D:._N]?7;6Y2_M_30"\[,V&#M*JYVK %7*U'H_?_7HKQ[5J7W
MZAEI94MG,A*EB][9=Q3.&<:G19:<.SCF[^HXF)'GH[%!UM7]S#'%7UX?5-40
MRU$E /[E$"B]#MOQN14OQFGU%)78WR<I6J%2Z!UW-6]DV]Z(S>H];6:9'S6B
M3W./QIA(W(0GE[4F1?QC'<9^!;JMP[*MT-Q+$%Y\&[N3!7PE.DEHKZ]Q6R*I
MKU HI(DW(;]I?.A=A]$NLH#+Y,Z.Z/9<"=14 AS11N9^,O<C5+X.Z\I' &5$
M@W78&>0=+!2.TB)_\_.(,U/]GRW /2W$T?;KL*:@=1CRT'?5J'78MG8V>64W
M%+<.HP3SZM9A^O?)_V@U4FY/E!7MVS(9VL-Z9Y*"^+%JO0[;U"YD9'Z,6!)J
M(63683W6/ 6Q2G<B1SAJ]R^-IG^Y:+>H2>[N6(=-2NY_C*]+_CR(%"H@EI>Q
M09]9_^BUQ3]:=7YB9U%=O Y#2[#ZEK60_1]9_$<6_Y'%?V3Q'UG\1Q;_ARQ2
MGO@J.<<OV-*>N75LA >93+=D*F36IXL6%SOQ+QL'0FUL>=\<!NC>^QV_KDHW
M9&>DGGKRC5AT]>S(T\2,L7!<[7>\D]@[X2?#I=^SZM#IT-Z][?#3OYL3#S_^
M57)MG3&_=\33\EE=A%J()7>7[O.3Q8Y9AW*/3)XP/Q<B:ZIK=E_JP-T3E%OK
ML%AD"VW%&;6?/%G'Q:S#C)16-#7O/PJS&V9X(D5'C(@)]_>4AQ_"3S_BCI$L
MS06A+(^%;QSH#Z&E)#$)E@Q?FK1G'?:M,D^\D[6;W'OYY_!O<^+0PH6 GJ+"
MQ4.C"$B'M@X[8/&"&LF"#"5B.;HL%%1UD[G2H(9(KELR9=J0PSKL?1OUGXW2
M_WA*]=/ID4Q=R#KLQTZ^W9+S.FR+A#6F<[&T,,DL["<=7(<]??4393:QMI%_
M_-25K=@$])>*GZ32A&^FB</T?L["_^R'ZEL323H^.<<15G5^^]IM\B\"0/^C
M:Q*P,7G68"JY2?\Z[)/IB$4C5J@B@:","%+TB$2IXZ T<>+G%J107GAD'?;9
MT^*?'1O^J=69ON3)>K+P3M3A[Z7KL)A2\G(WLKO!^/L_9.?[K_-RF']O$2Y4
MD'R["_=2724#H7BQR_2/[SX_C4*!AUG3HDE@S TH7(?EI"#^T:O_,@KW)Y)[
MS*[#EO<OY$W0Q3LDJMYIS$+]]^<T;]2Z&@VXH\5G3>Y'#4J$/,CZX9/Y>3PW
MZI^BUR7_HUL_K<HRC"*6EGQ[0_F/4OQ'*?Y_I129EZ$ZH)2ME#]$X6$26'"&
M2?FE'PA<[VJW(A1L.7A4W(^7F:X;K1:(K":^<A;E,W>ZGYEISL4Q@&[5+\_,
MK],@+'H#^4L5\; DT4K@PL67G:\?4\PYUW:C$W2(G5)LOO':UN[1P;3DO$-F
MQ>:6A8KJ_3:Z"U<T/QSN:+OTTMPN\$1RY3W[Y+0J&\-A&SWOW.)Q5 ']OS=X
M.I>J2E!N6X<%_AQI&TD6#.?[C+"J6=R]H#R5O@[S$=4M(CP%X7S':<X(:IAO
M3:^*SNO\)NX*FL8O7QL;'-:[-/S$_F*I?8A_V\>!N9X4P[LS5G8SL9//Z/+/
M*M+[;7Q[R]2LGEV<';@_N>3'WN5D%Q86=J^HO\K&)-S&)/"_/TE.I/]38P_]
MQVS^OVPV[QU^!QXI'1J?*0TO]1<?&L8_31S"16'%;\4]5-N_*!3K*LK9OFIW
M33;&LF[<6B8C._![9F @?KK^X7[?^OK#Q;B.\096?<?U>ZX'ZP\]U3F>+/>T
MK":J=DSRP=4-UH[-28#GV?]:??6_*K#^0 >!6GP?@"64JY]H1B1CMY>+M0EY
M_ O0+2Y&B1!^"6K/]\_5?@&:TZ:HM[(^QS(1+A#&'71?Y-S^"]"Y2R?\W*<9
MS.W2.M./1XU-=2=*/<:4$?+:<M4'61<8VCSZ=L(4.Q*13)3CF6QI4]T%HC*]
M*@@!K1[R0S]7<A#P+8;J^;^Z^XVV42K\#!0BO<OS.6.6*ET93ZZ$!OF%;DS0
ME;54UE+5AZ<B-E60CG@096HA%L"<FO*@Y5>\(@,D. *RQ28Z&6J-C,X=*?,@
MHJE.>'DW/WPAQP6K\T3_[XP4GXB $/5CE\\NS<F-)Y<N>L;]#][>/"[)]/OC
M9J;%TM3<<Z7-W&,JS32%*5-'3<F]-&7,,1?&J-2D1"@WW/U-N7S'C<P4=S)%
M2Q%44&<J<\?2%($IRR7ONQ3O8O&AY^_G[^>/FS^ UXOK.N=<Y[P_]\5U'Y_J
MT,)/8:8^/LV!%?Y4>)301RW>[-1X8<2^\>Q"X:ZS+^(\;WX)JQ?;73&(&:O7
M%<1,WJA!/WC[^G)6?ZQ_7<6YR1KO9P,O?+MS+;\Q"=)FUG]3J&B:V'8D=POV
MO<7!#9-/:D<,4)0)-R ML<5E62]+T\$1#!<Q -O^-<V/):7D%;YP;2>>-62D
M BG >Y.B2%$CJC$SE3EQM.AY ]#S-0W5GX1*_1[0Q=4!91,3!&7F\TR\"WO(
MDL+ZSJ35X$GNDQNK2;X3ZYZJYR;6$I(C+TVMQ;;/6?PVWCX;C;,Q1/M.XHPS
M7K/13]HRL(VSL_6/.N@=V9<6BT]5)QK=!JA":A^B0,^+2I.H0 , 37@R_='2
M(5>N#2T=M9=A#&JXC2=<[<C8B.]!^P 9M*9+;V*L(F_L>/.TJ]3B0:SUB4Q&
MO=HL%3'(,+8)7(KC6#K>]O.-P^ZIB%$AMW+8;T9F?.LZR?2:U4/#RC4)&2<4
M6VT<RSC].<WNOUSW]NKV:W1YVG@VE.OP('6&^)IZ^'ED3=,63%OB*6!!1TJR
MMF#1N#>=O92?"5BQC<0!Y-UKI[T=$9 SD CLO,,HPTH(5Y'\-+&.S4'?@[>Y
M]F*@\QMSJ$&]_&KQKTZ":"O&&:"Q#YR-T@[=QB7@!&O9>B2)I2I<XC@N.X"G
MK(AILA=W+(GJ(+H@@;3KHVS_!.HJ9O8L&K*H;3CZ.9ZG[YR\!5,ZW0N^B\;0
MM^'/+(!Y0YP\7X%EZ-$QI@8^,L2-D"A0_7E82%,FV$[8J.X(7>KZ<PLV8?C[
MD("F]%*0P]KN+/#<B=&[&&6?F"TO*D:M5%:V)0/1N&1?^]=CZ/[:K\&IC<%1
M]K7-C[!!5RN:/*-*DS]7/XXI#IA6?_<F9$#G<EQ[?9+IZ)"7&E7+;.0745%3
M\1&-LL8-QX,U.;[51J'N6G5A#35V@\3IO]^C9Y+<_/M=O*H+P_;H&%MTGO7.
MIF[4EC>3W]=;?)VJ":"?'CQJ0!FFL7M\18C)>%Z*WA8LA[X%>QO %NE %6*,
MY Y4(1A).4D\#MD)6&]QHH3)!-K;C!$VJVV3C<[7M@_M%JBFS.\$7;.L''0$
MM%Q[\MT-_;X%3U51+I1>=Q%OGYS(L0],)3C7)=/Y&!W)GT#@CU.M9Y\ "OD2
M#Z!MH!()T0$3OBI9$B%05?K$M 03R;(]A//0&^8>(/EE%$K#>BY@'KTWF& T
M*;$[^A<BJWWYN25]UY^14Y8T?OX:NDMZO1T,S$!(W)HA^R'.'>6U'(9-S4>]
MQ4R)1713]";R\*@U6FND90;"7.2NG[H&]QUO9ZE?AC <[LS.JF3LCMI6%#GA
M3?RGEC_&;79TSM=S%MW;'E%3'^29KV/%#LYXP8%39P21NUYH_?*OE_^![-R8
M@(:&KO6/W@F:[X?M0N$6\46!!N=Q/D7N#NMF]L?3'C\!RG*K0I[5H57-SE;8
M>OI4!#6HF(]A[E8>E;80K?#8UU $F"1Z\^-  7P/I!,J?<ZPH\HFO[-22)&-
M*'5).+C8A\B<5QE#*A%^ 7^&>/R35, +KMF90O 5*&,O R7L$;),':0._"NQ
MB$3=%0)-=URS8VU(CW]L66=BM"6^8F])1 ?T#1P:NH/C4+2(KWEMJ(%_4.$\
MK7EYH#,< 1G: -K&WD1IR)U-GM]1UB>B:,?SE DGH?LXHJY; ZD_K/XC;R9H
MZG4%>%0XP'3,^97;3N,V_#N](57J+]6F"PHTL4'H#,D)?H^)S[3$66!%\FD;
M6[?:=G9LY<-D0C(V:&I#M[E=:N$VWB[&YJQZ^#"?I;P>?+V[I:4V>U?%M/G?
M-8KMYOQ/$85F?AS?"EN?\NN2%W$<MIJ.FZN"[@ 2<Y6_:OS2Z"*_TFCW1,5$
M;P UH"+F?]_I!URN4P[/)>CLNU"D327XIA(WVQ<O%)SH;FG\MW[HVQB(6W4$
M??V@-CX\6P\S<!MY@CC&VWV4M5!;VD1J+<6C^YZ^(>P#$?T(,L6P7>X3M:YQ
MP@Y^K([P9%8"2&83]XY^%K1!=&&!IKS^ZFK+$4*?H(DT!"KRI"EG=%9_ E\.
MPG<2#(5K^TA]YYD&SL $FT)'K:S"LX@G9<-;L';2RBQH$0# 4Y$'/GX7%0F:
M3X@R09NA%93806(E?SO6IE%USQ+Q9X"61]1Z]^X=MO(P&/ 7B/('DVM*4MM#
M5+^K03= 5SYE$*$X@U_FZW P/TM\ 9>J&TG184(XV>@HL 7+=[!(2JQ]UU-9
MC8T6P/<LZ=7^%7<C+%&SN/,)&_\EZ-T@X-7Z(K>:% 3:9DA.?K<D'@1W9CW\
M5^!Y;8*--"P(FOK3NG.:X4;:,3=50%[W9SZ[1_>\]F6F__N'"?=6#=Z[,Q&)
MUB?7#!FO*GQ>FPY>>/PEQKO197*\].&23]H-K>7):L6;O5_8[A.UY?6O8UXG
MO \->/_A4L0E,[]+-:Y>M#7]G(8J'Y_JLT7V3^L-,-8;-;KBMES,\3PM=]L/
MDOUEHC%IRR-H0!R&^;@%TY(O@SRG0,BIACBK;:0FS:+S<HBZ)<(*#GP;PTYX
M>N3MUX'Y7=)R.0V\3>KGZ1VU@6<!D&UO)6J*X=I,G&)I(8V@ZEZX%L&I">_1
MC]3O(BGBD_H<KQ6 X>Y<XC%9W[PQ0)9HE0V1#)C[\"Q!8AY#0XA1_S1O*LUM
M)Y&9)Z"_;_\X%&VT'T#U%JA_0JG(MD%8S[9IV<&0G$;#;?S7K+@;8/$@?._2
M[H6*Q-_ RWJWGE-E'\8N?QE^0OFR9E'ENGGBT3=D\U%<-+G>M:+KF?D#G[2&
MI(NG7A^/O<DMNEIE>NWI.]?95Q;^TI68%A).^[F%;\.C(LN04S?_]?VOM#!"
ML^:.]^-R(6I1B4];?2D.6<;L(9Z6_ 9&KNJ*':._TRFIZV^)!P@'QI&F$D?H
M'K@H.L)-0,T@>N'*Q,/X-E]HA\Y*/9#*@2L23H@=""=!%&<N?$#$:P_D8&:N
MZ,-U\-MZ2^P'6UOPER17"+[K)GTC^V;D]+@% RY2#""<<$?!JE7-$*@@X-;P
M1W)#30$*VPKK!%'"'Y+Z;%D198[(+9@_L$:6Z#XF&(#S]W3',^XEWJZ&C%!D
ME)JU]&1($.]<UZ@-[R!NMI0#K&4Q; 52<\?$?N+^,0?OJN'$AHM.35!BP!/N
M>CUNW3%@\RQWI7HR?C:GS+5[;*/'UGMLPR/B?\/4I0Z=KN09IT2LP[&Y\SQE
M8Q^_XPVG\"_H9J@(<W?%O8WIS7KJ)5-:+F7]?N^E2[D]38OV"9%>Q[4<.A@A
M-H&_U(<,%IWK>53WWZ)YPB?WA@*N@5;Q00=>]\W+?^6:>)VX0<H/U8-X8M<9
M@C=.QQ7L^()*G]\K?8KZ@_?VVM"",I5-2N,:[9@D:(%E(AMI&2-1( WW!ZTH
M*8^@!SN?U^ WA8XC.0YJ.AF,,'Z/_KDREY*SW/4132C0^^GHNB*O [4:]F/=
MKMJ P;V56E(JB7]YF;D="A&;01.B9&G9(8#4'^N.FZ$(<)R"'(RF@YU@"Y:.
M)OWH](?E[96<4<VVINS&8]CDLQ!:@%*$IME8&EIXVC-FQ&M\S8GX9EJC1F('
M7,L!MPVB-./GX"OSI\%-LH,:'Z&]S)K1:^+-S,.A&XE"BRW8SFCY<BG1&?\H
M@K^9)NUU"$',K \C7V]ZRZ;?-KSCN8;5&A?'?SVOU] P]3+*XRT_>BS]E"_;
M=*K</"RXXMJ?)PJL^1YJJQ;V"3?419+LQT%Y49>!?92KGR8&IPH<;T\5OK?_
M[,<W#737_(:MOSGH6_VOFY=F^,KS.;N0B1+!Y@!O!B&JET\7ETW1:F)%75SW
M/!0@91(/REZMT: /N%3X+J0Z\15KIX,AJ"- /N!OP0QB,%IK6["KB'PRNW0Z
MD^#Z$&_"5U[,ER&@$X+$>VE&-J/Q[X':=*'%()0I^Y<D=I+-&NE),Q-4<[HL
MMV!/.P<W1IE*DG.@\MJJ&9 C9':"^=B*8/;WM3SK506.3 >*6QAY&]F+4F8>
M9=[CQ]JR[6D<PW 7T+4_>2=)=Q;_V5&)GT&IBKJ#(6\43-N;&Y>&1>AYW_92
MZ\+7A/JTAZV:N3BT/I06F2=9O2O_Y%ECWFYB:^?6M//@\3IN>)9[O*'IT*6;
MDP\^)/@VVI?U%/J9;'\7/95[VX]4H;Q-E)+3QU(CHK!,#>FSQ6FD,L%5^H@5
M@2.'RA=62LJ[:$K;YT;X/:3^%HR-)(2!@2)I0=XZ*5V$>1JRKD<=Q.R$T**K
MI,P)@E4WX)I^E'#C-K_BYC@IAZ@SZ? K\\$"?/:04$%R!/.T#+\LJF@%R1FR
M_5#U(',[@+C+U(]!M>'2F?:R2?L_6>WRV/M)HB1][! +D :W8'ML$'OEGT=R
M:.FA6@"7*L!EHMJN=@,SB^S :;U%3K-%?VEG_["//$CYN#6;*_@"SKP^<"OO
MM@"E@T]U FCD]K6V+5@4=O[05).UHQY[M>3ZQ:#D-K_)SU9_QA*GDA-B(W&+
MKRN3YSC:X+72J+$NXS(^-@AA5N-S,\_<K3.CD-?6S[ TN/S+WO*KLU0;O9OI
M^[K\ILSWUH\$W':UXO@$7LK[S>5XA6M$B%QR'\J\'X/_UWGPQ8V;=51_L5M7
M4:1*T U)GMR*8<3Q+1A</A+'R- I&8) D%(<"#:4#",C,#)+I@ %"A&IC&"0
M+2) U<B65GQ.7]=FOZH*\26F;3%'M@=R<B_=@@4 M30^/+?R!/1-R%.%<MAZ
M1O<I&@F;L23,M,3IUS&9L8?<0*16'-OQ=* G5K9[2F'5%63QLSI'*Q?=NB>9
M5@1'4%$NZ1T9)V(3ZQQF0AM5,Q@HD";X_%?M;&:HH>T@O*TR/4%:8KB:7ED3
M+?[F?.7KG1N<*XT7>KVKW1G18DO+/WKR]-J%]N9-A=%G_-'*&"V/O\R)TBAN
M88TYH6TL@FZXQ]'\V0MZC$]A3\UM9W%0^WM3O^LY16Y=N-FQ*M_2K^[6[SV=
MS>91PYLY2"/Y4$XA+8C_&,D3 Z!(VCY/D*=U 0\R&6+S9F)P&=];J.%@QH>A
M 5(G9852A7]!FJE=]K1H_$1IWS&495.1W!X;*-QHQ^AF/"6:_<L_*^K :%23
M5^&0"24;>0B+:B]9+>*C<VNQE%R,@F2'V%BR'RII*=.?/0W7QU:JI KY8TSC
M3SM!C56]Q '$]ABD!I2_H]M-Y>_;@K+AGP,\Y@Y^WL>Z;-I J[!_<SY4>;S9
MYU3I@T;%9^48KL6%\J6%2&-=:2C%QLYIQS[WW6=7QRG'_>S,S>V":C+9 BWW
M"T7[7,H_C;*3]!+"%?%U \_$T5^&/=07=6TM$-'ZH31K5-DWTK6"F8!E/B_;
M(7 !,9,Q,8C1:I$C!R77R!&2 HD7H 0@Y?NT:#LTS:?E4/803!9&,CJ#7,@+
M6S!EB.=</+,\@$1!R8ER1!"E@3IYLOWX#ZH_8: )=A?SK]B'4/%WE@\KNHR7
M^__V09&-&/T$N*[N$#X&"PI8T?!TWB[));";4ZD"63037"8=#(4Y/ U69DOL
MNB.*3[P'D-"@?VV9@?:\YE0L4T=9QV,R?ACN#2ID$$*B2C__)8#WU#4M?\#?
MH9NZ%P=G5"O:-$P5.E;J>77:NQ?9/>.;#4Q4K9GV]7O7Z^@$G&C4"4AT_2FH
MW'RPUK[GDA_5JSQB)!0Y\E>GSW6TQDEJL*N9F<L%PHNR7#TJ?%%'H#.(F E=
M$T5"K3H#J)EMEZ!N/BN7U :7:,WR7U/Y(7'\Z7[,[C=1:+$)*@>ICU<:NA-0
M([=#7^B^Z0\@+<>:I8SMW(*I"5A31QUVURT9F13(]HYLPZO/.G6F?!V6N $:
M[)GI-.(!V:NN+=@]@IK8<IYP1EI'6J#HC$JTI)6(]QBRD?XH(8(_6Z'O)*U'
M:F-'\4Y\BZ5Y*[ S9STDG!UJ.26$@A>RXFD&A)\[1C_7@K',L@B!-/%[RJ.N
M3Z!J*^99GR^;'N1?\J3<=,#S2KW %!7AGF;ZW)OJKFGWWG/R?DIIN6;#1/VP
M0\F,]9)@\5*2C5O#:-&E4PX.=5->->Y/&V/:RI>^-&2KW;QQHRS/COVM=5QV
MDN )+LFXJ)T.X< RI_*8])%,KB/@;:XKW6 !/Y']C:'S"!MZ:@*Y3[+W*8A8
M]6Z"#&5R$N-34ZP<-$#?!3B;IK_$5)Q*V(+MBRH]61$F1X(N__?#FYF?5PF(
M!BD+."U@<:P49+N'P-/]Q_!#;$H;;A#SU@NA1WRU*H3/) YLP53CDT_PTRIW
MZCG3^G :!%^PXZ]Z21@41\4W^D,Z@I&T2G,F]W.P@)+>S$@0'*[<=(<JJBR"
M\64;S&RV6KD/;9?/I63S>#YF=]9[T=.*)7[=!-N]U#?U\1/Z+^O"'6?]J*9N
M9E[TB_.J,781[CY%KGGU=B^*#Z;/V>C[TGP2)F?3IEPSTZ.?VS<\#C>=/U;C
M.8/]U@:5;,%VZ$)%U9]0;1G-0+<H!7Q\$QW)-_0(E</,-U!)].MX,RMJ<Q*%
MI>TE:()'<@ V>PNV&_4'1OV,V.-(62T^+HC9#;JN+(,8$1[HR '0/G)!?/QK
MX'-P9T_+.^I8I2&X!5N]!Z*$J S)L4CQ%?QT+U$/ZA0[D_J<F'N#/A$-()3X
M=(P/X110L#(LI]T.EN(&?.>2D05TB3;'@P9<R?N!H1PZQI"52SA-D]@R>\:;
M' X]E'AID_8UHZZ;-E3>2!41VH\3C,UX:N)_AU0SQ]O-S3WNMR@/;6J9[![D
M^OA-65=IK_[R\IC#,/<5:'-(7'!3G>8R_\)/2NU!:PV+/Y[U+IK/OT9<+V:]
M#LT2)TOBP(0"]IHFCSA17*D$U;3\>$I[2HSD N0O/AI-W /]VL%J_W$#,-K3
MMO][R1!M5Y"3H& ;%J/)"*9>?!OJ:LP@[9 $\@T#%WHZ,^&#E2C6I,0XF3]K
M:)O?(ZUA1<'3D>J #GLD@V=(W$9\9:0U*;DD)N'%KE")V%D2)I<N:^101ZBD
M5L;C&5J?DFRKATH$J)4A\;EHILVXY!CU<M3,%BR+J0\I788.@0C_48:;H^P!
M:.&9,H:S9GUD.<L!B:<"\8;@:NW)^BO$X]!?T7P+N!X6-:/7/"0:IMUKMO&
M*SE+*0G)R"(J*6)F.:@P>+U17Q=!G&!Y)ST_T(GORD/[3L1[VE[@)E2<'7(;
M6R_3[T'[3R6<[DY2MCT_\>?^^TOB"Y.(EL?9W!>#+[AFUZY]_AR1/3^SZW%I
MM+KU57V'95AY&-JDVOSR>L.+0FF*3_GU!U7_OMQCU>!2$4,W]ZW 8>WBW.@*
MIP:+/<P';<S\7BT-4BT7&IQF.JHLSYL_CT.KX>W&J8IQZ?"(73-F<74O_$FG
M4)&H@DH+$+5*!3<71O)D#A]Y&AM6IYU!=+8$ ? 6%G.9._!K?)T^U!Y\("<4
M!N2MI3#-7*L(-L#0JBXP*TIMGZ;/%B!<H;^%JIIX#8%VJDDVX\P"9XR.5EJ>
M5X"2OZW6RN;@<(8G&"FB ('D+1@6G<Y2MK9032<9./@^1(M=)&'2RC\3T&\I
M''E98<7(EPIE9WN/B: ;CQ$Y E>+Q/98(V-@.I?@%K; 4B9@)EG8.3<:@@G'
M5A[(D"5Y^KJ T^M:MX6\;=$SKAETJ=-@I4;K*".R#A_W&T#LO"UP-)K^#0QM
M%.X^D-,?%)E!-UM3'PF9=/"U&F80#9Z.?^AZSOVO4G/B8%?T!=M+ER?;#(S-
M7M><?Y3G;'_QSH7<"N-=?NSH@,?AEI8/%X/?)?CF)*(K?7UOV)ND</S2#NQY
MT70[)J#>S+7BQ75:\ZF3K6KW\U!);]M7KS[WN^R+.L0\1.2B]OXNC_B;!'MH
M \ -RDS*?$%J'D-IH2)<B!MJ#ES@I=,D.GPKG/ P1940#N(&9*<A#R!.@%E9
MJ\)[>'1V/BMC\_:MDU)#3T%VV 7QJH(@G_H0_Z!?;LUB\0?#.-$K:0W#8H%W
MMXTM]I=H0)1J?,/BX*@D"6(#%@.8W:PHG!)!2TJQ9)Z6_ )49HD]EWA[K='W
MY&*( 6\D_ JL5YI-R92@LG,=4& -_F?PZ 8Z5QNE//T;I ^&_"%+_5CC:MWG
MX^/SXOJ&QF @AVKG<],OIO\"-<,+'SU4G%KB>/)1O?N-G H%3>'!EFU:W@--
M+]JM,JJ=ZP:C[=L7=5\SBR9Z(HS<:M]-&AOKU=.-(>4(<8QL5(W@#J4KL%D%
MQXFC<!V)#?A IFB[L%SP)F.VEZ1L_&."BC^V!>&BK"G9SP2G8O@VR,0=FKTY
MO053ER@ B0N$.^\7\XXZV @'H3)<U:?O?[+4'$XW+W>^ZV339D\+BZ;[L' U
M:%&T(:VDR72A66'B"LC'["..LW;)3DA^@MX+:6]Q_4@[@,Q94X<Z2)F;-XE#
MJ+:U/GA:4&0>(6QA)%TN!!Q4X8.(-/C>!(Q2J,09NF>2R?!.JH^NW&MOLA9Y
M5V8 V?*+_VZ.DNT:VX*U6J_MA6:'2&KT'-RJ<J"/.#*7>03?>1&<SMLH.!W(
M9%7RQ+B!(%%S RERYN7.HEHI;<7>.2^C8@>]W)&.<^ A&(7'":?S/M7Y%5X?
MK:M6I)MC[I]R&_>)N9'BXX_;9RHP,E<MBC#HU*TNCKATVO-%:<)[KZ]4K]UQ
M#N=BVLLC3%Z:WRI\5]?D4')"1F#$B<]*SD-G!*A9Q !+&74-HRVYPVR75J"N
MHC(IVZWA<'RWZ%8W<+01H PBC9$[(;;X,N2CFDYI>__") VYYU/ _'Z0FD4\
MC%?H0QI#'C4QVC/-BYPUF.1,ZY@U2B4Z*4AG-1HDJNXF[)L@FA-YK&T,.V!M
M0(:25FW'T!-[T9F8GUC1OVT,8WN-5"!T@\186DZ($#XG755-PRC8D#*-K*<8
M-\#@RY1>RAXF#$(($G,<#@&SO:%P(#!+ 'I5"58#,=*OCZK%X;M-!]#F[!?8
M(ON._OHO[!U[+ ]6;R@XWWP-O[19[W6TZ7&-KK-K,:OMF+G/C5=8%ROWR;7,
MZQ^*S2]FV9KDB%J DB>;,6?=2[V.>[XLXQ= 1S:S&0B26%4V*-O="AY)31*B
M=LH&6$]M%G,DAW[<'C<R 9KE<]^-CX)N+G-*]]BJ-GR\-;]?[^C3>+<-#X^+
M=._'2U?[J.(=TT6;CIJ!!5E-K?NR-R8-;8*:EI[9F7UY\;C\O^>%80FO>(BN
MT@#/CC)BL=&#ZK-Y.L:H""_-R<+;MPL/5NN\'+8X;4RZ7?MYZL%3TT?9O6_D
M+[#_/R]9,BEV"_;-'I[%VS3>@BTQ@ I"-2:0.+L%^Q*/TF!]]MB"3=WFVW]S
M8;4_"Y2YY1O(HUP%O05KD-A!*G%;L$.YT[+!BVM2]P9B"ZGO&.J#G'SG;.27
MC JZKK:"U6SD,:C^NC4IXPXMA:A'G C="ZDII%DQ; 3/"$F"YA,#U M?Z(:(
M 0Q0.1>]6V!A_'1/Z16\RF>>=\'(7T'_.-$?RO/G%=(P;@O6A=V"=4N3+\GQ
MR@.PO8NTD 1#K)99O.]0J 64!2JBC?"1 5.,;=4#/UJ:)S  SYJH4&,&@YM@
M\C7W@QNN'7SX+6VOZ(_6,$AV^W_7F2&#A#A,UB_67\VDK@?R_>]5[)XLME!;
M^1*86X7>^XA_-^'X%JQI\.(G=YOKP,U*-;\!<[_W(FC/T82<?_ WB[VSBM51
MEUY5VFKHM:9%^2P.24.;/MD.9U\82#KRY%_[A(BHZ1N/%HT-R:L%P+0/&%KV
M*!A*'!KJMY\>$+/NZ=D.C%&A*[B,+MJ ?O#M\T3XT]+I@4XCZ_O3WI/\Y&UN
MH#YDCMJS%/3LX/3%!UZ7;#2_8++AG;YG +@@<6 D%:7,"&XYL_!IK=G!\4<O
MK5##!_S73^+1ADX+/7'>++(KE!<NF#NR+Q(?.2$Y+3@-5X06?5NY\<E)7D"/
M*'WG\\2:52A.=(3RZZ3#L8>= P<2@+@^4KLFI1V705#22=&>&. RCZ9$;QCJ
M_,J$TN8MNR?6' X]QG:>6,*$=P+:E":,D\6;R\M))[W^IS>]H@K/N0I-) M8
M6?:6=V@#:^E/)79=+$"U/_80?RETB3WD0SB;*DCD))_P!&UD1:""0&NP6YN"
M:U[6BZ7<"Y]JS]S0/[4P\6'2ZO/ZZ_-:J%U/WN:K]US^ SQU^:2%6:-/!0&9
M%+J/H64Y+>W(/Z1L<$2_Y#BMY.;DT.M]]>_C_6W)+Y^\Z7KVW+\7FT4Q"N@/
MI*)5]?R7O8=\<S_YOS1[D7$$K[5QI[#1P1F[\$EH5Y6>6]<4ZT6*S:&1TW>@
MM3;.8]0)SJA>?5[V)G)?&9MXI!.*:(*&";:";37O'NM5ECT,7;KUZ!/AF"#D
MSO!ZA9?'15SS[W3P<%=*M&TQ@'E)77J9B(W^@F9C9MJ$)I)#J*<\#BW[%ES%
MAB+'GO:1+"NB(;WS+@,A0"GB"_@C!03WZ<C> DO9?BA+&(S6QR<%)FM<;IL.
M,D3UV]Y13W[@FQ)[J=K>>6V,*OH3N-:X\"!"L*8J07")EA18#'(;)K<KL;_9
MP@-4;M+ WQ3WWPFM_CW!,9)3:=R>?/K,\XSQ)&]AM/K*4'S'U^B.Q*P(['N,
M,BJ\.8X= /^)< Q4$M#)^00%\:GY=_B<7J0VL,@6K_W$;!->'(\B. H*X#$E
MK+V2..ESD[2#+.Z146NYZGJ#=]$@U?U-CZ8'[_IO_#.AO$VMU^^Z[JL;1=>+
M&OV'C]F8C=87755L^C+]8/'_:C+^:0T8F*Q:^1K]W]3U_Y4/:11?,?FG&)G[
MI'5@M'DVMWI ZYA=7)7B.A^]PUVCWN"65E^X-LJB</EJ/.J&8OF;?1^LE\?[
M?09]"D[@@_YJ-M<RVYC7E;81]?#5'*321+-\#GKL?I0ZX88 1<:HR"QB2E'D
MWZ';0I0V_FKPR^ RY8,>)*TY:'"7C?XJ<M-K+,$PLF\FE%+/>SLWZW33Z/7R
MOS6/9+.D/0D%Z:4%@ZY  4>*Z*WY4Z?O3IXLG?^6)R@2405S'KW<(,3=P3S!
M7- [*!^M$7W_TC"?I?,.\KC<VE9DT^.$IH\V;QAZ#>4#I!6W)'X]4PNZ)A:L
MS-#Z<7+ 4F-X@[9\4EHS02FR!C_DR=T8=I(KJ"24&B3"J,>4XC+C:7MXRW>:
MIYI[6/>LW>B[KW'UQ>2)U=@_P_@V*,CD:(7  YWE@\\1G+RWLU782"+?G'%>
M(*7IH5((NRJ-H<3ZT*6 >1N0Q?X?P;<Q*M061&0&7V!U@-N+3^!/>Y1.!($&
M)^TC4I:51 BWWQGPRH/7*V_D5*?GFR"NT]PS;H<VGV?:?3Z9?U"]QO<G9^]7
M2_\=?PG^790TW<M?'AT(>UI^Y$C+T8KS"H<XX'JTBW?OA?I+8P-F/A67.\H/
M9-^^JE=C9L;6\I[L8Y^XR$"J%]4+8B;J73KL>\SCC?<$OF7M8MI"D<+M\W83
MUL/ZG'E-,)"-T;!-D]Q8X.T+_MB*[=K9P%U.C/IR&8H, 5$9&_K*[F_:13HS
MJ$R;?4=^>SQ_Y7<MANH">?7:_ %I&>.V^%="9([SJ/7:S]#0D)[Q.E%U? -S
M-/DTNVN@XZ]'P3.?ON?3FD(N+W<-S,VU4/:)$WK*-S<O*'><_."F,2=3(A@7
M\)%E+9?RX NU12=;D[$W%Q<Z^Q*@8[7O7+';!O9.6X\)*88G.Y.5/&S?XO)6
M[\^>L9AM;M2^7?:>IRIC,P]-R'9)SDDKZ*R<>4,N<A^T!?.3V[LR&)&NE_]
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M(D1N$+KZHES!JK&B2?>(:A-T"JP/1+.K Z#JA<E)1C"P]-6=FS!\8A"I.':
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M$<:*.*'"$%QO&;Z+8;8%VS5=P#0GF()4,A,>9;2[=$(P5;,%8R?ON$;4E1@
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M(-= C$33I ^^)P&=?D=G2/4>J1W3.QPI8 V(55-G8ED<N(KDETGK F5>S/>
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M$ /#=BF<V;T@F8/0&'X0=X/8 1KUCWWP:(H(3[@Q.I%*A^%MO535GN M1&A
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MA*I*3-P_2SC\S@US&<3T\06Y[<3]B]5IK+96_"_?L._6$[W.C=)3[5PV_'I
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MVL.4HR'FVY] #Y[YHG-.4G2,_)]!G?"^_]4KRCRSC'+V0Z1:%YA><T9>$3-
M%@BAY_*XV'W3^"+I+(#FKFD17U$8_E39Y:4M-5U'>$F8U8"?D[0\;XCU8Y'P
MA?+U!EO_'L&D*SQA'J*A;M&WU*(3_LO2ZNI_GGI+G+G8CG S,EA;7<@A)<"G
MHX9"_Q.GW*F@LF-4)D/P$7\B!"I)B!)BBRDZ3(^,%&#C-(O%<Q28GTYLP)=^
MC6,:/UP*BZ31XF</EYC^DT=7^4S?X2])=O86Y.H7B@?_UW5AQ;,[1X=RY7%
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MU(,W2+D-D_-/_*[_-<;S36C)O3!21;BIH+.V*]\*U/ZM:)!CQ2C8,E:KLP'
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MJ1 .(2R3AH>;SOQ7<C?T]MCGX'/8.?(>9=_L0<#H)6D[_H0T==PQ')=?98Z
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M%>-LS77Z^VU2%D2F78QG[T$@?X+2(P'8 .S]WY=59\FM@0[I[XH'<NM$%39
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MJ2 H /0=$G305HZ)2#E8+<*Q.829<L1DH9]>>!?>P1Y:,\77#7L8AJ!^8)*
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M<N3C_5].>Q"/*!*E9>/ D20]4"*__GD3CQPH" I29/Q,M:2W8;/>5F&&S3&
MK!1^YQ+]S&%QMW[LIP)1/"S](?\ +@W''LL+8/ B.H=H_>-T5JI]3\T1*+G
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M5*VM7_ LFU?X=NX8 ZH\G\K&%QA0+_/[VTNGL\JU%N(<Y_3;:H$TFCA@>(!
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M63C,8IS<X)AGFVOU^=OXL$1&@NQ48]*\$C,<;LR(HM $II"VQLP=FAZ@_BY
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M"-HV![,Q4;?62-W<[BN2R4'FN*:9D=901)E(0 "36-7U0OCM>A_3&^OHGP^
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MVRV1+W&6?6&4A]VS/F.@RVO4&UH&W()@26!9N&B>0OFZ%PPR_0]6SXB&J&U
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M"2:F6+'"LX3G=1-#U%\R?QXU4O[_1 Q%Q9[VD'\:K-3BTQ!,ZC;_7MFK%VL
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M?OO5ZF0;B3&]] B\$9'(&+]%00/+VC0#/#G*::(KAOG7XNSTQQ*6U;O_Z5W
MG61]QSU>5)CIE$E?XUY@ .KRV?',P,5,02%)G5@7[+CQ(("?*+0/*OS @07"
M?$S3]O..*C7N'H\<8]?4/GM\_/M6=FQ<HVXJ0),&TY_M0ET+6-9BY/ =0/WU
M_CXHG)9B%K[\)$1K+;4W,2RZ@VTR6",GOPUR42"DUBN;4B!!3%^_ L2G7@3W
M^D3#U(9*:FX_*S31CJCV*Z=*X.BNY/54B0N,$'*/$_NG\P$+CN8QW>");_UT
M <$L@+;;2IRX-RRNQ;#7H,?FX$?2#)T)6M:C_&98K,=[C J_]QR5L]5\,]8
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MU O!4ZE2\A;3Z"&1K2QNCI4\^]L%W[+ZO"*4Z(2FQ\-J9LU;-QW03/5OMZ(
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M&9FB+\>8H@@=-OT81V(_/95D7_T/DR )V,AM+O$P#H^4P_]2']5^0=OD,O>
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M;?9_ZU<(73@ZE^OOO'XKB>NZWK]IVP>[)U@C?.X [YM@W)MI&BZ9TC6&>]9
MS^DZ9'T]I-:YS7(=[M*2'= 4K!S'4R8=%L?S^;]_(CV1^9<?<\[4^?^EN=!&
M&SC%7YERU7-GD[JHN+6BFS2%>XQ^=G&OMD1B%FT'NJ/O/PMS.N[7QMOEAU;-
M_;@(^PDG^Y3[N-)9<7S#R*'(/+V<VRIRYR1BZQ%4LT8*D/R3^_:IS(5BZ37T
MWT5_A\S)T$87&9^%DCFNU/Z*M&>J44SW++&X'0P%K,::!OG[X)5H$7]$6^93
MI9ZY))8="ZTK=IM;KJTD>M\!'IFO[%Y&'D6+$^=PW1R85QY,7$X&?SD@6UQ]
M#)'>R!(2)V =YD\,*^[0)T\<Y+,S/&E9=[@#P,LEV-JQ0R3K6#VDO<8";W/S
M%2<T"(%(CW-WUUE*4R"F_^0VPR[5^]9;N#GT$!W>NVX+\CI*PJUMQ7HIU!"E
M17S^J4INE)9@AR'NTS7MUK.HH,FN<NB@#>\A]P/S+2E<Z:5Q3UO%+'YM:738
MKLL;A"N,;;O"V>T!X(3RQPMQ734MD_E1@>KBZK^W-,I2N)HB\10 R+)<(4FQ
MLC"7NG!"D@'#CM<-;#WIPYJ6CO*XG ZCGY.>D\E1_4=FS5KYYI1^GCAO$1"E
M9PEPB,BSR3'NQ&Y:O"0_@] _E68+C=SBX"_7IJ)Y8Q A.P!4MS[0=N,;[+;U
MKB&E*K5V\^C@_I^Y$F!K6L&4N6(YI*?;'0W-]@B+E(2@IHL6*1'L:V\\Y$ "
M&T@S.W/%\Y7%F:ZIRKWAIPAFH8KO?=WE#M8\+=I9D;10I(Y/H9NVP=IOKD\8
MU74M)3G%XIM<DZIEI]C#)]]A7>_8(D;D3Y;;8F:6YT=<+'5//^8)RN]G2"GT
MKGUA/+<][N_I)!@I,;XH6U<-$ULAFM/:*-;2MGQBLA\BT=(R);AYB\OP6SZ9
MQ$G,0':SU 098&WQL+*?1#AOABH<-/.]&3G'(5-";:&82#/42.<C'[O@68K"
M(%E..>8!]4!EZZQ1I 3'Q,B+DQE6-NC;),-8T%?&!'_W0P, &8PC@6%,>$"8
M>D-&[]LI UU L^F4O<9]J)\,DCL&<[!CONXP)#X--K@#+#$#$>8,3150P^*2
MH2CZ_L?K^!?8Z"3O[#4W9+7X\33/EO?>UIFC02\$R? 1:^,V_3SNO#E Z";R
M>U647\ OX[B)'H,D%F/+QG;O*QV_?EC:#JZ#*%SS K[*V1I]Q:IT_);$R@:C
M]*[3KL%IX6>-+W9%_;^(]K96$?FI;Q,Y+?,* A>9UK-AR[_K,[-0F9[Q\6/"
M.X%HI&GPP:-%QE&AYS9_PE%YB*S? D]GQYI@\0.VKYMS%TT4L]AC_!,,V<F?
M^'\DX4BLCN(7'I"NN'FYF_4TWT8"S;3K)+XIO'C0 .T,U\YB9YK56P"/L-$_
M0[:C$82"21L)1LCTM=I;YBHB:0L"JJU'PSEZ9M,UR.?:0.V.YU?@B[C1.T![
M#GPJ1QW#A5I(/[X(O8\XC@+F,,4+H,%HJ9&I)&9N2^$R(KT$=-P_D]QKC:?<
MOCDTT]R;*M.3'@27>89RJH;RIS(ZU2;$H?4^*7BQ)VR2?OFI]ON2Z62+ZY0\
M^1,CH2KA@Q1?/N_5J*-9*8[M+^'KOC@!R:YS!MK8(,4-+?;>5NY8B[_6-!\.
MO9VY3L:[ N5AVHB_J;1QKS.((UD,6FP)/;+PQ=S/8P;IY&7^2#.[HWPVN#HU
MOEJ[-5_+N?NIJX^7[!#20\J4=<O +CFFGH6F5'OZ"/O'RNXH=I_*RBS7\R ,
MX_L1MY3^K5-$]1D:BBJ4H:Z>C'2DME4E!Q>SDH,3'3TC33TQ$''>OE]R0WCW
M],O"-=^$S>F#SNJ=9*W _?T\-L;LMJC&8"[_KH2EK\8'2?.ZJKE*S^DD_LO@
MEPVE50E)+C%V$IW?7W"NL)ELX)/]0<\&(WAT&KD\+*/Y'O< $,N.O ]X)1'"
M;6+;F/H/!Q\K+1:+# W0O64*1[V0[N)^EM1PIM,EN\];^>XLF1J6X],M^\ET
M0\=_GE5$5C(6DS-')I)"3X]X,YA"Y=(;Y!*(4!7*,5L@A4,L_DP_UYY&6^!1
MP9'V4.$P!/RD>3E'>O]0.OW=]4Z<5$"NGAPH-++^9RCE'M5N:/TPM9]!\G2-
M2,6CB81I%A,E&2]'05>G0VDT=]O:&,DN-G_)D>&V0;P1LU/F</DV(U&@XELJ
MZ,3$-+O^P2N*HL(_.^1']OI#C?+L. 8J?:HO%_G^4L>+&;_8ZI)NYWN7.<Q4
M".<].:[2]AP6AB,UM#H'!"E [*Y=ED^++O+6F95QKYI;:HYOTTGZRCA&V;GZ
MYF$_/]?5B0XM*VOQM(@H<TFEB3[[:T 1]&=#)ZR#Z>>I@\2E97*0UOH1/1>V
M:G?^3\2L"DR+9FATPE>&IFYM)( XNOY+W"^:)@9T8>F(<PELD<J5STY!>J-D
MFSZBML7&7:S&+V)O.HGU'O3+NU9$";A!G.$W;W>N^0B1Z;J[(<H&:K!>BI'B
M_KM9IRGAGCW,GF$;G__1>K+"5$JSLI&/.OU[!@TZ $R'$N#1&YS:'=?:<&].
M,H9BE5%.I]"B),4^"_));U;:T&ZCM9SG[:QK9</#'Z]%Z7+0I*[%ZN<@?TG:
MK#W-KX,RU3V93W&_JN^Y%$Y7'/X2L/H7(5U^+B[S8E%3PU09D1D2L*]^<3\H
M5-.XG]GFZ'U2XR[Z?LVX$<CZ"&[!,2ODM>],,'9(7!@*']X>E-/AH\F:6%+]
MQ* AJ\.PV#'M;^VCA*(<<M+=FTTSK^C(=_>ETA>#0KIK%_RKZVJNQ,A5:X@I
M3$R7/4R^ _JWW@52\9761M%;'\^U2M'RLU7PSE39*F,XI0RKN'9DCBU&_6+!
M38KUA@QZ[<D%.&ND/^1K.>YQ,F[+Q>_1.K<^9:RZE>.)'@9&#=%&FQE*73VV
M7M+4J3^_G=?;#/J)9DE=SQ&Y VBFVU6M.;_2;4PZ7U[0G&+4^:)!?[B%%)S8
MY009"T*7EC[[G*P\B7 3+;0I-LLTJ;Q^%2BZ+Q3@4N T>-@@_8G:$-/:^:E(
M??-D\?D3L&PDE/MY5%)Z4<71.6<N9GW3E7RO29)&3Z/T6Z,>W$V=NJ8.5A:?
MN/>NN3U1(-VQK C<+")OLW=)4^B\SJRCFK'.^WRB.%=:4 !%1U16HG?_M:FD
MB.(1Y9 UD\BQ<M;"0E^%.@3I*+8'U$=L,5!&UZ.UBW:QD(SGX")LH)'.CPYO
M:;#<X@A81/)RH@>:R^*7( X<SY=!<NH00EGF$QG.>+ 3&4"1*DA8%3!D2+L
MRZOOJ=^@IGD',*QP69;5N9!@-:KWS3*N"%T-#XAL4^M]<J)*>$VY[?!CKM)&
M5 9K#=)MV>"SW+PO7R1LLF#!>5/4Y^NP6:</M%B0$5R?!(W_Y2+<9:H9_3:"
M WT<O -8'I&#;/Z1G-79'**.ZA]MD>RY8UW,X^X 70KVNK#I).D_57B\-;@
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MI;Z9Y5P99?RP*!..,J8L<5AZ2SN7H>*=( SR!:R-*AN^=^B(;>8=GBL]JZ%
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M(N&&2!/67>H[ ('FPSM U,N;ZFS6=L5ZPHBF&KEJ%L),QXW&Q9HQCQZ?JL.
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M_["+OE\GTOD#CY[%L 0H2F5*6D-Q1*$=;7Q'?6N,N4O'JJDV8ID32L;VG=*
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M$^O'?J2/U1J9 KN-Z4_6)J[T1=C673AI-T+%QM52O2ILSPL_V&1R]Y%F( Q
M'DZS>;9C$S3."H9I<ZLFKZ2;8$V.J*6N[</M8CV4=;E^,;^:!"3PW4**O,RT
M^O]1=EY136W1&LXY%J1&I->H] [2$8B"@(#T7B,@4@($!"1((!9Z5:ITD=Y[
M%8@0BG3IO21($2D)0HP0PLUYN"_W[3[D(2-C9Z\UUYSS__Z]]UA;CZ'2/X=Y
M4TFDW? X?CHEU=7-1T"#<#4G).]T%NYF\ET.7X[LU2P9JUAV7#3R]J9OWD]/
ML5W[^\0;9C@#WW[\7*1#1)N#UDMTP6GHOZV7R%I72EWF\W_GJ5%Y3C!&10JF
MENM9B/0B6M-$TX1G+/V2?2NIM7V#],;O&1Q %<8["Q5J4YZS(T: ^E0QM9%F
M!/-&;EXNF1X#PYPR/?9XAGNY7I)W>8>+Y@4\_6-][B64LM<?,H/2_N3\/GX/
M=NP\-Y,V>IB5=4.@(T\LQ/U'ND>N2RR_Z>&Q,DU%12%_LB_@ZOPRJ#Z(Q/2'
MD'K1J0Y>)H\A&^>C2.!*A$5^S]*?1&0#P@1['T;G@=_EY;%[/LN?8?HETGWJ
MX-HL*@VZE9&-O/I/5BU43S:"U[WC=_P.C6FJ^=8-N6(!GA7G%3,/&V7^K1 .
MS7_BJB-J,\4E M.=*B?1SGXSNW-YK!$('=E"[< MN':S]72Y:,#*S!:G?ZK+
M".O\ ($SL/J@:Z2[W-LUB'FN_%KUJ&E:1ZSS+]41OYNNT4L'"5F*\9GIFO6I
M YJOCGHN ?\@U/%!?;54<)?!=98 5,0:[;Q\B .X/T]]IBGI)G3.D7Y*("+O
M3Y_I3T?.EFS+V8'LYI+6*2_L[V;:_+O]Q6\$0MHN 6$2R(UI$%&<$_UR'DQ+
MOMG5\T"")4S6_;,,GPS=,;*OD<_YN(V?=>#!E>SOR)YR,,Z&UEO201T8GG]M
M"AICL3,#'$BX4PI_'VG];ZZTJ#:[SWU=_E,EEB''=,&B'P4JAPQ5?,*U3GHR
MI<+3A$06KPJE?A$]?)>%J:%T.7O_B]#K%@E#TDV^IS)R]]J</9[6L_S$"ER4
M)E3;L6ETW\%X.$L[SEF+PF./TU3N13Q&2Z1?3U!9R)'WG"X_S92O)?+M[,OC
MT)NH ^9UUC#QL,FSP?U)##@.5 ?:Q^/X3' 2$^A<6>Q$3/>=L!7P%>\P<4T\
M$"NNLA,E'PK4P]6^K98[8MRKW,A5&*:'F$-S01JP6W;];J'5*\$9_1-$OC_[
MY[@X3% _*HKS$M"'C&W-;PEZ!W8#+^T0>KXW.S# J%OW?Z@SD8?RFP;[@:]5
M\M%=FII?)DN(48&;$,Z?("H2=/,^C F-#0F5>C##3T&QJ!HY!PVAV68QY"+P
M.K)'!KSQ W*-9$[,Q;NJTY'[\\1GPT1_0AKW?G6S$]^&<1"/OG:X)2!=D?_N
M.@*(5'@(.HP%#XXZ%:-GPKJA<[D>Z@8D,=GL9]FM&EE#=VN\3SFJ?[U&47KO
M(V3/T*OY_0/L)6!QWA'GMM]3LTA<UB<F8'A<-AGJ:Q"*71>?7(BN^'=8B\$!
M<&P^==,E(/X>T8O8,8B93^H6AGCR2N.!49A.1GN(9U97D:EFR5[KG/^I<:FM
MQ'#3WZPT5_8!&N9998L7A>X5*3XF1074X][M!GK&"<)#TZI/YMG2S1-$E1U9
MOI>**GOKS58Z"\7T&W$829;JRP1ZSO1B9D0L1UUC^IS*G%)%OJ,-$^@,GO1V
ML3MODGI)URGCAY&\+CZ=&"T&V>."HLG</PFHYM)$L <20%(QNKEW-E8]\*$J
M;$3]'QRRSRB:C5=4WX#FU*LJT(!M8,FB-5)@>MDLZ[=IY#'7;L"NJ<CVV2 :
MB7L$BLV[@^-]LZF_OI1-,,!%C%'D&_D,P@N/0ZO?P2OVQS2O7X/[$S"XKL0O
MYZH@1KM="-5IB(W\!.M>*P[^XH_F=ZGF]@#JZ+G3X.JFZP[:J$+PXA\RM1I%
M!-LN,OXCZ\7YC:A>X*(^0:^#V(@SPN8?V&T>$>U1K*HV&T;1BEF"F>=:<"I,
M_FOM;%SS48# +(*I;*P #NGO0,;Y8-MS V61F+@16./*[O!/C!4%B[77B4J)
MO_7GY)X1G<YE--VJB58$7ESDIY'-?+JFVA(*.(+E#L!Z1&J!ILBO:DW8"?U&
M"/L]"E"'?^B+W!RQHNG0590K',VR)YWWJZ6ZOFS__-=ADVVT]8^9 1ZS<\,D
M5V\XXK&>(WKAB[BF55RY9?CGXOV*:;.X"+U)<[<J;QL-\PQ\#QZY,9$01H70
M)6;B\@?36UZ298E:>*8!""W)'U;JR9H5F5]*;/R:QS=#$L'2VMFU_="5\L;.
M!<01/WW1#XC%KM[-?1FCD20B)'1R9G5J@"\DTT=2EG@- 2<.XMTVHQ+#.$@,
MZO+$";SL8#X+R>7B ][EX73 .VQ^=)[(+ *"!>YW*?"H]CN5(J&_V)X/#*L-
M0;VW'H17/9W/I)2E "5.-J S03 5"G>\BR+5?+Y9SE4^9/XG^UU\L++SZE38
M27M1[I' <%9#\[2WL]C&GBC$HM"*+HU=%%\9;1UAQLCB,5,\$O7YIUEZ@FEV
MQ::B0D5;VP H%873;3 BL2B2J<N3?<&PVH5]@-'#2P ]/6Y_@V$E[UT7LC44
M&8_<?W,NA["X2*0XF?9\BFO?G\1_>3(MAXQ%4:,V/D/J7T9L2MS7FBV8E_OB
MH'$)V+3J1=Y<EBBI]*E'!W/]S.J/C]^-:[""QT8F5%[DB#VN!ADXYG:B+'Z,
MJU2W"X6<5TPXF';8%9T%GOR?!P%%UHG*K;UGVI1ROQ9W4;>LT]*1;=?ZCO"J
M;7[RF_M61^M%>C=M<^&B\-.=D<FPT6?18JZ;>48/D'FY"9C@ZI+Z&;ZV2 U!
M=U=+;5WS@^-#)Y]_W[-\_?&8 ?,NYQ+P&(3SC4J(>@?>:$6U6A;#W H<'4-3
M"*^FO7U@!]=6M]/*UL,&+P'_7C732"3;F^I[2[JT/WL:6_6:=>,2 .8D9)<Z
M.'@$?1B#EJ\VGU:O%=]LE2F\T[8ND1DD6F)RG6[C'^#HYWL ^;^=]=:Q-C6N
M[_HUBG!2'([%(N-ZA>6BOZM-BY6%J/;=OQNF"AN,J__:VO*-?WX)X,R[SZ:C
M/MZP_TS,?$0=%5L=56GJN&11&E,97>L8OBGJHX10X)2,EYX5,&6+O\AZ%WY'
MV04)^Y4UEK%8)13_D+M6S&-%5SSLE>CP[B%=PZ/#H+O7U4W&5R1".7#SA,#N
M;N)]+"01Q"BOVWD?-Z$W<]BI5O)5HJ!]1M5C4[#5J,&#4TXVC76NY9:]EF!U
M.9],K)!U ;V2J"I-OUSYZ?FO,3J)]"Q)^;AL*>7>'F_H-?3'[^\Y%N\F?/]G
MW/)QSVFM'S$*_]D!B8'TK$<J,(W+&0'@2"N['K[1CD#R%RR(^9?*Q=B?Q: ;
M6?HFR&M9#JD>N7R/W!BU7\-M-L=*CE>NZ[ _=8H;K3L>\Y,,%XCMV:HKB.US
MME"4]-3GB*[6CJ3)M1$9CZ,X?1;15!>!XQ7#WWNHA44([72DG;[TN&_*A%\#
MVBQ=47*H'..W,/K,7;E\TB91BBD2[=KDQQ3A^=$MH3(NW,T*2!,5NR 9]1D>
M9AV0P&0Z3?*6BI8Z+)P)Y-$\('.B<"MSR?T,\7(ET>RGP@(?BLDS60]&X_D8
M$]E]__!*S35!M>O;ZU 9^[4=XTO0G40NW2#8;V9)6[M@9?7'3RMSO[[+.K%+
M /5EN1$<"RH6Y"RS7B<>CV4%_(M="XA]?,BG_6+-;D!3F$\BAU<V9X+=UF/I
M35MLKPQW2[V=/IU7'O1^@9EOY6U^'_B(Z[.G-WBN*Q'J9GVG:]+<=3@,.[<L
M ]?N%B/=E&:,?UB$%I72&/NG6LC]]2@UT4E7_8[4?]/WM#1&KTMI6ZX^T-6V
M1@1;@0U-T NT$-*3OZBJF"[4G?%+8)'4$[4HX'VL;/:\MO;G]UW>JQTX574Y
M"$</5+U^4W]59YCSQ2\V*P_YHC">IAB;ZBJOI[%\A,7\P+YC_G?03Q-^90B=
MF1_6/(%*IW+=+:W>SPT<A_$UA3.2_-!J6Z4EYS53+7_Z3HAGI,SQDV^9&@/%
MV7U+A@6?W9?4$X ?W$J)AE/#QW!6X9IFVL7#K.U#'M,-)EG:D.A9;TMNK6N=
M)IG4I@.=YW;I@J]O\+O>1-8R<G^0^WA/?H#]R-+UF^O&CP_QSFTB)H5Q 9CH
M'CVFXNA^)7U&)<O:(<<OE==,?3+D^ R&Q-78Y>G4U/6,<ON%_YK[+B#\B_79
MT@US=IWQQ^%XBSLQ?1W65>:5TPF>R>CR7N8MX2I6SFSCWDG?PN#C8G:$427<
MT5TN"+<Z=K UTXW(:BY-$UNR$1&.9-_QVWYL^RB(VX]VH";H+>UA\S(7])S6
M[LO"Y_I5[VLG<Y:_[;O2JC[+"@RK2!X0,'F/.,;Q6]WF6=4>+$TRQ;DY'ER.
M7^LG^%\(;@>\?"_GQ?!CO0UVFWZ!*_(%]"R+(ABO*'+7J<YQ47H)<#MZM]Z,
MC+T$>"6]5F?^KGZ;&&*.OX(0PGM/V^Z=:1>7P*,<<!<U&9NTQ--HJH5:R0#W
M(TE3]MMM(;0%S$]'8H!>F"%M8S3&+S,<=R+#(F(<@1#MQRIOL; /P#,T@1P5
MR01S!UTD?X7ARNBIJ.:BTPZ=X!69,4^,-+%C1OI[WP;?1^>+XL<5?J567.(*
MK/(6-A7L09:>0[V!%38&J)T_&-@@)'R=3ET<'H0]B@X#$JTVCR([!9Q"W4H1
M4L1L+-?/)BE&3\(K@=/:R.P!:0]MKEQ-]!DL&J2/]]^=HZ?/^R3.$!5P"7C6
MT>%_H1KVG7R7F%" ['F VFC+!X'=8$!-[W,WN"R9NO7\.GQS@UO]7]SS_&IX
M;<]+LB(N:#_(&X_N!],@> /&-/=MHZ(ZJ2LA6JSE13:ZY7!_[2^YU:Q:Z<8K
M@M67@.L?=2OVSA*KO2DB(GD1=U*,0K5]T:>_)U+0,#T5O 2K7]2Y!%#+-EGB
MQ#X^U7[Y+,985I'__!6RIP/9_#P!WVAX4:3*13FVARB$026U=!A^^)04^U)=
M<G:?Y*00]XD8\@17DE384EY*_+QD5RV(1I\II!0]+''@)SB/&-1KQZPM"4'*
MOM4EB1=RWR^--JXH$#JH,"W;'9:;^I'[>#8[VS(^>#-01$1O^&#D4 DBE:X?
ME<BTZ%QHV% J6"]?9IG':US(,F1:!9U)T^$2#GG<RC&DYRF6.6R]#FH&)5%&
MWLEU#B-/@AJ0X;5R,*+(0.VY-+*'43XI21,SB'8 6A*;-_*92! <54+-)<!#
M;*&3"OII'7A]SU$1_S(3US*"??<SZVFZ]IPIO4-UADW;QS"[L+GU1K:O1O'Y
MN!?JN>=*O]98IKW5.1!V%Q5@5P@-R04'>\<?AW[Y,D^4F+L!#%<$\ZBJE0Q^
M+K(D<WY)PC*T;W*%_**79Y'S-EY=TNBI;KO0PH%)7%WGKB19(AI;FT2^0DEU
M/ F(JQU8YZHI8(LG"WHX@O&J%!Q_8ON1-A2&Y;'H=/^]]UWA6[C"G[4 !4>M
MML;$]?WOP:_ C2 25Q1>D_#BHH;B)N;G(3@+\,(T-C^!?(OD@4L:6%X&<L"C
M;)*->(CO>M<$6O"JW^%Q?4;8D /[[N9@GZ'0\A1_N.K.1YCO/W\JS<I--),]
M)>7Y% YGIX*@CPZSIB;T%U%297VFE99R%VF&.C1UY2'#BK&O^H]+1W,<DAMF
M!9?!JI< 9R110*B')^P/YBMQ%0?%.D: XU ;7SZ$H4N6^ZS6!'!]*H/[J\ >
M2)RZY(PJV!4:[ $EC&G,]SNR?W=-Z7\9/RWU03X9?/1<Y C5V+H_?0FX.GKQ
M20ZY8$H +Z &S^A0+:"#=OPO L<,MN7B<Z>%'^@M21;73N(0S,>W>DS=Z")F
M^ $33M+;IMX)13R%2CS32-A9$#[/QD;]][Z>2P"Q?)/8&43)_IZ0L*O]@N_P
MSR'Q*&! )+ZE&NF&6Q^HTZK^N<1:BW'KP"MX!T* 1"1D)H!6S5P[PW_1_LF\
MP'9:#N(2@ $1%7X1\G',2 8,+HC$^HO@ACL!48?=A:ZS=G/VE_QJ]15Z2Q:
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M?V+$Y7/L[;)_2MQAG:RZ8O)(W11.1Y$3MQT2\TNI6YZRRR3/BZAF*88$O>"
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M@>H.)6M_IP ,VU4[1)VB9;CCH!:>!?^]FL066@/ES"N6C)/!ET9MX;5*TIR
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M"R<@\) (UKF73KS4GB?.^;RFNMN"$G^(HGW]><%T!_XBGQ_0X57OR9*D1]F
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MGIG5S OF^(GR. B"#HQ>6/-<1DH\,%QV$'I1.T6I6@<I\0YWNRD+W$S,WT,
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M??//)]&P]MG&8S2RM7VZE?=8F)=Q*DKP9^#2=GLR8J7MY_J+,^T70P?<]F_
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M8J:<80I3@J.:,2H;001/9@[]=(JK369,Z0B7REQ*Q>O7?>XSVA.O.R-[(N%
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M-"V22(*IBM2K/:N9_EKKKQ0@4DR_M=:1'B#/-(#I]<,Q*$L6LP"V\^DX[0S
MO.RUDD;?]R13P/YP9Z-*= [W&-.'&*Z$TD3C:CVS-/7)JJP1]GKAF&#?NF#F
M@,_^XFEE4E.R65E#O <^CT$M>IA<V+W?5TOSKL  ^BC1P>E^6[41'M9SR @B
M?927^(A.O'-#X&5%*C0EU0/@');0 6?P=%Y&O;_#B^4KFZ$9LJ'_EJR/WMF%
M1GCQ1?/-'MQ2DG)]J;# 9O3&MB99J[+(!5[6>W,E;9F/,PZS\4A(.-4<7(73
MM+=W_!-O7\F'^:"23,S^@!=V97H<N_3\9(,7]55\H]_%=*9)X%$]!F0)#Z$C
M79*NYMQ-!W;-Q9UBZ^/*#-*X!,9]NQKT4P=VEJH(N_.LK '\O)1:=(H+*7NQ
M"+M":VG0RO.J)_"N/H?OH9,2ATV0A.^[E_@^T0@[5^/2E-$S3^:0#&=:1BC]
M_GR.%;5T'#%=<FD:?+35W6@ A4Z3'TVSB\N1CEJZP\/1$Z!GK=&FN!<RB.+7
M<W]$"^HEAC>;U1 ]J3R\#)7@BTEM8I0:7$M.==.H/5-R8\4(C!+@RQJ/O0TR
MEV#C>[^)8X1<VV(5$"6M'<="UR2@7-C% ML "_4M0[C_3&^4"WO_ZJ-!^OZC
M +2,=ONTP#&R;37DOPWSMAA]9;[)\SE;X<R72K5;46@7KM1>Y8;_O?[#!O(P
MG./Z-M,*7'897LQWI'GB2.V_ ;K#0VZN](VO*B-R 6^SOG:9.SX=KR@SZ ?<
MZ^>Q6;@ CMKR8K9U(_%U[D6 L7HSOTO)+9W"UKOJV4>(=C3L3XL;@Z,S+?LB
MPJ]81.#J[ [/>$-!8 S3R=C_)"F-)[#6GM6B4E^G.'!= ];+S-SNIDN1".L@
M<W_AKE>^*<8E@9$U+W8R]Z&PQ:PQW3?XJ(?M:0JU7>Y>>.</>R[#5U7*B:[V
M%?A[@!ZF?#A# JS;L#01AO1 0F:AFGW,8E-PB&.C=/F,.WAHY:>EZ&=%0E?C
MD49+ISS5\9,8+9I"<=LQ$<WC#P>M7WE5 ESM_@]G9_40!=>%>WQ5D.XNI;M;
MA%=YZ1ZZI1F&SD$0E&ZD0T*:81AZZ!"&!D&Z8X;N&1 <I([?Q3E_P+G8=_MJ
MK;77\_S6Q5[)&RMG_R49_53OV:+[GKQA%.B?-) ZHH/<+79+LR280S_$D)1#
M5PY6DKOM[7V]RQ%<N8(_Q2RL++5&.3ZX3S2HG+JV/N672*;_EHP3X;%=]!_&
M$Y'PB$/"*!W-C#?(X'C:_&'LV)JQ/=&4LUG]Q5SSTOLO,<F_-=J_\(X0'>-[
ML7!IW!76BF429%1-0L,SV!GT,LI'MG4F*6):=R.JVH.^^F2J;*U\D KE3499
MFES#W?S=0JJV?:7C"LRF=_JF:QHLSSJ+541*HRJJ(7.^I3JB&M*5.N211EU'
MH'L3K::VGR=U9LW!X1<2^D]>.5K$;C#FE.1Z<0<:4.2,91 *YV@D+KA]2$X7
MF%7UNBPO,_89LW(PZ5WPQW<OU=06>QZ[MX*7FUG!HV"S(<[DY1S$H>]/\]6-
M,^^!(C:)EY#(HB"0OV<O<DA3O<&,$/HD&F&?.UVS^_$#1QJ]MQ,7^0^"F_0!
M"@KB@RBCKE_P?QU3]<3%(*LCHP>5&@5J)OZ,%3OI!:ZB47+SEB69&FG>6-=.
M/N^"\KJ>TBEJ3]](;QFW3I%"S]A1K_9!RW;Y45N,1'H_RG4ZW!>6:PN4J;%F
M$=.[;N;F)#A*2RP?/66[?XTL^]U#-*]21]->#5P,H.0JYBS,IBKW@P1T*E]#
M#\HB^_PL^*!4G\Y?.Q#5C(4V8<VJ0ARPRZ786R1>WT=[JUG607/"(X:SE.!
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M/D1'/ZWBHM=U<ZEU.^Q$T/N;BR(-Q?R=['8WI<["Z;F$TZU.D6UU_TQ*@V8
M]"&A]O"HUJE5 .IKZTWY:7HD6<$B9KA!,FI CX.8JZ*^?^53BXOD"]BIUS=S
MBO%=B6H.2W=[GH 41M/T^V=A?<$]<DK;@MS7;NC0IBV8_?=0T<50.F 169?R
MEC"9N:9]U<%*;^S+YEFVWH67?J)KZA SE[K ,G6BFJP6V@2/';D1^-TEUE,I
MKF:R6(+ GW!T.T*K-=L5 :1[7=:5JOLLG*#?@@?"U,04P1+V=OND,MJK2S7W
M)_*\QD[,4G&>S[;:CB$#(K>DQ<5-KF)DX3.@2A@+,4Z ZE<:3;OWGRJ')J"N
M-?L-P5/,44B3^*$=&3<% X-G&$DKDRAP?N_3Q(&M^:#;^2JD:.8Q %"]':@3
M,NW.&A@ZH-C('=4+U*4ZZI!.[@4^XD2P-CF69;GV,*1O$R\4N_2PS3MGVLWZ
M':O5V&:8KBF$[+=WI_&#44E+!6/58.%DFQ==FK<R=]Z8X;Y[I4%K<DS2(\ZG
M$/W[I%KLU/>5 8;]:/FW1.8?RY'9RIWP2PK4S&O^N?NCW9(VBO]6'=[AS?]%
M;VV;I=K%ZW9LMR]Z:N@# LQR/!"*OP"?BMYX->_/_T98"4/27FH'*E!X$ZB7
MQ?_"'Z\A_A1FF^<OVM&<6#Y/4UI_G_I M?$PNTFC\/QXDZ'Y$2>RZ8!%6($8
M&PPAU*R+8V'%>,;MYKK72L L!N7PLVB:-/=$-X_J)1J":C 0E]-1!8&+[%Q'
MF0]8+:&W^%-B8&H;RB(]A'VUH2EPSN^22(&?49?P<[G-<A72=3Z:7J?97B/_
M2%M]>"J&V& (O:=9X/"(<P3ZP5TXUV<4S1_'NW4IP*PE*6 0S1KKU9[%%VT5
M$>U4/[I[]6KL:R3OK4E</E+U<G]P9FD37&30\GDRO4R[RD+3\7UV4DB'U;=$
MOINI?,:$U-WQ('9DUV*&Z!@/K([Y0/0@U<6<*J^E"/*9:1;W)YQ.>.O2L_3F
M%W9%K'91"^JJ[N00YQ!"W)EQKP\+(9Y]Q'&R2=FDD">^-0-SF]-ND+1:=#,B
M/C"IO,$;DKLJOV^]8T^"NHK2%BH^P9;JM';F@8[_6:2D-;)J5.5:5URQ^[U%
M4K=]*HX2[M/]W#&%\'QQ+!>0$E:-];69]4R)V<;0S>X7 :;OF'UE+^&,C.TE
MX<'!K2YSSY=RS*![H)UY$;"6FVBF,9X8\JBY_JKQ V90E]FZYK!+\D-\,T0G
MD?LS],5,;0-=C'$7J+_Y3;6_,VDZ2B""U.+)UWVZN\DLBR%Z(5M ;7#?,4^A
M#=VVZ%*-"B,U4[6I1MARCGF0NZY33RFIK0:=UG\]$ *P&]_^3>>0S0L%?I>>
MIVB\V"Y]I+9N?QAISRO@[S^]$?[:&NN[831F+G\R)Q,@FUS0W2!1<\3'RC>E
M2QQ#QED_RF2UC*D"@<'VGF5KQ]X''T)S*U$@0U".W<=)!N9KC.BM=:7H)5=[
MA]=_Y,-,H-U:I$U=&%/O5HD"&19SBP<.NY;'M'Y/HOS^FQ5?TJ*.[NX)IC7J
M3J?>"JLS=G:T$D8%=AY@8-X18UQ]W></65^JD2X).[5 SZA,K_8HLH5P5H8Y
MZOK7 A<-&LTW++/2]5N;.T&K*JE]X6!N]5*@5.Q@/Y\<'8.3R7=BZU"N9*WZ
M=D=7F94Q2?3&)KD*G;]Y!:&$:3S64ID'Q4FG/S $D_/#&/(O3Q;P'46!=*)T
MPKX,;\F8;?E8CD7;VQ"&#]H>='G8Z%")RT\)3F8<([TOBN52^_2&;3$:D;Y$
M+*_@ H("'P5ZR0'^7OY0XYTK5EIPYOM;A83J#:&X@,;OT<IJH8MN:4-U3 &'
M[7NJCIOUMA7IQ*]'+%*@?^N--#&,-H1T>Q,7S.L/LQ..8'F%60R'W?DB0=V:
M^BG]#Z_B=<D.?M-$#!AW6 CNIPH5$T?.].$_&Z7B%?#Y)KK0.^!)*7WJB(JH
M6<::?'_$P7\0<%&@>1BQP0?3(AI-#UBIN'Y^CU!N0K>DEJ_^<"_';@_0A*VT
M2CO9""T"DL>&0%:U)Z ="#Q)":$_C'K>->?G[@0L8?!(Q6^O+[H-UNE-/M+V
MACEZ>[NS%($3B$MUGE4\*,J'54L>=%!=="&>)(]3RWM8,3FR0NP/;>?Y<MKU
MP>972.M(UTE#43_T%1>TOUQ5T\PP(HM&HZRUD*!0-=?1K%;W1%R^Z/@79[93
MCIL\<&YHBE2 .D2;R9JAD,VW;X_**SW?6\*;^F-!&89L;_QH%F;P^^DU\7UN
MB!6&\H% '_T5%?-9.(0<J?M/Z%18Z]3)]IOA<(>YLW/.#K26(CP;443".1PN
M27]Z?82YKSZ;!#JGCV<BTT>3ZHN$_R0LWOQ5]CZ>7A?%. 6&^PY%>](7%MA*
M@VC2V$WX(\Y)=RFX5;LS<Z?Y;R#LMW]_JDR>+[[([=K+=.H!5G[AM])T]WJ2
M$6USE5=7-BX*MG1>K%3ZIUY2H3>^P*5?P]"5[ZK:I.1@2#22MS^#+_C%$+F^
M5SG]^IB/\Z*CS!W)&_LCV\:VW<P%YV1(G*&K+Q(Z3!E;R$W*1W7#.Q1?3-"(
M\)FQ'O,[F($P3OIFQ/.4="LM_+]1_H3% ZF&72_:L.A3A,O*(TX]=_^\8'+E
M P/[=57__INF?/O>"M#-:TQ,Y$F7+ A)V,E*#K1^R<*#GC.__U&8RY/W&Y$.
MOSJ-S%.HKR9 ?/RJV*)*_SJI8+ZSH_B]Q6W<7P7KDN?=H@]SC<$,QX<HDC2A
M!,6O*;#<)6"5TT@;UQFA.D671YP5I5/::Q^!=T>L+]?[KB'F0$'M3GA#RZ:?
MHPU291Y@1E!WMK/VO6I+%F_73G0(#Z!._S31UZ;4R5+RH<XA1#IV:/QI,FRH
MZ[6FPMA]DINA:! S@^7;G%T/F3S++PAC6'*R?L).Q;XY.<*.=_$W?]5_]\[2
M2+S^->E^F:XA,P_'6 QI% ]&2OM$E&X,O,&$T$>%+')Y#^GY'6YAJ"^I4[>M
M^  %'[SZ4%4H6BXN"=2!V/O\TO<.OU:6?M,?_Q(0SX-3EXZS?B7R::P@&AYW
M2N9<HZ*WR"38V:),^5H!KH/+XZ-OKWV:[G/N##"LPW]Z8_T]XWZOK)]'^Q'C
M_3L/*Y'#+;ZV]2VUL0&B>(TD5L^%D'O=<XC5J6?"H,KJ#;NWF!\]T"J+P^P5
M)A,.8.MO$<OU?V/CK?=&VELV>5E *B6J*\77-*]R1(U>3K7)U1$BVSPI<_?,
M5#B]54EK7_;;BH6XB1,%6*AT52.$$<X2J*K9[W8-8F65!J0$2WE+'RA]H<_-
MQ4J2N;:85'&1,JJ,^7LW+*+>V82J\5XR1#&BE7E[LBJLU'*_+B98R0#QQ9H"
M0]O<;PTA45$A5B%<-![^!S7*TC&&,[+-MU4>@GMD:RL_F#".%B& 5V9L[E$V
M7L\@3^8@3/D0B#_A+<Q$KV?.DX*C:\Z#JZLM2Y*\C^-2-"V(FNS%SU%V^2@3
M OH<MJKO^/Q]8O@<MQKKU0-5'$[IDWQ]5E9KX<7L3\?'R>'_*8-Q(=0WONUJ
M]O7#ES2LO#<C= 3X!ZMQ %FZNJS\RA<=$M6:1[,0AH<A<0\2[T1(OV]D9K'1
M.X,D5$:&0QX@(D&!KUQ]M@+]JWK4EEO?[F.DJ[3V7**S"B4$GWO46B1_:T7#
M56S/\F>&YY$-F7_O/Y51(;1;4WC 0I:>CIF3DH4NS>WQ-Z]-FQ;A,%^35@I+
M<.CIE69)2B78K75I&_2:\#4(6AZ<DUCU[!*\&2H#!5@T.RM$[#W)C&<1+6B_
M,66"L#.GO $Q.:<L-NPGBQ?9GV-G)YOX;EKD3#NPEBR$6=&TA*KXGQ U4C31
MC'@QY5&(V4K"R7)UE4R>8#<5-IB;-5=3(3NU=0M;N7E:B-)7E/A$O^F="NF3
M;!]DO2D?'5,3(1,7(6'$.#K#RU1# GBI U-_%T47'*+#U\+.F# @UU;CP=;#
M!S-O/.*"-UJQJG5'6">C+F[@5'/-_BT=9GYQ;C\ZS-2]^2/<?5DJB6;H'%N=
M@@-:<KGUK,5^!?*HOVTW"\CYI+3'8SMI15<-X4WZ1H:_9NK\;$$+T/Q?ZF]3
M=]LCN90!)K*/RB[_)DZF?;&F;/.P%B/W47J^[U,W\3TY/R(9I%C#-Y/"20>
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MJ58(M2DA0_:(4[79_X,?(8=W1W9[S3+K#UHE#D2$TMQG/.)LY4VQ5/IQS];
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MRF9G_3*N^$O8QJ;00::0[D=#.ZZ0'Y_)V)$JL:QMMB MM0YEY;AVZXD#1(<
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MT47%J;V9^1GZ88SU2:%X#)>$HUI4CK'!'O\769S%?2;/S# GU/%NCOSXTP*
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MV8?=V8<S>\[G.W/FBQ@OMT_<0<S&R%-'E\DU&44[24XP;#8)'RM>JX4OY?3
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MNSUON%J#YS/+C%HZRS=;#8S\/7(H>DKG]OP*Q?/R<O\5>!WXZ\5[[W:VGI_
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M?K5B6MHN^D74?:G+K#7TDE'3Q2GQ6F,T7:QBIE/':8WV9\>[Z',]KBI],JA
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M+)!UJ?]H\?(K@TE6)^3;&RM&NPT\PEB=$_4_8PF#S^^,W86,>$SA'RR*KU]
MW[Q/>GBVC'L]OQ>LYP-=*%,5_VHROA^'0#5V@-&5>M"0;.UV4(U[QKZO>^['
M*E)-M8'93&N4S$BL_*CX32JYSN-\I\ F]Q]Y0F0B@QJ,L56JY.8/;92T[P&]
MA2T!Y54=<@TFV[2ZLWE,5>/DE_+U":SDDJPQ0+*OEC=:E8=VI+40+=;XEE_$
M,QQV+LWS#!RP(\,Y%E^&:;>DYI=B-7S-S--TE'FBY9H,.IK'0ONP*2&:J[22
MCIQ9-<BJ8EY:V[(44:J03BR75(H>%1XPG!,GB)W8ZFOUD1Y.C=W@P$7XP]5
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M<#X<Q(M @U*]579@7/) +]^"HX2@VMLPO!5+NRV<V"<(AMX88_7V-H?,3RB
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MX%6/",-3!@! 7@Z#<K'OORS)_/!>Y([Q5HJ=7$FR'18>YFM@@^2[K<,9<#?
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M!;O1%>#3$DPP7 QX+D+,NL2B CHR3H4+1]/==1<,/'\!2NI?'/@P'J_"KF*
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M5G=/2[T$-#LF00B6<[UGV_LX@>[Q]^H,)UW7@.M&!DB&E4M KW$7?8?=9U
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MT\R(HU.>,*M]'<< VX?=R6%A3*7YB.2I/$6YFP$9N^+OJ8'I2X#1)6!I2*&
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MHIIHPZUC102,]$Y40 1$E-ZC(" B1'HG"M(%I$F00)3>(TB3%A4A]-Y;Z'R
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MF<?"@Q?[>W&E^X"H/DTP 8I/76T82H2ZOZ<Z'X/Z;C,(;D+"V *.&D)0MVK
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M-%3US.59X3S^C>E6_:[W*RYGX/T_F7NL^05YS"#:$J3XE,H<<)^1<F,(L-@
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MF\3A,S"'NE!?*.U_.'O/H*:^+_PW7QL"(DIO@DKOTJ03 >D"TCN(U%!$>H
MBO0J7:DB)80JD- AT@5$>@LUH0D()#0CA'##[W_GOKGWU7UQ9LZ<9#(Y:Z^]
MGL^S]BE2'"14/^,I_W\=19[QP&P"[68)<N?=HPWGGR\,\#TD?^!4;:&\2OT?
M00(G'>/8T!2J:H*+Z2NDP[-:(J98]K=%]JK@5(RK3;WRK.<R0H9#F\MGX30@
MDF5<M+'0@5KT@.@O=MN]*B#VWSKJ4]#(]V$L^%J]M.G"EZTX9%\X"<,[$!TT
M]=4=F=$?L X8#\;3:H 6RV&HCEZFDW.D>>O#YO -=R*G-BGW3,/'Z2[:2:5W
M"G+K$O [IS*+ QM,1J I.]NG-,,KG_N!MA426&WM('QX=N&'=YX=\3Y%PC,7
M,5*_S =N)-[2--(V2N3D'^PT[QN<EY7G#G3MD]4Z-=#M2//,&2LRH[7,I- 6
M*77[6*JK5RKW<@O&S70T7<E'JH6#OL8P&:.(OU"^OJ=(V JK6SBC$(<.QUV%
M^]BM/I"01"-\^2F^%.,5<V#_MHRZOJ^T+ H;@C&?1G^2&BP(:9'4:!1[QMG4
MRD@C50]&DD30R:4(^(Y4G]9Z6Z-Z::7CJMOM2/I!O-TP(6(J*.%U-RJT&,*&
M?P^,_9(5.,69L_9RLEV4Z[[E_,^L)NIP!9; HR#, 5X^@4B"0ETJJ3D(_;DI
MOOXZ=[V6"UKT!H%F2DK>K\UF7%^*)!9[9*7?(N]RNZ(T8G&/1:B"Z JQP1P$
MF@J9\8$NY$*CND=TG!(M@>KH<7_X#.-%*8V(YO?#]?0T><=DMEN@=R-\YY!;
MCV7BM4M@LGPF'Y(T2Q9=*#Y&:<I+3N:]+LG9>//[+%EX54EXU;K/2<$L?7I(
M;*)K_"?_!"SN.P8TVS6;!YNLC>Y=K9/)$Q$0>9O'RZ;HU@#ETY-R(&/FOG@)
MSB;%POVK*R,[-4G%DP)[LY^H+/-/0'2NQ)1N7-(]"QZU%?,,=RL;Z]L?2.2.
MD#\M0+$F:?0HT:6%:!9UA%@%04.5%F>E]!,:B8QC^P1I$AFR-"6)4#41N HX
M9I4$P+D]1,8)54OMORZJN-"8KE%:M^5'3^R$&$Z[+P'?B4R,IFDZ0?P-.73?
M"O^9 ;'!=@2:*G\\_WE02FUWRKN5"UJ_0AR+"X&FEAA;N[=Q"8@N7I4FX<)2
M,-F/PFE3*(Q@G=!U9K.?LIH2(TT$YKB:66)_07$ZO2C]#\?G 5;%WB+9:[EV
M'U SB"I=6NZ/T93(F!P6O2;&%W\9^G]Q=^HD71$QSR_B[!4/\>"3CS*1V-(!
M$M4M@'E0"WM-8G%5Q(<:6)\#F\Z\[5T7/\]-/ C:+^K2\HU1G=(<P3JZ847D
M?$&:&2:7@''ZBW;D_STS<HO_OP]_H=XI];^B:!H[) DD17O?RYBW\R#I%5X0
M;X=X-0TPY^C'\JYBW,?U)!N$5YOLHHW4O284)9<H@UA-8NM)S#6X.J)R;D :
MK03]6&^]W5*P[3 &&H>@OF6[0.ZIHEL./@S_D./<4J8WUO$GQ<L3NV:6Q-V$
MB+31S$X;=2!4AO>""K':R+/'R*9L(LO_B3#I6#A6NV%R%;JW'KZ?\?_\T4J-
M_R&KL/-1+SL)6<O ^^0UV3W+;.-$?G"N#38+]B:K,<5%I&'-:N7#\H,92?X:
M4?:SY1U*#@ X25C8LUH$T]R1=>HN>+T'5=@W7'AW]Z^2(%:C)Y^Q+VMLJ2D*
MKD\-,<1)QQ'DJQ:Y$[0<&)"8))W5OY'^HE2JWK ;\+9"/6Q,_/)07ZY!]#(1
M?2OK$C T2E!/N03<J%X-[\ZX:#_TO@1(%JYJA$/W).*)B<!7!PLZ:#L"G?RI
M(=[LW!Y".T8(08]& QE3DC6B_;SBSO3>%^$QHT1Z$EZF,$%$9O2:2O$.O43Q
ML3VUT5@%VHJE[4)['$_QUN^C[;^,=@[M.9CN:9Z"N)4STD@:)6952[;/GES8
M-2C.=E^U)49$;;/[E\GPWN@]MV6J9:9OV/\U)@9T9D3"1GV6]3HJ=TA"K$ 9
MB&Y6FLEZ>U&L/ZY@PCN_U=)Z+OH91%^ZO3IBA-D[#A[$1UUU 1BS;C_THH9^
MN)HT ]X[@4)-ZCL/G&V\5K=ZLL:^1*7]4/9V8HPM:;%**$N;F9KO;EI.41/7
ME\8JP7#!Q/U_2EQX5C0R\H]#4Q)\(>4ZP00'[!5L:VO@X8X^&[;%2V.''B@M
M/;I8#S3]>Y:7-GA>!H\*#S7 "Y+D)1QFTX=CO&H_"1:7YG9$_8WH%,)#!U"9
MO[Z(/#)N;)OP7XE8H?+TJ$)-U_"$_/;/5_%KCF>UARKX=BPUE1D\8W=!VYBM
M/=B*%15N]R1191@[MEX5C IK0-LE*/'C4F)%WM!L<G^+/^JQ1'9Y7=N>>;*(
M8MYJ+^!@<!-U\&4S_;:P<__%WX\\'_Z'6B8CT#@"";4TL-HZY0G >[^!# 03
M#)!>_X;>FE;:5A<JIDN?8OMIVLISSE!UIG;_X!RKM@%/I6]U5?5GGG3_;5H&
MD"3?CGG8H1)/B<Y,Z>GKF%K[T,<2V(>D=RN02->+%RPNMM%9E2^,R%&*H=HC
M##JQ0U\5WM_ZH!F/V7&WT;$*D?G2:8ZP2XSI+^OV(HEN"GIV@4<-]\*.H=U(
M.DFOH/'7S%^-[Z)84ZK;MCH!G!'N]W'<7R+FE[>E6.,<K&3#;U\"O,+QLL6G
M)$B." B;+*1#.G$DA9,#W5/H"*IXM4O ;6D"%VJV>_0:@6F&P!AX":"\COX;
MV<GU&SG7&I/0J83GL&LYE 0R;P?D?.S SN393U<?H!&,6096.XQVC*0?(".A
M0Y?01IK,P'>[A1.%00;%0XCP17Z6I%!7H'QXCW%^!?DP&PV E_X^C)R_>5!+
MQ3!RKU:H"*=VTKI'='Y;K?>U'"TS:)BW/05:2?,CR@PWI)ALMA5.>_ZJQ"4I
MN#4R7!D,8$]QD&L*)K>0-(AP7,7V@2>EW6+MN]=XX9 BQ0W$FK4RZ'485PEC
MX[BJ_]-B>Z$#%P\W5&V_#,3>W:D(3(TN*%XE:Y](^]N+:B+!RN_.)TV3F^[>
M-=8H/,OH:B/RZ[(M:&A60[LN&_,@D658]4U3<'*DB*.[_J:\'LD#]%P"5C_G
M5(_.5X61$9=H[]7LR1$D\-=/G327TC0D4E >,/.AM+Y AX=WZA8L9^RP@4@"
MK9U!9[H^',]]_E9+2"!%,@F[M7I#['F:F''@$1)4OMD#,!?H=>0$/ HP5C :
MJ=^!+$\R:K.E&A5*N&<)S\O:@ *_=M0<6Q8X65\">+YN5FPR!8?]HBC5"^0[
M5.XTX5]6VO%2"WEZK%4X,1M+RH_&3AX$ IO]KI/9/>RNK_WI4DCO5=\;'4YK
M%<?=7^X)X2V#T.&BL\$>JS^SKMFQF"=IVRTN/N 'AE$S[B"9/1!MF@K729;
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M5D"./FSPD4UG[A]*=Y^'N>B:@NA]]P11>*QG\93(F%LA8SCZMO36%:N3]:8
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MJ=D.-]*8UEDM)&PY23[QV4Z3*0?6QF[!T%-N<W/X97WX?(VF5S5/2$BLR27
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MOY\M&GL.^SR[UOYG*Z:.>8.C B,FY;,H1:[B9VN7W#>1I#E&I)++*!^FV)Y
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MEIGR^[1\;H,]-&^G5/BX8#6W3>7_I@F5'RG,U]S1W)2911EYV!O!S_[[0>7
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MW,T/Q]_M+_#RU)A!($EF&FH(K*J2HL^NRN7-O -]8&ONT9/ 1PHOB@XGZ:M
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M>>LT;YN[% ^#<87>$[EVQ5U23&6+.?%ZADV2.:8^$)CZ0:!CYG*<1SC#3)Z
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MR[\&QG)1"@:!&'L?KZQ@3MV/:YPR,1@W2W0LMQAWH\3 ,!,_3T$:<0E4&<^
MJI^G.U,CD!DA+*D,U.3\N)-JN52=H9-,"WWA:);S%N2HS2!SOI"!W>M7Q>]
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M^EN3GM\6_T['=YM4]":P7A30IF95K=OI!,._5_]G)\LWP:LBBT^EMT863_O
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MV"'E\MTW"#N#G[+FP*=;PFO;J'I+VS<>RC,Y7DA:@3FDDV<X#ZE,A"AO]T$
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MR6A:V6^@GUB$=^*!2C@:6;16!<!Q@\U]?$.>F6U(R83^JGX17U;3!S]66O:
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MEA:>D&N1SJ 9G<Y9=WF2T@!:^H[EA85E8Q-6Z()/=$MQT>DI.6KAT KJ!M/
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MFI+W&RK/5=[*+N8.UR3OFUDZ-TSM3= D!9N/JG1$_V2SEII@,1#4W,M6>0:
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M],SI2_V+)>8D$0,CB8'[J$'] 6W*B"1&VWKR_<%^>\[8*.M:D!_ ;E>O&=@
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MK=4]6%FB02+ZRK.QI%3XZ,;T$>N_GLPMQI[)!<5S18OL4I6?O=K3*)H3<6U
M(".#S+!*&4<%TDG:@%V[ -29_FNA"K8,H2^@2RVVRJVFJ?SBE5Y]ZTFV;UI#
M$E.F$5UA&]J+W\1)*"_L)X@QU?.SE]4OT.1C )98":8?V5;.$"1\@X^0PD$&
M!_R6!9Z#<$>XVTOS[^[O=Y:@34W&38525P1J#KH4J;BQO/)!8:4C#75&NON?
MV]QKDE5F=^OGQ!ZQ7H):T>9FPVPN?I0%PTMEU8NC$W%GY4E"%$]%[7GX-5X!
MGOM8&V'T'_#??O3> P?O4@\\8L4P4]P1W.?FXL:&R"E$7Q81'M%=9322U+MZ
M80HWU(N,_F4-?H6MPYNRDKP<5EX!*ILW\%#!?QFOX*BED!I-$O' '/($PX<0
M>'84]'$[H1S\T5?C%"@Z=X9P,X] CG1UN%E3_] BR+%?9&N:_\TG0,GO?F"H
MS?)@:<R(E#W2G<AZ.E*Z9:'0-*H:=_[+\4JPLHQK$5@=0L00L,). RRMF.'W
MI:15'J4Y!IJ8A#):BZ*3JBWD=;H$H$8>+>0;[[[LAGRC-;3 AP,+#.!V'\9I
M2R8=\7UJ>>4T<TT,8]+9"4? ,;Q$ A/:L4;U"=W2 _/_N1"2;:E_>.5<_F53
M(WL0]J)OO'+^JVW7J[]U/")]#X!E>09PIR):(7(_*L3XFQ7[4M36:8>EV<9T
M?XFP.H&L8RE$"/S=S\&+AF&E(D0:G=Q/STB"#/E!)4O[OVUJ.\WF*4/IK3'!
M0T*'9D[15S_3?G8NZ^GR;)LI>\8B/AM.+YU/_^B2S1LP4^OIIO:)M/46TJ67
MF,'_6]GCHA/04>-]GO2U\+ERZ*!*&2HGVC*Y#VD?.: HZ;(TO##8Q>%1G^UG
MUC&H4A"4 4# @DT1;J/DJB1!*?FV> ,+8;,8UW$3AA]<4\*3#EZ2=#K]B]79
MN@.RO;%4MI&)(7K](X6 9M=5:4"W)A4'S3B-&&#QZ)])J)8!6;_%6"-KAV9(
M,(VZ:,^8K@"D^[.1PM<];1TKLAK%1ZWKXM7!8LBS0O&>^O;PL$9)_"*G"S.)
M1%U&4V/*A,#*(R86-/O26;,WS/5F!%[!N[Y<4C'C#3O*32J6:9X:GIH:FN%;
M6IP>H@JT_,&Z[XAE5UA<_*)&P&;AC+*ZJH3@_8F*DY?^5 K>?M+/OUX!0GTL
MOI5FV,:S1RW*!&Q3O+4'%($,78&;)9BN?44:#CP;, LAR5/)D*?7JY-BA'R
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MC\/!)'?TZE5FT#NJV^O7\Q2=%O^L0E/*IH'0><G]EP=YH,27'QW::7O)3^(
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M 6Y>?IR=2=Q%+CZN]O%SC$)!5?PIB5_-U2]:IF-DI0.+/RS>@> ;YM-^Y6J
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MTI?9Z34_!0B%OPI]B0D(03F81<OR8PAVQOLWY5#ZO<C8M@1@ZC.'V="0HL"
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M.;_3;E_R?5TW/;T]W42UM/B'RFX[F$9[:,<&F.ZD==U8K;+2 8?PL.E76$&
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M)MV2U6>MY06,,FH>% ZDN=.VB.WI(^J"F-I.9BXD9#K@^)*2)]B(G] B2?K
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M7CY1H*EQ!7\'[V2ST'BV&3T??ZSD?">'02."1#OO+8:9\%&B&S!>;.E?,+;
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M.V1ZB3Z(<74[#]7RJ'3.O"Y@7>1_W=/MM*4V7U/::J8P$,*]/%GS==H312_
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MI8N5'0/+.)FI*FO1Q9.D@&;/'%U\RN[["E85;6D?3ZSN. -W)$I>POY]'O+
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MK :3BI4.] B5_Z>.8?YJ?+F:Y<+-NF,A8KM09VM=Q87,7M"DI+$#1FM_@22
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M%8;;WD(@G)^CDL-RL,76XH6F&[=41N!0S=O6N._-@0R*42FFM Z6A&H\_'L
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MC@<>MNP&1$XZS@CI)XY#SWW^9I[EPEW1@,C2D02N@$PKX?$&1K7D>Q0M0-X
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MKJ\,"V_KT<,V,,/N+&H\Z$(G-F2UUM@^_1ZJ/FEXT*V4[31R3*9KH-CG'6<
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MUI'7U31*FB8#"2^:+WC<O/\-M=D/P?EH7R\GTQOH"X)H2.P>9-KE;/V/(/A
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M6R%HP<NRVBG4VWI [6M P',D@_;6QT""AW9BB;_PA'QQ1TKPIS"^)VOZ!9A
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M$!*W5*,_3G%A+,/;/1>'4 ((,G/%A07H7>D6>F@+[3Y^2_Y7KW7/\):+7?<
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M FFR4SCI>&?:]L@H6Q_0F*\DO4GB+T*#4(3ND@S'$0CM9N@3K7YB^W0PUS'
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MJ&YWIWQ)D%[YIM;3SG7.&[6A+BWKJ=UX?E#GJ3CY=W#DSH@R*28TUE=8\AY
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M(GWZ=BCV'[$[,^G<R&)XRY%U1SU::>K-I@#ZKKSFQV@(]8:!#W<:_:QBP9(
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MZ)HC"C$/1S80]+&7+&#YBXZ<NVWY3I@94,TJ!-0G8PZ5< G0OK2E-Z%<[N_
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M9A*<9"+QO<FQEZDP1W%T-RX9)]8STST]7&N6$] @NFI:%=']MA82U?P:*WI
M%7]6)2C]J  UH"/+:&=1&E&E\]"6'G,OJ(&='%*/Z<NK #,UM*J'-63=G7AD
MP?ITT7J*JW-J_^#)>.;#6V9MK7%F&T:)#Z(G.?';9$_;%E@X* J($KA53">*
M))"-Z(S[E"SO$5)-_ BC#SZR> ;2G))Z3=1=>VBHF1 >P7&NF#C'-3)3[++P
MJ7L>65W[N+VQ-M&X(<,0?A'3(7XYUDG2KH]742-LX^QT"(5KRE&!]"TXUZ9,
MQ9>+&$?4A\O!MD_,/7D/_:()P_+JD9*L=GLF]"<RE$,>%8N"9T!<;O<AAOYD
M_U:O,KNRXP' *8^\0YHH,*5H=BX"59^I(FJL1:_2$+RQ.M$],DPE>7;01F7R
M2SY3<W]]D.FBUIV-<IMO(.N%[8!)*^8LO5EJQ8Y_XF>^\,D^C,36^IS'WGJ:
M(7S N/*P?316TR!?\1.+(-L3@S[^:L]^]+2S_LDTDY3 &EX2_+'A4) -%/'#
M8:Y:(C\-[?*N=JC,MN97STQY-U$[I,<0'ER::\-K<XF4-UT =81YI/73ZL2X
M:* _-4H(#7LFG:X>IUQ4$K7.C8D!TX&\4'V<5>Q8S\C;^:U+@;H@\*Z"Q?D(
MQ>MP]6A#NK0W!QY5UL79ABN,]F"Y5RZU%CU9A<J*A#8K_^+I*JCZMVUI.-Q9
M8B&60N_7MXX:;?DS#&_B7ZTHTQ ZF:^U<1 I9A+!WTTM7Q*X;+S66=FOE_WV
M-D(DYN/!'<)'ZTGH$UCYTM@W2TB8J.)S7PWA!XOF+B=.KFX(]\KQF9'?36&T
MF;Q3Z=/D]ZA+KN.#=&I:ZMF?J@\?W5K^^++*[PAQ'S^4UM"?44UXUY*HQ1O'
M(=;O0JNERM)&EL"M6&DM9BMFVJX*Q9+BTS-K>VQ=QON[(=!/ 8;)Z_H?E9>T
M-2N7"@UD_?:?HJ5S"H>P)AA%>\%^L>$M?(X@MU^Z;2H'JV*]9*ABIRA<DR'3
M#^RS5E1#ZV04)UXEVVHJ^[*:K?*B2D9GZ0H@31A;N\P"E^S07](AIPX<FOS^
MVM%3#M#"^YV/=WM?9SUJE_Y5-*304.?_YMM-TXJ\S(BNQS%4N85? SYT70+/
M\#CJ8U^\3+\N\S:(S'=9ZT6PQ2Q7B_05P#W[U&%E9FE)RP,L6-_O(/6@:"5A
M<8?ME?? ;:^EI:([GT\[CS=QG=WL)(2A[K-[J&3<90YFC'2[M33H4MC)FFD"
M*22CV8#O#/=C3:/_-53Q9G(GC5Y_.>N9BD%CT*16\Y3D;G[1HE",YP#/-E3J
MJR-DA6$$DD9K\I"E5+C7!@>Q!$*MZ VE>D>KF5)Y2-+*1G6I(GY,]J)KTZ/X
MJ;)%?2#Q 53>RL;HCCL82]1GB7A*K^:8DK@7*5A1,_<'5!;20RYV$DM]56^X
M%!VHA;K1M5("1CWV_[SFWKASIVC2<-;XE%MG5I1A6$46#P@2#2+$9SMKR63J
M>\7XLO+?#&/')RB;YK<LB<5)M[^$\\@!V(\T$8?_.;94D0%!I,7_Z!\[%X"Z
M&J^Q?*DDRGN*^[.+!R<$3_ERLA_I5)L1===/.39X\,IIOX,Z(Y07^B\I^*X
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M;%[8[EX!9!RO  -L\80XG\M:ORM 5OT5X'<\J*>S;VS^)Y&933FG0X HBE>
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M/^].^1-.^422I1=/\IIX&OT9I53VZ4U\/N5I1*DGV&G/=\MD E:1M!%<-;0
M.9LO<5YF,DTR?Q4T($#'J+?Q+%'&GW9$5VR/&&XY<Y(+_%UH'I3T'#?:&IF*
MU?;B%_<%RZHIC<MI'):K(IRFA+.+N6=^$JL[Y$-9!.VT*/2G8ST^,C+(J%!N
M]UWWTF[V>:D!7 _ZD*.QLLV+,!I7XH*4=H'=O-!#?SW<=P6#9B"8MEJMEJKB
M^N:4/?='%L[OP&9%D?:0DV]/OL+Y$[J%%L;(T@)"].LJXQ).-6M?CTC&"HAA
M-Y\/OTP4O4OSEBRF$"K]Q.A+Q#VH>^7S/5%QN7]=+.^8OMM]$FRBM#Q @K/4
MU8(6=FC 9M*?>B!S^WY",>78+PDSR/)LK%@MZNVN T,4X8VR1/?;G9&9;G1Q
M1!R;;%2RTU2V<Y^!:8"![UHA7ZODVN\46:GOKE< ]G34O<\]#I!VM7LD^VP/
M;A@7P==JDGI5'I)962JQ5;V>""FIF>+B-\(R&J602A9SEALV;?/L\50X41(\
M,'X=7W"[*OCPOB$P=1F!_MSZF;P?'8*A*4$(.V7Z19*Z:>&W:=)PII18Y",.
M[D M_/4:80]#N"QXQ$'YZ,.)%N#JI87E\HFJ?PP??IHB6UYCPR:>-S&G,E)[
M?AHZ[Y/:J'%INGR$%^J,@,I@!-+]P"JTZQV(PHQ_VY6(GV:<4>R"?2N6!M3D
MOQ3+.;9(,X^_"QPG$T++P??S:/TX\/>>3PFY^7ZWG;1 UC9W6C$)A*3D:76>
MBV9. K^0Q7KXM2RG)_N$+2F[Q#-[KE)ZJI/B[CTR'O$65">UK1=D8Z=.?7MH
M"2)S@+@.40MJ#O\=A-B'#Y=MTNQ^)!.LEY?R05[DA964H;&R1J$>6TZ0R&Y+
M773_'0BH%_FW@[G7TUA">@@W5YEW S7WAWS4,Z-/&(+,]N(2Y/1LZ6!7*@;M
M-/,Y,@00U:$($DU)T:_EFE6*ZJ-I\F]P2])I7BQX+==#/H.B6M[7O'?ERW_R
MY&_>K9<0ROYV<*-06;AO,.8WRUIVS>T@BL>;I;0G!_OW<.'HRYP""!C#@V*G
MZ8P@LF.[4<]SI1)/S'_]F9CA$_9%/*I\WCK$$H/O]UI7Y51E=7]Z_U935YKY
MN^,3&;H3@TK#+N$!CCS>?CFNP^<_^Q]COWK+[IYVLN'4''_,3UO"Z06E_'OU
M$:']:V+)8LTLQO=HPXMCAKP87*W9O(LC\J.ZIDJC4,!@S6+&4GL#J2<4 XK:
M.*P,;C7"Y3=D,Z37*'P:+RLX)C LVA)F<7U?L[GL7BE]2+^-BTX8S\.8'\#"
MF&Z34LZ*7^5WT4R_X#HY?%0YR34;+W5>K G[-)._#PI(%-BG".4*%('>QI=V
MC<,<9>*A @@+PN8/X[/BD=5%$4D%-Z77BB^^;=WY+3UA-3RN^JPC\[.&>"&#
M7HH<H4:\FWG(2YA%0.PGZ*U$#JI&3RSN$WSRDO%[!:'^=:HN96>(R(R>9!Z5
MA7N<D 0P849!(6M;)=C9CO&]170R8R2S)\.R(?J/=UWN8Z-=F_S8H?HE.HGP
M^LK;>-\:,&WJ)DU@.7"\SQC\,+P/+3 8IRS28TN=K\X>BAJ%ZQF\@YCD529%
M?8KC(-$5&VQ.$N['(2C7_<0:/!\P)SM.L=VM1V'QY+**PG9?$/R,)<"H7IYP
ME -$44BSRC"FJ+EM1'K;;0;?^(=:R\V+Q.'OMU3NA?$Q1@5LPNLN==0[2D#O
M1X]NY;M0.CQ%&-3?"V_2+X\(@6J4;KM?WIT0]-UVL HXWSL<8AJ04!N\-5J[
M>*H^U/W:7;&;8^$O5!,'Z@$%FX]%0)\@<MCUPGOIWLM/CR)*->RKG%M'ZE][
M5$FQ"ACR[I,E9N3\=F*3*S(6&V4TNO'';4WY_N4X>WUJ"@+"*+C?(0UEG*PV
M[#-GFPDZZ>V@BE.37@@-;="T:VNMMZ2T>\%-]YK3P8LM<#&$P$ZE&RFQ1W-H
M26??0Y3YNLFPT'ZO=^Z-->,F)(8ZEUJ\VS[^5CK:BZ$=*SRX"ZM,5Y3DN1-1
M_KG7H)C,R&GR;',KFPK=)YQ&AY>V,@ROVUN-:58/\]E#4:'S6->\YF1Z9"MO
ME7\9J9%3&*JW9!-@SK.7D^:X<!O"><*U;2OLYP9I^.R>A!?47@'$B<Z$(TQG
MM'$'PZ^#RBJH CJ>U%F:R3T/_9TEW1<>O:PT[6H!:D6^BA/9_]C,\:K9CZQ3
M^(6@6=8/"FRNSQ5@Y@JP.WV.>DH7]<[IMSH_7KRN53R1T8QYP]A U.CSB[68
M:8J_EUZ@&"^Z3]E>PFZ1(W_W4-09&Z:AFK1>IJ6TAHFAO/J%:I)H!H-"S5!^
MSU+-6'[?[6XJ35'SU=._T;)92IB]$\8\+V'GZ%$)J'F^3H<$$WH?J"C%!($J
ML=%L=^<PT7C^XWL9RT3C;%"L0Z4?*P6'[6Y? >ZVP@9).VT0_V^[?DP!O1JO
MQ$9X<&P[\6]7X 8"$C>&ZI!JQENG^6$N5%20-1,(XUUM9.=GQ7%>?&9UL4>^
M>?77H4WGKR7E[ =W!JVN /GA_^]\BX[.AMGM<YO+7];(2V\8TK$[E@+-@]*=
M/]?Y!07A#GH"Q?"?PJ,14FV@NR"SW7LO@F9[:BC(\BAWC),&W&#5VB7+.VSV
M)?DEBSOFXMO'C1]TY:-M\W+Q;"I:RD.[-OA'134-SU("?I5#=.!Q,O?V;$)[
MNL5Z;/!B92EF6@^M0UW2Y2&#AL?ISK:/3P\K2_E'"1]C<8RS%.O^&Z0EVFG
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MO8OTZD)[ QI?%F%G,);8)JK#K,W"A_=/!:>&56@EQ$"')2?6YI0K4U1?P,T
M67A1LU0G;5+,/GQA*PD.@ZN&2)-&(78(!EOE'J"8SNXU14*'[62!4.KOI'I9
MKPFO?XFW6[W"+SO?-NY@:G^>*J6 ^9Q<T/(%25S@.8%4D'4&^+W.TP>N])L
M*K(0CH&%],>8D!.UKXY5)5K%-[".:1).LZM6]CBCOT3'3\*^0(.6)_AGY'QU
MP+2?HMW\*:P 05<SZFWU<0>41+Z!-6:@*V%MR.$F\5<[UH]N,>*[U?P;J[@#
M)R(R(2B MQ%_2.=Q9 CVJ738Y>4(%Q]^57?*65SK)+&)3 RAMO:X&NYO94!*
M88R63].)P_L%Q"!;PB&J9"EH8,&1"TJ]/D9=.7W2SP71UYK% %AL/:BK1B1^
M\\J@?VM?S7:@V[[/6S'I"!:ZIO\J+5*17>7)&,9)LW_6"PNGLQ15*9?VS!:?
MX?!U-&)I_NLR46(A-@%&H^#U(N9-,/C2.?L-R^[8HI[&&(09$#<IPV'II]<C
M6Z?FE%16B!Z8J8J>+#:&39<E#L]_=<T=-:H9TA<)D5%^H_#3::?.0,R)&%+2
MU$T():XA#A?_(!RD25%$#7M+=4SMUSZ%>3(5UN]=B[%23'MDW)5$<W/L'SU2
M"HY63/M]P[Y\BN7JH<'L[\=+=_(JDWN8=11/R.8D-#%H",#;)P1!X[937S47
MH-04Y@47%#K0XEATV\:7SZ*QCQ\+^W_\^MZ$47M;68JONU7E H!_G>E#?(RZ
M4B >(B]^6-F2TG#9W;,]6CA[+[,^U=[A!+Y$%\7&.L/'.<6X7R:<NTPKPP]=
MV)W?!4:J6-]WTVS[B-*]Q7W [Z_]E(KCV]X"O]6>LJ_@6/.2(E<LR8_62@J[
M7_F7]9MKV6O..M0\>UC#\O58A&B6R@FM$/!;-5MV6_U%+'@P:TWI5[ORGO@P
M89+J?9<4M9G(.C3S?G,S8K:"QOKJP41EK4G<O0 6#Z, Y#;CP-AN3;80'>\_
M)4_$6831]2*S5]7]ZY._W?\VL3Z]T<^,$:/]G!M!:,\B/^QX&'<R^>@1GHJK
M-15_:29&KE?_ORL]_*D'U%M*AO[[_&MMN9]^Q.2H6"/6):,GDDW+[T2_ ?Q_
MI%[N_T?JA>2ZHD%=4X@8_CT!%KET37&U!#B?=F2LO>SS^O^7:.U-+?GAJ :O
M*6(C"7J' %(K;F&@ )!ZQ=YRV;'.VG=CE@RNA0","QP<8QWI?=MZ+?^8S,A?
MFAJ:HHT5T9>UB,YY)4[+9A]@DZ=,[Y<6I3#L5.J5X&5CY*LIDK C\I#W!\EO
M !.7IB8;\2U?7MC'YX2!'B*&Z+BF8.FY60JF#0'7*4?9-$__7@X*K^NK=NZ8
M=T\S*X9X'TARSJ\1'B6273C6YZT2A]T^#X[O#@/'(6@)7)V:BV6J&)N^^,!+
MN56N*:^-7/%&QGQC\3+QP7YZ+!@?9*#&Q>#(["W?G NU!])S,ET%C*NEA@D^
MEIN"Q+A;8)%G_0D<4CPOCQ-)T BU6'W8IIW9P(I9 K:NFV_(O3W03KX5:G5[
M'>RFLL5,&87$^WPH=HH>GAZ3)ME<4S@X=OI%399>L%[-8H320OHY2+U0F?](
M#$/J].U^K(L14[96L0]! *8=IJ*@];X"PJ=Y=6YP!%=7QB]UAKT,LK%FC;V6
M["(I8M='[?1J:W.M(Z8SMD<7#G5']P$\.;73:TEO<5+[QPT1F-,<N,\U!355
M<J2K;O $]]AE9FTIFV4Q)>$D8\\V+DD^R5]24L*)R#*!PMGL*KYQJ"?'3#M2
M9H5S>;E^'#7OPK$(9;GEP<#:,+88^,O W?8@98*A*A$.0P#K-20BX<?#(C/^
M+Z;DZ-0"-(IHEBQ4K1M'NR)_>L6/B+RB<1 RJU4#3,G5'3-H4GZ=E>WYU.M]
M  $;,]-\5E 30CJ]G"&<5KIS9@GHR9-*% >(K*PP-L9T$P2^OV8-HW4E#KZF
MN'M-X<L5F19 YNBX3"A9KZSUNN#%[$1A:\7(FEYWJ!!FZ\][U-2QC[Q*:WV^
MS$VVE3^%IPA&4DO//)HK!SS;_4OS]]JN*7C .;S*45B?SOV'81?\-O;DB*N5
MN*\B\%U>J:3!IL6=%)P,M&Q(29EPF9+2&'M.@BS:>KTPBFQ_]'VF/SG__.9I
M\F49.>C"B(1 1"@0K_*P/E(6A/\M3Z<C*Z'7"2FQM56+AJ4DBW8J]*_&1W,G
MO:]QAI:AL[\X3R&^]?L;2(W5H46QVSC4)3?Q*$P-I D<L;QA,ODPSZ6)+-OD
M_W4.GNV_:O-A_&BE8GL.@^MYU9)X5BR7L*IJES=:E@ML,1)-.I:YIM <GP_$
M[A?0(\F*+16Q.)JP27#T>D6.Z>B>Y;<N)8&QH,*<!U"+Q"S(L4SQT\3)X[N*
M8867)8PU'-TC;GAN8']I9)0Z-]!OW8?OBIJ#D(3XHWHK@IJT0%A#O5%'=O-H
M(K[P-K[%\;#I3=>Q(C15BZO<0]Y6[I29]"H=/ZT8<Q4XN,PNM\I8L:E 99$/
MW\G;LPVNWKO\V*/TZ:F[2SDD\HJFFQCZ=,9'PJ6SX\."X<Q)?^+YZQ(O/SI:
M;FD$2YWB"TTZX71^YU7EZ1?/VLDH$T=]T,^SF*QFYD$B#_!^\]RQN(.+J,JM
M^ZUT;H^YAD-^XHB^*NU*(,8/ P%%XBU%MH7'Q5R"%2RBYD3IL@\70.-I,4H5
MO.A+R% J"(AF*70Y3L!VF=*$];GD;44(XPB+9&AIR0PDV<$>1DK3%"ASZ&R#
M P%WOR>[:J0J%G-)7A4 K7U 3TD>2YT^:P1_UO)7WD.!<3BI--J<)]]1&VP2
M VFC4V,M5:1VHL,:+BU&?;W*X08)A36F)2UC ?M51-"Z7P*4<EV"=UB?(+"1
M#X+JS[4#>"!A0-?_=AH;P']6U3L(2(Q@*ZX+M1;OG9;0/K*_S62GZ<=VS*'E
MI?^53MSK;]IUI<PAUYN[[%[?9*'[!(%:.CJDL6P4:CHT4+'H*%LG\PJQY&Q"
MQF-PA#D1JXK8B0 6O(@V\Z"S4NEOXP%-QN@A9V74PI#K9QB5_&CS+"FBDAF0
MA?,GAR'L[),:L_%-9$UN!_N485<57J?!1D!4K2:S)E6)<[-TX0ZZ]AWJ*LYS
MK2UNGS:LPO-UOB.9V?T"8/8%?2CQ^P!TQ<6,URZ]S(E\TI9NZZG^LNL[;/7/
MOA(]S]22D&OL]NB1Z\M49$04*>F4[[*R_]7A(AZG@UB+=J3_!?3!EZ3T,;4N
M7%. TY(^0I:Q6P58]9MD94([K!.^"I4A:"<T0A"&Q+N=U<.N0=5IS)!B*8:Q
MVW GN*.-AU>8/^95OOKQG%9X;!"VDN_>43X'&R..L.3 I3"X=39I,<3>)TV\
MR5#D+#LZ*V,CSV>EC$^6%!(ORW$1F>(!*O+6&P@ZI<3^TZ!.[U#L2*,0J8E3
MIR3F5GW$=H&2 TC 3,KB]=:K1]]Z-(=),;AYA@29,$$AVA3LJ'\CTD%PO3E/
MD$MH7'AN?#MJ8*'^W40K9Y@%=($JH2)K!K%PJ7'YCJ4AXF;D@,Z^N+UZ1\FI
M>?^L4\P=MK32'27;[.$$UWAAV0)E[V+&R$Y&']@-&1KSM(8>*>(%=GC_+][=
MVO_;4M]"GQ/3OJ:(X=V3@J5XH:'S?6R&=:1#6T)VVCLHZ!,41"Q:X17.U$7+
M3YA.H0(UY9;TP> :% TXM./UEY28B=YS!- Q3;UUZH 6G[94-1S:!R0HY,2>
M))RDW2'E?"WF(VPGBX?PZ"!X!0A5B0=,RQ;3)P7V?);?VW4ZY9ZZ5O\[;]N;
M# ^OPLBG27058R*I&]6!A,Y+#YS!?%] ?!$PBA&Y1,6BS0ZT?$R;-%[,]D&N
MCW9<5K6KL)LGQZ7EG#NW4- ):"AZ L=[6")=V_V/*FQ[2C>(ZN_[]X8YMKN*
M'Z)FRP9S^^2Q1JHIXMT\>>M!=-AUJ!S.C[XU@JTQ9:35H$1NU+^F6$EJHL;%
MPSG@?I"XI!!;QL*@42P?FW*D_EJSU(&34^G5F!KPLDQ-Y?)=6GP)X<4:XS!N
MBLD:5%$&N7N!,QXXI-J1P%U3T&KY2RT8\S)=3?.^R%;@6">LO(E^L/*#)9<0
M27%UKVJ_"$!FX4,X<K:)]"E#9,>PH>^ WO @_%_O'$'=2>$X0V.<8&F%YQ%I
M64L)TU 0CKL5YC(7HB_5]D.S?ME3A'E%6'?S*M2C48AQW9(#IURQKIQHXWLS
M*6!)FT_FJU/+E[9B+FK$TJEAX0;$KI$K>H( Z>EHH/F;BU^!#DP5ZF!N-$-2
M51P"%UACS+SN?)74I>),PF[:.0(+1/'[Z+CFL"&+J!&Q[^?%-Z,AM7'*F;'2
M*KPN[W#<_8 ,G.PHAUM8MCX@9Z[LP*GX)?&W?Y>!FY:V]=I26MPY54+D>CV
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M;Q6M_*/C3[UW,O"SKJW:]8.-I*;X*,_LPY$'@.QW &$#PEO\?]R<I_WOUVB
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M#KN.2ED2.QSB;)A6T534#B$%A&H^<+?62QT_>&.M1T.[0W!43%6H+33YBMQ
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M66KWH;S_#B?=#4&J+W'C:-Y_2;X0PUZ"M#M:WRU;K0QL[WEY?HW;890>YFM
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MB0"?L&\\WB*]&KC[Q2YK'K7>\.8'U*%((ZK?T+@LH>A1IJ[B* 1]5?^TB*M
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M4.A*%UI"%%^5&;&9&L9P10MI+[7LSF@?SF#NJ[^<#:)0I1^X3!S;T+ZC\/Q
M4S8G:_>[\^-\S5(S%%2$5<T)15^Y<:_V1F:SDSZWYNOU%.U;S]4VZQRS'IT>
MBF<-7,WS-K7#MR@I/XL\'[LW8LJ,/U@&< 55[I[VDJB);5L6HHLZH!TF$S>8
M*#=P6??#8K((2B]*[V.!HUNAQX]7/TPNR?_/L/FW&B,QES2B2Z<,@M*8:]JG
M=0]FK_1XJ92E)*95$M*RR]C=T"'%]D!#]'MW:8[6,PI%U_&$<!5I\W9#U&0T
M$YA&6:I"7UG7/^618<9*X?-F5G2M'-F72G$/"QVMK<&MM(G[G"*HZ2P>"F7:
M:DW=!*1A\IN&(*=7<XDZ1E5%[($K[C5.'$]UI3/_I<8S0&HQ6Q&!5KW,1-!0
M#YV-Z9I=[SQ4%59L[<$NZL57G;P5^VN^:5GDI^WTKF*18HT7=,QGCRPO5"\N
M@B8M[?= WE!J"A]!/<8YWXS 8\E];YC_$U(A9N]!VZ$M\RN.K@/KY?WXX;\O
M0JB=G%:#%X['"&A8+!AO"OMQV,^E3!! JT== ^Z&*T)5"31170]Q]RF&]$N6
M(=S6LUT:/O>SHR^,@K!6]Q5_*U/-%YTHH^%(US>!9N>V</E>DN)@[.H29OW*
MV_N*W&W):;ZB%+QS[C#BV^HC6TV59)F2&%:R:F-=/9]=*X>!5$DT$;MVQL<X
M9]AZOHHZ'=CE]D3*?I6V_IQ8J\>14I+I@(L9;UA98( R"\B5Q"2SX[-8J)XB
MA[I$ZYNNRDPS2LB>BE?Y,9;%E,6K:P_]@H H#H$&\N*,=:%91K8U%CD$9E+1
M82#N=@'^WR>"1;#Q5JKWRQ35;WT+F:RX ]$!R>$G=O6AULAOERH=-SS&%3Y]
M#:!2=[PINMS-UX!WO$07 ARC?XJ"DU]H$C;+,.K,.VH/B)'X22_KY:QOWE U
M9K:MSFEL1W-"F#[S9JCMKI/%WF#]>,6D.[Q9_B-!^T1J6MWY&L!TP3'=S-I%
MAN5FW+54V./&WL96=/E]'JI<V<Z>7V6K;[/Z<136J6?W9:VT@[4Y"\6>O+<L
M5_8]#>LSG4KD0>R%_&.!W%Z/1?N\4V_:2O04#>I-8<DN(L'__8@="QN[O&WP
M37:*,MGGV6Q3/D=K^M.6!4<"5=6P5E?O^S)]O\#X[_,"]!(8^)Z^4R54?@[H
M<@.-NNE#)]Q4LOMT5K]76?&G\3Q%,Y:2JU:;QU\^I/+_E0GR"G$1(Z9(1;5F
M5N^M!C!!"D"Q@Z^=,AVDH=KUB"&V0!-W!O3T\-A=EL1(9-3&24 AT%')=S(/
MR:EJ^3+38^A)A7TX1XIOV\J74'D'E&)ED_^D\FCY0#>EEGB,<YV8@W'EQJ0X
M4R%P-*KB^XET59W)CB$$P4[W&0=TB2:JG,#:";714!\"4TU5=A^<!L,P5CU1
MOCST-C2P-2OK^Z(V(MYI]J%3V+;W@,X-U,DP4@DE_XK] R+R@5"IY%??N9O#
M&_$L0^<TJ&HSU#6 ]D@,ID?4OP906.D3.#M4AP>K972S?@\HV\SV,"X$JH8\
MFSX^6])CDZ.P:%8R_&,IXMJZS1_3JPIDP!3:8R=/AU@20UPPOR_%K\Z.]$0N
M1\1*66PM:^HJXEF!VT[)G,!\4X75SR#1\ZV8"[L:B.WNL.'TTO[3GN]!8BI#
M(.P^A:U<3V^Q>.:70C/]YJ;VN&7].UGZG"'9M[P?M(>*393*#(O+C/_>R'DQ
MS20RQI(_G81_B;9#F)$"5>^]K(ZM2$1&?\;/GM77%;(:%Y//2=&='"0)[ G)
MZ827Y1'+!BYDHO#_Q#%73-6@.'_.WNSD .@P7<RD\);1>+WBTO3@NB1;]-U,
MS,[,UT8@K_]%CSG[84G.4];FY&HC.I/>\O!'VR=PBBN>"P^B#0Q?,@ G.=Y3
M'RSBG8%:5;M__$WK%LZ<K]WNP7$-((4J-1*$TDV*R(X9I9:Z%PI]6Z;8N@^8
M3.D.X)%\<X$2M! 7K-<O=D,(]=@0R$YL[ZJ0I-M#QE7^=YC'EZEBF^;N[I6\
MAJ&[7:U&CYC"6K)=#^3-5O(0>W9O;W2&AL ]4!L-9E/C)8;>U"<F2,G *E<Z
MNH@OUJ"%H'[!I]"2Z% #R3O0JQ#%M<T%W1<>T_I6:[VK_+:F5;ZPY*?M^'FZ
MC;O6\-[:/TYBY$EHMBZ>)!%!? \4P?Q\Y,,T44:,_".&G.*J"+2T\;Y5:OW3
M=2F)RNY^5$OVO$(C12+$.^GCX$<#Y":N8;2-4DN"FUUQQ< F;],$GW:SB *Z
M=!6&<DIO*_VRN+)$Z*AU#/MGHB2-2\B&:;1>(HS@>,XMOL&-MJYP_[JS&+MT
ME\5) 5+1TQO37/S$7N15D(!N:U,)IYPHNDJ*D?ODK7#@P?FKI"SR3'?:(!'H
M>P(/%IRHQ@MIM"9.X'*K'+OGV$AB2\N%$&YY-H5=)UG*SJD.%*',)WGNO#3N
MS \YK+5<SG*$U$M@MVY\ S@:S@AS4559!^_=)L1B*8M8>^:H]J.ZU$.^+.VJ
M,>#1]91ODI-[:M<76M)L7 P(HO$^H136>KYY\I^H>N"A9< 9\6*6C>&$HY]&
M5W2E[>G:%D?5+D\B]:=YTE94W%Z:CZE.%B,T?3SW57:EW\8\/@TXTS1UHY?F
MN;LP &7"9M1]EZUM6G/]N&P!'K[?%,*"F6C4K) [N.SV&DE[7M(9$#QQ1YS.
M%K+TS*:^ID#"](L5^;%DF[M<7?STF%_HBRW++'#"F#U&X7V%!IEM4J6_V2<,
MZ_P6@OVHS,*H\+FAWQ%4>:@JHDB%211.E;,AA]%[,+2A&(_#GP59MS"@YI#1
M);%]#KX9?HI)?+K":<4Y&@PQT19ZM'6I=)QB[NHOKQ:Y[A,;\9$#'>I):L/5
MN[UWY?;L]1DPZ&+L<S$?'YX9+WWL=EYLW+$8^<"41NR064LPB^'R$]&*,#_'
M5G&OI7OFM;_ <= G%<1\HVSC.6_'CO8/O':_E(0H-3Q?B4LRT3TV>?E?.2N
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MQ';R6+7(?R80\+IVI"QX$8:"T==VP<HO!.KPV6BE+I8P? 2,:H48@=.>O7#
M%!KU&4[XX800,W\]05$^#VU,M\;_.:%+Z\?(-3CT*6$+]'CP^P!N"H$A)6>G
MR\+!T!" ;[!#X;#R1$]UYNO&&C&<-]O80=5YD&I4&67M_71[8HE8;;3M-"NE
MK7X,6J?=H6((%@3:/L5\\5AO-I =:83]*1(;A4JL4R['%0]:;,T>O.B,@VP-
M&M",2=OR%YK%%!2G;5J0J"0U%!B0A5F&VJH\Z,=MA#H;V_<^%*Q=6GN?B-3
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MGA?WB?K.#!ZJ"S&ND7+_[@>T.?5A#/;'3E2T7RD0@X]L+M_X<*L\0^!23TJ
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MK?$?@AY&<?$;41Z@3S:!3S%[1%$I:G3;4GI IG4",/7''2B7QV-%G7Z(YL9
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M<@W=@Y&@A7J..L/UO8@$/=)+]3YX*GP&]FBY*=K66!C5*-#2TBTW\2"-_5$
M<Z*@U*0Q8QLO_]K@QA"*XL7"=:4K?A NG,\A:&':9H)[0]I0FXH99+ Y-C^\
MG^S9+KQ-(YF;?[TY] ^:=^^G*?B!:P#$?$ $Q3ZDUK=NH%ADFZUK60LM>*!+
M[TM]-'(LK=2^3R_-5I$89/OYE_C8BQ(HIXT I.G2YI;@B\\PFK[3HR<:V[KC
MR@2XU^L+YPC(<^5*0950Y3' 6V/T(I"RK/KYG7T0)O]K9F7,"*8P:"PXKLC
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M\#1[/VD<:VF$G$<.H"B/L'1!,%&>+LA#:*4+B+%F&XTF!*< 40=)@>G@LV4
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M5GMXC[K!VI,<K5,++JB':_JO]3^CL4EAH?@3$-P#H0#.=7 E=3$2W /^QEL
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MD3TJNH)>WVKV[@J_;]7R!^USKX"$Z!*:"&5\\6XH0>8&J=4?#4?"(7]4/4T
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MP1\!:AQ'\>=+#DU9G:O#$=W'*0YUJINZG<_?J7(V&.@+H1I"VF+*RB<)K"8
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MEM 5I5AJG>@>J-8'BF$WGD-<-GVU@:N01 ?.2?J-$N_2E&X7B5<,>8*#?40
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MS976@N3"VX'5@]&LYLGY;T/GGS6W2UA7@J2+!H;/S/&"_GH0%9H/;]KHA>_
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M8'80@X+&GD#D6ESO&6' .1"9OMH<+@%BI\@$'P1*M25:*4<F@N&9/VB[!?L
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M=T+F8#XGO-?1E36]LL%FS@6\Y/D?E,CH:Z)W&.F_]K)--(4>6=6] LS/\3)
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M'8\OD9*!.&*[-_XK\M@NE*;7CO5]TJ9<\,9'Q*Q\WSZ^:"+$@3FXUE<N]>E
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M##ZWK(B"&>#]+H)J+O[^IR;I-3:WP^1I44\1]Q-6"DD31-Z,MA7<GPG+/K<
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M&I#3>SL7 &7\DFCSVQE=(YH^DZBG!"3=B*NL H(MNEKC;T_K.B]_5-N,V(.
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MI\&0'-13/YF<?EGND@%OD;?>4WNCI#)/7;L9]&BCU?EIS4<C_:6?Z/#MS36
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MM2S1-=#6U/7HZSE?00YZ%=&]0L7$$=]!Z *F)'C_(LB\D9J6H(;C=>I_Z[0
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MT%SZ&NCX/PH?(BK #@&SQ/I[WQ:RW@JWR$=;=+2*..4AAN#*_Z0K.@Q]V'.
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MC_V4_OHP+!]]#GCV^^/$X8#0=OTV,HIJ*?OP9QG=%'A4O>\2ALI"?8!1C%0
MMNIN13!SZQ ^1('6_J"DO/!L+8:25=H(G,PV&T9H$?#>(I=1>V,+Q23VY^67
M(U+8_00]E8H?UH-:F8]K/1)+PYA>)6T-;B:O'$L5E27L'G5R+9_,GG#2587M
M'08'=DOAFZD"U8N+<YHCE /I4VE&B;759*K_0P]/:Y+?H-T1*$Q8RCC:PK?2
MIB*@KC<Y.6(%%^V?_XK-::W)IC^595Y<BCYSR?!*DX5BW/UDV5*'B"M/[&[9
M?+H9[;\+)@4-JB2B<58IO\'/($V*DQLLCKBTBK[T5%'OZ$&ZLC$B<+NYYAW-
M0B+W48U&Y['I23NJ;>T_<_DP,/9G<1A2G_#R\\5ZU[FITNCAM^HSDIHCU+3)
M]UXO71?F'8MVL=859S5Y"W^0JNE99"\=PMDC4&+P*VX1@XE"-V_/M$K*@8-M
MK!EB:U@@0&X\?FK#MKU(1L Q)UXD>]W&,3CV4"7M"-0<]!RE  R0:>',;"M:
M;J+4;D!G&%5SXEX>-*Y6H+^[^$)N35^CT4.EX0,MUJ64D0R=Q$GD=8&E>G7'
M"\MFK,_X)G0,V@=_MNMYYA&(#R_DSR'6K4+%;EWT<YE>0LZTMGZ=Z(I/"5)3
M<X%_5,@)VJO9J-MQ_PFVIIBOH)]U'T=H+O=ZG&T\^/:K3F,;M2&I.YJDH7XS
M#5WU.=G@]OZ''$T>'GC%G]L"[4$9$14T^;W=SY*])B> H'@Y^Y[@/7EC1*>1
M7>FKD O2N82T$1EQSYNJG6^='T+>$J0K-'19>WI?,Q,:; ;J+I-<LJBO&$19
M8O#>0HX[ ?"K>OS7KP_FIHY9-L_5KF70@%<R9[3O=GI;&PE0?;[$1>ST+1\(
M-F/HLC#.?_.^C;LX.Q7(80E]YC7<G# .1$7/4^E_BA0H9[6>&%RF7&@CI9E%
M/44G2HBF$ ZSNVO*D;<I4=BZ%^5^&4Y+_KI7VC56?W9X!H27SR%B"*V";S=;
M1#TW>K'V'"0YSU*X^?Q,6L1-:DJ6YT-],2-+OS39&W0#(SD9FU#BB,9"SN>[
MGWY]-,XV&Z6;'VN3:S=SR)'/>-3EDE4\?.*@;&=7':/HI6!$QPIDOB;4+7P_
M1$K(3#6GP6#/ORI757W7E5I/4(\<QGYR"8 :3FD<@?B7-EI6S9X%A)#$78S^
M^A3X\JK]3.VZ ,?G:P5^ ZI9]VTX_03X7<V"[2]9EJ1.K"576?*9UB&,'9-7
M4AZE/B#+:O%_E1I:O3#]]0%1KF=(Q618SOC'8J;#PY)D>3/.;XS'*] 32"M*
M4=N*2B+K/&4V78^/Y"^LOGP>,.\_E"XDJ9SS?\*[TE5>4;HYL^\@^#;'/LQT
M)3BCQ"S_P2W/&6M+U2PO86-+U12;U)+YK >%4R73>? WDY8;F[$3&2$9-JF9
M-BFFY7E-%OHB_L9%:9!A_#:,S9"[Z-YK)"57<CB#3Y34M?,>FGABI-*#<9Z*
MPE;ZP;CT+._[YP],-.L_^:5_[PADF QW,KI/7!;Z@FCM'0E3-Q5G4\\><.(%
M<IBNSV;D!V@_E2\F@RV0IEP&O^O*?@I*S./+RUIL&54I>V])J*LAV>DB&^:7
M9)NC DYE[5P>R'O^K I8?O\'8SJ)H5MSY07Z@3UI60+J WV&:=[_>P<ES$ #
M[D1(<C=G]]=U$ZK#RU8;^+YBL7'9:S^*1G<K$7M/XP_/F4[]RHVGS5S9T;2K
MG\#?=1PAI-)89Q->3[D0"0OI>A.AM@8[B<]U$)X1D1>UV=LN KZDP@,'Y:N=
ML#YO)%]<53)K^D.#P",Q$N=XW\JRE$CU!EW12,+9MLJHN=X8J_O%J[8;*S=O
M?IH6Q:QB<: F48*3#"L*9J#=X5WN#(\?^ W7@LQTP/8WQ>ZG4F4CTT55]^K*
MH+A0\Q%S<^5;QE0?,&<4&/9A?; >N(3?=J<+(TKVR0D,WG2R)1[[O3V*C(@F
MTX*!N'H3?Y)HQ,ISDK-)=*?+[H:N3&+9'SFS5BW3[!%3;FI,_Y ^@+J"?_=K
M^0OZ/@;0/C5I3@UA%J%7BO%@ACGE.(GU#)%WKJ8:46/4-9:W<#?=JQ->[^SG
M\/3AF.FCN39X?8!ZU86O?8H_]>P?!RN+4 L@N6M[%2^#+77(&V7;"@^</O86
M!<5UUZE+25D*?3!:O*FL7C/R:_)U0U.729%@LMK9ZC=7W6#13L;S<8H[ISE&
ME?H>9C7PDS:M3FL6KFM;=DMPF&'#H^.JZC<YDU<9HN2@,PQ#RN^$%#UNDCZD
MWT-T^K+SP[ T7IHH72[FLD[J1ZYK\22-%WITYQF%_"<!F?VBJR;6,(Q]F4.<
MZ3B;,D6F*N3#Y.QCJZ8JM%O*.'KA9GPI%F:J[#4,5_L)MZ]P*5"PKN)LKAY0
MJW#((ML4WC;U4(M=^>HC+%W@=8&][K\H]*#], >:*O,JK ^P?@SS3]SA?C4%
M-E_!LDBAI1R!&@6I/D>@NTJHKD#1(U!&"MN<-,RP37?5U#G%!9:1,X:90L4?
MIMGM5\N6=-J._3>F&"B,=DLCI0%W:FGO;-$9H(ORHP?"QQ!'@><9U\@[7-^[
ME<;6'I4Y!&TM/AHZG%:^]_F[<FF:<L W+D7>P<LUX!OU@S! &=*/28&</ +=
MAYU%+*RTLIT <52LGVZ./#FI=(]R.@V7GG"XGER+ _.Y89>C9:@2:6'^>B)6
M*6?O;HAD"7J3[^0)]^";VJ+5>/8>W>%&#FL-OQ5R,YD.T>YT%^&_IC>1T%!C
MXW>U<EW8^*YU@):4[*^=L/L8U;Z)GI5KB.JIPJ=VLI9E9O+REF\NXQ(4+,SH
MSA51M339'T<@BG%0_#(X#&LU@'\+V^:ATFG'J>45H:VM+B:]H_Q+B!\K3[#A
MN-814M SUO6IP- H^(DRJ9:WK;-[A=*C^PT+\/$WB9?H/K0;X]  _%E$T("'
M*!/7Z4^Y3@IL>^,_<PVI!;R@!-V<9<A$D78X32L48(L,(TI1Q0E=Y3A2HH9]
MZ',P1TS)Q_N7_WA5 O=BL/]1P@MTCQUTXS3D/)JJVBV.WBVN7X!Q;KH,-!'1
MW#\D+HU!>O-8-:^_'^:T$2,TSFC ];1J87#:ODO1WX?8YKNN?D&E2\,&!?-Q
MG>=[GLZLK<F6/C>Z\7-]^EWR<]XBB $V:\U@L<Q05 QE6.C='!53(2?G[1RH
M(OCR9D$)&>R3AI7G2\DH.X<8LMY5;8^PN'-K<S6+^L7*.[\F >$VJ?Q^BM;Y
M42.V?ZPX-FNRL^WMWO3M#IUNA\RE?Q,UTE__EPD:N^;L%5M#1M//=PL?@3:.
M0"3L4_'_R5?H('06^LI38<Q_M,I9A1Y6_]LIY_9_W7*C<X<8SDC>Q],,D YL
M^U]&%MDSV\7'+?]26#H"?3F@NK+M=6XJ? ]5\^O%LA7+"#%*!P^C?T,T]'GQ
MUZ&!8$!&IA>VP#L$%70=42& Y[D(.;0) $+6BK?>#G,*"JWB)9LT4A]HVKB,
MU&\XA)\?"*4WM[503R<42 TD5/5P?MW87RX)M?$[5)LB&BB3+$^-7D6:]K[J
M5I'Z'*P:^%R%0[UMPW)I@2NY6$//0.MX4C(-47M..?NAM'QFZ(_QJE,DU#GD
M<;9-BF=X,[,-+L'9N[R>P?_#PD!TYLY55Z0V\\UVJ3_^#&+4+(G4V-).=6@(
M.*'92HMMMAXE1T:ZFF\;1$C&D"ZDE,'23-R@'0Z.+4^S"\M+*]P78!O[M#&/
M+\O.5@+3A=N%4Z;ZV,6R*? 50<W9J[<S;^@I4RWXWKSHD#R&?$S>V=JA)-#R
M@:@JI#HPLK(-[2\2ZW:^TI3C==[?0WQJ7C"9.YP@\LF<M@UV:3YWQS$G0WY4
M@GX="%+?^/EPG:'>.@WUAP*2QO@@+Y(@567;D [:#-\.J%B>+S\""2-%7#NJ
M+#K/2BD%$ \(9AVU/N\2B/O)/\V.0-Z+"+4^E\+^1J76Z?#M'RPT^O&^SC<]
M47*S5,I*K;+]>Y2RF6I5&H6E 5_1-GS^0W;7KH]R09)/P^3BJ-^[(7N$N7BB
MDZ);A?"#=^_,!-Z.'FJ5=&:NI _"XM#-,,*B* G=<P02W.B^2GG>),05YG7I
M.=V\V\ZX?3R,J1R0>RC1=L_=8==\ZG7TIH9OQ:V,F<B(U=_M/KMUGKGD7P5/
M5!1'KCK5=EQ[?T^>>.W+V3#.=V[>? (W PL?&LB 7:[6&./D^GO+=/]))5^9
M-(WCM[XQ\'^R.RR,!]USNUL':<',PWO6S]N2,3T=KJZ8)-@YE,0(%N%AOG!&
MP]Q"GA0 ,YO889B&E"^::)0Q/ 0F@GZ#>7%E6ZIS;MPR0UW)Y@ZOP LX$JPY
M/+[[*F)P):$/=A9Y?!8% 1Z3UEJ+L>DQ.*OD]A-+LL!C6I(&EV3UQM*UL8#M
MH/(I=?W'-]QM;W4XU09)G)PRFIAW>ZF7NS-4<;/()]>N;[+8D=L*$E-T.4?>
M)EX$>X8D-X35NU-L64N^&3I5ZF)=9F.6GYFFTUQRT-!0I2>AS._C4.CL63.0
M];U,?JQ*WO9NH5#;I&7M@\GR@I6""<L0E_I8E!QKH>@898?!IP4#=HGX!1EB
M-<,4Q\R_3(7%&Z@<'(&X<.:CYY&PF)YK_D^?O#H"<<Z+1H3*A:7S 8U@P"1(
M[Z3/Z_*J"BXZ5G5)5-^ES\.5F4 70MI3\8,J<Y(T/V"0*F.:;D3=[]N)AG(C
M0TATH8"1P@[_)4E*>6[5IDA<65(R7X73#[ZOFO7WR[.#MGZ8?W_8^2-=<IOW
M"*3 DF06H-DE^XM/WPQ> +]2BOFWU(P0%]R?B,YU0UD?\.*=</).].[R@IY<
M1!ATJX;*1^I^=2&%N. =&7 S &HS3A[/&R*%XL:D<X9(IUAM!J<8]@":.KBR
M0X"RB8#3)X-,Q/?!3GZ74*"8C[P9??VI2'PZ%/"9#%@=K_.,=E<UO\TY__&!
M),^?8UFM$0%]-O@O(9:.N:MM7AQ>[QX:JX!31T*$$M<SGUM2&BRCS>5[9S]2
MOP 6)DM8FR)Y)]VL0NUJQ-GKV9$,EFE:/_D:[H(J3E[@+2!B5^0J?'_:FUFV
MI(O30XERR[8RM(>2^V[Z!6$$'*:V-[,<4/7*->>RJT9>S\'95>H")E(YK<+O
ML/!S4AELLV'![# LIZ)V;D/B8N>$.KVFYZQ@>V%=#/;K%U=3I2D1XS)%4Q^M
M;[#>'4 6TL<EB_8;Y4&,#N*;3+9]**TT/V;F&V:)QF@JI&$MB83F0H!O 6G$
M?%AB'C[U".13:.LR:Z",1%+VD_6L'Q,QG' #Z;'?A9"^PU.MQ?!96W2O%V77
M,MV9,C*]/^#Y5H,:C-7E5 V-R@@.-+,)JS;.XO<:WB)]7>7/=LGZNN"7VYSE
M); SVS].L,R2;S.9IYN;7B%#?$[KZ"@'/FFS#>CENXO;U):Y< 3RE*W_8.%(
M6V*6HKV_=VJ1P/-X4T"-C#^+-&6FH?104R@1',!%!(L#8%L@B@R9&WSO(0@4
MD_$Q+-EI9!@50K+']"E!^@QXJ ]R6.> LC=PZ+D=42<*ZDU84!S%!9$\2C\S
MC0[8F=>B!:804!>9-7N8&(/KE,$^S)=9\N"V";$&]G?W>>KRW[^A"4O7F 7(
MDT1TLL1U $I*<QR$\;"DG!DWQQF&1,@%TZ"5G607XTS*3RHN_?2FB0, .UF1
M6'L$>ML^8YZ:J](4ZD>WMR:VR4-I]?>W#=Y6/C;6)3+38/#MJ QD^IQNP=C:
M.FN*H+!;W<S,CZX?/<D:W8["-(1%>"DI1/HABT;G-4;H_>><?[&ZQF'YL--H
M7\Q\I!$P1]=EJ##+^582$D-WYCM68&DH:4#B"+22$(V,7)EC\3%N /#[E"-0
MGX<RX$56&!5E6 !Q 50%PF%N?/>E>$I%'_;"(+'L]T#5"M9:PRJ^Y4GWE<:H
MXWLY[T*T75XZ]ZIER8C\$R8W52$C:Q==99-:X%8J'(FKG'YS4"HZE!^R%I-:
M-FO(<_:6E^Q <'!&+-%&7BVV4-L^^<FC]"XSK$Z-Z9R%G(N?M1&_M=L \?]K
MI,)#@ASHC,9":3>AOJ-,)VCC=&07HJ6><IRXU$9VZK[DQ\<PEU!LI?LY+SLA
M0X#%TB\;M+S"I?2H:KANX+,W2,,&"NW5Z\W9(HFQNK @L!/<85ZB2O-%A3X+
M$QQP:6[KP;O44X("'G4&=<K9.EYSY1=RIRC-(8^S'Z)<D]_;TEY@T]X/%,KJ
M6347D'4SFW7NF[:Y1QRDB5D\Y:\B>MY\]%SMN =J"6?&8T=Y-R14]:@=@33,
M^E;YRUCY:MKJIS6LS[;ZOR< 7_\/0?#$)7WF2W8%'DTN0C,4CT!SNVREO_^X
M8_OT()I3[S1I#8->4FW!O]X\N]J4\<ET5&<D,DT@='.J3/FIO8R9.=RVH%CJ
M"!1D5 &\T VN;/.[R9?^Z[.\^<\,7T8;=8?!X\KB"***CNKN;(501LTC]GE9
MQSJIZ02P7+XVXC(00D)S+O2_+:CU!V>^=TC+E$<I40<9HDI'H!-+5+WT$*(Y
M?IZ/:#'Q+F^$(4 UMYHB-A<*F7+),VY2$M)VQ"6#*[BB!'JL?[GU2\\Y'@J5
M=#T5,\$0:]GTGWJO);8AK-H6MG^N=AW,R-JM>?!*'TU:?<G>H7G:?G<QK-.6
MUS"6Z[O0(] Y$+!-(:\S7^%7L'C<8*\VMJUQ(HR#85WE]"%E7RGP#<6G'YTP
M@[H!4<@9"RR6C'FP^21]]3Z+,XQ^#;6$/HWV%]+CHKL#Z23P(#X)I99@.F[
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M6G3K>],4:.)3HP/0X\ L"1;[&Y:"X=#3 ?_-$*;:LO@;$1AGJDQ2?))7!8)
M^I,RFO*-LO.L3W V5W?OA:^6JH=HI#F/QC_O_#_H!XI7)&&+5M7?AE5[4NVO
M ;YWL6;Q$#Z;;&>[Y%1R0O]T<5SM))K0YU!VTVP3>]LPSSQ3,UO(Z^4&26X
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MH6YL7UPC$*!\BMT7EWQG\J\UJOH K>0 \>FW)8;@6*6LOX\;7@0YCJ*]O@E
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M2;W*N;4RI4[0,C%TI\Z9&OAQ*EFUQ%.YTN![]5R5?6YO%:?9VA% @R1LK!F
M;!%^VVOU"]8B&5*2CZGE;, HC("\@J/L#HM8 LA^FXCLQUC).)5 .^\UL?:B
MR!(ILNU#EB("-A,16*.9*? 681?C6^$%W;^M_< /#Z4+7\0?)B$,\[]2.1Y5
MY>)2WMZS7CH"G!Z1>_3\Z7Q_MFSZ[6VR&7QK2RJ</"MGKEQ04#TXKA3"]53L
M"&  ;G%A\@>RN)X>G,\,_KITLIN-Y;'4D%2$O;VM$&/;CFJ[!5K.?FRLW'$L
MEK!XGI&YO$'B9TRRE$8&47:%5OJ?'YSKW9K>KH+>O_AL*7M?GXJ#IX%Y& _
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MP=Q@-TD"PO"P3"<7)NV2.$ELUQE#N=^KG3]?N/0U>V 2;V;#%=0Y>GDZ3V'
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M:^ SD5N6/PC(L])4CC2$=0P%>^*RW]*I0FN:=)?YNI: 2TG:@)6@8M!4I9E
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M$9$>Z5;/7]TQN_&YYMB.QT"I[&$#F\6GN!\!LN/DX" "N'4\VX4@*3$9=S+
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M6I+A>V""^(WQL0:.,F-HT4:6?@ST0OKM/4R7593(V83Q$XP?]M0\3"[)_>,
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MBTX"%&/K5'C,;?K^L3W6"->&)]YGO6X>^744\S[:C4YZRTJK<87$1L06N,]
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M=JJ--W08-;RC$#98@4N3FW=N9Z^;$Q(%BK&! O,_ETR[I<&)."&,D)^[R O
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M,-;!$Q-,=G,?),[Y&*DU:92 _0Q[TL\\LR^0[QUUD+UN:?K8UB;7WC8X;,6
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MKHE%KD<[0&) T(LMI#%=>Y<,B5N>PZK+4LYMTA;PYS!<%LEHXL,?\,WEJ81
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MRH!O^Q)2AR;;'UV@CZ'>'W,Y^(GG95MHE0\NV^,,[=[(1Q[7_1N04;7H$!9
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M&,1?X/Y'RAB(5""=+$@]/OBQB9A"CT7J*O7HA+*^DG;VUJ=4;MJU4K3+=6&
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MH7$.KNRMQ!U@:BYI/S%@A/T#,9 S'(Q.!#G^< Q4)/"'R1'M9Y/2)KSRT*O
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MXZ!> UEC'1.QENJWC0 NDZ;EK#%[2#T934!K3?GRPH*16;$.]+P/(7DATVM
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M<3,::[ 8/'PE:TB&+5^5#^V-AL08I-_\C-WJ [_B(>J<[38YUPQ4+9NI4PQ
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M5PIQD_^Q'%@^6@F$FK"VTCAFBTVM+.F4<9%;XJG'.@;$: (HSK6D#)$"I:2
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MS;*H-=.\V(K_V6KISI^'K[_ /U>]<I<&/ 49*"_J4O>2@8)(*R501<@Y7#R
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M^+1ZAC@N51N\%W'X1(*2#&EA*.($N-91PW+I:B><%8&4Z]2Z>^6IUR?',<O
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M^'H(5(O:'%^V>=Q$]+6QQR\O3>Q;<^FN?8[-(+_G %"Z6YJOO3 \W$R](>J
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M]XT_;.,/*ZHZS) =MST"]L(B=Z+@!D7. N+!@,H=C0!&PSJPQ$FZVC,J"9]
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MW-=MMK_A+4< 5G5S.C/)8>^H-ZFXU^]]COW>85V'_!P@$@_O\[RR;?4UPG[
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M#$Q,E93IV'+\&9"#LBB2DYK17Y6C4%J G.U'K^FAT;,8G54K2UC( <6L,I?
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MCEI1\XW%HD%?JYY"T='-*T6%,*.G5A3 N^[,0+D+*FY>7#+F< S;;,E%N[
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M-()XKL3:W-,7'/>5AS<Y;>=X0CN1-"%YR".:"&YE ,K(+$MM%[O "J#U!-:
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MI1US^"A:JI;E'P#)XMKZ2B1,I2 H3JN@XXR[Z]7YV_#74<2GO0/FZHN$D^W
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MNYMDYS<#<;57O3"3-$G19$G]$;S<_;KA1:/^E.N'CZ[6!Z6A2Q6FZZ\V!!?
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MC,M.&CY[!3DDBBYTONEO"5L'3D7J7_#=TP(%3'QTN^,\7KF%0$&WC$?[>$X
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M+R\V$!FREHG4_+@V+\5PJZ8'%^T=#(7J(F'-]&3@;E5$]8_A,]#Y21(EX,/
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MJ:MTA6R00@G^6SS9_"FGF9@"K9?KDK99ZO^/? -$[<L)##I6?0YBXLFXY\O
M1S&=(G@ K&C_POTR:;?HX?<2CIQCII:O&Y%Q8(MNF96U<K.N*3K*I&BB*KV]
M4KM,O1#JU@.7)K=3M9R)&7[_AG!"^_P=(-_%"AWBK4PY ZD6/XA[B5]P.C2L
MI0@VP03%UR_M4ZGQI]S3-\CV)$"'=$$,.NZ0,),FW+Q*O2?V6Z:35]/@!_%2
M/1<V'.\QL_404<&E',=!+236$3J12+RF2 G9V"VX475Y=?93[,+RTR;=AQ*)
MZE2;#'?XG$]?M^B_U*M/S6729#F-*AEA609SC/=H6<2,WAJ>H^X[*BMS4U[!
M;M%*8"Y=ZF0S-3>=COCFA+NH06/*DD'.<D=/:UPD@PM+A4,NB.+%U%$3WP!A
M)\/OBATG<6GQK(O)Z8H@$"9MUI5L(:NUYN.(&R(8[X/;,T,_'CSTX^L9^C%#
M/V;HQS@GF00\BLG7B$&HR]BUC)WA<+Q.GG71O[D%T_X["1\H :/1_JHPY8TT
M/O# 7DE&1!?-IR&([)]3"6\*5#&+Q9_Q5["A#;^A9<JBO1/G.KP%]5O@8H>3
M:SF@8N2"H'XHR6=>GAR=?LX['!(LKHZKG;%2#+@3-6\2F03\!\QW]/YW<"E*
M4 D51LURZ\!PD;[MN3&"GYBSI#*DQ&&QP6OJ2=JMRIB$A1M7O)=T$618U%I.
MN5Y<>F96"G5=$@HZ^*_>,54*BTBZ/[8@^LTMC\VD"T(5SBN [FW^JUL,F3E=
M,?&G-K.KV6_^G8EVB<>89EB11J!QZ?.=&MD0Y*[%[5S6Y= !"^]XCS"RR]]Q
M?HV([2Q1![=?D>;>_?)9ZT])09BT,<VWH[KBY '7H2/IU>#"4YGU,37I(OW2
M@'/1@&7"K')ZZ;5L$++-N'D+0Y<$*&7HC;45%AQNW BUY*G%,+;]G;S"F@UL
MW>0W(V.&G8A7'WZ"'?<5!9&8)(+--$F&E[WO'9/^(4,[Q,C@17O)DTGG6R,4
M=M)+F@_%]7TPO(@6SE\(QMV=Q7U4O\00NN:Z")L*=GLJ"GE^IU%:(F&S,,*K
M+$DMHN_OT??!%=L!S82?+[Y'&2=GFLRJN-G)NE^?M(1Q/[B^)+R5?!F&7X/J
MQJ5C!F(R#'3"L.M^BH P0]:/ J>F5(1>3I%K^/2R;TMPE2E^H^BX")2OJ1P5
M',[SWVC:^<4FP9U.4IV4A%T+TT2&RZ@;_9CZ%/+GV[13M Y3D,.XX\YD3355
MXM+P28U\9RO8II*IW[8VF$$%DED9BO<Y65ZZA7MV-5JHHD/QAK!%SZ,B! WL
M96G:6V_1>4%$MN&Z;YZ_?)LE-&B%D9$-?9APJ*'@SY*3:&T.QS]=@<F890FV
M<GTNVU9$S9 +&HPFSS9Q!:T!"C5</KGW]WA\6".&$R3*QOP:":2P/]#:C-@N
M3"?(F^ ,+(\\#CD?2V[IC#EG9@O5DX9)GS!35STATK)(Z A7KZ_T[V"^9OWR
MG:2Y8JHHWD-Q7&'3#Z</D_AY%@II[,FLYS6"JES"%],D_'+:#ULK-S0*#D"@
M<KI93N5H[=5TSGZUS:LKSG"-_ I%A'J&0:^!G=1]ARDY+O:(YYA:;7)\#9M/
M:4L<)MEH?Y#J07(T)/E%R?A2[":U?<97ALL&N]D'8UZMPCX9:S1Z9T+8@N!M
MJVL.;DYZ2.KAY).$VH3G1I74\H>GE386BTP(M@MW@ TK#XZ1,F6CY$>(08>8
M0RP$8^>QVYT,20P4.0!Z=-SZFL[UO1?_N,<GVJ^ DGK^_A"V,>PT W[06$<$
MD?&,_GH03HR!],-.T !1TN^7E+?8H!!XVZMN[5W#X>!R]M%3R$8/4S:]/ 00
M/S7YZIU^E=F='#^!W-,5IR++2NS.E0$Q>NDFUAF9!:X(^Z4!>"62(!"Q'"2H
MY4RP<%.L$<ZG*Q"P0%PX#E=A.A&[?QQQ*W34;A%;5R;[,*9HJ:3%V;>N^I 4
M$A.(ZQ9]%4YT(X\DWL56"99/$%Z=> 1!*RF\B7D'$D+KR5YBZ>,8I9&<P\F%
M=.Y@X*U]G;:SP#V>&)9+3Z0M"C':5*C$IA'^89K]1I,,UA?A- Z[(IC8[;S&
MP<N*\)&RC=F2DQIK[$4GEC) 5I#W>M='A+M-#M;PFL$#VK$SPGB0-"4E[AC*
MR$Y\/1A?S(6J]TXOW"[']!R>^-AZ\-,\GIL( :_H*XP=%9')2,TPK=[A-^,1
M1;<MOVH*J8,R6&MJ_+P^QBDXNSD%":Z$&2U5QHM>INH8\V01H=<?ZFIBT)QB
M:U,-9Z.=U0M3U*QY$7TBP%GD?9^PH,'>0K0R?1O[GN3=H+4*96;/I"D8@G6!
M.+VJ%]3T(. [OEMQ!OQH ?=J=JONP7-?3MC 9SDX3NX=/U )4%ET?P+EXC$Y
M /Q1BX+'Y E/^]CTCL7&67SX1@B4(CU:)$=2QJ2)(L,47<=. B2&A-AIA4W?
MQTX<A0) "PK8V/C#*<EXRGKL;[E'/,F1*&%[([ZZ,\)*V@@FH!Q#*JAJS;UA
M,3SW=\*[QGV4U:U> B2V%O)&WW3DW@IO/,G,&@HXIGHG'*Q- :F>-E'F%%B[
M-D8SQ[:=I;  2E$@P(PRI>&+/,;(/R1B0=J\IR4UACRQ=(2SM&'0[\*&TTPM
M,>4O,AR:+VC#RF!T2WX5?-?[N]7-V(R'B,WX9L9FS-B,&9LQT2]FC56T8S^^
M"$?.T_"G/ASO3^FD65R2\-S3NKI"T IMF$+%R)["0W:A?5YQ70WY:7\XV %&
M\'D6XI%C)!X932%27*#WD+Q\/+*'LD8K.O[<7SLGC=QQ ;ZHPCLH"A\QMD93
MC].3@@O^;/R[U,;,+;&$1,_%6,CFK+;>F8CHZ//%'XMTU/'(H\=3PLE]O>;"
M+8U#W*5=D0M?;8ARX:_PIU86S/.'*3K#H)EW#2D2K0U7I37ZQ;+EZ7D]GFLM
M\Y1S./1&W[R\_&GH%):=H.@1;878M 8&0=,U?UA\<?&E)!/R6U_S\?O%%X_U
MHR.O.N/Y.%+9&+P73+T'A/Y'^]O?XSU_\>3+CW-IP] HC_'161U1!9Q.[%PF
M?!HQ"'50EQB&3D@O@#^AXE>S,M*^W5$\ZB9AXG \(!.*?S08[:^:NA,&M469
M"D'#>FP0=\BI:$/7#LI[ZUC7T>B##*8-CU%?Y9V$"I0R"--*/YM;'G63J)[Q
MCJ#"J%'1]!,RAL[=\+7X6I47-5R1#(W>//QB9 Y8$U.;/M'+EH=7F9,-42-M
MS*8*3>L/K@2*%YRDY3R-AH8#PQ27)AG*=M6WG#9PI<\/3H!7*O.@I(FIG0[_
M,(C1&V1+MVKW]*N"&%<B+8]BD/T]J;N1380IW)3H742;A/NKOO6Q48[68[88
MXG:F"J)9Y,EHZ[Y9%:*P0Z7ZNMFMW>4TK@-985.'2QMO3$$=T>WWDEC;[6("
M:4>Z!%C"FY( *H098 Q9V 6_YP*VGPM'9R(MV+%"C6U*ZMGN7#GRF@&C>-<^
M -#Z;\EKJHZN8#ILVW-MXI/-[*= <'&[%6S#J7P_(Z$^E*W))C=B*>P?#X6R
MK<3"SV3M9I"$CW)]#+:E*DY<1!.I<P>>N?5$8#>B3/OO3B33%G>IPBAN2K %
M-X!OQ#8SG^;Q&2-BSSI54P??K=(VCY-*C,$)3W4%TE3JS,Y&SYF<E$5>F2SQ
M5",K()7*B%8Y\,'0[I3W*[:9BD?_#>L;<RLI[5'WF/'TM[2#I#RZ=_2])\_A
MCUDX'UV^;"6DX]8WD"RH3Q)]$/$6;O7%AAX8G]")+'1Z06E=#DN$<%*<4"VU
M.%(V' &4'"0URW(M39![(B/D?MOPTXN7+[.[C2]YS/"UZ$",1]YQ-R<TBX@V
MI:^DA$5CPJV;O-$AA!M<$P_?RB#VZ60#G<M[B75R[FC+AZ,0?+Z*(R7+-1.<
MKDWXN^F3$Y8QZ&6,P@0*4_)E->9%@(ZJ0;>\X")AN(@,9 #X&8&HF3JDIQ)V
ML-Q"0$TT+YNC&)<@_/'@3MSTCM.?(JX,)3:-V*P]]C*V*(@BY/1JREC4UB,I
M$S^/R<,VX8VU[M&D7+=FX-XXWD@RXL#B*^0Y2SE$C"]0-1I/+?SX>D=O-M*-
M8 YORE;9'",A'ZA5@9THSI+)H[0(T4IV9:N(:B(YK0T$S\!BYRX Q!%\]F)O
MN(-&>-02I#XC*(6S,@*3:31=N7?8,]<JL\O[*GQU.'^P@;KF;N]GU.#S:E^5
MR[#3O2E@Q)?*KP*V>ZQ,*F5$(./PU)5.G4YQ>4"O1D3PAL2A0^SPSGEL*5A2
MKDW)"1J!W632S(+);V](\C6B/NG-:6^&A(6,SG!036&72&(+)B,<=5&'2 0K
M-'P!X$A5QK;BOMPCKJ"X:BK16!'$4!0!(8::$>[R9-3W6\623_OMV1T\]F$D
MGDU1?2S6-2O<PN!X%S?V"A]< %T K/FIFIW_L#CSYXOGQ!U;^FTT)3=)*K0&
M!)4@(@7Q,IYAV+FMER7 0U@_A#ZU[.' U.7.L7-E>"VDM [DY? ^Y$(5_W"^
M4ZT-ZSR\J6(]>\(/ \[YBCFQL,V[Q3&#4A_$;OA7.%NT5OU[1%G);Q7(-2Y.
MO&JNBMP->-- "70BMG$DKTZD:SH,POZ2"ZAC4]QHX/'XT:,L3!^\RNMRW;,?
MA =)N/_@^NN':T<]>-N7'/*R4V+@JHYQ2[%@*F>7I.4MLX6#Z7"TC/%'E!+S
M%).WS+D]VJ%KQ$&@!,3Q@!U^<H:TY8FRI-?LJ%+"O VQSBU/AT&/WN/YR?>N
M5(R1-40 =9)9,^*6$!0E;>8PI_;4=46D5EB;U+OT%41RCSMS!&-.7OCYT +)
M=@:.X77D#8X2Z>RFGGHTXRP![],1N7]KPPLS"!.2LXH/[MZ(G97LRW%RCHX\
M/<_O[2$W(VD>(I+FVQE),R-I9B3-5 -Q]%"L2GYJ\R<4*?<][ Q_VSJP>D),
M?%M72-JML<W;42$Z;7V@,@P=>CMVFAQ'+5%F['I 2.W.7R 3QK\.!^67QKD@
MA0L'4" ?+J61.TIB9-#,[D4_^MU.6@@2[N8VWZ<$SO;+09L*ZYP<B[QIC?*#
M!'!$[GE5-JM^S[POKDJ5T[%Z(_FFF,'L$48BT$[9C15&,9XJZ/8=93K"Q:Z0
M76_2LE%FOX[L UR'XEG8YW_G-QI[?:,X1W"2FL*)@&Q#Q,(8!/KIU)B"9X5W
MT5JW=IIBWCAV7*]Z.'%9>C,*,&(X"[%\:_7:^G0^8)O);.:>*=E\O]%#F(-$
M*?2BBJ;&R Q'W$<<E 5T*D\XLV(]TU%!\HFI[R<WF ;P( ^(J8/)^][X4UL
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M;!TH8"\(,R&-T8K0;L,P:>-Z&@["HHN"P!/]U3^\?OKBTA@7024&FIU\N6P
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MH+D' \ZVV(FTA<U*=#W*/1D58#)8#L'&J(+\FU=P_EN!"J[()YP DBGX")N
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M:NFJQGNHVQ;,,K #:J4&XV5SFWDY96@G[2.)[-W1$1+@M A68)0[U,^@XD)
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M P:#]UK%"AY8@4!0JW[*OAAK.!$W2F$1<L]$FD9:*)&L'!5N/XB9HVI>?;_
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MW0SB?"YZ/?2BUS=ST6LN>MVKHM>B7'/K]/]<Y/_3E.V[_R'8;-A^[ZMS\H(
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MS.;4TG"#1J?E,E!^\2>L1HIG4;8HE"A\ZHH[TG9Y65$XVI 8Y1G%W14'/E8
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M@K.EEI._02H-9.WCDSX,VL1P%NF0T0=[UJ>0<JM;'K11P>ONN(OQI/7<^ZV
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M0KTM'/I_$M(=VQ+C@,9=+POWHX9[HZD]5Q<V?=CKO#U@_$:2[G&'OZDS$0'
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M?_\TC6!T]F+B%%NR_DPNVAI8_,-];[8SUV=,1B#6,6F\QH /?S0*&"ERY.5
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M1]QVV5SD8DV^\#\8!5&0%8@U8_9ZJE=(%\YDTL:Y9IDX52J2>U_(?(AS\C*
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M=(39)V^*\MBS6($*WB:;WBR,=: 32X,O_8V/8^=X'52+B<2:_;/ L,2])\G
MQ\4RL>;<MP^Z)+F8W>7JY82B(!O)SC/[E%IT7QY$A7(J>]T)XHQS^'/455QO
M_(47I@K?Z7XPT9V6IF86P)""5;Q$.37@%;5;+%2:Q(BY#2J^G>];GJ"NI5/"
M_ H\1ADT%D9>)N5BMF6^KQOL:_RA=OM=AD0/5+L2+."NV0Q2JXP?CZ16X'JA
M'CT81]D()2;O',+N/77PV(5D8*KTC6BTX)B4<!$>CWI&6.<[5".G-.)8E#L$
MA"=ZH'?T 9CJE]F73YZLCD6#!+MB,_^LZ;:O>YIBFLOOKT3V9W*!OS[Y#X>L
M"U-1&62: 7]8A,VQ.@^&6G2A5_U[5E6$&]!7FL.I@:M<BZ(DQ" -56^1S2RQ
M*7!K[61OD'4H",JY536=>,?-G60M"2#]A.GO#$QGD%,2#V*;)-VJ__?RV<75
M\Q?92 D%.YN(69Y?)TZ)'#MA/19>F!+>D#YH8,RDAR1(QL,>2&@K9;FF].X)
M +O3RJ+!" (P,8BDSC9+9'.[N;Z=:+!C+OZ@OA;>FQ6S]2B3A0N?HOF9! ?1
M\B3Z=%W0I%Y XO&J1N"$9<<P!>)9"=3UI7!_AN+ZIUJ9_BDP<D^)827V&L'>
M$Z0[??X6)QAU=G5->"$Y=[S5@AW"??Z5S-0HGIF;*(35:/Q"S\ J OP[R#"P
MCI6/0A_B84);JWK<0%">=R%3']J7#2TO$G]G,?,I,5QDG@\\\':@75-?-3\"
M4\5+2^.\J,WJM;Q/][I&@80,4K3(IC7ZC\%.5PM@8,FUW==8:-] R)P#+"H.
MD_7%(B+TI<RPV-A[V1CO%GP\V("Q(8PUT*ZPJD"]^I\!36W&S)9FB4?8+/'G
M)TNSQ-(L<=]FB64G67:2.Z,5S->=3])IGR[N+ZDC\Q+%++;W7K87:!P8/T:R
M%=Q*TLTB^26.IB3,8GF+Y3W8\CA/4>9U)_E'=G+BS/2S0)U!J19EH++F-Y/K
M/F.IG/QSTCN\.3,&4@2BC9#%^%9\104++=C7APP*CM9Y78S)5N(B:MY&BEOU
M?EDHRT)Y+Q<M]FE<$JX"8+P,2$LS-6.G@AY^U#MQM6D&5=?>*).X&.]BO.^7
M)=F!<^1,^B[?H U3:9,K?CXK/4%H+":WF-Q[F5S0E[ ZCM'O)#K%N?C=(O_+
M8,VKTQKB3IC,'%2$^\.MMW\QV,5@W^\,9A12NZ)MB60)X:;"(FQ X<4C+@;V
MGA%D0#$I&[2Y1NUTJ$S9D) \3'%KKFUI?%BL[[W=&^'/2B'RF)QF8I!35RK9
MG\+)201"$96?>.L# G;*>@I*O .(2O,YB7M&%/0>E:K8'VL+4  LH_>4(,<3
M64SDG:N^V9- ^N7JNQ#GRY4-29.2%0IC4G6=;40PPC([\R@@%5#@)PRJ43=Y
M-7BUJ"-IC2/2:4.:7_BX@>W&S;+TC[FN;V']0WV/B,_O%CO&P)7"Y#Q_]5-*
MZ$,L' FRB^H(+Y!9F7B='$D%WB&3!0RX2_+O" F(,?4J K6L=Q4Q<*RPR43"
M5.'N1F@\8T[=TT3$/5WA!"8\/!E1D%R+EOPO?NNZ8"4N45K\G5!#[XE[_Q?S
M)0JY31-$\_2=45<@0[Z*"(X9@[91L<(1^A;ORBZ%R.2DIJ4KTQ@M]75)SDG6
M7(]'I:@Y)6.W_J0&^?I]YM(Q%1T*%(&!=X6&'DGXN/,,@4-Y5!\3^NM29#L_
M49!FY%^*-,?M [:!A"/)(B_BP+F^S<SE:HQDQ;77I #8C^2%_0$-. )^I?:J
MG]HC0F:_18)F;HX0M'V[>H7O^"6I,;7E9O6MH-C\MXQ#_DS71=@FUEBZ"]#2
MC'L)Y7,U)M<C781:X)B ;V;8XUX4Y_[H7M2K6+R#KW1$*9C-^#_ZV!C=9 .>
MN>=C,;0/[1E>I8EJ,)9#B_@9CG,= HJYG25^+U'72":R'SRCA92ZD.=?&" [
MV3>E;8>Z 1WM97?(0V^?@RY0V:[AET8$Y-H"< GWUPC"O]0KY+K6!MMX3+E1
MF =:2K3MZ/K@&4M6XYH,-^?&)46",KY<J3U-$(R)J4F,%<R^5E+E!"H#UMNN
ML)Z>9T^>9/#RJ:?@IMP.K$^3FFF,O&:NIQ?1D#K9X$,B-%3$*4@5 H.7O&MX
M]3*EI=0W,0/*FWS7,T<HA= FE(D3IL#RMB#Z ZQE8K,QZOFE'^!376L_)%_F
MG.]&E]?C%.8KIIC 1H+@"8TR'-8D?H8L?]J9T^?O?&$;G3><7UHPMF)UFZ->
M!>J?'#$$'6IAI$2]D):Z"8>:5WASF[>3DP>?FXP!=%V,M$BFBH0I3X#?]$N)
M>L*1M;,2;2>P4&X:O$YZDM $2)N)AJ*RC =IY@NTN]BH/EW[M ?ELUL"*5$1
M#V'/G65,I=B3K'';]0E2Q7$5W^U 94_R+?2*HKW.8P[*3E\[$PP0"+V^0&T7
MC-5+%F$)]XTV0;X/B2D-6QDH^D!N_:<1<FJ.J[G1Z"MEA=('Z/*#+&^T'O\X
M[!-02YQ'E.$HD!$>EKJ>'C=ENQD.(F-GM+S:)8I-(C[R-&J5X(3=@Z% ,ZM!
M#5VTTYO660TGIWX0#00Y1-KX)?#GHQ!Y\?!X"K7 '>:,ZNBTQ8AI@:T<;@,R
M-(=T\LC,XJ\2K3NL$SHZ%MI;QBG^5#WE:Q85XZ,HS>1W V8V8&3@/775V&>D
MWMBQ[N5P%!(]W(X.<-;81B+)W[VXLG;%(/J([T&\P OLGR*=\9?6:TB.L9OU
M$\SB>VC$ D<\M@[SPW@>B2J"JZ#^8]04%3( B=P#X3=<I2IWQ45_33QNM3!X
M;*[;AIPMA1IK+HQKGV(92#5$?(8=C?5#:Y72%"<H$N@Y;*" Y,\X^4\YGD!*
M:+S>S.MHVHS<*98_PX:42205=#!).X4" ^VJH9 K=5%)O5%#H1U(8:HEM\T-
MFT:XP# IA0$DPA3:$4B,=T,MJAS]D*(P4\"X',C)*5[=[_7$,TF/&<2ZA,\9
M25(:%F7AC5KO0KF?;K03A+8/&R2>F9VK4+9NPK1ACL>WY-$=;$3T\*GW]I#@
MXVS( 6'?L E!+;-3^WAC$?AX[#TK3Y>>E:5G91'X2"7B*![D,%:/OQI]SWE8
MY8YX\J5K^',[BO!O!(J)]->48.)2+X8_DA_0J$2H00#Z<T%./#0=?R+ LJ9[
MRCMJR)Y,)K+(VGQ.,83\@44A5KW@](2RUF*8 UO P.+'+!ZM<X+EN3-J7Y>K
M?S2W!;&EI;.8-)BUYJGGWIFCD'EHJG-\[HNUYNXX 9ENW3F)M3S*B=JIQ623
M*R*KZUEVLDF+HM&;]V0^RH&#"?VBI>(KA;/"G#=!K].YRB7%"#P\\U3;INA$
M+8]IZF8.K'9=.BS%(R&2/#G0.BX.GEM1JAZE]SH.YPL;F!\3H0N,TDX'A$\;
M)0/D*S <EKPX?X).3X[B 0GA^NY8MM$YQ1W\H[,P'P_+0"&(>FQZWI?#+8])
MGU8S,IAC'>CW4HM%E0\*SU'AHQ8%6Y1+:9EZT EQ^VIE'^2I798VXW.#61M7
M!=Y2!'G(?Q8JC@1Y-)( %9>KG^K5U;#'0/>+;/7LR=._9.!TZGU+8C:PF$1I
M&Y_X51$KI%QQ=9M_A,1"WUZ]NKKD_P$+/#1X6I(3$+*LH] X6%$9+FDG0K!$
M*\2Z [L)Y&G*9B1]([DETN(F/4JO%NFJM3K_ EL962:_D8['>EL*X(",AA/(
M(FCN)7JG]A5EJ,FG4)+<]H"YY<C$7$C3A)D4&"D*W_2=9%\PJU1@S^#JNJFD
M "#6-LJ]HV<\K,O]P".5>7+6B:\0S^9PD/FE\&F[A)W'2<&<+'5,;N8F-9*^
M9(?\'%])1>YMN[K":8,'DJW&#.?94V=M$/ZT:ATRY/C]DQN>\6EF67![,D Y
MQ:*#($;/C3"=20*>9H.81;?>'-R>X[U$#:=3BP_HZK"<Y&+JS2T5N2'#,9GY
MZ8]'.=+<9U3]2]6=Y X#"H63:%?(5PR=8=M>MTV^U8+';*+4PI7I?-"@/VZ$
MR/,<?G$"3_82J4^[RPR&O+E<W5RNOH'G:MO\8P)&9*NG?UI]?_FG]QP3++4>
M5Z&$Y;06W4"_O/S+!X0!?DSSMGKZ[*NO5I\]?0JQW?.RO20O\KE*W0YMCY:=
M@T?1 '"\U2#5%6ZOY$SU",7K9&Z!-36[_DJ 1;V7^1JX(!F"(+HMA4>!E$I6
MFPN'X0O_-Z\'3*'!$WP18I[CL*[*[AK]$J[^<F.UQ.]A(T"$^:MB3S+HS.*&
M3E,2?+?&F2=,Q@01PD';3- 4V5SP'E4^EH7],=EA>&&<6.[&L#39>?J1Q4VW
M-,Z9[ZWL3D>;OD=AL&;H20M$8U.O,[>\L@>[#C9WLOZG7^O6F/D%0R7U\!9/
M$X4_=A$7$Q<A7H'T(R-OX,$PN9T-PE%'BH<H]]U+"*KQ;.?AJT%E72^#U\7>
MYM0]Q06Y$URTGP?I]0A+H?ES46 \%;TDTDVZ\,V]([LOLY5PQ8+%-W TNJ70
MK%BWZO.^C,X#Y6B=Z,J:KI51W.M\*L6TN#,.;?U(ELEU<=,VOYO_O=>8MLT&
MSHMU\?'O"S\2YOH;RNNNOF-C*7$U0,CW*B_A,+AM/J:9I8B^K,%A()Z]Q3,E
M'OS>%GBV*WB]KZF-!Y9+-U Z:P^KOPL'.-QDE*,V7C#;8E-V@<\?5NAF1(;@
M#M;!=94!<L_= E61$P9BJ"%F1M_C6=O!QPQPP#X9<C[#X2A?+N5 "CQG=-?E
MT>LMA%[VG00QY'#QR@&.OAE:RB^-U"QQTG10Z._TT1B?']_=[Z-TSZ!R$$:C
MSTMOXP#O?<38Z^O(>!AGGL]M0T[Q;8U<USN\1L%*N<CX:5?6TRS]14#C/P^8
M],6386 7QGOSV/U)G/SZ^!GL>>49^:J9LO=3F5=>%8T%$Y8Z+0=:&ER?C+0@
M+E??%B@93(=ZS/PBH$-^Y#%\F$HB;M>^N]<@L^@N@7E?Y#DJG7'2P;6<@;OR
MA9JF5^:E%9[&M!F#-P+E7'I.<G%%CSMK[?,@F!DI.B:T]@?^V[PS16O&$(:,
M6HJ:%M;^@&5K?,6N4OX_ Z;N:-&,B$T4RL\%]&+;1?AN"]%GH8Z7L_GQ6I &
MW773@J_I)G (@@TA]BNX $QJP6KBOUA042,<S>!6@D,Z!5#;:*&Y"S5M"%*$
M\>JQH&C^ !#Y]SE8X)LVW[S-8 ,K\K?]==L,^VL2C,^/)_(?<- C2"M9H92.
MBM45OHL-+ #Y:@R)$9$#;L7BO%%4%M.D$AHNV;FZUGRUR[M^+ >=,IG$FV9O
M9(4%4O41S^\"UW0-Y;%8R6]0OK1ZWEWF<']K8,-Y<?4F2Y<6J<YSWU)AQGG.
M8EI\DV/)I+JV8L3@>]?FWHRR-7>O$S0\?-[H<440H(N17]AL\^X(,Y<&C.DF
M"AZ\4HJ^5/5TA".+RL)=P6%=@#A2&Z;"P@B2F2>HKLJ[+IS;I4E]?E=<K#PJ
M+9SA1'W#HAF/#89;Y9,JB0PFU&(,ZXQ>8;NEY#RB>^L#;%Y2$J8-3$:*M:Y0
M>:0SIQ1D"*Y,>9 =UX?<^UR:0/[7_W>5L 35;PA'=2I"K;WQ]^(5)BT3L!PJ
M:>PM26YB7=8A*1F+UU/$D,!XNZZ+L<F=M3C$(-=XMC=S@^V"%6$D->&CL/2#
M>]OT95 (&C$#P8L!^V*M6M@;7]9,3_-([!ZFZ=B4)/#S?;IY*21!*/D1OXC$
M:Y!3%FR=HC,GPCR'H=:,\+KH;_%:_CCDUXE6=QGI#W9)[<5>:@7_?, 0M[!
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MA;^'^2HM<922$#OG!]7WX:RYG^%ANFA'_*;C&7]XR_,K.[Y.+,(WN"6ZCUS
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M3O+L;QS+S321F'F&\ <E1 @$?F:XY/)G[SNJ]GKU]$P^[;C(:TKV5".U#&"
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MCRZ58^( %C_3'T\2U1&!]>@Y5GP&M9PB1NW[8C(!,F__K,E-ONZ%]FN[^FY
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M$P&4 ^)>KOY)Q'N<"BG;S7#HB&:E&SW<N;3O^-ETCT*/M"TQ*[$>,.-/#S:
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M0[*:T:]G^#5'/EOA":E\6FWO5 (HN* ,>T?=2[8)S*<B.%O2%L>A5_*2;7X
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M/>[%^G1!_X$<4\@3_Q,$IO2!Y0NV<.INP92L(5ZN%X; "2;?+;7:-@4'G9[
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M$5LN37RF6^&J\L@Z9\&UKEG;Q;(M;=QJT4D63!KO].HOFHD^2+TJAG=IF>Q
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MI,W>8S;>^:1U)>6=)'9V[>1D:KRRD68:61#U.38RNX /JBGJBQ;,IE2R4(P
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M1_LG[7:&^*L=#[&C!OCSSORIM/BU[FGX58P(7"&N\"88.ZIFLJ\[0OYC^R
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M5>4VJX2]TGB<>8I UE2[RDL>CG-^2P"<CDP4<F >QPMK1TA%O>G"(@.K_ST
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MP.EZ2*V'U$\\I"*$SJ<'<_V;ALE^?*#5Y" ?/9,4ZO>T1MERC1F00]298S=
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MUHSD!U2T0/<5#NC("ZL,$C5%^KM(B'&UZ8'S49L["AJY^@F$5RAI&&.J4*J
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MPH.@R-T8!55\#?-&0["2IGF'+(<BOX.\*0S]1G.[V7QK=7-8 ?[V,'N=9H-
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M I5<ZQ7<,S+5KOUX/>1JK$CXY0S?Q( 6Y@2(VX9KH, 0C4W7]H,W^[=G@.E
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MNH#"VIZAY(_4"0@Q>"Z(1+^+)"3N9B1]6?"R:O?,>L3!@F1P@')Z(V#6(QZ
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M_;=RZ(!M!5O)V7J2^%N-'(P6^/9\P0F1SM!769P25NS)IW9/V^WBX\FP8EP
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M*:Y2)+G+TRXU2$#>M[+U#)'X8(*%F-6$(:N3."@+_+>>T0ZG+X<-5(G].:K
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M=A<*3HJY9!H'AD'E@Y*SICG)RL\Q1>EUYX>,HS+_WHXDQQB94EP<K[7W2>Q
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M1+%C<>_)GKWT+["'8<0J%YXD?\?JQR]IU3OX)2SWVG[ZA=\(_.=_KGN(,-[
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MI'9XK-_NS'-GGG<W3RZJ"L\!616S?Y-Y&@Z=G7'MC.L3?1^1M@S9.RQG2M9
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MHTDHQ.Q(T)I2DH TG K-FRNYF'C6I^^9HA2[5/>29\P=AJ"52?):6-D/#WU
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M4QBLS1VA2X.#XH%P9:%K#YD*M=!!]?E+POP(X^ )&+M\'X-U$I">4.$=3%%
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M%I@5,Q9SKEKV2:H*\N:,NV)+L'Z*7"_32DY8$ZF9M3[)P&-(F&?IS-KR59L
MO>+WPQB[=&FN9T=ERY3RNEYY0K M'(06ADL4T]*RDXUY8IJ>I)T'3E/+0%O
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M3LWO(*WA\OB\EZ;PKC+WUW6C.6Y__[WD)U<'4K? S4<&HXQ[Q$B']"=^HZ1
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M$/S8%Z&-2" 9^H?;;K3/W"AZRGU/N<<Z"P)_5R_CC0UZ8W_\P[Q:P7FM((9
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MN!*U,:MR "9LTT@7$N]JUEKCVE[FKW"ILI[#-KNEX#;\,[O9Q0A>.ZWS>@X
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M8-4RZ[I,\MY,(=J7?1;TM!54&$#G@'];[>E6;2FZ75MJEM33ELZ.#YN>RAB
MAQH M:)$:2:K"8#K4BI%;!A <EP[<W9)<O^0H'PF*)93 RXTRYE$8@+[ 3"I
MG! )BAFHD=]),05$ W/#Z\RFSNZYD]9Z>C;L>3$%'"U@)ZEQKH\$5D3N";##
M :EE)DFY)ML!%RASM+):NZM=,GS.1%X9EZ)0^+_N:)D FM/^@/HN0$4?+DO!
M(4I!39+G4R*0?/G(;CHX2+[\$/1,VK[LJV\E2+QM1<J-T-<S0\OO$BA]U),N
M/?IM%P3/G\)7\$HT.#MR(VGXM[,O9\9Y"30]53X5V/&U 4_[!O(]6TQ3)1G7
MWVE\11FVJ*Z-6H*93<VO1L95/K^@G;4^JQ7I5Y1@=7<K!$XFZT.A_BME1<5E
MD6X'KW[)_[W(TWQ^39!/Q"S7WCTXA.1Y*O'6UWXHO. Y@'@BF_RBC@\90]&<
M\+[.\K Y_<Z5KR_ TZ7F@8F<S<D2N)+&A0!C9EK.M:U#_L I,N%+.05&EU7E
M!#U[Z2*9&[4HM)5!=[5^R1HVFV=Y(H#Y=DI=4=:UOGP*-@I938FH+XP,6&>M
MGHSKT7>4T_K,^(<RK.!=RKZ G_L/;XTNXN<WW]1((_A7UE)BG 78_WQ1267R
M@ EW*1 *>%'K[.Q[XP&O<47-?N&=:9X28S?6P ^>4Y6+\XM5D4>01<DCTQM;
M[,F1YFYX6R)EJB%"/GJ ,ZZ%?/1ULZH[U%8,/4Q [#6?$#R(3GH)5Z*JQ%3/
MEVT_ (1G0,X79/S2\_N/Z#6%; [J8S(O<9<DU'_.IP!+_/TK/*X6Y,(%R?FK
MN%87?*KR2P"=\:D Y$;HXF\8VB$;=\VO'SY]I 42!-KP1>/6AK.759(K0QTO
MP:U55R"P957_?_\K=.S@C>%:9@KO+_7Q]#:(;L6Y&IC2075YQR3S.Z\X.@?:
MHZG7G3Y&K!  /XPCK[.3SXRW]/ 'ZT%$A"F1QD@1".P<H%.@EJ+.<IW"T^HM
M7UJ]A10VQ_-[&AJI;+83GHT[^[^O> U$8]DY._PX;;#1TZ>#%)L7R/[PV E"
MBUI-8]8!&>6ZZ?T(RX4G +N9U'@7(&I#JS++%(0!VV21 <C/M>N(\ T03/&;
MJ?$SW&U\,=V1D1+:M0ABNRV"T&O4(S!:AZLHX05H#@.AUO4"N9K"E(9U+&:X
MWA^"<2_N> /CD3CP5MH9+OKMUU^!+E40YS8D7I89-0AN$A?K:6KI#;CJI3=\
MF"YQ%'IR)7+T)_U@CV]XXI D0)ML-,F653Z()RFC'K]?(FIR<'ENS\5%P0EC
MWMVL7&$#(9)]6(>Q+##JK-PA)"6>RJ8Z\\J(18$8"P0$<(=7 )5E(.%S364H
MM90<ALO([&LE_9("T" #?0GL'05]A8NJ9+,&>!I@1GAF?(3'J10#K1%T-DGO
M!EI/*O%Q2)L31.T,,*&LM'.U(M'T+ZV@( )6>?U-_;B +548.J$]8@ 6. .(
M%( $RB>GB\,,TP?R 9B28;_=T2(?IZP/$V*?X>R-GQ5^# EL9X1O]IL#85M[
ML +?M78(FZ_],Z4,AX%*HZ]DVA5P:!0&(/.N7DS0FOH/ZAYH*VK_!+%CG:FC
M3,ZG.RJ-EQ1P*Q<U_%R_ZG?BHH0^O9"EQ C* J#,!YV%@/#!#0+-X.5F(:[+
MA;Y$[=6VK#/KQ^9Z@'$A9K5\74M0*T$Q7,XHH/M>K)2B7N9U'F,#_^O7S0/6
MU9BJ%_K^612Y/_93)IH4 ,J9^,-M-]IGOO.4VYYRCW,6AJ[5_?>DA_ >[ZE=
M#N_L)[B.P-?7,Z\RCH>D$V\X=WA]1DJXH5R?+OU[$.4$#+O[8 ?(C#_]Z87_
M8BMP?&*[BGU ^LEJS8,.XI\D6M^OB-;=HO63FU4<%^HSMS_(8V/8;8K;.\SM
MM\KMT5YBSLXLXO!@QRQB=RSB2>6ES"*VJ/SM9HCG^*FC R9YFA9RXZ,#K+/(
M.8;) ;_)N?)G+FI5#MA%QC!>><FC.X^GJ=D&26$OJ/YPL.ZN[</387HT;1^B
M<#3V=]5FYW1P>'W;!^:ZS'6'BK',=7?(=4-[9.]L5.;IX/!09Z>Q_;,C^T=E
M'++]PY)X -#=-2!9 #_"[+%&SMAAU#U8L^<@<9CY+?/;0\'5#?-;;V0%NVJ>
M?WBHNW>#AP,^AV7PS*KR,L?4NOC:R-HR-S9Z3L;HX1ET.Q33/(.N3>*P_5$0
M/2G5:U?H/_@A= =(  -&;V;GC,W,SI^(_6$X"@)_R-A_&MQ\_R$J>LN03#;[
M+!R[QV*SM5V%7S8-!%]AN I-.;;4CMQ2&RIT.5%D^/+9"491R&&J(](]!XRY
MS&Z9W1X<TFXX+\\?>9P6L.LPU0"&X&VRX20]^?&MG#[>4;LSS!6?:N_DGQXV
M>6)$[27OK<]JQ@3*='E*(#:PP@=@-V,](M'JNG<V;4!57U[JTKPZVR);GIC1
MCJ[ !I^P^FK]V(W%3%TK\UG;P'3=; NR8.]J0IQ/VSZ[U'TTZKK.XG-7H)-<
MB.FYFFC3 U1=2]VJN,@%M;-2+?EI^[=.NOO!=GJ3"K!Y\FVS '4/2=4:]\9-
MJ81-X?B<FQ>*20GO_(_Z 6'4K1=^51%9; 8)_-LL,W.!M]%&>!S>736Q2S'[
MY1YG QJ'YZ\]0QZ'Q^/P!C4.;Z!RT=NT7(S";H9K*Q=P9MH:L8"C>U$TC!\C
M&O007! .P5KYU4_&>90,HSFQN7ZVM4/!<QQ(^42U]<,=12+#7/&)*]J/5++7
M%0$10_@AZ@\9IY;AZUE,,R:"^,M#NYB3BAZ-.WW[/EZT/.A##5,I*V,BYKU'
M/NKMUKC'V&CH1W\CA8BI1WL[V^0'JUOL$;*'+<NL.]#,NS$D[18TH_$1[<B5
MAY\UR9'^80[D\#:IBC^14_Y\1R[L,%=\XKS]$4Z4^W*>[R*SI4$?[5#/QXP-
M61T/,J);;Q]P1'<$;L<+ED;MWK*:I7DIS2R76DTWHO?!NUSC_9=/GXR7\)14
M B00)+(HKUYIIKXLX^[8=G^&DGJC&I54ZP?9*Z+L5G>+M:Q2PP$ "&>B@*NO
M%4>;B%3B%(U.!#7::D&#C ?"Q 9*"-YN".'7.T9R$5*$X2VCHU<QX/%H]Q T
M\QC-GCJ\1X_2HX%4ZP;G+,V^Z0WT[L_<@^-0;M^I<DNJ,6DTU&YZ7B[CX4B=
M8;(H1 7W+0_=(Z^R%.F:Z7IJG!\YJ/O3^&9J4E1]9KQ-T)$-+\-)L?!,FM.#
M6\VG:ABKW@G-C9O#JG%@7..*IID_TY1HKJ2!7F4U;R;JX1/PE]X0PA/%%QRO
M,<\GC6=!3'">>^-_T4.3EIT/MX]0@O,_Q_G=ZT<I]88+OMZ1'?YXS:SG#X3W
M3\P"^*LIU2@X6L.LYQ+L>SN]L[$3_KCLMK^)+FL=].0W?D.(8>(KZ]?HH4+/
M\0H*=3N M[G!C\,9V>*=!6/'#D+?BQPW\ )G_&,_9?6;E#-89]&"1[O&"4IW
M0 5=MZ'C^*WOMN<C7W[44*(&*/?R*3 @H4:MU@D0STCQ-%D##2A:HVF,BT([
M"VG:G!:FQ"-A;PD.MJ8!V;*=65K/@7H:9MY\.:^ ZZDIJ.N'F**S@<BPF8#6
M_@ L=2*N&^;;.<C1.:[_E^F!Z>$Y]( HJ3SAURB&,<8RIY@U?*_")R![+_)9
MK12,=V4U147S;U-0):L:[AH9;U/X<S$9&2BJ/LMSDC= +'][]^4GY5M'[%9Z
MQ#=Y;8!=#CH/SNXK4=87A8A+$%_P!6,X8_A6.'[+Y?,2?7<Z;$,CL!=DW6E]
M"@=4D^6%/ZW3>=\8C**,HMM 4=(Q1GU5OUS,*0\(K7,IO[5?Q\B@\5,ES\&D
M \8)-MT,G1&D9S36_<\_O=7*RP1GU='4];*2<.Q+-R[F%V6ES<1NN#BYQ$M<
M'IILJ+O4"R2+[NJ^>4=3:$%9 33'J<O&I*SD6L4(&?X-O0CNI3E^=?<8&E]/
M)FYC*5<ZGHOKRJMERX:\=.KQ]( +LF7E95XN:GA$+"50.BAWE&_%$H;)=]LZ
ME*PQC3:OE11I-:I.TU&>W2G8W9>E(DS,Z$/ZRPQ 8(09HRFCZ3:DC$@N<&YX
MXT:&)P*VPDW$FLM$<=Z$9,Z*XT_S5^#;Y^?P2^OI53$1U/&74%PQ7>U]TL/I
M*:P.;!V3#&D,.",Z(_I6$!T.1:JQ]4TH@Z;$E\"8S\5<Y5Z#,C2)%Q4FEI48
M[YGG\^+&+YI01C?4%NT14IA_&]8K?CZ]9AQG'-^>R;"D<8Q:=6.$NC/H'_#O
M%'3R1&J3-D/'?VL2-W8OW".+ E3M!8;P*HPG@"Z# 9FL+/*R;QG ML"<(!=I
M!BJ/-DK@'DR,H1C$3!#I 0H70#$ZH-BLJ[E!K8I"/+>^G[(GZ]["57'$FDM-
M<E5AVF@A\@G[D9CB=B=5$F4#EXC%IO)M2JT\W1)2G<OD8@J[. >;E5&5476+
MPH%\1XG*;(%G+##4JSZ)JD*/BM+/,_+$3R:8#Z+8*N(M<.ZUZ,GE4@=9+K7<
M]I?+I;A<ZHYR*19!+((V)H):^X3T?97@56%^&GRDV +57"AO:?5-TO>)F+45
M6FA(7TD=^5@?]J#8-=Y[2Y+%&WP\ZUJ,Z-MP_D]5<,G()S.%./TD1S18*_RC
MOJ[QM G/\VE6B7I>+5 =DV=KH\HGE.3X#Y7H%$MC,54!D=*H!*8FW\@6K;6G
M3KN/>S'*Y?#*"'8$?\KS/*'D5Y!\*HN%/-":QXPPCVM>Y?%"Y8(IXTWS*&7!
MU3GL3%1]7S9F:_5UYW6!'+R& CEGQM?2Z%N..L2YLKDF:7-^496+\POEH@&V
M2.P3+,SYM6:<;9N'5,;S7C72R+A&5*0\[HNR0,=D>:6WK7 0N+!* P4PIWFQ
MF,OTS/A G#43>='!O%G+,JA5 /AV. A=2'MU(:<C(@F9CIH4-O+^XT.6,IA3
M4#BN,0</-XJM-?&AE%O7I!!?R*4TC"4SI5]]>VMBW3FL<-YXDF !^FD]8;/N
MQN:8KLI%H5.@KQ RJK7&+<\IT6%<7/92VX= 6DO9LQ?.412E/6CC[Y NT&,O
MD@1SILDU60*--QF:/5PT_K5(SS4:HW,2Y-,$$:&%W85S4OSXXP+9Y%0HVD:1
M; =O:B+-15TWN5-P07%=YW6;C:YJ8(@93W6_&;RN2:7MRN0Q ([A&%7K7TYO
MW ZZP+R)H2A'&_$/2N50_F=5^BFH_H#*&"@[D2HUSR5P/:I7@9_E#+W"?0Q0
ME2J%5%R:[OCKV[>?SBA[43U\B:VL6Y7>E7(Y(U"*L@8Q7C>)*;6QT!KI-]DA
M$]W5(1KQ&)%EF.""? Y>75:T6DKQ)W"IE@&CY6X%3<V(8K?$(MLE-*M6'!13
M,?OW&OGMD#XS_J'.0]6EM(L&2%R E"PKHB5\=Y5CB'AD?)N"@#'FE42Q3&1S
MV0+G4E28?Z.EJ"XP:-EJ#-HN7$PH@)4MI1+Z77%=DE?)8H(E(PGN4X&G12*%
M$I1IA+_ HG/EP@)XXQGWB#DN%PJZ"<BJ:_P1K(6%[ 'W9C<(?2ZPLFDYQ]6E
M6+4%9H"HJ(@)TZNT;@" @N41X"0^%JNTEH%'5%+7B\FL3?H XFXJ=&CA9P82
MFU#QC&:3E/6=9RAKFGRNNH])"E+J"E(W^^^H.O(;2M7,SIG_/R[R0AU&G\NO
ME005JAAU FJ@8BJ4O);*.:I$\/$WT# -AUIUX3DM + R7<\5VAY@LJ@EJ$$5
MEAK V0%VOIU.\7P_$XV/^C2@<BHN,#FO*,HK5;FU?IDJ2VX"5K61-,)MKM3+
M6^176R0_7\_<[MK.H:#.E7(>QJ#S[JI6_/,M:<+/J7#?PS8&4O*^<^;P5O4!
M:5L_8(5LK>M[='#[+H6DD5LDZE,=?R=Z4S25)-5"IK?GDC?R&U6.O&Y?GT\O
M2[0>FJ<U:;@%WJH".=4E6*A-EBWU&E3R']A_B4V*I"I50D:TH : *!3)DM2W
MHFW6)F.A?+O&>EY4J_#M<$7:FKYD[\ EP#OQVZP14>344]K21/P+DX';;E#M
M E5==%4W3T5U"-4U6).HE*C6U]:]W:!PQ!,P@?F"&4WU]'5R(=-%0>%56GSC
M.L2E]++7\$0F<O[&N"BO %X5&)68.MTD*#?%KDW.&LGL&]I9PQ+U\765N<J%
M*> D8U'08^H+"7!#4['AK6OE0:O=HOZCJ\+ZBDVC094('Z&= [ <>6:\G:LW
MHK958K:$,J5!W:U*<G(HVUA@QIY(FJKR)1V!-.+^X7?'HHS6;P@7],5UV4I3
MB:@HJNLSX_UW@=ZLQG]+#TT?CMR-,-1"JU&68:^9Q%,7.7ZXJ\YTYVQA,W6F
M[IGKNCMS"^NW#8;1NF>>%T1V9'MCV_+=*#A1KS!80FE)#'"E1K^M'=6)4UV5
M1)^.NNK]S6:(,'HR>K[X\[O/']?BYFW%S'/586OS031&1T9'0,=?UZ-C7SM?
M8H[HO:6@P6+6[[?3Z,-=_A(5.8#F0;5F9\.*LNW>*2)UZW$=D>IU,T6UCOQ/
MK9K6*-K+JMYR#MF2^W9)D^[IG;W.0^2;R$#=!VV87I]*W90/U%+R?/3J<5>[
MDM!K4&<N9'HN>^8;M6Z 15^)*JVIX+&0S>EKWR%M8=3'HM&:#?6DKK9=='L:
MTO6;='\%&+@$8U&+J4YR[BHOD;N.#$3J4:^%#M5A3G6/2*R6Z1M4G<F6=FVH
MM/*OJQIOL]C>M&C?/DEYH;1ITJYWJ1.E08E4VI#KK!>*7W;61"_<)U0;GW^1
MN[H$2^&\;)MH7(+%T+1-TUC3PZ &T-?:O8D+6TS16=S88T96E%=J+54;"<ZG
MC9D$URN7[W)S*>V2:U0M"FW*[PG%XM?8S777KZL+2I!9JLS^ZZ8HJD<<9\:'
MJ2(./)/&D$(+ALRQUNZ?JR8][9&A?J?7W+Z]";VNFN_M2A5MX,9BV1$(++%G
M"U+(5ME^A#ZZ8+@A!O5PH6NXVI=K/\#--Z&;7O9JAIL-*2\'&8>-G4G\03^F
M:T)$D,O3CIET':' B"W ^,-@-CPL+0E[^ZVO6GZA]MNPZ>*ZY]BFE34!$;5C
MZGREB&5$#R*R1%Q)>X! ,WRA)4(+H35.AR;GK7&D:J@^]';$5<+^5117\1SB
M*GK];61A7I;&10Z 07C"WX#]A(C %+I.7>UY?U7LA\(@5<]WHRJ;X9X&<GUS
MOJ$.:GFPS)L?;,/WO"E7U)<&WWJ^$!A2E]ISK;(">N\E-%?+4V3:>$BHN\U=
MH?']&OR<U'R02<TA)S5S4O/P9T ,,?SSI=?RTQ"D.W, ZY ,N?,I/->H+T"E
MN&N@4L^HJU>/7&7(81/;QICK*X(II@96*FFB4:WT??I*LHS@%Y5HMZB5&?>7
M0B3?S"_)14DA!/5"T$7(GIJ4J2R4Y:'NHF>LOJB_,_W2O.YVGNIT"DSS*3"M
M2&TB[W=IAN>C"MUTB)](T$BU>JX,PW\O<F 4LA]<(P6^M]5VQ%=-WS7/6KX2
ME"G4;%&35$L],[[TEM]:+F@ZE5-3@HE:7F,D!'M+:R7_NVYRLQ0?Z]*D:!X8
MJ5(KD-(9HF@R50N=C$#//3/>K4,)>L-2HVF]C#7+ \6O0(44P:N.%]]X_P&K
M/.>ZFW9V-]1;LT6KO8-5%$^(SWR]Y:#-Y8-NL][P<!>JGS2:-V"I:8\!D467
MH]10%.(V9:A00JT.^MY$\3MX%O&0>NG1C?MCN)'%X\"?)TKL]V3_PXE_A<,>
MTA$I<22;Y=&(Q0J'/]4Z67/9'=>FVM\B3!&SNX>1?Z-<S%LGA6:-O42'CK/6
M6$6BLBZTN'JY))HG>6K.RGR*%O;\"GT ?:E$HK1Q+%&3YVS)"[C03KY7S&"'
M32!_+]%NP9YB0SJH&V2B2 "E 6!@NV"#LIJ:@0=+R-M+)>Y=CTXI8[:( 51P
MPUSI;#AJ #V,<LEWOJJY-"0'!)0HX?'AT\>1<IGBU:)-HOGWHDN8;+< I-8I
MG.L>K*M:VK;]VK/=M+A/0:LN#4S7+)0SC/S HNMY!9OY-Z4&]_8.5"JPCE%4
M;;?%97!0(W_*KE:PZ."L\H4)*N=5N9BI.5G+H.O A7.0$LS F2Z=0]Y5-B&&
M8+64.&]==022Y#I1:5? R@1Y/V<X"*^87Q]*8N@.\D#S^IOY<R4!Y9H"J\]P
MTL,CV H7FN%"VTHPRB'+ZV7R7/I59VEA?\UNYI6V$^)KNGYY-!;%;(62G529
M^[V?Q[A"<6NIC<72(#&]%4L_Y1A"Z[) AG!,E,VIPB(8K2"T55Q;1YUP\@B.
MIYE3!BA5?M( GU1OIFYBV.1QH"!)?_Z3#DQB]]S1,BHW#S"N<UFDQ&W)%FF5
MOO_(JF1^V4Z%0ZON[XWCXIT",;DAAX5.7U><+!UBJ.JJI>%@H*<C ^S88E\M
M6N<F.Q2,>(Y+]V%L92)QX>>HRER!\%"*BXJFUA-1%++JQ5&;7U5P]D!@N V?
MS']__,L7XRWHHC,T'RFSPZ"<+^N-7 ]1^M5^H\.U37WB7.6 7P)*"I50(Z:J
M4AVUR#E.W5-5G(WI6ZKD&BWJI[#\$@_H,J^7JRS)T"6#6'<!U#7]2E'MZ:=*
M;U8YXMU--\NN\2'46GFF9Z&U#^A8ORP42T9^#U=J<(!V@89WLWVD9(3 [7ML
M7%- TM.F8!'K#D2[/"1XK07U-X\6/:;IU/VRO*X%HJ$*R]$@T4 HJ]7M=%.T
M1(I+5Y/BEJ#<+D.7C:FTDYL/>LC]:-7@J]9;,$VMILPI>PD'=N<5/*3$P[Q6
MX'X.H'%--,Y[BOD/4^PHC/99GM& ,L3#]9C<9 E1-U=:FOPN&^>?2NQ)%PFE
M-S1\8ZE=?']HW[Q/2\V&\<&]#O2JL!,><V;\C)D4JBQBI!=Y-]6-&G#HQZJ5
MJJ26+U+/L[2]MR_%*S6#/'[5F*+OFV# 6TR@TMT&;Y!%4]VBB/FE_0K=K< /
MC$16U"D'WH<].2_E<F (E/(YEH%@0 CEFFX7 8P@K[&KSF4Y1U1L>(7>8RVN
M373]BFY;R[]DN!XY3;K?<4_ZFG-\!R9\56"7+[ A3_^BE\ZKIHA9WK?Z)IQ%
M6;_M(I6/JVI&UK2^L5L>0JEPO:!#-R@!0##M!/U%+K/>,\HL YE>M07Q2\_4
M&3>@_.6$OBJ$LG0-L2M1U-AA& <J3A7#U?C;Y6%56/*DCA>Q2AVPQEP*>6'=
M9MFM P\4I:*"CQJD-VT[JU+W&7( ED6MPC!=QE]')K-%A6-.B:HU=AJ>Y?60
M\HNH8C&5M?GQ>R&O$35I0VO&_F&<_N%2J9$"0"&B*G(T0/4;VZ+8UX3?Y)T0
M-48,VTF:68ZIP&IF9U=#JW[)T""=JEE%F*6E;VF4,84T_6Q1!-F'3Q_?$$;>
M][8V+Q'OFI?8,D6H.E_89HV1KTN)$ &!T?J>L$J]5",SIL8/]IGCCHU8#=*$
ME[JO>NN;=DU&2<)IH;-TN]7<C(L!O6&E04P_G50/Q< >,U(-.:W?$!OV;GFM
MJHV6G3DCU C!I9!KEJ.6UH5<$7?;'. O[]^Q13^ ??]#'2:Q'M'R[=LT[):!
MHQ:DT$=K&[K536L7=7&0"S2 0:9B^%ADV!I:52$";RXH.YLP-K LP-EV+#+A
MR7\OIM)P+35G6D^^J1I*:FCHQG/LI>?TD)RJXS'AG*2W)F["TI9N=?'G]1++
M(N2^W>3(LU81TFSHT9#(ES;@C/L;0"($AK-FW_G&MMU&A9ZY\CN.L%7[%)A5
M;RG"NSM V]=C,<V4)MWJ$[E5"VP;2RV+'253>PJA2DK7"D6O3<KRB-TF+U=<
MBKQH;)7;5DQ6QQ=TAF-7B0)'WZ(N>,<.FZ5>E*7:F@XKPEH+I83.K\K^$?:/
M3:7LZCX-6"M1%M2DZM8>%'2>2_TF$"8_8[<4VS+_CT%-X1OO/Q:OKX4P&2-W
M@$")I$;7[C>@41,6"/I=A&.]&G;&";@'GX ;<0(N)^">> +N YO&:.FL]?BE
MIF3E%/Y.% _?5Q(N*]!W]8S13:)FC:58/?0XE7J!"D#;K!3O CFJ"Z$Z.=[0
M3#=]^D;+/)KN7E^H>CG*(-).DW1+K:K8>!LB$?Y?=)3.5=T:XL2_T6W3?-'O
M1ZCZWVF%'Y, F+<<1*#TPU*6QG,/C@LQMNU6N=WX(^,PE1DE>8)I_1D]N[83
MFT[/9=9W]JMZ_+;]9-=DK''_JCP=\ER3+&H>@V$I8.\GSK&-/%4]2'X/Q.]H
M9E>7,ATJ'__PO%RQK:]O8@1OSPSX[[,&Y*!7R^6\!^]-L"WV)K W88/>A.>!
MMB=-PM];.^KWSH[Z'83U[_5BAF,_6,@\5<B$)&-^;NW4+\N-UK\H^,)G#.'^
M).;B63K.X,R89^+HXRC\/D'R' K?YEZU%!LJD?WR_G_>?S2^_M?[SV\_O?_;
MUP_OOHR,#[^]>VRBY[&"Y\-O/[W_'^/K1^/G#[^]_>W=A[>_&%^^OOWZ_M?W
MOWW]PL0\-+.VOVF0V,8?YQ04U:O2^@TN!)\$N\!?3="<RX76QM1#*5K]XQM]
M/0UHFM7R=:W:T*,(QX?#TUOU[C*O<QK$</VZN;RY"BY+6R9'CX^<L\CYL:]Y
M-9H$J5Y_N.V^X,P*[[WMCW^85RO+6WL"O8Z-2M'$+]:<[,IJEC5.RT:]4G^E
ME#GX@I)Y$E'H1\&E*X9)[S:M]:EG[41!>JCP>:K..$\9;L^!VUHTUJ8,;>D1
M*+U[%%X#MET<C3 N*IG]Z<7_4MZ\W\OL=[1#J!W?=/Y[)<_S&OVSZ>\JE?MV
MKIUEZP%,+TVQ,0;Y\%Z3#P\M5X/2.QX55509'IGQH5NB\;E=HO%)99N_[<)3
M/^?5Q'C9E[I__F/^'5_SVV(B*[@8K9Z??\\B.PP<WS6S(/),SW(<,XJ<"/['
MSZ),)EZ2V2\H 0=V\QD!]NYW*XF$):4P'5]:IA>[KAFZPC6#(!5!ZF6)YZ0O
MC*F88"]:F;]^JQ)9?X,O]@G%__/IU[\:O_SRJ:6A)7C\^1X-9?OK&QGW'Y<O
M;2M.QD"X &,XKC TX\ 1IN7Y,HR]U(H<;T/']4NIBAKV>61(T?\LJV\CX[=_
M#O?8-, 4S7WXZ?4#SC&)K=@6H0>'D$C3<S)IQM(=F^/$#5P1!:$86QLZ1US5
MASN\X]N'D!V.AWIXK]J%B?TI(VM-O&W*0'K[4^V0!SIYG4>K*OYQ:"K^ &S%
MAQF QKZU\(<B_J9 NGV\OP6FK*$_1T/'28?8T2[]O9\:_;L>U/0[#6JJ]RG@
M_J)'1GVAE3Q1J#W%<\-":[-"RV6AQ4*+A18+K4T(K0G Y +D5GXI?R_*>J\2
MJA=M+3/CXW*V\;O^4HU?8*DL8+8D8#P6,"Q@#D' <+1BF&*%:GA5+X_Z=TPY
M3O+Y< 3+E][J=-\*XSVU+6>)LB6),F:)PA+E$"0*FRQ#ERU8=?@[51T.1Z*\
MPTK(GW%-?0FR ]?:P$GUH&24SS**913+*)91SY=14VQ;^/N\_/V6H%"6[S=A
MI=2S3M<5.K -M"7Y$MQ-:/ ')B\/*>5S^Y58O->]>,=V7&+'1:^'4O1J<]$K
M%[T^L.CU&>4XXZU6XSCWU]2L*<6YOWYGDSKQR13EY)-SHZZ2/[V /VPOL,=6
MZ/B_1V?_FIV_,$0Q7__#<G65-?O^1L/9<V=T(%R3,U!-Y"@WL%%+8*7"8UMV
M]\GPF-V$A(\;;AM%<=<;&Y]$]<UX2ZVC&=,9TX<#MXUB>K_VR[ M>^R9EFW=
M4U:R$U?/^CX,Q^H :79+E6O/+I;=J=7]Q+K982ITAXU%0^I\\55-!^XG*U$>
M[%]*')D%V/(3^<_*ZK'CYXX".K_([[*D^5MB)A<@?>H1D$]R]KH/C)Y[Z1&+
M>'%+#;HGHF0<>J:=AI'I16EL1I8'?[EI$J:.ZX3N>$/%L!]G^30OIU_A07\I
MX/A?&+).8)]_>C&O%G+8S<LW?= :%LWPRCLC5B?7\55-]=;=M1$\V/J;FKVB
ME-"E9X8J/4.6<1O5&"_QYG?JUE=ZDLI/,I&36%:&:_<&XL ?GAH]VTP_JY=2
M86[V"%_*VL<"@Y'1GPP%/V:RJMK!XC1N<TU^IJ3\S-'-ON,XQ!#7HL:3S'$\
M(@WY&[4C9II54DC6>(G>0XPZ7$J<EJ+&:*TV)7]U!F!1D\\5^MU^:3M!!:>T
MXC-QVEA1X&0[8!XT/@?'E<_KFX]H7*K-?*IWS1":>X'?;:WMS(Z3-V] 'K]Z
M$*1@P7 BV,47)[[3.$T:IGTNI_! [!"/,[9F\YN=Y7/8QZR0]?+HE)NE\^AU
M/B6J_(NH<P5MS;E.E#L!DZEOH1A1R09_9X"MVK%_@P[:@8+P6G%.=YX9'Q?5
MS;MR2F20WY$,:0YFN20P;EM#.VN^G4^@!KBJ'MIZ+FH/W3/LFM%9$(I,<+F?
MWKW]^)>V4W:_2W:,S;$[A9[NT,R )M[V:!YY!KRK2HE?M\\F,LQDBF38GWQ?
MB*NZY0*]L;9JWIV:/'J^*#0S:.;?=??C%6VC;YQ]G==U,XJRW=.A3(;>@EC%
MK)T%C?#ML..V,^I&!6LX*^"!D%T>)-Q,2&UFN\X*L33[4YTEOHJF9L0T)JR2
MHBZG=+8XS+U2 T)IDL+5A:0A<+?*)43'#*<KPKI:880GW5PR:I^1JJ%E((>!
M;<'_914L1%%;NWD]I$.O5DF ,I$I#7> FV%]:C";&A)0W_K:;GSEZJ+O6=*H
M#[";2T"X*MZ0*O)"^--2SHPO. FN=W$W<^0[H OBQ(@FH!HXNQ1Y0PY+D=CC
M'@'>S0ZC,YH@3U!$U!]PD4]OW=82*&GP8;> =JAOJ[^M"%ACT8QUKH%8:-8;
M@!%6FD]H*-Y$I!(;^G><DEK]7TD<WES?? 4.744%1>LMHJ^#K%\\4$0LBUQ>
M:NSM$44["+:/JG$K GL:U"[92>?Z6A]]M*W;PH_-+TOQ1]N)N@"D:_<"D*?%
M%LG:4-WWFSG'-X6UG@8,B(J$ ^JJ?:IBI.<8UG\=\C2,H_ 9_2HJ$ -ZO*O/
M_E/>Z_[Z7--:PHUMO<DI ,%O_"3!/D#MK\@GY!@J<J&-I9FHYF#4UQ?Y3)DL
MQD1Y&<B\*;.3A!W*,8+?>5'&H/J4U;F8YO]I%:.^$=<#%PB[9BZQ,@=/$G@$
M.)H1-B6  ?Q^46B'J @Z["6.#7L_/2_RNAV9W&(F**WG"P%FS5Q*GL![^.G#
M#J</<_KP<&;F;'20@[_UV.5NM30*:SZS:>%^X;B^H>&16#3TY,>/OWSY =U0
MY:(&]0Y]6-\Q<F/4%^375LZSYI/R8[W:D5GZQ/T,>H+1%OGM:G%%7U"0<-S8
M\),EH4/W/;, P_?/HLA]0A&&?>8_98R*_91[G+,P=*WNOR<]A/=X3R8O6AJQ
M2+Z=5\!M4E,SEHS^VW^&KV($STQ6#?>4L+GG+-]!P6X/^=& ROC3GUXX+XX%
MBAL>W?8@,/<378X>39G$F<2'B(%,X@=+XJQ\'>2Q'1/LCI SMT[@)GJ 3A1T
MCQD-DQP,CFZ7=V/J\6X1^(! ?X#LX0[H*KE@N<Q"3@V/M\Y"U@\48!:RUP[V
MJYIA N2?)?O7#$^I@/QM7=\(7@U*1SSD#@8#,M\/&8P,.@8=$^^!@I%!MR/=
M:2A>M5/2G=XMJ@JS<@7I4*^9"I@/#Q6,##H&'1/O@8*10;=C!]0SQHC0=G.J
MUKFCC>0FM:B[AHWTDS;MLW#L_KBT0.MF-NEAJ%W85:9MQ(-]#2Y%<;,1TT,I
MZ$G'\TBRVM,XF$%PJ/Z+I^610G<9O1\.UA\. &./90".;JKW<R6H:D]WU;/M
M)(V\.#$MUTM-+QTGIO##Q'02RX_3.+7E.+[95<^18S<;>]*,7,\RO;%PS#BV
M0],7P@W#<1K%=MM5;U&;YT+,7B//>CM-\9_W'<-Z.W\GJ@J;I?U=% OYPEA,
M<_66O_W^MR\_@=($)PA/<5\8J4SRB2CJ/[TPX1,V(!'8/.+[_/5T,3'3DD8S
MX14O_NR[(X!7TPJKV?"?F7IOH=Y=LT$6,RQF6,R<E)B1TG/#""2,DUF)Z;E.
M:(IH+,TD=:+,B2(1>MY*\]8HCJ0?1Z:,QF/32V1DQE$LS+$5I'X6!E:<1?L4
M,^YX9-D>BYF=BIEG1 ;8J!VT4:MC"=B+O6W\<2GKN>JFET]5-\:OV.=L45WW
MVC$> '-G=>08H7N$>O-Q:R&N;WEVYCJ@=F3"]#PO,\,@=4S?$V,YSJ0;I>$F
MC-VWER(OL!C\Y[+Z II%U_KU)QG/NT^:YVU('['M<!3X 2LD3+_[H%^6-8RK
MAX*K.Y UB1/Y@64GIITX8/'&(C:C-+-,D61I-$YD"%;L)BS>_<B:T!^-+;9]
M!V_[<D#W$&S?3Y6<B1R[H<^P&9CJ;5Y2'_9D*<7N +@ZF[K/@>X3*Z<& /\#
M5%">#^SC5F%L/[3]- +](_9 ';%D; JT?VTK$WX<^U)$UB;,9<W^WBON]W::
M?D36IPJS-JNV^",?RZF'IK4PU0^#ZN^NP!X N%G(,;JSD-NHD,N<-/ B$'*^
M;PO3RV(06$):9ISY?N8Y5FK+C42F=R?DO)%ON2SD!D;U^P]<.X,RWMVSP J.
MP7C_6LY%P7;Z::DP0X7N 2HH)ZY^>)&5N8$P99 $)B@BEADZ@6^&KN,%?B:<
MV$\V$I+>@J)AA^'(C9SAJ1I,G2Q&6(PPHIZ0&$D2:QS8F>G9O@=B) 0Q$J>9
M::=AFH9.%B7CC5BQ6Q$CCC^R'9O%R-#MT0T$D_=J?AZB=?E;.3433HUF!>*P
MH,L*Q($I$+8;1L%86J;M"=?T_,@V(\^QS#3SL@#8?BH<L<O4:.![R69#O]XH
MM%C).&4*9E%SC- ]0D0];E&3R-CQHG%@QJZ/:45CQXQ2)S#M!$S.P(]]*W!V
MF1F]<5$3C"R;O:*#-V<W$%YE<_:1'.&7$@$HJTG/@CT ALR:PS%"ES6' ],<
MO-!SI!]&9F(%MNFEB66*./;-L>M)S[+"+' V$BS%UB'SZTY#^/GOOWW8N);@
MCMR(FU2=,K&R5#E&Z!XAHAZW5'&DC$3H)J8[3B+3<V+;C)S0,>UQ8L=1$#O"
MWDCL=!M2)<N_R]3\CZS*%W\V69@,W>3D".KN3<[/8&96>3*7JE_R ;!;U@N.
M$;JL%QR87N!'0J1^&IFI-P9KT[>D*7Q[;/JI9TLGE($8VYNP-CL&A6TKMV!G
M.E[(JL$)DRG+DV.$[A$BZG'+$Y 78&?&L1E8TC$]$25F9 <@3T(79(F?II&_
MTFK_*7;F]N7)F*.;@S<U.;JY>U/S4U7. !K7U+\)Y_+,,+XY,J:2@YRL)APP
M_QD6HAZWFB!CX<NQEYE.%DO3B_S %+'P3.DDTK9\QY791IH4-\SJ4R&F\[?3
M]'W#KWZ3&ZOL&=ENQ*K""9,JRY1CA.X1(NIQRY0H<UTKM6W3M44$,D5(4]B)
M9;H!R(; &UMV$FVFR=$.9(KEL#MS\.8G1SKWD%PK12T-VJ)99N8"/JAV1(9I
M9/E43!-Y )R8589CA"ZK# >F,F2Q)604"C/Q4Q#_:>";D6,G9N*(Q'>3)!+Q
MROR"IYBA/RO&1+SK,^[U8_:W6E*?B<U9H1XGVIXRI;)(.4;H'B&B'K=(2:65
MI8[T39EEGNGYL6^"&1F98^FX/GPW]D6V"2MT%R+%\UFD#-X(Y1CHL(Q0= Z)
M.3SB %@QZPS<[/M M IN\7^/WN&&<9S8KBE%F)B>DWJF&'NQF5E>:CN>)Z2W
MD=Y&'QOVMD7-PQ^-@P&ZOYG>AT'O/,&&T?V$T)W%&XBW6/BN&TAIVC)T0539
M(-Z$G9J1G8"E[,9!$,A-F-6[$&_AR/('F#%TXO2^_\&S/+MF*PQ%S:[AF34G
MJ+0X9PYRL;1<Q(4</!M;QOJ'@_Z' 6#U)N!^W!J,[8]MQPELTQU'PO1<US9#
MRP:S.QCCOXF7./[FAN!L2%5Q_'#DAX.WQ0^+S@_>/+D!;K;'&>59M)VP:(MM
M*5,OB$P[<U(0;2"AQ'@<FK8;AZDO'.G*%='V],$\FPIO>_XH\@98Y'O(=+[O
M(/@Z[-ZH><Z6^#.XA_$4VF)+^Y'J"!P9_O2G%\Z+O8!UC[)N;XH>0_,PH,DD
MST@Z>"0]2F@^([RR::6.,QOOR&S,19P7U+J7&KS4\S+Y=E$68)'4_YO:O<RO
MAT4MS-*9"3%+/REH,LDSD@X>28\2F@-RS;$6=_L)ZMGU1M%I<Z^'11W,PIGI
M, L_*6@RR3.2#AY)CQ*:^T]MM@>5VFR?A6/W& *J;Y,$#FU>&S-QC4.@!Y M
M<Z)28$>Y(4.%[B'G=PU8).RB!98?9>$X3DPW#3+32YW8C&TW,"V9A4XJ(M]Q
M-]("JV%5GQ2G>K?1<0W>*!S[P\OD&BJU'F "\E!!R6*%Q0J+E56QDLC,B3TO
M-45J1:9G1Y$91=(WQY%GIZZ43F1OI W65L6*/_+L@,7*H23_LJTZ<%NU6LC4
MD-]G<EKK]))R?B$K(UD-5QP  V>5XQBA>X2Z\7%K&O$XB$+?!XLUE1*T!N&9
M(LA2TTG3+!H'@>.DSQHE5'R7Y6O-O'K9<6^GZ4=D7KVO-JM\1",G8.7CE.F6
M!<PQ0O<($?6X!8P((]^-?,=,/=LS/2=+S-!! 1-$(O*R<18'SG-,V7T)&-L=
M!>,!]J$Z:L+E4.R1FK=-RMVLK(AWE)E14)?HGE'+(XI8^S@&)C8L1#UR[2,%
MXU;$TDS\T#8].P7MPXU3TT_'[M@/DC3,W$V/*&I4CNO-*AQC>X"-I)A06:*P
M1&%$/1V)DEE1$,O8-\<R2D Z9"'8IL(SK<BRA1<(6\;!IB<4;4NB!#R@:/#V
M*X=GC\A^Y>E&IZ)OG'@[>![_,"2=Q1*Q$X]#UPR=4)I>%*1F&-N^">:P/8Z"
M<>*Z*^,?GC_=:$M:BS.RQP.,[#+!#X/@N9TRH_L)H3O+-Y!OKA\*$5A@B<O4
M-3U+>F84N"#?9#8.PLA+ A%O?KS1]N2;-4"[_,0)?O^19YYOM!6.HN8;<0[U
MZ:DP0X7N 2HH)ZY^V'&8>C(QW204IA>&EBDD?'32( CLQ!.A9VW"O-Y>+IL_
M"BV.+I\RA;(H.4;H'B&B'K<H$:YK>6B&^D&$LX"2P!1^Y)ACX<<R2[W0];U-
M6+);$R6.,PH];B8Q>..4^XKNWM3\K9R:&S(TCX\0N,_@X77&XSZ#1P%-)GE&
MTL$CZ5%"<_]1!<X'W+JJQS5MPY83;(&RC^B0?$3CV$HL$:>F'#N9Z4F!083
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M69J!- LM+W%BQS7C4$0@F2+;#.U$F&X4^.,DR!PG66DI_LP2O4VE6EG<6F:
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MX\1Q["  /<IR?-/S09..QR(S_2"T[3#PA)3;H=E-<F<Z3WOD^.MTY6%Q9V\
M-1I#M=*/H]QHJ- ]P&*B 3L"=S+-*XBMS$I,.P3M&=0I:88BDZ8=99:$'YS
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M$H'\1_BWV?1_R'7P_;7S)BOD=S/-*TDT\1J@L9A,WZ1Y/2O$]6O\=05SS\:
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M]?SR>??XR?7" XV&G]].LB4P7339-L[,'[_X6 Y8GK56P_ETD<GXEUU2:H=
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M>X"6[2P\X%*(H\#&/6,<Y8%S:88(0*^ZSBAMJ?WSXM"#Q[\-F^5!HSY2HV:
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MLW:!<$UNP[!+VM*(,=*TV+]"1F1-4L@YS[%T-&&JGQ^&J<8CH@"* 8KWD*0
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M[L(B@H^OLL!DQ+D&E=E;V09*#@4E(98 ; N4!     "V!4H"     -L")0$
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M=YJ?]M=6)/]W*9&/KC'14HT8AJQJ?T4=*#D4T(00 K M4!(     V!8H"0
M  !L"Y0$     +8%2@(     VP(E 0    Z$;0^\D\8>I<T_3#*9QWG1H63-
M\P><Q4E3?XK51UM/JI)%G'R*R[%:^??JP]&[H^I]OJ=9S"ZK)OK%K)[7$3+H
MH = #P#; B5W3TD   " /61;H"0   #  ;,M4!(   #@@-D6*#D4 !A<%;W1
MSBE*/#))&\2#34@3[Q$6(6 <K)9<W:ZB3ZR\;&)I4,80-UPA*YQ"TO&D!?.1
M"W?[2-EU..ZOMI[\-FV:D\G;ZPC<MGJ-&0)U\;T57J#D4& 0["!@6Z#D 0/
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M(@H)0K7PE ME-\XP;+MMRMWNT,.#&EJ/%(&A/OV58J#D4/ 0#")@6Z D
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M4MOQZ<*-:W^RC+1MR5A1!J+=ARW%H&R&1]P!LBE$.(%E(8\X!/?O$7E$<.A
MQ_:%N(>F8R'6_2@',C!L2306Z4 \XLDD9 352"<JA)22Z<T3+A%[30*G2+E
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M35.*LQ*E\--FWE1U.[LEAC(!TGK?Q3TN[*4M74Y*H""_.%OD]^.7BSAI(#(
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M.#MOEE4;*QK=* )9RO>2'.U=-WDC+R/OZ[Y(Z9/G_/^HFW]VZN##Q'>E%@5
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MWOB6+)W'V\M&[!VQEF[8Q.'+M@^+<]:;%EI=$Q=7<- $UIW7NW^#F]\RK;%
MRCGNWY6^84SS5:\(9?UI9TWFCE]^F+!0NX1?U[)HM4#7#:M3>KHMWI%HL+'<
MEH)Q/\-CL7HZYNRWCVX?=!Y]N' *TK87<K$5!2<")VW.VH#65F!Z+4O9MN0$
M3/M+G&7E4PI\VH4C;-=MHTOK7&^GTZ5#.&UQU7ZF*71?2XYX[@"TD*6,TR0G
M6:' 4 <K"LQOQHD6A;4VLX(6R2%8X1]-B<R[J?EA55;SHX=5*"+8;-'1+T3J
M06R$#/&/6VNF'-/H**@WH<,E#6^_L2.A-CO1^5KK16^\APOM^N8;9UW]U5E_
MI<C,EY\&C3=Z3MBV)T+WJ+->Q+64VC6O(*T=ZU<%8")C1N[4N\LYWU=<'1#9
ME:<A=S_W,FRPZ:8KSZJQ1GM'PZ8=0QER&N<QOQU2;4N&S65-,V\'VR6 S8N;
M&#07*:VLJUZWGV8ZCYR A)CZ5MM-EPRP0Y^;.=DB9J@?DDQ037@19Z1(LIB4
MS J3)'D!_.DQS,FE0?V'GPL%C.F= 4S'<(1[[X8W-5I;T-UV\X$&@GZXU "&
M(TR<Z6]6#C:[R78&2='>@>.94=<\QQ5S3C]A6,C5>_B" *29J6[=6JB-N0&#
MOJ[#/;A3#L\&Q8S]?CL72W@QI/S9<JY;5N/'"*[& OH2I38G^SS:Y^WDI)YU
M@RB[3,N9UDLX'GW3UJ[.L!67[;&Z 0=T#[C$LEO?L>:LT7";*6L1,N8+B[-)
MVL+9MCZBS=)T?8=*ZSH6NI*J^34^K[2VZP)4+^J^+['?0\=5&;<S-C$?&HMP
MGIL_<2,XC7-!P'AD8+UJ3@JLU#2EX4DI65K(@Y1F.G_S]Q@31<,#CL.[I*^:
MP<8_3]'E!&?\._9^"\K4!LV[7J&1 V#4AV#4\/@1LJF^E=EP"^^M=294,SOV
MRG=#;4K"HT_H?&X*S#L&U691]_I]]1H8#Q.UFOJNU<VK[*55>C:+61+]V%P2
M>=#^WN:F( ;Z0<%O_'4??O_]C>^9W-^X[A]"J\,,,N"'V65N?\,EFG>^_5U;
M&\P-!=Q(-W,\S#'#_99?6\R%%MPX3OQ7TW3 U<PT!3).$& *8PNL_N//\/ZS
M[O[V@54]J&!W1^JOV@D_SR<'#T(@]$,9S>*M_?YIZFH*X%!:V".[]O9R^[:M
M>>XRV>H*.V0V'+K-:6C*-/V&KYM>9^V/*")P]^@I<(T&SH>4US[8;;OQ /A-
M.J_']CA,7X5W0#_SU:'=&V$2X[1)>>V'/F ))^Y6C=TJUZ],^;S,MDWECNA/
MV[6RB1F9]9)$+,MTT93& :+:YG=P@"U<VKJD]5X5NP#@M(8=^_'"'2,A]79*
M6C5*6-2##?F=>E5A)[KV*>@VM'0;G2T7:+1,/_7H8Z.?A5MD;RP>4O >.#O$
MO6VHM_-=UQ)5.W;7,:_VS?UXZ/;]W5&ND767GX<=6%>^I)8@]GCY/5YU;5G_
MKJCBN3)A#,6TK_SA+G9;-LUNA\@WK*VNVF!I;WKO+G_6(&>KU7^1@:YR>5I=
MKN$D;1G/#)-LC:MC7^LF?(7)XHM._5M/@73:\.2F/3Y\H^6TR7T;LOHV8FN:
MPD-,SQGFU.T0=;0M*.N4K#491]UGE'%?5]_X$N-N)LI>&QH@G5^MY6HK/VM;
M2M^6>'?^TK522^=U[3E.,6F9H&72.%#WJ8[O<78X,,?Q7#?1W:NB='=6CL<A
M?&$$!\##O_0M6#CDWQV>[Y(ZJY* U0,];<'CX'D.6UUBAE<&NE2]/9)F]^L<
MX,BXI8#;_-F.F+'/M.F[Y7L@.H]^\IGHR[G=]*V[C$XTRN:O-2/PXX8L\0??
M;X;D!=$V$FK;2:TKKK=3<^*IN?'KS3Y99]0ZB3Q8WD<.FEG7SNQJAUTWG/XN
MN7+F_:*K;OS3@8#=\I* ^"US?:PL&F;K^ Y0N/#W$PDRXX,&C$9:<4\GR!Y=
M1Y>9P1ZR</Z3;7VKW#:<(MMJM*TYLO;V+8/#]K23;E+W9.9VX7GQL$;AW^HU
MFAV""O_M'G6.PUQ\K;0O?ZY<IM+54H%!O +"UV]^_OVW-]_@,K\"O_&IE2ZS
M,EEK/.M8[%4S($:WQAAZ'@!,#4.#KP@"$UEPO\F%:QZ"_73ANNL9AM =U^X[
M>SIKKA,*#<2:JA+?GJJ_HQ6Z.#/-34_L)$OO*8C:<W0=#V1R;W>]:S'0UL (
M?<U>;:J;@EK;U [[UMD[-[PJ4L=] 7C/!K,FZFW;]2?=V\C*V?9<N_:YOMV6
M'08[K:@5-@,4[?8_J<H.\;8NW":)=<,MNX;^&+6816!Q]B2"S\9'&#GG>]>W
MN??B@.HHZS_)>9>M/H2%:RSS>=H!8@5AK_MV>W=-6_;H,K<"$N[)EWZUI7M
MT?CD?[5;:;A@[= =U<:&%;9U3@ZDC3F-EI;O0>XTF.96X%(@ Z[AO"83V=[=
MM]*?%I8;T&G!.8"(AR2VG2<E-K"J,,L+<PJ=P[>J^P!2:!8"OW%=]!K\&3;5
MN*FPP1-(=U>/WV7L];IB=&96WXCR"7OX<YLL/RQTWXZQ_5-WRZQA15?FYG<%
M[_(O.Y]M*PR=8G]N7PKG5-U5"6%C;0XXM8M6S:R//_FGN4HF>1/Y[(G!"BOW
MROK8UOUR$OM922$K\:BS$HN0E1BR$I\K*Y$]+"LQ.7168I8G12D-)RI+2L*S
M+"%2*D7RS-",%U(PE1ZFA1?6XWV47T),^[9R-%>T"% :5P>A)E3563J="8--
MF\"&B;?8,-/HEU_>.Z.@2?*PDT8O< 7U"^"+0SOM=^"G0(#U177EW7-^HF:C
M0?P\=;DAD^B/9@#'>[ ,SUVC=:=3H4V)U_4>^KG)0;FN[.?6I;607PAH BYE
MSE^%73=AS_]<@I*%C8"[./.J+X'/?VF2!+L=]9Z$\ZGPS2[F;EA6HPD!_T U
MP[7.<N"J6_^ -[,PY:5YP@)/W!=P=.Z884NN\^BWZ5UPAP,#1:F!L8S>]WL%
MGO^[FG_[-_?'SBC?8#.K@W$-( <MMF]:+7N]EU?.1U_5/58:.X_^;"!>M<T:
M-H9>>X]E+Q,7CFI7"_2V&+A)I,(K,<,$='7KQQ4N? 5TVR3$-Y_VO[7=/[S?
M9Z.5]7HS34<2]DO5!)UVMW%?K+<'P5VAX=T,SEUU*<7")'<';MMW.'4/A;=J
M.I'_L <,T-O51&!,XW&R4^FY$-PU=VZ"E<$R0[O&Y[[!SPXP#4DT5H*OF^U5
M"F,-$\ $B6Q^,P!AFX#88WEX@$"?OAF,+QYK;2)OB+GNM7>_E7-#^/"7VUCW
M)FMAR>G:[MM6+RX8N0I-6@^3+D0%3#7R71 =*\0F/\X5W0\/(')MVVI5-F'.
M2^1OD^HOETH(6W6,V#W9C3QTX4A,N.Y&'PYRHGLKNC HWNP V/2EZWPU>/.J
MU4TW--!YX>VG)@7)F7KHE+BM9?'M?9.'0P_;+K!P#-CY8"NTI.N=Y]O0;GNO
MU>!2&G^S@SGW*%YZ4K%3"UP#WASC3W? VE-7J[SVIB#63M-U\+-?9->,LI$W
MF(\ZP5L=+2\!QWV)ZMG00^:2QIQO [7)12<5V^<U[8I6FU['S1V\I<GA]Y'H
M9BU/30N,KW?4/-C,Q%6Z+#KX?'+*Q=Q#(XV_\M"I+F8SUPM<65_?V6"3*\_L
M%7-VCO<N"PR/K8%$T_VR%WUN7JO%YW[$UX=7RD;Q&9+AH-_ BIK_N32??)P3
MHS!W]-F^ VG1=S+^RFO&M6#&"!)+*L'N*2A1,<ZOSV3*<ZGS7&<;%DBA"INI
M@M@B30G7MB"J4& KQ;G)2I''JBPVYM=,5P@(TO_[!BUOZS^X7DA-:JNQF/HS
M<,':3G>]D392)SKFA$M58D\!G#$-6[1Q%B="@-64;Y0WW*>1XE.^T72VI21\
MQ#7BBZ9!ON_*#DB_&N_79W_U=A;[;S5<@?;HV<I]B0OO6L5K.2X!R+<T ["M
M?+*NCQ((TXD3T[T<TEVKM1RAM78VM/#GSBW-35Y(78+YSRP%6I0I$:(TA')9
M@L4?RX0?I*'W3[*:_R<&\?Z^XI8AY?TN7$>H10YL40]NH[)B&D_!3ZLH;;6:
MV2[;9+6J'=/<5;MUV2MN="MJ==/&[IPUGG^D3QP&CQ-R9,\2K?QXH;GK=^TO
M:9AQ:\4T<RNZQG:N1Y;7D-;3LQJMQ<T*F6#%2S,(ZFJY:#M2-G.SFYE*S0+]
ML+3K*5ZW[3'?GEX>Q0,-[U\0GA$=(;;^[,\7#VXXD>7KY=2G/%KSS9WC61K%
M'J=S](RUC6GD%PT5]$<F^VG#NW R8-  @]BX,6BF,'D,[5%L.=ZBSUZC?NH*
M=B/GVS'IEM6&>'C70OCP]JE=);CK+^9V=.9R?EP&4I_O#5\-K]%RZJ8GS>;S
MF9KY FFP(7L7-8S7!;_=^RT5YKUA@LSDIG%.32:#0'%7_+AMYX$2AI20C)L2
MEM,>+C2XU'HE.]G>"?+G5G5!9V4VU@E);0YJ*Q.4R#3G1.8%%5HKSNFFV7G?
M,L]?9M-/'P&]PP";O;!ZAC%PY 8K>(T0Q7?'3^#O2?<.J\D1R'%AX;DUUEXZ
M:F@B-:Z3ZM6\=0_Z_)4MTU<'1J)32?N#4^CX0RZK&1IDW+-2SM9#E6TSW(%;
MKU>G[J)Y5>/NW"Q"V?_8.POHLQRT5$?C9L5&NU15E\;D#".7Z3;=G!-XFVG4
M3$[L]Q!P)4RR[G67:4*FNS!ZF"R[F; ^J"68KH^5<6T)G):!E3>KR,\P9+%:
M_YX-3=QQ;-UYZP?'LVPC0PCG)DZV 6OOFOW:SZS9 DO\!2LN< UL%5S-_1Q:
M5Q7V[%+-FE28DA8DHU(3;G5)1!$GA'%:Q$Q;5O"#-)EZ/W.Y[/X4_JCJO]Z[
M(!W^*XBT_EC6/IP<Y_: BA!28V)\K>-F,)IPOO1,VUD 71M.P/]N5$)/%/HT
MV;6W;6*WF,"ZO<$!\K&SC2&*9^L3%)O!F/U19CTQ/!QK>NL QL?-5]S]T/X$
MR%X#F?[XJ+T&JZY&DO<*$=QPRRWS\VZ=FK=KJ]N@O0UDLAT(ZX2%"['=.KFR
M-P]>^0JN=L N;!.'^+;(X%*Q72!MULS(.[Z@50EF@HF5)+E5C'">*2)9(D@L
MN+8EHY2K8IW/&B;2PN0Y*4QF"*>Y(2JGE)@XC17C)1.L7+,>ZOJ/+L*#O8'_
MG#J4M.;[!I_WGYZU7Z1G/ QI,:A*!<1HFL>ZWK3.T[!L@=%1]W-+6\-,KI0R
M&-G#!M!<$$7Q(V=IPA6/<[71</Q!K3BLBPG_T99QAU#)G<TW/,2 KW>E3V-"
M[BV6I&>?=7]<L]-O405_)#]<.R3D!*3Z0BXJ S;#6U : ?4,MZ T,I$ 8\IB
M(K GGY9%*@6U.C/96-+T,8EKT@UB&?XUAOV!"/:8UPWC6((^T<Q \IT0FJ+(
M59\,GVWJICCYON.^^=)Z-Q)84B^;K!=LBC2IIEW57_<!["20T]@0R9FF8,RU
MG8W:@D&GP,$2:+B".)9-8Z-N#*ZI:BN;#3NQO01=91%-[5H/BDZI>']1V3+Z
MK3/A?H#GN&CVWR6 +/KZS?O??OC[FV_P#1"YGQB9F3%%GJ/=0V-)N#$9*=(2
MY*T&BX@E\!>S8T%F#[D?NZ9:O[GN5PYD/V*UJ--Y<?:YG59NZKLT38+TPLK+
M\1)!@R=P[(#-F'X]J.GJ$*>O3:XJ5+W/0W[ZA/5RB[:=AJ.GQ]#2NTD7HNLT
MV\;+ %H5/N<#NAC6J*[M8XA#@AH]Y&H^PU1P?#.7B-YF?3]DK&>H(#NE"C(6
MAPJR4$'V7!5DR<,JR'COT1L&#15Y8@15H/_9DG#X-Y%@SA+-K5(T+9/R<;U/
M6X/F]SFJN(L;;,NP>#<U&!.X"N&QVY&R!5HW<7ZLO9D'&[7M1OV,U84/[_L^
MS:#1U/5@+NZM[3ZQZ..6G]=;6:U:C Q[536U2ZON<UV#"]"NR^6DZ[7@>C,X
MG>$\^H )Z:N.63Z)NU&FO8[3E$4T51YM>H_K"K>*"[BB,(WM1 ?CY)OU>S\V
M!1IG^(;P%CY44DJ-/V(JB#,$@#2DAJ><M2Y$'WLRSC9H]?Z9JK&SBG9M 3 L
MU;5[Q6;838S&W=CI59A!/UM>^;J>[OP&R2([:UM:=<@-673!402,#Z[@#"#G
M6RS=Y&@W*F^.K;:FD7&=)&:1]E/A>Z&TMC-4T^35==[JMSUP]0*K,[SSJ5\W
M6J#3 %VSK-JZ$ Y>YV-4+OSC8;EQ=2TG]IL3S$39,YS1]LM;=>%RX$&4N,$D
MRXG4KM3!Y7'Z)EJNQ?@PJH@.;.#H3G\%*4E IP9UOZGYZGB ,W6UW;;H>?3G
ME9MXC#UG?%C0'XUW)K<MDYO=H6H\<Y9SV;G7NTRC?;E/PUXN9]>V-UVK2P!P
ME[NB'1P/@9S'A3G1;,-BMJHC:6=VN._<(BM?S[GO#&N:WER>F2#C\(N[JB/K
MVSD[4FP&,@-SF<.>\$DN>=V_7K]?3*_@KF<!M5W?L=MHVQ=MK4*E[9G_H:U5
MRIH,]96U-FQJLAEO6!W[*L:+;],VIIZ@K\$/PB:SDF"XW>]Q0&(']=H6J4X-
MU3EH*$H0GAE)1%PD1)<RE8;+1/.#3)_8J>3L4F_6];E]-OH/^B1:D;M\I$S(
M95JX[&J7,-",6L6A,G,74KS:H7ZX&-==1+^]VNIL>[E5/[D;;(/FOW_W-;5#
MF\\9.,ZH:PPLA!2^*O!ZO)R Z3Y;-I?XMQ;Q>?Q5>SD >R*O:ONV!I: R99#
M6\G=]J:W"=A%9W9BWI!71]ZVRPROA8M-9V2Y9Z?Q><&_ZMN%K9WC#,-O;[^;
MGF</OY>?9X^X^S%/?OB=[%R\Q&-/]V7__=O%? <V-ZX, ?Q$2?T7:JI30QIF
M5+K_MC,CC'QZ;\I;[U/!+[8PN1TO,'2QQ!0=*<U7WGL!7[CL+C *F@7AT@U/
M7.^VQLWAU]K.QL4A?2U[NU,>ZB-9F ,"S[]&@-_AX=>Y^%K?\!66Y4\J$[7"
M_ 4@W#AZ#^5\V>L(_O3V_B^@*X_L'#P?BY-7A>MPV'C!_WG#W@2\?TJ\W]!O
M1X;]8SN-4^3T@<.\;IQ^7@[#1X;]8SN-I\;^N^TIYZ#9-*@T\(A2[["=[F,K
M;7W#0QI06_C+DT>O'TA3^W5[6,)%+H#A_:5?G%OXX73TH .XIQ$V@C-X85E]
M@E ><JSM/G55L)S&*B=)(3GAEA9$%CDE15;F-H//(MGPJ8M29&G&*"D3ESU-
M8R(4SXF1<6)5FB="\[U]ZMZ40TMN,^O=+.?8N>\IB37MTAHW$KT>'I[?Z\FN
M)V' U^/A"M/9B<)XB-;[ _=_'0WVKCCA4\+6/?U)58OM-4TVE3J3S!)J,TVX
MR!51+!5$\D1QE7/@XQO)7P?EX?\QG]5;*IIJ.#JX/>G7-I%DP.:QL(F8V8(T
M5[SY6R*RG>5-@7ZWTF]0DH+0.3H8!Z%SW$(G3KEBI4B(R0U.,\_1<"@*PE5*
MJ4DR(6B^+G2X%@5/8D62W(#0*6*X)V.:%)(66:IB6:@\")WCH-\Q^+C:I('@
MXWIN']<O4JTRM(Z&(P=]XE2@O(]KBQ8ES<"2(2)5BG *%I&R7)$X*7-F.0@K
MR39:/4BF65Q*8O-4$@XRB0A>"L) 5("<TSJ.DV-Q;>7!M34:?!TY5PA:RK$Q
MV=,V+EBI:)F!<1%KX, \1F<632PI1*Z!AR=I5FRTLS\HZSZD<4'/&&/!O B$
M&Z1-0-KC1-K3EC9)G.82Y V19<()SQDC*F8%X2(V,4MYP=.-GG T3U)C64ZD
MD"4:%P9+[RG)\D1D@F5:9]F+2!O!>9 UQ^?*"NE:+^;*PD+6BQEV%?(%N8/9
M/*-GS4&?.!4H[Y6NE28RIU(1*H4!PRC31*2&D51EI58)E0G=,(RXTC13BA(K
M,5)CE"%2RXPH(5@N=$+S5?O2X-,*/JT3X0J/5E<>F(4^@E,X6C;\>)"?MJ6B
M9<KB)(T)Y:G"SIA@LR1)1AA/<A.G:1D7&YE>!V7_A[146#Y:KU@@_3&1_NT5
M;R, >I!Z8SB%4T3](/5 ZG$5IQDO&9$YSL8!0X<HRBVQB:1I26/&Y(;4PXZ:
M;BP<-64.DI))(IDNX*U%*6F9*A6_C'\N2+UQDWY(1CLZ#]['&38TW-X];#1,
M?JPG,2+=Y42@/,I6%"<(YY%C<PB7'1O2GK86G>64Q045).<X5<5D&O3I6)$R
M%F5LA*1<INM:-+-I4J:@:A<)CPE/)2-*P1*9E(D0J2D4W;][ZF%SJH2(QZI'
M!\(-TB9(FX"TKUG:Q"S.;288,;S &5[:$!$GEEC&C4R*5!7)1J Z+E1A,U40
M6Z0IW&,+H@HE21KG)BL%"*NR>"%ID\:C]=J\ L(-655'YY/YQ=;UVYWMVH^&
M20?-XE2@'+PR 9M#D.0HT3K$1]N#^?K)TQRW:_-YDA>QBZ;R0A*>93D1%/Y0
M6NA2F((627D(W]&[E;[0GQ@'_YY8_ <H^.]ZDYUV*O\'TOMS3L>J]1\O&WIH
MXY]OCH$?A52E0 -!% =1_'2BV&AK;5QHDG!E".=:D:(P!:&%2F-9,*;IABA^
MB&-M9**8YZ,M:SQ>-O04HCCD3QV=K^ZV_*DSG*X[&O$SUN,8D59UVI&KUP7H
M@,Z'EL[LG*%X-K,E3GH]5?D\GAZYAX#^J5@,.TKZ>&IBJTIB%&6$)PH;B8"6
M'M,RE3)67*CX2=.R?K6'TM'I&4V*X]#2CXL/'*V NQ7HP5<6T#^(P2 &O5M+
MB2R1MB0:>\KSO#1$QIH1R^+,%%;2)--/FB]V2#$8,Q'$X*C%X)J7"CY*@,"6
MKC*FNM[UK?L#?L''5M.E[&%SD>K44)V3/%>"\,Q((N(B >26J31<)IHG_Z!O
M_,K]^WMK[P#N;?!\L[UID#"IL3AQ(56)(5RPD@@#VJ,"JM*6ZR(3F[F8NI"Q
MM9*PS(**J9*$B$0F\$)&YH:7FK,-%1-SOJQU_;3JWV>32M]\A 6_G\ST7V\B
M"[1T!1<OYDN['^[<^;I/Y#/;&)RZ'_#ODQN'$'I,_.#0._K?_U,PRK[[>8H9
M>\ AY%3;Z'.UN(C>?7@??9Q= 2X)SLZB9]JT6_EMM8##U/<&['-M<K\PT1N$
M(,#NS3=GT>+"1N]GE["M&Q H(,WA+EBW*B/8J)S/Y?23ZSX7574TFSN*E-6T
MCF0TP3>+)/P")W.%G.(\>N<N0/FRZWI8&!_970;_N+8WM?O2,?=H,?._SB;N
MRR7<-'.[J0SLHRHK:R()5+U D0?K@NRL9@:O60!(8#>1_:(O<-_N EBKACOG
MTN_P8^]]]036P05KO[D:WP:?Z;>J9Y?PYMJ_OI$+>%EXIRNWU/03OEU931U:
MMG=/332WB*SXONYMR*PD^ 9^PWA!"XA))54UJ18W$;!H?*B2$[=8?6';=YM,
MVJ4=XB,,0!NH9/-UA,>%+_YI;F%[<U@&+J$LN@3X7=3GT2_;;VYOZZ[$=YD
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M$OT UNIDAAZ0^ME>;*_7@">!TE+.]!(5OL9D=68LJN]3#?I78[!.4=EW+[3
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MJQL9\;__IV T_ZX1'VYLN'?V>*?.-D_/4,:XI[H!YJLQZ\:ZJ 8J$XX 8!6
ME6GGE2/\\4GH;UH 7;CI[7-KW!WH(@8". )1HU4BTSPN"%>Z!+71@'F1LI@4
M)6B2:2JTV4S,L'&A4RT+HED!JF9B)%$BY428V%!C8I[;9&-8= /6'SQ4#\6
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MP6U"*0:*.'<:Z6@\,D*QY C3,H@]C66W]>(/6R_[([SK[QG(_I%#W;L\D.F
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M>/F-@5[;_=S_4?K!7]_2=VD2OZ(P7L22S7,'ZM7E]%T8%_.)O7J;OVTPXD@
M1^7[UQBF^N"_5\5RG*[6CU*>BN(TO)O/BG%Y[46<P")\CML-H#<<_?6!/$GH
MHQJP[^OSNAT:P+MMNO%3->:AEY%0L7<-+Q8W ASCZ60\A6=:VD7=97SW"UB!
MZN.Y_10K+(G*_99O[>2+O2KJMMO;S+&KQ?+:7K-+8]D/N[K/$[K'+&QK)-)/
M;%'DY833U^W0\[_P=UR\N2FP8@_!WY2C&O:/74C.6BJ\14[1!*95)&0\,8C:
M1+TE3E.B#S%VX8_ES/]U,9O <A>YVW1V<Y?QQW'A)[,\%^ZVH0N#6CO'\'[Y
MT.?]+W*460T'\S0:/;JKI[M/<3V<H]1H\(.=C[.K4M)]F[=:3)=#"];[(@<_
M&R,?!G8:&I_RX=[Q%<##9<OZ?$K>*V#SQ@&?X5@"0+:,^0;CJ9\MYK-%-0>C
MGI 1X')V65X3M.O%;%%.H/#UJA1Y56Z,S!A\L<5@7RGV(VCS O@=*T:4X2!V
M(G#$4Q9^[QS\L+EZ&TLJFF/KC#-1.H.B$0)Q'PURQEDDL HRP4DNF9L*HV;@
M/P&O%^\W%-P!\,6%A3791NZ__/KS/=!]_TLQ'K +N?;<&XTX, FR>4<9?"82
M"4XG$@_AE!SII03!0UCP_/\]?LDMCDH;)'10O6VF;#$&>#C]E(6B_4( 2^Y<
MM!K%8+(%C("<C,# T$+C*+"SO#'1^$E",+N\G$U+'?Y'2:FC2X+P"H<0!%*.
M$\0-4\AH3I'AEH4DI :+>Q!)..*;"=QQ<0 9\"5]:D.1K4_[A4++D#SC'F'B
M%; .,+C)C74]T\2 8?# \X<0BM\6,<7%(H:7E MXDZ2T]4C*$!%7$BP$\QJ
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M=C*YJA728#6?5?LN8R;?(-;TJYS<BH+K3$%%PY(7R\O!?>#X>O=F6LPNR^L
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MY^URS(1&T\*G;&C]V8X7917F^Z*(R^+]-/S]>N[6OY4[I7,GFM]S-BT[CG#
MK[/I8OWG][88%_G\LB#P8_07T_'_K&+Q,7/\0X<//.1=R^$#;5B\/W/WEG$=
M7*AP6M6S(-\6P-G,EQU4$]#UNDOJ#FKL8G.#2,&=S0U;I#8!'!>B\V0I\&I)
M,B0FD@)Y5O_JTNIM>/':.3E0X(;*4<MSM)OH7^Z"T37N8+"B,<@ ?BQ7B#,:
MD9/)HA!D,B8([M-1N..I>;*:A_!C*FK)R+2[J+;T7]>9L-J/S;TO<J.IRU(G
MK8HR@#SX?F+]7^@/#V G1^'F]8 -<"[AZ\M9B),*(&2ME8!PLR]5H7BQNJSZ
MN+S=5#?>G/YU7?2X-=CH$:];<5AM'^QVF=,#;<1F0%DYG^S&T*9R0E$YE:F>
MD)37)1,6ORL/1Q-[-5O5AU0T)AB/\#?KXWUFHWD1WQ9Q;A= U-UI1^5Y;_;.
M'?T\+L;5L+RWZXO<-E"TNK&2(VG$-]MCG=9CBLJY3G^[ZV0R4ORIIS[U/#,2
M\K@W[8>Z=FJH:YF&&931QI:,$6TKV9])Z,/-0'_VI,RV4KCK W!?]W!;0;&A
MU"D$@#$A;C$#U)@X8 '/'%7"$MG8H\RQ2BDW%4\^I^TD5<@RAY%W.''/O8C!
MWG2&U[@2G-PJ)_+ANM%G[0OG/.<OT_EJ>7O0[5&PDH*E;N?0V[:*\L'TXA/A
M!/@R./D>3KPTG%AG;7I$T2.*%E"X1Q1=1A2>"::C(H@$9A#W*6\>L %)8;2E
M-,$'C?!ZDBEY8@7RR@"B$  K3+GU.U">8IZJHU(K$,4=93N]*+<04?0!BM,@
MBM_'Q5\H+6+.(>>6,L5RD&-Z'5'0/;3H]='AB-DCBF<BBL"I#4DPY+W#B"M!
MD,&,H:1\"LY&'TBCM-,9PKBV$3DM\P@TF9 U>2(:5EAPBF/$C38>)T 4?'1'
M2_A>@@_H''S3!RM:LF;/#E;D^N'<,BLN+@??CJ?EJ(+BNXZHZAY;G*MFZK'%
MH;#%_KJ]H&G@(4@DN0VY'0M&AH))UTYA2RQW\3##IN^" 1]!YS2[=(75(NN@
M8VJ]"BC<6QK2"V4?@.A1PC9*^#R;V&59'=01?=L#A%X7]0"A-<$'+()6D3@D
M U&(1R:0RX"",:<--2;RT P^>)&T"PQABDT>M9W'> :,O&642\F#5ZP%P8=<
M@,EN[X34RW ??NB!Q:W 8CVU;7 UCI/0$5W=@XMS54P]N.@@N%!)<\UB1$%'
MEYN-)V1Q<"A1R:C17'#2:(X??")!R=R+UN01133DT6LY.<*<<%8$PMI0*X'[
MS$:[H 7\D3?B5.&C[6U \ G8LI?HI=ZF23COV[3!K&N[$I-QD@8B4&(V3ZEB
MN0D3UT@2$67 CD;3Z'7XE,[K+]KKD/..#+D:=H%%A+(:2\T0E8$C3E5$&H,/
MG)16L-H6\]1HSF]L,$(:.)*"R\R!DY A,;-((LIX+X(][;Q%BCNRV;DK7;NT
M3=8(K9%7/'?@D@KIH SRVDH9A%2!-@"0=5((KPW".M <72' 61[XQ0>E,8D^
MYHC,";F$\ XU,[SNLG!C8M"F9>_]S0FKAKV;!@UU2Y?KWNB[?='OZ[1RLT=8
MYF;X:%+V)]GN_N!RAXRJT4OY!/#$>2]QV9O%+V(85^W],]S+2Y ;2=AQ0/ ^
MWLYSCY2ZY<VBZI94K-Q_EXW"9H,,AS>H>#1X7[Y%8Q+-_JXN[1*PA",W"GP$
MKG+C$B$Y,DP'I"Q8:H<3 <>CL;\K&N($LR"%>7]7;D_K,/S0C@>7C(TJ-<*7
M+SLPH#$;*5.FW2)WLU5)YKSVLP\%8\UXGC<A4P(>P@R5#6<CJ&N;I*!^S_0V
M0843&E1SI+;:'NCR;Q$$40N9QYDVK/BIYTUHJ88,M[TGYW,:R%[84,W=VO1-
M' U^F0[^GP4O<%&>)4$=UJ:@$^WBE @$X^"13IPAGI1#Q@"KTJ"8!N 0L&XX
M(<%H+3.N5#S/3W%PCO.6(Q*"PHHPQA+9;:5=\^":X]9;Y<+K8+G'\UEIB:][
M<WY;Q#CX=0:'$/[=SNBV1A5+&80H?_Y_@\%VDY-_@,D.\>M;^BY-XE<4QHNJ
M]V%N][&ZG+X+XV(^L5=O\[>-@,](C*?E^]7IE.J#>JK;^E7+4U&<AG?S65&"
MA;=KP+'=/:-N55(VSWA8O(0^?6QP'?G<[J^"=WNBX+;$4@B5.RN[7L.+32ZK
M?N[Q=#*>PC,M[:)NZ;+[!:Q ]?'<?HI56@N5'03?VLD7>U74/4NVF6,W6IC7
M]II=&LM^V-5]7O3O,0O[<DNY)SFP+9%E \2\G'#ZNI=,_A?^CHLW-P56["'X
MFX/W+TK.6BJ\14Y1P"A")&0\,8C:1+TE3E.BRQYWKRO ^6$Z^."7L^RP$'G_
ML.]I-8OS2P9:N275]2#.6:7\JTF1Y7"_SDV*)"1@3( [/ L2<6(ITC;/39#:
MT^"TP<U)?A(3)[WCR"MA %Z$B'2.<2IJ@]32>>Z;XX9>9E(D$4,)JXGOR+"T
M@0/OFMA7#4?KT$PT<%VBM@ O';<ZS]M+R$KJX8EB,EKI*$AC8I5T21!-'/))
M<_"$G$".N8"BH291ZSUCM!43J_1=R;I6L-)6!_E);FB]HZP  /H\%[WRJK?&
M<PS+KK6#^<I-QOYZ0D?9;MY/9AF@SJ[5),65FJS;=5]_G(%N=8GUC/'<N!N\
MIW5H:5>Q?LJ0.5;=AS?/&1>;T<AW71B>EF&4.R?7S0.WYU.NYE6[[^V05OLE
MATLJL5 \C] &/\U$L,^&@BNK: !?C#)0Q8U,@ [8"06^G<UQX6 $LAX,.P:%
MC2D'+RTGQD\SIG?(.!LJT7*!>= T[FZI8.8!TEGB<R()+#()&EF:&TVHR'C(
M>ADW5+#SU.,\Q9+1Y,#A=P89(@5*2;DD S<LZEX%'U$%U\JT5FI_7JO#P8=2
MP;WY;CB E_ 754?53>  %'=:32:/G"IXIVH=3_UD%2H#$,NK7\]-JN7DUL?L
MZ%#"X**-D8(SI CX1CAFD8D841(%?$*C5PV1B8I@#J &,:\5B PFR 8<$77>
M"I8X-LU>YR^<7V-]&O; 0V2T$@P')'@>)FTY@%OJ- * FXQ(@''%L]CD!%,)
M">.CE@\T/]>QA%BJ$+QCL!@N3[]P!&F9.$I",!:Q\40VDD9/4CK''TMH1BT/
MT&]E\K=<C5M&%%[W*[\QK' [WG?@P.<9A<@&Q281>>V3[03*ZO!8J"-F^Q)V
MV_Y<^T59)*$2%PHQKG/^5S'D&/,(6Z,U\R"S!C<@=[2>4<&S*)NJY$!+1L'?
M,TKB2))VI_+=R) */,2DY>/?'^:[E1&T-2MUR8_CVB<MC4-4&)RK! RR26KD
M*( -3P(7MM%S6#GBG(@$F61]]N/ IB@F$?&>4A*P5[Q1DW(2/TZ-C&GYJ*];
MAK^O@V5U2G>^2>D^)5S6F ]?#^2:?8JE*=I,P;@[&%;/\+K5+:O4]>Z]?QY/
M 0;DTS_":Q75 A2/'E!_]_MTU!]D$@3)@"L8L6:Y-L<C8T&]TQ1((#XES1L]
M-+BW4A&7"RP]P+F49Q-9*Q#(*7&)>A9)8\/)R_J#_9#Z U=]<1J"E;1.?8&"
M19KGG%F0PEJXE5"-08R/X9(3N(.F,[7]9^8,.G#ZM'-@W94$YDA<(XL5L)9+
MEO'H/&WN WB2QCF^,XA'JA,\E&'@M?6VG_+/%..#/,'21MY?:'B/<=R9K[DI
MLKYC?KV=WAAAWQ$HJV0N&50 92/3X!\E#U"61&2DI40%3R1I]J12TDD!VE6
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M7"'6XJ?_68V75Q]SC/(C7/][T"Q_O1E$4,MS.'>Y6,7#[Q-L,R;]N 77,Q>
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MW">_0.GE $'@/=?8<=<ZKRMW1H.'HU0XT<=%N?-IU\7:5 W!0Z+K+7VET7D
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MGIN^R(6HAU8@ZX_NQ%(\![KC;"(?2!F'7'?D6.L/'(*8N>[( W-@JD")C34
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MK:76FQ6Q3N>_14)M6,:P$%?&+Z+?8OW*FX\[]H$=OULRU7CZ.74(27^$V!P
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MA?U!#M;=0HEX)%3&HX-(]6'[CN0=SB?>X7PWNSB#][R9+3[FW<ULH/2!PME
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M-4:<<(Z,+BVBRC,OJ;7EPQJR+Q7Y>WOFW6+LWX6M>IBG$_=+K4T]3NOT(7+
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MDSO^XJ?;)L>5VFK_WM=V[@D15;8ULM!FE,D,.RR&/6Z4L<0P;RU'Q$H/B*'
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MZI_;I?XISDS'=8E=;'IB$E/,\<J-N.X?](=Y1NNN3O98[N"QQ!TPFW@P/6(
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M'-;?!([*X ,!#40<5]=/4JPB!Q.W#E:SF>YB[J^[_;</T]_\+*[9S]/9NQC
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M=L'2Z(]:W9P-)(PIM="!:(PPCLFGU@<DN30H"*<=EIR0L%4XS&INK6 &,4K
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MO"FIWY55V!3!@01+0]]U9%$5V^$D/5EHL=#T,R9<TE:IY;M1NE&-Y>X2=ZK
MNE:\ED)E7B-3GCDB:/06JV:GI1(0E;UNC,FT)R&)A10ALF9E$8IT-;ZI[&6I
M%)=5SAHY6U91E(7(FPZ7JE/ 2E&0 0A>D%I"=O-CCDAEJ[[(86&62.ES37(U
M[=BU-U2=E]A"U;0*G5 P-Q4>X[$=,\L6CNN$F5Q??R9XK<+[;8G=V_7^+K>4
M/WODZ2Y^P^ H XO'*6D<4CRAPUPSC5ADTD<S3-(TC",G=C;T4"P<*Y*A3#\)
M4MGWD03#%!8C_6,)/XB%G[B/+ [>4-21"NLU[<A6-G$LMU&T3;]6P_,_:5^@
MEL;-S!^Y1"Y*#@UC30P\*S;E1O+,(C/>%8[-5,9DQD,[<+B3)O9&1O?=97$;
M2[XCB\L>"FV83ZX@N)=Y%@.4HS#V:.@#:1@%M%P%0<9"WR9CR71]/[#2U+,V
M\BX\-TE])S59[+B93,\-6!BG&0OBP'$"R^&N%^Z\TAWSK\M_U%VI]01IJ<-Z
M@C0RIN-919;7][96FJ$(X%Y1M3X'C$(F&KSWU^NC!48;[FG[PAK)C$;[0I;Y
M7@3KU:[#9277YG-O'VHUBYMC5:.@WK;"T>:>PM&*0"U$9[2])]!HT>2H)4]/
MC"NX\39\K1J"]6GR)I2]0HPWI/D*/=ZMOY4L:$&OUB0BK)(7H\6%)2_>IS+:
MBB]</6S':XSZB!6+ )=1T5NJ'D[2>.@]5],LL'FH8V4!.R&560.KE7"N$^*U
MWK]/\V<M;2NJ&YW_M)>(PB6])-IV1,]&=#&ZFFH])7<WR:U/BER:][J7+BJA
MJ-&F^UT2N*FL8- 5 5K8@%V#/+JJO*R<.E7WE(NCE#1U#>76*9RFYV)7T$5F
ME*NI1M\]S2^?&6DANOW=,EECT=)K,>V6C)+J+B49I5N"/5%PJ(*8G0BS>,XZ
M:8YY)7L[K@[)XK'2G.2NH;U;5='TJFU2CA8V<M^3O[4\J'93LO>A:$K.-,^[
M;>?R)FNFD-P8C5%O8JM"A2M;O1^P+)/P/>&$2<A2TPV8Z]L>BRU!AK0?^V;B
MQ:$79?<.+B%=93]5F5:G\D;.RK&N Q\GRT*S5M K-+M,"%$-^51GYS;I\51F
M??2+4URK\C=KO]SV&EU&1[?'C)QZL=*M8S@Q;"?+8LOS4F;%-OG>61HR;KDI
M2YT@--/ LDUSHTE"DJ9)YLOP8TA>NFLEG$5V;#-+.O>6DYE9MK5LY-=B20[T
MX]B?Y'I:[<IQ'TR^KS)1EUO$5ED0E?W;X$)7/%:%\'I6=I;57/#2:'H2;2]&
MO<QO[AI%#F#Z)8X($M\+6>A;-)5\WV5A[&>,FTF<6HDP([&1;^][)@]DS7AN
MR7Q[WT]8Z#F<)6G@<F'Z:>SS>]:EON/$LX<Q\1:9]0,0D#@.HI"L/68'L8R-
MIK)+0)8P+CQ2PE&<<-/9A8"T*KHB'9VH;0'O)JU:WBXZQZ:LK]AY<=JV2;LZ
M^_/$N)D2<Z]08D,25EK[LX"[I,B:<BY1Q.+8\UD0^G&81K$3.1L^2R(<S[*]
MB*693/D)')_%9A8P+TY#3\A=[7QCZ_IC:+,KM@-F5IS%B<^$;;O,=6A.QID9
M,X(Q,%V;IF2V42SW+F^XM^D8;)F.AST_!V):/7CUV2^U4-MSORX3D:N1:DZI
MTX"W56BO?MA%[=#VD&7VO4P+F1@T><9SF;EZ)F24NHE1-1-):NE)07^262XF
MQ4K9S-._LV:_6R\[6E(?TH@ON:IK4Z8Y3U2R?-X4ONPU02O+\WE]?E'0V7)W
MZF9F^]</']XY_3N>SV4D7&:);YQP8I"C_#!1)]<5//1,FZ62@'63.&(1-TV6
MQJ$?N;;I\V!CDQ1W35=8<H^\SZ4[Z$FJ+N-RG[2=!GY@"L];UV^_SLBM(6W6
M:[#[1M56SR\%N8;B8];[Q5K56K+(.KN@1SB7UY2[@)A<5YDLAZN%C/YE-IX;
MEM\TC1U :&K5\N!)NRU4?WO#=#SREBS!$I_3RLH%.4Z>*YB?B,AW/6%SL=E"
MR_23S/4L*>&A7(T=%CF1R8* FY%M67YB;92/VR*MGT0I$_M)BWS,_E[4] +O
MU%ZEJJ[:%3M=69.GLU(L%F5FW[*$CN84\B\=W=$O"]=4T*$?.EW=ZXRA^"X2
M,14"46J9-)^H&]EK #:FO?U1;T^__&J<?GEEA"8Y^X_TZNK*+W*9 9W< HQ.
M6.2$BMM@NE8-KC=V@Z]O!&^31MK&%VK]&EKV2)*1"C S9EJ>3=Z('[(HM&75
M#BOTS2PE?;&QC(6Q"&-.KK49!@YS73H[SA*;^6YF67;F"'^S4%LWUKVA?M6O
M]-1%. G<-X1Q/5\HB:9VFTP;WU9GZSX]8NVA],]I8^T+8ER6X#HG\U:455]M
M7%7KHR,XM[;A(6-0$?C#:4%K1Y83Q61J<2&XM+QL63$P9;:9<(?;EFF)C4!\
MY-NNZ<E"'8Y#WFAFD=$E+)?9GD_^ILCBE#M[%]EKG4Y_((U ;]SPJ:V8T12M
M62T6XVYV@RIF)3FK:X>=&*_+$^.--,Q/T[$H5TRT_U)N!]F1QBNZ8V;\)E)5
M>^9CEI%[VW '_R-X*B_6A0M&S2.2 #&ZH]I2U)MCS9[=+3.17(UL*!W0XC!,
M@\STF1V'"4T)F@BQ:]-LB&+?MCS?Y>$F8QX$J<A<SI(HB65=5UHH?),ST[&R
MR(D3,PS-1^^ -O )T=8G'RD15M(KR]J(7/5"FT[+XD<N:RV0CS0 H;+-S#-C
M8;+,C4UR,4C%ACY9!;:=F$EF.V'JI^M"9;NR2[,7,RM-294[9%-$;AJSU$WH
M7S=.,G.ULN%"@#ZW.!U99>"3A2*22HH4VUF_YL.BVT0_.\!3WK7=[+D7*C*C
MVJOE58V(7B\+]+,X4P5Y6@>MUV-'-N^@ER !FN1\9'RA%WB=B[-")P%9B_:M
ME -9*7>Q+,*PT65(RDU;8\1I>E9=62VD*7SYMU=?7F_F>C0QY35(U:'T++VN
M+5T9F;;OS;;LUM5>+AOE%M:"A4VFFNPV0M; ;,S+C6C@LHO0ZJ.W]ZG6VK8L
M.]STN_1F=.NZB6?*XE[O_R&#5\M>*N^VQ]>WW7:SCXI4_(M&*O?NG)+76QNF
M+!K7K/<[6<K&[3J?W+#?R<_@;_WJ102D\:^O;4ZLVGJHG8G#<+=]CT<BE)55
M7>F,>&G*HB#U6.;[PHQ<-W$V<Q5=*TS)3DO(P>$^^3N^P^(D-&EAS63K-4_N
M]=]-B^);;$$;P(Y8.4%5@B]?J<?;REJU,O>Z[:^+Z,WU$Z"W?XAD;S!E6LGD
MYVF618RG0<3<-/$8MTFD7)YXCBM,DJD-"8P#QY:E?.6>HI2D5FX[<V3RK)W%
M4<S#@.1Q10)[)C]YP;O8/'23.K^:5TYO3;A681??F9289;'(C;U"W6%7_+PH
M*KD4VN76(J5JB\EX?FVW^67^1#Q?J-\VO[N=':/6%6^:*76-Y[<N\&T?L8V\
MLZO:TV]?%:5M6]^D-WVG_@>B_<TT=2)R@YC@,E,]\P2CV9.P,(M--R$WR>8;
MVX\SE_PGW[68968N<\W8DMO[R+>*:5;&;F*'<@=[;^[]7.G?;^.Q_EI_L\#!
M<@]#O;Z-8ZLMPFNU=:65.]G@@+!XL%J;J><$H2U"%M@6J=8TLUG(Y9Y,,S!=
M/T[M,-F(O]N>R7G$!4LM4QH1-HE18L7,MA+7\RPKB&+W #<O^$/8O+!::W-S
MW\(6K;E1(ZY?)0I5X@9=)<Y#E3A4B7NL*G'VW:K$.<=5)>[^(;+9&6E)P[\F
M1-;NF-IWC.RZ[+A%/R;+W;J-; VE]DU;3YH4EKSS)DSJ]>3[+#9^;3LOGZ@(
MF@QRE:)N=YIOQ:W9B_;DM'>5S]U5MI[PI.T9?O,SFF)730QNE4)L]B#^3#ZD
M(_>0(S6B4VDI3WH1LD5@<9&-MFA?+1J';?' XWE/I-+^3JI;/K2\G0IWVLMP
M9_<\-&DO\V)6C1<%%0_->_/=*,A,D3#N^X*YONS:E:8>LX0=6K$=),+9R#MP
MR*?+;)ZPV.1DU&>1W#08^W(K8)+(7% _NJ*6V'''[C9:SJS.U5O/[2,/^F5T
M-<NW/.;8(0F?[[AR&UW"?$>DLM1=DL0;-8*XQUT19RD+/+GA+HL3.L?DS'-L
ME[N!ESG<VGO0SQY(W[G1443SML^]MF;[+:;KX48 1>C$OBPYX24R IA:,>-!
M%K,DMH4996'J)='Z1 P"V5E-ME".(LY<-W99[(<A35Y3<"'"R$\21 #O%@&\
MQ1+RN''!, OE;K>4I4DJ.^/Y-.A!ZK,P\(*8W([$\S=HFEL;&X@+#B8N>$0.
M.CFE'Y.ZD M.XY):/W=);^:X_[SOS58OO;4!E4O4N%$_S>:XTT+7>Y+5GZH'
M#A4H/\X<[2RM9AN.]TZK,:]-J]EVVV-,J[D"_FZ[RA:OY^!L*]NW(VZ+B&6V
M0TMFY&4L=C)R6#R1A)X9N4ZTX>38B<?)'G/)PI&9T#R,Z)PP8UX<^)GMI7+1
MA'^^Z=:L)-(\C 5DRY[!9D1.JB><9F=2[)$5; ;"(A\T,KFW4<\CL[R8QM-A
MMI#]"KG+&?<RGXF C.7$YX&YEBIUVGE;-W=>1964^51^J<EZ>9PAC< -/)*/
MC%GD$<G=J9+:B!P6B\P*HL2V3'\CE\+*/!Y:9$5'/."RY';*0HN$R[*=Q$Q<
M)W7<>.\A#7<@>QING,?TL]#& "SWD\7.H*N"+M5*U&6]PU\;::E^&FJY(J"R
M=55OBB6(@XR/<-/V?=-V6>B:L<Q)%"Q,Y7;4P$_D8N!YR491?-_Q+#<-8F;[
MF2F[:KN,^]QFID4+A65;#C=3Q$=Z:S>9EJJ4;#6,_9Z^'60B"%+FN:KRFV.Q
MT*%%W<M2/XW3)'8WVU69=FB% 1?,CM.4N::5L"@U+<9-\C.L,#)M+W[TW6J#
M*>%UT^V;Z;)>U]8MG+<*Q6W5=8^<C!<*Q_7(@W#2D*0F(742RO8_L>,[0>"G
M)D\V:@S>VH- T U!-RV#;DN:Y]JHF_Z+ALEYYL1D/@0B,-N--I9L>6C*@J&)
M",@%V%@THMCR?>DSJH7&362A)CMB=A;1' ^<S$Q6J_62S!->LKE.6VEN$;Q;
M63%D78 S4;ZKQ<7/7 $UR6G1^%Z4:25+--7?"[W7BXHT<E5(J5CRD@L(KHY;
M-KD\O1#JE\^G3QII>](/DS9?KP=A5V*F;2O)Q?'+J&FVRGHN8HY=W+/=MB>O
MOIK24EU5(6\M/GMB_&V[T;[Q3*L3J5L&,_7^;5-QFE-%K(IT3%;:@??SCD;+
M-B+25%UTVR"7EY>JL<A4E%.A(KXJ%-W6IU!^P$9H?-&C@89N-JZ['N!-8-0H
MOD\:;V;;^,E";MM.^F>1JZ8%[<FB_B[$9,,?VG+%T2)TWAW8-!CIV0M5TYWI
MNL?M7:,Q/C8&H]D2=LX)7/Y D2LK]),H]DT6J%():>2QR/1EH07/-",K<'BT
M0?(*ST[(5 U8DF8.&;FFR2+7S23?EY EE=F!NTKR;NH<:4ALM1H6"D4+K4%:
M356A,P9@0*@&.5(V97^-6"PMUK2ICKCA[Z^;J_+'L_Q2BJO2#GGY<-:KG7 K
M22+. L>W&NLUYHG/N"><*)5%<RQW]V(W3//5.53S57VIFE'32%>-VHQE6M!E
MD2?++,Y%I8C+&ZU@AJS;.8!002!$Y$>!SQPGLYD;F-+M%S'C<19FPN>.N1DJ
MN,T4^'E9Y=-2ML=5L^(5W4(^VM>"IH.<"6^+\J/D6*M7<E3>M?'"/Y?%SKHY
M>$-I?'V\'E937,-RMI4Q7\UJ:.,I/S.P?V)?7Y_J0)/Z9I;RPBR^RBJ^(C_W
M"MMX]1%@&._/,%X=B29GX:$:= 69G3F^WQHFGL5)*Y.=8OE.'$1NZ*7Q1E#?
ML<F \7V/K!<[9"YI;O+?,Y^%4FAIXOJV&QZ6/3P @\08E#T<14XF5 OW.$EE
M9-9AW/<"$B'+(4/!2Y/-TJ;W%SO8P_K9P[>VA+<O5T.Q@N-(>&XDVSD'F2J0
M&K,XE*:P8PG73UPGB#=SAV\A^#I;P=O[<N@CPZO9$WT!E"I5Y1'T-^@UDCL,
M[C[+;-.*N,TRUR%'R@L<%LKZHG:2IF;L6%EJ;82][JYO;R]SRY9Z*]*W,\$;
MAOO52S59TV[YLE)T5<]24HFJX2\9V(W_?R$&4S#RD7TWU2%XZT[I?JO,-6IC
MTTU;;&]>)T%N[*,IBIX@;"ZSOIJM/P ]UX+S4W3]\8ZN(@4(IG:4H]&R!/47
M,:U;C(*[#_XJV_63L=^@Q=0Z49P)J<,VVS6MCVFWJFQSM)\LXGG7291UG=>_
M;?_#ZJ;<M1=NA++:D,FUP]9$TN^Z>UZ2@UZM]P&]<C.D5%]=!;4N1^^VD=&E
MFKSBC09B#(K,B=/8]9DIUU4WH;4V%")B<41.>>#[661O[%JWS,0,4G+3?2>C
M5=D.;18E3LK2S'+M-'*<2 0P!A$21=/::R9?:'E9FGD!"Y)4]A<-I'GKRMY+
M@2?5K)58&VV7?#OE(A09BQ,N$]OC@,QHSV26"$QA9IYO1N8^VCR:0^F6,J0^
MH&Z6!7'H^\RR;!KL1/I,?F2QT!,^#V/N1?%FT]H[" B:UE[;86=;0/^:7ID+
M>^J^K6L'(*FAYP@WC!(6N$UO5K(C4L]CKLA"+XD=,_$VL@ML._.<+/98'%AT
MI!W0.588L]@T4]\)(Q$EV3Y4F87^VP]@:"9N:L9A1E:B(PM+VP[CH2F8Z:5.
M$&6A&3J;VR_O("![4F764.([]U9EZSG[FPVVD]G%K"E;V#A40XE0)E$@XHS;
M+.$AEQ%*P7ABRV+F/HTSC_S8V4@*SJ+ M:*,Q%I520^2B/2>%;'(-4WN>HD;
M1?X^=)@W$-]&2<T 9,-RO=#U8Y/QR);5\.V4<3<QF9]&EA4%89P&FTF;+K?,
M("9Y2F6'5$=N,$I\BP;)"6W'=#S?V^@JMR?UY9Y$@Q"745?QH,OUWJ[-N/IS
MBZ=X8S6'HLL'6W391]%E%%V^1='E.Z><W+50L^85EQ^\W=IO\T)EJ,G4O7>3
MY$2GA:AMI/9N8OQE-A'75D2FK\=C3K.U+=\CMQ.U!9E.US(U\W'.Y6)&CRYF
M=9Y4S<N/C$GQW?B=_B=[>QOKV!A/GRR_>K+@=WI?]HL>CWKUB-J:3GE+G,@R
M3W5769@G!BU4LAM@9="SC)72H;>9T$7'*M7R,B_YV/C\X=2@Y:R6ML6Q1JFO
M2&7=-@"KDB(O4>;Q3*7'_9 5N')5H;,;( EY-QK=Z%S(#K6Y:LO<D?&J5:,\
MEEXSH95)=;#=6M^K)0M[1:R:XMO?R;:27%>B.AG3TRB!W!SM5(QET\/Y<LB-
MTTJ^QK+I\:(^U^+EFD):JSFJ70]3(RUF\5BPIB0(/:.T(V@U-81JF&QT&EF"
MTL-3OD7WS/*K>MSP<]FLGLE$A/4&JM5H66ZDP:"8UJ3V>QFR'9@MK_FT>C84
M<7YP;7P:Y\6%Y*$;=?.7XGQ2T9#\)[^8OC2Z3]4L)B'(>3E_IJ>V[M/&M]'8
M:UIZ#8PG[>>>XFV_V="Z,NN:YJFJ;S,N$EDDB(Y::-MN:I'VZ!?<ZV?*;URY
M>8TIV:>Y2DN7%+I*]TXO^21IRB9,"PF%W*TC9%-KGC3)Y!7/A)Q@99'1;%F_
M:W]!X./Q7*D=E<;;E/:[Y%53Z6^Q2,1*G<GI*W$C971Z^G=V2?J'+K1XMY9"
M/R<WMI9G+"%1JFY6RW^92$D!E,6L;BI.\90&ES1<.QZRZ7H31W]W,245Q^\H
M;I=2W=++M3.PFI'VZ<F@?Q+LKGOL;SI-B1;^Z>QBNE$EL)L1:9X.8 \_CV,_
MRM*0!5:4,5>XCFQ5Z#(K"!-7I)859QLA&3>)HS#R39:Z0<+<) I9[$0^<T/A
MF:GO1[YX$/;4__E6_JO8OR")Z,E8XKB24Q$N"T,O8]P*S3CUG,3R-SB5N[S@
M \6<KGGGR;;J!1J'H.HV_98TFJJA-_E)N?4F@^BJ8-.Z'E\D6_TLR^%&$:FN
M1=#&9H?,BF0A)(<Y3DJB9/E<MA;D-&%B.XM\VPZRS7H72<1-(3BS2688G2PC
MX=QA09#R('6SQ+73=5'Z(L[D&WT6TZ*4VOQU7B7CHB*S["M=^%=:^'Y_8@@2
MERF=5)<S\?"N;AL^V[%]=5VP[#8!J1.CA8VLBF;&T) ^HOEY!4*WCG=L2%W@
M95%BBX!9*>DN-W)]QC,O9"EW;&XF:>!L<GZ[D+I6-_?0_%LETE_GKXKT0K\"
MG;V5][\JX]7'U[\9>:6<J/MO?.J?*34PRW^P\SQ-Q>3%VV^.$X5^Z/G,SA*"
MVA>R@R\/F6T*7UB.:5J)I8N7_>K-Q\9P%1/9;6DL.)G%U7DNC1A^L9@L*__H
M\-SD(I.CVL8$UI-II5O>&+_-[LPFD5YV2A+?-_9E+LY2$B)7D[S9,%?17#!4
M&?&F!5G675?N\&R+NM)+GM.4D-XSJ>.*'/\F8?C*%>QI/.^<X6=&ZPV4[0;9
MODE^J2(6$RX];WK7)*'E7=;YG&]NWDU%LQ]0I9XW=;)WM:WTIV+.32<0W"+A
M)N.$N68D&!F(#ME%(O-=X<5)%EQ[D9BLR5 F( 1!0-:4D%4DL\ D8S/S+-^+
MLLC.=)DK3:'5[7-"HZDAFY:1OE;;K*MV 6R",]VLZ+XE49LEC81M49:E.)/.
MJ&I_(V=.U:9Q+\JO]O.\Y:2J:-'+I3,L;UB2 VM4,SD%I(A*;[JI3]6FEC<U
MGU0'M]^%,F\K-;%H!DT,<<G'L^99ZY4'R_()N>#2[9XVV<S2(5]SL@IZFDE1
M=Q<1_4/EE"//NTCD]S1)BUF9]&OE+O"J*E$;*:]Y%X$H!5U#-&^4+Q= N:3(
MFTWEC*<12!O%-"[(XQXWT3AYJ48#-?=5#?A492NR]E5K.5FL?VF';M\)*NV5
M^Y FFW5K+"MR8S-@F6\F327G2%B!+,UL^X&7D)>W477Q3D9$<B[2V5A\S-;-
MB9X=\>N\_?$J<W:]Q>9-GOZ;]2!6L+)1=V<(/X39DQ4DX]_5]&G*$3?T7-7?
MQM$7XF*R-L]DI6BYH(W:LL=*:_2F=S=/%M._[VI55_E::BYM)&>^Z(GX_S*:
M__[4JJ\5YEC1I(H:;FE:":?$@ZQN>3@;\WDQ:P]IH+%,\\3\I3M>UK/CTTJ\
MJ*0^HEFW2KFJ\YXLGH$>8L%=7Y)VBO-Q7L]?=!?I'TF'I@N>5MW8#T_,R/VE
MSRUW7*DBEY__[&3KKN<Y)Y;MF,O_[GRANYYWXON'_<Y_>EZ76R6DS3$(:1['
M//G]K"QFDY2U2B!3_VU7 C)PTZ0YO&B2'>076UB,K8^^FOE@6C*_H?VJ22J@
M+]9"LHT6V\B1Z9W9)B TE]NN0L,=94&T"2XW3G6X:_Y"G:[A1P,C?U:QM8?
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MR-M@Y0U,,Z0.3#/D[;#E[6-2%W)7LZ4IVSQ,X0/5K,U0 #-@ICMF1ZDC 1@
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M1^;=H\^NK17S?GHA)JGJUOZA.#&LCG'_C<][?'M=*#(=+#W,B /C$<#20^3
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MW+##17F Z[G]KDK JZ*<B/'8^-N$[EU6>3W7D7J'6:$;@X &-Q"Y(8L<&MQ
M[E = ")W!"*'!C>@[0]W'! ?&)3B!&!8G $9( -D@ R0 3) !LB.&C(-O%;0
M]GNA[7W0]G#+-=%FPZ#M([UH>Z=/VY].RWS<;J]W%[3]%[KK) 5O#[OB$)D%
M\/80.?#VD+LCD#LRV"/=\(/(';3(@;<';W^XXX  P: 4)P##X@S( !D@ V2
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M_=66DY[=E=V^)7 W!\;0D3]'GU7M,#OTZNX0.>TP.Y+R[I \[3#;^6YP^\@
MA-#M>X75OL#[0'T^D/%ZC /(^$'I3@"&.#D@ V2 #) !,D &R #944.F@=<*
M,GXO9+R-"N]PRS719GO/(;A9A?>]IP_\I,+[7V9TO6:3NS>Z=E=\6P_>OWVZ
M ;;%'Z.Y,23. 17>(7*H\ ZY.P*YTY+3A\P=M,RAPCOX_,,=!P0.!J4X 1@6
M9T &R  9( -D@ R0 ;*CADP#KQ5\_E[X? <5W@]&&SQ&A7='"S);I(I1_BRJ
M6A'36QCK)<>]"#U:"Z)[O9J[H!<$;8U5%9 !,D &R  9( -D@&P D&G@N@_:
M71_F., SQV0'8%A0 !D@ V2 #) !,D &R(8"F09>*PCGO1#.+JJY'YA.T'$;
M]M8Z[GOGKK&Q&M5<!X$9ZJ5#Y(8L<JB7#LG;W][JPZU6#:'34NA0+QUT]T$'
M<$!W#TIW C!$H@$9( -D@ R0 3) !LB.&C(-O%;0W7NANSW42X=;KHDVTY&H
MWU(O?>\T_4_JI?_&YX9CWKA>^C#:L^N4#  CY:"9"E19A\BARCKD[@CD3LM,
M ,C<0<L<JJPC"^!PQP'AAD$I3@"&Q1F0 3) !L@ &2 #9(#LJ"'3P&M%%L!>
ML@!\;'H_,)V@(Y>^==.[NW<V7;+5GT4E.+W%)D?^6B1-R+)AR:W1LBK[FW^\
M^;B#/>\C@U<&;\O&QW-C@][OD_7>VOXIC:AQ[.+3#C/LDX?(#5GDL$\>DK<_
M=MP],@ A=/M>8;%/'@SY(<=\P) /2G<", 2O 1D@ V2 #) !,D &R(X:LCUY
MK?0'C\>"?DKS2_G-G^C?[O[_9ODD%3]>V"^SL?C!TKR4>T$+&M]B/+N8O$SS
M:CKF\Q?RUPT,3SS"3#Y:2[PW7_QS5M5Y-N^>4IW*Q"1].2VJ7%V[%&,N-YR^
MC(L?$F+YFC%YRJ*D2_^X8?# LNGS_82W/:(1F^Y3*PUW#=4LG_5GSW:+4*)K
MKPQO-X;GBTA$^]SY1!*8K*IY6;_@L[IXN?H#C4#S]92?B29(P7A&,+S@X^]\
M7KU\\GQ=.%;FF1K;I;AL#/MN1_=^D^PV _MX0[EELO9G9#+F526'DTYO3U+_
MTF=1/EF?L-X6P)O TI_4=%^3#@6%&OYV*.0+RR<F\.3AC"9Y,6L/:1[>,LT3
M\Y?N>)+_,9]6XD4EIKSDM5B%59WW9"-*=IE7>9R/\WK^HKO MO!7<\/PE[[(
M=! HF7E^U3G6B6G?X337O\N][G#.8]W'NM-)=SCG3H-TEW/<D^AA[H74,7U2
MQP*DCNEF+&L(VFVSQV36V T3R+Q])Y!]_?#AG3.<##)KC5J\)6XWQ\5 DIHF
M"D%OS)"D!I$;LL@A20V2M[\D->UJ:$#HM,,,26I#</F0I*;'."!);5"Z$X"!
M/P9D@ R0 3) !L@ &2 [:L@T\%K!Q>^%BP_!Q1^83M@[$7]3%M[?-PO_-B^K
MVKBRU8ELC&*'BT8G/R'@W[]_I?CW5T4Y$>-QCW0'GXU)!3X;(J<?9N"S(7D'
M('F2S_:/#$ (W;Y76/#9X+,/.4(#/GM0NA. (=0,R  9( -D@ R0 3) =M20
M:>"U@L_>"Y\=@<\^,)TP&#X[V#>?_84N,DE!:&.EW3MF(+0A<D,6.1#:D+S]
M$=H0.@@=".U#\)M :.LQ#B"T!Z4[ 1ABS8 ,D $R0 ;( !D@ V1'#9D&7BL(
M[7T0VHX)*OM@M,'>J>Q;U$@/]\UF7U&1_"]\,N/EW+":TNCVR*@+5>G\ENSW
M7!'<-RJK?C4+?DMP;O[R*(2.*0^>'2*G(6;@V2%Y!R!YDF</CPQ "-V^5UCP
M[.#9#SER!)Y]4+H3@"$$#L@ &2 #9( ,D $R0';4D&G@M8)GWPO/;H%G/QAM
ML'>>_:8D>Z0KR3X;SPUWC6"_7;GT>_'KZNO59[-7GLVZ!_EO//UIZ_.;7G(]
M$>$9*'MH#U#V$#G], -E#\D[ ,F3E'UT9 !"Z/:]PH*R!V5_R$$H4/:#TIT
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M;)$#EP^YVQ>7'^H&(&3NH&4.7#ZX_+W'1?34 H@A0,JT1VRH&A*0 3) !L@
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ML\[V@+= 6Z'QMY,O)Z].%ORPY7CFM21R9/H#)9$Q?X 8$ -B0 R( 3$@!L2
M&-CDP<9+P"8/:K8#,  &P  8  -@  R  3  !L# )NL7.M@UFVQKR28/4ZP/
M2>8VR>3A;F$^.C(9TP>  3  !L  &  #8  ,@(%#'MHXP 7'9 =@  R  3
M!L  &  #8  ,@(%#UH=#CH(32T/W=:#Y^X<D<AV%?%[7T^K%\^??OW\_J41R
M<E9</C\MD_/\4E3/17K&R^<IK_ES*S(#RPR?2ZF,/-,*3-LU[3!RK><M"QT%
M^]_2_(F.3^;&9S&F*TW.5(ELNBZ-Q5QRPF_*DLXN9M5X;IQ^YV4J4N-5<3$5
MDTK=64>Z&'-E;XAM[PFY4P5MF>RO!XL?)$Y#B3--B[E6Z'D'"R+$3D.Q>Q!+
M5!?\('$:2MQOG,Q8P[)&ADVVZL$BJ8%C/VAG?I@!%M#/@]*;  R  3  !L
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MUO8]C\48A"TD%(@!,2 &Q( 8$ -B0.P@$0-AJ\<X@+ =U&P'8  ,@ $P  ;
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M)O%VE@:U_G0Y1@-0;#A!O2Q%;T=GVJ.#:"ANZE.\0,(MC9(=9@__3^IM\1T
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MU''#]Y2[HTP?U<47T**]&*VLJ[V_ZJ&G86W!1:616C]QL<VDILY+SZ?1&>H
M\&X:;9W%5F.$3#RL8E<&$$O/9T,P1$T7:[NM6/(PPKE2:M,4P]_4;6BI"T11
M6"?\0Q; MH0C&(/6AY]4C=35KN?0P>R5'(=Z.T[+3O.]A1MO/W:WH4 ^QN4[
MT.A#WQ-E5]XBP&2#RJ^70(5*[S&:<]'CYSM!S74R#&5[49ZBU"+.)5'K+3::
MQ-KTG)<7L10ESK:D1Y0Y[V^-1=0Y^->'E7UPMN68J[-G_"JO JU&L#<9^W&
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M\872-+0GZ0/MQ5JQH]4< WW;D: N/H=!\NSOK@(,PO"9>9^]>[IKJ+&//5^
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M:FTH0"<2<_ ?"V!Q:6?' BO4S41N"6[<[$UN26=>X:JU@29U/8;VCNAB\A5
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M^O?#$X@;(PYJ : S,T 6(SUY1$37^5D&9_(0G4 R4X?I:&AM3S!@MCQA!FD
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M4>IFE25QQ *]Q;HE4"U3$E9AI+4]?#6\V5..P^ )P^&5%#N3\JMI:2_K(Y>
MVP8%UW:9B;D[,R;4!WDU=+*X*S[,-.0N6C4-D)= 6QG^K#C?&XNO#3J$_51?
MX2NB" M+GS!5U]7@B>Q)9&+,)[;&'K?S8 2")GS;V'0^OC+ET3"#$3;ULJB]
MP&JVN\^U3>W?@P:D%7.[F4GP]1[+^CX6+^[,R,CC-R(AN]0& S;ULFU4P9C<
M7-@JF,WJ[2EU'6=@ST?+ .@UZ#%;9SJM.$.G-*!K+^EHKN].T3Z<"9H[X^=+
M/WQM@J>K[3(WMX+ LG]E?^GH/2CUG<%1U9NS5+6HCX-I'\)V]_LY]%T0X[CK
M^R9,:(?HSM;][3F'G @=$3&<1K8_32R9V\\F,4KFQITCC D%?1U-J-W $HP$
MYB#T*H)KRRBQ2H]9:E%[UI"MI61=GEF&)ROX\B-Z'ZZ3UVJ=H.;V%J-.DMQ,
M;PPI4=L,;[25"&":H -SQ'"K?H?GK1*/I&(#@Q,/DD3LK1HC#$<9S[[FR8QI
MZ/=H975C#>WA) @(>;0@,PQY96%1IS>PT-C-9L:KHD"J02_,5LO<V>8(^+:]
M#^\[K<O75T6**=S)VG$'K[H'6Y=NRJA"YONYOL-,;A7Y(+>Z6;+&AW=:"Q&\
MK*0@/S'+$'^E0"-D>?F3O#K[S\=R88X&PT:IT<"?H@#X C&'!2,BP']#5=A*
MT\,[P6W#:&R%[UB-VV'QB.=4QB4*K FI&VHQ)\PA._L0F]BC=>G%*\=GA0SA
M-V5>ZEH._2JN5E%*747UE@NC_$KO,^[>W]Z=UZ+"+;=\9?;J0GST.7TTWI1#
MD!YX4_-7']3=,Y#,=Y=AA'<!"EH>CUPS10VW[FO1QO28Y''L8BDQK4>F^^2B
M.37&^'8D8MV@9KCT?_:2YQP)N?( Q*<[,RAR#2K3V*/:-!8Q[+DH1$7#/=T]
ML)PZ[JC&(&=NVO<:"Q/M0<C>[<>SJ6+8'I1(&VJRZ1L?;.IK,><O$X9J8__'
M&,ZB=,5E/"'WW(1!**]XHPAE[C&T[32BERGFWTC[48VYU-!TGE$:3=55&GO.
MTGNL5T+V<"4;" V=L\R<MFMXA&#T?%P%)&D9GM+[T->G'[?O;;\@CN(<[))K
MV[[_T'J'MH!UC3&NKKW-1&X6L(V!VFJ$0!;_;;0J-_4;>+FK886E.@*Z-6_N
M9/_<*T6;&B2VVBXC+;>\/63.BY^Z*!R49"S$H.)J=%TQN-XTK8;4>UGA3IY%
M]40#K/F6[T7#[G6C,9L@#_9B=*^#4>DV3X@#!?G_!AZ*Y2OU7^AGV)MG8ZK'
MON3F@ 0(IRX&92\2B ,\1V<1*!D )DFH$XVAA2!9?%$8HTYY>M EC+AZAK>&
M92VBN8JE(/%<V2P#22L7]2)HU6R4FW=JC1^5AK/__!@6(#,2PR+W_/:*M(9&
M>Q/9XX709\RADQ4-L=A3DO@BJK8^1D;[3@X\@KWSFCUK/(HZASKQ,7B,/?\5
M4T23$-23J+WX3U'LEA<",ZB/&<@8,\C$RS#!XG#YWY&[FS#Y.Q8!-%3B&G\\
M>U9 B?5Q&4;X(.5:5),ON+FC96>V1K2O]6OKVL\%*[5/\/Y>I*SBD().#]-5
MY*.Z\K'&]@?@3NCM1K!IY&B!@=O0>"R8&!TJ@]9X7-MA%F6_2HB.=Q3!PJ6<
MAB&4)I=%1R(313J(5V+WX>/CTDLJ\97:)G-(*RHAG5\%3#K$Y_QT)_Y8BYB\
M!R7KSN5B[@7<24U29&,_RQA ,#%40$]WN9?ZO^"HQ:ZWXH#0Y@WL0&"^,6AQ
M0]BB*"F#)E #H&RA$NN^(6E#3V.^"]ZWN \N02]L9ON3LV=SA2=\]]F)?J4)
M.HCKZ^48&@_NUL[].UI[Q$G@WD;TN.C07H:W(C&\9+E8K)(09HGC9'!\*NZ(
MWET^[13LW_CM$UYKN\Q "!D BJ:=C#+80+/1GI6HO99*LMIC%("T\Y0^P#<6
MU=9V,34=>$8]</ORV-8"@I^.F1%&&:E$1S6AK?+G62B'I:K.+33!<H_Y@=TW
MW=(M.AZ>0%C-5AU#\!YH]#F]Z0TJ:5T/^U$J(ITJ4/,DA,_?7: ;&"XY[IJ"
M5S>2_X3M\VH?\N'HVXQ-;LX?:7)0=*)AK[8GKKQP \%!%>A')LNPJ;7%'!IM
M;DNMME7?9T8)9^8CE/O+C<%R@Y&U?U$I@4B7$:O\MMK5UKMLT]/R,Y*!=%WC
M(/6)+W4])C*<@W*%#_/];O,8^AJK>?'OLPA]1;@H&7C8(N*UT/SP1+C6>/C.
M%ZMP_&+XH</)L'B*^["*W?9("HU]#J[HC"EL9%]RT]34K 1TZQTY2WBS'K;<
M&BR Y;6!5H,/8C440:US"D,U!"+H6@^.DK#9>'',$ >#8MAW'5Y"4Z>9 )=D
MD8<-PGU3K[G%?N3U<GJFDM81.KQLS#K4G[K@AA$'G)6T'6=*>JU"U:KK1(+J
M19# AWCQ)8=<UY;RK&TZ V<+=P-\ILESZ"J Y=<-Y0(Z$)A]]'C/@/&9,O@0
MN%[,DJ(P"0K!-[65P_O1FK7DFA<^EQZ9'G*KAIA]J.X2LDI<)[75]CF\%[4U
M IDI)E ZX5+''^4%'GZ"8[EG+\/HPED]_W?J1* _=W#6UG:T)YDJ@ W\@Z[7
M6LWM[=UNQ6^TU@2I;SOX6:&HME]Z49R@(:,-?F1#EXDAQTZ" #ZDQ@(ZA6;V
M=$4T"^"61O093F+V,DF#;.V!:-G9&G.G:0RR(8@0"*'-Q>&:=\O4>N #?I/B
MH<1\31&[(4^K-KJLIO5LSTS-&K?J:L^-<;NH50KSOX^59L$OA7,G<9@&MZ91
M4Q%>?0^[R:0C99#.+&V4PB%><9$=02 VF'WPKSJ<GKH>P[(11XG" OPKGS[\
MXQ_"8Z$]Z]6_VU,Z<R-V^\3#ADZ3KO,=2NZ:V[#XM_DZYIK2"F00D]7<AFZ3
ML(K-(FZXNAR#2K.!;W)N?%'C%W%$&O D0DPT8 <3=/B*\-J]_RPB.F'?@Y6W
MQ<B86@3W^C[3^ UST\\BVCX[P7F4/O%?='</-M,:!_?_U L3NGH.0C]\\O"K
M7#4B_QN[6%6+MXTYN.56<\@OY*[@*KCP6H +&V63]A1F5"WJ,F2XXG&,%A47
M_N*M=UQP9(TQ=P;&=I*X;S&I/08:Y>;N@BH3IMJ/;C]"0^='W(2^$RS#UR"F
ML(;&&T+;;N"Y9/GI=6!,U4:S]D@P(SS&*<,,_*R=,:*R%\E)W:"WZ:/OK2[]
MT-$9UZIMYBM=[U.WYR?X&A+VH4Y=,:@T\DRJ3)6!8HU!D;6=AJ]3A_(5/"&+
M]>(U@+?EV=M*/#KJPE,BLD"E:J(U\'0F8A\SJK'<M*[EI+?''7WR,+0G2&Z<
MC0XJ0]ML;ID,.70"#1Q?1+O+D%01"M\MVZ$5Q=D@:B%PH *.M5JEFY3!JGV*
M0%A%%AT?&431]92"W(J<F3(G!J$]Z2&&JSB%FR':78),$NEJVNC;C0'Z746]
MXK=K!GN59Z:4\72-6:W#$+;W0I5+MV)E)*9&Z--U36]65S)V_4%=?>$-G88^
MJSE:D >7W]I;P=W^$(2/,8U>\.MG:, Q#PA%$8B)3)]#E_K+\").O(T*P5%;
MZ'S\\>82O=T4;VML/@,#0L@=O/$BXH#7":7X76U1P,+'P'?*13N&H#BT*YDF
M,MU':J68]E.&AM/ZE5MVM9^9+&X$(:F8/+.&UO9#CT]WNH2]&A=YFYYV:Y;<
MT:W KJG"71IC IOZS2*_3NN0-NJ43?T.S_1PW12+W9^P_2^R1PY_]E(OT5WA
MP1<9U\H"TXX]J1*B''0NF"M8%T:-I+:31==L@*8642H 7G7N)L.?C%Y:<X^A
MD]-$94M\UUP)X<=5G--4H%YG-0#P!VWL?2]2DT CB8?[^F_0X;W6$]"BV^ I
MN!': %@8$OYTJI03+9H4ZU)R.]*PB1 B;1WF,+TX9J>CQI[2D<JD 3EH/PU]
MSV7?+7N/#-$YAH;SL2D8,9O:6A/,! Y/;&G$UV0HFEF T-#"3=?A+8/XFS[<
M >MS]TL4-..1M<):;.AN7Z/%I[7@3&6>]CM6O\?@@MZ/QL'F6LTGJ6K*[*FA
M87A:(;E56\_L_N<;P=Q1*'/#P<8/.^9E,SM=Y?64!I8=U7#"DZ>GB#XA5 S6
M6//94^'X/C,;BB/')&UMD/Q^A.90QDWFKJC(KU?=JK@UDYC&J54LY3*<3ZL;
MW=F"UYAUSL''L&OZ;/1*UMD_FSO/"]VY,:RFJ=?,7I(A1/EBV?G)-8G2\-8S
M*X&_1WB?V-P:Q(W:+O9BEYP(9;@8%I1MR3F6OC97JS.TMF_4YN?COU,'[:P,
M1EZIOMQDUN]*Q6*<^V/"[6<(O+6(O"<X23[^EK\.)BV@N=\,U-Y6=8P:' W[
M4K./52:F5%]4Q-3:ODYORKVY#"-0&TV2;NON$[EVSA#P+:+.6>CJ@B,+?QY#
M\)9B+XNUDP[6/!+6*%@W]9MAJGRC(7U4ZWD-$B+:.S#$D4<DR:P'#7I5FQX3
MG=N3%#Z6,#+$]*I_G45*8I9M@Z5?4+4SFNV;>HUHM#"9N]2T=5-9C[WH#,S+
M)Q@&OY4%_'_PA"/DF'&Z.=>VGT]F7_8V[)759^@];59\%@:4@9F<,<"W:.M$
M<+KA,]6BSG3K.U^1H $BKGW_H5_@WJ;RK1?ERFG7*GMVYF#MF/SD1!YZ%40.
M?6QZ :KM[,OJ_<KH=B9C3S<SZU!-*G6KKH,GX/\S%9BHR]!0$00N%=^)8Q:1
MCG_&Z,5SF&3L)9E\83!?(; @3S43QGGQS>F^8UM3&5X>%MB5''V6N9%5X:8Y
M$Z K"8L0KTF"KA;^RM2JX=JF<[)%RCQ)_G(*7"R8K+2O\KPVX4]"AR#&[YIC
M"X8<87[EX6Z,9>YJN]A_AG)]N.FE45J.%,RH%/B$^ZD9L[)5/VM+?$<3>(7A
M- M[=^UM8&AL+YS7B3%(%/^#!_;%\6D]8'%-AYEYL#KYF^Q-7LE;87EN#'HK
M!Q"HKQO=JJ_U0$PA=\C$#^:G;PB]U'8946 IRMG=))7:OG8@R2X";6!%A][V
M7ZR.UK_F?O8=CSR1]1HC\C^TJZBAZ6'OK4 -1'R832J=ONT!E,4Q\-.!@+W]
M><:/E]5W1#,?!LYP:#Z?YK^ZQPPBM&,^;%V,B'7#K=F%WX?BM-Z,:X&);/9H
M9"T&?T6B@/I^N89<;36LVAX#SZ]X+V:C73"MRSVO(B.U[671:)R5LVD/==O0
M:7YE$9KJ<S7VLV_4%]%M27VQ5F-SJY$S"JQ-"?2F+K&B3<]),T^9<<5A:'4(
M>WZF%:$:F\\E2%_>X2W.DZG/W$20[*+M6YFOCI ]R3>- I8\>Q*XE]X7ED9;
M+_B:.]C,]8PH,SDI7OC%^ES4WL(,]5M0PKUT$RNOC('!/8E-F5;,JY]&X5/D
M5.3[KKT'GC<K9O2*MVOPE"W97B5)]Z0TZ>4-;Z* SQ5>'Y[A8;R]3>TMFD9?
M:) VWFB59O:,#]&3$XB/LI#6S#_+&$/D^ <K-#_'SQZ:.!<GFR)/!Q]F\- F
M41VJ?37MIBX3?3CXVONWSV% C=]*I8FUTU9RYQ?SMQ2TCX;/IS.9:57SQ=8+
M6-B:_INH:SGPL;Z(O-6)Z]/(?(S+3>85 JD CB/6^/(U[!(*J>D]JJVA;%MN
MMC-4>MB4^:3%"S->FZ7RF@ZVGU^,%9%YUS][R?-9&B>@(4477U9^RBX&!M;/
M(A_K7^A.E&QJ6KD/NUF9TK0=&N-:UA\3;R,+=+BDE&57@P3:K8A9:R+6-N 3
M#>"K]K%LE[N!*SUFX$\O+2U;;7M;#/YI5Q/"4%=B;S*S</S4FEXT#>WM$D:*
MG"# !\-7J@?8-32>641#BZ38HO"G&B!9/&^GF(@!AK,/LT^C%[@O]0S>A,S"
M I(SB^Q?AHGCJW]'Q9\CO=UE./ \5AH8%+_"=J;@W8DG836(J!P0%+CWSV&4
M%%-#ZH**6A*80>ZI$/5B^!#PL.-#Q4'_53"&-DB7O4C.8"'8/7^Z8[=^.[BI
M:H])#6H7(*L^\=3'5Y!>X2MS@C(L3E-KW82Q)_FR\>&GX.DOW]#@^.'^FP(/
M<#O"$VXL[%C-HHI/)#85+A,F,?[#?_1E]RCT*5\#6(+7U]?OV#+@1GY\__[[
M=_CG=VR(;_X#21\C;:(0)T[@$H7\$8$!_OU=/K5#83+!Z_*Z*Z='A%VS!\DP
M8JH+AA6Z1R08?P.G@NIHS$3:\U-@DSMFLR,J!T1A@3SNB-I.L$$8'T>$<T(4
M5@CCA23 #!'<'!'.#_$"PCDZ(I(G(I@BC"N";!'DBS#&WG:PQ;'/EM(12_G$
MEA*#C\@:E_(%1S@B7*P::TEY0*4P=N-[#2O$JQJP;UP7L0XB#58X"".:-<BC
M?S1F_3Z+)&9V1)2)'1$Y+"E,C-V1V=3R1OGD?D.+Z!?6CRV-,BWQG.RWBB2?
M'OD%)TC8#/^_W]#JNN&*W1\\%*^PRDYIE2.Y@*O**L?9*F>-G'R5W6R:WXU]
MG[);L-8=ON?QXX]*=H:0:84V$<0/CSWUBCKQ?1(R/B.53U?ADT[#YWVX3EX1
MHBH?FOM_^DEG\*_ \<D#'' YPL%P(D4F0:]P^G[A)$>[MVJ]6'LR(F@11NR(
M9.0.@@=5RV&:"UD+=GRD2_S<2C 6/VJ,X"J,MN(Z9F$)#%4BVB'2T9Z[PRF3
M NDCPHB3,")B ((C6-DPC3E^X'-X1)*0/%*"6=]'! <A.,JA<JM>A!_??_QA
M;#X:@4"DVVC? RIK/A,^$@'*!(O[DN* 1^P/?$R0O1E@'OE%#C[ZC3G:,JC[
MF7,8_S@!0Q&>S7/*_YOEHDA3:2\!1) B6T[KX)CQI:3!Z9%O)>7?H>DA8^_V
M0-E3G[V6/$YDV4-GQ:4?OF)V(?S(#7&\%I4F)2S7FX;X_.[3[=9GJ@[( ;FN
M0\(U"<+@&.=#G&SLKVTEQ)''80F.>T3$R"0;FFD1V> D'[V@?T]V)R,@!&)M
M88[\GMPB"8(T8-I 9?0IUZI\0YSA.\L*WR@,^AK>-$K[A$>/6VW[BC[<Y#W=
MK)FUF+(,GC3F821[3EU0(IP4^843&XT!I78?3YS*$*WX!/HI1X(FR8@*MD:U
M'BZ?O<B]=2*\/B_#Z/;9B3;.BJ:)MW+\STZ0KK&8BRC#F'U5V8W;WXK")D#$
M#,@:E,'B'$AA$D7S[,GHKZ"]-?)URW/9M#PG^N49W:)C;YU*!F>^7EOE.&V+
MZ[6I'*?<.)E-97R[LHP*%&_&('I;1E2^LJ,+AX.QX9<YD 0G?)9TF!P?^U]P
MC [Y.)U1=3@VI$DK<U\?$4[TB$S-506\=_^ &4F*67(X,18T@@I65E>8G/B@
M?*#I[! X4Q5IY,25+"; HL.HCJXG8FIE%@.#203P&=-@55 *!_%\*R.Q^[LP
MUF&SZ;?@T(J3.0<(04SA#*:\EW%.DL372M DT&!S"(SX91YR<F1Y(#R4)"?C
M?HPN#%4*H>=5L_K>$\!"C'2/2$[S@-AYH=%CJ&6(Q(PT<0Z1+;_ SSW?($YT
MPGTJ%6P#Q641,8\D+T0HRUKU.X)9>7.RE?7-Y8D$)85'LATHHU)#E=1%[.01
M:JOHU.5#<,$1PR3Y#D\2 ;D/:'YC!&16;_0J2$!YC+T5+U@I\SOZ/8:"-O$D
M<1GEF KR3!*@>07>MX6T%OV;[U;&@=2/,B;&=\;)V'!>LG<0T5H).#^8^?OE
MJ<,%Q"B27\1_)Q"2!^>J^/*SS(>DF/DPII'[7(B&EZ!J.+[,1EOM;>&6] @G
M*(+F"2,YJJC\V=DM7\/E<YC&<'TN7V$.NTNL=1UY+_#]WOK.2@$QV9,[&(3
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M8"M&'#UHHUS3F?L[AO'E"-IY)+Q-E\XHC!;RO02W2E7L*9*Z-$4^DS,GBG;
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MO<17K(SQ;R+/<5P+_BH)X<@A%D"&P+^$&S=&\%QXN@?PQ? 1.-Q CO*O#G*
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M1L7HM4: CSCQ5F<8713M>@6U2UH:\,Z)HIT'X<;"+L@JA[*4XU5P3B/OQ<&
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MN4CHN/],XX27'@W1>I$A6]V?7%Y@P=71;[)QV5>NLSVW?^0T%!X?3U__#H+
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M+V;O9\QO)?,N)EHSYG?(_!J&'/>!&I7[0M;>,P4I&JF-CI.(YMM/-*"1XX.
M>>)NO,##PI[XUO9$AF3^ 4&;E]$J4)=2YB&R6(#4\7V!GO.D\.H4>:7C\EJ6
MGTXFDQX3*3WB_Q(N029,@J1<@O0R"7([I00YT@KH5(>9J@\CK8!6C#YPGHJR
M\_3*058K%2.K@A6\*^P+NPD#EV/+/OKRIF*WV;[A.:SND&*PA!%Y1:+BN,R/
MFX^<FP/8X&.7SYAJ40H8ZE,R5N<O&RV34Y.X.JI;:S)FV_M*19U[$0:=#3BZ
M$9=#[IV&01K3>$ ,OT=.\2#F[Q>G+HA-!\,W! _%5Z*P"U*^FV(S\(J*0>M
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M>A!$[ [ZI3[1988 ?;)Z^V392JJU&&3,6;B",O\Q#A)L,\?SZCIB/^WK*V9
M.7 T+0_7>KB-_GJQ?8+/"2&*MO.X^/UKD 9\4O=9$>.JS7*>"5A26LQI 5U"
MXAYZK5E#$QB;Z,&)&IUDV)M+C$^,"3![WF/&'E1&F@F0G7P46.%II5-Z\DU4
M+%6[+,HHGP6LGK!GUT1:+;7+]'@ X!GQZ)SJZ@Y/IN* ARO+ZO4U(4\PQ5'+
MJ\FMH3*NK,9FIJ@^ N=)BR^G5ATW,_D^'SW?Y@5Y#/,3@CE-3L-S\LZ3<;H.
M/0U47-%/'X.C.V.K)NDT#^,"#F*F:^4QNV9"C.9VPHR=/C_G"&D.'EE.5*9/
MBG$)U0-_/S)J4(V.3,E62=?&Y$"_EM+VDU]=00L5^9,W*=-X5\@1L^NC\^U%
M%JV,H$1?8*(3E;!IC C0Z1$([V)V^=6*A?AK^GN(B[.?WKT&9N.AON$3H!'Z
ME$P;I&5%"-@E.B@WV/J\*C#H6]DF3=>R,ES>AO<3_&4 QVMTBCYRRUCA ,N_
M*L8P#R'GEFK_W#9VU$ _(ZPY8.9CAQY_6WYO;4315AS1Q=PRM_XAUTVQ\[[Q
M9:I)CR$4 T.&QY7TZRW8V[SW[]'F9_I\=LN^9]CXZ3/:TNAP=MY3N+D6?_&2
M4WJU6B?9EO+DV'OAN>P-5^(G<O5P?S]^ML0*-N%+X'!$CB?KU\6(IP2:<"&'
M2GX67^$=K'M&EW#!<@UE@N]IYXO:Z"9$R(*BN,YRKFZR&TH[[_PY#,4T$(Y;
M3<1T(P[#>6@"/$ W#@C[S9;W>?P*&2))$-(.[=ULV I)'NXZ,0!1(XR33ZM@
M+4=GH,7R6K"Y'C>;]O=MKVILK*H-.<;V<UT 1I:^B!#"2XP(>AO@SI /L#\4
MCEN(_$+C)+G(\I0FR5<: =#5198D]+F'^D6D301Q(J@307Y47"4',.3G_NZ;
ML\I5;7.X$AR&? 3G^=2U)*H[VC4OIR&G;$(@WNLO,:=/KLS/2[$&.-N>FKD^
M;)X*^C\;MF&N7L$6Z\?YH8@23G4T7"0M#'C17T2OOX)"TY/I,]-I5YR9KNBI
MG"()%$FG2*H]LI%4.-#4W .F]L-!K<UD\UJX-9@4M/@%^Q-< -,TFM-GR'3+
M\NW7.*%,O4F[Y;,*RJCNY(HV64GBF%DU1BZEWB^<4K,E4;RR 8@>@:@AQLAF
M"RC^(>SZ5R-N4F&*JH\TC2ZAR66V[F#:U54+"&N=2:M7?[M,#L9H8^?>^HQY
M<B9F1LW_*5BM_^W2>4M7"S'XEP <PZ4,?-)C<UYU=%]2)(KD.!AI13)^DPQ1
M2=IQ9_6^.&H& J^SXPW =7B5'Q.1C_CQ1""^2Z=E1'YD5P<:Z;$3B%,4C+XY
M:.C%,I+YR]TH0">JJ>#W@8]JW.YLU.&W"@NKAH.-.'?0<EVQ6&33D T(K>A[
MZ74K@S@%[SWOK?5I+_PT)@.,FJ-&>ZB ST40)3?CY,C\BO:PY3@C5(<\Q)7'
M@YE!/LLQ433"W+I[FF.Z1->0AX7>-&$&N@":Q.QOS(0>)Y_6&5+!J I*S><X
MN4NJC#WPY6/T(?[*1Q!=D-D8/+/F%%V3KOZ(BY)BL(ZGC"XR!"SI9#<HHG""
M9AQH@GVJ% F/FDNQKJV=HBS.9XIS/ACYK<P!0B9("O>I4BIG7>""62I,U](M
M29NG2=:!]WSU2[97N5*F,*>0M\7^**Z+[BYZ04\ WJR%]PU<PV[]+L[9%.M:
MV<YU; TM NEZ=.[A=\Y[Q853A9)]JY9LY4H&Y@9P[EYM21/%/-"<F74O=/&6
M=4,JVU>0*<8AD&GG"P+9(=OFM_T-(')F;(61N5\INZ9]<?A80-Y[4<8K=JAV
M,L4 ) $2_26M8<\\:9XTTY%XZXD3M* PZA#P&OM*RY<L,BR++AG7XF;D- US
MQ5?N] ):S&SR+=[7O&=>MWQ;04^JMJ(-GZ_/IC=VK!Y1%D_^<-[9P0,>4MP/
M7&OLS@L0/5-4A3(Z&DZ2'4QX6Q=4.4"UO5FM\^R5IP)T7QE%EIAT1\1,LHL/
MYZL#<.Y7:0EF3!2Q9PKQG]LXI5^./9R1'A&4)O(?!&B"2N <8$EV*0'TNB0K
M '"GERPOW4R'W3QPMOG9;+WRD]18,:AZ35IOA!O]&I28?M]?76*]%E$;7JKD
MJ=(8;_:4Q,\<4F;$4I!+W8K!6F;DB8IVFW)(CQ6KS:4MUUBP&FUXICE7])S4
M,UWSF*P<27I;3EC(U"_K!_3,77(<5R4"T3]W[;^@J5_6*\5Y?S[5,NN$IJ=2
M]]VZ"U;=ZBN!G-$@;D* HI_:2G472<02=KQ2J/3L(W1QK3I_&2 ^N1C ?8S&
M#8/U"W>F %@D;?=A"S>\58Z8 ]?/[=$R#<-\0Z/F3$&!8=$#=+L8AK%GY$A&
M>B0_280.F4UL/G5&NIT+JF!!' .ZNV:WLI4/75X)>>G<97V^*9CYQ.PS"-%S
MZ#J560:M&6=+XR_=\(2P4C_0U'A;1O9%&[\;-[MB;\M!P-WVQ+1DGH:G$_8N
M!=]3?WP?W=Q3'N&5H,Y]'H?JN)?).,=&:GN 4E(773T>AE,UT,G4;+]/F3?V
M))!Q,XF\"Z6YCKO4+U[BO-R>70;;QS2B^1LS$FG>@S=2T(V"+3$(^_)*NF&M
M<HG\]/ECL6=NR=/QU@:(!L!GS,Z+7^-H$R2+N$PH4Q DSNLL_SG/-FL#.@*,
M)MU/R&@GU!]D&H=%TY,B."O4)>2\((,)9R:,.,\=CG"C/(9%] # %5EN*%>J
M7J_39_YX\7!)%'%#C=3E@%X^!B<\6@'CO8R.C[_*>88L%HK%O%[:Z5P-!K=-
M9_\)^G[\^4R$+;&GV7;!_H -V0$>G2*41I!<4UKT:*P^&^VX [L=MS17.7H'
MS -04-1$R)+Z,64]2ZEBY<I^Y=/6?N4%_@VG0,PY$)B$3R/8LZ!:[....\JY
M^2P:-T(OUZ)@$[[< "K-/2]'0@5= ^SPQ =\^)$=<K+J#Y!WZ-GUAFDZD:P(
M/#K7$YN[XDP(GPKA<Y%&CPFO))) ^$LP(U70R<&7Z-D2)Z4*/C^X$"M;\&8G
M9A$U1+76HI*UEQ]]PYFG?R=!380?UUN0FY<[LM/+P"@5T?9HELX!G@TDRAZX
MR])<_@CHY9BT<%/2U;&?I_;13V35)9Q=QD1DW)\=:"E1<\&GS-D@F#I3;&%"
M!&?DW!JZ8).*R^L@Q-AN!TQU3HA(2IZ@U9MS!&=O['8I7N*U:)<7/'>*+RER
M1-,;+6-BN=HR(2?$)[<MK5Z8\.,@2;93=*FR[S>?L^^'W?Y/R?8V_ITFVT56
M?6I.GU&'@ 1T!PU@Y&!$S@D,<#TKPJ<%J1&U9XF>FC]TI&GTMXU,F,VF481.
M@R"!I(V;5(!7L(/(ZC $N(&7= T>!I7MT>+D3"-]Z^!%)+#N'W$CB4(N\;N'
MS=/?F!@6V9Q*_R,>EEU52<TAB#U0/*K69*%HYY97^.38A1'G5+5?W/(;BV"'
M >SWHOS4V+[,N._X-9B)+@D;P7/EUP5G&^:6*\9%W;?C4.;'6WMI;QEKOLB(
MY@VSD=@Q1F0+ORI_!!@D@D.=S"2""DVQ";;F2F^>B1(KU1E#\EKYM6 7YC8W
MUMQIHX>/NN26(V+%FP#J+YF)OO$K!F4+]5/H*PB3 [6*?;(TR)/MF4).J7RK
M3(%]C;--P<[LEL]6=S3D\*<J/0%G@=2M(^(]AX*  @NS'#3HH&ABRC%@Q)Z>
M:^ <R$M<?OW+N:^>:VIT$*SQ^_F)8),;<R]E/?SEAMZQJ2S>:/)*OV9I^7*T
M67%0 B;62<W<0:GY8KJ2>_<7MX;VL:%;<<8QHXU_WI40KCPE,93;:^16G2T8
MN9WH\\7035SV:1JNV,PD@\:+W$@R.+<O?+M_AKS$U2SKN09*(;AW'C\?I*PK
M*OA#J\)L)W:8BK4LV U0YO)>3)7,:[6^]L[W!J%XP>;\3 M> -GU?E/ 7(+J
M*0LL^V6P$99Y)E'<+YRCN'?]3+[AKJLWD:M\-3^#]0YY7<K?V.OI_HS. <R7
M6ZIDV D9X1'O39Z]'_M\YNI'8^[U>P"GS_/\M//W'^OB](H0'X/\T?@@ZG=&
MX_?DUNEB),EWC/;9*?]>@G0]3'YG3K^?\%D/7+27E;QY60?#R!(!^>Y(ATMA
M1W(L%1%>'SH;33:PS*48^MRKGT*3_-UG/+6UZ>M'HY7D)U@15Z*.HH8XI7KK
MBF\;*X^/87/MFK-I&((7E.G5#]!]F]V-Q>,:[CB=^WD;%QU2F01UHL@33M][
M=FD-7>""_7.6+[*W8U/WJM@"0! B>$#2"WJM=H8WI'9T2@LR*-NY01.1'#0^
M_NPZ?.4F5\6!X^/(1A15$#<\.* C 2-BK!&VMY6QPM=FE!C\/)L>K .17W_L
M1Z;Q]S5)(FF.AYOFE@*Y9JG@A%T>Z0\BP'/U1XB0]9!*?731A(@525J8E^TW
M6:I3+GDM7<I'1KGH;G<=YT5Y&X>@A_99RB";YR%](@;P5<C@@+?D,+;\%*(X
MX*]BIT@^E\AG(OCT4*0Q@@R&/F .1IJPY -[X>.MO;2JQIFPY!Y3Y ,N^3\2
MENR$)4^-$5K</=B1NQ,.*3I/UZ:KA_IR]?3+U6$N.R0]+L:JS94.X7!"V/.\
MU@([,8V18[,AUF$\G]/G.$U'R[;5>.8@AIUVGSGE#?81M)$/K&!\)$/A(^O^
M'T##<^M0+?+RKQ? (LW7[+;9@G^M2WF@04I@*'@I$.3-,V_9G0";YB*#"->&
M+8!H,<(D?4Z7&71%$WT^:7'U1YD'3+6-TR#?8A7F7<;^FI:,'S;$\PTP0M\?
M:#,O,9@0WRV9F@AYPIFP[QO[?98PE^](/&*CB&ZGGV!./W 1Z6F164U:NCLJ
MV!SV5(B<RW<DQDI/-[:+B"72[T@4=M#MCAG$XM/ZE.#FJGUO,CG#4_-"E:_$
MIH9UX^HRZZ$0'=CED(R?%%GGB]\?1^9AN9>MT:U72YJ9AM3W8<#4>E>S[XS1
M@2P/_G-'-5:E@\.7%2#%"?O8Y!CB5VZUR]YY%%]:4Z=M35K\9ER<6= ?BM9I
M&AD8=650WP8H[^Z+Z&"4L7)K5\_]]-DU'T8?DYMTO2D7[*5.\7"#($&*!$@Z
M#XM;6*Y/^]/KG_956XF?K[-\2>-Z]=5IZDB6<C;_$&/_T,3*IZ7K!F5T34U_
M<N(2$I5"RK3Q*$XV +0F4FAB6G0&1C3)$DW74X,)E9T3%"_P_^ ,9AL?3M0Y
M6X\\!K@6^,,TC>Q?&$]V#3T N0D)V?]BE$A0%8$R.2;_>U 2:$0,P3DD\J'D
MDICB@/\EFMB$Z&$(?P+D4_FE]4*3Z?^AY&7:.8U"*]XM-=?1CQ-^;V;@ZWU?
MW),*@#G_[E ]EYF;M52M?A(WZ]E9X^ FJ3+B.4NP-T8JMNZNE?'8EEJJ5%IY
M84H)7:V3;$NIV\;4QD G:$SM@''KP\O2,^_<2;<GF*AWM),C6)+" .+ YYU4
MILPM]*L_PF2#>1LB)AC_G4;*OS\ANF7\%)JP,*O:8Z-JL3,>:/[*OOZ62&22
M9#QZ">G\8?:< @>\] )A$KKTM=[[=8I*1HXE8$AP0G@<TW4#;(@FSF$ZW0XA
M.&Z+,@Z#Q.RDZL_"@$BO*BZ>Y7.PZ2Q %5UY+/Y:'-MD",>""T401+Q)H#BI
MH- 8SQ3J(>=N.R^B,(\P=@"8.#!&2;9SHQG=J<?"Z=?*L05TN7!_#WKRTKP7
MOGO'*/5JRORDI%'S07IL77PMM1/S+<X:DF(<E\B[Y?.=-X)3;?LF#:$@D-ZD
M!F2YN'UD)\F"79HTNL[RZTW)SG,).GY\]@".B+EL)@Z^3&Q3'33YN."B(WQD
MA:'_4412Q;V7HH'\,1/.72:3J<:;0C1+)IHE%TTLIN V6.=1-K9RK 43/#.S
M#2I:2:HL.B&7*@J^):?8\=Z!\LE+L9[WTO4(SN-.Z2&\A<05=.9DI 8_=QE[
M%;2(I_G;F2V+X ^[-3QV2U&_2I\Q@67Z!(#?X;$WKNXEJ=.;R!RVI3WV1'24
M,8;G?0.T7B]GXBG3SJUX+%1^Y-Q('_W7TV#R0\^)_\CBM/S&?F!'4N>U;T'F
MYZY-'(G(H3PN[]$ 9&:'CLV*1\8JX;QO6<*H02A\?ORQT$,HST#>,B;;$+S3
M$\:O\ON5O6VAK7EGA%=%<J*@V<Y$B-I;CI;A'RC4+_\]9I/(PY=NM?O&-E$$
M>2^7Z3?GO@BX36_"93[=1'&9Y=.R9.<#SXI/@N=CU>:+ZSD1%(E!D@#-P>[N
M.IHA=\/W$V+A:I^*[_M X!R,1/H[4E5VA#&G">&S<FI,S'<U>Y<>VP9[NU.
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MF0X. QO.&!"+'/P#R<4"-/;$WKRQD[+Q;<@ V2)C"BP@DEQG.3I&"E0S&-L
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MD);6QWU"[S&M&3Q<]WGV&D<T.M\^%I IS0]0* J%"A;\KKL8_J";HV&_%N,
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M"[#.2027BWG&#B]@\!(N[)VI1/D=LEHBDB#]@\=6"*IP7#2 *;?'X1Z8:V4
M RBJ8^$CJ;'P'YL\+J(XY'5EGE < .+\@8:;'*VVZ6L0)^"IOLYR:.6ZZ) !
MC+#JFC2S/B3QLV66GV'[6NZ>=VJ#7 $^/\]O1CN9LKLXN.CDWN(DB4$3](N
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M0TI]$.J,JJN)_5$=Q"95X7#I0=OUD;4^/ A6FN"IO[3K^3L>'P0[EY0WI 6
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M8?X:VT#W/L(@UOW0;)-=!^+[2 R"[:;>99;CR8XS-[']3A*#8+MCT<#YMIE
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M105PH=9VER)PVR)>L7,K#AA+NX?])MRG><U *.-N Q?IH6T7.[&1$8Q*P;;
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M$;W@&J6=_@4,0&VM L@;^*V=M:O_A'ZR%16L6DFT[=^,.&]UXQ>G]&X/KS'
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M;:'E$&9DI56/ I0_KZ.L+I%[#!!]"XC)S14?!6M_AG35FX-N!8B_N;LP4GF
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MH@!A5M Z_9_0"Y+?X'\(N+YE1S%W+\4?$+D#Z%MD55RT*'S^\@ZOWO@^CE,
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M2M_@YNC/&8C(4]#1\E>YOAA !?DL?_7H!3Y4T&[9?D0QVA&!CPH"+=O-TYM
MG3?R3\NVQ<4()0,/5=!MV594#[I1X:F*>+S5-."A7Q64LESIEP79*LAFN1$@
MA_)5$&V"^$53RJ-7KJ'R9MQ MCIE;[35)3G+BNEK;>_IE_$%:NJ0Q]"!N@_.
M*;^D-*.#,8O =Q&^F)A(V]QNQBR(4YV2VEPW4/ <JPP6(G03N)F[9)LF<>($
M+LXU:!*:LB*I(8QALH;72.K@D'H:N7\[$)UZ[!GN9LP^/7OQGW<1 /<!U%5
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M2G=CF@QH.RK,C7=,5,1[MC.JQZAX9M.>J+E.V$DM8]3L,M73H6>G5&9\CU+
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MG*'8'D&P]Y:4QH4]P/6E\9Q%C Z*;;\';X^!TX\1P+@_.Q"=O" 'L$[@CT\
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M2+KP=20O+2WK!9*WLE6\,19=]D#6%OT%94VV=\YZNFTNN0K !&;/D:N '9<
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M]O>-6C>H<>,V>L5_&W&>V4/87]H#>;.E+K1)?:[2]E'2YUPJ(]I:>+,--8/
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MV*=+Q/2"8-_BR<4G5'CL%.EEA!$]_/:7H.]+T/<EZ'MQ_GB)CEZ<SQ2<F\A
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M&,N9!Y5ET8,,CK+WD_&G,R9\$@X)&<F19,:Q5$EO@8%!$C0VNC*%S#XI@V>
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MQ3*C+PN5\U9S==V 4<Q414:'C,N(JA$J2GQ%.M/($#)P:J^ 4C6GX]+/4"A
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MH2KM>&#!F+.CI+T[GHA[#"Z*M@+' R'&(".W2S@>@C"2LZA;.!P/ 1B)#]=
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MN^(A, V3K?F_H7;5![R6+W&TY?R\P?]*/6IOEIHRC7X"0+I4 ^M1RY5J[$/
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M"X0.^83PTB2[CLNRI"5/TCP+G@Z]Z:MEA'8=I;FI3CD#]2Q GL&[JW9*[%F
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MA5=4UK%P#('^!BIL=>.CC7M<>TERVL7)NY?X#J^^M:NJ%$_;N;I>U44*GC'
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MIT1M_SJ5-@2YF8/XJ;X=H%J@0D-G..XMUO57?HB2[AX._@QRQ\0&\WJ_I,W
M,%35\+?V&U,[;(WZB*?]A/G2ULY0ZYBD3HZF<BK+7C]?/]WP7UF9E;+5NH!<
M]. 9?;/'TZ[,UL1=A10=E;^^R[J!7'SK>;-X\2R\X]:10EH@AG?4B#' V?WQ
MQM:YW?L%"U@_@=U77D&YQBPE:P6%1RLXQ9:Z&7F5Q$<PI3</U64*5D0$^R+A
M8O%W@1/)39!NPYB4I1NXZ,_]E3XI@7'L9R^0?2.HM05Y:IZ.:$N\ ,3*</L$
MZ?1PYS2QW'=)>9[FQ8[JDZQF UJ8.A!(0JG-)JS-'MA6V(W * !R>BB-)$6A
M0C7#MJ0MR%VM#'V5XVB=9;%O"60T,"K&F*E@TPBHJ]&BK7)/D!NJ&/CRA(]>
M;<W6Z]/>=@CA,@.M9!TANH=F=)R1HX$D#LXJVED/JMISRMJ?K#-(("Q5"--Q
M8Y[E\PY=P&U/HB1XPXP&4]66(7PK- 1)@\+(/&X<6K.SP\J12C%_(T>&=]E+
M?79^_*NR>P]I"N9LJ!0C-Y283BWV;<K #$<<".%P+3+ 1*%F.M+KXX[JVZOW
M*TOLQVD%YOC(%TPR@&>G[V^\$XUO>4_P))+BCARF"I<T!'FU#!-C#^UZHB9@
MC7(E$5)-A$1C[S+*:O!'UCM\?VWI=#")]I.VZ??K:#E 8D$_>]^"0WZH0K?6
MR0VJ@KB:9&6#%%>ZO<QS;!-/%)4=8IA!LW +Z-LK^.W:.PO#@<F2.@"A9C+8
M8,R:X6-V01XN:""8LF_.V-X@;Y//1'0>1E['>2)6S/3[@5S^\*;DU!]2: CV
M8F69O4;9REPSB;53D)&Y4_&^;0J59RY3Z@9VY]N3[@56/"*R041>.L18;OIC
MD$EC7%^(HE7EPM5:7.=/$.<LM&JH./)/& ",MB<UEA2/&W5\<QU^6L4Z"YT?
M1O4%>]0;*7^]:\J#8'$DP-(*\N_BI+3W5;):*VY5MR-,+8)C&:5!8X8RJVF.
M!>8@*27\IWICHS^R KE/+6.B6G,P$$AY23=+ N_&8]PE(SH:OG&,N F2RGD/
MQ(2"4GSF'["B=L 2?$Y3RGSVHGR'QZ%'H>4@MMIB.9 1YFAH,)!"Y69<YNE.
M_.RT,<"<*:V'OOIVI99EKRB$P7WM$[:V2A?_]0-9:;K=XY/]__T_4$L#!!0
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MR<7UI1C@7WK=8+NWV]G=6Z?PERQL#*OIP5,2]%MFJC?Y\UJY82U7K9&,MGE
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MB[0K\FI;9&IL?$TEH9L4!<C-ND4FP;7PJW&00D_[HXISM^1+=D PP>.D264
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M;@.N]J;J[O-.86WH6+REAR,6UCK[3 EM^AX!;1SH)K\?2M.\' ZI(  7&=F
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M8,X*K7F2I(A*=++:%IRN"$FCSLDJY6.!4SYV5RD?JY2/)U_+[S?E8R6POX[
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M^?J6RLMG@S2:_?PG. O%./[Y_P%02P,$%     @ Z(Q^7/;?]5AE#0  RIH
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M4@,%E?E-@#%4ILI4IE<[*C,"I6@"-ZBLY"'BQ0'*K$K$O0J#*")I&JM_HL[
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MC/FLX= TO<;HM$0G&?TAU9'3&\ Q4%^\0':8A+@OVHIM>38%=<.4*>XW>.7
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MQ^6Z#? =QQ(G'G!C#KT-T?J4Q7[BJI7/ $<M )KZD,-/"%EK!C\#,C"0]1'
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MLT9RH1U18ZK[Y<JH2MI(4TRY."W90#&A$ZD71B&1Q3RSJ\_U-D*]#?31Z=H
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M$?7]"A%U0QSJCU"&.+R<LS3$P1 '0QP,<3 JA"$$AA 80G#'6;;;U3G+E#C
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MS4YK_]40W.OZ(%XY(S3+S<,*"T@J01]W'D]##<&L'<&L$=82'LIX$3B"@KE
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M5>E&++,;H?L1%%LX  JZ2_0G8<X7<EN=US;T4?'"$ACLC%IS&8:Z,Q3:7@/
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M$LO%]S0]_/<T'9?4'PA]_>*XI/^VZ+]02P,$%     @ Z(Q^7%%G:&RU,P
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M<;]P=;A?J^Z@@5/I";.ZJJQ@S:%KVX/6CDHM8(5J=1  ><GA:UF"6RZ6B_;
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M:<"#S)@B['87BT4G2;DLE9@9KF39B57>!<_;FUB#KS4R6PT'S""$?;\_]/S
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M-(+@.;<W, 5G=;X=%$P;B;K,>%'=XV208QZAAI3K'%3Z*+FS%U K_J9"14R
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M$1(^)TOM,JK7L&^4#[9Z#?<N^F]02P,$%     @ Z(Q^7)KS&;'@!0  U1\
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M-S$U,#@R-E\P+FIP9U!+ 0(4 Q0    ( .B,?ER%A/H'LJ8! %/I 0 2
M          "  :DJ 0!I;6<Q-#<Q-3 X,C9?,2YJ<&=02P$"% ,4    " #H
MC'Y<=?>Q@ L-  "N#0  $P              @ &+T0( :6UG,30W,34P.#(V
M7S$P+FIP9U!+ 0(4 Q0    ( .B,?EQ]]G%XP>X! *DH @ 2
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M,34P.#(V7S8N:G!G4$L! A0#%     @ Z(Q^7/9K%B>?(P4 JC$% !(
M         ( !?PH. &EM9S$T-S$U,#@R-E\W+FIP9U!+ 0(4 Q0    ( .B,
M?ESP=90!CYT! (?? 0 2              "  4XN$P!I;6<Q-#<Q-3 X,C9?
M."YJ<&=02P$"% ,4    " #HC'Y<L($F7KT0  "$$0  $@
M@ $-S!0 :6UG,30W,34P.#(V7SDN:G!G4$L! A0#%     @ Z(Q^7 6BQ$E[
MXP0 QSD[ !$              ( !^MP4 &QX96\M,C R-3$R,S$N:'1M4$L!
M A0#%     @ Z(Q^7%,)K&^?YP$ LBH= !$              ( !I, 9 &QX
M96\M,C R-3$R,S$N>'-D4$L! A0#%     @ Z(Q^7.#-LM\%,@  O70! !
M             ( !<J@; &QX96\M97@Q,%\Q-"YH=&U02P$"% ,4    " #H
MC'Y<]M_U6&4-  #*F@  $               @ &EVAL ;'AE;RUE>#$P7S(P
M+FAT;5!+ 0(4 Q0    ( .B,?ES7S.&P^%0  )^Y P 0              "
M 3CH&P!L>&5O+65X,3!?,C,N:'1M4$L! A0#%     @ Z(Q^7* 0FV+Y"@
M/G4  !               ( !7CT< &QX96\M97@Q,%\T,2YH=&U02P$"% ,4
M    " #HC'Y<46=H;+4S  #2<P$ $               @ &%2!P ;'AE;RUE
M>#$P7S0R+FAT;5!+ 0(4 Q0    ( .B,?ER)_(T(G 4  ,1    /
M      "  6A\' !L>&5O+65X,C-?,2YH=&U02P$"% ,4    " #HC'Y<-J_^
MJ8P)  #6/0  #P              @ $Q@AP ;'AE;RUE>#,Q7S$N:'1M4$L!
M A0#%     @ Z(Q^7 XQ<\>."0  VCT   \              ( !ZHL< &QX
M96\M97@S,5\R+FAT;5!+ 0(4 Q0    ( .B,?EQ:Y7U<U04  &X?   /
M          "  :65' !L>&5O+65X,S)?,2YH=&U02P$"% ,4    " #HC'Y<
MFO,9L> %  #5'P  #P              @ &GFQP ;'AE;RUE>#,R7S(N:'1M
64$L%!@     7 !< I@4  +2A'     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>lxeo-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxeo="http://www.lexeotx.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxeo-20251231.xsd" xlink:type="simple"/>
    <context id="C_80886119-480b-48c9-8ffb-65158995fa72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_80a79c85-4eb7-478c-9356-9eedeabc3701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lxeo:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_80d471cc-64f2-4ab5-9d83-c7f5596929ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-28</instant>
        </period>
    </context>
    <context id="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-28</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <context id="C_8453d8e7-a1f5-4915-bf2c-6ebc643f48ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_84571f91-58c3-4594-8881-2ecd5286cf9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_84e826fb-ff2b-461e-a57d-ab9f5b605b0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8525b582-4e2a-4627-be2a-eadd8568fd9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_890b7df4-85e3-41e4-b1fd-4859a5a3807e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="C_8be8bafc-0873-440f-bfc2-64f112f3e6ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_8d5bfde0-a484-4470-9cd3-618c66bc014d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8eaec952-271e-49b4-9770-a01b8320fedf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8f865621-f365-4210-8b47-da03eb5738c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_929d55a0-9e11-462d-ad46-1599e64792f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lxeo:InvestmentInEquitySecuritiesOfInvesteeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9610981c-dbfa-4244-b967-0edb48cea85b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_96240578-4334-4f1a-be14-256259efbda3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9779ca0e-2456-4a3d-a96f-ccee925f0ee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_97bf9bb9-fd01-4c00-b07e-186f54c06f37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="C_98d0b57c-8a4e-4d95-ac5f-068c0243f116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:Thirty-DayUnderwriterOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_99561f6d-e4ca-4b39-a707-cdaeb6211e33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lxeo:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9ad4d83e-62ad-4f4d-afe5-59f007561415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9ad9569e-82f6-46d0-91e6-51f179cc5dad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-28</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <context id="C_9af02223-ca95-445a-b4e5-6659c2e7fccc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_9b72a311-fda5-4b44-874c-7a79d1c0981d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:ThirdPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_9c4cb1e5-c1a2-4e02-af65-dbb6700815f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a00433da-f67f-4690-982b-b7fff11be3f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a240413b-0d7d-487c-bc56-518232b357e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-28</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <context id="C_a31771a9-2900-4c49-8cb5-d8544ddd403d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyFiveInducementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="C_a404e138-86a1-415f-86fa-bd92d7670e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_a5a4ebfd-7511-4fbc-860a-5324a475f3a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="C_a707e4a6-c6ec-4da3-a440-f202623bc25e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_a71aae44-530b-4c44-887c-3235e51cb928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_a77def4a-c9cb-4e98-960a-031f93bc0880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a87f627d-9dbd-40af-86cb-7af479bf48e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_aa8f2f22-e100-44a6-a895-7f6b95043573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-21</endDate>
        </period>
    </context>
    <context id="C_ab655c89-08d2-4df1-80c6-4cd7801eced4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-28</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <context id="C_ac474d05-a4df-41bb-8c49-c9dddccf1523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ae431a33-037b-46c8-a9af-9018491b4fb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_af7f7cbb-e358-4e01-9e01-445a10e44bc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b108cd4a-1106-42e3-838b-ca809495548e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lxeo:InvestmentInEquitySecuritiesOfInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b5e6a80b-0a90-4061-b5e3-d557692232e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b7328e55-a04d-45a3-8322-e2fb9ba87bc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-23</instant>
        </period>
    </context>
    <context id="C_b7718c79-bbe6-4525-98cb-4ccd075faa86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b783d3da-cc32-4fce-b2ea-93ee7627889c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b80b39e4-ee70-4ac9-8254-8612c66068cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b91348ae-b86b-4d6f-a90a-d0705420ee0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b95a7326-401b-4311-bbad-80ce85f07dc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2029-08-01</startDate>
            <endDate>2034-07-31</endDate>
        </period>
    </context>
    <context id="C_ba4e7baf-9823-4208-bf61-fb7520c113df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ba541477-4977-4a4d-8ea6-08f08a69b3a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bc2c08ed-32fb-4bb9-9165-ff7bf6d493e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:Thirty-DayUnderwriterOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="C_bc5f8bd3-0209-4df6-a1d0-ca324664dc73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bcddf2df-722a-4a3c-bd72-c6695de021e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_be3196c0-6c7d-48a3-80e1-3571e67be6c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-21</endDate>
        </period>
    </context>
    <context id="C_beac3254-3c89-4564-8632-f79760e1f8b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_bf8a2e00-8278-456e-a9f7-bbc406b2f028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bfb6f0b8-2842-4607-80c2-158502e95022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c04bdcf3-b841-4689-9b64-38b332249fe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:PerformanceRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c0f2a034-41be-457c-99b1-4288da908b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_c104adc9-73de-4e0a-aec0-20142b5b14fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_c43d4a9b-6f01-447c-8344-401a3e883847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c6383d22-c520-4a85-89c6-6b07e625c012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-28</instant>
        </period>
    </context>
    <context id="C_c6ce4425-ba2c-49ff-99d6-85aeeb9dd72e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c8a465c9-e39f-4d34-ac7a-5fe710f82f82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_c8d1b98f-fda8-4237-9715-247e14f34e52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c98b542f-c785-4f70-99a0-bd604bf1c422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_cddcf69a-38e1-41ca-92b2-1dc2813f0ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondAmendmentToTheThirdCornellLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-17</instant>
        </period>
    </context>
    <context id="C_ce351259-df29-4736-b0f7-5bd85eaae4a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondAmendmentToTheThirdCornellLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ceb6a661-0f1c-4d6c-bf35-6817f0cf2a23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lxeo:InvestmentInEquitySecuritiesOfInvesteeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_cf7275ec-9001-4e72-987c-f42dac6949d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="C_cf9feab1-814e-43f8-90af-29fdc96653e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d1c75657-09b5-459b-b8d8-8d04ceccb855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d2859d77-9d6d-417d-b711-d050b24f282f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2017-02-17</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d3d8d14a-d897-4e92-bd97-3e0646e0e634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_d5204099-2478-4b5e-b1d3-d4947afd3ec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d6948e0b-b33e-4c10-b2f9-1d23d6fdb1f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d98675e8-bd97-4502-824d-9b7f8f9d89bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d98866d0-7481-4b7b-bca4-1dd7071333f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_da57ec1f-8f38-4bd6-9e52-115625f9b6b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_db28a574-1df7-4c2a-a2c9-fa8fa1f5bb06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2029-08-01</instant>
        </period>
    </context>
    <context id="C_dcf1d763-8592-412d-b293-cc3b5ba5d13f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ddd009c3-4182-4517-ab43-5a05f6879a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="C_de179b0b-31a8-495a-bf4e-3b6ec6689dce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e04e0666-d468-4c9d-9610-e8fa883f856b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e09c5ca9-c296-43da-b854-8d0d1dd047e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_e0c81d42-7bd1-4198-a287-73123a961a0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e272bdc5-b039-4362-8f99-fa87bcc9aa26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxeo:RNolanTownsendMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e4a107b2-cde8-4301-ac61-de3823035653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedUCSDSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e52cbdd7-cdf3-4600-944f-875c024f274c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="C_e5d2a857-7730-4e56-882a-9078bd9748d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_e8b9a53b-cf8f-4ca6-984a-ef4b65858fd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e9b9062b-8c12-49f1-a351-c5a94c169bed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e9dc71b0-9639-4d01-9da6-f620a88b25a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="C_eca6767a-469e-41ac-95c7-b2ab4461a834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ee384e21-7454-414e-9150-7230bc2c8387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f0efe85b-fed2-44b8-8e9c-9573fb1386d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="C_f15ba613-2ee7-4a4a-a5f6-e7630c6a7078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f35a4807-02c2-465e-a506-734387ea3d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="C_f3a8649e-4f53-4947-a5b7-6b4f853ce45b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f42c0641-10f4-40b1-862a-8bb73b4c2821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="C_f55932cf-ba63-4d0b-b12f-3a6366360e35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f5b4784b-582b-414e-b258-a9581e148ae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f5cfe846-47a5-4562-b31a-858c10c03a88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2026-03-27</instant>
        </period>
    </context>
    <context id="C_f6ffc1a5-c795-4565-95e3-4d24febe677f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f806ed52-1a8c-4157-881e-dbcb5b86b7fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f97419ff-d263-47c9-8d19-9400a45c4996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedUCSDSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fb7cdb9c-5e73-4b92-9e27-ac79a42a2be1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fc0d444a-c280-451e-a6ac-f592154451d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="C_fc4e6f8b-c480-46e3-af2f-471fb85da201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff8f1290-9480-4529-b296-ace3425207d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="C_ffbe2738-6916-44a3-9ab9-b7d08af02d03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_00ff945d-1722-46c0-8cb8-739f6c508cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_016a9c4e-9503-4416-a9e9-6e06fb5aba55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_028187ae-2bdd-401c-9d01-a0eff189025b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_02c649ee-2689-4467-af86-e845ba2c5b89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_04fb7643-33b5-4b2c-b8e1-4cf6f989f885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0869a89c-0354-44a1-82dc-7940298b2ae8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_08eca4a4-adfe-4cb1-ad4d-04bbfa80f9d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="C_09b1664a-a411-44c8-8629-2f95a673f0c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0bf10b12-a23b-4f45-9d50-7e648eecff42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="C_0c86e317-598b-4fc3-9ec5-6c3828cd4653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0d4934d2-685d-4142-9a39-88dfc50f3990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0eb85a0b-e29d-45c6-a281-a90d66d244dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0f7ea42a-4e43-4f1e-a004-b523e0aeb298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_10c07d1a-63f8-4282-9c3d-df142d9339e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedFirstUcsdAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="C_112bc5bb-417e-47b7-868a-20b951733299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_15d4c068-ac5b-4885-91c7-6d538b1e1b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1735de27-a8af-415d-8fe1-67386826cc66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_18edec8b-db33-4c8f-b074-18226230e3bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1f09b079-161e-4135-8af4-e2998386a171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-28</instant>
        </period>
    </context>
    <context id="C_1f1718fb-6b55-4400-93d6-9f15b60b4646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MarchTwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1f3e3006-1af0-48a7-9634-48ce1dc96196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1f5a81d6-9a7a-4e3d-81e3-123c0c43d34b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-04</instant>
        </period>
    </context>
    <context id="C_1fd1bb70-d88e-4bd3-9f2b-0ae04cc83ef6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="C_213bc6a0-4d38-4376-bd17-5ea5dbcd6e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxeo:RNolanTownsendMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_22f53fb5-b715-4275-818b-b00d6389e9cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_23f2cf9c-eb2c-4874-9bb5-0b7e43ac44cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_248d415b-1dda-43fc-94db-d4c94d4bcf0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_250aa9ae-d108-452e-bc1b-21c4551179b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="C_25fca7a5-ade5-42ee-82c0-94f05ff45965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_26366915-140b-4c96-93b7-e237b4213687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_276b6562-55aa-419f-88ec-75b79f842098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="C_2917ec7c-ddbb-4d8a-a527-3f8895a2283c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_292ca90b-72fb-49a6-a3ab-69036c90f439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_29a85535-be63-45f2-b8b1-970ed18a0e41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_29e7aba1-e6b3-4d85-8383-eedc450375e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2c5a6104-de8c-4a89-b38f-5b76f25de136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="C_2d45877d-8c3e-4498-98ab-785fe7b33f59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="C_2d6d8b8b-f338-4359-9fa9-714c220f91b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2f5d2c9e-b849-4bde-ac52-df6ce3e72476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_304ec79b-72af-4cbd-af93-f335e40345bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_306cf451-d0e8-4733-9390-77a092116c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_30c2f2ac-b0af-4f98-a1b6-41ccc4e13693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-14</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <context id="C_324cf665-a528-4a30-91f6-882210006248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-13</startDate>
            <endDate>2024-04-13</endDate>
        </period>
    </context>
    <context id="C_33a1d373-61e1-4dbc-8ca5-46559d2ba9d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_349227bb-1ea5-4421-9800-ea1f0cfc9551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_34b52306-94cc-4920-be25-ed2fc77dc45f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_357e96c3-27bb-4127-968c-48df3cab0274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3740bd83-e4cd-4204-8ee9-2432a933e74a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_38fa9b64-95c3-4a46-9bf4-5fef14d31d49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_39a48e76-d9cd-4ef5-a9db-a32bb4c223a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-31</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3b196e9a-f7ba-488f-8a3f-bdc43e626635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="C_3bd21372-e009-4064-a11c-8bf9c564cecf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellFirstLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_3bd640a5-6ed0-4cd8-a0d7-639661192341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3cd08b17-0362-4b62-b0f6-efc4c3963b9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3d145bd9-a80d-4e38-8f51-01b475e8e55b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:TwoPortfoliosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_3e5cdc3c-a4d4-462c-af4f-ff0564c0387a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_3efbfffb-0778-4c28-91b0-3428da47503f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_407ffdfb-fc65-4627-a3b0-cb0f4c4c5eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_40e7b7c8-b1b6-4586-9359-a5aa9b41336e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_418db8cc-20a6-4c63-bc80-22f00e85ab78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="C_425a9b2c-585d-47dc-ace4-2331628255c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4295b1e1-3df8-42bb-8a20-af116ecee6bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="C_44925c32-c071-4fdb-951d-3cec6e8d40c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:PerformanceRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_464f0f91-9b5b-4c2d-9f37-9b998e5a31ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_46c792b5-6c67-472c-9304-76b2d83ce68a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_487136e8-5828-4a30-8230-e11cfaee5e4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4883c806-04d5-4bad-8a04-6447a094163d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4bb6390f-6ce6-4793-8fc3-7a90375636cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-28</instant>
        </period>
    </context>
    <context id="C_4bc16bb1-ead2-4dbd-aca6-b88278c3172f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4c89430b-37d5-4909-a62c-9a1965b0a9b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_4cb98960-d47c-4c98-b396-48e50d6696e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AbiomedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4cdd6443-84d6-48d5-acd5-108c91102bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4e91b53a-c865-4846-b046-8b4dbf9ae7f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_51b02334-8c26-4f78-ac6e-af4cbca2320e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="C_54cd63d0-b34f-4997-8bdf-7b733713a458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-21</instant>
        </period>
    </context>
    <context id="C_58b9ae1c-e54e-4971-8058-707bb52b2a1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_59ff464b-49f8-40f8-92d9-92d1e9a17142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5b4016c9-50ff-46d1-a19f-672dd8c141a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c2eaa43-838e-4de5-ab2b-12e3438f3233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-21</endDate>
        </period>
    </context>
    <context id="C_5f0fb589-18d5-4129-b711-24379e2c8f87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5f20fea3-e69b-4604-90bc-497426fe388f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_601b6cb4-c759-4fde-8d48-72ad686bc4c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_62dae8ef-bcab-47b7-8b50-1e70e0f56090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_63514d7b-26f0-4ca4-a6a2-01e151213a0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="C_63a872cf-6e8e-4d40-9cbb-3023e8fdb46c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lxeo:PerformanceRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_650a7937-a18f-466c-853a-cd74ae06db6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondAmendmentToTheThirdCornellLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6b7cf2f5-7ba2-40f3-98b8-0a47a4bcab82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:MayTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-28</instant>
        </period>
    </context>
    <context id="C_6bba1c1b-df97-48f4-bb20-fa63b15d96c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2029-07-01</startDate>
            <endDate>2029-07-31</endDate>
        </period>
    </context>
    <context id="C_6bf5181b-cf84-46b5-b3bd-e929f2acc332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="C_6efb2e92-a65f-43f5-9c07-dfb2973f3821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025FinancingTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_725ecbd1-08d1-4d48-b06f-22dc4a077218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_72e10212-d78b-4f0e-a46a-69781278fac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_736d03a4-f8aa-492d-b0a2-7f25fcc32295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_73d54a48-f66f-434c-bf6c-25a6a7ff448b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_74917b61-bde0-47fb-a510-eeb410d819a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_75180180-4d90-42c6-8270-15e1f3cc0ebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="C_75647768-9be4-4729-b3de-fab3b1e0526d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_76a788a3-f953-4f3e-ab5a-d2f1c0ac015b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_773cd297-399a-44b4-b688-630eaee896cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-14</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <context id="C_79952fb3-c2a3-4723-8ef3-9b6960397749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7b1bb5e1-9fac-4bb1-8736-1cc221d0c743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lxeo:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:October2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="C_7c175820-3a63-46e1-a5a5-b8abc4c71645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7e067386-c3d6-4f06-8490-86af6f1f1e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="C_7e56c74e-cfef-48b5-b83f-54670366ec44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_Installment">
        <measure>lxeo:Installment</measure>
    </unit>
    <unit id="U_Segment">
        <measure>lxeo:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_IntegerItem">
        <measure>lxeo:IntegerItem</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Employees">
        <measure>lxeo:Employees</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_e7a01de1-bf3e-40e8-9e7e-4cd9492acbf1">FY</dei:DocumentFiscalPeriodFocus>
    <ecd:TrdArrDuration
      contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"
      id="F_6085f8d5-1d88-4b06-8022-add485b42a8d">P605D</ecd:TrdArrDuration>
    <dei:AmendmentFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_2541e626-1367-458b-bbab-46a459670ae0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_38234b1c-5edd-4426-bbe6-7a9362d9b0dd">0001907108</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      id="F_ceacd56d-047e-42df-8382-2f180e72f798"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      id="F_368454f4-1de5-47d4-a463-ff48edb9c65d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="INF"
      id="F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4283524d-7551-4b90-bb15-d2729ab6b502">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_33986856-2fc0-46e5-a0a8-20e6e13001c1">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="INF"
      id="F_a037ea15-adec-409e-8c43-b3ef64e5bcf7"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="0"
      id="F_b1bf8275-7776-4ea4-af70-17f51659f92f"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_e0a776b4-cd38-4a5b-a550-b174de5f9791">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4c373ade-17c9-42a4-8fca-94f68ac71857">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4b046694-f296-4bda-81c8-a1694365c5bb">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_b91d79a0-c67e-443d-a0f1-de72a46d783a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_ef6143c7-40ca-47ed-bba3-3e02960ea5ea">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_54184ca8-2817-4c72-a416-25c1444dfd33">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_a26e98e3-8309-4c29-bc73-0c2fc2b1f8e4">001-41855</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_80f3740b-8306-412b-a0a8-017c5b78fde8">LEXEO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_0280aeed-0d23-4730-9854-12115c0638f2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_a16615ff-d376-44b7-b6f7-d3936bfe6eb6">85-4012572</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_ad6bb34f-8403-4d29-b855-bccb6ae1ba53">345 Park Avenue South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_cfaf305d-eddb-479b-868a-60c8295ca6e2">Floor 6</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_973c998a-a639-4e54-8d76-820d21acdc5b">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_85dd90ad-6ea7-40d3-bbad-a5ac9738c8f5">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_be0308c6-cb64-4089-b1cc-b5e66ebb9e88">10010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4a294f0d-2543-400b-8cb4-020328ece41b">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_b81d9c79-cecf-40dc-98f6-45b3801cecd5">547-9879</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_767d0f28-eee6-4994-831a-77d2efc545cb">Common stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_2c6fff88-97bd-46d3-bf06-f481c8035d6e">LXEO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_991a37e5-e1b1-4103-bfec-b75a8d04b261">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_a29c0ca0-98a8-4996-a7fd-3f3de7b9ea1b">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_3fcaa6e2-ff60-4b99-a275-1b11379dd84d">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4210625f-858d-4816-9e52-eccb3888eda1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_bbe00754-361e-4855-ac39-f22cd40b79ac">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_3773621d-e60d-4505-a141-b361e2f7b1fd">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_cf83e2fe-79cf-4541-8359-f3133dcf2271">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_67c6dfd6-e4c0-4151-acf3-3d7b451c23ec">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_8b3e257f-508e-4c72-83c7-9c50022e8826">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_92bf24e8-b018-4172-be48-40d9adf3deef">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_34f30981-b50b-4387-90c6-72eb5ff6ed77">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_0aaae845-30a0-4f82-9bd0-c75a4f26b0a9">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_ffbe2738-6916-44a3-9ab9-b7d08af02d03"
      decimals="-5"
      id="F_3f6d003c-d867-42b9-89ac-493f659b5790"
      unitRef="U_USD">216500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_f5cfe846-47a5-4562-b31a-858c10c03a88"
      decimals="INF"
      id="F_05de7b49-e43d-4d9e-be95-4208d3f41f61"
      unitRef="U_shares">74087063</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_c288761d-28b1-42b5-ae2b-b6e8d33ac086">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s definitive Proxy Statement relating to the 2026 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_2cb3fa28-d975-4f6e-b3f2-b03d1bf1830e">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;It&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;em 1C.    Cybersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with our overall risk management processes. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; specialized third parties in connection with our risk assessment processes. These &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third parties assist &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;us in designing and implementing our cybersecurity policies and procedures, as well as in monitoring and testing our safeguards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also conduct IT security assessments on our key third-party service providers and require them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of their security measures that may affect our company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not previously experienced any cybersecurity risk or cybersecurity incident which has been determined to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;material&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K, including the risk factor entitled &#x201c;Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#x2019;, CROs&#x2019;, manufacturers&#x2019;, contractors&#x2019;, consultants&#x2019; or collaborators&#x2019; cybersecurity&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The day-to-day implementation of our cybersecurity policies and processes is primarily overseen by our Vice President, Associate General Counsel in consultation with our Chief Financial Officer and external advisors including our IT and Cybersecurity consultant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Vice President, Associate General Counsel has more than a decade of advising on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our information security policies are developed and implemented, and are reviewed at least annually with updates authorized and approved, by the security governance steering committee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the like. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our audit committee provides updates to the board of directors on such reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_3920ee7b-9952-46a0-9a3e-72c172346ea0">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with our overall risk management processes. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_606fd40d-2748-45da-9a78-bd0e87176290">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We devote resources and designate high-level personnel, including our Vice President, Associate General Counsel, who reports to our Chief Financial Officer, to manage the risk assessment and mitigation process in a manner that is consistent and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with our overall risk management processes. &lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_e11aa698-34fc-464a-bd10-e0735db5d9fa">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_757c3ef2-efc5-4c06-ad08-8723bfa89d8d">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_5ce4fb98-c1c3-4eee-8537-f8078274f53a">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_06785609-6331-4c5c-b390-3bf32e4f4581">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_35427883-a395-402e-a99d-4625a3960e67">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The day-to-day implementation of our cybersecurity policies and processes is primarily overseen by our Vice President, Associate General Counsel in consultation with our Chief Financial Officer and external advisors including our IT and Cybersecurity consultant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Vice President, Associate General Counsel has more than a decade of advising on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our information security policies are developed and implemented, and are reviewed at least annually with updates authorized and approved, by the security governance steering committee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the like. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our audit committee provides updates to the board of directors on such reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_416bdb1c-ed4f-460d-85f8-f2669f63016c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our security governance steering committee, which includes senior representatives from key functions including Clinical Operations, Legal, Finance and Human Resources, has primary responsibility for assessing and managing our risks from cybersecurity threats. &lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4cb19957-994e-42f8-9c3e-11f91bb09252">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our security governance steering committee oversees our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_fbfb4b45-843b-4871-8419-0c6b19ddab6d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Vice President, Associate General Counsel has more than a decade of advising on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk management and compliance in the highly regulated biopharmaceutical industry. Our IT and Cybersecurity consultant has &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;over 20 years of experience with IT, with an emphasis on cybersecurity over the past four years.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_96c51d91-2318-487a-8548-cd8079a080ae">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is informed about the prevention, detection, mitigation, and remediation of cybersecurity incidents through support by our security governance steering committee which, in consultation with external advisors, oversees, works with, and delegates daily operations to the IT/IS and other teams.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_a8a01c89-23ea-4309-955f-d6cd7487eed5">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_cb5c1cdf-953f-4ca1-958c-546ed3a31260">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Representatives from our security governance steering committee provide periodic briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_c057350e-7249-439e-b047-314d1215c2cc">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorName
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_f9187263-f794-4022-9929-996f9fec4cf1">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_6e10bc5d-b42d-4088-b72a-046e8b4d0924">New York, NY</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_cb0b1a84-77ce-42fe-be35-5c373a978a50">185</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_f4a9c584-1d89-49db-9049-43dc8d232835">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_11cd94bc-034d-4d5c-a68c-2c06bdbd1e5b"
      unitRef="U_USD">63000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_ee43894d-2f0c-4328-a95e-cd29f299a844"
      unitRef="U_USD">35014000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_36041f32-cdfa-444f-87d2-64a5e5fe39d8"
      unitRef="U_USD">118767000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_c296701c-1c2c-4bab-9df0-acfd95ce807d"
      unitRef="U_USD">86504000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_16816d9a-5b45-40eb-a5a2-10fa6bb6ea90"
      unitRef="U_USD">6625000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_f2d7499a-661a-4fb2-bae0-bf66f420d1e4"
      unitRef="U_USD">4603000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_f490f37a-e7c7-4990-8276-832476fa2b6c"
      unitRef="U_USD">188392000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_fcc0571f-4164-4980-8bdf-1d8dd82f9c54"
      unitRef="U_USD">126121000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_138975e0-14a3-4691-9420-df4f7f0fda2a"
      unitRef="U_USD">64801000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_ceb24957-b365-4052-9d27-1c70b76b6072"
      unitRef="U_USD">7012000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_4842e689-c071-4dc0-abb6-534e4008f72c"
      unitRef="U_USD">3390000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_2ee9a83c-35c9-42b1-9282-15c1b97b2a14"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_69aad6d9-d451-460e-a615-6d41e28e7a51"
      unitRef="U_USD">3248000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_7a59a8bb-70e2-4a9c-9175-683e7a6dd96b"
      unitRef="U_USD">3252000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_eba6e54f-2fbe-4967-aba4-e2ce10623ef8"
      unitRef="U_USD">1139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_9f330d11-31a9-49ae-a1c0-375d974501c9"
      unitRef="U_USD">1028000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_fb0ae98a-c6d5-4d76-921c-c2ac63cc9abd"
      unitRef="U_USD">1140000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_de0fd2e6-eff4-46b6-8709-5e236eff56af"
      unitRef="U_USD">1460000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_d38bbc13-ea8c-42d4-a54b-f04d1244ae4a"
      unitRef="U_USD">6578000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_ba6337ee-1e83-4514-aa1d-91c9ba3b777e"
      unitRef="U_USD">8069000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_16512271-359a-4331-8010-4758010c4c26"
      unitRef="U_USD">268688000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_b1eed479-1f2d-4318-a558-13b8d6a2e3e6"
      unitRef="U_USD">146942000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_f69f85bc-3d7f-4d2b-b137-0ef82da9623d"
      unitRef="U_USD">4856000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_cef2b44d-ad09-4199-99e6-5941d3ee291f"
      unitRef="U_USD">6417000</us-gaap:AccountsPayableCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_b5798667-0dee-4ca4-a7fd-2ddf957722d8"
      unitRef="U_USD">9277000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_a8963962-d414-42fc-82fd-279a94f5fb72"
      unitRef="U_USD">13759000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_ad866abe-c681-41dc-83bd-6d53567cd8f3"
      unitRef="U_USD">518000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_f097beb6-5e9c-45f8-b9a4-0901a47a1eb7"
      unitRef="U_USD">570000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_0ab2b583-828e-497d-8b16-1dc15975c33e"
      unitRef="U_USD">2157000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_368aa708-bed3-40e4-9736-1ef57894c7ab"
      unitRef="U_USD">2100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_31b8d4ec-3c8a-4880-aeec-2d7771c4a840"
      unitRef="U_USD">16808000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_a33049ba-679d-43c7-a692-5a6befd48364"
      unitRef="U_USD">22846000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_5b0c0abd-e52f-4eae-9370-0febd9a06695"
      unitRef="U_USD">327000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_34b2fb84-c480-46ad-8496-816e4dd4caaf"
      unitRef="U_USD">817000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_5f020d6f-721a-4b70-9a53-263bea9ae2bb"
      unitRef="U_USD">4884000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_0b6dc946-8bc6-43d5-a99a-4baf367ea619"
      unitRef="U_USD">6437000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_9100e677-6bcf-4388-ab8e-c84ac1257d22"
      unitRef="U_USD">22019000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_804c2b23-b8a9-4591-81ca-39765c7f22c3"
      unitRef="U_USD">30100000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_fb9534a0-503c-44ce-a758-0a0322ac3e81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_400fa09b-1951-4349-a387-4ad5ad8459ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_d24b4bef-032a-479c-8122-d4b42d61f0a8"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_f6a5b704-50d7-4bb1-975d-caae7845d8a1"
      unitRef="U_shares">73001766</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_949a5c99-b3c4-4365-8321-1e14d923c0ff"
      unitRef="U_shares">73001350</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_657ab82a-9f94-485b-8f1f-b6df4bed9e41"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_0c7ce63a-70a9-4223-a08f-271a1731ac26"
      unitRef="U_shares">33079209</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_bc22177c-8026-4649-b5af-67811874aee1"
      unitRef="U_shares">33071261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_a37b0f0c-1899-485e-8afe-19f0e0f0276e"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_63a7693b-6765-4b77-8eba-d5c3c12bd600"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_c326932d-dfea-4abf-bea9-876770df2ab5"
      unitRef="U_shares">3827</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_0d617b7a-3af2-4251-add5-29d8bb39d25f"
      unitRef="U_shares">3827</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_e769f0fa-9802-4133-8978-7f2649272a43"
      unitRef="U_USD">17000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_f06cc5ee-f461-453b-aa8d-8aa5df4c1c70"
      unitRef="U_USD">17000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_7db15c86-8801-4bc5-a6f4-0192e00140ac"
      unitRef="U_USD">626625000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_70419780-cf1d-4daa-a821-9db99e09311a"
      unitRef="U_USD">397132000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_e4431c10-149d-4676-bf16-8249d40af340"
      unitRef="U_USD">188000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_60774371-b1b8-4895-b48d-f91a8bc58237"
      unitRef="U_USD">-103000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_d0321b32-1e28-4d56-a90b-bae1eabe8d8d"
      unitRef="U_USD">-380134000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_a61523e7-c4d1-46d4-86a8-9bb6dad242b6"
      unitRef="U_USD">-280173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_81e31564-23ce-4c3b-8980-8af9cb337951"
      unitRef="U_USD">246669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_5dd4a5fa-1af6-418f-8d65-d06efb168cab"
      unitRef="U_USD">116842000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_c7899df8-a28a-40a8-bdcb-b7f826368a73"
      unitRef="U_USD">268688000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_8118d413-3d11-421a-bc48-5051f832a97f"
      unitRef="U_USD">146942000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_af7c918e-5403-4c30-b588-74bbde0b9801"
      unitRef="U_USD">63797000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_74465d86-4e2f-4ca7-aa25-ec78bfc5afb1"
      unitRef="U_USD">74091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_32b5ff73-6d34-471b-aabe-2dba4917dc6b"
      unitRef="U_USD">45460000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_79b1df42-efd2-4727-893b-c603ac3d9533"
      unitRef="U_USD">31675000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_69e49168-9486-440f-aa9c-f6f0a2ae61f2"
      unitRef="U_USD">109257000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_92ac435d-ec19-4114-9451-3d7c58825a51"
      unitRef="U_USD">105766000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_eeab5b70-1d49-423a-a835-19db70fafd03"
      unitRef="U_USD">-109257000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_c63512c6-dbe2-4f1c-9c5c-ecde19989cc2"
      unitRef="U_USD">-105766000</us-gaap:OperatingIncomeLoss>
    <lxeo:GainLossOnLongTermInvestment
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_0636fc8d-fa46-4834-9a4b-906f8036fc37"
      unitRef="U_USD">3390000</lxeo:GainLossOnLongTermInvestment>
    <lxeo:GainLossOnLongTermInvestment
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_b99fde9d-977a-4e01-a1ab-e4181b929e43"
      unitRef="U_USD">0</lxeo:GainLossOnLongTermInvestment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_b7870828-2901-43a2-816d-c3ed73e2f47a"
      unitRef="U_USD">-18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_d128fb34-baaf-4885-87c3-c4a657d225c3"
      unitRef="U_USD">-9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_f183d57d-95f4-4dcc-80d6-e46f0f0e4d2e"
      unitRef="U_USD">95000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_6215676e-5693-4d64-8a1a-c96d336f0634"
      unitRef="U_USD">137000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_7c394868-9bb8-4789-b905-f86a7792b7fb"
      unitRef="U_USD">6130000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_594c4403-ba0a-4a70-8fc8-09e27b89f6dd"
      unitRef="U_USD">7556000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_45d76906-bc2f-45e9-8e11-93b82efa1a06"
      unitRef="U_USD">-111000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_abfee1cb-3437-4222-aa0b-2c7fdf64377b"
      unitRef="U_USD">23000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_80fdfbd2-c4d6-41a1-a26c-16facac6d2bc"
      unitRef="U_USD">9296000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_a4862f17-608e-4732-8fe5-d242e820bf11"
      unitRef="U_USD">7433000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_9f187737-bc80-4043-8530-18afa481460a"
      unitRef="U_USD">-99961000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_24180deb-ee78-4783-bef3-b0917264dc49"
      unitRef="U_USD">-98333000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_9dfeacdd-8e84-4e7b-926e-7cbd084300c9"
      unitRef="U_USD">-99961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_cf843747-66a2-4716-9ab5-6479814962a4"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_51d8a6ed-78cf-474f-bd3a-b9d802267235"
      unitRef="U_USD">291000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_d4508b5c-9b08-4949-b54d-3fda4d556f6a"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_297110b3-ca72-4248-8504-90552c9c9978"
      unitRef="U_USD">291000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_c62f26ed-d0db-44d1-acbc-b7bce22fcd08"
      unitRef="U_USD">-103000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_7001bd0e-95c7-4375-bef0-61cf0a2850fa"
      unitRef="U_USD">-99670000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_68b3d33d-fee6-47b3-9e7b-6322aaabe1cb"
      unitRef="U_USD">-98436000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="2"
      id="F_4da3ad9d-c46a-4ffd-bd7b-7bf7e60919c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="2"
      id="F_1f1ee703-c271-42ff-95f2-43e079acf5bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="2"
      id="F_5e147f05-641a-46af-922d-8df91ddd0b04"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="2"
      id="F_b10529a1-1918-4c41-8eeb-ef2e7409632c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="0"
      id="F_6c46047c-3d36-48fc-be78-03b99c9ecef6"
      unitRef="U_shares">53645323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="0"
      id="F_bee34e93-6a25-4435-98af-00f68e594cdd"
      unitRef="U_shares">53645323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="0"
      id="F_e41677eb-9444-4470-acad-e704730c4e92"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="0"
      id="F_1f8354d8-bb43-41c8-ac4e-de5ed225a894"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387"
      decimals="INF"
      id="F_eab061b3-afdd-4482-b3e0-509cf9d7cd92"
      unitRef="U_shares">33071261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387"
      decimals="-3"
      id="F_fbf3ab88-d5d7-46b7-ad93-e6b49aebf8c4"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c98b542f-c785-4f70-99a0-bd604bf1c422"
      decimals="-3"
      id="F_c47092d0-66b2-4b12-9416-5c039d2f462f"
      unitRef="U_USD">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d5204099-2478-4b5e-b1d3-d4947afd3ec0"
      decimals="-3"
      id="F_0ec28fb7-0674-49a5-8435-f499a268807c"
      unitRef="U_USD">397132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_73d54a48-f66f-434c-bf6c-25a6a7ff448b"
      decimals="-3"
      id="F_6be7b679-6f4f-4ccc-879c-8b338ee7c79f"
      unitRef="U_USD">-103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bf8a2e00-8278-456e-a9f7-bbc406b2f028"
      decimals="-3"
      id="F_c9cdf4f8-490e-4bd3-92d1-73b678bd1481"
      unitRef="U_USD">-280173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_facdff5e-37c0-4d28-919b-ecd2ee353678"
      unitRef="U_USD">116842000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_112bc5bb-417e-47b7-868a-20b951733299"
      decimals="INF"
      id="F_6e9b9d2d-418e-43c4-b910-f67b55a7c4b5"
      unitRef="U_shares">15300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf"
      decimals="-3"
      id="F_11538c6a-26e8-4bae-9c2e-d875dffdb4fb"
      unitRef="U_USD">59000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_b1b9fd2c-a4ae-42ff-a45e-f56904e77a1b"
      unitRef="U_USD">59000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lxeo:IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits
      contextRef="C_112bc5bb-417e-47b7-868a-20b951733299"
      decimals="INF"
      id="F_c5cb9ef9-53d3-4852-8dc8-c111731488a5"
      unitRef="U_shares">101448</lxeo:IssuanceOfCommonStockUponVestingAndSettlementOfRestrictedStockUnits>
    <lxeo:IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits
      contextRef="C_112bc5bb-417e-47b7-868a-20b951733299"
      decimals="INF"
      id="F_35bffbcd-1a4e-4af9-8ea1-87ddc79cce0e"
      unitRef="U_shares">76800</lxeo:IssuanceOfCommonStockUponVestingAndSettlementOfPerformanceRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7c175820-3a63-46e1-a5a5-b8abc4c71645"
      decimals="INF"
      id="F_9247c9f6-dc4d-4dee-92f2-6bff7eabc3fa"
      unitRef="U_shares">102837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c6ce4425-ba2c-49ff-99d6-85aeeb9dd72e"
      decimals="-3"
      id="F_23770fb5-46e2-4b03-a79d-a4948d9215d0"
      unitRef="U_USD">270000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_425a9b2c-585d-47dc-ace4-2331628255c0"
      decimals="-3"
      id="F_04494a20-9beb-4467-9055-3085d5196f23"
      unitRef="U_USD">270000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare
      contextRef="C_112bc5bb-417e-47b7-868a-20b951733299"
      decimals="INF"
      id="F_3f8c5157-a3f7-43f0-a891-520f6cb1a368"
      unitRef="U_shares">7532</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf"
      decimals="-3"
      id="F_dde38d27-11a4-4fd5-a11a-bfc495ed501e"
      unitRef="U_USD">37000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_80d8a434-062b-47a8-adc6-eaeae017d49c"
      unitRef="U_USD">37000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_5f0fb589-18d5-4129-b711-24379e2c8f87"
      decimals="-3"
      id="F_41c72c9f-7663-473a-9873-53606eb163dd"
      unitRef="U_USD">6917000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_15d4c068-ac5b-4885-91c7-6d538b1e1b06"
      decimals="INF"
      id="F_f1aca9c2-d211-4095-b368-e78fc92fdc2c"
      unitRef="U_shares">20790120</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_15d4c068-ac5b-4885-91c7-6d538b1e1b06"
      decimals="-3"
      id="F_0660f0cc-6141-4e75-bef8-b8f48e69e364"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_29a85535-be63-45f2-b8b1-970ed18a0e41"
      decimals="-3"
      id="F_246d2a0c-49f3-4bad-bf3a-255d688a7ccd"
      unitRef="U_USD">73080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c"
      decimals="-3"
      id="F_657fdb4b-f8bc-4a9f-9bfc-e0b59ac29041"
      unitRef="U_USD">73082000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d98675e8-bd97-4502-824d-9b7f8f9d89bc"
      decimals="-3"
      id="F_b5bce218-74a0-4d7e-82b1-6e4df1b70c6c"
      unitRef="U_USD">9833000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6efb2e92-a65f-43f5-9c07-dfb2973f3821"
      decimals="INF"
      id="F_736b899f-3b0d-40f0-b1b0-6d795d99024f"
      unitRef="U_shares">17968750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6efb2e92-a65f-43f5-9c07-dfb2973f3821"
      decimals="-3"
      id="F_18bba22b-765f-4f54-9d9a-44e6cd031c99"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4cdd6443-84d6-48d5-acd5-108c91102bcf"
      decimals="-3"
      id="F_aa7f28e3-3d82-4157-8aa9-0c37a3ffe5a0"
      unitRef="U_USD">143915000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_00ff945d-1722-46c0-8cb8-739f6c508cf4"
      decimals="-3"
      id="F_3f649258-3087-4370-9153-4e5d63e5ba46"
      unitRef="U_USD">143917000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lxeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants
      contextRef="C_112bc5bb-417e-47b7-868a-20b951733299"
      decimals="INF"
      id="F_7423311e-4168-4071-8fd3-62d2a4a13c99"
      unitRef="U_shares">867302</lxeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfPre-FundedWarrants>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_f3a8649e-4f53-4947-a5b7-6b4f853ce45b"
      decimals="-3"
      id="F_98bb721c-9f89-4daf-81cc-05dd00da8647"
      unitRef="U_USD">291000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_35380284-3759-4f5a-a499-86ca0ac2f62c"
      unitRef="U_USD">291000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_3ae1180f-5b76-420c-85ff-d3be022ee9cf"
      decimals="-3"
      id="F_20413f96-cdb6-45ee-ac0f-72406c4bdc2e"
      unitRef="U_USD">12132000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_1e60075c-2d04-41e2-a6ca-1fcea783c9bc"
      unitRef="U_USD">12132000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_34b52306-94cc-4920-be25-ed2fc77dc45f"
      decimals="-3"
      id="F_320091d4-ac11-4b06-b4cd-ca271e954bf7"
      unitRef="U_USD">-99961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_35ee62a4-aafa-4066-99f1-14074c487851"
      unitRef="U_USD">-99961000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e5d2a857-7730-4e56-882a-9078bd9748d6"
      decimals="INF"
      id="F_ed28f6a2-93f6-410d-9716-5b16b2fd735e"
      unitRef="U_shares">73001350</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e5d2a857-7730-4e56-882a-9078bd9748d6"
      decimals="-3"
      id="F_4c5af0e5-0739-4ad6-8570-cb6a83fc7d8b"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f806ed52-1a8c-4157-881e-dbcb5b86b7fd"
      decimals="-3"
      id="F_39499fe0-71b6-4ace-8065-1e4bd3ada84b"
      unitRef="U_USD">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a87f627d-9dbd-40af-86cb-7af479bf48e9"
      decimals="-3"
      id="F_41999666-d7a1-41f8-acf3-b637d68230cc"
      unitRef="U_USD">626625000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0869a89c-0354-44a1-82dc-7940298b2ae8"
      decimals="-3"
      id="F_143b5e35-4237-4198-8ea7-0bd086e13cb5"
      unitRef="U_USD">188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_04fb7643-33b5-4b2c-b8e1-4cf6f989f885"
      decimals="-3"
      id="F_56811452-7ba9-4260-a67c-21e427438622"
      unitRef="U_USD">-380134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_167152cf-046d-42d4-8819-0e1bc1494229"
      unitRef="U_USD">246669000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c"
      decimals="INF"
      id="F_2cc26037-cc74-45db-be39-10de7cb86f1b"
      unitRef="U_shares">26646378</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b4ac534d-0bf9-4194-93c0-70fb4a00c49c"
      decimals="-3"
      id="F_9e88b0b4-d095-41c8-bfe8-bff29f02124c"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_44925c32-c071-4fdb-951d-3cec6e8d40c7"
      decimals="-3"
      id="F_eab4ffee-bfc2-4c4b-8b03-51fa0dbc73da"
      unitRef="U_USD">295372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_84571f91-58c3-4594-8881-2ecd5286cf9b"
      decimals="-3"
      id="F_5d290633-b538-4721-ad16-712046dcdb4b"
      unitRef="U_USD">-181840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e"
      decimals="-3"
      id="F_662ac55f-bb25-4d22-acef-0d576b04c04c"
      unitRef="U_USD">113535000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603"
      decimals="INF"
      id="F_53e87738-6cca-4220-b0c5-0288f69cf39d"
      unitRef="U_shares">135646</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022"
      decimals="-3"
      id="F_40defbee-0168-4cbd-bd93-b3ba6dd40f7d"
      unitRef="U_USD">491000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_d5b1d745-739e-4544-8211-57c0a77fff48"
      unitRef="U_USD">491000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare
      contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603"
      decimals="INF"
      id="F_016de2cb-bc74-4a6c-b392-fe7542717336"
      unitRef="U_shares">14159</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022"
      decimals="-3"
      id="F_24e1c2a2-925a-48c1-8530-93cc13bd237f"
      unitRef="U_USD">59000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_d2f1687a-6934-489a-85dc-daebae331732"
      unitRef="U_USD">59000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0d4934d2-685d-4142-9a39-88dfc50f3990"
      decimals="-3"
      id="F_5f3304f5-1d4e-4672-86c7-cc8db8cd8513"
      unitRef="U_USD">6287000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603"
      decimals="INF"
      id="F_a29a6639-faf8-476b-ba85-e252d1942294"
      unitRef="U_shares">6278905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022"
      decimals="-3"
      id="F_fe3f9d51-6602-463f-ba17-51285c2457a6"
      unitRef="U_USD">88712000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_8c0e57c7-d5a7-43e8-ad19-e49f5b999db0"
      unitRef="U_USD">88712000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lxeo:StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred
      contextRef="C_1e28f21b-7c6d-47a7-8fd0-439588bd5603"
      decimals="INF"
      id="F_92ceedff-904e-4388-975a-443c14bda726"
      unitRef="U_shares">3827</lxeo:StockIssuedDuringPeriodSharesNewIssuesAdditionalOfferingCostsIncurred>
    <lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred
      contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022"
      decimals="-3"
      id="F_07526941-8850-494c-87bb-9efc859fa5ab"
      unitRef="U_USD">-24000</lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred>
    <lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_da09ce65-2461-4ec3-b063-2593393fc12e"
      unitRef="U_USD">-24000</lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_7e56c74e-cfef-48b5-b83f-54670366ec44"
      decimals="-3"
      id="F_48be89ee-53b4-4a19-8e09-f13c20a72612"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_410030fa-e185-46e6-90e9-9125a8e41825"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_736d03a4-f8aa-492d-b0a2-7f25fcc32295"
      decimals="-3"
      id="F_4a267839-ec6d-4815-ae3f-be691d6042b2"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_9c2f9297-0697-42f1-9a17-2a8a1e5496f5"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_bfb6f0b8-2842-4607-80c2-158502e95022"
      decimals="-3"
      id="F_923795fa-9ddf-4015-92dd-a67fb83db0f5"
      unitRef="U_USD">12474000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_2b363799-b2ff-43db-90ae-761cba3c5ec1"
      unitRef="U_USD">12474000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_de179b0b-31a8-495a-bf4e-3b6ec6689dce"
      decimals="-3"
      id="F_1be0b22a-ef6e-4de2-abde-b181b9858bbc"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_472cdfe2-4487-41db-8dd3-22d676b47efb"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387"
      decimals="INF"
      id="F_6d8c0210-22cf-4878-a19f-f269c554fd6b"
      unitRef="U_shares">33071261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ee384e21-7454-414e-9150-7230bc2c8387"
      decimals="-3"
      id="F_b83934ec-bdd1-4f88-b8bb-07ae0d3e035c"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c98b542f-c785-4f70-99a0-bd604bf1c422"
      decimals="-3"
      id="F_4ba7fd7a-6f02-4407-bbcd-9c3327a9e8ff"
      unitRef="U_USD">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d5204099-2478-4b5e-b1d3-d4947afd3ec0"
      decimals="-3"
      id="F_c70659a2-68ba-4fb7-ba74-63e4882b3ee5"
      unitRef="U_USD">397132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_73d54a48-f66f-434c-bf6c-25a6a7ff448b"
      decimals="-3"
      id="F_0f81b5d6-3043-4d80-9e65-0433935222d2"
      unitRef="U_USD">-103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bf8a2e00-8278-456e-a9f7-bbc406b2f028"
      decimals="-3"
      id="F_e9336e11-45ce-45cf-a647-6980eadb3a07"
      unitRef="U_USD">-280173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_1d959a49-53d6-4d55-bbb3-85594d18ef09"
      unitRef="U_USD">116842000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_d8834712-2616-406c-b09d-4c0782a6b322"
      unitRef="U_USD">-99961000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_d4efb90c-fb37-45dd-80e5-56ebc61a0c21"
      unitRef="U_USD">-98333000</us-gaap:ProfitLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_bdb5d2cb-fd6e-4e1e-b93a-40a7b161c080"
      unitRef="U_USD">1491000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_f87397a6-f013-446d-a5a1-cd313421aa56"
      unitRef="U_USD">1373000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_48c3d67a-ac89-4e7d-b62e-dcc36c32408e"
      unitRef="U_USD">320000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_bafbe454-a396-44a6-8177-77d068313678"
      unitRef="U_USD">325000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_a2f130ad-cb63-43c2-95fb-c2d0a260959b"
      unitRef="U_USD">12132000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_59d9adc4-b966-4b33-b029-49603a371dd6"
      unitRef="U_USD">12474000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_d0c3be5c-0681-4396-8d85-af0353683565"
      unitRef="U_USD">268000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_b9b42cab-34bd-45c4-8926-37826c3bd9a4"
      unitRef="U_USD">304000</us-gaap:DepreciationAndAmortization>
    <lxeo:Non-CashGainLossOnLong-TermInvestment
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_71abbca2-eac9-4ac0-af3f-d331c70777ac"
      unitRef="U_USD">3390000</lxeo:Non-CashGainLossOnLong-TermInvestment>
    <lxeo:NetRealizedGainOnInvestmentsInUSTreasurySecurities
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_f069d183-56ce-404d-84e1-79ccb8a44fcd"
      unitRef="U_USD">17000</lxeo:NetRealizedGainOnInvestmentsInUSTreasurySecurities>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_379063fb-0b60-4cc5-8887-0a46affc1f64"
      unitRef="U_USD">-111000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_5bd004c8-b345-45c3-9d1b-b3efe773ab2d"
      unitRef="U_USD">23000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_60802085-d0e3-4b12-b6dd-4b4101b68f58"
      unitRef="U_USD">2004000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_c7606991-4685-4319-82b8-ef129be70015"
      unitRef="U_USD">1690000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_e5fe5324-515b-4249-84dd-14e28d814efe"
      unitRef="U_USD">-1561000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_a906b40e-6151-4d8e-95c1-0ab4e6c55ac6"
      unitRef="U_USD">2378000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_663f693e-34ce-40ce-9c12-af7ae80e833b"
      unitRef="U_USD">-4445000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_fd54ef0e-3c83-4021-a2e2-118425fbba46"
      unitRef="U_USD">3367000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_c0a6968a-da58-4bd4-b8d9-7d00ec78ddda"
      unitRef="U_USD">-1496000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_35f64803-d4fc-42e3-8335-47dfaa821369"
      unitRef="U_USD">-1336000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <lxeo:IncreaseDecreaseInFinanceLeaseLiability
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_7e4e0309-d561-4898-9af6-1479541184ee"
      unitRef="U_USD">-9000</lxeo:IncreaseDecreaseInFinanceLeaseLiability>
    <lxeo:IncreaseDecreaseInFinanceLeaseLiability
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_bf498c41-6e5f-456c-8cfb-653ace04b289"
      unitRef="U_USD">10000</lxeo:IncreaseDecreaseInFinanceLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_99da0629-49bc-4d75-9944-b5e1e7778d3c"
      unitRef="U_USD">-98561000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_5b9428e8-c62b-4dfd-939f-d874c5db28ce"
      unitRef="U_USD">-81151000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_bb4445fb-2a6d-489d-86bb-2597f553e7eb"
      unitRef="U_USD">397000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_a4c0e199-b531-41ec-8c1b-8f1ed668e29c"
      unitRef="U_USD">481000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_528e28e3-92d2-4c8c-957b-92684f685359"
      unitRef="U_USD">195382000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_8d268cfd-5b33-4052-978f-090999ec95ed"
      unitRef="U_USD">93596000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_c2474a81-df57-47c2-8be2-52e402b9f2d3"
      unitRef="U_USD">105527000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_0d2f8480-abf0-4a9c-8314-47469a105364"
      unitRef="U_USD">-90252000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_b10802fb-54b9-46aa-a6b7-5a42b5d872df"
      unitRef="U_USD">-94077000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_8c193c66-f75e-477a-a0ab-f22ccdf4ae10"
      unitRef="U_USD">59000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_4e52e039-433f-4836-b2e6-33563f072791"
      unitRef="U_USD">491000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_4ccefd7c-9288-4088-a27f-6bdca3b29f9b"
      unitRef="U_USD">533000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_58dd4593-4894-45c9-9f20-99fe2c670b3f"
      unitRef="U_USD">410000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_4d43dfd3-d9b1-4a74-85ef-91a081d9a984"
      unitRef="U_USD">270000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <lxeo:TreasuryStockRepurchase
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_fdc30b41-6e3d-4fa4-9df3-b2dea8a095e0"
      unitRef="U_USD">17000</lxeo:TreasuryStockRepurchase>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_6bdce0f9-6f4b-44b5-bcd0-84b910508503"
      unitRef="U_USD">94999000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_1f1718fb-6b55-4400-93d6-9f15b60b4646"
      decimals="-3"
      id="F_632f2e8b-c19c-45d5-848c-301be7fbb9fb"
      unitRef="U_USD">6287000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_0f4fd527-d5c3-43b6-b1b8-59db0523c0d0"
      unitRef="U_USD">79999000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c"
      decimals="-3"
      id="F_d30a1e9a-8d1c-4f9f-9528-8f25566638e0"
      unitRef="U_USD">6917000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <lxeo:ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_1e201160-205d-460d-991d-d2c37fe91407"
      unitRef="U_USD">153750000</lxeo:ProceedsFromIssuanceOfCommonStockAndPre-FundedWarrantsToPurchaseCommonStockUponOctober2025FinancingTransactions>
    <lxeo:Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_64d30f02-c347-4185-af3c-bc0a969426ee"
      unitRef="U_USD">9833000</lxeo:Third-PartyCommissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactionsmmissionsAndOfferingCostsIncurredUponOctober2025FinancingTransactions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_fe3678e4-f233-47ac-b902-79929fccd094"
      unitRef="U_USD">216795000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_f11d8000-fb97-4345-8169-669942c4439b"
      unitRef="U_USD">88776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_ec7df91c-0a8b-4a9a-b1b4-4c67afc87bad"
      unitRef="U_USD">27982000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_52d0b26c-d106-4d52-b9a5-fc7ac32920ba"
      unitRef="U_USD">-86452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_1be64c03-dcc0-4b0f-9dc9-9dbc31fecf61"
      unitRef="U_USD">38266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e"
      decimals="-3"
      id="F_ac4a2a67-067d-428b-aa47-14b1ff5869cd"
      unitRef="U_USD">124718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_062576d5-d055-4322-b904-c81838e04dbc"
      unitRef="U_USD">66248000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_57c21e09-4f88-4ad2-bccd-760cee342765"
      unitRef="U_USD">38266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_acde7595-1341-4527-810b-f7188a5d32b8"
      unitRef="U_USD">104000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_0df762a0-ec50-4a74-9eb6-5996a69d7710"
      unitRef="U_USD">127000</us-gaap:InterestPaidNet>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_c0f16817-5e7e-4399-8ba4-196c929a507e"
      unitRef="U_USD">291000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_bc2b2be0-182a-48c2-b73f-f113567b3be5"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_648c4baf-86ad-4535-ae6f-d4e0504cc145"
      unitRef="U_USD">37000</lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord>
    <lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_e91e0092-4938-4312-835e-964ba5f672b1"
      unitRef="U_USD">59000</lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord>
    <lxeo:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_ea95e97d-1601-4b88-8858-94e2b9d2f69f"
      unitRef="U_USD">25000</lxeo:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_fe4c35d7-9bb9-46b7-93d5-e8e075dc15aa"
      unitRef="U_USD">18000</lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses>
    <lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_832a25bf-cc5b-462d-bcc0-ac8efd9d420a"
      unitRef="U_USD">98000</lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses>
    <lxeo:FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_4256e468-0674-4ad8-9a18-b7dc6288d971"
      unitRef="U_USD">22000</lxeo:FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized>
    <lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_5a0fa78f-b96b-4018-9fe1-e597fe114ca7"
      unitRef="U_USD">-120000</lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_07b461a2-4814-4ac1-bda2-486cd7529a7f">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Description of Business and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Lexeo Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular disease. The Company utilizes adeno-associated viruses (&#x201c;AAV&#x201d;) that have been engineered to transfer genes to patients. The Company&#x2019;s therapeutic investigational treatments include AAV-based gene therapies primarily in the clinical and late pre-clinical stages of research and development.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is located in New York, NY and was first formed on February 17, 2017, as an LLC under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company filed and executed a certificate of conversion to a corporation on November 20, 2020, to convert the LLC to Lexeo Therapeutics, Inc, a Delaware corporation. All of the Company&#x2019;s tangible assets are held in the United States (&#x201c;U.S.&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The accompanying financial statements and these notes reflect the operations of the Company that have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The Company has no unconsolidated subsidiaries. Certain prior period balances have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Need for Additional Capital&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Since inception, the Company has incurred net losses and negative cash flows from operations, including net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the years ended December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025, the Company had cash, cash equivalents, and investments in U.S. Treasury Securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;246.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. During the year ended December 31, 2024, the Company received total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commissions and offering expenses in the March 2024 Private Placement (as defined below) (see Note 7). During the year ended December 31, 2025, the Company received total net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commissions and offering expenses in the May 2025 Private Placement (as defined below) (see Note 7), as well as net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of underwriter commissions, placement agent fees and estimated offering expenses in the October 2025 Financing Transactions (as defined below) (see Note 7). Management estimates that the Company's current cash, cash equivalents, and investments in U.S. Treasury securities balances are sufficient to fund its operations for at least 12 months from the issuance date of these financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the ability to secure additional capital to fund operations, and commercial success of its product candidates. Any of the Company&#x2019;s current product candidates and future product candidates that it may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance- reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-5"
      id="F_a1c2afbc-77e5-4b14-ad44-ebd4c629e7e2"
      unitRef="U_USD">-100000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-5"
      id="F_503cae36-5d13-403d-9a1a-7fab00a669ab"
      unitRef="U_USD">-98300000</us-gaap:NetIncomeLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_464f0f91-9b5b-4c2d-9f37-9b998e5a31ca"
      decimals="-5"
      id="F_aa135659-ca41-4113-805d-bbc5cf3005be"
      unitRef="U_USD">246600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-5"
      id="F_9e8898a5-d476-4c41-b9d8-a8f3048d44be"
      unitRef="U_USD">-380100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_1f1718fb-6b55-4400-93d6-9f15b60b4646"
      decimals="-5"
      id="F_4f033471-e1b5-4065-8be9-cb5221adca30"
      unitRef="U_USD">88700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_1f1718fb-6b55-4400-93d6-9f15b60b4646"
      decimals="-5"
      id="F_2fc1a8f9-a108-4487-a355-32cb4e533e9e"
      unitRef="U_USD">6300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c"
      decimals="-5"
      id="F_775e1ffe-22d9-421b-9289-26d80550cb96"
      unitRef="U_USD">73100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e0c81d42-7bd1-4198-a287-73123a961a0c"
      decimals="-5"
      id="F_7c0ba0ae-510c-414f-9461-8e981350f92c"
      unitRef="U_USD">6900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_39a48e76-d9cd-4ef5-a9db-a32bb4c223a3"
      decimals="-5"
      id="F_4f7b3d3b-ee28-4498-8ac2-f6086724105c"
      unitRef="U_USD">143900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_39a48e76-d9cd-4ef5-a9db-a32bb4c223a3"
      decimals="-5"
      id="F_938eafbc-aede-4e06-8d3e-3c3520b31fee"
      unitRef="U_USD">9800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_adb28d5c-9803-40dd-8b2a-58b62ff3cfbe">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#x2019;s stock option awards. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2025 and December 31, 2024, the Company&#x2019;s cash equivalents were held in U.S. government money market funds. As of December 31, 2025 and 2024, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#x2019;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&#x2014;Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of premiums of approximately $149,000 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, at December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company follows the two-class method when computing net income (loss) as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares and pre-funded warrants to purchase shares of common stock outstanding for the period. In accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the pre-funded warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During the years ended December 31, 2025 and December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,117,976&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,724,218&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; total potential common shares, respectively, related to the exercise of outstanding stock options, settlement of outstanding restricted stock units ("RSUs"), settlement of outstanding RSUs that vest upon the achievement of certain performance conditions ("PRSUs"), and exercise of outstanding warrants were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering in stockholders&#x2019; equity as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and Administrative&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent and occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Based Compensation Expense&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of RSUs and PRSUs. The measurement date for employee stock option, RSU, and PRSU awards is the date of grant, and stock-based compensation costs for employee non-performance awards are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on a graded basis. Compensation expense for equity awards with performance conditions, including PRSUs, is recognized if and when the Company concludes that it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each reporting period for equity awards with such performance conditions and adjusts compensation expense based on its probability assessment. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award, and stock-based compensation costs for non-employees are recognized as expense over the vesting period on a graded basis. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation expense for all equity awards is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the Company's 2021 Equity Incentive Plan (the "2021 Plan"), (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#x2019;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#x2019;s balance sheet and statement stockholders&#x2019; equity are reduced until such awards vest. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option grant under the 2021 Plan and the Company's 2023 Equity Incentive Plan (the "2023 Plan", and together with the 2021 Plan, the &#x201c;Plans&#x201d;), and shares issued under the 2023 ESPP, are estimated on the date of stock option grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU and PRSU granted under the 2023 Plan is equal to the closing price of the Company's common stock on the date of the grant. Prior to its initial public offering ("IPO") on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options granted has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.&lt;br/&gt;&lt;br/&gt;The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. As of December 31, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against its deferred tax assets (see Note 10).&lt;br/&gt;&lt;br/&gt;The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2025 and December 31, 2024, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t identified any uncertain tax positions.&lt;br/&gt;&lt;br/&gt;The Company's policy, to the extent uncertain tax positions exist, is to record interest and penalties related to uncertain tax positions in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-term Investment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company accounts for its long-term investment in nonredeemable convertible preferred stock in accordance with the provisions of ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received was based upon an observable price of cash paid for an identical security in an orderly transaction with a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#x2019;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#x2019;s cash equivalents consist of investments in U.S. government money market funds, and the Company's cash investments consist of U.S. Treasury securities. The Company&#x2019;s cash, cash equivalents, and restricted cash are held with large financial institutions that management believes to be of high credit quality. To date, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any losses caused by uninsured balances.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#x2019;s Chief Operating Decision Maker ("CODM") is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer ("CEO") and its senior leadership team&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The CODM reviews the Company&#x2019;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 6 for information regarding the Company&#x2019;s capitalized operating and finance lease right-of-use assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:50.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:14.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of the Company&#x2019;s leases include options to extend or terminate the lease. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Adopted&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&#x2014;Improvements to Income Tax Disclosures, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which focuses on the rate reconciliation and income taxes paid (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires a public business entity (a "PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4283524d-7551-4b90-bb15-d2729ab6b502;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU No. 2023-09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in ASU No. 2023-09 prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for all periods presented, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December 31, 2025, the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ASU No. 2023-09 retrospectively, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which only impacted the Company's income tax disclosures with no impact to its balance sheet or its statements of operations and comprehensive loss, stockholders' equity, or cash flows (see Note 10)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Adopted&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ncome Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure of specified information about certain costs and expenses in the notes to financial statements. ASU No. 2024-03 will be effective for the Company starting in annual periods after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the FASB issued ASU No. 2025-11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interim Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 270) ("ASU No. 2025-11"). ASU No. 2025-11 clarifies interim disclosure requirements and the applicability of Topic 270. ASU No. 2025-11 will be effective for the Company starting in interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_dd9251d7-d441-4586-8c90-32edc7e52c59">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#x2019;s stock option awards. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_c0f8f576-bbcc-4184-86e5-cf9520df9881">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2025 and December 31, 2024, the Company&#x2019;s cash equivalents were held in U.S. government money market funds. As of December 31, 2025 and 2024, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#x2019;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_0499df78-d87c-47dd-9372-6fdd1068c1fd">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&#x2014;Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of premiums of approximately $149,000 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, at December 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <lxeo:InvestmentCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="0"
      id="F_2653fba8-e4bb-464e-80fc-7a10d713da51"
      unitRef="U_USD">39000</lxeo:InvestmentCurrent>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_604d5608-7491-4afa-a586-ec1db37b5088">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company follows the two-class method when computing net income (loss) as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares and pre-funded warrants to purchase shares of common stock outstanding for the period. In accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the pre-funded warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During the years ended December 31, 2025 and December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,117,976&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,724,218&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; total potential common shares, respectively, related to the exercise of outstanding stock options, settlement of outstanding restricted stock units ("RSUs"), settlement of outstanding RSUs that vest upon the achievement of certain performance conditions ("PRSUs"), and exercise of outstanding warrants were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f55932cf-ba63-4d0b-b12f-3a6366360e35"
      decimals="INF"
      id="F_eb97fa16-88c1-447c-9b02-dfbfbb9bc5c4"
      unitRef="U_shares">19117976</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_25fca7a5-ade5-42ee-82c0-94f05ff45965"
      decimals="INF"
      id="F_5fbe8c77-bca6-4943-815c-2b69d7d302cd"
      unitRef="U_shares">3724218</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_e2db8082-7e6f-42f3-b476-cd8c1cfb293a">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering in stockholders&#x2019; equity as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_8afa0537-69b1-4fca-ba24-c89eee6e8193">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <lxeo:GeneralAndAdministrativeExpensesPolicyPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_e902b28d-681c-4906-9360-f2e8d33796e8">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and Administrative&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent and occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.&lt;/span&gt;&lt;/p&gt;</lxeo:GeneralAndAdministrativeExpensesPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_4d841078-4762-40c4-9576-dfd43fa259a1">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Based Compensation Expense&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of RSUs and PRSUs. The measurement date for employee stock option, RSU, and PRSU awards is the date of grant, and stock-based compensation costs for employee non-performance awards are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on a graded basis. Compensation expense for equity awards with performance conditions, including PRSUs, is recognized if and when the Company concludes that it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each reporting period for equity awards with such performance conditions and adjusts compensation expense based on its probability assessment. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award, and stock-based compensation costs for non-employees are recognized as expense over the vesting period on a graded basis. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation expense for all equity awards is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the Company's 2021 Equity Incentive Plan (the "2021 Plan"), (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#x2019;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#x2019;s balance sheet and statement stockholders&#x2019; equity are reduced until such awards vest. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option grant under the 2021 Plan and the Company's 2023 Equity Incentive Plan (the "2023 Plan", and together with the 2021 Plan, the &#x201c;Plans&#x201d;), and shares issued under the 2023 ESPP, are estimated on the date of stock option grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU and PRSU granted under the 2023 Plan is equal to the closing price of the Company's common stock on the date of the grant. Prior to its initial public offering ("IPO") on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options granted has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_6739fad4-b63f-4663-aabb-76d1649a82b5">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.&lt;br/&gt;&lt;br/&gt;The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. As of December 31, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against its deferred tax assets (see Note 10).&lt;br/&gt;&lt;br/&gt;The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2025 and December 31, 2024, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t identified any uncertain tax positions.&lt;br/&gt;&lt;br/&gt;The Company's policy, to the extent uncertain tax positions exist, is to record interest and penalties related to uncertain tax positions in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_24c82dd8-0a1a-4091-b00c-46a547ac77c6"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_cdac3c04-4abf-4d05-a9e9-e06038826e73"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_7d79acfb-72e1-40a5-88fd-14af0ee0a34d">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <lxeo:LongTermInvestmentPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_a0e2e0c3-5e70-4281-a574-a7918ccb4416">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-term Investment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company accounts for its long-term investment in nonredeemable convertible preferred stock in accordance with the provisions of ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received was based upon an observable price of cash paid for an identical security in an orderly transaction with a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.&lt;/span&gt;&lt;/p&gt;</lxeo:LongTermInvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_ed58df19-61ac-4ecf-8903-241902ce294a">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#x2019;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#x2019;s cash equivalents consist of investments in U.S. government money market funds, and the Company's cash investments consist of U.S. Treasury securities. The Company&#x2019;s cash, cash equivalents, and restricted cash are held with large financial institutions that management believes to be of high credit quality. To date, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any losses caused by uninsured balances.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <lxeo:LossRecognizedFromUninsuredBalances
      contextRef="C_d2859d77-9d6d-417d-b711-d050b24f282f"
      decimals="0"
      id="F_fa79d0ba-7eb2-446b-a238-084cef2114b9"
      unitRef="U_USD">0</lxeo:LossRecognizedFromUninsuredBalances>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_d2d7bbbd-e065-4248-b1bd-e42534b407b4">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e7dad4e9-6283-4160-8fca-ca95a81ec6d6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#x2019;s Chief Operating Decision Maker ("CODM") is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_2dd977cf-810a-4dd6-95fd-4c1ac234c12e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer ("CEO") and its senior leadership team&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The CODM reviews the Company&#x2019;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_1873d81b-8fef-43d8-aef2-c4ebb15f3fe8">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 6 for information regarding the Company&#x2019;s capitalized operating and finance lease right-of-use assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:50.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:14.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_95c5d1c7-77b8-46da-8093-cfa5ad4a3c43">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:50.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:14.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8f865621-f365-4210-8b47-da03eb5738c4"
      id="F_b92710b7-39a4-4e19-a971-96f7e64e1833">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8f865621-f365-4210-8b47-da03eb5738c4"
      decimals="-3"
      id="F_e5ac6a2e-1e6c-487b-b258-a43b4b74e648"
      unitRef="U_USD">386000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4c89430b-37d5-4909-a62c-9a1965b0a9b7"
      decimals="-3"
      id="F_054b2f83-d7d2-4079-a999-4b511d368817"
      unitRef="U_USD">386000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      id="F_19f16573-85bb-4158-be4b-03f72e4999a2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      decimals="-3"
      id="F_2fb1f683-0cb0-4058-a13e-987cbe43569d"
      unitRef="U_USD">1222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1735de27-a8af-415d-8fe1-67386826cc66"
      decimals="-3"
      id="F_3057a1f6-af34-4722-b029-480d02549459"
      unitRef="U_USD">844000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4bc16bb1-ead2-4dbd-aca6-b88278c3172f"
      id="F_b53a71ab-1a8d-406c-85d2-5b6fcb31a31d">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4bc16bb1-ead2-4dbd-aca6-b88278c3172f"
      decimals="-3"
      id="F_ca520350-145b-4c16-a336-2437d055f098"
      unitRef="U_USD">272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_db28a574-1df7-4c2a-a2c9-fa8fa1f5bb06"
      decimals="-3"
      id="F_4b0564f2-a7ac-4fcb-b14e-e3a15f1022a8"
      unitRef="U_USD">272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_67120918-74fd-4d6c-a70b-f08f0d8a14a5"
      unitRef="U_USD">1880000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_0207e682-d49d-4ccd-803e-e24da395b93d"
      unitRef="U_USD">1502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_73790574-149a-4667-8167-bc8cf8d9193f"
      unitRef="U_USD">741000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_dceee09c-34bd-44cb-99d9-19b50a922c1f"
      unitRef="U_USD">474000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_c45d0ebf-db12-43bd-8f55-01f5aa0b48b0"
      unitRef="U_USD">1139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_db863aef-cf83-47fd-a0c2-e206d9ea136c"
      unitRef="U_USD">1028000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_8d5de7d5-5b3d-482f-8d4e-ba13ce4c968d">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of the Company&#x2019;s leases include options to extend or terminate the lease. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_31f10eff-b248-423a-90a1-53562b246264">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Adopted&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&#x2014;Improvements to Income Tax Disclosures, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which focuses on the rate reconciliation and income taxes paid (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires a public business entity (a "PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4283524d-7551-4b90-bb15-d2729ab6b502;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU No. 2023-09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in ASU No. 2023-09 prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for all periods presented, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December 31, 2025, the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ASU No. 2023-09 retrospectively, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which only impacted the Company's income tax disclosures with no impact to its balance sheet or its statements of operations and comprehensive loss, stockholders' equity, or cash flows (see Note 10)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Adopted&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ncome Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure of specified information about certain costs and expenses in the notes to financial statements. ASU No. 2024-03 will be effective for the Company starting in annual periods after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the FASB issued ASU No. 2025-11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interim Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 270) ("ASU No. 2025-11"). ASU No. 2025-11 clarifies interim disclosure requirements and the applicability of Topic 270. ASU No. 2025-11 will be effective for the Company starting in interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      id="F_2fc1fd20-0cff-407d-8cfd-63e49f13e4c0">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      id="F_4ccf7dc1-37c2-4bd9-83f8-36c702f9e673">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_f916b79e-12db-4fb1-9ed8-ef9bcf3d8bc9">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents consist of investments in U.S. government money market funds stated at carrying value, which approximates fair value and is based on quoted prices in active markets for identical securities. Cash is stated at carrying value, which approximates fair value due to its short-term nature. The Company classifies its investments in U.S. Treasury securities as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The carrying values of the Company&#x2019;s prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:31.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:23.745%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All investments in U.S. Treasury securities classified as available-for-sale securities held as of December 31, 2025 and December 31, 2024 had contractual maturities of less than one year for the current portion of investments in U.S. Treasury securities and between one to two years for the non-current portion of investments in U.S. Treasury securities. There have been no material realized gains or losses on investments classified as available-for-sale securities for the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_a63b3892-c7e6-4020-a69d-65d97fed61fb">
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:31.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of investments in U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_80886119-480b-48c9-8ffb-65158995fa72"
      decimals="-3"
      id="F_ce836692-84d6-4ea7-99a0-5ab86d9f8042"
      unitRef="U_USD">40178000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_357e96c3-27bb-4127-968c-48df3cab0274"
      decimals="-3"
      id="F_340d4635-30e4-4af9-8b65-72daa0cda89c"
      unitRef="U_USD">40178000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9779ca0e-2456-4a3d-a96f-ccee925f0ee6"
      decimals="-3"
      id="F_b33bb2b5-f112-4080-ae6f-6fb3a6960351"
      unitRef="U_USD">118767000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_fb7cdb9c-5e73-4b92-9e27-ac79a42a2be1"
      decimals="-3"
      id="F_337ecc9d-14a9-48a0-8163-3f9b7a480903"
      unitRef="U_USD">118767000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_9779ca0e-2456-4a3d-a96f-ccee925f0ee6"
      decimals="-3"
      id="F_16bd91f6-78a1-4d21-9aae-ae505749ad17"
      unitRef="U_USD">64801000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_fb7cdb9c-5e73-4b92-9e27-ac79a42a2be1"
      decimals="-3"
      id="F_a4bf2334-fe95-4175-aad9-d1fbfe8e57d7"
      unitRef="U_USD">64801000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e9b9062b-8c12-49f1-a351-c5a94c169bed"
      decimals="-3"
      id="F_a008288e-d604-43e8-a9eb-e5045587c7e4"
      unitRef="U_USD">40178000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b80b39e4-ee70-4ac9-8254-8612c66068cd"
      decimals="-3"
      id="F_b9b20bce-05a0-4a3e-903a-19ec334fdf49"
      unitRef="U_USD">183568000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_75647768-9be4-4729-b3de-fab3b1e0526d"
      decimals="-3"
      id="F_ed9ef1d5-ad4c-4e45-b432-38e7526eb105"
      unitRef="U_USD">223746000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0c86e317-598b-4fc3-9ec5-6c3828cd4653"
      decimals="-3"
      id="F_52047b41-3be3-4dcb-ba4a-b79c62b14e88"
      unitRef="U_USD">17636000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d1c75657-09b5-459b-b8d8-8d04ceccb855"
      decimals="-3"
      id="F_5fbbc0d5-5e31-4019-bac1-e8db81d93b94"
      unitRef="U_USD">17636000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_76a788a3-f953-4f3e-ab5a-d2f1c0ac015b"
      decimals="-3"
      id="F_d8e0aa79-2210-4f25-a0a1-6521d9710a2c"
      unitRef="U_USD">86504000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9c4cb1e5-c1a2-4e02-af65-dbb6700815f2"
      decimals="-3"
      id="F_3cc7e6b7-35ee-40ec-9605-ba3c70b7dbe8"
      unitRef="U_USD">86504000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_76a788a3-f953-4f3e-ab5a-d2f1c0ac015b"
      decimals="-3"
      id="F_1ed63692-43dc-461c-b1bd-70f256cc6671"
      unitRef="U_USD">7012000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_9c4cb1e5-c1a2-4e02-af65-dbb6700815f2"
      decimals="-3"
      id="F_dcc431c2-2650-4519-b8a9-b76a78325d5b"
      unitRef="U_USD">7012000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fc4e6f8b-c480-46e3-af2f-471fb85da201"
      decimals="-3"
      id="F_83274359-65df-4523-8118-e9682465654e"
      unitRef="U_USD">17636000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d6948e0b-b33e-4c10-b2f9-1d23d6fdb1f8"
      decimals="-3"
      id="F_0f9d18e2-7a9c-475f-ae15-c758d612ea40"
      unitRef="U_USD">93516000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5b4016c9-50ff-46d1-a19f-672dd8c141a0"
      decimals="-3"
      id="F_7f7fa953-25e6-49b1-9bac-dd7ff8d7ff65"
      unitRef="U_USD">111152000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_329f31e8-d449-4c3a-84c0-8445358c733d">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments in U.S. Treasury securities, which are classified as available-for-sale securities, consisted of the following as of December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:23.745%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53"
      decimals="-3"
      id="F_43b8e0a9-8023-473a-8496-1d197ac44a0e"
      unitRef="U_USD">183380000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53"
      decimals="-3"
      id="F_c94bbc33-c595-4cd4-b4fe-9361841c043c"
      unitRef="U_USD">188000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_db784c16-eeae-4c2d-8b2e-9f8cf9399b53"
      decimals="-3"
      id="F_4f9cce25-9d86-49a6-a28a-1a823058b006"
      unitRef="U_USD">183568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_d2a07f08-19c5-45da-9a46-096bd6609338"
      unitRef="U_USD">183380000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_d304f311-d08a-456a-ba27-1c12612ba872"
      unitRef="U_USD">188000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_4f35ef88-38a0-40db-89cd-64918ffc0294"
      unitRef="U_USD">183568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9610981c-dbfa-4244-b967-0edb48cea85b"
      decimals="-3"
      id="F_82074b83-094f-43e2-ac15-f1239d9448fe"
      unitRef="U_USD">93619000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9610981c-dbfa-4244-b967-0edb48cea85b"
      decimals="-3"
      id="F_0bfccba4-e49d-46e0-8671-87a1f8b86f93"
      unitRef="U_USD">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9610981c-dbfa-4244-b967-0edb48cea85b"
      decimals="-3"
      id="F_1c8145ff-699e-43d7-ae25-538e38c25e5a"
      unitRef="U_USD">93516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_10896243-ea0a-4b60-bb4a-fb62b08d2ed6"
      unitRef="U_USD">93619000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_f575657b-647d-4f3e-9340-8c2d962f9441"
      unitRef="U_USD">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_33811a91-1463-419d-8beb-ae5dd277d3f9"
      unitRef="U_USD">93516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <lxeo:LongTermInvestmentTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_2dee90cd-663b-43ed-a8c3-4c68b8b60878">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Long-term Investment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2025, the Company entered into a collaboration and license agreement (the "June 2025 CLA") and a preferred stock purchase agreement (the "June 2025 Preferred Stock Purchase Agreement") with Tilia Therapeutics, Inc., now known as Myoventive, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a privately-held Delaware corporation (the "Investee"), to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. In exchange for access to certain of the Company's expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology contributed under the terms of the June 2025 CLA, the Company received &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Investee's nonredeemable convertible preferred stock issued under the June 2025 Preferred Stock Purchase Agreement, initially representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Investee's issued and outstanding voting stock as of June 30, 2025. Under the terms of the June 2025 CLA, the Company is entitled to certain future milestone payments, royalties, and opt-in rights to certain program(s) (see Note 12).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its investment in the Investee in accordance with the provisions of ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and elected to use the measurement alternative therein. The fair value of the nonredeemable convertible preferred stock received of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.338983&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, was based upon an observable price of cash paid for an identical security in an orderly transaction between the Investee and a third-party and was capitalized as a long-term investment in the Company's balance sheet and recorded as an unrealized gain to other non-operating income in the Company's statement of operations and comprehensive loss. The long-term investment will be remeasured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.&lt;/span&gt;&lt;/p&gt;</lxeo:LongTermInvestmentTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_ceb6a661-0f1c-4d6c-bf35-6817f0cf2a23"
      decimals="INF"
      id="F_95ba0add-ffdb-421a-a858-a1816ceb6b22"
      unitRef="U_shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_b108cd4a-1106-42e3-838b-ca809495548e"
      decimals="2"
      id="F_7fa731f1-119d-43d3-9b31-741e25b680ed"
      unitRef="U_pure">0.12</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <lxeo:FairValueOfSharesReceived
      contextRef="C_929d55a0-9e11-462d-ad46-1599e64792f2"
      decimals="-5"
      id="F_bbe99505-1c25-4543-9c1b-4aede782e84b"
      unitRef="U_USD">3400000</lxeo:FairValueOfSharesReceived>
    <lxeo:FairValueOfSharesReceivedPerShare
      contextRef="C_929d55a0-9e11-462d-ad46-1599e64792f2"
      decimals="6"
      id="F_4b7d037d-97ba-4edb-95be-3ff7c10cba5a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.338983</lxeo:FairValueOfSharesReceivedPerShare>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_000d43df-4d35-4146-8878-ffe5f2b00f15">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:72.793%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.693000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.965%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation and other personnel costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued general and administrative expenses and other professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_18a748a0-ca5f-4319-afb5-552a018e2228">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:72.793%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.693000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.965%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation and other personnel costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued general and administrative expenses and other professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <lxeo:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_96128b8f-2bf0-4b37-99d1-e0ce064282ec"
      unitRef="U_USD">4299000</lxeo:AccruedResearchAndDevelopmentExpenseCurrent>
    <lxeo:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_37c98e95-d7f8-45fe-a701-1491888e3667"
      unitRef="U_USD">6696000</lxeo:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_dfa5f565-1525-4371-a8db-86f6bb353328"
      unitRef="U_USD">4066000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_0e086d2b-c727-45cf-855a-e3f0a173e810"
      unitRef="U_USD">4112000</us-gaap:WorkersCompensationLiabilityCurrent>
    <lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_c3e0695f-6d9e-4043-a3d6-1fe3be5e7b33"
      unitRef="U_USD">839000</lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent>
    <lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_368b6e01-1d5e-43ea-8559-e0483b279520"
      unitRef="U_USD">2406000</lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_24ea29d7-89d5-49a8-b200-dfb40b5aa6a3"
      unitRef="U_USD">73000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_9d2f3bc6-454b-4e2c-a5d0-1174cfd19051"
      unitRef="U_USD">545000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_d7f282d2-89f1-45c5-9bf6-1d1c263e8fd6"
      unitRef="U_USD">9277000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_feb770ac-e2f6-471a-a93e-73ec48512efc"
      unitRef="U_USD">13759000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_11587ebb-2479-408d-885d-96b411205c69">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Lease Right-of-Use Asset&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company entered into a lease agreement for an office facility and laboratory space in New York, New York that commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ends in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend the lease beyond July 2029 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;at the then-prevailing effective market rental rate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Upon commencement of this lease, the Company recorded operating lease right-of-use assets and operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based on the present value of payments over the lease term using an estimated incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% in accordance with the provisions of ASC 842. In connection with the Company&#x2019;s lease of office space and laboratory space, the Company provided a security deposit to the landlord in the form of a letter of credit totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The cash collateralizing the letter of credit was included in long-term restricted cash in the Company&#x2019;s balance sheets as of December 31, 2025, and December 31, 2024. This lease was classified as an operating lease in accordance with the provisions of ASC 842. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any right-of-use assets and lease liabilities associated with the potential option to renew or extend. The Company&#x2019;s operating lease agreement does not contain any significant residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The remaining lease terms and payment terms as of December 31, 2025 and December 31, 2024 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of this operating lease were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:73.135%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equipment Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commencing in April 2022, the Company leases certain laboratory equipment under financing arrangements accounted for as finance leases in accordance with the provisions of ASC 842 that are classified in the Company&#x2019;s balance sheet as finance lease liabilities with related right-of-use assets recorded and depreciated on a straight-line basis over the estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. In connection with the Company&#x2019;s leases of laboratory equipment, the Company provided a security deposit to the lessor in the form of a letter of credit totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and assigned all rights and interests in the equipment to the lessor. The cash collateralizing the letter of credit is included in long-term restricted cash in the Company&#x2019;s balance sheet as of December 31, 2025. The total gross, accumulated amortization, and net book values of equipment finance lease right-of-use assets capitalized under such finance lease arrangements at December 31, 2025 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Under the terms of the equipment finance lease agreements executed through the issuance date of these financial statements, the principal balances plus interest for the equipment are to be repaid in full after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; monthly installments following lease commencement, with lease commencement dates ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, annual imputed interest rates ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and monthly installment payment amounts ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The total aggregate monthly installment payment amount is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the Company's equipment finance lease agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2025 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively. The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2024 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the equipment finance leases were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reduction in the carrying amount of ROU assets, finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:77.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.259999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Equipment Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock>
    <lxeo:OperatingLeaseAgreementEnteredDate
      contextRef="C_cf7275ec-9001-4e72-987c-f42dac6949d8"
      id="F_b7e9fda6-d374-4d30-a36c-fc3a0dd3f45d">2022-01</lxeo:OperatingLeaseAgreementEnteredDate>
    <lxeo:OperatingLeaseCommencementDate
      contextRef="C_3efbfffb-0778-4c28-91b0-3428da47503f"
      id="F_faa37477-2614-4ec2-9ce9-aeca5c2ecf6a">2022-04</lxeo:OperatingLeaseCommencementDate>
    <lxeo:OperatingLeaseEndDate
      contextRef="C_6bba1c1b-df97-48f4-bb20-fa63b15d96c9"
      id="F_afb41a11-38d4-43b8-bd7a-f149727db238">2029-07</lxeo:OperatingLeaseEndDate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_40e7b7c8-b1b6-4586-9359-a5aa9b41336e"
      id="F_2563a45d-2f4d-4e00-b412-52f8f376edd4">additional five-year option to extend the lease beyond July 2029 at the then-prevailing effective market rental rate</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c"
      id="F_4203fa42-0f4b-4159-92bd-2982d4807ac3">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_b95a7326-401b-4311-bbad-80ce85f07dc5"
      id="F_4f88269a-2360-4de8-b2f6-2c99fbe4290f">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160"
      decimals="-5"
      id="F_66d00ea3-bf17-42e6-989c-8ede531562aa"
      unitRef="U_USD">11600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160"
      decimals="-5"
      id="F_94d4a640-6844-4905-bb2c-6a0a0c0b1fe8"
      unitRef="U_USD">11600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_005a3d71-bf0a-4db8-bd14-dbd66bdd5160"
      decimals="4"
      id="F_01c713b9-1283-4541-a06d-62ea344fdc1d"
      unitRef="U_pure">0.0853</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:SecurityDeposit
      contextRef="C_e09c5ca9-c296-43da-b854-8d0d1dd047e3"
      decimals="-5"
      id="F_cb3a5709-4bcf-40d7-b520-9f5a7558cdfc"
      unitRef="U_USD">1200000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c"
      decimals="INF"
      id="F_e0736cab-8983-4e47-882f-5bb20910a53a"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_db7c3917-a8ae-4687-b0dc-f85c6a744d3c"
      decimals="INF"
      id="F_418b57e9-1f56-4d79-8e48-204de2095297"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      id="F_769d32ef-e2fd-48af-9631-095bcdca5036">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      id="F_b4fd2d49-1232-446d-935a-9eec11bfbdde">P4Y7M6D</lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm>
    <lxeo:ComponentsOfOperatingLeaseTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_65f77b9d-d0ac-4156-91ab-bcefb78e8077">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of this operating lease were as follows:&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</lxeo:ComponentsOfOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_c1820131-98a2-41e8-a713-be8fc988b437"
      unitRef="U_USD">2147000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_d7271b16-7ecc-40b6-8624-c8903085eb66"
      unitRef="U_USD">2147000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_3d5bbe24-dd73-456b-a5b1-2618e141e798"
      unitRef="U_USD">503000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_7b43c451-c8e2-4791-abf3-0c6bbeb288e3"
      unitRef="U_USD">459000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_934e08ed-5765-4763-ac37-7b88f94448d2"
      unitRef="U_USD">2650000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_e1267d26-b849-479f-9c57-5058b0b9e313"
      unitRef="U_USD">2606000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_ba691967-47de-48a1-a241-ddc3399e429a"
      unitRef="U_USD">2152000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_97fd628a-c894-4109-9bf0-b82a60afe6b3"
      unitRef="U_USD">2110000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_551ee565-5393-476d-80d3-b0dcade46103">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:73.135%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_2bbd241f-bf2b-4852-b15f-1f70bb3b344b"
      unitRef="U_USD">2206000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_a80c2a34-f8eb-4d1a-822f-4baae042eb29"
      unitRef="U_USD">2261000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_4aa968f5-a191-4678-944f-da8c2c8bd1ae"
      unitRef="U_USD">2318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_5faa0e7b-d0b8-4297-8be6-7f53172de91d"
      unitRef="U_USD">1372000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <lxeo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_dfd03428-aaaa-4167-8406-7831c9200950"
      unitRef="U_USD">0</lxeo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_8156e568-77e3-497e-a5fe-68ec64a97ebd"
      unitRef="U_USD">8157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_9ef75209-9499-4f0c-bb6c-21b5783760a6"
      unitRef="U_USD">1116000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_182df78c-4143-44e8-aef9-72d1fb8a9073"
      unitRef="U_USD">7041000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_256fbd84-fb2b-4bc7-b551-113e79ec11a7"
      unitRef="U_USD">2157000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_1bd1cb90-a8a7-49f9-885e-bd2ca360e549"
      unitRef="U_USD">4884000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_ed6fc30d-bb2e-4afa-b9ff-8e5509c56721"
      unitRef="U_USD">7041000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      id="F_630c23f8-0b23-483e-aa8a-fc0e637a4fcf">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SecurityDeposit
      contextRef="C_3e5cdc3c-a4d4-462c-af4f-ff0564c0387a"
      decimals="-5"
      id="F_1a327348-5edf-454a-be5c-28485bd73ad3"
      unitRef="U_USD">1900000</us-gaap:SecurityDeposit>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      decimals="-5"
      id="F_78bdf078-3313-40e8-b05f-73e19f6788ef"
      unitRef="U_USD">2200000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      decimals="-5"
      id="F_a9811a8b-7f84-454a-ab2e-255e79735e5d"
      unitRef="U_USD">1100000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      decimals="-5"
      id="F_e39bdcc9-1f67-4134-b6d3-4d8db605d5ad"
      unitRef="U_USD">1100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <lxeo:NumberOfMonthlyInstallmentsLease
      contextRef="C_97bf9bb9-fd01-4c00-b07e-186f54c06f37"
      decimals="INF"
      id="F_5795f6f9-25e5-43aa-a4c9-0d22b1586355"
      unitRef="U_Installment">60</lxeo:NumberOfMonthlyInstallmentsLease>
    <lxeo:LesseeFinanceLeaseCommencementDateRangeStart
      contextRef="C_f0efe85b-fed2-44b8-8e9c-9573fb1386d5"
      id="F_78e83308-325c-4983-807c-acfdf4f88558">2022-04-01</lxeo:LesseeFinanceLeaseCommencementDateRangeStart>
    <lxeo:LesseeFinanceLeaseCommencementDateRangeEnd
      contextRef="C_08eca4a4-adfe-4cb1-ad4d-04bbfa80f9d6"
      id="F_7cde0f60-7c14-4286-a424-c34768457271">2023-04-01</lxeo:LesseeFinanceLeaseCommencementDateRangeEnd>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="C_4295b1e1-3df8-42bb-8a20-af116ecee6bc"
      decimals="4"
      id="F_20c2d5ac-c41e-441f-8ca7-a8ddfce99117"
      unitRef="U_pure">0.079</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="C_7e067386-c3d6-4f06-8490-86af6f1f1e3e"
      decimals="4"
      id="F_a6673c55-4d77-4ebe-a389-ec06f8b39a3f"
      unitRef="U_pure">0.093</us-gaap:LesseeFinanceLeaseDiscountRate>
    <lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts
      contextRef="C_4295b1e1-3df8-42bb-8a20-af116ecee6bc"
      decimals="0"
      id="F_ff9484e6-5217-4f2e-a3b3-85512c72f8e1"
      unitRef="U_USD">4000</lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts>
    <lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts
      contextRef="C_7e067386-c3d6-4f06-8490-86af6f1f1e3e"
      decimals="0"
      id="F_8151eb60-3a9b-42f2-acbc-3d3a1c3a90a1"
      unitRef="U_USD">18000</lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts>
    <lxeo:FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts
      contextRef="C_da2c20fa-e75a-45b0-84f8-2dec7d2cc003"
      decimals="0"
      id="F_a85d9d7e-6fa1-4b2c-85d2-ea338e4ae3a9"
      unitRef="U_USD">49000</lxeo:FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      id="F_7bd8b253-264d-4d47-be0d-0162c097bb3c">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_95db7359-f894-4355-8b06-af3830e986bb">P3Y9M18D</lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="4"
      id="F_322ef0f9-2162-4f5f-b301-675364694d76"
      unitRef="U_pure">0.0861</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      id="F_a19acbcf-4a31-4782-a5a7-0cc8fc5db8ad">P2Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      id="F_072d1d62-8d1a-4fb1-9855-d4b316e180cf">P4Y9M18D</lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_fbcb1003-e23a-41f4-84d0-8daacf617f9e"
      decimals="4"
      id="F_b74a0ae3-054a-42ed-9e7c-4c84717c63f9"
      unitRef="U_pure">0.0859</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <lxeo:ComponentsOfEquipmentFinanceLeaseTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_af621183-5beb-4177-a735-855172c29368">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the equipment finance leases were as follows:&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reduction in the carrying amount of ROU assets, finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</lxeo:ComponentsOfEquipmentFinanceLeaseTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_c55b2708-95e1-472d-8a3d-15c1b8f768ba"
      unitRef="U_USD">320000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_9e38af33-964a-4ee1-b9c4-72c445c4d55c"
      unitRef="U_USD">325000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_08f80b10-3683-41cb-b278-531e98d7d6f1"
      unitRef="U_USD">104000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_6777c3fe-7b7a-4a2b-8ff7-daaf53aa23ae"
      unitRef="U_USD">127000</us-gaap:FinanceLeaseInterestExpense>
    <lxeo:FinanceLeaseExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_8a15c8e9-437b-4121-9971-336feec5a400"
      unitRef="U_USD">424000</lxeo:FinanceLeaseExpense>
    <lxeo:FinanceLeaseExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_ac7f25ac-f4d1-4de6-95f5-0f3845be5122"
      unitRef="U_USD">452000</lxeo:FinanceLeaseExpense>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_2bfb35c6-1e37-42cd-945a-da8a857feca3"
      unitRef="U_USD">533000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_ef74cc26-1074-4ed3-bb24-6d942344e4f7"
      unitRef="U_USD">410000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_2a1e73ed-2894-4acd-b78e-c7e635fe8eda">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:77.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.259999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Equipment Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_5a42e152-c874-45e0-b84c-e9f36edc6cb6"
      unitRef="U_USD">537000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_a3da16d6-6911-44c2-8fbd-f73960ba6b7f"
      unitRef="U_USD">359000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_41330d2b-ac18-47d7-a5ff-9396109f2220"
      unitRef="U_USD">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_8ea402ee-6285-4a79-b0f3-dba17598a2e6"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <lxeo:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_82a35aba-cb1e-495f-bc8d-1d6f634525ea"
      unitRef="U_USD">0</lxeo:FinanceLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_74c7da06-d566-446d-9e4a-a846032e3067"
      unitRef="U_USD">907000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_451fbc25-b9cb-4eac-8087-85e47f3f0ec3"
      unitRef="U_USD">62000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_efcb8fbd-662c-46c6-9700-590c414d16bf"
      unitRef="U_USD">845000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_d95149b1-ee6c-431a-8990-ea7a11696c74"
      unitRef="U_USD">518000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_8ba6d10b-e58d-403d-a53e-35d2ba53aa61"
      unitRef="U_USD">327000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_9c97177c-a3f2-47e6-a775-8d0db6f74ffc"
      unitRef="U_USD">845000</us-gaap:FinanceLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_fbaa25ca-b72f-455f-9c19-2af2ca1b8218">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Capital Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and December 31, 2024, the Company&#x2019;s amended and restated certificate of incorporation provided that the authorized capital stock of the Company was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;510,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of undesignated preferred stock, both with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. As of December 31, 2025 and December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,001,766&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,079,209&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, of the Company's common stock authorized were issued, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,948&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, that were legally issued upon the early exercise of unvested stock options and that are excluded from the number of shares outstanding until the right to repurchase subsequently lapses upon vesting. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t repurchase any shares of its common stock during the year ended December 31, 2025, and repurchased a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,827&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 8). Each common share entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company&#x2019;s Board of Directors. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cash dividends have been declared or paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 11, 2024, the Company entered into a common stock purchase agreement to issue and sell an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,278,905&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, in a private placement that closed on March 13, 2024 (the "March 2024 Private Placement"). The gross and net proceeds received from the March 2024 Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commissions and other offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 24, 2025, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC ("Leerink") to sell shares of the Company's common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from time to time through an at-the-market equity offering program (the "ATM Program") under which Leerink is acting as the Company's agent. Leerink is entitled to compensation for its services in an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds of any of the shares of the Company's common stock sold under the Sales Agreement. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock have been sold under the Sales Agreement through December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 28, 2025, pursuant to a securities purchase agreement, the Company issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,790,120&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,963,556&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock to certain purchasers, together with accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,876,838&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock, at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8825&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of common stock and accompanying common warrant, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8824&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant and accompanying warrant (the "May 2025 Private Placement"). The gross and net proceeds received from the May 2025 Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commissions and other offering costs. The warrants and pre-funded warrants issued in the May 2025 Private Placement are immediately exercisable at exercise prices of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively, except that the warrants and pre-funded warrants cannot be exercised by the holder if, after giving effect thereto, the holder would beneficially own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s common stock (the "Maximum Percentage"). The Maximum Percentage can be changed at the holder's election to any other percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and any increase in the Maximum Percentage will not be effective until the 61st day after the holder provides notice to the Company of the desired increase. The warrants are exercisable until May 28, 2029, and the pre-funded warrants do not expire. The warrants and pre-funded warrants are classified as equity in accordance with ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging - Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon issuance, the total pre-allocated fair value of the warrants of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant share, was estimated using a Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;pproximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the total gross proceeds received in the May 2025 Private Placement were allocated to the shares of common stock, warrants and pre-funded warrants, respectively, on a relative fair value basis, and were recorded as credits to additional paid-in capital, and are not subject to remeasurement. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;867,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants issued in the May 2025 Private Placement had been exercised. In January 2026, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;867,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants issued in the May 2025 Private Placement were exercised (see Note 14).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 16, 2025, the Company entered into an underwriting agreement to issue and sell an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,625,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, less underwriting discounts and commissions, in a public offering that closed on October 20, 2025 (the "October 2025 Public Offering"). In addition, the Company granted the underwriters of the October 2025 Public Offering a 30-day option to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,343,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, less underwriting discounts and commissions (the "30-day Underwriter Option"), which was exercised in full. The gross and net proceeds received from the October 2025 Public Offering including the full exercise of the 30-day Underwriter Option were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of underwriter commissions and other estimated offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 16, 2025, the Company entered into a securities purchase agreement to sell and issue pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,250,015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant, in a private placement that closed on October 20, 2025 (the "October 2025 Private Placement", and together with the October 2025 Public Offering and the 30-day Underwriter Option, the "October 2025 Financing Transactions"). The gross and net proceeds received from the October 2025 Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of placement agent fees and other estimated offering costs. The pre-funded warrants issued in the October 2025 Private Placement do not expire and are immediately exercisable at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant share, except that the pre-funded warrants cannot be exercised by the holder if, after giving effect thereto, the holder would beneficially own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s common stock (the "October 2025 Private Placement Maximum Percentage"). The October 2025 Private Placement Maximum Percentage can be changed at the holder's election to any other percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and any increase in the October 2025 Private Placement Maximum Percentage will not be effective until the 61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;st &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;day after the holder provides notice to the Company of the desired increase.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;pproximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the total gross proceeds received in the October 2025 Financing Transactions were allocated to the shares of common stock and pre-funded warrants, respectively, on a relative fair value basis, and were recorded as credits to additional paid-in capital, and are not subject to remeasurement. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the pre-funded warrants issued in the October 2025 Financing Transactions had been exercised.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved the following number of shares of common stock for the exercise of outstanding warrants, exercise of outstanding pre-funded warrants, exercise of o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;utstanding stock options, settlement of outstanding RSUs and PRSUs, and future issuances of stock-based awards:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.278%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.925999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.384%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase shares of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,876,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants to purchase shares of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,096,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase shares of common stock under the 2021 Plan and 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,396,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs and PRSUs subject to settlement in shares of common stock under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,132,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,185,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;505,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,079,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,414,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_0731794f-95d4-4f33-8cbb-8ca808706253"
      unitRef="U_shares">510000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_34d0bd87-8c98-4025-aa06-bd85f1db8f1e"
      unitRef="U_shares">510000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_934bbea8-ed90-4bee-b950-50580e50ba42"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_5c70ddd5-7b41-4937-9842-94a3df56855f"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_86dfc34c-01c7-49e9-9911-c3819706c4ce"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_991f78ac-66de-4765-a3c8-83d94ab3f828"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_9b45ef07-191b-4c29-ae0a-b214a86d438c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_adcfd0bf-53cb-4803-8f59-749fd6a8aa9c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_d1a27d2d-5715-437e-b171-44454759acc9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_3651ca3e-a87f-476d-be67-2db87e8beef2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_f5ac5a0a-d9fb-4dfb-81e0-1fbaf4229fa0"
      unitRef="U_shares">73001766</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_d89e75d0-f89f-4df7-8fb9-1a3cf4044d84"
      unitRef="U_shares">33079209</us-gaap:CommonStockSharesIssued>
    <lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_9e727019-7c2e-4618-bbf2-34007dae06a6"
      unitRef="U_shares">416</lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions>
    <lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_24ea20da-b9cc-4ee4-aeb1-21d6518fe5a7"
      unitRef="U_shares">7948</lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_725ecbd1-08d1-4d48-b06f-22dc4a077218"
      decimals="INF"
      id="F_eb94a9ac-8e0e-47d6-a12f-245351881475"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7"
      decimals="INF"
      id="F_b2aa782a-7c08-426e-a2f3-5b0d283a7cdb"
      unitRef="U_shares">3827</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7"
      decimals="0"
      id="F_9ecf6c0e-7682-4fd1-8b5c-8cd0236d35eb"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="INF"
      id="F_f56bd61b-df54-444a-9307-590284933c61"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fc0d444a-c280-451e-a6ac-f592154451d5"
      decimals="INF"
      id="F_b3a58c3a-d4a7-413e-8e2d-9061d4127a9e"
      unitRef="U_shares">6278905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ff8f1290-9480-4529-b296-ace3425207d0"
      decimals="INF"
      id="F_21dc31ce-4676-4b89-89aa-3b0186f18921"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd"
      decimals="-5"
      id="F_d0371ae1-133d-4951-8f35-dcfb219b0b3f"
      unitRef="U_USD">95000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lxeo:NetProceedsReceivedFromPrivatePlacement
      contextRef="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd"
      decimals="-5"
      id="F_517790d2-72e2-41b3-bfb9-64be2e8df1f4"
      unitRef="U_USD">88700000</lxeo:NetProceedsReceivedFromPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_cf8378dc-3bee-4ad1-8fd9-5c9982695ccd"
      decimals="-5"
      id="F_a12efeff-12a9-451a-8797-c0924c04de13"
      unitRef="U_USD">6300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <lxeo:StockOfferingValueSharesAuthorizedToBeSold
      contextRef="C_3b196e9a-f7ba-488f-8a3f-bdc43e626635"
      decimals="-5"
      id="F_ad1ea9c6-fa30-4937-8ada-8f3f6d6ab7ce"
      unitRef="U_USD">75000000</lxeo:StockOfferingValueSharesAuthorizedToBeSold>
    <lxeo:StockOfferingGrossProceedsPercentage
      contextRef="C_890b7df4-85e3-41e4-b1fd-4859a5a3807e"
      decimals="2"
      id="F_f6b9d3e0-6a0c-474d-9cf0-3a84e019a1c6"
      unitRef="U_pure">0.03</lxeo:StockOfferingGrossProceedsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e04e0666-d468-4c9d-9610-e8fa883f856b"
      decimals="INF"
      id="F_e5b65690-3d3f-443f-96de-63c310046fa1"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a240413b-0d7d-487c-bc56-518232b357e0"
      decimals="INF"
      id="F_4704a977-8480-42e7-b52e-c8feabfa8e8a"
      unitRef="U_shares">20790120</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_1f09b079-161e-4135-8af4-e2998386a171"
      decimals="INF"
      id="F_40e2d5fc-110a-46c3-85a2-c9536c227612"
      unitRef="U_shares">6963556</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_80d471cc-64f2-4ab5-9d83-c7f5596929ec"
      decimals="INF"
      id="F_a37073c7-4c81-4d25-bb99-43daf4e0c59d"
      unitRef="U_shares">13876838</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_4bb6390f-6ce6-4793-8fc3-7a90375636cc"
      decimals="INF"
      id="F_eb45166e-e8ed-43b6-91b4-f8ba522df4a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.8825</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_1f09b079-161e-4135-8af4-e2998386a171"
      decimals="INF"
      id="F_970b615f-251c-440d-9b35-6736d6c41727"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.8824</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7"
      decimals="-5"
      id="F_737479c4-9e8b-400e-a772-51de701f3125"
      unitRef="U_USD">80000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lxeo:NetProceedsReceivedFromPrivatePlacement
      contextRef="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7"
      decimals="-5"
      id="F_9bfdf372-a501-4985-b846-a86ef9b4cf72"
      unitRef="U_USD">73100000</lxeo:NetProceedsReceivedFromPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_8378d9e9-e126-4b92-9e5e-1d2f17c4f9d7"
      decimals="-5"
      id="F_3cfeaf9a-29b3-4b8f-aa93-57e802f9b222"
      unitRef="U_USD">6900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_80d471cc-64f2-4ab5-9d83-c7f5596929ec"
      decimals="INF"
      id="F_9599e9ea-e665-47a0-82c0-1fc98504e46e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1f09b079-161e-4135-8af4-e2998386a171"
      decimals="INF"
      id="F_31bcd0b6-364c-4e7d-9625-ab3c341f8844"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lxeo:PercentageOfOwnershipConsideredForWarrantExercise
      contextRef="C_c6383d22-c520-4a85-89c6-6b07e625c012"
      decimals="4"
      id="F_ac6462ce-2622-48da-a9e2-aff2e7f54b9d"
      unitRef="U_pure">0.0999</lxeo:PercentageOfOwnershipConsideredForWarrantExercise>
    <lxeo:MaximumIncreaseOrDecreaseInOwnershipPercentage
      contextRef="C_6b7cf2f5-7ba2-40f3-98b8-0a47a4bcab82"
      decimals="4"
      id="F_5cbc19fb-e123-4aa6-b441-fedcc2fce7fd"
      unitRef="U_pure">0.1999</lxeo:MaximumIncreaseOrDecreaseInOwnershipPercentage>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_43526e0c-699a-4db8-915d-0ae427a939d9">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon issuance, the total pre-allocated fair value of the warrants of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant share, was estimated using a Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <lxeo:FairValueOfWarrants
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-5"
      id="F_e271c06f-689d-4e18-8d05-91f91ef1fd1f"
      unitRef="U_USD">26800000</lxeo:FairValueOfWarrants>
    <lxeo:FairValueOfWarrantsPerShare
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="2"
      id="F_3aa3ed6d-ab47-432e-b6fa-dd6f99d54cff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.93</lxeo:FairValueOfWarrantsPerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_407ffdfb-fc65-4627-a3b0-cb0f4c4c5eda"
      decimals="2"
      id="F_520922b7-f54f-4a03-93f4-69c3b275a163"
      unitRef="U_pure">2.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_f6ffc1a5-c795-4565-95e3-4d24febe677f"
      decimals="2"
      id="F_c3538e71-1d39-4cf6-91ad-6598a22fcf69"
      unitRef="U_pure">2.82</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_b91348ae-b86b-4d6f-a90a-d0705420ee0b"
      decimals="2"
      id="F_d42adf53-ccb0-4751-9033-f7cfdbaecd14"
      unitRef="U_pure">4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      id="F_d82d4dd6-64ad-46c0-920a-8b70a1a4be8c">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_bc5f8bd3-0209-4df6-a1d0-ca324664dc73"
      decimals="2"
      id="F_05d87e1b-6d17-4e35-b54e-33b89299e4d4"
      unitRef="U_pure">100.35</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_dcf1d763-8592-412d-b293-cc3b5ba5d13f"
      decimals="2"
      id="F_7f8483ee-d8eb-4c9f-a0db-f26329845416"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_a240413b-0d7d-487c-bc56-518232b357e0"
      decimals="-5"
      id="F_f9b62d15-f3ae-4a35-9d48-615e6d0b2e95"
      unitRef="U_USD">44300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_9ad9569e-82f6-46d0-91e6-51f179cc5dad"
      decimals="-5"
      id="F_57a80683-26d4-427e-80d0-f7872b3a04fa"
      unitRef="U_USD">20800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_ab655c89-08d2-4df1-80c6-4cd7801eced4"
      decimals="-5"
      id="F_8afa9588-c74e-4167-8d79-c8a66d567d26"
      unitRef="U_USD">14900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_4e91b53a-c865-4846-b046-8b4dbf9ae7f3"
      decimals="INF"
      id="F_f0e4972d-47e0-4564-938d-7a5e6b0f18eb"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_8525b582-4e2a-4627-be2a-eadd8568fd9d"
      decimals="INF"
      id="F_287234c7-46ff-4703-af9a-e74eaf652cc6"
      unitRef="U_shares">867302</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lxeo:NumberOfWarrantsExercised
      contextRef="C_d98866d0-7481-4b7b-bca4-1dd7071333f1"
      decimals="INF"
      id="F_75d100dc-8f43-4f7b-99c7-2d7387d2d085"
      unitRef="U_shares">867302</lxeo:NumberOfWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_601b6cb4-c759-4fde-8d48-72ad686bc4c1"
      decimals="INF"
      id="F_11d0012f-c3d6-41a2-8a9a-268c2db89012"
      unitRef="U_shares">15625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_6bf5181b-cf84-46b5-b3bd-e929f2acc332"
      decimals="INF"
      id="F_d85e8ac7-b4a8-43df-a62c-faef9878e517"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_98d0b57c-8a4e-4d95-ac5f-068c0243f116"
      decimals="INF"
      id="F_46260574-e8f3-49ef-992e-f72d66d238a9"
      unitRef="U_shares">2343750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_bc2c08ed-32fb-4bb9-9165-ff7bf6d493e8"
      decimals="INF"
      id="F_3c2afa1c-80d9-41d8-a271-17e34db4a807"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d"
      decimals="-5"
      id="F_dbeaee29-271f-40e8-a2e0-21e571f2ec77"
      unitRef="U_USD">143800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lxeo:NetProceedsReceivedFromPrivatePlacement
      contextRef="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d"
      decimals="-5"
      id="F_ac87530d-5499-4a4f-a2b8-62cf95ffae57"
      unitRef="U_USD">134600000</lxeo:NetProceedsReceivedFromPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e7104ef9-3c87-4b01-ad0e-2bca53f4092d"
      decimals="-5"
      id="F_067ddcb3-deb5-40b1-86f4-f5533e09c166"
      unitRef="U_USD">9200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_beac3254-3c89-4564-8632-f79760e1f8b6"
      decimals="INF"
      id="F_5f57f457-348f-4773-b33c-0a9883c10490"
      unitRef="U_shares">1250015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_7b1bb5e1-9fac-4bb1-8736-1cc221d0c743"
      decimals="INF"
      id="F_48cf869b-2590-4e29-af68-b2f95c1d45a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.9999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f"
      decimals="-5"
      id="F_367b191f-e083-462c-9a57-2fd1d1cff84c"
      unitRef="U_USD">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lxeo:NetProceedsReceivedFromPrivatePlacement
      contextRef="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f"
      decimals="-5"
      id="F_242dda62-c759-4221-84a2-8d65aaace57d"
      unitRef="U_USD">9300000</lxeo:NetProceedsReceivedFromPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_4ca671b6-4cc5-4f05-9aa5-d451bf2c3e1f"
      decimals="-5"
      id="F_b5538bb8-b766-4f48-a072-cbfa34ebc2fa"
      unitRef="U_USD">700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_276b6562-55aa-419f-88ec-75b79f842098"
      decimals="INF"
      id="F_76333f7b-2e38-47fc-af1e-96a217dc161c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lxeo:PercentageOfOwnershipConsideredForWarrantExercise
      contextRef="C_f35a4807-02c2-465e-a506-734387ea3d75"
      decimals="4"
      id="F_13e1a7f7-468a-4b63-8134-1d11c72e668c"
      unitRef="U_pure">0.0999</lxeo:PercentageOfOwnershipConsideredForWarrantExercise>
    <lxeo:MaximumIncreaseOrDecreaseInOwnershipPercentage
      contextRef="C_51b02334-8c26-4f78-ac6e-af4cbca2320e"
      decimals="4"
      id="F_69974909-80ec-4172-8418-127669f89193"
      unitRef="U_pure">0.1999</lxeo:MaximumIncreaseOrDecreaseInOwnershipPercentage>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_c8a465c9-e39f-4d34-ac7a-5fe710f82f82"
      decimals="-5"
      id="F_133a3ddf-c0e2-4769-ad44-5dc9799ac6a9"
      unitRef="U_USD">143800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_9af02223-ca95-445a-b4e5-6659c2e7fccc"
      decimals="-5"
      id="F_5134efb6-5e2b-4087-ad87-60cd6e1069aa"
      unitRef="U_USD">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ba4e7baf-9823-4208-bf61-fb7520c113df"
      decimals="INF"
      id="F_4665afd5-2b0f-498d-89b2-eecd35e59c9f"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_bd39d219-31f0-4895-9cb0-7a7f933b07ca">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved the following number of shares of common stock for the exercise of outstanding warrants, exercise of outstanding pre-funded warrants, exercise of o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;utstanding stock options, settlement of outstanding RSUs and PRSUs, and future issuances of stock-based awards:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.278%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.925999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.384%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase shares of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,876,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants to purchase shares of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,096,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase shares of common stock under the 2021 Plan and 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,396,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs and PRSUs subject to settlement in shares of common stock under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,132,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,185,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;505,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,079,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,414,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79952fb3-c2a3-4723-8ef3-9b6960397749"
      decimals="INF"
      id="F_70678ca7-5741-4bb9-a2f2-72aedd91c3b3"
      unitRef="U_shares">13876838</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_33a1d373-61e1-4dbc-8ca5-46559d2ba9d0"
      decimals="INF"
      id="F_74ecda13-6770-45ee-aa27-be3fbd6cfd92"
      unitRef="U_shares">6096254</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_58b9ae1c-e54e-4971-8058-707bb52b2a1a"
      decimals="INF"
      id="F_2513ba9d-b7fc-49e9-8ef0-c525a5b98a21"
      unitRef="U_shares">4396860</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b5e6a80b-0a90-4061-b5e3-d557692232e5"
      decimals="INF"
      id="F_09144b14-8d02-4ebd-82b0-4f41b8731910"
      unitRef="U_shares">3457918</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2f5d2c9e-b849-4bde-ac52-df6ce3e72476"
      decimals="INF"
      id="F_a4c2ddb7-bf15-4143-bbbc-1eda51ea0de5"
      unitRef="U_shares">844278</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_da57ec1f-8f38-4bd6-9e52-115625f9b6b6"
      decimals="INF"
      id="F_24337c2b-8755-4af3-a9b0-bdd69250c0ba"
      unitRef="U_shares">266300</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f5b4784b-582b-414e-b258-a9581e148ae5"
      decimals="INF"
      id="F_8fe1dda9-6c6a-4561-85a8-bf9de802ba0a"
      unitRef="U_shares">2132156</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b7718c79-bbe6-4525-98cb-4ccd075faa86"
      decimals="INF"
      id="F_6ebd16ce-c9d1-4b76-a720-192ccfe9a566"
      unitRef="U_shares">2185328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_016a9c4e-9503-4416-a9e9-6e06fb5aba55"
      decimals="INF"
      id="F_6011cd79-0094-43cb-b0f2-f165efa75147"
      unitRef="U_shares">733239</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4883c806-04d5-4bad-8a04-6447a094163d"
      decimals="INF"
      id="F_e3fb513c-d817-4507-bb14-58d087341854"
      unitRef="U_shares">505284</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_c684afc3-9339-4795-aa8d-a1f1f7c82dbe"
      unitRef="U_shares">28079625</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_d51aa528-06e4-4ad0-97b1-96bab214f850"
      unitRef="U_shares">6414830</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_7f7f0bce-354f-46dc-9906-5e11225cde8a">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2021, the Company adopted the 2021 Plan for the issuance of stock options granted to the Company&#x2019;s key directors, officers, employees and consultants, as a means to secure the benefits arising from capital stock ownership. In connection with the Company&#x2019;s IPO in November 2023, the Company adopted the 2023 Plan for the issuance of equity awards granted to the Company's directors, officers, employees, and consultants, and for the issuance of shares purchased under the 2023 ESPP to the Company's employees, as a means to secure the benefits arising from capital stock ownership. The purposes of the Plans and the 2023 ESPP are also to promote the alignment of the interests of directors, officers, employees, and consultants with the success of the Company and to provide compensation opportunities to attract, retain and motivate directors, officers, employees, and consultants of the Company. Upon adoption of the 2023 Plan, no further grants may be made under the 2021 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, beginning on January 1, 2024, and continuing through and including January 1, 2033, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s Board of Directors prior to the applicable January 1. The number of shares of common stock reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2024 and continuing through and including January 1, 2033, by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;477,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, and (iii) a number of shares determined by the Company&#x2019;s Board of Directors. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full do not reduce the number of shares available for issuance under the 2023 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 1, 2026, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,650,088&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;477,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, to totals of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,804,770&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,210,439&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,132,156&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for future issuance under the 2023 Plan and 2023 ESPP, respectively. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,837&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been issued under the 2023 ESPP through December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 4, 2025, the Company's board of directors adopted the Lexeo Therapeutics, Inc. 2025 Inducement Equity Incentive Plan (the "2025 Inducement Equity Plan") and, subject to the adjustment provisions of the 2025 Inducement Equity Plan, reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock for issuance pursuant to equity awards granted under the 2025 Inducement Equity Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock option activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options granted under the 2021 Plan are issued from new shares upon exercise, have a contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from grant date, and generally (i) are subject to requisite service requirements, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and (iii) allow for early exercise subject to repurchase. Stock options granted under the 2021 Plan to certain of the Company&#x2019;s non-employees vest in equal monthly installments over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period or vested upon the achievement of a certain milestone event. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t repurchase any shares of its common stock during the year ended December 31, 2025, and repurchased a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,827&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 7).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options granted under the 2023 Plan are issued from new shares upon exercise, have a contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from grant date, and generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the options granted vesting after approximately one year and the remainder vesting in equal monthly installments over the following 36 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to requisite service requirements. Stock options granted under the 2023 Plan to certain of the Company's non-employee directors vest in equal annual installments over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period for initial grants or over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period for subsequent annual grants, subject to requisite service requirements.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.298%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.398%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,450,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;415,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,396,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,556,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of stock options granted during the years ended December 31, 2025 and December 31, 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The total aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total grant date fair values of stock options vested during the years ended December 31, 2025 and December 31, 2024 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions during the years ended December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years), weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.79&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility, range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility, weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expected dividend yields are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% as the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to stock options estimated to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;RSU and PRSU activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs granted under the 2023 Plan generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to requisite service requirements. During the year ended December 31, 2025, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PRSUs were granted to certain employees under the 2023 Plan that vest upon the achievement of certain performance conditions generally over an approximate 18-month period, subject to requisite service requirements. Additionally, during the year ended December 31, 2025, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,650&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs were granted to employees under the 2023 Plan that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following four quarters&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to requisite service requirements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to RSUs estimated to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the PRSU activity under the 2023 Plan for the nine months ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the 2023 ESPP, eligible employees may purchase shares of the Company's common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market values of the stock as of the beginning of the offering period or the end of each six-month purchase period. Each offering period of two years will consist of four six-month purchase periods, subject to reset on the first day of each purchase period depending on the fair market values of the Company's stock. Employees may not purchase more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock during any purchase period. The first purchase period within the first offering period under the 2023 ESPP commenced during the three months ended December 31, 2024 and concluded during the three months ended March 31, 2025; following reset, the first purchase period within the second offering period commenced during the three months ended March 31, 2025 and concluded during the three months ended September 30, 2025; and the second purchase period within the second offering period commenced during the three months ended September 30, 2025. As of and during the year ended December 31, 2025, stock-based compensation expense recorded, as well as the estimated fair value of unearned and unrecognized stock-based expense expected to be recorded, related to the 2023 ESPP were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material. During the year ended December 31, 2025, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,837&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued under the 2023 ESPP at a weighted average purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share with total proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million received by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was classified as follows in the Company&#x2019;s statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear
      contextRef="C_c0f2a034-41be-457c-99b1-4288da908b5a"
      decimals="2"
      id="F_d3df08ce-1aa1-40c1-aa99-bc36fce93ec4"
      unitRef="U_pure">0.05</lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear>
    <lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear
      contextRef="C_b783d3da-cc32-4fce-b2ea-93ee7627889c"
      decimals="2"
      id="F_fb12b338-b5f4-42f6-950d-dc925f47c747"
      unitRef="U_pure">0.01</lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear>
    <lxeo:NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan
      contextRef="C_a707e4a6-c6ec-4da3-a440-f202623bc25e"
      decimals="INF"
      id="F_849e1780-25fc-4bd8-9247-0b80e65431e7"
      unitRef="U_shares">477200</lxeo:NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan>
    <lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c43d4a9b-6f01-447c-8344-401a3e883847"
      decimals="INF"
      id="F_979b3b17-c19b-423d-a3b2-d1049044bfff"
      unitRef="U_shares">3650088</lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0bf10b12-a23b-4f45-9d50-7e648eecff42"
      decimals="INF"
      id="F_3e47a685-7e42-42b0-8027-966e53b892fb"
      unitRef="U_shares">477200</lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c43d4a9b-6f01-447c-8344-401a3e883847"
      decimals="INF"
      id="F_42246ed6-0090-4d12-9772-e87af2d81f44"
      unitRef="U_shares">6804770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0bf10b12-a23b-4f45-9d50-7e648eecff42"
      decimals="INF"
      id="F_15d35f00-121b-4689-bcbb-0ebe572b3578"
      unitRef="U_shares">1210439</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_292ca90b-72fb-49a6-a3ab-69036c90f439"
      decimals="INF"
      id="F_63486fa5-3725-4b72-8b5a-f0b9bf22d137"
      unitRef="U_shares">2132156</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_59ff464b-49f8-40f8-92d9-92d1e9a17142"
      decimals="INF"
      id="F_d35cfe5e-5224-423d-a58d-508483e569a0"
      unitRef="U_shares">733239</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_59ff464b-49f8-40f8-92d9-92d1e9a17142"
      decimals="INF"
      id="F_2e858896-4a23-447d-83a0-bc66a3506bc9"
      unitRef="U_shares">102837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a31771a9-2900-4c49-8cb5-d8544ddd403d"
      decimals="INF"
      id="F_55abf72c-edf6-4bad-8949-a0f689a2b00c"
      unitRef="U_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate
      contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc"
      id="F_5d8787ee-93cf-4b91-bce3-9f4c5bcb153f">P10Y</lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_c104adc9-73de-4e0a-aec0-20142b5b14fb"
      id="F_9a51e7ce-109a-4cc0-983c-55ae9f7650d4">vest over a four-year period with 25% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc"
      id="F_11d4489d-3002-4b34-a8db-17278407632f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc"
      decimals="2"
      id="F_57f955dd-4434-4794-b4dc-db340dac372d"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_18edec8b-db33-4c8f-b074-18226230e3bc"
      id="F_824ee549-19e7-4bfc-ab9b-95d8d55732bc">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_725ecbd1-08d1-4d48-b06f-22dc4a077218"
      decimals="INF"
      id="F_91c2d0a0-77d3-4fa7-b0c1-f6d79f382b40"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_e9363952-b0a5-43f2-b3c3-01c35fe72ac7"
      decimals="INF"
      id="F_d6641b3a-21b0-499e-ae4d-5ccbfb079bef"
      unitRef="U_shares">3827</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_3cd08b17-0362-4b62-b0f6-efc4c3963b9e"
      decimals="0"
      id="F_e04ee4e9-bbc0-40ed-a67f-249686f9caa7"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate
      contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2"
      id="F_dce42545-a742-4fe5-8daf-a1490d348c66">P10Y</lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2"
      id="F_a8ffe535-f1a2-4118-9b04-6b393d3ffd84">vest over a four-year period with 25% of the options granted vesting after approximately one year and the remainder vesting in equal monthly installments over the following 36 months</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2"
      id="F_881ec931-2a42-45eb-8901-6fb27c50bd17">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_62ce8fa6-bb47-43a9-a091-7505fa290aa2"
      decimals="2"
      id="F_2fe8e78c-df17-4ce8-975e-e06abbe8cf97"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a00433da-f67f-4690-982b-b7fff11be3f1"
      id="F_7c9cf7ae-45f3-45e2-aec5-d7e881f18d98">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_304ec79b-72af-4cbd-af93-f335e40345bd"
      id="F_b24cc2ab-b18c-4f40-ab36-aed2c99ccc36">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_eb9c8e41-9adb-4644-a3e5-fb609db2854d">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.298%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.398%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,450,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;415,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,396,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,556,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f"
      decimals="INF"
      id="F_44734bfe-5fdc-4d05-bba7-a06dd68fe9be"
      unitRef="U_shares">3457918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f"
      decimals="2"
      id="F_1eae7390-9424-45c4-9e88-7f879012a81a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_5f20fea3-e69b-4604-90bc-497426fe388f"
      id="F_403e9d08-1b40-4cce-b962-47f90391e44d">P8Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b3daad36-4fa0-45d0-8cf8-028089ceaf2f"
      decimals="-3"
      id="F_1d84773d-ac1f-4ea3-bdf7-725018e72298"
      unitRef="U_USD">2851000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="INF"
      id="F_2d811520-64cb-4a33-a182-2c269969d423"
      unitRef="U_shares">1450904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="2"
      id="F_c2e21ff3-78f3-4a2d-940e-f3bb2be9e103"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="INF"
      id="F_10cd3a73-68a2-46d3-b00b-5b2cbd62c0c6"
      unitRef="U_shares">15300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="2"
      id="F_ae5cf9d8-4d00-4ae8-9a61-0c6d2eee9b83"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="-3"
      id="F_045258be-89be-4a20-bc7c-c020f7672b77"
      unitRef="U_USD">62000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="INF"
      id="F_1510903c-6ed7-44e9-8e68-518273a0ac3c"
      unitRef="U_shares">415707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="2"
      id="F_d63bd412-426b-4127-a206-2d3c13a5d776"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="INF"
      id="F_4cfd6a7b-cd5b-4c01-a51a-9651dd710b0d"
      unitRef="U_shares">80955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      decimals="2"
      id="F_00395dcc-863f-4369-8c98-d7bda355259c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"
      decimals="INF"
      id="F_73719c3d-0cb5-4177-b12b-0003db5272e1"
      unitRef="U_shares">4396860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"
      decimals="2"
      id="F_cdbcf500-0a15-4ae3-99a4-b2d0e384015e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      id="F_17cc78ff-d37d-4081-829b-0dccb43f1638">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"
      decimals="-3"
      id="F_ef18e134-1605-40e5-9ee2-7f2ccbbddc0c"
      unitRef="U_USD">11304000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"
      decimals="INF"
      id="F_cecf1394-72d1-4675-9aa4-3f153605d17c"
      unitRef="U_shares">2556582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"
      decimals="2"
      id="F_c53107b7-f029-4852-87ac-605526e0621c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_bcddf2df-722a-4a3c-bd72-c6695de021e4"
      id="F_2b6cf6ed-3aae-4696-8afe-8aa8bbba82d9">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b7d0b0c4-d452-4016-9a76-9a335b6c0f20"
      decimals="-3"
      id="F_64349bab-a0e9-4ef4-bd36-a01ceb9530b3"
      unitRef="U_USD">6529000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="2"
      id="F_22512593-2a9d-471c-b8d8-62e75523abf8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="2"
      id="F_c6dc512e-60bc-4472-8bc3-4326e1c39820"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="-5"
      id="F_896f1169-165b-499a-a88f-e25e04917935"
      unitRef="U_USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="-5"
      id="F_f2e2e4f4-b1b8-4dd7-9276-80ca7d80a679"
      unitRef="U_USD">10300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="-5"
      id="F_83ffcfd9-97c6-4ca0-9e80-ee2aa74891e7"
      unitRef="U_USD">7100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_da008a81-2fb6-438d-abb9-43902b2593d2">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions during the years ended December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years), weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.79&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility, range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility, weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_770e8d52-241f-42db-bec7-b08b83897625"
      unitRef="U_pure">0.0378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_114c9d1e-a5fd-485d-8a94-def1fac536cc"
      unitRef="U_pure">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="4"
      id="F_113206bb-7053-4612-ad43-f77ebbb5cd04"
      unitRef="U_pure">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="4"
      id="F_7a3967c2-bfc0-431d-88f8-12cf7c500869"
      unitRef="U_pure">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      id="F_ae9d3430-4265-4162-9e26-27d3d7464404">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      id="F_5f09b8be-3dcd-4c2e-8854-c8923243a295">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_6bbc9e47-3f26-45ac-a0f8-aed8ff9d18b0"
      unitRef="U_pure">0.8812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_15ca8112-437c-4992-9a66-82d80edefb9a"
      unitRef="U_pure">0.989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="4"
      id="F_ad0508da-6932-4bfa-aef8-f649471ff644"
      unitRef="U_pure">0.8461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="4"
      id="F_b8ac5d2f-e830-4fef-92a2-c981b0e1c74a"
      unitRef="U_pure">0.8819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_fc0d0f3f-f73d-497c-bd5d-e335efacf909"
      unitRef="U_pure">0.9225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="4"
      id="F_81946e7c-7a8c-4109-9ce0-67861105af6c"
      unitRef="U_pure">0.8585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_4f23d8e7-fb1d-4b25-ad85-988d078dbb20"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_29e7aba1-e6b3-4d85-8383-eedc450375e7"
      decimals="4"
      id="F_a35e5e08-8cb6-4416-87f1-09e777f73693"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      decimals="4"
      id="F_cd4e13f1-9968-488a-90e3-2249c007524c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_02c649ee-2689-4467-af86-e845ba2c5b89"
      decimals="-5"
      id="F_0a799e73-8a11-4a1f-850c-2c0e952a7deb"
      unitRef="U_USD">6300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2e276f52-dfaa-44a5-b7b9-a0bedf3d5c30"
      id="F_8d5cadbc-2e63-4d8f-ab6a-a0fae195a922">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d"
      id="F_fbd54905-c7b0-4a6b-8ca5-1e4978c422ca">vest over a four-year period with 25% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d"
      id="F_2def982d-580b-40fe-912a-eed367f9e87a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_000f6d8e-e3fa-40af-9c58-0f23b236dc8d"
      decimals="2"
      id="F_c3ff910c-8688-49d6-ab96-a50eb735f294"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_63a872cf-6e8e-4d40-9cbb-3023e8fdb46c"
      decimals="INF"
      id="F_f2832fa3-0d38-46eb-a510-ba4f8fe06c61"
      unitRef="U_shares">217500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_3bd640a5-6ed0-4cd8-a0d7-639661192341"
      decimals="INF"
      id="F_6a37124e-28ec-4790-b969-b9f25f25a2a7"
      unitRef="U_shares">77650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      id="F_1e0037e2-614e-46fa-b126-8e8f9d0848a4">vest over a two-year period with 50% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following four quarters</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      id="F_7092d679-7cb5-442a-92b7-b05674a3d918">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="2"
      id="F_d42bafb8-614f-4ea5-b02b-4594532c678e"
      unitRef="U_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_434296fa-9c83-410d-a74a-f3611ecc4567">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the PRSU activity under the 2023 Plan for the nine months ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79"
      decimals="INF"
      id="F_7f21c968-ed51-45eb-9e23-fc8278ccf590"
      unitRef="U_shares">266300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b27aa265-ccf4-4e5c-8bd2-f28f7fa62a79"
      decimals="2"
      id="F_98c8d347-ba21-4f8b-af4a-7161a5e44d70"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="INF"
      id="F_db25365c-a57d-4b1c-a52a-d1708233f5b2"
      unitRef="U_shares">664684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="2"
      id="F_f7b17619-8c75-4d87-8c3b-adab7eb40cf7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="INF"
      id="F_3ed06f60-76e7-4efb-9c8e-d47954929e67"
      unitRef="U_shares">101448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="2"
      id="F_7d736255-17d8-4b27-8d51-01307f7e25aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="INF"
      id="F_baaf8282-3725-436a-b1e4-d15ab4c667d2"
      unitRef="U_shares">125958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_349227bb-1ea5-4421-9800-ea1f0cfc9551"
      decimals="2"
      id="F_8bcc335f-43d6-48b1-b1d6-98c19366aa50"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_74917b61-bde0-47fb-a510-eeb410d819a3"
      decimals="INF"
      id="F_c61ca445-d549-425a-aa40-3925d96ebfd5"
      unitRef="U_shares">703578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_74917b61-bde0-47fb-a510-eeb410d819a3"
      decimals="2"
      id="F_86af1cf7-d4ac-4f1b-9cf8-66265be9ae0a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_c8d1b98f-fda8-4237-9715-247e14f34e52"
      decimals="-5"
      id="F_3f170f75-a1e3-42ab-8ae7-2a2bbd61601e"
      unitRef="U_USD">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e272bdc5-b039-4362-8f99-fa87bcc9aa26"
      id="F_f5d47c0a-faa5-44d2-bf26-0adf8b99df93">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8"
      decimals="INF"
      id="F_3daf70b2-74ba-4cab-b807-84aec32d5115"
      unitRef="U_shares">217500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8"
      decimals="2"
      id="F_f3ae2d65-5424-4c64-b3dd-0e25a37033d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8"
      decimals="INF"
      id="F_2e08e7da-3430-4eac-a8b3-442e47a4e31f"
      unitRef="U_shares">76800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_44ee7a2f-6ca3-4c91-8c62-7bf03a8e58e8"
      decimals="2"
      id="F_211e8c65-2d91-4122-b2d3-1c7c133ee007"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c04bdcf3-b841-4689-9b64-38b332249fe2"
      decimals="INF"
      id="F_a61a859a-115f-490c-b303-385e84e2e4ec"
      unitRef="U_shares">140700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c04bdcf3-b841-4689-9b64-38b332249fe2"
      decimals="2"
      id="F_6604ca46-283d-4a6f-94ef-3f5526d5b5cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <lxeo:PayrollDeductionsAtPrice
      contextRef="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f"
      decimals="2"
      id="F_383568db-8ac7-4176-a481-7fe8b33b1c65"
      unitRef="U_pure">0.85</lxeo:PayrollDeductionsAtPrice>
    <lxeo:CommonStockDuringOfferingPeriod
      contextRef="C_cf9feab1-814e-43f8-90af-29fdc96653e8"
      decimals="INF"
      id="F_8656d267-9504-4db1-b512-5e0c022ad0f6"
      unitRef="U_shares">6000</lxeo:CommonStockDuringOfferingPeriod>
    <lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans
      contextRef="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f"
      decimals="0"
      id="F_4bd4a072-da9c-422b-9ae4-624efbd7538f"
      unitRef="U_USD">0</lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_46c792b5-6c67-472c-9304-76b2d83ce68a"
      decimals="INF"
      id="F_3e286ebd-4170-4daa-8445-be7c3c9f5f96"
      unitRef="U_shares">102837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_46c792b5-6c67-472c-9304-76b2d83ce68a"
      decimals="2"
      id="F_7c65a105-357b-489b-b1ef-8afffc2b8b39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_d53fa0a9-c52f-4c31-8723-a5c4098d083f"
      decimals="-5"
      id="F_4f8bb8eb-c466-475f-97a9-74ed791941b9"
      unitRef="U_USD">300000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_ddaf99aa-bf9e-46b4-852e-a37e225bbb1a">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was classified as follows in the Company&#x2019;s statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8eaec952-271e-49b4-9770-a01b8320fedf"
      decimals="-3"
      id="F_7a24bc99-8280-4474-b8aa-a93add2d4541"
      unitRef="U_USD">5524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_26366915-140b-4c96-93b7-e237b4213687"
      decimals="-3"
      id="F_92a4d749-49db-4a25-bfd7-cadc4748c0b7"
      unitRef="U_USD">6001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0f7ea42a-4e43-4f1e-a004-b523e0aeb298"
      decimals="-3"
      id="F_8a59f6a8-4d7e-4704-9083-d2f301e66dc0"
      unitRef="U_USD">6608000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8d5bfde0-a484-4470-9cd3-618c66bc014d"
      decimals="-3"
      id="F_409744fb-5e1f-448c-ad5a-d96d6f2f5be7"
      unitRef="U_USD">6473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_a7fe7989-9c1e-4932-96c5-c1e1e8befadb"
      unitRef="U_USD">12132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_ae7e242c-1715-4414-891b-2175a56ce03f"
      unitRef="U_USD">12474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_54e25091-788e-44ff-a8dc-7aa0124486da">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,645,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,787,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_0e817e09-8181-4eaf-a477-374a7bc9745e">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,645,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,787,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_8ee58ca8-d9f5-48c8-b1d9-5ee787bd4d6f"
      unitRef="U_USD">-99961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_645e77e2-0214-436f-96ea-a593f6a9367d"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="0"
      id="F_96af58ce-092d-46f3-88e5-b008b68e80b6"
      unitRef="U_shares">53645323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="0"
      id="F_13b22d64-5767-4ac4-aea0-9716c7f8d36f"
      unitRef="U_shares">53645323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="0"
      id="F_812c55d6-7606-4b84-9202-f785687dd506"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="0"
      id="F_93104e0e-e255-4287-a57a-cce89ba226a2"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="2"
      id="F_2df25bcb-a9e1-4ccf-801a-085a1983ceb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="2"
      id="F_b78b6786-947a-4ccb-b04f-a58e5d1d2663"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="2"
      id="F_b0b7b0c5-aedc-4cdf-890a-0c8d221e4448"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="2"
      id="F_f84b27bd-10ec-4d0d-a2a1-1697b9c11ab9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_39fcdd1a-92e9-47d8-ae09-e194779bf143">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of net income (loss) before income tax expense are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company's statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended December 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:46.038%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.604000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.145%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.384%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pretax Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US Federal Statutory Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credits:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credit - Federal R&amp;amp;D Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credit - Orphan Drug Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or Nondeductible Items:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's effective tax rate includes the effects of state and local income taxes, net of the federal income tax benefit, which are primarily attributable to New York and New York City, where the Company has significant business activities. This state has higher effective tax rates compared to other jurisdictions where the Company operates, and together, it accounts for more than half of the Company's total state tax expense.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company's deferred tax assets and liabilities at December 31, 2025 and December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, the Company had federal net operating loss ("NOL") carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which can be carried forward indefinitely. As of December 31, 2025 and 2024, the Company had state and local net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, the Company had federal tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Tax Cuts and Jobs Act (the "TCJA") resulted in significant changes to the treatment of research and developmental (&#x201c;R&amp;amp;D&#x201d;) expenditures under Section 174 of the Internal Revenue Code of 1986, as amended (the "IRC"). For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;amp;D activities must be amortized over five years and costs for foreign R&amp;amp;D activities must be amortized over 15 years, both using a midyear convention.&lt;br/&gt;&lt;br/&gt;For tax years beginning after December 31, 2024, the One Big Beautiful Bill Act enacted a new rule under Section 174A of the IRC allowing companies to immediately expense any domestic R&amp;amp;D expenditures. For domestic R&amp;amp;D, companies may either immediately expense or elect to capitalize and amortize over at least 60 months under Section 174A of the IRC. However, foreign R&amp;amp;D continues to require capitalization subject to the mandatory 15-year amortization period under Section 174 of the IRC.&lt;br/&gt;&lt;br/&gt;For domestic R&amp;amp;D expenditures that were previously capitalized in tax years 2022-2024 under the prior TCJA, companies may elect to recover the remaining unamortized balance by either (1) expensing fully in the first year beginning after December 31, 2024, (2) expensing ratably over two years beginning after December 31, 2024, or (3) continue amortizing over the remaining life.&lt;br/&gt;&lt;br/&gt;The Company has elected to continue amortizing the previously capitalized costs over their remaining life. Beginning in tax year 2025, instead of immediately expensing domestic R&amp;amp;D expenditures under Section 174A of the IRC, the Company elected to capitalize and amortize its domestic R&amp;amp;D expenditures under Section 59(e) of the IRC over a 10-year period. Any foreign R&amp;amp;D costs will continue to be capitalized and amortized over 15 years in accordance with the requirements of Section 174 of the IRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2025 and December 31, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. As a result, the Company increased its valuation allowance by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% or more in the ownership positions of certain stockholders during a rolling three-year period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company conducted ownership analyses under IRC Section 382 as of September 30, 2024 and December 31, 2025 and determined the Company experienced ownership changes on November 7, 2023 and May 28, 2025, respectively, that limit the Company&#x2019;s ability to utilize its federal NOLs and tax credits. As a result of the ownership changes, the Company is subject to an annual limitation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on its ability to utilize its federal NOLs and tax credits recognized before May 28, 2025, inclusive of the ownership change that occurred on November 7, 2023. Due to the limitations, no federal NOLs are expected to expire unutilized and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership changes, are expected to expire unutilized. As a result, during the year ended December 31, 2025, the Company reduced its deferred tax assets related to the federal tax credits, which was offset by a corresponding decrease in the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2025 and December 31, 2024, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any uncertain tax positions in its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying statements of operations. As of December 31, 2025 and December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties are included on the related tax liability line in the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company's financial statements. The Company&#x2019;s tax years remain open under statute from December 31, 2022 to the present.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the Company's capital base and franchise taxes paid (net of refunds received) for the years presented below:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the jurisdictions that exceeded 5% of the Company's total capital base and franchise taxes paid (net of refunds) for the years presented below:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;New York&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;New York City&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_1312c9e1-d4f9-433e-bf6e-22de8c5da91e">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of net income (loss) before income tax expense are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_4f2b2534-f12b-43be-9404-2c665b3c03b5"
      unitRef="U_USD">-99670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_c81fb4b5-2618-44af-87a6-165312a26dbe"
      unitRef="U_USD">-98436000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_c6c6f973-0d26-4eea-82cb-9e262f83ed89"
      unitRef="U_USD">-99670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_aae2103f-f11f-45e1-8d31-54a0e6d50ea4"
      unitRef="U_USD">-98436000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_6b4e9a52-c243-475a-b5ae-08812a816722">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company's statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended December 31, 2025, and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:46.038%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.604000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.145%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.384%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pretax Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US Federal Statutory Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credits:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credit - Federal R&amp;amp;D Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credit - Orphan Drug Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or Nondeductible Items:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_06fc9ad1-0873-4ca0-9ca1-10d6e64bc392"
      unitRef="U_USD">-99670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_851a9a5b-5edd-4400-ba7f-d8b35b1270ce"
      unitRef="U_USD">-98436000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_dbdfe9ce-58a1-41fe-81c1-26979c21d310"
      unitRef="U_USD">-20931000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="4"
      id="F_bb2806e0-f367-4c75-be27-3464f883c5fe"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_88e8174f-939d-4800-ae3e-0c1767465513"
      unitRef="U_USD">-20671000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="4"
      id="F_c80a3710-67a4-4a46-870a-76efe2fa5fab"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_72f43e06-badc-4dd7-a749-00e108688043"
      unitRef="U_USD">-5523000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="4"
      id="F_93ccf4b8-79bb-4a67-88b9-366ebc2419fe"
      unitRef="U_pure">0.0554</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_5578da52-5dbb-413c-a8b1-641cb3eae5e6"
      unitRef="U_USD">678000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="4"
      id="F_9424377e-6ef2-4bf2-bd70-9f17d4ea7da0"
      unitRef="U_pure">-0.0069</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_3cd9a9b0-1010-4100-8b85-86dd78bdeee5"
      unitRef="U_USD">1970000</lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount>
    <lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="4"
      id="F_8f9bf904-3854-4001-a3bb-3dd9f571582a"
      unitRef="U_pure">-0.0198</lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent>
    <lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_0effb244-f8a8-4077-a7d2-233506e3a4e4"
      unitRef="U_USD">2995000</lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditAmount>
    <lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="4"
      id="F_415a87d3-b8a9-45ab-a9b6-eb0775d37d17"
      unitRef="U_pure">-0.0304</lxeo:IncomeTaxReconciliationTaxCreditsOrphanDrugCreditPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_8d6fa13d-d358-4d7a-a032-d20b6c99e015"
      unitRef="U_USD">16430000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="4"
      id="F_e9b87cfc-b591-4a61-9cf6-715b4aa22538"
      unitRef="U_pure">-0.1648</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_c1a3e022-dc65-4f55-844a-3afbf60d1f7c"
      unitRef="U_USD">22903000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="4"
      id="F_794e3f18-381f-4733-9062-1721a0dcc02b"
      unitRef="U_pure">-0.2327</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_39084d10-df6b-4ff6-aed1-fd2672ae93e5"
      unitRef="U_USD">948000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="4"
      id="F_f3e00751-f001-4fff-a4ff-9f97e73eb1d3"
      unitRef="U_pure">-0.0095</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_ce65855f-bebc-418f-bbe7-cb89d777651d"
      unitRef="U_USD">1441000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="4"
      id="F_b6501ea7-2be7-4fee-847d-9547d00269ad"
      unitRef="U_pure">-0.0146</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_02d323c1-3d58-4697-bd40-fdbd6bbe7d1a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="4"
      id="F_064c1bdf-ea0c-40fa-b1f0-a5f5cdd66de0"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_ad7ac9e4-3ce7-4d8e-b8a6-d0129a620b49"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="4"
      id="F_52e980e8-10e7-4dc0-9776-aa25810ac24c"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_83a5b986-04a0-4144-ba5c-29e3e82cc52a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company's deferred tax assets and liabilities at December 31, 2025 and December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_16c2588d-6a7a-49e5-b011-e76b5d5ae821"
      unitRef="U_USD">56868000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_5b7d4068-d01e-40b5-b408-ea76078a9059"
      unitRef="U_USD">33295000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_993a8a78-ce76-406d-a2ad-dc72d73aba0b"
      unitRef="U_USD">7190000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_45c660be-f081-4111-807d-17d9abb3bb06"
      unitRef="U_USD">10743000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <lxeo:DeferredTaxAssetsIntangibleAssets
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_2ebf57c2-faa3-4b1b-bfe0-65ec5588dfa9"
      unitRef="U_USD">5167000</lxeo:DeferredTaxAssetsIntangibleAssets>
    <lxeo:DeferredTaxAssetsIntangibleAssets
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_c1b3ecc4-1c8e-4591-83c7-8b354ddb39ce"
      unitRef="U_USD">5918000</lxeo:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_eccf8581-61e7-4db9-9f50-7fc2f66b50d8"
      unitRef="U_USD">43720000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_9533b81a-f9cd-4403-83ee-ccbb84e7a363"
      unitRef="U_USD">39338000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lxeo:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_5fb80c7e-6d8a-4431-81d4-16bfc4e96ff6"
      unitRef="U_USD">2204000</lxeo:DeferredTaxAssetsLeaseLiabilities>
    <lxeo:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_7b136398-feca-4f7b-949e-3b8055020d7b"
      unitRef="U_USD">2818000</lxeo:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_0c6e0b28-0fb5-4f5f-b741-29d758a2633a"
      unitRef="U_USD">6225000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_872a42b3-3b3f-4c82-9357-68438705dc1a"
      unitRef="U_USD">6292000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_7cdb2ca9-031e-4421-a055-fe1d575dc695"
      unitRef="U_USD">121374000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_0ec43ec4-503a-4060-8993-39e58f807c40"
      unitRef="U_USD">98404000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_42bd943d-2831-4963-a7a5-3282246edc28"
      unitRef="U_USD">118935000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_dcb81302-9ad4-4a59-9f73-73f13563ddb9"
      unitRef="U_USD">95426000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_31bae685-0bce-4736-96e0-5a13b66ca666"
      unitRef="U_USD">2439000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_d365fddf-0535-4a76-a631-0a9ba1e13d66"
      unitRef="U_USD">2978000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_9652a9e8-fd81-4d94-a7d8-e36f8a9cd430"
      unitRef="U_USD">2059000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_650a08b6-4227-4469-a700-102eb346494a"
      unitRef="U_USD">2663000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_4addbed7-773f-4865-bad6-b1742f7c80b6"
      unitRef="U_USD">380000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_e485aeea-3d32-43fd-ab03-0f16bcae52ea"
      unitRef="U_USD">315000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_132abf1f-34c8-4d64-b4c0-0d4abbf49f82"
      unitRef="U_USD">2439000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_4b214400-32ce-4960-9991-2c5533b74c06"
      unitRef="U_USD">2978000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="-3"
      id="F_8d0222ab-5da5-406a-b8c0-3590cbaf5168"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="-3"
      id="F_9958904a-e655-43f3-81fc-15a6c5930088"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ba541477-4977-4a4d-8ea6-08f08a69b3a2"
      decimals="-5"
      id="F_552f51f7-41fa-4c87-ab36-ef0c914e370e"
      unitRef="U_USD">182000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_af7f7cbb-e358-4e01-9e01-445a10e44bc0"
      decimals="-5"
      id="F_5c96b0ec-36a1-4326-9256-c8f25f330391"
      unitRef="U_USD">106400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_487136e8-5828-4a30-8230-e11cfaee5e4f"
      decimals="-5"
      id="F_98eee0ba-d0bc-4c15-a052-c810015460ad"
      unitRef="U_USD">362900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0eb85a0b-e29d-45c6-a281-a90d66d244dd"
      decimals="-5"
      id="F_d73cd22e-be40-4a7f-b879-33bb3ae09f41"
      unitRef="U_USD">212700000</us-gaap:OperatingLossCarryforwards>
    <lxeo:TaxCreditCarryForwardExpirationYear
      contextRef="C_2d6d8b8b-f338-4359-9fa9-714c220f91b8"
      id="F_1fd60be2-f1ea-4fb7-899c-e3837b9f8d5d">2040</lxeo:TaxCreditCarryForwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_ba541477-4977-4a4d-8ea6-08f08a69b3a2"
      decimals="-5"
      id="F_917a4c97-18a6-43ca-b9ae-33f822509c8a"
      unitRef="U_USD">7200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_af7f7cbb-e358-4e01-9e01-445a10e44bc0"
      decimals="-5"
      id="F_8bce338c-3171-4bc5-a10e-edf57932b09b"
      unitRef="U_USD">10700000</us-gaap:TaxCreditCarryforwardAmount>
    <lxeo:TaxCreditCarryForwardExpirationYear
      contextRef="C_2917ec7c-ddbb-4d8a-a527-3f8895a2283c"
      id="F_fc0f6a8f-d0a8-4cec-9971-1d154ccf096e">2040</lxeo:TaxCreditCarryForwardExpirationYear>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-5"
      id="F_f95a8b26-a85c-43c1-9ad3-d767d8babf69"
      unitRef="U_USD">23500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <lxeo:PercentageOfCumulativeOwnershipChange
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="2"
      id="F_885dff74-86f0-452d-98aa-c47419dce9d2"
      unitRef="U_pure">0.50</lxeo:PercentageOfCumulativeOwnershipChange>
    <lxeo:AnnualLimitationAbilityToUtilize
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-5"
      id="F_ba55906d-e651-4588-98f6-5b829352cacc"
      unitRef="U_USD">2400000</lxeo:AnnualLimitationAbilityToUtilize>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-5"
      id="F_cbeecf9f-b259-428c-b788-32988a53561c"
      unitRef="U_USD">10600000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_60a45da4-ed4f-4450-a26f-10c21744da63"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_d80b9627-1a56-4e1c-8bc1-1d8a47022172"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_2e53f54e-9340-45a2-bb18-6aa3885d9b1d"
      decimals="INF"
      id="F_f70a58bc-69f8-47ee-a859-6b71225225ee"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_09b9e6b9-e955-4ce9-b9ba-507d6f870bf9"
      decimals="INF"
      id="F_34b2c76c-adad-45be-8f1f-fe786b0dbe73"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <lxeo:SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_663d7840-9f15-4586-998a-bbbb4b8e04fc">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the Company's capital base and franchise taxes paid (net of refunds received) for the years presented below:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the jurisdictions that exceeded 5% of the Company's total capital base and franchise taxes paid (net of refunds) for the years presented below:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;New York&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;New York City&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</lxeo:SummaryOfCapitalBaseAndFranchiseTaxesPaidNetOfRefundsReceived>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_07de70fa-41b5-4895-b2b9-f435b17b54e8"
      unitRef="U_USD">0</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_64257ac2-ec57-40d4-bdb1-2c6fb6d4a456"
      unitRef="U_USD">0</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_cee69d5a-5801-4f86-a417-6851f6c2012f"
      unitRef="U_USD">551000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_e448d675-ebc4-4c46-8091-c93fa2644a2b"
      unitRef="U_USD">133000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="-3"
      id="F_13f66bf3-244e-4e4e-9519-f5876ba01aa0"
      unitRef="U_USD">551000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_4bf1812c-b3ca-48be-9ba4-e26a677f8ae0"
      decimals="-3"
      id="F_5dca5255-838b-4351-bce9-974fa303dadf"
      unitRef="U_USD">133000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="C_23f2cf9c-eb2c-4874-9bb5-0b7e43ac44cb"
      decimals="-3"
      id="F_3c4ccd1d-b9b4-4ed7-bd73-9e100423fcf9"
      unitRef="U_USD">352000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="C_ac474d05-a4df-41bb-8c49-c9dddccf1523"
      decimals="-3"
      id="F_0f8ebd1e-15db-4afc-baa1-a323ed22e1c1"
      unitRef="U_USD">98000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="C_99561f6d-e4ca-4b39-a707-cdaeb6211e33"
      decimals="-3"
      id="F_4fbb602d-d37f-4605-a83e-fe0164ad8b99"
      unitRef="U_USD">192000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="C_80a79c85-4eb7-478c-9356-9eedeabc3701"
      decimals="-3"
      id="F_419ccec3-12ca-453d-896e-9dd6756e6f98"
      unitRef="U_USD">35000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_0be18ea4-c95e-4582-885b-504cf3bcd544">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;As of December 31, 2025, the Company had entered into commitments under lease agreements to rent laboratory and office space and finance equipment (see Note 6).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;As of December 31, 2025, the Company had entered into commitments under license, acquisition, research collaboration and sponsored research agreements with third parties (see Note 12). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-days&#x2019; written notice, unless otherwise indicated. Further, certain of the Company&#x2019;s manufacturing agreements could require early termination and wind-down payments due from the Company upon either the termination of its clinical trials or if the Company terminates such agreements for convenience.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company recognizes any associated legal fees as incurred and accrues a liability for such contingent liability matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings, except that on October 12, 2023, Rocket Pharmaceuticals, Inc. (&#x201c;Rocket&#x201d;) filed a lawsuit in the U.S. District Court for the Southern District of New York against the Company and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; former employees that claimed, among other things, misappropriation of confidential information and trade secrets. The complaint alleged the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they became employed at the Company. The complaint sought unspecified damages and asked the court to enjoin the Company from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, the Company asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. The Company's counterclaims sought equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. In June 2025, the litigation was resolved amicably and without admission of liability by any party, and all claims have been dismissed with prejudice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. For all periods presented, the Company has not incurred any material costs as a result of such indemnifications.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_1f3e3006-1af0-48a7-9634-48ce1dc96196"
      id="F_41ae52af-4461-4af2-aa87-ba1034f0e9aa">P30D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_84e826fb-ff2b-461e-a57d-ab9f5b605b0a"
      id="F_afaa2a08-da17-408e-86db-08eede9b48d9">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:NumberOfFormerEmployees
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      decimals="INF"
      id="F_6c77bbc0-42aa-47bd-8b45-b54e1ab96f70"
      unitRef="U_Employees">2</lxeo:NumberOfFormerEmployees>
    <lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_8eb75d59-3929-42be-b7c0-0863233ab782">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. License, Acquisition, Research and Collaboration and Sponsored Research Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adverum Biotechnologies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;On January 25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#x201c;Adverum&#x201d;) to in-license materials and technology related to the treatment of cardiomyopathy due to Friedreich's ataxia ("FA") (as amended in February 2022, the &#x201c;Adverum Agreement&#x201d;). In connection with the Adverum Agreement, the Company gained access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop, and the Company will assume all development and commercialization activities worldwide. Pursuant to the Adverum Agreement, the Company paid a one-time up-front non-refundable fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and is obligated to pay aggregate development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million including a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved and paid in the first quarter of 2023, and aggregate sales event and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of December 31, 2025, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; research and development expenses recorded by the Company or payments made to Adverum under the terms of the Adverum Agreement other than the one-time up-front non-refundable fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved and paid in the first quarter of 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Adverum Agreement remains in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days&#x2019; written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach of contractual terms, or insolvency by either party.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cornell University&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;On May 28, 2020, the Company entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exclusive license agreements with Cornell University (&#x201c;Cornell&#x201d;) (each, as amended, the &#x201c;First Cornell License Agreement&#x201d; and the &#x201c;Second Cornell License Agreement,&#x201d; respectively; collectively the &#x201c;May 2020 Cornell License Agreements&#x201d;). The First Cornell License Agreement is for the in-license of technology related to portfolios for APOE-associated Alzheimer&#x2019;s disease and Anti-Tau, although the Company&#x2019;s license is not restricted by such indications and it includes assignment to the Company of Cornell&#x2019;s IND for the use of AAVrh10.hAPOE2 vector to treat APOE4 homozygous patients who are at risk for or have Alzheimer&#x2019;s disease to support development of the Company&#x2019;s LX1001 program. The Second Cornell License Agreement is for the in-license of technology related to a portfolio for FA although the Company&#x2019;s license is not restricted by such indications, and it includes assignment to the Company of Cornell&#x2019;s IND for the use of AAVrh.10cUhCLN2 to treat children with CLN2 Batten disease to support development of the Company&#x2019;s LX1004 program. Through the May 2020 Cornell License Agreements, the Company gains access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop. Under the terms of the May 2020 Cornell License Agreements, the Company has assumed all development and commercialization activities worldwide with respect to the licensed technology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As initial consideration for the May 2020 Cornell License Agreements, the Company paid Cornell an upfront payment in cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and issued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of notes (the &#x201c;Cornell Notes&#x201d;). In November 2020, the Cornell Notes with outstanding principal of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million were cancelled in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,337,610&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of series A convertible preferred stock, which converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,258&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the closing of the Company's IPO on November 7, 2023. As additional consideration, the Company is required to pay Cornell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specific clinical and regulatory milestones under the First Cornell License Agreement and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in two portfolios and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for a third portfolio upon the achievement of specific clinical and regulatory milestones under the Second Cornell License Agreement. In the second quarter of 2022, a clinical and regulatory milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized and paid to Cornell in connection with the Second Cornell License Agreement. The Company is also required to pay Cornell a flat royalty in the mid-single-digits based on net sales of the products covered by the licenses, subject to certain adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes non-exclusive and royalty-free. In addition, each of the May 2020 Cornell License Agreements may be terminated by the Company for any reason upon ninety (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; advance notice to Cornell and by Cornell upon the Company&#x2019;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 21, 2024, the Company entered into the Third License Agreement (as amended, the &#x201c;Third Cornell License Agreement,&#x201d; together with the May 2020 Cornell License Agreements, the &#x201c;Cornell License Agreements&#x201d;) with Cornell. Pursuant to the Third Cornell License Agreement, Cornell has granted the Company an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell on behalf of the Company and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell has also granted the Company a right of reference to Cornell&#x2019;s Investigational New Drug application for a gene therapy for FA cardiomyopathy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Third Cornell License Agreement, the Company paid a license issue fee and an initial data transfer fee to Cornell totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Additionally, the Company will be paying an annual data transfer fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; until data is no longer being gathered. The Company has agreed to pay annual license maintenance fees ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; until such time the Company commercializes a licensed product. In addition, the Company will pay Cornell up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in regulatory milestones and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in commercial milestones, plus low single digit royalties on net sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Third Cornell License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, the Company shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cornell may terminate the Third Cornell License Agreement if the Company (i) breaches the Third Cornell License Agreement (subject to a cure period), (ii) participates in any proceeding challenging the validity of the licensed patents, (iii) publishes the licensed data without Cornell&#x2019;s prior written consent, or (iv) does not reach certain milestones. Cornell may also terminate the Third Cornell License Agreement in part on a product-by-product basis if the Company does not diligently develop and sell a product. The Company may terminate the Third Cornell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days&#x2019; prior written notice to Cornell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 17, 2025, the Company executed a Second Amendment to the Third Cornell License Agreement (the &#x201c;Second Amendment to the Third Cornell License Agreement&#x201d;), which added a one-time fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for additional data transfer and processing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in connection with the Amended Cornell License Agreements. During the year ended December 31, 2024, the Company incurred and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in connection with the Amended Cornell License Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stelios Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Stelios Therapeutics, Inc. (&#x201c;Stelios&#x201d;) was an early-stage company developing novel adeno-associated AAV-based gene therapies for rare cardiac conditions including arrhythmogenic cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy. On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 16, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company acquired &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding stock of Stelios that was accounted for as an asset acquisition pursuant to FASB ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company is required to pay up to a remaining aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the selling shareholders of Stelios upon the achievement of certain development milestones, excluding a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved in the third quarter of 2024 and paid in the fourth quarter of 2024. Dr. Eric Adler, the Company's former Chief Medical Officer and Head of Research, was a co-founder of Stelios and a selling shareholder. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone payment, Dr. Adler received approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Stelios was merged into the Company on December 15, 2022 and ceased to exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Regents of the University of California, San Diego&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Stelios entered into an exclusive worldwide license agreement on April 23, 2020 (as amended, the &#x201c;First UCSD Agreement&#x201d;) with The Regents of UCSD to in-license materials and intellectual property related to a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The First UCSD Agreement relates to the Company&#x2019;s development efforts for its LX2021 program. In connection with the First UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The First UCSD Agreement required Stelios to pay one-time up-front non-refundable cash fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each agreement and requires the Company to pay aggregate development and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and low- to mid-single digit royalties and low-single digit royalties based on aggregate net sales. The only research and development expense incurred by Stelios or the Company, and payment made to The Regents of UCSD through December 31, 2025 under the terms of the First UCSD Agreement, was the one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has the right to terminate the First UCSD Agreement at any time upon sixty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to The Regents of UCSD.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stelios entered into an exclusive worldwide license agreement on August 6, 2020 (as amended, the &#x201c;Second UCSD Agreement&#x201d;) with The Regents of UCSD to in-license materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy. On November 14, 2025, the Company entered into an amended and restated license agreement with UCSD, which amended and restated in its entirety, the Second UCSD Agreement (the "Amended and Restated Second UCSD Agreement"). The Amended and Restated Second UCSD Agreement maintained the Company's prior exclusive worldwide license to materials and intellectual property related to a gene therapy for hypertrophic cardiomyopathy, replaced Stelios with the Company as licensee, and exclusively in-licensed additional materials and intellectual property related to the LX2022 program. Stelios previously paid a one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; under the Second UCSD Agreement. The Amended and Restated Second UCSD Agreement requires the Company to pay aggregate development and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and low-single digit royalties based on aggregate net sales. The only research and development expense incurred by Stelios or the Company, and payment made to The Regents of UCSD through December 31, 2025 under the terms of the Second UCSD Agreement and the Amended and Restated Second UCSD Agreement, was the one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has the right to terminate the Amended and Restated Second UCSD Agreement at any time upon sixty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to The Regents of UCSD.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 4, 2021, the Company entered into an exclusive worldwide license agreement (as amended, the &#x201c;Third UCSD Agreement&#x201d; and collectively with the First UCSD Agreement and the Amended and Restated Second UCSD Agreement, the &#x201c;UCSD Agreements&#x201d;) with The Regents of UCSD to in-license materials and intellectual property related to LX2020, a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The Third UCSD Agreement relates to the Company&#x2019;s development efforts for its LX2020 program. In connection with the Third UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The Third UCSD Agreement required the Company to pay a one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and requires &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company to pay aggregate development and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and low- to mid-single digit royalties based on aggregate net sales&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Research and development expenses incurred by the Company and payments made to The Regents of UCSD under the terms of the Third UCSD Agreement include the one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as well as a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved during the third quarter of 2024. The Company has the right to terminate the Third UCSD Agreement at any time upon sixty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to The Regents of UCSD.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 3, 2021, the Company entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sponsored research agreements with The Regents of UCSD (the "First UCSD SRA", the "Second UCSD SRA", and collectively, the &#x201c;Initial UCSD SRAs&#x201d;) for the Company&#x2019;s LX2020, LX2021 and LX2022 programs in connection with the UCSD Agreements. Under the terms of the Initial UCSD SRAs, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by The Regents of UCSD or resulting inventions jointly owned between the Company and The Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Initial UCSD SRAs each have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two-year &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;term and may be terminated early by the Company at any time upon the giving of thirty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to The Regents of UCSD. The total costs to be invoiced to the Company over the terms of the Initial UCSD SRAs are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 13, 2024, the Company entered into a third sponsored research agreement with The Regents of UCSD (as amended, the &#x201c;Third UCSD SRA&#x201d;) for the Company&#x2019;s LX2022 program in connection with the Second UCSD Agreement. Under the terms of the Third UCSD SRA, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by The Regents of UCSD or resulting inventions jointly owned between the Company and The Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Third UCSD SRA has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and may be terminated early by the Company at any time upon the giving of thirty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to The Regents of UCSD. The costs to be invoiced to the Company over the term of the Third UCSD SRA are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and the Company may incur additional costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Third UCSD SRA if certain study objectives are met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 13, 2024, the Company also entered into an amendment to the Second UCSD SRA (as amended, the "Amended Second UCSD SRA") for the Company&#x2019;s LX2022 program that extended the term of the Second UCSD SRA to December 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On each of April 19, 2024 and September 27, 2024, the Company also entered into an amendment to the First UCSD SRA (as amended, the "Amended First UCSD SRA", and together with the Amended Second UCSD SRA and the Third UCSD SRA, the "UCSD SRAs") for the Company&#x2019;s LX2021 program in connection with the First UCSD Agreement. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to the Company under the Amended First UCSD SRA are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to The Regents of UCSD in connection with the Amended UCSD SRAs. During the year ended December 31, 2024, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to The Regents of UCSD in connection with the Amended UCSD SRAs. The Company has incurred and paid cumulative totals of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, to The Regents of UCSD as of December 31, 2025, in connection with the Amended UCSD SRAs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Myoventive, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In June 2025, the Company entered into a Collaboration and License Agreement with Tilia Therapeutics, Inc., now known as Myoventive, Inc. ("Myoventive" and the "Myoventive Agreement"), to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Myoventive Agreement, the Company contributed expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform. As consideration for its contributions, the Company received a double-digit percentage equity position in Myoventive and will be entitled to future milestone payments, royalties, and opt-in rights to certain program(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Abiomed, Inc. (Johnson &amp;amp; Johnson subsidiary)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of gene therapy. Under the Abiomed Agreement, the parties intend to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV-vector delivery to the heart by investigating cutting-edge routes of administration using the Impella&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; heart pump technology. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t incur or pay any research and development costs in connection with the Abiomed Agreement for the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;</lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_75180180-4d90-42c6-8270-15e1f3cc0ebf"
      decimals="-5"
      id="F_82db6f07-1589-4107-817c-6668b17c2cd2"
      unitRef="U_USD">7500000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:DevelopmentAndRegulatoryMilestonesDue
      contextRef="C_e9dc71b0-9639-4d01-9da6-f620a88b25a4"
      decimals="INF"
      id="F_8f40ec92-2cfc-4e19-b2a2-605f2466bea2"
      unitRef="U_USD">17500000</lxeo:DevelopmentAndRegulatoryMilestonesDue>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2"
      decimals="-5"
      id="F_6056e926-e3e9-4bdc-aa43-d6af7f3382e7"
      unitRef="U_USD">3500000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:CommercializationMilestonesDue
      contextRef="C_e9dc71b0-9639-4d01-9da6-f620a88b25a4"
      decimals="INF"
      id="F_328d4109-03eb-4986-9598-3bb9a3528d90"
      unitRef="U_USD">49000000</lxeo:CommercializationMilestonesDue>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
      contextRef="C_38fa9b64-95c3-4a46-9bf4-5fef14d31d49"
      id="F_8f452e53-9937-4175-adad-90bdc65a04ac">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_eca6767a-469e-41ac-95c7-b2ab4461a834"
      decimals="INF"
      id="F_e5bac99c-1e86-4dae-ad9f-084a4f9e1c51"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2"
      decimals="-5"
      id="F_a1584e20-5108-4d07-bcb8-d1c58d6383fb"
      unitRef="U_USD">7500000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_c516a661-4d58-44d3-bdde-7aff8c4b82b2"
      decimals="-5"
      id="F_98537fcf-7878-4141-8f96-2ce3efcf6a1b"
      unitRef="U_USD">3500000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_75180180-4d90-42c6-8270-15e1f3cc0ebf"
      id="F_7f9a7ce4-3b7b-4095-92de-7a68422a9e4e">P120D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:NumberOfLicenseAgreements
      contextRef="C_3740bd83-e4cd-4204-8ee9-2432a933e74a"
      decimals="INF"
      id="F_ee25079c-4089-4f9d-9d9f-69e200e86271"
      unitRef="U_IntegerItem">2</lxeo:NumberOfLicenseAgreements>
    <lxeo:UpfrontCashPayment
      contextRef="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852"
      decimals="-5"
      id="F_8a6af1a0-0029-4cef-848b-f6dad08411f4"
      unitRef="U_USD">300000</lxeo:UpfrontCashPayment>
    <us-gaap:NotesIssued1
      contextRef="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852"
      decimals="-5"
      id="F_0b88bd0b-894c-4c42-9e05-c7a1122c6718"
      unitRef="U_USD">1300000</us-gaap:NotesIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="C_d3d8d14a-d897-4e92-bd97-3e0646e0e634"
      decimals="-5"
      id="F_6cdc8b95-56fd-4054-ac9a-31194e3f9446"
      unitRef="U_USD">1300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_8453d8e7-a1f5-4915-bf2c-6ebc643f48ed"
      decimals="INF"
      id="F_ccf09982-2837-499f-b310-b2c463a506c7"
      unitRef="U_shares">1337610</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_a71aae44-530b-4c44-887c-3235e51cb928"
      decimals="INF"
      id="F_32438ea1-a118-41b3-8c34-b32f2bd273e7"
      unitRef="U_shares">126258</us-gaap:PreferredStockConvertibleSharesIssuable>
    <lxeo:SpecificClinicalAndRegulatoryMilestonesDue
      contextRef="C_3bd21372-e009-4064-a11c-8bf9c564cecf"
      decimals="INF"
      id="F_c46de854-9948-410a-8153-ac4a3fe2c69a"
      unitRef="U_USD">8400000</lxeo:SpecificClinicalAndRegulatoryMilestonesDue>
    <lxeo:SpecificClinicalAndRegulatoryMilestonesDue
      contextRef="C_3d145bd9-a80d-4e38-8f51-01b475e8e55b"
      decimals="INF"
      id="F_703a86c1-91dc-4f50-8ab3-2ddf18e715d5"
      unitRef="U_USD">4300000</lxeo:SpecificClinicalAndRegulatoryMilestonesDue>
    <lxeo:SpecificClinicalAndRegulatoryMilestonesDue
      contextRef="C_9b72a311-fda5-4b44-874c-7a79d1c0981d"
      decimals="INF"
      id="F_03cd2bfe-8897-42f3-bd9c-bd7ab61b1205"
      unitRef="U_USD">600000</lxeo:SpecificClinicalAndRegulatoryMilestonesDue>
    <lxeo:PaymentOfClinicalAndRegulatoryMilestone
      contextRef="C_e8b9a53b-cf8f-4ca6-984a-ef4b65858fd3"
      decimals="-5"
      id="F_6c6d86f5-2778-49e8-bfa8-18e34428d64b"
      unitRef="U_USD">100000</lxeo:PaymentOfClinicalAndRegulatoryMilestone>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_ca4cc63b-321c-4b7a-b6c0-567e6bcd7852"
      id="F_164ac19c-2c7c-4b25-a8e7-4e6b55d77cd6">P90D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:PaymentOfLicenseIssueFeeAndInitialDataTransferFee
      contextRef="C_aa8f2f22-e100-44a6-a895-7f6b95043573"
      decimals="-5"
      id="F_72469ed7-39ec-4534-a8ab-b28ab32399b1"
      unitRef="U_USD">600000</lxeo:PaymentOfLicenseIssueFeeAndInitialDataTransferFee>
    <lxeo:PaymentOfAnnualDataTransferFee
      contextRef="C_aa8f2f22-e100-44a6-a895-7f6b95043573"
      decimals="0"
      id="F_68643639-23a0-4f81-806f-e4632d1649d0"
      unitRef="U_USD">50000</lxeo:PaymentOfAnnualDataTransferFee>
    <lxeo:PaymentOfAnnualLicenseMaintenanceFees
      contextRef="C_5c2eaa43-838e-4de5-ab2b-12e3438f3233"
      decimals="0"
      id="F_7d1e0e9a-3ed4-4893-8fc1-80402212b421"
      unitRef="U_USD">2500</lxeo:PaymentOfAnnualLicenseMaintenanceFees>
    <lxeo:PaymentOfAnnualLicenseMaintenanceFees
      contextRef="C_be3196c0-6c7d-48a3-80e1-3571e67be6c4"
      decimals="0"
      id="F_71abd32d-e483-40d9-902d-08cdd8b93b30"
      unitRef="U_USD">25000</lxeo:PaymentOfAnnualLicenseMaintenanceFees>
    <lxeo:PaymentOfRegulatoryMilestones
      contextRef="C_be3196c0-6c7d-48a3-80e1-3571e67be6c4"
      decimals="-5"
      id="F_751b0b7b-f159-4e32-9982-fa8273a3dc28"
      unitRef="U_USD">2100000</lxeo:PaymentOfRegulatoryMilestones>
    <lxeo:CommercializationMilestonesDue
      contextRef="C_54cd63d0-b34f-4997-8bdf-7b733713a458"
      decimals="-6"
      id="F_8b5e6775-7f7e-477f-8626-a046671dd515"
      unitRef="U_USD">100000000</lxeo:CommercializationMilestonesDue>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_aa8f2f22-e100-44a6-a895-7f6b95043573"
      id="F_e65e38c8-d047-4625-b1e2-f6b60c5b859f">P90D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:PaymentToAdditionalDataTransferProcess
      contextRef="C_cddcf69a-38e1-41ca-92b2-1dc2813f0ff2"
      decimals="-5"
      id="F_3ffb155d-1b2d-4fd8-a14d-d3780d712002"
      unitRef="U_USD">100000</lxeo:PaymentToAdditionalDataTransferProcess>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_650a7937-a18f-466c-853a-cd74ae06db6a"
      decimals="-5"
      id="F_c3e7c658-8611-4664-8b6f-a0cbd1ce09eb"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_650a7937-a18f-466c-853a-cd74ae06db6a"
      decimals="-5"
      id="F_bb7985b8-27bd-48d5-adfc-ae5dcf9bca03"
      unitRef="U_USD">100000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ce351259-df29-4736-b0f7-5bd85eaae4a8"
      decimals="-5"
      id="F_13ff7a41-494c-4c99-bb56-786b8d9b393f"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_ce351259-df29-4736-b0f7-5bd85eaae4a8"
      decimals="-5"
      id="F_0f1bfbc6-e224-43bd-bf0b-ace7042dcffe"
      unitRef="U_USD">700000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1
      contextRef="C_a404e138-86a1-415f-86fa-bd92d7670e55"
      id="F_44ea8502-d0e1-4cb9-9a00-db8694206a76">2021-07-16</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_306cf451-d0e8-4733-9390-77a092116c12"
      decimals="INF"
      id="F_0358b61e-c6a9-4aef-a54e-6ce9645e2aec"
      unitRef="U_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_8be8bafc-0873-440f-bfc2-64f112f3e6ed"
      decimals="INF"
      id="F_8cfce90f-0152-4968-982c-bd1860fdc6a6"
      unitRef="U_USD">12500000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_96240578-4334-4f1a-be14-256259efbda3"
      decimals="-5"
      id="F_29139b00-aeea-4cb2-a1fd-20ca3a2101e2"
      unitRef="U_USD">6000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_a77def4a-c9cb-4e98-960a-031f93bc0880"
      decimals="-5"
      id="F_b88d7f06-2b8c-4314-b424-29b621564a8f"
      unitRef="U_USD">6000000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:MilestoneReceived
      contextRef="C_248d415b-1dda-43fc-94db-d4c94d4bcf0f"
      decimals="-5"
      id="F_20f50be0-f4b0-4a1a-86c2-22c0cf238d6d"
      unitRef="U_USD">1300000</lxeo:MilestoneReceived>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_418db8cc-20a6-4c63-bc80-22f00e85ab78"
      decimals="0"
      id="F_65a9e850-8478-45dd-97d5-f66e0944c39f"
      unitRef="U_USD">20000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:DevelopmentAndCommercializationMilestonesDue
      contextRef="C_b7328e55-a04d-45a3-8322-e2fb9ba87bc8"
      decimals="INF"
      id="F_2b8adff9-ad79-4dc5-a263-4ac534e0f00f"
      unitRef="U_USD">4800000</lxeo:DevelopmentAndCommercializationMilestonesDue>
    <lxeo:OneTimeUpFrontNonRefundableFees
      contextRef="C_f42c0641-10f4-40b1-862a-8bb73b4c2821"
      decimals="0"
      id="F_0dd39d6d-ea47-4f5e-ba8c-8fb04cc0c2a0"
      unitRef="U_USD">20000</lxeo:OneTimeUpFrontNonRefundableFees>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_250aa9ae-d108-452e-bc1b-21c4551179b4"
      id="F_d53782e8-721d-4df2-8a4f-407046bd28c6">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_30c2f2ac-b0af-4f98-a1b6-41ccc4e13693"
      decimals="0"
      id="F_6497f0ec-a66e-4653-add5-1e281b27ce32"
      unitRef="U_USD">20000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:DevelopmentAndCommercializationMilestonesDue
      contextRef="C_a5a4ebfd-7511-4fbc-860a-5324a475f3a1"
      decimals="INF"
      id="F_face1615-3286-4634-861c-63edaa43ccb5"
      unitRef="U_USD">2400000</lxeo:DevelopmentAndCommercializationMilestonesDue>
    <lxeo:OneTimeUpFrontNonRefundableFees
      contextRef="C_773cd297-399a-44b4-b688-630eaee896cc"
      decimals="0"
      id="F_e83b6100-5c47-4d1b-a7fb-cb2e09f8d5c9"
      unitRef="U_USD">20000</lxeo:OneTimeUpFrontNonRefundableFees>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_30c2f2ac-b0af-4f98-a1b6-41ccc4e13693"
      id="F_8f8e4a8d-dcd5-4b64-b7d6-8757b020c56f">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_2c5a6104-de8c-4a89-b38f-5b76f25de136"
      decimals="0"
      id="F_2629a2e9-f235-495f-b3fa-55ec85094395"
      unitRef="U_USD">20000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:AggregateDevelopmentAndCommercializationMilestonesDescription
      contextRef="C_f15ba613-2ee7-4a4a-a5f6-e7630c6a7078"
      id="F_261b109c-65e3-4968-b597-07e153290a53">the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales</lxeo:AggregateDevelopmentAndCommercializationMilestonesDescription>
    <lxeo:DevelopmentAndCommercializationMilestonesDue
      contextRef="C_1f5a81d6-9a7a-4e3d-81e3-123c0c43d34b"
      decimals="INF"
      id="F_7475b10f-144b-473e-b793-bef179c21060"
      unitRef="U_USD">4000000</lxeo:DevelopmentAndCommercializationMilestonesDue>
    <lxeo:OneTimeUpFrontNonRefundableFees
      contextRef="C_63514d7b-26f0-4ca4-a6a2-01e151213a0d"
      decimals="0"
      id="F_a0266024-840b-4ace-8d2c-b76c109c55c8"
      unitRef="U_USD">20000</lxeo:OneTimeUpFrontNonRefundableFees>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_028187ae-2bdd-401c-9d01-a0eff189025b"
      decimals="-5"
      id="F_627fe77d-5411-4631-83f6-5fd6dbdcb4b1"
      unitRef="U_USD">100000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_2c5a6104-de8c-4a89-b38f-5b76f25de136"
      id="F_d8e345e9-3d8d-4cf0-8de5-b363776d0acb">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:NumberOfResearchAgreements
      contextRef="C_09b1664a-a411-44c8-8629-2f95a673f0c2"
      decimals="INF"
      id="F_0aaf3bce-7e70-45dd-91d7-30a0cbce79a7"
      unitRef="U_IntegerItem">2</lxeo:NumberOfResearchAgreements>
    <lxeo:ResearchAgreementsTerm
      contextRef="C_e52cbdd7-cdf3-4600-944f-875c024f274c"
      id="F_186c9b60-79cb-4d95-906c-435009173a99">P2Y</lxeo:ResearchAgreementsTerm>
    <lxeo:ResearchAgreementTerminationNoticePeriod
      contextRef="C_e52cbdd7-cdf3-4600-944f-875c024f274c"
      id="F_2ca1cc9a-7361-4cf0-bac6-a5e39d913914">P30D</lxeo:ResearchAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_e52cbdd7-cdf3-4600-944f-875c024f274c"
      decimals="-5"
      id="F_7ee96976-33f2-470c-9deb-abf8fe6a30b1"
      unitRef="U_USD">5600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <lxeo:ResearchAgreementsTerm
      contextRef="C_324cf665-a528-4a30-91f6-882210006248"
      id="F_e7f2f366-7361-451a-9d9a-163b79485db8">P2Y</lxeo:ResearchAgreementsTerm>
    <lxeo:ResearchAgreementTerminationNoticePeriod
      contextRef="C_324cf665-a528-4a30-91f6-882210006248"
      id="F_993fe38e-4bcd-4a83-a657-88137ee5dca6">P30D</lxeo:ResearchAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_324cf665-a528-4a30-91f6-882210006248"
      decimals="-5"
      id="F_b9e549df-77fa-4cbb-b80c-931e46c437bf"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <lxeo:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred
      contextRef="C_324cf665-a528-4a30-91f6-882210006248"
      decimals="-5"
      id="F_ff2019a2-f433-4573-8b8c-2cdd0b31fd19"
      unitRef="U_USD">600000</lxeo:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_10c07d1a-63f8-4282-9c3d-df142d9339e7"
      decimals="-5"
      id="F_ef3bdb46-01f6-4c65-8ee9-b9f2f766f922"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_62dae8ef-bcab-47b7-8b50-1e70e0f56090"
      decimals="-5"
      id="F_815fdf57-7cdf-4670-914f-a57520211c1c"
      unitRef="U_USD">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_62dae8ef-bcab-47b7-8b50-1e70e0f56090"
      decimals="-5"
      id="F_4ff7b866-112b-4c73-8691-85e6a8ba59b3"
      unitRef="U_USD">100000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_22f53fb5-b715-4275-818b-b00d6389e9cf"
      decimals="-5"
      id="F_853e489c-7429-4735-8d55-4ef85cb30c54"
      unitRef="U_USD">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_22f53fb5-b715-4275-818b-b00d6389e9cf"
      decimals="-5"
      id="F_ec4d0b8f-df39-4d23-a80e-05d379f80835"
      unitRef="U_USD">1600000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f97419ff-d263-47c9-8d19-9400a45c4996"
      decimals="-5"
      id="F_c97ebfa2-ca8a-457e-ac23-836deca96b37"
      unitRef="U_USD">5700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_e4a107b2-cde8-4301-ac61-de3823035653"
      decimals="-5"
      id="F_145846b0-a923-4a2d-a4c0-6d911978bd79"
      unitRef="U_USD">4900000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4cb98960-d47c-4c98-b396-48e50d6696e0"
      decimals="-6"
      id="F_abb69fd8-719f-4e43-a264-178c4ed11bf9"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_4cb98960-d47c-4c98-b396-48e50d6696e0"
      decimals="-6"
      id="F_4f7c948e-c349-47e4-885f-a180bd53c164"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_f19cb4b3-33d9-416a-ba8a-a2b2f96227f7">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_33986856-2fc0-46e5-a0a8-20e6e13001c1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CEO and senior leadership team&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. All of the Company&#x2019;s operating results are reviewed by the Company&#x2019;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a037ea15-adec-409e-8c43-b3ef64e5bcf7;"&gt;&lt;span style="-sec-ix-hidden:F_b1bf8275-7776-4ea4-af70-17f51659f92f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.094%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX1001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab-related costs and supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income and expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_75f9c2e7-1de4-4946-af58-da32a0cd7335">The Company's CODM is its CEO and senior leadership team. All of the Company&#x2019;s operating results are reviewed by the Company&#x2019;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a single reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_21194b07-f60c-473e-9e17-81e2675cbf9b">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2025 and December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.094%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX1001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab-related costs and supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income and expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <lxeo:ResearchAndDevelopmentExpenseLX2006
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_051c46a6-171e-4dae-8208-202a4508b31b"
      unitRef="U_USD">18163000</lxeo:ResearchAndDevelopmentExpenseLX2006>
    <lxeo:ResearchAndDevelopmentExpenseLX2006
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_c68ac81a-dd40-4c8f-bba1-47ca86e980ab"
      unitRef="U_USD">14256000</lxeo:ResearchAndDevelopmentExpenseLX2006>
    <lxeo:ResearchAndDevelopmentExpenseLX2020
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_930dcf8a-dbfe-4d2a-90ae-d7feb7f12fc7"
      unitRef="U_USD">15413000</lxeo:ResearchAndDevelopmentExpenseLX2020>
    <lxeo:ResearchAndDevelopmentExpenseLX2020
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_a3fadca9-40c4-4020-bd66-c1afab53c2c6"
      unitRef="U_USD">23451000</lxeo:ResearchAndDevelopmentExpenseLX2020>
    <lxeo:ResearchAndDevelopmentExpenseLX1001
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_fe54bead-27da-47a9-aeaf-3cbe20c5975a"
      unitRef="U_USD">1168000</lxeo:ResearchAndDevelopmentExpenseLX1001>
    <lxeo:ResearchAndDevelopmentExpenseLX1001
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_628483ff-009d-45c7-ac3b-e413acd4dccc"
      unitRef="U_USD">4501000</lxeo:ResearchAndDevelopmentExpenseLX1001>
    <lxeo:ResearchAndDevelopmentExpenseOtherPrograms
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_b74e06ce-394b-434a-8617-eef0fa61684b"
      unitRef="U_USD">2075000</lxeo:ResearchAndDevelopmentExpenseOtherPrograms>
    <lxeo:ResearchAndDevelopmentExpenseOtherPrograms
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_5f14cefc-0001-4f67-9740-533b90adb5b9"
      unitRef="U_USD">3424000</lxeo:ResearchAndDevelopmentExpenseOtherPrograms>
    <lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_04ae0929-38e7-49b8-ab95-263f2c7504f1"
      unitRef="U_USD">15183000</lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses>
    <lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_e2092c2c-f49b-48f4-b5ea-5b1b4adf6b54"
      unitRef="U_USD">16010000</lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_7394a62a-4d2b-4537-9b0c-b50eeca7152d"
      unitRef="U_USD">1550000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_2093c8e8-73ff-4bdd-8618-cd8eca12676a"
      unitRef="U_USD">1367000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_bee2f5c6-c0af-4c37-b510-486a7043d91f"
      unitRef="U_USD">10245000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_e530a1cf-dca7-4da2-b97c-90b1e9640166"
      unitRef="U_USD">11082000</us-gaap:OtherResearchAndDevelopmentExpense>
    <lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_6639f4af-cea7-4d43-bdf8-1bf0bbf55c50"
      unitRef="U_USD">8461000</lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses>
    <lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_83da1dd6-7e2e-469e-9884-2b4a69371571"
      unitRef="U_USD">6685000</lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_abbe3fac-7330-4c67-8533-17dea25c12bc"
      unitRef="U_USD">36999000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_eb018f3e-7b7b-4a06-81e2-4033043fab9f"
      unitRef="U_USD">24990000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_81423b7f-dfb4-4a02-9704-de77fcd71131"
      unitRef="U_USD">9296000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_48c1fc4f-8dbc-4cf6-bdd5-5638b94f4a82"
      unitRef="U_USD">7433000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_9ad4d83e-62ad-4f4d-afe5-59f007561415"
      decimals="-3"
      id="F_8645e3d8-1a78-45d3-a262-db301c2504ba"
      unitRef="U_USD">-99961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ae431a33-037b-46c8-a9af-9018491b4fb5"
      decimals="-3"
      id="F_e0e4f5d1-ca12-4777-a964-b2def156a752"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_0c9a0eea-26e0-4b33-83a3-77da7d4fc42d"
      id="F_79ef6a36-7f61-44ca-8757-86074adfabb2">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent events have been evaluated through March 30, 2026, which is the date that these financial statements were issued and were available to be issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2026, warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;867,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share that were issued in the May 2025 Private Placement were exercised with total proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million received by the Company (see Note 7).&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ddd009c3-4182-4517-ab43-5a05f6879a2e"
      decimals="INF"
      id="F_127398a8-7357-41ba-a384-c7baf95b6631"
      unitRef="U_shares">867302</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1fd1bb70-d88e-4bd3-9f2b-0ae04cc83ef6"
      decimals="INF"
      id="F_e91bc11b-abd8-47b2-8235-8b19412352f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_2d45877d-8c3e-4498-98ab-785fe7b33f59"
      decimals="-5"
      id="F_7a2a1d54-0fa2-42e0-bfa6-036ca6dfdf2e"
      unitRef="U_USD">2400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8"
      id="F_048fc93d-46e5-436a-8a59-2516eec8f7ce">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Securities Trading Plans of Directors and Executive Officers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 13, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;R. Nolan Townsend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and a member of our board of directors, adopted a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; trading arrangement providing for the sale from time to time of an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, commencing on April 3, 2026. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 11, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or earlier if all transactions under the trading arrangement are completed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; other officers, as defined in Rule 16a-1(f), or directors adopted or terminated a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or a &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as defined in Regulation S-K Item 408, during the last fiscal quarter.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"
      id="F_e6d393ce-a29f-40de-a71c-f00edc6ba18e">November 13, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"
      id="F_e90d4e68-356c-4402-add7-992bb0955c71">R. Nolan Townsend</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"
      id="F_dc050157-7e44-4988-8759-b85e1f367081">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"
      id="F_eef29a01-66db-49a3-9f0d-a41e81cee4c2">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_213bc6a0-4d38-4376-bd17-5ea5dbcd6e55"
      decimals="0"
      id="F_447ddffa-3023-413c-b5c5-5011e1e03ef1"
      unitRef="U_shares">116500</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_e4951459-4c5a-425c-9f51-9c9146ed2fe5"
      id="F_b31d022a-740e-4046-8c6f-82aff704ac34">January 11, 2027</ecd:TrdArrExpirationDate>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8"
      id="F_fc4ed2c1-c164-4f0f-b787-08ee656f3506">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8"
      id="F_31bf3974-8980-408a-87df-9de93bef0fec">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8"
      id="F_d521d87e-819c-40c1-868a-f224189fea37">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_72e10212-d78b-4f0e-a46a-69781278fac8"
      id="F_65facba3-b66a-44bb-afb8-eec4e2e89c7f">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
